PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hahm, SH; Eiden, LE				Hahm, SH; Eiden, LE			Two separate cis-active elements of the vasoactive intestinal peptide gene mediate constitutive and inducible transcription by binding different sets of AP-1 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; SCAVENGER RECEPTOR GENE; C-JUN; RAT-BRAIN; CHROMAFFIN CELLS; POLYPEPTIDE VIP; MESSENGER-RNA; KINASE; ACTIVATION; FOS	Vasoactive intestinal peptide (VIP) gene expression is highly restricted throughout the neuroaxis and regulated by extracellular factors that activate tyrosine- or serine/threonine-directed protein kinase pathways. Cytokine, cyclic AMP, and tissue-specific response elements on the VIP gene have been characterized, Those mediating responsiveness to protein kinase C have not, The endogenous VIP gene and a 5.2-kilobase pair (kb) VIP-luciferase reporter gene, are up-regulated by phorbol 12-myristate 13-acetate (PMA) in SK-N-SH neuroblastoma cells. PMA stimulation was abolished by deletion of sequences at -1.37 to -1.28 or -1.28 to -0.904 kb, but not by removal of the single phorbol ester response element (TRE; TGACTCA) located at -2.25 kb. Mutation of sites at -1.32 or -1.20 that mediate neurotrophin responsiveness of the VIP gene (Symes, A., Lewis, S,, Corpus, L., Rajan, P., Hyman, S.E,, and Fink, J.S. (1994) Mol. Endocrinol. 8, 1750-1763) each reduced PMA induction in SK-N-SH cells by >50%, and double mutation abolished it. The two mutations also reduced basal VIP reporter gene transcription in SH-EP neuroblastoma cells expressing VIP constitutively. Both cis-active elements bound pre-existing AP-1 proteins in SH-EP- or PIMA-stimulated SK-N-SH cell nuclear extracts. The AP-1 complex at both sites contained a Fos-related protein with c-Jun in SH-EP cells and c-Fos with a Jun-related protein in SK-N-SH cells. Recruitment of combinatorially distinct AP-1 complexes to these elements may underlie cell type-specific regulation of the VIP gene.	NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Hahm, SH (corresponding author), NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, 36 Convent Dr,MSC 4090,Bldg 36,Rm 2D10, Bethesda, MD 20892 USA.	sungho@codon.nih.gov		Eiden, Lee/0000-0001-7524-944X				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ban Y, 1997, J NEUROSCI, V17, P3920; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EIDEN LE, 1983, LIFE SCI, V33, P687, DOI 10.1016/0024-3205(83)90772-5; EMSON PC, 1979, BRAIN RES, V177, P437, DOI 10.1016/0006-8993(79)90462-1; GOZES I, 1987, MOL BRAIN RES, V2, P137, DOI 10.1016/0169-328X(87)90007-6; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hahm SH, 1998, J BIOL CHEM, V273, P17086, DOI 10.1074/jbc.273.27.17086; Hahm SH, 1996, J NEUROCHEM, V67, P1872; HILL JM, 1994, J COMP NEUROL, V342, P186, DOI 10.1002/cne.903420204; Huang XC, 1998, ENDOCRINOLOGY, V139, P245, DOI 10.1210/en.139.1.245; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LINDH B, 1987, ACTA PHYSIOL SCAND, V131, P475, DOI 10.1111/j.1748-1716.1987.tb08265.x; LINDH B, 1989, CELL TISSUE RES, V256, P259; LUNDBERG JM, 1982, P NATL ACAD SCI-BIOL, V79, P1303, DOI 10.1073/pnas.79.4.1303; LUNDBERG JM, 1980, P NATL ACAD SCI-BIOL, V77, P1651, DOI 10.1073/pnas.77.3.1651; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; ROSTENE WH, 1984, PROG NEUROBIOL, V22, P103, DOI 10.1016/0301-0082(84)90022-4; SAMSON WK, 1979, NEUROSCI LETT, V12, P265, DOI 10.1016/0304-3940(79)96073-7; Schutz B, 1998, ANN NY ACAD SCI, V865, P537, DOI 10.1111/j.1749-6632.1998.tb11232.x; SENA M, 1994, DNA SEQUENCE, V5, P25, DOI 10.3109/10425179409039701; SENDTNER M, 1994, J NEUROBIOL, V25, P1436, DOI 10.1002/neu.480251110; SIMS KB, 1980, BRAIN RES, V186, P165, DOI 10.1016/0006-8993(80)90263-2; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Symes A, 1997, J BIOL CHEM, V272, P9648; TYRRELL S, 1994, J NEUROSCI, V14, P4529; WASCHEK JA, 1987, ANN NY ACAD SCI, V493, P308, DOI 10.1111/j.1749-6632.1987.tb27215.x; WASCHEK JA, 1988, P NATL ACAD SCI USA, V85, P9547, DOI 10.1073/pnas.85.24.9547; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657	35	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25588	25593		10.1074/jbc.274.36.25588	http://dx.doi.org/10.1074/jbc.274.36.25588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464293	hybrid			2022-12-25	WOS:000082554200057
J	Aiston, S; Trinh, KY; Lange, AJ; Newgard, CB; Agius, L				Aiston, S; Trinh, KY; Lange, AJ; Newgard, CB; Agius, L			Glucose-6-phosphatase overexpression lowers glucose 6-phosphate and inhibits glycogen synthesis and glycolysis in hepatocytes without affecting glucokinase translocation - Evidence against feedback inhibition of glucokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER GLUCOSE-6-PHOSPHATASE; REGULATORY PROTEIN; GENE-EXPRESSION; CATALYTIC SUBUNIT; FRUCTOSE 2,6-BISPHOSPHATE; HEXOKINASE-I; INSULIN; CELLS; REPRESSION; MECHANISM	In hepatocytes glucokinase (GK) and glucose 6-phosphatase (Glc-6-Pase)(1) have converse effects on glucose 6-phosphate (and fructose 6-phosphate) levels. To establish whether hexose B-phosphate regulates GK binding to its regulatory protein, we determined the effects of Glc-6-Pase overexpression on glucose metabolism and GK compartmentation. Glc-6-Pase overexpression (4-fold) decreased glucose 6-phosphate levels by 50% and inhibited glycogen synthesis and glycolysis with a greater negative control coefficient on glycogen synthesis than on glycolysis, but it did not affect the response coefficients of glycogen synthesis or glycolysis to glucose, and it did not increase the control coefficient of GK or cause dissociation of GK from its regulatory protein, indicating that in hepatocytes fructose 6-phosphate does not regulate GK translocation by feedback inhibition. GK overexpression increases glycolysis and glycogen synthesis with a greater control coefficient on glycogen synthesis than on glycolysis, On the basis of the similar relative control coefficients of GK and Glc-6-Pase on glycogen synthesis compared with glycolysis, and the lack of effect of Glc-6-Pase overexpression on GK translocation or the control coefficient of GK, it is concluded that the main regulatory function of Glc-6-Pase is to buffer the glucose 6-phosphate concentration. This is consistent with recent findings that hyperglycemia stimulates Glc-6-Pase gene transcription.	Univ Newcastle Upon Tyne, Sch Med, Sch Clin Med Sci, Dept Diabet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Toronto, Dept Med, Toronto, ON M5G 2C4, Canada; Univ Minnesota, Sch Med, Dept Biochem, Minneapolis, MN 55455 USA; Univ Texas, SW Med Ctr, Dept Biochem, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	Newcastle University - UK; University of Toronto; University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Agius, L (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Clin Med Sci, Dept Diabet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.				PHS HHS [NIH1P50H2598801] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agius L, 1998, ADV ENZYME REGUL, V38, P303, DOI 10.1016/S0065-2571(97)00001-0; Agius L, 1997, BIOCHEM J, V325, P667, DOI 10.1042/bj3250667; AGIUS L, 1990, BIOCHEM J, V266, P91, DOI 10.1042/bj2660091; AGIUS L, 1995, BIOCHEM J, V309, P711, DOI 10.1042/bj3090711; AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; ALEGRE M, 1988, ANAL BIOCHEM, V173, P185, DOI 10.1016/0003-2697(88)90176-5; Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; CLARK DG, 1973, BIOCHEM BIOPH RES CO, V54, P1141, DOI 10.1016/0006-291X(73)90811-5; CLIFTON PM, 1988, ANAL BIOCHEM, V172, P165, DOI 10.1016/0003-2697(88)90426-5; DETHEUX M, 1991, EUR J BIOCHEM, V200, P553, DOI 10.1111/j.1432-1033.1991.tb16218.x; FELL D, 1997, UNDERSTANDING CONTRO, P219; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; GROEN AK, 1986, BIOCHEM J, V237, P379, DOI 10.1042/bj2370379; HERS HG, 1982, BIOCHEM J, V206, P1; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; Hue L, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P247; IYNDEJIAN PB, 1993, BIOCHEM J, V293, P1; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; Kacser H, 1979, BIOCHEM SOC T, V7, P1149, DOI 10.1042/bst0071149; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Mevorach M, 1998, J CLIN INVEST, V102, P744, DOI 10.1172/JCI2720; Niculescu L, 1997, BIOCHEM J, V321, P239, DOI 10.1042/bj3210239; Niculescu L, 1998, DIABETOLOGIA, V41, P947, DOI 10.1007/s001250051012; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Trinh K, 1997, J BIOL CHEM, V272, P24837, DOI 10.1074/jbc.272.40.24837; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VanSchaftingen E, 1997, BIOCHEM SOC T, V25, P136, DOI 10.1042/bst0250136; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VANSCHAFTINGEN E, 1995, BIOCHEM J, V308, P23, DOI 10.1042/bj3080023; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078	43	57	58	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24559	24566		10.1074/jbc.274.35.24559	http://dx.doi.org/10.1074/jbc.274.35.24559			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455119	hybrid			2022-12-25	WOS:000082193400018
J	Hamberg, M; Sanz, A; Castresana, C				Hamberg, M; Sanz, A; Castresana, C			alpha-oxidation of fatty acids in higher plants - Identification of a pathogen-inducible oxygenase (PIOX) as an alpha-dioxygenase and biosynthesis of 2-hydroperoxylinolenic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VICIA-FABA L; LIPOXYGENASE PATHWAY; LINOLEIC-ACID; HYDROPEROXIDE ISOMERASE; CUCUMIS-SATIVUS; STERIC ANALYSIS; GREEN LEAVES; CYCLOOXYGENASE; BIOCHEMISTRY; JASMONATE	A pathogen-inducible oxygenase in tobacco leaves and a homologous enzyme from Arabidopsis were recently characterized (Sanz, A., Moreno, J. I., and Castresana, C. (1998) Plant Cell 10, 1523-1537), Linolenic acid incubated at 23 degrees C with preparations containing the recombinant enzymes underwent alpha-oxidation with the formation of a chain-shortened aldehyde, i.e., 8(Z),11(Z),14(Z)-heptadecatrienal (83%), an alpha-hydroxy acid, 2(R)-hydroxy-9(Z),12(Z),15(Z)-octadecatrienoic acid (15%), and a chain-shortened fatty acid, 8(Z),11(Z),14(Z)-heptadecatrienoic acid (2%). When incubations were performed at 0 degrees C, 2(R)-hydroperoxy-9(Z),12(Z),15(Z)-octadecatrienoic acid was obtained as the main product. An intermediary role of 2(R)-hydroperoxy-9(Z),12(2),15(2)octadecatrienoic acid in alpha-oxidation was demonstrated by re-incubation experiments, in which the hydroperoxide was converted into the same alpha-oxidation products as those formed from linolenic acid. 2(R)-Hydroperoxy-9(Z),12(Z),15(Z)-octadecatrienoic acid was chemically unstable and had a half-life time in buffer of about 30 min at 23 degrees C, Extracts of cells expressing the recombinant oxygenases accelerated breakdown of the hydroperoxide (half-life time, about 3 min at 23 degrees C), however, this was not attributable to the recombinant enzymes since the same rate of hydroperoxide degradation was observed in the presence of control cells not expressing the enzymes. No significant discrimination between enantiomers was observed in the degradation of 2(R,S)-hydroperoxy-9(Z)-octadecenoic acid in the presence of recombinant oxygenases, A previously studied system for alpha-oxidation in cucumber was re-examined using the newly developed techniques and was found to catalyze the same conversions as those observed with the recombinant enzymes, i.e. enzymatic alpha-dioxygenation of fatty acids into 2(R)-hydroperoxides and a first order, non-stereoselective degradation of hydroperoxides into alpha-oxidation products. It was concluded that the recombinant enzymes from tobacco and Arabidopsis were both alpha-dioxygenases, and that members of this new class of enzymes catalyze the first step of alpha-oxidation in plant tissue.	Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden; CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Karolinska Institutet; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Hamberg, M (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden.	Mats.Hamberg@mbb.ki.se	Sánchez, Arturo/L-3622-2019	Sánchez, Arturo/0000-0002-4946-1559; Hamberg, Mats/0000-0002-8910-7810				Adam W, 1998, J AM CHEM SOC, V120, P11044, DOI 10.1021/ja981252r; ADAM W, 1977, J AM CHEM SOC, V99, P5768, DOI 10.1021/ja00459a038; Akakabe Y, 1999, TETRAHEDRON LETT, V40, P1137, DOI 10.1016/S0040-4039(98)02547-7; BAARDSETH P, 1987, BIOCHIM BIOPHYS ACTA, V922, P170, DOI 10.1016/0005-2760(87)90151-2; Blee E, 1998, PROG LIPID RES, V37, P33, DOI 10.1016/S0163-7827(98)00004-6; Borge GIA, 1997, BBA-LIPID LIPID MET, V1344, P47; BRODOWSKY ID, 1992, J BIOL CHEM, V267, P14738; Conconi A, 1996, PLANT PHYSIOL, V111, P797, DOI 10.1104/pp.111.3.797; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; FAHLSTADIUS P, 1989, CHEM PHYS LIPIDS, V51, P15, DOI 10.1016/0009-3084(89)90061-3; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; GALLIARD T, 1972, BIOCHEM J, V129, P743, DOI 10.1042/bj1290743; GALLIARD T, 1976, BIOCHIM BIOPHYS ACTA, V424, P26, DOI 10.1016/0005-2760(76)90046-1; GALLIARD T, 1980, BIOCH PLANTS, V4, P85; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; Grechkin A, 1998, PROG LIPID RES, V37, P317, DOI 10.1016/S0163-7827(98)00014-9; GRECHKIN AN, 1995, FEBS LETT, V371, P159, DOI 10.1016/0014-5793(95)00895-G; HAMBERG M, 1968, EUR J BIOCHEM, V6, P135, DOI 10.1111/j.1432-1033.1968.tb00430.x; HAMBERG M, 1971, ANAL BIOCHEM, V43, P515, DOI 10.1016/0003-2697(71)90282-X; HAMBERG M, 1992, PLANT PHYSIOL, V99, P987, DOI 10.1104/pp.99.3.987; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V283, P409, DOI 10.1016/0003-9861(90)90662-I; Hamberg M, 1998, LIPIDS, V33, P1061, DOI 10.1007/s11745-998-0306-7; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; HAMBERG M, 1993, ARCH BIOCHEM BIOPHYS, V305, P115, DOI 10.1006/abbi.1993.1400; HAMBERG M, 1986, BIOCHIM BIOPHYS ACTA, V877, P447, DOI 10.1016/0005-2760(86)90211-0; HATANAKA A, 1993, PHYTOCHEMISTRY, V34, P1201, DOI 10.1016/0031-9422(91)80003-J; HITCHCOC.C, 1966, BIOCHIM BIOPHYS ACTA, V116, P413, DOI 10.1016/0005-2760(66)90112-3; KAJIWARA T, 1988, PHYTOCHEMISTRY, V27, P1643, DOI 10.1016/0031-9422(88)80419-9; KONEN DA, 1975, J ORG CHEM, V40, P3253, DOI 10.1021/jo00910a020; Landino LM, 1997, J BIOL CHEM, V272, P21565, DOI 10.1074/jbc.272.34.21565; LATIES GG, 1967, PHYTOCHEMISTRY, V6, P49, DOI 10.1016/0031-9422(67)85007-6; McConn M, 1996, PLANT CELL, V8, P403, DOI 10.1105/tpc.8.3.403; Mueller MJ, 1997, PHYSIOL PLANTARUM, V100, P653, DOI 10.1034/j.1399-3054.1997.1000329.x; NAMAI T, 1993, BIOSCI BIOTECH BIOCH, V57, P611, DOI 10.1271/bbb.57.611; PROTEAU PJ, 1993, LIPIDS, V28, P783, DOI 10.1007/BF02536231; RATCLIFF.R, 1970, J ORG CHEM, V35, P4000, DOI 10.1021/jo00836a108; Reymond P, 1998, CURR OPIN PLANT BIOL, V1, P404, DOI 10.1016/S1369-5266(98)80264-1; Ryu SB, 1998, BBA-LIPID LIPID MET, V1393, P193, DOI 10.1016/S0005-2760(98)00048-4; Sanz A, 1998, PLANT CELL, V10, P1523, DOI 10.1105/tpc.10.9.1523; SHINE WE, 1974, ARCH BIOCHEM BIOPHYS, V162, P147, DOI 10.1016/0003-9861(74)90113-1; SMITH CR, 1969, LIPIDS, V4, P9, DOI 10.1007/BF02531787; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; STUMPF PK, 1956, J BIOL CHEM, V223, P643; TURNIPSEED SB, 1994, ANAL BIOCHEM, V216, P241; TURNIPSEED SB, 1993, ANAL BIOCHEM, V213, P218, DOI 10.1006/abio.1993.1412; Verhoeven NM, 1998, J INHERIT METAB DIS, V21, P697, DOI 10.1023/A:1005476631419; WEILER EW, 1993, PHYTOCHEMISTRY, V32, P591, DOI 10.1016/S0031-9422(00)95142-2; YANUKA Y, 1968, TETRAHEDRON LETT, P1725	48	122	128	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24503	24513		10.1074/jbc.274.35.24503	http://dx.doi.org/10.1074/jbc.274.35.24503			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455113	hybrid			2022-12-25	WOS:000082193400012
J	Tsukamoto, T; Nigam, SK				Tsukamoto, T; Nigam, SK			Cell-cell dissociation upon epithelial cell scattering requires a step mediated by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CADHERIN-CATENIN COMPLEX; HEPATOCYTE GROWTH-FACTOR; TIGHT JUNCTIONS; BETA-CATENIN; PHOSPHORYLATION; CYTOSKELETON; INVOLVEMENT; INHIBITION; BIOGENESIS; POLARITY	During development, tissue repair, and tumor metastasis, both cell-cell dissociation and cell migration occur and appear to be intimately linked, such as during epithelial "scattering." Here we show that cell-cell dissociation during scattering induced by hepatocyte growth factor (HGF) or activation of the temperature-sensitive v-Src tyrosine kinase in MDCK cells can be blocked by inhibiting the proteasome with lactacystin and MG132. Although both proteins of the tight junction and the adherens junction redistributed during cell scattering, proteasome inhibitors largely prevented this process, resulting in the stabilization of Triton X-100-insoluble tight junction proteins as well as adherens junction proteins at sites of cell-cell contact, Proteasome inhibition also led to a decrease of E-cadherin turnover in S-35-labeled cells. In addition, proteasome inhibition partly preserved cell polarity, as determined by the subcellular distribution of Na+,K+-ATPase (basolateral marker) and gp135 (apical marker), and the structure of the subcortical actin ring, both of which are normally disrupted during scattering. However, cells were able to establish focal contacts, and single cell migration toward HGF was unaffected by proteasome inhibition in quantitative assays, indicating that cell-cell dissociation during scattering occurs independently of anchorage-dependent cell migration. Thus, a proteasome-dependent step during scattering induced by HGF and pp60(v-Src) appears to be essential for cell-cell dissociation, disassembly of junctional components, and (at least indirectly) it also plays a role in the loss of protein polarity.	Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Nigam, SK (corresponding author), Univ Calif San Diego, Dept Pediat, Div Nephrol & Hypertens, 9500 Gilman Dr, La Jolla, CA 92093 USA.							Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bauer A, 1998, J BIOL CHEM, V273, P28314, DOI 10.1074/jbc.273.43.28314; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Brown D, 1996, PHYSIOL REV, V76, P245, DOI 10.1152/physrev.1996.76.1.245; Bush KT, 1997, J BIOL CHEM, V272, P9086; CANTLEY LG, 1994, AM J PHYSIOL, V267, pF271, DOI 10.1152/ajprenal.1994.267.2.F271; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; DRENCKHAHN D, 1988, J CELL BIOL, V107, P1037, DOI 10.1083/jcb.107.3.1037; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FATH KR, 1993, J CELL SCI, P65; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pasdar M, 1997, CELL GROWTH DIFFER, V8, P451; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P1079; Saha C, 1998, J BIOL CHEM, V273, P21629, DOI 10.1074/jbc.273.34.21629; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; Stuart RO, 1996, J BIOL CHEM, V271, P13636, DOI 10.1074/jbc.271.23.13636; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; Taya S, 1998, J CELL BIOL, V142, P1053, DOI 10.1083/jcb.142.4.1053; TSUKAMOTO T, 1991, J BIOL CHEM, V266, P10143; Tsukamoto T, 1997, J BIOL CHEM, V272, P16133, DOI 10.1074/jbc.272.26.16133; TSUKAMOTO T, 1999, IN PRESS AM J PHYSL; Tsukita S, 1998, GENES CELLS, V3, P569, DOI 10.1046/j.1365-2443.1998.00212.x; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847	37	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24579	24584		10.1074/jbc.274.35.24579	http://dx.doi.org/10.1074/jbc.274.35.24579			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455122	hybrid			2022-12-25	WOS:000082193400021
J	Lenting, PJ; Neels, JG; van den Berg, BMM; Clijsters, PPFM; Meijerman, DWE; Pannekoek, H; van Mourik, JA; Mertens, K; van Zonneveld, AJ				Lenting, PJ; Neels, JG; van den Berg, BMM; Clijsters, PPFM; Meijerman, DWE; Pannekoek, H; van Mourik, JA; Mertens, K; van Zonneveld, AJ			The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-VIII; VON-WILLEBRAND-FACTOR; CELL-SURFACE PROTEOGLYCANS; ALPHA-2-MACROGLOBULIN RECEPTOR; HIGH-AFFINITY; VONWILLEBRAND-FACTOR; FACTOR XA; PLASMINOGEN-ACTIVATOR; FACTOR IXA; C2 DOMAIN	In the present study, the interaction between the endocytic receptor low density lipoprotein receptor-related protein (LRP) and coagulation factor VIII (FVIII) was investigated. Using purified components, FVIII was found to bind to LRP in a reversible and dose-dependent manner (K-d approximate to 60 nM). The interaction appeared to be specific because the LRP antagonist receptor-associated protein readily inhibited binding of FVIII to LRP (IC50 approximate to 1 nM). In addition, a 12-fold molar excess of the physiological carrier of FVIII, i.e. von Willebrand factor (vWF), reduced the binding of FVIII to LRP by over 90%. Cellular degradation of I-125-labeled FVIII by LRP-expressing cells (approximate to 8 fmol/10(5) cells after a 4.5-h incubation) was reduced by approximately 70% in the presence of receptor-associated protein. LRP-directed antibodies inhibited degradation to a similar extent, indicating that LRP indeed contributes to binding and transport of FVIII to the intracellular degradation pathway. Degradation of FVIII was completely inhibited by vWF, Because vWF binding by FVIII involves its light chain, LRP binding to this subunit was studied. In ligand blotting experiments, binding of FVIII light chain to LRP could be visualized, More detailed analysis revealed that FVIII light chain interacts with LRP with moderate affinity (k(on) approximate to 5 x 10(4) M-1 s(-1); k(off) approximate to 2.5 x 10(-3) s(-1); K-d approximate to 50 nM). Furthermore, experiments using recombinant FVIII C2 domain showed that this domain contributes to the interaction with LRP. In contrast, no association of FVIII heavy chain to LRP could be detected under the same experimental conditions. Collectively, our data demonstrate that in vitro LRP is able to bind FVIII at the cell surface and to mediate its transport 60 the intracellular degradation pathway. FVIII-LRP interaction involves the FVIII light chain, and FVIII-vWF complex formation plays a regulatory role in LRP binding. Our findings may explain the beneficial effect of vWF on the in vivo survival of FVIII.	CLB, Dept Plasma Prot Technol, NL-1066 CX Amsterdam, Netherlands; CLB, Dept Blood Coagulat, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Lenting, PJ (corresponding author), CLB, Dept Plasma Prot Technol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.		Lenting, Peter/AAH-5663-2019; van Zonneveld, Anton Jan/D-8060-2018; Neels, Jaap G/F-5534-2010; Lenting, Peter/F-8269-2013	Lenting, Peter/0000-0002-7937-3429; van Zonneveld, Anton Jan/0000-0002-1676-7738; Neels, Jaap G/0000-0002-5900-8395; Lenting, Peter/0000-0002-7937-3429				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brinkman HJM, 1997, BIOCHEM J, V323, P735, DOI 10.1042/bj3230735; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; CONESE M, 1994, J BIOL CHEM, V269, P17886; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1991, J BIOL CHEM, V266, P8957; Fijnvandraat K, 1998, BLOOD, V91, P2347, DOI 10.1182/blood.V91.7.2347.2347_2347_2352; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Hamik A, 1999, J BIOL CHEM, V274, P4962, DOI 10.1074/jbc.274.8.4962; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HORN IR, 1995, J BIOL CHEM, V270, P11770, DOI 10.1074/jbc.270.20.11770; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; Kaufman RJ, 1998, THROMB HAEMOSTASIS, V79, P1068; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; MANNUCCI PM, 1992, BLOOD, V79, P3130; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; Narita M, 1998, BLOOD, V91, P555, DOI 10.1182/blood.V91.2.555.555_555_560; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; Noe DA, 1996, HAEMOSTASIS, V26, P289; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OVER J, 1981, J LAB CLIN MED, V97, P332; ROTBLAT F, 1985, BIOCHEMISTRY-US, V24, P4294, DOI 10.1021/bi00337a007; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; Saenko EL, 1998, J BIOL CHEM, V273, P27918, DOI 10.1074/jbc.273.43.27918; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; SCANDELLA D, 1995, BLOOD, V86, P1811, DOI 10.1182/blood.V86.5.1811.bloodjournal8651811; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WISE RJ, 1991, J BIOL CHEM, V266, P21948; Yakhyaev A., 1997, Blood, V90, p31A	45	171	192	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23734	23739		10.1074/jbc.274.34.23734	http://dx.doi.org/10.1074/jbc.274.34.23734			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446132	hybrid			2022-12-25	WOS:000082110900011
J	Miller, BG; Smiley, JA; Short, SA; Wolfenden, R				Miller, BG; Smiley, JA; Short, SA; Wolfenden, R			Activity of yeast orotidine-5 '-phosphate decarboxylase in the absence of metals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION	Yeast orotidine-5'-phosphate decarboxylase was recently shown to contain zinc and to be inhibited by zinc-complexing agents. When the gene for the yeast enzyme was expressed in Escherichia coli, the gene product was devoid of metal atoms but exhibited a specific activity and molecular mass similar to those of the enzyme obtained directly from yeast. This invalidates the hypothesis that zinc is involved in substrate decarboxylation. The zinc-free enzyme undergoes thermal inactivation at a somewhat lower temperature than does the zinc-containing enzyme isolated from yeast.	Glaxo Wellcome Inc, Mol Sci, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Youngstown State Univ, Dept Chem, Youngstown, OH 44555 USA	GlaxoSmithKline; University of North Carolina; University of North Carolina Chapel Hill; Youngstown State University	Short, SA (corresponding author), Glaxo Wellcome Inc, Mol Sci, Res Triangle Pk, NC 27709 USA.				NIGMS NIH HHS [GM-18324] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL JB, 1991, J BIOL CHEM, V266, P12662; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Jones M E, 1978, Methods Enzymol, V51, P155; KALMAN T, 1979, DRUG ACTION DESIGN M, P285; LIVINGSTONE LR, 1987, J BIOL CHEM, V262, P15726; MILLER BG, 1998, J AM CHEM SOC, V104, P6434; Miller J. H., 1972, EXPT MOL GENETICS, P433; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH AA, 1994, BIOCHEMISTRY-US, V33, P6468, DOI 10.1021/bi00187a012; VOGEL HJ, 1956, J BIOL CHEM, V218, P97	11	33	33	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23841	23843		10.1074/jbc.274.34.23841	http://dx.doi.org/10.1074/jbc.274.34.23841			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446147	hybrid			2022-12-25	WOS:000082110900026
J	Toyoshima, M; Nakajima, M				Toyoshima, M; Nakajima, M			Human heparanase - Purification, characterization, cloning, and expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; PLATELET HEPARANASE; TUMOR-METASTASIS; CELL HEPARANASE; SULFATE; DEGRADATION; GLYCOSAMINOGLYCANS; PROTEOGLYCANS; MELANOMA; ENZYMES	Heparan sulfate and heparan sulfate proteoglycans are present in the extracellular matrix as well as on the external cell surface. They bind various molecules such as growth factors and cytokines and modulate the biological functions of binding proteins. Heparan sulfate proteoglycans are also important structural components of the basement membrane. Heparanase is an endo-P-D-glucuronidase capable of cleaving heparan sulfate and has been implicated in inflammation and tumor angiogenesis and metastasis. In this study, we report the purification of a human heparanase from an SV40-transformed embryonic fibroblast cell line WI38/VA13 by four sequential column chromatographies. The activity was measured by high speed gel permeation chromatography of the degradation products of fluorescein isothiocyanate-labeled heparan sulfate. The enzyme was purified to homogeneity, yielding a peptide with an apparent molecular mass of 50 kDa when analyzed by SDS-polyacrylamide gel electrophoresis. Using the amino acid sequences of the N-terminal and internal heparanase peptides, a cDNA coding for human heparanase was cloned. NIH3T3 and COS-7 cells stably transfected with pBK-CMV expression vectors containing the heparanase cDNA showed high heparanase activities. The homology search revealed that no homologous protein had been reported.	Novartis Pharma KK, Takarazuka Res Inst, Discovery Res, Takarazuka, Hyogo 6658666, Japan	Novartis	Nakajima, M (corresponding author), Novartis Pharma KK, Takarazuka Res Inst, Discovery Res, 10-66 Miyuki Cho, Takarazuka, Hyogo 6658666, Japan.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bame KJ, 1997, J BIOL CHEM, V272, P2245; BERNFIELD M, 1993, DEVELOPMENT, P205; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Freeman C, 1997, BIOCHEM J, V325, P229, DOI 10.1042/bj3250229; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; Godavarti R, 1996, BIOCHEM BIOPH RES CO, V229, P770, DOI 10.1006/bbrc.1996.1879; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Ho GY, 1997, J BIOL CHEM, V272, P16838, DOI 10.1074/jbc.272.27.16838; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; Ihrcke NS, 1998, J CELL PHYSIOL, V175, P255, DOI 10.1002/(SICI)1097-4652(199806)175:3<255::AID-JCP3>3.0.CO;2-N; IRIMURA T, 1983, ANAL BIOCHEM, V130, P461, DOI 10.1016/0003-2697(83)90616-4; JIN L, 1990, INT J CANCER, V45, P1088, DOI 10.1002/ijc.2910450618; KEREN Z, 1989, CANCER RES, V49, P295; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kovalszky I, 1998, MOL CELL BIOCHEM, V183, P11, DOI 10.1023/A:1006898920637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Mollinedo F, 1997, BIOCHEM J, V327, P917, DOI 10.1042/bj3270917; Najjam S, 1997, CYTOKINE, V9, P1013, DOI 10.1006/cyto.1997.0246; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NAKAJIMA M, 1986, ANAL BIOCHEM, V157, P162, DOI 10.1016/0003-2697(86)90209-5; NAKAJIMA M, 1983, SCIENCE, V220, P661; ORKIN RW, 1982, J BIOL CHEM, V257, P5821; OTOTANI N, 1981, CARBOHYD RES, V88, P291, DOI 10.1016/S0008-6215(00)85542-1; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Schulz JG, 1998, EUR J NEUROSCI, V10, P2085, DOI 10.1046/j.1460-9568.1998.00220.x; Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7; Tumova S, 1997, J BIOL CHEM, V272, P9078; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361	36	278	301	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24153	24160		10.1074/jbc.274.34.24153	http://dx.doi.org/10.1074/jbc.274.34.24153			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446189	hybrid			2022-12-25	WOS:000082110900068
J	Zacharias, U; Norenberg, U; Rathjen, FG				Zacharias, U; Norenberg, U; Rathjen, FG			Functional interactions of the immunoglobulin superfamily member F11 are differentially regulated by the extracellular matrix proteins tenascin-R and tenascin-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; FIBRONECTIN TYPE-III; TYROSINE PHOSPHATASE-ZETA/BETA; CHONDROITIN SULFATE PROTEOGLYCANS; NEURITE OUTGROWTH; HETEROPHILIC INTERACTIONS; POLYSIALIC ACID; NR-CAM/BRAVO; BINDING-SITE; AXON GROWTH	The axon-associated protein F11 is a GPI-anchored member of the immunoglobulin superfamily that promotes axon outgrowth and that shows a complex binding pattern toward multiple cell surface and extracellular matrix proteins including tenascin-R and tenascin-C. In this study, we demonstrate that tenascin-R and tenascin-C differentially modulate cell adhesion and neurite outgrowth of tectal cells on F11, While soluble tenascin-R increases the number of attached cells and the percentage of cells with neurites on immobilized F11, tenascin-C stimulates cell attachment to a similar extent but decreases neurite outgrowth. The cellular receptor interacting with F11 has been previously identified as NrCAM; however, in the presence of tenascin-a or tenascin-C cell attachment and neurite extension are independent of NrCAM. Antibody perturbation experiments indicate that beta(1), integrins instead of NrCAM function as receptor for neurite outgrowth of tectal cells on an F11 TN-R complex. Cellular binding assays support the possibility that the interaction of F11 to NrCAM is blocked in the presence of tenascin-R and tenascin-C. Furthermore, a sandwich binding assay demonstrates that tenascin-R and tenascin-C are able to form larger molecular complexes and to link F11 polypeptides by forming a molecular bridge, These results suggest that the molecular interactions of F11 might be regulated by the presence of tenascin-R and tenascin-C.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Zacharias, U (corresponding author), MDC, Robert Rossle Str 10, D-13092 Berlin, Germany.	uzachar@mdc-berlin.de	Zacharias, Ute/AAS-4998-2020					Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; BRUMMENDORF T, 1989, NEURON, V2, P1351, DOI 10.1016/0896-6273(89)90073-1; BRUMMENDORF T, 1993, NEURON, V10, P711; Brummendorf T, 1996, CURR OPIN NEUROBIOL, V6, P584, DOI 10.1016/S0959-4388(96)80089-4; Buchstaller A, 1996, J CELL BIOL, V135, P1593, DOI 10.1083/jcb.135.6.1593; CHANG S, 1987, J CELL BIOL, V104, P355, DOI 10.1083/jcb.104.2.355; CHUNG CY, 1995, J BIOL CHEM, V270, P29012, DOI 10.1074/jbc.270.48.29012; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EHRISMANN RC, 1994, PERSPECT DEV NEUROBI, V2, P3; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; Faissner A, 1997, CELL TISSUE RES, V290, P331, DOI 10.1007/s004410050938; Fischer D, 1997, J CELL SCI, V110, P1513; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; Gotz B, 1996, J CELL BIOL, V132, P681, DOI 10.1083/jcb.132.4.681; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; KADMON G, 1995, EUR J NEUROSCI, V7, P993, DOI 10.1111/j.1460-9568.1995.tb01087.x; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kunz S, 1998, J CELL BIOL, V143, P1673, DOI 10.1083/jcb.143.6.1673; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LIU L, 1993, J NEUROSCI RES, V35, P327, DOI 10.1002/jnr.490350313; Meiners S, 1997, MOL CELL NEUROSCI, V10, P100, DOI 10.1006/mcne.1997.0643; MILEV P, 1995, J BIOL CHEM, V270, P24650, DOI 10.1074/jbc.270.42.24650; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; MORALES G, 1993, NEURON, V11, P1113, DOI 10.1016/0896-6273(93)90224-F; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; NORENBERG U, 1995, J CELL BIOL, V130, P473, DOI 10.1083/jcb.130.2.473; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Rader C, 1996, EMBO J, V15, P2056, DOI 10.1002/j.1460-2075.1996.tb00559.x; Rathjen F G, 1990, Acta Histochem Suppl, V38, P59; RATHJEN FG, 1987, CELL, V51, P841, DOI 10.1016/0092-8674(87)90107-3; RATHJEN FG, 1991, DEVELOPMENT, V113, P151; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; RUTISHAUSER U, 1991, TRENDS NEUROSCI, V14, P528, DOI 10.1016/0166-2236(91)90006-G; Sakurai T, 1997, J CELL BIOL, V136, P907, DOI 10.1083/jcb.136.4.907; Schumacher S, 1997, J CELL BIOL, V136, P895, DOI 10.1083/jcb.136.4.895; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Sonderegger P, 1997, CELL TISSUE RES, V290, P429, DOI 10.1007/s004410050950; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; SUTER DM, 1995, J CELL BIOL, V131, P1067, DOI 10.1083/jcb.131.4.1067; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tuvia S, 1997, P NATL ACAD SCI USA, V94, P12957, DOI 10.1073/pnas.94.24.12957; VARNUMFINNEY B, 1995, NEURON, V14, P1213, DOI 10.1016/0896-6273(95)90268-6; Volkmer H, 1996, J CELL BIOL, V135, P1059, DOI 10.1083/jcb.135.4.1059; Volkmer H, 1998, J CELL BIOL, V142, P1083, DOI 10.1083/jcb.142.4.1083; Weber P, 1996, FEBS LETT, V389, P304, DOI 10.1016/0014-5793(96)00609-6; WEHRLEHALLER B, 1993, J CELL SCI, V106, P597; WOLFF JM, 1987, EUR J BIOCHEM, V168, P551, DOI 10.1111/j.1432-1033.1987.tb13453.x; Xiao ZC, 1996, EUR J NEUROSCI, V8, P766, DOI 10.1111/j.1460-9568.1996.tb01262.x; Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423; Zhang ZQ, 1998, J NEUROSCI, V18, P6928; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	70	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24357	24365		10.1074/jbc.274.34.24357	http://dx.doi.org/10.1074/jbc.274.34.24357			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446214	hybrid			2022-12-25	WOS:000082110900093
J	Bronstein-Sitton, N; Wang, L; Cohen, L; Baniyash, M				Bronstein-Sitton, N; Wang, L; Cohen, L; Baniyash, M			Expression of the T cell antigen receptor zeta chain following activation is controlled at distinct checkpoints - Implications for cell surface receptor down-modulation and re-expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ENDOPLASMIC-RETICULUM; TRANSCRIPTIONAL REGULATION; CD3-DELTA GENE; CD3-ZETA CHAIN; LYMPHOCYTES-T; MICE LACKING; TCR-ALPHA; CARCINOMA; PROTEINS	The multisubunit T cell antigen receptor (TCR) is involved in antigen recognition and signal transduction, leading to T cell activation and rapid down-modulation of the cell surface expressed TCRs, Although the levels of TCR cell surface expression are pivotal to the efficiency and duration of the immune response, the molecular mechanisms controlling TCR down-modulation and re-expression upon activation, remain obscure. Here, we provide a biochemical characterization of the regulatory mechanisms governing TCR expression following long-term T cell activation. We focused primarily on the TCR zeta chain, as this is considered the limiting factor in TCR complex formation and transport to the cell surface. We found that following TCR-mediated activation zeta mRNA is up-regulated by a transcription-dependent mechanism. Concomitantly, zeta protein levels are modified according to a biphasic pattern: rapid degradation coinciding with TCR cell surface down-regulation, followed by a rebound to normal levels 24 h subsequent to T cell activation. Even though there are adequate levels of all the TCR subunits within the cell following 24 h of activation, TCR cell surface expression remained very low, provided the activating antibody is continuously present. Correlative with the latter, we detected a previously undescribed monomeric form of the zeta chain. This form could be indicative of adverse endoplasmic reticulum conditions affecting correct protein folding, dimerization, and TCR assembly, all critical for optimal receptor surface re-expression. Cumulatively, our results indicate that the levels of TCR expression following activation, are tightly controlled at several checkpoints.	Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Baniyash, M (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, POB 12272, IL-91120 Jerusalem, Israel.							AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CAPLAN S, 1995, IMMUNOL RES, V14, P98, DOI 10.1007/BF02918171; CAPLAN S, 1995, P NATL ACAD SCI USA, V92, P4768, DOI 10.1073/pnas.92.11.4768; DOro U, 1997, IMMUNITY, V7, P619, DOI 10.1016/S1074-7613(00)80383-0; DUBOIS PM, 1994, EUR J IMMUNOL, V24, P348, DOI 10.1002/eji.1830240212; FINKE JH, 1993, CANCER RES, V53, P5613; GEORGOPOULOS K, 1988, EMBO J, V7, P2401, DOI 10.1002/j.1460-2075.1988.tb03085.x; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; HSU VW, 1992, NEW BIOL, V4, P166; Huppa JB, 1997, J EXP MED, V186, P393, DOI 10.1084/jem.186.3.393; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; Lauritsen JPH, 1998, J IMMUNOL, V161, P260; LEE O, 1987, P NATL ACAD SCI USA, V84, P1374; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; Liossis SNC, 1998, J CLIN INVEST, V101, P1448, DOI 10.1172/JCI1457; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; Maurice MM, 1997, J IMMUNOL, V159, P2973; MIZOGUCHI H, 1992, SCIENCE, V258, P1795, DOI 10.1126/science.1465616; NAKAGOMI H, 1993, CANCER RES, V53, P5610; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; PAILLARD F, 1992, BIOCHEM BIOPH RES CO, V186, P603, DOI 10.1016/0006-291X(92)90789-N; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; Rabinowich H, 1996, INT J CANCER, V68, P276, DOI 10.1002/(SICI)1097-0215(19961104)68:3<276::AID-IJC2>3.3.CO;2-0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROZDZIAL MM, 1995, IMMUNITY, V3, P623, DOI 10.1016/1074-7613(95)90133-7; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; Shores EW, 1997, CURR OPIN IMMUNOL, V9, P380, DOI 10.1016/S0952-7915(97)80085-4; Stefanova I, 1996, J CLIN INVEST, V98, P1290, DOI 10.1172/JCI118915; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TARTOUR E, 1995, INT J CANCER, V63, P205, DOI 10.1002/ijc.2910630210; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WANG L, 1995, INT IMMUNOL, V7, P1627, DOI 10.1093/intimm/7.10.1627; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILKINSON MF, 1989, EUR J IMMUNOL, V19, P2355, DOI 10.1002/eji.1830191226; WILLEMS F, 1995, INT IMMUNOL, V7, P1593, DOI 10.1093/intimm/7.10.1593; Zier K, 1996, IMMUNOL TODAY, V17, P39, DOI 10.1016/0167-5699(96)80567-6	44	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23659	23665		10.1074/jbc.274.33.23659	http://dx.doi.org/10.1074/jbc.274.33.23659			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438549	hybrid			2022-12-25	WOS:000082012800099
J	Gallet, C; Rosa, JP; Habib, A; Lebret, M; Levy-Toldano, S; Maclouf, J				Gallet, C; Rosa, JP; Habib, A; Lebret, M; Levy-Toldano, S; Maclouf, J			Tyrosine phosphorylation of cortactin associated with Syk accompanies thromboxane analogue-induced platelet shape change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA(IIB)BETA(3); SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; RECEPTOR ISOFORMS; A(2) RECEPTOR; GROWTH-FACTOR; G-PROTEINS; ACTIVATION; CYTOSKELETON; KINASE	Thromboxane A(2) (TxA(2)) is a potent vasoconstrictor and platelet agonist. Pharmacological studies have defined two classes of thromboxane receptors (TPs) in human platelets; sites that bind the agonist 1S-(1,2(5Z),3-(1E,3S),4)-7- 3-(3-hydroxy-4-(4'-iodophenoxy)-1-butenyl)- 7-oxabicyclo-2.2.1-heptan-2-yl-5-heptenoic acid (I-BOP) with high affinity support platelet shape change, whereas low affinity sites that bind irreversibly the antagonist GR 32191 transduce platelet aggregation. As the mechanisms of signal transduction involved in platelet aggregation bean to be elucidated, few results concern those involved in platelet shape change, which is independent of the engagement of GPIIb/IIIa, To elucidate the respective role of the two classes of pharmacological binding sites of TPs in shape change, platelets were incubated with I-BOP at low concentrations or stimulated by I-BOP at high concentrations after pretreatment with GR 32191 or activated with low concentrations of 8-epi-prostaglandin F(2)alpha. Under these three conditions, there is a rapid stimulation of protein tyrosine phosphorylation of the 80/85-kDa doublet identified as the cytoskeletal protein cortactin, Tyrosine phosphorylation of cortactin is kinetically correlated with the occurrence of shape change, These biochemical and morphological events are both inhibited by SQ 29548, a TP antagonist, indicating the specificity of the signal. Since tyrosine kinase Syk was activated early during platelet activation, we examined the possibility that cortactin is a potential substrate of Syk in TxA(2)-induced platelet shape change. p72 Syk phosphorylation and kinase activity took place during the period when platelets were changing shape upon low concentrations of I-BOP stimulation, Furthermore, cortactin was associated with Syk, and this association increases along with the level of phosphorylation. These data suggest a novel pathway for a Gr protein coupled TxA(2) high affinity receptor to the protein-tyrosine kinase Syk, which is associated with cortactin in the very early steps of platelet activation.	Hop Lariboisiere, U INSERM 348, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Levy-Toldano, S (corresponding author), Hop Lariboisiere, U INSERM 348, 8 Rue Guy Patin, F-75475 Paris 10, France.		Habib, Aida/H-8647-2019; ROSA, JEAN-PHILIPPE/B-6245-2018	Habib, Aida/0000-0001-6027-0043; ROSA, JEAN-PHILIPPE/0000-0001-7342-0389				ALI S, 1993, J BIOL CHEM, V268, P17397; Allan CJ, 1996, J PHARMACOL EXP THER, V277, P1132; BALDASSARE JJ, 1993, BIOCHEM J, V291, P235, DOI 10.1042/bj2910235; CLARK EA, 1994, J BIOL CHEM, V269, P28859; DORN GW, 1991, AM J PHYSIOL, V260, pH327, DOI 10.1152/ajpheart.1991.260.2.H327; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; FOX JEB, 1993, J BIOL CHEM, V268, P25973; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Habib A, 1999, J BIOL CHEM, V274, P2645, DOI 10.1074/jbc.274.5.2645; HALUSHKA PV, 1995, J LIPID MEDIAT CELL, V12, P361, DOI 10.1016/0929-7855(95)00023-J; HANASAKI K, 1990, BIOCHEM PHARMACOL, V40, P2535, DOI 10.1016/0006-2952(90)90096-4; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; LEVYTOLEDANO S, 1995, THROMB HAEMOSTASIS, V73, P857; MAA MC, 1992, ONCOGENE, V7, P2429; Maruyama S, 1996, J BIOL CHEM, V271, P6631, DOI 10.1074/jbc.271.12.6631; Minuz P, 1998, ARTERIOSCL THROM VAS, V18, P1248, DOI 10.1161/01.ATV.18.8.1248; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; NEGISHI M, 1993, J BIOL CHEM, V268, P26067; NEGRESCU EV, 1995, J BIOL CHEM, V270, P1057, DOI 10.1074/jbc.270.3.1057; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; OZAWA K, 1995, EXP CELL RES, V221, P197, DOI 10.1006/excr.1995.1367; Pratico D, 1996, J BIOL CHEM, V271, P14916, DOI 10.1074/jbc.271.25.14916; Rosa JP, 1997, BLOOD, V89, P4385, DOI 10.1182/blood.V89.12.4385; TAKAHARA K, 1990, J BIOL CHEM, V265, P6836; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; USHIKUBI F, 1993, J EXP MED, V178, P1825, DOI 10.1084/jem.178.5.1825; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YIN K, 1994, J PHARMACOL EXP THER, V270, P1192; Zoller KE, 1997, J IMMUNOL, V158, P1650	39	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23610	23616		10.1074/jbc.274.33.23610	http://dx.doi.org/10.1074/jbc.274.33.23610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438543	hybrid			2022-12-25	WOS:000082012800093
J	Silvente-Poirot, S; Escrieut, C; Gales, C; Fehrentz, JA; Escherich, A; Wank, SA; Martinez, J; Moroder, L; Maigret, B; Bouisson, M; Vaysse, N; Fourmy, D				Silvente-Poirot, S; Escrieut, C; Gales, C; Fehrentz, JA; Escherich, A; Wank, SA; Martinez, J; Moroder, L; Maigret, B; Bouisson, M; Vaysse, N; Fourmy, D			Evidence for a direct interaction between the penultimate aspartic acid of cholecystokinin and histidine 207, located in the second extracellular loop of the cholecystokinin B receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; FUNCTIONAL EXPRESSION; ANGIOTENSIN-II; MUTANT CYCLES; A RECEPTOR; ANTAGONISTS; BINDING; SELECTIVITY; ACTIVATION; RESIDUE	Recently, we reported that the mutation of His(207) to Phe located in the second extracellular loop of the cholecystokinin B receptor strongly affected cholecystokinin (CCK) binding (Silvente-Poirot, S., Escrieut, C., and Wank, S. A. (1998) Mol. Pharmacol. 54, 364-371), To characterize the functional group in CCK that interacts with His(207), we first substituted His(207) to Ala. This mutation decreased the affinity and the potency of CCK to produce total inositol phosphates 302-fold and 456-fold without affecting the expression of the mutant receptor. The screening of L-alanine-modified CCK peptides to bind and activate the wild type and mutant receptors allowed the identification of the interaction of the C-terminal Asp(8) of CCK with His(207). The H207A-CCKBR mutant, unlike the wild type receptor, was insensitive to substitution of Asp(8) of CCK to other amino acid residues. This interaction was further confirmed by mutating His(207) to Asp, The affinity of CCK for the H207D-CCKBR mutant was 100-fold lower than for the H207ACCKBR mutant, consistent with an electrostatic repulsion between the negative charges of the two interacting aspartic acids. Peptides with neutral amino acids in position eight of CCK reversed this effect and displayed a gain of affinity for the H207D mutant compared with CCK. To date, this is the first report concerning the identification of a direct contact point between the CCKB receptor and CCK.	CHU Rangueil, INSERM U151, Inst Louis Bugnart, F-31403 Toulouse, France; Univ Nancy, Chim Theor Lab, F-54506 Vandoeuvre Nancy, France; NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; Max Planck Inst Biochem, D-82143 Martinsried, Germany	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Max Planck Society	Silvente-Poirot, S (corresponding author), CHU Rangueil, INSERM U151, Inst Louis Bugnart, Bat L3, F-31403 Toulouse, France.		Fourmy, Daniel/AAE-3703-2019; Poirot, Sandrine/D-5448-2017; Martinez, Jean/R-9421-2019	Fourmy, Daniel/0000-0001-9910-4827; Martinez, Jean/0000-0002-9267-4621; Silvente-Poirot, Sandrine/0000-0003-2245-9069; Moroder, Luis/0000-0001-9570-5713; GALES, Celine/0000-0002-4938-1583				Betancur C, 1997, TRENDS PHARMACOL SCI, V18, P372, DOI 10.1016/S0165-6147(97)01109-7; Bischoff KM, 1997, PROTEIN SCI, V6, P156; Bragg PD, 1998, BBA-BIOENERGETICS, V1365, P98, DOI 10.1016/S0005-2728(98)00049-8; BROCCHIERI L, 1994, P NATL ACAD SCI USA, V91, P9297, DOI 10.1073/pnas.91.20.9297; CHANG RSL, 1989, MOL PHARMACOL, V35, P803; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; FONG TM, 1993, NATURE, V362, P350; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; Gigoux V, 1998, J BIOL CHEM, V273, P14380, DOI 10.1074/jbc.273.23.14380; HEFFORD MA, 1989, BIOCHIM BIOPHYS ACTA, V998, P267, DOI 10.1016/0167-4838(89)90283-5; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Horwell DC, 1996, BIOORGAN MED CHEM, V4, P1573, DOI 10.1016/0968-0896(95)00190-5; IVERSEN LL, 1991, BIOCHEM SOC T, V19, P913, DOI 10.1042/bst0190913; JOSEPH MP, 1995, J PROTEIN CHEM, V14, P381, DOI 10.1007/BF01886795; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; Lu DS, 1998, MOL ENDOCRINOL, V12, P592, DOI 10.1210/me.12.4.592; MAGOUS R, 1983, REGUL PEPTIDES, V5, P327, DOI 10.1016/0167-0115(83)90290-2; MENARD R, 1991, BIOCHEMISTRY-US, V30, P5531, DOI 10.1021/bi00236a028; MORODER L, 1981, H-S Z PHYSIOL CHEM, V362, P929, DOI 10.1515/bchm2.1981.362.2.929; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; Pritchard M C, 1997, Expert Opin Investig Drugs, V6, P349, DOI 10.1517/13543784.6.4.349; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; SCHIANTARELLI P, 1993, PHARMACOL RES, V28, P1, DOI 10.1006/phrs.1993.1104; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Silvente-Poirot S, 1996, J BIOL CHEM, V271, P14698, DOI 10.1074/jbc.271.25.14698; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Wank SA, 1998, AM J PHYSIOL-GASTR L, V274, pG607, DOI 10.1152/ajpgi.1998.274.4.G607; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; WOODRUFF GN, 1991, ANNU REV PHARMACOL, V31, P469	39	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23191	23197		10.1074/jbc.274.33.23191	http://dx.doi.org/10.1074/jbc.274.33.23191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438490	hybrid			2022-12-25	WOS:000082012800040
J	Tortola, S; Marcuello, E; Risques, RA; Gonzalez, S; Aiza, G; Capella, G; Peinado, MA				Tortola, S; Marcuello, E; Risques, RA; Gonzalez, S; Aiza, G; Capella, G; Peinado, MA			Overall deregulation in gene expression as a novel indicator of tumor aggressiveness in colorectal cancer	ONCOGENE			English	Article						RNA differential display; genetic instability; prognostic assessment	ARBITRARILY PRIMED-PCR; DNA METHYLATION; RNA; INSTABILITY; COLON; HYBRIDIZATION; CARCINOMAS; SEQUENCES; MECHANISM; CELLS	Malignant transformation of the cell is accompanied and characterized by disruption of genetic material and aberrant expression of multiple genes. Systematic analysis of differential gene expression in human tumor samples may provide an estimate of the degree of genetic and epigenetic deregulation in neoplastic cells. We have assessed, by means of a RNA differential display technique, the overall gene expression deregulation in a prospectively collected series of 68 human colorectal carcinomas. An index of differential expression has been calculated for each case. A similar proportion of the displayed sequences (23%) was under- and over-represented in the tumor in respect of the normal tissue. An increased variation in the expression profile was observed in advanced Dukes' stages (P<0.02) and correlated with lymph node invasion (P<0.05). Furthermore, a diminished overall survival was associated to increased rates of deregulation (Log-rank, P<0.02) and especially down-regulation (P<0.001), When Cox multivariate analysis was performed in front of Dukes' stage, both indexes of differential expression were independent indicators of a worse outcome (P=0.05 and P<0.01 respectively). We conclude that estimation of the fraction of differentially displayed tags by RNA fingerprinting ma!: have relevant applications in the prognostic assessment of colorectal cancer.	Hosp Duran & Reynals, Dept Canc & Metastasis, Inst Recerca Oncol, Lhospitalet De Llobregat 08025, Barcelona, Spain; Hosp Santa Creu & St Pau, Serv Oncol, Barcelona, Spain; Hosp Santa Creu & St Pau, Lab Invest Gastrointestinal, Barcelona, Spain; Inst Catala Oncol, Lhospitalet De Llobregat 08907, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau; Catalan Institute of Oncology	Peinado, MA (corresponding author), Hosp Duran & Reynals, Dept Canc & Metastasis, Inst Recerca Oncol, Autovia Castelldefels Km 2,7, Lhospitalet De Llobregat 08025, Barcelona, Spain.		Peinado, Miguel A./A-5591-2008; Capella, Gabriel/I-1879-2015; Gonzalez, Sara/D-8427-2019	Peinado, Miguel A./0000-0002-4090-793X; Capella, Gabriel/0000-0002-4669-7320; Gonzalez, Sara/0000-0002-7765-1325				Arribas R, 1997, J CLIN ONCOL, V15, P3230, DOI 10.1200/JCO.1997.15.10.3230; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; DELATTRE O, 1989, LANCET, V2, P353; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KIM HG, 1994, AM J PATHOL, V145, P148; KOKAL W, 1986, JAMA-J AM MED ASSOC, V255, P3123, DOI 10.1001/jama.255.22.3123; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Ricote M, 1997, MUTAT RES-FUND MOL M, V374, P153, DOI 10.1016/S0027-5107(97)00002-X; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Scicchitano David A., 1997, Environmental Health Perspectives, V105, P145, DOI 10.2307/3433403; THEIN SL, 1987, BRIT J CANCER, V55, P353, DOI 10.1038/bjc.1987.71; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS JH, 1995, P NATL ACAD SCI USA, V92, P480, DOI 10.1073/pnas.92.2.480; Tortola S, 1998, LAB INVEST, V78, P309; Versteeg R, 1997, AM J HUM GENET, V60, P751; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965	25	5	5	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4383	4387		10.1038/sj.onc.1202757	http://dx.doi.org/10.1038/sj.onc.1202757			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439046				2022-12-25	WOS:000081732700011
J	Gibbons, DL; MacDonald, D; McCarthy, KP; Cleary, HJ; Plumb, M; Wright, EG; Greaves, MF				Gibbons, DL; MacDonald, D; McCarthy, KP; Cleary, HJ; Plumb, M; Wright, EG; Greaves, MF			An E mu-BCL-2 transgene facilitates leukaemogenesis by ionizing radiation	ONCOGENE			English	Article						apoptosis; leukaemogenesis; BCL-2; irradiation	IMMUNOGLOBULIN HEAVY-CHAIN; MYELOID-LEUKEMIA; CELL-SURVIVAL; PROGENITOR CELLS; PRE-B; MICE; GENE; BCL-2; P53; IRRADIATION	Clonogenic murine B cell precursors are normally ultrasensiti ve to apoptosis following genotoxic exposure in vitro but can be protected by expression of an E mu-BCL-2 transgene. Such exposures are likely to be mutagenic. This in turn suggests that a level of in vivo genotoxic exposure that usually has minimal pathological consequences might become leukaemogenic when damaged cells fail to abort by apoptosis. If this were to be the case, then the cell type that becomes leukaemic and the chromosomal/molecular changes that occur would also be of considerable interest. We tested this possibility by exposing E mu-BCL-2 and wild-type mice of differing ages to a single dose of X-irradiation of 1-4 Gy, Young (similar to 4-6 weeks) transgenic mice developed leukaemia at a high rate following exposure to 2 Gy but adult mice (4-6 months) did not. Exposure to 4 Gy produced leukaemia in both young and adult transgenic mice but at a higher frequency in the former. Leukaemic cell populations showed clonal rearrangements of the IGH gene but in most cases analysed had immunophenotypic features of an early B lympho-myeloid progenitor population which has not previously been recorded in radiation leukaemogenesis. Molecular cytogenetic analysis of leukaemic cells by banded karyotype and FISH revealed a consistent double abnormality: trisomy 15 plus an interstitial deletion of chromosome 4 that was confirmed by LOH analysis.	Inst Canc Res, Leukaemia Res Fund Ctr, Chester Beatty Labs, London SW3 6JB, England; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England; Cheltenham Gen Hosp, Dept Histol, Cheltenham GL53 7AN, Glos, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital	Greaves, MF (corresponding author), Inst Canc Res, Leukaemia Res Fund Ctr, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.			Gibbons, Deena/0000-0002-7953-3576				Alexander BJ, 1995, LEUKEMIA, V9, P2009; Boice J. D., 1996, LEUKEMIA, P195; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Doll R, 1997, BRIT J RADIOL, V70, P130, DOI 10.1259/bjr.70.830.9135438; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fennelly J, 1997, LEUKEMIA, V11, P807, DOI 10.1038/sj.leu.2400674; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORD AM, 1988, EMBO J, V7, P2393, DOI 10.1002/j.1460-2075.1988.tb03084.x; FORD AM, 1992, P NATL ACAD SCI USA, V89, P3424, DOI 10.1073/pnas.89.8.3424; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GRIFFITHS SD, 1994, J EXP MED, V179, P1789, DOI 10.1084/jem.179.6.1789; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; GRIFFITHS SD, 1994, INT J RADIAT BIOL, V66, P197, DOI 10.1080/09553009414551101; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JI WZ, 1995, CANCER RES, V55, P2876; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Koyama M, 1997, INT IMMUNOL, V9, P1767, DOI 10.1093/intimm/9.11.1767; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIU YF, 1994, P NATL ACAD SCI USA, V91, P8910, DOI 10.1073/pnas.91.19.8910; MAJOR IR, 1978, NATURE, V272, P455, DOI 10.1038/272455a0; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; Nishii K, 1998, CELL DEATH DIFFER, V5, P77, DOI 10.1038/sj.cdd.4400317; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; OSMOND DG, 1993, IMMUNOL TODAY, V14, P34, DOI 10.1016/0167-5699(93)90322-C; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PURDIE CA, 1994, ONCOGENE, V9, P603; Santos J, 1996, ONCOGENE, V12, P669; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; UPTON AC, 1958, CANCER RES, V18, P842; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WIENER F, 1978, NATURE, V275, P658, DOI 10.1038/275658a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhuang SM, 1998, ONCOGENE, V16, P803, DOI 10.1038/sj.onc.1201600	40	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	1999	18	26					3870	3877		10.1038/sj.onc.1202721	http://dx.doi.org/10.1038/sj.onc.1202721			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445850				2022-12-25	WOS:000081171700008
J	Babu, BR; Frey, C; Griffith, OW				Babu, BR; Frey, C; Griffith, OW			L-arginine binding to nitric-oxide synthase - The role of H-bonds to the nonreactive guanidinium nitrogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-L-ARGININE; SELECTIVE-INHIBITION; L-THIOCITRULLINE; HEME-BINDING; L-CANAVANINE; ENDOTOXEMIC RATS; ESCHERICHIA-COLI; NERVOUS-SYSTEM; NO SYNTHASE; SUBSTRATE	Nitric-oxide synthase (NOS) catalyzes the oxidation of L-arginine to nitric oxide and L-citrulline. Because overproduction of nitric oxide causes tissue damage in neurological, inflammatory, and autoimmune disorders, design of NOS inhibitors has received much attention. Most inhibitors described to date include a guanidine-like structural motif and interact with the guanidinium region of the L-argnine-binding site. We report here studies with L-arginine analogs having one or both terminal guanidinium nitrogens replaced by functionalities that preserve some, but not all, of the molecular interactions possible for the -NH2, =NH, or =NH2+ groups of L-arginine, Replacement groups include -NH-alkyl, -alkyl, =O, and =S, Binding of L-canavanine, an analog unable to form hydrogen bonds involving a N-5-proton, was also examined. From our results and previous work, we infer the orientation of these compounds in the L-arginine-binding site and use IC50 or K-i values and optical difference spectra to quantitate their affinity relative to L-arginine, We find that the non-reactive guanidinium nitrogen of L-arginine binds in a pocket that is relatively intolerant of changes in the size or hydrogen bonding properties of the group bound. The individual H-bonds involved are, however, weaker than expected (<2 versus 3-6 kcal), These findings elucidate substrate binding forces in the NOS active site and identify an important constraint on NOS inhibitor design.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Griffith, OW (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048423] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48423] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; Babu BR, 1998, CURR OPIN CHEM BIOL, V2, P491, DOI 10.1016/S1367-5931(98)80125-7; Babu BR, 1998, J BIOL CHEM, V273, P8882, DOI 10.1074/jbc.273.15.8882; Berka V, 1996, J BIOL CHEM, V271, P33293, DOI 10.1074/jbc.271.52.33293; BOYAR A, 1982, J AM CHEM SOC, V104, P1995, DOI 10.1021/ja00371a033; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Clancy RM, 1998, ARTHRITIS RHEUM-US, V41, P1141, DOI 10.1002/1529-0131(199807)41:7<1141::AID-ART2>3.0.CO;2-S; Fan BC, 1997, BIOCHEMISTRY-US, V36, P12660, DOI 10.1021/bi9715369; FASEHUN O, 1990, FASEB Journal, V4, pA309; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Fishman D, 1997, CRIT CARE MED, V25, P469, DOI 10.1097/00003246-199703000-00016; FREY C, 1994, J BIOL CHEM, V269, P26083; FUKUTO JM, 1995, ANNU REV PHARMACOL, V35, P165, DOI 10.1146/annurev.pharmtox.35.1.165; FURFINE ES, 1994, J BIOL CHEM, V269, P26677; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; GOUREAU O, 1995, J IMMUNOL, V154, P6518; Grant SK, 1998, BIOCHEMISTRY-US, V37, P4174, DOI 10.1021/bi972481d; Griffith O. W., 1996, METHODS NITRIC OXIDE, P187; Griffith OW, 1997, ADV ENZYME REGUL, V37, P171, DOI 10.1016/S0065-2571(96)00008-8; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Guslandi M, 1998, EUR J CLIN INVEST, V28, P904; HIBBS JB, 1987, J IMMUNOL, V138, P550; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; KILBOURN RG, 1992, J NATL CANCER I, V84, P827, DOI 10.1093/jnci/84.11.827; Lassen LH, 1997, LANCET, V349, P401, DOI 10.1016/S0140-6736(97)80021-9; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; NARAYANAN K, 1995, J BIOL CHEM, V270, P11103, DOI 10.1074/jbc.270.19.11103; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; Neuberger A, 1943, BIOCHEM J, V37, P515, DOI 10.1042/bj0370515; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; OLKEN NM, 1994, BIOCHEMISTRY-US, V33, P14784, DOI 10.1021/bi00253a017; Pauling L, 1960, NATURE CHEM BOND, P269; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SALERNO JC, 1995, J BIOL CHEM, V270, P27423, DOI 10.1074/jbc.270.46.27423; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; SCANNELL JP, 1972, J ANTIBIOT, V25, P179, DOI 10.7164/antibiotics.25.179; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; SESSA WC, 1994, J VASC RES, V31, P131, DOI 10.1159/000159039; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; STEFANOVICRACIC M, 1993, ARTHRITIS RHEUM, V36, P1036, DOI 10.1002/art.1780360803; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Tierney DL, 1998, J AM CHEM SOC, V120, P2983, DOI 10.1021/ja973648t; UMANS JG, 1995, ANNU REV PHYSIOL, V57, P771, DOI 10.1146/annurev.ph.57.030195.004011; UMANS JG, 1992, EUR J PHARMACOL, V210, P343, DOI 10.1016/0014-2999(92)90425-4; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Zhang HQ, 1997, J MED CHEM, V40, P3869, DOI 10.1021/jm970550g; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	59	45	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25218	25226		10.1074/jbc.274.36.25218	http://dx.doi.org/10.1074/jbc.274.36.25218			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464242	hybrid			2022-12-25	WOS:000082554200007
J	Gallegos, MT; Cannon, WV; Buck, M				Gallegos, MT; Cannon, WV; Buck, M			Functions of the sigma(54) region I in Trans and implications for transcription activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSED PROMOTER COMPLEXES; BINDING-PROTEIN NTRC; RNA-POLYMERASE; ESCHERICHIA-COLI; FACTOR SIGMA-54; ATPASE ACTIVITY; DNA; IDENTIFICATION; DOMAINS; REQUIREMENT	Control of transcription frequently involves the direct interaction of activators with RNA polymerase, In bacteria, the formation of stable open promoter complexes by the sigma(54) RNA polymerase is critically dependent on sigma(54) amino Region I sequences. Their presence correlates with activator dependence, and removal allows the holoenzyme to engage productively with melted DNA independently of the activator. Using purified Region I sequences and holoenzymes containing full-length or Region I-deleted sigma(54), we have explored the involvement of Region I in transcription activation, Results show that Region I in trans inhibits a reversible conformational change in the holoenzyme believed to be polymerase isomerization. Evidence is presented indicating that the holoenzyme land not the promoter DNA per se) is one interacting target used by Region I in preventing polymerase isomerization, Activator overcomes this inhibition in a reaction requiring nucleotide hydrolysis. Region I in trans is able to inhibit activated transcription by the holoenzyme containing full-length sigma(54). Inhibition appeared to be noncompetitive with respect to the activator, suggesting that a direct activator interaction occurs with parts of the holoenzyme outside Region I. Stabilization of isomerized holoenzyme bound to melted DNA by Region I in trans occurs largely independently of the initiating nucleotide, suggesting a role for Region I in maintaining the open complex.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England	Imperial College London	Buck, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Sir Alexander Fleming Bldg,Imperial Coll Rd, London SW7 2AZ, England.	m.buck@ic.ac.uk	Gallegos, María-Trinidad M.T./K-6501-2014	Gallegos, María-Trinidad M.T./0000-0001-7633-8807				ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; Buckle M, 1999, J MOL BIOL, V285, P955, DOI 10.1006/jmbi.1998.2391; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; CANNON W, 1995, NUCLEIC ACIDS RES, V23, P351, DOI 10.1093/nar/23.3.351; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; Cannon W, 1999, NUCLEIC ACIDS RES, V27, P2478, DOI 10.1093/nar/27.12.2478; CANNON W, 1994, MOL MICROBIOL, V11, P227, DOI 10.1111/j.1365-2958.1994.tb00303.x; Cannon WV, 1997, P NATL ACAD SCI USA, V94, P5006, DOI 10.1073/pnas.94.10.5006; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Gallegos MT, 1999, J MOL BIOL, V288, P539, DOI 10.1006/jmbi.1999.2704; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HSIEH ML, 1994, J MOL BIOL, V239, P15, DOI 10.1006/jmbi.1994.1347; HSIEH ML, 1994, J BIOL CHEM, V269, P373; Jovanovic G, 1996, J BACTERIOL, V178, P1936, DOI 10.1128/jb.178.7.1936-1945.1996; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MORRIS L, 1994, J BIOL CHEM, V269, P11563; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; Syed A, 1998, J BACTERIOL, V180, P5619, DOI 10.1128/JB.180.21.5619-5625.1998; Wang JT, 1996, J BIOL CHEM, V271, P32707, DOI 10.1074/jbc.271.51.32707; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; Wang JT, 1997, P NATL ACAD SCI USA, V94, P9538, DOI 10.1073/pnas.94.18.9538; Wang L, 1998, J BACTERIOL, V180, P5626, DOI 10.1128/JB.180.21.5626-5631.1998; Wang XY, 1997, NUCLEIC ACIDS RES, V25, P3478, DOI 10.1093/nar/25.17.3478; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120	35	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25285	25290		10.1074/jbc.274.36.25285	http://dx.doi.org/10.1074/jbc.274.36.25285			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464252	hybrid			2022-12-25	WOS:000082554200017
J	Ndubuisi, MI; Guo, GG; Fried, VA; Etlinger, JD; Sehgal, PB				Ndubuisi, MI; Guo, GG; Fried, VA; Etlinger, JD; Sehgal, PB			Cellular physiology of STAT3: Where's the cytoplasmic monomer?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; PHASE RESPONSE FACTOR; DEPENDENT NUCLEAR IMPORT; SIGNAL TRANSDUCER GP130; ENDOPLASMIC-RETICULUM; DNA-BINDING; JAK-STAT; COMPLEX-FORMATION; GENE-EXPRESSION; INTERLEUKIN-6	In the standard model of cytokine-induced signal transducer and activator of transcription (STAT) protein family signaling to the cell nucleus, it is assumed that STATE is recruited to the cytoplasmic side of the cell surface receptor complex from within a cytosolic monomer pool. By using Superose-6 gel-filtration chromatography, we have discovered that there is little monomeric STATE (91 kDa) in the cytosol of liver cells (human hepatoma Hep3B cell line and rat liver). The bulb: of STAT3 (and STAT1, STAT5a, and -b) was present in the cytosol as high molecular mass complexes in two broad distributions in the size range 200-400 kDa ("statosome I") and 1-2 MDa ("statosome II"). Upon treatment of Hep3B cells with interleukin-6 (IL-6) for 30 min (i) cytosolic tyrosine-phosphorylated STAT3 was found to be in complexes of size ranging from 200-400 kDa to 1-2 MDa; (ii) a small pool of monomeric STATE and tyrosine-phosphorylated STATE eluting at 80-100 kDa was observed, and (iii) most of the cytoplasmic DNA-binding competent STAT3 (the so-called SIE-A "homodimer") coeluted with catalase at 230 kDa. In order to identify the protein components of the 200-400-kDa statosome I cytosolic complexes, we used the novel technique of antibody-subtracted differential protein display using anti-STAT3 antibody. Eight polypeptides in the size range from 20 to 114 kDa co-shifted with STATE; three of these (p60, p20a, and p20b) were co-shifted in an IL-6-dependent manner. In-gel tryptic fragmentation and mass spectroscopy identified the major IL-6-dependent STAT3-co-shifted p60 protein as the chaperone GRP58/ER-60/ERp57. Taken together, these data (i) emphasize the absence of a detectable STAT3 monomer pool in the cytosol of cytokine-free liver cells as posited by the standard model, and (ii) suggest an alternative model for STAT signaling in which STAT3 proteins function in the cytoplasm as heteromeric complexes with accessory scaffolding proteins, including the chaperone GRP58.	New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Sehgal, PB (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Rm 201,Basic Sci Bldg, Valhalla, NY 10595 USA.							ALTIERI F, 1993, BIOCHEM BIOPH RES CO, V194, P992, DOI 10.1006/bbrc.1993.1919; [Anonymous], 1989, Ann N Y Acad Sci, V557, P1; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; Brown RT, 1995, J BIOL CHEM, V270, P31129, DOI 10.1074/jbc.270.52.31129; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DonellaDeana A, 1996, EUR J BIOCHEM, V235, P18, DOI 10.1111/j.1432-1033.1996.00018.x; Elliott JG, 1998, EUR J BIOCHEM, V252, P372, DOI 10.1046/j.1432-1327.1998.2520372.x; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GUO GG, 1994, J BIOL CHEM, V269, P12399; GUO GG, 1997, THESIS STATE U NEW Y; Hallek M, 1997, EXP HEMATOL, V25, P1367; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; JOHNSON E, 1992, J BIOL CHEM, V267, P14412; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1981, J CELL PHYSIOL, V106, P119, DOI 10.1002/jcp.1041060113; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LEWIS MJ, 1986, ARCH BIOCHEM BIOPHYS, V245, P389, DOI 10.1016/0003-9861(86)90230-4; Li X S, 1992, Biochemistry, V31, P11964; Li Y, 1996, EXP HEMATOL, V24, P94; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACKIEWICZ A, 1995, ANN NY ACAD SCI, V762, P1; MACKIEWICZ A, 1998, MOL ASPECTS CANC ITS; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MAZZARELLA RA, 1994, ARCH BIOCHEM BIOPHYS, V308, P454, DOI 10.1006/abbi.1994.1064; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; PLANT PW, 1983, J BIOL CHEM, V258, P5355; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; Rayanade RJ, 1997, J BIOL CHEM, V272, P4659, DOI 10.1074/jbc.272.8.4659; Rayanade RJ, 1998, J IMMUNOL, V161, P325; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; SCHIRG P, 1992, DESALINATION, V89, P89, DOI 10.1016/0011-9164(92)80154-2; Schumann RR, 1996, MOL CELL BIOL, V16, P3490; SEHGAL PB, 1994, ONCOGENE, V8, P3417; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stancato LF, 1996, J BIOL CHEM, V271, P4134; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stephanou A, 1998, BIOCHEM J, V330, P189, DOI 10.1042/bj3300189; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Symes A, 1997, J BIOL CHEM, V272, P9648; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; Urade R, 1997, J BIOCHEM-TOKYO, V122, P834; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WANG L, 1995, J BIOL CHEM, V270, P23159, DOI 10.1074/jbc.270.39.23159; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	79	143	144	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25499	25509		10.1074/jbc.274.36.25499	http://dx.doi.org/10.1074/jbc.274.36.25499			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464281	hybrid			2022-12-25	WOS:000082554200045
J	Velling, T; Kusche-Gullberg, M; Sejersen, T; Gullberg, D				Velling, T; Kusche-Gullberg, M; Sejersen, T; Gullberg, D			cDNA cloning and chromosomal localization of human alpha(11) integrin - A collagen-binding, I domain-containing, beta(1-)associated integrin alpha-chain present in muscle tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROPELLER DOMAIN; EXTRACELLULAR-MATRIX; CELL-ADHESION; A-DOMAIN; ALPHA(2)BETA(1) INTEGRIN; MUSCULAR-DYSTROPHY; MURINE DEVELOPMENT; MOLECULAR-CLONING; LAMININ; SUBUNIT	We previously identified a novel integrin ru-chain in human fetal muscle cells (Gullberg, D,, Veiling, T,, Sjoberg, G., and Sejersen, T, (1995) Dev, Dyn. 204, 57-65), We have now isolated the full-length cDNA for this integrin subunit, alpha(11). The open reading frame of the cDNA encodes a precursor of 1188 amino acids. The predicted mature protein of 1166 amino acids contains seven conserved FG-GAP repeats, an I domain with a metal ion-dependent adhesion site motif, a short transmembrane region, and a unique cytoplasmic domain of 24 amino acids containing the sequence GFFRS, alpha(11), like other I domain integrins, lacks a dibasic cleavage sits for generation of a heavy chain and a light chain, and it contains three potential divalent cation binding sites in repeats 5-7, The presence of 22 inserted amino acids in the extracellular stalk portion (amino acids 804-826) distinguishes the alpha(11) integrin sequence from other integrin alpha-chains, Amino acid sequence comparisons reveal the highest identity of 42% with the alpha(10) integrin chain. Immunoprecipitation with antibodies to alpha(11) integrin captures a 145-kDa protein distinctly larger than the 140-kDa alpha(2) integrin chain when analyzed by SDS-polyacrylamide gel electrophoresis under nonreducing conditions. Fluorescence in situ hybridization maps the integrin alpha(11) gene to chromosome 15q23, in the vicinity of an identified locus for Bardet-Biedl syndrome. Based on Northern blotting, integrin alpha(11) mRNA levels are high in the adult human uterus and in the heart and intermediate in skeletal muscle and some other tissues tested. During in vitro myogenic differentiation, alpha(11) mRNA and protein are up-regulated. Studies of ligand binding properties show that alpha(11)beta(1) binds collagen type I-Sepharose, and cultured muscle cells localize alpha(11)beta(1) into focal contacts on collagen type I. Future studies will reveal the importance of alpha(11)beta(1) for muscle development and integrity in adult muscle and other tissues.	Uppsala Univ, BMC, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Univ Uppsala, BMC, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Karolinska Inst, Dept Cell & Mol Genet, CMB, S-17177 Stockholm, Sweden	Uppsala University; Uppsala University; Karolinska Institutet	Gullberg, D (corresponding author), Uppsala Univ, BMC, Dept Cell & Mol Biol, Box 596, S-75124 Uppsala, Sweden.		Gullberg, Donald/H-2495-2016; Velling, Teet/G-6129-2016; Kusche-Gullberg, Marion/P-4466-2016	Gullberg, Donald/0000-0002-7245-4437; Kusche-Gullberg, Marion/0000-0002-5636-1695; Sejersen, Thomas/0000-0001-5961-7097				ADAMS JC, 1993, DEVELOPMENT, V117, P1183; AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; Bloor JW, 1998, GENETICS, V148, P1127; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; Bruford EA, 1997, GENOMICS, V41, P93, DOI 10.1006/geno.1997.4613; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; FOGERTY FJ, 1994, DEVELOPMENT, V120, P1747; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; Gardner H, 1999, J CELL SCI, V112, P263; Genini M, 1996, INT J CANCER, V66, P571; GOODMAN SL, 1991, J CELL BIOL, V113, P931, DOI 10.1083/jcb.113.4.931; GULLBERG D, 1994, DEV DYNAM, V199, P116, DOI 10.1002/aja.1001990205; GULLBERG D, 1995, DEV DYNAM, V204, P57, DOI 10.1002/aja.1002040108; GULLBERG D, 1990, EXP CELL RES, V190, P254, DOI 10.1016/0014-4827(90)90194-F; GULLBERG D, 1998, FRONT BIOSCI, V3, P1028; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; JASPERS M, 1991, SOMAT CELL MOLEC GEN, V17, P505, DOI 10.1007/BF01233174; JIN P, 1993, DIFFERENTIATION, V54, P47; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; Martin PT, 1996, DEV BIOL, V174, P125, DOI 10.1006/dbio.1996.0057; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; Miyagoe Y, 1997, FEBS LETT, V415, P33, DOI 10.1016/S0014-5793(97)01007-7; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; Pozzi M, 1998, J CELL BIOL, V142, P587; PYTELA R, 1994, METHOD ENZYMOL, V245, P420; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; Sambrook J., 2002, MOL CLONING LAB MANU; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; Seymour AB, 1996, GENOME RES, V6, P538, DOI 10.1101/gr.6.6.538; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; Takada Y, 1997, MATRIX BIOL, V16, P143, DOI 10.1016/S0945-053X(97)90002-0; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tuckwell DS, 1996, EUR J BIOCHEM, V241, P732, DOI 10.1111/j.1432-1033.1996.00732.x; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wong DA, 1996, GENE, V171, P291, DOI 10.1016/0378-1119(95)00869-1; WRIGHT TRF, 1960, J EXP ZOOL, V143, P77, DOI 10.1002/jez.1401430107; WU JE, 1994, DEV DYNAM, V199, P292, DOI 10.1002/aja.1001990405; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Ziober BL, 1997, MOL BIOL CELL, V8, P1723, DOI 10.1091/mbc.8.9.1723	60	135	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25735	25742		10.1074/jbc.274.36.25735	http://dx.doi.org/10.1074/jbc.274.36.25735			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464311	hybrid			2022-12-25	WOS:000082554200075
J	Chen, YR; Sturgeon, BE; Gunther, MR; Mason, RP				Chen, YR; Sturgeon, BE; Gunther, MR; Mason, RP			Electron spin resonance investigation of the cyanyl and azidyl radical formation by cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; SODIUM-AZIDE; CHEMICAL ISCHEMIA; HORSERADISH-PEROXIDASE; NITRIC-OXIDE; IN-VITRO; CYANIDE; ACTIVATION; MECHANISM; RAMAN	Cyanide (CN-) is a frequently used inhibitor of mitochondrial respiration due to its binding to the ferric heme a(3) of cytochrome c oxidase (CcO), As-isolated CcO oxidized cyanide to the cyanyl radical ((CN)-C-.) that was detected, using the ESR spin-trapping technique, as the 5,5-dimethyl-1-pyrroline N-oxide (DMPO)/(CN)-C-. radical adduct, The enzymatic conversion of cyanide to the cyanyl radical by CcO was time-dependent but not affected by azide (N-3(-)), The small but variable amounts of compound P present in the as-isolated CcO accounted for this one-electron oxidation of cyanide to the cyanyl radical, In contrast, as-isolated CcO exhibited little ability to catalyze the oxidation of azide, presumably because of azide's lower affinity for the CcO. However, the DMPO/N-.(3) radical adduct was readily detected when H2O2 was included in the system. The results presented here indicate the need to re-evaluate oxidative stress in mitochondria "chemical hypoxia" induced by cyanide or azide to account for the presence of highly reactive free radicals.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Chen, YR (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				BAKER GM, 1987, J BIOL CHEM, V262, P595; Bennett M C, 1992, J Geriatr Psychiatry Neurol, V5, P93; Bennett MC, 1996, J NEUROCHEM, V66, P2606; Bennett MC, 1996, P NATL ACAD SCI USA, V93, P1330, DOI 10.1073/pnas.93.3.1330; Budinger GRS, 1998, J BIOL CHEM, V273, P3320, DOI 10.1074/jbc.273.6.3320; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P127; Cada A, 1995, METAB BRAIN DIS, V10, P303, DOI 10.1007/BF02109361; Castric P.A., 1981, CYANIDE BIOL, P233; CHAWLA OP, 1975, J PHYS CHEM-US, V79, P2693, DOI 10.1021/j100591a020; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; DAVIES MJ, 1992, J CHEM SOC PERK T 2, P333, DOI 10.1039/p29920000333; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; DEMONTELLANO PRO, 1988, BIOCHEMISTRY-US, V27, P5470, DOI 10.1021/bi00415a013; ERECINSKA M, 1972, ARCH BIOCHEM BIOPHYS, V151, P188, DOI 10.1016/0003-9861(72)90487-0; FABIAN M, 1995, BIOCHEMISTRY-US, V34, P13802, DOI 10.1021/bi00042a011; FABIAN M, 1995, BIOCHEMISTRY-US, V34, P1534, DOI 10.1021/bi00005a009; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Ferreira IL, 1997, BRAIN RES, V768, P157, DOI 10.1016/S0006-8993(97)00634-3; FORRESTER AR, 1971, J CHEM SOC C, P701, DOI 10.1039/j39710000701; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; Gunasekar PG, 1996, J PHARMACOL EXP THER, V277, P150; Gunasekar PG, 1998, J PHARMACOL EXP THER, V285, P236; JANZEN EG, 1981, J PHYS CHEM-US, V85, P3952, DOI 10.1021/j150625a049; KALYANARAMAN B, 1985, J BIOL CHEM, V260, P4003; Kitagawa T, 1997, PROG INORG CHEM, V45, P431; LI WB, 1993, BIOCHEMISTRY-US, V32, P1833, DOI 10.1021/bi00058a018; MORENO SNJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P267, DOI 10.1016/0003-9861(88)90127-0; Morgan JE, 1996, BIOCHEMISTRY-US, V35, P12235, DOI 10.1021/bi961634e; Nishimura Y, 1998, HEPATOLOGY, V27, P1039, DOI 10.1002/hep.510270420; OHATA H, 1994, RES COMMUN MOL PATH, V86, P259; PALMER G, 1993, J BIOENERG BIOMEMBR, V25, P145, DOI 10.1007/BF00762856; PARTRIDGE RS, 1994, ARCH BIOCHEM BIOPHYS, V310, P210, DOI 10.1006/abbi.1994.1159; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P8580, DOI 10.1021/bi952096t; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P76, DOI 10.1021/bi9511705; PROSHLYAKOV DA, 1994, J BIOL CHEM, V269, P29385; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; RAJDEV S, 1994, NEUROSCIENCE, V62, P667, DOI 10.1016/0306-4522(94)90468-5; Sakaida I, 1996, J GASTROENTEROL, V31, P684, DOI 10.1007/BF02347617; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; SHAH MM, 1991, ARCH BIOCHEM BIOPHYS, V290, P173, DOI 10.1016/0003-9861(91)90604-H; Solomonson LP, 1981, CYANIDE BIOL, P11; STOLZE K, 1989, J INORG BIOCHEM, V37, P45, DOI 10.1016/0162-0134(89)80028-5; Sun PW, 1997, J PHARMACOL EXP THER, V280, P1341; VANBUUREN KJ, 1972, BIOCHIM BIOPHYS ACTA, V256, P258, DOI 10.1016/0005-2728(72)90057-6; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; Verkhovsky MI, 1996, P NATL ACAD SCI USA, V93, P12235, DOI 10.1073/pnas.93.22.12235; WALTER TH, 1982, CAN J CHEM, V60, P1621, DOI 10.1139/v82-514; Wilson D F, 1978, Methods Enzymol, V53, P191; WILSON DF, 1972, ARCH BIOCHEM BIOPHYS, V151, P180, DOI 10.1016/0003-9861(72)90486-9; YAMAZAKI I, 1963, BIOCHIM BIOPHYS ACTA, V77, P47, DOI 10.1016/0006-3002(63)90468-2; Yang C W, 1996, J Biochem Toxicol, V11, P251, DOI 10.1002/(SICI)1522-7146(1996)11:5<251::AID-JBT6>3.0.CO;2-J; YONETANI T, 1965, J BIOL CHEM, V240, P3392; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P9757; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; YU CA, 1975, J BIOL CHEM, V250, P1383	55	24	25	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24611	24616		10.1074/jbc.274.35.24611	http://dx.doi.org/10.1074/jbc.274.35.24611			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455126	hybrid			2022-12-25	WOS:000082193400025
J	Potter, JL; Narasimhan, J; Mende-Mueller, L; Haas, AL				Potter, JL; Narasimhan, J; Mende-Mueller, L; Haas, AL			Precursor processing of Pro-ISG15/UCRP, an interferon-beta-induced ubiquitin-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEUBIQUITINATING ENZYMES; 15-KDA PROTEIN; ISOPEPTIDASE-T; CONJUGATION; DEGRADATION; CLONING; HOMOLOG; ACTS	Induction of the 17-kDa ubiquitin-like protein ISG15/UCRP and its subsequent conjugation to cellular targets is the earliest response to type I interferons. The polypeptide is synthesized as a precursor containing a carboxyl-terminal extension whose correct processing is required for subsequent ligation of the exposed mature carboxyl terminus. Recombinant pro-ISG15 is processed in extracts of human lung fibroblasts by a constitutive 100-kDa enzyme whose activity is unaffected by type I interferon stimulation. The processing enzyme has been purified to apparent homogeneity by a combination of ion exchange and hydrophobic chromatography and found to be stimulated 12-fold by micromolar concentrations of ubiquitin, Analysis of the products of pro-ISG15 processing enzyme demonstrates specific cleavage exclusively at the Gly(157)-Gly(158) peptide bond to generate a mature ISG15 carboxyl terminus. Irreversible inhibition of pro-ISG15 processing activity by thiol-specific alkylating agents and a pH rate dependence conforming to titration of a single group of pK(a) 8.1 indicate the 100-kDa enzyme is a thiol protease, Partial sequencing of a trypsin-derived peptide indicates the enzyme is either the human ortholog of yeast Ubp1 or a Ubp1-related protein. As yeast do not contain ISG15, these results suggest that a ubiquitin-specific enzyme was recruited for pro-ISG15/UCRP processing by adaptive divergence.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Haas, AL (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NIGMS NIH HHS [GM15977, GM47426] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047426, F32GM015977] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; Haas AL, 1997, FASEB J, V11, P1257; HADARI T, 1992, J BIOL CHEM, V267, P719; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; KORANT BD, 1984, J BIOL CHEM, V259, P4835; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LOEB KR, 1994, MOL CELL BIOL, V14, P8408, DOI 10.1128/MCB.14.12.8408; Mitruka BM, 1981, CLIN BIOCH HEMATOLOG, V2nd; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; PICKART CM, 1985, J BIOL CHEM, V260, P7903; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEIN RL, 1995, BIOCHEMISTRY-US, V34, P12616, DOI 10.1021/bi00039a017; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543	26	75	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25061	25068		10.1074/jbc.274.35.25061	http://dx.doi.org/10.1074/jbc.274.35.25061			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455185	hybrid			2022-12-25	WOS:000082193400084
J	Bhagwat, SV; Biswas, G; Anandatheerthavarada, HK; Addya, S; Pandak, W; Avadhani, NG				Bhagwat, SV; Biswas, G; Anandatheerthavarada, HK; Addya, S; Pandak, W; Avadhani, NG			Dual targeting property of the N-terminal signal sequence of P4501A1 - Targeting of heterologous proteins to endoplasmic reticulum and mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; OUTER-MEMBRANE; PRECURSOR PROTEINS; RECOGNITION PARTICLE; PROCESSING PEPTIDASE; ESCHERICHIA-COLI; TRUNCATED FORM; IMPORT; CYTOCHROME-P-450; TRANSLOCATION	Recent studies from our laboratory showed that the P-naphthoflavone-inducible cytochrome P4501A1 is targeted to both the endoplasmic reticulum (ER) and mitochondria, In the present study, we have further investigated the ability of the N-terminal signal sequence (residues 1-44) of P4501A1 to target heterologous proteins, dihydrofolate reductase, and the mature portion of the rat P450c27 to the two subcellular compartments. In vitro transport and in vivo expression experiments show that N-terminally fused 1-44 signal sequence of P4501A1 targets heterologous proteins to both the ER and mitochondria, whereas the 33-44 sequence strictly functions as a mitochondrial targeting signal. Site-specific mutations show that positively charged residues at the 34th and 39th positions are critical for mitochondrial targeting. Cholesterol 27-hydroxylase activity of the ER-associated 1-44/1A1-CYP27 fusion protein can be reconstituted with cytochrome P450 reductase, but the mitochondrial associated fusion protein is functional with adrenodoxin + adrenodoxin reductase. Consistent with these differences, the fusion protein in the two organelle compartments exhibited distinctly different membrane topology. The results on the chimeric nature of the N-terminal signal of P4501A1 coupled with interaction with different electron transport proteins suggest a co-evolutionary nature of some of the xenobiotic inducible microsomal and mitochondrial P450s.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Hunter Holmes McGuire Vet Adm Med Ctr, Gastroenterol Sect, Richmond, VA 23298 USA	University of Pennsylvania; University of Pennsylvania; Virginia Commonwealth University; Hunter Holmes McGuire Veterinary Affairs Medical Center	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu			NIGMS NIH HHS [GM-34883] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDYA S, 1991, BIOCHEMISTRY-US, V30, P8323, DOI 10.1021/bi00098a007; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Anandatheerthavarada HK, 1999, J BIOL CHEM, V274, P6617, DOI 10.1074/jbc.274.10.6617; Anandatheerthavarada HK, 1998, BIOCHEMISTRY-US, V37, P1150, DOI 10.1021/bi972046j; Anandatheerthavarada HK, 1997, ARCH BIOCHEM BIOPHYS, V339, P136, DOI 10.1006/abbi.1996.9855; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BASU A, 1993, J BIOL CHEM, V268, P4188; Bhagwat SV, 1999, TOXICOL APPL PHARM, V156, P231, DOI 10.1006/taap.1999.8646; BHAT NK, 1982, BIOCHEMISTRY-US, V21, P2452, DOI 10.1021/bi00539a026; BHAT NK, 1985, BIOCHEMISTRY-US, V24, P8107, DOI 10.1021/bi00348a041; BLACK SD, 1982, J BIOL CHEM, V257, P5929; BLACK SD, 1992, FASEB J, V6, P680, DOI 10.1096/fasebj.6.2.1537456; BOGUTA M, 1994, MOL CELL BIOL, V14, P2298, DOI 10.1128/MCB.14.4.2298; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; DEGLIESPOSTI M, 1990, EUR J BIOCHEM, V190, P207, DOI 10.1111/j.1432-1033.1990.tb15566.x; Dong MS, 1996, ARCH BIOCHEM BIOPHYS, V327, P11, DOI 10.1006/abbi.1996.0086; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; FUJIIKURIYAMA Y, 1979, J CELL BIOL, V81, P510, DOI 10.1083/jcb.81.3.510; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; Guzov VM, 1998, ARCH BIOCHEM BIOPHYS, V359, P231, DOI 10.1006/abbi.1998.0901; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Isenman L, 1995, BBA-REV BIOMEMBRANES, V1241, P341, DOI 10.1016/0304-4157(95)00009-7; Isenmann S, 1998, MOL BIOL CELL, V9, P1649, DOI 10.1091/mbc.9.7.1649; JAUSSI R, 1995, EUR J BIOCHEM, V228, P551, DOI 10.1111/j.1432-1033.1995.tb20294.x; Jefcoate C.R., 1986, CYTOCHROME P 450 STR, P387; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NIRANJAN BG, 1984, J BIOL CHEM, V259, P2495; OHTA S, 1984, EMBO J, V3, P651, DOI 10.1002/j.1460-2075.1984.tb01862.x; OKUDA K, 1988, J BIOL CHEM, V263, P18138; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; OMURA T, 1964, J BIOL CHEM, V239, P2370; OU WJ, 1994, J BIOL CHEM, V269, P24673; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PETRACK B, 1993, J LIPID RES, V34, P643; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; Pikuleva IA, 1997, ARCH BIOCHEM BIOPHYS, V343, P123, DOI 10.1006/abbi.1997.0142; PORTER TD, 1991, J BIOL CHEM, V266, P13469; RIZZOLO LJ, 1985, J CELL BIOL, V101, P1351, DOI 10.1083/jcb.101.4.1351; Robin Marie-Anne, 1997, Journal of Hepatology, V26, P23, DOI 10.1016/S0168-8278(97)82329-X; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; Sakaki T, 1996, J BIOL CHEM, V271, P26209, DOI 10.1074/jbc.271.42.26209; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Stravitz RT, 1996, J STEROID BIOCHEM, V57, P337, DOI 10.1016/0960-0760(95)00282-0; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Von Wachenfeldt Claes, 1995, P183; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Waterman M.R, 1991, METHOD ENZYMOL, V206, P100, DOI 10.1016/0076-6879(91)06081-d; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WIKWALL K, 1993, HDB EXPT PHARM, V105, P705; WU DF, 1992, HEPATOLOGY, V15, P515, DOI 10.1002/hep.1840150326; YABUSAKI Y, 1984, NUCLEIC ACIDS RES, V12, P2929, DOI 10.1093/nar/12.6.2929	72	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24014	24022		10.1074/jbc.274.34.24014	http://dx.doi.org/10.1074/jbc.274.34.24014			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446170	hybrid			2022-12-25	WOS:000082110900049
J	Li, XR; Cai, MJ				Li, XR; Cai, MJ			Recovery of the yeast cell cycle from heat shock-induced G(1) arrest involves a positive regulation of G(1) cyclin expression by the S phase cyclin Clb5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; GENE-EXPRESSION; CDK INHIBITOR; STRESS TOLERANCE; PROTEIN-KINASE; G1 CYCLINS; START; CLN2; PHOSPHORYLATION	In the yeast Saccharomyces cerevisiae, heat shock stress induces a variety of cellular responses including a transient cell cycle arrest before G(1)/S transition. Previous studies have suggested that this G(1) delay is probably attributable to a reduced level of the G(1) cyclin gene (CLN1 and CLN2) transcripts. Here we report our finding that the G(1) cyclin Cln3 and the S cyclin Clb5 are the key factors required for recovery from heat shock-induced G(1) arrest. Heat shock treatment of G(1) cells lacking either CLN3 or CLB5/CLB6 functions leads to prolonged cell cycle arrest before the initiation of DNA synthesis, concomitant with a severe deficiency in bud formation. The inability of the clb5 clb6 mutant to resume normal budding after heat shock treatment is unanticipated, since the S phase cyclins are generally thought to be required mainly for initiation of DNA synthesis and have no significant roles in bud formation in the presence of functional G(1) cyclins. Further studies reveal that the accumulation of G(1) cyclin transcripts is markedly delayed in the clb5 clb6 mutant following heat shock treatment, indicating that the CLN gene expression may require Clb5/Clb6 to attain a threshold level for driving the cell cycle through G(1)/S transition. Consistent with this assumption, overproduction of Clb5 greatly enhances the transcription of at least two G(1) cyclin genes (CLN1 and CLN2) in heat-shocked G(1) cells. These results suggest that Clb5 may positively regulate the expression of G(1) cyclins during cellular recovery from heat shock-induced G(1) arrest. Additional evidence is presented to support a role for Clb5 in maintaining the synchrony between budding and DNA synthesis during normal cell division as well.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Cai, MJ (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbcaimj@imcb.nus.edu.sg						Attfield PV, 1997, NAT BIOTECHNOL, V15, P1351, DOI 10.1038/nbt1297-1351; BARNES CA, 1990, J BACTERIOL, V172, P4352, DOI 10.1128/jb.172.8.4352-4358.1990; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; CRAIG EA, 1992, MOL CELLULAR BIOL YE, P501; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DICOMO CJ, 1995, MOL CELL BIOL, V15, P1835; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FINKELSTEIN DB, 1982, J BIOL CHEM, V257, P8405; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Futcher B, 1996, YEAST, V12, P1635; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Hall DD, 1998, EMBO J, V17, P4370, DOI 10.1093/emboj/17.15.4370; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; Lew DJ, 1997, MOL CELLULAR BIOL YE, P607; Li XR, 1997, MOL CELL BIOL, V17, P2723, DOI 10.1128/MCB.17.5.2723; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Lindquist S, 1992, CURR OPIN GENET DEV, V2, P748, DOI 10.1016/S0959-437X(05)80135-2; Mai B, 1997, MOL CELL BIOL, V17, P6491, DOI 10.1128/MCB.17.11.6491; Mendenhall MD, 1998, MICROBIOL MOL BIOL R, V62, P1191, DOI 10.1128/MMBR.62.4.1191-1243.1998; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nishizawa M, 1998, MOL BIOL CELL, V9, P2393, DOI 10.1091/mbc.9.9.2393; Oehlen LJWM, 1998, MOL GEN GENET, V258, P183, DOI 10.1007/s004380050722; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROWLEY A, 1993, MOL CELL BIOL, V13, P1034, DOI 10.1128/MCB.13.2.1034; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Schoffl F, 1998, PLANT PHYSIOL, V117, P1135, DOI 10.1104/pp.117.4.1135; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHIN DY, 1987, MOL CELL BIOL, V7, P244, DOI 10.1128/MCB.7.1.244; SIEDE W, 1994, GENETICS, V138, P271; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; TOONE WM, 1995, EMBO J, V14, P5824, DOI 10.1002/j.1460-2075.1995.tb00270.x; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	52	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24220	24231		10.1074/jbc.274.34.24220	http://dx.doi.org/10.1074/jbc.274.34.24220			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446197	hybrid			2022-12-25	WOS:000082110900076
J	Schnare, MN; Gray, MW				Schnare, MN; Gray, MW			A candidate U1 small nuclear RNA for trypanosomatid protozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICED LEADER RNA; CRITHIDIA-FASCICULATA; LEISHMANIA-TARENTOLAE; SEQUENCE; BRUCEI; RIBONUCLEOPROTEINS; SNRNPS; GENE	In trypanosomatid protozoa, all mRNAs obtain identical 5'-ends by trans splicing of the 5'-terminal 39 nucleotides of a small spliced leader RNA to appropriate acceptor sites in pre-mRNA Although this process involves spliceosomal small nuclear (sn) RNAs, it is thought that trypanosomatids do not contain a homolog of the cis-spliceosomal U1 snRNA. We show here that a trypanosomatid protozoon, Crithidia fasciculata, contains a novel small RNA that displays several features characteristic of a U1 snRNA, including (i) a methylguanosine cap and additional 5'-terminal modifications, (ii) a potential binding site for common core proteins that are present in other trans-spliceosomal ribonucleoproteins, (iii) a U1-like 5'-terminal sequence, and (iv) a U1-like stem/loop I structure. Because trypanosomatid pre-mRNAs do not appear to contain cis-spliced introns, we argue that this previously unrecognized RNA species is a good candidate to be a trans spliceosomal U1 snRNA.	Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University	Gray, MW (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada.			Gray, Michael/0000-0001-7125-2625				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; BANGS JD, 1992, J BIOL CHEM, V267, P9805; BRANLANT C, 1980, NUCLEIC ACIDS RES, V8, P4143, DOI 10.1093/nar/8.18.4143; Breckenridge DG, 1999, P NATL ACAD SCI USA, V96, P852, DOI 10.1073/pnas.96.3.852; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CROSS M, 1991, MOL CELL BIOL, V11, P5516, DOI 10.1128/MCB.11.11.5516; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; GABRIEL A, 1987, J BIOL CHEM, V262, P16192; GRAY MW, 1979, CAN J BIOCHEM CELL B, V57, P914, DOI 10.1139/o79-111; Greenwood SJ, 1996, CURR GENET, V30, P338, DOI 10.1007/s002940050142; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; KRAINER AR, 1988, NUCLEIC ACIDS RES, V16, P9415, DOI 10.1093/nar/16.20.9415; Logsdon JM, 1998, CURR OPIN GENET DEV, V8, P637, DOI 10.1016/S0959-437X(98)80031-2; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MACKAY RM, 1980, EUR J BIOCHEM, V112, P561; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; MUHICH ML, 1987, NUCLEIC ACIDS RES, V15, P3141, DOI 10.1093/nar/15.7.3141; PALFI Z, 1992, J BIOL CHEM, V267, P20159; REDDY R, 1981, BIOCHEM BIOPH RES CO, V98, P1076, DOI 10.1016/0006-291X(81)91221-3; SEIWERT SD, 1993, MOL CELL BIOL, V13, P3135, DOI 10.1128/MCB.13.6.3135; SHI XM, 1994, MOL BIOCHEM PARASIT, V65, P23, DOI 10.1016/0166-6851(94)90112-0; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3; Sturm NR, 1998, J BIOL CHEM, V273, P18689, DOI 10.1074/jbc.273.30.18689; THWEATT R, 1990, ANAL BIOCHEM, V190, P314, DOI 10.1016/0003-2697(90)90200-S; XU GL, 1994, MOL CELL BIOL, V14, P4565, DOI 10.1128/MCB.14.7.4565; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473; Zaug AJ, 1996, NUCLEIC ACIDS RES, V24, P532, DOI 10.1093/nar/24.3.532; Zwieb C, 1997, NUCLEIC ACIDS RES, V25, P102, DOI 10.1093/nar/25.1.102	30	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23691	23694		10.1074/jbc.274.34.23691	http://dx.doi.org/10.1074/jbc.274.34.23691			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446125	hybrid			2022-12-25	WOS:000082110900004
J	Hodzic, D; Frey, B; Marechal, D; Scarcez, T; Grooteclaes, M; Winkler, R				Hodzic, D; Frey, B; Marechal, D; Scarcez, T; Grooteclaes, M; Winkler, R			Cloning of breakpoints in and downstream the IGF2 gene that are associated with overexpression of IGF2 transcripts in colorectal tumours	ONCOGENE			English	Article						IGF2; overexpression; gene rearrangement; imprinting; colon cancer	GROWTH-FACTOR-II; BECKWITH-WIEDEMANN-SYNDROME; WILMS-TUMOR; HUMAN CANCER; INSULIN; HETEROZYGOSITY; CHROMOSOME-11; HYPOGLYCEMIA; EXPRESSION; REGION	The human IGF2 gene belongs to a group of imprinted genes clustered on the short arm of chromosome 11, band p15.5. It contains 9 exons and spans over 30 kb, IGF2 mRNA overexpression has been reported in human tumours and in some inherited growth disorders. It was recently demonstrated that IGF2 mRNA overexpression contributes to tumour progression and that loss of parental imprinting as well as altered transcription factors are contributing to this overexpression. We have reported structural alterations in the 3 ' region of the IGF2 gene in two colorectal tumours that overexpressed the IGF2 transcript by 200- and 800-fold. We cloned by the, vectorette-PCR strategy, genomic DNA fragments containing the breakpoints from these tumours, The sequencing of these fragments positioned the breakpoint 2 kb downstream the IGF2 gene in one tumour, and in exon 9 in the second. Both breakpoints occurred in regions containing repetitive elements: a TGGA repeat we have identified downstream the gene, and the (CA)n repetition in exon 9, We hypothesize that a negative regulatory element, located downstream the IGF2 gene, has been deleted following these structural alterations and leads to IGF2 gene overexpression.	Univ Liege, Dept Pathol, Mol Oncol Lab, B-4000 Liege, Belgium; Roche Mol Biochem, Munich, Germany; Eurogentec, B-4102 Seraing, Belgium	University of Liege	Winkler, R (corresponding author), Univ Liege, Dept Pathol, Mol Oncol Lab, Tour Pathol B23, B-4000 Liege, Belgium.							Arnold C, 1991, PCR Methods Appl, V1, P39; Baffa R, 1996, CANCER RES, V56, P268; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAUGHADAY WH, 1988, NEW ENGL J MED, V319, P1434, DOI 10.1056/NEJM198812013192202; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DEMOOR CH, 1994, EUR J BIOCHEM, V222, P1017; ELLSWORTH DL, 1994, MOL BIOL EVOL, V11, P875; FIDLER AE, 1992, LANCET, V339, P243, DOI 10.1016/0140-6736(92)90042-2; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GICQUEL C, 1995, EUR J ENDOCRINOL, V133, P133, DOI 10.1530/eje.0.1330133; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IRMINGER JC, 1989, EUR J PEDIATR, V148, P620, DOI 10.1007/BF00441514; Ishida S, 1995, INTERNAL MED, V34, P1201, DOI 10.2169/internalmedicine.34.1201; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Karnik P, 1998, ONCOGENE, V17, P237, DOI 10.1038/sj.onc.1201959; LAMBERT S, 1990, INT J CANCER, V46, P405, DOI 10.1002/ijc.2910460313; Mannens M., 1994, European Journal of Human Genetics, V2, P3; MINNITI CP, 1994, CURRENT DIRECTIONS G, P327; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; SCHNEID H, 1992, GROWTH REGULAT, V2, P45; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; SUSSENBACH JS, 1994, CURRENT DIRECTIONS I, P63; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; WINQVIST R, 1995, CANCER RES, V55, P2660	28	7	8	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4710	4717		10.1038/sj.onc.1202877	http://dx.doi.org/10.1038/sj.onc.1202877			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467418				2022-12-25	WOS:000082154400008
J	Lassus, P; Bertrand, C; Zugasti, O; Chambon, JP; Soussi, T; Mathieu-Mahul, D; Hibner, U				Lassus, P; Bertrand, C; Zugasti, O; Chambon, JP; Soussi, T; Mathieu-Mahul, D; Hibner, U			Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant	ONCOGENE			English	Article						apoptosis; oncogenesis; p53	DNA-BINDING FUNCTION; WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; GROWTH ARREST; TRANSCRIPTIONAL ACTIVATION; P53-INDUCED APOPTOSIS; GENE-EXPRESSION; PROTEIN; CELLS; IDENTIFICATION	The tumour suppressor p53 plays a complex role in the regulation of apoptosis, High levels of wild type p53 potentiate the apoptotic response, while physiological range, low levels of the protein have an anti-apoptotic activity in serum starved immortalized fibroblasts. Here we report that primary fibroblast-like cells that show normal growth control are also efficiently protected from apoptosis by the endogenous p53 activity, The capacity to inhibit apoptosis is not restricted to the wild type protein: the R --> H175 p53 mutant fully retains the anti-apoptotic activity of the wild type p53, providing a possible explanation for its high oncogenicity. Using a series of point and deletion mutants of p53 under the control of tetracycline-regulated promoter we show that certain mutants, like the wild type, protect cells at low levels but lead to apoptosis when overexpressed, This latter effect is lost upon deletion of a proline-rich domain in the NH2 part of the protein. The anti-apoptotic activity can be mapped to the extreme carboxy-terminal part of the protein and is therefore independent of other well characterized p53 activities. Our results add a new level of complexity to the network of interactions mediated by p53 in normal physiology and pathology.	Inst Med Genet, CNRS, UMR 5535, F-34293 Montpellier 5, France; Inst Curie, CNRS, UMR 218, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)	Hibner, U (corresponding author), Inst Med Genet, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.		BERTRAND-GADAY, Christelle/ABA-8619-2021; Mathieu, Daniele/G-6092-2012; Zugasti, Olivier/P-1352-2017; chambon, jean-philippe/A-5532-2013	BERTRAND-GADAY, Christelle/0000-0003-0461-2402; soussi, thierry/0000-0001-8184-3293; Lassus, Patrice/0000-0002-2785-7843; Hibner, Urszula/0000-0002-5520-7311; Zugasti, Olivier/0000-0002-5616-734X				Abarzua P, 1996, ONCOGENE, V13, P2477; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN JY, 1993, ONCOGENE, V8, P2159; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GOH HS, 1995, CANCER RES, V55, P5217; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hansen S, 1996, J BIOL CHEM, V271, P3917; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Lassus P, 1998, NUCLEIC ACIDS RES, V26, P5233, DOI 10.1093/nar/26.22.5233; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; MacCallum DE, 1996, ONCOGENE, V13, P2575; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMID P, 1991, DEVELOPMENT, V113, P857; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SUBLER MA, 1994, ONCOGENE, V9, P1351; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; YONISHROUACH E, 1996, ONCOGENE, V12, P2197	68	20	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4699	4709		10.1038/sj.onc.1202841	http://dx.doi.org/10.1038/sj.onc.1202841			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467417				2022-12-25	WOS:000082154400007
J	Vazquez, F; Hastings, G; Ortega, MA; Lane, TF; Oikemus, S; Lombardo, M; Iruela-Arispe, ML				Vazquez, F; Hastings, G; Ortega, MA; Lane, TF; Oikemus, S; Lombardo, M; Iruela-Arispe, ML			METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL PROLIFERATION; HEPARIN-BINDING; I REPEATS; THROMBOSPONDIN; ANGIOGENESIS; PEPTIDES; GENE; EXPRESSION; ADHESION; MOUSE	We have studied two related proteins that contain a repeated amino acid motif homologous to the anti-angiogenic type 1 repeats of thrombospondin-1 (TSP1), Complete sequence analysis revealed no other similarities with TSP1, but identified unique signal sequences, as well as metalloprotease and disintegrin-like domains in the NH2 termini. We named these proteins METH-1 and METH-S due to the novel combination of metalloprotease and thrombospondin domains, Overall amino acid sequence identity between METH-1 and METH-2 is 51.7%, yet transcript distribution revealed non-overlapping patterns of expression in tissues and cultured cell lines. To characterize these proteins functionally, we isolated full-length cDNAs, produced recombinant protein, and generated antisera to the recombinant proteins. Both METH-1 and METH-2 represent single copy genes, which encode secreted and proteolytically processed proteins. METH proteins suppressed fibroblast growth factor-alpha-induced vascularization in the cornea pocket assay and inhibited vascular endothelial growth factor-induced angiogenesis in the chorioallantoic membrane assay. Suppression of vessel growth in both assays was considerably greater than that mediated by either thrombospondin-1 or endostatin on a molar basis. Consistent with an endothelial specific response, METH-1 and METH-2 were shown to inhibit endothelial cell proliferation, but not fibroblast or smooth muscle growth. We propose that METH-1 and METH-2 represent a new family of proteins with metalloprotease, disintegrin, and thrombospondin domains. The distinct distribution of each gene product suggests that each has evolved distinct regulatory mechanisms that potentially allow for fine control of activity during distinct physiological and pathological states,	Univ Calif Los Angeles, Inst Mol Biol, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Human Genome Sci, Rockville, MD 20850 USA; Univ Calif Los Angeles, Jonsson Canc Ctr, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; GlaxoSmithKline; Human Genome Sciences Inc; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Iruela-Arispe, ML (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Dept Mol Cell & Dev Biol, 5th Fl,Rm 559,611 Circle Dr E, Los Angeles, CA 90095 USA.		Iruela-Arispe, M. Luisa/AAJ-1297-2020	Iruela-Arispe, M. Luisa/0000-0002-3050-4168; Lane, Timothy F./0000-0002-0210-970X	NATIONAL CANCER INSTITUTE [R01CA077420] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA63356-01, R01CA77420-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1995, THROMBOSPONDIN GENE, P1; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Dhanabal M, 1999, CANCER RES, V59, P189; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; GUO NH, 1992, J BIOL CHEM, V267, P19349; Guo NH, 1997, J PEPT RES, V50, P210; Guo NH, 1997, CANCER RES, V57, P1735; IRUELAARISPE ML, 1993, J CELL BIOCHEM, V52, P414, DOI 10.1002/jcb.240520406; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; IRUELAARISPE ML, 1999, IN PRESS CIRCULATION; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; PFAFF M, 1994, CELL ADHES COMMUN, V2, P491, DOI 10.3109/15419069409014213; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; USAMI Y, 1994, BIOCHEM BIOPH RES CO, V201, P331, DOI 10.1006/bbrc.1994.1706; Vazquez F, 1999, J BIOL CHEM, V274, P2185, DOI 10.1074/jbc.274.4.2185; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; WOLSBERG TG, 1996, DEV BIOL, V180, P389	38	358	390	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23349	23357		10.1074/jbc.274.33.23349	http://dx.doi.org/10.1074/jbc.274.33.23349			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438512	hybrid			2022-12-25	WOS:000082012800062
J	Imyanitov, EN; Birrell, GW; Filippovich, I; Sorokina, N; Arnold, J; Mould, MA; Wright, K; Walsh, M; Mok, SC; Lavin, MF; Chenevix-Trench, G; Khanna, KK				Imyanitov, EN; Birrell, GW; Filippovich, I; Sorokina, N; Arnold, J; Mould, MA; Wright, K; Walsh, M; Mok, SC; Lavin, MF; Chenevix-Trench, G; Khanna, KK			Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target	ONCOGENE			English	Article						p73; ovarian adenocarcinoma; loss of heterozygosity; tumour suppressor	REGION; P53; NEUROBLASTOMA; MUTATIONS; NEOPLASMS; CANCERS	Loss of heterozygosity (LOH) involving the distal part of the short arm of chromosome 1 occurs frequently in ovarian adenocarcinomas but the tumour suppressor gene(s) targeted by this event is unknown, We have used five microsatellite markers in a panel of 56 ovarian adenocarcinomas to determine which part of 1p34-36 is the focus of this LOH, LOH was considerably more common at 1p36 (43%) than at 1p34-35 (18%), and 11 tumours showed LOH at 1p36 but not at 1p34-35, These data strongly suggest the presence of a tumour suppressor gene inactivated in ovarian adenocarcinoma at 1p36, The p53 homologue, p73, has recently been isolated and mapped to 1p36 and therefore is a candidate for this tumour suppressor gene, However, RT-PCR and Western analyses revealed strong expression of p73 in ovarian adenocarcinoma cell lines but very low or undetectable levels in normal ovarian surface epithelial cells. Immunohistochemical analysis of primary ovarian tumours showed that only 3/22 (14%) contained p73 expressing cells. There was no association between 1p36 LOH and p73 expression in ovarian tumours, nor between p73 and p53 expression, These findings strongly suggest that p73 is not the target of 1p36 LOH in ovarian adenocarcinomas but indicate the presence of an, as yet unidentified, tumour suppressor gene in this region that plays an important role in ovarian tumorigenesis.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; NN Petrov Inst Oncol, Grp Mol Diagnost, St Petersburg 189646, Russia; Russian Federat Minist Hlth, Inst Biophys, Lab Mol Radiol, Moscow 123182, Russia; Univ Queensland, PO Royal Brisbane Hosp, Dept Pathol, Brisbane, Qld 4029, Australia; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Univ Queensland, PO Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; N.N. Petrov Research Institute of Oncology; Ministry of Health of the Russian Federation; Royal Brisbane & Women's Hospital; University of Queensland; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Royal Brisbane & Women's Hospital; University of Queensland	Khanna, KK (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.		Lavin, Martin F/F-5961-2014; Imyanitov, Evgeny/ABG-8619-2021; Chenevix-Trench, Georgia/AAV-2014-2020; Khanna, Kum Kum/I-1747-2013	Lavin, Martin F/0000-0002-5940-4769; Chenevix-Trench, Georgia/0000-0002-1878-2587; Birrell, Geoff/0000-0002-6593-1514; Khanna, Kum Kum/0000-0001-8650-5381				CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; NAGAI H, 1995, CANCER RES, V55, P1752; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; TENERIELLO MG, 1993, CANCER RES, V53, P3103; Thompson FH, 1997, CANCER GENET CYTOGEN, V96, P106, DOI 10.1016/S0165-4608(96)00307-X; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; WEBB PM, IN PRESS J NATL CANC; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	15	36	38	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4640	4642		10.1038/sj.onc.1202863	http://dx.doi.org/10.1038/sj.onc.1202863			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467409				2022-12-25	WOS:000082018600014
J	Fabbrizio, E; Le Cam, L; Polanowska, J; Kaczorek, M; Lamb, N; Brent, R; Sardet, C				Fabbrizio, E; Le Cam, L; Polanowska, J; Kaczorek, M; Lamb, N; Brent, R; Sardet, C			Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity	ONCOGENE			English	Article						E2F transcription factors; peptidic inhibitors; cell proliferation; DNA binding and dimerization domains	S-PHASE ENTRY; TRANSCRIPTION FACTOR; CYCLE PROGRESSION; DEREGULATED EXPRESSION; RETINOBLASTOMA PROTEIN; NA+/H+ ANTIPORTER; FAMILY MEMBERS; DNA-SYNTHESIS; APOPTOSIS; LEADS	The p16-cyclin D-pRB-E2F pathway is frequently deregulated in human tumors. This critical regulatory pathway controls the G1/S transition of the mammalian cell cycle by positive and negative regulation of E2F-responsive genes required for DNA replication. To assess the value of the transcription factors E2Fs as targets for antiproliferative strategies, we have initiated a program aiming to develop inhibitors targeting specifically these proteins in vitro and in vivo. The cellular activity of E2F is the result of the heterodimeric association of two families of proteins, E2Fs and DPs, which then bind DNA. Here, we use a two hybrid approach to isolate from combinatorial libraries peptide aptamers that specifically interact with E2Fs DNA binding and dimerization domains. One of these is a potent inhibitor of E2F binding activity in vitro and in mammalian fibroblasts, blocks cells in G1, and the free variable region from this aptamer has the same effect. Our experiments argue that the variable region of this aptamer is structured, and that it functions by binding E2F with a motif that resembles a DP heterodimerization region, and blocking E2F's association with DP. Those results show that cell proliferation can be inhibited using genetically-selected synthetic peptides that specifically target protein-protein interaction motifs within cell cycle regulators. These results also emphasize the critical role of the E2F pathway for cell proliferation and might allow the design of novel antiproliferative agents targeting the cyclin/CDK-pRB-E2F pathway.	Inst Mol Genet, UMR 5535 CNRS, F-34293 Montpellier, France; Syntiem, F-30000 Nimes, France; Inst Genet Humaine, F-34094 Montpellier, France; Inst Mol Sci, Berkeley, CA 94704 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; The Molecular Sciences Institute	Sardet, C (corresponding author), Inst Mol Genet, UMR 5535 CNRS, 1919 Route Mende, F-34293 Montpellier, France.		Polanowska, Jolanta/P-9117-2016; Le Cam, Laurent/O-1408-2016	Polanowska, Jolanta/0000-0001-7666-7010; LE CAM, Laurent/0000-0003-0325-878X				Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY R, 1996, DNA CLONING EXPRESSI, V6, P169; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hayashida W, 1996, J BIOL CHEM, V271, P21985, DOI 10.1074/jbc.271.36.21985; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MANN D, 1996, CURR BIOL, V4, P474; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SARDET C, 1997, PROGR GENE EXPRESSIO, V2, P1; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; VIDAL M, 1996, P NATL ACAD SCI USA, V93, P19; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wu CL, 1996, MOL CELL BIOL, V16, P3698; XU W, 1997, P NATL ACAD SCI USA, V94, P12473	38	71	80	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4357	4363		10.1038/sj.onc.1202825	http://dx.doi.org/10.1038/sj.onc.1202825			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439043				2022-12-25	WOS:000081732700008
J	Atfi, A; Prunier, C; Mazars, A; Defachelles, AS; Cayre, Y; Gespach, C; Bourgeade, MF				Atfi, A; Prunier, C; Mazars, A; Defachelles, AS; Cayre, Y; Gespach, C; Bourgeade, MF			The oncogenic TEL/PDGFR beta fusion protein induces cell death through JNK SAPK pathway	ONCOGENE			English	Article						TEL/PDGFR beta; apoptosis; JNK SAPK; PI-3 kinase	SIGNAL-TRANSDUCTION PATHWAY; GROWTH-FACTOR-BETA; CHRONIC MYELOMONOCYTIC LEUKEMIA; JUN ACTIVATION DOMAIN; C-JUN; RECEPTOR-BETA; MAP KINASE; HEMATOPOIETIC-CELLS; PDGFR-BETA; KAPPA-B	The TEL/PDGFR beta (T/P) fusion protein isolated from patients bearing a t(5;12) translocation is transforming when expressed in haematopoietic cells. To examine the signal transduction events activated by this protein, we measured the effect of T/P on activation of the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) in mouse bone marrow-derived Ba/F3 cells. Significant increase in the activity of JNK/SAPK1 was observed in transient transfection as well as in Ba/F3 cells stably expressing T/P, This activation was abrogated when the T/P-expressing cells were treated with a specific inhibitor of the PDGFR beta tyrosine kinase, indicating that the activity of the PDGFR beta part of the fusion protein was involved in JNK/SAPK activation. Expression of a dominant negative mutant of mitogen-activated protein kinase kinase 4 (MKK4), a direct activator of JNK/SAPK, prevented T/P-induced JNK/SAPK activation. In addition, inhibition of phosphoinositide-3 OH kinase (PI-3 kinase), a promoting survival factor, potentiated the effect of T/P on JNK/SAPK activation. Interestingly, expression of T/P was shown to initiate an apoptotic response that was enhanced by treatment of cells with the PI-3 kinase inhibitor LY294002, suggesting that T/P mediated cell death through activation of JNK/SAPK signalling pathway. Consistent with this hypothesis, expression of the dominant negative mutant of MKK4 decreased T/P-mediated apoptosis, while a dominant-negative mutant of PI-3 kinase enhances cell death. These findings indicate that activation of JNK/SAPK by T/P is related to apoptosis rather than cell proliferation and transformation.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Hop St Antoine, INSERM, U417, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Bourgeade, MF (corresponding author), CJF 95-02,32 Rue Carnets, F-92140 Clamart, France.		Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273; DEFACHELLES, Anne-Sophie/0000-0002-4277-9871				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Bourgeade MF, 1998, BLOOD, V91, P3333, DOI 10.1182/blood.V91.9.3333.3333_3333_3339; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	48	20	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	1999	18	26					3878	3885		10.1038/sj.onc.1202734	http://dx.doi.org/10.1038/sj.onc.1202734			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445851				2022-12-25	WOS:000081171700009
J	Aguilar, L; Ortega-Pierres, G; Campos, B; Fonseca, R; Ibanez, M; Wong, C; Farfan, N; Naciff, JM; Kaetzel, MA; Dedman, JR; Baeza, I				Aguilar, L; Ortega-Pierres, G; Campos, B; Fonseca, R; Ibanez, M; Wong, C; Farfan, N; Naciff, JM; Kaetzel, MA; Dedman, JR; Baeza, I			Phospholipid membranes form specific nonbilayer molecular arrangements that are antigenic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHOSPHATIDATE; LIPOSOMES; LIPIDS; ANTIBODIES; PHASES	Hexagonal phase (H-II)-preferring lipids such as phosphatidate, cardiolipin, and phosphatidylserine form nonbilayer molecular arrangements in lipid bilayers. While their presence in biological membranes has not been established, in vitro studies suggest that alterations in membrane properties modify their function. In this study, antiphospholipid monoclonal antibodies were developed against nonbilayer structures. One of the monoclonal antibodies identifies nonplanar surfaces in Liposomes and in membranes of cultured cells. These results are the first evidence that natural membranes maintain a fragile balance between bilayer and nonbilayer Lipid arrangements. Therefore, these antibodies can be used to evaluate the role of H-II-preferring lipids in the modulation of membrane activities, Our studies demonstrated that nonplanar surfaces are highly immunogenic, Although these structures are normally transient, their formation can be stabilized by temperature variations, drugs, antibiotics, apolar peptides, and divalent cations, Our studies demonstrated that abnormal exposure of nonbilayer arrangements may induce autoimmune responses as found in the antiphospholipid syndrome.	Inst Politecn Nacl, Natl Sch Biol Sci, Dept Biochem, Mexico City 06401, DF, Mexico; Ctr Res & Adv Studies, Dept Genet & Mol Biol, Mexico City 07000, DF, Mexico; Ctr Res & Adv Studies, Dept Chem, Mexico City 07000, DF, Mexico; Univ Cincinnati, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA	Instituto Politecnico Nacional - Mexico; University System of Ohio; University of Cincinnati	Baeza, I (corresponding author), Inst Politecn Nacl, Natl Sch Biol Sci, Dept Biochem, Apartado Postal 4-897,Admon 4, Mexico City 06401, DF, Mexico.			Ibanez Hernandez, Miguel Angel Antonio/0000-0003-4013-6888; Aguilar Faisal, J. Leopoldo/0000-0003-0519-3254	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046433] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46433] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHERSON RA, 1996, ANTIPHOSPHOLIPID SYN, P1; BAEZA I, 1995, BIOCHEM CELL BIOL, V73, P289, DOI 10.1139/o95-036; BAEZA I, 1994, J MOL EVOL, V39, P560, DOI 10.1007/BF00160401; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; CULLIS PR, 1991, MEMBRANE FUSION, P65; DARZYNKIEWICZ Z, 1990, FLOW CYTOMETRY SHORT, P290; Epand RM, 1996, CHEM PHYS LIPIDS, V81, P101, DOI 10.1016/0009-3084(96)02575-3; FENSKE DB, 1993, CHEM PHYS LIPIDS, V64, P143, DOI 10.1016/0009-3084(93)90063-9; Ibanez M, 1996, BIOCHEM CELL BIOL, V74, P633, DOI 10.1139/o96-068; KILLIAN JA, 1994, BBA-BIOMEMBRANES, V1189, P225; Kinnunen PKJ, 1996, CHEM PHYS LIPIDS, V81, P151, DOI 10.1016/0009-3084(96)02579-0; LAFLEUR M, 1990, BIOCHEM CELL BIOL, V68, P1, DOI 10.1139/o90-001; LEE YC, 1993, BIOPHYS J, V65, P1429, DOI 10.1016/S0006-3495(93)81206-2; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; Morein S, 1996, J BIOL CHEM, V271, P6801, DOI 10.1074/jbc.271.12.6801; Naciff JM, 1996, AM J PHYSIOL-CELL PH, V271, pC2004; ORTEGAPIERRES G, 1984, PARASITOLOGY, V88, P359, DOI 10.1017/S0031182000054603; Rauch J, 1998, THROMB HAEMOSTASIS, V80, P936; RAUSCH J, 1990, P NATL ACAD SCI USA, V87, P4112; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; SMAAL EB, 1987, BIOCHIM BIOPHYS ACTA, V897, P453, DOI 10.1016/0005-2736(87)90442-1; Verkleij AJ, 1991, MEMBRANE FUSION, P155; Wegener J, 1996, CHEM PHYS LIPIDS, V81, P229, DOI 10.1016/0009-3084(96)02585-6	23	34	43	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25193	25196		10.1074/jbc.274.36.25193	http://dx.doi.org/10.1074/jbc.274.36.25193			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464237	hybrid			2022-12-25	WOS:000082554200002
J	Alphey, MS; Leonard, GA; Gourley, DG; Tetaud, E; Fairlamb, AH; Hunter, WN				Alphey, MS; Leonard, GA; Gourley, DG; Tetaud, E; Fairlamb, AH; Hunter, WN			The high resolution crystal structure of recombinant Crithidia fasciculata tryparedoxin-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2.2 ANGSTROM RESOLUTION; ESCHERICHIA-COLI; HYDROGEN-BOND; ACTIVE-SITE; C-H...O; MACROMOLECULAR STRUCTURES; DISULFIDE OXIDOREDUCTASE; THIOREDOXIN PEROXIDASE; REDOX PROPERTIES; DIFFRACTION DATA	Tryparedoxin-I is a recently discovered thiol-disulfide oxidoreductase involved in the regulation of oxidative stress in parasitic trypanosomatids, The crystal structure of recombinant Crithidia fasciculata tryparedoxin-I in the oxidized state has been determined using multi-wavelength anomalous dispersion methods applied to a selenomethionyl derivative. The model comprises residues 3 to 145 with 236 water molecules and has been refined using all data between a 19- and 1.4-Angstrom resolution to an R-factor and R-free of 19.1 and 22.3%, respectively. Despite sharing only about 20% sequence identity, tryparedoxin-I presents a five-stranded twisted beta-sheet and two elements of helical structure in the same type of fold as displayed by thioredoxin, the archetypal thiol disulfide oxidoreductase, However, the relationship of secondary structure with the linear amino acid sequences is different for each protein, producing a distinctive topology. The beta-sheet core is extended in the trypanosomatid protein with an N-terminal beta-hairpin, There are also differences in the content and orientation of helical elements of secondary structure positioned at the surface of the proteins, which leads to different shapes and charge distributions between human thioredoxin and tryparedoxin-I. A right-handed redox-active disulfide is formed between Cys-40 and Cys-43 at the N-terminal region of a distorted cu-helix (arl), Cys-40 is solvent-accessible, and Cys-43 is positioned in a hydrophilic cavity, Three C-H ... O hydrogen bonds donated from two proline residues serve to stabilize the disulfide-carrying helix and support the correct alignment of active site residues. The accurate model for tryparedoxin-I allows for comparisons with the family of thiol-disulfide oxidoreductases and provides a template for the discovery or design of selective inhibitors of hydroperoxide metabolism in trypanosomes. Such inhibitors are sought as potential therapies against a range of human pathogens.	Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; European Synchrotron Radiat Facil, Joint Struct Biol Grp, F-38043 Grenoble, France; Univ Bordeaux 2, Mol Parasitol Lab, CNRS, UPRESA 5016, F-33076 Bordeaux, France	University of Dundee; European Synchrotron Radiation Facility (ESRF); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Hunter, WN (corresponding author), Univ Dundee, Dept Biochem, Wellcome Trust Bldg, Dundee DD1 5EH, Scotland.		Hunter, William/AAE-3947-2019; Fairlamb, Alan/A-5272-2009; Leonard, Gordon/D-2160-2019	Fairlamb, Alan/0000-0001-5134-0329; Leonard, Gordon/0000-0001-5030-0122				Alphey MS, 1999, J STRUCT BIOL, V126, P76, DOI 10.1006/jsbi.1999.4091; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BAILEY S, 1993, EUR J BIOCHEM, V213, P67, DOI 10.1111/j.1432-1033.1993.tb17734.x; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; Bond CS, 1999, STRUCTURE, V7, P81, DOI 10.1016/S0969-2126(99)80011-2; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chakrabarti P, 1998, J MOL BIOL, V284, P867, DOI 10.1006/jmbi.1998.2199; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DEREWENDA ZS, 1994, J MOL BIOL, V241, P83, DOI 10.1006/jmbi.1994.1475; DESIRAJU GR, 1991, ACCOUNTS CHEM RES, V24, P290, DOI 10.1021/ar00010a002; DOCAMPO R, 1990, CHEM-BIOL INTERACT, V73, P1, DOI 10.1016/0009-2797(90)90106-W; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V20, P3685; GANE PJ, 1995, J MOL BIOL, V249, P376, DOI 10.1006/jmbi.1995.0303; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; Hu SH, 1997, J MOL BIOL, V268, P137, DOI 10.1006/jmbi.1997.0940; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jacobi A, 1997, J BIOL CHEM, V272, P21692, DOI 10.1074/jbc.272.35.21692; Jeng MF, 1998, EUR J BIOCHEM, V257, P299, DOI 10.1046/j.1432-1327.1998.2570299.x; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATTI SK, 1995, PROTEIN SCI, V4, P1998, DOI 10.1002/pro.5560041005; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levick MP, 1998, MOL BIOCHEM PARASIT, V96, P125, DOI 10.1016/S0166-6851(98)00122-4; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Montemartini M, 1998, BIOL CHEM, V379, P1137, DOI 10.1515/bchm.1998.379.8-9.1137; Montemartini M, 1998, J BIOL CHEM, V273, P4864, DOI 10.1074/jbc.273.9.4864; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1993, GRASP MANUAL VERSION; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Ravelli RBG, 1997, J APPL CRYSTALLOGR, V30, P551, DOI 10.1107/S0021889897003543; Ren B, 1998, NAT STRUCT BIOL, V5, P602, DOI 10.1038/862; SAARINEN M, 1995, STRUCTURE, V3, P1097, DOI 10.1016/S0969-2126(01)00245-3; STEINER T, 1993, J AM CHEM SOC, V115, P4540, DOI 10.1021/ja00064a016; Sun CH, 1998, J MOL BIOL, V280, P687, DOI 10.1006/jmbi.1998.1913; TAYLOR R, 1982, J AM CHEM SOC, V104, P5063, DOI 10.1021/ja00383a012; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; Tetaud E, 1998, MOL BIOCHEM PARASIT, V96, P111, DOI 10.1016/S0166-6851(98)00120-0; WANG CC, 1997, PARASITOLOGY, V114, P31; WEBSTER LT, 1990, PHARMACOL BASIS THER, P954; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; Westhead DR, 1998, TRENDS BIOCHEM SCI, V23, P35, DOI 10.1016/S0968-0004(97)01161-4; *WHO, 1993, 10 WHO; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	68	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25613	25622		10.1074/jbc.274.36.25613	http://dx.doi.org/10.1074/jbc.274.36.25613			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464297	hybrid			2022-12-25	WOS:000082554200061
J	Bretz, JD; Arscott, PL; Myc, A; Baker, JR				Bretz, JD; Arscott, PL; Myc, A; Baker, JR			Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN T-CELLS; HASHIMOTOS-THYROIDITIS; GRAVES-DISEASE; DEATH; LIGAND; MECHANISMS; EXPRESSION; INVOLVEMENT; PATHOGENESIS	The occurrence of apoptosis in thyroid follicular cells induced by Fas activation has been a subject of much debate. This is due, in part, to the fact that no physiologically relevant treatment conditions have been reported to cause rapid and extensive Fas-mediated apoptosis in thyroid cells, whereas treatment with the protein synthesis inhibitor cycloheximide prior to Fas activation allows for massive cell death. This indicates that the Fas signaling pathway is present but that its function is blocked in the overwhelming majority of cultured thyroid cells. To reconcile the conflicting reports, we set out to identify physiologically relevant conditions in which rapid, massive thyroid cell apoptosis in response to Fas activation could be demonstrated. We determined that susceptibility to Fas-activated apoptosis could be influenced by certain combinations of inflammatory cytokines. Although no single cytokine was effective, pretreatment of thyroid cells with the combination of gamma-interferon and either tumor necrosis factor-alpha or interleukin 1 beta allowed for massive Fas-mediated apoptosis. Susceptibility to Fas-induced death correlated with an increase in expression of a tunicamycin-inhibitable high molecular weight form of Fas but not with aggregate expression of Fas.	Univ Michigan, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Baker, JR (corresponding author), Univ Michigan, Med Ctr, Dept Med, 9220 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	jbakerjr@umich.edu			NIAID NIH HHS [R01 AI37141] Funding Source: Medline; NIDDK NIH HHS [P60DK20572] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Arscott PL, 1997, ENDOCRINOLOGY, V138, P5019, DOI 10.1210/en.138.11.5019; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; DARZYNKIEWICZ Z, 1997, MANUAL CLIN LAB IMMU, P334; FIEDLER P, 1998, SCIENCE, V279, pA2015; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Hammond LJ, 1997, J PATHOL, V182, P138, DOI 10.1002/(SICI)1096-9896(199706)182:2<138::AID-PATH810>3.0.CO;2-F; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOBSON MD, 1994, BIOCHEM SOC T, V22, P600, DOI 10.1042/bst0220600; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Katsikis PD, 1997, J EXP MED, V186, P1365, DOI 10.1084/jem.186.8.1365; Kawakami A, 1996, ENDOCRINOLOGY, V137, P3163, DOI 10.1210/en.137.8.3163; Kawakami A, 1997, CLIN EXP IMMUNOL, V110, P434, DOI 10.1046/j.1365-2249.1997.4301447.x; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOTANI T, 1995, AUTOIMMUNITY, V20, P231, DOI 10.3109/08916939508995700; Lendeckel U, 1997, IMMUNOBIOLOGY, V197, P55, DOI 10.1016/S0171-2985(97)80057-5; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Luttmann W, 1998, EUR J IMMUNOL, V28, P2057, DOI 10.1002/(SICI)1521-4141(199807)28:07<2057::AID-IMMU2057>3.0.CO;2-T; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1998, INTERNAL MED, V37, P179, DOI 10.2169/internalmedicine.37.179; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; Roura-Mir C, 1997, EUR J IMMUNOL, V27, P3290, DOI 10.1002/eji.1830271228; Rudin CM, 1997, ANNU REV MED, V48, P267; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; Smith D, 1998, J IMMUNOL, V160, P4159; Stassi G, 1999, J IMMUNOL, V162, P263; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STOKES TA, 1998, SCIENCE, V279, pA2015; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tamura M, 1998, ENDOCRINOLOGY, V139, P3646, DOI 10.1210/en.139.8.3646; TANIMOTO C, 1995, ENDOCR J, V42, P193, DOI 10.1507/endocrj.42.193; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wyllie A H, 1980, Int Rev Cytol, V68, P251	43	72	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25433	25438		10.1074/jbc.274.36.25433	http://dx.doi.org/10.1074/jbc.274.36.25433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464273	hybrid			2022-12-25	WOS:000082554200037
J	Hellmark, T; Burkhardt, H; Wieslander, J				Hellmark, T; Burkhardt, H; Wieslander, J			Goodpasture disease - Characterization of a single conformational epitope as the target of pathogenic autoantibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR BASEMENT-MEMBRANE; IV COLLAGEN; ALPHA-3(IV) CHAIN; MONOCLONAL-ANTIBODIES; GLOBULAR DOMAIN; ANTIGEN; IDENTIFICATION; AUTOANTIGEN; CARTILAGE; PROTEINS	Goodpasture disease is a prototype autoimmune disease characterized by the formation of autoantibodies against the heterotrimeric basement membrane collagen type IV, which causes a rapidly progressive glomerulonephritis, The pathogenic antibody response is directed to the non-collagenous (NC1) domain of the alpha 3 chain of type IV collagen (alpha 3(IV)NC1), but not to the homologous region of the alpha 1(IV)NC1, To identify the conformation-dependent immunodominant epitope on the alpha 3(IV)NC1, a variety of recombinant NC1 domains were constructed by replacing single residues of alpha 3(IV) with the corresponding amino acids from the nonreactive alpha 1(IV) chain. Replacement mutations were identified that completely destroyed the Goodpasture epitope in the alpha 3(IV) chain. Based on the identification of these critical positions, the epitope was finally reconstructed within the frame of the alpha 1(IV) chain. The substitution of nine discontinuous positions in the alpha 1(IV)NC1 with amino acid residues from the alpha 3 chain resulted in a recombinant construct that was recognized by all patients' sera (n = 20) but by none of the sera from healthy controls (n = 10). This provides, for the first time, the molecular characterization of a single immunodominant conformational epitope recognized by pathogenic autoantibodies in a human autoimmune disease, representing the basis for the development of new epitope-specific strategies in the treatment of Goodpasture disease.	Univ Lund, Dept Nephrol, S-22185 Lund, Sweden; Univ Erlangen Nurnberg, Dept Internal Med 3, D-91054 Erlangen, Germany; Wieslab AB, S-22370 Lund, Sweden	Lund University; University of Erlangen Nuremberg	Hellmark, T (corresponding author), Univ Lund Hosp, Dept Nephrol, S-22185 Lund, Sweden.		Hellmark, Thomas/U-6289-2017	Hellmark, Thomas/0000-0002-2952-1155				AHMED EE, 1996, AUTOANTIBODIES, P185; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Girkontaite I, 1996, MATRIX BIOL, V15, P231, DOI 10.1016/S0945-053X(96)90114-6; Goodpasture EW, 1919, AM J MED SCI, V158, P863, DOI 10.1097/00000441-191911000-00012; HELLMARK T, 1994, KIDNEY INT, V46, P823, DOI 10.1038/ki.1994.338; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JOHANSSON C, 1991, CONNECT TISSUE RES, V25, P229, DOI 10.3109/03008209109029159; KALLURI R, 1991, J BIOL CHEM, V266, P24018; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; KALLURI R, 1995, J AM SOC NEPHROL, V6, P1178; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; PUSEY CD, 1987, LAB INVEST, V56, P23; QUINONES S, 1992, J BIOL CHEM, V267, P19780; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; Ryan JJ, 1998, CLIN EXP IMMUNOL, V113, P17, DOI 10.1046/j.1365-2249.1998.00623.x; SAUS J, 1988, J BIOL CHEM, V263, P13374; Schulte S, 1998, J BIOL CHEM, V273, P1551, DOI 10.1074/jbc.273.3.1551; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; STANTON M. C., 1958, AUSTRALASEAN ANN MED, V7, P132; TURNER N, 1993, DISEASES KIDNEY, P1865; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P1544, DOI 10.1073/pnas.81.5.1544; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564	25	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25862	25868		10.1074/jbc.274.36.25862	http://dx.doi.org/10.1074/jbc.274.36.25862			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464328	hybrid			2022-12-25	WOS:000082554200092
J	Ong, E; Yeh, JC; Ding, YL; Hindsgaul, O; Pedersen, LC; Negishi, M; Fukuda, M				Ong, E; Yeh, JC; Ding, YL; Hindsgaul, O; Pedersen, LC; Negishi, M; Fukuda, M			Structure and function of HNK-1 sulfotransferase - Identification of donor and acceptor binding sites by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; MYELIN-ASSOCIATED GLYCOPROTEIN; MONOCLONAL-ANTIBODY HNK-1; SULFATED GLUCURONIC-ACID; HEPARAN-SULFATE; CARBOHYDRATE EPITOPE; ESTROGEN SULFOTRANSFERASE; L2/HNK-1 CARBOHYDRATE; NERVOUS-SYSTEM; MUTATIONAL ANALYSIS	HNK-1 glycan, sulfo-->3GlcA beta 1-->3Gal beta 1-->4GlcNAc-->R, is uniquely enriched in neural cells and natural killer cells and is thought to play important roles in cell-cell interaction. HNK-1 glycan synthesis is dependent on HNK-1 sulfotransferase (HNK-1ST), and cDNAs encoding human and rat HNK-1ST have been recently cloned. HNK-1ST belongs to the sulfotransferase gene family, which shares two homologous sequences in their catalytic domains. In the present study, we have individually mutated amino acid residues in these conserved sequences and determined how such mutations affect the binding to the donor substrate, adenosine 3'-phosphate 5'-phosphosulfate, and an acceptor. Mutations of Lys(128), Arg(189), Asp(190), Pro(191), and Ser(197) to Ala all abolished the enzymatic activity. When Lys(128) and Asp(190) were conservatively mutated to Arg and Glu, respectively, however, the mutated enzymes still maintained residual activity, and both mutant enzymes still bound to adenosine 3',5'-diphosphate-agarose. K128R and D190E mutant enzymes, on the other hand, exhibited reduced affinity to the acceptor as demonstrated by kinetic studies. These findings, together with those on the crystal structure of estrogen sulfotransferase and heparan sulfate N deacetylase/sulfotransferase, suggest that Lys(128) may be close to the 3-hydroxyl group of beta-glucuronic acid in a HNK-1 acceptor. In contrast, the effect by mutation at Asp(190) may be due to conformational change because this amino acid and Pro(191) reside in a transition of the secondary structure of the enzyme. These results indicate that conserved amino acid residues in HNK-1ST play roles in maintaining a functional conformation and are directly involved in binding to donor and acceptor substrates.	Burnham Inst, Glycobiol Program, Ctr Canc Res, La Jolla, CA 92037 USA; NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	Sanford Burnham Prebys Medical Discovery Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Fukuda, M (corresponding author), Burnham Inst, Glycobiol Program, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Negishi, Masahiko/F-7805-2019; Pedersen, Lars/C-6173-2019	Negishi, Masahiko/0000-0002-2076-8928; Pedersen, Lars/0000-0002-4488-4077	NCI NIH HHS [R01 CA33895, P01 CA71932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895, P01CA071932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; ARIGA T, 1987, J BIOL CHEM, V262, P848; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; BRONNERFRASER M, 1986, DEV BIOL, V115, P44, DOI 10.1016/0012-1606(86)90226-5; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; Cloutier J, 1996, MOL PLANT MICROBE IN, V9, P523, DOI 10.1094/MPMI-9-0523; COLE GJ, 1987, NEUROSCI LETT, V78, P227, DOI 10.1016/0304-3940(87)90638-0; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Ding YL, 1998, BIOORG MED CHEM LETT, V8, P1903, DOI 10.1016/S0960-894X(98)00332-1; EISENMAN LM, 1993, J COMP NEUROL, V335, P586, DOI 10.1002/cne.903350410; FILBIN MT, 1991, NEURON, V7, P845, DOI 10.1016/0896-6273(91)90286-9; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; GENNARINI G, 1989, J NEUROSCI RES, V22, P1, DOI 10.1002/jnr.490220102; GRIFFITH LS, 1992, J NEUROSCI RES, V33, P639, DOI 10.1002/jnr.490330417; Habuchi H, 1998, TRENDS GLYCOSCI GLYC, V10, P65, DOI 10.4052/tigg.10.65; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; KATUTA Y, 1999, J BIOL CHEM, V274, P10673; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; KONG ANT, 1993, BIOCHIM BIOPHYS ACTA, V1171, P315, DOI 10.1016/0167-4781(93)90073-M; KONG ANT, 1993, PHARMACEUT RES, V10, P627, DOI 10.1023/A:1018926825475; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Ouyang YB, 1998, J BIOL CHEM, V273, P24770, DOI 10.1074/jbc.273.38.24770; POWERS PA, 1991, GENETICS, V129, P133; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; VARIN L, 1992, P NATL ACAD SCI USA, V89, P1286, DOI 10.1073/pnas.89.4.1286; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; Yoshinari K, 1998, J BIOCHEM-TOKYO, V123, P479	49	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25608	25612		10.1074/jbc.274.36.25608	http://dx.doi.org/10.1074/jbc.274.36.25608			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464296	hybrid			2022-12-25	WOS:000082554200060
J	Taylor, P; Anderson, V; Dowden, J; Flitsch, SL; Turner, NJ; Loughran, K; Walkinshaw, MD				Taylor, P; Anderson, V; Dowden, J; Flitsch, SL; Turner, NJ; Loughran, K; Walkinshaw, MD			Novel mechanism of inhibition of elastase by beta-lactams is defined by two inhibitor crystal complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE PANCREATIC ELASTASE; HUMAN-LEUKOCYTE ELASTASE; IONIZATION MASS-SPECTROMETRY; E-I-COMPLEXES; ISOCOUMARIN INHIBITORS; 7-AMINO SUBSTITUENT; ANGSTROM RESOLUTION; MOLECULAR-STRUCTURE; INTERMEDIATE; KINETICS	Two structurally related beta-lactams form different covalent complexes upon reaction with porcine elastase, The high resolution x-ray structures of these two complexes provide a clear insight into the mechanism of the reaction and suggest the design of a new class of serine protease inhibitors that resist enzyme reactivation by hydrolysis of the acyl intermediate. The presence of a hydroxyethyl substituent on the beta-lactam ring provides a new reaction pathway resulting in the elimination of the hydroxyethyl group and the formation of a stabilizing conjugated double bond system. In contrast, the presence of a diethyl substituent on the beta-lactam ring leads to addition of water. The two enzyme complexes show very different binding modes in the enzyme active site.	Univ Edinburgh, Struct Biochem Grp, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Edinburgh, Edinburgh Ctr Prot Technol, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Edinburgh, Edinburgh Ctr Prot Technol, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; Nycomed Amersham PLC, Amersham HP7 9LL, England	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh	Walkinshaw, MD (corresponding author), Univ Edinburgh, Struct Biochem Grp, Michael Swann Bldg,Kings Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.		Flitsch, Sabine/AAJ-6812-2020; walkinshaw, malcolm/AAB-7497-2019; Dowden, James/N-5739-2014	Dowden, James/0000-0002-7825-8971; Flitsch, Sabine/0000-0003-3974-646X; walkinshaw, malcolm/0000-0001-5955-9325; Turner, Nicholas/0000-0002-8708-0781				BIRRER P, 1994, AM J RESP CRIT CARE, V150, P207, DOI 10.1164/ajrccm.150.1.7912987; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; Brown RPA, 1996, BIOCHEMISTRY-US, V35, P12421, DOI 10.1021/bi961044g; CHEN CCH, 1992, J MOL BIOL, V224, P1103, DOI 10.1016/0022-2836(92)90472-V; EDWARDS PD, 1992, J AM CHEM SOC, V114, P1854, DOI 10.1021/ja00031a046; GREEN BG, 1995, BIOCHEMISTRY-US, V34, P14331, DOI 10.1021/bi00044a010; HERNANDEZ MA, 1992, J MED CHEM, V35, P1121, DOI 10.1021/jm00084a018; HUANG K, 1994, STRUCTURE, V2, P679, DOI 10.1016/S0969-2126(00)00068-X; Janusz MJ, 1997, INFLAMM RES, V46, P503, DOI 10.1007/s000110050233; KERRIGAN JE, 1995, J MED CHEM, V38, P544, DOI 10.1021/jm00003a017; KNOWLES JR, 1985, ACCOUNTS CHEM RES, V18, P97, DOI 10.1021/ar00112a001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MATTOS C, 1994, NAT STRUCT BIOL, V1, P55, DOI 10.1038/nsb0194-55; MATTOS C, 1995, BIOCHEMISTRY-US, V34, P3193, DOI 10.1021/bi00010a008; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NAVIA MA, 1987, NATURE, V327, P79, DOI 10.1038/327079a0; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; PEISACH E, 1995, SCIENCE, V269, P66, DOI 10.1126/science.7604279; POWERS JC, 1990, BIOCHEMISTRY-US, V29, P3108, DOI 10.1021/bi00464a030; Sheldrick G. M., 1997, SHELX 97; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TAKAHASHI LH, 1989, BIOCHEMISTRY-US, V28, P7610, DOI 10.1021/bi00445a016; TAKAHASHI LH, 1988, J MOL BIOL, V201, P423, DOI 10.1016/0022-2836(88)90148-9; Tew DG, 1998, BIOCHEMISTRY-US, V37, P10087, DOI 10.1021/bi9801412; Tsunemi M, 1996, BIOCHEMISTRY-US, V35, P11570, DOI 10.1021/bi960900l; UNDERWOOD DJ, 1995, BIOCHEMISTRY-US, V34, P14344, DOI 10.1021/bi00044a011; VIJAYALAKSHMI J, 1991, BIOCHEMISTRY-US, V30, P2175, DOI 10.1021/bi00222a022; WEI AZ, 1988, FEBS LETT, V234, P367; Wilmouth RC, 1997, NAT STRUCT BIOL, V4, P456, DOI 10.1038/nsb0697-456; Wilmouth RC, 1998, BIOCHEMISTRY-US, V37, P17506, DOI 10.1021/bi9816249	30	16	16	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24901	24905		10.1074/jbc.274.35.24901	http://dx.doi.org/10.1074/jbc.274.35.24901			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455164	hybrid			2022-12-25	WOS:000082193400063
J	Byrd, JC; Devi, GR; De Souza, AT; Jirtle, RL; MacDonald, RG				Byrd, JC; Devi, GR; De Souza, AT; Jirtle, RL; MacDonald, RG			Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; FACTOR-BETA RECEPTORS; MANNOSE 6-PHOSPHATE; IGF-II; MANNOSE-6-PHOSPHATE RECEPTOR; HEPATOCELLULAR-CARCINOMA; LIVER CARCINOGENESIS; BREAST CARCINOMAS; CATHEPSIN-D; GENE	The insulin-like growth factor II/mannose 6-phosphate receptor (IGF2R) carries out multiple regulatory and transport functions, and disruption of IGF2R function has been implicated as a mechanism to increase cell proliferation. Several missense IGF2R mutations have been identified in human cancers, including the following amino acid substitutions occurring in the extracytoplasmic domain of the receptor: Cys-1262 --> Ser, Gln-1445 --> His, Gly-1449 --> Val, Gly-1464 --> Glu, and Ile-1572 --> Thr. To determine what effects these mutations have on IGF2R function, mutant and wild-type FLAG epitope-tagged IGF2R constructs lacking the transmembrane and cytoplasmic domains were characterized for binding of insulin-like growth factor (IGF)-II and a mannose 6-phosphate-bearing pseudoglycoprotein termed PMP-BSA (where PMP is pentamannose phosphate and BSA is bovine serum albumin). The Ile-1572 --> Thr mutation eliminated IGF-II binding while not affecting PMP-BSA binding. Gly-1449 --> Val and Cys-1262 --> Ser each showed 30-60% decreases in the number of sites available to bind both I-125-IGF-II and I-125-PMP-BSA In addition, the Gln-1445 --> His mutant underwent a time-dependent loss of IGF-II binding, but not PMP-BSA binding, that was not observed for wild type. In all, four of the five cancer-associated mutants analyzed demonstrated altered ligand binding, providing further evidence that loss of IGF2R function is characteristic of certain cancers.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Zeneca Pharmaceut, Dept Safety Med, Macclesfield SK10 4TG, Cheshire, England; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	University of Nebraska System; University of Nebraska Medical Center; Duke University	MacDonald, RG (corresponding author), 984525 Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.				NATIONAL CANCER INSTITUTE [R01CA025951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008823] Funding Source: NIH RePORTER; NCI NIH HHS [CA25951] Funding Source: Medline; NIDDK NIH HHS [DK44212] Funding Source: Medline; NIEHS NIH HHS [ES08823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BRAULKE T, 1988, BIOCHEM BIOPH RES CO, V150, P1287, DOI 10.1016/0006-291X(88)90769-3; Chappell SA, 1997, BRIT J CANCER, V76, P1558, DOI 10.1038/bjc.1997.596; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; GARMROUDI F, 1994, J BIOL CHEM, V269, P26944; Goldenberg David P., 1992, P353; Hankins GR, 1996, ONCOGENE, V12, P2003; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; KIESS W, 1990, EUR J BIOCHEM, V190, P71, DOI 10.1111/j.1432-1033.1990.tb15547.x; KIESS W, 1989, J BIOL CHEM, V264, P4710; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1990, BIOCHEM SOC T, V18, P367, DOI 10.1042/bst0180367; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MACDONALD RG, 1991, ENDOCRINOLOGY, V128, P413, DOI 10.1210/endo-128-1-413; Marron-Terada PG, 1998, J BIOL CHEM, V273, P22358, DOI 10.1074/jbc.273.35.22358; MATHIEU M, 1990, MOL ENDOCRINOL, V4, P1327, DOI 10.1210/mend-4-9-1327; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; MURRAY GJ, 1980, J BIOL CHEM, V255, P1942; OKA Y, 1986, J BIOL CHEM, V261, P9090; OKA Y, 1985, J BIOL CHEM, V260, P9435; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; Ouyang H, 1997, CANCER RES, V57, P1851; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERDUE JF, 1983, J BIOL CHEM, V258, P7800; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; ROSS JS, 1995, AM J CLIN PATHOL, V104, P36, DOI 10.1093/ajcp/104.1.36; Saltis J, 1996, MOL CELL ENDOCRINOL, V116, P227, DOI 10.1016/0303-7207(95)03721-7; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; SLEAT DE, 1995, CANCER RES, V55, P3424; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; TONG PY, 1989, J BIOL CHEM, V264, P7962; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164; Zaina S, 1998, ENDOCRINOLOGY, V139, P3886, DOI 10.1210/en.139.9.3886	52	78	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24408	24416		10.1074/jbc.274.34.24408	http://dx.doi.org/10.1074/jbc.274.34.24408			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446221	hybrid			2022-12-25	WOS:000082110900100
J	Child, SJ; Miller, MK; Geballe, AP				Child, SJ; Miller, MK; Geballe, AP			Translational control by an upstream open reading frame in the HER-2/neu transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; MESSENGER-RNA; NEU ONCOGENE; HUMAN-BREAST; 5'-UNTRANSLATED REGION; EUKARYOTIC RIBOSOMES; NEUROSPORA-CRASSA; PROTO-ONCOGENE; AUG CODON	Overexpression of the HER-2 (neu, erbB-2) receptor results in cellular transformation and is associated with a variety of human cancers. Multiple mechanisms, including gene amplification and transcriptional, posttranscriptional, and translational controls contribute to the regulation of HER-S expression, One of the components of these regulatory mechanisms is a short upstream open reading frame (uORF) in the HER-2 mRNA that represses downstream translation in a variety of cell types. Here we explore the mechanism by which this uORF exerts its inhibitory effect. As judged by comparisons of protein and mRNA abundance and by polysomal distribution analyses, the uORF represses translation of the HER-2 cistron or of a heterologous reporter gene. Despite its conservation among mammalian species, the peptide sequence of the uORF is not required for this inhibitory effect. Rather, the majority of ribosomes that load on the HER-S mRNA most likely translate the uORF and are then unable to reinitiate at the downstream AUG codon, in part due to the short intercistronic spacing. A minority of ribosomes gain access to the HER-P initiation codon either by leaky scanning past the upstream AUG codon or by reinitiating after having translated the uORF despite the short intercistronic region. These results suggest that the HER-2 uORF controls synthesis of this oncoprotein by limiting ribosomal access to downstream initiation sites.	Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Geballe, AP (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, 1100 Fairview Ave N,Mailstop C2-023,POB 19024, Seattle, WA 98109 USA.			Child, Stephanie/0000-0002-1987-9540				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERGER MS, 1988, CANCER RES, V48, P1238; BIEGALKE BJ, 1990, VIROLOGY, V177, P657, DOI 10.1016/0042-6822(90)90531-U; BUHRING HJ, 1995, BLOOD, V86, P1916, DOI 10.1182/blood.V86.5.1916.bloodjournal8651916; CAO JH, 1995, J VIROL, V69, P1030, DOI 10.1128/JVI.69.2.1030-1036.1995; Cao JH, 1996, MOL CELL BIOL, V16, P603; Cao JH, 1996, MOL CELL BIOL, V16, P7109; Child SJ, 1999, INT J BIOCHEM CELL B, V31, P201, DOI 10.1016/S1357-2725(98)00068-5; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEGNIN CR, 1993, J VIROL, V67, P5514, DOI 10.1128/JVI.67.9.5514-5521.1993; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GRANT CM, 1994, MOL CELL BIOL, V14, P606, DOI 10.1128/MCB.14.1.606; GUERIN M, 1988, ONCOGENE RES, V3, P21; HILL JR, 1993, J BIOL CHEM, V268, P726; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; LIU E, 1992, ONCOGENE, V7, P1027; Luo ZL, 1996, J BACTERIOL, V178, P2172, DOI 10.1128/jb.178.8.2172-2177.1996; MATTHEWS MB, 1996, TRANSLATIONAL CONTRO, P1; NAKAMURA T, 1994, GENE, V140, P251, DOI 10.1016/0378-1119(94)90553-3; OSHIMA M, 1995, J NEUROCHEM, V65, P427; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Reynolds K, 1996, J CELL BIOL, V134, P827, DOI 10.1083/jcb.134.4.827; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHLEISS MR, 1991, J VIROL, V65, P6782, DOI 10.1128/JVI.65.12.6782-6789.1991; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SIEBERT PD, 1993, NUCLEIC ACIDS RES, V21, P2019, DOI 10.1093/nar/21.8.2019; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Steel LF, 1996, CELL GROWTH DIFFER, V7, P1415; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; Wang LJ, 1998, PLANT CELL, V10, P1733, DOI 10.1105/tpc.10.10.1733; Wang Z, 1997, J BIOL CHEM, V272, P255; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; WHITE MRA, 1992, ONCOGENE, V7, P677; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	54	89	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24335	24341		10.1074/jbc.274.34.24335	http://dx.doi.org/10.1074/jbc.274.34.24335			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446211	hybrid			2022-12-25	WOS:000082110900090
J	Hsu, CC; Thomas, C; Chen, WQ; Davis, KM; Foos, T; Chen, JL; Wu, E; Floor, E; Schloss, JV; Wu, JY				Hsu, CC; Thomas, C; Chen, WQ; Davis, KM; Foos, T; Chen, JL; Wu, E; Floor, E; Schloss, JV; Wu, JY			Role of synaptic vesicle proton gradient and protein phosphorylation on ATP-mediated activation of membrane-associated brain glutamate decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; PANCREATIC BETA-CELLS; ACID DECARBOXYLASE; MONOCLONAL-ANTIBODIES; MOLECULAR-FORMS; 2 FORMS; GAD; PURIFICATION; INHIBITION; IDENTIFICATION	Previously, me have shown that the soluble form of brain glutamic acid decarboxylase (GAD) is inhibited by ATP through protein phosphorylation and is activated by calcineurin-mediated protein dephosphorylation (Bao, J., Cheung, W. Y., and Wu, J. Y. (1995) J. Biol. Chem. 270, 6464-6467); Here we report that the membrane-associated form of GAD (MGAD) is greatly activated by ATP, whereas adenosine 5'-[beta,gamma-imido]triphosphate (AMP-PNP), a non-hydrolyzable ATP analog, has no effect on MGAD activity. ATP activation of MGAD is abolished by conditions that disrupt the proton gradient of synaptic vesicles, e.g. the presence of vesicular proton pump inhibitor, bafilomycin Al, the protonophore carbonyl cyanide m-chorophenylhydrazone or the ionophore gramicidin, indicating that the synaptic vesicle proton gradient is essential in ATP activation of MGAD. Furthermore, direct incorporation of P-32 from [gamma-(32)p] ATP into MGAD has been demonstrated. In addition, MGAD (presumably GAD65, since it is recognized by specific monoclonal antibody, GAD6, as well as specific anti-GAD65) has been reported to be associated with synaptic vesicles. Based on these results, a model linking gamma-aminobutyric acid (GABA) synthesis by MGAD to GABA packaging into synaptic vesicles by proton gradient-mediated GABA transport is presented. Activation of MGAD by phosphorylation appears to be mediated by a vesicular protein kinase that is controlled by the vesicular proton gradient.	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA; Acad Sinica, Inst Biol Chem, Taipei, Taiwan	University of Kansas; University of Kansas; Academia Sinica - Taiwan	Wu, JY (corresponding author), Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA.	jywu@kuhub.cc.ukans.edu		Schloss, John/0000-0002-6586-7508				BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BAO J, 1995, J BIOL CHEM, V270, P6464, DOI 10.1074/jbc.270.12.6464; BAO J, 1994, J BIOMED SCI, V1, P2325; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Chen CH, 1998, ARCH BIOCHEM BIOPHYS, V349, P175, DOI 10.1006/abbi.1997.0457; CHRISTGAU S, 1992, J CELL BIOL, V118, P309, DOI 10.1083/jcb.118.2.309; DENNER LA, 1985, J NEUROCHEM, V44, P957, DOI 10.1111/j.1471-4159.1985.tb12910.x; DENNER LA, 1987, P NATL ACAD SCI USA, V84, P668, DOI 10.1073/pnas.84.3.668; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GOTTLIEB DI, 1986, P NATL ACAD SCI USA, V83, P8808, DOI 10.1073/pnas.83.22.8808; HAGOPIAN WA, 1993, DIABETES, V42, P631, DOI 10.2337/diabetes.42.4.631; HENRY S, 1991, NEUROSCI LETT, V131, P253, DOI 10.1016/0304-3940(91)90626-5; ITOH M, 1981, NEUROCHEM RES, V6, P1283, DOI 10.1007/BF00964349; Kash SF, 1997, P NATL ACAD SCI USA, V94, P14060, DOI 10.1073/pnas.94.25.14060; KAUFMAN DL, 1991, J NEUROCHEM, V56, P720, DOI 10.1111/j.1471-4159.1991.tb08211.x; MARTIN DL, 1991, J NEUROSCI, V11, P2725; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; MEELEY MP, 1983, CELL MOL NEUROBIOL, V3, P39, DOI 10.1007/BF00734997; MILLER LP, 1978, J NEUROCHEM, V30, P361, DOI 10.1111/j.1471-4159.1978.tb06538.x; Namchuk M, 1997, J BIOL CHEM, V272, P1548, DOI 10.1074/jbc.272.3.1548; NATHAN B, 1994, J BIOL CHEM, V269, P7249; NATHAN B, 1995, J NEUROSCI RES, V40, P134, DOI 10.1002/jnr.490400115; NATHAN B, 1994, BRAIN RES, V642, P297, DOI 10.1016/0006-8993(94)90934-2; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; ROBERTS EUGENE, 1968, BRAIN RES, V8, P1, DOI 10.1016/0006-8993(68)90170-4; SEISSLER J, 1993, J CLIN INVEST, V92, P1394, DOI 10.1172/JCI116714; Soghomonian JJ, 1997, SYNAPSE, V27, P122, DOI 10.1002/(SICI)1098-2396(199710)27:2<122::AID-SYN3>3.0.CO;2-G; SOLIMENA M, 1991, TRENDS NEUROSCI, V14, P452, DOI 10.1016/0166-2236(91)90044-U; Sze P Y, 1979, Adv Exp Med Biol, V123, P59; Tang XW, 1997, J NEUROSCI, V17, P6947; TANG XW, 1996, J BIOMED SCI, V96, P442; TUNNICLIFF G, 1979, CAN J PHYSIOL PHARM, V57, P873, DOI 10.1139/y79-133; TURSKY T, 1978, J NEUROCHEM, V30, P903, DOI 10.1111/j.1471-4159.1978.tb10800.x; UBBINK JB, 1990, ENZYME, V43, P72, DOI 10.1159/000468709; WU JY, 1979, NEUROCHEM RES, V4, P575, DOI 10.1007/BF00964435; WU JY, 1973, J BIOL CHEM, V248, P3029; WU JY, 1974, J NEUROCHEM, V23, P759, DOI 10.1111/j.1471-4159.1974.tb04401.x; WU JY, 1986, BRAIN RES, V373, P1, DOI 10.1016/0006-8993(86)90309-4; WU JY, 1976, NERVOUS SYSTEM FUNCT, P7; YANG SD, 1994, J BIOL CHEM, V269, P29855	40	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24366	24371		10.1074/jbc.274.34.24366	http://dx.doi.org/10.1074/jbc.274.34.24366			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446215	hybrid			2022-12-25	WOS:000082110900094
J	Miyata, M; Kudo, G; Lee, YH; Yang, TJ; Gelboin, HV; Fernandez-Salguero, P; Kimura, S; Gonzalez, FJ				Miyata, M; Kudo, G; Lee, YH; Yang, TJ; Gelboin, HV; Fernandez-Salguero, P; Kimura, S; Gonzalez, FJ			Targeted disruption of the microsomal epoxide hydrolase gene - Microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-dimethylbenz[a]anthracene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT HUMAN-LIVER; COMPLEMENTARY-DNA; MESSENGER-RNA; DIOL-EPOXIDE; EXPRESSION; CELLS; MICE; SUSCEPTIBILITY; 7,12-DIMETHYLBENZ(A)ANTHRACENE; METABOLISM	Microsomal epoxide hydrolase (mEH) is a conserved enzyme that is known to hydrolyze many drugs and carcinogens, and a few endogenous steroids and bile acids. mEH-null mice were produced and found to be fertile and have no phenotypic abnormalities thus indicating that mEH is not critical for reproduction and physiological homeostasis, mEH has also been implicated in participating in the metabolic activation of polycyclic aromatic hydrocarbon carcinogens, Embryonic fibroblast derived from the mEH-null mice were unable to produce the proximate carcinogenic metabolite of 7,12-dimethylbenz[a]anthracene (DMBA), a widely studied experimental prototype for the polycylic aromatic hydrocarbon class of chemical carcinogens, They were also resistant to DMBA-mediated toxicity. Using the two-stage initiation-promotion skin cancer bioassay, the mEH-null mice were found to be highly resistant to DMBA-induced carcinogenesis. In a complete carcinogenesis bioassay, the mEH mice were totally resistant to tumorigenesis, These data establish in an intact animal model that mEH is a key genetic determinant in DMBA carcinogenesis through its role in production of the ultimate carcinogenic metabolite of DMBA, the 3,4-diol-1,2-epoxide.	NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; NCI, Mol Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gonzalez, FJ (corresponding author), NCI, Lab Metab, NIH, Bldg 37,Rm 3E-24, Bethesda, MD 20892 USA.		Fernandez-Salguero, Pedro M./J-8437-2014	Fernandez-Salguero, Pedro M./0000-0003-2839-5027	NATIONAL CANCER INSTITUTE [Z01BC005562, ZIABC005562] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUEHLER BA, 1990, NEW ENGL J MED, V322, P1567, DOI 10.1056/NEJM199005313222204; Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977; CHRISTOU M, 1994, CARCINOGENESIS, V15, P725, DOI 10.1093/carcin/15.4.725; CHRISTOU M, 1989, CARCINOGENESIS, V10, P1883, DOI 10.1093/carcin/10.10.1883; CRESTEIL T, 1985, EUR J BIOCHEM, V151, P345, DOI 10.1111/j.1432-1033.1985.tb09107.x; DIGIOVANNI J, 1980, CARCINOGENESIS, V1, P381, DOI 10.1093/carcin/1.5.381; DIPPLE A, 1978, CHEM-BIOL INTERACT, V20, P17, DOI 10.1016/0009-2797(78)90077-7; Eltom SE, 1998, CARCINOGENESIS, V19, P1437, DOI 10.1093/carcin/19.8.1437; FALANY CN, 1987, J BIOL CHEM, V262, P5924; FRENKEL K, 1995, FREE RADICAL BIO MED, V19, P373, DOI 10.1016/0891-5849(95)00046-Z; FRIEDBERG T, 1994, CARCINOGENESIS, V15, P171, DOI 10.1093/carcin/15.2.171; GAEDIGK A, 1994, PHARMACOGENETICS, V4, P142, DOI 10.1097/00008571-199406000-00005; GONZALEZ FJ, 1981, J BIOL CHEM, V256, P4697; GRANT DF, 1993, J BIOL CHEM, V268, P17628; GUENGERICH FP, 1982, REV BIOCHEM TOXICOL, V4, P5; GUENTHNER TM, 1990, CONJUGATION REACTION, P365; HASSETT C, 1994, GENOMICS, V23, P433, DOI 10.1006/geno.1994.1520; HASSETT C, 1989, ARCH BIOCHEM BIOPHYS, V271, P380, DOI 10.1016/0003-9861(89)90287-7; Hassett C, 1997, ARCH BIOCHEM BIOPHYS, V337, P275, DOI 10.1006/abbi.1996.9794; HENNINGS H, 1981, CANCER RES, V41, P773; Hennings H, 1997, MOL CARCINOGEN, V20, P143, DOI 10.1002/(SICI)1098-2744(199709)20:1<143::AID-MC16>3.0.CO;2-1; JERINA DM, 1983, DRUG METAB DISPOS, V11, P1; KANEKO S, 1991, REPROD TOXICOL, V5, P179, DOI 10.1016/0890-6238(91)90050-P; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAU HHS, 1995, CHEM RES TOXICOL, V8, P970, DOI 10.1021/tx00049a011; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LIM SK, 1992, MOL CELL BIOL, V12, P1149, DOI 10.1128/MCB.12.3.1149; MCGLYNN KA, 1995, P NATL ACAD SCI USA, V92, P2384, DOI 10.1073/pnas.92.6.2384; OESCH F, 1977, BIOCHEM PHARMACOL, V26, P603, DOI 10.1016/0006-2952(77)90032-6; Oesch F, 1983, Prog Clin Biol Res, V135, P81; OGURA K, 1990, MOL PHARMACOL, V37, P848; OMIECINSKI CJ, 1994, J PHARMACOL EXP THER, V269, P417; PACIFICI GM, 1983, ARCH TOXICOL, V54, P331, DOI 10.1007/BF01234486; PHILLIPS DH, 1994, DRUG METAB REV, V26, P443, DOI 10.3109/03602539409029808; PORTER TD, 1986, ARCH BIOCHEM BIOPHYS, V248, P121, DOI 10.1016/0003-9861(86)90408-X; Reiners JJ, 1997, CARCINOGENESIS, V18, P593, DOI 10.1093/carcin/18.3.593; SEIDEGARD J, 1983, BIOCHIM BIOPHYS ACTA, V695, P251, DOI 10.1016/0304-419X(83)90014-8; Shou MG, 1996, MOL CARCINOGEN, V17, P241, DOI 10.1002/(SICI)1098-2744(199612)17:4<241::AID-MC8>3.3.CO;2-9; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SKODA RC, 1988, J BIOL CHEM, V263, P1549; Smith CAD, 1997, LANCET, V350, P630, DOI 10.1016/S0140-6736(96)08061-0; TIERNEY B, 1978, CHEM-BIOL INTERACT, V23, P243, DOI 10.1016/0009-2797(78)90010-8; VOGELBINDEL U, 1982, EUR J BIOCHEM, V126, P425; vonDippe P, 1996, J BIOL CHEM, V271, P18176, DOI 10.1074/jbc.271.30.18176; WISLOCKI PG, 1980, CANCER RES, V40, P3661; Zhang J, 1996, RNA, V2, P235	46	162	166	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23963	23968		10.1074/jbc.274.34.23963	http://dx.doi.org/10.1074/jbc.274.34.23963			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446164	hybrid			2022-12-25	WOS:000082110900043
J	Wang, DM; Yu, X; Brecher, P				Wang, DM; Yu, X; Brecher, P			Nitric oxide inhibits angiotensin II-induced activation of the calcium-sensitive tyrosine kinase proline-rich tyrosine kinase 2 without affecting epidermal growth factor receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; PROTEIN-COUPLED RECEPTORS; RAT CARDIAC FIBROBLASTS; KINASE-SHC-GRB2-SOS PATHWAY; SIGNALING PATHWAY; EPITHELIAL-CELLS; EGF RECEPTOR; PYK2; PHOSPHORYLATION; MYOCYTES	In a previous study, me showed that nitric oxide donors and N-acetylcysteine, either alone or in combination, inhibited the activation of several mitogen-activated protein kinases by angiotensin II in rat cardiac fibroblasts (Wang, D., Yu, X., and Brecher, P. (1998) J. Biol. Chem. 273, 33027-33034). In the present study, we have focused on the mechanism by which nitric oxide exerts this effect on the activation of extracellular signal-regulated kinase (ERR). We contrasted the effects of nitric oxide on ERR activation by angiotensin II and epidermal growth factor (EGF), since the transactivation of the EGF receptor has been implicated as a response to angiotensin II. We found that nitric oxide inhibited ERK activation by angiotensin II but did not inhibit the relatively slight but significant transactivation of the EGF receptor by angiotensin II. The tyrphostin AG1478, known to inhibit EGF receptor phosphorylation, also inhibited the angiotensin II and EGF-induced activation of ERK; the phosphorylation of the EGF receptor, and the subsequent association of Shc and Grb2. Nitric oxide did not affect either EGF receptor phosphorylation or Shc-Grb2 activation induced by either Ang II or EGF. However, the activation of the calcium-sensitive tyrosine kinase PYK2, which occurred in response to angiotensin II, but not EGF, was inhibited by nitric oxide. The data suggested that PYK2 activation may be an important inhibitory site in signaling pathways affected by nitric oxide.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Brecher, P (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St, Boston, MA 02118 USA.			Brecher, Peter/0000-0002-9347-6643	NHLBI NIH HHS [HL55620, HL53471] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055620, R01HL053471] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Estrada C, 1997, BIOCHEM J, V326, P369, DOI 10.1042/bj3260369; Farivar RS, 1996, CIRC RES, V78, P759; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; Jiao HY, 1998, P NATL ACAD SCI USA, V95, P7417, DOI 10.1073/pnas.95.13.7417; Kelm M, 1997, J BIOL CHEM, V272, P9922; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; PERANOVICH TMS, 1995, BIOCHEM J, V305, P613, DOI 10.1042/bj3050613; Pomerance M, 1998, J BIOL CHEM, V273, P24301, DOI 10.1074/jbc.273.38.24301; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Wink DA, 1997, J BIOL CHEM, V272, P11147; Yu SM, 1997, CIRCULATION, V95, P1269	29	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24342	24348		10.1074/jbc.274.34.24342	http://dx.doi.org/10.1074/jbc.274.34.24342			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446212	hybrid			2022-12-25	WOS:000082110900091
J	Bretz, JD; Rymaszewski, M; Arscott, PL; Myc, A; Ain, KB; Thompson, NW; Baker, JR				Bretz, JD; Rymaszewski, M; Arscott, PL; Myc, A; Ain, KB; Thompson, NW; Baker, JR			TRAIL death pathway expression and induction in thyroid follicular cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING LIGAND; NF-KAPPA-B; HASHIMOTOS-THYROIDITIS; MEDIATED APOPTOSIS; RECEPTOR SIGNALS; APO-2 LIGAND; FAS ANTIGEN; T-CELLS; FAMILY; INHIBITOR	To determine whether programmed cell death in thyroid follicular cells can be related to activation of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway, we examined the expression and function of this pathway in primary thyroid follicular cells and a papillary thyroid carcinoma cell line in vitro. Despite the expression of TRAIL receptors death receptor 4 and death receptor 5, purified TRAIL could not induce programmed cell death (PCD) in any of the thyroid follicular cells examined. However, pre-incubation with cycloheximide before TRAIL facilitated the induction of rapid and massive PCD. This suggested that despite the presence of a labile inhibitor of the TRAIL pathway, TRAIL could mediate PCD under appropriate conditions. To determine whether there were sources of TRAIL in the thyroid that could interact with thyroid follicular cell TRAIL receptors, RNase protection assays were used to determine TRAIL mRNA expression. TRAIL message was expressed in intrathyroidal lymphocytes isolated from a patient with thyroiditis, and unexpectedly, thyroid follicular cells themselves could be induced to express abundant TRAIL message in the presence of the inflammatory cytokines interferon gamma, tumor necrosis factor alpha, and interleukin 1 beta. Furthermore, the papillary thyroid carcinoma cell line could be induced to kill the TRAIL-sensitive lymphoma cell line BJAB through a TRAIL-dependent mechanism.	Univ Michigan, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Surg, Ann Arbor, MI 48109 USA; Univ Kentucky, Med Ctr, Dept Internal Med, Lexington, KY 40536 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Kentucky	Baker, JR (corresponding author), Univ Michigan, Med Ctr, Dept Med, 9220 MSRB 3, Ann Arbor, MI 48109 USA.	jbakerjr@umich.edu	Ain, Kenneth/A-5179-2012	Ain, Kenneth/0000-0002-2668-934X	NIAID NIH HHS [AI 37141] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037141] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Arscott PL, 1997, ENDOCRINOLOGY, V138, P5019, DOI 10.1210/en.138.11.5019; BAKER JR, 1993, ENDOCR REV, V14, P729, DOI 10.1210/er.14.6.729; BAKER JR, 1995, J CLIN ENDOCR METAB, V80, P3419, DOI 10.1210/jc.80.12.3419; BOGNER U, 1988, IMMUNOBIOLOGY, V176, P423, DOI 10.1016/S0171-2985(88)80023-8; DARZYNKIEWICZ Z, 1997, MANUAL CLIN LAB IMMU, P334; Dayan CM, 1997, IMMUNOL TODAY, V18, P203; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Katsikis PD, 1997, J EXP MED, V186, P1365, DOI 10.1084/jem.186.8.1365; KOTANI T, 1995, AUTOIMMUNITY, V20, P231, DOI 10.3109/08916939508995700; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MATSUBAYASHI S, 1995, J CLIN ENDOCR METAB, V80, P3421, DOI 10.1210/jc.80.12.3421; Mongkolsapaya J, 1998, J IMMUNOL, V160, P3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NATOLI G, 1995, ONCOGENE, V11, P1157; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rudin CM, 1997, ANNU REV MED, V48, P267; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STOKES TA, 1998, SCIENCE, V279, pA2105; Tamura M, 1998, ENDOCRINOLOGY, V139, P3646, DOI 10.1210/en.139.8.3646; TANIMOTO C, 1995, ENDOCR J, V42, P193, DOI 10.1507/endocrj.42.193; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Venkataraman GM, 1998, THYROID, V8, P63, DOI 10.1089/thy.1998.8.63; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	50	74	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23627	23632		10.1074/jbc.274.33.23627	http://dx.doi.org/10.1074/jbc.274.33.23627			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438545	hybrid			2022-12-25	WOS:000082012800095
J	Cavallo, D; Rudy, D; Mohammadi, A; Macri, J; Adeli, K				Cavallo, D; Rudy, D; Mohammadi, A; Macri, J; Adeli, K			Studies on degradative mechanisms mediating post-translational fragmentation of apolipoprotein B and the generation of the 70-kDa fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; HEP G2 CELLS; TRIGLYCERIDE TRANSFER PROTEIN; ENDOPLASMIC-RETICULUM; B-100-CONTAINING LIPOPROTEINS; INTRACELLULAR DEGRADATION; APO-B; OLEIC-ACID; SECRETION; TRANSLOCATION	It has been well established that the biogenesis of apoB is mediated co-translationally by the cytosolic proteasome, Here, however, we investigated the role of both the cytosolic proteasome as well as non-proteasome-mediated degradation systems in the post-translational degradation of apoB. In pulse-chase labeling experiments, co-translational (0-h chase) apoB degradation in both intact and permeabilized cells was sensitive to proteasome inhibitors. Interestingly, turnover of apoB in intact cells over a 2-h chase was partially inhibitable by lactacystin, thus suggesting a role for the cytosolic proteasome in the post-translational degradation of apoB, In permeabilized cells, however, there was no posttranslational protection of apoB by lactacystin, Further investigations of proteasomal activity in HepG2 cells revealed that, following permeabilization, there was a dramatic loss of the 20 S proteasomal subunits, and consequently the cells exhibited no detectable lactacystin-inhibitable activity. Thus, apoB fragmentation and the generation of the 70-kDa apoB degradation fragment, characteristic of permeabilized cells, continued to occur in these cells despite the absence of functional cytosolic proteasome. Similar results were observed when we used a derivative of lactacystin, clastolactacystin beta-lactone, which represents the active species of the inhibitor. Interestingly, however, the abundance of the 70-kDa fragment could be modulated by the microsomal triglyceride transfer protein inhibitor, BMS-197636, as well as by pretreatment of the permeabilized cells with dithiothreitol, These data thus suggest that although the cytosolic proteasome appears to be involved in the posttranslational turnover of apoB in intact cells, the specific post-translational fragmentation of apoB generating the 70-kDa fragment observed in permeabilized cells occurs independent of the cytosolic proteasome.	Univ Toronto, DPLM, Div Clin Biochem, Hosp Sick Children,Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Windsor	Adeli, K (corresponding author), Univ Toronto, DPLM, Div Clin Biochem, Hosp Sick Children,Lab Med & Pathobiol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Adeli, Khosrow/0000-0002-5839-5709				ADELI K, 1994, J BIOL CHEM, V269, P9166; Adeli K, 1997, J BIOL CHEM, V272, P5031, DOI 10.1074/jbc.272.8.5031; Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; ADELI K, 1990, FEBS LETT, V2, P345; Adeli Khosrow, 1996, Circulation, V94, pI149; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; CARTWRIGHT IJ, 1993, J BIOL CHEM, V268, P20937; Cavallo D, 1998, J BIOL CHEM, V273, P33397, DOI 10.1074/jbc.273.50.33397; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DASHTI N, 1989, J LIPID RES, V30, P1365; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; Dick LR, 1997, J BIOL CHEM, V272, P182; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DU EZ, 1994, J BIOL CHEM, V269, P24169; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIO W, 1998, J BIOL CHEM, V273, P27225; Macri J, 1997, ARTERIOSCL THROM VAS, V17, P2982, DOI 10.1161/01.ATV.17.11.2982; Mellgren RL, 1997, J BIOL CHEM, V272, P29899, DOI 10.1074/jbc.272.47.29899; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; PULLINGER CR, 1989, J LIPID RES, V30, P1065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; RUSINOL AE, 1995, J BIOL CHEM, V270, P13318, DOI 10.1074/jbc.270.22.13318; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SALLACH SM, 1995, BBA-MOL CELL RES, V1265, P29, DOI 10.1016/0167-4889(95)00239-O; SASKI T, 1990, J ENZYM INHIB, V3, P195; Shelness GS, 1996, J LIPID RES, V37, P408; Sparks Janet D., 1993, Current Opinion in Lipidology, V4, P177, DOI 10.1097/00041433-199306000-00002; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TWINING SS, 1984, ANAL BIOCHEM, V143, P30, DOI 10.1016/0003-2697(84)90553-0; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	47	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23135	23143		10.1074/jbc.274.33.23135	http://dx.doi.org/10.1074/jbc.274.33.23135			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438483	hybrid			2022-12-25	WOS:000082012800033
J	Groarke, DA; Wilson, S; Krasel, C; Milligan, G				Groarke, DA; Wilson, S; Krasel, C; Milligan, G			Visualization of agonist-induced association and trafficking of green fluorescent protein-tagged forms of both beta-arrestin-1 and the thyrotropin-releasing hormone receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; CARBOXYL-TERMINUS; PHOSPHOLIPASE-C; DOWN-REGULATION; DESENSITIZATION; ENDOCYTOSIS; BINDING; INTERNALIZATION	A fusion protein (beta-arrestin-1-green fluorescent protein (GFP)) was constructed between beta-arrestin-1 and a modified form of the green fluorescent protein from Aequorea victoria. Expression in HEK293 cells allowed immunological detection of an 82-kDa cytosolic polypeptide with antisera to both beta-arrestin-1 and GFP, Transient expression of this construct in HEK293 cells stably transfected to express the rat thyrotropin-releasing hormone receptor-1 (TRHR-1) followed by confocal microscopy allowed its visualization evenly distributed throughout the cytoplasm, Addition of thyrotropin-releasing hormone (TRH) caused a profound and rapid redistribution of beta-arrestin-1 GFP to the plasma membrane followed by internalization of beta-arrestin-1-GFP into distinct, punctate, intracellular vesicles. TRH did not alter the cellular distribution of GFP transiently transfected into these cells nor the distribution of beta-arrestin-1-GFP following expression in HEK293 cells lacking the receptor. To detect potential co-localization of the receptor and p-arrestin-l in response to agonist treatment, beta-arrestin-1-GFP was expressed stably in HEK293 cells. A vesicular stomatitis virus (VSV)-tagged TRHR-1 was then introduced transiently. Initially, the two proteins were fully resolved. Short term exposure to TRH resulted in their plasma membrane co-localization, and sustained exposure to TRH resulted in their co-localization in punctate, intracellular vesicles. In contrast, beta-arrestin-1-GFP did not relocate or adopt a punctate appearance in cells that did not express VSV-TRHR-1, Reciprocal experiments were performed, with equivalent results, following transient expression of beta-arrestin-1 into cells stably expressing VSV-TRHR-1-GFP. These results demonstrate the capacity of beta-arrestin1-GFP to interact with the rat TRHR-1 and directly visualizes their recruitment from cytoplasm and plasma membrane respectively into overlapping, intracellular vesicles in an agonist-dependent manner.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; SmithKline Beecham Pharmaceut, Harlow CM19 5AD, Essex, England; Univ Wurzburg, Inst Pharmakol, D-97078 Wurzburg, Germany	University of Glasgow; GlaxoSmithKline; University of Wurzburg	Milligan, G (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.		Krasel, Cornelius/AAH-7074-2019; Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519; Krasel, Cornelius/0000-0001-8309-8696				ANDERSON L, 1995, BIOCHEM J, V311, P385, DOI 10.1042/bj3110385; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Drmota T, 1998, J BIOL CHEM, V273, P24000, DOI 10.1074/jbc.273.37.24000; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Gershengorn MC, 1996, PHYSIOL REV, V76, P175, DOI 10.1152/physrev.1996.76.1.175; Goodman O B Jr, 1998, Adv Pharmacol, V42, P429; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hinkle PM, 1996, TRENDS ENDOCRIN MET, V7, P370, DOI 10.1016/S1043-2760(96)00188-9; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Kakinoki Y, 1997, J BIOL CHEM, V272, P32308, DOI 10.1074/jbc.272.51.32308; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; KIM GD, 1994, J BIOL CHEM, V269, P19933; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TW, 1995, BIOCHEM J, V310, P291, DOI 10.1042/bj3100291; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Milligan G, 1998, TRENDS ENDOCRIN MET, V9, P13, DOI 10.1016/S1043-2760(98)00004-6; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; Oatey PB, 1997, BIOCHEM J, V327, P637; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; SELLAR RE, 1993, J MOL ENDOCRINOL, V10, P199, DOI 10.1677/jme.0.0100199; SMITH PK, 1985, ANAL BIOCHEM, V150, P75; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; Svoboda P, 1996, MOL PHARMACOL, V49, P646; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Yu R, 1997, J BIOL CHEM, V272, P28301, DOI 10.1074/jbc.272.45.28301; ZernickaGoetz M, 1997, DEVELOPMENT, V124, P1133	34	38	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23263	23269		10.1074/jbc.274.33.23263	http://dx.doi.org/10.1074/jbc.274.33.23263			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438501	hybrid			2022-12-25	WOS:000082012800051
J	LeBlanc, A; Liu, H; Goodyer, C; Bergeron, C; Hammond, J				LeBlanc, A; Liu, H; Goodyer, C; Bergeron, C; Hammond, J			Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PROGRAMMED CELL-DEATH; RAT HIPPOCAMPAL-NEURONS; ENZYME-LIKE PROTEASES; GENE-EXPRESSION; BETA-PROTEIN; IN-VIVO; C-JUN; POSTMITOTIC NEURONS; CYSTEINE PROTEASES	Neuronal cell death, neurofibrillary tangles, and amyloid beta peptide (A beta) deposition depict Alzheimer's disease (AD) pathology, but neuronal loss correlates best with dementia. We have shown that increased production of A beta is a consequence of neuronal apoptosis, suggesting that apoptosis activates proteases involved in amyloid precursor protein (APP) processing, Here, we investigate key effecters of cell death, caspases, in human neuronal apoptosis and APP processing. We find that caspase-6 is activated and responsible for neuronal apoptosis by serum deprivation. Caspase-6 activity precedes the time of commitment to neuronal apoptosis by 10 h, indicating possible activity without subsequent apoptosis, Inhibition of caspase-6 activity prevents serum deprivation-mediated increase of A beta. Caspase-6 directly cleaves APP at the C terminus and generates a C-terminal fragment of 3 kDa (Capp3) and an A beta-containing 6.5-kDa fragment, Capp6.5, that increases in serum-deprived neurons. A pulse-chase experiment reveals a precursor-product relationship between Capp6.5, intracellular A beta, and secreted A beta, indicating a potential alternate amyloidogenic pathway. Caspase-6 proenzyme is present in adult human brain tissue, and the p10 active caspase-6 fragment is detected in AD brain tissue. These results indicate a possible alternate pathway for APP amyloidogenic processing in human neurons and a potential implication for this pathway in the neuronal demise of AD.	Mortimer B Davis Jewish Gen Hosp, Bloomfield Ctr Res Aging, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Pediat, Montreal, PQ H3H 1P3, Canada; Univ Toronto, Dept Pathol, Toronto, ON M5S 1A8, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; University of Toronto	LeBlanc, A (corresponding author), Mortimer B Davis Jewish Gen Hosp, Bloomfield Ctr Res Aging, Lady Davis Inst Med Res, 3755 Ch Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.				NINDS NIH HHS [R01 NS31700] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031700] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHUJA HS, 1994, BIOCHEM CELL BIOL, V72, P523, DOI 10.1139/o94-070; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; Barnes NY, 1998, J NEUROSCI, V18, P5869; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Busser J, 1998, J NEUROSCI, V18, P2801; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cotman CW, 1996, BRAIN PATHOL, V6, P493, DOI 10.1111/j.1750-3639.1996.tb00878.x; Desjardins P, 1998, NEUROSCI LETT, V244, P69, DOI 10.1016/S0304-3940(98)00138-4; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Estevez AG, 1998, J NEUROSCI, V18, P923; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Jordan J, 1997, J NEUROCHEM, V68, P1612; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LEBLANC A, 1996, MOL MECH DEMENTIA, P57; LeBlanc AC, 1999, J NEUROCHEM, V72, P1832, DOI 10.1046/j.1471-4159.1999.0721832.x; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; LeBlanc AC, 1998, J NEUROSCI, V18, P2907; LeBlanc AC, 1997, J NEUROCHEM, V68, P1183; LOCKSHIN RA, 1990, J GERONTOL, V45, P135; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MASLIAH E, 1994, NEUROSCI LETT, V174, P67, DOI 10.1016/0304-3940(94)90121-X; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; McLoughlin DM, 1996, FEBS LETT, V397, P197; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Morsch R, 1999, J NEUROPATH EXP NEUR, V58, P188, DOI 10.1097/00005072-199902000-00008; Nishimura I, 1998, J NEUROSCI, V18, P2387, DOI 10.1523/jneurosci.18-07-02387.1998; Paradis E, 1996, J NEUROSCI, V16, P7533; PETITO CK, 1995, AM J PATHOL, V146, P1121; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SATOU T, 1995, BRAIN RES, V697, P35, DOI 10.1016/0006-8993(95)00748-F; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Taylor J, 1997, J NEUROCHEM, V68, P1598; THOMPSON C, 1994, SCIENCE, V267, P1456; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vincent I, 1997, J NEUROSCI, V17, P3588; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x; Yang FS, 1998, AM J PATHOL, V152, P379; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0; Zhang FY, 1997, J NEUROSCI, V17, P7655, DOI 10.1523/jneurosci.17-20-07655.1997; ZHANG P, 1992, NEUROSCIENCE, V46, P9, DOI 10.1016/0306-4522(92)90004-L	65	254	263	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23426	23436		10.1074/jbc.274.33.23426	http://dx.doi.org/10.1074/jbc.274.33.23426			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438520	hybrid			2022-12-25	WOS:000082012800070
J	Majello, B; Napolitano, G; Giordano, A; Lania, L				Majello, B; Napolitano, G; Giordano, A; Lania, L			Transcriptional regulation by targeted recruitment of cyclin-dependent CDK9 kinase in vivo	ONCOGENE			English	Article						CDK9 kinase; cyclin T; transcription elongation; recruitment	RNA-POLYMERASE-II; TATA-BINDING PROTEIN; FACTOR P-TEFB; HIV-1 TAT; IN-VITRO; CDC2-RELATED KINASE; CATALYTIC SUBUNIT; TERMINAL DOMAIN; CELL-CYCLE; ELONGATION	The CDK9 kinase in association with Cyclin T is a component of the transcription positive-acting complex pTEFb which facilitates the transition from abortive to productive transcription elongation by phosphorylating the carboxyl-terminal domain of RNA polymerase II. The Cyclin T1/CDK9 complex is implicated in Tat transactivation, and it has been suggested that Tat functions by recruiting this complex to RNAPII through cooperative binding to RNA. Here, we demonstrate that targeted recruitment of Cyclin T1/CDK9 kinase complex to specific promoters, through fusion to a DNA-binding domain of either Cyclin T1 or CDK9 kinase, stimulates transcription in vivo. Transcriptional enhancement was dependent on active CDK9, as a catalytically inactive form had no transcriptional effect. We determined that, unlike conventional activators, DNA-bound CDK9 does not activate enhancerless TATA-promoters unless TBP is overexpressed, suggesting that CDK9 acts in vivo at a step subsequent to TFIID recruitment DNA-bound, Finally, we determined that CDK9-mediated transcriptional activation is mediated by preferentially stimulating productive transcription elongation.	Univ Naples Federico II, Dept Genet Mol & Gen Biol, Naples, Italy; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19107 USA	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Jefferson University	Lania, L (corresponding author), Univ Naples Federico II, Dept Genet Mol & Gen Biol, Naples, Italy.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Majello, Barbara/0000-0003-2789-3585; Napolitano, Giuliana/0000-0002-1637-6016				Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; Gold MO, 1998, NUCLEIC ACIDS RES, V26, P3784, DOI 10.1093/nar/26.16.3784; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; He S, 1998, MOL CELL BIOL, V18, P2876, DOI 10.1128/MCB.18.5.2876; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Majello B, 1998, AIDS, V12, P1957, DOI 10.1097/00002030-199815000-00006; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Majello B, 1998, J BIOL CHEM, V273, P16509, DOI 10.1074/jbc.273.26.16509; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rickert P, 1996, ONCOGENE, V12, P2631; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	33	63	65	2	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4598	4605		10.1038/sj.onc.1202822	http://dx.doi.org/10.1038/sj.onc.1202822			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467404				2022-12-25	WOS:000082018600009
J	McIlroy, D; Sakahira, H; Talanian, RV; Nagata, S				McIlroy, D; Sakahira, H; Talanian, RV; Nagata, S			Involvement of caspase 3-activated DNase in internucleosomal DNA cleavage induced by diverse apoptotic stimuli	ONCOGENE			English	Article						apoptosis; caspase; DNase; anti-cancer drugs	PROGRAMMED CELL-DEATH; THYMOCYTE APOPTOSIS; RAT THYMOCYTES; GRANZYME-B; PROTEASES; IDENTIFICATION; FRAGMENTATION; ACTIVATION; INHIBITOR; FAMILY	Degradation of chromosomal DNA into nucleosome-sized fragments is one of the characteristics of apoptotic cell death. Here, we examined whether caspase-activated DNase (CAD) is responsible for the DNA fragmentation that occurs upon exposure to various apoptotic stimuli. When human Jurkat cells were exposed to etoposide, or UV or gamma radiation, a caspase-3-like protease was activated, and nuclear DNA was fragmented. Human TF-1 cells, which are dependent on granulocyte-macrophage colony-stimulating factor (GM-CSF), also underwent apoptosis accompanied by the activation of caspase-3-like protease and DNA fragmentation, when cultured without the cytokine. Both Jurkat and TF-1 cells expressed two forms of ICAD, ICAD-L and ICAD-S, which were cleaved upon exposure to these apoptotic stimuli. Among eight different caspases examined, recombinant caspases 3 and 7 specifically cleaved ICAD synthesized in a cell-free system. An expression plasmid containing mouse ICAD-L mutated at the caspase-3-recognition sites was then introduced into Jurkat and TF-1 cells. When the transformants were induced to undergo apoptosis (by treatment with etoposide, UV or gamma radiation for Jurkat cells, or factor withdrawal for TF-1 cells) they did not show DNA fragmentation, although they still died as a result of these stimuli. These results indicated that CAD, released from ICAD by caspase activation, is involved in the nuclear DNA fragmentation induced by these apoptotic stimuli.	Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan; BASF Biores Corp, Worcester, MA 01605 USA	Osaka University; BASF	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamadaoka, Osaka 5650871, Japan.		McILROY, Dorian/AAE-4398-2021; Nagata, Shigekazu/AAG-3203-2019	McILROY, Dorian/0000-0002-3731-4017; Nagata, Shigekazu/0000-0001-9758-8426				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Shiokawa D, 1998, APOPTOSIS, V3, P89, DOI 10.1023/A:1009692807692; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	36	100	107	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	1999	18	31					4401	4408		10.1038/sj.onc.1202868	http://dx.doi.org/10.1038/sj.onc.1202868			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442630				2022-12-25	WOS:000081813500001
J	Mossner, E; Huber-Wunderlich, M; Rietsch, A; Beckwith, J; Glockshuber, R; Aslund, F				Mossner, E; Huber-Wunderlich, M; Rietsch, A; Beckwith, J; Glockshuber, R; Aslund, F			Importance of redox potential for the in vivo function of the cytoplasmic disulfide reductant thioredoxin from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE MUTATIONS; BOND FORMATION INVIVO; HIGH-LEVEL EXPRESSION; IN-VIVO; CLONED GENES; PROTEIN; GLUTAREDOXIN; DSBA; ISOMERASE; OXIDOREDUCTASES	The thioredoxin superfamily consists of enzymes that catalyze the reduction, formation, and isomerization of disulfide bonds and exert their activity through a redox active disulfide in a Cys-Xaa(1)-Xaa(2)-Cys motif, The individual members of the family differ strongly in their intrinsic redox potentials. However, the role of the different redox potentials for the in vivo function of these enzymes is essentially unknown. To address the question of in vivo importance of redox potential for the most reducing member of the enzyme family, thioredoxin, me have employed a set of active site variants of thioredoxin with increased redox potentials (-270 to -195 mV) for functional studies in the cytoplasm of Escherichia coli, The variants proved to be efficient substrates of thioredoxin reductase, providing a basis for an in vivo characterization of NADPH-dependent reductive processes catalyzed by the thioredoxin variants. The reduction of sulfate and methionine sulfoxide, as well as the isomerization of periplasmic disulfide bonds by DsbC, which all depend on thioredoxin as catalyst in the E. coli cytoplasm, proved to correlate well with the intrinsic redox potentials of the variants in complementation assays. The same correlation could be established in vitro by using the thioredoxin-catalyzed reduction of lipoic acid by NADPH as a model reaction. We propose that the rate of direct reduction of substrates by thioredoxin, which largely depends on the redox potential of thioredoxin, is the most important parameter for the in vivo function of thioredoxin, as recycling of reduced thioredoxin through NADPH and thioredoxin reductase is not rate-limiting for its catalytic cycle.	ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Schering AG, PDR Prot Chem, D-13342 Berlin, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Harvard University; Harvard Medical School; Schering AG	Glockshuber, R (corresponding author), ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland.	rudi@mol.biol.ethz.ch		Rietsch, Arne/0000-0002-1556-7064	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055090, R01GM041883] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55090, GM41883] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; Debarbieux L, 1998, P NATL ACAD SCI USA, V95, P10751, DOI 10.1073/pnas.95.18.10751; DUVOISIN RM, 1986, GENE, V45, P193, DOI 10.1016/0378-1119(86)90254-4; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hennecke J, 1999, J MOL BIOL, V286, P1197, DOI 10.1006/jmbi.1998.2531; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1982, J BIOL CHEM, V257, P6926; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; LOFERER H, 1995, J BIOL CHEM, V270, P26178, DOI 10.1074/jbc.270.44.26178; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; Mossner E, 1998, PROTEIN SCI, V7, P1233; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; PIGIET VP, 1977, J BIOL CHEM, V252, P6367; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Rossmann R, 1997, FEBS LETT, V406, P249, DOI 10.1016/S0014-5793(97)00270-6; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	39	63	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25254	25259		10.1074/jbc.274.36.25254	http://dx.doi.org/10.1074/jbc.274.36.25254			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464247	hybrid			2022-12-25	WOS:000082554200012
J	Nakamura, K; Liu, XB; Ascoli, M				Nakamura, K; Liu, XB; Ascoli, M			The rate of internalization of the gonadotropin receptors is greatly affected by the origin of the extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEYDIG TUMOR-CELLS; FOLLICLE-STIMULATING-HORMONE; HUMAN CHORIO-GONADOTROPIN; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; MEDIATED ENDOCYTOSIS; BETA(2)-ADRENERGIC RECEPTOR; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; LUTEINIZING-HORMONE; SIGNAL-TRANSDUCTION; BETA-ARRESTINS	Previous results from this laboratory have shown that human kidney (293) cells transfected with the rat follitropin receptor (rFSHR) internalize agonist (i.e. human follitropin, hFSH) at a rate similar to that of other agonist-G protein-coupled receptor complexes while 293 cells transfected with the rat lutropin/choriogonadotropin receptor (rLHR) internalize agonist (human choriogonadotropin, hCG) at a rate that is about 1 order of magnitude slower. Taking advantage of this difference and the high degree of homology between the rLHR and rFSHR, we have now used chimeras of these two receptors to begin to delineate structural features that influence their internalization. Analysis of six chimeras that exchanged only the transmembrane domains (designated FLF and LFL), only the COOH-terminal domains (FFL or LLF) or both domains (FLL or LFF) show that the origin of the extracellular domain is at least as important, if not more, than the origin of the transmembrane and COOH-terminal domains in determining the rate of internalization of the gonadotropin receptors, Thus, the rates of internalization of agonist internalization mediated by Fn, FLF, and FLL more closely resemble rFSHR than rLHR, while the rates of agonist internalization mediated by LLF, LFL, and LFF more closely resemble rLHR than rFSKR. The importance of the extracellular domain was also evident even upon overexpression of arrestin-3, a protein that enhances the rate of internalization of the wild-type receptors and chimeras by binding to their intracellular regions.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Ascoli, M (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, 2-319A BSB, Iowa City, IA 52242 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028962] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA040629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40629] Funding Source: Medline; NICHD NIH HHS [HD-28962] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1984, J CELL BIOL, V99, P1242, DOI 10.1083/jcb.99.4.1242; ASCOLI M, 1982, J BIOL CHEM, V257, P13306; ASCOLI M, 1987, ENDOCRINOLOGY, V120, P1161, DOI 10.1210/endo-120-3-1161; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dhanwada KR, 1996, MOL ENDOCRINOL, V10, P544, DOI 10.1210/me.10.5.544; Faussner A, 1998, J BIOL CHEM, V273, P2617, DOI 10.1074/jbc.273.5.2617; Ferguson SSG, 1997, NEWS PHYSIOL SCI, V12, P145; FLETCHER PW, 1984, MOL CELL ENDOCRINOL, V34, P39, DOI 10.1016/0303-7207(84)90157-6; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; Hirsch B, 1996, MOL ENDOCRINOL, V10, P1127, DOI 10.1210/me.10.9.1127; HOELSCHER SR, 1991, ENDOCRINOLOGY, V128, P2837, DOI 10.1210/endo-128-6-2837; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LLOYD CE, 1983, J CELL BIOL, V96, P521, DOI 10.1083/jcb.96.2.521; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Min KS, 1998, J BIOL CHEM, V273, P34911, DOI 10.1074/jbc.273.52.34911; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; Nakamura K, 1998, MOL ENDOCRINOL, V12, P580, DOI 10.1210/me.12.4.580; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; NAKAMURA K, 1999, IN PRESS MOL ENDOCRI; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Riezman H, 1997, CELL, V91, P731, DOI 10.1016/S0092-8674(00)80461-4; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SEGALOFF DL, 1981, J BIOL CHEM, V256, P1420; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHIMIZU A, 1989, J BIOL CHEM, V264, P13632; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TSENG MJ, 1995, J BIOL CHEM, V270, P18858, DOI 10.1074/jbc.270.32.18858; Wang Z, 1997, MOL ENDOCRINOL, V11, P183, DOI 10.1210/me.11.2.183; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	45	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25426	25432		10.1074/jbc.274.36.25426	http://dx.doi.org/10.1074/jbc.274.36.25426			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464272	hybrid			2022-12-25	WOS:000082554200036
J	van den Wijngaard, PWJ; Vredenberg, WJ				van den Wijngaard, PWJ; Vredenberg, WJ			The envelope anion channel involved in chloroplast protein import is associated with Tic110	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION APPARATUS; MEMBRANE; MACHINERIES; COMPONENT	An anion channel of the chloroplast envelope was previously shown to be involved in protein import. Some gating characteristics of the channel are presented. The pore size of the channel is estimated to be around 6.5 Angstrom Antibodies raised to Tic110 completely inactivate the protein import-related channel. These observations suggest that the channel is associated with the Tic machinery and can function as the protein conducting channel of the inner envelope membrane.	Agr Univ Wageningen, Lab Plant Physiol, NL-6703 BD Wageningen, Netherlands	Wageningen University & Research	van den Wijngaard, PWJ (corresponding author), Agr Univ Wageningen, Lab Plant Physiol, Arboretumlaan 4, NL-6703 BD Wageningen, Netherlands.							DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; FLUGGE UI, 1984, FEBS LETT, V169, P85, DOI 10.1016/0014-5793(84)80294-X; Fuks B, 1997, PLANT PHYSIOL, V114, P405, DOI 10.1104/pp.114.2.405; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heins L, 1998, TRENDS PLANT SCI, V3, P56, DOI 10.1016/S1360-1385(97)01161-8; HILLE B, 1992, IONIC CHANNELS EXCIT, P294; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; Jackson DT, 1998, J BIOL CHEM, V273, P16583, DOI 10.1074/jbc.273.26.16583; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; LOHRET TA, 1995, J BIOL CHEM, V270, P15950, DOI 10.1074/jbc.270.27.15950; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; Schnell DJ, 1997, TRENDS CELL BIOL, V7, P303, DOI 10.1016/S0962-8924(97)01111-2; Scott SV, 1996, J CELL BIOL, V132, P63, DOI 10.1083/jcb.132.1.63; Smart OS, 1997, BIOPHYS J, V72, P1109, DOI 10.1016/S0006-3495(97)78760-5; vandenWijngaard PWJ, 1997, J BIOL CHEM, V272, P29430, DOI 10.1074/jbc.272.47.29430; VREDENBERG W, 1995, BBA-BIOENERGETICS, V1230, P77, DOI 10.1016/0005-2728(95)00036-I	17	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25201	25204		10.1074/jbc.274.36.25201	http://dx.doi.org/10.1074/jbc.274.36.25201			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464239	hybrid			2022-12-25	WOS:000082554200004
J	Alexanian, AR; Bamburg, JR				Alexanian, AR; Bamburg, JR			Neuronal survival activity of S100 beta beta is enhanced by calcineurin inhibitors and requires activation of NF-kappa B	FASEB JOURNAL			English	Article						immunosuppressants; immunophilins; cyclosporin A; FK506; rapamycin; cypermethrin	PROTECTS HIPPOCAMPAL-NEURONS; TRANSCRIPTION FACTOR; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; ALZHEIMERS-DISEASE; MOTOR-NEURONS; GROWTH-FACTOR; CELL-DEATH; PROTEINS	S100 beta beta is a calcium binding, neurotrophic protein produced by nonneuronal cells in the nervous system. The pathway by which it enhances neuronal survival is unknown. Here we show that S100 beta beta enhances survival of embryonic chick forebrain neurons in a dose-dependent manner. In the presence of suboptimal amounts of S100 beta beta, neuronal survival is enhanced by the immunosuppressants FK506 and cyclosporin A at concentrations that inhibit calcineurin, which is present in these cells. Rapamycin, an immunosuppressant that does not inhibit calcineurin, did not enhance cell survival, Cypermethrin, a direct and highly specific calcineurin inhibitor, mimicked the immunophilin ligands in its neurotrophic effect. None of the drugs stimulated neuronal survival in the absence of S100 beta beta, In the presence of suboptimal amounts of S100 beta beta, FK506, cyclosporin A, and cypermethrin (but not rapamycin) also increased NF-kappa B activity, as measured by immunofluorescence of cells stained with antibody to the active subunit (p65) and by immunoblotting of nuclear extracts. Antioxidant and glucocorticoid inhibitors of NF-kappa B decreased both the amount of active NF-kappa B and the survival of neurons caused by S100 beta beta alone or in the presence of augmenting drugs. We conclude that S100 beta beta enhances the survival of chick embryo forebrain neurons through the activation of NF-kappa B.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Bamburg, JR (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	jbamburg@vines.colostate.edu		Alexanian, Arshak/0000-0001-6107-9427	FOGARTY INTERNATIONAL CENTER [F05TW005357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035126] Funding Source: NIH RePORTER; FIC NIH HHS [TW05357] Funding Source: Medline; NIGMS NIH HHS [GM35126] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; BARGER SW, 1992, BIOCHIM BIOPHYS ACTA, V1160, P105, DOI 10.1016/0167-4838(92)90043-D; BAUDIER J, 1982, FEBS LETT, V148, P231, DOI 10.1016/0014-5793(82)80813-2; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BHATTACHARYYA A, 1992, J NEUROBIOL, V23, P451, DOI 10.1002/neu.480230410; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Boissiere F, 1997, NEUROREPORT, V8, P2849, DOI 10.1097/00001756-199709080-00009; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; FRIEDMAN B, 1995, J NEUROSCI, V15, P1044; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grothe C, 1996, INT J DEV BIOL, V40, P403; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Harhaj EW, 1997, J BIOL CHEM, V272, P5409, DOI 10.1074/jbc.272.9.5409; Hu JR, 1997, J NEUROCHEM, V69, P2294; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; ISOBE T, 1977, BIOCHIM BIOPHYS ACTA, V494, P222, DOI 10.1016/0005-2795(77)90150-7; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Kanno T, 1996, J IMMUNOL, V157, P5277; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1989, J BIOL CHEM, V264, P12800; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marinovich M, 1996, EXP CELL RES, V226, P98, DOI 10.1006/excr.1996.0207; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Migheli A, 1997, J NEUROPATH EXP NEUR, V56, P1314, DOI 10.1097/00005072-199712000-00006; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MITTAL CK, 1994, BIOCHEM BIOPH RES CO, V203, P8, DOI 10.1006/bbrc.1994.2141; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; Natarajan K, 1998, ARCH BIOCHEM BIOPHYS, V352, P59, DOI 10.1006/abbi.1998.0576; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PerezOtano I, 1996, GLIA, V16, P306, DOI 10.1002/(SICI)1098-1136(199604)16:4<306::AID-GLIA3>3.0.CO;2-Y; PETTMANN B, 1979, NATURE, V281, P378, DOI 10.1038/281378a0; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; STAAL FJT, 1995, METHOD ENZYMOL, V252, P168; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; Suzuki T, 1997, NEUROREPORT, V8, P2931, DOI 10.1097/00001756-199709080-00025; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANELDIK LJ, 1988, CALCIUM CALCIUM BIND, P114; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zhao BY, 1998, J NEUROSCI RES, V52, P7, DOI 10.1002/(SICI)1097-4547(19980401)52:1<7::AID-JNR2>3.0.CO;2-I	61	49	49	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1999	13	12					1611	1620		10.1096/fasebj.13.12.1611	http://dx.doi.org/10.1096/fasebj.13.12.1611			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463953				2022-12-25	WOS:000082347600017
J	Elisseeva, E; Mandal, SS; Reha-Krantz, LJ				Elisseeva, E; Mandal, SS; Reha-Krantz, LJ			Mutational and pH studies of the 3 '-> 5 ' exonuclease activity of bacteriophage T4 DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID; 3'->5'-EXONUCLEASE ACTIVITY; 3'-5' EXONUCLEASE; BIOCHEMICAL BASIS; ESCHERICHIA-COLI; KLENOW FRAGMENT; ION MECHANISM; SITE; RNA; IDENTIFICATION	The 3' --> 5' exonuclease activity of proofreading DNA polymerases requires two divalent metal ions, metal ions A and B, Mutational studies of the 3' --> 5' exonuclease active center of the bacteriophage T4 DNA polymerase indicate that residue Asp-324, which binds metal ion A, is the single most important residue for the hydrolysis reaction. In the absence of a nonenzymatic source of hydroxide ions, an alanine substitution for residue Asp-324 reduced exonuclease activity 10-100-fold more than alanine substitutions for the other metal-binding residues, Asp-112 and Asp-219, Thus, exonuclease activity is reduced 10(5)-fold for the D324A-DNA polymerase compared with the wild-type enzyme, while decreases of 10(3)- to 10(4)-fold are detected for the D219A- and D112A/E114A-DNA polymerases, respectively. Our results are consistent with the proposal that a water molecule, coordinated by metal ion A, forms a metal-hydroxide ion that is oriented to attack the phosphodiester bond at the site of cleavage. Residues Glu-114 and Lys-299 may assist the reaction by lowering the pK(a) of the metal ion-A coordinated water molecule, whereas residue Tyr-320 may help to reorient the DNA from the binding conformation to the catalytically active conformation.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Reha-Krantz, LJ (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.		Reha-Krantz, Linda/A-3748-2014	Reha-Krantz, Linda/0000-0003-4497-423X; Mandal, Subhrangsu/0000-0001-8495-9881				AULD DS, 1970, BIOCHEMISTRY-US, V9, P4352, DOI 10.1021/bi00824a016; Baker RP, 1998, P NATL ACAD SCI USA, V95, P3507, DOI 10.1073/pnas.95.7.3507; Beechem JM, 1998, BIOCHEMISTRY-US, V37, P10144, DOI 10.1021/bi980074b; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BLASCO L, 1992, GENE AMST, V112, P139; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; Good N E, 1972, Methods Enzymol, V24, P53; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lam WC, 1998, BIOCHEMISTRY-US, V37, P1513, DOI 10.1021/bi9720181; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; Lippard S. J., 1994, PRINCIPLES BIOINORGA; Lott WB, 1998, P NATL ACAD SCI USA, V95, P542, DOI 10.1073/pnas.95.2.542; Marquez LA, 1996, J BIOL CHEM, V271, P28903, DOI 10.1074/jbc.271.46.28903; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; Pontius BW, 1997, P NATL ACAD SCI USA, V94, P2290, DOI 10.1073/pnas.94.6.2290; REDDY MK, 1992, J BIOL CHEM, V267, P14157; Reha-Krantz LJ, 1998, J BIOL CHEM, V273, P22969, DOI 10.1074/jbc.273.36.22969; REHAKRANTZ LJ, 1977, J MOL BIOL, V116, P99, DOI 10.1016/0022-2836(77)90121-8; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; Sattar AKMA, 1996, BIOCHEMISTRY-US, V35, P16621, DOI 10.1021/bi961552q; Scott WG, 1996, TRENDS BIOCHEM SCI, V21, P220; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; STOCKI SA, 1995, J MOL BIOL, V254, P15, DOI 10.1006/jmbi.1995.0595; WANG CC, 1995, J BIOL CHEM, V270, P26558, DOI 10.1074/jbc.270.44.26558; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r	36	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25151	25158		10.1074/jbc.274.35.25151	http://dx.doi.org/10.1074/jbc.274.35.25151			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455197	hybrid			2022-12-25	WOS:000082193400096
J	Kapeller, R; Moriarty, A; Strauss, A; Stubdal, H; Theriault, K; Siebert, E; Chickering, T; Morgenstern, JP; Tartaglia, LA; Lillie, J				Kapeller, R; Moriarty, A; Strauss, A; Stubdal, H; Theriault, K; Siebert, E; Chickering, T; Morgenstern, JP; Tartaglia, LA; Lillie, J			Tyrosine phosphorylation of tub and its association with Src homology 2 domain-containing proteins implicate tub in intracellular signaling by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE RETINITIS-PIGMENTOSA; MESSENGER-RNA EXPRESSION; NEUROPEPTIDE-Y; LEPTIN RECEPTOR; C-CBL; RETINAL DEGENERATION; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; KINASE-ACTIVITY; FOOD-INTAKE	A mutation in the tub gene leads to maturity-onset obesity, insulin resistance, and progressive retinal and cochlear degeneration in mice. tub is a member of a growing family of genes that encode proteins of unknown function that are remarkably conserved across species. The absence of obvious transmembrane domain(s) or signal sequence peptide motif(s) suggests that Tub is an intracellular protein. Additional sequence analysis revealed the presence of putative tyrosine phosphorylation motifs and Src homology 2 (SH2)binding sites. Here we demonstrate that in CHO-IR cells, transfected Tub is phosphorylated on tyrosine in response to insulin and insulin-like growth factor-1 and that in PC12 cells, insulin but not EGF induced tyrosine phosphorylation of endogenous Tub. In vitro, Tub is phosphorylated by purified insulin receptor kinase as well as by Abl and JAK 2 but not by epidermal growth factor receptor and Src kinases, Furthermore, upon tyrosine phosphorylation, Tub associated selectively with the SH2 domains of Abl, Lck, and the C-terminal SH2 domain of phospholipase Cy and insulin enhanced the association of Tub with endogenous phospholipase Cy in CHO-IR cells. These data suggest that Tub may function as an adaptor protein linking the insulin receptor, and possibly other protein-tyrosine kinases, to SH2-containing proteins.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Kapeller, R (corresponding author), Millennium Pharmaceut Inc, 75 Sidney St, Cambridge, MA 02139 USA.	kapeller@mpi.com						ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Banerjee P, 1998, NAT GENET, V18, P177, DOI 10.1038/ng0298-177; BASKIN DG, 1988, TRENDS NEUROSCI, V11, P107, DOI 10.1016/0166-2236(88)90155-5; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Cantley LC, 1997, ADV SEC MESS PHOSPH, V31, P41; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; Elmquist JK, 1998, J COMP NEUROL, V395, P535; GORLIN RJ, 1995, HEREDITARY HEARING L, P105; Gu SM, 1998, LANCET, V351, P1103, DOI 10.1016/S0140-6736(05)79384-3; Guan XM, 1998, MOL BRAIN RES, V59, P273, DOI 10.1016/S0169-328X(98)00150-8; Hagstrom SA, 1998, NAT GENET, V18, P174, DOI 10.1038/ng0298-174; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; MILLAY RH, 1986, AM J OPHTHALMOL, V102, P482, DOI 10.1016/0002-9394(86)90078-4; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; North MA, 1997, P NATL ACAD SCI USA, V94, P3128, DOI 10.1073/pnas.94.7.3128; OHLEMILLER KK, 1995, NEUROREPORT, V6, P845, DOI 10.1097/00001756-199504190-00005; Ohlemiller KK, 1997, AUDIOL NEURO-OTOL, V2, P175, DOI 10.1159/000259242; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Sahly I, 1998, HUM MOL GENET, V7, P1437, DOI 10.1093/hmg/7.9.1437; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHWARTZ MW, 1993, ANN NY ACAD SCI, V692, P60; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; SCHWARTZ MW, 1991, ENDOCRINOLOGY, V128, P2645, DOI 10.1210/endo-128-5-2645; SCHWARTZ MW, 1992, ENDOCRINOLOGY, V130, P3608, DOI 10.1210/en.130.6.3608; Shioda S, 1998, NEUROSCI LETT, V243, P41, DOI 10.1016/S0304-3940(98)00082-2; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UNGER JW, 1991, PROG NEUROBIOL, V36, P343, DOI 10.1016/0301-0082(91)90015-S; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24980	24986		10.1074/jbc.274.35.24980	http://dx.doi.org/10.1074/jbc.274.35.24980			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455176	hybrid			2022-12-25	WOS:000082193400075
J	Loewen, SK; Ng, AML; Yao, SYM; Cass, CE; Baldwin, SA; Young, JD				Loewen, SK; Ng, AML; Yao, SYM; Cass, CE; Baldwin, SA; Young, JD			Identification of amino acid residues responsible for the pyrimidine and purine nucleoside specificities of human concentrative Na+ nucleoside cotransporters hCNT1 and hCNT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; OVERLAP EXTENSION; TRANSPORT-SYSTEM; ADENOSINE; PROTEIN; ANALOGS; EI; RECEPTORS	hCNT1 and hCNT2 mediate concentrative (Na+-linked) cellular uptake of nucleosides and nucleoside drugs by human cells and tissues. The two proteins (650 and 658 residues, 71 kDa) are 72% identical in sequence and contain 13 putative transmembrane helices (TMs), When produced in Xenopus oocytes, recombinant hCNT1 is selective for pyrimidine nucleosides (system cit), whereas hCNT2 is selective for purine nucleosides (system cif), Both transport uridine, We have used (i) chimeric constructs between hCNT1 and hCNT2, (ii) sequence comparisons with a newly identified broad specificity concentrative nucleoside transporter (system cib) from Eptatretus stouti, the Pacific hagfish (hfCNT), and (iii) site-directed mutagenesis of hCNT1 to identify two sets of adjacent residues in TMs 7 and 8 of hCNT1 (Ser(319)/Gln(320) and Ser(353)/Leu(354)) that, when converted to the corresponding residues in hCNT2 (Gly(313)/Met(314) and Thr(347)/Val(348)), changed the specificity of the transporter from cit to cif. Mutation of Ser(319) in TM 7 of hCNT1 to Gly enabled transport of purine nucleosides, whereas concurrent mutation of Gln(320) to Met (which had no effect on its own) augmented this transport. The additional mutation of Ser(353) to Thr in TM 8 converted hCNT1/S319G/Q320M, from cib to cif, but with relatively low adenosine transport activity. Additional mutation of Leu(354) to Val (which had no effect on its own) increased the adenosine transport capability of hCNT1/S319G/Q320M/S353T, producing a full cif-type transporter phenotype, On its own, the S353T mutation converted hCNT1 into a transporter with novel uridine-selective transport properties. Helix modeling of hCNT1 placed Ser319 (TM 7) and Ser(353) (TM 8) within the putative substrate translocation channel, whereas Gln(320) (TM 7) and Leu(354) (TM 8) may exert their effects through altered helix packing.	Univ Alberta, Dept Physiol, Membrane Transport Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Membrane Transport Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Leeds	Young, JD (corresponding author), Univ Alberta, Dept Physiol, Membrane Transport Res Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.							BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BELT J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P20; BELT JA, 1993, ADV ENZYME REGUL, V33, P235; CASS CE, 1999, MEMBRANE TRANSPORTER; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CONANT AR, 1994, BIOCHEM PHARMACOL, V48, P873, DOI 10.1016/0006-2952(94)90357-3; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; FREDHOLM BB, 1997, CURR MED CHEM, V4, P35; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HANDSCHUMACHER RE, 1993, CANC METABOLISM, P712; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; LEE CW, 1991, BIOCHEM J, V274, P85, DOI 10.1042/bj2740085; Mackey JR, 1998, CANCER RES, V58, P4349; Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; Wang J, 1997, J BIOL CHEM, V272, P28845, DOI 10.1074/jbc.272.46.28845; Wang J, 1999, J BIOL CHEM, V274, P2298, DOI 10.1074/jbc.274.4.2298; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; WU XC, 1992, J BIOL CHEM, V267, P8813; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1996, MOL PHARMACOL, V50, P388; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	33	67	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24475	24484		10.1074/jbc.274.35.24475	http://dx.doi.org/10.1074/jbc.274.35.24475			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455109	hybrid			2022-12-25	WOS:000082193400008
J	Nurse, P; Liu, J; Marians, KJ				Nurse, P; Liu, J; Marians, KJ			Two modes of PriA binding to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN PRIA; ESCHERICHIA-COLI; PHI-X174 DNA; DEPENDENT ATPASE; FACTOR-Y; PRIMOSOME; CONVERSION; HELICASE; FORM; IDENTIFICATION	The role of PriA, required for the assembly of the phi X174-type primosome on DNA, in cellular DNA replication has been unclear since its discovery. Recent evidence, based on the phenotypes of strains carrying priA null mutations, has led to proposals that the primosome assembly activity of PriA was required to load replication forks at intermediates such as D loops during homologous recombination. McGlynn et al. (McGlynn, P., Al-Deib, A. A., Liu, J., Marians, K. J., and Lloyd, R. G, (1997) J. Mol. Biol. 270, 212-221) demonstrated that PriA could, in fact, bind D loops. We show here that there are two modes of stable binding of PriA to DNA One mode, in which the enzyme binds 3'-single-stranded extensions from duplex DNAs, presumably reflects the 3' --> 5' DNA helicase activity of PriA. The D loop DNA binding activity of PriA can be accounted for by the second mode, where the enzyme binds bent DNA at three strand junctions.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Grad Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Nurse, P (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.				NIGMS NIH HHS [GM34557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABARZUA P, 1984, J BIOL CHEM, V259, P4286; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; GREENBAUM JH, 1985, J BIOL CHEM, V260, P2266; IMBER R, 1983, P NATL ACAD SCI-BIOL, V80, P7132, DOI 10.1073/pnas.80.23.7132; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LEE MS, 1990, J BIOL CHEM, V265, P17078; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MARIANS KJ, 1984, CRC CR REV BIOCH MOL, V17, P153, DOI 10.3109/10409238409113604; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MASAI H, 1990, J BIOL CHEM, V265, P15124; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; NOMURA N, 1991, GENE, V108, P15; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; Sandler SJ, 1996, MOL MICROBIOL, V19, P871, DOI 10.1046/j.1365-2958.1996.429959.x; Sandler SJ, 1996, GENETICS, V143, P5; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SHLOMAI J, 1980, J BIOL CHEM, V255, P6794; SOELLER W, 1984, J BIOL CHEM, V259, P4293; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WICKNER S, 1977, P NATL ACAD SCI USA, V74, P2815, DOI 10.1073/pnas.74.7.2815; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; YONG YQ, 1995, J BIOL CHEM, V270, P24509, DOI 10.1074/jbc.270.41.24509; ZAVITZ KH, 1991, MOL MICROBIOL, V5, P2869, DOI 10.1111/j.1365-2958.1991.tb01846.x; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZIPURSKY SL, 1980, P NATL ACAD SCI-BIOL, V77, P6521, DOI 10.1073/pnas.77.11.6521	37	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25026	25032		10.1074/jbc.274.35.25026	http://dx.doi.org/10.1074/jbc.274.35.25026			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455181	hybrid			2022-12-25	WOS:000082193400080
J	Hertz, JM; Schell, G; Doerfler, W				Hertz, JM; Schell, G; Doerfler, W			Factors affecting de novo methylation of foreign DNA in mouse embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL GENE-EXPRESSION; ADENOVIRUS TYPE-2; TRANSFORMED-CELLS; MAMMALIAN GENOME; TYROSINE KINASE; CPG ISLAND; INTEGRATION; PROMOTER; SEQUENCES; PATTERNS	Integration of foreign DNA into an established host genome can lead to changes in methylation in both the inserted DNA and in host sequences and potentially alters transgene and cellular transcription patterns. This work addresses the questions of what factors influence de novo methylation, and whether the integration site or inserted DNA can affect de novo methylation. Homologous recombination was used to integrate foreign DNA into a specific gene, B lymphocyte kinase (BLK), in mouse embryonic stem (ES) cells. Two plasmids were chosen for integration; one contained the adenovirus type 2 E2AL promoter upstream of the luciferase reporter gene, and the second carried the early SV40 promoter. The methylation patterns were analyzed using HpaII and MspI restriction endonucleases for both homologously recombined and randomly integrated foreign DNA in the ES cell clones. Upon homologous reinsertion of the BLK gene into the genome of mouse ES cells, methylation patterns in this gene were reestablished. In DNA segments adjoined to the BLK gene, the de novo patterns of DNA methylation depended on the viral sequences in these clones and on the locations of the inserts, i.e. on whether the insertions resulted from homologously recombined or randomly integrated foreign DNA. In homologously recombined DNA, sequences carrying the adenovirus type 2 promoter were heavily methylated, and those with an SV40 promoter and an SV40 enhancer element remained unmethylated or hypomethylated. Upon removal of the enhancer element, these inserted constructs also became heavily methylated. In addition, all randomly integrated constructs were heavily methylated independently of the promoter and enhancer element present in the construct. These results indicate that modes and sites of integration as well as the inserted nucleotide sequence, possibly promoter strength, are factors affecting de novo methylation.	Univ Cologne, Genet Inst, D-50931 Cologne, Germany	University of Cologne	Doerfler, W (corresponding author), Univ Cologne, Genet Inst, Weyertal 121, D-50931 Cologne, Germany.							BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DEURING R, 1981, NATURE, V293, P81, DOI 10.1038/293081a0; Doerfler W, 1996, BBA-REV CANCER, V1288, pF79, DOI 10.1016/0304-419X(96)00024-8; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; DOERFLER W, 1993, PROG NUCLEIC ACID RE, V46, P1, DOI 10.1016/S0079-6603(08)61016-8; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; GAHLMANN R, 1982, EMBO J, V1, P1101, DOI 10.1002/j.1460-2075.1982.tb01303.x; GUNTHERT U, 1976, P NATL ACAD SCI USA, V73, P3923, DOI 10.1073/pnas.73.11.3923; Guy LG, 1997, NUCLEIC ACIDS RES, V25, P4400, DOI 10.1093/nar/25.21.4400; HELLER H, 1995, P NATL ACAD SCI USA, V92, P5515, DOI 10.1073/pnas.92.12.5515; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; JAENISCH R, 1982, J CELL BIOCHEM, V20, P331, DOI 10.1002/jcb.240200403; JAHNER D, 1985, MOL CELL BIOL, V5, P2212; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; Koetsier PA, 1996, TRANSGENIC RES, V5, P235, DOI 10.1007/BF01972877; KOZAK CA, 1991, GENOMICS, V9, P762, DOI 10.1016/0888-7543(91)90372-L; KRUCZEK I, 1982, EMBO J, V1, P409, DOI 10.1002/j.1460-2075.1982.tb01183.x; Laird PW, 1997, MOL MED TODAY, V3, P223, DOI 10.1016/S1357-4310(97)01019-8; LANGNER KD, 1984, P NATL ACAD SCI-BIOL, V81, P2950, DOI 10.1073/pnas.81.10.2950; LEDERMANN B, 1991, EXP CELL RES, V197, P254, DOI 10.1016/0014-4827(91)90430-3; Lei H, 1996, DEVELOPMENT, V122, P3195; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LICHTENBERG U, 1988, VIRUS RES, V11, P335, DOI 10.1016/0168-1702(88)90006-8; LILJESTROM P, 1991, J VIROL, V65, P4107; Machon O, 1998, GENE, V208, P73, DOI 10.1016/S0378-1119(97)00659-8; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; Melton DW, 1997, NUCLEIC ACIDS RES, V25, P3937, DOI 10.1093/nar/25.19.3937; MUIZNIEKS I, 1994, FEBS LETT, V344, P251, DOI 10.1016/0014-5793(94)00394-7; Neumann B, 1996, CURR OPIN GENET DEV, V6, P159, DOI 10.1016/S0959-437X(96)80045-1; OREND G, 1995, J VIROL, V69, P1226, DOI 10.1128/JVI.69.2.1226-1242.1995; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; RAZIN A, 1991, MICROBIOL REV, V55, P41; Remus R, 1999, J VIROL, V73, P1010, DOI 10.1128/JVI.73.2.1010-1022.1999; Sasaki H., 1993, DNA methylation: molecular biology and biological significance., P469; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUTTER D, 1980, P NATL ACAD SCI-BIOL, V77, P253, DOI 10.1073/pnas.77.1.253; SUTTER D, 1978, CELL, V14, P569, DOI 10.1016/0092-8674(78)90243-X; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; TORRES RM, 1997, LAB PROTOCOLS CONDIT, P73; VARDIMON L, 1980, NUCLEIC ACIDS RES, V8, P2461, DOI 10.1093/nar/8.11.2461; WEISSHAAR B, 1988, J MOL BIOL, V202, P255, DOI 10.1016/0022-2836(88)90456-1; WIENHUES U, 1985, J VIROL, V56, P320, DOI 10.1128/JVI.56.1.320-324.1985; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	53	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24232	24240		10.1074/jbc.274.34.24232	http://dx.doi.org/10.1074/jbc.274.34.24232			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446198	hybrid			2022-12-25	WOS:000082110900077
J	Tornaletti, S; Reines, D; Hanawalt, PC				Tornaletti, S; Reines, D; Hanawalt, PC			Structural characterization of RNA polymerase II complexes arrested by a cyclobutane pyrimidine dimer in the transcribed strand of template DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ELONGATION COMPLEX; EXCISION-REPAIR; THYMINE DIMER; TERMINATION; TRANSLOCATION; GENE; RECOGNITION; CLEAVAGE; DAMAGE	We have characterized the properties of immunopurified transcription complexes arrested at a specifically located cyclobutane pyrimidine dimer (CPD) using enzymatic probes and an in vitro transcription system with purified RNA polymerase II (RNAP II) and initiation factors. To help understand how RNAP II distinguishes between a natural impediment and a lesion in the DNA to initiate a repair event, we have compared the conformation of RNAP II complexes arrested at a CPD with complexes arrested at a naturally occurring elongation impediment. The footprint of RNAP II arrested at a CPD, using exonuclease III and T4 DNA polymerase's 3'-->5' exonuclease, covers similar to 35 base pairs and is asymmetrically located around the dimer. A similar footprint is observed when RNAP II is arrested at the human histone H3.3 arrest site. Addition of elongation factor SII to RNAP II arrested at a CPD produced shortened transcripts of discrete lengths up to 25 nucleotides shorter than those seen without SII. After addition of photolyase and exposure to visible light, some of the transcripts could be reelongated beyond the dimer, suggesting that SII-mediated transcript cleavage accompanied significant RNAP II backup, thereby providing access of the repair enzyme to the arresting CPD.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Stanford University; Emory University	Hanawalt, PC (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.		excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NCI NIH HHS [R56 CA077712, R01 CA077712, CA-77712] Funding Source: Medline; NIGMS NIH HHS [R01 GM046331] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077712, R56CA077712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CIARROCCHI G, 1982, J MOL BIOL, V155, P177, DOI 10.1016/0022-2836(82)90445-4; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; Jing YQ, 1998, NUCLEIC ACIDS RES, V26, P3845, DOI 10.1093/nar/26.16.3845; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; LEADON SA, 1992, J BIOL CHEM, V267, P23175; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MOTE J, 1994, J MOL BIOL, V236, P725, DOI 10.1006/jmbi.1994.1185; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REINES D, 1991, J BIOL CHEM, V266, P10510; REINES D, 1994, TRANSCRIPTION MECHAN, P263; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; Samkurashvili I, 1998, MOL CELL BIOL, V18, P5343, DOI 10.1128/MCB.18.9.5343; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Tornaletti S, 1997, J BIOL CHEM, V272, P31719, DOI 10.1074/jbc.272.50.31719; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	34	110	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24124	24130		10.1074/jbc.274.34.24124	http://dx.doi.org/10.1074/jbc.274.34.24124			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446184	hybrid, Green Accepted			2022-12-25	WOS:000082110900063
J	Weisenberger, DJ; Romano, LJ				Weisenberger, DJ; Romano, LJ			Cytosine methylation in a CpG sequence leads to enhanced reactivity with benzo[a]pyrene diol epoxide that correlates with a conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOGEN-DNA ADDUCTS; OPTICAL ENANTIOMERS; P53 GENE; MODIFIED DEOXYGUANOSINE; COMPLEX-FORMATION; HOT-SPOTS; BASE; MUTATIONS; OLIGONUCLEOTIDES; DUPLEX	Benzo[a]pyrene (B[a]P) is a widespread environmental carcinogen that must be activated by cellular metabolism to a diol epoxide form (BPDE) before it reacts with DNA It has recently been shown that BPDE preferentially modifies the guanine in methylated 5'-CpG-3' sequences in the human p53 gene, providing one explanation for why these sites are mutational hot spots. Using purified duplex oligonucleotides containing identical methylated and unmethylated CpG sequences, we show here that BPDE preferentially modified the guanine in hemimethylated or fully methylated CpG sequences, producing between 3- and 8-fold more modification at this site. Analysis of this reaction using shorter duplex oligonucleotides indicated that it was the level of the (+)-trans isomer that was specifically increased. To determine if there were conformational differences between the methylated and unmethylated B[a]P-modified DNA sequences that may be responsible for this enhanced reactivity, a native polyacrylamide gel electrophoresis analysis was carried out using DNA containing isomerically pure B[a]P-DNA adducts. These experiments showed that each adduct resulted in an altered gel mobility in duplex DNA but that only the presence of a (+)-trans isomer and a methylated C 5' to the adduct resulted in a significant gel mobility shift compared with the unmethylated case.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	Wayne State University	Romano, LJ (corresponding author), Wayne State Univ, Dept Chem, Detroit, MI 48202 USA.		Weisenberger, Daniel/AAA-8314-2020	Weisenberger, Daniel/0000-0001-8303-2603	NCI NIH HHS [CA 40605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arghavani MB, 1998, BIOCHEMISTRY-US, V37, P8575, DOI 10.1021/bi980237w; BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358; CHEN JH, 1988, NUCLEIC ACIDS RES, V16, P6803, DOI 10.1093/nar/16.14.6803; Chen JX, 1998, CANCER RES, V58, P2070; CHENG SC, 1989, CHEM RES TOXICOL, V2, P334, DOI 10.1021/tx00011a011; CONNEY AH, 1982, CANCER RES, V42, P4875; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Cosman M, 1996, BIOCHEMISTRY-US, V35, P9850, DOI 10.1021/bi9605346; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P4145, DOI 10.1021/bi00067a001; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; DIEKMANN S, 1987, EMBO J, V6, P4213, DOI 10.1002/j.1460-2075.1987.tb02769.x; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; GEACINTOV NE, 1991, CARCINOGENESIS, V12, P2099, DOI 10.1093/carcin/12.11.2099; GEACINTOV NE, 1988, BIOCHEMISTRY-US, V27, P8380, DOI 10.1021/bi00422a013; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAGERMAN PJ, 1990, BIOCHEMISTRY-US, V29, P1980, DOI 10.1021/bi00460a003; HAUSHEER FH, 1989, CARCINOGENESIS, V10, P1131, DOI 10.1093/carcin/10.6.1131; HEINEMANN U, 1992, J BIOL CHEM, V267, P7332; HODGESGARCIA Y, 1992, BIOCHEMISTRY-US, V31, P7595, DOI 10.1021/bi00148a022; HODGESGARCIA Y, 1995, J BIOL CHEM, V270, P197, DOI 10.1074/jbc.270.1.197; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JOHNSON WS, 1995, BIOORGAN MED CHEM, V3, P851, DOI 10.1016/0968-0896(95)00067-Q; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KOEBERL DD, 1990, AM J HUM GENET, V47, P202; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Liu TM, 1996, CHEM RES TOXICOL, V9, P255, DOI 10.1021/tx9501086; MAO B, 1993, BIOCHEMISTRY-US, V32, P11785, DOI 10.1021/bi00095a006; MATHISON BH, 1993, CARCINOGENESIS, V14, P323; Mathur P, 1997, BIOCHEMISTRY-US, V36, P14868, DOI 10.1021/bi971533w; Mekhovich O, 1998, BIOCHEMISTRY-US, V37, P571, DOI 10.1021/bi971544p; NAGAICH AK, 1994, J BIOL CHEM, V269, P7824; NEWBOLD RF, 1976, NATURE, V261, P52, DOI 10.1038/261052a0; PERLOW RA, 1999, P AM ASSOC CANC RES, V40, P506; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; Saenger W., 1984, PRINCIPLES NUCL ACID, P116, DOI DOI 10.1007/978-1-4612-5190-3_6; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; SLAGA TJ, 1979, CANCER RES, V39, P67; SOWERS LC, 1987, BIOCHEM BIOPH RES CO, V148, P790, DOI 10.1016/0006-291X(87)90945-4; SUH M, 1995, BIOPHYS CHEM, V56, P281, DOI 10.1016/0301-4622(95)00055-3; Tommasi S, 1997, CANCER RES, V57, P4727; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Tsao H, 1998, BIOCHEMISTRY-US, V37, P4993, DOI 10.1021/bi980291c; ULYANOV NB, 1984, J BIOMOL STRUCT DYN, V2, P361, DOI 10.1080/07391102.1984.10507573; WEINSTEIN IB, 1976, SCIENCE, V193, P592, DOI 10.1126/science.959820; WOOD AW, 1977, BIOCHEM BIOPH RES CO, V77, P1389, DOI 10.1016/S0006-291X(77)80133-2; Xu R, 1998, BIOCHEMISTRY-US, V37, P769, DOI 10.1021/bi971785x; XU R, 1995, NUCLEIC ACIDS RES, V23, P2814; YAGI H, 1977, J AM CHEM SOC, V99, P1604, DOI 10.1021/ja00447a053; YANG SK, 1977, SCIENCE, V196, P1199, DOI 10.1126/science.870975; YANG SK, 1976, BIOCHEM PHARMACOL, V25, P2221, DOI 10.1016/0006-2952(76)90138-6; ZACHARIAS W, 1988, BIOCHEMISTRY-US, V27, P2970, DOI 10.1021/bi00408a046	58	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23948	23955		10.1074/jbc.274.34.23948	http://dx.doi.org/10.1074/jbc.274.34.23948			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446162	hybrid			2022-12-25	WOS:000082110900041
J	Karni, R; Jove, R; Levitzki, A				Karni, R; Jove, R; Levitzki, A			Inhibition of pp60(c-Src) reduces Bcl-X-L expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors	ONCOGENE			English	Article						c-Src; Bcl-X; EGFR; HER-2	GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASES; HUMAN BREAST-CANCER; SRC-FAMILY KINASES; C-SRC; V-SRC; SIGNAL-TRANSDUCTION; STAT3 ACTIVATION; FACTOR-I; GENE	Tumors that overexpress HER-2/neu receptor or exhibit enhanced EGFR signaling have been reported to possess constitutively activated Src family kinases especially pp60(c-Srcs). High levels of pp60(c-Src) activity have also been reported for cell lines that overexpress the EGFR or the chimeric EGFR-HER-2 receptor. It has therefore been suggested that Src kinases may contribute significantly to the oncogenic phenotype of these cells and to the degree of malignancy of tumors that overexpress EGFR family receptors, In this study we show that the induced expression of c-SRC antisense RNA or the application of a selective Src kinase inhibitor induces growth arrest, programmed cell death and reverses the transformed properties of cells that overexpress EGFR or HER-2 receptors. We show that inhibition of Src kinase expression or activity results in the reduction of Stat3 tyrosine phosphorylation, decline of Bcl-X-1, expression, and induction of cell death. Using a construct in which the promoter of Bcl-X, which possesses putative Stat3 sites, is tethered to the luciferase reporter gene, we show that inhibition of Src activity or expression induces a decline in Bcl-S expression. We also show that the expression of activated Src induces activation of the Bcl-X promoter. This activation is inhibited by the expression of kinase dead Src or of Stat3 beta, the dominant-negative form of Stall, Taken together, these results support the hypothesis that Src positively regulates the transformed phenotype of cells overexpressing EGFR family kinases, Furthermore, these results also suggest that Src positively regulates Bcl-X-L, expression via Stat3 activation and thus acts not only as a potent mitogenic signaling element, but also as an anti-apoptotic signaling protein. The combination of both activities probably confers upon activated Src its oncogenic activity. Since Src kinase is activated in many tumors, pp60(c-Src) kinase inhibitors may prole useful as anti-cancer agents for mana types of cancer.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	Hebrew University of Jerusalem; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.							Ben-Bassat H, 1995, Exp Dermatol, V4, P82, DOI 10.1111/j.1600-0625.1995.tb00227.x; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BROOME MA, 1996, J BIOL CHEM, V271, P16796; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRILLOT DA, 1997, J IMMUNOL, V158, P4759; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; IMAMOTO A, 1994, CURR OPIN GENET DEV, V4, P40, DOI 10.1016/0959-437X(94)90089-2; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mangeney M, 1996, ONCOGENE, V13, P1441; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Sabe H, 1997, ONCOGENE, V14, P1779, DOI 10.1038/sj.onc.1201022; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SCHINDLER T, 1999, IN PRESS MOL CELL; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	32	159	164	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4654	4662		10.1038/sj.onc.1202835	http://dx.doi.org/10.1038/sj.onc.1202835			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467412				2022-12-25	WOS:000082154400002
J	Denver, RJ; Ouellet, L; Furling, D; Kobayashi, A; Fujii-Kuriyama, Y; Puymirat, J				Denver, RJ; Ouellet, L; Furling, D; Kobayashi, A; Fujii-Kuriyama, Y; Puymirat, J			Basic transcription element-binding protein (BTEB) is a thyroid hormone-regulated gene in the developing central nervous system - Evidence for a role in neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RECEPTOR SUPERFAMILY; ASTROCYTE CULTURES; NEURO-2A CELLS; STEP METHOD; RAT-BRAIN; EXPRESSION; MATURATION; SERUM; PROGRAM	Thyroid hormone (3,5,3'-triiodothyronine; T-3) is essential for normal development of the vertebrate brain, influencing diverse processes such as neuronal migration, myelin formation, axonal maturation, and dendritic outgrowth. We have identified basic transcription element-binding protein (BTEB), a small GC box-binding protein, as a T-3-regulated gene in developing rat brain. BTEB mRNA levels in cerebral cortex exhibit developmental regulation and thyroid hormone dependence. T-3 regulation of BTEB mRNA is neural cell specific, being up-regulated in primary cultures of embryonic neurons (E16) and in neonatal astrocytes (P2), but not in neonatal oligodendrocytes (P2), T-3 rapidly up-regulated BTEB mRNA in neuro-2a cells engineered to express thyroid hormone receptor (TR) pi but not in cells expressing TR alpha 1, suggesting that the regulation of this gene is specific to the TR beta 1 isoform, Several lines of evidence support a transcriptional action of T-3 on BTEB gene expression. Overexpression of BTEB in Neuro-2a cells dramatically increased the number and length of neurites in a dose-dependent manner suggesting a role for this transcription factor in neuronal process formation. However, other T-3-dependent changes were not altered; i.e. overexpression of BTEB had no effect on the rate of cell proliferation nor on the expression of acetylcholinesterase activity.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; CHU Laval, Dept Human Genet, Quebec City, PQ G1V 4G2, Canada; Tohoku Univ, Dept Chem, Div Biochem, Aoba Ku, Sendai, Miyagi 9808578, Japan	University of Michigan System; University of Michigan; Laval University; Tohoku University	Denver, RJ (corresponding author), Univ Michigan, Dept Biol, 3077 Nat Sci Bldg, Ann Arbor, MI 48109 USA.		Denver, Robert/AAT-7481-2021; Furling, Denis/M-2346-2017	Furling, Denis/0000-0001-7912-4409	NICHD NIH HHS [HD36419-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD036419] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baas D, 1997, GLIA, V19, P324, DOI 10.1002/(SICI)1098-1136(199704)19:4<324::AID-GLIA5>3.0.CO;2-X; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Denver RJ, 1997, J BIOL CHEM, V272, P8179, DOI 10.1074/jbc.272.13.8179; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; FORREST D, 1994, SEMIN CANCER BIOL, V5, P167; FUH VL, 1989, MOL ENDOCRINOL, V3, P1148, DOI 10.1210/mend-3-7-1148; GARZA R, 1988, DEV BRAIN RES, V43, P287, DOI 10.1016/0165-3806(88)90106-X; HARTMANN KKP, 1990, ENDOCRINOLOGY, V127, P2038, DOI 10.1210/endo-127-4-2038; Iglesias T, 1996, EMBO J, V15, P4307, DOI 10.1002/j.1460-2075.1996.tb00805.x; IGLESIAS T, 1995, BIOCHEM BIOPH RES CO, V210, P995, DOI 10.1006/bbrc.1995.1755; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644; LEBEL JM, 1993, GLIA, V9, P105, DOI 10.1002/glia.440090203; LEGRAND J, 1983, J PHYSIOLOGY PARIS, V78, P603; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO M, 1986, BRAIN RES, V381, P275, DOI 10.1016/0006-8993(86)90077-6; LUO M, 1989, DEV BRAIN RES, V46, P131, DOI 10.1016/0165-3806(89)90150-8; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MUNOZ A, 1991, MOL ENDOCRINOL, V5, P273, DOI 10.1210/mend-5-2-273; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; PUYMIRAT J, 1986, NEUROSCI LETT, V68, P299, DOI 10.1016/0304-3940(86)90506-9; PUYMIRAT J, 1992, DEV BRAIN RES, V69, P173, DOI 10.1016/0165-3806(92)90156-Q; Puymirat J, 1995, J BIOL CHEM, V270, P30651, DOI 10.1074/jbc.270.51.30651; PUYMIRAT J, 1983, NEUROSCIENCE, V10, P801, DOI 10.1016/0306-4522(83)90217-8; PUYMIRAT J, 1992, PROG NEUROBIOL, V39, P281, DOI 10.1016/0301-0082(92)90019-B; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; STOTT D, 1991, GENE TRANSFER EXPRES, P327; STRAIT KA, 1992, MOL ENDOCRINOL, V6, P1874, DOI 10.1210/me.6.11.1874; Thompson CC, 1996, J NEUROSCI, V16, P7832; Thompson CC, 1997, P NATL ACAD SCI USA, V94, P8527, DOI 10.1073/pnas.94.16.8527; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VAGANUNEZ E, 1995, J CLIN INVEST, V96, P893; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505	38	105	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23128	23134		10.1074/jbc.274.33.23128	http://dx.doi.org/10.1074/jbc.274.33.23128			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438482	hybrid			2022-12-25	WOS:000082012800032
J	Fujita-Yoshigaki, J; Dohke, Y; Hara-Yokoyama, M; Furuyama, S; Sugiya, H				Fujita-Yoshigaki, J; Dohke, Y; Hara-Yokoyama, M; Furuyama, S; Sugiya, H			Presence of a complex containing vesicle-associated membrane protein 2 in rat parotid acinar cells and its disassembly upon activation of cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; AMYLASE RELEASE; REGULATED EXOCYTOSIS; 3T3-L1 ADIPOCYTES; SECRETION; CALCIUM; PHOSPHORYLATION; SYNTAXIN-4; TRANSLOCATION; POTENTIATION	Amylase release from parotid acinar cells is mainly induced by the accumulation of intracellular cAMP, presumably through the phosphorylation of substrates by cAMP-dependent protein kinase (PKA), However, the molecular mechanisms of this process are not clear. In a previous study (Fujita-Yoshigaki, J,, Dohke, Y,, Hara-Yokoyama, M,, Kamata, Y,, Kozaki, S,, Furuyama, S,, and Sugiya, H. (1996) J. Biol. Chem, 271, 13130-13134), we reported that vesicle-associated membrane protein 2 (VAMPS) is localized at the secretory granule membrane and is involved in cAMP-induced amylase secretion. To study the formation of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex containing VAMPS in parotid acinar cells, we prepared rabbit polyclonal antibody against the peptide corresponding to Arg(47)-Asp(64) Of VAMPS (anti-SER4256), The recognition site of anti-SER4256 overlaps the domain involved in binding target membrane SNAREs (t-SNARES). Then we examined the condition of VAMPS by immunoprecipitation with anti-SER4256, VAMPS was not included in the immunoprecipitate from solubilized granule membrane fraction under the control conditions, but incubation with cytosolic fraction and cAMP caused immunoprecipitation of VAMPS, The effect of cytosolic fraction and cAMP was reduced by addition of PKA inhibitor H89, Addition of both the catalytic subunit of PKA and the cytosolic fraction allowed immunoprecipitation of VAMPS, whereas the PKA catalytic subunit alone did not. These results suggest that (1) the t-SNARE binding region of VAMPS is masked by some protein X and activation of PKA caused the dissociation of X from VAMPS; and (2) the effect of PKA is not direct phosphorylation of X, but works through phosphorylation of some other cytosolic protein.	Nihon Univ, Sch Dent, Dept Physiol, Matsudo, Chiba 2718587, Japan	Nihon University	Fujita-Yoshigaki, J (corresponding author), Nihon Univ, Sch Dent, Dept Physiol, 2-870-1 Sakaecho Nishi, Matsudo, Chiba 2718587, Japan.	yosigaki@mascat.nihon-u.ac.jp	Yoshigaki, Junko/AAE-6702-2020	Fujita-Yoshigaki, Junko/0000-0002-3271-6498				AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; BALDYSWALIGORSKA A, 1987, BIOCHIM BIOPHYS ACTA, V929, P190, DOI 10.1016/0167-4889(87)90175-3; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BAUM BJ, 1981, ARCH ORAL BIOL, V26, P333, DOI 10.1016/0003-9969(81)90056-X; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; CAIN CC, 1992, J BIOL CHEM, V267, P11681; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; Dohke Y, 1998, ARCH BIOCHEM BIOPHYS, V357, P147, DOI 10.1006/abbi.1998.0793; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Fujita-Yoshigaki J, 1998, CELL SIGNAL, V10, P371, DOI 10.1016/S0898-6568(97)00178-2; FujitaYoshigaki J, 1996, J BIOL CHEM, V271, P13130, DOI 10.1074/jbc.271.22.13130; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; JAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P6903, DOI 10.1073/pnas.78.11.6903; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; MACRAE MB, 1990, BIOCHEM J, V271, P635, DOI 10.1042/bj2710635; Mandon B, 1996, J CLIN INVEST, V98, P906, DOI 10.1172/JCI118873; NIELSEN S, 1995, J CLIN INVEST, V96, P1834, DOI 10.1172/JCI118229; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; QUISSELL DO, 1993, BIOL SALIVARY GLANDS, P181; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; SPEARMAN TN, 1982, MOL PHARMACOL, V21, P121; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; YAMAMOTO T, 1995, AM J PHYSIOL-CELL PH, V268, pC1546, DOI 10.1152/ajpcell.1995.268.6.C1546; YOSHIMURA K, 1992, BIOCHEM PHARMACOL, V43, P1031, DOI 10.1016/0006-2952(92)90610-U	31	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23642	23646		10.1074/jbc.274.33.23642	http://dx.doi.org/10.1074/jbc.274.33.23642			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438547	hybrid			2022-12-25	WOS:000082012800097
J	Miller, JR; Edmondson, DE				Miller, JR; Edmondson, DE			Influence of flavin analogue structure on the catalytic activities and flavinylation reactions of recombinant human liver monoamine oxidases A and B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINATE-DEHYDROGENASE FLAVOPROTEIN; COVALENTLY BOUND FLAVIN; SACCHAROMYCES-CEREVISIAE; SCHIZOPHYLLUM-COMMUNE; GENE DISRUPTION; YEAST; FAD; CLONING; ATTACHMENT; CONSTRUCTION	Two riboflavin-deficient (rib5) Saccharomyces cerevisiae expression systems have been developed to investigate the influence of riboflavin structural alterations on the covalent flavinylation reaction and activity of recombinant human liver monoamine oxidases A and B (MAO A and B). Nineteen different riboflavin analogues were tested with MAO A and nine with MAO B. MAO expression and flavinylation were determined immunochemically with antisera to MAO and an anti-flavin antisera. Expression levels of both MAO A and B are invariant with the presence or absence of riboflavin or riboflavin analogues in the growth medium. Flavin analogues with a variety of seven and eight substitutions are found to be covalently incorporated and to confer catalytic activity, The selectivities of MAO A and MAO B for flavin analogue incorporation are found to be similar, although 8 alpha-methylation of the flavin resulted in a higher level of catalytic activity for MAO B than for MAO A. N(3)-Methylriboflavin and 8-nor-8-aminoriboflavin are not covalently bound as they are not converted to their respective FAD forms by yeast. 5-Carba-5-deazaflavin and 7,8-nor-7-chlororiboflavin are not covalently incorporated into MAO A and do not support catalytic activity. A flavin peptide was isolated from MAO A containing 7-nor-7-bromo-FAD and was demonstrated to be covalently attached to Cys-406 by an 8 alpha-8-thioether linkage by sequence analysis and by matrix-assisted laser desorption ionization time of flight mass spectroscopy. MAO A partially purified from yeast grown on 8-nor-8-chlororiboflavin exhibited an absorption spectrum indicating the covalent flavin is an 8-nor-8-S-thioflavin, suggesting a nucleophilic displacement mechanism that supports the quinone-methide mechanism previously suggested as a general mechanism for covalent flavin attachment.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Chem, Atlanta, GA 30322 USA	Emory University; Emory University	Edmondson, DE (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367, R01GM029433] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29433, GM-08367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; [Anonymous], [No title captured]; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BACHER A, 1971, J BIOL CHEM, V246, P7018; BARBER MJ, 1987, BIOCHEM J, V242, P89, DOI 10.1042/bj2420089; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; BLAUT M, 1989, J BIOL CHEM, V264, P13599; Chen HY, 1997, J BIOL CHEM, V272, P20077, DOI 10.1074/jbc.272.32.20077; DIX BA, 1981, J NUTR, V111, P1397, DOI 10.1093/jn/111.8.1397; DOMBROWSKI JJ, 1981, INT J BIOCHEM, V13, P171, DOI 10.1016/0020-711X(81)90153-1; Earley MC, 1996, GENE, V169, P111, DOI 10.1016/0378-1119(95)00805-5; EDMONDSON DE, 1991, CHEM BIOCH FLAVOENZY, V1, P73; Fazekar A. G., 1971, METHODS ENZYMOL    B, V18B, P385; FROST JW, 1980, J AM CHEM SOC, V102, P7157, DOI 10.1021/ja00543a069; GHISLA S, 1986, BIOCHEM J, V239, P1; GHISLA S, 1993, FLAVINS FLAVOPROTEIN, P283; GOMES B, 1983, P SOC EXP BIOL MED, V172, P250; GROSSMAN S, 1976, FLAVINS FLAVOPROTEIN, P302; Hiro I, 1996, J BIOCHEM-TOKYO, V120, P759; Holt A, 1997, ANAL BIOCHEM, V244, P384, DOI 10.1006/abio.1996.9911; KEARNEY EB, 1971, BIOCHEM BIOPH RES CO, V42, P490, DOI 10.1016/0006-291X(71)90397-4; KEARNEY EB, 1952, J BIOL CHEM, V194, P747; KEKELIDZE TN, 1995, J LABELLED COMPD RAD, V36, P953, DOI 10.1002/jlcr.2580361007; Kim J, 1995, J BIOL CHEM, V270, P31202, DOI 10.1074/jbc.270.52.31202; KIM YS, 1978, P SOC EXP BIOL MED, V157, P466, DOI 10.3181/00379727-157-40078; KIM YS, 1985, INT J BIOCHEM, V17, P975; KRAJL M, 1965, BIOCHEM PHARMACOL, V14, P1684, DOI 10.1016/0006-2952(65)90025-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambooy J. P., 1971, METHODS ENZYMOL B, V18, P437; MAYCOCK AL, 1976, BIOCHEMISTRY-US, V15, P114, DOI 10.1021/bi00646a018; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; MOORE EG, 1979, J BIOL CHEM, V254, P8173; MOORE EG, 1978, J BIOL CHEM, V253, P6413; Murthy YVSN, 1996, J BIOL CHEM, V271, P19915, DOI 10.1074/jbc.271.33.19915; MURTHY YVSN, 1995, J BIOL CHEM, V270, P28586, DOI 10.1074/jbc.270.48.28586; OESTREICHER G, 1980, COMP BIOCHEM PHYS B, V67, P395, DOI 10.1016/0305-0491(80)90327-2; OLTMANNS O., 1967, Zeitschrift fur Naturforschung, V226, P751; OLTMANNS O, 1969, MOL GEN GENET, V105, P306, DOI 10.1007/BF00277585; PERL M, 1976, J BIOL CHEM, V251, P3221; Robinson KM, 1996, J BIOL CHEM, V271, P4055; Robinson KM, 1996, J BIOL CHEM, V271, P4061; SANTOS MA, 1995, J BIOL CHEM, V270, P437, DOI 10.1074/jbc.270.1.437; Stankovich M.T., 1991, CHEM BIOCH FLAVOENZY, V1, P401; TAN AK, 1991, BIOCHEM BIOPH RES CO, V181, P1084, DOI 10.1016/0006-291X(91)92048-O; URBAN P, 1991, FEBS LETT, V286, P142, DOI 10.1016/0014-5793(91)80960-B; WALKER MC, 1994, BIOCHEMISTRY-US, V33, P7088, DOI 10.1021/bi00189a011; WEYLER W, 1990, PHARMACOL THERAPEUT, V47, P391, DOI 10.1016/0163-7258(90)90064-9; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3; WU M, 1995, MOL CELL BIOL, V15, P264, DOI 10.1128/MCB.15.1.264; ZHOU BP, 1995, BIOCHEMISTRY-US, V34, P9526, DOI 10.1021/bi00029a029; ZHOU BP, 1995, J BIOL CHEM, V270, P23653, DOI 10.1074/jbc.270.40.23653	51	35	35	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23515	23525		10.1074/jbc.274.33.23515	http://dx.doi.org/10.1074/jbc.274.33.23515			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438531	hybrid			2022-12-25	WOS:000082012800081
J	Bertrand, P; Akhmedov, AT; Delacote, F; Durrbach, A; Lopez, BS				Bertrand, P; Akhmedov, AT; Delacote, F; Durrbach, A; Lopez, BS			Human POMp75 is identified as the pro-oncoprotein TLS/FUS: both POMp75 and POMp100 DNA homologous pairing activities are associated to cell proliferation	ONCOGENE			English	Article						TLS/FUS; DNA homologous pairing; cell proliferation; recombination	STRAND-BREAK REPAIR; RNA-POLYMERASE-II; ABL TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; ESCHERICHIA-COLI; BINDING PROTEIN; RAD51 PROTEIN; RECA PROTEIN; C-ABL	We have previously developed an assay to measure DNA homologous pairing activities in crude extracts: The POM blot. In mammalian nuclear extracts, we detected two major DNA homologous pairing activities: POMp100 and POMp75. Here, we present the purification and identification of POMp75 as the pro-oncoprotein TLS/FUS. Because of the pro-oncogene status of TLS/FUS, we studied in addition, the relationships between cell proliferation and POM activities. We show that transformation of human fibroblasts by SV40 large T antigen results in a strong increase of both POMp100 and TLS/POMp75 activities. Although detectable levels of both POMp100 and TLS/POMp75 are observed in non-immortalized fibroblasts or lymphocytes, fibroblasts at mid confluence or lymphocytes stimulated by phytohaemaglutinin, show higher levels of POM activities. Moreover, induction of differentiation of mouse F9 line by retinoic acid leads to the inhibition of both POMp100 and TLS/POMp75 activities. Comparison of POM activity of TLS/FUS with the amount of TLS protein detected by Western blot, suggests that the POM activity could be regulated by post-translation modification. Taken together, these results indicate that POMp100 and TLS/POMp75 activitites are present in normal cells but are connected to cell proliferation. Possible relationship between cell proliferation, response to DNA damage and DNA homologous pairing activity of the pro-oncoprotein TLS/FUS are discussed.	CEA, DSV, DRR, CNRS,UMR 217, F-92265 Fontenay Aux Roses, France; Inst Curie, Biol Sect, F-75231 Paris 05, France; Grp Hosp Bichat Claude Bernard, F-75877 Paris 18, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Lopez, BS (corresponding author), CEA, DSV, DRR, CNRS,UMR 217, 60-68 Av Gen Leclerc,BP6, F-92265 Fontenay Aux Roses, France.		Lopez, Bernard S/O-7308-2017	Lopez, Bernard S/0000-0001-5088-0155; BERTRAND, Pascale/0000-0002-9019-742X				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; AKHMEDOV AT, 1995, P NATL ACAD SCI USA, V92, P1729, DOI 10.1073/pnas.92.5.1729; Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BERTRAND P, 1993, NUCLEIC ACIDS RES, V21, P3653, DOI 10.1093/nar/21.16.3653; Bertrand P, 1995, BIOCHIMIE, V77, P840, DOI 10.1016/0300-9084(95)90001-2; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P6225, DOI 10.1073/pnas.93.13.6225; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GOLUB EI, 1992, NUCLEIC ACIDS RES, V20, P3121, DOI 10.1093/nar/20.12.3121; Hong XK, 1996, MOL MICROBIOL, V21, P953, DOI 10.1046/j.1365-2958.1996.591419.x; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; KASLIN E, 1994, J BIOL CHEM, V269, P14103; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; LOPEZ B, 1987, NUCLEIC ACIDS RES, V15, P6813, DOI 10.1093/nar/15.17.6813; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; LUISIDELUCA C, 1995, J BACTERIOL, V177, P566, DOI 10.1128/jb.177.3.566-572.1995; Luo CM, 1996, J BIOL CHEM, V271, P4497; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Noirot P, 1998, J BIOL CHEM, V273, P12274, DOI 10.1074/jbc.273.20.12274; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RADDING CM, 1991, J BIOL CHEM, V266, P5355; Rice MC, 1997, P NATL ACAD SCI USA, V94, P7417, DOI 10.1073/pnas.94.14.7417; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; ROSSIGNOL JL, 1994, EXPERIENTIA, V50, P307, DOI 10.1007/BF01924014; Sambrook J., 2002, MOL CLONING LAB MANU; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Thyagarajan B, 1997, J BIOL CHEM, V272, P23328, DOI 10.1074/jbc.272.37.23328; Thyagarajan B, 1996, NUCLEIC ACIDS RES, V24, P4084, DOI 10.1093/nar/24.20.4084; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; Yamamoto A, 1996, MOL GEN GENET, V251, P1; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zinszner H, 1997, J CELL SCI, V110, P1741	65	71	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4515	4521		10.1038/sj.onc.1203048	http://dx.doi.org/10.1038/sj.onc.1203048			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442642				2022-12-25	WOS:000081813500013
J	Ciminale, V; Zotti, L; D'Agostino, DM; Ferro, T; Casareto, L; Franchini, G; Bernardi, P; Chieco-Bianchi, L				Ciminale, V; Zotti, L; D'Agostino, DM; Ferro, T; Casareto, L; Franchini, G; Bernardi, P; Chieco-Bianchi, L			Mitochondrial targeting of the p13(II) protein coded by the x-II ORF of human T-cell leukemia/lymphotropic virus type I (HTLV-I)	ONCOGENE			English	Article						HTLV; X region; p13(II); mitochondria; Delta psi	GREEN-FLUORESCENT PROTEIN; CYTOCHROME-C; CYCLOSPORINE-A; MESSENGER-RNA; BCL-2; APOPTOSIS; RELEASE; LOCALIZATION; INFECTIVITY; EXPRESSION	The X region of the HTLV-I genome contains four major open reading frames (ORFs), two of which, termed x-I and x-II, are of still undefined biological significance. By indirect immunofluorescence and dual labeling with marker proteins, we demonstrate that p13(II), an 87-amino acid protein coded by the x-II ORF, is selectively targeted to mitochondria, Mutational analysis revealed that mitochondrial targeting of p13(II) is directed by an atypical 10-amino acid signal sequence that is not cleaved upon import and is able to target the Green Fluorescent Protein to mitochondria, Expression of p13(II) results in specific alterations of mitochondrial morphology and distribution from a typical string-like, dispersed network to round-shaped clusters, suggesting that p13(II) might interfere with processes relying on an intact mitochondrial architecture. Functional studies of mitochondria with the cationic fluorochrome tetramethylrhodamine revealed that a subpopulation of the cells with p13(II)-positive mitochondria show a disruption in the mitochondrial inner membrane potential (Delta psi), an early event observed in cells committed to apoptosis, Taken together, these results suggest novel virus-cell interactions that might be important in HTLV-I replication and/or pathogenicity.	Univ Padua, Dept Oncol & Surg Sci, I-35128 Padua, Italy; NCI, Basic Res Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy	IRCCS Istituto Oncologico Veneto (IOV); University of Padua; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Padua	Ciminale, V (corresponding author), Univ Padua, Dept Oncol & Surg Sci, Via Gattamelata 64, I-35128 Padua, Italy.		Ciminale, Vincenzo/L-1416-2016; Bernardi, Paolo/C-3656-2008; D'Agostino, Donna/AAW-1765-2021	Ciminale, Vincenzo/0000-0001-6197-1802; Bernardi, Paolo/0000-0001-9187-3736; D'Agostino, Donna/0000-0002-3451-5622	NATIONAL CANCER INSTITUTE [ZIABC005645, Z01BC005645] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZZONE GF, 1965, P NATL ACAD SCI USA, V53, P1084, DOI 10.1073/pnas.53.5.1084; BENKO D M, 1990, New Biologist, V2, P1111; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1999, IN PRESS PHYSL REV; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; Cann A.J., 1996, FIELDS VIROLOGY, P1849; Chen YMA, 1997, INT J CANCER, V71, P196, DOI 10.1002/(SICI)1097-0215(19970410)71:2&lt;196::AID-IJC12&gt;3.0.CO;2-G; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; DAgostino DM, 1997, J VIROL, V71, P75, DOI 10.1128/JVI.71.1.75-83.1997; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; DERSE D, 1995, J VIROL, V69, P1907, DOI 10.1128/JVI.69.3.1907-1912.1995; DIETEL M, 1994, J CANCER RES CLIN, V120, P263, DOI 10.1007/BF01236382; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HICKISH T, 1994, CANCER RES, V54, P2808; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; Mulloy JC, 1996, J VIROL, V70, P3599, DOI 10.1128/JVI.70.6.3599-3605.1996; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Petronilli V, 1998, BIOFACTORS, V8, P263, DOI 10.1002/biof.5520080314; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rabson A. B., 1997, P205; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Rojo G, 1998, J VIROL, V72, P7583, DOI 10.1128/JVI.72.9.7583-7588.1998; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SMITH DB, 1994, CURRENT PROTOCOLS MO, V2, P1671; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tollefson AE, 1996, VIROLOGY, V220, P152, DOI 10.1006/viro.1996.0295; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida M, 1996, SEMIN VIROL, V7, P349, DOI 10.1006/smvy.1996.0042	42	80	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4505	4514		10.1038/sj.onc.1203047	http://dx.doi.org/10.1038/sj.onc.1203047			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442641	Green Published			2022-12-25	WOS:000081813500012
J	Corradin, S; Ransijn, A; Corradin, G; Roggero, MA; Schmitz, AAP; Schneider, P; Mauel, J; Vergeres, G				Corradin, S; Ransijn, A; Corradin, G; Roggero, MA; Schmitz, AAP; Schneider, P; Mauel, J; Vergeres, G			MARCKS-related protein (MRP) is a substrate for the Leishmania major surface protease leishmanolysin (gp63)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; CATHEPSIN-B; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; MEMBRANE; FAMILY; METALLOPROTEASE; TRYPANOSOMATIDS; PATHOGENICITY	Myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP; MacMARCKS) are protein kinase C substrates in diverse cell types. Activation of murine macrophages by cytokines increases MRP expression, but infection with Leishmania promastigotes during activation results in MRP depletion, We therefore examined the effect of Leishmania major LV39 on recombinant MRP, Both live promastigotes and a soluble fraction of LV39 lysates degraded MRP to yield lower molecular weight fragments. Degradation was independent of MRP myristoylation and was inhibited by protein kinase C-dependent phosphorylation of MRP, MRP was similarly degraded by purified leishmanolysin (gp63), a Leishmania surface metalloprotease. Degradation was evident at low enzyme/substrate ratios, over a broad pH range, and was inhibited by 1,10-phenanthroline and by a hydroxamate dipeptide inhibitor of leishmanoiysin, Using mass spectrometric analysis, cleavage was shown to occur within the effector domain of MRP between Ser(92) and Phe(93), in accordance with the substrate specificity of leishmanolysin, Moreover, an MRP construct in which the effector domain had been deleted was resistant to cleavage. Thus, Leishmania infection may result in leishmanolysin-dependent hydrolysis of MRP, a major protein kinase C substrate in macrophages.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; RMF Dictagene SA, CH-1066 Epalinges, Switzerland; Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland	University of Lausanne; University of Basel	Corradin, S (corresponding author), Univ Lausanne, Inst Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.			Schneider, Pascal/0000-0003-0677-9409; Schmitz, Arndt/0000-0002-7104-6191				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Barik S, 1997, Methods Mol Biol, V67, P173; BEHIN R, 1979, EXP PARASITOL, V48, P81, DOI 10.1016/0014-4894(79)90057-2; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOUVIER J, 1990, BIOCHEMISTRY-US, V29, P10113, DOI 10.1021/bi00495a015; BOUVIER J, 1995, METHOD ENZYMOL, V248, P614; BOUVIER J, 1985, J BIOL CHEM, V260, P5504; BOUVIER J, 1987, MOL BIOCHEM PARASIT, V24, P73, DOI 10.1016/0166-6851(87)90117-4; BRITTON HTS, 1956, MONOGRAPHS APPLIED C, P364; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; BUCHMULLERROUILLER Y, 1994, BIOCHEM J, V301, P243, DOI 10.1042/bj3010243; COGGINS PJ, 1994, J NEUROCHEM, V63, P1491; Corradin S, 1999, J BIOL CHEM, V274, P16782, DOI 10.1074/jbc.274.24.16782; Desjardins M, 1997, J EXP MED, V185, P2061, DOI 10.1084/jem.185.12.2061; LAUMAS S, 1989, P NATL ACAD SCI USA, V86, P3021, DOI 10.1073/pnas.86.9.3021; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LOBACH DF, 1993, GENOMICS, V17, P194, DOI 10.1006/geno.1993.1301; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; Michielin O, 1998, BBA-BIOMEMBRANES, V1375, P110, DOI 10.1016/S0005-2736(98)00141-2; Mottram JC, 1997, J BIOL CHEM, V272, P14285, DOI 10.1074/jbc.272.22.14285; Rittig MG, 1998, INFECT IMMUN, V66, P4331; Rose SD, 1996, J NEUROSCI RES, V44, P235; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; Sakanari JA, 1997, EXP PARASITOL, V85, P63, DOI 10.1006/expr.1996.4116; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schlagenhauf E, 1998, STRUCTURE, V6, P1035, DOI 10.1016/S0969-2126(98)00104-X; Schleiff E, 1996, J BIOL CHEM, V271, P26794, DOI 10.1074/jbc.271.43.26794; Schmitz AAP, 1999, ANAL BIOCHEM, V268, P343, DOI 10.1006/abio.1998.3080; SCHNEIDER P, 1992, EXP PARASITOL, V75, P196, DOI 10.1016/0014-4894(92)90179-E; Spizz G, 1997, J BIOL CHEM, V272, P23833, DOI 10.1074/jbc.272.38.23833; Spizz G, 1996, J BIOL CHEM, V271, P553, DOI 10.1074/jbc.271.1.553; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; Wu M, 1996, P NATL ACAD SCI USA, V93, P2110, DOI 10.1073/pnas.93.5.2110; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652	38	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25411	25418		10.1074/jbc.274.36.25411	http://dx.doi.org/10.1074/jbc.274.36.25411			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464270	Green Published, hybrid			2022-12-25	WOS:000082554200034
J	Hishida, T; Iwasaki, H; Yagi, T; Shinagawa, H				Hishida, T; Iwasaki, H; Yagi, T; Shinagawa, H			Role of Walker motif A of RuvB protein in promoting branch migration of Holliday junctions - Walker motif A mutations affect ATP binding, ATP hydrolyzing, and DNA binding activities of RuvB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RUVA; INDUCED CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; HOMOLOGOUS RECOMBINATION; HELICASE-II; NUCLEOTIDE; COMPLEX; REPAIR; PURIFICATION; RESOLUTION	Escherichia coli RuvB protein, an ATP-dependent hexameric DNA helicase, acts together with RuvA protein to promote branch migration of Holliday junctions during homologous recombination and recombinational repair. To elucidate the role of the Walker motif A of RuvB (GXGKT; X indicates a nonconserved residue) in ATP hydrolysis and branch migration activities, we constructed four ruvB mutant genes by site-directed mutagenesis, altering the highly conserved Lys(68) and Thr(69) K68R, K68A, and T69A mutants except T69S failed to complement W-sensitive phenotype of the ruvB strain. These three mutant proteins, when overexpressed, made the wild-type strain UV-sensitive to varying degrees. K68R, K68A, and T69A were defective in ATP hydrolysis and branch migration activities in vitro, In the presence of Mg2+, K68R showed markedly reduced affinity for ATP, while K68A and T69A showed only mild reduction. K68A and T69A could form hexamers in the presence of Mg2+ and ATP, while K68R failed to form hexamers and existed instead as a higher oligomer, probably a dodecamer. In contrast to wild-type RuvB, K68R, K68A, and T69A by themselves were defective in DNA binding. However, RuvA could facilitate binding of K68A and T69A to DNA, whereas it could not promote binding of R68R to DNA, All of the three mutant RuvBs could physically interact with RuvA. These results indicate the direct involvement in ATP binding and ATP hydrolysis of the invariant Lys(68) and Thr(69) residues of Walker motif A of RuvB and suggest that these residues play key roles in interrelating these activities with the conformational change of RuvB, which is required for the branch migration activity.	Osaka Univ, Microbial Dis Res Inst, Dept Mol Microbiol, Suita, Osaka 5650871, Japan	Osaka University	Shinagawa, H (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Mol Microbiol, Suita, Osaka 5650871, Japan.	shinagaw@biken.osaka-u.ac.jp	Iwasaki, Hiroshi/Y-7946-2018	Iwasaki, Hiroshi/0000-0002-0153-6873; Hishida, Takashi/0000-0002-9752-6599				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; CHAO KL, 1990, J BIOL CHEM, V265, P1067; Eggleston AK, 1997, CELL, V89, P607, DOI 10.1016/S0092-8674(00)80242-1; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; Hishida T, 1996, GENE, V182, P63, DOI 10.1016/S0378-1119(96)00474-X; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Marrione PE, 1996, BIOCHEMISTRY-US, V35, P11228, DOI 10.1021/bi960316c; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Mezard C, 1997, J MOL BIOL, V271, P704, DOI 10.1006/jmbi.1997.1225; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; Nishino T, 1998, STRUCTURE, V6, P11, DOI 10.1016/S0969-2126(98)00003-3; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; Roe SM, 1998, MOL CELL, V2, P361, DOI 10.1016/S1097-2765(00)80280-4; Sambrook J., 2002, MOL CLONING LAB MANU; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; YAMADA K, 1999, IN PRESS MOL GEN GEN; YONG YQ, 1995, J BIOL CHEM, V270, P24509, DOI 10.1074/jbc.270.41.24509	45	53	54	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25335	25342		10.1074/jbc.274.36.25335	http://dx.doi.org/10.1074/jbc.274.36.25335			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464259	hybrid			2022-12-25	WOS:000082554200024
J	Hurskainen, TL; Hirohata, S; Seldin, MF; Apte, SS				Hurskainen, TL; Hirohata, S; Seldin, MF; Apte, SS			ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases - General features and genomic distribution of the ADAM-TS family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I N-PROTEINASE; HUMAN DERMATOSPARAXIS; TISSUE INHIBITOR; MATRIX; PROCOLLAGEN; CLONING; DOMAIN; MOTIFS; CELL; SUPERFAMILY	We report the primary structure of three novel, putative zinc metalloproteases designated ADAM-TS5, ADAM-TS6, and ADAM-TS7. All have a similar domain organization, comprising a preproregion, a reprolysin-type catalytic domain, a disintegrin-like domain, a thrornbospondin type-1 (TS) module, a cysteine-rich domain, a spacer domain without cysteine residues, and a COOH-terminal TS module. These genes are differentially regulated during mouse embryogenesis and in adult; tissues, with Adamts5 highly expressed in the periimplantation period in embryo and trophoblast. These proteins are similar to four other cognate gene products, defining a distinct family of human reprolysin-like metalloproteases, the ADAM-TS family. The other members of the family are ADAM-TS1, an inflammation-induced gene, the procollagen I/II amino-propeptide processing enzyme (PCINP, ADAM-TS2), and proteins predicted by the KIAA0366 and KIAA0688 genes (ADAM-TS3 and ADAM-TS4). Individual ADAM-TS members differ in the number of COOH-terminal TS modules, and some have unique COOH-terminal domains. The ADAM-TS genes are dispersed in human and mouse genomes.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Univ Calif Davis, Dept Biol Chem, Rowe Program Genet, Davis, CA 95616 USA; Univ Calif Davis, Dept Med, Rowe Program Genet, Davis, CA 95616 USA	Cleveland Clinic Foundation; University of California System; University of California Davis; University of California System; University of California Davis	Apte, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.			Apte, Suneel/0000-0001-8441-1226	NHGRI NIH HHS [HGO0734] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000734] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apte SS, 1997, J BIOL CHEM, V272, P25511, DOI 10.1074/jbc.272.41.25511; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Green EL, 1981, GENETICS PROBABILITY, P77; HANSET R, 1967, ANN MED VET, V7, P451; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; LAPIERE CM, 1993, ARCH DERMATOL, V129, P1316, DOI 10.1001/archderm.129.10.1316; LAPIERE CM, 1971, P NATL ACAD SCI USA, V68, P3054, DOI 10.1073/pnas.68.12.3054; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; NUSGENS BV, 1980, BIOCHEM J, V191, P699, DOI 10.1042/bj1910699; PENDAS AM, 1995, GENOMICS, V26, P615, DOI 10.1016/0888-7543(95)80186-P; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; SMITH LT, 1992, AM J HUM GENET, V51, P235; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; WATSON BC, 1994, COMPUT SYST ENG, V5, P389, DOI 10.1016/0956-0521(94)90021-3; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275	35	170	200	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25555	25563		10.1074/jbc.274.36.25555	http://dx.doi.org/10.1074/jbc.274.36.25555			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464288	hybrid			2022-12-25	WOS:000082554200052
J	Kim, SY; Nam, TW; Shin, D; Koo, BM; Seok, YJ; Ryu, S				Kim, SY; Nam, TW; Shin, D; Koo, BM; Seok, YJ; Ryu, S			Purification of Mlc and analysis of its effects on the pts expression in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; TRANSCRIPTIONAL REGULATION; CATABOLITE REPRESSION; ALLOSTERIC REGULATION; POSITIVE REGULATION; MESSENGER-RNA; OPERON; PHOSPHOENOLPYRUVATE; PROTEIN; GENE	Products of the pts operon of Escherichia coli have multiple physiological roles such as sugar transport, and the operon is controlled by two promoters, PO and P1, Expression of the pts PO promoter that is increased during growth in the presence of glucose is also activated by cAMP receptor protein cAMP. Based on the existence of a sequence that has a high similarity with the known Rile binding site in the promoter, the effects of the Mlc protein on the pts PO promoter expression were studied. In vivo transcription assays using wild type and mlc-negative E. coli strains grown in the presence and absence of glucose indicate that Mlc negatively regulates expression of the PO promoter, and Mlc-dependent repression is relieved by glucose in the growth medium. In vitro transcription assay using purified recombinant Mlc showed that Mlc repressed transcription from the PO but did not affect the activity of the P1, DNase I footprinting experiments revealed that a Rile binding site was located around +1 to +25 of the pro meter and that Mlc inhibited the binding of RNA polymerase to the PO promoter. Cells overexpressing Mlc showed a very slow fermentation rate compared with the wild type when grown in the presence of various phosphoenolpyruvate-carbohydrate phosphotransferase system sugars but few differences in the presence of non-phosphoenolpyruvate-carbohydrate phosphotransferase system sugars except maltose, These results suggest that the pts operon is one of major targets for the negative regulation by Mlc, and thus Mle regulates the utilization of various sugars as well as glucose in E. coli, The possibility that the inducer of Mlc may not be sugar or its derivative but an unknown factor is proposed to explain the Mlc induction mechanism by various sugars.	Chungbuk Natl Univ, Coll Med, Dept Microbiol, Chongju 361763, South Korea; Seoul Natl Univ, Dept Microbiol, Seoul 151742, South Korea	Chungbuk National University; Seoul National University (SNU)	Ryu, S (corresponding author), Chungbuk Natl Univ, Coll Med, Dept Microbiol, Bldg 150,Rm 308, Chongju 361763, South Korea.	sryu@med.chungbuk.ac.kr		Seok, Yeong-Jae/0000-0003-0379-3619; Koo, Byoung-Mo/0000-0003-1001-6367				Decatur AL, 1996, GENE DEV, V10, P2348, DOI 10.1101/gad.10.18.2348; Decker K, 1998, MOL MICROBIOL, V27, P381, DOI 10.1046/j.1365-2958.1998.00694.x; DEREUSE H, 1988, J BACTERIOL, V170, P3827, DOI 10.1128/jb.170.9.3827-3837.1988; DEREUSE H, 1992, J MOL BIOL, V226, P623, DOI 10.1016/0022-2836(92)90620-Y; DEREUSE H, 1991, J BACTERIOL, V173, P727, DOI 10.1128/jb.173.2.727-733.1991; GEORGELLIS D, 1995, MOL MICROBIOL, V16, P1259, DOI 10.1111/j.1365-2958.1995.tb02347.x; HOSONO K, 1995, BIOSCI BIOTECH BIOCH, V59, P256, DOI 10.1271/bbb.59.256; ISHIZUKA H, 1993, MOL MICROBIOL, V10, P341, DOI 10.1111/j.1365-2958.1993.tb01960.x; Kimata K, 1998, MOL MICROBIOL, V29, P1509, DOI 10.1046/j.1365-2958.1998.01035.x; KUSUKAWA N, 1988, GENE DEV, V2, P874, DOI 10.1101/gad.2.7.874; MORRIS PW, 1985, J BACTERIOL, V163, P785, DOI 10.1128/JB.163.2.785-786.1985; Oh H, 1999, J BIOL CHEM, V274, P14006, DOI 10.1074/jbc.274.20.14006; OHNISHI K, 1992, MOL MICROBIOL, V6, P3149, DOI 10.1111/j.1365-2958.1992.tb01771.x; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; Plumbridge J, 1998, NUCLEIC ACIDS RES, V26, P1254, DOI 10.1093/nar/26.5.1254; Plumbridge J, 1998, MOL MICROBIOL, V27, P369, DOI 10.1046/j.1365-2958.1998.00685.x; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; ROEHL RA, 1980, J BACTERIOL, V142, P120, DOI 10.1128/JB.142.1.120-130.1980; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; RYU S, 1994, J BIOL CHEM, V269, P4767; RYU S, 1995, NATURE, V376, P560, DOI 10.1038/376560a0; RYU S, 1995, J BIOL CHEM, V270, P2489, DOI 10.1074/jbc.270.6.2489; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; Seok YJ, 1997, J BIOL CHEM, V272, P26511, DOI 10.1074/jbc.272.42.26511; Seok YJ, 1997, P NATL ACAD SCI USA, V94, P13515, DOI 10.1073/pnas.94.25.13515; Seok YJ, 1996, P NATL ACAD SCI USA, V93, P347, DOI 10.1073/pnas.93.1.347	27	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25398	25402		10.1074/jbc.274.36.25398	http://dx.doi.org/10.1074/jbc.274.36.25398			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464268	hybrid			2022-12-25	WOS:000082554200032
J	Sontag, E; Nunbhakdi-Craig, V; Lee, G; Brandt, R; Kamibayashi, C; Kuret, J; White, CL; Mumby, MC; Bloom, GS				Sontag, E; Nunbhakdi-Craig, V; Lee, G; Brandt, R; Kamibayashi, C; Kuret, J; White, CL; Mumby, MC; Bloom, GS			Molecular interactions among protein phosphatase 2A, tau, and microtubules - Implications for the regulation of tau phosphorylation and the development of tauopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN NEURONS; ALZHEIMERS-DISEASE; CELL-CYCLE; BRAIN; BINDING; TUBULIN; KINASE; DEPHOSPHORYLATION; DIFFERENTIATION; IDENTIFICATION	Hyperphosphorylated forms of the neuronal microtubule (MT)-associated protein tau are major components of Alzheimer's disease paired helical filaments. Previously, we reported that AB alpha C, the dominant brain isoform of protein phosphatase 2A (PP2A), is localized on MTs, binds directly to tau, and is a major tau phosphatase in cells. We now describe direct interactions among tau, PP2A, and MTs at the submolecular level. Using tau deletion mutants, we found that ABaC binds a domain on tau that is indistinguishable from its MI-binding domain. AB alpha C binds directly to MTs through a site that encompasses its catalytic subunit and is distinct from its binding site for tau, and AB alpha C and tau bind to different domains on MTs. Specific PP2A isoforms bind to MTs with distinct affinities in vitro, and these interactions differentially inhibit the ability of PP2A to dephosphorylate various substrates, including tau and tubulin. Finally, tubulin assembly decreases PP2A activity in vitro, suggesting that PP2A activity can be modulated by MT dynamics in vivo, Taken together, these findings indicate how structural interactions among AB alpha C, tau, and MTs might control the phosphorylation state of tau. Disruption of these normal interactions could contribute significantly to development of tauopathies such as Alzheimer's disease.	Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neurosci & Cell Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany; Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Iowa; Ruprecht Karls University Heidelberg; University System of Ohio; Ohio State University	Sontag, E (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Lee, Gloria/F-5965-2011; White, Charles L/AAJ-1858-2021; SONTAG, ESTELLE/AAE-9805-2020	White, Charles L/0000-0002-3870-2804; Lee, Gloria/0000-0002-8633-1534; Brandt, Roland/0000-0003-0101-1257	NHLBI NIH HHS [HL31107] Funding Source: Medline; NIA NIH HHS [AG12300] Funding Source: Medline; NIGMS NIH HHS [GM49505] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG012300] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BRANDT R, 1993, J BIOL CHEM, V268, P3414; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; DIAZNIDO J, 1990, J NEUROCHEM, V54, P211, DOI 10.1111/j.1471-4159.1990.tb13303.x; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Fullerton AT, 1998, MOL BIOL CELL, V9, P2699, DOI 10.1091/mbc.9.10.2699; GARD DL, 1985, J CELL BIOL, V100, P764, DOI 10.1083/jcb.100.3.764; GOEDERT M, 1995, J NEUROCHEM, V65, P2804; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1997, MOL MECH DEMENTIA, P199; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; Khan IA, 1996, BIOCHEMISTRY-US, V35, P3704, DOI 10.1021/bi951247p; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; Leger J, 1997, J BIOL CHEM, V272, P8441, DOI 10.1074/jbc.272.13.8441; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; Merrick SE, 1996, J BIOL CHEM, V271, P5589, DOI 10.1074/jbc.271.10.5589; Merrick SE, 1997, J NEUROSCI, V17, P5726; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PINNA LA, 1994, BBA-MOL CELL RES, V1222, P415, DOI 10.1016/0167-4889(94)90050-7; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SERRANO L, 1985, EUR J BIOCHEM, V153, P595, DOI 10.1111/j.1432-1033.1985.tb09342.x; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; VALLEE RB, 1981, J CELL BIOL, V90, P568, DOI 10.1083/jcb.90.3.568; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILSON DM, 1995, J BIOL CHEM, V270, P24306, DOI 10.1074/jbc.270.41.24306; Wilson DM, 1997, AM J PATHOL, V150, P2181; Xie HQ, 1998, BRAIN RES, V798, P173, DOI 10.1016/S0006-8993(98)00407-7; YAMAMOTO H, 1988, J NEUROCHEM, V50, P1614, DOI 10.1111/j.1471-4159.1988.tb03051.x	48	257	272	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25490	25498		10.1074/jbc.274.36.25490	http://dx.doi.org/10.1074/jbc.274.36.25490			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464280	hybrid			2022-12-25	WOS:000082554200044
J	Jensen-Jarolim, E; Wiedermann, U; Ganglberger, E; Zurcher, A; Stadler, BM; Boltz-Nitulescu, G; Scheiner, O; Breiteneder, H				Jensen-Jarolim, E; Wiedermann, U; Ganglberger, E; Zurcher, A; Stadler, BM; Boltz-Nitulescu, G; Scheiner, O; Breiteneder, H			Allergen mimotopes in food enhance type I allergic reactions in mice	FASEB JOURNAL			English	Article						Bet v 1; Bet mim 1; Prof mim 1; type 1 allergy; bacteriophage; mimotope; oral immunization; digestion; food allergen; BALB/c mouse model	BIRCH POLLEN ALLERGEN; MONOCLONAL-ANTIBODIES; IGE BINDING; AFFINITY PURIFICATION; BET-V-1; PHAGE; VEGETABLES; PROFILIN; PROTEINS; MODULATE	BIP1 is a murine IgG antibody capable of enhancing the IgE binding to Bet v 1, the major birch pollen allergen, We have previously generated a mimotope of BIP1, designated Bet mim 1, from a constrained phage display peptide library. We dem onstrated that oral immunization of BALB/c mice with the Bet mim 1 mimotope resulted in the induction of Bet v I-specific IgG, The aim of this study was to test the influence of such an oral immunization with Bet mim 1 on a subsequent type I allergic response to Bet v 1, Phages displaying Bet mim 1 or control mimotopes, or PBS alone, were delivered to BALB/c mice by intragastric gavages prior to systemic sensitization with recombinant Bet v I and AI(OH),, an adjuvant inducing preferentially IgE antibody responses. Only mice fed with Bet mim 1-phages displayed substantially enhanced type I allergic skin reactivity to Bet v 1, as compared to mice pretreated with control mimotopes or PBS, A gastric digestion assay indicated that Bet v I and its homologue from apple, Mal d 1, were degraded within seconds under physiological conditions. In contrast, phage-displayed mimotopes were resistant to digestion. Our data indicate that allergen mimics in the diet that resist digestion, can induce allergen specific IgG able to enhance an allergic response. We therefore conclude that sensitization via the oral route may represent a mechanism for aggravating type I allergic reactions, probably leading to an earlier onset of symptoms even at lower allergen dosage.	Univ Vienna, Dept Gen & Expt Pathol, AKH, EBO 3Q, A-1090 Vienna, Austria; Univ Bern, Inst Immunol & Allergol, CH-3010 Bern, Switzerland	University of Vienna; University of Bern	Jensen-Jarolim, E (corresponding author), Univ Vienna, Dept Gen & Expt Pathol, AKH, EBO 3Q, Waehringer Guertel 18, A-1090 Vienna, Austria.	erika.jensen-jarolim@akh-wien.ac.at	Jensen-Jarolim, Erika/C-5120-2018	Jensen-Jarolim, Erika/0000-0003-4019-5765; Wiedermann, Ursula/0000-0002-1302-3223				AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FRICK OL, 1989, PROGRESS IN ALLERGY AND CLINICAL IMMUNOLOGY, P304; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; Jensen-Jarolim E, 1998, FASEB J, V12, P1635, DOI 10.1096/fasebj.12.15.1635; JensenJarolim E, 1997, CLIN EXP ALLERGY, V27, P1299, DOI [10.1046/j.1365-2222.1997.1580956.x, 10.1111/j.1365-2222.1997.tb01175.x]; Knippels LMJ, 1998, CLIN EXP ALLERGY, V28, P368, DOI 10.1046/j.1365-2222.1998.00242.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laffer S, 1996, J IMMUNOL, V157, P4953; Lebecque S, 1997, J ALLERGY CLIN IMMUN, V99, P374, DOI 10.1016/S0091-6749(97)70056-3; Lehrer SB, 1996, CRIT REV FOOD SCI, V36, P553, DOI 10.1080/10408399609527739; Leitner A, 1998, EUR J IMMUNOL, V28, P2921, DOI 10.1002/(SICI)1521-4141(199809)28:09<2921::AID-IMMU2921>3.0.CO;2-D; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; Pastorello EA, 1998, ALLERGY, V53, P48, DOI 10.1111/j.1398-9995.1998.tb04960.x; PAULI G, 1992, ACI NEWS, V4, P43; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Visco V, 1996, J IMMUNOL, V157, P956; Wen J, 1997, MOL PHYLOGENET EVOL, V8, P317, DOI 10.1006/mpev.1997.0447; Wiedermann U, 1998, CLIN EXP IMMUNOL, V111, P144; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x; Zwick MB, 1998, CURR OPIN BIOTECH, V9, P427, DOI 10.1016/S0958-1669(98)80017-7	32	57	64	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1999	13	12					1586	1592		10.1096/fasebj.13.12.1586	http://dx.doi.org/10.1096/fasebj.13.12.1586			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463950	Bronze			2022-12-25	WOS:000082347600014
J	Aubert, J; Dessolin, S; Belmonte, N; Li, M; McKenzie, FR; Staccini, L; Villageois, P; Barhanin, B; Vernallis, A; Smith, AG; Ailhaud, G; Dani, C				Aubert, J; Dessolin, S; Belmonte, N; Li, M; McKenzie, FR; Staccini, L; Villageois, P; Barhanin, B; Vernallis, A; Smith, AG; Ailhaud, G; Dani, C			Leukemia inhibitory factor and its receptor promote adipocyte differentiation via the mitogen-activated protein kinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; ADIPOSE-CELLS; MAP KINASE; PC12 CELLS; NEURONAL DIFFERENTIATION; MEDIATED PHOSPHORYLATION; REGULATED EXPRESSION; NEUROTROPHIC FACTOR; MOUSE DEVELOPMENT; CANCER CACHEXIA	Extracellular factors and intracellular signaling pathways involved in early events of adipocyte differentiation are poorly defined. It is shown herein that expression of leukemia inhibitory factor (LIF) and LIF receptor is developmentally regulated during adipocyte differentiation. Preadipocytes secrete bioactive LIF, and an antagonist of LIF receptor inhibits adipogenesis, Genetically modified embryonic stem (ES) cells combined with culture conditions to commit stem cells into the adipocyte lineage were used to examine the requirement of LIF receptor during in vitro development of adipose cells. The capacity of embryoid bodies derived from lifr(-/-) ES cells to undergo adipocyte differentiation is dramatically reduced. LIF addition stimulates adipocyte differentiation of Ob1771 and 3T3-F442A preadipocytes and that of peroxisome proliferator-activated receptor gamma 2 ligand-treated mouse embryonic fibroblasts. Expression of the early adipogenic transcription factors C/EBP beta and C/EBP delta is rapidly stimulated following exposure of preadipose cells to LIF, The selective inhibitors of mitogen-activated protein kinase kinase, i.e. PD98059 and U0126, inhibit LIE-induced C/EBP gene expression and prevent adipocyte differentiation induced by LIF, These results are in favor of a model that implicates stimulation of LIF receptor in the commitment of preadipocytes to undergo terminal differentiation by controlling the early expression of C/EBP beta and C/EBP delta genes via the mitogen-activated protein kinase cascade.	Univ Nice Sophia Antipolis, Fac Sci, Ctr Biochim, CNRS,UMR 6543, F-06108 Nice 2, France; Univ Edinburgh, Ctr Genome Res, Edinburgh EHG 3JQ, Midlothian, Scotland; Aston Univ, Sch Life & Hlth Sci, Birmingham B47 HET, W Midlands, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Edinburgh; Aston University	Dani, C (corresponding author), Univ Nice Sophia Antipolis, Fac Sci, Ctr Biochim, CNRS,UMR 6543, Parc Valrose, F-06108 Nice 2, France.		DANI, Christian/G-3639-2014; Li, Meng/I-6941-2013	DANI, Christian/0000-0003-3228-0230; Smith, Austin/0000-0002-3029-4682; Ailhaud, Gerard/0000-0003-0596-2906				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON MS, 1992, TRENDS BIOCHEM SCI, V17, P289, DOI 10.1016/0968-0004(92)90437-E; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chambers I, 1997, BIOCHEM J, V328, P879, DOI 10.1042/bj3280879; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dani C, 1997, J CELL SCI, V110, P1279; DANI C, 1989, J BIOL CHEM, V264, P10119; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GAILLARD D, 1989, BIOCHEM J, V257, P389, DOI 10.1042/bj2570389; GIMBLE JM, 1994, J CELL BIOCHEM, V54, P122, DOI 10.1002/jcb.240540113; Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756-3282(96)00258-X; GREENBERG AS, 1992, CANCER RES, V52, P4113; GRIMALDI P, 1984, P NATL ACAD SCI-BIOL, V81, P5440, DOI 10.1073/pnas.81.17.5440; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; IBRAHIMI A, 1993, BIOCHEM J, V289, P141, DOI 10.1042/bj2890141; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Leroy P, 1996, J BIOL CHEM, V271, P2365, DOI 10.1074/jbc.271.5.2365; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; Marvulli D, 1996, DEV DYNAM, V206, P447, DOI 10.1002/(SICI)1097-0177(199608)206:4<447::AID-AJA10>3.0.CO;2-U; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MORI M, 1989, BIOCHEM BIOPH RES CO, V160, P1085, DOI 10.1016/S0006-291X(89)80114-7; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Neophytou C, 1997, DEVELOPMENT, V124, P2345; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Stephens JM, 1998, J BIOL CHEM, V273, P31408, DOI 10.1074/jbc.273.47.31408; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Van Vlasselaer Peter, 1992, Progress in Growth Factor Research, V4, P337, DOI 10.1016/0955-2235(92)90015-A; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; WARE CB, 1995, DEVELOPMENT, V121, P1283; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; YOSHIDA K, 1994, MECH DEVELOP, V45, P163, DOI 10.1016/0925-4773(94)90030-2; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	60	100	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24965	24972		10.1074/jbc.274.35.24965	http://dx.doi.org/10.1074/jbc.274.35.24965			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455174	hybrid			2022-12-25	WOS:000082193400073
J	Fischer, C; Page, S; Weber, M; Eisele, T; Neumeier, D; Brand, K				Fischer, C; Page, S; Weber, M; Eisele, T; Neumeier, D; Brand, K			Differential effects of lipopolysaccharide and tumor necrosis factor on monocytic I kappa B kinase signalsome activation and I kappa B proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; IKK-ALPHA; COMPLEX; BETA; CELLS; PHOSPHORYLATION; MECHANISMS; TRANSDUCTION; PROTEASOMES; MACROPHAGES	The inflammatory mediators lipopolysaccharide (LPS) and tumor necrosis factor (TNF) are potent activators of NF-kappa B, This study compared the effect of these stimuli on endogenous I kappa B kinase (IKK) signalsome activation and I kappa B phosphorylation/proteolysis in human monocytic cells and investigated the role of the signal-some proteins IKK-alpha, IKK-beta, NF-kappa B-inducing kinase (NIK), IKK-gamma (NF-kappa B essential modulator), and IKK complex-associated protein. Kinase assays showed that TNF elicited a rapid but short-lived induction of IKK activity with a 3-fold greater effect on IKK-alpha than on IKK-beta, peaking at 5 min. In contrast, LPS predominantly stimulated IKK-beta activity, which slowly increased, peaking at 30 min. A second peak was observed at a later time point following LPS stimulation, which consisted of both IKK-alpha and -beta activity. The endogenous levels of the signalsome components were unaffected by stimulation. Furthermore, our studies showed association of the IKK-alpha/beta heterodimer with NIK, I kappa B-alpha and -epsilon in unstimulated cells. Exposure to LPS or TNF led to differential patterns of I kappa B-alpha and I kappa B-epsilon disappearance from and reassembly with the signalsome, whereas IKK-alpha, IKK-beta, and NIK remained complex-associated. NIK cannot phosphorylate I kappa B-alpha directly, but it appears to be a functionally important subunit, because mutated NIK inhibited stimulus-induced kappa B-dependent transcription more effectively than mutated IKK-alpha or -beta, Overexpression of IKK complex-associated protein inhibited stimulus-mediated transcription, whereas NF-kappa B essential modulator enhanced it. The understanding of LPS- and TNF-induced signaling may allow the development of specific strategies to treat sepsis-associated disease.	Tech Univ Munich, Klinikum Rechts Isar, Inst Clin Chem & Pathobiochem, D-81675 Munich, Germany	Technical University of Munich	Brand, K (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Inst Clin Chem & Pathobiochem, Ismaninger Str 22, D-81675 Munich, Germany.			Page, Sharon/0000-0003-0228-3609				Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; BRAND K, 1993, J CLIN INVEST, V91, P2031, DOI 10.1172/JCI116425; BRAND K, 1994, ARTERIOSCLER THROMB, V14, P790, DOI 10.1161/01.ATV.14.5.790; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; GRILLI M, 1993, INT REV CYTOL, V143, P1; Haas M, 1998, J LEUKOCYTE BIOL, V63, P395, DOI 10.1002/jlb.63.3.395; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; Parrillo J E, 1993, N Engl J Med, V328, P1471; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Schmidt M, 1997, FASEB J, V11, P1235, DOI 10.1096/fasebj.11.14.9409542; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	49	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24625	24632		10.1074/jbc.274.35.24625	http://dx.doi.org/10.1074/jbc.274.35.24625			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455128	hybrid			2022-12-25	WOS:000082193400027
J	Marin-Hincapie, M; Garofalo, RS				Marin-Hincapie, M; Garofalo, RS			The carboxyl terminal extension of the Drosophila insulin receptor homologue binds IRS-1 and influences cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNAL-TRANSDUCTION; ACTIVATION; PROTEINS; GROWTH; DOMAIN; SHC; SPECIFICITY; SUBSTRATE-1; EXPRESSION	The Drosophila insulin receptor (INR) homolog includes an extension of approximately 400 amino acids at the carboxyl-terminal end of its beta subunit containing several tyrosine-based motifs known to mediate interactions with signaling proteins. In order to explore the role of this extension in INR function, mammalian expression vectors encoding either the complete INR beta subunit (beta-Myc) or the INR beta subunit without the carboxyl-terminal extension (beta Delta) were constructed, and the membrane-bound beta subunits were expressed in 293 and Madin-Darby canine kidney cells in the absence of the ligand-binding cu subunits, beta-Myc and beta Delta proteins were constitutively active tyrosine kinases of 180 and 102 kDa, respectively. INR beta-Myc co-immunoprecipitated a phosphoprotein of 170 kDa identified as insulin receptor substrate-1 (IRS-1), whereas INR beta Delta did not, suggesting that the site of interaction was within the carboxyl-terminal extension. IRS-1 was phosphorylated on tyrosine to a much greater extent in cells expressing INR beta-Myc than in parental or INR beta Delta cells. Despite this, a variety of PTB or SH2 domain-containing signaling proteins, including IRS-2, mSos-1, Shc, p85 subunit of phosphatidylinositol 3-kinase, SHP-2, Raf-1, and JAK2, were not associated with the INR beta-Myc IRS-1 complex. Overexpression of INR beta-Myc and beta Delta kinases conferred an equivalent increase in cell proliferation in both 293 and Madin-Darby canine kidney cells, indicating that this growth response is independent of the carboxyl-terminal extension. However, INR beta-Myc-expressing cells exhibited enhanced survival relative to parental and beta Delta cells, suggesting that the carboxyl-terminal extension, through its interaction with IRS-1, plays a role in the regulation of eel death.	Pfizer Inc, Div Cent Res, Groton, CT 06340 USA; SUNY Hlth Sci Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA	Pfizer; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Garofalo, RS (corresponding author), Pfizer Inc, Div Cent Res, POB 8002, Groton, CT 06340 USA.							BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; FERNANDEZALMONACID R, 1987, MOL CELL BIOL, V7, P2718, DOI 10.1128/MCB.7.8.2718; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GAROFALO RS, 1989, MOL CELL BIOL, V9, P2806, DOI 10.1128/MCB.9.7.2806; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HERRERA R, 1988, INSULIN RECEPTORS, P181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LEBWOHL DE, 1991, J BIOL CHEM, V266, P386; MARINHINCAPIE M, 1995, ENDOCRINOLOGY, V136, P2357, DOI 10.1210/en.136.6.2357; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PETRUZZELLI L, 1985, CANCER CELL, V3, P115; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; RUAN YM, 1995, J BIOL CHEM, V270, P4236, DOI 10.1074/jbc.270.9.4236; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SNYDER M, 1982, CELL, V29, P1027, DOI 10.1016/0092-8674(82)90466-4; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YAMAGUCHI T, 1995, BIOCHEMISTRY-US, V34, P4962, DOI 10.1021/bi00015a007; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, MOL CELL BIOL, V16, P2509	33	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24987	24994		10.1074/jbc.274.35.24987	http://dx.doi.org/10.1074/jbc.274.35.24987			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455177	hybrid			2022-12-25	WOS:000082193400076
J	Masaoka, A; Terato, H; Kobayashi, M; Honsho, A; Ohyama, Y; Ide, H				Masaoka, A; Terato, H; Kobayashi, M; Honsho, A; Ohyama, Y; Ide, H			Enzymatic repair of 5-formyluracil I. Excision of 5-formyluracil site-specifically incorporated into oligonucleotide substrates by AlkA protein (Escherichia coli 3-methyladenine DNA glycosylase II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDONUCLEASE-III; HUMAN HOMOLOG; IONIZING-RADIATION; ALKYLATING-AGENTS; SACCHAROMYCES-CEREVISIAE; ADAPTIVE RESPONSE; MOLECULAR-CLONING; BASE EXCISION; OGG1 GENE; CDNA	5-Formyluracil (fU) is a major thymine lesion produced by reactive oxygen radicals and photosensitized oxidation. We have previously shown that fU is a potentially mutagenic lesion due to its elevated frequency to mispair with guanine. Therefore, fU can exist in DNA as a correctly paired fU:A form or an incorrectly paired fU:G form. In this work, fU was site-specifically incorporated opposite A in oligonucleotide substrates to delineate the cellular repair mechanism of fU paired with A. The repair activity for fU was induced in Escherichia coli upon exposure to N-methyl-N'-nitro-N-nitrosoguanidine, and the induction was dependent on the alkA gene, suggesting that AlkA (3-methyladenine DNA glycosylase II) was responsible for the observed activity. Activity assay and determination of kinetic parameters using purified AlkA and defined oligonucleotide substrates containing fU, 5-hydroxymethyluracil (hU), or 7-methylguanine (7mG) revealed that fU was recognized by AlkA with an efficiency comparable to that of 7mG, a good substrate for AlkA, whereas hU, another major thymine methyl oxidation products, was not a substrate. H-1 and C-13 NMR chemical shifts of 5-formyl-2'-deoxyuridine indicated that the 5-formyl group caused base C-6 and sugar C-1' to be electron deficient, which was shown to result in destabilization of the N-glycosidic bond. These features are common in other good substrates for AlkA and are suggested to play key roles in the differential recognition of fU, hU, and intact thymine. Three mammalian repair enzymes for alkylated and oxidized bases cloned so far (MPG, Nth1, and OGG1) did not recognize fU, implying that the mammalian repair activity for fU resided on a yet unidentified protein. In the accompanying paper (Terato, H., Masaoka, A., Robayashi, M., Fukushima, S., Ohyama, Y., Yoshida, M., and Ide, H., J. Biol. Chem. 274, 25144-25150), possible repair mechanisms for fU mispaired with G are reported.	Hiroshima Univ, Fac Sci, Grad Dept Gene Sci, Higashihiroshima 7398526, Japan	Hiroshima University	Ide, H (corresponding author), Hiroshima Univ, Fac Sci, Grad Dept Gene Sci, Higashihiroshima 7398526, Japan.			Terato, Hiroaki/0000-0002-7070-5263				Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; BJELLAND S, 1995, BIOCHEMISTRY-US, V34, P14758, DOI 10.1021/bi00045a017; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; BREIMER L, 1980, NUCLEIC ACIDS RES, V8, P6199, DOI 10.1093/nar/8.24.6199; BREIMER LH, 1984, J BIOL CHEM, V259, P5543; BREIMER LH, 1985, BIOCHEMISTRY-US, V24, P4018, DOI 10.1021/bi00336a032; CANNONCARLSON SV, 1989, J BIOL CHEM, V264, P13306; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1980, NATURE, V287, P203, DOI 10.1038/287203a0; DIDZAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105; ENGELWARD BP, 1993, CARCINOGENESIS, V14, P175; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; HOLLSTEIN MC, 1984, P NATL ACAD SCI-BIOL, V81, P4003, DOI 10.1073/pnas.81.13.4003; IDE H, 1993, BIOCHEM MOL BIOL INT, V31, P485; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; KAO JY, 1993, J BIOL CHEM, V268, P17787; KASAI H, 1990, MUTAT RES, V243, P249, DOI 10.1016/0165-7992(90)90139-B; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; KOW YW, 1985, P NATL ACAD SCI USA, V82, P8354, DOI 10.1073/pnas.82.24.8354; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LAWLEY PD, 1963, BIOCHEM J, V89, P127, DOI 10.1042/bj0890127; LEVY DD, 1991, NUCLEIC ACIDS RES, V19, P3337, DOI 10.1093/nar/19.12.3337; Lindahl T, 1996, PHILOS T ROY SOC B, V351, P1529, DOI 10.1098/rstb.1996.0139; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; MACARTHY TV, 1984, EMBO J, V3, P545; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3730; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; ONO A, 1994, CHEM PHARM BULL, V42, P2231; PEGG AE, 1984, CANCER INVEST, V2, P223, DOI 10.3109/07357908409104376; Purmal AA, 1996, MUTAT RES-DNA REPAIR, V364, P193, DOI 10.1016/S0921-8777(96)00032-8; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P1087, DOI 10.1093/nar/19.5.1087; RoldanArjona T, 1996, NUCLEIC ACIDS RES, V24, P3307, DOI 10.1093/nar/24.17.3307; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SAITO Y, 1997, J BACTERIOL, V179, P3773; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SANDERSON BJS, 1989, BIOCHEMISTRY-US, V28, P3894, DOI 10.1021/bi00435a040; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SARKER AH, 1998, J MOL BIOL, V273, P21585; SCHARER OD, 1995, J AM CHEM SOC, V117, P6623, DOI 10.1021/ja00129a039; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Singer B, 1997, CHEM RES TOXICOL, V10, P713, DOI 10.1021/tx970011e; SINGER B, 1978, BIOCHEMISTRY-US, V17, P1246, DOI 10.1021/bi00600a018; Terato H, 1999, J BIOL CHEM, V274, P25144, DOI 10.1074/jbc.274.35.25144; Terato H, 1998, NUCLEOS NUCLEOT, V17, P131, DOI 10.1080/07328319808005164; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; VOLKERT MR, 1986, GENETICS, V112, P11; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WANG G, 1995, GENETICS, V141, P813; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6; Yoshida M, 1997, NUCLEIC ACIDS RES, V25, P1570, DOI 10.1093/nar/25.8.1570; Zhang QM, 1995, INT J RADIAT BIOL, V68, P603, DOI 10.1080/09553009514551601	67	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25136	25143		10.1074/jbc.274.35.25136	http://dx.doi.org/10.1074/jbc.274.35.25136			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455195	hybrid			2022-12-25	WOS:000082193400094
J	Morris, MC; Robert-Hebmann, V; Chaloin, L; Mery, J; Heitz, F; Devaux, C; Goody, RS; Divita, G				Morris, MC; Robert-Hebmann, V; Chaloin, L; Mery, J; Heitz, F; Devaux, C; Goody, RS; Divita, G			A new potent HIV-1 reverse transcriptase inhibitor - A synthetic peptide derived from the interface subunit domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; DRUG-RESISTANCE; DIMERIZATION; BINDING; HETERODIMER; CELLS	The biologically relevant and active forms of human immunodeficiency viruses type 1 and 2 reverse transcriptase found in infectious virions are heterodimers produced in a two-step dimerization process. Dimerization involves first the rapid association of the two subunits, followed by a slow conformational change yielding a fully active form. We have shown that the dimeric nature of reverse transcriptase represents a important target for the design of a new class of antiviral agents. In this work, we propose a new strategy for its inhibition by targeting protein/protein interactions during viral formation in infected cells. From the screening of peptides derived from the tryptophan cluster at the interface of the connection subdomain, we have designed a short peptide (10 residues) corresponding to residues 395-404, which can block dimerization of reverse transcriptase in vitro and in infected cells. This peptide is highly efficient in abolishing the production of viral particles, without any adverse toxic side effects, when transduced into human immunodeficiency virus type 1-infected cells together with a new peptide carrier.	CNRS, Ctr Rech Biochim Macromol, Dept Biophys, F-34283 Montpellier 5, France; CNRS, Lab Infect Retrovirales & Signalisat, CRBM, Inst Biol, F-34060 Montpellier 1, France; Max Planck Inst Mol Physiol, D-44139 Dortmund, Germany	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Max Planck Society	Divita, G (corresponding author), CNRS, Ctr Rech Biochim Macromol, Dept Biophys, 1919 Ropute de Mende, F-34283 Montpellier 5, France.	gilles@puff.crbm.cnrs-mop.fr	MORRIS, May/ABB-2629-2021; MORRIS, May C/J-5940-2016; Goody, Roger S/J-8845-2014; Chaloin, Laurent/C-5592-2017	MORRIS, May/0000-0001-8106-9728; MORRIS, May C/0000-0001-8106-9728; Goody, Roger S/0000-0002-0772-0444; Chaloin, Laurent/0000-0002-5757-5804				BAILLON JG, 1991, NEW BIOL, V3, P1015; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BENKIRANE M, 1993, EMBO J, V12, P4909, DOI 10.1002/j.1460-2075.1993.tb06185.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Debyser Z, 1996, PROTEIN SCI, V5, P278; DIVITA G, 1994, J BIOL CHEM, V269, P13080; Divita G, 1995, BIOCHEMISTRY-US, V34, P16337, DOI 10.1021/bi00050a014; DIVITA G, 1995, J MOL BIOL, V245, P508, DOI 10.1006/jmbi.1994.0042; DIVITA G, 1995, J BIOL CHEM, V270, P28642, DOI 10.1074/jbc.270.48.28642; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; GOODY RS, 1995, NAT MED, V1, P519, DOI 10.1038/nm0695-519; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MERY J, 1993, INT J PEPT PROT RES, V42, P44; Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER B, 1989, J BIOL CHEM, V264, P13975; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RESTLE T, 1992, FEBS LETT, V300, P97, DOI 10.1016/0014-5793(92)80172-D; Richman DD, 1996, ADV EXP MED BIOL, V394, P383; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242	28	66	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24941	24946		10.1074/jbc.274.35.24941	http://dx.doi.org/10.1074/jbc.274.35.24941			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455170	hybrid, Green Published			2022-12-25	WOS:000082193400069
J	Nakayama, K; Hara, T; Hibi, M; Hirano, T; Miyajima, A				Nakayama, K; Hara, T; Hibi, M; Hirano, T; Miyajima, A			A novel oncostatin M-inducible gene OIG37 forms a gene family with MyD118 and GADD45 and negatively regulates cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; NUCLEAR ANTIGEN; DNA-REPLICATION; PCNA BINDING; MULTIPLE CYTOKINES; SIGNAL TRANSDUCERS; EXPRESSION; DIFFERENTIATION; RECEPTOR; PROLIFERATION	Oncostatin M (OSM) is a member of the IL-6 family cytokines that use gp130 as a common signal transducer and exhibits both growth stimulatory as well as growth inhibitory activity depending on the cells. To analyze the mechanism of OSM function, we isolated immediate early responsive genes upon OSM stimulation. Here we describe the novel OSM-inducible gene OIG37 that is related to MyD118 and GADD45, The MyD118 gene has been described as an immediate early gene induced by IL-6 in M1 monocytic cells, and GADD45 was identified as a gene induced by UV or gamma-ray irradiation. Both are considered to function in growth arrest and/or DNA repair. Although the expression of OIG37, MyD118, and GADD45 was rather ubiquitous, it was differentially regulated. As the gp130 mutant defective for activating the STAT3 pathway showed the reduced induction of OIG37 by cytokine stimulation and expression of dominant negative STATE inhibited the induction of OIG37 by OSM, STAT3 is involved in OIG37 induction by IL-6 family cytokines, To examine the function of OIG37, we expressed it in NIH3T3 and IL-3-dependent BaF3 cells and found that OIG37 suppressed cell growth without any evidence of apoptosis. Whereas both MyD118 and OIG37 suppressed cell growth in both cell lines, suppression by OIG37 was more efficient than by MyD118. Immunoprecipitation experiments indicated that OIG37 associates with p21, a cyclin-dependent kinase inhibitor, and proliferating cell nuclear antigen.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Osaka Univ, Sch Med, Suita, Osaka 5650871, Japan	University of Tokyo; Osaka University	Miyajima, A (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.		Hibi, Masahiko/I-6215-2014; Hirano, Toshio/C-8194-2009; Nakayama, Koh/U-9232-2019	Hibi, Masahiko/0000-0002-9142-4444; 				ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; BORMAN AM, 1994, EMBO J, V13, P3149, DOI 10.1002/j.1460-2075.1994.tb06613.x; BRUCE AG, 1992, J IMMUNOL, V149, P1271; Chida D, 1999, BLOOD, V93, P1567, DOI 10.1182/blood.V93.5.1567.405k29_1567_1578; Chida D, 1998, MOL ENDOCRINOL, V12, P1792, DOI 10.1210/me.12.11.1792; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DU XX, 1994, BLOOD, V83, P2023; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; HALL PA, 1995, ONCOGENE, V10, P2427; HAPP B, 1993, CELL GROWTH DIFFER, V4, P9; HARA T, 1994, BLOOD, V84, P189; Ichihara M, 1997, BLOOD, V90, P165; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LINSLEY PS, 1990, MOL CELL BIOL, V10, P1882, DOI 10.1128/MCB.10.5.1882; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Onishi M, 1996, EXP HEMATOL, V24, P324; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tanaka M, 1999, BLOOD, V93, P804, DOI 10.1182/blood.V93.3.804.403a16_804_815; THOMA B, 1994, J BIOL CHEM, V269, P6215; Vairapandi M, 1996, ONCOGENE, V12, P2579; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wijelath ES, 1997, J CELL SCI, V110, P871; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	49	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24766	24772		10.1074/jbc.274.35.24766	http://dx.doi.org/10.1074/jbc.274.35.24766			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455148	hybrid			2022-12-25	WOS:000082193400047
J	Sacksteder, KA; Morrell, JC; Wanders, RJA; Matalon, R; Gould, SJ				Sacksteder, KA; Morrell, JC; Wanders, RJA; Matalon, R; Gould, SJ			MCD encodes peroxisomal and cytoplasmic forms of malonyl-CoA decarboxylase and is mutated in malonyl-CoA decarboxylase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE; CARBOXYLASE; CLONING; CARDIOMYOPATHY; PURIFICATION; TRANSLATION; ENZYMES	Malonyl-CoA decarboxylase (MCD) catalyzes the proton-consuming conversion of malonyl-CoA to acetyl-CoA and CO2. Although defects in MCD activity are associated with malonyl-CoA decarboxylase deficiency, a lethal disorder characterized by cardiomyopathy and developmental delay, the metabolic role of this enzyme in mammals is unknown. A computer-based search for novel peroxisomal proteins led to the identification of a candidate gene for human MCD, which encodes a protein with a canonical type-1 peroxisomal targeting signal of serine-lysine-leucine(COOH). We observed that recombinant MCD protein has high intrinsic malonyl-CoA decarboxylase activity and that a malonyl-CoA decarboxylase-deficient patient has a severe mutation in the MCD gene (c.947-948delTT), confirming that this gene encodes human MCD, Subcellular fractionation experiments revealed that MCD resides in both the cytoplasm and peroxisomes. Cytoplasmic MCD is positioned to play a role in the regulation of cytoplasmic malonyl-CoA abundance and, thus, of mitochondrial fatty acid uptake and oxidation, This hypothesis is supported by the fact that malonyl-CoA decarboxylase-deficient patients display a number of phenotypes that are reminiscent of mitochondrial fatty acid oxidation disorders. Additional support for this hypothesis comes from our observation that MCD mRNA is most abundant in cardiac and skeletal muscles, tissues in which cytoplasmic malonyl-CoA is a potent inhibitor of mitochondrial fatty acid oxidation and which derive significant amounts of energy from fatty acid oxidation, As for the role of peroxisomal MCD, we propose that this enzyme may be involved in degrading intraperoxisomal malonyl-CoA, which is generated by the peroxisomal beta-oxidation of odd chain-length dicarboxylic fatty acids.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Texas, Med Branch, Childrens Hosp, Galveston, TX 77555 USA; Univ Amsterdam, Acad Med Ctr, Dept Clin Biochem & Pediat, NL-1105 AZ Amsterdam, Netherlands	Johns Hopkins University; University of Texas System; University of Texas Medical Branch Galveston; University of Amsterdam; Academic Medical Center Amsterdam	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St,409 Physiol Bldg, Baltimore, MD 21205 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10981] Funding Source: Medline; NIDDK NIH HHS [DK45787] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An JH, 1998, EUR J BIOCHEM, V257, P395, DOI 10.1046/j.1432-1327.1998.2570395.x; BROWN GK, 1984, J INHERIT METAB DIS, V7, P21, DOI 10.1007/BF01805615; COURCHESNESMITH C, 1992, ARCH BIOCHEM BIOPHYS, V298, P576, DOI 10.1016/0003-9861(92)90452-3; CRANE DI, 1994, J BIOL CHEM, V269, P21835; ELGERSMA Y, 1995, EMBO J, V14, P3472, DOI 10.1002/j.1460-2075.1995.tb07353.x; Geisbrecht BV, 1998, J BIOL CHEM, V273, P33184, DOI 10.1074/jbc.273.50.33184; Geraghty MT, 1999, P NATL ACAD SCI USA, V96, P2937, DOI 10.1073/pnas.96.6.2937; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Ha J, 1996, P NATL ACAD SCI USA, V93, P11466, DOI 10.1073/pnas.93.21.11466; HAAN EA, 1986, EUR J PEDIATR, V144, P567, DOI 10.1007/BF00496037; JANG SH, 1989, J BIOL CHEM, V264, P3500; KIM YS, 1978, ARCH BIOCHEM BIOPHYS, V190, P234, DOI 10.1016/0003-9861(78)90273-4; KIM YS, 1978, ARCH BIOCHEM BIOPHYS, V190, P585, DOI 10.1016/0003-9861(78)90314-4; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; MACPHEE GB, 1993, ARCH DIS CHILD, V69, P433, DOI 10.1136/adc.69.4.433; MATALON R, 1993, J INHERIT METAB DIS, V16, P571, DOI 10.1007/BF00711684; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MICHAUD J, 1992, GENOMICS, V13, P389, DOI 10.1016/0888-7543(92)90258-T; MIHALIK SJ, 1992, PROG CLIN BIOL RES, V357, P239; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; Roe C. R., 1995, METABOLIC MOL BASES, P1501; SCHOLTE HR, 1969, BIOCHIM BIOPHYS ACTA, V178, P137, DOI 10.1016/0005-2744(69)90140-5; SUZUKI H, 1989, BIOCHIM BIOPHYS ACTA, V990, P25, DOI 10.1016/S0304-4165(89)80007-8; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Warren DS, 1998, AM J HUM GENET, V63, P347, DOI 10.1086/301963; Yano S, 1997, EUR J PEDIATR, V156, P382, DOI 10.1007/s004310050619; YEH LA, 1980, J BIOL CHEM, V255, P2308	30	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24461	24468		10.1074/jbc.274.35.24461	http://dx.doi.org/10.1074/jbc.274.35.24461			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455107	hybrid			2022-12-25	WOS:000082193400006
J	Taules, M; Rodriguez-Vilarrupla, A; Rius, E; Estanyol, JM; Casanovas, O; Sacks, DB; Perez-Paya, E; Bachs, O; Agell, N				Taules, M; Rodriguez-Vilarrupla, A; Rius, E; Estanyol, JM; Casanovas, O; Sacks, DB; Perez-Paya, E; Bachs, O; Agell, N			Calmodulin binds to p21(Cip1) and is involved in the regulation of its nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; DNA-POLYMERASE-ALPHA; CELL-CYCLE; NRK CELLS; CDK4; G1; PHOSPHORYLATION; INHIBITOR; PROTEIN; P21	p21(Cip1), first described as an inhibitor of cyclin-dependent kinases, has recently been shown to have a function in the formation of cyclin D-Cdk4 complexes and in their nuclear translocation. The dual behavior of p21(Cip1) may be due to its association with other proteins. Different evidence presented here indicate an in vitro and in vivo interaction of p21(Cip1) With calmodulin: 1) purified p21(Cip1) is able to bind to calmodulin-Sepharose in a Ca2+-dependent manner, and this binding is inhibited by the calmodulin-binding domain of calmodulin-dependent kinase II; 2) both molecules coimmunoprecipitate when extracted from cellular lysates; and 3) colocalization of calmodulin and p21(Cip1) can be detected in vivo by electron microscopy immunogold analysis. The carboxyl-terminal domain of p21(Cip1) is responsible for the calmodulin interaction, since p21(145-164) peptide is also able to bind calmodulin and to compete with full-length p21(Cip1) for the calmodulin binding. Because treatment of cells with anti-calmodulin drugs decreases the nuclear accumulation of p21(Cip1), We hypothesize that calmodulin interaction with p21(Cip1) is important for p21(Cip1), and in consequence for cyclin D-Cdk4, translocation into the cell nucleus.	Univ Barcelona, Fac Med, IDIBAPS, Dept Biol Cellular & Anat Patol, Barcelona 08036, Spain; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Valencia, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Valencia	Agell, N (corresponding author), Univ Barcelona, Fac Med, Dept Cellular Biol, C Casanova 143, Barcelona 08036, Spain.	agell@medicina.ub.es	Estanyol, Josep M/I-1039-2015; Agell, Neus/E-9640-2016; Casanovas, Oriol/L-5210-2014	Estanyol, Josep M/0000-0001-8621-0057; Agell, Neus/0000-0002-1205-6074; Sacks, David/0000-0003-3100-0735; Casanovas, Oriol/0000-0002-4298-3995; Taules, Marta/0000-0003-2895-7376	NCI NIH HHS [CA75205] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075205, R55CA075205] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Cai K, 1998, P NATL ACAD SCI USA, V95, P12254, DOI 10.1073/pnas.95.21.12254; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; Depoortere F, 1998, J CELL BIOL, V140, P1427, DOI 10.1083/jcb.140.6.1427; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HARPER JW, 1993, CELL, V75, P805; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LOPEZGIRONA A, 1992, BIOCHEM BIOPH RES CO, V184, P1517, DOI 10.1016/S0006-291X(05)80055-5; LopezGirona A, 1995, BIOCHEM BIOPH RES CO, V217, P566, DOI 10.1006/bbrc.1995.2813; LOPEZGIRONA A, 1995, CELL CALCIUM, V18, P30, DOI 10.1016/0143-4160(95)90043-8; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; QUINTANA C, 1994, MICRON, V25, P63, DOI 10.1016/0968-4328(94)90056-6; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TAKUWA N, 1993, J BIOL CHEM, V268, P138; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	44	55	56	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24445	24448		10.1074/jbc.274.35.24445	http://dx.doi.org/10.1074/jbc.274.35.24445			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455103	hybrid			2022-12-25	WOS:000082193400002
J	Whistler, JL; von Zastrow, M				Whistler, JL; von Zastrow, M			Dissociation of functional roles of dynamin in receptor-mediated endocytosis and mitogenic signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MU-OPIOID RECEPTOR; COATED VESICLE FORMATION; IN-VIVO; AGONIST; INTERNALIZATION; DESENSITIZATION; RESENSITIZATION; MECHANISMS; NEURONS	Dynamin plays a critical role in the membrane fission mechanism that mediates regulated endocytosis of many G protein-coupled receptors. in addition, dynamin is required for ligand-induced activation of mitogen-activated protein kinase by certain receptors, raising a general question about the role of dynamin in mitogenic signal transduction. Here we report that endocytosis of mu and delta opioid receptors is not required for efficient ligand-induced activation of mitogen-activated protein kinase. Nevertheless, mitogenic signaling mediated by these receptors is specifically dynamin-dependent. Thus a functional role of dynamin in mitogenic signaling can be dissociated from its role in receptor-mediated endocytosis, suggesting a previously unidentified and distinct role of dynamin in signal transduction by certain G protein-coupled receptors.	Univ Calif San Francisco, Dept Psychiat, Cell Biol Program, Nina Ireland Lab, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Cell Biol Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	von Zastrow, M (corresponding author), Univ Calif San Francisco, Dept Psychiat, Cell Biol Program, Nina Ireland Lab, Box 0984 IRE,401 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R29DA010711, R01DA010711, R37DA010711] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10711, DA05844] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Burt RP, 1996, BRIT J PHARMACOL, V117, P224, DOI 10.1111/j.1476-5381.1996.tb15178.x; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Evans CJ, 1993, BIOL BASIS SUBSTANCE, P31; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Keith DE, 1998, MOL PHARMACOL, V53, P377, DOI 10.1124/mol.53.3.377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Li LY, 1996, MOL PHARMACOL, V50, P599; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Raynor K, 1996, NIDA Res Monogr, V161, P83; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schulz S, 1998, EUR J NEUROSCI, V10, P1196, DOI 10.1046/j.1460-9568.1998.00103.x; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	33	94	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24575	24578		10.1074/jbc.274.35.24575	http://dx.doi.org/10.1074/jbc.274.35.24575			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455121	hybrid			2022-12-25	WOS:000082193400020
J	Ghosh, S; Wolan, D; Adak, S; Crane, BR; Kwon, NS; Tainer, JA; Getzoff, ED; Stuehr, DJ				Ghosh, S; Wolan, D; Adak, S; Crane, BR; Kwon, NS; Tainer, JA; Getzoff, ED; Stuehr, DJ			Mutational analysis of the tetrahydrobiopterin-binding site in inducible nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE NO SYNTHASE; HIGH-LEVEL EXPRESSION; ESCHERICHIA-COLI; L-ARGININE; SPECTRAL CHARACTERIZATION; SUBUNIT DIMERIZATION; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; HEME ENVIRONMENT; OXYGENASE DOMAIN	Inducible nitric-oxide synthase (iNOS) is a hemeprotein that requires tetrahydrobiopterin (H4B) for activity. The influence of H4B on iNOS structure-function is complex, and its exact role in nitric oxide (NO) synthesis is unknown. Crystal structures of the mouse iNOS oxygenase domain (iNOSox) revealed a unique H4B-binding site with a high degree of aromatic character located in the dimer interface and near the heme. Four conserved residues (Arg-375, Trp-455, Trp-457, and Phe-470) engage in hydrogen bonding or aromatic stacking interactions with the H4B ring. We utilized point mutagenesis to investigate how each residue modulates H4B function. All mutants contained heme ligated to Cys-194 indicating no deleterious effect on general protein structure. Ala mutants were monomers except for W457A and did not form a homodimer with excess H4B and Arg. However, they did form heterodimers when paired with a full-length iNOS subunit, and these were either fully or partially active regarding NO synthesis, indicating that preserving residue identities or aromatic character is not essential for H4B binding or activity. Aromatic substitution at Trp-455 or Trp-457 generated monomers that could dimerize with H4B and Arg. These mutants bound Arg and H4B with near normal affinity, but Arg could not displace heme-bound imidazole, and they had NO synthesis activities lower than wild-type in both homodimeric and heterodimeric settings. Aromatic substitution at Phe-470 had no significant effects. Together, our work shows how hydrogen bonding and aromatic stacking interactions of Arg-375, Trp-457, Trp-455, and Phe-470 influence iNOSox dimeric structure, heme environment, and NO synthesis and thus help modulate the multiple effects of H4B.	Lerner Res Inst, Cleveland Clin, Dept Immunol, Cleveland, OH 44195 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Mol Biol, La Jolla, CA 92037 USA; Chung Ang Med Sch, Dept Biochem, Seoul 156756, South Korea	Cleveland Clinic Foundation; Scripps Research Institute; Chung Ang University	Stuehr, DJ (corresponding author), Lerner Res Inst, Cleveland Clin, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Ghosh, Sanjay/0000-0001-8624-1494; Wolan, Dennis/0000-0001-9879-8353	NCI NIH HHS [CA53914] Funding Source: Medline; NHLBI NIH HHS [HL58883] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Chen PF, 1998, J BIOL CHEM, V273, P34164, DOI 10.1074/jbc.273.51.34164; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Dawson TM, 1996, ANNU REV MED, V47, P219, DOI 10.1146/annurev.med.47.1.219; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Gerber NC, 1997, ARCH BIOCHEM BIOPHYS, V343, P249, DOI 10.1006/abbi.1997.0187; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P11316, DOI 10.1021/bi00036a003; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Hampele IC, 1997, J MOL BIOL, V268, P21, DOI 10.1006/jmbi.1997.0944; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; McAlpine AS, 1997, J BIOL INORG CHEM, V2, P690, DOI 10.1007/s007750050185; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; RAMAKRISHNAN S, 1988, AM MATH MON, V95, P939, DOI 10.2307/2322391; Renodon A, 1998, BIOCHEMISTRY-US, V37, P6367, DOI 10.1021/bi972297s; RodriguezCrespo I, 1996, ARCH BIOCHEM BIOPHYS, V336, P151, DOI 10.1006/abbi.1996.0543; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P7626, DOI 10.1021/bi960607l; Sambrook J., 2002, MOL CLONING LAB MANU; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891; Yan XJ, 1997, J MOL BIOL, V266, P1043, DOI 10.1006/jmbi.1996.0865	50	64	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24100	24112		10.1074/jbc.274.34.24100	http://dx.doi.org/10.1074/jbc.274.34.24100			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446182	hybrid			2022-12-25	WOS:000082110900061
J	Nastasi, T; Scaturro, M; Bellafiore, M; Raimondi, L; Beccari, S; Cestelli, A; Di Liegro, I				Nastasi, T; Scaturro, M; Bellafiore, M; Raimondi, L; Beccari, S; Cestelli, A; Di Liegro, I			PIPPin is a brain-specific protein that contains a cold-shock domain and binds specifically to H1 degrees and H3.3 mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; RAT CORTICAL-NEURONS; SECONDARY STRUCTURE; REMODELING FACTOR; SYNTHETIC MEDIUM; GENE-EXPRESSION; EUKARYOTES; TRANSCRIPTION; LOCALIZATION; DEGRADATION	During maturation of mammalian brain, variants of both linker (i.e. Hi degrees) and core (i.e. H3.3) histone proteins accumulate in nerve cells, As the concentration of the corresponding transcripts decreases, in postmitotic cells, even if the genes are actively transcribed, it is likely that regulation of variant histone expression has relevant post-transcriptional components and that cellular factors affect histone mRNA stability and/or translation. Here we report that PIPPin, a protein that is highly enriched in the rat brain and contains a cold-shock domain, binds with high specificity to the transcripts that encode H1 degrees and H3.3 histone variants, Both mRNAs are bound through the very end of their 3'-untranslated region that encompasses the polyadenylation signal, Although PIPPin is present both in the cytoplasm and the nucleus of nerve cells, PIPPin-RNA complexes can be obtained only from nuclear extracts. The results of two-dimensional electrophoretic analysis suggest that a relevant proportion of nuclear PIPPin is more acidic than expected, thus suggesting that its RNA binding activity might be modulated by post-translational modifications, such as phosphorylation.	Univ Palermo, Dipartimento Biol Cellulare & Sviluppo A Monroy, I-90128 Palermo, Italy	University of Palermo	Di Liegro, I (corresponding author), Univ Palermo, Dipartimento Biol Cellulare & Sviluppo A Monroy, Viale Sci,Parco Orleans, I-90128 Palermo, Italy.		Bellafiore, Marianna/AAN-5526-2021; nastasi, tommaso/AAR-8730-2020; Scaturro, Maria/B-5005-2013; Raimondi, Lavinia/K-4085-2016	Bellafiore, Marianna/0000-0002-3092-1666; Scaturro, Maria/0000-0001-5614-8678; Raimondi, Lavinia/0000-0001-9394-2002; Di Liegro, Italia/0000-0002-0546-1274				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Burns LG, 1997, BBA-GENE STRUCT EXPR, V1350, P159; CASTIGLIA D, 1994, NEUROCHEM RES, V19, P1531, DOI 10.1007/BF00969002; Castiglia D, 1996, BIOCHEM BIOPH RES CO, V218, P390, DOI 10.1006/bbrc.1996.0068; CASTIGLIA D, 1993, NUCLEIC ACIDS RES, V21, P1674, DOI 10.1093/nar/21.7.1674; CASTIGLIA D, 1992, CELL MOL NEUROBIOL, V12, P259, DOI 10.1007/BF00712930; CESTELLI A, 1985, DEV BRAIN RES, V22, P219, DOI 10.1016/0165-3806(85)90173-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corpet F, 1998, NUCLEIC ACIDS RES, V26, P323, DOI 10.1093/nar/26.1.323; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; HENTZE MW, 1995, CURR OPIN CELL BIOL, V7, P393, DOI 10.1016/0955-0674(95)80095-6; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Lee MS, 1997, CURR OPIN GENET DEV, V7, P212, DOI 10.1016/S0959-437X(97)80131-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsumoto K, 1998, EMBO J, V17, P2107, DOI 10.1093/emboj/17.7.2107; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; Oleynikov Y, 1998, TRENDS CELL BIOL, V8, P381, DOI 10.1016/S0962-8924(98)01348-8; ROCCHERI MC, 1993, J SUBMICR CYTOL PATH, V25, P173; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Savettieri G, 1998, CELL MOL NEUROBIOL, V18, P369, DOI 10.1023/A:1022562813846; SCATURRO M, 1995, NEUROCHEM RES, V20, P969, DOI 10.1007/BF00970744; Scaturro M, 1998, J BIOL CHEM, V273, P22788, DOI 10.1074/jbc.273.35.22788; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Weeks KM, 1997, CURR OPIN STRUC BIOL, V7, P336, DOI 10.1016/S0959-440X(97)80048-6	38	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24087	24093		10.1074/jbc.274.34.24087	http://dx.doi.org/10.1074/jbc.274.34.24087			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446180	hybrid			2022-12-25	WOS:000082110900059
J	Quilliam, LA; Castro, AF; Rogers-Graham, KS; Martin, CB; Der, CJ; Bi, C				Quilliam, LA; Castro, AF; Rogers-Graham, KS; Martin, CB; Der, CJ; Bi, C			M-Ras/R-Ras3, a transforming Ras protein regulated by Sos1, GRF1, and p120 Ras GTPase-activating protein, interacts with the putative Ras effector AF6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; MAP KINASE KINASE; R-RAS; SIGNALING PATHWAY; HA-RAS; N-RAS; K-RAS; TRANSCRIPTIONAL ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; SKELETAL MYOGENESIS	M-Ras is a Ras-related protein that shares similar to 55% identity with K-Ras and TC21. The M-Ras message was widely expressed but was most predominant in ovary and brain. Similarly to Ha-Ras, expression of mutationally activated M-Ras in NIH 3T3 mouse fibroblasts or C2 myoblasts resulted in cellular transformation or inhibition of differentiation, respectively. M-Ras only weakly activated extracellular signal-regulated kinase 2 (ERK2), but it cooperated with Raf, Rac, and Rho to induce transforming foci in NIH 3T3 cells, suggesting that M-Ras signaled via alternate pathways to these effecters. Although the mitogen-activated protein kinase/ERK kinase inhibitor, PD98059, blocked M-Ras-induced transformation, M-Ras was more effective than an activated mitogen-activated protein kinase/ERK kinase mutant at inducing focus formation. These data indicate that multiple pathways must contribute to M-Ras-induced transformation. M-Ras interacted poorly in a yeast two-hybrid assay with multiple Res effecters, including c-Raf-1, A-Raf, B-Raf, phosphoinositol-3 kinase delta, RalGDS, and Rin1. Although M-Ras coimmunoprecipitated with AF6, a putative regulator of cell junction formation, overexpression of AF6 did not contribute to fibroblast transformation, suggesting the possibility of novel effector proteins. The M-Ras GTP/GDP cycle was sensitive to the Ras GEFs, Sos1, and GRF1 and to p120 Ras GAP. Together, these findings suggest that while M-Ras is regulated by similar upstream stimuli to Ha-Ras, novel targets may be responsible for its effects on cellular transformation and differentiation.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Quilliam, LA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,MS-4053, Indianapolis, IN 46202 USA.		Quilliam, Lawrence/Q-4987-2019	Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R29CA063139, R01CA069577] Funding Source: NIH RePORTER; NCI NIH HHS [CA63139, CA69577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Clark Geoffrey J., 1995, P17; Clark GJ, 1996, ONCOGENE, V12, P169; Clark GJ, 1997, J BIOL CHEM, V272, P10608; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; Graham SM, 1996, MOL CELL BIOL, V16, P6132; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; HUANG Y, 1995, ONCOGENE, V11, P1255; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MALY FE, 1994, J BIOL CHEM, V269, P18743; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; PRASAD R, 1993, CANCER RES, V53, P5624; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	72	96	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23850	23857		10.1074/jbc.274.34.23850	http://dx.doi.org/10.1074/jbc.274.34.23850			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446149	hybrid, Green Published			2022-12-25	WOS:000082110900028
J	Tian, GL; Bhamidipati, A; Cowan, NJ; Lewis, SA				Tian, GL; Bhamidipati, A; Cowan, NJ; Lewis, SA			Tubulin folding cofactors as GTPase-activating proteins - GTP hydrolysis and the assembly of the alpha/beta-tubulin heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-TUBULIN; CYTOPLASMIC CHAPERONIN; DIMER DISSOCIATION; FLUORESCENCE ANISOTROPY; MICROTUBULE NUCLEATION; CHICKEN ERYTHROCYTES; POLYMERIZATION; SUBUNITS; EXPRESSION; DYNAMICS	In vivo, many proteins must interact with molecular chaperones to attain their native conformation. In the case of tubulin, newly synthesized alpha- and beta-subunits are partially folded by cytosolic chaperonin, a double-toroidal ATPase with homologs in all kingdoms of life and in most cellular compartments. alpha- and beta-tubulin folding intermediates are then brought together by tubulin-specific chaperone proteins (named cofactors A-E) in a cofactor-containing supercomplex with GTPase activity. Here we show that tubulin subunit exchange can only occur by passage through this supercomplex, thus defining it as a dimer-making machine. We also show that hydrolysis of GTP by beta-tubulin in the supercomplex acts as a switch for the release of native tubulin heterodimer. In this folding reaction and in the related reaction of tubulin-folding cofactors with native tubulin, the cofactors behave as GTPase-activating proteins, stimulating the GTP-binding protein beta-tubulin to hydrolyze its GTP.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA	New York University	Lewis, SA (corresponding author), NYU, Med Ctr, Dept Biochem, 550 1St Ave, New York, NY 10016 USA.	LewisS01@mcrcr.med.nyu.edu						BHATTACHARYYA B, 1985, J BIOL CHEM, V260, P208; Carlier MF, 1997, BIOPHYS J, V73, P418, DOI 10.1016/S0006-3495(97)78081-0; CARLIER MF, 1981, BIOCHEMISTRY-US, V20, P1918, DOI 10.1021/bi00510a030; DAVIS A, 1994, SCIENCE, V264, P839, DOI 10.1126/science.8171338; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DETRICH HW, 1978, BIOCHEMISTRY-US, V17, P3900, DOI 10.1021/bi00612a002; Erickson HP, 1998, TRENDS CELL BIOL, V8, P133, DOI 10.1016/S0962-8924(98)01237-9; FONTALBA A, 1993, J CELL SCI, V106, P627; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Giraudel A, 1998, BIOCHEMISTRY-US, V37, P8724, DOI 10.1021/bi972747g; Hamel E, 1996, MED RES REV, V16, P207, DOI 10.1002/(SICI)1098-1128(199603)16:2<207::AID-MED4>3.3.CO;2-I; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P5314, DOI 10.1021/bi00317a033; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; Lewis SA, 1997, TRENDS CELL BIOL, V7, P479, DOI 10.1016/S0962-8924(97)01168-9; LIN CM, 1981, J BIOL CHEM, V256, P9242; MEJILLANO MR, 1989, BIOCHEMISTRY-US, V28, P6518, DOI 10.1021/bi00441a053; MURPHY DB, 1987, J BIOL CHEM, V262, P14305; MURPHY DB, 1983, J BIOL CHEM, V258, P8357; MURPHY DB, 1977, BIOCHEMISTRY-US, V16, P2598, DOI 10.1021/bi00631a004; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; PANDA D, 1992, BIOCHEMISTRY-US, V31, P9709, DOI 10.1021/bi00155a026; RUDIGER M, 1993, EUR J BIOCHEM, V218, P107, DOI 10.1111/j.1432-1033.1993.tb18357.x; SACKETT DL, 1985, J BIOL CHEM, V260, P43; SACKETT DL, 1989, BIOCHEMISTRY-US, V28, P2662, DOI 10.1021/bi00432a045; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SCHILSTRA MJ, 1989, J BIOL CHEM, V264, P8827; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SPIEGELMAN BM, 1977, CELL, V12, P587, DOI 10.1016/0092-8674(77)90259-8; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; Tran PT, 1997, J STRUCT BIOL, V118, P107, DOI 10.1006/jsbi.1997.3844; VANDECANDELAERE A, 1994, BIOCHEMISTRY-US, V33, P2792, DOI 10.1021/bi00176a007; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WANG D, 1986, J CELL BIOL, V103, P1903, DOI 10.1083/jcb.103.5.1903; Zabala JC, 1996, J CELL SCI, V109, P1471	41	93	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24054	24058		10.1074/jbc.274.34.24054	http://dx.doi.org/10.1074/jbc.274.34.24054			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446175	hybrid			2022-12-25	WOS:000082110900054
J	Guo, W; Grant, A; Novick, P				Guo, W; Grant, A; Novick, P			Exo84p is an exocyst protein essential for secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN RSEC6/8 COMPLEX; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; IDENTIFICATION; GENES; INHIBITOR; TRANSPORT; POLARITY; DELIVERY; HOMOLOGS	The exocyst is a multiprotein complex that plays an important role in secretory vesicle targeting and docking at the plasma membrane. Here we report the identification and characterization of a new component of the exocyst, Exo84p, in the yeast Saccharomyces cerevisiae. Yeast cells depleted of Exo84p cannot survive. These cells are defective in invertase secretion and accumulate vesicles similar to those in the late sec mutants. Exo84p co-immunoprecipitates with the exocyst components, and a portion of the Exo84p co-sediments with the exocyst complex in velocity gradients. The assembly of Exo84p into the exocyst complex requires two other subunits, Sec5p and Sec10p, Exo84p interacts with both Sec5p and Sec10p in a two-hybrid assay. Overexpression of Exo84p selectively suppresses the temperature sensitivity of a secb mutant. Exo84p specifically localizes to the bud tip or mother/daughter connection, sites of polarized secretion in the yeast S. cerevisiae. Exo84p is mislocalized in a secb mutant. These studies suggest that Exo84p is an essential protein that plays an important role in polarized secretion.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Yale University	Novick, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, POB 208002, New Haven, CT 06520 USA.	peter.novick@yale.edu			NIGMS NIH HHS [GM-35370] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035370, R01GM035370] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Guo W, 1997, FEBS LETT, V404, P135, DOI 10.1016/S0014-5793(97)00109-9; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Hazuka CD, 1997, GENE, V187, P67, DOI 10.1016/S0378-1119(96)00720-2; Hazuka CD, 1999, J NEUROSCI, V19, P1324; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Mondesert G, 1997, GENETICS, V147, P421; NAIR J, 1990, J CELL BIOL, V110, P1897, DOI 10.1083/jcb.110.6.1897; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; RINE J, 1987, GENETICS, V116, P9; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; Roth D, 1998, MOL BIOL CELL, V9, P1725, DOI 10.1091/mbc.9.7.1725; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	25	153	158	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23558	23564		10.1074/jbc.274.33.23558	http://dx.doi.org/10.1074/jbc.274.33.23558			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438536	hybrid			2022-12-25	WOS:000082012800086
J	McAleer, MA; Breen, MA; White, NL; Matthews, N				McAleer, MA; Breen, MA; White, NL; Matthews, N			PABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELLS; PHARMACOLOGICAL CHARACTERIZATION; METAL RESISTANCE; PLASMA-MEMBRANE; EXPORT ACTIVITY; P-GLYCOPROTEIN; CMOAT MRP2; YEAST; GENE; GLUTATHIONE	Several members of the ABC family of proteins have been implicated in multidrug resistance associated with cancer therapies. A novel member of this gene family, designated pABC11, has been identified using degenerate polymerase chain reaction. The full-length cDNA spans 5881 base pairs and encodes an open reading frame of 1437 amino acids predicted to contain two sets of transmembrane domains and two nucleotide binding domains characteristic of ABC proteins. The nucleotide sequence described herein extends that of three recently reported sequences, MRP5 (Kool, M., de Haas, M., Scheffer, G., Scheper, R., van Eijk, M., Juijn, J., Baas, F., and Borst, P. (1997) Cancer Res. 57, 3537-3547), SMRP (Suzuki, T., Nishio, K., Sasaki, H., Kurokawa, H,, Saito-Ohara, F., Ikeuchi, T., Tanabe, S., Terada, M., and Saijo, N. (1997) Biochem. Biophys. Res. Commun. 238, 790-794), and MOAT-C (Belinsky, M., Bain, L., Balsara, B., Testa, J., and Kruh, G. (1998) J. Natl. Cancer Inst. 90, 1735-1741), in the 5' direction. Northern blot analysis detected five transcripts that were differentially expressed in several tissue types, and the gene encoding pABC11 was mapped to chromosome 3. Confocal imaging of HEK293 cells expressing a green fluorescent protein-pABC11 construct confirmed plasma membrane localization of the fusion protein. Overexpression of pABC11 resulted in reduced labeling with the fluorochromes 5-chloromethylfluorescein diacetate, fluorescein diacetate, and 2',7'-bis-(2-carboxyethyl)-5 (and-6)carboxyfluorescein acetoxymethyl ester but not with calcein or rhodamine derivatives, consistent with pABC11 being an anion transporter. Fluorochrome export was ATP-dependent but glutathione-independent. We also show that this export pump does not confer resistance to various classes of cytotoxic drugs but does provide small but significant resistance to CdCl2 and potassium antimonyl tartrate.	Yamanouchi Res Inst, Oxford OX4 4SX, England		Matthews, N (corresponding author), Yamanouchi Res Inst, Littlemore Pk,Armstrong Rd, Oxford OX4 4SX, England.			Breen, Maria/0000-0003-2808-8027				Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; Belinsky MG, 1998, J NATL CANCER I, V90, P1735, DOI 10.1093/jnci/90.22.1735; Broeks A, 1996, EMBO J, V15, P6132, DOI 10.1002/j.1460-2075.1996.tb01001.x; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; CHEN YN, 1990, J BIOL CHEM, V265, P10073; Chen ZS, 1998, EXP CELL RES, V240, P312, DOI 10.1006/excr.1998.3938; COLE SPC, 1994, CANCER RES, V54, P5902; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Draper MP, 1997, EUR J BIOCHEM, V243, P219, DOI 10.1111/j.1432-1033.1997.0219a.x; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Eytan GD, 1997, EUR J BIOCHEM, V248, P104, DOI 10.1111/j.1432-1033.1997.00104.x; FELLER N, 1995, BRIT J CANCER, V72, P543, DOI 10.1038/bjc.1995.371; Fromm MF, 1999, BBA-BIOMEMBRANES, V1415, P369, DOI 10.1016/S0005-2736(98)00233-8; Ghosh M, 1999, P NATL ACAD SCI USA, V96, P5001, DOI 10.1073/pnas.96.9.5001; Grant CE, 1997, GENOMICS, V45, P368, DOI 10.1006/geno.1997.4950; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Higgins CF, 1997, SEMIN CANCER BIOL, V8, P135, DOI 10.1006/scbi.1997.0067; Higgins CF, 1993, CURR OPIN CELL BIOL, V5, P684, DOI 10.1016/0955-0674(93)90140-L; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Ishikawa T, 1997, BIOSCIENCE REP, V17, P189, DOI 10.1023/A:1027385513483; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; KONEN PL, 1989, J HISTOCHEM CYTOCHEM, V37, P1141, DOI 10.1177/37.7.2567301; Kool M, 1997, CANCER RES, V57, P3537; Kool M, 1999, CANCER RES, V59, P175; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; LUTZKY J, 1989, CANCER RES, V49, P4120; Makhina EN, 1998, J BIOL CHEM, V273, P3369, DOI 10.1074/jbc.273.6.3369; Miyake K, 1999, CANCER RES, V59, P8; NEALE ML, 1989, EUR J CANCER CLIN ON, V25, P133, DOI 10.1016/0277-5379(89)90061-8; RIORDAN J, 1985, NATURE, V16, P817; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roelofsen H, 1997, GASTROENTEROLOGY, V112, P511, DOI 10.1053/gast.1997.v112.pm9024305; Shen DW, 1998, CANCER RES, V58, P268; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; Suzuki T, 1997, BIOCHEM BIOPH RES CO, V238, P790, DOI 10.1006/bbrc.1997.7346; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Taniguchi K, 1996, CANCER RES, V56, P4124; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; Versantvoort CHM, 1995, INT J CANCER, V63, P855, DOI 10.1002/ijc.2910630617; Vezmar M, 1998, BIOCHEM PHARMACOL, V56, P733, DOI 10.1016/S0006-2952(98)00217-2; Yan G, 1999, J IMMUNOL, V162, P852	48	170	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23541	23548		10.1074/jbc.274.33.23541	http://dx.doi.org/10.1074/jbc.274.33.23541			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438534	hybrid			2022-12-25	WOS:000082012800084
J	Nagpal, S; Gupta, V; Kaur, KJ; Salunke, DM				Nagpal, S; Gupta, V; Kaur, KJ; Salunke, DM			Structure-function analysis of tritrypticin, an antibacterial peptide of innate immune origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PERMEABILIZATION; CRYSTAL-STRUCTURE; MOTIF COMMON; ANTIBIOTICS; PROTEIN; FAMILY; POLYPEPTIDES; INDOLICIDIN; NEUTROPHILS; MECHANISMS	The structural requirements for the antibacterial activity of a pseudosymmetric 13-residue peptide, tritrypticin, were analyzed by combining pattern recognition in protein structures, the structure-activity knowledge-base, and circular dichroism, The structure-activity analysis, based on various deletion analogs, led to the identification of two minimal functional peptides, which by themselves exhibit adequate antibacterial activity against Escherichia coli and Salmonella typhimurium. The common features between these two peptides are that they both share an aromatic-proline-aromatic (ArProAr) sequence motif, and their sequences are retro with respect to one another. The pattern searches in protein structure data base using the ArProAr motif led to the identification of two distinct conformational clusters, namely polyproline type II and p-turn, which correspond to the observed solution structures of the two minimal functional analogs. The role of different residues in structure and function of tritrypticin was delineated by analyzing antibacterial activity and circular dichroism spectra of various designed analogs. Three main results arise from this study. First, the ArProAr sequence motif in proteins has definitive conformational features associated with it. Second, the two minimal bioactive domains of tritrypticin have entirely different structures while having equivalent activities. Third, tritrypticin has a p-turn conformation in solution, but the functionally relevant conformation of this gene-encoded peptide antibiotic may be an extended polyproline type II.	Natl Inst Immunol, Struct Biol Unit, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Salunke, DM (corresponding author), Natl Inst Immunol, Struct Biol Unit, Aruna Asaf Ali Marg, New Delhi 110067, India.		Gagneja, Kanwalinderjit K/K-3204-2017	Gagneja, Kanwalinderjit K/0000-0001-7844-8583				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barra D, 1998, FEBS LETT, V430, P130, DOI 10.1016/S0014-5793(98)00494-3; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1994, CIBA F SYMP, V186, P1; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; Chavali GB, 1997, J MOL BIOL, V272, P731, DOI 10.1006/jmbi.1997.1274; EFIMOV AV, 1994, FEBS LETT, V355, P213, DOI 10.1016/0014-5793(94)01194-X; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; Gazit E, 1996, J MOL BIOL, V258, P860, DOI 10.1006/jmbi.1996.0293; GUPTA HM, 1993, PROTEINS, V16, P48, DOI 10.1002/prot.340160106; GUPTA HM, 1992, CURR SCI INDIA, V62, P374; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P7620, DOI 10.1021/bi00420a008; Kaur KJ, 1997, J BIOL CHEM, V272, P5539, DOI 10.1074/jbc.272.9.5539; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Lawyer C, 1996, FEBS LETT, V390, P95, DOI 10.1016/0014-5793(96)00637-0; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; LEVY O, 1993, J BIOL CHEM, V268, P6058; LICHTENSTEIN AK, 1988, J IMMUNOL, V140, P2686; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; PUNGERCAR J, 1993, FEBS LETT, V336, P284, DOI 10.1016/0014-5793(93)80821-B; RICE PA, 1990, PROTEINS, V8, P334, DOI 10.1002/prot.340080407; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; SKALICKY JJ, 1994, PROTEINS, V20, P52, DOI 10.1002/prot.340200107; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; STORICI P, 1992, FEBS LETT, V314, P187, DOI 10.1016/0014-5793(92)80971-I; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6010; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YAO J, 1994, J MOL BIOL, V243, P736, DOI 10.1016/0022-2836(94)90044-2; YONEZAWA A, 1992, BIOCHEMISTRY-US, V31, P2998, DOI 10.1021/bi00126a022; ZANETTI M, 1993, J BIOL CHEM, V268, P522; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O	39	42	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23296	23304		10.1074/jbc.274.33.23296	http://dx.doi.org/10.1074/jbc.274.33.23296			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438505	hybrid			2022-12-25	WOS:000082012800055
J	Manna, SK; Kuo, MT; Aggarwal, BB				Manna, SK; Kuo, MT; Aggarwal, BB			Overexpression of gamma-glutamylcysteine synthetase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappa B and activator protein-1	ONCOGENE			English	Article						TNF; NF-kappa B; AP-1; ROI; gamma-GCS	INDUCED CELL-DEATH; MANGANESE SUPEROXIDE-DISMUTASE; HUMAN-IMMUNODEFICIENCY-VIRUS; ALPHA-INDUCED APOPTOSIS; C-JUN KINASE; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; HEAVY SUBUNIT; MITOCHONDRIAL-FUNCTION; GLUTATHIONE REGULATION	Tumor necrosis factor (TNF) is a highly pleiotropic cytokine whose activity is at least partially regulated by the redox status of the cell. The cellular redox status is controlled primarily by glutathione, a major cellular antioxidant, whose synthesis is regulated by the rate-limiting enzyme gamma-glutamylcysteine synthetase (gamma-GCS). In the present report we investigated the effect of gamma-GCS overexpression on the TNF-induced activation of nuclear transcription factors NF-kappa B and AP-I, stress-activated protein kinase/c-Jun amino-terminal kinase (JNK) and apoptosis, Transfection of cells with gamma-GCS cDNA blocked TNF-induced NF-kappa B activation, cytoplasmic I kappa-B alpha degradation, nuclear translocation of p65, and NF-kappa B-dependent gene transcription. gamma-GCS overexpression also completely suppressed NF-kappa B activation induced by phorbol ester and okadaic acid, whereas that induced by H2O2, ceramide, and lipopolysaccharide was minimally affected. gamma-GCS also abolished the activation of AP-1 induced by TNF and inhibited TNF-induced activation of JNK and mitogen-activated protein kinase kinase. TNF-mediated cytotoxicity and activation of caspase-3 were both abrogated in gamma-GCS-overexpressing cells. Overall, our results indicate that most of the pleiotropic actions of TNF are regulated by glutathione-controlled redox status of the cell.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [CA 72404-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; delArco PG, 1996, J BIOL CHEM, V271, P26335; DROGE W, 1994, FASEB J, V8, P1131; ESPOSITO F, 1994, BIOCHEM J, V301, P649, DOI 10.1042/bj3010649; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Haridas V, 1998, J IMMUNOL, V160, P3152; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; ISHII Y, 1992, J CLIN INVEST, V89, P794, DOI 10.1172/JCI115658; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Kuo MT, 1996, CANCER RES, V56, P3642; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1998, TRENDS BIOCHEM SCI, V13, P185; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; MULCAHY RT, 1994, MOL PHARMACOL, V46, P909; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MULCAHY RT, 1995, CANCER RES, V55, P4771; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Obrador E, 1997, BIOCHEM J, V325, P183, DOI 10.1042/bj3250183; PHELPS DT, 1995, AM J PHYSIOL-LUNG C, V269, pL551, DOI 10.1152/ajplung.1995.269.4.L551; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SCHRODER FH, 1989, PROSTATE, P17; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Sen CK, 1997, BIOCHEM BIOPH RES CO, V237, P645, DOI 10.1006/bbrc.1997.7206; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Yamane Y, 1998, J BIOL CHEM, V273, P31075, DOI 10.1074/jbc.273.47.31075; YAO KS, 1995, CANCER RES, V55, P4367; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	74	132	135	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4371	4382		10.1038/sj.onc.1202811	http://dx.doi.org/10.1038/sj.onc.1202811			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439045				2022-12-25	WOS:000081732700010
J	D'Alessio, C; Fernandez, F; Trombetta, ES; Parodi, AJ				D'Alessio, C; Fernandez, F; Trombetta, ES; Parodi, AJ			Genetic evidence for the heterodimeric structure of glucosidase II - The effect of disrupting the subunit-encoding genes on glycoprotein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA CELL-LINE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; UDP-GLC; MOLECULAR CHAPERONE; CARBOXYPEPTIDASE-Y; QUALITY-CONTROL; FISSION YEAST; IN-VIVO	It has been proposed that in rat and murine tissues glucosidase II (GII) is formed by two subunits, GII alpha and GII beta, respectively, responsible for the catalytic activity and the retention of the enzyme in the endoplasmic reticulum (ER), To test this proposal we disrupted genes (gls2 alpha(+) and gls2 beta(+)) encoding GII alpha and GII beta homologs in Schizosaccharomyces pombe, Both mutant cells (gls2 alpha and gls2 beta) were completely devoid of GII activity in cell-free assays. Nevertheless, N-oligosaccharides formed in intact gls2 alpha cells were identified as Glc(2)Man(9)GlcNAc(2) and Glc(2)Man(8)GlcNAc(2), whereas gls2 beta cells formed, in addition, small amounts of Glc(1)Man(9)GlcNAc(2). It is suggested that this last compound was formed by GIIa! transiently present in the ER, Monoglucosylated oligosaccharides facilitated glycoprotein folding in S. pombe as mutants, in which formation of monoglucosylated glycoproteins was completely (gls2 alpha) or severely (gls2 beta and UDP-Glc glycoprotein:glucosyltransferase null) diminished, showed ER accumulation of misfolded glycoproteins when grown in the absence of exogenous stress as revealed by (a) induction of binding protein-encoding mRNA and (b) accumulation of glycoproteins bearing ER-specific oligosaccharides. Moreover, the same as in mammalian cell systems, formation of monoglucosylated oligosaccharides decreased the folding rate and increased the folding efficiency of glycoproteins as pulse-chase experiments revealed that carboxypeptidase Y arrived at a higher rate but in decreased amounts to the vacuoles of gls2 alpha than to those of wild type cells.	Fdn Campomar, Inst Invest Bioquim, RA-1405 Buenos Aires, DF, Argentina; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Leloir Institute; Yale University	Parodi, AJ (corresponding author), Fdn Campomar, Inst Invest Bioquim, Antonio Machado 151, RA-1405 Buenos Aires, DF, Argentina.	aparodi@iib.uba.ar		D'Alessio, Cecilia/0000-0001-7371-5080	NIGMS NIH HHS [GM44500] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arendt CW, 1997, J BIOL CHEM, V272, P13117, DOI 10.1074/jbc.272.20.13117; BALOW JP, 1995, J BIOL CHEM, V270, P29025, DOI 10.1074/jbc.270.48.29025; Fanchiotti S, 1998, J CELL BIOL, V143, P625, DOI 10.1083/jcb.143.3.625; Fernandez F, 1998, EMBO J, V17, P5877, DOI 10.1093/emboj/17.20.5877; Fernandez F, 1996, EMBO J, V15, P705, DOI 10.1002/j.1460-2075.1996.tb00406.x; FERNANDEZ FS, 1994, J BIOL CHEM, V269, P30701; Flura T, 1997, GLYCOBIOLOGY, V7, P617, DOI 10.1093/glycob/7.5.617; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Jakob CA, 1998, GLYCOBIOLOGY, V8, P155, DOI 10.1093/glycob/8.2.155; JAMSA E, 1994, YEAST, V10, P355, DOI 10.1002/yea.320100308; JANNATIPOUR M, 1995, J BIOL CHEM, V270, P4845, DOI 10.1074/jbc.270.9.4845; KAUSHAL GP, 1990, J BIOL CHEM, V265, P16271; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; PARLATI F, 1995, EMBO J, V14, P3064, DOI 10.1002/j.1460-2075.1995.tb07309.x; PARODI AJ, 1983, J BIOL CHEM, V258, P8260; Petrescu AJ, 1997, EMBO J, V16, P4302, DOI 10.1093/emboj/16.14.4302; PIDOUX AL, 1992, EMBO J, V11, P1583, DOI 10.1002/j.1460-2075.1992.tb05203.x; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; REITMAN ML, 1982, J BIOL CHEM, V257, P357; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Simons JF, 1998, EMBO J, V17, P396, DOI 10.1093/emboj/17.2.396; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Tabuchi M, 1997, J BACTERIOL, V179, P4179, DOI 10.1128/jb.179.13.4179-4189.1997; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; TROWBRIDGE IS, 1978, EUR J IMMUNOL, V8, P716, DOI 10.1002/eji.1830081009; UGALDE RA, 1979, BIOCHEM BIOPH RES CO, V91, P1174, DOI 10.1016/0006-291X(79)92003-5; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943; ZIEGLER FD, 1994, J BIOL CHEM, V269, P12527	35	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25899	25905		10.1074/jbc.274.36.25899	http://dx.doi.org/10.1074/jbc.274.36.25899			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464333	hybrid			2022-12-25	WOS:000082554200097
J	Sims, B; Mahnke-Zizelman, KM; Profit, AA; Prestwich, GD; Sabina, RL; Theibert, AB				Sims, B; Mahnke-Zizelman, KM; Profit, AA; Prestwich, GD; Sabina, RL; Theibert, AB			Regulation of AMP deaminase by phosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PROTEIN KINASE-C; RAT-TISSUES; INOSITOL POLYPHOSPHATE; PHOSPHOLIPID-BILAYERS; ADENYLATE DEAMINASE; BINDING-SITE; CLONING; PHOSPHORYLATION; SEQUENCE	AMP deaminase (AMPD) converts AMP to IMP and is a diverse and highly regulated enzyme that is a key component of the adenylate catabolic pathway. In this report, we identify the high affinity interaction between AMPD and phosphoinositides as a mechanism for regulation of this enzyme. We demonstrate that endogenous rat brain AMPD and the human AMPD3 recombinant enzymes specifically bind inositide-based affinity probes and to mixed lipid micelles that contain phosphatidylinositol 4,5-bisphosphate. Moreover, we show that phosphoinositides specifically inhibit AMPD catalytic activity, Phosphatidylinositol 4,5-bisphosphate is the most potent inhibitor, effecting pure noncompetitive inhibition of the wild type human AMPD3 recombinant enzyme with a K-i of 110 nM. AMPD activity can be released from membrane fractions by in vitro treatment with neomycin, a phosphoinositide-binding drug. In addition, in vivo modulation of phosphoinositide levels leads to a change in the soluble and membrane-associated pools of AMPD activity. The predicted human AMPD3 sequence contains plecktrin homology domains and (R/ K)X-n(R/K)XKK sequences, both of which are characterized phosphoinositide-binding motifs. The interaction between AMPD and phosphoinositides may mediate membrane localization of the enzyme and function to modulate catalytic activity in vivo.	Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; Univ Utah, Dept Chem Mat, Salt Lake City, UT 84112 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Medical College of Wisconsin; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Utah System of Higher Education; University of Utah	Theibert, AB (corresponding author), Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD032901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH050102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NICHD NIH HHS [P50HD32901] Funding Source: Medline; NIMH NIH HHS [R29MH50102] Funding Source: Medline; NINDS NIH HHS [NS 29632] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGRANOFF B, 1991, BASIC NEUROCHEMISTRY, P333; ALMARAZ L, 1988, J PHYSIOL-LONDON, V407, P557, DOI 10.1113/jphysiol.1988.sp017431; ASHBY B, 1978, J BIOL CHEM, V253, P8728; ASKARI A, 1963, SCIENCE, V141, P44, DOI 10.1126/science.141.3575.44; BAUSCHJURKEN MT, 1992, J BIOL CHEM, V267, P22407; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Kanematsu T, 1996, BIOCHEM J, V313, P319, DOI 10.1042/bj3130319; LI YP, 1991, BRAIN RES, V553, P89, DOI 10.1016/0006-8993(91)90234-M; Liscovitch M, 1996, J LIPID MEDIAT CELL, V14, P215, DOI 10.1016/0929-7855(96)00528-7; Mahnke-Zizelman DK, 1998, J BIOL CHEM, V273, P35118, DOI 10.1074/jbc.273.52.35118; MahnkeZizelman DK, 1997, BIOCHEM J, V326, P521, DOI 10.1042/bj3260521; MAHNKEZIZELMAN DK, 1992, J BIOL CHEM, V267, P20866; Mehrotra B, 1997, J BIOL CHEM, V272, P4237, DOI 10.1074/jbc.272.7.4237; MEYER SL, 1989, BIOCHEMISTRY-US, V28, P8734, DOI 10.1021/bi00448a009; MORISAKI T, 1990, J BIOL CHEM, V265, P11482; OGASAWARA N, 1982, BIOCHIM BIOPHYS ACTA, V714, P298; OGASAWARA N, 1975, FEBS LETT, V58, P245, DOI 10.1016/0014-5793(75)80270-5; OGASAWARA N, 1978, EUR J BIOCHEM, V87, P297, DOI 10.1111/j.1432-1033.1978.tb12378.x; PIPOLY GM, 1979, J CLIN INVEST, V63, P1066, DOI 10.1172/JCI109376; Prestwich GD, 1996, ACCOUNTS CHEM RES, V29, P503, DOI 10.1021/ar960136v; PRESTWICH GD, 1998, ADV PHOSPHOINOSITIDE, P24; Profit AA, 1998, ARCH BIOCHEM BIOPHYS, V357, P85, DOI 10.1006/abbi.1998.0796; PRUS E, 1983, INT J BIOCHEM, V15, P1169, DOI 10.1016/0020-711X(83)90233-1; RAFFIN JP, 1985, COMP BIOCHEM PHYS B, V80, P685, DOI 10.1016/0305-0491(85)90446-8; RAO N, 1968, BIOCHIM BIOPHYS ACTA, V151, P651; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; RUNDELL KW, 1992, AM J PHYSIOL, V263, pC294, DOI 10.1152/ajpcell.1992.263.2.C294; SABINA RL, 1990, J BIOL CHEM, V265, P9423; Sims B, 1998, NEUROBIOL AGING, V19, P385, DOI 10.1016/S0197-4580(98)00083-9; SKLADANOWSKI A, 1978, INT J BIOCHEM, V9, P43, DOI 10.1016/0020-711X(78)90136-2; SOHN RH, 1995, J BIOL CHEM, V270, P21114, DOI 10.1074/jbc.270.36.21114; SOTERIOU A, 1993, J CELL SCI, V104, P119; SPYCHALA J, 1987, BIOCHEM BIOPH RES CO, V148, P106, DOI 10.1016/0006-291X(87)91082-5; SPYCHALA J, 1991, INT J BIOCHEM, V23, P1155, DOI 10.1016/0020-711X(91)90158-J; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; TANFANI F, 1993, BIOCHEM J, V291, P921, DOI 10.1042/bj2910921; THAKKAR JK, 1993, BIOCHEM J, V291, P523, DOI 10.1042/bj2910523; THEIBERT AB, 1992, J BIOL CHEM, V267, P9071; THEIBERT AB, 1997, SIGNALING INOSITOL L, P117; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOVMASIAN EK, 1990, FEBS LETT, V259, P321, DOI 10.1016/0014-5793(90)80037-J; VANWAARDE A, 1988, BIOL REV, V63, P259; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; WEILMALHERBE H, 1975, J NEUROCHEM, V24, P801; WOZNIAK M, 1988, BIOCHEM J, V255, P977; YOSHINO M, 1976, J BIOCHEM-TOKYO, V80, P309, DOI 10.1093/oxfordjournals.jbchem.a131278; YOSHINO M, 1976, J BIOCHEM-TOKYO, V80, P299, DOI 10.1093/oxfordjournals.jbchem.a131277; YOSHINO M, 1976, FEBS LETT, V72, P143, DOI 10.1016/0014-5793(76)80831-9; YOSHINO M, 1988, BIOCHIM BIOPHYS ACTA, V954, P271, DOI 10.1016/0167-4838(88)90082-9; YOSHINO M, 1979, J BIOL CHEM, V254, P1521; YU FX, 1992, J BIOL CHEM, V267, P14616	52	25	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25701	25707		10.1074/jbc.274.36.25701	http://dx.doi.org/10.1074/jbc.274.36.25701			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464307	hybrid			2022-12-25	WOS:000082554200071
J	Liu, J; Subirana, JA				Liu, J; Subirana, JA			Structure of d(CGCGAATTCGCG) in the presence of Ca2+ ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-DNA DODECAMER; CRYSTAL-STRUCTURE; HELIX STRUCTURE; GEOMETRY; PACKING; WATER	The dodecamer d(CGCGAATTCGCG) was the first oligonucleotide to be crystallized as a B-DNA duplex. Its structure was analyzed in detail in the early 1980s. Here we show that, in the presence of Ca2+, it crystallizes in a different way (R3 space group). The dodecamers form parallel columns of straight duplexes with ten base pairs in the B form. The terminal cytosines in each molecule are disordered, whereas the terminal guanines are placed in the minor groove of neighbor duplexes. The central GAATTC region is practically identical to that found in the classic structure of the same dodecamer crystallized in the P2(1)2(1)2(1) space group in the presence of Mg2+ and spermine. Its structure is thus independent of the crystallization conditions which have been used.	Univ Politecn Catalunya, Dept Enginyeria Quim, E-08028 Barcelona, Spain	Universitat Politecnica de Catalunya	Subirana, JA (corresponding author), Cornell Univ, Coll Med, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.		Subirana, juan/L-7192-2014	Subirana, juan/0000-0002-1706-9341				Abrescia NGA, 1999, NUCLEIC ACIDS RES, V27, P1593, DOI 10.1093/nar/27.7.1593; BERMAN HM, 1992, BIOPHYS J, V63, P751, DOI 10.1016/S0006-3495(92)81649-1; BRUNGER AT, 1998, CRYSTALLOGRAPHY NMR; DICKERSON RE, 1987, J BIOMOL STRUCT DYN, V5, P557, DOI 10.1080/07391102.1987.10506413; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; DREW HR, 1982, P NATL ACAD SCI-BIOL, V79, P4040, DOI 10.1073/pnas.79.13.4040; DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; KOPKA ML, 1983, J MOL BIOL, V163, P129, DOI 10.1016/0022-2836(83)90033-5; Liu J, 1998, FEBS LETT, V438, P211, DOI 10.1016/S0014-5793(98)01295-2; MINASOV G, 1999, IN PRESS J MOL BIOL; Nunn CM, 1997, BIOCHEMISTRY-US, V36, P4792, DOI 10.1021/bi9628228; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shui XQ, 1998, BIOCHEMISTRY-US, V37, P8341, DOI 10.1021/bi973073c; Shui XQ, 1998, BIOCHEMISTRY-US, V37, P16877, DOI 10.1021/bi982063o; Soler-Lopez M, 1999, J BIOL CHEM, V274, P23683, DOI 10.1074/jbc.274.34.23683; SPINK N, 1995, P NATL ACAD SCI USA, V92, P10767, DOI 10.1073/pnas.92.23.10767; Tereshko V, 1999, ACTA CRYSTALLOGR D, V55, P810, DOI 10.1107/S0907444999000591; Tereshko V, 1999, J AM CHEM SOC, V121, P470, DOI 10.1021/ja9832919; Tereshko V, 1999, J AM CHEM SOC, V121, P3590, DOI 10.1021/ja984346+	23	43	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24749	24752		10.1074/jbc.274.35.24749	http://dx.doi.org/10.1074/jbc.274.35.24749			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455145	hybrid			2022-12-25	WOS:000082193400044
J	Pazzagli, L; Cappugi, G; Manao, G; Camici, G; Santini, A; Scala, A				Pazzagli, L; Cappugi, G; Manao, G; Camici, G; Santini, A; Scala, A			Purification, characterization, and amino acid sequence of cerato-platanin, a new phytotoxic protein from Ceratocystis fimbriata f. sp platani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHYNCHOSPORIUM-SECALIS; RESISTANCE; PATHOGEN; PEPTIDES; NECROSIS; HYDROPHOBINS; ACCUMULATION; AVIRULENCE; CYSTEINE; DISEASE	A new phytotoxic protein (cerato-platanin) of about 12.4 kDa has been identified in culture filtrates of the Ascomycete Ceratocystis fimbriata f. sp, platani, the causal agent of canker stain disease. The toxicity of the pure protein was bioassayed by detecting the inducing necrosis in tobacco leaves. The pure protein also elicited host synthesis of fluorescent substances in tobacco and plane (Platanus acerifolia) leaves. We purified the protein from culture medium to homogeneity, Its complete amino acid sequence was determined; this protein consists of 120 amino acid residues, contains 4 cysteines (S-S-bridged), and has a high percentage of hydrophobic residues. The molecular weight calculated from the amino acid sequence agrees with that determined by mass spectrometry, suggesting that no post-transnational modification occurs. Searches performed by the BLAST program in data banks (Swiss-Prot, EBI, and GenBank(TM)) revealed that this protein is highly homologous with two proteins produced by other Ascomycete fungi, One, produced during infection of wheat leaves, is codified by the snodprot1 gene of Phaeosphaeria nodorum (the causal agent of glume blotch of wheat), whereas the other is the rAsp f13 allergen from Aspergillus fumigatus. Furthermore, the N terminus of cerato-platanin is homologous with that of cerato-ulmin, a phytotoxic protein belonging to the hydrophobin family and produced by Ophiostoma (Ceratocystis) ulmi, a fungus responsible for Dutch elm disease.	Univ Florence, Ist Patol & Zool Forestale & Agr, I-50144 Florence, Italy; Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Florence; University of Florence	Scala, A (corresponding author), Univ Florence, Ist Patol & Zool Forestale & Agr, Ple Delle Cascine 28, I-50144 Florence, Italy.	scala@ipaf.fi.cnr.it	Santini, Alberto/Q-2655-2015; Camici, Giovanni/H-1631-2018	Santini, Alberto/0000-0002-7955-9207; Camici, Giovanni/0000-0002-0523-0695				ACCORDI SM, 1978, PHYTOPATHOL Z, V91, P39; AKE S, 1992, PHYTOCHEMISTRY, V31, P1199, DOI 10.1016/0031-9422(92)80260-L; Anselmi N., 1994, Bulletin OEPP, V24, P159, DOI 10.1111/j.1365-2338.1994.tb01058.x; BENSON JR, 1975, P NATL ACAD SCI USA, V72, P619, DOI 10.1073/pnas.72.2.619; BURKI N, 1996, THESIS U NEUCHATEL S; CAMICI G, 1989, J BIOL CHEM, V264, P2560; CLERIVET A, 1994, EUR J FOREST PATHOL, V24, P1; Ebbole DJ, 1997, TRENDS MICROBIOL, V5, P405, DOI 10.1016/S0966-842X(97)01130-X; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ElModafar C, 1996, CAN J BOT, V74, P1982, DOI 10.1139/b96-237; ELMODAFAR C, 1993, PHYTOCHEMISTRY, V34, P1271, DOI 10.1016/0031-9422(91)80014-R; ELMODAFAR C, 1995, EUR J PLANT PATHOL, V101, P503, DOI 10.1007/BF01874474; FINDLAY JBC, 1989, AUTOMATED SOLID PHAS, P69; HONEE G, 1994, EUPHYTICA, V79, P219, DOI 10.1007/BF00022522; HUET JC, 1995, MOL PLANT MICROBE IN, V8, P302, DOI 10.1094/MPMI-8-0302; INGLIS AS, 1991, ANAL BIOCHEM, V195, P183, DOI 10.1016/0003-2697(91)90316-L; Jin H, 1996, PHYTOPATHOLOGY, V86, P277, DOI 10.1094/Phyto-86-277; JOOSTEN MHAJ, 1994, NATURE, V367, P384, DOI 10.1038/367384a0; Kershaw MJ, 1998, FUNGAL GENET BIOL, V23, P18, DOI 10.1006/fgbi.1997.1022; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERRE JY, 1994, PLANT PHYSIOL BIOCH, V32, P251; LEE KS, 1979, J BIOL CHEM, V254, P6248; MANSOORI B, 1995, J PHYTOPATHOL, V143, P33, DOI 10.1111/j.1439-0434.1995.tb00196.x; MARTIN JF, 1992, APPLIED MOL GENETICS, P214; MONTECCHIO L, 1996, PETRIA, V6, P269; NakariSetala T, 1996, EUR J BIOCHEM, V235, P248, DOI 10.1111/j.1432-1033.1996.00248.x; NESPOULOUS C, 1992, PLANTA, V186, P551, DOI 10.1007/BF00198035; PANCONESI A, 1981, EUR J FOREST PATHOL, V11, P385; PENKE B, 1974, ANAL BIOCHEM, V60, P45, DOI 10.1016/0003-2697(74)90129-8; RICCI P, 1989, EUR J BIOCHEM, V183, P555, DOI 10.1111/j.1432-1033.1989.tb21084.x; RICHARDS WC, 1993, DUTCH ELM DISEASE RESEARCH, P89; ROHE M, 1995, EMBO J, V14, P4168, DOI 10.1002/j.1460-2075.1995.tb00090.x; SCHAREN AL, 1970, PHYTOPATHOLOGY, V60, P1480, DOI 10.1094/Phyto-60-1480; SEETHARAM R, 1995, TECH PROT CHEM, V6, P125, DOI 10.1016/S1080-8914(06)80018-9; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STRINGER MA, 1993, PLANT CELL, V5, P145, DOI 10.1105/tpc.5.2.145; TEMPLETON MD, 1994, MOL PLANT MICROBE IN, V7, P320, DOI 10.1094/MPMI-7-0320; Vigouroux A., 1979, Revue Forestiere Francaise, V31, P28; VIGOUROUX A, 1997, P 10 C MED PHYT UN M, P633; Wessels JGH, 1997, ADV MICROB PHYSIOL, V38, P1; WESSELS JGH, 1994, ANNU REV PHYTOPATHOL, V32, P413, DOI 10.1146/annurev.py.32.090194.002213; WEVELSIEP L, 1991, PHYSIOL MOL PLANT P, V39, P471, DOI 10.1016/0885-5765(91)90013-8; YAGUCHI M, 1993, DUTCH ELM DISEASE RESEARCH, P152; Zhang HF, 1997, PHYTOPATHOLOGY, V87, P154, DOI 10.1094/PHYTO.1997.87.2.154	46	142	148	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24959	24964		10.1074/jbc.274.35.24959	http://dx.doi.org/10.1074/jbc.274.35.24959			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455173	hybrid			2022-12-25	WOS:000082193400072
J	Zizak, M; Lamprecht, G; Steplock, D; Tariq, N; Shenolikar, S; Donowitz, M; Yun, CHC; Weinman, EJ				Zizak, M; Lamprecht, G; Steplock, D; Tariq, N; Shenolikar, S; Donowitz, M; Yun, CHC; Weinman, EJ			cAMP-induced phosphorylation and inhibition of Na+/H+ exchanger 3 (NHE3) are dependent on the presence but not the phosphorylation of NHE regulatory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; H+ EXCHANGER; MEDIATED INHIBITION; IDENTIFICATION; PHOSPHOPROTEIN; COFACTOR; ISOFORM; DOMAIN; EBP50; EZRIN	The members of the regulatory factor (RF) gene family, Na+/H+ exchanger (NHE)-RF and NHE3 kinase A regulatory factor (E3KARP) are necessary for cAMP to inhibit the epithelial brush border NHE isoform 3 (NRE3). The mechanism of their action was studied using PS120 fibroblasts stably transfected with rabbit NHE3 and wild type rabbit NHE-RF or wild type human E3KARP, 8-Bromo-cAMP (8-Br-cAMP) had no effect on Na+/H+ exchange activity in cells expressing NHE3 alone. In contrast, in cells co-expressing NHE-RF, 8-Br-cAMP inhibited NHE3 by 39%. In vivo phosphorylation of NHE3 demonstrated that cAMP increased phosphorylation in two chymotrypsin-generated phosphopeptides of NHE3 in cells containing NHE-RF or E3KARP but not in cells lacking these proteins. The requirement for phosphorylation of NHE-RF in this cAMP-induced inhibition of NHE3 was examined by studying a mutant NHE-RF in which serines 287, 289, and 290 were mutated to alanines, Wild type NHE-RF was a phosphorylated protein under basal conditions, but treatment with 8-Br-cAMP did not alter its phosphorylation, Mutant NHE-RF was not phosphorylated either under basal conditions or after 8-Br-cAMP, 8-Br-cAMP inhibited NHE3 similarly in PS120/NHE3 cells containing wild type or mutant NHE-RF, NHE-RF and NHE3 co-precipitated and did so similarly with and without cAMP. Mutant NHE-RF also similarly immunoprecipitated NHE3 in the presence and absence of 8-Br-cAMP, This study shows that members of the regulatory factor gene family, NHE-RF and E3KARP, are necessary for cAMP inhibition of NHE3 by allowing NHE3 to be phosphorylated, This inhibition is not dependent on the phosphorylation of NHE-RF.	Johns Hopkins Univ, Sch Med, Dept Med, GI Div, Baltimore, MD 21205 USA; W Virginia Univ, Sch Med, Dept Med, Morgantown, WV 26506 USA; Dept Vet Affairs Med Ctr, Med Serv, Clarksburg, WV 26301 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Johns Hopkins University; West Virginia University; Duke University	Donowitz, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, GI Div, 918 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044484, R01DK037319, R01DK026523] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK37319, P01 DK44484, R01 DK26523] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; Cabado AG, 1996, J BIOL CHEM, V271, P3590; Donowitz M, 1998, AM J PHYSIOL-GASTR L, V274, pG971, DOI 10.1152/ajpgi.1998.274.6.G971; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; WEINMAN EJ, 1990, AM J PHYSIOL, V258, pF1254; WEINMAN EJ, 1989, J MEMBRANE BIOL, V109, P233, DOI 10.1007/BF01870280; WEINMAN EJ, 1988, J MEMBRANE BIOL, V101, P11, DOI 10.1007/BF01872815; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978	21	101	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24753	24758		10.1074/jbc.274.35.24753	http://dx.doi.org/10.1074/jbc.274.35.24753			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455146	hybrid, Green Submitted			2022-12-25	WOS:000082193400045
J	Burton, KA; Treash-Osio, B; Muller, CH; Dunphy, EL; McKnight, GS				Burton, KA; Treash-Osio, B; Muller, CH; Dunphy, EL; McKnight, GS			Deletion of type II alpha regulatory subunit delocalizes protein kinase A in mouse sperm without affecting motility or fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SPERM; ADENYLATE-CYCLASE; FIBROUS SHEATH; ANCHORING PROTEINS; EPIDIDYMAL SPERM; BULL SPERM; GERM-CELLS; SPERMATOZOA; LOCALIZATION; BICARBONATE	Cyclic AMP stimulates sperm motility in a variety of mammalian species, but the molecular details of the intracellular signaling pathway responsible for this effect are unclear. The type II alpha isoform of protein kinase A (PKA) is induced late in spermatogenesis and is thought to localize PRA to the flagellar apparatus where it binds cAMP and stimulates motility. A targeted disruption of the type II alpha regulatory subunit (RII alpha) gene allowed us to examine the role of PKA localization in sperm motility and fertility. In wild type sperm, PKA is found primarily in the detergent-resistant particulate fraction and localizes to the mitochondrial-containing midpiece and the principal piece. In mutant sperm, there is a compensatory increase in RI alpha protein and a dramatic relocalization of PKA such that the majority of the holoenzyme now appears in the soluble fraction and colocalizes with the cytoplasmic droplet. Unexpectedly the RII alpha mutant mice are fertile and have no significant changes in sperm motility. Our results demonstrate that the highly localized pattern of PKA seen in mature sperm is not essential for motility or fertilization.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	McKnight, GS (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Box 357750, Seattle, WA 98195 USA.	mcknight@u.washington.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD012629, F32HD008034] Funding Source: NIH RePORTER; NICHD NIH HHS [5F32 HD08034-03, U54-HD12629] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adham IM, 1997, MOL REPROD DEV, V46, P370, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;370::AID-MRD16&gt;3.0.CO;2-2; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; Berndtson WE, 1997, J ANDROL, V18, P717; BRANDT H, 1980, J BIOL CHEM, V255, P982; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; CONTI M, 1983, BIOL REPROD, V28, P860, DOI 10.1095/biolreprod28.4.860; CROSS NL, 1986, GAMETE RES, V15, P213, DOI 10.1002/mrd.1120150303; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Gabers D. L, 1970, Biology Reprod., V3, P327; Garbers D L, 1980, Adv Cyclic Nucleotide Res, V13, P251; GARTY NB, 1987, FEBS LETT, V218, P148, DOI 10.1016/0014-5793(87)81036-0; GROSS MK, 1987, J BIOL CHEM, V262, P8672; HOROWITZ JA, 1984, J BIOL CHEM, V259, P832; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; HYNE RV, 1979, BIOL REPROD, V21, P1135, DOI 10.1095/biolreprod21.5.1135; ISHIGURO K, 1982, J CELL BIOL, V92, P777, DOI 10.1083/jcb.92.3.777; Johnson LR, 1997, DEV BIOL, V192, P340, DOI 10.1006/dbio.1997.8767; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; LANDMARK BF, 1993, J REPROD FERTIL, V99, P323, DOI 10.1530/jrf.0.0990323; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; LIEBERMAN SJ, 1988, J CELL BIOL, V107, P1809, DOI 10.1083/jcb.107.5.1809; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LINDEMANN CB, 1978, CELL, V13, P9, DOI 10.1016/0092-8674(78)90133-2; LINDEMANN CB, 1989, ARCH ANDROLOGY, V23, P1, DOI 10.3109/01485018908986783; Miki E, 1998, J BIOL CHEM, V273, P34384, DOI 10.1074/jbc.273.51.34384; Moos J, 1998, MOL REPROD DEV, V50, P79, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;79::AID-MRD10&gt;3.0.CO;2-T; NEILL JM, 1987, GAMETE RES, V18, P121, DOI 10.1002/mrd.1120180204; OKAMURA N, 1985, J BIOL CHEM, V260, P9699; OLDSCLARKE P, 1993, DEV BIOL, V155, P14, DOI 10.1006/dbio.1993.1002; OYEN O, 1990, BIOL REPROD, V43, P46, DOI 10.1095/biolreprod43.1.46; TASH JS, 1983, BIOL REPROD, V28, P75, DOI 10.1095/biolreprod28.1.75; Vijayaraghavan S, 1997, BIOL REPROD, V57, P1517, DOI 10.1095/biolreprod57.6.1517; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; Visconti PE, 1997, DEV BIOL, V192, P351, DOI 10.1006/dbio.1997.8768; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; VISCONTI PE, 1990, BIOCHIM BIOPHYS ACTA, V1054, P231, DOI 10.1016/0167-4889(90)90246-A; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; Wiesner B, 1998, J CELL BIOL, V142, P473, DOI 10.1083/jcb.142.2.473; YOVICH JL, 1993, HUM REPROD, V8, P1786, DOI 10.1093/oxfordjournals.humrep.a137935	42	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24131	24136		10.1074/jbc.274.34.24131	http://dx.doi.org/10.1074/jbc.274.34.24131			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446185	hybrid			2022-12-25	WOS:000082110900064
J	Chaudhuri, AR; Khan, IA; Prasad, V; Robinson, AK; Luduena, RF; Barnes, LD				Chaudhuri, AR; Khan, IA; Prasad, V; Robinson, AK; Luduena, RF; Barnes, LD			The tumor suppressor protein Fhit - A novel interaction with tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN TUBULIN; 3P14.2; SITE; GENE; PURIFICATION; PROTEOLYSIS; COMPLEXES; INVITRO; CANCER; FORM	FHIT (fragile histidine triad) is a candidate human tumor suppressor gene located at chromosome 3p14.2, a location that encompasses the FRA3B chromosomal fragile site. Aberrant transcripts have been detected in a variety of primary tumors, and homozygous deletions in the FHIT locus have been detected in different tumor cell lines. The gene product Fhit in vitro possesses the ability to hydrolyze diadenosine 5',5'''-P-1,P-3-triphosphate (Ap(3)A). The mechanism of action of Fhit as a tumor suppressor is unknown. Because the tubulin-microtubule system plays an important role in cell division and cell proliferation, we investigated the interaction between wild-type Fhit or mutant Fhit (H96N) and tubulin in vitro. The mutant form of Fhit (H96N) lacks Ap,A hydrolase activity but retains tumor suppressor activity. We found that both wild-type and mutated forms of Fhit bind to tubulin strongly and specifically with K-d values of 1.4 and 2.1 mu M, respectively. Neither wild-type nor mutant Fhit cause nucleation or formation of microtubules, but in the presence of microtubule-associated proteins, both wild-type and mutant Fhit promote assembly to a greater extent than do microtubule-associated proteins alone, and the microtubules formed appear normal by electron microscopy. Our results suggest the possibility that Fhit may exert its tumor suppressor activity by interacting with microtubules and also indicate that the interaction between Fhit and tubulin is not related to the Ap(3)A hydrolase activity of Fhit.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Chaudhuri, AR (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL CANCER INSTITUTE [R01CA026376, P30CA054174] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 54174, CA 26376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANERJEE A, 1990, J BIOL CHEM, V265, P1794; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BREITLING F, 1986, J MOL BIOL, V189, P367, DOI 10.1016/0022-2836(86)90517-6; Brenner C, 1997, PROTEIN ENG, V10, P1461, DOI 10.1093/protein/10.12.1461; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; DELAVINA S, 1988, BIOCHEMISTRY-US, V27, P5352, DOI 10.1021/bi00414a060; Dustin P., 1984, MICROTUBULES; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; HESKETH R, 1997, ONCOGENE TUMOR SUPPR; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Kastury K, 1996, CANCER RES, V56, P978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lovry O.H., 1951, J BIOL CHEM, V193, P265; LUDUENA R F, 1992, Current Opinion in Cell Biology, V4, P53, DOI 10.1016/0955-0674(92)90058-K; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; LUDUENA RF, 1982, BIOCHEMISTRY-US, V21, P4787, DOI 10.1021/bi00262a041; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OLMSTED JB, 1973, BIOCHEMISTRY-US, V12, P4282, DOI 10.1021/bi00745a037; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SACKETT DL, 1985, J BIOL CHEM, V260, P43; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; SMITH KJ, 1994, CANCER RES, V54, P3672; Sozzi G, 1998, ADV CANCER RES, V74, P141, DOI 10.1016/S0065-230X(08)60766-6; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770	29	52	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24378	24382		10.1074/jbc.274.34.24378	http://dx.doi.org/10.1074/jbc.274.34.24378			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446217	hybrid			2022-12-25	WOS:000082110900096
J	Kuge, O; Saito, K; Nishijima, M				Kuge, O; Saito, K; Nishijima, M			Control of phosphatidylserine synthase II activity in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-EVIDENCE; BIOSYNTHESIS; MUTANT; PHOSPHATIDYLETHANOLAMINE; INHIBITION; PROTEIN; DNA	Phosphatidylserine (PtdSer) in Chinese hamster ovary (CHO) cells is synthesized through the action of PtdSer synthase (PSS) I and II, which catalyzes the exchange of L-serine with the base moiety of phosphatidylcholine and phosphatidylethanolamine, respectively. The PtdSer synthesis in a CHO cell mutant, PSA-3, which lacks PSS I but has normal PSS II activity, was almost completely inhibited by the addition of PtdSer to the culture medium, like that in the wild-type CHO-K1 cells. In contrast, the PtdSer synthesis in a PSS II-overproducing stable transformant of CHO-K1, K1/wt-pssB, was reduced by only 35% upon addition of PtdSer. The serine exchange activity in a membrane fraction of K1/wt-pssB cells was not inhibited by PtdSer at all, whereas those of PSA-3 and CHO-K1 cells were inhibited by >95%. These results indicated that PSS II activity in PSA-S and CHO-K1 cells is inhibited by exogenous PtdSer and that overproduction of PSS II leads to the loss of normal control of PSS II activity by exogenous PtdSer, Although overproduced PSS II in K1/wt-pssB cells was not normally controlled by exogenous PtdSer, K1/wt-pssB cells cultivated without exogenous PtdSer exhibited a normal PtdSer biosynthetic rate similar to that in CHO-K1 cells. In contrast to K1/wt-pssB cells, another stable transformant of CHO-K1, K1/R97K-pssB, which overproduces R97K mutant PSS II, exhibited a similar to 4-fold higher PtdSer biosynthetic rate compared with that in CHO-K1 cells. These results suggested that for maintenance of a normal PtdSer biosynthetic rate, the activity of overproduced wild-type PSS II in K1/wt-pssB cells is depressed by an as yet unknown post-translational mechanisms other than those for the exogenous PtdSer-mediated inhibition and that Arg-97 of PSS II is critical for this depression of overproduced PSS II activity. When the cDNA-directed wild-type and R97K: mutant PSS II activities were expressed at nonoverproduction levels in a PSS I- and PSS II-defective mutant of CHO-K1 cells, expression of the mutant PSS LI activity but not that of the wild-type PSS Il activity induced the PtdSer-resistant PtdSer biosynthesis. This suggested that Arg-97 of PSS II is critical also for the exogenous PtdSer-mediated inhibition of PSS II.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID)	Kuge, O (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Toyama 1-23-1, Tokyo 1628640, Japan.			Kuge, Osamu/0000-0003-4962-3519				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; GERLACH E, 1963, BIOCHEM Z, V337, P477; HASEGAWA K, 1989, J BIOL CHEM, V264, P19887; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1986, J BIOL CHEM, V261, P5795; Kuge O, 1998, P NATL ACAD SCI USA, V95, P4199, DOI 10.1073/pnas.95.8.4199; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; LEWIS WH, 1980, SOMAT CELL GENET, V6, P333, DOI 10.1007/BF01542787; LOURY OH, 1951, J BIOL CHEM, V193, P265; NISHIJIMA M, 1986, J BIOL CHEM, V261, P5784; Saito K, 1996, FEBS LETT, V395, P262, DOI 10.1016/0014-5793(96)01049-6; Saito K, 1998, J BIOL CHEM, V273, P17199, DOI 10.1074/jbc.273.27.17199; VOELKER DR, 1986, J BIOL CHEM, V261, P1002	16	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23844	23849		10.1074/jbc.274.34.23844	http://dx.doi.org/10.1074/jbc.274.34.23844			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446148	hybrid			2022-12-25	WOS:000082110900027
J	Courtemanche, C; Anderson, A				Courtemanche, C; Anderson, A			The p53 tumor suppressor protein reduces point mutation frequency of a shuttle vector modified by the chemical mutagens (+/-)7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene, aflatoxin B-1 and meta-chloroperoxybenzoic acid	ONCOGENE			English	Article						p53; mutation frequency; shuttle vector	WILD-TYPE P53; HUMAN OSTEOSARCOMA CELLS; UV-INDUCED MUTATIONS; EXPRESSING CYTOCHROME-P450IA2 CDNA; DOSE-DEPENDENT DIFFERENCES; DNA-DAMAGE; P53-DEFICIENT MICE; EMBRYO FIBROBLASTS; MOUSE CELLS; SEQUENCE SPECIFICITY	p53 has been postulated to be the guardian of the genome. However, results supporting the prediction that point mutation frequencies are elevated in p53-deficient cells either have not been forthcoming or have been equivocal, To analyse the effect of p53 on point mutation frequency, we used the supF gene of the pYZ289 shuttle vector as a mutagenic target. pYZ289 was treated in vitro by ultraviolet irradiation, aflatoxin B-1, (+/-)7,8-dihy droxy-9, 10-epoxy-7,8,9, 10-tetrahydrobenzo/a/pyrene and meta-chloroperoxybenzoic acid and then transfected into p53-deficient cells with or without a p53 expression, vector. p,53 reduced the mutant frequency up to fivefold when pYZ289 was treated with aflatoxin B-1, (+/-)7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo/a/ or meta-chloroperoxybenzoic acid but not when it was ultraviolet-irradiated. The p53-dependent mutation frequency reduction was higher at a higher level of premutational lesions for aflatoxin B-1 and (+/-)7,8-dihydroxy-9, 10-epoxy-7,8,9, 10-tetrahydrobenzo/a/pyrene and at a lower level of lesions for meta-chloroperoxybenzoic acid. This suggests that the chemical mutagens produce, in a dose-dependent fashion, two kinds of DNA damage, one subject to p53-dependent mutation frequency reduction and the other not. These results indicate that p53 can reduce the point mutation frequency in a shuttle vector treated by chemical mutagens and suggest that p53 can act as guardian of the genome for at least some kinds of point mutations.	Univ Laval, CHU Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Dept Biol, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Anderson, A (corresponding author), Hop Hotel Dieu, Ctr Rech, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.							AMES BN, 1975, MUTAT RES, V31, P347, DOI 10.1016/0165-1161(75)90046-1; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISTOW RG, 1994, ONCOGENE, V9, P1527; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; COURTEMANCHE C, 1994, MUTAT RES, V306, P143, DOI 10.1016/0027-5107(94)90025-6; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FOSTER PL, 1983, P NATL ACAD SCI-BIOL, V80, P2695, DOI 10.1073/pnas.80.9.2695; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; HALL PA, 1993, ONCOGENE, V8, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; HAVRE PA, 1995, CANCER RES, V55, P4420; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Ishizaki K, 1996, MUTAT RES-DNA REPAIR, V364, P43, DOI 10.1016/0921-8777(96)00020-1; JACOBSEN JS, 1986, CARCINOGENESIS, V7, P491, DOI 10.1093/carcin/7.3.491; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAPP LN, 1974, BIOCHIM BIOPHYS ACTA, V361, P140, DOI 10.1016/0005-2787(74)90341-4; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane D, 1998, NATURE, V394, P616, DOI 10.1038/29166; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVY DD, 1992, CANCER RES, V52, P5668; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARIEN K, 1987, J BIOL CHEM, V262, P7455; MORIWAKI S, 1991, CANCER RES, V51, P6219; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; MURNANE JP, 1993, NATURE, V365, P22, DOI 10.1038/365022a0; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NISHINO H, 1995, ONCOGENE, V11, P263; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; ROSENTHAL A, 1990, BIOCHEM BIOPH RES CO, V173, P272, DOI 10.1016/S0006-291X(05)81052-6; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; Smith ML, 1996, AM J PATHOL, V148, P1019; TROTTIER Y, 1992, MUTAT RES, V281, P39, DOI 10.1016/0165-7992(92)90034-F; TROTTIER Y, 1992, MOL CARCINOGEN, V6, P140, DOI 10.1002/mc.2940060209; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEI SJC, 1993, CANCER RES, V53, P3294; WEI SJC, 1994, CARCINOGENESIS, V15, P1729, DOI 10.1093/carcin/15.8.1729; WEI SJC, 1991, P NATL ACAD SCI USA, V88, P11227, DOI 10.1073/pnas.88.24.11227; Yagi T, 1998, CANCER LETT, V123, P71, DOI 10.1016/S0304-3835(97)00406-0; Yamagishi N, 1997, CARCINOGENESIS, V18, P695, DOI 10.1093/carcin/18.4.695; Yamagishi N, 1997, MUTAGENESIS, V12, P191, DOI 10.1093/mutage/12.3.191; YANG JL, 1987, P NATL ACAD SCI USA, V84, P3787, DOI 10.1073/pnas.84.11.3787; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295	59	6	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4672	4680		10.1038/sj.onc.1202805	http://dx.doi.org/10.1038/sj.onc.1202805			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467414				2022-12-25	WOS:000082154400004
J	Janosi, JBM; Ramsland, PA; Mott, MR; Firth, SM; Baxter, RC; Delhanty, PJD				Janosi, JBM; Ramsland, PA; Mott, MR; Firth, SM; Baxter, RC; Delhanty, PJD			The acid-labile subunit of the serum insulin-like growth factor-binding protein complexes - Structural determination by molecular modeling and electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; 3-DIMENSIONAL STRUCTURE; GONADOTROPIN RECEPTORS; SPATIAL RESTRAINTS; FACTOR-I; IGF-I; SATISFACTION; COLLAGEN; DECORIN; LIGAND	The acid-labile subunit (ALS) is a glycosylated 85-kDa member of the leucine-rich repeat (LRR) protein superfamily and circulates in ternary complexes with the insulin-like growth factors (IGFs) and their binding proteins (IGFBPs), These complexes are thought to regulate the serum IGFs by restricting IGF movement out of the circulation. However, little is known about how ALS binds to IGFBP-3 or -5, which link the IGFs to ALS, To investigate potential sites of interaction, the ALS structure has been modeled with the crystal structure of the LRR protein porcine ribonuclease inhibitor as a template. ALS is predicted to be a donut-shaped molecule with an internal diameter of 1.7 nm, an external diameter of 7.2 nm, and a thickness of 3.6 nm, These dimensions are supported by rotary shadowing electron microscopy of ALS, The internal face is lined with a substantial region of electronegative surface potential that could interact with the positively charged region on IGFBP-3 known to be involved in ALS binding. The model also predicts that three potential N-linked oligosaccharide sites within the LRR domain are clustered together, which may be important in light of recent studies showing ALS glycan involvement in complex formation with IGFBP-3.	Univ Sydney, Kolling Inst Med Res, Growth Res Lab, Royal N Shore Hosp, St Leonards, NSW 2065, Australia; Univ Technol Sydney, St Leonards, NSW 2065, Australia; Univ Sydney, Key Ctr Microscopy, Sydney, NSW 2006, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; University of Technology Sydney; University of Sydney	Delhanty, PJD (corresponding author), Univ Sydney, Kolling Inst Med Res, Growth Res Lab, Royal N Shore Hosp, St Leonards, NSW 2065, Australia.		Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142; Ramsland, Paul/0000-0002-2107-2738				BAXTER RC, 1990, BIOCHEM J, V271, P773, DOI 10.1042/bj2710773; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; BRUNGER AT, 1992, XPLOR A SYSTEM XRAY; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; Hocking AM, 1998, MATRIX BIOL, V17, P1; Holman SR, 1996, GROWTH REGULAT, V6, P42; Hua QX, 1996, J MOL BIOL, V259, P297, DOI 10.1006/jmbi.1996.0320; Janosi JBM, 1999, J BIOL CHEM, V274, P5292, DOI 10.1074/jbc.274.9.5292; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; LEWITT MS, 1993, ENDOCRINOLOGY, V133, P1797, DOI 10.1210/en.133.4.1797; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; NAGAYAMA Y, 1991, J BIOL CHEM, V266, P14926; NICHOLLS A, 1993, GRASP GRAPHICAL REPR; Ramsland PA, 1997, J COMPUT AID MOL DES, V11, P453, DOI 10.1023/A:1007932211514; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1995, MOL MED TODAY, V1, P270, DOI 10.1016/s1357-4310(95)91170-7; SATO A, 1993, INT J PEPT PROT RES, V41, P433; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; TWIGG SM, 1998, J BIOL CHEM, V273, P6704; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; XIE YB, 1990, J BIOL CHEM, V265, P21411; [No title captured]	32	54	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23328	23332		10.1074/jbc.274.33.23328	http://dx.doi.org/10.1074/jbc.274.33.23328			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438509	hybrid			2022-12-25	WOS:000082012800059
J	Liu, HC; Shen, JT; Augustin, LB; Ko, JL; Loh, HH				Liu, HC; Shen, JT; Augustin, LB; Ko, JL; Loh, HH			Transcriptional regulation of mouse delta-opioid receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM STIMULATORY FACTOR; HELIX-ZIPPER PROTEIN; BOX-BINDING-PROTEINS; MESSENGER-RNA; NG108-15 CELLS; FACTOR USF; COOPERATIVE INTERACTION; MAMMALIAN-CELLS; CONTROL ELEMENT; FACTOR SP1	Three major types of opioid receptors, mu (MOR), delta (DOR), and kappa (KOR), have been cloned and characterized. Each opioid receptor exhibits a distinct pharmacological profile as well as a distinct pattern of temporal and spatial expression in the brain, suggesting the critical role of transcription regulatory elements and their associated factors. Here, we report the identification of a minimum core promoter, in the 5'-flanking region of the mouse DOR gene, containing an E box and a GC box that are crucial for DOR promoter activity in NS20Y cells, a DOR-expressing mouse neuronal cell line. In vitro protein-DNA binding assays and in vivo transient transfection assays indicated that members of both the upstream stimulatory factor and Sp families of transcription factors bound to and trans-activated the DOR promoter via the E box and GC box, respectively. Furthermore, functional and physical interactions between these factors were critical for the basal as well as maximum promoter activity of the DOR gene. Thus, the distinct developmental emergence and brain regional distribution of the delta opioid receptor appear to be controlled, at least in part, by these two regulatory elements and their associated factors.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Liu, HC (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 3-249 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA001583, R37DA001583, K05DA070554, P50DA011806] Funding Source: NIH RePORTER; NIDA NIH HHS [DA11816, P50 DA011806, DA-00546, R01 DA001583, DA-01583, K05 DA070554] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABOOD ME, 1995, J PHARMACOL EXP THER, V274, P1566; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; AUGUSTIN LB, 1995, BIOCHEM BIOPH RES CO, V207, P111, DOI 10.1006/bbrc.1995.1160; Beczkowska IW, 1996, BRAIN RES BULL, V39, P193, DOI 10.1016/0361-9230(95)02104-3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRESNICK EH, 1994, J BIOL CHEM, V269, P21110; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Ghosh AK, 1997, ONCOGENE, V14, P589, DOI 10.1038/sj.onc.1200866; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; Gylys KH, 1997, NEUROREPORT, V8, P2369, DOI 10.1097/00001756-199707070-00053; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HERZ A, 1993, HDB EXPT PHARM; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Jenab S, 1997, MOL BRAIN RES, V47, P44, DOI 10.1016/S0169-328X(97)00061-2; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P192; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; KERHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Ko JL, 1998, J BIOL CHEM, V273, P27678, DOI 10.1074/jbc.273.42.27678; Ko JL, 1997, BIOCHEM BIOPH RES CO, V234, P351, DOI 10.1006/bbrc.1997.6640; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; KUBO T, 1995, CANCER RES, V55, P3860; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lanigan TM, 1997, J BIOL CHEM, V272, P18316, DOI 10.1074/jbc.272.29.18316; MAJELLO B, 1995, ONCOGENE, V10, P1841; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; MANSOUR A, 1994, J COMP NEUROL, V350, P412, DOI 10.1002/cne.903500307; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Schreiber G, 1998, ANTICANCER RES, V18, P1787; Sharp BM, 1997, J NEUROIMMUNOL, V78, P198, DOI 10.1016/S0165-5728(97)00101-X; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Solecki D, 1997, J BIOL CHEM, V272, P5579, DOI 10.1074/jbc.272.9.5579; Standifer KM, 1997, CELL SIGNAL, V9, P237, DOI 10.1016/S0898-6568(96)00174-X; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Vaishnaw AK, 1998, J IMMUNOL, V160, P4353; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Zhu YX, 1998, J NEUROSCI, V18, P2538	56	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23617	23626		10.1074/jbc.274.33.23617	http://dx.doi.org/10.1074/jbc.274.33.23617			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438544	Green Accepted, hybrid			2022-12-25	WOS:000082012800094
J	Nakano, M; Morita, T; Yamamoto, T; Sano, H; Ashiuchi, M; Masui, R; Kuramitsu, S; Yagi, T				Nakano, M; Morita, T; Yamamoto, T; Sano, H; Ashiuchi, M; Masui, R; Kuramitsu, S; Yagi, T			Purification, molecular cloning, and catalytic activity of Schizosaccharomyces pombe pyridoxal reductase - A possible additional family in the aldo-keto reductase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BETA-SUBUNIT; BAKERS-YEAST; EXPRESSION; SEQUENCE; GENE	Pyridoxal reductase (PL reductase), which catalyzes reduction of PL by NADPH to form pyridoxine and NADP(+), was purified from Schizosaccharomyces pombe. The purified enzyme was very unstable but was stabilized by low concentrations of various detergents such as Tween 40. The enzyme was a monomeric protein with the native molecular weight of 41,000 +/- 1,600, The enzyme showed a single absorption peak at 280 nm (E-1% = 10.0), PL and 2-nitrobenzaldehyde were excellent substrates, and no measurable activity was observed with short chain aliphatic aldehydes; substrate specificity of PL reductase was obviously different from those of yeast aldo-keto reductases (AKRs) so far purified. The peptide sequences of PL reductase were identical with those in a hypothetical 333-amino acid protein from S. pombe (the DDBJ/EMBL/GenBank(TM) accession number D89205), The gene corresponding to this protein was expressed in Escherichia coli, and the purified protein was found to have PL reductase activity. The recombinant PL reductase showed the same properties as those of native PL reductase. PL reductase showed only low sequence identities with members of AKR superfamily established to date; it shows the highest identity (18.5%) with human Shaker-related voltage-gated K+ channel beta 2 subunit, The elements of secondary structure of PL reductase, however, distributed similarly to those demonstrated in the three-dimensional structure of human aldose reductase except that loop A region is lost, and loop B region is extended. Amino acid residues involved in substrate binding or catalysis are also conserved. Conservation of these features, together with the major modifications, establish PL reductase as the first member of a new AKR family, AKRS.	Kochi Univ, Fac Agr, Dept Bioresources Sci, Nankoku, Kochi 7838502, Japan; Kochi Univ, Res Inst Mol Genet, Nankoku, Kochi 7838502, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan	Kochi University; Kochi University; Osaka University	Yagi, T (corresponding author), Kochi Univ, Fac Agr, Dept Bioresources Sci, Nankoku, Kochi 7838502, Japan.	yagito@cc.kochi-u.ac.jp	Morita, Tomotake/L-7073-2018	Morita, Tomotake/0000-0001-6956-3096				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMORE R, 1991, GENE, V109, P89, DOI 10.1016/0378-1119(91)90592-Y; Bolen PL, 1996, YEAST, V12, P1367, DOI 10.1002/(SICI)1097-0061(199610)12:13<1367::AID-YEA33>3.3.CO;2-R; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; ENGLAND SK, 1995, J BIOL CHEM, V270, P28531, DOI 10.1074/jbc.270.48.28531; GUIRARD B M, 1988, Biofactors, V1, P187; HOLZER H, 1961, BIOCHIM BIOPHYS ACTA, V48, P71, DOI 10.1016/0006-3002(61)90516-9; Ireland LS, 1998, BIOCHEM J, V332, P21, DOI 10.1042/bj3320021; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; Jez JM, 1997, BIOCHEM PHARMACOL, V54, P639, DOI 10.1016/S0006-2952(97)84253-0; KITA K, 1996, APPL ENVIRON MICROB, V54, P1770; KUHN A, 1995, APPL ENVIRON MICROB, V61, P1580, DOI 10.1128/AEM.61.4.1580-1585.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOLOWA DT, 1986, J BIOL CHEM, V261, P2624; MORINO Y, 1960, J BIOCHEM-TOKYO, V48, P733, DOI 10.1093/oxfordjournals.jbchem.a127224; NAKAMURA K, 1991, J ORG CHEM, V56, P4778, DOI 10.1021/jo00015a038; Nakamura K, 1997, BIOSCI BIOTECH BIOCH, V61, P375, DOI 10.1271/bbb.61.375; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Snell E. E., 1970, COMPREHENSIVE BIOCH, V21, P47; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847; Yagi T, 1998, FEMS MICROBIOL LETT, V161, P145, DOI 10.1016/S0378-1097(98)00066-4; Yoshida KI, 1997, J BACTERIOL, V179, P4591, DOI 10.1128/jb.179.14.4591-4598.1997	24	29	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23185	23190		10.1074/jbc.274.33.23185	http://dx.doi.org/10.1074/jbc.274.33.23185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438489	hybrid			2022-12-25	WOS:000082012800039
J	Rumsey, SC; Welch, RW; Garraffo, HM; Ge, P; Lu, SF; Crossman, AT; Kirk, KL; Levine, M				Rumsey, SC; Welch, RW; Garraffo, HM; Ge, P; Lu, SF; Crossman, AT; Kirk, KL; Levine, M			Specificity of ascorbate analogs for ascorbate transport - Synthesis and detection of [I-125]-6-deoxy-6-iodo-1-ascorbic acid and characterization of its ascorbate-specific transport properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROASCORBIC ACID; VITAMIN-C; LIQUID-CHROMATOGRAPHY; HUMAN NEUTROPHILS; GLUCOSE; CELLS; ACCUMULATION; MECHANISMS; PLASMA	Cellular ascorbic acid accumulation occurs in vitro by two distinct mechanisms: transport of ascorbate itself or transport and subsequent intracellular reduction of its oxidized product, dehydroascorbic acid. It is unclear which mechanism predominates in vivo, An easily detectable compound resembling ascorbate but not dehydroascorbic acid could be a powerful tool to distinguish the two transport activities. To identify compounds, 21 ascorbate analogs were tested for inhibition of ascorbate or dehydroascorbic acid transport in human fibroblasts. The most effective analogs, competitive inhibitors of ascorbate transport with K-i values of 3 mu M, were 6-deoxy-6-bromo-, 6-deoxy-6-chloro-, and 6-deoxy-6-iodo-L-ascorbate, No analog inhibited dehydroascorbic acid transport. Using substitution chemistry, [I-125]6-deoxy-6-iodo-L-ascorbate (1.4 x 10(4) mCi/mmol) was synthesized. HPLC detection methods were developed for radiolabeled and nonradiolabeled compounds, and transport kinetics of both compounds were characterized. Transport was sodium-dependent, inhibited by excess ascorbate, and similar to that of ascorbate, Transport of oxidized ascorbate and oxidized 6-deoxy-6-iodo-L-ascorbate was investigated using Xenopus laevis oocytes expressing glucose transporter isoform GLUT1 or GLUT3, Oxidation of ascorbate or its analog in media increased uptake of ascorbate in oocytes by 6-13-fold compared with control but not that of 6-deoxy-6-iodo-L-ascorbate. Therefore, 6-deoxy-6-iodo-L-ascorbate, although an effective inhibitor of ascorbate transport, either in its reduced or oxidized form was not a substrate for dehydroascorbic acid transport. Thus, radiolabeled and nonradiolabeled 6-deoxy-6-iodo-L-ascorbate provide a new means for discriminating dehydroascorbic acid and ascorbate transport in ascorbate recycling.	NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Levine, M (corresponding author), NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bldg 10,Rm 4D52,MSC 1372, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032002, ZIADK054506, Z01DK054506] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODE AM, 1990, CLIN CHEM, V36, P1807; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; GOLDENBERG H, 1994, J BIOENERG BIOMEMBR, V26, P359, DOI 10.1007/BF00762776; HORNIG D, 1975, ANN NY ACAD SCI, V258, P103, DOI 10.1111/j.1749-6632.1975.tb29271.x; KISS J, 1980, HELV CHIM ACTA, V63, P1728, DOI 10.1002/hlca.19800630642; Koshiishi I, 1998, CLIN CHEM, V44, P863; Levine M, 1999, JAMA-J AM MED ASSOC, V281, P1415, DOI 10.1001/jama.281.15.1415; Levine M, 1996, PRESENT KNOWLEDGE NU, P146; MAELLARO E, 1994, BIOCHEM J, V301, P471, DOI 10.1042/bj3010471; MANN GV, 1975, ANN NY ACAD SCI, V258, P243, DOI 10.1111/j.1749-6632.1975.tb29285.x; May JM, 1996, FREE RADICAL BIO MED, V20, P543, DOI 10.1016/0891-5849(95)02130-2; Prasad PD, 1998, BBA-BIOMEMBRANES, V1369, P141, DOI 10.1016/S0005-2736(97)00215-0; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 1998, J NUTR BIOCHEM, V9, P116, DOI 10.1016/S0955-2863(98)00002-3; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spielholz C, 1997, CANCER RES, V57, P2529; TOLBERT BM, 1982, ADV CHEM SER, P101; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; VERA JC, 1994, BLOOD, V84, P1628; WASHKO P, 1992, J BIOL CHEM, V267, P23568; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WELCH RW, 1995, J BIOL CHEM, V270, P12584, DOI 10.1074/jbc.270.21.12584; WELCH RW, 1993, BIOCHEM J, V294, P505, DOI 10.1042/bj2940505; WELLS WW, 1994, J BIOENERG BIOMEMBR, V26, P369, DOI 10.1007/BF00762777	25	41	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23215	23222		10.1074/jbc.274.33.23215	http://dx.doi.org/10.1074/jbc.274.33.23215			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438494	hybrid			2022-12-25	WOS:000082012800044
J	Benuck, ML; Li, Z; Childs, G				Benuck, ML; Li, Z; Childs, G			Mutations that increase acidity enhance the transcriptional activity of the glutamine-rich activation domain in stage-specific activator protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC AMINO-ACIDS; TRANSACTIVATION DOMAIN; SACCHAROMYCES-CEREVISIAE; STIMULATE TRANSCRIPTION; FACTOR-TFIIB; YEAST; GENE; BINDING; VP16; INTERACTS	Sea urchin stage-specific activator protein (SSAP) activates transcription of the late H1 gene at the midblastula stage of development. Its C-terminal 202 amino acids form a potent glycine/glutamine rich activation domain (GQ domain) that can transactivate reporter genes to levels B-fold higher than VP16 in several mammalian cell lines. We observed that, unlike other glutamine-rich activation domains, the GQ domain activates transcription to moderate levels in yeast. We utilized this activity to screen in yeast for intragenic mutations that enhance or inhibit the transcriptional activity of the GQ domain. We identified 37 loss of function and 23 gain of function mutants. Most gain of function mutations increased the acidity of the domain. The most frequently isolated mutations conferred enhanced transcriptional activity when assayed in mammalian cells. These mutations also enhance the ability of SSAP to up-regulate the late H1 promoter in sea urchin embryos, We conclude that the GQ domain fundamentally differs from other glutamine-rich activators and may share some properties of acidic activators, The ability of acidity to enhance SSAP-mediated transcription may reflect a mechanism by which phosphorylation of SSAP activates late H1 gene transcription during embryogenesis.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Childs, G (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIGMS NIH HHS [T32 GM07491, GM30333] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030333, T32GM007491] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; Blau J, 1996, MOL CELL BIOL, V16, P2044; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; COLIN AM, 1986, METHOD CELL BIOL, V27, P395, DOI 10.1016/S0091-679X(08)60360-X; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEANGELO DJ, 1995, MOL CELL BIOL, V15, P1254; DEANGELO DJ, 1993, MOL CELL BIOL, V13, P1746, DOI 10.1128/MCB.13.3.1746; DeFalco J, 1996, P NATL ACAD SCI USA, V93, P5802, DOI 10.1073/pnas.93.12.5802; DEFALCO JA, 1996, THESIS YESHIVA U BRO; Edelmann L, 1998, GENE EXPRESSION, V7, P133; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; Hua QX, 1998, BIOCHEMISTRY-US, V37, P5858, DOI 10.1021/bi9800808; John M, 1996, PEPTIDE RES, V9, P71; KIM TK, 1993, J BIOL CHEM, V268, P20866; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; LAI ZC, 1989, MOL CELL BIOL, V9, P2315, DOI 10.1128/MCB.9.6.2315; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; LEHMING N, 1995, P NATL ACAD SCI USA, V92, P10242, DOI 10.1073/pnas.92.22.10242; Li Z, 1999, MOL CELL BIOL, V19, P3684; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MCMAHON AP, 1984, P NATL ACAD SCI-BIOL, V81, P7490, DOI 10.1073/pnas.81.23.7490; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Remacle JE, 1997, EMBO J, V16, P5722, DOI 10.1093/emboj/16.18.5722; RUDEN DM, 1992, CHROMOSOMA, V101, P342, DOI 10.1007/BF00346013; Sainz MB, 1997, MOL CELL BIOL, V17, P115, DOI 10.1128/MCB.17.1.115; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEIPEL K, 1994, BIOL CHEM H-S, V375, P463, DOI 10.1515/bchm3.1994.375.7.463; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Xiao H, 1998, J BIOL CHEM, V273, P22873, DOI 10.1074/jbc.273.36.22873; Zhang D, 1998, J BIOL CHEM, V273, P6868, DOI 10.1074/jbc.273.12.6868	46	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25419	25425		10.1074/jbc.274.36.25419	http://dx.doi.org/10.1074/jbc.274.36.25419			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464271	hybrid			2022-12-25	WOS:000082554200035
J	Hanner, M; Schmalhofer, WA; Green, B; Bordallo, C; Liu, J; Slaughter, RS; Kaczorowski, GJ; Garcia, ML				Hanner, M; Schmalhofer, WA; Green, B; Bordallo, C; Liu, J; Slaughter, RS; Kaczorowski, GJ; Garcia, ML			Binding of correolide to K(v)1 family potassium channels - Mapping the domains of high affinity interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; OVERLAP EXTENSION; LYMPHOCYTES-T; BETA-SUBUNIT; CHARYBDOTOXIN; MARGATOXIN; ACTIVATION; BLOCKERS; VENOM; TOXIN	Correolide, a novel nortriterpene natural product, potently inhibits the voltage-gated potassium channel, K(v)1.3, and [H-3]dihydrocorreolide (diTC) binds with high affinity (K-d similar to 10 nM) to membranes from Chinese hamster ovary cells that express K(v)1.3 (Felix, J. P., Bugianesi, R. M., Schmalhofer, W. k, Borris, R., Goetz, M. k, Hensens, O. D., Bao, J.-M., Kayser, F., Parsons, W. H., Rupprecht, K., Garcia, M. L., Kaczorowski, G. J., and Slaughter, R. S. (1999) Biochemistry 38, 4922-4930). Mutagenesis studies were used to localize the diTC binding site and to design a high affinity receptor in the diTC-insensitive channel, K(v)3.2. Transferring the pore from K(v)1.3 to Kv3.2 produces a chimera that binds peptidyl inhibitors of Kv(1.3) with high affinity, but not diTC. Transfer of the S-6 region of K(v)1.3 to K(v)3.2 reconstitutes diTC binding at 4-fold lower affinity as compared with K(v)1.3, whereas transfer of the entire S-5-S-6 domain results in a normal K(v)1.3 phenotype, Substitutions in S-5-S-6 of K(v)1.3 with nonconserved residues from K(v)3.2 has identified two positions in S-5 and one in S-6 that cause significant alterations in diTC binding. High affinity diTC binding can be conferred to K(v)3.2 after substitution of these three residues with the corresponding amino acids found in K(v)1.3. These results suggest that lack of sensitivity of K(v)3.2 to diTC is a consequence of the presence of Phe(382) and Ile(387) in S-5 and Met(458) in S-6. Inspection of K(v)1.1-1.6 channels indicates that they all possess identical S-5 and S-6 domains. As expected, diTC binds with high affinity (K, values 7-21 nM) to each of these homotetrameric channels. However, the kinetics of binding are fastest with K(v)1.3 and K(v)1.4, suggesting that conformations associated with C-type inactivation will facilitate entry and exit of diTC at its binding site. Taken together, these findings identify K(v)1 channel regions necessary for high affinity diTC binding, as well as, reveal a channel conformation that markedly influences the rate of binding of this Ligand.	Merck Res Labs, Dept Membrane Biochem & Biophys, Rahway, NJ 07065 USA	Merck & Company	Garcia, ML (corresponding author), Merck Res Labs, Dept Membrane Biochem & Biophys, POB 2000, Rahway, NJ 07065 USA.	maria_garcia@merck.com						AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; CHANDY KG, 1995, HDB RECEPTORS CHANNE; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Felix JP, 1999, BIOCHEMISTRY-US, V38, P4922, DOI 10.1021/bi982954w; Garcia M L, 1997, Adv Pharmacol, V39, P425, DOI 10.1016/S1054-3589(08)60078-2; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; Goetz MA, 1998, TETRAHEDRON LETT, V39, P2895, DOI 10.1016/S0040-4039(98)00427-4; GROSS A, 1994, NEURON, V13, P961, DOI 10.1016/0896-6273(94)90261-5; Hanner M, 1998, J BIOL CHEM, V273, P16289, DOI 10.1074/jbc.273.26.16289; HANNER M, 1999, BIOPHYS J, V76, P77; Helms LMH, 1997, BIOCHEMISTRY-US, V36, P3737, DOI 10.1021/bi962351p; Hille B., 1992, IONIC CHANNELS EXCIT; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Koo GC, 1997, J IMMUNOL, V158, P5120; Koschak A, 1998, J BIOL CHEM, V273, P2639, DOI 10.1074/jbc.273.5.2639; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Nguyen A, 1996, MOL PHARMACOL, V50, P1672; PENNINGTON MW, 1995, INT J PEPT PROT RES, V46, P354; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Salinas M, 1997, J BIOL CHEM, V272, P24371, DOI 10.1074/jbc.272.39.24371; SANDS SB, 1989, J GEN PHYSIOL, V93, P1061, DOI 10.1085/jgp.93.6.1061; SLAUGHTER RS, 1991, BIOPHYS J, V59, P213; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; Wunderler D, 1999, BIOPHYS J, V76, pA186	30	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25237	25244		10.1074/jbc.274.36.25237	http://dx.doi.org/10.1074/jbc.274.36.25237			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464244	hybrid			2022-12-25	WOS:000082554200009
J	Mizushina, Y; Ohkubo, T; Date, T; Yamaguchi, T; Saneyoshi, M; Sugawara, F; Sakaguchi, K				Mizushina, Y; Ohkubo, T; Date, T; Yamaguchi, T; Saneyoshi, M; Sugawara, F; Sakaguchi, K			Mode analysis of a fatty acid molecule binding to the N-terminal 8-kDa domain of DNA polymerase beta - A 1 : 1 complex and binding surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; CATALYTIC DOMAIN; FOMITELLIC ACIDS; CROSS-LINKING; IN-VITRO; IDENTIFICATION; INHIBITOR; MECHANISM; ALPHA; SITE	We reported previously that long-chain fatty acids are potent inhibitors of mammalian DNA polymerase beta, At present, based on information available from the NMR structure of the N-terminal 8-kDa domain, we examined the structural interaction with the 8-kDa domain using two species, C-18-linoleic acid (LA) or C-24-nervonic acid (NA), In the 8-kDa domain with LA or NA, the structure that forms the interaction interface included helix-1, helix-2, helix-4, the three turns (residues 1-13, 48-51, and 79-87) and residues adjacent to an Omega-type loop connecting helix-1 and helix-2 of the same face. No significant shifts were observed for any of the residues on the opposite side of the 8-kDa domain. The NA interaction interface on the amino acid residues of the 8-kDa domain fragment was mostly the same as that of LA, except that the shifted cross-peaks of Leu-11 and Thr-79 were significantly changed between LA and NA. The 8-kDa domain bound to LA or NA as a 1:1 complex with a dissociation constant (K-D) of 1.02 or 2.64 mM, respectively.	Sci Univ Tokyo, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan; Japan Adv Inst Sci & Technol, Tatsunokuchi, Ishikawa 9231292, Japan; Kanazawa Med Univ, Dept Biochem, Uchinada, Ishikawa 9200293, Japan; Teikyo Univ Sci & Technol, Dept Biol Sci, Yamanashi 4090193, Japan	Tokyo University of Science; Japan Advanced Institute of Science & Technology (JAIST); Kanazawa Medical University	Sakaguchi, K (corresponding author), Sci Univ Tokyo, Dept Appl Biol Sci, 2641 Yamazaki, Noda, Chiba 2788510, Japan.							DATE T, 1988, BIOCHEMISTRY-US, V27, P2983, DOI 10.1021/bi00408a048; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; KORNBERG A, 1992, DNA REPLICATION, P197; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU DJ, 1994, BIOCHEMISTRY-US, V33, P9537, DOI 10.1021/bi00198a020; Liu DJ, 1996, BIOCHEMISTRY-US, V35, P6188, DOI 10.1021/bi952656o; Mizushina Y, 1998, BIOCHEM J, V330, P1325, DOI 10.1042/bj3301325; Mizushina Y, 1998, BIOL PHARM BULL, V21, P444, DOI 10.1248/bpb.21.444; Mizushina Y, 1998, BIOCHEM PHARMACOL, V55, P537, DOI 10.1016/S0006-2952(97)00536-4; Mizushina Y, 1997, BBA-GEN SUBJECTS, V1336, P509, DOI 10.1016/S0304-4165(97)00067-6; Mizushina Y, 1996, BBA-GENE STRUCT EXPR, V1308, P256, DOI 10.1016/0167-4781(96)00121-2; Mizushina Y, 1996, J ANTIBIOT, V49, P491, DOI 10.7164/antibiotics.49.491; Ohta K, 1999, BIOL PHARM BULL, V22, P111, DOI 10.1248/bpb.22.111; Ohta K, 1998, CHEM PHARM BULL, V46, P684, DOI 10.1248/cpb.46.684; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PRASAD R, 1993, J BIOL CHEM, V268, P22746; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; RAFTERY MA, 1968, J BIOL CHEM, V243, P4175; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; Tanaka N, 1998, J NAT PROD, V61, P193, DOI 10.1021/np970127a; Togashi H, 1998, BIOCHEM PHARMACOL, V56, P583, DOI 10.1016/S0006-2952(98)00197-X; WEBER DJ, 1992, PROTEINS, V13, P275, DOI 10.1002/prot.340130402; Yamaguchi T, 1997, NUCLEIC ACIDS RES, V25, P2352, DOI 10.1093/nar/25.12.2352	28	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25599	25607		10.1074/jbc.274.36.25599	http://dx.doi.org/10.1074/jbc.274.36.25599			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464295	hybrid			2022-12-25	WOS:000082554200059
J	Savonen, R; Obermoeller, LM; Trausch-Azar, JS; Schwartz, AL; Bu, GJ				Savonen, R; Obermoeller, LM; Trausch-Azar, JS; Schwartz, AL; Bu, GJ			The carboxyl-terminal domain of receptor-associated protein facilitates proper folding and trafficking of the very low density lipoprotein receptor by interaction with the three amino-terminal ligand-binding repeats of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LDL RECEPTOR; VLDL RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; MEDIATES ENDOCYTOSIS; CHYLOMICRON REMNANTS; MOLECULAR CHAPERONE; PLASMA-LIPOPROTEINS; MESSENGER-RNA; GENE-TRANSFER; ER RETENTION	The 39-kDa receptor-associated protein (RAP) is a specialized antagonist that inhibits all known ligand interactions with receptors that belong to the low density lipoprotein (LDL) receptor gene family. Recent studies have demonstrated a role for RAP as a molecular chaperone for the LDL receptor-related protein during receptor folding and trafficking within the early secretory pathway. In the present study, we investigated a potential role for RAP as a chaperone for the very low density lipoprotein (VLDL) receptor, another member of the LDL receptor gene family, Using intracellular crosslinking techniques, we found that RAP is associated with newly synthesized VLDL receptor. In the absence of RAP co-expression, newly synthesized VLDL receptor exhibited slower trafficking along the early secretory pathway, most likely due to misfolding of the receptor. The role of RAP in the folding of the VLDL receptor was further studied using an anchor-free, soluble VLDL receptor. Metabolic pulse-chase labeling experiments showed that while only 3% of the soluble VLDL receptor was folded and secreted in the absence of RAP co-expression, over 50% of the soluble receptor was secreted in the presence of RAP co-expression. The functions of RAP in VLDL receptor folding and trafficking were mediated by its carboxyl-terminal repeat but not by the amino-terminal and central repeats. Using truncated VLDL receptor constructs, we identified the RAP-binding site within the first three ligand-binding repeats of the VLDL receptor. Thus, our present study demonstrates that RAP serves as a folding and trafficking chaperone for the VLDL receptor via interactions of its carboxyl-terminal repeat with the three amino-terminal ligand-binding repeats of the VLDL receptor.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8116,1 Childrens Pl, St Louis, MO 63110 USA.				NHLBI NIH HHS [HL-59150] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059150] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BIERI S, 1995, FEBS LETT, V371, P341, DOI 10.1016/0014-5793(95)00939-7; BIERI S, 1995, BIOCHEMISTRY-US, V34, P13059, DOI 10.1021/bi00040a017; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Bu GJ, 1997, J CELL SCI, V110, P65; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1994, J BIOL CHEM, V269, P29874; BU GJ, 1993, J BIOL CHEM, V268, P13002; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; Kobayashi K, 1996, J BIOL CHEM, V271, P6852, DOI 10.1074/jbc.271.12.6852; Kozarsky KF, 1996, NAT GENET, V13, P54, DOI 10.1038/ng0596-54; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MOESTRUP SK, 1994, ANN NY ACAD SCI, V737, P124, DOI 10.1111/j.1749-6632.1994.tb44306.x; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; NARITA M, 1995, J CLIN INVEST, V96, P1164, DOI 10.1172/JCI118105; Niemeier A, 1996, J LIPID RES, V37, P1733; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; Rettenberger PM, 1999, J BIOL CHEM, V274, P8973, DOI 10.1074/jbc.274.13.8973; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; Takahashi S, 1996, FEBS LETT, V386, P197, DOI 10.1016/0014-5793(96)00439-5; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Wyne KL, 1996, ARTERIOSCL THROM VAS, V16, P407, DOI 10.1161/01.ATV.16.3.407; YAMAMOTO T, 1995, ANN NY ACAD SCI, V748, P217; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	47	25	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25877	25882		10.1074/jbc.274.36.25877	http://dx.doi.org/10.1074/jbc.274.36.25877			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464330	hybrid			2022-12-25	WOS:000082554200094
J	Wu, WJ; Chen, YH; Hazen, SL				Wu, WJ; Chen, YH; Hazen, SL			Eosinophil peroxidase nitrates protein tyrosyl residues - Implications for oxidative damage by nitrating intermediates in eosinophilic inflammatory disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ENZYMES MYELOPEROXIDASE; MASS-SPECTROMETRIC QUANTIFICATION; LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE; HYDROGEN-PEROXIDE; ANTIMICROBIAL ACTIVITY; CATALYZED OXIDATION; HYPOCHLOROUS ACID; HUMAN-NEUTROPHILS; ASTHMA	Eosinophil peroxidase (EPO) has been implicated in promoting oxidative tissue injury in conditions ranging from asthma and other allergic inflammatory disorders to cancer and parasitic/helminthic infections. Studies thus far on this unique peroxidase have primarily focused on its unusual substrate preference for bromide (Br-) and the pseudohalide thiocyanate (SCN-) forming potent hypohalous acids as cytotoxic oxidants, However, the ability of EPO to generate reactive nitrogen species has not yet been reported. We now demonstrate that EPO readily uses nitrite (NO2-), a major end-product of nitric oxide ((NO)-N-.) metabolism, as substrate to generate a reactive intermediate that nitrates protein tyrosyl residues in high yield. EPO-catalyzed nitration of tyrosine occurred more readily than bromination at neutral pH, plasma levels of halides, and pathophysiologically relevant concentrations of NO2-. Furthermore, EPO was significantly more effective than MPO at promoting tyrosine nitration in the presence of plasma levels of halides, Whereas recent studies suggest that MPO can also promote protein nitration through indirect oxidation of NO2- with HOCl, we found no evidence that EPO can indirectly mediate protein nitration by a similar reaction between HOBr and NO2-. EPO-dependent nitration of tyrosine was modulated over a physiologically relevant range of SCN- concentrations and was accompanied by formation of tyrosyl radical addition products (e.g. o,o'-dityrosine, pulcherosine, trityrosine), The potential role of specific antioxidants and nucleophilic scavengers on yields of tyrosine nitration and bromination by EPO are examined. Thus, EPO may contribute to nitrotyrosine formation in inflammatory conditions characterized by recruitment and activation of eosinophils.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University	Hazen, SL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	hazens@ccf.org	Hazen, Stanley L/ABD-5845-2021		NHLBI NIH HHS [HL62526, HL61878] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062526, R01HL061878] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agner K., 1972, STRUCTURE FUNCTION O, P329; AUNE TM, 1977, EUR J BIOCHEM, V80, P209, DOI 10.1111/j.1432-1033.1977.tb11873.x; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P177, DOI 10.1016/0167-4838(84)90125-0; BOS AJ, 1981, INFECT IMMUN, V32, P427, DOI 10.1128/IAI.32.2.427-431.1981; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BOZEMAN PM, 1990, J IMMUNOL METHODS, V126, P125, DOI 10.1016/0022-1759(90)90020-V; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CRAMER R, 1981, BLOOD, V58, P1112; Crowley JR, 1998, ANAL BIOCHEM, V259, P127, DOI 10.1006/abio.1998.2635; DECHATELET LR, 1977, BLOOD, V50, P525; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; Freeman GL, 1998, ALLERGY, V53, P331, DOI 10.1111/j.1398-9995.1998.tb03901.x; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GLEICH GJ, 1989, INT ARCH ALLER A IMM, V88, P59, DOI 10.1159/000234749; GLEICH GJ, 1994, EOSINOPHILS ALLERGY; GUSTAFSSON LE, 1998, EUR RESPIR J, V26, P49; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1997, FREE RADICAL BIO MED, V23, P909, DOI 10.1016/S0891-5849(97)00084-1; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Heinecke JW, 1999, METHOD ENZYMOL, V300, P124; HORWITZ RJ, 1995, CLIN CHEST MED, V16, P583; HUNT J, 1995, LANCET, V346, P1235, DOI 10.1016/S0140-6736(95)92947-9; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Jiang Q, 1997, J BIOL CHEM, V272, P32767, DOI 10.1074/jbc.272.52.32767; JORG A, 1982, BIOCHIM BIOPHYS ACTA, V701, P185, DOI 10.1016/0167-4838(82)90112-1; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; KLEBANOFF SJ, 1989, J IMMUNOL, V143, P239; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KNAPP DR, 1979, HDB ANAL DERIVATIZAT, P485; LINDER M, 1992, NUTR BIOCH METABOLIS, P98; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; MCCORMICK ML, 1994, J BIOL CHEM, V269, P27914; Nelson BV, 1997, J PEDIATR-US, V130, P423, DOI 10.1016/S0022-3476(97)70204-X; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NIELSEN FH, 1986, TRACE ELEMENTS HUMAN, V2, P426; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SIBBETT SS, 1985, FEBS LETT, V189, P271, DOI 10.1016/0014-5793(85)81038-3; SLUNGAARD A, 1991, J EXP MED, V173, P117, DOI 10.1084/jem.173.1.117; SLUNGAARD A, 1990, J EXP MED, V171, P2025, DOI 10.1084/jem.171.6.2025; Spry CJ, 1988, EOSINOPHILS COMPREHE; TEITZ NW, 1994, TEITZ TXB CLIN CHEM, P2216; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1994, J DENT RES, V73, P544, DOI 10.1177/00220345940730021001; THOMAS EL, 1995, J BIOL CHEM, V270, P2906, DOI 10.1074/jbc.270.7.2906; THOMAS EL, 1981, J DENT RES, V60, P785, DOI 10.1177/00220345810600040401; Torre D, 1996, J CLIN PATHOL, V49, P574, DOI 10.1136/jcp.49.7.574; vanDalen CJ, 1997, BIOCHEM J, V327, P487; Wajon J. E., 1980, WATER CHLORINATION E, V3, P171; WAJON JE, 1982, INORG CHEM, V21, P4258, DOI 10.1021/ic00142a030; WARDLAW AJ, 1994, POSTGRAD MED J, V70, P536, DOI 10.1136/pgmj.70.826.536; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEVER R, 1982, ADV EXP MED BIOL, V141, P501; WHITE GC, 1972, CHEM CHLORINATION, P182; WOOD JL, 1975, CHEM BIOCH THIOCYANI, P156; Wu WJ, 1999, BIOCHEMISTRY-US, V38, P3538, DOI 10.1021/bi982401l; Ye YZ, 1996, METHOD ENZYMOL, V269, P201	71	240	246	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25933	25944		10.1074/jbc.274.36.25933	http://dx.doi.org/10.1074/jbc.274.36.25933			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464338	hybrid			2022-12-25	WOS:000082554200102
J	Ishizaki, J; Suzuki, N; Higashino, K; Yokota, Y; Ono, T; Kawamoto, K; Fujii, N; Arita, H; Hanasaki, K				Ishizaki, J; Suzuki, N; Higashino, K; Yokota, Y; Ono, T; Kawamoto, K; Fujii, N; Arita, H; Hanasaki, K			Cloning and characterization of novel mouse and human secretory phospholipase A(2)s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-MOLECULAR-WEIGHT; PANCREATIC PHOSPHOLIPASE-A2; BINDING-SITE; STRUCTURAL DETERMINANTS; RECOMBINANT EXPRESSION; RHEUMATOID-ARTHRITIS; ESCHERICHIA-COLI; MAST-CELLS; RAT; GENE	Mammalian secretory phospholipase A(2)s (sPLA(2)s) are classified into several groups according to molecular structure and the localization of intramolecular disulfide bridges. Among them, group IIA sPLA(2) has been thought to be one of the key enzymes in the pathogenesis of inflammatory diseases owing to its augmented expression under various inflammatory conditions. However, in a number of inbred mouse strains, the group IIA sPLA(2) gene is naturally disrupted by a frameshift mutation. Here, we report the cloning of a cDNA encoding a novel sPLA(2) expressed in the spleen of group IIA sPLA(2)-deficient mouse. We also cloned its human homolog and mapped its gene location on chromosome 1p36.12 near the loci of group IIA and V sPLA(2) genes. The human mature sPLA(2) protein consists of 125 amino acids (M-r = 14,500) preceded by a 20-residue prepeptide and is most similar to group IIA sPLA(2) with respect to the number and positions of cysteine residues as well as overall identity (48%). Based on these structural properties, the novel sPLA(2) should be categorized into group II, called group IID to follow the already identified IIA to IIC sPLA(2)s. When the cDNA was expressed in COS-7 cells, PLA(2) activity preferentially accumulated in the culture medium. It is maximally active at neutral to alkaline pH and with 2 mm Ca2+. In assays with individual substrates, L-alpha-1-palmitoyl-2-linoleoyl phosphatidylethanolamine was more efficiently hydrolyzed than the other phospholipids examined. An RNA blot hybridized with the cDNA exhibited two transcripts (2.0 and 1.0 kb) in human spleen, thymus, and colon. The expression of a novel sPLA(2) mRNA was elevated in the thymus after treatment with endotoxin in rats as well as in group IIA sPLA(2)-deficient mice, suggesting its functional role in the progression of the inflammatory process.	Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Osaka 5530002, Japan	Shionogi & Company Limited	Hanasaki, K (corresponding author), Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Sagisu 5-12-4, Osaka 5530002, Japan.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARITA H, 1991, J BIOL CHEM, V266, P19139; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; BRACKERTZ D, 1977, ARTHRITIS RHEUM, V20, P841, DOI 10.1002/art.1780200314; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CROWL RM, 1991, J BIOL CHEM, V266, P2647; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; FROSSARD PM, 1994, HUM GENET, V93, P720; Furue S, 1997, GUT, V41, P826, DOI 10.1136/gut.41.6.826; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GRAY NCC, 1982, CAN J BIOCHEM CELL B, V60, P108, DOI 10.1139/o82-015; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; GRONROOS JM, 1992, DIGESTION, V52, P232, DOI 10.1159/000200958; Hagishita S, 1996, J MED CHEM, V39, P3636, DOI 10.1021/jm960395q; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; HARDISON R, 1993, MOL BIOL EVOL, V10, P73; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KORYSTOV YN, 1993, RADIAT RES, V134, P301, DOI 10.2307/3578189; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LANGLAIS J, 1992, BIOCHEM BIOPH RES CO, V182, P208, DOI 10.1016/S0006-291X(05)80132-9; LI WH, 1988, J LIPID RES, V29, P245; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; OHARA O, 1990, NUCLEIC ACIDS RES, V18, P6997, DOI 10.1093/nar/18.23.6997; ONO T, 1988, J BIOL CHEM, V263, P5732; PRUZANSKI W, 1988, J RHEUMATOL, V15, P1351; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SHAPOSHNIKOVA VV, 1994, FEBS LETT, V348, P317, DOI 10.1016/0014-5793(94)00616-4; SURGUCHOV AP, 1991, BIOMED SCI, V1, P344; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; TOJO H, 1993, J LIPID RES, V34, P837; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; VADAS P, 1986, LAB INVEST, V55, P391; WANG SD, 1994, J IMMUNOL, V152, P5014; WEISS J, 1991, J BIOL CHEM, V266, P4162; WEISS J, 1994, J BIOL CHEM, V269, P26331; WOOLEY PH, 1985, J IMMUNOL, V135, P2443	59	120	132	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24973	24979		10.1074/jbc.274.35.24973	http://dx.doi.org/10.1074/jbc.274.35.24973			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455175	hybrid			2022-12-25	WOS:000082193400074
J	Schmidt, PJ; Rae, TD; Pufahl, RA; Hamma, T; Strain, J; O'Halloran, TV; Culotta, VC				Schmidt, PJ; Rae, TD; Pufahl, RA; Hamma, T; Strain, J; O'Halloran, TV; Culotta, VC			Multiple protein domains contribute to the action of the copper chaperone for superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS PROTECTION; CEREVISIAE LYS7 GENE; SACCHAROMYCES-CEREVISIAE; WILSON-DISEASE; ATX1 GENE; YEAST; TRAFFICKING; COX17; HOMEOSTASIS; EXPRESSION	The copper chaperone for superoxide dismutase (SOD1) inserts the catalytic metal cofactor into SOD1 by an unknown mechanism. We demonstrate here that this process involves the cooperation of three distinct regions of the copper chaperone for SOD1 (CCS): an amino terminal Domain I homologous to the Atx1p metallochaperone, a central portion (Domain II) homologous to SOD1, and a short carboxyl-terminal peptide unique to CCS molecules (Domain III), These regions fold into distinct polypeptide domains as revealed through proteolysis protection studies. The biological roles of the yeast CCS domains were examined in yeast cells. Surprisingly, Domain I was found to be necessary only under conditions of strict copper limitation. Domain I and Atx1p were not interchangeable in vivo, underscoring the specificity of the corresponding metallochaperones. A putative copper site in Domain II was found to be irrelevant to yeast CCS activity, but SOD1 activation invariably required a CXC in Domain III that binds copper. Copper binding to purified yeast CCS induced allosteric conformational changes in Domain III and also enhanced homodimer formation of the polypeptide, Our results are consistent with a model whereby Domain I recruits cellular copper, Domain II facilitates target recognition, and Domain III, perhaps in concert with Domain I, mediates copper insertion into apo-SOD1.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Northwestern University; Northwestern University; Johns Hopkins University; Johns Hopkins University	Culotta, VC (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	t-ohalloran@nwu.edu	O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111, R37GM050016, R01GM050016] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES08996] Funding Source: Medline; NIGMS NIH HHS [R01 GM054111, GM50016, GM54111] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DJINOVIC K, 1992, J MOL BIOL, V225, P791, DOI 10.1016/0022-2836(92)90401-5; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; HORECKA J, 1995, GENE, V162, P87, DOI 10.1016/0378-1119(95)00325-Z; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LIU XF, 1992, J BIOL CHEM, V267, P18298; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; Nishihara E, 1998, NEUROREPORT, V9, P3259, DOI 10.1097/00001756-199810050-00023; Ogihara NL, 1996, BIOCHEMISTRY-US, V35, P2316, DOI 10.1021/bi951930b; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Rothstein JD, 1999, J NEUROCHEM, V72, P422, DOI 10.1046/j.1471-4159.1999.0720422.x; Sherman F., 1978, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	32	150	160	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23719	23725		10.1074/jbc.274.34.23719	http://dx.doi.org/10.1074/jbc.274.34.23719			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446130	hybrid			2022-12-25	WOS:000082110900009
J	Summers, SA; Whiteman, EL; Cho, H; Lipfert, L; Birnbaum, MJ				Summers, SA; Whiteman, EL; Cho, H; Lipfert, L; Birnbaum, MJ			Differentiation-dependent suppression of platelet-derived growth factor signaling in cultured adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; GLYCOGEN-SYNTHASE KINASE-3; RAT ADIPOSE-CELLS; 3T3-L1 ADIPOCYTES; GLUCOSE-TRANSPORT; INSULIN STIMULATION; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; GLUT4-CONTAINING VESICLES	A critical component of vertebrate cellular differentiation is the acquisition of sensitivity to a restricted subset of peptide hormones and growth factors. This accounts for the unique capability of insulin (and possibly insulin-like growth factor-1), but not other growth factors, to stimulate glucose uptake and anabolic metabolism in heart, skeletal muscle, and adipose tissue. This selectivity is faithfully recapitulated in the cultured adipocyte Line, 3T3-L1, which responds to insulin, but not platelet derived growth factor (PDGF), with increased hexose uptake. The serine/threonine protein kinases Akt1 and Akt2, which have been implicated as mediators of insulin-stimulated glucose uptake, as well as glycogen, lipid, and protein synthesis, were shown to mirror this selectivity in this tissue culture system. This was particularly apparent in 3T3-L1 adipocytes overexpressing an epitope-tagged form of Akt2 in which insulin activated Akt2 10-fold better than PDGF. Similarly, in 3T3-L1 adipocytes, only insulin stimulated phosphorylation of Akt's endogenous substrate, GSK-3 beta. Other signaling molecules, including phosphatidylinositol 3-kinase, pp70 SG-kinase, mitogen-activated protein kinase, and PHAS-1/4EBP-1, did not demonstrate this selective responsiveness to insulin but were instead activated comparably by both insulin and PDGF. Moreover, concurrent treatment with PDGF and insulin did not diminish activation of phosphatidylinositol 3-kinase, Akt, or glucose transport, indicating that PDGF did not simultaneously activate an inhibitory mechanism. Interestingly, PDGF and insulin comparably stimulated both Akt isoforms, as well as numerous other signaling molecules, in undifferentiated 3T3-L1 preadipocytes. Collectively, these data suggest that differential activation of Akt in adipocytes may contribute to insulin's exclusive mediation of the metabolic events involved in glucose metabolism. Moreover, they suggest a novel mechanism by which differentiation-dependent hormone selectivity is conferred through the suppression of specific signaling pathways operational in undifferentiated cell types.	Univ Penn, Sch Med, Howard Hughes Med Inst, Cox Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Birnbaum, MJ (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Cox Inst, 415 Curie Blvd, Philadelphia, PA 19104 USA.		/AAE-5384-2020	Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039615, F32DK009375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39615, DK09375] Funding Source: Medline; NIGMS NIH HHS [GM07229] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Conricode KM, 1995, BIOCHEM MOL BIOL INT, V36, P835; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GOULD GW, 1994, CELL SIGNAL, V6, P313, DOI 10.1016/0898-6568(94)90036-1; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; Huppertz C, 1996, DIABETOLOGIA, V39, P1432, DOI 10.1007/s001250050595; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OKADA T, 1994, J BIOL CHEM, V269, P3568; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	47	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23858	23867		10.1074/jbc.274.34.23858	http://dx.doi.org/10.1074/jbc.274.34.23858			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446150	hybrid			2022-12-25	WOS:000082110900029
J	Tao, JC; Mallat, A; Gallois, C; Belmadani, S; Mery, PF; Tran-Van Nhieu, J; Pavoine, C; Lotersztajn, S				Tao, JC; Mallat, A; Gallois, C; Belmadani, S; Mery, PF; Tran-Van Nhieu, J; Pavoine, C; Lotersztajn, S			Biological effects of C-type natriuretic peptide in human myofibroblastic hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-INHIBITORY PROPERTIES; GLOMERULAR MESANGIAL CELLS; NF-KAPPA-B; ITO CELLS; RAT-LIVER; SIGNAL TRANSDUCTION; MEDIATED INHIBITION; CLEARANCE RECEPTOR; GENE-EXPRESSION	During chronic liver diseases, hepatic stellate cells (HSC) acquire a myofibroblastic phenotype, proliferate, and synthetize fibrosis components. Myofibroblastic HSC (mHSC) also participate to the regulation of intrahepatic blood flow, because of their contractile properties. Here, we examined whether human mHSC express natriuretic peptide receptors (NPR). Only NPR-B mRNA was identified, which was functional as demonstrated in binding studies and by increased cGMP levels in response to C-type natriuretic peptide (CNP). CNP inhibited mHSC proliferation, an effect blocked by the protein kinase G inhibitor 8-(4 chlorophenylthio)-cGMP and by the NPR antagonist MS-142-1 and reproduced by analogs of cGMP. Growth inhibition was associated with a reduction of extracellular signal-regulated kinase and c-Jun N-terminal kinase and with a blockade of AP-1 DNA binding. CNP and cGMP analogs also blunted mHSC contraction elicited by thrombin, by suppressing calcium influx. The relaxing properties of CNP were mediated by a blockade of store-operated calcium channels, as demonstrated using a calcium-free/calcium readdition protocol. These results constitute the first evidence for a hepatic effect of CMP and identify mHSC as a target cell. Activation of NPR-B by CNP in human mHSC leads to inhibition of both growth and contraction. These data suggest that during chronic liver diseases, CNP may counteract both liver fibrogenesis and associated portal hypertension.	Hop Henri Mondor, INSERM, U99, AP,HP, F-94010 Creteil, France; Hop Henri Mondor, Dept Pathol, AP, HP, F-94010 Creteil, France; Fac Pharm, INSERM, U446, F-92296 Chatenay Malabry, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Lotersztajn, S (corresponding author), Hop Henri Mondor, INSERM, U99, AP,HP, F-94010 Creteil, France.		VAN NHIEU, Jeanne TRAN/R-5235-2018; MERY, Pierre-François/C-5903-2019; Pavoine, Catherine/N-4405-2018; Lotersztajn, Sophie/K-9160-2017	Pavoine, Catherine/0000-0002-0598-5545; lotersztajn, Sophie/0000-0002-0053-7807; Mery, Pierre-Francois/0000-0001-6214-5422				ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; Awazu M, 1997, KIDNEY INT, V52, P356, DOI 10.1038/ki.1997.341; Bataller R, 1997, GASTROENTEROLOGY, V113, P615, DOI 10.1053/gast.1997.v113.pm9247484; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BILZER M, 1995, GASTROENTEROLOGY, V108, P803, DOI 10.1016/0016-5085(95)90454-9; BRECHLER V, 1992, J BIOL CHEM, V267, P15496; CAHILL PA, 1994, AM J PHYSIOL, V266, pR194, DOI 10.1152/ajpregu.1994.266.1.R194; Canaan-Kuhl S, 1998, KIDNEY INT, V53, P1143, DOI 10.1046/j.1523-1755.1998.00895.x; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; Chrisman TD, 1999, J BIOL CHEM, V274, P4293, DOI 10.1074/jbc.274.7.4293; FAILLI P, 1995, AM J PHYSIOL-CELL PH, V269, pC1133, DOI 10.1152/ajpcell.1995.269.5.C1133; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FUJISAKI H, 1995, J CLIN INVEST, V96, P1059, DOI 10.1172/JCI118092; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; GARBERS DL, 1992, CELL, V71, P1; GEERTS A, 1991, HEPATOLOGY, V13, P1193, DOI 10.1002/hep.1840130628; HAGIWARA H, 1994, J BIOL CHEM, V269, P10729; Hagiwara H, 1996, AM J PHYSIOL-CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311; HANEDA M, 1993, BIOCHEM BIOPH RES CO, V192, P642, DOI 10.1006/bbrc.1993.1463; Isono M, 1998, KIDNEY INT, V53, P1133, DOI 10.1046/j.1523-1755.1998.00869.x; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; Itatsu T, 1998, BIOCHEM BIOPH RES CO, V251, P533, DOI 10.1006/bbrc.1998.9458; Kashiwagi S, 1997, AM J PHYSIOL-GASTR L, V272, pG742, DOI 10.1152/ajpgi.1997.272.4.G742; KAWADA N, 1994, FEBS LETT, V356, P109, DOI 10.1016/0014-5793(94)01178-8; KAWADA N, 1993, EUR J BIOCHEM, V213, P815, DOI 10.1111/j.1432-1033.1993.tb17824.x; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KOMEICHI H, 1995, J HEPATOL, V22, P319, DOI 10.1016/0168-8278(95)80285-1; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Levin ER, 1998, NEW ENGL J MED, V339, P321; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MALLAT A, 1995, J CLIN INVEST, V96, P42, DOI 10.1172/JCI118052; Mallat A, 1998, J BIOL CHEM, V273, P27300, DOI 10.1074/jbc.273.42.27300; Mallat A, 1996, J CLIN INVEST, V98, P2771, DOI 10.1172/JCI119103; Mallat A, 1998, DIGESTION, V59, P416, DOI 10.1159/000007501; MANCINI R, 1992, J HEPATOL, V15, P361, DOI 10.1016/0168-8278(92)90069-2; MCCARTHY RT, 1990, AM J PHYSIOL, V258, pF473; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; NAIR BG, 1991, J BIOL CHEM, V266, P567; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; Pedram A, 1998, J BIOL CHEM, V273, P13966, DOI 10.1074/jbc.273.22.13966; PINZANI M, 1992, J CLIN INVEST, V90, P642, DOI 10.1172/JCI115905; PORTER JG, 1990, BIOCHEM BIOPH RES CO, V171, P796, DOI 10.1016/0006-291X(90)91216-F; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; RASHED HM, 1993, HEPATOLOGY, V17, P677, DOI 10.1002/hep.1840170423; ROCKEY DC, 1993, J CLIN INVEST, V92, P1795, DOI 10.1172/JCI116769; ROCKEY DC, 1995, J CLIN INVEST, V95, P1199, DOI 10.1172/JCI117769; SAKAMOTO M, 1993, HEPATOLOGY, V18, P978, DOI 10.1002/hep.1840180432; Sakamoto M, 1997, HEPATOLOGY, V25, P1412, DOI 10.1002/hep.510250618; Sauvadet A, 1997, J BIOL CHEM, V272, P12437, DOI 10.1074/jbc.272.19.12437; SAUVADET A, 1995, CELL CALCIUM, V18, P76, DOI 10.1016/0143-4160(95)90047-0; SERRADEILLEGAL C, 1991, J CLIN INVEST, V87, P133, DOI 10.1172/JCI114962; St-Pierre MV, 1998, GASTROENTEROLOGY, V114, P782, DOI 10.1016/S0016-5085(98)70592-X; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; TOHSE N, 1995, BRIT J PHARMACOL, V114, P1076, DOI 10.1111/j.1476-5381.1995.tb13316.x; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vazquez G, 1998, J BIOL CHEM, V273, P33954, DOI 10.1074/jbc.273.51.33954; Vollmar AM, 1997, GUT, V40, P145, DOI 10.1136/gut.40.1.145; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121	59	56	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23761	23769		10.1074/jbc.274.34.23761	http://dx.doi.org/10.1074/jbc.274.34.23761			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446136	hybrid			2022-12-25	WOS:000082110900015
J	Antonetti, DA; Barber, AJ; Hollinger, LA; Wolpert, EB; Gardner, TW				Antonetti, DA; Barber, AJ; Hollinger, LA; Wolpert, EB; Gardner, TW			Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1 - A potential mechanism for vascular permeability in diabetic retinopathy and tumors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; POSSIBLE INVOLVEMENT; FACTOR VEGF; IN-VIVO; CELLS; ZO-1; MOUSE; RAT; NEOVASCULARIZATION; EXPRESSION	Vascular endothelial growth factor (VEGF) may have a physiologic role in regulating vessel permeability and contributes to the pathophysiology of diabetic retinopathy as well as tumor development. We set out to ascertain the mechanism by which VEGF regulates paracellular permeability in rats. Intra ocular injection of VEGF caused a post-translational modification of occludin as determined by a gel shift from 60 to 62 kDa. This event began by 15 min post-injection and was maximal by 45 min. Alkaline phosphatase treatment revealed this modification was caused by a change in occludin phosphorylation, In addition, the quantity of extracted occludin increased a-fold in the same time frame, The phosphorylation and increased extraction of occludin was recapitulated in retinal endothelial cells in culture after VEGF stimulation. The data presented herein are the first demonstration of a change in the phosphorylation of this transmembrane protein under conditions of increased endothelial permeability, In addition, intraocular injection of VEGF also caused tyrosine phosphorylation of ZO-1 as early as 15 min and increased phosphorylation ii-fold after 90 min. In conclusion, VEGF rapidly increases occludin phosphorylation as well as the tyrosine phosphorylation of ZO-1, Phosphorylation of occludin and ZO-1 likely contribute to regulated endothelial paracellular permeability.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Penn State Retina Res Grp, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Antonetti, DA (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.	dantonetti@psu.edu		Gardner, Thomas/0000-0002-5112-5810; Barber, Alistair/0000-0003-4235-2293; antonetti, david/0000-0003-1130-6577	NATIONAL EYE INSTITUTE [R01EY012021] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY/DK12021] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ANDERSON JM, 1995, BIOCHEM SOC T, V23, P470, DOI 10.1042/bst0230470; ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953; Balda MS, 1998, J CELL SCI, V111, P541; Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Feng D, 1996, J EXP MED, V183, P1981, DOI 10.1084/jem.183.5.1981; Feng D, 1997, J PHYSIOL-LONDON, V504, P747, DOI 10.1111/j.1469-7793.1997.747bd.x; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gardner TW, 1996, BIOCHEM J, V320, P717, DOI 10.1042/bj3200717; Hirase T, 1997, J CELL SCI, V110, P1603; ITALLIE CMV, 1995, J CELL SCI, V108, P1735; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KLEIN R, 1995, OPHTHALMOLOGY, V102, P7; McCarthy KM, 1996, J CELL SCI, V109, P2287; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Murata T, 1996, LAB INVEST, V74, P819; Muresan Z, 1998, MOL BIOL CELL, V9, p83A; SAGATIES MJ, 1987, INVEST OPHTH VIS SCI, V28, P2000; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; SONE H, 1998, DIABETIC COMPLICATIO, P28; STADDON JM, 1995, J CELL SCI, V108, P609; TAKEDA H, 1995, CELL STRUCT FUNCT, V20, P387, DOI 10.1247/csf.20.387; VanItallie CM, 1997, J CELL SCI, V110, P1113; Vinores SA, 1998, J NEUROIMMUNOL, V89, P43, DOI 10.1016/S0165-5728(98)00075-7; WITTCHEN WS, 1998, P AM SOC CELL BIOL 3, V9, pA82; Yaccino JAM, 1997, CURR EYE RES, V16, P761, DOI 10.1076/ceyr.16.8.761.8991; Yap AS, 1998, J MEMBRANE BIOL, V163, P159, DOI 10.1007/s002329900380	34	493	524	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23463	23467		10.1074/jbc.274.33.23463	http://dx.doi.org/10.1074/jbc.274.33.23463			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438525	hybrid			2022-12-25	WOS:000082012800075
J	Chusacultanachai, S; Glenn, KA; Rodriguez, AO; Read, EK; Gardner, JF; Katzenellenbogen, BS; Shapiro, DJ				Chusacultanachai, S; Glenn, KA; Rodriguez, AO; Read, EK; Gardner, JF; Katzenellenbogen, BS; Shapiro, DJ			Analysis of estrogen response element binding by genetically selected steroid receptor DNA binding domain mutants exhibiting altered specificity and enhanced affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; AMINO-ACID-SEQUENCE; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTORS; DETERMINANTS; MUTAGENESIS; SUPERFAMILY; ACTIVATION; EXPRESSION; MODULATION	To analyze the role of amino acids in the steroid receptor DNA binding domain (DBD) recognition helix in binding of the receptor to the estrogen response element (ERE), we adapted the powerful P22 challenge phage selection system for use with a vertebrate protein. We used the progesterone receptor DNA binding domain and selected for mutants that gained the ability to bind to the ERE. We used a mutagenesis protocol based on degenerate oligonucleotides to create a large and diverse pool of mutants in which 10 nonconsensus amino acids in the DNA recognition helix of the progesterone receptor DNA binding domain were randomly mutated. After a single cycle of modified P22 challenge phage selection, 37 mutant proteins were identified, all of which lost the ability to bind to the progesterone response element. In gel mobility shift assays, approximately 70% of the genetically selected mutants bound to the consensus ERE with a >4-fold higher affinity than the naturally occurring estrogen receptor DBD, In the P-box region of the DNA recognition helix, the selected mutants contained the amino acids found in the wildtype estrogen receptor DBD, as well as other amino acid combinations seen in naturally occurring steroid/nuclear receptors that bind the aGGTCA half-site. We also obtained high affinity DBDs with Trp(585) as the first amino acid of the P-box, although this is not found in the known steroid/nuclear receptors, In the linker region between the two zinc fingers, G597R was by far the most common mutation. In transient transfections in mammalian cells using promoter interference assays, the mutants displayed enhanced affinity for the ERE, When linked to an activation domain, the transfected mutants activated transcription from ERE containing reporter genes. We conclude that the P-box amino acids can display considerable variation and that the little studied linker amino acids play an important role in determining affinity for the ERE, This work also demonstrates that the P22 challenge phage genetic selection system, modified for use with a mammalian protein, provides a novel, single cycle selection for steroid/nuclear receptor DBDs with altered specificity and greatly enhanced affinity for their response elements.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, 413 RAL,600 S Mathews, Urbana, IL 61801 USA.	djshapir@uiuc.edu		Glenn, Kevin/0000-0002-6941-9649	NCI NIH HHS [CA 60514] Funding Source: Medline; NICHD NIH HHS [HD-16720] Funding Source: Medline; NIGMS NIH HHS [GM 28717] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA060514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALROY I, 1992, NUCLEIC ACIDS RES, V20, P1045, DOI 10.1093/nar/20.5.1045; ARBUCKLE ND, 1995, NAT STRUCT BIOL, V2, P341, DOI 10.1038/nsb0595-341; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; CHIANG CM, 1993, PEPTIDE RES, V6, P62; DETERAWADLEIGH SD, 1994, MOL PHYLOGENET EVOL, V3, P192, DOI 10.1006/mpev.1994.1022; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kosztin D, 1997, BIOPHYS J, V73, P557, DOI 10.1016/S0006-3495(97)78093-7; Kuntz MA, 1997, J BIOL CHEM, V272, P27949, DOI 10.1074/jbc.272.44.27949; LEE EC, 1992, EMBO J, V11, P305, DOI 10.1002/j.1460-2075.1992.tb05053.x; Leung DW, 1989, TECHNIQUE, V1, P11; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MALOY S, 1994, METH MOL G, V3, P205; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Nardulli AM, 1996, MOL ENDOCRINOL, V10, P694, DOI 10.1210/me.10.6.694; NARDULLI AM, 1992, MOL CELL BIOL, V12, P2037, DOI 10.1128/MCB.12.5.2037; NELSON CC, 1995, J BIOL CHEM, V270, P16981, DOI 10.1074/jbc.270.28.16981; NELSON CC, 1995, J BIOL CHEM, V270, P16988, DOI 10.1074/jbc.270.28.16988; Nelson CC, 1996, J BIOL CHEM, V271, P19464, DOI 10.1074/jbc.271.32.19464; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; NUMRYCH TE, 1995, SEMIN VIROL, V6, P5, DOI 10.1016/S1044-5773(05)80004-6; Parikh A, 1998, BIOTECHNIQUES, V24, P428, DOI 10.2144/98243st01; Parker MG, 1998, BIOCHEM SOC SYMP, P45; Petz LN, 1997, J STEROID BIOCHEM, V60, P31, DOI 10.1016/S0960-0760(96)00171-9; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1995, STRUCTURE, V3, P201, DOI 10.1016/S0969-2126(01)00150-2; Todo T, 1996, MOL CELL ENDOCRINOL, V119, P37, DOI 10.1016/0303-7207(96)03792-6; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WEILER IJ, 1987, MOL ENDOCRINOL, V1, P355, DOI 10.1210/mend-1-5-355; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2; ZILLIACUS J, 1994, P NATL ACAD SCI USA, V91, P4175, DOI 10.1073/pnas.91.10.4175; ZILLIACUS J, 1995, PROTEINS, V21, P57, DOI 10.1002/prot.340210107	42	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23591	23598		10.1074/jbc.274.33.23591	http://dx.doi.org/10.1074/jbc.274.33.23591			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438541	hybrid			2022-12-25	WOS:000082012800091
J	Harvey, AK; Yu, XP; Frolik, CA; Chandrasekhar, S				Harvey, AK; Yu, XP; Frolik, CA; Chandrasekhar, S			Parathyroid hormone-(1-34) enhances aggrecan synthesis via an insulin-like growth factor-I pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCHONDRAL BONE-FORMATION; RABBIT COSTAL CHONDROCYTES; PROTEOGLYCAN SYNTHESIS; ALKALINE-PHOSPHATASE; SKELETAL DEVELOPMENT; INDIAN HEDGEHOG; PEPTIDE GENE; DIFFERENTIATION; RECEPTORS; CULTURES	During endochondral bone formation, the growth plate chondrocytes proliferate, become hypertrophic, lose the cartilage phenotype, undergo mineralization, and provide a scaffold upon which subsequent longitudinal bone growth occurs. Parathyroid hormone (PTH), a calcium-regulating hormone, and parathyroid hormone-related peptide (PTHrP), which shares several properties with PTH, have profound effects on skeletal growth and new bone formation. In order to define further the mechanism by which PTH/PTHrP promotes the cartilage phenotype, chondrocytes isolated from the rib cages of developing rat embryos were evaluated for the biosynthesis of aggrecan. Cells treated with PTH-(1-34) for a 4-h period followed by a 20-h recovery period showed a significant increase in cartilage proteoglycan (aggrecan) synthesis in a dose-dependent manner. Only N-terminally intact PTH and PTHrP were effective in stimulating aggrecan synthesis. Addition of a neutralizing antibody to insulin-like growth factor-I (IGF-I) during PTH treatment resulted in the inhibition of PTH-stimulated aggrecan synthesis, whereas the addition of a neutralizing antibody to insulin-like growth factor-binding protein-2 (IGFBP-2) resulted in an increase in synthesis in both the control and PTH-treated cells. In addition, PTH treatment resulted in an increase in the mRNA for aggrecan, a reduction in IGFBP-3 mRNA, and no discernible changes in IGF-I mRNA levels, which was complemented by quantitative changes in IGFBP-3 and free IGF-I levels. The reciprocal relationship in the expression of aggrecan and IGFBP was further confirmed in chondrocytes from various gestational stages during normal development, Collectively, our results indicate that the effect of PTH may be mediated at least in part through the regulation of the IGF/IGFBP axis, by a decrease in the level of IGFBP-3, and an increase in free IGF-I levels. It is likely that the local increase in IGF-I may lead to an increase in cartilage type proteoglycan synthesis and maintenance of the cartilage phenotype. The consequence of the prolonged maintenance may be to halt mineralization while a new scaffolding is created.	Eli Lilly & Co, Lilly Res Labs, Div Endocrine, Indianapolis, IN 46285 USA	Eli Lilly	Chandrasekhar, S (corresponding author), Eli Lilly & Co, Lilly Res Labs, Div Endocrine, DC 0403, Indianapolis, IN 46285 USA.							Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Amizuka N, 1996, ENDOCRINOLOGY, V137, P5055, DOI 10.1210/en.137.11.5055; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; Byers S, 1997, CALCIFIED TISSUE INT, V60, P71, DOI 10.1007/s002239900188; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CHANDRASEKHAR S, 1988, ARCH BIOCHEM BIOPHYS, V265, P294, DOI 10.1016/0003-9861(88)90131-2; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; ENOMOTO M, 1989, BIOCHEM BIOPH RES CO, V162, P1222, DOI 10.1016/0006-291X(89)90804-8; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FISHER LW, 1987, J BIOL CHEM, V262, P9702; GUNNESSHEY M, 1984, METAB BONE DIS RELAT, V5, P177, DOI 10.1016/0221-8747(84)90026-2; HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110; IANNOTTI JP, 1990, J ORTHOPAED RES, V8, P136, DOI 10.1002/jor.1100080118; ITAGANE Y, 1991, ENDOCRINOLOGY, V128, P1419, DOI 10.1210/endo-128-3-1419; IWAMOTO M, 1994, J BIOL CHEM, V269, P17245; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KATO Y, 1988, ENDOCRINOLOGY, V122, P1991, DOI 10.1210/endo-122-5-1991; KOIKE T, 1990, J CLIN INVEST, V85, P626, DOI 10.1172/JCI114484; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Lee K, 1996, ENDOCRINOLOGY, V137, P5109, DOI 10.1210/en.137.11.5109; MAOR G, 1993, ACTA ENDOCRINOL-COP, V128, P56, DOI 10.1530/acta.0.1280056; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MURRAY TM, 1989, ENDOCRINOLOGY, V124, P1097, DOI 10.1210/endo-124-2-1097; OLSSON C, 1992, J ENDOCRINOL, V133, P291; OTOTANI N, 1978, J BIOCHEM-TOKYO, V84, P1005, DOI 10.1093/oxfordjournals.jbchem.a132181; Reddi A. H., 1984, EXTRACELLULAR MATRIX, P375; RIMOIN DL, 1983, PRINCIPLES PRACTICE, P703; Segre Gino V., 1994, P213; SUTHERLAND MK, 1994, J BONE MINER RES, V9, P453; TAKIGAWA M, 1991, ENDOCRINOLOGY, V129, P868, DOI 10.1210/endo-129-2-868; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; [No title captured]	34	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23249	23255		10.1074/jbc.274.33.23249	http://dx.doi.org/10.1074/jbc.274.33.23249			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438499	hybrid			2022-12-25	WOS:000082012800049
J	Narusaka, Y; Narusaka, M; Satoh, K; Kobayashi, H				Narusaka, Y; Narusaka, M; Satoh, K; Kobayashi, H			In vitro random mutagenesis of the D1 protein of the photosystem II reaction center confers phototolerance on the cyanobacterium Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; CHLOROPHYLL FLUORESCENCE; SP PCC-6803; CHLOROPLAST MEMBRANES; INVIVO DEGRADATION; THYLAKOID MEMBRANE; PHOTOINHIBITION; PHOSPHORYLATION; LIGHT; TURNOVER	The D1 protein of the photosystem II reaction center is thought to be the most light-sensitive component of the photosynthetic machinery. To understand the mechanisms underlying the light sensitivity of D1, we performed in vitro random mutagenesis of the psbA gene that codes for D1, transformed the unicellular cyanobacterium Synechocystis sp, PCC 6803 with mutated psbA, and selected phototolerant transformants that did not bleach in high intensity light. A region of psbA2 coding for 178 amino acids of the carboxyl-terminal portion of the peptide was subjected to random mutagenesis by low fidelity polymerase chain reaction amplification or by hydroxylamine treatment, This region contains the binding sites for Q(B), D2 (through Fe), and P680, Eighteen phototolerant mutants with single and multiple amino acid substitutions were selected from a half million transformants exposed to white light at 320 mu mol m(-2) s(-1). A strain transformed with non-mutagenized psbA2 became bleached under the same conditions. Site-directed mutagenesis has confirmed that one or more substitutions of amino acids at residues 234, 254, 260, 267, 322, 326, and 328 confers phototolerance, The rate of degradation of D1 protein was not appreciably affected by the mutations. Reduced bleaching of mutant cyanobacterial cells may result from continued buildup of photosynthetic pigment systems caused by changes in redox signals originating from D1.	Univ Shizuoka, Grad Sch Nutr & Environm Sci, Lab Plant Cell Technol, Shizuoka 4228526, Japan; Natl Inst Basic Biol, Lab Biol Regulat & Photobiol, Okazaki, Aichi 4448585, Japan; Okayama Univ, Fac Sci, Dept Biol, Okayama 7008530, Japan	University of Shizuoka; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Okayama University	Kobayashi, H (corresponding author), Univ Shizuoka, Grad Sch Nutr & Environm Sci, Lab Plant Cell Technol, 52-1 Yada, Shizuoka 4228526, Japan.		Kobayashi, Hirokazu/E-7903-2010	Kobayashi, Hirokazu/0000-0002-8040-0826				ALLEN JF, 1995, PHYSIOL PLANTARUM, V93, P196, DOI 10.1034/j.1399-3054.1995.930128.x; Allen JF, 1997, PHYSIOL PLANTARUM, V100, P863, DOI 10.1034/j.1399-3054.1997.1000412.x; ALLEN JF, 1995, CURR BIOL, V5, P869, DOI 10.1016/S0960-9822(95)00176-X; ANDERSON JM, 1988, TRENDS BIOCHEM SCI, V13, P351, DOI 10.1016/0968-0004(88)90106-5; ANDERSSON B, 1991, CURR TOP BIOENERG, P2; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Asada K., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P77; CAROTHERS AM, 1989, BIOTECHNIQUES, V7, P494; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DZELZKALNS VA, 1986, J BACTERIOL, V165, P964, DOI 10.1128/jb.165.3.964-971.1986; ErmakovaGerdes S, 1996, PLANT MOL BIOL, V30, P243, DOI 10.1007/BF00020111; Gal A, 1997, PHYSIOL PLANTARUM, V100, P869, DOI 10.1034/j.1399-3054.1997.1000413.x; GENTY B, 1989, BIOCHIM BIOPHYS ACTA, V990, P87, DOI 10.1016/S0304-4165(89)80016-9; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; GREER DH, 1986, PLANTA, V168, P253, DOI 10.1007/BF00402971; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JANSSON C, 1987, PLANT PHYSIOL, V85, P1021, DOI 10.1104/pp.85.4.1021; KLESS H, 1994, BIOCHEMISTRY-US, V33, P10501, DOI 10.1021/bi00200a035; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; Kyle D.J., 1987, PHOTOINHIBITION, P197; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung DW, 1989, TECHNIQUE, V1, P11; MAENPAA P, 1993, PLANT MOL BIOL, V22, P1, DOI 10.1007/BF00038991; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; Minagawa J, 1999, BIOCHEMISTRY-US, V38, P770, DOI 10.1021/bi981217x; MIYAO M, 1994, BIOCHEMISTRY-US, V33, P9722, DOI 10.1021/bi00198a043; MOHAMED A, 1989, PLANT MOL BIOL, V13, P693, DOI 10.1007/BF00016024; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; Narusaka Y, 1996, PLANT SCI, V115, P261, DOI 10.1016/0168-9452(96)04393-2; NIXON PJ, 1995, J BIOL CHEM, V270, P14919, DOI 10.1074/jbc.270.25.14919; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; POWLES SB, 1984, ANNU REV PLANT PHYS, V35, P15, DOI 10.1146/annurev.pp.35.060184.000311; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; REES D, 1990, PHOTOSYNTH RES, V25, P199, DOI 10.1007/BF00033161; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAMUELSSON G, 1985, PLANT PHYSIOL, V79, P992, DOI 10.1104/pp.79.4.992; SATOH K, 1993, PHOTOSYNTHETIC REACT, V1, P289; SAYRE RT, 1986, CELL, V47, P601, DOI 10.1016/0092-8674(86)90624-0; TELFER A, 1991, BIOCHIM BIOPHYS ACTA, V1060, P106, DOI 10.1016/S0005-2728(05)80125-2; Thomas DJ, 1998, PLANT PHYSIOL, V116, P1593, DOI 10.1104/pp.116.4.1593; THOMPSON LK, 1988, BIOCHEMISTRY-US, V27, P6653, DOI 10.1021/bi00418a002; TREBST A, 1986, Z NATURFORSCH C, V41, P240; TYYSTJARVI T, 1994, PLANT MOL BIOL, V25, P517, DOI 10.1007/BF00043879; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; WEIS E, 1987, BIOCHIM BIOPHYS ACTA, V894, P198, DOI 10.1016/0005-2728(87)90190-3	48	10	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23270	23275		10.1074/jbc.274.33.23270	http://dx.doi.org/10.1074/jbc.274.33.23270			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438502	hybrid			2022-12-25	WOS:000082012800052
J	Pleass, RJ; Dunlop, JI; Anderson, CM; Woof, JM				Pleass, RJ; Dunlop, JI; Anderson, CM; Woof, JM			Identification of residues in the CH2/CH3 domain interface of IgA essential for interaction with the human Fc alpha receptor (Fc alpha R) CD89	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; HUMAN-IMMUNOGLOBULIN-E; BINDING-SITE; HEAVY-CHAIN; EPSILON-RI; LOCALIZATION; REGION; CELLS; MUTAGENESIS; EXPRESSION	Cellular receptors for IgA (Fc alpha R) mediate important protective functions. An extensive panel of site-directed mutant IgAs was used to identify IgA residues critical for Fc alpha R (CD89) binding and triggering. Although a tailpiece-deleted IgA1 was able to bind and trigger CD89, antibodies featuring CH3 domain exchanges between human IgA1 and IgG1 could not, indicating that both domains but not the tailpiece are required for Fc alpha R recognition. To further investigate the role of the interdomain region, numerous IgA1s, each with a point substitution in either of two interdomain loops (Leu-257-Gly-259 in C alpha 2; Pro-440-Phe-443 in C alpha 3), were generated. With only one exception (G259R), substitutions produced either ablation (L257R, P440A, A442R, F443R) or marked reduction (P440R) in CD89 binding and triggering, Further support for involvement of these interdomain loops was provided by interspecies comparisons of IgA Thus a human IgA1 mutant, LA441-442MN, which mimicked the mouse IgA loop sequence through substitution of two adjacent residues in the C alpha 3 loop, was found, like mouse IgA, not to bind CD89, In contrast, bovine IgA1, identical to human IgA1 within these interdomain loops despite numerous differences elsewhere in the Fc region, did bind CD89, We have thus identified motifs in the interdomain region of IgA Fc critical for Fc alpha R binding and triggering, significantly enhancing present understanding of the molecular basis of the IgA-Fc alpha R interaction.	Univ Dundee, Sch Med, Ninewells Hosp, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	University of Dundee	Woof, JM (corresponding author), Univ Dundee, Sch Med, Ninewells Hosp, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Pleass, Richard J/L-4148-2015; Pleass, Richard/N-7831-2019	Pleass, Richard J/0000-0001-7438-8296; Pleass, Richard/0000-0001-7438-8296				Atkin JD, 1996, J IMMUNOL, V157, P156; Boehm MK, 1999, J MOL BIOL, V286, P1421, DOI 10.1006/jmbi.1998.2556; CARAYANNOPOULOS L, 1994, P NATL ACAD SCI USA, V91, P8348, DOI 10.1073/pnas.91.18.8348; Carayannopoulos L, 1996, J EXP MED, V183, P1579, DOI 10.1084/jem.183.4.1579; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; Helm BA, 1996, J BIOL CHEM, V271, P7494, DOI 10.1074/jbc.271.13.7494; Henry AJ, 1997, BIOCHEMISTRY-US, V36, P15568, DOI 10.1021/bi971299+; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; Kerr MA, 1998, MUCOSAL IMMUNOLOGY, P213; KNIGHT KL, 1988, J IMMUNOL, V140, P3654; Krugmann S, 1997, J IMMUNOL, V159, P244; LUND J, 1991, J IMMUNOL, V147, P2657; Ma JKC, 1998, NAT MED, V4, P601, DOI 10.1038/nm0598-601; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; Mattu TS, 1998, J BIOL CHEM, V273, P2260, DOI 10.1074/jbc.273.4.2260; MORTON HC, 1993, J IMMUNOL, V151, P4743; Morton HC, 1996, CRIT REV IMMUNOL, V16, P423; NISSIM A, 1991, EMBO J, V10, P101, DOI 10.1002/j.1460-2075.1991.tb07925.x; Pleass RJ, 1996, BIOCHEM J, V318, P771, DOI 10.1042/bj3180771; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PUTNAM FW, 1979, J BIOL CHEM, V254, P2865; Sayers I, 1998, BIOCHEMISTRY-US, V37, P16152, DOI 10.1021/bi981456k; SUN LK, 1995, BIO-TECHNOL, V13, P779, DOI 10.1038/nbt0895-779; TERSKIKH A, 1994, MOL IMMUNOL, V31, P1313, DOI 10.1016/0161-5890(94)90049-3; WALKER MR, 1988, VOX SANG, V55, P222, DOI 10.1111/j.1423-0410.1988.tb04701.x; WHITTLE N, 1987, PROTEIN ENG, V1, P499, DOI 10.1093/protein/1.6.499; Wines BD, 1999, J IMMUNOL, V162, P2146; WOOF JM, 1986, MOL IMMUNOL, V23, P319, DOI 10.1016/0161-5890(86)90059-3; WOOF JM, 1990, BACTERIAL IMMUNOGLOB, V1, P305	34	88	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23508	23514		10.1074/jbc.274.33.23508	http://dx.doi.org/10.1074/jbc.274.33.23508			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438530	hybrid			2022-12-25	WOS:000082012800080
J	Ma, ZQ; Chua, SS; DeMayo, FJ; Tsai, SY				Ma, ZQ; Chua, SS; DeMayo, FJ; Tsai, SY			Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B	ONCOGENE			English	Article						Cdc25B cell cycle; transgenic mice; hyperplasia	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; C-MYC; FISSION YEAST; DIFFERENTIAL REGULATION; REDUNDANT CYCLIN; MITOTIC INDUCER; BREAST-CANCER; HA-RAS; OVEREXPRESSION	Cdc25 A and B are dual-specificity phosphatases which have been implicated in neoplastic transformation. Although Cdc25A and Cdc25B have been found to be over-expressed in many cancer cell lines and primary tumors, the physiological roles of Cdc25A and B in vivo are largely undefined. To investigate the roles of these proteins in the ontogenic transformation of the mammary gland we used the mouse mammary tumor virus (MMTV) promoter to target over-expression of the Cdc25B transgene in the mammary glands of transgenic mouse Lines. Here we report that the over-expression of Cdc25B enhances the proliferation of mammary epithelial cells resulting in the formation of precocious alveolar hyperplasia. At the molecular level, marked increases in cyclin D1 protein have been found in transgenic mammary epithelial cells. The accelerated growth rate of the mammary epithelial cells could also be attributed to the increased levels of cyclin E/cdk2 activity, In addition, a pronounced decrease in apoptosis was also observed during the involution of mammary gland, The reduction of apoptosis during involution correlated well with the reduced expression of c-myc and p53, both of which have been implicated in apoptosis. Taken together, our results clearly indicate that the deregulated expression of Cdc25B generates mammary gland hyperplasia.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Tsai, SY (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336				ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; Barnes DM, 1997, J PATHOL, V181, P267, DOI 10.1002/(SICI)1096-9896(199703)181:3<267::AID-PATH783>3.0.CO;2-X; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; Cardiff RD, 1996, J MAMMARY GLAND BIOL, V1, P61, DOI 10.1007/BF02096303; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRANA X, 1995, ONCOGENE, V11, P211; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hernandez S, 1998, CANCER RES, V58, P1762; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Hundley JE, 1997, CANCER RES, V57, P600; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Iavarone A, 1997, NATURE, V387, P417; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; Morgan DO, 1996, NATURE, V382, P295, DOI 10.1038/382295a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRANGE R, 1992, DEVELOPMENT, V115, P49; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WICKRAMASINGHE D, 1995, DEVELOPMENT, V121, P2047; Wu WG, 1998, CANCER RES, V58, P4082; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu X, 1996, J BIOL CHEM, V271, P5118; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	58	81	83	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4564	4576		10.1038/sj.onc.1202809	http://dx.doi.org/10.1038/sj.onc.1202809			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467401				2022-12-25	WOS:000082018600006
J	Verheijen, MHG; Wolthuis, RMF; Defize, LHK; den Hertog, J; Bos, JL				Verheijen, MHG; Wolthuis, RMF; Defize, LHK; den Hertog, J; Bos, JL			Interdependent action of RalGEF and Erk in Ras-induced primitive endoderm differentiation of F9 embryonal carcinoma cells	ONCOGENE			English	Article						Ras; RalGEF; Erk; F9 embryonal carcinoma; primitive endoderm	PROTEIN-KINASE ACTIVATION; DISSOCIATION STIMULATOR; C-JUN; TRANSFORMATION; PHOSPHORYLATION; INDUCTION; CASCADE; PATHWAY	Previous work by us and others has implicated a role for Ral guanine exchange factors (RalGEFs) in Ras-induced cell growth and oncogenic transformation. Here we show for the first time that RalGEFs are involved in Ras-induced differentiation as well. Expression of oncogenic Ras in F9 embryonal carcinoma (EC) cells is known to induce differentiation to a primitive endoderm (PrE)-like phenotype, but the downstream signal transduction mechanisms involved are unclear. We found that PrE differentiation is induced by the Ras effector domain mutants, RasV12G37 and RasV12E38, but not by RasV12C40. Accordingly, expression of constitutively active forms of RalGEF (Rlf-CAAX) or Raf1 (Raf-CAAX) is sufficient to induce differentiation. Inhibition of RalGEF activity by expression of dominant negative Ral completely abolishes Rlf-CAAX- and RasV12G37-induced differentiation, while it reduces differentiation by RasV12 and Raf-CAAX. Finally, while Rlf-CAAX does not increase Erk activity, inhibition of MEK blocks both Ras- as web as Rlf-CAAX-induced differentiation, suggesting that RalGEFs induce PrE differentiation in a manner depending on basal MEK or Erk activity. Based on these results we conclude that Ras induces PrE differentiation of F9 EC cells via an interplay of Erk- and RalGEF-mediated pathways.	Univ Utrecht, Physiol Chem Lab, NL-3508 TC Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3508 TC Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Utrecht University; Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Bos, JL (corresponding author), Univ Utrecht, Physiol Chem Lab, Univ Weg 100, NL-3508 TC Utrecht, Netherlands.		Verheijen, Mark/AAD-8112-2019; Verheijen, Mark/GQY-5157-2022	Verheijen, Mark/0000-0002-3739-3755; Wolthuis, Rob/0000-0002-3109-1588				BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; RODRIGUEZ VP, 1997, CELL, V89, P457; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	21	29	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4435	4439		10.1038/sj.onc.1202834	http://dx.doi.org/10.1038/sj.onc.1202834			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442634				2022-12-25	WOS:000081813500005
J	Bennicelli, JL; Advani, S; Schafer, BW; Barr, FG				Bennicelli, JL; Advani, S; Schafer, BW; Barr, FG			PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma	ONCOGENE			English	Article						PAX3; PAX7; FKHR; transcription factor; chromosomal translocation; fusion protein	PAX3-FKHR FUSION PROTEIN; CHROMOSOMAL TRANSLOCATIONS; GENE; ACTIVATOR; POTENT; ENCODES; CELLS; EWS	The t(2;13) and t(1;13) translocations of alveolar rhabdomyosarcoma (ARMS) result in chimeric PAX3-FKHR or PAX7-FKHR transcription factors, respectively, In each chimera, a PAX DNA-binding domain is fused to the C-terminal FKHR transactivation domain. Previously we demonstrated that PAX3-FKHR is more potent than PAX3 because the FKHR transactivation domain is resistant to repression mediated by the PAX3 N-terminus. Here me test the hypothesis that the cis-acting repression domain is a conserved feature of PAX3 and PAX7 and that PAX7-FKHR gains function similarly, Using PAX-specific DIVA-binding sites, we found that PAX7 was virtually inactive, while PAX7-FKHR exhibited activity 600-fold above background and was comparable to PAX3-FKHR, Deletion analysis showed that the transactivation domains of PAX7 and PAX7-FKHR are each more potent than either full-length protein, and resistance to cis-repression is responsible for the PAX7-FKHR gain of function. Further deletion mapping and domain swapping experiments with PAX3 and PAX7 showed that their transactivation domains exhibit subtle dose-dependent differences in potency, likely due to regions of structural divergence; while their repression domains are structurally and functionally conserved. Thus, the data support the hypothesis and demonstrate that PAX3 and PAX7 utilize a common gain of function mechanism in ARMS.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs, Philadelphia, PA 19104 USA; Univ Zurich, Dept Pediat, Zurich, Switzerland	University of Pennsylvania; University of Zurich	Bennicelli, JL (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs, Room 506,422 Curie Blvd, Philadelphia, PA 19104 USA.			Schafer, Beat/0000-0001-5988-2915	NATIONAL CANCER INSTITUTE [R01CA064202] Funding Source: NIH RePORTER; NCI NIH HHS [CA64202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barr FG, 1997, CURR TOP MICROBIOL, V220, P113; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BENNICELLI JL, 1995, ONCOGENE, V11, P119; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; Clark J, 1996, ONCOGENE, V12, P229; DAVIS RJ, 1994, CANCER RES, V54, P2869; Davis RJ, 1997, P NATL ACAD SCI USA, V94, P8047, DOI 10.1073/pnas.94.15.8047; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; Fujimura Y, 1996, ONCOGENE, V12, P159; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; KAZ K, 1997, NAT GENET, V15, P170; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; Vorobyov E, 1997, GENOMICS, V45, P168, DOI 10.1006/geno.1997.4915; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; Xue L, 1996, EMBO J, V15, P3722, DOI 10.1002/j.1460-2075.1996.tb00742.x; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	30	79	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4348	4356		10.1038/sj.onc.1202812	http://dx.doi.org/10.1038/sj.onc.1202812			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439042				2022-12-25	WOS:000081732700007
J	Eto, K; Suga, S; Wakui, M; Tsubamoto, Y; Terauchi, Y; Taka, J; Aizawa, S; Noda, M; Kimura, S; Kasai, H; Kadowaki, T				Eto, K; Suga, S; Wakui, M; Tsubamoto, Y; Terauchi, Y; Taka, J; Aizawa, S; Noda, M; Kimura, S; Kasai, H; Kadowaki, T			NADH shuttle system regulates K-ATP channel-dependent pathway and steps distal to cytosolic Ca2+ concentration elevation in glucose-induced insulin secretion.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELL; MOUSE B-CELLS; SULFONYLUREA RECEPTOR; DIABETES-MELLITUS; MITOCHONDRIAL-DNA; ENDOPLASMIC-RETICULUM; POTASSIUM CHANNELS; GLUCOKINASE GENE; ISLETS; RELEASE	The NADH shuttle system is composed of the glycerol phosphate and malate-aspartate shuttles. We generated mice that lack mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH), a rate-limiting enzyme of the glycerol phosphate shuttle. Application of aminooxyacetate, an inhibitor of the malate-aspartate shuttle, to mGPDH-deficient islets demonstrated that the NADH shuttle system was essential for coupling glycolysis with activation of mitochondrial ATP generation to trigger glucose induced insulin secretion. The present study revealed that blocking the NADH shuttle system severely suppressed closure of the ATP-sensitive potassium (K-ATP) channel and depolarization of the plasma membrane in response to glucose in beta cells, although properties of the K-ATP channel on the excised beta cell membrane were unaffected. In mGPDH-deficient islets treated with aminooxyacetate, Ca2+ influx through the plasma membrane induced by a depolarizing concentration of KCl in the presence of the K-ATP channel opener diazoxide restored insulin secretion. However, the level of the secretion was only similar to 40% of wild-type controls. Thus, glucose metabolism through the NADH shuttle system leading to efficient ATP generation is pivotal to activation of both the K-ATP channel-dependent pathway and steps distal to an elevation of cytosolic Ca2+ concentration in glucose-induced insulin secretion.	Univ Tokyo, Grad Sch Med, Dept Metabol Dis, Bunkyu ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Physiol, Tokyo 138655, Japan; Hirosaki Univ, Sch Med, Dept Physiol, Bunkyu ku, Hirosaki 0368562, Japan; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Dept Morphogenesis, Kumamoto 862, Japan	University of Tokyo; University of Tokyo; Hirosaki University; Kumamoto University	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Metabol Dis, Bunkyu ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Terauchi, Yasuo/AAO-4347-2020; Noda, Mitsuhiko/W-3905-2019	Noda, Mitsuhiko/0000-0003-0413-4631; Kasai, Haruo/0000-0003-2327-9027				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; AIZAWA T, 1994, AM J PHYSIOL, V266, pC622, DOI 10.1152/ajpcell.1994.266.3.C622; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; Ashcroft FM, 1996, HORM METAB RES, V28, P456, DOI 10.1055/s-2007-979837; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ATWATER I, 1978, J PHYSIOL-LONDON, V278, P117, DOI 10.1113/jphysiol.1978.sp012296; BERGSTEN P, 1988, AM J PHYSIOL, V255, pE422, DOI 10.1152/ajpendo.1988.255.4.E422; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; deVargas LM, 1997, J BIOL CHEM, V272, P26573, DOI 10.1074/jbc.272.42.26573; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; DUKES ID, 1994, J BIOL CHEM, V269, P10979; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; HAMAKAWA N, 1995, CELL CALCIUM, V17, P21, DOI 10.1016/0143-4160(95)90099-3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hayakawa T, 1998, J BIOL CHEM, V273, P20300, DOI 10.1074/jbc.273.32.20300; HENQUIN JC, 1987, HORM RES, V27, P168, DOI 10.1159/000180806; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; LEBRUN P, 1983, AM J PHYSIOL, V245, pE38, DOI 10.1152/ajpendo.1983.245.1.E38; LEBRUN P, 1984, HORM METAB RES, V16, P322, DOI 10.1055/s-2007-1014780; LEVITAN ES, 1990, NATURE, V348, P545, DOI 10.1038/348545a0; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MALAISSE WJ, 1982, ENDOCRINOLOGY, V111, P392, DOI 10.1210/endo-111-2-392; MALAISSE WJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P190, DOI 10.1016/0167-4889(87)90134-0; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Mertz RJ, 1996, J BIOL CHEM, V271, P4838, DOI 10.1074/jbc.271.9.4838; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NIKI I, 1991, BIOCHIM BIOPHYS ACTA, V1133, P95, DOI 10.1016/0167-4889(91)90246-T; OHTA M, 1990, J BIOL CHEM, V265, P17525; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; ROE MW, 1994, J BIOL CHEM, V269, P18279; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; Rustenbeck I, 1997, DIABETES, V46, P1305, DOI 10.2337/diabetes.46.8.1305; SAKURA H, 1992, J CLIN ENDOCR METAB, V75, P1571, DOI 10.1210/jc.75.6.1571; SALA S, 1991, J MEMBRANE BIOL, V122, P177, DOI 10.1007/BF01872640; Sato Y, 1998, DIABETES, V47, P1713, DOI 10.2337/diabetes.47.11.1713; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; Schuit FC, 1996, HORM RES, V46, P99, DOI 10.1159/000185004; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Suga S, 1997, DIABETES, V46, P1755, DOI 10.2337/diabetes.46.11.1755; SUTTON R, 1986, TRANSPLANTATION, V42, P689, DOI 10.1097/00007890-198612000-00022; Takahashi N, 1999, P NATL ACAD SCI USA, V96, P760, DOI 10.1073/pnas.96.2.760; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; Tsuruzoe K, 1998, DIABETES, V47, P621, DOI 10.2337/diabetes.47.4.621; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; WOLF BA, 1988, AM J PHYSIOL, V254, pE121, DOI 10.1152/ajpendo.1988.254.2.E121; WOLLHEIM CB, 1990, BIOCHEM SOC T, V18, P111, DOI 10.1042/bst0180111; Zawalich WS, 1997, J BIOL CHEM, V272, P3527, DOI 10.1074/jbc.272.6.3527	63	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25386	25392		10.1074/jbc.274.36.25386	http://dx.doi.org/10.1074/jbc.274.36.25386			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464266	hybrid			2022-12-25	WOS:000082554200106
J	Lai, TS; Slaughter, TF; Peoples, KA; Greenberg, CS				Lai, TS; Slaughter, TF; Peoples, KA; Greenberg, CS			Site-directed mutagenesis of the calcium-binding site of blood coagulation factor XIIIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDNA CLONES; MOLECULAR-CLONING; HUMAN-PLASMA; A-CHAINS; TRANSGLUTAMINASE; SEQUENCE; THROMBIN; ENZYME; ACTIVATION; CLEAVAGE	Blood coagulation factor XIIIa is a calcium-dependent enzyme that covalently ligates fibrin molecules during blood coagulation. X-ray crystallography studies identified a major calcium-binding site involving Asp(438) Ala(457), Glu(485), and Glu(490). We mutated two glutamic acid residues (Glu(485) and Glu(490)) and three aspartic acid residues (Asp(472), Asp(476), and Asp(479)) that are in close proximity. Alanine substitution mutants of these residues were constructed, expressed, and purified from Escherichia coli, The K-act values for calcium ions increased by 3-, 8-, and 21-fold for E485A, E490A, and E485A,E490A, respectively. In addition, susceptibility to proteolysis was increased by 4-, 9-, and 10-fold for E485A, E490A, and E485A,E490A, respectively. Aspartic acids 472, 476, and 479 are not involved directly in calcium binding since the K-act values were not changed by mutagenesis. However, Asp(476) and Asp(479) are involved in regulating the conformation for exposure of the secondary thrombin cleavage site. This study provides biochemical evidence that Glu(485) and Glu(490), Ca2+-binding ligands that regulate catalysis, The binding of calcium ion to this site protects the molecule from proteolysis. Furthermore, Asp(476) and Asp(479) play a role in modulating calcium-dependent conformational changes that cause factor XIIIa to switch from a protease-sensitive to a protease-resistant molecule.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Greenberg, CS (corresponding author), Duke Univ, Med Ctr, Dept Pathol, POB 2603, Durham, NC 27710 USA.			, Thung-Shen/0000-0002-8791-9698	NCI NIH HHS [CA 68438, CA 71753] Funding Source: Medline; NHLBI NIH HHS [HL28391] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071753, P50CA068438] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL028391] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; CHUNG SI, 1972, J BIOL CHEM, V247, P2798; FICKENSCHER K, 1991, THROMB HAEMOSTASIS, V65, P535; FOLK JE, 1967, J BIOL CHEM, V242, P1838; FOLK JE, 1967, J BIOL CHEM, V242, P2615; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; Fox BA, 1999, J BIOL CHEM, V274, P4917, DOI 10.1074/jbc.274.8.4917; GENTILE V, 1991, J BIOL CHEM, V266, P478; GRANT FJ, 1994, BIOCHEM BIOPH RES CO, V203, P1117, DOI 10.1006/bbrc.1994.2298; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HETTASCH JM, 1994, J BIOL CHEM, V269, P28309; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; IKURA K, 1995, ARCH BIOCHEM BIOPHYS, V318, P307, DOI 10.1006/abbi.1995.1234; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; LAI TS, 1994, J BIOL CHEM, V269, P24596; LAI TS, 1994, PROTEIN EXPRES PURIF, V5, P125, DOI 10.1006/prep.1994.1019; LEWIS BA, 1978, BIOCHEM J, V169, P397, DOI 10.1042/bj1690397; LORAND L, 1962, NATURE, V194, P1148, DOI 10.1038/1941148a0; Lorand L, 1980, Prog Hemost Thromb, V5, P245; MARY A, 1988, ARCH BIOCHEM BIOPHYS, V261, P112, DOI 10.1016/0003-9861(88)90110-5; MCDONAGH J, 1975, BRIT J HAEMATOL, V30, P465, DOI 10.1111/j.1365-2141.1975.tb01861.x; McDonagh J, 1987, HEMOSTASIS THROMBOSI, P289; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MIRAGLIA CC, 1985, ANAL BIOCHEM, V144, P165, DOI 10.1016/0003-2697(85)90099-5; NAKANISHI K, 1991, EUR J BIOCHEM, V202, P15, DOI 10.1111/j.1432-1033.1991.tb16338.x; PEDERSEN LC, 1994, THESIS U WASHINGTON; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; SANTIAGO MA, 1992, CIRCULATION, V86, P464; SCHWARTZ ML, 1971, J BIOL CHEM, V246, P5851; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; Tulinsky A, 1996, SEMIN THROMB HEMOST, V22, P117, DOI 10.1055/s-2007-998998; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Yee Vivien C., 1996, Seminars in Thrombosis and Hemostasis, V22, P377, DOI 10.1055/s-2007-999035	40	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24953	24958		10.1074/jbc.274.35.24953	http://dx.doi.org/10.1074/jbc.274.35.24953			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455172	hybrid			2022-12-25	WOS:000082193400071
J	Pohnke, Y; Kempf, R; Gellersen, B				Pohnke, Y; Kempf, R; Gellersen, B			CCAAT/enhancer-binding proteins are mediators in the protein kinase A-dependent activation of the decidual prolactin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOMETRIAL STROMAL CELLS; TRANSCRIPTION FACTOR; C/EBP-BETA; GENE-EXPRESSION; LEUCINE-ZIPPER; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; PROLIFERATIVE ENDOMETRIUM; ADIPOCYTE DIFFERENTIATION; INVITRO DECIDUALIZATION; CORTICAL ASTROCYTES	In the course of decidualization, human endometrial stromal cells (ESC) activate the alternative upstream promoter of the decidual prolactin (dPRL) gene. The dPRL promoter is induced by the protein kinase A pathway in a delayed fashion via the region -332/-270 which contains two overlapping consensus binding sequences, B and D, for CCAAT/enhancer-binding proteins (C/EBP). Here we show that sites B and D both bind C/EBP beta and -delta from ESC nuclear extracts. When decidualization of cultured ESC was induced by treatment with 8-Br-cAMP, complex formation on sites B and D was enhanced. Western blot analysis revealed an elevation of both C/EBP beta isoforms, liver-enriched activator protein and liver-enriched inhibitory protein, with a delayed onset between 8 and 24 h of cAMP treatment, while C/EBP delta expression remained unaffected. Cyclic AMP-mediated activation of dPRL promoter construct dPRL-332/luc3 was abrogated by mutation of sites B and D at -310/-285. An expression vector for liver-enriched activator protein potently induced transcription of dPRL-332/luc3 and further enhanced cAMP-mediated induction, while liver-enriched inhibitory protein expression vector abolished the cAMP response, implying that C/EBPs serve as mediators in the delayed cAMP signal transduction to the dPRL promoter. The ratio between activating and repressing isoforms is likely to dictate the transcriptional output.	Univ Hamburg, IHF Inst Hormone & Fertil Res, D-252529 Hamburg, Germany	University of Hamburg	Gellersen, B (corresponding author), Univ Hamburg, IHF Inst Hormone & Fertil Res, Grandweg 64, D-252529 Hamburg, Germany.	gellersen@ihf.de						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; BERWAER M, 1994, MOL ENDOCRINOL, V8, P635, DOI 10.1210/me.8.5.635; Bonhoff A, 1996, ENDOCRINE, V5, P241, DOI 10.1007/BF02739056; BRAR AK, 1998, 80 ANN M END SOC NEW, P481; BROWN NA, 1994, BIOL REPROD, V50, P543, DOI 10.1095/biolreprod50.3.543; Cardinaux JR, 1996, J NEUROSCI, V16, P919; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; CHANG CJ, 1995, DNA CELL BIOL, V14, P529, DOI 10.1089/dna.1995.14.529; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Chinery R, 1998, J BIOL CHEM, V273, P15308; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; COUGH NM, 1988, ANAL BIOCHEM, V173, P93; DALY DC, 1983, AM J OBSTET GYNECOL, V145, P672, DOI 10.1016/0002-9378(83)90572-0; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; FERRARI A, 1995, J STEROID BIOCHEM, V54, P251, DOI 10.1016/0960-0760(95)00142-M; FRANK GR, 1994, ENDOCRINOLOGY, V134, P258, DOI 10.1210/en.134.1.258; GELLERSEN B, 1991, ENDOCRINOLOGY, V129, P158, DOI 10.1210/endo-129-1-158; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; GELLERSEN B, 1994, MOL ENDOCRINOL, V8, P356, DOI 10.1210/me.8.3.356; Gronning LM, 1999, ENDOCRINOLOGY, V140, P835, DOI 10.1210/en.140.2.835; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hu HM, 1998, J IMMUNOL, V160, P2334; HUI HZ, 1990, J CLIN ENDOCR METAB, V71, P889; IRWIN JC, 1989, FERTIL STERIL, V52, P761; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lu M, 1997, J BIOL CHEM, V272, P28349, DOI 10.1074/jbc.272.45.28349; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Miau LH, 1997, MOL CELL BIOL, V17, P230, DOI 10.1128/MCB.17.1.230; Nalbant D, 1998, ENDOCRINOLOGY, V139, P272, DOI 10.1210/en.139.1.272; Nemansky M, 1998, J CLIN ENDOCR METAB, V83, P575, DOI 10.1210/jc.83.2.575; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Osada S, 1996, J BIOL CHEM, V271, P3891; Pall M, 1997, EMBO J, V16, P5273, DOI 10.1093/emboj/16.17.5273; PELLEGRINI I, 1992, MOL ENDOCRINOL, V6, P1023, DOI 10.1210/me.6.7.1023; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; RITTENHOUSE J, 1984, ANAL BIOCHEM, V138, P442, DOI 10.1016/0003-2697(84)90836-4; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; SIROIS J, 1993, J BIOL CHEM, V268, P21931; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; TABANELLI S, 1992, J STEROID BIOCHEM, V42, P337, DOI 10.1016/0960-0760(92)90137-8; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TANG BQ, 1993, J STEROID BIOCHEM, V47, P115, DOI 10.1016/0960-0760(93)90064-4; TANG BQ, 1993, ENDOCRINOLOGY, V133, P2197, DOI 10.1210/en.133.5.2197; Telgmann R, 1997, ENDOCRINOLOGY, V138, P929, DOI 10.1210/en.138.3.929; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Yano S, 1996, J BIOL CHEM, V271, P23520, DOI 10.1074/jbc.271.38.23520; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	60	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24808	24818		10.1074/jbc.274.35.24808	http://dx.doi.org/10.1074/jbc.274.35.24808			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455153	hybrid			2022-12-25	WOS:000082193400052
J	Dong, D; Ruuska, SE; Levinthal, DJ; Noy, N				Dong, D; Ruuska, SE; Levinthal, DJ; Noy, N			Distinct roles for cellular retinoic acid-binding proteins I and II in regulating signaling by retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT UTERUS; EXPRESSION; CELLS; RECEPTORS; CRABP; AFFINITIES; MECHANISM	The pleiotropic effects of retinoic acid (RA) in mammalian cells are mediated by two classes of proteins: the retinoic acid receptors (RAR) and cellular retinoic acid-binding proteins (CRABP-I and CRABP-II), Here we show that expression of CRABP-II, but not CRABP-I, markedly enhanced RAR-mediated transcriptional activation of a reporter gene in COS-7 cells. The equilibrium dissociation constants of complexes of CRABP-I or CRABP-II with RA were found to differ by 2-fold. It is thus unlikely that the distinct effects of the two proteins on transactivation stem from differential ligand-binding affinities. The mechanisms by which RA transfers from the CRABPs to RAR were thus investigated directly. The rate constant for movement of RA from CRABP-II, but not from CRABP-I, to RAR strongly depended on the concentration of the acceptor. The data suggest that transfer of RA from CRABP-I to RAR involves dissociation of the ligand from the binding protein, followed by association with the receptor. In contrast, movement of RA from CRABP-II to the receptor is facilitated by a mechanism that involves direct interactions between CRABP-II and RAR, These findings reveal a striking functional difference between CRABP-I and CRABP-II, and point at a novel mechanism by which the transcriptional activity of RA can be regulated by CRABP-II.	Cornell Univ, Div Nutrit Sci, Ithaca, NY 14853 USA	Cornell University	Noy, N (corresponding author), Cornell Univ, Div Nutrit Sci, Savage Hall, Ithaca, NY 14853 USA.		Levinthal, David/AAJ-6606-2021	Levinthal, David/0000-0001-8453-8382	NATIONAL CANCER INSTITUTE [R01CA068150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158] Funding Source: NIH RePORTER; NCI NIH HHS [CA68150] Funding Source: Medline; NIDDK NIH HHS [5-T32-DK07158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; Bucco RA, 1997, BIOCHEMISTRY-US, V36, P4009, DOI 10.1021/bi962094o; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507; Chen ZP, 1998, J MOL BIOL, V275, P55, DOI 10.1006/jmbi.1997.1413; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; DANIELS C, 1985, BIOCHEMISTRY-US, V24, P3286, DOI 10.1021/bi00334a032; Dong D, 1998, BIOCHEMISTRY-US, V37, P10691, DOI 10.1021/bi980561r; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; Gaub MP, 1998, J HISTOCHEM CYTOCHEM, V46, P1103, DOI 10.1177/002215549804601002; GORRY P, 1994, P NATL ACAD SCI USA, V91, P9032, DOI 10.1073/pnas.91.19.9032; JAMISON RS, 1994, BIOCHEMISTRY-US, V33, P2873, DOI 10.1021/bi00176a017; Jing YK, 1997, CANCER RES, V57, P1668; Kersten S, 1996, BIOCHEMISTRY-US, V35, P3816, DOI 10.1021/bi952737k; KERSTEN S, 1995, P NATL ACAD SCI USA, V96, P10014; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P112; Maden M., 1994, Vitamin A in health and disease., P289; Mangelsdorf David J., 1994, P319; Newcomer M. E., 1994, RETINOIDS BIOL CHEM, P288; NORRIS AW, 1994, BBA-PROTEIN STRUCT M, V1209, P10, DOI 10.1016/0167-4838(94)90130-9; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; RUDOLPH J, 1995, BIOCHEMISTRY-US, V34, P2241, DOI 10.1021/bi00007a019; TAKASE S, 1986, ARCH BIOCHEM BIOPHYS, V247, P328, DOI 10.1016/0003-9861(86)90591-6; Venepally P, 1996, BIOCHEMISTRY-US, V35, P9974, DOI 10.1021/bi9603276; Vo HP, 1998, ANTICANCER RES, V18, P217; Wardlaw SA, 1997, BIOL REPROD, V56, P125, DOI 10.1095/biolreprod56.1.125; Yamamoto M, 1998, EUR J BIOCHEM, V257, P344, DOI 10.1046/j.1432-1327.1998.2570344.x; Zheng WL, 1996, ENDOCRINOLOGY, V137, P5028, DOI 10.1210/en.137.11.5028; Zheng WL, 1998, BIOL REPROD, V58, P963, DOI 10.1095/biolreprod58.4.963	30	271	282	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23695	23698		10.1074/jbc.274.34.23695	http://dx.doi.org/10.1074/jbc.274.34.23695			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446126	hybrid			2022-12-25	WOS:000082110900005
J	Xu, J; Nakamura, MT; Cho, HP; Clarke, SD				Xu, J; Nakamura, MT; Cho, HP; Clarke, SD			Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids - A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; PROLIFERATOR-ACTIVATED RECEPTORS; ACETYL-COA CARBOXYLASE; RAT-LIVER; S14 GENE; INSULIN REGULATION; SYNTHASE PROMOTER; LIPID-METABOLISM; TRANSCRIPTION; CHOLESTEROL	Polyunsaturated fatty acids (PUFA) coordinately suppress the transcription of a wide array of hepatic lipogenic genes including fatty acid synthase (FAS) and acetyl-CoA carboxylase, Interestingly, the over-expression of sterol regulatory element binding protein-1 (SREBP-1) induces the expression of all of the enzymes suppressed by PUFA, This observation led us to hypothesize that PUFA coordinately inhibit lipogenic gene transcription by suppressing the expression of SREBP-1, Our initial studies revealed that the SREBP-1 and FAS mRNA contents of HepG2 cells were reduced by 20:4(n-6) in a dose-dependent manner (i.e. EC50 similar to 10 mu M), whereas 18:1(n-9) had no effect, Similarly, supplementing a fat-free, high glucose diet with oils rich in (n-6) or (n-3) PUFA reduced the hepatic content of precursor and nuclear SREBP-1 60 and 85%, respectively; however, PUFA had no effect on the nuclear content of upstream stimulatory factor (USF)-1, The PUFA-dependent decrease in nuclear content of mature SREBP-1 was paralleled by a 70-90% suppression in FAS gene transcription. In contrast, dietary 18:1(n-9), i.e. triolein, had no inhibitory influence on the expression of SREBP-1 or FAS, The decrease in hepatic expression of SREBP-1 and FAS associated with PUFA ingestion was mimicked by supplementing the fat-free diet with the PPAR alpha-activator, WY 14,643. Interestingly, nuclear run-on assays revealed that changes in SREBP-1 mRNA abundance were not accompanied by changes in SREBP-1 gene transcription. These results support the concept that PUFA coordinately inhibit lipogenic gene transcription by suppressing the expression of SREBP-1 and that the PUFA regulation of SREBP-1 appears to occur at the post-transcriptional level.	Univ Texas, Div Nutr Sci, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Clarke, SD (corresponding author), Univ Texas, Div Nutr Sci, 115 Gearing, Austin, TX 78712 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052573, F32DK009723, R01DK053872] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53872, DK 09723, DK 52573] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTHOU L, 1995, EUR J BIOCHEM, V232, P179, DOI 10.1111/j.1432-1033.1995.tb20797.x; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; Clarke SD, 1997, PROSTAG LEUKOTR ESS, V57, P65, DOI 10.1016/S0952-3278(97)90494-4; Clarke SD, 1997, ANN NY ACAD SCI, V827, P178, DOI 10.1111/j.1749-6632.1997.tb51833.x; CLARKE SD, 1977, J NUTR, V107, P1170, DOI 10.1093/jn/107.7.1170; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; GEELEN MJH, 1995, J NUTR, V125, P2449; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1994, J LIPID RES, V35, P1076; JUMP DB, 1988, J BIOL CHEM, V263, P7254; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KATSURADA A, 1987, EUR J BIOCHEM, V168, P487, DOI 10.1111/j.1432-1033.1987.tb13443.x; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Latruffe N, 1997, BIOCHIMIE, V79, P81, DOI 10.1016/S0300-9084(97)81496-4; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; NESTEL PJ, 1990, ANNU REV NUTR, V10, P149, DOI 10.1146/annurev.nu.10.070190.001053; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; Power GW, 1997, J NUTR, V127, P2142, DOI 10.1093/jn/127.11.2142; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Schoonjans K, 1996, J LIPID RES, V37, P907; Sessler AM, 1996, J BIOL CHEM, V271, P29854, DOI 10.1074/jbc.271.47.29854; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; Thuillier P, 1998, J LIPID RES, V39, P2329; TOUSSANT MJ, 1981, J NUTR, V111, P146, DOI 10.1093/jn/111.1.146; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; Waters KM, 1997, BBA-LIPID LIPID MET, V1349, P33, DOI 10.1016/S0005-2760(97)00069-6; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	44	363	376	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23577	23583		10.1074/jbc.274.33.23577	http://dx.doi.org/10.1074/jbc.274.33.23577			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438539	hybrid			2022-12-25	WOS:000082012800089
J	Khoo, US; Ozcelik, H; Cheung, ANY; Chow, LWC; Ngan, HYS; Done, SJ; Liang, ACT; Chan, VWY; Au, GKH; Ng, WF; Poon, CSP; Leung, YF; Loong, F; Ip, P; Chan, GSW; Andrulis, IL; Lu, J; Ho, FCS				Khoo, US; Ozcelik, H; Cheung, ANY; Chow, LWC; Ngan, HYS; Done, SJ; Liang, ACT; Chan, VWY; Au, GKH; Ng, WF; Poon, CSP; Leung, YF; Loong, F; Ip, P; Chan, GSW; Andrulis, IL; Lu, J; Ho, FCS			Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer	ONCOGENE			English	Article						BRCA1; somatic mutations; breast cancer; ovarian cancer; Chinese	EXPRESSION; GERMLINE; TUMOR	Inherited mutations in the BRCA1 gene confer increased susceptibility to breast and ovarian cancer. Its role in sporadic carcinogenesis is not well defined. Somatic mutations in breast cancers have not been reported and to date there are only three reports of somatic mutations in sporadic ovarian cancers. To investigate the contribution of BRCA1 mutations to sporadic breast and ovarian cancer in the Chinese population, we analysed 62 samples from Chinese women using the protein truncation test. There were 40 cases of breast cancer under age 50 and 22 cases of ovarian cancer, all unselected for family history. There was no age selection for the ovarian cancers. We found two somatic BRCA1 mutations in exon 11, one in a breast cancer and the other in an ovarian cancer, both of which result in truncated proteins. Our results indicate that somatic BRCA1 mutations, like somatic mutations in the BRCA2 gene, though very rare, can be found in both breast and ovarian cancers and support a tumor suppressor function for BRCA1 in sporadic tumors.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Peoples R China; Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Obstet & Gynecol, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Radiat Therapy & Oncol, Hong Kong, Peoples R China; Ruttonjee Hosp, Dept Pathol, Hong Kong, Peoples R China; Pamela Youde Nethersole Hosp, Dept Pathol, Hong Kong, Peoples R China; Jockey Club Polyclin, Inst Pathol, Hong Kong, Peoples R China; CCO, Div Prevent Oncol, Toronto, ON M5G 2L7, Canada; Monash Univ, Dept Pathol & Immunol, Melbourne, Vic 3004, Australia	University of Hong Kong; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Hong Kong; University of Hong Kong; University of Hong Kong; Pamela Youde Nethersole Eastern Hospital; Monash University	Khoo, US (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam Rd, Hong Kong, Peoples R China.		Poon, Chi Sun/H-4152-2015; Ip, Philip/AAV-5995-2021; Khoo, Ui Soon/C-1345-2014; Khoo, Ui Soon/C-4293-2009; Khoo, Ui Soon/K-2041-2019; Ozcelik, Hilmi/A-3952-2011; Andrulis, Irene L./E-7267-2013; Cheung, Annie Nga Yin/C-4231-2009	Ip, Philip/0000-0002-0493-9838; Khoo, Ui Soon/0000-0003-2200-7505; Khoo, Ui Soon/0000-0003-2200-7505; Ngan, Hextan Y S/0000-0003-3945-159X; Cheung, Annie Nga Yin/0000-0002-1584-7568; Done, Susan/0000-0002-1770-988X				Berchuck A, 1998, CLIN CANCER RES, V4, P2433; Foster KA, 1996, CANCER RES, V56, P3622; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Katagiri T, 1996, HUM MUTAT, V7, P334, DOI 10.1002/(SICI)1098-1004(1996)7:4<334::AID-HUMU7>3.0.CO;2-8; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; Ozcelik H, 1998, INT J CANCER, V77, P1; Ozcelik H, 1996, HUM GENET, V98, P310, DOI 10.1007/s004390050212; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Szabo CI, 1997, AM J HUM GENET, V60, P1013; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Weber BHF, 1996, AM J HUM GENET, V59, P962	16	58	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4643	4646		10.1038/sj.onc.1202847	http://dx.doi.org/10.1038/sj.onc.1202847			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467410				2022-12-25	WOS:000082018600015
J	Wang, WX; Abbruzzese, JL; Evans, DB; Chiao, PJ				Wang, WX; Abbruzzese, JL; Evans, DB; Chiao, PJ			Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA	ONCOGENE			English	Article						urokinase-type plasminogen activator; NF-kappa B; pancreatic adenocarcinoma	NF-KAPPA-B; HEPATOCYTE GROWTH-FACTOR; PHORBOL ESTER INDUCTION; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; HA-RAS; CELLS; ALPHA; ONCOGENE	The Rel/NF-kappa-B transcription factors regulate the expression of many genes. The activity of RelA, a member of the Rel/NF-kappa B transcription factor family, is constitutively activated in the majority of pancreatic adenocarcinomas and cell lines. We report that the urokinase-type plasminogen activator (uPA), one of the critical proteases involved in tumor invasion and metastasis, is overexpressed in pancreatic tumor cells and its overexpression is induced by constitutive RelA activity. The uPA promoter contains an NF-kappa B binding site that directly mediates the induction of uPA expression by RelA. Expression of a dominant-negative I kappa B alpha mutant inhibits kappa B site-dependent transcriptional activation of a uPA promoter-CAT reporter gene. Treating the pancreatic tumor cell lints with the known NF-kappa B inhibitors, dexamethasone and n-tosylphenyalanine chloromethyl ketone (TPCK), abolishes constitutive RelA activity and uPA overexpression, These results show that uPA is one of the downstream target genes induced by constitutively activated RelA in human pancreatic tumor cells, and suggests that constitutive RelA activity may play a critical role in tumor invasion and metastasis. Inhibition of constitutive RelA in pancreatic tumor cells may reduce their invasive and metastatic potential.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol & Tumor Biol, Box 107,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA073675] Funding Source: NIH RePORTER; NCI NIH HHS [CA71836-01, CA73675-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BELL SM, 1990, J BIOL CHEM, V265, P1333; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; Besser D, 1995, ONCOGENE, V11, P2383; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BLASI F, 1990, SEMIN CANCER BIOL, V2, P117; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDONCARDO C, 1994, CANCER RES, V51, P6372; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIGIUSEPPE JA, 1996, ADV ANAT PATHOL, V3, P139; DUFFY MJ, 1990, CANCER RES, V50, P6827; GHERSA P, 1992, J BIOL CHEM, V267, P19226; Gilmore TD, 1996, ONCOGENE, V13, P1367; Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216; Gogly B, 1998, ANAL BIOCHEM, V255, P211, DOI 10.1006/abio.1997.2318; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HARVEY SR, 1988, CLIN EXP METASTAS, V6, P431, DOI 10.1007/BF01784375; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Jankun J, 1997, CANCER RES, V57, P559; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Lengye E, 1995, ONCOGENE, V11, P2639; LENGYEL E, 1995, BBA-MOL CELL RES, V1268, P65, DOI 10.1016/0167-4889(95)00050-3; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LU D, 1991, ONCOGENE, V6, P1235; MARKSITZER R, 1995, J BIOL CHEM, V270, P21833, DOI 10.1074/jbc.270.37.21833; Mars WM, 1996, CANCER RES, V56, P2837; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE BE, 1988, MUTAT RES, V195, P79, DOI 10.1016/0165-1110(88)90016-4; MURDOCH GH, 1982, NATURE, V300, P192, DOI 10.1038/300192a0; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; POLLANEN J, 1991, ADV CANCER RES, V57, P273; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rosewicz S, 1997, LANCET, V349, P485; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Sinicrope FA, 1996, CLIN CANCER RES, V2, P2015; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TESTA JE, 1989, INT J CANCER, V43, P816, DOI 10.1002/ijc.2910430513; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wang WX, 1999, CLIN CANCER RES, V5, P119; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; WEINEL RJ, 1995, GASTROENTEROLOGY, V108, P523, DOI 10.1016/0016-5085(95)90082-9; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x	75	143	147	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4554	4563		10.1038/sj.onc.1202833	http://dx.doi.org/10.1038/sj.onc.1202833			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467400				2022-12-25	WOS:000082018600005
J	Yang, XL; Pater, A; Tang, SC				Yang, XL; Pater, A; Tang, SC			Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants	ONCOGENE			English	Article						BAG-1; promoter; mutant p53; transactivation	APOPTOTIC PROTEIN BAG-1; HUMAN HSP70 PROMOTER; BAX GENE; NEGATIVE REGULATOR; DNA METHYLATION; SUPPRESSOR P53; CANCER-CELLS; EXPRESSION; BCL-2; MUTATIONS	BAG-1 is an anti-apoptotic protein that interacts with Bcl-2, BcL-X-L, Hsp70/Hsc70, Raf-1 and numerous hormone or growth factor receptors, Recently, BAG-1 has been found to be overexpressed in a variety of human cancer cell lines and some tumors. However, the molecular mechanism of BAG-1 upregulation is still unclear. In this study, me cloned 0.9 kb of human genomic DNA, BGEV, 5' flanking the BAG-1 open reading frame. BGEV subcloned into a promoterless luciferase reporter vector conferred high promoter activity in various human cancer cell lines. Deletion analysis of this sequence localized the region of maximal BAG-1 promoter activity from nucleotide positions -353 to -54, upstream of the first start codon CTG. Sequence analysis of the BAG-1 promoter region showed the absence of a TATA box but identified a CCAAT box, several GC boxes, a CpG island and several transcriptional factor binding sites, which may be important in the regulation of BAG-1 transcription. Most importantly, functional characterization of the BAG-1 promoter in vivo demonstrated that gain-of-function p53 mutants derived from human tumors upregulated the transcription of BAG-1 RNA and the expression of a reporter gene from the BAG-1 promoter. These results indicated that me have isolated the functional constitutive BAG-1 promoter. Furthermore, the data suggested that overexpression of BAG-1 in some tumors may be due to upregulation of the human BAG-1 promoter by mutant p53.	Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, St Johns, NF A1B 3V6, Canada; Newfoundland Canc Treatment & Res Fdn, Dr H Bliss Murphy Canc Ctr, St Johns, NF A1B 3V6, Canada	Memorial University Newfoundland	Yang, XL (corresponding author), Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, 300 Prince Philip Dr, St Johns, NF A1B 3V6, Canada.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Baylin SB, 1998, ADV CANCER RES, V72, P141; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Grillot DAM, 1997, J IMMUNOL, V158, P4750; HALDAR S, 1994, CANCER RES, V54, P2095; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hirose Y, 1997, MOL CARCINOGEN, V19, P25, DOI 10.1002/(SICI)1098-2744(199705)19:1<25::AID-MC4>3.0.CO;2-M; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IKEGAKI N, 1994, CANCER RES, V54, P6; Ji CH, 1996, J CELL BIOCHEM, V63, P478; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; ORRENIUS S, 1995, J INTERN MED, V237, P529, DOI 10.1111/j.1365-2796.1995.tb00881.x; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yang XL, 1997, J CELL BIOCHEM, V66, P309, DOI 10.1002/(SICI)1097-4644(19970901)66:3<309::AID-JCB4>3.3.CO;2-Y; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	44	50	53	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4546	4553		10.1038/sj.onc.1202843	http://dx.doi.org/10.1038/sj.onc.1202843			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467399				2022-12-25	WOS:000082018600004
J	Benbow, U; Schoenermark, MP; Mitchell, TI; Rutter, JL; Shimokawa, K; Nagase, H; Brinckerhoff, CE				Benbow, U; Schoenermark, MP; Mitchell, TI; Rutter, JL; Shimokawa, K; Nagase, H; Brinckerhoff, CE			A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMELYSIN GENE-EXPRESSION; TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; RETINOIC ACID; HUMAN FIBROBLASTS; POOR-PROGNOSIS; ALL-TRANS; TUMOR; CANCER; METASTASIS	Along with degradation of type TV collagen in basement membrane, destruction of the stromal collagens, types I and III, is an essential step in the invasive/metastatic behavior of tumor cells, and it is mediated, at least in part, by interstitial collagenase 1 (matrix metalloproteinase 1 (MMP-1)), Because A2058 melanoma cells produce substantial quantities of MMP-1, we used these cells as models for studying invasion of type I collagen, With a sensitive and quantitative in vitro invasion assay, we monitored the ability of these cells to invade a matrix of type I collagen and the ability of a serine proteinase inhibitor and all-trans-retinoic acid to block invasion. Although these cells produce copious amounts of MMP-1, they do not invade collagen unless they are cocultured with fibroblasts or with conditioned medium derived from fibroblasts. Our studies indicate that a proteolytic cascade that depends on stromal/tumor cell interactions facilitates the ability of A2058 melanoma cells to invade a matrix of type I collagen. This cascade activates latent MMP-1 and involves both serine proteinases and MMPs, particularly stromelysin 1 (MMP-3). All-trans-retinoic acid (10(-6) M) suppresses the invasion of tumor cells by several mechanisms that include suppression of MMP synthesis and an increase in levels of tissue inhibitor of metalloproteinases 1 and 2. We conclude that invasion of stromal collagen by A2058 melanoma cells is mediated by a novel host/tumor cell interaction in which a proteolytic cascade culminates in the activation of pro-MMP-1 and tumor cell invasion.	Dartmouth Med Sch, Dept Med, Hanover, NH 03755 USA; Dartmouth Med Sch, Dept Pharmacol Toxicol, Hanover, NH 03755 USA; Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Univ Kansas, Med Ctr, Dept Biochem, Kansas City, KS 66160 USA	Dartmouth College; Dartmouth College; Dartmouth College; University of Kansas; University of Kansas Medical Center	Brinckerhoff, CE (corresponding author), Dartmouth Med Sch, Dept Med, Hanover, NH 03755 USA.			Rutter, Joni/0000-0002-6502-2361	NATIONAL CANCER INSTITUTE [R01CA077267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026599, R01AR039189, R37AR026599] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77267] Funding Source: Medline; NIAMS NIH HHS [AR39189, AR-26599] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Benbow U, 1999, CLIN CANCER RES, V5, P203; Benbow U, 1996, J BIOL CHEM, V271, P10715, DOI 10.1074/jbc.271.18.10715; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; DELANY AM, 1992, J CELL BIOCHEM, V50, P400, DOI 10.1002/jcb.240500409; Durko M, 1997, BBA-MOL CELL RES, V1356, P271, DOI 10.1016/S0167-4889(97)00004-9; Gogly B, 1998, ANAL BIOCHEM, V255, P211, DOI 10.1006/abio.1997.2318; GOSLEN JB, 1985, J INVEST DERMATOL, V85, P161, DOI 10.1111/1523-1747.ep12276589; Guo HM, 1997, J BIOL CHEM, V272, P24; Heppner KJ, 1996, AM J PATHOL, V149, P273; HIMELSTEIN BP, 1994, J CELL SCI, V107, P477; JAMES TW, 1993, J CELL PHYSIOL, V157, P426, DOI 10.1002/jcp.1041570227; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; LIOTTA LA, 1989, CANCER PRINCIPLES PR, V1, P98; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MACKAY AR, 1992, INVAS METAST, V12, P168; Martorana AM, 1998, CANCER RES, V58, P4970; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; MORTON DL, 1997, CANC MED, P2467; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; Murray GI, 1998, J PATHOL, V185, P256; Nagase H, 1997, BIOL CHEM, V378, P151; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; PAN LY, 1995, J CELL BIOCHEM, V57, P575, DOI 10.1002/jcb.240570402; Parsons SL, 1997, BRIT J SURG, V84, P160, DOI 10.1002/bjs.1800840206; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; RIGEL DS, 1991, DERMATOL CLIN, V9, P631; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Schonermark MP, 1997, NAT MED, V3, P1167, DOI 10.1038/nm1097-1167; STAHL A, 1994, CANCER RES, V54, P3066; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; Suzuki K, 1998, BIOL CHEM, V379, P185, DOI 10.1515/bchm.1998.379.2.185; TEMPLETON NS, 1990, CANCER RES, V50, P5431; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; WRIGHT JK, 1991, BIOCHIM BIOPHYS ACTA, V1133, P25, DOI 10.1016/0167-4889(91)90237-R; Yoshizaki T, 1997, CANCER, V79, P139, DOI 10.1002/(SICI)1097-0142(19970101)79:1<139::AID-CNCR20>3.0.CO;2-4	44	86	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25371	25378		10.1074/jbc.274.36.25371	http://dx.doi.org/10.1074/jbc.274.36.25371			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464264	hybrid			2022-12-25	WOS:000082554200029
J	Carraway, CAC; Carvajal, ME; Carraway, KL				Carraway, CAC; Carvajal, ME; Carraway, KL			Association of the Ras to mitogen-activated protein kinase signal transduction pathway with microfilaments - Evidence for a p185(neu)-containing cell surface signal transduction particle linking the mitogenic pathway to a membrane-microfilament association site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; GROWTH-FACTOR RECEPTORS; SIALOMUCIN COMPLEX; MAMMARY ADENOCARCINOMA; GLYCOPROTEIN COMPLEX; SH3 DOMAINS; ASCITES ADENOCARCINOMA; MOLECULAR-CLONING; ADAPTER PROTEIN	Microvilli of the aggressive 13762 ascites mammary adenocarcinoma contain a large, microfilament-associated signal transduction particle whose scaffolding is a stable glycoprotein complex (Li. Y., Hua. F., Carraway, K. L., and Carraway, C. A. C. (1999) J. Biol, Chem, 274, 25651-25658) associated with the growth factor receptor p185(neu). The receptor is constitutively tyrosine-phosphorylated in the cells and microvilli, predicting that it should recruit mitogenic pathway components to this membrane-microfilament interaction site. Immunoprecipitation of cell lysates with anti-phosphotyrosine and immunoblotting showed phosphorylated forms of the mitogenic pathway proteins Shc and MAPK in addition to p185(neu), Suggesting that the Ras to MAPK mitogenic pathway is activated. Immunoblotting of p185(neu) containing microvillar fractions revealed the presence in each of stably associated She, Grb-2, Sos, Ras, Raf, mitogen-activated protein kinase kinase, and mitogen-activated protein kinase/extracellular signal-regulated kinase, as well as the transcription factor-phosphorylating kinase Rsk, All of these pathway components coimmunoprecipitated with p185(neu) from cleared lysates of microvilli solubilized under microfilament-depolymerizing conditions, The recruitment of constitutively phosphorylated p185(neu) and the activated mitogenic pathway proteins to this membrane-microfilament interaction site provides a physical model for integrating the assembly of the mitogenic pathway with the transmission of growth factor signal to the cytoskeleton, This linkage is probably a requisite step in the global. cytoskeleton remodeling accompanying mitogenesis.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, CAC (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, R-629, Miami, FL 33101 USA.				NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033795] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72074] Funding Source: Medline; NIGMS NIH HHS [GM 33795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; Carraway C. A. C., 1996, TREATISE CYTOSKELETO, V2; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY CAC, 1985, EXP CELL RES, V161, P150, DOI 10.1016/0014-4827(85)90499-9; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1991, J BIOL CHEM, V266, P16238; CARRAWAY CAC, 1985, EXP CELL RES, V157, P71, DOI 10.1016/0014-4827(85)90153-3; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1982, J CELL BIOL, V94, P624, DOI 10.1083/jcb.94.3.624; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; CARRAWAY KL, 1998, SIGNAL TRANSDUCTION; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DEPOTTER CR, 1993, CLIN EXP METASTAS, V11, P453, DOI 10.1007/BF00054936; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; Downward J, 1996, CANCER SURV, V27, P87; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; Huang JQ, 1999, ONCOGENE, V18, P4099, DOI 10.1038/sj.onc.1202779; HUGGINS JW, 1980, BIOCHIM BIOPHYS ACTA, V127, P31; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; JANES PW, 1994, ONCOGENE, V9, P3601; JUANG SH, 1994, J BIOL CHEM, V269, P15067; Juang SH, 1996, ONCOGENE, V12, P1033; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li YQ, 1999, J BIOL CHEM, V274, P25651, DOI 10.1074/jbc.274.36.25651; LIU YC, 1989, J BIOL CHEM, V264, P1208; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARUTA H, 1994, BIOESSAYS, V16, P489, DOI 10.1002/bies.950160708; McNeer RR, 1998, J CELL PHYSIOL, V176, P110, DOI 10.1002/(SICI)1097-4652(199807)176:1<110::AID-JCP13>3.3.CO;2-U; McNeer RR, 1998, BIOCHEM J, V330, P737, DOI 10.1042/bj3300737; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEUNG Y, 1996, THESIS U MIAMI; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUEN KL, 1995, ONCOGENE, V11, P825; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; VANDERPUYE OA, 1988, EXP CELL RES, V178, P211, DOI 10.1016/0014-4827(88)90392-8; VOTJEK AB, 1993, CELL, V74, P205; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WIEGANT FAC, 1986, J CELL BIOL, V103, P87, DOI 10.1083/jcb.103.1.87; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YU DH, 1994, CANCER RES, V54, P3260; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	90	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25659	25667		10.1074/jbc.274.36.25659	http://dx.doi.org/10.1074/jbc.274.36.25659			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464302	hybrid			2022-12-25	WOS:000082554200066
J	Iordanov, MS; Magun, BE				Iordanov, MS; Magun, BE			Different mechanisms of c-Jun NH2-terminal kinase-1 (JNK1) activation by ultraviolet-B radiation and by oxidative stressors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; N-ACETYLCYSTEINE; HYDROGEN-PEROXIDE; RIBOTOXIC STRESS; SIGNAL-TRANSDUCTION; CELLULAR-RESPONSE; MAMMALIAN-CELLS; UVB IRRADIATION; ARSENITE; FIBROBLASTS	Irradiation of mammalian cells with ultraviolet-B radiation (UV-B) triggers the activation of a group of stress-activated protein kinases known as c-Jun NH2-terminal kinases (JNKs), UV-B activates JNKs via UV-B-induced ribotoxic stress. Because oxidative stress also activates JNKs, we have addressed the question of whether the ribotoxic and the oxidative stress responses are mechanistically similar. The pro-oxidants sodium arsenite, cadmium chloride, and hydrogen peroxide activated JNK1 with slow kinetics, whereas UV-B potentiated the activity of JNK1 rapidly. N-acetyl cysteine (a scavenger of reactive oxygen intermediates) abolished the ability of all oxidative stressors tested to activate JNK1, but failed to affect the activation of JNK1 by UV-B or by another ribotoxic stressor, the antibiotic anisomycin. In contrast, emetine, an inhibitor of the ribotoxic stress response, was unable to inhibit the activation of JNK1 by oxidative stressors, Although UV-A and long wavelength UV-B are the spectral components of the ultraviolet solar radiation that cause significant oxidative damage to macromolecules, the use of a filter to eliminate the radiation output from wavelengths below 310 nm abolished the activation of JNK1 by UV. Our results are consistent with the notion that UV-B and oxidative stressors trigger the activation of JNK1 through different signal transduction pathways.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University	Magun, BE (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA.				NATIONAL CANCER INSTITUTE [R01CA039360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008456] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39360] Funding Source: Medline; NIEHS NIH HHS [ES-08456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Adler V, 1996, CARCINOGENESIS, V17, P2073, DOI 10.1093/carcin/17.9.2073; APPLEGATE LA, 1991, CANCER RES, V51, P974; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Carbonare M. Dalle, 1992, J PHOTOCH PHOTOBIO B, V14, P105; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dhar V, 1996, CELL GROWTH DIFFER, V7, P841; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Gillissen A, 1997, RES EXP MED, V196, P389, DOI 10.1007/s004330050049; Iordanov MS, 1998, J BIOL CHEM, V273, P15794, DOI 10.1074/jbc.273.25.15794; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Iordanov MS, 1998, J BIOL CHEM, V273, P3528, DOI 10.1074/jbc.273.6.3528; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JENNETTE KW, 1981, ENVIRON HEALTH PERSP, V40, P233, DOI 10.2307/3429236; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Masaki H, 1997, J DERMATOL SCI, V14, P207, DOI 10.1016/S0923-1811(96)00576-2; MASAKI H, 1995, BIOCHEM BIOPH RES CO, V206, P474, DOI 10.1006/bbrc.1995.1067; Matsuoka M, 1998, BIOCHEM BIOPH RES CO, V251, P527, DOI 10.1006/bbrc.1998.9487; MINERS JO, 1984, BIOCHEM PHARMACOL, V33, P2995, DOI 10.1016/0006-2952(84)90599-9; MOLDEUS P, 1986, RESPIRATION, V50, P31, DOI 10.1159/000195086; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SALA R, 1993, EUR RESPIR J, V6, P440; Shattuck KE, 1998, JPEN-PARENTER ENTER, V22, P228, DOI 10.1177/0148607198022004228; TAIRA J, 1992, J BIOCHEM-TOKYO, V111, P693, DOI 10.1093/oxfordjournals.jbchem.a123820; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WINSKI SL, 1995, J TOXICOL ENV HEALTH, V46, P379, DOI 10.1080/15287399509532043; YAN MH, 1994, NATURE, V372, P798; Zhang XS, 1997, PHOTOCHEM PHOTOBIOL, V65, P119, DOI 10.1111/j.1751-1097.1997.tb01886.x; Zhang XS, 1997, FREE RADICAL BIO MED, V23, P980, DOI 10.1016/S0891-5849(97)00126-3	36	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25801	25806		10.1074/jbc.274.36.25801	http://dx.doi.org/10.1074/jbc.274.36.25801			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464319	hybrid			2022-12-25	WOS:000082554200083
J	Li, CH; Hu, YH; Mayr, M; Xu, QB				Li, CH; Hu, YH; Mayr, M; Xu, QB			Cyclic strain stress-induced mitogen-activated protein kinase (MAPK) phosphatase 1 expression in vascular smooth muscle cells is regulated by Ras/Rac-MAPK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; ENDOTHELIAL-CELLS; MECHANICAL STRAIN; ANGIOTENSIN-II; SHEAR-STRESS; C-JUN; TRANSCRIPTION FACTOR; CAROTID ARTERIES; GENE-EXPRESSION; HYPERTENSION	Recently, we demonstrated that mechanical stress results in rapid phosphorylation or activation of platelet-derived growth factor receptors in vascular smooth muscle cells (VSMCs) followed by activation of mitogen-activated protein kinases (MAPKs) and AP-1 transcription factors (Hu, Y,, Beck, G,, Wick, G., and Xu, Q, (1998) FASEB J. 12, 1135-1142). Herein, we provide evidence that VSMC responses to mechanical stress also include induction of MAPK phosphatase-1 (MKP-1), which may serve as a negative regulator of MAPK signaling pathways. When rat VSMCs cultivated on a flexible membrane were subjected to cyclic strain stress (60 cycles/ min, 5-30% elongation), induction of MKP-1 proteins and mRNA was observed in time- and strength-dependent manners. Concomitantly, mechanical forces evoked rapid and transient activation of all three members of MAPKs, i.e. extracellular signal-regulated kinases (ERKs), c-Jun NH2-terminal protein kinases (JNKs), or stress-activated protein kinases (SAPKs), and p38 MAPKs. Suramin, a growth factor receptor antagonist, completely abolished ERK activation, significantly blocked MKP-1 expression, but not JNK/SAPKs and p38 MAPK activation, in response to mechanical stress. Interestingly, VSMC lines stably expressing dominant negative Ras (Ras N17) or Rac (Rac N17) exhibited a marked decrease in MKP-1 expression; the inhibition of ERK kinases (MEK1/2) by PD 98059 or of p38 MAPKs by SE 202190 resulted in a down-regulation of MKP-1 induction. Furthermore, overexpressing MKP-1 in VSMCs led to the dephosphorylation and inactivation of ERKs, JNKs/SAPKs, and p38 MAPKs and inhibition of DNA synthesis. Taken together, our findings demonstrate that mechanical stress induces MKP-1 expression regulated by two signal pathways, including growth factor receptor-Ras-ERK and Rac-JNK/SAPK or p38 MAPK, and that MKP-1 inhibits VSMC proliferation via MAPK inactivation. These results suggest that MKP-1 plays a crucial role in mechanical stress-stimulated signaling leading to VSMC growth and differentiation.	Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria	Austrian Academy of Sciences	Xu, QB (corresponding author), Austrian Acad Sci, Inst Biomed Aging Res, Rennweg 10, A-6020 Innsbruck, Austria.	qingbo.xu@oeaw.ac.at		Mayr, Manuel/0000-0002-0597-829X				BANES AJ, 1990, AM BIOTECHNOL LAB, V8, P12; Begum N, 1998, AM J PHYSIOL-CELL PH, V275, pC42, DOI 10.1152/ajpcell.1998.275.1.C42; Begum N, 1998, J BIOL CHEM, V273, P25164, DOI 10.1074/jbc.273.39.25164; BENES AJ, 1985, J CELL SCI, V75, P35; BHAGYALAKSHMI A, 1989, BIOCHEM BIOPH RES CO, V158, P31, DOI 10.1016/S0006-291X(89)80172-X; Bokemeyer D, 1998, HYPERTENSION, V32, P661, DOI 10.1161/01.HYP.32.4.661; Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cheng GC, 1997, CIRC RES, V80, P28, DOI 10.1161/01.RES.80.1.28; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cowan DB, 1998, CIRC RES, V82, P786, DOI 10.1161/01.RES.82.7.786; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DEBAKEY ME, 1985, ANN SURG, V201, P115; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DZAU VJ, 1994, HYPERTENSION, V23, P1132, DOI 10.1161/01.HYP.23.6.1132; Folkow B, 1995, J HYPERTENS, V13, P1546; Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hamada K, 1998, J BIOL CHEM, V273, P6334, DOI 10.1074/jbc.273.11.6334; HENRY JP, 1990, J HYPERTENS, V8, P783, DOI 10.1097/00004872-199009000-00001; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Hu YH, 1997, J BIOL CHEM, V272, P9113; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Koyama H, 1998, CIRC RES, V82, P713, DOI 10.1161/01.RES.82.6.713; KUCHAN MJ, 1993, AM J PHYSIOL, V264, pH150, DOI 10.1152/ajpheart.1993.264.1.H150; Kudoh S, 1998, J BIOL CHEM, V273, P24037, DOI 10.1074/jbc.273.37.24037; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lai KH, 1996, J CLIN INVEST, V98, P1560, DOI 10.1172/JCI118949; Li Q, 1998, J VASC RES, V35, P93, DOI 10.1159/000025570; Lille S, 1997, J SURG RES, V70, P178, DOI 10.1006/jsre.1997.5114; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Metzler B, 1998, J BIOL CHEM, V273, P33320, DOI 10.1074/jbc.273.50.33320; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Ohya Y, 1998, HYPERTENSION, V31, P254, DOI 10.1161/01.HYP.31.1.254; Okada M, 1998, ARTERIOSCL THROM VAS, V18, P894, DOI 10.1161/01.ATV.18.6.894; Park JM, 1998, AM J PHYSIOL-CELL PH, V275, pC1247, DOI 10.1152/ajpcell.1998.275.5.C1247; PATRICK CW, 1995, BLOOD PURIFICAT, V13, P112; PICKERING TG, 1988, BEHAV MED CARDIOVASC, P27; Pomerantz KB, 1997, BIOCHEMISTRY-US, V36, P9523, DOI 10.1021/bi963069l; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; Pyles JM, 1997, CIRC RES, V81, P904; Redmond EM, 1998, ARTERIOSCL THROM VAS, V18, P75, DOI 10.1161/01.ATV.18.1.75; Reusch HP, 1997, BIOCHEM BIOPH RES CO, V237, P239, DOI 10.1006/bbrc.1997.7121; Ross R., 1980, HDB PHYSL CARDIOVA 2, P69; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Songu-Mize E, 1998, AM J MED SCI, V316, P196, DOI 10.1097/00000441-199809000-00008; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THUBRIKAR MJ, 1995, ANN THORAC SURG, V59, P1594, DOI 10.1016/0003-4975(94)01037-D; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; VINTERS HV, 1987, DIABETES METAB, V13, P294; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; Xu QB, 1997, HYPERTENSION, V30, P106, DOI 10.1161/01.HYP.30.1.106; Xu QB, 1997, J CLIN INVEST, V100, P1089, DOI 10.1172/JCI119619; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; XU QB, 1995, CIRCULATION, V92, P1223, DOI 10.1161/01.CIR.92.5.1223; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; Yamazaki T, 1996, MOL CELL BIOCHEM, V164, P197, DOI 10.1007/BF00408658; Zou YP, 1998, INT J MOL MED, V1, P827	64	170	179	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25273	25280		10.1074/jbc.274.36.25273	http://dx.doi.org/10.1074/jbc.274.36.25273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464250	hybrid, Green Submitted			2022-12-25	WOS:000082554200015
J	Okamoto, I; Kawano, Y; Matsumoto, M; Suga, M; Kaibuchi, K; Ando, M; Saya, H				Okamoto, I; Kawano, Y; Matsumoto, M; Suga, M; Kaibuchi, K; Ando, M; Saya, H			Regulated CD44 cleavage under the control of protein kinase C, calcium influx, and the Rho family of small G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; ACTIN STRESS FIBERS; SMALL GTPASES; MDCK CELLS; GLYCOPROTEIN CD44; PUTATIVE TARGET; HYALURONIC-ACID; FOCAL ADHESIONS; KIT-LIGAND; RAC	CD44 is a cell surface receptor for several extracellular matrix components and is implicated in tumor cell invasion and metastasis. Our previous studies have shown that CD44 expressed in cancer cells is proteolytically cleaved at the extracellular domain through membrane-associated metalloproteases and that CD44 cleavage plays a critical role in CD44-mediated tumor cell migration (Okamoto, I., Kawano, Y., Tsuiki, H., Sasaki, J., Nakao, M., Matsumoto, M., Suga, M,, Ando, M., Nakajima, M., and Saya, H. (1999) Oncogene 18, 1435-1446). In the present study, we first demonstrate rapid degradation of the membrane-tethered CD44 cleavage product through intracellular proteolytic pathways, and it occurs only after CD44 extracellular cleavage. To address the mechanisms regulating CD44 cleavage at the extracellular domain, we show that 12-O-tetradecanoylphorbol 13-acetate (TPA) and the calcium ionophore ionomycin rapidly enhance metalloprotease-mediated CD44 cleavage in U251MG cells via protein kinase C-dependent and -independent pathways, respectively, suggesting the existence of multiple distinct pathways for regulation of CD44 cleavage. Concomitant with TPA-induced CD44 cleavage, TPA treatment induces redistribution of CD44 and ERM proteins (ezrin, radixin, and moesin) to newly generated membrane ruffling areas. Treatment with lysophosphatidic acid, which is known to activate the Rho-dependent pathway, inhibits TPA-induced CD44 redistribution and CD44 cleavage. Furthermore, overexpression of Rac dominant active mutants results in the redistribution of CD44 to the Rac-induced ruffling areas and the enhancement of CD44 cleavage, These results suggest that the Rho family proteins play a role in regulation of CD44 distribution and cleavage.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Internal Med 1, Kumamoto 8600811, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan	Kumamoto University; Kumamoto University; Nara Institute of Science & Technology	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BAZIL V, 1994, J IMMUNOL, V152, P1314; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Goebeler M, 1996, J CELL SCI, V109, P1957; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Miyake H, 1998, J UROLOGY, V160, P1562, DOI 10.1016/S0022-5347(01)62613-2; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Okada H, 1996, INT J CANCER, V66, P255, DOI 10.1002/(SICI)1097-0215(19960410)66:2<255::AID-IJC20>3.0.CO;2-A; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Svee K, 1996, J CLIN INVEST, V98, P1713, DOI 10.1172/JCI118970; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.0.CO;2-T; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; YEE NS, 1993, J BIOL CHEM, V268, P14189; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	50	87	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25525	25534		10.1074/jbc.274.36.25525	http://dx.doi.org/10.1074/jbc.274.36.25525			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464284	hybrid			2022-12-25	WOS:000082554200048
J	Parolini, I; Sargiacomo, M; Galbiati, F; Rizzo, G; Grignani, F; Engelman, JA; Okamoto, T; Ikezu, T; Scherer, PE; Mora, R; Rodriguez-Boulan, E; Peschle, C; Lisanti, MP				Parolini, I; Sargiacomo, M; Galbiati, F; Rizzo, G; Grignani, F; Engelman, JA; Okamoto, T; Ikezu, T; Scherer, PE; Mora, R; Rodriguez-Boulan, E; Peschle, C; Lisanti, MP			Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane - Retention of caveolin-2 at the level of the Golgi complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; GENE FAMILY; MUTATIONAL ANALYSIS; IN-VITRO; PROTEIN; RECEPTOR; DOMAINS; IDENTIFICATION; SIGNAL; VIP21-CAVEOLIN	Caveolins-1 and -2 are normally co-expressed, and they form a hetero-oligomeric complex in many cell types. These caveolin hetero-oligomers are thought to represent the assembly units that drive caveolae formation in vivo. However, the functional significance of the interaction between caveolins-1 and -2 remains unknown. Here, we show that caveolin-1 co-expression is required for the transport of caveolin-2 from the Golgi complex to the plasma membrane. We identified a human erythroleukemic cell line, K562, that expresses caveolin-2 but fails to express detectable levels of caveolin-1, This allowed us to stringently assess the effects of recombinant caveolin-1 expression on the behavior of endogenous caveolin-2, We show that expression of caveolin-1 in K562 cells is sufficient to reconstitute the de nov formation of caveolae in these cells. In addition, recombinant expression of caveolin-1 allows caveolin-2 to form high molecular mass oligomers that are targeted to caveolae-enriched membrane fractions. In striking contrast, in the absence of caveolin-1 expression, caveolin-2 forms low molecular mass oligomers that are retained at the level of the Golgi complex. Interestingly, we also show that expression of caveolin-1 in K562 cells dramatically up-regulates the expression of endogenous caveolin-2, Northern blot analysis reveals that caveolin-2 mRNA levels remain constant under these conditions, suggesting that the expression of caveolin-1 stabilizes the caveolin-2 protein. Conversely, transient expression of caveolin-2 in CHO cells is sufficient to up-regulate endogenous caveolin-1 expression. Thus, the formation of a hetero-oligomeric complex between caveolins-1 and -2 stabilizes the caveolin-2, protein product and allows caveolin-2 to be transported from the Golgi complex to the plasma membrane.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Ist Super Sanita, Dept Hematol Oncol, I-00161 Rome, Italy; Univ Perugia, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA; Cornell Univ, Dyson Vis Res Inst, Weill Med Coll, New York, NY 10021 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Istituto Superiore di Sanita (ISS); University of Perugia; Cleveland Clinic Foundation; Cornell University; Dyson; Jefferson University	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Lisanti, Michael P/C-6866-2013; Scherer, Philipp E/K-7819-2012; Galbiati, Ferruccio/AAF-3527-2020; parolini, Isabella/J-9955-2016; Grignani, Francesco/AAC-2565-2022; Lisanti, Michael/B-6131-2018	Scherer, Philipp E/0000-0003-0680-3392; parolini, Isabella/0000-0001-9863-1051; Lisanti, Michael/0000-0003-2034-1382; Ikezu, Tsuneya/0000-0002-3979-8596; Sargiacomo, Massimo/0000-0003-4040-706X	NCI NIH HHS [R01-CA-80250] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288, R01 GM034107] Funding Source: Medline; NIMH NIH HHS [MH-56036] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288, R01GM034107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH056036] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Borroto A, 1998, J BIOL CHEM, V273, P12807, DOI 10.1074/jbc.273.21.12807; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GRAEVE L, 1990, J BIOL CHEM, V265, P1216; Grignani F, 1998, CANCER RES, V58, P14; HELM R, 1995, NATURE, V373, P663; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SEVERS NJ, 1988, J CELL SCI, V90, P341; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P158; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255	41	179	183	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25718	25725		10.1074/jbc.274.36.25718	http://dx.doi.org/10.1074/jbc.274.36.25718			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464309	hybrid			2022-12-25	WOS:000082554200073
J	Buczek-Thomas, JA; Nugent, MA				Buczek-Thomas, JA; Nugent, MA			Elastase-mediated release of heparan sulfate proteoglycans from pulmonary fibroblast cultures - A mechanism for basic fibroblast growth factor (bFGF) release and attenuation of bFGF binding following elastase-induced injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; RAT LUNG FIBROBLASTS; EMPHYSEMA; GLYCOSAMINOGLYCANS; EXPRESSION; COLLAGEN; PROTEINS; REPAIR; MODEL; CELLS	We have investigated elastase-mediated alterations in the expression of basic fibroblast growth factor (bFGF) receptors and proteoglycan co-receptors and characterized the subsequent effects on bFGF receptor binding profiles. For these studies, pulmonary fibroblast cultures were treated with porcine pancreatic elastase, and elastase-mediated changes in bFGF receptor expression and binding profiles were assessed. Quantitation of [S-35]sulfate-labeled proteoglycan and total glycosaminoglycan release from fibroblast matrices indicated that elastase treatment released sulfated proteoglycan from the cell surface in a time- and dose-dependent fashion that correlated strongly with elastase-mediated bFGF release. Ligand binding studies indicated that elastase treatment decreased total binding of I-125-bFGF to the cell surface and affected both fibroblast growth factor receptor and heparan sulfate proteoglycan (HSPG) binding sites. Western blot analyses indicated that elastase treatment did not release significant amounts of fibroblast growth factor receptor protein. These findings indicate that elastase-mediated HSPG release from fibroblast matrices reduces the effective affinity of bFGF for its receptor. Collectively, these studies suggest that HSPG co-receptors are important mediators of the pulmonary fibroblast response to elastase treatment and that bFGF, HSPG, and other elastase-released entities play an important role in the response of the lung to chronic injury.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Nugent, MA (corresponding author), Boston Univ, Sch Med, Dept Biochem, 80 E Concord St, Boston, MA 02118 USA.			Buczek-Thomas, JoAnn/0000-0003-2784-9453; Nugent, Matthew/0000-0002-8630-4712	NHLBI NIH HHS [P01HL46902] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046902] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BRETTELL LM, 1994, AM J RESP CELL MOL, V10, P306, DOI 10.1165/ajrcmb.10.3.8117449; CAMPAGNONE R, 1987, LAB INVEST, V56, P224; CARDOSO WV, 1993, AM REV RESPIR DIS, V147, P975, DOI 10.1164/ajrccm/147.4.975; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Dowd CJ, 1999, J BIOL CHEM, V274, P5236, DOI 10.1074/jbc.274.8.5236; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Finlay GA, 1996, AM J PATHOL, V149, P1405; FOSTER JA, 1990, AM J PHYSIOL, V259, pL13, DOI 10.1152/ajplung.1990.259.2.L13; FOSTER JA, 1990, J BIOL CHEM, V265, P15544; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGOWAN SE, 1993, ARCH BIOCHEM BIOPHYS, V302, P322, DOI 10.1006/abbi.1993.1218; Morris SM, 1998, ANAT RECORD, V250, P397, DOI 10.1002/(SICI)1097-0185(199804)250:4<397::AID-AR2>3.0.CO;2-V; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RAABERG L, 1991, HISTOCHEMISTRY, V95, P471, DOI 10.1007/BF00315742; RAO NV, 1990, AM REV RESPIR DIS, V142, P407, DOI 10.1164/ajrccm/142.2.407; RAPRAEGER A, 1989, ANAL BIOCHEM, V179, P361, DOI 10.1016/0003-2697(89)90145-0; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; Rich CB, 1996, J BIOL CHEM, V271, P23043, DOI 10.1074/jbc.271.38.23043; ROSENBLOOM J, 1987, METHOD ENZYMOL, V144, P172; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; SNIDER GL, 1986, AM REV RESPIR DIS, V133, P149, DOI 10.1164/arrd.1986.133.1.149; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; VANDELEST CHA, 1995, EUR RESPIR J, V8, P238, DOI 10.1183/09031936.95.08020238; vanKuppevelt TH, 1997, AM J RESP CELL MOL, V16, P75, DOI 10.1165/ajrcmb.16.1.8998082; WALSH RL, 1991, CLIN SCI, V81, P341, DOI 10.1042/cs0810341; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	34	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25167	25172		10.1074/jbc.274.35.25167	http://dx.doi.org/10.1074/jbc.274.35.25167			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455199	hybrid			2022-12-25	WOS:000082193400098
J	Negrerie, M; Berka, V; Vos, MH; Liebl, U; Lambry, JC; Tsai, AL; Martin, JL				Negrerie, M; Berka, V; Vos, MH; Liebl, U; Lambry, JC; Tsai, AL; Martin, JL			Geminate recombination of nitric oxide to endothelial nitric-oxide synthase and mechanistic implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; MOLECULAR-DYNAMICS SIMULATION; L-ARGININE BINDING; CATALYTIC ACTIVITY; LIGAND DIFFUSION; HEME; MYOGLOBIN; CALMODULIN; SUBSTRATE; NO	The nitric-oxide synthase (NOS) catalyzes the oxidation of L-arginine to L-citrulline and NO through consumption of oxygen bound to the heme, Because NO is produced close to the heme and may bind to it, its subsequent role in a regulatory mechanism should be scrutinized. We therefore examined the kinetics of NO rebinding after photodissociation in the heme pocket of human endothelial NOS by means of time-resolved absorption spectroscopy. We show that geminate recombination of NO indeed occurs and that this process is strongly modulated by L-Arg, This NO rebinding occurs in a multiphasic fashion and spans over 3 orders of magnitude. In both ferric and ferrous states of the heme, a fast nonexponential picosecond geminate rebinding first takes place followed by a slower nanosecond phase. The rates of both phases decreased, whereas their relative amplitudes are changed by the presence of L-Arg; the overall effect is a slow down of NO rebinding, For the isolated oxygenase domain, the picosecond rate is unchanged, but the relative amplitude of the nanosecond binding decreased. We assigned the nanosecond kinetic component to the rebinding of NO that is still located in the protein core but not in the heme pocket. The implications for a mechanism of regulation involving NO binding are discussed.	Ecole Natl Super Tecn Avancees, Ctr Yvette, INSERM, U451, F-91761 Palaiseau, France; Univ Texas, Sch Med, Div Hematol, Houston, TX 77030 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; University of Texas System	Negrerie, M (corresponding author), Ecole Natl Super Tecn Avancees, Ctr Yvette, INSERM, U451, Chemin Huniere, F-91761 Palaiseau, France.	negrerie@enstay.ensta.fr	Negrerie, Michel/L-2283-2018	Negrerie, Michel/0000-0001-9918-031X; Lambry, Jean-Christophe/0000-0001-8264-0391; LIEBL, Ursula/0000-0003-0869-4388; Vos, Marten/0000-0003-0493-4831	NIGMS NIH HHS [GM44911] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Berka V, 1996, J BIOL CHEM, V271, P33293, DOI 10.1074/jbc.271.52.33293; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BRETTHORST GL, 1989, FUND THEOR, V36, P377; Carlson ML, 1996, BIOCHEMISTRY-US, V35, P1125, DOI 10.1021/bi951767k; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHEN PF, 1994, J BIOL CHEM, V269, P25062; Clague MJ, 1997, BIOCHEMISTRY-US, V36, P14465, DOI 10.1021/bi971024u; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; ELBER R, 1987, SCIENCE, V235, P318, DOI 10.1126/science.3798113; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; Hellermann GR, 1997, J BIOL CHEM, V272, P12030, DOI 10.1074/jbc.272.18.12030; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; Ignarro LJ, 1996, KIDNEY INT, pS2; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; KLATT P, 1993, J BIOL CHEM, V268, P14781; KUCZERA K, 1993, P NATL ACAD SCI USA, V90, P5805, DOI 10.1073/pnas.90.12.5805; LI HY, 1993, J BIOL CHEM, V268, P17908; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; LIVESEY AK, 1986, J CHEM PHYS, V84, P5102, DOI 10.1063/1.450663; Marin J, 1997, PHARMACOL THERAPEUT, V75, P111, DOI 10.1016/S0163-7258(97)00051-X; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARTIN JL, 1992, ANNU REV BIOPH BIOM, V21, P199, DOI 10.1146/annurev.bb.21.060192.001215; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; PERUTZ MF, 1966, J MOL BIOL, V21, P199, DOI 10.1016/0022-2836(66)90088-X; PETRICH JW, 1994, J MOL BIOL, V238, P437, DOI 10.1006/jmbi.1994.1302; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PRESS WH, 1988, NUMERICAL RECIPES C, P51; Presta A, 1997, NITRIC OXIDE-BIOL CH, V1, P74, DOI 10.1006/niox.1996.0110; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RodriguezCrespo I, 1996, ARCH BIOCHEM BIOPHYS, V336, P151, DOI 10.1006/abbi.1996.0543; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; SALERNO JC, 1995, J BIOL CHEM, V270, P27423, DOI 10.1074/jbc.270.46.27423; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; STEINBACH PJ, 1992, BIOPHYS J, V61, P235, DOI 10.1016/S0006-3495(92)81830-1; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Tsai AL, 1996, J BIOL CHEM, V271, P32563, DOI 10.1074/jbc.271.51.32563; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Zhang HQ, 1997, J MED CHEM, V40, P3869, DOI 10.1021/jm970550g	49	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24694	24702		10.1074/jbc.274.35.24694	http://dx.doi.org/10.1074/jbc.274.35.24694			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455137	hybrid			2022-12-25	WOS:000082193400036
J	Kim, BC; Lee, MN; Kim, JY; Lee, SS; Chang, JD; Kim, SS; Lee, SY; Kim, JH				Kim, BC; Lee, MN; Kim, JY; Lee, SS; Chang, JD; Kim, SS; Lee, SY; Kim, JH			Roles of phosphatidylinositol 3-kinase and Rac in the nuclear signaling by tumor necrosis factor-alpha in rat-2 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; KAPPA-B ACTIVATION; N-TERMINAL KINASE; ARACHIDONIC-ACID; TNF RECEPTOR; CELL-DEATH; C-FOS; TRANSDUCTION PATHWAYS; RHO; PROTEINS	We investigated the extent to which phosphatidylinositol S-kinase (PI 3-kinase) and Rac, a member of the Rho family of small GTPases, are involved in the signaling cascade triggered by tumor necrosis factor (TNF)-alpha leading to activation of c-fos serum response element (SRE) and c-Jun amino-terminal kinase (JNK) in Rat-a fibroblasts. Inhibition of PI 3-kinase by LY294002 or wortmannin, two specific PI 3-kinase antagonists, or co-transfection with a dominant negative mutant of PI 3-kinase dose-dependently blocked stimulation of c-fos SRE: by TNF-alpha. Similarly, LY294002 significantly diminished TNF-alpha-induced activation of JNK; suggesting that nuclear signaling triggered by TNF-alpha is dependent on PI S-kinase-mediated activation of both c-fos SRE and JNK We also found nuclear signaling by TNF-alpha to be Rac-dependent, as demonstrated by the inhibitory effect of transient co-transfection with a dominant negative Rac mutant, RacN17. Our findings suggest that Rac is situated downstream of PI 3-kinase in the TNF-alpha signaling pathway to the nucleus, and we conclude that PI 3-kinase and Rac each plays a pivotal role in the nuclear signaling cascade triggered by TNF-alpha.	Kwang Ju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Kyung Hee Univ, Sch Med, Dept Biol Mol, Seoul 130701, South Korea; Hallym Univ, Coll Med, Dept Orthoped Surg, Chunchon 200702, South Korea; Ewha Womans Univ, Coll Med, Ewha Biotechnol Inst, Seoul 120750, South Korea	Gwangju Institute of Science & Technology (GIST); Kyung Hee University; Hallym University; Ewha Womans University	Kim, JH (corresponding author), Kwang Ju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.	jkim@eunhasu.kjist.ac.kr	Kim, Jae-Hong/B-2530-2009; Kim, Sung Soo/S-2540-2017	Kim, Jae-Hong/0000-0002-8019-0208; Kim, Sung Soo/0000-0002-6817-7668				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kang I, 1998, EXP MOL MED, V30, P263, DOI 10.1038/emm.1998.39; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kim BC, 1997, BIOCHEM J, V326, P333, DOI 10.1042/bj3260333; Kim BC, 1998, MOL CELLS, V8, P90; Kim BC, 1998, BIOCHEM J, V330, P1009, DOI 10.1042/bj3301009; Kim JH, 1997, FEBS LETT, V406, P93, DOI 10.1016/S0014-5793(97)00249-4; KIMURA K, 1995, BIOSCI BIOTECH BIOCH, V59, P678, DOI 10.1271/bbb.59.678; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WONG GHW, 1992, J IMMUNOL, V149, P3350; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485	40	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24372	24377		10.1074/jbc.274.34.24372	http://dx.doi.org/10.1074/jbc.274.34.24372			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446216	hybrid			2022-12-25	WOS:000082110900095
J	Bachmann, C; Fischer, L; Walter, U; Reinhard, M				Bachmann, C; Fischer, L; Walter, U; Reinhard, M			The EVH2 domain of the vasodilator-stimulated phosphoprotein mediates tetramerization, F-actin binding, and actin bundle formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; MICROFILAMENT PROTEIN VASP; INTACT HUMAN PLATELETS; PROLINE-RICH MOTIFS; FOCAL-ADHESION; LISTERIA-MONOCYTOGENES; IN-VITRO; PHOSPHORYLATION; VINCULIN; MOTILITY	Vasodilator-stimulated phosphoprotein (VASP) is a member of the Ena/VASP family of proteins that are implicated in regulation of the actin cytoskeleton, All family members share a tripartite structural organization, comprising an N-terminal Ena/VASP homology (EVH) 1 domain, a more divergent proline-rich central part, and a common C-terminal EVH2 region of about 160-190 amino acids. Using chemical cross-linking, sucrose gradient sedimentation, and gel filtration analyses of different truncated VASP constructs, we demonstrate that the VASP EVH2 region is both necessary and sufficient for tetramerization. Moreover, co-sedimentation and fluorescent phalloidin staining showed that the EVH2 region binds and bundles F-actin in vitro and localizes to stress fibers in transfected cells. Analysis of the functional contribution of highly conserved blocks within this region indicated that residues 259-276 of human VASP are essential for the interaction with F-actin, whereas residues 343-380 are required for tetramerization, probably via coiled-coil formation, Interactions with F-actin are enhanced by VASP tetramerization, The results demonstrate that the C-terminal EVH2 segment is not only conserved in sequence but also forms a distinct functional entity. The data suggest that the EVH2 segment represents a novel oligomerization and F-actin binding domain.	Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, D-97078 Wurzburg, Germany	University of Wurzburg	Reinhard, M (corresponding author), Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, Versbacher Str 5, D-97078 Wurzburg, Germany.	Matthias.Reinhard@mail.uni-wuerzburg.de	Walter, ulrich/W-2478-2017; Reinhard, Martin/A-1006-2008	Walter, ulrich/0000-0001-6784-2307; Reinhard, Martin/0000-0002-7833-6175				ABEL A, 1996, EUR J CELL BIOL S42, V69, P39; Ahern-Djamali SM, 1999, P NATL ACAD SCI USA, V96, P4977, DOI 10.1073/pnas.96.9.4977; Ahern-Djamali SM, 1998, MOL BIOL CELL, V9, P2157, DOI 10.1091/mbc.9.8.2157; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; BUTT E, 1994, J BIOL CHEM, V269, P14509; Callebaut I, 1998, FEBS LETT, V441, P181, DOI 10.1016/S0014-5793(98)01541-5; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Dramsi S, 1998, ANNU REV CELL DEV BI, V14, P137, DOI 10.1146/annurev.cellbio.14.1.137; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1995, GENE DEV, V9, P251; Golsteyn RM, 1997, J CELL SCI, V110, P1893; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; JOCKUSCH BM, 1981, P NATL ACAD SCI-BIOL, V78, P3005, DOI 10.1073/pnas.78.5.3005; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Korneeva NL, 1996, EUR J CELL BIOL, V71, P351; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; OTTO JJ, 1994, CURR OPIN CELL BIOL, V6, P105, DOI 10.1016/0955-0674(94)90123-6; PISTOR S, 1994, EMBO J, V13, P758, DOI 10.1002/j.1460-2075.1994.tb06318.x; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REINHARD M, 1999, GUIDEBOOK CYTOSKELET, P168; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; WALTER U, 1993, ADV EXP MED BIOL, V344, P237; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7	52	230	237	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23549	23557		10.1074/jbc.274.33.23549	http://dx.doi.org/10.1074/jbc.274.33.23549			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438535	hybrid			2022-12-25	WOS:000082012800085
J	Lin, R; Cerione, RA; Manor, D				Lin, R; Cerione, RA; Manor, D			Specific contributions of the small GTPases Rho, Rac, and Cdc42 to Dbl transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; CELL-SHAPE CHANGES; INDEPENDENT PATHWAYS; SIGNALING PATHWAY; HUMAN ONCOGENE; NADPH OXIDASE; ACTIVATION; FAMILY; EXPRESSION; EFFECTOR	Dbl is a representative prototype of a growing family of oncogene products that contain the Dbl homology/ pleckstrin homology elements in their primary structures and are associated with a variety of neoplastic pathologies. Members of the Dbl family have been shown to function as physiological activators (guanine nucleotide exchange factors) of the Rho-like small GTPases. Although the expression of GTPase-defective versions of Rho proteins has been shown to induce a transformed phenotype under different conditions, their transformation capacity has been typically weak and incomplete relative to that exhibited by dbl-like oncogenes, Moreover, in some cases (e.g, NIH3T3 fibroblasts), expression of GTPase-defective Cdc42 results in growth inhibition. Thus, in attempting to reconstitute dbl-induced transformation of NIH3T3 fibroblasts, we have generated spontaneously activated ("fast-cycling") mutants of Cdc42, Rad, and RhoA that mimic the functional effects of activation by the Dbl oncoprotein, When stably expressed in NIH3T3 cells, all three mutants caused the loss of serum dependence and showed increased saturation density. Furthermore, all three stable cell lines were tumorigenic when injected into nude mice. Our data demonstrate that all three Dbl targets need to be activated to promote the full complement of Dbl effects. More importantly, activation of each of these GTP-binding proteins contributes to a different and distinct facet of cellular transformation.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University; Cornell University	Manor, D (corresponding author), Cornell Univ, Div Nutr Sci, Savage Hall,Rm 312, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Busca R, 1998, MOL BIOL CELL, V9, P1367, DOI 10.1091/mbc.9.6.1367; Bussey H, 1996, SCIENCE, V272, P224, DOI 10.1126/science.272.5259.224; CERIONE RA, 1996, CURR OPIN CELL BIOL, V8, P205; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; COOPER GM, 1995, ONCOGENES, P69; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; HALL A, 1986, J BIOL CHEM, V261, P963; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Leonard DA, 1998, J BIOL CHEM, V273, P16210, DOI 10.1074/jbc.273.26.16210; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1996, J MOL MED-JMM, V74, P563, DOI 10.1007/s001090050060; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; Pal E.F., 1989, NATURE, V341, P209; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; SELF AJ, 1993, ONCOGENE, V8, P655; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TEMIN HM, 1958, VIROLOGY, V6, P669, DOI 10.1016/0042-6822(58)90114-4; TOKSOZ D, 1994, ONCOGENE, V9, P621; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	67	154	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23633	23641		10.1074/jbc.274.33.23633	http://dx.doi.org/10.1074/jbc.274.33.23633			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438546	hybrid			2022-12-25	WOS:000082012800096
J	Reddy, UR; Basu, A; Bannerman, P; Ikegaki, N; Reddy, CD; Pleasure, D				Reddy, UR; Basu, A; Bannerman, P; Ikegaki, N; Reddy, CD; Pleasure, D			ZPK inhibits PKA induced transcriptional activation by CREB and blocks retinoic acid induced neuronal differentiation	ONCOGENE			English	Article						ZPK; CREB; NT2 differentiation	ZIPPER-BEARING KINASE; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; CELLS; FAMILY; PHOSPHORYLATION; IDENTIFICATION; PRODUCT; MEMBER; DNA	Zipper Protein Kinase (ZPK) is a leucine zipper protein localized to the nucleus which exhibits serine-threonine kinase activity and is associated with the stress dependent signal transduction pathway. ZPK forms heterodimers with leucine zipper containing transcription factors such as the cyclic AMP responsive element binding protein (CREB) and MSc. Furthermore ZPK phosphorylates both Myc and CREB. Overexpression of ZPK in NTera-2 human teratocarcinoma cells results in inhibition of PKA induced transcriptional activation by CREB and prevents retinoic acid induced differentiation of the cells to neurons. Our results suggest that ZPK stifles neural differentiation of NT-2 cells partly due to its inhibitory effect on CREB function.	Univ Penn, Childrens Hosp Philadelphia, Dept Neurol Res, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Oncol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Neurooncol, Philadelphia, PA 19104 USA; Wistar Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; The Wistar Institute	Reddy, UR (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Dept Neurol Res, Room 516F, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025044, P20NS031102, P50NS008075, P01NS008075] Funding Source: NIH RePORTER; NINDS NIH HHS [NS08075, NS31102, NS25044] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM I, 1991, J NEUROSCI RES, V28, P29, DOI 10.1002/jnr.490280104; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V3; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Cheung WMW, 1996, NEUROREPORT, V7, P1204, DOI 10.1097/00001756-199604260-00022; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARLOW E, 1988, ANTIOBODIES LAB MANU; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; REEDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STOCKSCHLAEDER MAR, 1991, HUM GENE THER, V2, P33, DOI 10.1089/hum.1991.2.1-33; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4	29	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4474	4484		10.1038/sj.onc.1202813	http://dx.doi.org/10.1038/sj.onc.1202813			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442638				2022-12-25	WOS:000081813500009
J	Cho, EJ; Buratowski, S				Cho, EJ; Buratowski, S			Evidence that transcription factor IIB is required for a post-assembly step in transcription initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; START SITE SELECTION; TATA-BINDING PROTEIN; WHOLE-CELL EXTRACT; N-TERMINAL REGION; FACTOR-TFIIB; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; COMPLEX-FORMATION; COACTIVATOR PC4	Mutation of glutamate 62 to lysine in yeast transcription factor (TF) IIB (Sua7) causes a cold-sensitive phenotype. This mutant also leads to preferential transcription of downstream start sites on some promoters in vivo. To explore the molecular nature of these phenotypes, the TFIIB E62K mutant was characterized in vitro. The mutant interacts with TATA-binding protein normally. In three different assays, the mutant can also interact with RNA polymerase II and recruit it and the other basal transcription factors to a promoter. Despite the ability to assemble a transcription complex, the TFIIB E62K protein is severely defective in transcription in vitro. Therefore, the role of TFIIB must be more than simply bridging TATA-binding protein and polymerase at the promoter. We propose that the region around Glu-62 in yeast TFIIB plays a role in start site selection, perhaps mediating a conformational change in the polymerase or the DNA during the search for initiation sites. This step may be related to the yeast-specific spacing between TATA elements and start sites since mutations of the corresponding glutamate in mammalian TFIIB do not produce a similar effect.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Buratowski, S (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Av, Boston, MA 02115 USA.		Cho, Eun-Jung/AAR-1785-2020	Cho, Eun-Jung/0000-0002-6610-5329	NIGMS NIH HHS [GM46498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046498, R01GM046498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; Bangur CS, 1997, MOL CELL BIOL, V17, P6784, DOI 10.1128/MCB.17.12.6784; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; FURTERGRAVES EM, 1991, MOL CELL BIOL, V11, P4121, DOI 10.1128/MCB.11.8.4121; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GUARENTE L, 1988, CELL, V52, P303, DOI 10.1016/S0092-8674(88)80020-5; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hawkes NA, 1999, J BIOL CHEM, V274, P14337, DOI 10.1074/jbc.274.20.14337; Henry NL, 1996, J BIOL CHEM, V271, P21842, DOI 10.1074/jbc.271.36.21842; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PINTO I, 1994, J BIOL CHEM, V269, P30569; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Shaw SP, 1996, MOL CELL BIOL, V16, P3651; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; Werten S, 1998, J MOL BIOL, V276, P367, DOI 10.1006/jmbi.1997.1534; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; Winston, 1992, TRANSCRIPTIONAL REGU, P1271; WOONTNER M, 1990, J BIOL CHEM, V265, P8979; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	50	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25807	25813		10.1074/jbc.274.36.25807	http://dx.doi.org/10.1074/jbc.274.36.25807			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464320	hybrid			2022-12-25	WOS:000082554200084
J	Paulson, M; Pisharody, S; Pan, L; Guadagno, S; Mui, AL; Levy, DE				Paulson, M; Pisharody, S; Pan, L; Guadagno, S; Mui, AL; Levy, DE			Stat protein transactivation domains recruit p300/CBP through widely divergent sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED-GENE FACTOR-3; TRANSCRIPTION FACTOR; DNA-BINDING; INTERFERON-ALPHA; TYROSINE PHOSPHORYLATION; ISGF-3 PROTEINS; ACTIVATION; INDUCTION; EXPRESSION; RECEPTOR	The signal transduction and activator of transcription (Stat) gene family has been highly conserved throughout evolution. Gene duplication and divergence has produced 7 mammalian Stat genes, each of which mediates a distinct process. While some Stat proteins are activated by multiple cytokines, Stat2 is highly specific for responses to type I interferon, We have cloned mouse Stat2 and found that while its sequence was more divergent from its human homologue than any other mouse-human Stat pairs, it was fully functional even in human cells. Overall sequence identity was only 69%, compared with 85-99% similarity for other Stab genes, and several individual domains that still served similar or identical functions in both species were even less well conserved. The coiled-coil domain responsible for interaction with IRF9 was only 65% identical and yet mouse Stat2 interacted with either human or mouse IRFS; the carboxyl terminus was only 30% identical and yet both regions functioned as equal transactivation domains. Both mouse and human transactivation domains recruited the p300/CBP coactivator and were equally sensitive to inhibition by adenovirus E1A protein. Interestingly, the Stat3 carboxyl terminus also functioned as a transactivator capable of recruiting p300/CBP, as does the Stat1 protein, although with widely differing potencies. Yet these proteins share no sequence similarity with Stat2, These data demonstrate that highly diverged primary sequences can serve similar or identical functions, and that the minimal regions of similarity between human and mouse Stat2 may define the critical determinants for function.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Zymed Labs, S San Francisco, CA 94080 USA; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA	New York University; New York University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Levy, DE (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.		Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788	NIAID NIH HHS [AI28900] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barillas-Mury C, 1999, EMBO J, V18, P959, DOI 10.1093/emboj/18.4.959; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Borovkov AY, 1997, BIOTECHNIQUES, V22, P812, DOI 10.2144/97225bm04; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Darnell JE, 1997, P NATL ACAD SCI USA, V94, P11767, DOI 10.1073/pnas.94.22.11767; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Garcia-Sastre A, 1998, J VIROL, V72, P8550; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUMAR R, 1995, EXP CELL RES, V216, P143, DOI 10.1006/excr.1995.1018; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LEVY DE, 1995, SEMIN VIROL, V6, P181, DOI 10.1006/smvy.1995.0023; Levy DE, 1998, METHODS, V15, P167, DOI 10.1006/meth.1998.0621; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Ohmori Y, 1998, J BIOL CHEM, V273, P29202, DOI 10.1074/jbc.273.44.29202; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; REICH N, 1988, J VIROL, V62, P114, DOI 10.1128/JVI.62.1.114-119.1988; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Routes JM, 1996, J IMMUNOL, V156, P1055; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Sugiyama T, 1996, FEBS LETT, V381, P191, DOI 10.1016/0014-5793(96)00121-4; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	54	182	187	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25343	25349		10.1074/jbc.274.36.25343	http://dx.doi.org/10.1074/jbc.274.36.25343			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464260	hybrid			2022-12-25	WOS:000082554200025
J	Renne, T; Dedio, J; Meijers, JCM; Chung, D; Muller-Esterl, W				Renne, T; Dedio, J; Meijers, JCM; Chung, D; Muller-Esterl, W			Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein - Evidence for a critical role of apple domain-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; COAGULATION-FACTOR-XI; HUMAN-ENDOTHELIAL-CELLS; 4 TANDEM REPEATS; HEAVY-CHAIN; FUNCTIONAL-PROPERTIES; CONTACT SYSTEM; FACTOR-IX; IDENTIFICATION; ACTIVATION	Plasma prekallikrein, a zymogen of the contact phase system, circulates in plasma as heterodimeric complex with H-kininogen. The binding is mediated by the prekallikrein heavy chain consisting of four apple domains, A1 to A4, to which H-kininogen binds with high specificity and affinity (K-D = 1.2 x 10(-8) M). Previous work had demonstrated that a discontinuous kininogen-binding site is formed by a proximal part located in Al, a distal part exposed by A4, and other yet unidentified portion(s) of the kallikrein heavy chain. To detect relevant binding segment(s) we recombinantly expressed single apple domains and found a rank order of binding affinity for kininogen of A2 > A4 approximate to A1 > A3, Removal of single apple domains in prekalikrein deletion mutants reduced kininogen binding by 21 (A1), 64 (A2), and 24% (A4), respectively, whereas deletion of A3 was without effect. Transposition of homologous A2 domain from prekallikrein to factor XI conferred high-affinity kininogen binding from the former to the latter. The principal role of A2 for H-kininogen docking to the prekallikrein heavy chain was further substantiated by the finding that cleavage of a single peptide bond in A2 drastically diminished the H-kininogen binding affinity. Furthermore, the epitope of monoclonal antibody PKH6 which blocks kallikrein-kininogen complex formation with an IC50 of 8 nM mapped to the center portion of domain A2, Our data indicate that domain A2 and two flanking sequence segments of A1 and A4 form a discontinuous binding platform for H-kininogen on the prekallikrein heavy chain. Domain-specific antibodies directed to these critical sites efficiently interfered with contact phase-induced bradykinin release from H-kininogen.	Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany; Univ Utrecht, Med Ctr, Dept Haematol, NL-3584 CX Utrecht, Netherlands; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Johannes Gutenberg University of Mainz; Utrecht University; University of Washington; University of Washington Seattle	Muller-Esterl, W (corresponding author), Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, Duesbergweg 6, D-55099 Mainz, Germany.	wme@mail.uni-mainz.de	Meijers, J.C.M./S-5981-2019	Meijers, J.C.M./0000-0002-4198-6780; Chung, Dominic/0000-0002-2645-5703; Renne, Thomas/0000-0003-4594-5975	NHLBI NIH HHS [HL16929] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; COCHRANE CG, 1979, AM J MED, V67, P657, DOI 10.1016/0002-9343(79)90253-5; COCHRANE CG, 1982, ADV IMMUNOL, V33, P241, DOI 10.1016/S0065-2776(08)60837-8; COLMAN RW, 1985, BLOOD, V65, P311; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; Dedio J, 1998, J IMMUNOL, V160, P3534; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; Gailani D, 1997, BLOOD, V90, P1055, DOI 10.1182/blood.V90.3.1055.1055_1055_1064; Gessi S, 1997, BRIT J PHARMACOL, V122, P1450, DOI 10.1038/sj.bjp.0701536; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; Gresele P, 1998, J CLIN INVEST, V101, P667, DOI 10.1172/JCI575; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HENDERSON LM, 1994, BLOOD, V84, P474; HERWALD H, 1993, J BIOL CHEM, V268, P14527; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Herwald H, 1996, J BIOL CHEM, V271, P13061, DOI 10.1074/jbc.271.22.13061; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCK J, 1990, J BIOL CHEM, V265, P12005; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hsu TC, 1998, J BIOL CHEM, V273, P13787, DOI 10.1074/jbc.273.22.13787; JOHANNESSEN M, 1990, THROMB HAEMOSTASIS, V63, P54; Kaplan A P, 1983, Adv Exp Med Biol, V156, P45; Kaplan AP, 1997, ADV IMMUNOL, V66, P225, DOI 10.1016/S0065-2776(08)60599-4; KAUFMANN J, 1993, J BIOL CHEM, V268, P9079; LENICH C, 1995, THROMB HAEMOSTASIS, V74, P698; Li CZ, 1996, EXP CELL RES, V226, P239, DOI 10.1006/excr.1996.0224; Linz W, 1996, DIABETES, V45, pS51, DOI 10.2337/diab.45.1.S51; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2050, DOI 10.1021/bi00222a007; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; NUIJENS JH, 1989, J BIOL CHEM, V264, P12941; PAGE JD, 1991, J BIOL CHEM, V266, P8143; PAGE JD, 1994, ARCH BIOCHEM BIOPHYS, V314, P159, DOI 10.1006/abbi.1994.1424; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; Schmaier AH, 1997, THROMB HAEMOSTASIS, V78, P101; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P471, DOI 10.1016/0022-1759(84)90015-2; VANDERGRAAF F, 1982, J BIOL CHEM, V257, P4300; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VOGEL R, 1990, J BIOL CHEM, V265, P12494; Wu HM, 1999, AM J PHYSIOL-HEART C, V276, pH535, DOI 10.1152/ajpheart.1999.276.2.H535	51	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25777	25784		10.1074/jbc.274.36.25777	http://dx.doi.org/10.1074/jbc.274.36.25777			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464316	hybrid			2022-12-25	WOS:000082554200080
J	Chadee, DN; Hendzel, MJ; Tylipski, CP; Allis, CD; Bazett-Jones, DP; Wright, JA; Davie, JR				Chadee, DN; Hendzel, MJ; Tylipski, CP; Allis, CD; Bazett-Jones, DP; Wright, JA; Davie, JR			Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PROTEIN-KINASE; C-FOS; CHROMATIN STRUCTURE; METASTATIC PHENOTYPE; NUCLEOSOMAL ARRAYS; PHORBOL ESTERS; 3T3 CELLS; EXPRESSION; ACETYLATION	When the Ras mitogen-activated protein kinase (MAPK) signaling pathway of quiescent cells is stimulated with growth factors or phorbol esters, the early response genes c-fos and c-myc are rapidly induced, and concurrently there is a rapid phosphorylation of histone H3, Using an antibody specific for phosphorylated Ser-10 of H3, we show that Ser-10 of H3 is phosphorylated, and we provide direct evidence that phosphorylated H3 is associated with c-fos and c-myc genes in stimulated cells. H3 phosphorylation may contribute to proto-oncogene induction by modulating chromatin structure and releasing blocks in elongation. Previously we reported that persistent stimulation of the Ras-MAPK signaling pathway in oncogene-transformed cells resulted in increased amounts of phosphorylated histone H1, Here we show that phosphorylated H3 is elevated in the oncogene-transformed mouse fibroblasts, Further we show that induction of ras expression results in a rapid increase in H3 phosphorylation. H3 phosphatase, identified as PP1, activities in ras-transformed and parental fibroblast cells were similar, suggesting that elevated H3 kinase activity was responsible for the increased level of phosphorylated H3 in the oncogene-transformed cells. Elevated levels of phosphorylated H1 and H3 may be responsible for the less condensed chromatin structure and aberrant gene expression observed in the oncogene-transformed cells.	Univ Manitoba, Fac Med, Dept Biochem & Mol Biol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Calgary, Fac Med, Dept Cell Biol & Anat, Calgary, AB T2N 4N1, Canada	University of Manitoba; University of Manitoba; University of Virginia; University of Calgary	Davie, JR (corresponding author), Univ Manitoba, Fac Med, Dept Biochem & Mol Biol, Winnipeg, MB R3E 0W3, Canada.		Hendzel, Michael/C-3391-2009	Hendzel, Michael/0000-0002-9603-7945; Davie, James/0000-0002-0420-6888	NIGMS NIH HHS [GM40922] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040922] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; CANO E, 1995, J CELL SCI, V108, P3599; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLOSI P, 1987, MOL ENDOCRINOL, V1, P767, DOI 10.1210/mend-1-11-767; DELCUVE GP, 1989, BIOCHEM J, V263, P179, DOI 10.1042/bj2630179; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FENG J, 1992, BIOCHIM BIOPHYS ACTA, V1130, P253, DOI 10.1016/0167-4781(92)90437-5; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALIOTIS T, 1990, INT J CANCER, V45, P1177, DOI 10.1002/ijc.2910450631; HANSEN JC, 1997, CHEMTRACTS BIOCH MOL, V10, P56; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Herrera RE, 1996, P NATL ACAD SCI USA, V93, P11510, DOI 10.1073/pnas.93.21.11510; Holth LT, 1998, INT J ONCOL, V13, P827; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Krajewski WA, 1998, P NATL ACAD SCI USA, V95, P1540, DOI 10.1073/pnas.95.4.1540; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Leuba SH, 1998, BIOPHYS J, V74, P2823, DOI 10.1016/S0006-3495(98)77989-5; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Moore SC, 1997, BIOCHEM BIOPH RES CO, V230, P136, DOI 10.1006/bbrc.1996.5903; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; Patton SE, 1998, CANCER RES, V58, P2253; Paulson JR, 1996, J CELL SCI, V109, P1437; Pinaud S, 1998, J MOL BIOL, V280, P785, DOI 10.1006/jmbi.1998.1905; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; ROCHA E, 1984, J BIOL CHEM, V259, P8558; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Smith ML, 1998, EXP CELL RES, V242, P235, DOI 10.1006/excr.1998.4078; TAYLOR SS, 1982, J BIOL CHEM, V257, P6056; Tse C, 1997, BIOCHEMISTRY-US, V36, P11381, DOI 10.1021/bi970801n; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; Walia H, 1998, J BIOL CHEM, V273, P14516, DOI 10.1074/jbc.273.23.14516	45	235	238	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24914	24920		10.1074/jbc.274.35.24914	http://dx.doi.org/10.1074/jbc.274.35.24914			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455166	hybrid			2022-12-25	WOS:000082193400065
J	Guo, ZK; Jensen, MD				Guo, ZK; Jensen, MD			Blood glycerol is an important precursor for intramuscular triacylglycerol synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; ADIPOSE-TISSUE; SKELETAL-MUSCLE; PLASMA GLYCEROL; GLUCOSE; INVIVO; RAT; QUANTIFICATION; METABOLISM; LIPOLYSIS	The utilization of blood glycerol and glucose as precursors for intramuscular triglyceride synthesis was examined in rats using an intravenous infusion of [2-C-14]glycerol and [6-H-3]glucose or [6-C-14]glucose. In 24-h fasted rats, more glycerol than glucose was incorporated into intramuscular triglyceride glycerol in soleus (69 +/- 23 versus 4 +/- 1 nmol/mu mol triglyceride/h, respectively, p = 0.02 glycerol versus glucose) and in gastrocnemius (25 +/- 5 versus 9 +/- 2 nmol/mu mol triglyceride/h, respectively, p = 0.02). Blood glucose was utilized more than blood glycerol for triglyceride glycerol synthesis in quadriceps, In fed rats, the blood glycerol incorporation rates (4 +/- 2, 8 +/- 3, and 9 +/- 3 nmol/mu mol triglyceride/h) were similar (p > 0.3) to those of glucose (5 +/- 2, 8 +/- 2, and 5 +/- 2 nmol/mu mol triglyceride/h for quadriceps, gastrocnemius, and soleus muscle, respectively). Glucose incorporation into intramuscular triglycerides was less with [6-H-3]glucose than with [6-C-14]glucose, suggesting an indirect pathway for glucose carbon entry into muscle triglyceride. The isotopic equilibrium between plasma and intramuscular free glycerol ([U-C-13]glycerol) was complete in quadriceps and gastrocnemius, but not soleus, within 2 h after beginning the tracer infusion. We conclude that blood glycerol is a direct and important precursor for muscle triglyceride synthesis in rats, confirming the presence of functionally important amounts of glycerol kinase in skeletal muscle.	Mayo Clin, Endocrine Res Unit, Rochester, MN 55905 USA	Mayo Clinic	Jensen, MD (corresponding author), Mayo Clin, Endocrine Res Unit, 5-194 Joseph, Rochester, MN 55905 USA.				NIDDK NIH HHS [DK40484, DK50456] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040484, R37DK040484, P30DK050456, R29DK040484] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEYLOT M, 1987, J LIPID RES, V28, P414; CHRISTIE WW, 1985, J LIPID RES, V26, P507; ELIA M, 1993, CLIN SCI, V84, P99, DOI 10.1042/cs0840099; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRAYN KN, 1980, J LIPID RES, V21, P139; GORSKI J, 1992, CAN J PHYSIOL PHARM, V70, P123, DOI 10.1139/y92-019; Guo ZK, 1998, J APPL PHYSIOL, V84, P1674, DOI 10.1152/jappl.1998.84.5.1674; GUO ZK, 1992, ANAL BIOCHEM, V204, P273, DOI 10.1016/0003-2697(92)90238-3; HARDING JW, 1975, BIOCHEM J, V148, P545, DOI 10.1042/bj1480545; HOLLOSZY JO, 1969, ARCH BIOCHEM BIOPHYS, V130, P653, DOI 10.1016/0003-9861(69)90083-6; HUMPHREYS SM, 1990, ANN CLIN BIOCHEM, V27, P597, DOI 10.1177/000456329002700613; Judd RL, 1998, J LIPID RES, V39, P1106; KURLAND IJ, 1989, FASEB J, V3, P2277, DOI 10.1096/fasebj.3.11.2673899; KURPAD A, 1994, CLIN SCI, V86, P177, DOI 10.1042/cs0860177; LANDAU BR, 1993, METABOLISM, V42, P457, DOI 10.1016/0026-0495(93)90103-U; MALTIN CA, 1989, AM J PHYSIOL, V257, pE823, DOI 10.1152/ajpendo.1989.257.6.E823; Mayes P. A., 1988, HARPERS BIOCH, P218; NEWSHOLME EA, 1969, BIOCHEM J, V112, P465, DOI 10.1042/bj1120465; NURJHAN N, 1988, METABOLISM, V37, P386, DOI 10.1016/0026-0495(88)90140-0; POLLOCK RJ, 1975, BIOCHIM BIOPHYS ACTA, V380, P421, DOI 10.1016/0005-2760(75)90110-1; ROBINSON J, 1967, BIOCHEM J, V104, pC2, DOI 10.1042/bj1040002C; ROGNSTAD R, 1974, BIOCHEM J, V140, P249, DOI 10.1042/bj1400249; ROGNSTAD R, 1974, EUR J BIOCHEM, V47, P383, DOI 10.1111/j.1432-1033.1974.tb03703.x; Rosdahl H, 1998, AM J PHYSIOL-ENDOC M, V274, pE936, DOI 10.1152/ajpendo.1998.274.5.E936; RYALL RL, 1977, LIPIDS, V12, P272, DOI 10.1007/BF02533346; Saltin B, 1977, Ann N Y Acad Sci, V301, P3, DOI 10.1111/j.1749-6632.1977.tb38182.x; Samra JS, 1996, CLIN SCI, V90, P453, DOI 10.1042/cs0900453; SELTZER WK, 1989, MUSCLE NERVE, V12, P307, DOI 10.1002/mus.880120409; STRYER L, 1981, BIOCHEMISTRY-US, P457; TAGLIAFERRO AR, 1990, INT J OBESITY, V14, P957; ZAHLTEN RN, 1982, ARCH BIOCHEM BIOPHYS, V213, P200, DOI 10.1016/0003-9861(82)90456-8	31	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23702	23706		10.1074/jbc.274.34.23702	http://dx.doi.org/10.1074/jbc.274.34.23702			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446128	hybrid			2022-12-25	WOS:000082110900007
J	Shobe, J; Dickinson, CD; Edgington, TS; Ruf, W				Shobe, J; Dickinson, CD; Edgington, TS; Ruf, W			Macromolecular substrate affinity for the tissue factor-factor VIIa complex is independent of scissile bond docking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PATHWAY INHIBITOR; COAGULATION-FACTOR VIIA; FACTOR-XA; SERINE PROTEASES; CRYSTAL-STRUCTURES; RESIDUES LYS(165); FULL-LENGTH; FACTOR-IXA; SITE; RECOGNITION	The upstream coagulation enzymes are homologous trypsin-like serine proteases that typically function in enzyme-cofactor complexes, exemplified by coagulation factor VIIa (VIIa), which is allosterically activated upon binding to its cell surface receptor tissue factor (TF), TF cooperates with VIIa to create a bimolecular recognition surface that serves as an exosite for factor X binding. This study analyzes to what extent scissile bond docking to the catalytic cleft contributes to macromolecular substrate affinity, Mutation of the P1 Arg residue in factor X to Gin prevented activation by the TF VIIa complex but did not reduce macromolecular substrate affinity for TF VIIa. Similarly, mutations of the S and S' subsites in the catalytic cleft of the enzyme VIIa failed to reduce affinity for factor X, although the affinity for small chromogenic substrates and the efficiency of factor X scissile bond cleavage were reduced. Thus, docking of the activation peptide bond to the catalytic cleft of this enzyme-cofactor complex does not significantly contribute to affinity for macromolecular substrate. Rather, it appears that the creation of an extended macromolecular substrate recognition surface involving enzyme and cofactor is utilized to generate substrate specificity between the highly homologous, regulatory proteases of the coagulation cascade.	IMM17, Dept Vasc Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Ruf, W (corresponding author), IMM17, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NHLBI NIH HHS [P01 HL16411, R01 HL48752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL048752] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BROZE GJ, 1995, ANNU REV MED, V46, P103, DOI 10.1146/annurev.med.46.1.103; BUTENAS S, 1992, BIOCHEMISTRY-US, V31, P5399, DOI 10.1021/bi00138a023; CHO K, 1984, BIOCHEMISTRY-US, V23, P644, DOI 10.1021/bi00299a009; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DENNIS MS, 1994, J BIOL CHEM, V269, P22137; Dickinson CD, 1997, J BIOL CHEM, V272, P19875, DOI 10.1074/jbc.272.32.19875; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Dickinson CD, 1998, J MOL BIOL, V277, P959, DOI 10.1006/jmbi.1998.1639; FURIE B, 1982, J BIOL CHEM, V257, P3875; GIRARD TJ, 1990, SCIENCE, V248, P1421, DOI 10.1126/science.1972598; HAMAMOTO T, 1993, J BIOL CHEM, V268, P8704; Hopfner KP, 1997, EMBO J, V16, P6626, DOI 10.1093/emboj/16.22.6626; Huang MD, 1998, J MOL BIOL, V275, P873, DOI 10.1006/jmbi.1997.1512; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; PERONA JJ, 1995, PROTEIN SCI, V4, P337; RAO LVM, 1995, BIOCHEMISTRY-US, V34, P10867, DOI 10.1021/bi00034a020; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; RUF W, 1994, BIOCHEMISTRY-US, V33, P11631, DOI 10.1021/bi00204a026; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; Ruf W, 1998, TRENDS CARDIOVAS MED, V8, P350, DOI 10.1016/S1050-1738(98)00031-0; Ruf W, 1999, BIOCHEMISTRY-US, V38, P1957, DOI 10.1021/bi982254r; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; RUF W, 1991, J BIOL CHEM, V266, P15719; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shobe J, 1999, BIOCHEMISTRY-US, V38, P2745, DOI 10.1021/bi981951g; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; STASSEN JM, 1995, THROMB HAEMOSTASIS, V74, P646; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452	39	43	52	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24171	24175		10.1074/jbc.274.34.24171	http://dx.doi.org/10.1074/jbc.274.34.24171			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446191	hybrid			2022-12-25	WOS:000082110900070
J	Tsopanoglou, NE; Maragoudakis, ME				Tsopanoglou, NE; Maragoudakis, ME			On the mechanism of thrombin-induced angiogenesis - Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; TRANSCRIPTIONAL REGULATION; PROGELATINASE-A; IN-VITRO; EXPRESSION; ACTIVATION; INHIBITION; VEGF; IDENTIFICATION; HYPOXIA	Many of the cellular actions of thrombin may contribute to the angiogenesis-promoting effect of thrombin reported previously. In this study, we investigated the interaction between thrombin and vascular endothelial growth factor (VEGF), the specific endothelial cell mitogen and key angiogenic factor. Exposure of human umbilical vein endothelial cells to thrombin sensitizes these cells to the mitogenic activity of VEGF. This thrombin-mediated effect is specific, dose dependent and requires the activated thrombin receptor. Quantitative reverse transcription- polymerase chain reaction analysis reveals a time- and dose-dependent up-regulation of mRNA for VEGF receptors (KDR and fit-1). Optimal thrombin concentration for maximal expression of mRNA for KDR is 1.5 IU/ml (170% over controls) and appears 8-12 h after thrombin stimulation. Nuclear run-on experiments demonstrate that the up-regulation of KDR mRNA by thrombin occurred at the transcriptional level. In addition, functional protein of KDR receptor is increased to about 200% over control after 12 h of thrombin treatment. The up-regulation of KDR and flt-1 mRNA is also mimicked by the thrombin receptor activating peptide. These findings could explain at least in part the potent angiogenic action of thrombin.	Univ Patras, Sch Med, Dept Pharmacol, GR-26110 Patras, Greece	University of Patras	Maragoudakis, ME (corresponding author), Univ Patras, Sch Med, Dept Pharmacol, GR-26110 Patras, Greece.	maragoud@med.upatras.gr						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Borgstrom P, 1996, CANCER RES, V56, P4032; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1993, AM J PATHOL, V143, P1255; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CARMICHAEL J, 1987, CANCER RES, V47, P943; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FLOKMAN J, 1985, ADV CANCER RES, V43, P172; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Haralabopoulos GC, 1997, AM J PHYSIOL-CELL PH, V273, pC239, DOI 10.1152/ajpcell.1997.273.1.C239; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; Hewett PW, 1996, BIOCHEM BIOPH RES CO, V221, P697, DOI 10.1006/bbrc.1996.0659; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; Kanthou C, 1998, NATO ADV SCI I A-LIF, V298, P263; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Maeda K, 1996, CANCER, V77, P858, DOI 10.1002/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; McCarthy MJ, 1998, FEBS LETT, V423, P334, DOI 10.1016/S0014-5793(98)00122-7; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; NIERODZIK MLR, 1992, CANCER RES, V52, P3267; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; Pepper MS, 1998, EXP CELL RES, V241, P414, DOI 10.1006/excr.1998.4072; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RICKLES FR, 1983, BLOOD, V62, P14; Scarpati EM, 1996, J BIOL CHEM, V271, P3025, DOI 10.1074/jbc.271.6.3025; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; Sorensen HT, 1998, NEW ENGL J MED, V338, P1169, DOI 10.1056/NEJM199804233381701; Strawn LM, 1996, CANCER RES, V56, P3540; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; THIEME H, 1995, DIABETES, V44, P98, DOI 10.2337/diabetes.44.1.98; Trousseau A., 1872, LECT CLIN MED DELIVE, P281; Tsopanoglou N E, 1998, Angiogenesis, V1, P192; TSOPANOGLOU NE, 1993, AM J PHYSIOL, V264, pC1302, DOI 10.1152/ajpcell.1993.264.5.C1302; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZACHARSKI LR, 1995, THROMB HAEMOSTASIS, V73, P793; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.3.CO;2-N	60	194	208	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23969	23976		10.1074/jbc.274.34.23969	http://dx.doi.org/10.1074/jbc.274.34.23969			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446165	hybrid			2022-12-25	WOS:000082110900044
J	Devereux, TR; Anna, CH; Foley, JF; White, CM; Sills, RC; Barrett, JC				Devereux, TR; Anna, CH; Foley, JF; White, CM; Sills, RC; Barrett, JC			Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis	ONCOGENE			English	Article						beta-catenin mutations; chemical carcinogenesis; mouse liver tumors; beta-catenin expression; H-ras	TUMOR-SUPPRESSOR PROTEIN; LIVER-TUMORS; SOMATIC MUTATIONS; RAS PROTOONCOGENE; B6C3F1 MICE; METHYLENE-CHLORIDE; COLON TUMORS; APC; CANCER; ACTIVATION	beta-catenin activation, and subsequent upregulation of Wnt-signaling, is an important event in the development of certain human and rodent cancers. Recently, mutations in the beta-catenin gene in the region of the serine-threonine glycogen kinase (GSK)-3 beta phosphorylation target sites have been identified in hepatocellular neoplasms from humans and transgenic mice. In this study we: examined 152 hepatocellular neoplasms from B6C3F1 mice included in five chemical treatment groups and controls for mutations in the beta-catenin gene. Twenty of 29 hepatocellular neoplasms from mice treated with methyleugenol had point mutations at codons 32, 33, 33 or 41. sites which are mutated in colon and other cancers. Likewise, nine of 24 methylene chloride-induced hepatocellular neoplasms and 18 of 42 oxazepam-induced neoplasms exhibited similar mutations. In contrast,only three of 18 vinyl carbamate-induced liver tumors, one of 18 TCDD-induced liver tumors, and two of 22 spontaneous liver neoplasms had mutations in beta-catenin. Thus. there appears to be a chemical specific involvement of beta-catenin activation in mouse hepatocellular carcinogenesis. Expression analyses using Western blot and immunohistochemisty indicate that beta-catenin protein accumulates along cell membranes following mutation. The finding of mutations in both adenomas and carcinomas from diverse chemical treatment groups and the immunostaining of beta-catenin protein in an altered hepatocellular focus suggest that these alterations are early events in mouse hepatocellular carcinogenesis.	NIEHS, Mol Carcinogenesis Lab, Mol Toxicol Grp, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Expt Pathol, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Devereux, TR (corresponding author), NIEHS, Mol Carcinogenesis Lab, Mol Toxicol Grp, MD D4-04,POB 12233, Res Triangle Pk, NC 27709 USA.			Foley, Julie/0000-0001-9726-2821	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023006, Z01ES025001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Dashwood RH, 1998, CANCER RES, V58, P1127; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DEVEREUX TR, 1994, CARCINOGENESIS, V15, P1083, DOI 10.1093/carcin/15.5.1083; DEVEREUX TR, 1993, CARCINOGENESIS, V14, P795, DOI 10.1093/carcin/14.5.795; FUJIMORI M, 1991, CANCER RES, V51, P89; Fukuchi T, 1998, CANCER RES, V58, P3526; Gressani KM, 1998, CARCINOGENESIS, V19, P1045, DOI 10.1093/carcin/19.6.1045; GUMBINER BM, 1997, CURR BIOL, V7, P443; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HORII A, 1992, CANCER RES, V52, P6696; JEN J, 1994, CANCER RES, V54, P5523; KARI FW, 1993, CARCINOGENESIS, V14, P819, DOI 10.1093/carcin/14.5.819; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; MANENTI G, 1995, MOL CARCINOGEN, V13, P191, DOI 10.1002/mc.2940130309; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MARONPOT RR, 1995, TOXICOLOGY, V101, P125, DOI 10.1016/0300-483X(95)03112-S; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; *NAT TOX PROGR, 1993, 443 NTP TR US D HHS; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Takahashi M, 1998, CANCER RES, V58, P42; WATSON MA, 1995, CARCINOGENESIS, V16, P1705, DOI 10.1093/carcin/16.8.1705; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825	31	105	109	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4726	4733		10.1038/sj.onc.1202858	http://dx.doi.org/10.1038/sj.onc.1202858			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467420				2022-12-25	WOS:000082154400010
J	Brown, TL; Patil, S; Cianci, CD; Morrow, JS; Howe, PH				Brown, TL; Patil, S; Cianci, CD; Morrow, JS; Howe, PH			Transforming growth factor beta induces caspase 3-independent cleavage of alpha II-spectrin (alpha-fodrin) coincident with apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOMA-CELL LINE; TGF-BETA; B-CELLS; SJOGRENS-SYNDROME; SALIVARY-GLANDS; KNOCKOUT MICE; HUMAN-BRAIN; FACTOR-BETA-1; GROWTH-FACTOR-BETA-1; INHIBITION	Transforming growth factor beta (TGF-beta) is a potent growth inhibitor and inducer of cell death in B-lymphocytes and is essential for immune regulation and maintenance of self-tolerance. In this report the mouse immature B cell line, WEHI 231, was used to examine the mechanisms involved in TGF-beta-mediated apoptosis. Induction of apoptosis is detected as early as 8 h after TGF-P administration. Coincident with the onset of apoptosis, the cytoskeletal actin-binding protein, alpha II-spectrin (cy-fodrin) is cleaved into 150-, 115-, and 110-kDa fragments. The broad spectrum caspase inhibitor (Boc-D-fmk (BD-fmk)) completely abolished TGF-P-induced apoptosis and alpha II-spectrin cleavage. Caspase 3, although present in WEH1 231 cells, was not activated by TGF-P, nor was its substrate, poly(ADP-ribose) polymerase. These results identify alpha II-spectrin as a novel substrate that is cleaved during TGF-P-induced apoptosis. Our data provide the first evidence of calpain and caspase 3-independent cleavage of alpha II-spectrin during apoptosis and suggests that TG;F-P induces apoptosis and alpha II-spectrin cleavage via a potentially novel caspase. This report also provides the first direct evidence of caspase 3 activation in WEH1 231 cells and indicates that at least two distinct apoptotic pathways exist.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol NC1, Cleveland, OH 44195 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Cleveland Clinic Foundation; Yale University	Howe, PH (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol NC1, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NCI NIH HHS [CA80095] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080095] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; BECKWITH M, 1995, BLOOD, V85, P2461, DOI 10.1182/blood.V85.9.2461.bloodjournal8592461; Brown TL, 1998, CELL GROWTH DIFFER, V9, P869; BROWN TL, 1994, ARCH BIOCHEM BIOPHYS, V309, P105, DOI 10.1006/abbi.1994.1091; CHAOUCHI N, 1995, ONCOGENE, V11, P1615; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; CHRIST M, 1994, J IMMUNOL, V153, P1936; CHUANG LY, 1994, ANTICANCER RES, V14, P147; CIAN K, 1996, BIOCHEM J, V314, P27; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DANG H, 1995, J IMMUNOL, V155, P3205; DEOLACOSTE MC, 1992, J NEUROSCI, V18, P558; Diebold RJ, 1995, P NATL ACAD SCI USA, V92, P12215, DOI 10.1073/pnas.92.26.12215; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; Gamen S, 1997, FEBS LETT, V417, P360, DOI 10.1016/S0014-5793(97)01282-9; GOTTSCHALK AR, 1995, IMMUNOL CELL BIOL, V73, P8, DOI 10.1038/icb.1995.2; Haneji N, 1997, SCIENCE, V276, P604, DOI 10.1126/science.276.5312.604; HARRIS AS, 1985, BIOCHIM BIOPHYS ACTA, V830, P147, DOI 10.1016/0167-4838(85)90022-6; HARRIS AS, 1988, J NEUROSCI, V8, P2640; Hocevar BA, 1998, MINER ELECTROL METAB, V24, P131, DOI 10.1159/000057360; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Letterio JJ, 1998, MINER ELECTROL METAB, V24, P161, DOI 10.1159/000057365; LIN JK, 1992, CANCER RES, V52, P385; MacDonald I, 1996, BLOOD, V87, P1147, DOI 10.1182/blood.V87.3.1147.bloodjournal8731147; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; McCartneyFrancis NL, 1996, J IMMUNOL, V157, P1306; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; MORROW JS, 1997, HDB PHYSIOL 14, P485; Nakabayashi T, 1997, J IMMUNOL, V158, P5527; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; WINKELMANN JC, 1993, BLOOD, V81, P3173; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; YANAGIHARA K, 1992, CANCER RES, V52, P4042; Yaswen L, 1996, BLOOD, V87, P1439, DOI 10.1182/blood.V87.4.1439.bloodjournal8741439	48	59	60	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23256	23262		10.1074/jbc.274.33.23256	http://dx.doi.org/10.1074/jbc.274.33.23256			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438500	hybrid			2022-12-25	WOS:000082012800050
J	Devchand, PR; Hihi, AK; Perroud, M; Schleuning, WDD; Spiegelman, BM; Wahli, W				Devchand, PR; Hihi, AK; Perroud, M; Schleuning, WDD; Spiegelman, BM; Wahli, W			Chemical probes that differentially modulate peroxisome proliferator-activated receptor alpha and BLTR, nuclear and cell surface receptors for leukotriene B-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; PPAR-ALPHA; POLYMORPHONUCLEAR LEUKOCYTES; HYPOLIPIDEMIC AGENTS; TARGETED DISRUPTION; ARACHIDONIC-ACID; GAMMA; ADIPOGENESIS; METABOLISM; PATHWAY	Peroxisome proliferator-activated receptor alpha (PPAR alpha) is a nuclear receptor for various fatty acids, eicosanoids, and hypolipidemic drugs. In the presence of ligand, this transcription factor increases expression of target genes that are primarily associated with lipid homeostasis. We have previously reported PPAR alpha as a nuclear receptor of the inflammatory mediator leukotriene B-4 (LTB4) and demonstrated an anti-inflammatory function for PPAR alpha in vivo (Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., and Wahli, W. (1996) Nature 384, 39-43). LTB4 also has a cell surface receptor (BLTR) that mediates proinflammatory events, such as chemotaxis and chemokinesis (Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y., and Shimizu, T. (1997) Nature 387, 620-624). In this study, we report on chemical probes that differentially modulate activity of these two LTB4 receptors. The compounds selected were originally characterized as synthetic BLTR effecters, both agonists and antagonists. Here, we evaluate the compounds as effecters of the three PPAR isotypes (alpha, beta, and gamma) by transient transfection assays and also determine whether the compounds are ligands for these nuclear receptors by coactivator-dependent receptor ligand interaction assay, a semifunctional in vitro assay. Because the compounds are PPAR alpha selective, we further analyze their potency in a biological assay for the PPAR alpha-mediated activity of lipid accumulation. These chemical probes will prove invaluable in dissecting processes that involve nuclear and cell surface LTB4 receptors and also aid in drug discovery programs.	Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Schering AG, Inst Cell & Mol Biol, D-1000 Berlin, Germany	University of Lausanne; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Schering AG	Wahli, W (corresponding author), Univ Lausanne, Inst Biol Anim, Batiment Biol, CH-1015 Lausanne, Switzerland.	walter.wahli@iba.unil.ch	Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009	Wahli, Walter/0000-0002-5966-9089	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37DK31405] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORGEAT P, 1979, J BIOL CHEM, V254, P7865; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DEVCHAND PR, 1997, HORMONES SIGNALLING, V1, P236; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FIORE S, 1992, J BIOL CHEM, V267, P16168; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GLESEN C, 1998, ARCH DERMATOL RES, V290, P51; Gonzalez FJ, 1997, ADV EXP MED BIOL, V422, P109; HARPER TW, 1986, J BIOL CHEM, V261, P5414; JEDLITSCHKY G, 1993, ADV ENZYME REGUL, V33, P181; Keller H, 1997, BIOL CHEM, V378, P651, DOI 10.1515/bchm.1997.378.7.651; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEIBOWITZ MD, Patent No. 28149; LEIBOWITZ MD, 1997, Patent No. 30779; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Lin QO, 1999, BIOCHEMISTRY-US, V38, P185, DOI 10.1021/bi9816094; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Peters-Golden M, 1998, AM J RESP CRIT CARE, V157, pS227, DOI 10.1164/ajrccm.157.6.mar4; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Sala A, 1998, BIOCHEMISTRY-MOSCOW+, V63, P84; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Serhan CN, 1996, NATURE, V384, P23, DOI 10.1038/384023a0; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; TANAKA Y, 1988, ARCH BIOCHEM BIOPHYS, V263, P178, DOI 10.1016/0003-9861(88)90626-1; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	43	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23341	23348		10.1074/jbc.274.33.23341	http://dx.doi.org/10.1074/jbc.274.33.23341			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438511	hybrid			2022-12-25	WOS:000082012800061
J	Jakupciak, JP; Wells, RD				Jakupciak, JP; Wells, RD			Genetic instabilities in (CTG center dot CAG) repeats occur by recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X-SYNDROME; ESCHERICHIA-COLI; MYOTONIC-DYSTROPHY; TRIPLET REPEATS; TRINUCLEOTIDE REPEAT; DISEASE GENES; DNA-SEQUENCES; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; FMR1 LOCUS	The expansion of triplet repeat sequences (TRS) associated with hereditary neurological diseases is believed from prior studies to be due to DNA replication. This report demonstrates that the expansion of (CTG . CAG)(n) in vivo also occurs by homologous recombination as shown by biochemical and genetic studies, A two-plasmid recombination system was established in Escherichia coli with derivatives of pUC19 (harboring the ampicillin resistance gene) and pACYC184 (harboring the tetracycline resistance gene). The derivatives contained various triplet repeat inserts ((CTG . CAG), (CGG . CCG), (GAA . TTC), (GTC . GAC), and (GTG . CAC)) of different lengths, orientations, and extents of interruptions and a control non-repetitive sequence. The availability of the two drug resistance genes and of several unique restriction sites on the plasmids enabled rigorous genetic and biochemical analyses. The requirements for recombination at the TRS include repeat lengths >30, the presence of CTG . CAG on both plasmids, and recA and recBC, Sequence analyses on a number of DNA products isolated from individual colonies directly demonstrated the crossing-over and expansion of the homologous CTG.CAG regions, Furthermore, inversion products of the type [(CTG)(13)(CAG)(67)].[(CTG)(67)(CAG)(13)] were isolated as the apparent result of "illegitimate'" recombination events on intrahelical pseudoknot, This work establishes the relationships between CTG . CAG sequences, multiple fold expansions, genetic recombination, formation of new recombinant DNA products, and the presence of both drug resistance genes. Thus, if these reactions occur in humans, unequal crossing-over or gene conversion may also contribute to the expansions responsible for anticipation associated with several hereditary neurological syndromes.	Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Med Ctr, Houston, TX 77030 USA	Texas A&M University System	Wells, RD (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Med Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Bacolla A, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P467; BEDBROOK JR, 1976, CELL, V9, P707, DOI 10.1016/0092-8674(76)90134-3; Bi X, 1996, J MOL BIOL, V256, P849, DOI 10.1006/jmbi.1996.0131; Bi X, 1996, P NATL ACAD SCI USA, V93, P819, DOI 10.1073/pnas.93.2.819; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Brown WT, 1996, AM J MED GENET, V64, P287, DOI 10.1002/(SICI)1096-8628(19960809)64:2<287::AID-AJMG11>3.0.CO;2-B; BULLOCK P, 1986, MOL CELL BIOL, V6, P3948, DOI 10.1128/MCB.6.11.3948; COGGINS LW, 1992, GENE, V121, P279, DOI 10.1016/0378-1119(92)90132-9; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; JANSEN G, 1994, AM J HUM GENET, V54, P575; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Losekoot M, 1997, J MED GENET, V34, P924, DOI 10.1136/jmg.34.11.924; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; MCMURRAY CT, 1995, CHROMOSOMA, V104, P2; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; RICHARDS RI, 1991, J MED GENET, V28, P818, DOI 10.1136/jmg.28.12.818; RICHARDS RI, 1992, NAT GENET, V1, P7, DOI 10.1038/ng0492-7; RIPPE K, 1992, EMBO J, V11, P3777, DOI 10.1002/j.1460-2075.1992.tb05463.x; ROSE RE, 1988, NUCLEIC ACIDS RES, V16, P355, DOI 10.1093/nar/16.1.355; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarkar PS, 1998, CELL, V95, P531, DOI 10.1016/S0092-8674(00)81620-7; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SINGER BS, 1982, CELL, V31, P25, DOI 10.1016/0092-8674(82)90401-9; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tishkoff SA, 1998, AM J HUM GENET, V62, P1389, DOI 10.1086/301861; TRECO D, 1986, MOL CELL BIOL, V6, P3934, DOI 10.1128/MCB.6.11.3934; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; VANDENOUWELAND AMW, 1994, HUM MOL GENET, V3, P1823, DOI 10.1093/hmg/3.10.1823; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WAHLS WP, 1990, MOL CELL BIOL, V10, P785, DOI 10.1128/MCB.10.2.785; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Warren ST, 1997, SCIENCE, V275, P408, DOI 10.1126/science.275.5298.408; WATT VM, 1985, P NATL ACAD SCI USA, V82, P4768, DOI 10.1073/pnas.82.14.4768; Wells R.D., 1998, GENETIC INSTABILITIE; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; Zhong N, 1996, AM J MED GENET, V64, P226, DOI 10.1002/(SICI)1096-8628(19960712)64:1<226::AID-AJMG41>3.0.CO;2-M	53	104	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23468	23479		10.1074/jbc.274.33.23468	http://dx.doi.org/10.1074/jbc.274.33.23468			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438526	hybrid			2022-12-25	WOS:000082012800076
J	Pan, Z; Hetherington, CJ; Zhang, DE				Pan, Z; Hetherington, CJ; Zhang, DE			CCAAT/enhancer-binding protein activates the CD14 promoter and mediates transforming growth factor beta signaling in monocyte development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; TRANSCRIPTION FACTOR PU.1; LUCIFERASE REPORTER GENE; SERUM-ALBUMIN GENE; DEFICIENT MICE; MYELOID CELLS; DNA-BINDING; C/EBP-BETA; TARGETED DISRUPTION; HEPATOMA-CELLS	Transcription factors from the CCAAT/enhancer-binding protein (C/EBP) family play important roles in myeloid cell differentiation. CD14 is a monocyte/macrophage differentiation marker and is strongly up-regulated during monocytic cell differentiation. Here, we report the direct binding of C/EBP to the monocyte-specific promoter of CD14. Transactivation analyses demonstrate that C/EBP family members significantly activate the CD14 promoter. These data indicate that C/EBP is directly involved in the regulation of CD14 gene expression. When myelomonoblastic U937 cells are treated with vitamin D-3 and TGF-beta, they differentiate toward monocytic cells. Using specific antibodies against different C/EBP family members in electrophoretic mobility shift assays and Western blot assays, we have identified a specific increase in the DNA binding and the expression of C/EBP alpha and C/EBP beta during U937 monocytic cell differentiation, and we found C/EBP alpha and C/EBP beta bind to the promoter in heterodimer. Furthermore, with stably transfected cell lines, we demonstrate that the C/EBP binding site in the CD14 promoter plays a critical role for mediating TGF-beta signaling in the synergistic activation of CD14 expression by vitamin D-3 and TGF-beta during U937 differentiation. This may indicate that C/EBPs have important functions in the process of TGF-beta signal transduction during monocyte differentiation.	Harvard Univ, Inst Med, Sch Med,Div Hematol Oncol, Beth Israel Deaconess Med Ctr,Dept Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Zhang, DE (corresponding author), Harvard Univ, Inst Med, Sch Med,Div Hematol Oncol, Beth Israel Deaconess Med Ctr,Dept Med, HIM 953,77 Ave Louis Pasteur, Boston, MA 02115 USA.				NCI NIH HHS [CA/AI59589] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059589] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Boudreau F, 1998, DNA CELL BIOL, V17, P669, DOI 10.1089/dna.1998.17.669; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; CLEUTJENS CBJM, 1993, GENOMICS, V16, P520, DOI 10.1006/geno.1993.1220; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; GRIFFIN JD, 1981, J CLIN INVEST, V68, P932, DOI 10.1172/JCI110348; Heidenreich S, 1997, J IMMUNOL, V159, P3178; Hetherington CJ, 1999, J IMMUNOL, V162, P503; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; Kamesaki H, 1998, J IMMUNOL, V160, P770; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsumoto M, 1998, INT IMMUNOL, V10, P1825, DOI 10.1093/intimm/10.12.1825; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; NATSUKA S, 1992, BLOOD, V79, P460; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OLSSON I, 1983, CANCER RES, V43, P5862; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; Robson CN, 1999, J ENDOCRINOL, V160, P257, DOI 10.1677/joe.0.1600257; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; Ross IL, 1998, J BIOL CHEM, V273, P6662, DOI 10.1074/jbc.273.12.6662; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SCOTT LM, 1992, BLOOD, V80, P1725; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Shapiro L H, 1995, Curr Opin Hematol, V2, P3; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SIMMONS DL, 1989, BLOOD, V73, P284; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; SORIANO HE, 1995, IN VITRO CELL DEV-AN, V31, P703, DOI 10.1007/BF02634092; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TESTA U, 1993, J IMMUNOL, V150, P2418; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; ZHANG DE, 1994, J IMMUNOL, V153, P3276; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	72	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23242	23248		10.1074/jbc.274.33.23242	http://dx.doi.org/10.1074/jbc.274.33.23242			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438498	hybrid			2022-12-25	WOS:000082012800048
J	Sinclair, C; Borchers, C; Parker, C; Tomer, K; Charbonneau, H; Rossie, S				Sinclair, C; Borchers, C; Parker, C; Tomer, K; Charbonneau, H; Rossie, S			The tetratricopeptide repeat domain and a C-terminal region control the activity of Ser/Thr protein phosphatase 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE PHOSPHATASE; CATALYTIC SUBUNIT; CELL-CYCLE; TYROSINE PHOSPHORYLATION; LIMITED PROTEOLYSIS; TPR; CALCINEURIN; RECEPTOR; KINASE; IDENTIFICATION	Protein Ser/Thr phosphatase 5 is a 58-kDa protein containing a catalytic domain structurally related to the catalytic subunits of protein phosphatases 1, 2A, and 2B and an extended N-terminal domain with three tetratricopeptide repeats. The activity of this enzyme is stimulated 4-14-fold in vitro by polyunsaturated fatty acids and anionic phospholipids. The structural basis for lipid activation of protein phosphatase 5 was examined by limited proteolysis and site-directed mutagenesis. Trypsinolysis removed the tetratricopeptide repeat domain and increased activity to approximately half that of lipid-stimulated, full-length enzyme. Subtilisin re moved the tetratricopeptide repeat domain and 10 residues from the C terminus, creating a catalytic fragment with activity that was equal to or greater than that of lipid-stimulated, full-length enzyme. Catalytic fragments generated by proteolysis were no longer stimulated by lipid, and degradation of the tetratricopeptide repeat domain was decreased by association with lipid. A truncated mutant missing 13 C-terminal residues was also insensitive to lipid and was as active as full-length, lipid-stimulated enzyme. These results suggest that the C-terminal and N-terminal domain act in a coordinated manner to suppress the activity of protein phosphatase 5 and mediate its activation by lipid. These regions may be targets for the regulation of protein phosphatase 5 activity in vivo.	Purdue Univ, Dept Biochem 1153, W Lafayette, IN 47907 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Rossie, S (corresponding author), Purdue Univ, Dept Biochem 1153, W Lafayette, IN 47907 USA.		BORCHERS, Christoph/U-5964-2019; Tomer, Kenneth B/E-8018-2013		NCI NIH HHS [CA59935] Funding Source: Medline; NIDDK NIH HHS [DK20542] Funding Source: Medline; NINDS NIH HHS [NS31221] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059935, R01CA059935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031221, R29NS031221] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECKER W, 1994, J BIOL CHEM, V269, P22586; BLACKBURN K, 1998, P 46 ASMS C MASS SPE, P219; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; FAVRE B, 1994, J BIOL CHEM, V269, P16311; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lee Ernest Y. C., 1999, Frontiers in Bioscience, V4, pD270, DOI 10.2741/Lee; LEGENDRE N, 1993, PRACTICAL GUIDE PROT, P75; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SIKORSKI RS, 1991, COLD SH Q B, V56, P663; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; TOMER KB, 1994, MASS SPECTROM REV, V13, P431, DOI 10.1002/mas.1280130504; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	37	66	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23666	23672		10.1074/jbc.274.33.23666	http://dx.doi.org/10.1074/jbc.274.33.23666			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438550	hybrid			2022-12-25	WOS:000082012800100
J	Bowden, ET; Barth, M; Thomas, D; Glazer, RI; Mueller, SC				Bowden, ET; Barth, M; Thomas, D; Glazer, RI; Mueller, SC			An invasion-related complex of cortactin, paxillin and PKC mu associates with invadopodia at sites of extracellular matrix degradation	ONCOGENE			English	Article						invasion; cortactin; paxillin; PKC mu; breast cancer	FOCAL ADHESION KINASE; BREAST-CANCER CELLS; TYROSINE PHOSPHORYLATION; TRANSFORMED-CELLS; CARCINOMA-CELLS; CONTACT SITES; CELLULAR INVASION; V-SRC; EXPRESSION; INTEGRIN	Invasive breast cancer cells have the ability to extend membrane protrusions, invadopodia, into the extracellular matrix (EC). These structures are associated with sites of active matrix degradation. The amount of matrix degradation associated with the activity of these membrane protrusions has been shown to directly correlate with invasive potential. We demonstrate here that microinjection of polyclonal anti-cortactin antibodies blocks matrix degradation at invadopodia supporting the hypothesis that cortactin has a direct role in invasive behavior. MDA-MB-231, invasive breast cancer cells were sheared from the surface of a gelatin matrix to isolate invadopodia. Cortactin, paxillin and protein kinase C (PKC) mu, a serine kinase, were co-immunoprecipitated as a complex from invadopodia-enriched membranes. We confirmed the subcellular distribution of these proteins by immunolocalization and Western blotting. We also determined that, in contrast to its presence in invasive cells, this complex of proteins was not detected in lysates from non-invasive cells that do not form invadopodia. Taken together, these data suggest that the formation of this cortactin-containing complex correlates,vith cellular invasiveness. We hypothesize that this complex of molecules has a role in the formation and function of invadopodia during cellular invasion.	Georgetown Univ, Sch Med, Lombardi Canc Ctr, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Lombardi Canc Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Mueller, SC (corresponding author), Georgetown Univ, Sch Med, Lombardi Canc Ctr, Dept Cell Biol, Washington, DC 20007 USA.				NCI NIH HHS [R21CA62232, R01CA61273] Funding Source: Medline; NIDDK NIH HHS [R01DK48910] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061273, R21CA062232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048910] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; Coopman PJ, 1998, CLIN CANCER RES, V4, P507; Coopman PJ, 1996, MOL BIOL CELL, V7, P1789, DOI 10.1091/mbc.7.11.1789; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; KELLY T, 1994, J CELL PHYSIOL, V158, P299, DOI 10.1002/jcp.1041580212; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; McCormack SJ, 1997, ONCOGENE, V15, P265, DOI 10.1038/sj.onc.1201186; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; MONSKY WL, 1994, CANCER RES, V54, P5702; MONSKY WL, 1993, CANCER RES, V53, P3159; Moonga BS, 1996, CALCIFIED TISSUE INT, V59, P105, DOI 10.1007/s002239900095; MUELLER SC, 1991, J CELL SCI, V99, P213; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; OBRIAN CA, 1989, CANCER METAST REV, V8, P199, DOI 10.1007/BF00047337; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, ONCOGENE, V7, P355; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tamaki M, 1996, J NEUROSURG, V84, P1013, DOI 10.3171/jns.1996.84.6.1013; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XIE B, 1994, AM J PATHOL, V144, P1058; Yazaki T, 1996, MOL PHARMACOL, V50, P236; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841	39	306	316	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4440	4449		10.1038/sj.onc.1202827	http://dx.doi.org/10.1038/sj.onc.1202827			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442635				2022-12-25	WOS:000081813500006
J	Glover, HR; Brewster, CEP; Dilworth, SM				Glover, HR; Brewster, CEP; Dilworth, SM			Association between src-kinases and the polyoma virus oncogene middle T-antigen requires PP2A and a specific sequence motif	ONCOGENE			English	Article						polyoma middle T; pp60(c-src); PP2A; cell transformation	PROTEIN PHOSPHATASE 2A; TUMOR-ANTIGEN; TYROSINE PHOSPHORYLATION; CELL-TRANSFORMATION; 3T3 CELLS; RAT-CELLS; BINDING; PP60C-SRC; ACTIVATION; PURIFICATION	Polyoma virus encodes a potent oncogene, the middle T-antigen (MT), that induces cell transformation by copying the actions of tyrosine kinase associated growth factor receptors, A crucial component of MT transformation is its ability to bind and stimulate the activity of src-family kinases. However, the mechanism by which this is achieved remains unclear. Tyrosine phosphorylation of MT by sr c-kinases then provides binding sites for SH2 and PTB domain containing molecules in a paradigm of receptor action. We present evidence here that the MT/src complex contains equi-molar amounts of PP2A, and that phosphatase activity may be required for the interaction of MT with both PP2A and the src-family. PP2A, then, is a necessary component of the;MT-src complex. We also show that tno motifs in the 185 to 210 region of MT, each consisting of a basic area followed by a serine or threonine, are essential for interaction with sr c-kinases, but not PP2A. The spacing between the serine or threonine and the basic sequence also appears to be important. Substituting a cysteine residue in place of Thr203 in MT has no affect on the binding of pp60(c-src), showing that these sites interact with src-kinases by a novel mechanism that does not require phosphorylation.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Metab Med, London W12 0NN, England	Imperial College London	Dilworth, SM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Metab Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.							ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOK DN, 1990, J VIROL, V64, P1879, DOI 10.1128/JVI.64.5.1879-1887.1990; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cullere X, 1998, J VIROL, V72, P558; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1982, EMBO J, V1, P1319, DOI 10.1002/j.1460-2075.1982.tb01317.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; KAMECH N, 1987, J VIROL, V61, P1546, DOI 10.1128/JVI.61.5.1546-1551.1987; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; WALTER G, 1982, P NATL ACAD SCI-BIOL, V79, P4025, DOI 10.1073/pnas.79.13.4025; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992	44	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4364	4370		10.1038/sj.onc.1202816	http://dx.doi.org/10.1038/sj.onc.1202816			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439044				2022-12-25	WOS:000081732700009
J	Honda, H; Harada, K; Komuro, I; Terasaki, F; Ueno, H; Tanaka, Y; Kawamura, K; Yazaki, Y; Hirai, H				Honda, H; Harada, K; Komuro, I; Terasaki, F; Ueno, H; Tanaka, Y; Kawamura, K; Yazaki, Y; Hirai, H			Heart-specific activation of LTK results in cardiac hypertrophy, cardiomyocyte degeneration and gene reprogramming in transgenic mice	ONCOGENE			English	Article						leukocyte tyrosine kinase (LTK); protein tyrosine kinase; transgenic mice	LEUKOCYTE TYROSINE KINASE; IN-VIVO; EXPRESSION; GROWTH; PROTEIN; DOMAIN; CELLS; OVEREXPRESSION; APOPTOSIS; MOLECULE	Leukocyte tyrosine kinase (LTK) is a receptor-type protein tyrosine kinase belonging to the insulin receptor superfamily. To elucidate its biological role, we generated transgenic mice expressing LTK under the control of cytomegarovirus enhancer and beta-actin promoter. The transgenic mice exhibited growth retardation and most of the transgenic mice died within several months after birth, Interestingly, although LTK was expressed in several major organs, the activation (tyrosine-phosphorylation, kinase activity, and multimerization) of LTK was observed selectively in the heart, where LTK was localized on intracellular membrane, presumably on endoplasmic reticulum. Echocardiography showed that the transgenic heart underwent severe concentric hypertrophy, which resulted in reduced cardiac output, low blood pressure, and increased heart rate. Histological examination of the heart exhibited focal degeneration of cardiomyocytes. These histological changes were considered to be due to apoptosis, based on the finding that the sarcolemmas of the degenerative cardiomyocytes were well preserved. In addition, expression of fetal genes, such as atrial natriuretic peptide and skeletal alpha-actin, was markedly induced in the transgenic heart. These results indicate that a certain tissue-specific mechanism of activating LTK exists in the heart and that the activated LTK resulted in cardiac hypertrophy, cardiomyocyte degeneration and gene reprogramming. These findings will provide novel insights into the activating mechanism and biological role of LTK in vivo.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan; Osaka Med Coll, Fac Med, Dept Internal Med 3, Takatsuki, Osaka 569, Japan	University of Tokyo; Osaka Medical College	Hirai, H (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.							BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BRASKIN AR, 1991, CELL, V66, P685; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CONTI FG, 1995, GROWTH REGULAT, V5, P101; Edwards JG, 1996, CIRC RES, V78, P379, DOI 10.1161/01.RES.78.3.379; FURUTA Y, 1993, TRANSGENIC RES, V2, P199, DOI 10.1007/BF01977350; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HASSANKHANI A, 1995, DEV BIOL, V169, P309, DOI 10.1006/dbio.1995.1146; HASSE VH, 1995, TRANSGENICS, V1, P487; HASSE VH, 1991, ONCOGENE, V6, P2319; HAYASHI T, 1995, AM HEART J, V129, P946, DOI 10.1016/0002-8703(95)90116-7; HERREN B, 1993, J BIOL CHEM, V268, P15088; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; JAMES TN, 1993, J LAB CLIN MED, V122, P309; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; KOZUTSUMI H, 1993, BIOCHEM BIOPH RES CO, V190, P674, DOI 10.1006/bbrc.1993.1101; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; MARU Y, 1990, ONCOGENE RES, V5, P199; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SNIJDERS AJ, 1993, ONCOGENE, V8, P27; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; UENO H, 1995, J BIOL CHEM, V270, P20135, DOI 10.1074/jbc.270.34.20135; Ueno H, 1996, J BIOL CHEM, V271, P27707, DOI 10.1074/jbc.271.44.27707; YEE SP, 1989, P NATL ACAD SCI USA, V86, P5873, DOI 10.1073/pnas.86.15.5873	38	10	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3821	3830		10.1038/sj.onc.1202736	http://dx.doi.org/10.1038/sj.onc.1202736			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445845				2022-12-25	WOS:000081171700003
J	Cresci, S; Clabby, ML; Kelly, DP				Cresci, S; Clabby, ML; Kelly, DP			Evidence for a novel cardiac-enriched retinoid X receptor partner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; ACYL-COA DEHYDROGENASE; VITAMIN-D RECEPTORS; HEAVY-CHAIN GENE; THYROID-HORMONE; RXR-ALPHA; SIGNALING PATHWAYS; ACID RECEPTORS; TRANSCRIPTION FACTOR; NUCLEAR RECEPTORS	Recent studies indicate that retinoid-mediated pathways play a pivotal role in cardiac morphogenesis and function. To identify proteins that serve as interacting partners of the retinoid X receptor alpha (RXR alpha) in heart, DNA-protein binding studies were performed with an RXR-responsive element (NRRE-1) derived from the medium chain acyl-CoA dehydrogenase gene promoter and nuclear protein extracts prepared from adult rat heart. NRRE-1 is a pleiotropic RXR-responsive element comprised of three potential recognition sites for class II members of the nuclear receptor superfamily. Gel mobility shift assays performed with an NRRE-1 probe in the absence or presence of bacterially overproduced RXRa and nuclear protein extracts prepared from adult rat heart, liver, or brain identified a cardiac specific, RXR-dependent DNA-protein interaction. The NRRE-1-RXR cardiac-enriched RXR-interacting protein (CERIP) complex exhibited a distinct mobility compared with NRRE-1-RXR-peroxisome proliferator-activated receptor, NRRE-1-RXR retinoic acid receptor, or NRRE-1-RXR thyroid receptor complexes. Mutational analysis demonstrated that two of the three potential binding half-sites of NRRE-1 (an everted repeat separated by an S-base pair spacer) are required for the NRRE-1-RXR CERIP interaction. Gel mobility shift assays demonstrated that CERIP interacted with RXR alpha and RXR gamma but not with RXR beta, indicating a receptor subtype-specific binding preference and suggesting an RXR AB region-dependent interaction. The RXR CERIP complex did not form on NRRE-1 when a mutant GST-RXR alpha fusion protein lacking the NH2-terminal AB region (but containing the receptor dimerization domain) of RXR alpha was added in place of the full-length RXR alpha, confirming a role for the AB region in the RXR CERIP interaction. DNA-protein cross-linking studies demonstrated that CERIP is a DNA-binding protein of approximately 110 kDa. These results provide evidence for the existence of a cardiac-enriched DNA-binding protein that interacts with RXR alpha via the AB region and suggest a mechanism whereby cardiac retinoid signaling is controlled in an RXR subtype-specific manner.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Kelly, DP (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, 660 S Euclid Ave,Campus Box 8086, St Louis, MO 63110 USA.		Kelly, Daniel/ABG-2056-2021		NHLBI NIH HHS [R01-HL58493, F32-HL09189] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058493, F32HL009189] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beinert H., 1963, ENZYMES, P447; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; BREMER J, 1984, FATTY ACID METABOLIS, P113; Brocard J, 1996, BIOCHEM BIOPH RES CO, V229, P211, DOI 10.1006/bbrc.1996.1782; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARTER ME, 1993, J BIOL CHEM, V268, P13805; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Disch DL, 1996, MOL CELL BIOL, V16, P4043; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Dowhan DH, 1996, NUCLEIC ACIDS RES, V24, P264, DOI 10.1093/nar/24.2.264; DYSON E, 1995, P NATL ACAD SCI USA, V92, P7386, DOI 10.1073/pnas.92.16.7386; GEBEL T, 1992, FEBS LETT, V309, P37, DOI 10.1016/0014-5793(92)80734-X; Gruber PJ, 1996, J CLIN INVEST, V98, P1332, DOI 10.1172/JCI118920; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KELLY DP, 1989, J BIOL CHEM, V264, P18921; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; Lee RY, 1997, CIRC RES, V80, P757; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEONE TC, 1995, J BIOL CHEM, V270, P24622; MAHDAVI V, 1987, CIRC RES, V60, P804, DOI 10.1161/01.RES.60.6.804; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1998, J BIOL CHEM, V273, P3212, DOI 10.1074/jbc.273.6.3212; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; ONATE SA, 1995, SCIENCE, V270, P1354; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Tolwani RJ, 1996, GENE, V170, P165, DOI 10.1016/0378-1119(95)00882-9; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4303; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WILSON JG, 1949, AM J ANAT, V85, P113, DOI 10.1002/aja.1000850106; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Wu JM, 1996, J CLIN INVEST, V97, P1577, DOI 10.1172/JCI118582; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHOU MD, 1995, P NATL ACAD SCI USA, V92, P7391, DOI 10.1073/pnas.92.16.7391	55	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25668	25674		10.1074/jbc.274.36.25668	http://dx.doi.org/10.1074/jbc.274.36.25668			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464303	hybrid			2022-12-25	WOS:000082554200067
J	Geisbrecht, BV; Liang, XQ; Morrell, JC; Schulz, H; Gould, SJ				Geisbrecht, BV; Liang, XQ; Morrell, JC; Schulz, H; Gould, SJ			The mouse gene PDCR encodes a peroxisomal Delta(2),Delta(4)-dienoyl-CoA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; RAT-LIVER PEROXISOMES; BETA-OXIDATION; 2,4-DIENOYL-COA REDUCTASE; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; BIOGENESIS DISORDERS; DEPENDENT PATHWAY; MEMBRANE-PROTEIN; DOUBLE-BONDS	Here we describe the identification and characterization of a novel mouse gene, PDCR, that encodes a peroxisomal Delta(2), Delta(4)-dienoyl-CoA reductase, The mouse PDCR cDNA contains an 892-base pair open reading frame and is predicted to encode a 292-amino acid protein with a deduced molecular mass of 31,298 Da that terminates in a consensus type-1 peroxisomal targeting signal. Purified recombinant PDCR protein was generated from Escherichia coli and catalyzed the NADPH-dependent reduction of Delta(2)-trans,Delta(4)-trans-decadienoyl CoA with a specific activity of 20 units/mg, Enzymatic characterization followed by high pressure liquid chromatography analysis of the products revealed that PDCR converted Delta(2)-trans, Delta(4)-trans-decadienoyl-CoA to a Delta(3)-enoyl-CoA but not to a Delta(2)-enoyl-CoA. Kinetic analyses demonstrated that PDCR is active on a broad range of Delta(2),Delta(4)-dienoyl-CoAs. Although the observed substrate preference was to Delta(2)-trans,Delta(4)-trans-decadienoyl-CoA, PDCR was also active on a C-22 substrate with multiple unsaturations, a result consistent with the role of peroxisomes in the oxidation of complex, very long chain, polyunsaturated fatty acids. The presence of a type-1 peroxisomal targeting signal Ala-Lys-Leu-COOH at the C terminus of PDCR suggested that this protein may be peroxisomal. We observed that tagged PDCR was efficiently transported to the peroxisome lumen in normal human fibroblasts but not in cells derived from a Zellweger syndrome patient with a specific defect in peroxisomal matrix protein import. We conclude that this protein resides within the peroxisome matrix and therefore represents the first mammalian peroxisomal Delta(2),Delta(4)-dienoyl-CoA reductase to be characterized at the molecular level.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; CUNY City Coll, Dept Chem, New York, NY 10031 USA	Johns Hopkins University; City University of New York (CUNY) System; City College of New York (CUNY)	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30847] Funding Source: Medline; NICHD NIH HHS [HD10981] Funding Source: Medline; NIDDK NIH HHS [DK45787] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CUEBAS D, 1982, J BIOL CHEM, V257, P4140; DOMMES V, 1984, J BIOL CHEM, V259, P1781; DOMMES V, 1981, J BIOL CHEM, V256, P8259; Filppula SA, 1998, J BIOL CHEM, V273, P349, DOI 10.1074/jbc.273.1.349; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; Geisbrecht BV, 1998, J BIOL CHEM, V273, P33184, DOI 10.1074/jbc.273.50.33184; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; HILTUNEN JK, 1986, J BIOL CHEM, V261, P6484; HIROSE A, 1990, BIOCHIM BIOPHYS ACTA, V1049, P346, DOI 10.1016/0167-4781(90)90109-F; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KIMURA C, 1984, J BIOCHEM, V96, P1463, DOI 10.1093/oxfordjournals.jbchem.a134975; KIMURA M, 1998, RYOIKIBETSU SHOKOGUN, V18, P411; KOIVURANTA KT, 1994, BIOCHEM J, V304, P787, DOI 10.1042/bj3040787; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNAU WH, 1978, EUR J BIOCHEM, V91, P533, DOI 10.1111/j.1432-1033.1978.tb12707.x; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LUO MJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P266, DOI 10.1006/abbi.1993.1348; MIZUGAKI M, 1982, J BIOCHEM-TOKYO, V92, P1671, DOI 10.1093/oxfordjournals.jbchem.a134095; MIZUGAKI M, 1984, J BIOCHEM-TOKYO, V95, P311, DOI 10.1093/oxfordjournals.jbchem.a134610; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; ROE CR, 1990, J CLIN INVEST, V85, P1703, DOI 10.1172/JCI114624; Shoukry K, 1998, J BIOL CHEM, V273, P6892, DOI 10.1074/jbc.273.12.6892; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; Steinman H M, 1975, Methods Enzymol, V35, P136, DOI 10.1016/0076-6879(75)35149-5; STOFFEL W, 1965, H-S Z PHYSIOL CHEM, V341, P76, DOI 10.1515/bchm2.1965.341.1.76; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Wanders RJA, 1996, ANN NY ACAD SCI, V804, P450, DOI 10.1111/j.1749-6632.1996.tb18636.x; Warren DS, 1998, AM J HUM GENET, V63, P347, DOI 10.1086/301963	36	23	25	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25814	25820		10.1074/jbc.274.36.25814	http://dx.doi.org/10.1074/jbc.274.36.25814			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464321	hybrid			2022-12-25	WOS:000082554200085
J	Ikeuchi, T; Todo, T; Kobayashi, T; Nagahama, Y				Ikeuchi, T; Todo, T; Kobayashi, T; Nagahama, Y			cDNA cloning of a novel androgen receptor subtype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE JAPANESE EEL; ANGUILLA-JAPONICA; HUMAN ESTROGEN; HORMONAL INDUCTION; MOLECULAR-CLONING; SPERMATOGENESIS; GONADOTROPIN; SEQUENCE; SALMON; ALPHA	There has been general acceptance that only one type of androgen receptor (AR) exists in an individual. This contrasts with other members of the nuclear receptor superfamily where multiple forms have been reported (e.g. estrogen receptor alpha/beta, thyroid hormone receptor alpha/beta, etc.). We have previously identified 11-ketotestosterone (a potent androgen in teleosts) as the spermatogenesis-inducing hormone of the Japanese eel and have cloned its receptor (eAR1) cDNA from eel testis. Here we report on the cloning of a cDNA encoding a second type of AR (eAR2) from the eel testis and the functional characterization of the encoded protein. This cDNA contains a complete open reading frame encoding 797 amino acid residues. The amino acid sequence of eAR2 shows high homology with other ARs, including eAR1, in the DNA-binding (98-88%) and ligand-binding (59-85%) domains, whereas the other domains show low homology (<35%). In transient transfection assays of mammalian cells, the eAR2 protein displayed androgen-dependent activation of transcription from the androgen-responsive murine mammary tumor virus promoter. Tissue distribution of its mRNA was different from that of eAR1, We conclude that eAR2 is a novel AR in the eel, which we suggest should be named eel ARP to distinguish it from eAR1 (eAR alpha).	Natl Inst Basic Biol, Reprod Biol Lab, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Nagahama, Y (corresponding author), Natl Inst Basic Biol, Reprod Biol Lab, Okazaki, Aichi 4448585, Japan.							HUANG CJ, 1991, P NATL ACAD SCI USA, V88, P7486, DOI 10.1073/pnas.88.17.7486; KITAHARA N, 1988, COMP BIOCHEM PHYS B, V91, P551, DOI 10.1016/0305-0491(88)90020-X; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Miura C, 1996, DEV GROWTH DIFFER, V38, P257, DOI 10.1046/j.1440-169X.1996.t01-2-00004.x; MIURA T, 1991, P NATL ACAD SCI USA, V88, P5774, DOI 10.1073/pnas.88.13.5774; MIURA T, 1991, ZOOL SCI, V8, P63; Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738; Nagae M, 1997, FISH PHYSIOL BIOCHEM, V17, P179, DOI 10.1023/A:1007708312999; NAGAHAMA Y, 1994, INT J DEV BIOL, V38, P217; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; SUZUKI M, 1992, ZOOL SCI, V9, P157; Takeo J, 1999, J BIOL CHEM, V274, P5674, DOI 10.1074/jbc.274.9.5674; Thornton JW, 1998, BIOESSAYS, V20, P860, DOI 10.1002/(SICI)1521-1878(199810)20:10<860::AID-BIES12>3.0.CO;2-S; Todo T, 1996, MOL CELL ENDOCRINOL, V119, P37, DOI 10.1016/0303-7207(96)03792-6; Todo T, 1999, BIOCHEM BIOPH RES CO, V254, P378, DOI 10.1006/bbrc.1998.9919; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; UMEZONO K, 1989, CELL, V57, P1139; WAGNER A, 1994, J MOL EVOL, V38, P28, DOI 10.1007/BF00175492; WILSON JD, 1981, SCIENCE, V211, P1278, DOI 10.1126/science.7010602	24	103	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25205	25209		10.1074/jbc.274.36.25205	http://dx.doi.org/10.1074/jbc.274.36.25205			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464240	hybrid			2022-12-25	WOS:000082554200005
J	Jensen, PH; Hager, H; Nielsen, MS; Hojrup, P; Gliemann, J; Jakes, R				Jensen, PH; Hager, H; Nielsen, MS; Hojrup, P; Gliemann, J; Jakes, R			alpha-synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; FAMILIAL PARKINSONS-DISEASE; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; LEWY BODIES; BETA COMPONENT; NEUROFIBRILLARY TANGLES; HIPPOCAMPAL-NEURONS; BRAIN	alpha-Synuclein has been implicated in the pathogenesis of several neurodegenerative disorders based on the direct linking of missense mutations in alpha-synuclein to autosomal dominant Parkinson's disease and its presence in Lewy-like lesions. To gain insight into alpha-synuclein functions, we have investigated whether it binds neuronal proteins and modulates their functional state. The microtubule-associated protein tau was identified as a ligand by alpha-synuclein affinity chromatography of human brain cytosol, Direct binding assays using I-125-labeled human tau40 demonstrated a reversible binding with a IC50 about 50 pM. The interacting domains were localized to the C terminus of alpha-synuclein and the microtubule binding region of tau as determined by protein fragmentation and the use of recombinant peptides. High concentrations of tubulin inhibited the binding between tau and alpha-synuclein. Functionally, a-synuclein stimulated the protein kinase A-catalyzed phosphorylation of tau serine residues 262 and 356 as determined using a phospho-epitope-specific antibody. We propose that alpha-synuclein modulates the phosphorylation of soluble axonal tau and thereby indirectly affects the stability of axonal microtubules.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Odense Univ, Dept Mol Biol, DK-5230 Odense, Denmark; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Aarhus University; University of Southern Denmark; MRC Laboratory Molecular Biology	Jensen, PH (corresponding author), Aarhus Univ, Dept Med Biochem, Ole Worms Alle,Bldg 170, DK-8000 Aarhus C, Denmark.		Højrup, Peter/ABG-8477-2020; Nielsen, Morten Schallburg/G-9498-2016	Nielsen, Morten Schallburg/0000-0001-9863-9694; Hojrup, Peter/0000-0002-7838-6180; Jensen, Poul Henning/0000-0002-4439-9020				AKOPIAN AN, 1995, J BIOL CHEM, V270, P21264, DOI 10.1074/jbc.270.36.21264; Baba M, 1998, AM J PATHOL, V152, P879; BERNIER I, 1984, BIOCHIM BIOPHYS ACTA, V790, P174, DOI 10.1016/0167-4838(84)90221-8; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; ELLURU RG, 1995, MOL BIOL CELL, V6, P21, DOI 10.1091/mbc.6.1.21; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1998, NEUROSCI NEWS, V1, P2; Goslin K., 1991, CULTURING NERVE CELL, P251; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Iwai A, 1996, BRAIN RES, V720, P230, DOI 10.1016/0006-8993(96)00014-5; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Jensen PH, 1996, J BIOL CHEM, V271, P26892, DOI 10.1074/jbc.271.43.26892; Ji HJ, 1997, CANCER RES, V57, P759; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; NAKAJO S, 1990, J NEUROCHEM, V55, P2031, DOI 10.1111/j.1471-4159.1990.tb05792.x; Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417; OLESEN OF, 1994, J BIOL CHEM, V269, P32904; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Riess O, 1998, MOL MED TODAY, V4, P438, DOI 10.1016/S1357-4310(98)01343-4; Schmidt ML, 1996, ACTA NEUROPATHOL, V91, P475, DOI 10.1007/s004010050454; SERRANO L, 1985, EUR J BIOCHEM, V153, P595, DOI 10.1111/j.1432-1033.1985.tb09342.x; SHIBAYAMAIMAZU T, 1993, BRAIN RES, V622, P17, DOI 10.1016/0006-8993(93)90796-P; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141	50	302	307	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25481	25489		10.1074/jbc.274.36.25481	http://dx.doi.org/10.1074/jbc.274.36.25481			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464279	hybrid			2022-12-25	WOS:000082554200043
J	Proks, P; Ashfield, R; Ashcroft, FM				Proks, P; Ashfield, R; Ashcroft, FM			Interaction of vanadate with the cloned beta cell K-ATP channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; SULFONYLUREA RECEPTOR; SKELETAL-MUSCLE; P-GLYCOPROTEIN; SMOOTH-MUSCLE; INSULIN-SECRETION; SUBUNIT; BINDING; STOICHIOMETRY; NUCLEOTIDE	Vanadate is used as a tool to trap magnesium nucleotides in the catalytic site of ATPases. However, is has also been reported to activate ATP-sensitive potassium (K-ATP) channels in the absence of nucleotides. K-ATP channels comprise Kir6.2 and sulfonylurea receptor subunits (SUR1 in pancreatic beta cells, SUR2A in cardiac and skeletal muscle, and SUR2B in smooth muscle). We explored the effect of vanadate (2 mM), in the absence and presence of magnesium nucleotides, on different types of cloned K-ATP channels expressed in Xenopus oocytes. Currents were recorded from inside-out patches. Vanadate inhibited Kir6.2/SUR1 currents by approximately-50% but rapidly activated Kir6.2/SUR2A (approximately-4-fold) and Kir6.2/SUR2B (approximately-2-fold) currents. Mutations in SUR abolish channel activation by magnesium nucleotides did not prevent the effects of vanadate. Studies with chimeric SUR indicate that the first six transmembrane domains account for the difference in both the kinetics and the vanadate response of Kir6.2/SUR2A. Boiling the vanadate solution, which removes the decavanadate polymers, largely abolished both stimulatory and inhibitory actions of vanadate. Our results demonstrate that decavanadate modulates K-ATP channel activity via the SUR subunit, that this modulation varies with the type of SUR, that it differs from that produced by magnesium nucleotides, and that it involves transmembrane domains 1-6 of SUR.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	University of Oxford	Ashcroft, FM (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.			Proks, Peter/0000-0001-6097-3646				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Ashfield R, 1999, DIABETES, V48, P1341, DOI 10.2337/diabetes.48.6.1341; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; CHASTEEN ND, 1983, STRUCT BOND, V53, P105; Chutkow WA, 1996, DIABETES, V45, P1439, DOI 10.2337/diabetes.45.10.1439; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; KOTOWSKI A, 1967, GMELINS HDB INORGA B, P132; LOBERT S, 1994, BIOCHEMISTRY-US, V33, P6244, DOI 10.1021/bi00186a026; MORBACH S, 1993, J BIOL CHEM, V268, P18617; NAKASHIMA H, 1993, EUR J PHARMACOL, V233, P219, DOI 10.1016/0014-2999(93)90053-K; NEUMCKE B, 1991, EUR BIOPHYS J, V19, P119; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; OKAMOTO Y, 1986, NATURE, V324, P78, DOI 10.1038/324078a0; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Schultz BD, 1996, J MEMBRANE BIOL, V151, P63, DOI 10.1007/s002329900058; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; TAGUCHI Y, 1997, FEBS LETT, V377, P285; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383	33	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25393	25397		10.1074/jbc.274.36.25393	http://dx.doi.org/10.1074/jbc.274.36.25393			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464267	hybrid			2022-12-25	WOS:000082554200031
J	De Benedictis, G; Rose, G; Carrieri, G; De Luca, M; Falcone, E; Passarino, G; Bonafe, M; Monti, D; Baggio, G; Bertolini, S; Mari, D; Mattace, R; Franceschi, C				De Benedictis, G; Rose, G; Carrieri, G; De Luca, M; Falcone, E; Passarino, G; Bonafe, M; Monti, D; Baggio, G; Bertolini, S; Mari, D; Mattace, R; Franceschi, C			Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans	FASEB JOURNAL			English	Article						MtDNA haplogroup; mitochondria; sex-specific mtDNA/longevity association	POPULATIONS; ANCIENT; HAPLOGROUPS; MIGRATIONS; SEQUENCE; REVEALS; DISEASE; MTDNA	Mitochondrial DNA (mtDNA) is characterized by high variability, maternal inheritance, and absence of recombination. Studies of human populations have revealed ancestral associated polymorphisms whose combination defines groups of mtDNA types (haplogroups) that are currently used to reconstruct human evolution lineages. We used such inherited mtDNA markers to compare mtDNA population pools between a sample of individuals selected for successful aging and longevity (212 subjects older than 100 years and in good clinical condition) and a sample of 275 younger individuals (median age 38 years) carefully matched as to sex and geographic origin (northern and southern Italy). All nine haplogroups that are typical of Europeans were found in both samples, but male centenarians emerged in northern Italy as a particular sample: I) mtDNA haplogroup frequency distribution was different between centenarians and younger individuals (P=0.017 by permutation tests); and 2) the frequency of the J haplogroup was notably higher in centenarians than in younger individuals (P=0.0052 by Fisher exact test). Since haplogroups are defined on the basis of inherited variants, these data show that mtDNA inherited variability could play a role in successful aging and longevity.	Univ Calabria, Dept Cell Biol, I-87030 Arcavacata, Italy; Italian Natl Res Ctr Aging, Ancona, Italy; Univ Modena, Dept Biomed Sci, I-41100 Modena, Italy; Univ Sassari, Dept Geriatr, I-07100 Sassari, Italy; Univ Milan, Maggiore Hosp, IRCCS, Inst Internal Med, Milan, Italy; Univ Catanzaro, Dept Geriatr, Catanzaro, Italy	University of Calabria; IRCCS INRCA; Universita di Modena e Reggio Emilia; University of Sassari; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Magna Graecia University of Catanzaro	De Benedictis, G (corresponding author), Univ Calabria, Dept Cell Biol, I-87030 Arcavacata, Italy.		Monti, Daniela/G-9556-2012; Franceschi, Claudio/L-4484-2017; /V-4899-2019; Mari, Daniela/K-5663-2016	Monti, Daniela/0000-0001-8651-8123; Franceschi, Claudio/0000-0001-9841-6386; Mari, Daniela/0000-0002-6950-0789; Rose, Giuseppina/0000-0002-4264-4184				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BALLINGER SW, 1992, GENETICS, V130, P139; BRAND FN, 1992, J CLIN EPIDEMIOL, V45, P169, DOI 10.1016/0895-4356(92)90009-C; CAVALLISFORZA LL, 1993, HIST GEOGRAPHY HUMAN, P277; CHEN YS, 1995, AM J HUM GENET, V57, P133; CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370; De Benedictis G, 1998, EUR J HUM GENET, V6, P534, DOI 10.1038/sj.ejhg.5200222; DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; Herskind AM, 1996, HUM GENET, V97, P319, DOI 10.1007/s004390050042; Ivanova R, 1998, HUM MOL GENET, V7, P187, DOI 10.1093/hmg/7.2.187; KADENBACH B, 1995, MUTAT RES-DNAGING G, V338, P161, DOI 10.1016/0921-8734(95)00021-W; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; Martin GM, 1996, EXP GERONTOL, V31, P49, DOI 10.1016/0531-5565(95)02021-7; MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Tanaka M, 1998, LANCET, V351, P185, DOI 10.1016/S0140-6736(05)78211-8; Torroni A, 1996, GENETICS, V144, P1835; TORRONI A, 1994, AM J HUM GENET, V55, P760; TORRONI A, 1992, GENETICS, V130, P153; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WEIR BS, 1996, GENETIC DATA ANAL, V2, P165	24	306	318	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1532	1536		10.1096/fasebj.13.12.1532	http://dx.doi.org/10.1096/fasebj.13.12.1532			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463944				2022-12-25	WOS:000082347600008
J	Crowe, AJ; Sang, L; Li, KK; Lee, KC; Spear, BT; Barton, MC				Crowe, AJ; Sang, L; Li, KK; Lee, KC; Spear, BT; Barton, MC			Hepatocyte nuclear factor 3 relieves chromatin-mediated repression of the alpha-fetoprotein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; TRANSCRIPTION FACTOR HNF3; LOCUS-CONTROL REGION; BETA-GLOBIN GENE; HYPERSENSITIVE SITES; FORK-HEAD; IN-VITRO; DEVELOPMENTAL REGULATION; SYNTHETIC NUCLEI	The alpha-fetoprotein gene (AFP) is tightly regulated at the tissue-specific level, with expression confined to endoderm-derived cells. We have reconstituted AFP transcription on chromatin-assembled DNA templates in vitro. Our studies show that chromatin assembly is essential for hepatic-specific expression of the AFP gene. While nucleosome-free AFP DNA is robustly transcribed in vitro by both cervical (HeLa) and hepatocellular (HepG2) carcinoma extracts, the general transcription factors and transactivators present in HeLa extract cannot relieve chromatin-mediated repression of AFP, In contrast, preincubation with either HepG2 extract or HeLa extract supplemented with recombinant hepatocyte nuclear factor 3 alpha (HNF3 alpha), a hepatic-enriched factor expressed very early during liver development, is sufficient to confer transcriptional activation on a chromatin-repressed AFP template, Transient transfection studies illustrate that HNF3 alpha can activate AFP expression in a non-liver cellular environment, confirming a pivotal role for HNF3 alpha in establishing hepatic-specific gene expression. Restriction enzyme accessibility assays reveal that HNF3 alpha promotes the assembly of an open chromatin structure at the AFP promoter. Combined, these functional and structural data suggest that chromatin assembly establishes a barrier to block inappropriate expression of AFP in non-hepatic tissues and that tissue-specific factors, such as HNF3 alpha, are required to alleviate the chromatin-mediated repression.	Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Kentucky, Coll Med, Dept Microbiol & Immunol, Lexington, KY 40536 USA	University System of Ohio; University of Cincinnati; University of Kentucky	Barton, MC (corresponding author), Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.	Michelle.Barton@uc.edu		Spear, Brett/0000-0002-4343-9393; Barton, Michelle/0000-0002-4042-1374	NCI NIH HHS [CA73083] Funding Source: Medline; NIGMS NIH HHS [GM53683, GM45253] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA073083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045253, R01GM053683] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; ARONOW BJ, 1995, MOL CELL BIOL, V15, P1123; Asenbauer H, 1996, EUR J IMMUNOL, V26, P142, DOI 10.1002/eji.1830260122; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARTON MC, 1994, GENE DEV, V8, P2453, DOI 10.1101/gad.8.20.2453; BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; Barton MC, 1996, METHOD ENZYMOL, V274, P299; Beato M, 1996, J MOL MED, V74, P711, DOI 10.1007/s001090050076; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; CAI H, 1987, MOL CELL BIOL, V7, P3371, DOI 10.1128/MCB.7.10.3371; CAMPER SA, 1989, PROG NUCLEIC ACID RE, V36, P131; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chen HM, 1997, CRIT REV EUKAR GENE, V7, P11, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.20; Chicca JJ, 1998, MOL CELL BIOL, V18, P1701, DOI 10.1128/MCB.18.3.1701; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Collart MA, 1996, MOL CELL BIOL, V16, P6668; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dufort D, 1998, DEVELOPMENT, V125, P3015; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GODBOUT R, 1986, MOL CELL BIOL, V6, P477, DOI 10.1128/MCB.6.2.477; GODBOUT R, 1988, GENE DEV, V2, P949, DOI 10.1101/gad.2.8.949; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; Graef IA, 1997, SCIENCE, V277, P193, DOI 10.1126/science.277.5323.193; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Henderson AJ, 1995, CRIT REV EUKAR GENE, V5, P255, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.30; JONES BK, 1995, MOL CELL BIOL, V15, P7010; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KOH J, 1993, J BIOL CHEM, V268, P15912; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MCGHEE JD, 1981, CELL, V27, P45, DOI 10.1016/0092-8674(81)90359-7; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Muldrow TA, 1999, MOL CELL BIOL, V19, P2835; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; NAHON JL, 1987, BIOCHIMIE, V69, P445, DOI 10.1016/0300-9084(87)90082-4; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; Nickel BE, 1996, MOL CELL ENDOCRINOL, V118, P155, DOI 10.1016/0303-7207(96)03778-1; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; RHODES D, 1989, METHOD ENZYMOL, V170, P575; SANDALTZOPOULOS R, 1994, EMBO J, V13, P373, DOI 10.1002/j.1460-2075.1994.tb06271.x; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; SPEAR BT, 1995, DNA CELL BIOL, V14, P635, DOI 10.1089/dna.1995.14.635; STADLER J, 1980, CELL, V20, P451; Steger DJ, 1997, EMBO J, V16, P2463, DOI 10.1093/emboj/16.9.2463; Stein GS, 1996, J CELL BIOCHEM, V62, P198, DOI 10.1002/(SICI)1097-4644(199608)62:2<198::AID-JCB8>3.3.CO;2-3; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; VALLET V, 1995, MOL CELL BIOL, V15, P5453; vanderKnaap JA, 1997, P NATL ACAD SCI USA, V94, P11827, DOI 10.1073/pnas.94.22.11827; Wade PA, 1996, MOL CELL BIOL, V16, P1641; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WOLFFE A P, 1990, New Biologist, V2, P211; Wolffe AP, 1997, GENES CELLS, V2, P291, DOI 10.1046/j.1365-2443.1997.1260323.x; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zaret KS, 1995, PROTEIN EXPRES PURIF, V6, P821, DOI 10.1006/prep.1995.0014; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	77	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25113	25120		10.1074/jbc.274.35.25113	http://dx.doi.org/10.1074/jbc.274.35.25113			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455192	hybrid			2022-12-25	WOS:000082193400091
J	Gerchman, Y; Rimon, A; Padan, E				Gerchman, Y; Rimon, A; Padan, E			A pH-dependent conformational change of NhaA Na+/H+ antiporter of Escherichia coli involves loop VIII-IX, plays a role in the pH response of the protein, and is maintained by the pure protein in dodecyl maltoside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; HISTIDINE-226; MUTAGENESIS; SENSITIVITY; EXPRESSION; ADAPTATION; LYSR; ANT	Digestion with trypsin of purified His-tagged NhaA in a solution of dodecyl maltoside yields two fragments at alkaline pH but only one fragment at acidic pH. Determination of the amino acid sequence of the N terminus of the cleavage products show that the pH-sensitive cleavage site of NhaA, both in isolated everted membrane vesicles as well as in the pure protein in detergent, is Lys-249 in loop VIII-IX, which connects transmembrane segment VIII to IX. Interestingly, the two polypeptide products of the split antiporter remain complexed and co-purify on Ni2+-NTA column. Loop VIII-IX has also been found to play a role in the pH regulation of NhaA; three mutations introduced into the loop shift the pH profile of the Na+/H+ antiporter activity as measured in everted membrane vesicles. An insertion mutation introducing ILe-Glu-Gly between residues Lys-249 and Arg-250 (K249-IEG-R250) and Cys replacement of either Val-254 (V254C) or Glu-241 (E241C) cause acidic shift of the pH profile of the antiporter by 0.5, 1, and 0.3 pH units, respectively. Interestingly, the double mutant E241C/V254C introduces a basic shift of more than 1 pH unit with respect to the single mutation V254C. Taken together these results imply the involvement of loop VIII-IX in the pH-induced conformational change, which leads to activation of NhaA at alkaline pH.	Hebrew Univ Jerusalem, Inst Life Sci, Div Microbial & Mol Ecol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Padan, E (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Div Microbial & Mol Ecol, IL-91904 Jerusalem, Israel.	etana@vms.huji.ac.il	Gerchman, Yoram/H-4698-2019; Gerchman, Yoram/F-5226-2015	Gerchman, Yoram/0000-0002-8637-9589				Carmel O, 1997, EMBO J, V16, P5922, DOI 10.1093/emboj/16.19.5922; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; He MM, 1998, MOL MEMBR BIOL, V15, P15, DOI 10.3109/09687689809027513; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Inoue H, 1999, FEBS LETT, V443, P11, DOI 10.1016/S0014-5793(98)01652-4; KARPEL R, 1991, J BIOL CHEM, V266, P21753; Noumi T, 1997, J BIOCHEM-TOKYO, V121, P661; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; Padan E, 1998, MICR EXTREM UNUSUAL, P163; PADAN E, 1992, ALKALI CATION TRANSP, P3; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1993, J BIOL CHEM, V268, P1729; PINNER E, 1994, J BIOL CHEM, V269, P26274; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; RIMON A, 1995, J BIOL CHEM, V270, P26813, DOI 10.1074/jbc.270.45.26813; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; ROTHMAN A, 1997, BIOCHEMISTRY-US, V36, P14577; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; Schuldiner S., 1992, ALKALI CATION TRANSP, P25; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	28	71	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24617	24624		10.1074/jbc.274.35.24617	http://dx.doi.org/10.1074/jbc.274.35.24617			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455127	hybrid			2022-12-25	WOS:000082193400026
J	Kouranov, A; Wang, HA; Schnell, DJ				Kouranov, A; Wang, HA; Schnell, DJ			Tic22 is targeted to the intermembrane space of chloroplasts by a novel pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER ENVELOPE MEMBRANE; PROTEIN IMPORT APPARATUS; THYLAKOID MEMBRANE; COMPONENT; BINDING; SIGNAL	Tic22 previously was identified as a component of the general import machinery that functions in the import of nuclear-encoded proteins into the chloroplast. Tic22 is peripherally associated with the outer face of the inner chloroplast envelope membrane, making it the first known resident of the intermembrane space of the envelope. We have investigated the import of Tic22 into isolated chloroplasts to define the requirements for targeting of proteins to the intermembrane space, Tic22 is nuclear-endoded and synthesized as a preprotein with a 50-amino acid N-terminal presequence. The analysis of deletion mutants and chimerical proteins indicates that the precursor of Tic22 (preTic22) presequence is necessary and sufficient for targeting to the intermembrane space. Import of preTic22 was stimulated by ATP and required the presence of protease-sensitive components on the chloroplast surface. PreTic22 import was not competed by an excess of an authentic stromal preprotein, indicating that targeting to the intermembrane space does not involve the general import pathway utilized by stromal preproteins. On the basis of these observations, we conclude that preTic22 is targeted to the intermembrane space of chloroplasts by a novel import pathway that is distinct from known pathways that target proteins to other chloroplast subcompartments.	Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA	Rutgers State University Newark; Rutgers State University New Brunswick	Schnell, DJ (corresponding author), Rutgers State Univ, Dept Biol Sci, 101 Warren St, Newark, NJ 07102 USA.							BRINK S, 1995, J BIOL CHEM, V270, P20808, DOI 10.1074/jbc.270.35.20808; Chen DD, 1997, J BIOL CHEM, V272, P6614, DOI 10.1074/jbc.272.10.6614; CLINE K, 1985, J BIOL CHEM, V260, P3691; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; Jackson DT, 1998, J BIOL CHEM, V273, P16583, DOI 10.1074/jbc.273.26.16583; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kouranov A, 1998, J CELL BIOL, V143, P991, DOI 10.1083/jcb.143.4.991; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; Li HM, 1996, PLANT CELL, V8, P2117, DOI 10.1105/tpc.8.11.2117; Li HM, 1997, J BIOL CHEM, V272, P10968; Lubeck J, 1997, J CELL BIOL, V137, P1279, DOI 10.1083/jcb.137.6.1279; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; Schnell DJ, 1997, TRENDS CELL BIOL, V7, P303, DOI 10.1016/S0962-8924(97)01111-2; Schnell DJ, 1998, ANNU REV PLANT PHYS, V49, P97, DOI 10.1146/annurev.arplant.49.1.97; Tranel PJ, 1996, PLANT CELL, V8, P2093, DOI 10.1105/tpc.8.11.2093; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x	22	57	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25181	25186		10.1074/jbc.274.35.25181	http://dx.doi.org/10.1074/jbc.274.35.25181			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455201	hybrid			2022-12-25	WOS:000082193400100
J	Maximov, A; Sudhof, TC; Bezprozvanny, I				Maximov, A; Sudhof, TC; Bezprozvanny, I			Association of neuronal calcium channels with modular adaptor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; N-TYPE; FUNCTIONAL EXPRESSION; CELL-ADHESION; BINDING; DOMAIN; SUBUNIT; SITE; NEUREXINS; RECEPTORS	Presynaptic voltage-gated calcium (Ca2+) channels mediate Ca2+ influx into the presynaptic terminal that triggers synaptic vesicle fusion and neurotransmitter release. The immediate proximity of Ca2+ channels to the synaptic vesicle release apparatus is critical for rapid and efficient synaptic transmission. In a series of biochemical experiments, we demonstrate a specific association of the cytosolic carboxyl terminus of the N-type Ca2+ channel pore-forming alpha(1B) subunit with the modular adaptor proteins Mint1 and CASK. The carboxyl termini of alpha(1B) bind to the first PDZ domain of Mint1 (Mint1-1). The proline-rich region present in the carboxyl termini of alpha(1B) binds to the SH3 domain of CASK. Mint1-1 is specific for the E/D-X-W-C/S-COOH consensus, which defines a novel class of PDZ domains (class III). The Mint1-1 PDZ domain-binding motif is present only in the "long" carboxyl-terminal splice variants of N-type (alpha(1B)) and P/Q-type (alpha(1A)) Ca2+ channels, but not in R-type (alpha(1E)) or L-type (alpha(1C)) Ca2+ channels. Our results directly link presynaptic Ca2+ channels to a macromolecular complex formed by modular adaptor proteins at synaptic junction and advance our understanding of coupling between cell adhesion and synaptic vesicle exocytosis.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bezprozvanny, I (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA.	bezprozv@utsw.swmed.edu						Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Hata Y, 1996, J NEUROSCI, V16, P2488; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kimura T, 1997, BIOCHEM BIOPH RES CO, V230, P147, DOI 10.1006/bbrc.1996.5732; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; NIIDOME T, 1993, ANN NY ACAD SCI, V707, P368, DOI 10.1111/j.1749-6632.1993.tb38073.x; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Smith LA, 1996, J NEUROSCI, V16, P7868; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; Wu LG, 1998, P NATL ACAD SCI USA, V95, P4720, DOI 10.1073/pnas.95.8.4720; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	28	238	243	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24453	24456		10.1074/jbc.274.35.24453	http://dx.doi.org/10.1074/jbc.274.35.24453			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455105	hybrid			2022-12-25	WOS:000082193400004
J	Tinsley, JH; Wu, MH; Ma, WY; Taulman, AC; Yuan, SY				Tinsley, JH; Wu, MH; Ma, WY; Taulman, AC; Yuan, SY			Activated neutrophils induce hyperpermeability and phosphorylation of adherens junction proteins in coronary venular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PERMEABILITY; MONOLAYERS; MIGRATION; CADHERIN; MECHANISMS; ADHESION; THROMBIN; ELASTASE; DISORGANIZATION	The endothelial adherens junction is formed by complexes of transmembrane adhesive proteins, of which beta-catenin is known to connect the junctional protein vascular endothelial (VE)-cadherin to the cytoskeleton and to play a signaling role in the regulation of junction-cytoskeleton interaction. In this study, we investigated the effect of neutrophil activation on endothelial monolayer integrity and on beta-catenin and VE-cadherin modification. Treatment of cultured bovine coronary endothelial monolayers with C5a-activated neutrophils resulted in an increase in permeability as measured by albumin clearance across the monolayer, Furthermore, large scale intercellular gap formation was observed in coincidence with the hyperpermeability response. Immunofluorescence analysis showed that beta-catenin and VE-cadherin staining changed from a uniform distribution along the membrane of control cells to a diffuse pattern for both proteins and finger-like projections for beta-catenin in neutrophil-exposed monolayers. Correlatively, there was an increase in actin stress fiber formation in treated cells. Finally, beta-catenin and VE-cadherin from neutrophil-treated endothelial cells showed a significant increase in tyrosine phosphorylation, Our results are the first to link neutrophil-mediated changes in adherens junctions with intercellular gap formation and hyperpermeability in microvascular endothelial cells. These data suggest that neutrophils may regulate endothelial barrier function through a process conferring conformational changes to beta-catenin and VE-cadherin.	Texas A&M Univ, Hlth Sci Ctr, Dept Surg, Temple, TX 76504 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Med Physiol, Temple, TX 76504 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Yuan, SY (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Surg, 1901 S 1st St,Bldg 4, Temple, TX 76504 USA.	yuan@tamu.edu	Wu, Mack/I-6536-2012; Yuan, Sarah Y/A-2111-2012		NHLBI NIH HHS [K02 HL-03606, HL-61507, HL-52221] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052221, K02HL003606, R01HL061507] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allport JR, 1997, J EXP MED, V186, P517, DOI 10.1084/jem.186.4.517; BEESLEY JE, 1978, J CELL SCI, V33, P85; BEYNON HLC, 1994, J IMMUNOL, V153, P3160; Burns AR, 1997, J IMMUNOL, V159, P2893; Carden D, 1998, AM J PHYSIOL-HEART C, V275, pH385, DOI 10.1152/ajpheart.1998.275.2.H385; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; DRAKE WT, 1992, LAB INVEST, V67, P617; Ehringer WD, 1996, J CELL PHYSIOL, V167, P562, DOI 10.1002/(SICI)1097-4652(199606)167:3<562::AID-JCP20>3.3.CO;2-K; FURIE MB, 1987, J CELL SCI, V88, P161; GIBBS LS, 1990, J CELL PHYSIOL, V145, P496, DOI 10.1002/jcp.1041450315; HUANG AJ, 1993, J CELL BIOL, V120, P1371, DOI 10.1083/jcb.120.6.1371; Huang QB, 1997, AM J PHYSIOL-HEART C, V273, pH2442, DOI 10.1152/ajpheart.1997.273.5.H2442; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lampugnani MG, 1997, J CELL SCI, V110, P2065; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; ROSENGREN S, 1991, J APPL PHYSIOL, V71, P1322, DOI 10.1152/jappl.1991.71.4.1322; Rubin Lee L., 1992, Current Opinion in Cell Biology, V4, P830, DOI 10.1016/0955-0674(92)90107-N; SCHAEFFER RC, 1993, AM J PHYSIOL, V264, pH1798, DOI 10.1152/ajpheart.1993.264.6.H1798; SCHELLING ME, 1988, AM J PHYSIOL, V254, pH1211, DOI 10.1152/ajpheart.1988.254.6.H1211; SEPPER R, 1995, J CLIN IMMUNOL, V15, P27, DOI 10.1007/BF01489487; SMEDLY LA, 1986, J CLIN INVEST, V77, P1233, DOI 10.1172/JCI112426; SUTTORP N, 1993, INT J MICROCIRC, V13, P187; TAYLOR RF, 1981, J CLIN INVEST, V67, P584, DOI 10.1172/JCI110071; WEISS SJ, 1984, J CLIN INVEST, V73, P1297, DOI 10.1172/JCI111332; YUAN Y, 1995, AM J PHYSIOL-HEART C, V268, pH490, DOI 10.1152/ajpheart.1995.268.1.H490; Yuan Y, 1998, AM J PHYSIOL-HEART C, V275, pH84, DOI 10.1152/ajpheart.1998.275.1.H84; YUAN YA, 1993, AM J PHYSIOL, V264, pH1734, DOI 10.1152/ajpheart.1993.264.5.H1734	31	118	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24930	24934		10.1074/jbc.274.35.24930	http://dx.doi.org/10.1074/jbc.274.35.24930			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455168	hybrid			2022-12-25	WOS:000082193400067
J	Williamson, LC; Bateman, KE; Clifford, JCM; Neale, EA				Williamson, LC; Bateman, KE; Clifford, JCM; Neale, EA			Neuronal sensitivity to tetanus toxin requires gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD NEURONS; RAT-BRAIN; SPHINGOLIPID BIOSYNTHESIS; NEUROTRANSMITTER RELEASE; PC12 CELLS; BOTULINUM; BINDING; NEUROTOXINS; INHIBITION; MEMBRANES	Tetanus toxin produces spastic paralysis in situ by blocking inhibitory neurotransmitter release in the spinal cord. Although di- and trisialogangliosides bind tetanus toxin, their role as productive toxin receptors remains unclear. We examined toxin binding and action in spinal cord cell cultures grown in the presence of fumonisin B-1, an inhibitor of ganglioside synthesis. Mouse spinal cord neurons grown for 3 weeks in culture in 20 mu M fumonisin B-1 develop dendrites, axons, and synaptic terminals similar to untreated neurons, even though thin layer chromatography shows a greater than 90% inhibition of ganglioside synthesis. Absence of tetanus and cholera toxin binding by toxin-horseradish peroxidase conjugates or immunofluorescence further indicates loss of mono- and polysialogangliosides. In contrast to control cultures, tetanus toxin added to fumonisin B-1-treated cultures does not block potassium-stimulated glycine release, inhibit activity-dependent uptake of FM1-43, or abolish immunoreactivity for vesicle-associated membrane protein, the toxin substrate. Supplementing fumonisin B-1-treated cultures with mixed brain gangliosides completely restores the ability of tetanus toxin to bind to the neuronal surface and to block neurotransmitter release. These data demonstrate that fumonisin B-1 protects against toxin-induced synaptic blockade and that gangliosides are a necessary component of the receptor mechanism for tetanus toxin.	NICHHD, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); US Food & Drug Administration (FDA)	Neale, EA (corresponding author), NICHHD, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000704] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERGEY GK, 1983, J NEUROSCI, V3, P2310; BERGEY GK, 1987, J NEUROPHYSIOL, V57, P121, DOI 10.1152/jn.1987.57.1.121; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BIGALKE H, 1986, TOXICON, V24, P1065, DOI 10.1016/0041-0101(86)90133-9; CRITCHLEY DR, 1986, J NEUROCHEM, V47, P213; FACCI L, 1988, J CELL BIOL, V106, P821, DOI 10.1083/jcb.106.3.821; FITZGERALD SC, 1989, DISSECTION TISSUE CU, P219; FUJITA K, 1990, NEUROCHEM RES, V15, P373, DOI 10.1007/BF00969922; GILOH H, 1982, SCIENCE, V217, P1252, DOI 10.1126/science.7112126; HABERMANN E, 1986, CURR TOP MICROBIOL, V129, P93; HABIG WH, 1986, J NEUROCHEM, V47, P930; HABIG WH, 1989, 8TH INT C TET ROM, P66; Halpern JL, 1995, CURR TOP MICROBIOL, V195, P221; HAREL R, 1993, J BIOL CHEM, V268, P14476; LAZAROVICI P, 1986, BIOCHEMISTRY-US, V25, P7047, DOI 10.1021/bi00370a044; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MARXEN P, 1989, TOXICON, V27, P849, DOI 10.1016/0041-0101(89)90097-4; MIDDLEBROOK JL, 1989, BOTULINUM NEUROTOXIN, P95; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; NEALE EA, 1993, J NEUROSCI RES, V34, P54, DOI 10.1002/jnr.490340107; NEALE EA, 1989, 8TH INT C TET ROM, P58; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; PARTON RG, 1988, BRAIN RES, V475, P118, DOI 10.1016/0006-8993(88)90204-1; PIERCE EJ, 1986, BIOCHEM J, V236, P845, DOI 10.1042/bj2360845; RANSOM BR, 1977, J NEUROPHYSIOL, V40, P1132, DOI 10.1152/jn.1977.40.5.1132; SANDBERG K, 1989, J BIOL CHEM, V264, P5679; Schengrund CL, 1996, J NEUROCHEM, V66, P2556; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; Shapiro RE, 1997, J BIOL CHEM, V272, P30380, DOI 10.1074/jbc.272.48.30380; SHONE CC, 1992, EUR J BIOCHEM, V207, P1009, DOI 10.1111/j.1432-1033.1992.tb17137.x; TUCKER LM, 1995, J NEUROSCI METH, V59, P217, DOI 10.1016/0165-0270(94)00207-W; Umland TC, 1997, NAT STRUCT BIOL, V4, P788, DOI 10.1038/nsb1097-788; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VANHEYNINGEN W, 1961, J GEN MICROBIOL, V24, P107, DOI 10.1099/00221287-24-1-107; WALTON KM, 1988, J BIOL CHEM, V263, P2055; WANG E, 1991, J BIOL CHEM, V266, P14486; WESTBROOK GL, 1984, DEV NEUROSCIENCE PHY, P11; WILLIAMSON LC, 1992, J NEUROCHEM, V59, P2148; Winter A, 1996, CHEM PHYS LIPIDS, V81, P21, DOI 10.1016/0009-3084(96)02529-7; YAVIN E, 1986, EUR J BIOCHEM, V154, P403, DOI 10.1111/j.1432-1033.1986.tb09412.x; [No title captured]; [No title captured]	44	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25173	25180		10.1074/jbc.274.35.25173	http://dx.doi.org/10.1074/jbc.274.35.25173			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455200	hybrid			2022-12-25	WOS:000082193400099
J	Hemrika, W; Renirie, R; Macedo-Ribeiro, S; Messerschmidt, A; Wever, R				Hemrika, W; Renirie, R; Macedo-Ribeiro, S; Messerschmidt, A; Wever, R			Heterologous expression of the vanadium-containing chloroperoxidase from Curvularia inaequalis in Saccharomyces cerevisiae and site-directed mutagenesis of the active site residues His(496), Lys(353), Arg(360), and Arg(490)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; STATE KINETIC-ANALYSIS; ASCOPHYLLUM-NODOSUM; CONTAINING ENZYME; ESCHERICHIA-COLI; BROMOPEROXIDASE; FUNGUS; GLUCOSE-6-PHOSPHATASE; GENE; REACTIVITY	The vanadium-containing chloroperoxidase from the fungus Curvularia inaequalis is heterologously expressed to high levels in the yeast Saccharomyces cerevisiae. Characterization of the recombinant enzyme reveals that this behaves very similar to the native chloroperoxidase. Site-directed mutagenesis is performed on four highly conserved active site residues to examine their role in catalysis. When the vanadate-binding residue His(496) is changed into an alanine, the mutant enzyme loses the ability to bind vanadate covalently resulting in an inactive enzyme. The negative charges on the vanadate oxygens are compensated by hydrogen bonds with the residues Arg(60), Arg(490), and Lys(353). When these residues are changed into alanines the mutant enzymes lose the ability to effectively oxidize chloride but can still function as bromoperoxidases. A general mechanism for haloperoxidase catalysis is proposed that also correlates the kinetic properties of the mutants with the charge and the hydrogen-bonding network in the vanadate-binding site.	Univ Amsterdam, EC Slater Inst Biochem Res, Fac Chem, NL-1018 TV Amsterdam, Netherlands; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany	University of Amsterdam; Max Planck Society	Wever, R (corresponding author), Univ Amsterdam, EC Slater Inst Biochem Res, Fac Chem, Plantage Muidergracht 12, NL-1018 TV Amsterdam, Netherlands.		Wever, Ron/AAM-4520-2020; Messerschmidt, Albrecht/A-8337-2008; Macedo-Ribeiro, Sandra/D-9258-2011	Macedo-Ribeiro, Sandra/0000-0002-7698-1170				ARBER JM, 1989, BIOCHEMISTRY-US, V28, P7968, DOI 10.1021/bi00445a062; Barnett P, 1998, J BIOL CHEM, V273, P23381, DOI 10.1074/jbc.273.36.23381; Barnett P, 1997, BBA-GENE STRUCT EXPR, V1352, P73, DOI 10.1016/S0167-4781(96)00238-2; BARNETT P, 1997, THESIS U AMSTERDAM; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brake A J, 1989, Biotechnology, V13, P269; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Butler A, 1997, STRUCT BOND, V89, P109; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CHEN YT, 1995, METABOLIC MOL BASES, V7, P935; DEBOER E, 1988, J BIOL CHEM, V263, P12326; DEBOER E, 1986, BIOCHIM BIOPHYS ACTA, V872, P104, DOI 10.1016/0167-4838(86)90153-6; DEBOER E, 1987, BIOTECHNOL BIOENG, V30, P607, DOI 10.1002/bit.260300504; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hamstra BJ, 1998, INORG CHEM, V37, P949, DOI 10.1021/ic9711776; Hemrika W, 1997, FEBS LETT, V409, P317, DOI 10.1016/S0014-5793(97)00530-9; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; HEMRIKA W, 1998, VANADIUM COMPOUNDS C, P186; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; Kanoh H, 1997, BBA-LIPID LIPID MET, V1348, P56, DOI 10.1016/S0005-2760(97)00094-5; KLEBE RJ, 1980, GENE, V11, P11; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Macedo-Ribeiro S, 1999, J BIOL INORG CHEM, V4, P209, DOI 10.1007/s007750050306; Messerschmidt A, 1997, BIOL CHEM, V378, P309, DOI 10.1515/bchm.1997.378.3-4.309; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; PLAT H, 1987, BIOCHEM J, V248, P277, DOI 10.1042/bj2480277; Sambrook J., 2002, MOL CLONING LAB MANU; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; SIMONS BH, 1995, EUR J BIOCHEM, V229, P566, DOI 10.1111/j.1432-1033.1995.tb20499.x; Slebodnick C, 1997, STRUCT BOND, V89, P51; SOEDJAK HS, 1991, BIOCHIM BIOPHYS ACTA, V1079, P1, DOI 10.1016/0167-4838(91)90016-S; SOEDJAK HS, 1990, BIOCHEMISTRY-US, V29, P7974, DOI 10.1021/bi00486a028; STJOHN TP, 1981, J MOL BIOL, V152, P285, DOI 10.1016/0022-2836(81)90244-8; Stukey J, 1997, PROTEIN SCI, V6, P469; VANSCHIJNDEL JWP, 1994, THESIS U AMSTERDAM A; VANSCHIJNDEL JWPM, 1993, FEBS LETT, V336, P239, DOI 10.1016/0014-5793(93)80811-8; VANSCHIJNDEL JWPM, 1993, BIOCHIM BIOPHYS ACTA, V1161, P249, DOI 10.1016/0167-4838(93)90221-C; VANSCHIJNDEL JWPM, 1994, EUR J BIOCHEM, V225, P151; VOLLENBROEK EGM, 1995, BIOCHEM SOC T, V23, P267, DOI 10.1042/bst0230267; Wever R, 1988, Prog Clin Biol Res, V274, P477	44	95	95	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23820	23827		10.1074/jbc.274.34.23820	http://dx.doi.org/10.1074/jbc.274.34.23820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446144	hybrid			2022-12-25	WOS:000082110900023
J	Jankowski, J; Tepel, M; van der Giet, M; Tente, IM; Henning, L; Junker, R; Zidek, W; Schluter, H				Jankowski, J; Tepel, M; van der Giet, M; Tente, IM; Henning, L; Junker, R; Zidek, W; Schluter, H			Identification and characterization of P-1,P-7-di(adenosine-5 ')-heptaphosphate from human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER-DESORPTION IONIZATION; DIADENOSINE PHOSPHATES; ADENINE DINUCLEOTIDES; PURINOCEPTORS; TETRAPHOSPHATE; PEPTIDES; RELEASE	Diadenosine pentaphosphate and diadenosine hexaphosphate have been isolated in human platelets and have been postulated to play an important role in the control of vascular tone. Here we describe the isolation and identification of diadenosine heptaphosphate from human platelets. Dinucleoside polyphosphates were concentrated by affinity chromatography from a nucleotide containing fraction from deproteinated human platelets. Dinucleoside polyphosphates were purified by anion-exchange and reversed phase high performance liquid chromatography to homogeneity. Analysis of one of these fractions with matrix-assisted laser desorption/ionization mass spectrometry revealed a molecular mass of 1076.4 (1077.4 = [M + H](+)) Da. UV spectroscopic analysis of this fraction showed the spectrum of an adenosine derivative. Comparison of the postsource decay matrix-assisted laser desorption/ionization mass spectrum of the fraction minus that of diadenosine heptaphosphate (Ap(7)A) demonstrated that the isolated substance was identical to Ap(7)A. The identity of the retention times of the authentic and the isolated compound confirmed this result. Enzymatic analysis demonstrated an interconnection of the phosphate groups with the adenosines in the 5'-positions of the riboses. With thrombin-induced platelet aggregation, Ap(7)A is released from the platelets into the extracellular space. The vasoconstrictive action of Ap(7)A on the vasculature of the isolated perfused rat kidney Ap(7)A was slightly less than that of Ap(6)A. The threshold of the vasoconstrictive action of Ap(7)A was 10(-5) mol/liter. The vasoconstrictive effect was abolished by suramin and pyridoxal phosphate 6-azophenyl-2',4'-disulfonic acid, suggesting an activation of P-2x receptors. Furthermore, Ap(7)A inhibits ADP-induced platelet aggregation. Thus, the potent vasoconstrictor Ap(7)A derived from human platelets, Like other diadenosine polyphosphates, may play a role in the regulation of vascular tone and hemostasis.	Ruhr Univ Bochum Klin, Marienhosp, Med Klin 1, D-44625 Herne, Germany; Univ Munster, Inst Arterioskleroseforsch, D-48149 Munster, Germany; Univ Munster, Inst Klin Chem & Lab Med, D-48149 Munster, Germany	Ruhr University Bochum; St. Marien Hospital; University of Munster; University of Munster	Schluter, H (corresponding author), Ruhr Univ Bochum Klin, Marienhosp, Med Klin 1, Holkeskampring 40, D-44625 Herne, Germany.		Schluter, Hartmut/D-1371-2015; Junker, Ralf/M-2358-2013	Schluter, Hartmut/0000-0002-9358-7036; Tepel, Martin/0000-0002-0086-0997				AGHA A, 1992, J VASC RES, V29, P281, DOI 10.1159/000158943; BARNES LD, 1985, ANAL BIOCHEM, V144, P296, DOI 10.1016/0003-2697(85)90120-4; BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185; BUSSE R, 1988, AM J PHYSIOL, V254, pH828, DOI 10.1152/ajpheart.1988.254.5.H828; Chan CM, 1998, AM J PHYSIOL-RENAL, V274, pF799, DOI 10.1152/ajprenal.1998.274.4.F799; FLODGAARD H, 1982, BIOCHEM J, V208, P737, DOI 10.1042/bj2080737; HARRISON MJ, 1975, FEBS LETT, V54, P57, DOI 10.1016/0014-5793(75)81067-2; HILLENKAMP F, 1990, METHOD ENZYMOL, V193, P280, DOI 10.1016/0076-6879(90)93420-P; KAUFMANN R, 1994, INT J MASS SPECTROM, V131, P355, DOI 10.1016/0168-1176(93)03876-N; Kitzler J.W., 1992, AP4A OTHER DINUCLEOS, P135; Kunapuli SP, 1998, TRENDS PHARMACOL SCI, V19, P391, DOI 10.1016/S0165-6147(98)01248-6; LUTHJE J, 1983, BIOCHEM BIOPH RES CO, V115, P258; MacKenzie AB, 1996, J BIOL CHEM, V271, P2879, DOI 10.1074/jbc.271.6.2879; NG KME, 1987, NUCLEIC ACIDS RES, V15, P3573, DOI 10.1093/nar/15.8.3573; Ogilvie A, 1996, J AUTON PHARMACOL, V16, P325, DOI 10.1111/j.1474-8673.1996.tb00045.x; OGILVIE A, 1992, AP4A OTHER DINUCLEOS, P229; Pintor J, 1996, BRIT J PHARMACOL, V119, P1006, DOI 10.1111/j.1476-5381.1996.tb15771.x; PLATEAU P, 1992, AP4A OTHER DINUCLEOS, P63; POHL U, 1991, AM J PHYSIOL, V260, pH1692, DOI 10.1152/ajpheart.1991.260.5.H1692; Remy P., 1992, AP4A OTHER DINUCLEOS, P151; Schluter H, 1996, J AUTON PHARMACOL, V16, P357, DOI 10.1111/j.1474-8673.1996.tb00053.x; Schluter H, 1998, J CLIN INVEST, V101, P682, DOI 10.1172/JCI119882; SCHLUTER H, 1994, NATURE, V367, P186, DOI 10.1038/367186a0; SULKOWSKI E, 1971, BIOCHIM BIOPHYS ACTA, V240, P443, DOI 10.1016/0005-2787(71)90538-7; vanderGiet M, 1997, BRIT J PHARMACOL, V120, P1453, DOI 10.1038/sj.bjp.0701074	25	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23926	23931		10.1074/jbc.274.34.23926	http://dx.doi.org/10.1074/jbc.274.34.23926			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446159	hybrid			2022-12-25	WOS:000082110900038
J	Jekely, G; Friedrich, P				Jekely, G; Friedrich, P			Characterization of two recombinant Drosophila calpains - CALPA and a novel homolog, CALPB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; SKELETAL-MUSCLE; MU-CALPAIN; ERYTHROCYTE-MEMBRANE; SCHISTOSOMA-MANSONI; MOLECULAR-CLONING; PROTEINASE; AUTOLYSIS; SUBUNITS; DOMAIN	We have sequenced the cDNA of a novel Ca2+-activated cysteine proteinase (calpain) from the fruit fly, Drosophila melanogaster, The predicted protein, designated as CALPB, shows high similarity to the previously identified Drosophila calpain, CALPA. The two proteins were expressed in Escherichia coli and purified to homogeneity by metal chelate affinity chromatography either from inclusion bodies or from the bacterial cytosol, Both enzymes were Ca2+-dependent proteinases and attained half-maximal activation in the presence of millimolar Ca2+. The activity and the rate of activation of CALPA, but not CALPB, could be activated by phosphatidylinositol 4,5-diphosphate, phosphatidylinositol C-monophosphate, phosphatidylinositol, and phosphatidic acid. A truncated form of CALPA, lacking the CALPA-specific unique insertion region, has also been expressed and characterized. Although it lacked the 16-amino acid long putative membrane-anchoring segment, its activation by phospholipids was similar to that of the full-length CALPA protein, The enzymes undergo N-terminal autolysis in a Ca2+-dependent manner which was shown with CALPB to ran parallel with enzyme activation. Moreover, fully autolyzed CALPB lacked the characteristic activation phase indicating the requirement for autolysis upon activation of this calpain form in vitro. The analysis of the mechanism of activation in Drosophila calpains seems to corroborate the autolysis model of calpain activation.	Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, H-1518 Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Jekely, G (corresponding author), Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, POB 7, H-1518 Budapest, Hungary.	jekely@enzim.hu	Jékely, Gáspár/I-8708-2012	Jékely, Gáspár/0000-0001-8496-9836				Amano S, 1997, J BIOCHEM, V122, P865; ANDRESEN K, 1991, J BIOL CHEM, V266, P15085; ASZODI A, 1991, P NATL ACAD SCI USA, V88, P5832, DOI 10.1073/pnas.88.13.5832; Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; Barnes TM, 1996, EMBO J, V15, P4477, DOI 10.1002/j.1460-2075.1996.tb00825.x; BROWN N, 1993, FEBS LETT, V322, P65, DOI 10.1016/0014-5793(93)81112-D; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; EDMUNDS T, 1991, BIOCHIM BIOPHYS ACTA, V1077, P197, DOI 10.1016/0167-4838(91)90059-9; Elce JS, 1997, J BIOL CHEM, V272, P11268; ELCE JS, 1995, PROTEIN ENG, V8, P843, DOI 10.1093/protein/8.8.843; EMORI Y, 1994, J BIOL CHEM, V269, P25137; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; FRIEDEN C, 1979, ANNU REV BIOCHEM, V48, P471, DOI 10.1146/annurev.bi.48.070179.002351; Gitler D, 1998, NEURON, V20, P1123, DOI 10.1016/S0896-6273(00)80494-8; GRAHAMSIEGENTHALER K, 1994, J BIOL CHEM, V269, P30457; JEKELY G, 1999, IN PRESS J MOL EVOL; Johnson GVW, 1997, BIOESSAYS, V19, P1011, DOI 10.1002/bies.950191111; KARCZ SR, 1991, MOL BIOCHEM PARASIT, V49, P333, DOI 10.1016/0166-6851(91)90078-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HJ, 1998, BIOL CHEM, V379, P175, DOI 10.1515/bchm.1998.379.2.175; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; MICHETTI M, 1991, EUR J BIOCHEM, V202, P1177, DOI 10.1111/j.1432-1033.1991.tb16487.x; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; PINTER M, 1988, BIOCHEM J, V253, P467, DOI 10.1042/bj2530467; PINTER M, 1992, BIOCHEMISTRY-US, V31, P8201, DOI 10.1021/bi00150a012; PONTREMOLI S, 1985, BIOCHEM BIOPH RES CO, V128, P331, DOI 10.1016/0006-291X(85)91683-3; PONTREMOLI S, 1988, P NATL ACAD SCI USA, V85, P1740, DOI 10.1073/pnas.85.6.1740; PONTREMOLI S, 1990, BIOCHEM BIOPH RES CO, V171, P569, DOI 10.1016/0006-291X(90)91184-T; PONTREMOLI S, 1985, BIOCHIM BIOPHYS ACTA, V831, P335, DOI 10.1016/0167-4838(85)90116-5; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P24876, DOI 10.1074/jbc.272.40.24876; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; SORIMACHI H, 1992, BIOCHIM BIOPHYS ACTA, V1160, P55, DOI 10.1016/0167-4838(92)90037-E; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P1787, DOI 10.1093/oxfordjournals.jbchem.a133656; THEOPOLD U, 1995, MOL CELL BIOL, V15, P824; Vilei EM, 1997, J BIOL CHEM, V272, P25802, DOI 10.1074/jbc.272.41.25802; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348; ZIMMERMAN UJP, 1991, BIOCHIM BIOPHYS ACTA, V1080, P275	44	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23893	23900		10.1074/jbc.274.34.23893	http://dx.doi.org/10.1074/jbc.274.34.23893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446155	hybrid			2022-12-25	WOS:000082110900034
J	Koch, KA; Thiele, DJ				Koch, KA; Thiele, DJ			Functional analysis of a homopolymeric (dA-dT) element that provides nucleosomal access to yeast and mammalian transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; ACTIVATED GLUCOCORTICOID RECEPTOR; PROMOTER IN-VIVO; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; MMTV PROMOTER; POSITIONED NUCLEOSOMES; CANDIDA-GLABRATA; RESPONSE ELEMENT; GENE	Eukaryotic organisms ranging from yeast to humans maintain a large amount of genetic information in the highly compact folds of chromatin, which poses a large DNA accessibility barrier to rapid changes in gene expression. The ability of the yeast Candida glabrata to survive copper insult requires rapid transcriptional autoactivation of the AMT1 copper-metalloregulatory transcription factor gene. The kinetics of AMT1 autoactivation is greatly enhanced by homopolymeric (dA-dT) element (A16)-mediated nucleosomal accessibility for Amt1p to a metal response element in this promoter. Analysis of the nucleosomal positional requirements for the Ale element reveal an impaired ability of the A16 element to stimulate AMT1 autoregulation when positioned downstream of the metal response element within the nucleosome, implicating an inherent asymmetry to the nucleosome positioned within the AMT1 promoter. Importantly, we demonstrate that the Ale element functions to enhance nucleosomal access and hormone-stimulated transcriptional activation for the mammalian glucocorticoid receptor, in a rotational phase-dependent manner. These data provide compelling evidence that nucleosomal homopolymeric (dA-dT) elements provide enhanced DNA access to diverse classes of transcription factors and suggest that these elements may function in this manner to elicit rapid transcriptional responses in higher eukaryotic organisms.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008353, R01GM041840] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41840, GM08353] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; Brown PM, 1998, BIOCHEM J, V333, P259, DOI 10.1042/bj3330259; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Filetici P, 1998, BIOCHEM BIOPH RES CO, V242, P84, DOI 10.1006/bbrc.1997.7918; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; HUGHES TO, 1994, CRIT REV EUKAR GENE, V4, P403; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Koch KA, 1996, MOL CELL BIOL, V16, P724; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LI Q, 1995, MOL CELL BIOL, V15, P4375; LOSA R, 1990, NUCLEIC ACIDS RES, V18, P3495, DOI 10.1093/nar/18.12.3495; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; Moreira JMA, 1998, MOL GEN GENET, V258, P95, DOI 10.1007/s004380050711; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; Reardon BJ, 1995, NUCLEIC ACIDS RES, V23, P4900, DOI 10.1093/nar/23.23.4900; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; WRANGE O, 1989, J BIOL CHEM, V264, P5253; WRANGE O, 1984, J BIOL CHEM, V259, P4534; ZHOU PB, 1994, GENE, V142, P135, DOI 10.1016/0378-1119(94)90368-9; ZHOU PB, 1993, GENE DEV, V7, P1824, DOI 10.1101/gad.7.9.1824; ZHOU PB, 1992, MOL CELL BIOL, V12, P3766, DOI 10.1128/MCB.12.9.3766; Zhu ZW, 1996, CELL, V87, P459, DOI 10.1016/S0092-8674(00)81366-5	43	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23752	23760		10.1074/jbc.274.34.23752	http://dx.doi.org/10.1074/jbc.274.34.23752			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446135	hybrid			2022-12-25	WOS:000082110900014
J	Ton-That, H; Schneewind, O				Ton-That, H; Schneewind, O			Anchor structure of staphylococcal surface proteins IV. Inhibitors of the cell wall sorting reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; D-ALANINE CARBOXYPEPTIDASES; ESCHERICHIA-COLI; PEPTIDOGLYCAN PRECURSOR; VANCOMYCIN RESISTANCE; AUREUS; BIOSYNTHESIS; PENICILLIN; IDENTIFICATION; SUBSTRATE	Surface proteins of Staphylococcus aureus are covalently linked to the bacterial cell wall by a mechanism requiring a COOH-terminal sorting signal with a conserved LPXTG motif. Cleavage between the threonine and the glycine of the LPXTG motif liberates the carboxyl of threonine to form an amide bond with the amino of the pentaglycine cross-bridge in the staphylococcal peptidoglycan. We asked whether antibiotic cell wall synthesis inhibitors interfere with the anchoring of surface proteins. Penicillin G, a transpeptidation inhibitor, had no effect on surface protein anchoring, whereas vancomycin and moenomycin, inhibitors of cell wall polymerization into peptidoglycan strands, slowed the sorting reaction. Cleavage of surface protein precursors did not require a mature assembled cell wall and was observed in staphylococcal protoplasts. A search for chemical inhibitors of the sorting reaction identified methanethiosulfonates and p-hydroxymercuribenzoic acid. Thus, sortase, the enzyme proposed 60 cleave surface proteins at the LPXTG motif, appears to be a sulfhydryl-containing enzyme that utilizes peptidoglycan precursors but not an assembled cell wall as a substrate for the anchoring of surface protein.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schneewind, O (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	olafs@ucla.edu	Ton-That, Hung/AAB-6155-2020	Ton-That, Hung/0000-0003-1611-0469	NIAID NIH HHS [AI 38897, AI 33985] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033985, R01AI038897] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; BOOTHBY D, 1971, ANAL BIOCHEM, V44, P645, DOI 10.1016/0003-2697(71)90255-7; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; CHATTERJEE AN, 1964, P NATL ACAD SCI USA, V51, P9, DOI 10.1073/pnas.51.1.9; Creighton T.E., 1993, PROTEINS; HANDWERGER S, 1992, J BACTERIOL, V174, P5982, DOI 10.1128/jb.174.18.5982-5984.1992; IZAKI K, 1966, P NATL ACAD SCI USA, V55, P656, DOI 10.1073/pnas.55.3.656; MATSUHAS.M, 1967, J BIOL CHEM, V242, P3191; MATSUHASHI M, 1965, P NATL ACAD SCI USA, V54, P587, DOI 10.1073/pnas.54.2.587; Matsuhashi M., 1994, BACTERIAL CELL WALL, P55; MOVITZ J, 1976, EUR J BIOCHEM, V68, P291, DOI 10.1111/j.1432-1033.1976.tb10788.x; MOVITZ J, 1974, EUR J BIOCHEM, V48, P131, DOI 10.1111/j.1432-1033.1974.tb03750.x; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; Navarre WW, 1999, J BIOL CHEM, V274, P15847, DOI 10.1074/jbc.274.22.15847; Navarre WW, 1996, J BACTERIOL, V178, P441, DOI 10.1128/jb.178.2.441-446.1996; Navarre WW, 1998, J BIOL CHEM, V273, P29135, DOI 10.1074/jbc.273.44.29135; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PANCHOLI V, 1989, J EXP MED, V170, P2119, DOI 10.1084/jem.170.6.2119; PETIT JF, 1968, J BIOL CHEM, V243, P757; RASMUSSEN JR, 1978, P NATL ACAD SCI USA, V75, P84, DOI 10.1073/pnas.75.1.84; SANDERMANN H, 1976, BIOCHIM BIOPHYS ACTA, V444, P783; SANDERMANN H, 1972, J BIOL CHEM, V247, P5123; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; STROMINGER JL, 1967, FED PROC, V26, P9; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; TIPPER DJ, 1968, BIOCHEMISTRY-US, V7, P1441, DOI 10.1021/bi00844a029; TIPPER DJ, 1968, J BIOL CHEM, V243, P3169; Ton-That H, 1998, J BIOL CHEM, V273, P29143, DOI 10.1074/jbc.273.44.29143; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VANDERIJN I, 1981, INFECT IMMUN, V32, P86, DOI 10.1128/IAI.32.1.86-91.1981; VANHEIJENOORT Y, 1987, J GEN MICROBIOL, V133, P667; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; YOCUM RR, 1979, P NATL ACAD SCI USA, V76, P2730, DOI 10.1073/pnas.76.6.2730	40	118	122	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24316	24320		10.1074/jbc.274.34.24316	http://dx.doi.org/10.1074/jbc.274.34.24316			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446208	hybrid			2022-12-25	WOS:000082110900087
J	Lin, S; Cheng, D; Liu, MS; Chen, J; Chang, TY				Lin, S; Cheng, D; Liu, MS; Chen, J; Chang, TY			Human Acyl-CoA : Cholesterol acyltransferase-1 in the endoplasmic reticulum contains seven transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; COENZYME-A; MOLECULAR-CLONING; ACAT-1 PROTEIN; MACROPHAGES; LIVER; ESTERIFICATION; EXPRESSION; GENE; IMMUNOLOCALIZATION	Acyl-CoA:cholesterol acyltransferase (ACAT) plays important roles in cellular cholesterol homeostasis and is involved in atherosclerosis. ACAT-1 protein is located mainly in the ER. The hydropathy plot suggests that ACAT-1 protein contains multiple transmembrane segments. We inserted either the hemagglutinin tag or the HisT7 tag at various hydrophilic regions within the human ACAT-1 protein and used immunofluorescence microscopy to determine the topography of the tagged proteins expressed in mutant Chinese hamster ovary cells lacking endogenous ACAT. All of the tagged proteins are located mainly in the ER and retain full or partial enzyme activities. None of the tagged proteins produces detectable intracellular degradation intermediates. Treating cells with digitonin at 5 mu g/ml permeabilizes the plasma membranes while leaving the ER membranes sealed; in contrast, treating cells with 0.25% Triton X-100 or with cold methanol permeabilizes both the plasma membranes and the ER membranes. After appropriate permeabilization, double immunostaining using antibodies against the N-terminal region and against the inserted tag were used to visualize various regions of the tagged protein. The results show that human ACAT-1 in the ER contains seven transmembrane domains.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Beckman Coulter Inc, Fullerton, CA 92634 USA	Dartmouth College; Beckman Coulter Inc.	Chang, TY (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.			Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036709, R01HL060306, R37HL036709] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36709, HL 60306] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; Brasseur R, 1997, TRENDS BIOCHEM SCI, V22, P167, DOI 10.1016/S0968-0004(97)01047-5; CADIGAN KM, 1989, J CELL BIOL, V108, P2201, DOI 10.1083/jcb.108.6.2201; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG CCY, 1994, SOMAT CELL MOLEC GEN, V20, P71, DOI 10.1007/BF02257489; CHANG TY, 1994, TRENDS CARDIOVAS MED, V4, P223, DOI 10.1016/1050-1738(94)90038-8; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; Chang TY, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P1; CHANG TY, 1983, ENZYMES, V16, P523; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; COLEMAN RA, 1983, ENZYMES, V16, P605; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; Harlow E., 1988, ANTIBODIES LAB MANUA; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Khelef N, 1998, J BIOL CHEM, V273, P11218, DOI 10.1074/jbc.273.18.11218; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P509; Krause B.R., 1995, INFLAMMATION MEDIATO, P173; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee O, 1998, J LIPID RES, V39, P1722; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Miyazaki A, 1998, ARTERIOSCL THROM VAS, V18, P1568, DOI 10.1161/01.ATV.18.10.1568; MUKHERJEE S, 1958, J BIOL CHEM, V230, P91; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Pease RJ, 1996, CURR OPIN LIPIDOL, V7, P132, DOI 10.1097/00041433-199606000-00004; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROST B, 1995, PROTEIN SCI, V4, P521; SPECTOR A A, 1979, Progress in Lipid Research, V18, P31, DOI 10.1016/0163-7827(79)90003-1; SPILLANE DM, 1995, BBA-LIPID LIPID MET, V1254, P283, DOI 10.1016/0005-2760(94)00190-A; SUCKLING KE, 1985, J LIPID RES, V26, P647; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; Thompson GR, 1996, J LIPID RES, V37, P439; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WILSON MD, 1994, J LIPID RES, V35, P943; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157; [No title captured]	49	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23276	23285		10.1074/jbc.274.33.23276	http://dx.doi.org/10.1074/jbc.274.33.23276			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438503	hybrid			2022-12-25	WOS:000082012800053
J	Liu, Y; Cruikshank, WW; O'Loughlin, T; O'Reilly, P; Center, DM; Kornfeld, H				Liu, Y; Cruikshank, WW; O'Loughlin, T; O'Reilly, P; Center, DM; Kornfeld, H			Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN SEMINAL PLASMA; CD4-BINDING GLYCOPROTEIN; CHEMOATTRACTANT FACTOR; HUMAN LYMPHOKINES; SURFACE-ANTIGENS; HIV-1 ENTRY; RAT CD4; RECEPTOR; CELLS	Interleukin-16 (IL-16) activates CD4(+) cells, possibly by direct interaction with CD4, IL-16 structure and function are highly conserved across species, suggesting similar conservation of a putative IL-16 binding site on CD4, Comparison of the human CD4 amino acid sequence with that of several different species revealed that immunoglobulin-like domain 4 is the most conserved extracellular region. Potential interaction of this domain with IL-16 was studied by testing murine D4 sequence-based oligopeptides for inhibition of IL-16 chemoattractant activity and inhibition of IL-16 binding to CD4 in vitro, Three contiguous Ig-residue D4 region peptides (designated A, B, and C) blocked IL-16 chemoattractant activity, with peptide B the most potent, Peptides A and B were synergistic for inhibition, but peptide C was not. Peptides A and B also blocked IL-16 binding to CD4 in vitro, whereas peptide C did not. CD4, in addition to its known function as a receptor for major histocompatibility complex class II, contains a binding site for IL-16 in the D4 domain, The D4 residues required for IL-16 binding overlap those previously shown to participate in CD4-CD4 dimerization following class II major histocompatibility complex binding, providing a mechanistic explanation for the known function of IL-16 to inhibit the mixed lymphocyte reaction.	Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA	Boston University; Boston University	Kornfeld, H (corresponding author), Boston Univ, Sch Med, Ctr Pulm, R-3,80 E Concord St, Boston, MA 02118 USA.		Kornfeld, Hardy/AAS-2903-2021	Center, David/0000-0002-5879-7978	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI041994] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32802] Funding Source: Medline; NIAID NIH HHS [U19 AI41994] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autiero M, 1997, EUR J BIOCHEM, V245, P208, DOI 10.1111/j.1432-1033.1997.00208.x; AUTIERO M, 1991, EXP CELL RES, V197, P268, DOI 10.1016/0014-4827(91)90432-T; AUTIERO M, 1995, EUR J IMMUNOL, V25, P1461, DOI 10.1002/eji.1830250550; Bannert N, 1998, IMMUNOGENETICS, V47, P390, DOI 10.1007/s002510050374; BERMAN JS, 1985, CELL IMMUNOL, V95, P105, DOI 10.1016/0008-8749(85)90299-0; BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; CENTER DM, 1982, J IMMUNOL, V128, P2563; Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; CLARK SJ, 1987, P NATL ACAD SCI USA, V84, P1649, DOI 10.1073/pnas.84.6.1649; CRUIKSHANK W, 1982, J IMMUNOL, V128, P2569; Cruikshank W W, 1998, Int Rev Immunol, V16, P523, DOI 10.3109/08830189809043007; CRUIKSHANK WW, 1991, J IMMUNOL, V146, P2928; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; CRUIKSHANK WW, 1987, J IMMUNOL, V138, P3817; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; FOTI M, 1995, J LAB CLIN MED, V126, P233; GORMAN SD, 1994, TISSUE ANTIGENS, V43, P184, DOI 10.1111/j.1399-0039.1994.tb02320.x; HAGUE BF, 1992, P NATL ACAD SCI USA, V89, P7963, DOI 10.1073/pnas.89.17.7963; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JULIUS M, 1993, IMMUNOL TODAY, V14, P177; Keane J, 1998, J IMMUNOL, V160, P5945; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; LUSSO P, 1994, P NATL ACAD SCI USA, V91, P3872, DOI 10.1073/pnas.91.9.3872; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; NEUDORF SML, 1990, CELL IMMUNOL, V125, P301, DOI 10.1016/0008-8749(90)90086-7; NORIMINE J, 1992, IMMUNOLOGY, V75, P74; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; Satoh T, 1996, BIOCHEM BIOPH RES CO, V224, P438, DOI 10.1006/bbrc.1996.1045; SONG L, 1998, IMMUNOL TODAY, V19, P455; Theodore AC, 1996, J IMMUNOL, V157, P1958; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144	40	43	47	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23387	23395		10.1074/jbc.274.33.23387	http://dx.doi.org/10.1074/jbc.274.33.23387			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438516	hybrid			2022-12-25	WOS:000082012800066
J	Oh, P; Schnitzer, JE				Oh, P; Schnitzer, JE			Immunoisolation of caveolae with high affinity antibody binding to the oligomeric caveolin cage - Toward understanding the basis of purification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; GPI-ANCHORED PROTEINS; RICH MEMBRANE DOMAINS; TRANS-GOLGI-NETWORK; CELL-SURFACE; TYROSINE KINASES; PLASMA-MEMBRANE; IN-VIVO; LOCALIZATION; MICRODOMAINS	Defining the molecular composition of caveolae is essential in establishing their molecular architecture and functions. Here, we identify a high affinity monoclonal antibody that is specific for caveolin-1 alpha and rapidly binds caveolin oligomerized around intact caveolae, We use this antibody (i) to develop a new simplified method for rapidly isolating caveolae from cell and tissue homogenates without using the silica-coating technology and (ii) to analyze various caveolae isolation techniques to understand how they work and why they yield different compositions. Caveolae are immunoisolated from rat lung plasma membrane fractions subjected to mechanical disruption. Sonication of plasma membranes, isolated with or without silica coating, releases caveolae along with other similarly buoyant microdomains and, therefore, requires immunoisolations 60 purify caveolae, Shearing of silica-coated plasma membranes provides a homogeneous population of caveolae whose constituents (i) remain unchanged after immunoisolation, (ii) all fractionate bound to the immunobeads, and (iii) appear equivalent to caveolae immunoisolated after sonication. The caveolae immunoisolated from different low density fractions are quite similar in molecular composition. They contain a subset of key signaling molecules (i.e. G protein and endothelial nitric oxide synthase) and are markedly depleted in glycosylphosphatidylinositol-anchored proteins, P-actin, and angiotensin-converting enzyme. All caveolae isolated from the cell surface of lung microvascular endothelium in vivo appear to be coated with caveolin-1 alpha, Caveolin-1 beta and -2 can also exist in these same caveolae, The isolation and analytical procedures as well as the time-dependent dissociation of signaling molecules from caveolae contribute to key compositional differences reported in the literature for caveolae. This new, rapid, magnetic immunoisolation procedure provides a consistent preparation for use in the molecular analysis of caveolae.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Schnitzer, JE (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.	jschnitzer@skcc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052766, R01HL058216] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52766, HL58216] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FINDLAY JBC, 1987, SUBCELLULAR FRACTION; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GRAHAM JM, 1997, BIOL MEMBRANES PRACT; Horner T., 1996, Molecular Biology of the Cell, V7, p265A; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Oh P, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P34; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schnitzer J. E., 1994, Molecular Biology of the Cell, V5, p75A; Schnitzer J. E., 1994, Molecular Biology of the Cell, V5, p320A; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHNITZER JE, 1997, VASCULAR ENDOTHELIUM, V3, P77; SCHNITZER JE, 1997, CAPILLARY PERMEATION, P31; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595	51	103	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23144	23154		10.1074/jbc.274.33.23144	http://dx.doi.org/10.1074/jbc.274.33.23144			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438484	hybrid			2022-12-25	WOS:000082012800034
J	Qin, XS; Liu, LL; Gerson, SL				Qin, XS; Liu, LL; Gerson, SL			Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT	ONCOGENE			English	Article						PMS2 deficiency; hMGMT; MNU; lymphoma	METHYL-N-NITROSOUREA; MAMMALIAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; CELL-CYCLE CHECKPOINT; ABERRANT CRYPT FOCI; REPAIR GENE; ADA GENE; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; INDUCED TUMORIGENESIS; ADDUCT FORMATION; RAS ONCOGENE	DNA mismatch repair (MMR) stabilizes the cellular genome, Mice defective in the MMR gene PMS2 are susceptible to spontaneous thymic lymphoma and sarcomas, To determine the sensitivity of PMS2 knockout mice to environmental carcinogens and the protective effect of O-6-methylguanine DIVA methyltransferase (MGMT), heterozygous PMS2 knockout mice and human MGMT (hMGMT) transgenic mice were mated and the PMS2(-/-) and PMS2(+/+) wit or without hMGMT offspring were treated at 5 weeks of age with 50 mg/kg N-methgl-N-nitrosourea (MNU), MNU produces carcinogenic O-6-methylguanine (O-6-meG) adducts, resulting in thymic lymphoma in mice, which can be prevented in normal mice by overexpression of hMGMT. A significantly higher incidence of thymic lymphomas,vas observed in MNU-treated PMS2(-/-) mice, compared to wildtype PMS2(+/+) mice (100 ra 52%; P < 0.001), The mean latency of lymphomas was also significantly shortened in PMS2(-/-) mice (81 vs 102 days, P<0.01), Transgenic expression of hMGMT significantly but incompletely blocked MNU lymphomagenesis in PMS2(-/-) mice. The incidence of lymphomas in PMS2(-/-)/hMGMT(+) mice was reduced to 80% (P<0.01) and mean latency increased to 91 days (P<0.05), Thy mic lymphomagenesis was efficiently blocked in PMS2(+/+)/hMGMT(+) mice with rapid repair of O-6-meG, Since O-6-meG:T mismatches in MMR+ cells may trigger mismatch repair resulting in abortive repair and cell death whereas in the absence of MMR, these mismatches are converted to A:T,,ve predicted that G to A point mutations in codon 12 of the K-ras gene would occur. In this study, we found G to A point mutations in codon 12 of the K-ras gene in many tumors. Thus, in MMR deficient tissues, methylating agents induce point mutations in cells with a higher rate of cell survival which together are potently carcinogenic in the thymus, These data suggest that PMS2 defective lymphomas may arise by the concerted action of environmental and perhaps endogenous methylation of DNA coupled to genomic instability.	Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Gerson, SL (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, BRB-3 10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA063193, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63193, P30CA43703] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allay E, 1997, ONCOGENE, V15, P2127, DOI 10.1038/sj.onc.1201384; ALLAY E, 1999, IN PRESS ONCOGENE; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BELINSKY SA, 1989, CANCER RES, V49, P5305; Carethers JM, 1996, J CLIN INVEST, V98, P199, DOI 10.1172/JCI118767; COROMINAS M, 1991, CANCER RES, V51, P5129; Davis TW, 1998, CANCER RES, V58, P767; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; DUMENCO LL, 1991, CANCER RES, V51, P3391; EADIE JS, 1984, NATURE, V308, P201, DOI 10.1038/308201a0; ELLISON KS, 1989, P NATL ACAD SCI USA, V86, P8620, DOI 10.1073/pnas.86.22.8620; Fink D, 1998, CLIN CANCER RES, V4, P1; GALLOWAY SM, 1995, MUTAT RES LETT, V346, P231, DOI 10.1016/0165-7992(95)90040-3; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; HAWN MT, 1995, CANCER RES, V55, P3721; Iwakuma T, 1997, CARCINOGENESIS, V18, P1631, DOI 10.1093/carcin/18.8.1631; LIM IK, 1990, CANCER RES, V50, P1701; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Liu LL, 1996, CANCER RES, V56, P5375; LIU LL, 1994, CANCER RES, V54, P4648; Lowsky R, 1997, BLOOD, V89, P2276, DOI 10.1182/blood.V89.7.2276; MATSUKUMA S, 1989, MUTAT RES, V218, P197, DOI 10.1016/0921-8777(89)90004-9; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NAKATSURU Y, 1991, MUTAT RES, V254, P225, DOI 10.1016/0921-8777(91)90060-3; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NEWCOMB EW, 1990, AM J PATHOL, V136, P307; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; PEGG AE, 1990, CANCER RES, V50, P6119; PROLLA AT, 1998, NAT GENET, V18, P276; QIN XS, 1990, CARCINOGENESIS, V11, P235, DOI 10.1093/carcin/11.2.235; QIN XS, 1994, CARCINOGENESIS, V15, P851, DOI 10.1093/carcin/15.5.851; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; ROMACH E, 1994, CARCINOGENESIS, V15, P2275, DOI 10.1093/carcin/15.10.2275; RUDIGER HW, 1989, CANCER RES, V49, P5623; SAKUMAR S, 1983, NATURE, V306, P658; Sakumi K, 1997, CANCER RES, V57, P2415; STRIKE PW, 1991, STAT METHODS LAB MED, P53; THOMALE J, 1990, P NATL ACAD SCI USA, V87, P9883, DOI 10.1073/pnas.87.24.9883; TSZUKI T, 1996, CARCINOGENESIS, V17, P1215; WANG Y, 1990, CANCER RES, V50, P1591; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451	46	33	33	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4394	4400		10.1038/sj.onc.1202798	http://dx.doi.org/10.1038/sj.onc.1202798			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439048				2022-12-25	WOS:000081732700013
J	Roche, KW; Tu, JC; Petralia, RS; Xiao, B; Wenthold, RJ; Worley, PF				Roche, KW; Tu, JC; Petralia, RS; Xiao, B; Wenthold, RJ; Worley, PF			Homer 1b regulates the trafficking of group I metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLIMBING FIBER SYNAPSES; POSTSYNAPTIC DENSITY; CLUSTERING ACTIVITY; GUANYLATE KINASES; PURKINJE-CELLS; MEMBRANE; PROTEINS; SUBUNITS; PARALLEL; PSD-95	The molecular basis for glutamate receptor trafficking to the plasma membrane is not understood. In the present study, we demonstrate that Homer 1b (H1b), a constitutively expressed splice form of the immediate early gene product Homer (now termed Homer 1a) regulates the trafficking and surface expression of group I metabotropic glutamate receptors, H1b inhibits surface expression of the metabotropic glutamate receptor mGluR5 in heterologous cells, causing mGluR5 to be retained in the endoplasmic reticulum (ER), In contrast, mGluR5 alone or mGluR5 coexpressed with Homer la successfully travels through the secretory pathway to the plasma membrane. In addition, point mutations that disrupt mGluR5 binding to H1b eliminate ER retention of mGluR5, demonstrating that H1b affects metabotropic receptor localization via a direct protein-protein interaction. Electron microscopic analysis reveals that the group I metabotropic receptor mGluR1a is significantly enriched in the ER of Purkinje cells, suggesting that a similar mechanism may exist in vivo. Because H1b is found in dendritic spines of neurons, local retention of metabotropic receptors within dendritic ER provides a potential mechanism for regulating synapse-specific expression of group I metabotropic glutamate receptors.	NIDCD, Neurochem Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Johns Hopkins University	Roche, KW (corresponding author), NIDCD, Neurochem Lab, NIH, Bldg 36,Rm 5D08, Bethesda, MD 20892 USA.		Roche, Katherine/W-9893-2019	Roche, Katherine/0000-0001-7282-6539	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000003, ZIADC000003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DUDEK SM, 1989, SCIENCE, V246, P673, DOI 10.1126/science.2573152; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kirsch J, 1996, MOL CELL NEUROSCI, V8, P93, DOI 10.1006/mcne.1996.0048; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Landsend AS, 1997, J NEUROSCI, V17, P834, DOI 10.1523/jneurosci.17-02-00834.1997; Matsubara A, 1996, J NEUROSCI, V16, P4457; Ottersen OP, 1997, EUR J NEUROSCI, V9, P2219, DOI 10.1111/j.1460-9568.1997.tb01640.x; Petralia RS, 1997, J CHEM NEUROANAT, V13, P77, DOI 10.1016/S0891-0618(97)00023-9; Petralia RS, 1998, NEUROPHARMACOLOGY, V37, P1321, DOI 10.1016/S0028-3908(98)00118-X; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; PETRALIA RS, 1998, IONOTROPIC GLUTAMATE, P219; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; Rubio ME, 1997, NEURON, V18, P939, DOI 10.1016/S0896-6273(00)80333-5; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Wang YX, 1998, J NEUROSCI, V18, P1148; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Zhao HM, 1998, J NEUROSCI, V18, P5517, DOI 10.1523/JNEUROSCI.18-14-05517.1998; Zhao HM, 1997, J NEUROCHEM, V68, P1041; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	29	177	182	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25953	25957		10.1074/jbc.274.36.25953	http://dx.doi.org/10.1074/jbc.274.36.25953			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464340	hybrid			2022-12-25	WOS:000082554200104
J	Sarkar, SN; Ghosh, A; Wang, HW; Sung, SS; Sen, GC				Sarkar, SN; Ghosh, A; Wang, HW; Sung, SS; Sen, GC			The nature of the catalytic domain of 2 '-5 '-oligoadenylate synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; 2'-5' OLIGOADENYLATE SYNTHETASE; INTERFERON-TREATED CELLS; 2-5A SYNTHETASE; PROTEIN-SYNTHESIS; NUCLEOTIDYLTRANSFERASE SUPERFAMILY; 2',5'-OLIGOADENYLATE SYNTHETASES; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; PRIMER BINDING	2'-5'-Oligoadenylate (2-5(A)) synthetases are a family of interferon-induced enzymes that are activated by double-stranded RNA. To understand why, unlike other DNA and RNA polymerases, they catalyze 2'-5' instead of 3'-5' phosphodiester bond formation, we used molecular modeling to compare the structure of the catalytic domain of DNA polymerase beta (pol beta) to that of a region of the P69 isozyme of 2-5(A) synthetase. Although the primary sequence identity is low, like pol beta, P69 can assume an alpha beta beta alpha beta beta beta structure in this region. Moreover, mutation of the three Asp residues of P69, which correspond to the three catalytic site Asp residues of pol beta, inactivated the enzyme without affecting its substrate and activator binding capacity, providing further credence to the concept that this region is the catalytic domain of P69. This domain is highly conserved among all 2-5(A) synthetase isozymes, Biochemical and mutational studies demonstrated that dimerization of the P69 protein is required for its enzyme activity. However, a dimer containing a wild type subunit and an inactive catalytic domain mutant subunit was also active. The rate of catalysis of the heterodimer was half of that of the wild type homodimer, although the two proteins bound double-stranded RNA and ATP equally well.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Sen, GC (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, 9500 Euclid Ave,NC20, Cleveland, OH 44195 USA.	seng@ccf.org	Sarkar, Saumendra N/B-5038-2011	Sarkar, Saumendra N/0000-0002-2850-6121	NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER; NCI NIH HHS [CA-68782, CA-62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bandyopadhyay S, 1998, BIOCHEMISTRY-US, V37, P3824, DOI 10.1021/bi972848e; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Ghosh A, 1997, J BIOL CHEM, V272, P15452, DOI 10.1074/jbc.272.24.15452; Ghosh A, 1997, J BIOL CHEM, V272, P33220, DOI 10.1074/jbc.272.52.33220; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; Hartmann R, 1998, NUCLEIC ACIDS RES, V26, P4121, DOI 10.1093/nar/26.18.4121; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; ICHII Y, 1986, NUCLEIC ACIDS RES, V14, P10117, DOI 10.1093/nar/14.24.10117; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; LAKOWITZ JR, 1983, PRINCIPLES FLUORESCE; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; Marie I, 1997, EUR J BIOCHEM, V248, P558, DOI 10.1111/j.1432-1033.1997.t01-1-00558.x; MARIE I, 1990, J BIOL CHEM, V265, P18601; MARIE I, 1992, J BIOL CHEM, V267, P9933; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; Menge KL, 1995, BIOCHEMISTRY-US, V34, P15934, DOI 10.1021/bi00049a008; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Rebouillat D, 1998, EUR J BIOCHEM, V257, P319, DOI 10.1046/j.1432-1327.1998.2570319.x; Rebouillat D, 1999, J BIOL CHEM, V274, P1557, DOI 10.1074/jbc.274.3.1557; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sarkar SN, 1999, J BIOL CHEM, V274, P1848, DOI 10.1074/jbc.274.3.1848; Sarkar SN, 1998, METHODS, V15, P233, DOI 10.1006/meth.1998.0627; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRUVE E, 1993, BIO-TECHNOL, V11, P1048, DOI 10.1038/nbt0993-1048; Turpaev K, 1997, FEBS LETT, V408, P177, DOI 10.1016/S0014-5793(97)00365-7; VILCEK J, 1996, FIELDS VIROLOGY, P375; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; WILLIAMS BRG, 1978, NATURE, V276, P88, DOI 10.1038/276088a0; Yamamoto A, 1998, BBA-GENE STRUCT EXPR, V1395, P181, DOI 10.1016/S0167-4781(97)00148-6; YANG BL, 1994, J BIOL CHEM, V269, P11859; Yue DX, 1996, RNA, V2, P895	40	68	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25535	25542		10.1074/jbc.274.36.25535	http://dx.doi.org/10.1074/jbc.274.36.25535			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464285	hybrid			2022-12-25	WOS:000082554200049
J	Olivera, A; Edsall, L; Poulton, S; Kazlauskas, A; Spiegel, S				Olivera, A; Edsall, L; Poulton, S; Kazlauskas, A; Spiegel, S			Platelet-derived growth factor-induced activation of sphingosine kinase requires phosphorylation of the PDGF receptor tyrosine residue responsible for binding of PLC gamma	FASEB JOURNAL			English	Article						platelet-derived growth factor; SPP; DNA synthesis; DMS	PHOSPHOLIPASE C-GAMMA; PROGRAMMED CELL-DEATH; FACTOR-BETA RECEPTOR; PHOSPHATIDYLINOSITOL-3 KINASE; CALCIUM MOBILIZATION; SIGNAL-TRANSDUCTION; 3T3 FIBROBLASTS; 2ND MESSENGER; PROTEIN; 1-PHOSPHATE	Sphingosine-1-phosphate, a sphingolipid metabolite, is involved in the mitogenic response of platelet-derived growth factor (PDGF) and is formed by activation of sphingosine kinase. We examined the effect of PDGF on sphingosine kinase activation in TRMP cells expressing wild-type or various mutant beta PDGF receptors. Sphingosine kinase was stimulated by PDGF in cells expressing wild-type receptors but not in cells expressing kinase-inactive receptors (R634). Cells expressing mutated PDGF receptors with phenylalanine substitutions at five major tyrosine phosphorylation sites 740/751/771/1009/1021 (F5 mutants), which are unable to associate with PLC gamma, phosphatidylinositol 3-kinase, Ras GTPase-activating protein, or protein tyrosine phosphatase SHP-2, not only failed to increase DNA synthesis in response to PDGF but also did not activate sphingosine kinase. Moreover, mutation of tyrosine-1021 of the PDGF receptor to phenylalanine, which impairs its association with PLC gamma, abrogated PDGF-induced activation of sphingosine kinase. In contrast, PDGF was still able to stimulate sphingosine kinase in cells expressing the PDGF receptor mutated at tyrosines 740/751 and 1009, responsible for binding of phosphatidylinositol 3-kinase and SHP-2, respectively. In agreement, PDGF did not stimulate sphingosine kinase activity in F5 receptor 'add-back' mutants in which association with the Pas GTPase-activating protein, phosphatidylinositol 3-kinase, or SHP-2 was individually restored. However, a mutant PDGF receptor that was able to bind PLC gamma (tyrosine-1021), but not other signaling proteins, restored sphingosine kinase sensitivity to PDGF. These data indicate that the tyrosine residue responsible for binding of PLC gamma is required for PDGF-induced activation of sphingosine kinase. Moreover, calcium mobilization downstream of PLC gamma, but not protein kinase C activation, appears to be required for stimulation of sphingosine kinase by PDGF.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA	Georgetown University; Harvard University; Harvard Medical School; Schepens Eye Research Institute	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [CA61774] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Bosch RR, 1998, EUR J PHARMACOL, V346, P345, DOI 10.1016/S0014-2999(98)00070-3; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; Choi OH, 1996, NATURE, V380, P634; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DESAI NN, 1992, J BIOL CHEM, V267, P23122; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Edsall LC, 1997, J NEUROSCI, V17, P6952; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; Kleuser B, 1998, CANCER RES, V58, P1817; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Mathes C, 1998, J BIOL CHEM, V273, P25020, DOI 10.1074/jbc.273.39.25020; Mathias RS, 1997, J BIOL CHEM, V272, P29076, DOI 10.1074/jbc.272.46.29076; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Montmayeur JP, 1997, J BIOL CHEM, V272, P32670, DOI 10.1074/jbc.272.51.32670; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pulcinelli FM, 1998, BIOCHEM PHARMACOL, V56, P1481, DOI 10.1016/S0006-2952(98)00146-4; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; SU Y, 1994, J BIOL CHEM, V269, P16512; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Wang F, 1996, GLYCOCONJUGATE J, V13, P937, DOI 10.1007/BF01053189; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; YEO EJ, 1994, J BIOL CHEM, V269, P27823	33	68	68	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1593	1600		10.1096/fasebj.13.12.1593	http://dx.doi.org/10.1096/fasebj.13.12.1593			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463951				2022-12-25	WOS:000082347600015
J	Graninger, M; Nidetzky, B; Heinrichs, DE; Whitfield, C; Messner, P				Graninger, M; Nidetzky, B; Heinrichs, DE; Whitfield, C; Messner, P			Characterization of dTDP-4-dehydrorhamnose 3,5-epimerase and dTDP-4-dehydrorhamnose reductase, required for dTDP-L-rhamnose biosynthesis in Salmonella enterica serovar typhimurium LT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; UDP-GALACTOSE 4-EPIMERASE; ESCHERICHIA-COLI; SACCHAROPOLYSPORA-ERYTHRAEA; ENZYMATIC-SYNTHESIS; GENE-CLUSTER; O-ANTIGEN; RFB LOCUS; SUPERFAMILY; BINDING	The thymidine diphosphate-L-rhamnose biosynthesis pathway is required for assembly of surface glycoconjugates in a growing list of bacterial pathogens, making this pathway a potential therapeutic target. However, the terminal reactions have not been characterized. To complete assignment of the reactions, the four enzymes (RmlABCD) that constitute the pathway in Salmonella enterica serovar Typhimurium LT2 were overexpressed. The purified RmlC and D enzymes together catalyze the terminal two steps involving NAD(P)H-dependent formation of dTDP-L-rhamnose from dTDP-6-deoxy-D-xylo-4-hexulose, RmlC was assigned as the thymidine diphosphate-4-dehydrorhamnose 3,5-epimerase by showing its activity to be NAD(P)H-independent. Spectrofluorometric and radiolabeling experiments were used to demonstrate the ability of RmlC to catalyze the formation of dTDP-6-deoxy-L-lyxo-4-hexulose from dTDP-6-deoxy-D-xylo-4-hexulose. Under reaction conditions, RmlC converted approximately 3% of its substrate to product. RmlD was unequivocally identified as the thymidine diphosphate-4-dehydrorhamnose reductase, The reductase property of RmlD was shown by equilibrium analysis and its ability to enable efficient biosynthesis of dTDP-L-rhamnose, even in the presence of low amounts of dTDP-6-deoxy-L-lyxo-4-hexulose. Comparison of 23 known and predicted RmlD sequences identified several conserved amino acid residues, especially the serine-tyrosine-lysine catalytic triad, characteristic for members of the reductase/epimerase/dehydrogenase protein superfamily, In conclusion, RmlD is a novel member of this protein superfamily.	Agr Univ Vienna, Zentrum Ultrastrukturforsch, A-1180 Vienna, Austria; Agr Univ Vienna, Ludwig Boltzmann Inst Mol Nanotechnol, A-1180 Vienna, Austria; Agr Univ Vienna, Inst Lebensmitteltechnol, A-1190 Vienna, Austria; Univ Guelph, Coll Biol Sci, Dept Microbiol, Guelph, ON N1G 2W1, Canada	University of Natural Resources & Life Sciences, Vienna; Ludwig Boltzmann Institute; University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna; University of Guelph	Messner, P (corresponding author), Agr Univ Vienna, Zentrum Ultrastrukturforsch, Gregor Mendel Str 33, A-1180 Vienna, Austria.		Heinrichs, David/ABD-5702-2021; Messner, Paul/Q-5345-2017	Heinrichs, David/0000-0002-7217-2456; Messner, Paul/0000-0002-3246-5801; Nidetzky, Bernd/0000-0002-5030-2643				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BAKER ME, 1992, FEBS LETT, V301, P89, DOI 10.1016/0014-5793(92)80216-4; BINOTTO J, 1991, CAN J MICROBIOL, V37, P474, DOI 10.1139/m91-078; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; FREY PA, 1986, COENZYMES COFACTORS, V2, P461; Giraud MF, 1999, ACTA CRYSTALLOGR D, V55, P706, DOI 10.1107/S0907444998015042; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KATO Y, 1983, LIQ CHROMATOGR HPLC, V1, P540; KOPLIN R, 1993, J BACTERIOL, V175, P7786; Koplin R, 1997, J BIOL CHEM, V272, P4121, DOI 10.1074/jbc.272.7.4121; KORNFELD S, 1961, J BIOL CHEM, V236, P1791; LABESSE G, 1994, BIOCHEM J, V304, P95, DOI 10.1042/bj3040095; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST L, 1993, EUR J BIOCHEM, V211, P763, DOI 10.1111/j.1432-1033.1993.tb17607.x; LINTON KJ, 1995, GENE, V153, P33, DOI 10.1016/0378-1119(94)00809-7; MACPHERSON DF, 1994, MOL MICROBIOL, V11, P281, DOI 10.1111/j.1365-2958.1994.tb00308.x; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; MARUMO K, 1992, EUR J BIOCHEM, V204, P539, DOI 10.1111/j.1432-1033.1992.tb16665.x; MCNEIL MR, 1991, RES MICROBIOL, V142, P451, DOI 10.1016/0923-2508(91)90120-Y; MELO A, 1968, J BIOL CHEM, V243, P1475; MESSNER P, 1984, INT J SYST BACTERIOL, V34, P202, DOI 10.1099/00207713-34-2-202; MESSNER P, 1996, CRYSTALLINE BACTERIA, P35; MILLS JA, 1994, J BACTERIOL, V176, P4803, DOI 10.1128/jb.176.16.4803-4808.1994; Mitchison M, 1997, J BACTERIOL, V179, P1262, DOI 10.1128/jb.179.4.1262-1267.1997; RAJAKUMAR K, 1994, J BACTERIOL, V176, P2362, DOI 10.1128/JB.176.8.2362-2373.1994; REEVES P, 1994, BACTERIAL CELL WALL, P281; Rizzi M, 1998, STRUCTURE, V6, P1453, DOI 10.1016/S0969-2126(98)00144-0; Sambrook J., 2002, MOL CLONING LAB MANU; Schaffer C, 1996, MICROB DRUG RESIST, V2, P17, DOI 10.1089/mdr.1996.2.17; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; Segel I.H, 1993, ENZYME KINETICS; Somers WS, 1998, STRUCTURE, V6, P1601, DOI 10.1016/S0969-2126(98)00157-9; Stein A, 1998, GLYCOCONJUGATE J, V15, P139, DOI 10.1023/A:1006912121278; Stern RJ, 1999, MICROBIOL-UK, V145, P663, DOI 10.1099/13500872-145-3-663; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6294, DOI 10.1021/bi970025j; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VARA JA, 1988, J BIOL CHEM, V263, P14992; WAHL HP, 1979, BIOCHIM BIOPHYS ACTA, V568, P243, DOI 10.1016/0005-2744(79)90291-2; Xu Y, 1998, INFECT IMMUN, V66, P4313; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	46	89	91	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25069	25077		10.1074/jbc.274.35.25069	http://dx.doi.org/10.1074/jbc.274.35.25069			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455186	hybrid			2022-12-25	WOS:000082193400085
J	Mori, M; Itabe, H; Takatoku, K; Shima, K; Inoue, J; Nishiura, M; Takahashi, H; Ohtake, H; Sato, R; Higashi, Y; Imanaka, T; Ikegami, S; Takano, T				Mori, M; Itabe, H; Takatoku, K; Shima, K; Inoue, J; Nishiura, M; Takahashi, H; Ohtake, H; Sato, R; Higashi, Y; Imanaka, T; Ikegami, S; Takano, T			Presence of phospholipid-neutral lipid complex structures in atherosclerotic lesions as detected by a novel monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MACROPHAGE FOAM CELLS; UNESTERIFIED CHOLESTEROL; RICH CORE; OXIDIZED PHOSPHATIDYLCHOLINES; FIBROUS PLAQUES; LADEN CELLS; DEPOSITS; DEATH; ATHEROGENESIS	A novel monoclonal antibody (ASH1a/256C) that recognizes atherosclerotic lesions in human and Watanabe heritable hyperlipidemic (WHHL) rabbit aortae is described. When I-123-labeled ASH1a/256C antibody is injected intravenously into WHHL rabbits, it associates specifically with fatty streaks on the aorta. The antigen recognized by the antibody is lipid, based on extraction with chloroform and methanol from WHHL rabbit tissues. The antigen, purified by high performance liquid chromatography, was shown to be phosphatidylcholine (PC), which contains unsaturated fatty acyl groups based on analyses utilizing H-1 and C-13 nuclear magnetic resonance, Fourier transfer-infrared spectrum, and mass spectrometry, The antibody did not react with other classes of phospholipids or neutral lipids when tested using an enzyme-linked immunosorbent assay. When PC was mixed with either cholesterol, cholesteryl ester, or triacylglycerol, however, the reactivity of the antibody to PC increased up to 8-fold. Homogenates of aorta tissue obtained from normal and WHHL rabbits were fractionated using sucrose density gradient ultracentrifugation in which neutral lipid droplets, cellular membranes, and proteins are separated. The phospholipid content in cellular membrane fractions from WHHL rabbits was twice as high as that of normal rabbits, and there was an enormous difference in the antigenic activity in these fractions. The content of cholesterol in the cellular membrane fraction of WHHL rabbits was approximately 50 times higher than that of normal rabbits. Addition of neutral lipids to the cellular membrane fraction of normal rabbit markedly increased the antigenic activity. Atheromatous lesions in thickened WHHL rabbit aortic intima that were rich in lipid droplets were stained positively with ASH1a/256C immunohistochemically. These results strongly suggest that PC-neutral lipid complex domains are formed in atherosclerotic lesions.	Teikyo Univ, Fac Pharmaceut Sci, Dept Microbiol & Mol Pathol, Sagamiko, Kanagawa 1990195, Japan; Daiichi Radioisotope Labs Ltd, Chiba 2891517, Japan; Teikyo Univ, Fac Pharmaceut Sci, Lab Organ & Med Chem, Kanagawa 1990195, Japan	Teikyo University; Teikyo University	Takano, T (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Dept Microbiol & Mol Pathol, Sagamiko, Kanagawa 1990195, Japan.	t_takano@pharm.teikyo-u.ac.jp	板部板部, 洋之/ABC-7746-2020	Imanaka, Tsuneo/0000-0003-4677-1356				ABELE J, 1979, CLIN CHEM, V25, P132; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCAN TMA, 1986, AM J PATHOL, V123, P413; BOCAN TMA, 1985, AM J PATHOL, V120, P193; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAO FF, 1988, AM J PATHOL, V131, P73; CHAO FF, 1994, J LIPID RES, V35, P71; Crisby M, 1997, ATHEROSCLEROSIS, V130, P17, DOI 10.1016/S0021-9150(96)06037-6; ELLENA JF, 1985, J AM CHEM SOC, V107, P1530, DOI 10.1021/ja00292a013; GUYTON JR, 1992, AM J PATHOL, V141, P925; GUYTON JR, 1993, AM J PATHOL, V143, P1444; GUYTON JR, 1989, AM J PATHOL, V134, P705; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; Harada K, 1997, ATHEROSCLEROSIS, V135, P235, DOI 10.1016/S0021-9150(97)00167-6; Itabe H, 1996, J BIOL CHEM, V271, P33208, DOI 10.1074/jbc.271.52.33208; ITABE H, 1994, J BIOL CHEM, V269, P15274; Itabe H, 1998, BBA-MOL BASIS DIS, V1406, P28, DOI 10.1016/S0925-4439(97)00069-0; KARASAWA K, 1991, J BIOCHEM-TOKYO, V110, P683, DOI 10.1093/oxfordjournals.jbchem.a123641; KATZ SS, 1981, J BIOL CHEM, V256, P2275; KIMURA J, 1986, VIRCHOWS ARCH A, V410, P159; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; LUPU F, 1987, ATHEROSCLEROSIS, V67, P127, DOI 10.1016/0021-9150(87)90273-5; Mori M, 1996, J Atheroscler Thromb, V3, P25; Oi V.T., 1980, SELECTED METHODS CEL, P351; RICHMOND W, 1973, CLIN CHEM, V19, P1350; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SATO R, 1990, J BIOL CHEM, V265, P21232; SIMIONESCU N, 1986, AM J PATHOL, V123, P109; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; TAKANO T, 1982, BIOCHEM INT, V4, P485; TAKANO T, 1994, J ATHEROSCLER THRO S, V1, P1; TANGIRALA RK, 1993, J BIOL CHEM, V268, P9653; TOUCHSTONE JC, 1978, PRACTICE THIN LAYER, P207; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; ZHOU X, 1992, J LIPID RES, V33, P1233	37	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24828	24837		10.1074/jbc.274.35.24828	http://dx.doi.org/10.1074/jbc.274.35.24828			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455155	hybrid			2022-12-25	WOS:000082193400054
J	Pajatsch, M; Andersen, C; Mathes, A; Bock, A; Benz, R; Engelhardt, H				Pajatsch, M; Andersen, C; Mathes, A; Bock, A; Benz, R; Engelhardt, H			Properties of a cyclodextrin-specific, unusual porin from Klebsiella oxytoca	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEINS; ESCHERICHIA-COLI; COMAMONAS-ACIDOVORANS; 3-D RECONSTRUCTION; SURFACE PROTEIN; CLONING VECTORS; CURRENT NOISE; TRANSPORT; BINDING; CHANNEL	The function of CymA, 1 of the 10 gene products involved in cyclodextrin uptake and metabolism by Klebsiella oxytoca, was characterized. CymA is essential for growth on cyclodextrins, but it can also complement the deficiency of a lamB (maltoporin) mutant of Escherichia coli for growth on linear maltodextrins, indicating that both cyclic and linear oligosaccharides are accepted as substrates, CymA was overproduced in E. coli and purified to apparent homogeneity. CymA is a component of the outer membrane, is processed from a signal peptide-containing precursor, and possesses a high content of antiparallel beta-sheet. Incorporation of CymA into lipid bilayers and conductance measurements revealed that it forms ion-permeable channels, which exhibit a substantial current noise. CymA-induced membrane conductance decreased considerably upon addition of cu-cyclodextrin, Titration experiments allowed the calculation of a half-saturation constant, K-S, of 28 mu M for its binding to CymA. CymA assembled in vitro to two-dimensionally crystalline tubular membranes, which, on electron microscopy, are characterized by a p1-related two-sided plane group. The crystallographic unit cell contains four monomeric CymA molecules showing a central pore. The lattice parameters are a = 16.1 nn, b = 3.8 nm, gamma = 93 degrees. CymA does not form trimeric complexes in lipid membranes and shows no tendency to trimerize in solution. CymA thus is an atypical porin with novel properties specialized to transfer cyclodextrins across the outer membrane.	Univ Munich, Inst Genet & Microbiol, D-80638 Munich, Germany; Univ Wurzburg, Biozentrum, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany; Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Martinsried, Germany	University of Munich; University of Wurzburg; Max Planck Society	Bock, A (corresponding author), Univ Munich, Inst Genet & Microbiol, Maria Ward Str 1A, D-80638 Munich, Germany.	august.boeck@/rz.uni-muenchen.de		Benz, Roland/0000-0002-9510-9265				Andersen C, 1998, J MEMBRANE BIOL, V164, P263, DOI 10.1007/s002329900411; ANDERSEN C, 1995, J GEN PHYSIOL, V105, P385, DOI 10.1085/jgp.105.3.385; Baldermann C, 1998, J BACTERIOL, V180, P3741, DOI 10.1128/JB.180.15.3741-3749.1998; BENDER H, 1980, CARBOHYD RES, V78, P133, DOI 10.1016/S0008-6215(00)83667-8; Bender H, 1982, P 1 INT S CYCL, P77; BENZ R, 1987, J GEN PHYSIOL, V89, P275, DOI 10.1085/jgp.89.2.275; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1986, J BACTERIOL, V165, P978, DOI 10.1128/jb.165.3.978-986.1986; BENZ R, 1987, J MEMBRANE BIOL, V100, P12; Benz R., 1994, BACTERIAL CELL WALL, P397; Boos Winfried, 1996, P201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; DORSET DL, 1983, J MOL BIOL, V165, P701, DOI 10.1016/S0022-2836(83)80275-7; ENGELHARDT H, 1994, MATER RES SOC SYMP P, V330, P201; ENGELHARDT H, 1988, METHOD MICROBIOL, V20, P357, DOI 10.1016/S0580-9517(08)70060-6; ENGELHARDT H, 1990, J STRUCT BIOL, V105, P92, DOI 10.1016/1047-8477(90)90103-J; Feederle R, 1996, ARCH MICROBIOL, V165, P206; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Fiedler G, 1996, J MOL BIOL, V256, P279, DOI 10.1006/jmbi.1996.0085; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; GARAVITO RM, 1986, METHOD ENZYMOL, V125, P309; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKEY M, 1980, P NATL ACAD SCI USA, V77, P165; MAIER C, 1988, J BIOL CHEM, V263, P2493; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Pajatsch M, 1998, J BACTERIOL, V180, P2630, DOI 10.1128/JB.180.10.2630-2635.1998; PAUL A, 1992, BIOPHYS J, V61, P172, DOI 10.1016/S0006-3495(92)81825-8; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sambrook J., 2002, MOL CLONING LAB MANU; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SAXTON WO, 1979, ULTRAMICROSCOPY, V4, P343, DOI 10.1016/S0304-3991(79)80044-3; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; Schmid G., 1996, COMPREHENSIVE SUPRAM, V3, P615; Schmidt AK, 1998, BIOCHEMISTRY-US, V37, P5909, DOI 10.1021/bi9729918; SCHULEIN K, 1991, MOL MICROBIOL, V5, P2233, DOI 10.1111/j.1365-2958.1991.tb02153.x; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; Szejtli J, 1998, CHEM REV, V98, P1743, DOI 10.1021/cr970022c; VANGELDER P, 1997, MOL B INT U, P63; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WANDERSMAN C, 1979, J BACTERIOL, V140, P1; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WERTS C, 1992, MOL GEN GENET, V233, P372, DOI 10.1007/BF00265433; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zeth K, 1998, ACTA CRYSTALLOGR D, V54, P650, DOI 10.1107/S0907444997018854	50	33	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25159	25166		10.1074/jbc.274.35.25159	http://dx.doi.org/10.1074/jbc.274.35.25159			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455198	hybrid			2022-12-25	WOS:000082193400097
J	Silberbach, M; Gorenc, T; Hershberger, RE; Stork, PJS; Steyger, PS; Roberts, CT				Silberbach, M; Gorenc, T; Hershberger, RE; Stork, PJS; Steyger, PS; Roberts, CT			Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC GENE-EXPRESSION; ANGIOTENSIN-CONVERTING ENZYME; MAP KINASE; NITRIC-OXIDE; MUSCLE-CELLS; NUCLEAR TRANSLOCATION; GROWTH; RECEPTOR; PATHWAY; HEART	Atrial natriuretic factor (ANF) inhibits proliferation in non-myocardial cells and is thought to be anti-hypertrophic in cardiomyocytes. We investigated the possibility that the anti-hypertrophic actions of ANF involved the mitogen-activated protein kinase signal transduction cascade. Cultured neonatal rat ventricular myocytes treated for 48 h with the alpha(1)-adrenergic agonist phenylephrine (PE) had an 80% increase in cross-sectional area (CSA). ANP alone had no effect but inhibited PE-induced increases in CSA by approximately 50%. The mitogen-activated protein kinase/ERK kinase (MER) inhibitor PD098059 minimally inhibited PE-induced increases in CSA, but it completely abolished ANF-induced inhibition of PE-induced increases, ANF-induced extracellular signal-regulated protein kinase (ERK) nuclear translocation was also eliminated by PD098059, ANF treatment caused MEK phosphorylation and activation but failed to activate any of the Raf isoforms, ANF induced a rapid increase in ERK phosphorylation and in vitro kinase activity. PE also increased ERK activity, and the combined effect of ANF and PE appeared to be additive. ANF-induced ERK phosphorylation was eliminated by PD098059, ANF induced minimal phosphorylation of JNK or p38, indicating that its effect on ERK was specific. ANF-induced activation of ERK was mimicked by cGMP analogs, suggesting that ANF-induced ERK activation involves the guanylyl cyclase activity of the ANF receptor. These data suggest that there is an important linkage between cGMP signaling and the mitogen-activated protein kinase cascade and that selective ANF activation of ERK is required for the anti-hypertrophic action of ANF. Thus, ANF expression might function as the natural defense of the heart against maladaptive hypertrophy through its ability to activate ERK.	Oregon Hlth & Sci Univ, Div Pediat Cardiol, Dept Pediat, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Silberbach, M (corresponding author), Oregon Hlth & Sci Univ, Div Pediat Cardiol, Dept Pediat, UHN-60,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	silberbm@ohsu.edu	Steyger, Peter S./B-9147-2011; Roberts, Charles/K-6953-2017	Steyger, Peter S./0000-0002-6103-5237; Roberts, Charles/0000-0003-1756-5772; Hershberger, Ray/0000-0001-5683-6526	NICHD NIH HHS [HD01051] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DECKER RS, 1995, CIRC RES, V77, P544, DOI 10.1161/01.RES.77.3.544; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gidh-Jain M, 1998, J MOL CELL CARDIOL, V30, P627, DOI 10.1006/jmcc.1997.0628; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Hansson M, 1997, CELL TISSUE RES, V290, P669, DOI 10.1007/s004410050973; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KNOWLTON KU, 1995, J CLIN INVEST, V96, P1311, DOI 10.1172/JCI118166; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LARSEN TH, 1993, VIRCHOWS ARCH B, V64, P309, DOI 10.1007/BF02915128; Levin ER, 1998, NEW ENGL J MED, V339, P321; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Ohta K, 1996, HYPERTENSION, V28, P627, DOI 10.1161/01.HYP.28.4.627; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SILBERBACH M, 1997, 79 ANN M AM SOC END, P82; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; THORBURN J, 1995, MOL BIOL CELL, V6, P1479, DOI 10.1091/mbc.6.11.1479; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WEINBERG EO, 1994, CIRCULATION, V90, P1410, DOI 10.1161/01.CIR.90.3.1410; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; Yamamoto K, 1996, HYPERTENSION, V28, P988, DOI 10.1161/01.HYP.28.6.988; Yamazaki T, 1996, MOL CELL BIOCHEM, V164, P197, DOI 10.1007/BF00408658; Zheng JS, 1996, CIRC RES, V78, P525, DOI 10.1161/01.RES.78.4.525	52	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24858	24864		10.1074/jbc.274.35.24858	http://dx.doi.org/10.1074/jbc.274.35.24858			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455158	hybrid			2022-12-25	WOS:000082193400057
J	Bell-Parikh, LC; Guengerich, FP				Bell-Parikh, LC; Guengerich, FP			Kinetics of cytochrome P450 2E1-catalyzed oxidation of ethanol to acetic acid via acetaldehyde	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; CONFORMATIONAL CHANGE; SUCCESSIVE REACTIONS; ESCHERICHIA-COLI; TRANSITION-STATE; PRODUCT RELEASE; DEUTERIUM; METABOLISM; SUBSTRATE; NITROSODIMETHYLAMINE	The P450 2E1-catalyzed oxidation of ethanol to acetaldehyde is characterized by a kinetic deuterium isotope effect that increases K-m with no effect on k(cat), and rate-limiting product release has been proposed to account for the lack of an isotope effect on k(cat) (Bell, L. C., and Guengerich, F. P. (1997) J. Biol. Chem. 272, 29643-29651). Acetaldehyde is also a substrate for P450 2E1 oxidation to acetic acid, and k(cat)/K-m for this reaction is at least 1 order of magnitude greater than that for ethanol oxidation to acetaldehyde, Acetic acid accounts for 90% of the products generated from ethanol in a 10-min reaction, and the contribution of this second oxidation has been overlooked in many previous studies. The non competitive intermolecular kinetic hydrogen isotope effects on acetaldehyde oxidation to acetic acid ((H)(k(cat)/K-m)/(D)(k(cat)/K-m) = 4.5, and (D)k(cat) = 1.5) are comparable with the isotope effects typically observed for ethanol oxidation to acetaldehyde, and k(cat) is similar for both reactions, suggesting a possible common catalytic mechanism. Rapid quench kinetic experiments indicate that acetic acid is formed rapidly from added acetaldehyde (similar to 450 min(-1)) with burst kinetics. Pulse-chase experiments reveal that, at a subsaturating concentration of ethanol, similar to 90% of the acetaldehyde intermediate is directly converted to acetic acid without dissociation from the enzyme active site. Competition experiments suggest that P450 2E1 binds acetic acid and acetaldehyde with relatively high K-d values, which preclude simple tight binding as an explanation for rate-limiting product release, The existence of a rate-determining step between product formation and release is postulated. Also proposed is a conformational change in P450 2E1 occurring during the course of oxidation and the discrimination of P450 2E1 between acetaldehyde and its hydrated form, the gem-diol, This multistep P450 reaction is characterized by kinetic control of individual reaction steps and by loose binding of all ligands.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638B Med Res Bldg 1,23rd & Pierce Ave, Nashville, TN 37232 USA.				NCI NIH HHS [R35 CA44353] Funding Source: Medline; NIEHS NIH HHS [T32 ES07028, P30 ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, T32ES007028] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKIYOSHISHIBATA M, 1994, EUR J BIOCHEM, V224, P335, DOI 10.1111/j.1432-1033.1994.00335.x; ANDERSEN ME, 1994, TOXICOL APPL PHARM, V128, P158, DOI 10.1006/taap.1994.1193; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bell LC, 1997, J BIOL CHEM, V272, P29643, DOI 10.1074/jbc.272.47.29643; BRADY JF, 1988, MOL PHARMACOL, V33, P148; BRODIE BB, 1958, ANNU REV BIOCHEM, V27, P427, DOI 10.1146/annurev.bi.27.070158.002235; CALI JJ, 1991, J BIOL CHEM, V266, P7774; Carey FA, 1990, ADV ORGANIC CHEM A, P439; CHRISTIANSON DW, 1985, P NATL ACAD SCI USA, V82, P6840, DOI 10.1073/pnas.82.20.6840; CORBETT MD, 1975, J NATL CANCER I, V55, P1247, DOI 10.1093/jnci/55.5.1247; DAGANI D, 1976, J NATL CANCER I, V57, P955, DOI 10.1093/jnci/57.4.955; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; GILLAM EMJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P59, DOI 10.1006/abbi.1994.1280; GREENZAID P, 1967, J AM CHEM SOC, V89, P756, DOI 10.1021/ja00980a005; Guengerich F. P., 1995, CYTOCHROME P, P473; Guengerich F. Peter, 1994, P1259; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P413, DOI 10.1021/tx00022a003; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUENGERICH FP, 1995, BIOCHIMIE, V77, P573, DOI 10.1016/0300-9084(96)88173-9; Guengerich FP, 1997, BIOCHEMISTRY-US, V36, P14741, DOI 10.1021/bi9719399; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; GUENGERICH FP, 1993, HDB EXP PHARM, V105, P89; Imai T, 1998, BIOCHEMISTRY-US, V37, P8097, DOI 10.1021/bi9802768; KEEFER LK, 1973, J NATL CANCER I, V51, P299, DOI 10.1093/jnci/51.1.299; KLINMAN JP, 1985, J AM CHEM SOC, V107, P1058, DOI 10.1021/ja00290a052; KOOP DR, 1990, CHEM RES TOXICOL, V3, P377, DOI 10.1021/tx00016a017; KUBY SA, 1991, STUDY ENZYMES, V1, P272; KUNITOH S, 1996, ALCOHOL CLIN EXP RES, V20, P22; LING KHJ, 1989, BIOCHEM BIOPH RES CO, V160, P844, DOI 10.1016/0006-291X(89)92511-4; Mackman R, 1996, CHEM RES TOXICOL, V9, P223, DOI 10.1021/tx950130z; MCCASKILL D, 1993, ANAL BIOCHEM, V215, P142, DOI 10.1006/abio.1993.1566; MCTIGUE PT, 1970, AUST J CHEM, V23, P381, DOI 10.1071/CH9700381; MICO BA, 1985, CANCER RES, V45, P6280; MILLER RE, 1982, BIOCHEMISTRY-US, V21, P1090, DOI 10.1021/bi00534a041; MIYAIRI S, 1985, J BIOL CHEM, V260, P320; Mueller Ernest J., 1995, P83; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; Northrop DB, 1998, J CHEM EDUC, V75, P1153, DOI 10.1021/ed075p1153; PALMER G, 1992, J BIOL CHEM, V267, P665; Poulos Thomas L., 1995, P125; RAAG R, 1993, BIOCHEMISTRY-US, V32, P4571, DOI 10.1021/bi00068a013; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; Raner GM, 1997, BIOCHEMISTRY-US, V36, P4895, DOI 10.1021/bi9630568; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHIMADA T, 1986, J BIOL CHEM, V261, P909; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; SHRINER RL, 1965, SYSTEMATIC IDENTIFIC, P253; TERELIUS Y, 1991, BIOCHEM BIOPH RES CO, V179, P689, DOI 10.1016/0006-291X(91)91427-E; Toy PH, 1998, J AM CHEM SOC, V120, P9718, DOI 10.1021/ja981990f; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; VAZ ADN, 1994, BIOCHEMISTRY-US, V33, P6442, DOI 10.1021/bi00187a008; Vaz ADN, 1996, P NATL ACAD SCI USA, V93, P4644, DOI 10.1073/pnas.93.10.4644; VISWANATHAN TS, 1982, BIOCHEMISTRY-US, V21, P339, DOI 10.1021/bi00531a022; WALSH C, 1979, ENZYMATIC REACTION M, P687; WISLOCKI PG, 1980, ENZYMATIC BASIS DETO, V1, P135; Yamazaki T, 1998, BIOCHEMISTRY-US, V37, P2800, DOI 10.1021/bi9715066; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082; YANG CS, 1991, CHEM RES TOXICOL, V4, P408, DOI 10.1021/tx00022a002; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YONG FC, 1970, ARCH BIOCHEM BIOPHYS, V138, P96, DOI 10.1016/0003-9861(70)90288-2; Yun CH, 1996, J BIOL CHEM, V271, P31312, DOI 10.1074/jbc.271.49.31312; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	62	117	120	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23833	23840		10.1074/jbc.274.34.23833	http://dx.doi.org/10.1074/jbc.274.34.23833			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446146	hybrid			2022-12-25	WOS:000082110900025
J	Dumler, I; Kopmann, A; Wagner, K; Mayboroda, OA; Jerke, U; Dietz, R; Haller, H; Gulba, DC				Dumler, I; Kopmann, A; Wagner, K; Mayboroda, OA; Jerke, U; Dietz, R; Haller, H; Gulba, DC			Urokinase induces activation and formation of Stat4 and Stat1-Stat2 complexes in human vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCER; JAK/STAT PATHWAY; INTERFERON-ALPHA; GENE-EXPRESSION; ANGIOTENSIN-II; RECEPTOR; TRANSCRIPTION; BINDING	Urokinase-type plasminogen activator (uPA) and its specific receptor (uPAR) act in concert to stimulate cytoplasmic signaling machinery and transcription factors responsible for cell migration and proliferation. Recently we demonstrated that uPA activates the Janus kinase/signal transducers and activators of transcription (Stat1) signaling in human vascular smooth muscle and endothelial cells, However, the important question whether other transcription factors of the Stat family, in addition to Stat1, are involved in the uPAR-related signaling has not been addressed, In this study, we demonstrate that Stat4 and Stat2, but not Stat3, Stat5, or Stat6, are rapidly activated in response to uPA, We demonstrate further that Stat4 and Stata rapidly and transiently translocate to the cell nucleus where they bind specifically to the regulatory DNA elements. Analysis of Stat complexes formed in response to uPA revealed a Stat2-Stat1 heterodimer, which lacks p48, a DNA-binding protein known to combine with Stat1-Stat2, This new uPA-induced Stat2-Stat1 heterodimer binds to GAS (the interferon-gamma activation site) distinct from the interferon-stimulated response element to which the p48 protein containing complexes generally bind. We conclude that uPA activates a specific and unusual subset of latent cytoplasmic transcription factors in human vascular smooth muscle cells that suggests a critical role of uPA in these cells.	Franz Volhard Clin, D-13125 Berlin, Germany; Humboldt Univ, Virchow Klinikum Charite, Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Univ Amsterdam, Inst Neurobiol, NL-1098 SM Amsterdam, Netherlands	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Amsterdam	Dumler, I (corresponding author), Franz Volhard Clin, Wiltbergstr 50, D-13125 Berlin, Germany.		Mayboroda, Oleg/N-4850-2019; Mayboroda, Oleg/B-5634-2008	Mayboroda, Oleg/0000-0001-8739-9875; Mayboroda, Oleg/0000-0001-8739-9875; Jerke, Uwe/0000-0001-6887-8010				BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; Baden HA, 1998, J BIOL CHEM, V273, P17109, DOI 10.1074/jbc.273.27.17109; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Dumler I, 1999, ARTERIOSCL THROM VAS, V19, P290, DOI 10.1161/01.ATV.19.2.290; DUMLER I, 1994, FEBS LETT, V343, P103, DOI 10.1016/0014-5793(94)80298-X; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Kodama H, 1998, CIRC RES, V82, P244; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Rabbani SA, 1997, J CELL PHYSIOL, V172, P137, DOI 10.1002/(SICI)1097-4652(199708)172:2<137::AID-JCP1>3.0.CO;2-P; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yamamoto K, 1997, BIOCHEM BIOPH RES CO, V233, P126, DOI 10.1006/bbrc.1997.6415; Yu CR, 1996, J IMMUNOL, V157, P126	32	36	43	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24059	24065		10.1074/jbc.274.34.24059	http://dx.doi.org/10.1074/jbc.274.34.24059			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446176	hybrid			2022-12-25	WOS:000082110900055
J	Manting, EH; Kaufmann, A; van der Does, C; Driessen, AJM				Manting, EH; Kaufmann, A; van der Does, C; Driessen, AJM			A single amino acid substitution in SecY stabilizes the interaction with SecA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN TRANSLOCATION; SIGNAL PEPTIDE MUTATIONS; ESCHERICHIA-COLI SECA; PREPROTEIN TRANSLOCASE; PLASMA-MEMBRANE; CYTOPLASMIC MEMBRANE; CATALYTIC CYCLE; ER MEMBRANE; SEQUENCE; EXPORT	The SecYEG complex constitutes a protein conducting channel across the bacterial cytoplasmic membrane. It binds the peripheral ATPase SecA to form the translocase. When isoleucine 278 in transmembrane segment 7 of the SecY subunit was replaced by a unique cysteine, SecYEG supported an increased preprotein translocation and SecA translocation ATPase activity, and allowed translocation of a preprotein with a defective signal sequence. SecY(I278C)EG binds SecA with a higher affinity than normal SecYEG, in particular in the presence of ATP. The increased translocation activity of SecY(1278C)EG was confirmed in a purified system consisting of SecYEG proteoliposomes, while immunoprecipitation in detergent solution reveal that translocase-preprotein complexes are more stable with SecY(I278C) than with normal SecY. These data imply an important role for SecY transmembrane segment 7 in SecA binding. As improved SecA binding to SecY was also observed with the prlA4 suppressor mutation, it may be a general mechanism underlying signal sequence suppression.	Univ Groningen, Dept Microbiol, NL-9751 NN Haren, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Microbiol, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@biol.rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; BASSILANA M, 1993, BIOCHEMISTRY-US, V32, P2626, DOI 10.1021/bi00061a021; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1989, P NATL ACAD SCI USA, V86, P968, DOI 10.1073/pnas.86.3.968; Bost S, 1997, J BIOL CHEM, V272, P4087, DOI 10.1074/jbc.272.7.4087; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DRIESSEN AJM, 1992, EMBO J, V11, P847, DOI 10.1002/j.1460-2075.1992.tb05122.x; Duong F, 1998, EMBO J, V17, P696, DOI 10.1093/emboj/17.3.696; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FLOWER AM, 1994, J BACTERIOL, V176, P5607, DOI 10.1128/JB.176.18.5607-5614.1994; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; HANADA M, 1994, J BIOL CHEM, V269, P23625; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HUIE JL, 1995, J BACTERIOL, V177, P3518, DOI 10.1128/jb.177.12.3518-3526.1995; ITO K, 1990, J BIOENERG BIOMEMBR, V22, P353, DOI 10.1007/BF00763172; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Nishiyama K, 1999, EMBO J, V18, P1049, DOI 10.1093/emboj/18.4.1049; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Nouwen N, 1996, P NATL ACAD SCI USA, V93, P5953, DOI 10.1073/pnas.93.12.5953; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; SAKO T, 1988, J BACTERIOL, V170, P5389, DOI 10.1128/jb.170.11.5389-5391.1988; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Snyders S, 1997, J BIOL CHEM, V272, P11302; STADER J, 1989, GENE DEV, V3, P1045, DOI 10.1101/gad.3.7.1045; STADER J, 1986, J BIOL CHEM, V261, P5075; TANI K, 1990, J BIOL CHEM, V265, P17341; TANJI Y, 1991, J BACTERIOL, V173, P1997, DOI 10.1128/jb.173.6.1997-2005.1991; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P1895, DOI 10.1073/pnas.86.6.1895; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498	47	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23868	23874		10.1074/jbc.274.34.23868	http://dx.doi.org/10.1074/jbc.274.34.23868			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446151	hybrid, Green Published			2022-12-25	WOS:000082110900030
J	Biswas, I; Ban, C; Fleming, KG; Qin, J; Lary, JW; Yphantis, DA; Yang, W; Hsieh, P				Biswas, I; Ban, C; Fleming, KG; Qin, J; Lary, JW; Yphantis, DA; Yang, W; Hsieh, P			Oligomerization of a MutS mismatch repair protein from Thermus aquaticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BASE PAIRS; HETERODUPLEX DNA; TRANSLOCATION MECHANISM; GENETIC-RECOMBINATION; REPLICATION FIDELITY; CANCER-CELLS; BINDS; HETERODIMER; BETA; ULTRACENTRIFUGE	The MutS DNA mismatch protein recognizes heteroduplex DNAs containing mispaired or unpaired bases. We have examined the oligomerization of a MutS protein from Thermus aquaticus that binds to heteroduplex DNAs at elevated temperatures. Analytical gel filtration, cross-linking of MutS protein with disuccinimidyl suberate, light scattering, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry establish that the Tag protein is largely a dimer in free solution, Analytical equilibrium sedimentation showed that the oligomerization of Tag MutS involves a dimer-tetramer equilibrium in which dimer predominates at concentrations below 10 mu M. The Delta G(2-4)(0) for the dimer to tetramer transition is approximately -6.9 +/- 0.1 kcal/mol of tetramer, Analytical gel filtration of native complexes and gel mobility shift assays of an maltose-binding protein-MutS fusion protein bound to a short, 37-base pair heteroduplex DNA reveal that the protein binds to DNA as a dimer with no change in oligomerization upon DNA binding.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA; Univ Connecticut, Natl Analyt Ultracentrifuge Facil, Storrs, CT 06269 USA; Univ Crete, Dept Biol, Heraklion 71409, Crete, Greece; Univ Crete, Inst Mol Biol & Biotechnol, Heraklion 71409, Crete, Greece	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Yale University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Connecticut; University of Connecticut; University of Crete; University of Crete	Hsieh, P (corresponding author), NIDDK, Genet & Biochem Branch, NIH, Bldg 10,Rm 9D04,10 Ctr Dr,MSC 1810, Bethesda, MD 20892 USA.		Ban, Changill/F-5426-2013; Yang, Wei/D-4926-2011; Fleming, Karen/E-7892-2011; Yang, Wei/ABB-4785-2020	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052015] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; ANSEVIN AT, 1970, ANAL BIOCHEM, V34, P237, DOI 10.1016/0003-2697(70)90103-X; Biswas I, 1996, J BIOL CHEM, V271, P5040; Biswas I, 1997, J BIOL CHEM, V272, P13355, DOI 10.1074/jbc.272.20.13355; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; RICHARDS EG, 1971, ANAL BIOCHEM, V41, P215, DOI 10.1016/0003-2697(71)90206-5; SQUIRE PG, 1961, J AM CHEM SOC, V83, P3521, DOI 10.1021/ja01477a039; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Takamatsu S, 1996, NUCLEIC ACIDS RES, V24, P640, DOI 10.1093/nar/24.4.640; Thomas DC, 1996, MUTAT RES-FUND MOL M, V350, P201, DOI 10.1016/0027-5107(95)00112-3; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; YPHANTIS DA, 1979, PROTEIN INTERACTIONS, P275	32	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23673	23678		10.1074/jbc.274.33.23673	http://dx.doi.org/10.1074/jbc.274.33.23673			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438551	hybrid			2022-12-25	WOS:000082012800101
J	Wilson, TE; Lieber, MR				Wilson, TE; Lieber, MR			Efficient processing of DNA ends during yeast nonhomologous end joining - Evidence for a DNA polymerase beta (POL4)-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND-BREAK; BASE-EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; LIGASE-IV; IN-VITRO; MAMMALIAN-CELLS; 2 PATHWAYS; INVOLVEMENT; MRE11	Repair of DNA double strand breaks by nonhomologous end joining (NHEJ) requires enzymatic processing beyond simple ligation when the terminal bases are damaged or not fully compatible. We transformed yeast with a series of linearized plasmids to examine the role of Pol4 (Pol IV, DNA polymerase beta) in repair at a variety of end configurations. Mutation of POL4 did not impair DNA polymerase-independent religation of fully compatible ends and led to at most a a-fold reduction in the frequency of joins that require only DNA polymerization, In contrast, the frequency of joins that also required removal of a 5'- or S'-terminal mismatch was markedly reduced in pol4 (but not rev3, exo1, apn1, or rad1) yeast. In a chromosomal double strand break assay, pol4 mutation conferred a marked increase in sensitivity to HO endonuclease in a rad52 background, due primarily to loss of an NHEJ event that anneals with a 3'-terminal mismatch. The NHEJ activity of Pol4 was dependent on its nucleotidyl transferase function, as well as its unique amino terminus. Paradoxically, in vitro analyses with oligonucleotide substrates demonstrated that although Pol4 fills gaps with displacement of mismatched but not matched 5' termini, it lacks both 5'- and 3'-terminal nuclease activities. Pol4 is thus specifically recruited to perform gap-filling in an NHEJ pathway that must also involve as yet unidentified nucleases.	Washington Univ, Sch Med, Dept Pathol, Div Lab Med, St Louis, MO 63110 USA; Univ So Calif, Norris Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Norris Comprehens Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	Washington University (WUSTL); University of Southern California; University of Southern California; University of Southern California	Wilson, TE (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine,M4214 Med Sci 1,Box 0602, Ann Arbor, MI 48109 USA.			Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909				Asefa B, 1998, CURR GENET, V34, P360, DOI 10.1007/s002940050407; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bennett RAO, 1996, INT J RADIAT BIOL, V70, P623; Bressan DA, 1998, GENETICS, V150, P591; Budd ME, 1997, MUTAT RES-DNA REPAIR, V384, P157, DOI 10.1016/S0921-8777(97)00024-4; Budd ME, 1995, METHOD ENZYMOL, V262, P108; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Chu G, 1996, CURR TOP MICROBIOL, V217, P113; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Feng JA, 1998, BIOCHEMISTRY-US, V37, P9605, DOI 10.1021/bi9808619; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Gu XY, 1996, J BIOL CHEM, V271, P19660, DOI 10.1074/jbc.271.33.19660; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Halas A, 1997, CURR GENET, V31, P292, DOI 10.1007/s002940050208; Hindges R, 1997, BIOL CHEM, V378, P345; Ivanov EL, 1997, CURR BIOL, V7, pR492, DOI 10.1016/S0960-9822(06)00246-6; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KING JS, 1993, NUCLEIC ACIDS RES, V21, P1055, DOI 10.1093/nar/21.5.1055; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; LEEM SH, 1994, NUCLEIC ACIDS RES, V22, P3011, DOI 10.1093/nar/22.15.3011; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Mages GJ, 1996, J BIOL CHEM, V271, P7910, DOI 10.1074/jbc.271.14.7910; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; SIKORSKI RS, 1989, GENETICS, V122, P19; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303	57	164	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23599	23609		10.1074/jbc.274.33.23599	http://dx.doi.org/10.1074/jbc.274.33.23599			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438542	hybrid			2022-12-25	WOS:000082012800092
J	Sunday, ME; Haley, KJ; Sikorski, K; Graham, SA; Emanuel, RL; Zhang, F; Mu, QQ; Shahsafaei, A; Hatzis, D				Sunday, ME; Haley, KJ; Sikorski, K; Graham, SA; Emanuel, RL; Zhang, F; Mu, QQ; Shahsafaei, A; Hatzis, D			Calcitonin driven v-Ha-ras induces multilineage pulmonary epithelial hyperplasias and neoplasms	ONCOGENE			English	Article						neuroendocrine cells; Clara cells; epithelial cell lineages; carcinoid; adenocarcinoma	CELL LUNG-CANCER; GASTRIN-RELEASING PEPTIDE; NEURO-ENDOCRINE DIFFERENTIATION; MEDULLARY-THYROID CARCINOMA; TRANSGENIC MOUSE MODEL; HUMAN-FETAL LUNG; SV40 T-ANTIGEN; GENE-EXPRESSION; HAMSTER LUNG; CHROMOGRANIN-A	We initiated a transgenic model for primary pulmonary neuroendocrine cell (PNEC) hyperplasia/neoplasia using v-Ha-ras driven by the neural/neuroendocrine (NE)-specific calcitonin promoter (rascal). Previously, we showed that nitrosamine treated rodents develop PNEC hyperplasia but non-NE lung tumors, with variable outcomes presumably reflecting ras activation in multiple cell lineages. Interestingly, all rascal transgenic mouse lineages develop hyperplasias of NE and non-NE cells but mostly non-NE lung carcinomas, with rascal mRNA in differentiated PNECs and tumor cells. Analyses of embryonic lung demonstrate rascal mRNA in undifferentiated epithelium, consistent with expression in a common pluripotent precursor cell. These unexpected observations indicate that v-Ha-ras can lead to both NE and non-NE hyperplasia/neoplasia in vivo, opening new avenues for studies of lung carcinogenesis.	Brigham & Womens Hosp, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sunday, ME (corresponding author), Brigham & Womens Hosp, Childrens Hosp, 75 Francis St, Boston, MA 02115 USA.			Sunday, Mary E./0000-0002-6788-1469	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050045, R01HL044984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50045, R01-HL44984] Funding Source: Medline; NICHD NIH HHS [N01-HD02911] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson Robert J., 1997, Current Opinion in Oncology, V9, P45; BAETSCHER M, 1991, ONCOGENE, V6, P1133; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASBAUM C, 1990, AM J PHYSIOL, V259, pL38, DOI 10.1152/ajplung.1990.259.2.L38; BAYLIN SB, 1989, J CLIN ONCOL, V7, P1375, DOI 10.1200/JCO.1989.7.10.1375; BENNETT MM, 1992, ANN NY ACAD SCI, V657, P36, DOI 10.1111/j.1749-6632.1992.tb22755.x; BENSCH KG, 1965, CANCER-AM CANCER SOC, V18, P592, DOI 10.1002/1097-0142(196505)18:5<592::AID-CNCR2820180508>3.0.CO;2-6; BENSCH KG, 1968, CANCER, V22, P1163, DOI 10.1002/1097-0142(196811)22:6<1163::AID-CNCR2820220612>3.0.CO;2-L; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BERENDSEN HH, 1989, J CLIN ONCOL, V7, P1614, DOI 10.1200/JCO.1989.7.11.1614; BOS JL, 1989, CANCER RES, V49, P4682; BOSTWICK DG, 1984, AM J PATHOL, V117, P195; BRAMBILLA E, 1991, J CLIN ONCOL, V9, P50, DOI 10.1200/JCO.1991.9.1.50; CHEJFEC G, 1985, CANCER, V56, P2683, DOI 10.1002/1097-0142(19851201)56:11<2683::AID-CNCR2820561127>3.0.CO;2-L; DAVIS LG, 1986, BASIC METHODS MOL BI, P1; DEBRUINE AP, 1990, ACTA HISTOCHEM S, V38, pS99; DEMAYO FJ, 1991, AM J PHYSIOL, V261, pL70, DOI 10.1152/ajplung.1991.261.2.L70; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; FRANCINEMARIE M, 1997, P NATL ACAD SCI USA, V94, P3330; Gardner DG, 1997, ADV INTERNAL MED, V42, P597; GAZDAR AF, 1988, CANCER RES, V48, P4078; GOODWIN G, 1983, P NATL ACAD SCI-BIOL, V80, P3807, DOI 10.1073/pnas.80.12.3807; GOULD VE, 1983, LAB INVEST, V49, P519; HACKETT BP, 1994, AM J RESP CELL MOL, V11, P123, DOI 10.1165/ajrcmb.11.2.8049073; Haley KJ, 1997, MICROSC RES TECHNIQ, V37, P62, DOI 10.1002/(SICI)1097-0029(19970401)37:1<62::AID-JEMT6>3.0.CO;2-Y; HAMID QA, 1987, VIRCHOWS ARCH A, V411, P185, DOI 10.1007/BF00712743; HAMMOND ME, 1985, CANCER, V56, P1624, DOI 10.1002/1097-0142(19851001)56:7<1624::AID-CNCR2820560727>3.0.CO;2-3; HANSBROUGH JR, 1993, J BIOL CHEM, V268, P9762; HAUBOLDREUTER BG, 1993, J NUCL MED, V34, P809; Johnston D, 1998, ONCOGENE, V16, P167, DOI 10.1038/sj.onc.1201478; JONES TC, 1985, MONOGRAPHS PATHOLOGY, P99; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEBEL M, 1995, CELL GROWTH DIFFER, V6, P1591; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MABRY M, 1989, J CLIN INVEST, V84, P194, DOI 10.1172/JCI114140; Maher J, 1996, LEUKEMIA, V10, P83; MANGUES R, 1990, ONCOGENE, V5, P1491; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; MARONPOT RR, 1991, EXP LUNG RES, V17, P305, DOI 10.3109/01902149109064420; MENDELSOHN G, 1986, PATHOL ANNU, V21, P91; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; Ogawa K, 1996, CARCINOGENESIS, V17, P341, DOI 10.1093/carcin/17.2.341; OREFFO VIC, 1993, CARCINOGENESIS, V14, P451, DOI 10.1093/carcin/14.3.451; OREFFO VIC, 1992, MOL CARCINOGEN, V6, P199, DOI 10.1002/mc.2940060305; PALADUGU RR, 1985, CANCER, V55, P1303, DOI 10.1002/1097-0142(19850315)55:6<1303::AID-CNCR2820550625>3.0.CO;2-A; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RODENHUIS S, 1992, CANCER RES, V52, pS2665; SABA SR, 1981, ULTRASTRUCT PATHOL, V2, P131, DOI 10.3109/01913128109064241; SAID JW, 1985, HUM PATHOL, V16, P236, DOI 10.1016/S0046-8177(85)80008-3; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STAHLMAN MT, 1987, LAB INVEST, V56, P629; STAHLMAN MT, 1985, LAB INVEST, V52, P52; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; SUNDAY ME, 1991, HUM PATHOL, V22, P1030, DOI 10.1016/0046-8177(91)90011-D; SUNDAY ME, 1995, AM J PATHOL, V147, P740; SUNDAY ME, 1992, CANCER RES, V52, pS2677; SUNDAY ME, 1994, LAB INVEST, V70, P875; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; TSUTSUMI Y, 1983, LAB INVEST, V48, P623; WARREN WH, 1984, J THORAC CARDIOV SUR, V87, P274; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Wikenheiser KA, 1997, AM J RESP CELL MOL, V16, P713, DOI 10.1165/ajrcmb.16.6.9191473; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493; Wuenschell CW, 1996, J HISTOCHEM CYTOCHEM, V44, P113, DOI 10.1177/44.2.8609367	68	24	26	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4336	4347		10.1038/sj.onc.1202810	http://dx.doi.org/10.1038/sj.onc.1202810			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439041				2022-12-25	WOS:000081732700006
J	Takahashi, T; Haruki, N; Nomoto, S; Masuda, A; Saji, S; Osada, H; Takahashi, T				Takahashi, T; Haruki, N; Nomoto, S; Masuda, A; Saji, S; Osada, H; Takahashi, T			Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers	ONCOGENE			English	Article						mitotic checkpoint; lung cancer; hsMAD2; p55CDC; pseudogene	SPINDLE ASSEMBLY CHECKPOINT; BUDDING YEAST; ARREST; P53; PROTEIN; TARGET; CDC20	The mitotic checkpoint is thought to be essential for ensuring accurate chromosome segregation by implementing mitotic delay in response to a spindle defect. To date, however, very little data has become available on the defects of the mitotic checkpoint in human cancer cells, In the present study, impaired mitotic checkpoint was found in four (44%) of nine human lung cancer cell lines. To our knowledge, this is the first demonstration of frequent impairment of the mitotic checkpoint in this leading cause of cancer deaths. iis an initial step towards elucidation of the underlying mechanism, we further undertook a search for mutations in a key component of the mitotic checkpoint, known as hsMAD2, and its immediate downstream molecule, p55CDC, No such mutations were found, however, in either 21 lung cancer cell lines or 25 primary lung cancer cases, although we could identify silent polymorphisms and the transcribed and processed hsMAD2 pseudogene that was subsequently mapped at 14q21-q23, The present observations appear to warrant further investigations, such as search for alterations in other components, to better understand the molecular pathogenesis of this fatal disease, and warn against potential misinterpretation when performing mutational analyses for other cancer types based on cDNA templates.	Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Gifu Univ, Sch Med, Dept Surg 2, Gifu 5008705, Japan	Aichi Cancer Center; Aichi Cancer Center; Gifu University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Takahashi, Takashi/I-7262-2014; Osada, Hiroyuki/AAY-6254-2020	Takahashi, Takashi/0000-0003-0615-7001; 				Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Elledge SJ, 1998, SCIENCE, V279, P999, DOI 10.1126/science.279.5353.999; GOTOH K, 1999, IN PRESS CARCINOGENE; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HIBI K, 1994, ONCOGENE, V9, P611; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; KONDO M, 1995, ONCOGENE, V10, P1193; Krishnan R, 1998, GENOMICS, V49, P475, DOI 10.1006/geno.1998.5233; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; *STAT INF DEP, 1998, VIT STAT JAP, V3, P384; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1986, CANCER RES, V46, P4770; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350	26	98	107	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4295	4300		10.1038/sj.onc.1202807	http://dx.doi.org/10.1038/sj.onc.1202807			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439037				2022-12-25	WOS:000081732700002
J	Copeland, PR; Driscoll, DM				Copeland, PR; Driscoll, DM			Purification, redox sensitivity, and RNA binding properties of SECIS-binding protein 2, a protein involved in selenoprotein biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; SELENOCYSTEINE INSERTION ELEMENT; MESSENGER-RNA; ESCHERICHIA-COLI; UGA CODON; FACTOR SELB; TRANSLATION; SEQUENCE; IDENTIFICATION; EUKARYOTES	In mammalian selenoprotein mRNAs, the highly structured 3' UTR contains selenocysteine insertion sequence (SECIS) elements that are required for the recognition of UGA as the selenocysteine codon, Our previous work demonstrated a tight correlation between codon-specific translational read-through and the activity of a 120-kDa RNA-binding protein that interacted specifically with the SECIS element in the phospholipid hydroperoxide glutathione peroxidase mRNA, This study reports the RNA binding and biochemical properties of this protein, SECIS-binding protein 2 (SBP2), We detected SBP2 binding activity in liver, hepatoma cell, and testis extracts from which SBP2 has been purified by anion exchange and RNA affinity chromatography, This scheme has allowed us to identify a 120-kDa polypeptide that co-elutes with SBP2 binding activity from wild-type but not mutant RNA affinity columns. A characterization of SBP2 biochemical properties reveals that SBP2 binding is sensitive to oxidation and the presence of heparin, rRNA, and poly(G), SBP2 activity elutes with a molecular mass of similar to 500 kDa during gel filtration chromatography, suggesting the existence of a large functional complex. Direct cross-linking and competition experiments demonstrate that the minimal phospholipid hydroperoxide glutathione peroxidase 3' UTR binding site is between 82 and 102 nucleotides, which correlates with the minimal sequence necessary for translational read-through, SBP2 also interacts specifically with the minimally functional 3' UTR of another selenoprotein mRNA, deiodinase 1.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Driscoll, DM (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.			Copeland, Paul/0000-0003-3343-0587	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009878] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 F32 DK09878-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; Bao YP, 1997, FEBS LETT, V410, P210, DOI 10.1016/S0014-5793(97)00591-7; BARON C, 1993, P NATL ACAD SCI USA, V90, P4181, DOI 10.1073/pnas.90.9.4181; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; CHEN GFT, 1993, J BIOL CHEM, V268, P23128; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; EHRENREICH A, 1992, EUR J BIOCHEM, V206, P767, DOI 10.1111/j.1432-1033.1992.tb16983.x; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; GODEAS C, 1994, BBA-BIOMEMBRANES, V1191, P147, DOI 10.1016/0005-2736(94)90242-9; Godeas C, 1996, BIOCHEM MOL MED, V59, P118, DOI 10.1006/bmme.1996.0076; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hubert N, 1996, NUCLEIC ACIDS RES, V24, P464, DOI 10.1093/nar/24.3.464; Huttenhofer A, 1996, RNA, V2, P354; Kaminski A, 1995, RNA, V1, P924; Lesoon A, 1997, MOL CELL BIOL, V17, P1977, DOI 10.1128/MCB.17.4.1977; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Martin GW, 1998, RNA, V4, P65; Martin GW, 1996, RNA, V2, P171; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Shen QC, 1998, J BIOL CHEM, V273, P5443, DOI 10.1074/jbc.273.10.5443; Shen QC, 1995, J BIOL CHEM, V270, P30448, DOI 10.1074/jbc.270.51.30448; SHEN QC, 1995, RNA, V1, P519; SHEN QC, 1993, J BIOL CHEM, V268, P11463; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; THOMAS JP, 1990, J BIOL CHEM, V265, P454; Walczak R, 1996, RNA, V2, P367; Walczak R, 1998, RNA, V4, P74; WEITZEL F, 1990, BIOCHIM BIOPHYS ACTA, V1036, P88, DOI 10.1016/0304-4165(90)90018-R; ZHANG LP, 1989, BIOCHIM BIOPHYS ACTA, V1006, P140, DOI 10.1016/0005-2760(89)90336-6; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	33	107	114	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25447	25454		10.1074/jbc.274.36.25447	http://dx.doi.org/10.1074/jbc.274.36.25447			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464275	hybrid			2022-12-25	WOS:000082554200039
J	Galbiati, F; Volonte, D; Minetti, C; Chu, JB; Lisanti, MP				Galbiati, F; Volonte, D; Minetti, C; Chu, JB; Lisanti, MP			Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C) - Retention of LGMD-1C caveolin-3 mutants within the Golgi complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; ONCOGENICALLY TRANSFORMED-CELLS; NITRIC-OXIDE SYNTHASE; ROUS-SARCOMA VIRUS; PLASMA-MEMBRANE; GENE FAMILY; IN-VIVO; SCAFFOLDING DOMAIN; INTEGRAL COMPONENT; TRANSPORT VESICLES	Caveolin-3, a muscle-specific caveolin-related protein, is the principal structural protein of caveolae membrane domains in striated muscle cell types (cardiac and skeletal). Autosomal dominant limb girdle muscular dystrophy (LGMD-1C) in humans is due to mutations within the caveolin-3 gene: (i) a 9-base pair microdeletion that removes three amino acids within the caveolin scaffolding domain (Delta TFT) or (ii) a missense mutation within the membrane spanning domain (P --> L). The molecular mechanisms by which these two mutations cause muscular dystrophy remain unknown. Here, we investigate the phenotypic behavior of these caveolin-3 mutations using heterologous expression. Wild type caveolin-3 or caveolin-3 mutants were transiently expressed in NIH 3T3 cells. LGMD-1C mutants of caveolin-3 (Delta TFT or P --> L) were primarily retained at the level of a perinuclear compartment that we identified as the Golgi complex in double-labeling experiments, while wild type caveolin-3 was efficiently targeted to the plasma membrane. In accordance with these observations, caveolin-3 mutants formed oligomers of a much larger size than wild type caveolin-3 and were excluded from caveolae-enriched membrane fractions as seen by sucrose density gradient centrifugation. In addition, these caveolin-3 mutants were expressed at significantly lower levels and had a dramatically shortened half-life of similar to 45-60 min. However, caveolin-3 mutants were palmitoylated to the same extent as wild type caveolin-3, indicating that targeting to the plasma membrane is not required for palmitoylation of caveolin-3. In conclusion, we show that LGrMD-1C mutations lead to formation of unstable high molecular mass aggregates of caveolin-3 that are retained within the Golgi complex and are not targeted to the plasma membrane. Consistent with its autosomal dominant form of genetic transmission we demonstrate that LGMD-1C mutants of caveolin-3 behave in a dominant-negative fashion, causing the retention of wild type caveolin-3 at the level of the Golgis. These data provide a molecular explanation for why caveolin-3 levels are down-regulated in patients with this form of limb girdle muscular dystrophy (LGMD-1C).	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Univ Genoa, Serv Malattie Neuromuscolari, Ist Gaslini, I-16147 Genoa, Italy	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Genoa; IRCCS Istituto Giannina Gaslini	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Galbiati, Ferruccio/AAF-3527-2020; Lisanti, Michael P/C-6866-2013; Minetti, Carlo/K-4666-2018	Lisanti, Michael/0000-0003-2034-1382; Minetti, Carlo/0000-0002-0640-1804	Telethon [1111] Funding Source: Medline	Telethon(Fondazione Telethon)		CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; McNally EM, 1998, HUM MOL GENET, V7, P871, DOI 10.1093/hmg/7.5.871; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MOLDOVAN NI, 1995, EXP CELL RES, V219, P309, DOI 10.1006/excr.1995.1233; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7	56	132	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25632	25641		10.1074/jbc.274.36.25632	http://dx.doi.org/10.1074/jbc.274.36.25632			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464299	hybrid			2022-12-25	WOS:000082554200063
J	Rein, T; Kobayashi, T; Malott, M; Leffak, M; DePamphilis, ML				Rein, T; Kobayashi, T; Malott, M; Leffak, M; DePamphilis, ML			DNA methylation at mammalian replication origins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							C-MYC GENE; ESCHERICHIA-COLI CHROMOSOME; INACTIVE-X-CHROMOSOME; BINDING PROTEIN MECP2; HUMAN BLADDER-CANCER; XENOPUS EGG EXTRACT; CPG ISLAND PROMOTER; BETA-GLOBIN LOCUS; HELA-CELLS; INITIATION ZONE	In Escherichia coli, DNA methylation regulates both origin usage and the time required to reassemble prereplication complexes at replication origins. In mammals, at least three replication origins are associated with a high density cluster of methylated CpG dinucleotides, and others whose methylation status has not yet been characterized have the potential to exhibit a similar DNA methylation pattern. One of these origins is found within the similar to 2-kilobase pair region upstream of the human c-myc gene that contains 86 CpGs. Application of the bisulfite method for detecting 5-methylcytosines at specific DNA sequences revealed that this region was not methylated in either total genomic DNA or newly synthesized DNA. Therefore, DNA methylation is not a universal component of mammalian replication origins, To determine whether or not DNA methylation plays a role in regulating the activity of origins that are methylated, the rate of remethylation and the effect of hypomethylation were determined at origin beta (ori-beta), downstream of the hamster DHFR gene. Remethylation at ori-beta did not begin until similar to 500 base pairs of DNA was synthesized, but it was then completed by the time that 4 kilobase pairs of DNA was synthesized (<3 min after release into S phase). Thus, DNA methylation cannot play a significant role in regulating reassembly of prereplication complexes in mammalian cells, as it does in E. coli, To determine whether or not DNA methylation plays any role in origin activity, hypomethylated hamster cells were examined for ori-beta activity. Cells that were >50% reduced in methylation at ori-beta no longer selectively activated ori-beta. Therefore, at some loci, DNA methylation either directly or indirectly determines where replication beans.	NICHD, NIH, Bethesda, MD 20892 USA; Max Planck Inst Psychiat, D-80804 Munich, Germany; Natl Inst Basic Biol, Okazaki, Aichi 444, Japan; Wright State Univ, Dept Biochem & Mol Biol, Dayton, OH 45435 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Max Planck Society; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); University System of Ohio; Wright State University Dayton	DePamphilis, ML (corresponding author), NICHD, NIH, Bldg 6,Rm 416, Bethesda, MD 20892 USA.	depamphm@box-d.nih.gov		Rein, Theo/0000-0003-2850-4289	NIGMS NIH HHS [GM53819] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053819] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES A, 1993, J BACTERIOL, V175, P7801, DOI 10.1128/JB.175.24.7801-7807.1993; ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; ANTEQUERA F, 1984, J BIOL CHEM, V259, P8033; Araujo FD, 1999, J BIOL CHEM, V274, P9335, DOI 10.1074/jbc.274.14.9335; Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; BERBERICH S, 1995, J MOL BIOL, V245, P92, DOI 10.1006/jmbi.1994.0010; BICKMORE WA, 1995, J CELL SCI, V108, P2801; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BLOW JJ, 1996, DNA REPLICATION EUKA, P971; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRENDLER T, 1995, EMBO J, V14, P4083, DOI 10.1002/j.1460-2075.1995.tb00080.x; BRENDLER T, 1991, J BACTERIOL, V173, P3935, DOI 10.1128/jb.173.13.3935-3942.1991; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CARROLL SM, 1993, MOL CELL BIOL, V13, P2971, DOI 10.1128/MCB.13.5.2971; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CUSICK ME, 1981, BIOCHEMISTRY-US, V20, P6648, DOI 10.1021/bi00526a020; CUSICK ME, 1988, BIOCHEMISTRY-US, V22, P3873; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; Depamphilis Melvin L., 1993, Trends in Cell Biology, V3, P161, DOI 10.1016/0962-8924(93)90137-P; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P45; Dimitrova DS, 1998, J CELL SCI, V111, P2989; DUBEY DD, 1994, EMBO J, V13, P3638, DOI 10.1002/j.1460-2075.1994.tb06671.x; Ermakova OV, 1999, MOL CELL, V3, P321, DOI 10.1016/S1097-2765(00)80459-1; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GHAZI H, 1992, GENE, V114, P203, DOI 10.1016/0378-1119(92)90575-A; Gonzalgo ML, 1998, CANCER RES, V58, P1245; GRUENBAUM Y, 1983, P NATL ACAD SCI-BIOL, V80, P4919, DOI 10.1073/pnas.80.16.4919; HALLE JP, 1995, MUTAT RES-DNAGING G, V316, P157, DOI 10.1016/0921-8734(95)90002-0; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; Helmstetter CE., 1987, ESCHERICHIA COLI SAL, P1594; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JABLONKA E, 1985, CHROMOSOMA, V93, P152, DOI 10.1007/BF00293162; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kalejta RF, 1998, MOL CELL, V2, P797, DOI 10.1016/S1097-2765(00)80294-4; KELLY RE, 1995, MOL CELL BIOL, V15, P4136; Kim SM, 1998, MOL CELL BIOL, V18, P7294, DOI 10.1128/MCB.18.12.7294; KIMURA T, 1989, MOL GEN GENET, V219, P69, DOI 10.1007/BF00261159; KIPLING D, 1990, MOL CELL BIOL, V10, P265, DOI 10.1128/MCB.10.1.265; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kobayashi T, 1998, MOL CELL BIOL, V18, P3266, DOI 10.1128/MCB.18.6.3266; Kornberg A., 1992, DNA REPLICATION; KRYSAN PJ, 1993, MOL CELL BIOL, V13, P2688, DOI 10.1128/MCB.13.5.2688; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LEFFAK M, 1989, MOL CELL BIOL, V9, P586, DOI 10.1128/MCB.9.2.586; Loebel DAF, 1996, GENOME RES, V6, P114, DOI 10.1101/gr.6.2.114; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; Lu ZH, 1998, MOL BIOL CELL, V9, P1163, DOI 10.1091/mbc.9.5.1163; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARTIN RG, 1977, CELL, V11, P859, DOI 10.1016/0092-8674(77)90297-5; MCWHINNEY C, 1995, DNA CELL BIOL, V14, P565, DOI 10.1089/dna.1995.14.565; MESSER W, 1985, EMBO J, V4, P1327, DOI 10.1002/j.1460-2075.1985.tb03780.x; MIYAMURA Y, 1993, GERONTOLOGY, V39, P3; MURCHIE AIH, 1989, J MOL BIOL, V205, P593, DOI 10.1016/0022-2836(89)90228-3; Nan XS, 1996, MOL CELL BIOL, V16, P414; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; ORRWEAVER TL, 1991, BIOESSAYS, V13, P97, DOI 10.1002/bies.950130302; Ortega JM, 1998, J CELL SCI, V111, P3663; PARK JG, 1994, MOL CELL BIOL, V14, P7975, DOI 10.1128/MCB.14.12.7975; Pemov A, 1998, P NATL ACAD SCI USA, V95, P14757, DOI 10.1073/pnas.95.25.14757; Phi-van L, 1998, J BIOL CHEM, V273, P18300, DOI 10.1074/jbc.273.29.18300; Qian XLC, 1997, CANCER RES, V57, P3672; RAO PM, 1989, CARCINOGENESIS, V10, P933, DOI 10.1093/carcin/10.5.933; Rein T, 1997, J BIOL CHEM, V272, P10021; Rein T, 1998, NUCLEIC ACIDS RES, V26, P2255, DOI 10.1093/nar/26.10.2255; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; Sardi I, 1998, EUR UROL, V33, P424, DOI 10.1159/000019629; Sardi I, 1997, EUR UROL, V31, P224; Sasaki T, 1999, MOL CELL BIOL, V19, P547; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SHAFER DA, 1984, AM J HUM GENET, V36, P534; SIMON I, 1996, DNA REPLICATION EUKA, P387; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; Subramanian PS, 1997, SOMAT CELL MOLEC GEN, V23, P97, DOI 10.1007/BF02679969; SZYF M, 1991, J BIOL CHEM, V266, P10027; Tanaka H, 1998, CANCER RES, V58, P3429; Tasheva ES, 1995, SOMAT CELL MOLEC GEN, V21, P369, DOI 10.1007/BF02310205; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5636, DOI 10.1128/MCB.14.9.5636; TAYLOR J, 1978, DNA SYNTHESIS PRESEN, P149; Trivedi A, 1998, DNA CELL BIOL, V17, P885, DOI 10.1089/dna.1998.17.885; van der Vliet P.C., 1996, DNA REPLICATION EUKA, P87; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; VIRTAPEARLMAN VJ, 1993, MOL CELL BIOL, V13, P5931, DOI 10.1128/MCB.13.10.5931; VOGEL MC, 1988, FEBS LETT, V236, P9, DOI 10.1016/0014-5793(88)80275-8; VONFREIESLEBEN U, 1994, MOL MICROBIOL, V14, P763; Waltz SE, 1996, NUCLEIC ACIDS RES, V24, P1887, DOI 10.1093/nar/24.10.1887; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; Weitzel JM, 1997, MOL CELL BIOL, V17, P5656, DOI 10.1128/MCB.17.9.5656; WESSEL R, 1992, VIROLOGY, V189, P293, DOI 10.1016/0042-6822(92)90705-T; Wold S, 1998, EMBO J, V17, P4158, DOI 10.1093/emboj/17.14.4158; WOODCOCK DM, 1986, EXP CELL RES, V162, P23, DOI 10.1016/0014-4827(86)90423-4; WOODCOCK DM, 1986, EXP CELL RES, V166, P103, DOI 10.1016/0014-4827(86)90511-2; Wu JR, 1998, EMBO J, V17, P1810, DOI 10.1093/emboj/17.6.1810; Wu JR, 1996, SCIENCE, V271, P1270, DOI 10.1126/science.271.5253.1270; YAMAKI H, 1988, NUCLEIC ACIDS RES, V16, P5067, DOI 10.1093/nar/16.11.5067; ZACHARIAS W, 1988, BIOCHEMISTRY-US, V27, P2970, DOI 10.1021/bi00408a046	108	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25792	25800		10.1074/jbc.274.36.25792	http://dx.doi.org/10.1074/jbc.274.36.25792			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464318	hybrid			2022-12-25	WOS:000082554200082
J	Bonaventura, C; Ferruzzi, G; Tesh, S; Stevens, RD				Bonaventura, C; Ferruzzi, G; Tesh, S; Stevens, RD			Effects of S-nitrosation on oxygen binding by normal and sickle cell hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; NITROSOHEMOGLOBIN; POLYMERIZATION; ERYTHROCYTES; GENERATION; SUPEROXIDE; MECHANISMS; OXIDATION; AFFINITY	S-Nitrosated hemoglobin (SNO-Hb) is of interest because of the allosteric control of NO delivery from SNO-Hb made possible by the conformational differences between the R- and T-states of Rb, To better understand SNO-Hb, the oxygen binding properties of S-nitrosated forms of normal and sickle cell Hb were investigated. Spectral assays and electrospray ionization mass spectrometry were used to quantify the degree of S-nitrosation. Hb A(0) and unpolymerized Hb S exhibit similar shifts toward their R-state conformations in response to S-nitrosation, with increased oxygen affinity and decreased cooperativity, Responses to 2,3-diphosphoglycerate were unaltered, indicating regional changes in the deoxy structure of SNO-Hb that accommodate NO adduction, A cycle of deoxygenation/reoxygenation does not cause loss of NO or appreciable heme oxidation, There is, however, appreciable loss of NO and heme oxidation when oxygen-binding experiments are carried out in the presence of glutathione, These results indicate that the in vivo stability of SNO-Hb and its associated vasoactivity depend on the abundance of thiols and other factors that influence transnitrosation reactions. The increased oxygen affinity and R-state character that result from S-nitrosation of Hb S would be expected to decrease its polymerization and thereby lessen the associated symptoms of sickle cell disease.	Duke Univ, Marine Biomed Ctr, NSOE Marine Lab, Beaufort, NC 28516 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27708 USA	Duke University; Duke University	Bonaventura, C (corresponding author), Duke Univ, Marine Biomed Ctr, NSOE Marine Lab, 135 Duke Marine Lab Rd, Beaufort, NC 28516 USA.				NHLBI NIH HHS [R01 HL58248] Funding Source: Medline; NIEHS NIH HHS [ESO-1908] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001908, P50ES001908] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BENESCH RE, 1978, ANAL BIOCHEM, V89, P162, DOI 10.1016/0003-2697(78)90737-6; Bonaventura C, 1998, BIOCHEMISTRY-US, V37, P496, DOI 10.1021/bi971574s; BONAVENTURA J, 1975, J BIOL CHEM, V250, P9250; DOMENGET C, 1985, BIOCHIM BIOPHYS ACTA, V830, P71, DOI 10.1016/0167-4838(85)90133-5; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; Feelisch M., 1996, METHODS NITRIC OXIDE, P71; Ferranti P, 1997, FEBS LETT, V400, P19, DOI 10.1016/S0014-5793(96)01258-6; GAREL MC, 1990, BIOCHIM BIOPHYS ACTA, V1041, P133, DOI 10.1016/0167-4838(90)90056-L; GAREL MC, 1986, J BIOL CHEM, V261, P4704; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Harrington DJ, 1997, J MOL BIOL, V272, P398, DOI 10.1006/jmbi.1997.1253; Head CA, 1997, J CLIN INVEST, V100, P1193, DOI 10.1172/JCI119631; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; IMAI K, 1973, BIOCHEMISTRY-US, V12, P798, DOI 10.1021/bi00729a003; Imai K., 1982, ALLOSTERIC EFFECTS H; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; MARTIN W, 1986, BRIT J PHARMACOL, V89, P563, DOI 10.1111/j.1476-5381.1986.tb11157.x; MCANINLY J, 1993, J CHEM SOC CHEM COMM, P1758, DOI 10.1039/c39930001758; MINTON A P, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1418, DOI 10.1073/pnas.71.4.1418; MOORE EG, 1976, J BIOL CHEM, V251, P2788; NAGEL RL, 1990, BLOOD CELLS, V16, P321; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PERUTZ MF, 1969, NATURE, V222, P1240, DOI 10.1038/2221240a0; RIGGS AF, 1956, J GEN PHYSIOL, V39, P585, DOI 10.1085/jgp.39.4.585; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; RUBBO H, 1995, FREE RADICALS OXIDAT, P33; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; SCHACTER LP, 1986, EUR J CLIN INVEST, V16, P204, DOI 10.1111/j.1365-2362.1986.tb01330.x; SHIH DTB, 1987, J MOL BIOL, V195, P453, DOI 10.1016/0022-2836(87)90666-8; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; WINTERBOURN CC, 1977, BIOCHEM J, V165, P141, DOI 10.1042/bj1650141	35	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24742	24748		10.1074/jbc.274.35.24742	http://dx.doi.org/10.1074/jbc.274.35.24742			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455144	hybrid			2022-12-25	WOS:000082193400043
J	Gatto, C; Thornewell, SJ; Holden, JP; Kaplan, JH				Gatto, C; Thornewell, SJ; Holden, JP; Kaplan, JH			Cys(577) is a conformationally mobile residue in the ATP-binding domain of the Na,K-ATPase alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CATION-BINDING; ADENOSINE-TRIPHOSPHATASE; CHEMICAL MODIFICATION; RENAL NA,K-ATPASE; ESCHERICHIA-COLI; ION-TRANSPORT; SODIUM-PUMP; AMINO-ACIDS; PROTEINS	2-[4'-Maleimidylanilino]naphthalene 6-sulfonic acid (MIANS) irreversibly inactivates Na,K-ATPase in a time- and concentration-dependent manner. Inactivation is prevented by 3 mM ATP or low K+ (<1 mM); the protective effect K+ is reversed at higher concentrations, This biphasic effect was also observed with K+ congeners, In contrast, Na+ ions did not protect. MIANS inactivation disrupted high affinity ATP binding. Tryptic fragments of MIANS-labeled protein were analyzed by reversed phase high performance liquid chromatography, ATP clearly protected one major labeled peptide peak. This observation was confirmed by separation of tryptic peptides in SDS-polyacrylamide gel electrophoresis revealing a single fluorescently-labeled peptide of similar to 5 kDa, N-terminal. amino acid sequencing identified the peptide (V(545)LGFCH...), This hydrophobic peptide contains only two Cys residues in all sodium pump alpha-subunit sequences and is found in the major cytoplasmic loop between M4 and M5, a region previously associated with ATP binding. Subsequent digestion of the tryptic peptide with V8 protease and N-terminal amino acid sequencing identified the modified residue as Cys(577). The cation-dependent change in reactivity of Cys(577) implies structural alterations in the ATP-binding domain following cation binding and occlusion in the intramembrane domain of Na,K-ATPase and expands our knowledge of the extent to which cation binding and occlusion are sensed in the ATP hydrolysis domain.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Kaplan, JH (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	kaplanj@ohsu.edu		Kaplan, Jack/0000-0002-7048-6574	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL09972] Funding Source: Medline; NIGMS NIH HHS [GM39500] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; ELLISDAVIES GCR, 1990, J BIOL CHEM, V265, P20570; Farley RA, 1997, BIOCHEMISTRY-US, V36, P941, DOI 10.1021/bi962153y; FARLEY RA, 1980, J BIOL CHEM, V255, P860; Gatto C, 1999, J BIOL CHEM, V274, P13737, DOI 10.1074/jbc.274.20.13737; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Gatto C, 1997, ARCH BIOCHEM BIOPHYS, V340, P90, DOI 10.1006/abbi.1997.9879; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; GREEN NM, 1994, SODIUM PUMP, P110; GUPTE SS, 1979, J BIOL CHEM, V254, P362; Hu YK, 1999, BIOPHYS J, V76, pA387; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JUNG H, 1994, BIOCHEMISTRY-US, V33, P12160, DOI 10.1021/bi00206a019; KAPLAN JH, 1991, SOC GEN PHY, V46, P117; KAPLAN JH, 1997, ACTA SCAND PHYSL, V643, P99; Kasho VN, 1997, BIOCHEMISTRY-US, V36, P8045, DOI 10.1021/bi970472z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUI R, 1996, BIOCHEMISTRY-US, V35, P11865; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; NICHOLAS RA, 1984, BIOCHEMISTRY-US, V23, P888, DOI 10.1021/bi00300a015; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; PEDEMONTE CH, 1992, FEBS LETT, V314, P97, DOI 10.1016/0014-5793(92)81470-7; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PEDEMONTE CH, 1988, BIOCHEMISTRY-US, V27, P7966, DOI 10.1021/bi00420a056; POST RL, 1972, J BIOL CHEM, V247, P6530; RAY WJ, 1961, J BIOL CHEM, V236, P1973; ROBINSON JD, 1980, J BIOENERG BIOMEMBR, V12, P165, DOI 10.1007/BF00744681; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; XIE XJ, 1994, SODIUM PUMP STRUCTUR, P49	45	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24995	25003		10.1074/jbc.274.35.24995	http://dx.doi.org/10.1074/jbc.274.35.24995			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455178	hybrid			2022-12-25	WOS:000082193400077
J	Johnson, LL; Bornemeier, DA; Janowicz, JA; Chen, J; Pavlovsky, AG; Ortwine, DF				Johnson, LL; Bornemeier, DA; Janowicz, JA; Chen, J; Pavlovsky, AG; Ortwine, DF			Effect of species differences on stromelysin-1 (MMP-3) inhibitor potency - An explanation of inhibitor selectivity using homology modeling and chimeric proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; HUMAN MATRIX METALLOPROTEINASE; HUMAN FIBROBLAST COLLAGENASE; CATALYTIC DOMAIN; HYDROXAMATE INHIBITOR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; EXPRESSION; OSTEOARTHRITIS; PURIFICATION	For an animal model to predict a compound's potential for treating human disease, inhibitor interactions with the cognate enzymes of separate species must be comparable. Rabbit and human isoforms of stromelysin-1 are highly homologous, yet there are clear and significant compound-specific differences in inhibitor potencies between these two enzymes. Using crystal structures of discordant inhibitors complexed with the human enzyme, we generated a rabbit enzyme homology model that was used to identify two unmatched residues near the active site that could explain the observed disparities, To test these observations, we designed and synthesized three chimeric mutants of the human enzyme containing the single (H224N and L226F) and double (H224N/L226F) mutations. A comparison of inhibitor potencies among the mutant and wild-type enzymes shows that the mutation of a single amino acid in the human enzyme, histidine 224 to asparagine, is sufficient to change the selectivity profile of the mutant to that of the rabbit isoform, These studies emphasize the importance of considering species differences, which can result from even minor protein sequence variations, for the critical enzymes in an animal disease model. Homology modeling provides a tool to identify key differences in isoforms that can significantly affect native enzyme activity.	Parke Davis Pharmaceut Res, Dept Canc Res, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Dept Discovery Informat, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Dept Biochem, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Dept Vasc & Cardiac Dis, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Dept Chem, Ann Arbor, MI 48105 USA	Pfizer; Pfizer; Pfizer; Pfizer; Pfizer	Johnson, LL (corresponding author), Parke Davis Pharmaceut Res, Dept Canc Res, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.			Bornemeier, Dirk/0000-0002-2271-6240				BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Betz M, 1997, EUR J BIOCHEM, V247, P356, DOI 10.1111/j.1432-1033.1997.00356.x; BLUNDELL T, 1988, EUR J BIOCHEM, V172, P513, DOI 10.1111/j.1432-1033.1988.tb13917.x; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Borkakoti N, 1998, PROG BIOPHYS MOL BIO, V70, P73, DOI 10.1016/S0079-6107(98)00003-0; BORKAKOTI N, 1994, NAT STRUCT BIOL, V1, P106, DOI 10.1038/nsb0294-106; Brandstetter H, 1998, PROTEIN SCI, V7, P1303, DOI 10.1002/pro.5560070605; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; BROWNER MF, 1994, PERSPECT DRUG DISCOV, V2, P343; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Dhanaraj V, 1996, STRUCTURE, V4, P375, DOI 10.1016/S0969-2126(96)00043-3; Finzel BC, 1998, PROTEIN SCI, V7, P2118, DOI 10.1002/pro.5560071008; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; GOOLEY PR, 1994, NAT STRUCT BIOL, V1, P111, DOI 10.1038/nsb0294-111; GRAMS F, 1995, BIOCHEMISTRY-US, V34, P14012, DOI 10.1021/bi00043a007; GUNJASMITH Z, 1993, AGENTS ACTIONS, V40, P228, DOI 10.1007/BF01984067; HARRISON RK, 1992, BIOCHEMISTRY-US, V31, P10757, DOI 10.1021/bi00159a016; Holman CM, 1999, BIOCHEMISTRY-US, V38, P677, DOI 10.1021/bi9822170; HUPE D, 1996, Patent No. 38434; HUPE D, 1997, Patent No. 23459; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; Keyszer G, 1998, ARTHRITIS RHEUM, V41, P1378, DOI 10.1002/1529-0131(199808)41:8<1378::AID-ART6>3.0.CO;2-J; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Li YC, 1998, BIOCHEMISTRY-US, V37, P14048, DOI 10.1021/bi981328w; Lochter A, 1997, J BIOL CHEM, V272, P5007, DOI 10.1074/jbc.272.8.5007; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; LOWRY CL, 1992, PROTEINS, V12, P42, DOI 10.1002/prot.340120106; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Nagase H, 1997, BIOL CHEM, V378, P151; Nagase H, 1996, ZINC METALLOPROTEASE, P153; Pavlovsky AG, 1999, PROTEIN SCI, V8, P1455, DOI 10.1110/ps.8.7.1455; PURCHASE C, 1998, Patent No. 09940; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; Sang QXA, 1996, J PROTEIN CHEM, V15, P137, DOI 10.1007/BF01887395; SPURLINO JC, 1994, PROTEINS, V19, P98, DOI 10.1002/prot.340190203; STAMS T, 1994, NAT STRUCT BIOL, V1, P119, DOI 10.1038/nsb0294-119; STEIN RL, 1994, ARCH BIOCHEM BIOPHYS, V308, P274, DOI 10.1006/abbi.1994.1038; StetlerStevenson WG, 1996, AM J PATHOL, V148, P1345; VANDOREN SR, 1995, PROTEIN SCI, V4, P2487, DOI 10.1002/pro.5560041205; WHITE AD, 1997, 214 ACS NAT M LAS VE; WILHELM SM, 1993, J BIOL CHEM, V268, P21906; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1991, J RHEUMATOL, V18, P99; YE QZ, 1994, J MED CHEM, V37, P206, DOI 10.1021/jm00027a027; YE QZ, 1992, BIOCHEM BIOPH RES CO, V186, P143, DOI 10.1016/S0006-291X(05)80786-7; YE QZ, 1995, BIOCHEMISTRY-US, V34, P4702, DOI 10.1021/bi00014a026; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038	52	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24881	24887		10.1074/jbc.274.35.24881	http://dx.doi.org/10.1074/jbc.274.35.24881			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455161	hybrid			2022-12-25	WOS:000082193400060
J	Appleyard, SM; Celver, J; Pineda, V; Kovoor, A; Wayman, GA; Chavkin, C				Appleyard, SM; Celver, J; Pineda, V; Kovoor, A; Wayman, GA; Chavkin, C			Agonist-dependent desensitization of the kappa opioid receptor by G protein receptor kinase and beta-arrestin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD INTRACELLULAR LOOP; COOH-TERMINAL TAIL; MOLECULAR MECHANISMS; XENOPUS OOCYTES; DOWN-REGULATION; AMINO-ACIDS; DELTA; PHOSPHORYLATION; LOCALIZATION; COEXPRESSION	We used the Xenopus oocyte expression system to examine the regulation of rat kappa opioid receptor (KOR) function by G protein receptor kinases (GRKs), kappa agonists increased the conductance of G protein-activated inwardly rectifying potassium channels in oocytes coexpressing KOR with Kir3.1 and Kir3.4. In the absence of added GRK and beta-arrestin 2, desensitization of the kappa agonist-induced potassium current was modest. Co expression of either GRK3 or GRK5 along with beta-arrestin 2 significantly increased the rate of desensitization, whereas addition of either beta-arrestin 2, GRK3, or GRK5 alone had no effect on the KOR desensitization rate, The desensitization was homologous as co-expressed delta opioid receptor-evoked responses were not affected by KOR desensitization. The rate of GRK3/beta-arrestin 2-dependent desensitization was reduced by truncation of the C-terminal 26 amino acids, KOR(Q355 Delta). In contrast, substitution of Ala for Ser within the third intracellular loop [KOR(S255A,S260A,S262A)] did not reduce the desensitization rate, Within the C-terminal region, KOR(S369A) substitution significantly attenuated desensitization, whereas the KOR(T363A) and KOR(S356A,T357A) point mutations did not. These results suggest that co-expression of GRK3 or GRK5 and beta-arrestin 2 produced homologous, agonist-induced desensitization of the kappa opioid receptor by a mechanism requiring the phosphorylation of the serine 369 of rKOR.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Neurobiol Program, Seattle, WA 98195 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Oregon Health & Science University	Chavkin, C (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.		Chavkin, Charles/G-2797-2010		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004123, R37DA011672] Funding Source: NIH RePORTER; NIDA NIH HHS [DA04123, R37 DA011672] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Appleyard SM, 1997, J NEUROCHEM, V69, P2405; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ARVIDSSON U, 1995, P NATL ACAD SCI USA, V92, P5062, DOI 10.1073/pnas.92.11.5062; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Cheng ZJ, 1998, J BIOL CHEM, V273, P24328, DOI 10.1074/jbc.273.38.24328; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Drake CT, 1996, J COMP NEUROL, V370, P377; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; HENRY DJ, 1995, MOL PHARMACOL, V47, P551; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LEONARD JP, 1991, MOL NEUROBIOLOGY PRA, P161; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; MA GH, 1995, MOL PHARMACOL, V47, P1035; NAKATA H, 1994, EUR J BIOCHEM, V220, P9; Nestler EJ, 1997, CURR OPIN NEUROBIOL, V7, P713, DOI 10.1016/S0959-4388(97)80094-3; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Wolf R, 1999, MOL PHARMACOL, V55, P263, DOI 10.1124/mol.55.2.263; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193; Zhao J, 1997, BIOCHEM BIOPH RES CO, V238, P71, DOI 10.1006/bbrc.1997.7242	32	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23802	23807		10.1074/jbc.274.34.23802	http://dx.doi.org/10.1074/jbc.274.34.23802			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446141	hybrid			2022-12-25	WOS:000082110900020
J	Clasper, S; Vekemans, S; Fiore, M; Plebanski, M; Wordsworth, P; David, G; Jackson, DG				Clasper, S; Vekemans, S; Fiore, M; Plebanski, M; Wordsworth, P; David, G; Jackson, DG			Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; HUMAN-LUNG FIBROBLASTS; RHEUMATOID-ARTHRITIS; HEMATOPOIETIC-CELLS; SYNOVIAL TISSUE; FACTOR-II; BINDING; RECEPTOR; STIMULATION; DEGRADATION	Monocyte/macrophages play important roles in regulating tissue growth and angiogenesis through the controlled release of heparin-binding growth factors such as fibroblast growth factor (FGF), vascular endothelial growth factor, and heparin binding epidermal growth factor. The action of these potent growth mediators is known to be regulated by adsorption to heparan sulfate proteoglycans (HSPGs) on the surface and within the extracellular matrix of other neighboring cells, which respectively promote or restrict interactions with their signal-transducing receptors on target cells. Here we report on the nature of HSPGs inducibly expressed on the surface of macrophages that confer these cells with the capacity to regulate endogenous growth factor activity. We reveal that activated human macrophages express only a single major 48-kDa cell surface HSPG, syndecan-2 (fibroglycan) as the result of de novo RNA and protein synthesis. In addition, we demonstrate this macrophage HSPG selectively binds the macrophage-derived growth factors FGF-8, vascular endothelial growth factor and heparin binding ECF and can present FGF-8 in a form that transactivates receptor-bearing BaF32 cells. These results define a novel and unique proteoglycan profile for macrophages and imply a key role for syndecan-2 in the delivery of sequestered growth factors by inflammatory macrophages for productive binding to their appropriate target cells ire vivo.	Univ Oxford, Inst Mol Med, John Radcliffe Hosp, Mol Immunol Grp, Oxford OX3 9DU, England; Nuffield Orthopaed Ctr, Oxford OX3 7LD, England; Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; VIB, B-3000 Louvain, Belgium	University of Oxford; Nuffield Orthopaedic Centre; KU Leuven; Flanders Institute for Biotechnology (VIB)	Jackson, DG (corresponding author), Univ Oxford, Inst Mol Med, John Radcliffe Hosp, Mol Immunol Grp, Oxford OX3 9DU, England.	djackson@worf.molbiol.ox.ac.uk	Plebanski, Magdalena/AAU-3144-2021	, Magdalena/0000-0001-6889-3667; , david/0000-0002-4133-9364				ALOUANI S, 1995, EUR J BIOCHEM, V227, P328, DOI 10.1111/j.1432-1033.1995.tb20393.x; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; AUGER MJ, 1992, MACROPHAGE; BAIRD A, 1985, BIOCHEM BIOPH RES CO, V126, P358, DOI 10.1016/0006-291X(85)90614-X; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carey DJ, 1997, BIOCHEM J, V327, P1; Chang MY, 1998, J BIOL CHEM, V273, P15985, DOI 10.1074/jbc.273.26.15985; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID G, 1993, DEVELOPMENT, V119, P841; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Drzeniek Z, 1997, BIOCHEM J, V327, P473, DOI 10.1042/bj3270473; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; KATO M, 1994, J BIOL CHEM, V269, P18881; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KOLSET SO, 1988, CANCER RES, V48, P6103; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LASKIN JD, 1991, HEPATOLOGY, V14, P306, DOI 10.1016/0270-9139(91)91420-6; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LORIES V, 1989, J BIOL CHEM, V264, P7009; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Miao HQ, 1996, J BIOL CHEM, V271, P4879; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Oravecz T, 1997, J IMMUNOL, V159, P4587; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; POLVERINI PJ, 1984, LAB INVEST, V51, P635; QU ZH, 1995, LAB INVEST, V73, P339; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RAULO E, 1994, J BIOL CHEM, V269, P12999; REMMERS EF, 1991, SEMIN ARTHRITIS RHEU, V21, P191, DOI 10.1016/0049-0172(91)90009-O; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; Seo T, 1997, J LIPID RES, V38, P765; Solari R, 1997, J BIOL CHEM, V272, P9617; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; SUND C, 1994, CHIRURG, V65, P410; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; Vlodavsky I, 1997, TUMOUR ANGIOGENESIS, P125; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; WERB Z, 1992, MONONUCLEAR PHAGOCYTES, P404; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YEAMAN C, 1993, J CELL PHYSIOL, V157, P413, DOI 10.1002/jcp.1041570226; YEAMAN C, 1993, J CELL BIOL, V122, P941, DOI 10.1083/jcb.122.4.941	60	103	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24113	24123		10.1074/jbc.274.34.24113	http://dx.doi.org/10.1074/jbc.274.34.24113			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446183	hybrid			2022-12-25	WOS:000082110900062
J	Han, DC; Guan, JL				Han, DC; Guan, JL			Association of focal adhesion kinase with Grb7 and its role in cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; SH2 DOMAIN PROTEINS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; ESOPHAGEAL-CARCINOMA; V-SRC; PHOSPHORYLATION; BINDING; PP125(FAK)	Focal adhesion kinase (FAK) has been implicated to play a key role in integrin-mediated signal transduction in cell migration. Grb7 is an Src homology (SH) a-containing and pleckstrin homology domain-containing molecule, which shares significant homology with the Caenorhabditis elegans gene for Mig-10 involved in cell migration during embryogenesis. Here, we report that the SH2 domain of Grb7: can directly interact with FAK through Tyr-397, a major autophosphorylation site in vitro and in vivo. This interaction is cell adhesion-dependent, suggesting that the FAK-Grb7 complex is involved in integrin signaling, Using tetracycline-regulated expression system, we showed that overexpression of Grb7 enhanced cell migration toward fibronectin, whereas overexpression of its SH2 domain alone inhibited cell migration. In addition, we found that phosphorylation of FAK, or p130(cas) was not affected by the expression of either Grb7 or its SH2 domain alone, suggesting that Grb7 is downstream of FAK and does not compete with Src for binding to FAK in vivo, Taken together, these results suggest that the FAK-Grb7 complex plays a role in cell migration stimulated by integrin signaling through FAK.	Cornell Univ, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM48050, GM52890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050, R01GM052890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CHAN PY, 1994, J BIOL CHEM, V269, P20567; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Freundlieb S, 1997, METHOD ENZYMOL, V283, P159; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Kishi T, 1997, BIOCHEM BIOPH RES CO, V232, P5, DOI 10.1006/bbrc.1997.6218; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LIOTTA LA, 1991, CELL, V64, P32; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; OWENS LV, 1995, CANCER RES, V55, P2752; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; TURNER CE, 1994, J CELL SCI, V107, P1583; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	54	191	198	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24425	24430		10.1074/jbc.274.34.24425	http://dx.doi.org/10.1074/jbc.274.34.24425			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446223	hybrid			2022-12-25	WOS:000082110900102
J	Jedsadayanmata, A; Chen, CC; Kireeva, ML; Lau, LF; Lam, SCT				Jedsadayanmata, A; Chen, CC; Kireeva, ML; Lau, LF; Lam, SCT			Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; GLYCOPROTEIN-IIB-IIIA; VON-WILLEBRAND FACTOR; ENDOTHELIAL-CELLS; VITRONECTIN RECEPTOR; VONWILLEBRAND-FACTOR; GAMMA-CHAIN; GPIIB-IIIA; FIBRINOGEN; PRODUCT	Cyr61 and connective tissue growth factor (CTGF) members of a newly identified family of extracellular matrix-associated signaling molecules, are found to me mediate cell adhesion, promote cell migration and enhance growth factor-induced cell proliferation in vitro, and induce angiogenesis in vivo, We previously showed that vascular endothelial cell adhesion and migration to Cyr61 and Fisp12 (mouse CTGF) are mediated through integrin alpha(v)beta(3). Both Cyr61 and Fisp12/mCTGF are present in normal blood vessel walls, and it has been demonstrated that CTGF is overexpressed in advanced atherosclerotic lesions, In the present study, we examined whether Cyr61 and Fisp12/mCTGF could serve as substrates for platelet adhesion, Agonist (ADP, thrombin, or U46619)-stimulated but not resting platelets adhered to both Cyr61 and Fisp12/mCTGF, and this process was completely inhibited by prostaglandin I-2, which prevents platelet activation. The specificity of Cyr61- and Fisp12/mCTGF-mediated platelet adhesion was demonstrated by specific inhibition of this process with polyclonal anti-Cyr61 and anti-Fisp12/mCTGF antibodies, respectively. The adhesion of ADP-activated platelets to both proteins was divalent cation-dependent and was blocked by RGDS, HHLGGAKQAGDV, or echistatin, but not by RGES, Furthermore, this process was specifically inhibited by the monoclonal antibody AP-2 (anti-alpha(IIb)beta(3)), but not by LM609 (anti-alpha(v)beta(3)), indicating that the interaction is mediated through integrin alpha(IIb)beta(3), In a solid phase binding assay, activated alpha(IIb)beta(3), purified by RGD affinity chromatography, bound to immobilized Cyr61 and Fisp12/mCTGF in a dose-dependent and RGD-inhibitable manner. In contrast, unactivated alpha(IIb)beta(3) failed to bind to either protein. Collectively, these findings identify Cyr61 and Fisp12/mCTGF as two novel activation-dependent adhesive ligands for the integrin alpha(IIb)beta(3) On human platelets, and implicate a functional role for these proteins in hemostasis and thrombosis.	Univ Illinois, Dept Pharmacol MC 868, Chicago, IL 60612 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lam, SCT (corresponding author), Univ Illinois, Dept Pharmacol MC 868, 835 S Wolcott Ave, Chicago, IL 60612 USA.		Jedsadayanmata, Arom/AAR-9251-2021; Kireeva, Maria/B-4391-2018	Jedsadayanmata, Arom/0000-0002-5776-1439; Kireeva, Maria/0000-0003-0527-3182; Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA80080, CA46565] Funding Source: Medline; NHLBI NIH HHS [HL41793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041793, R01HL041793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bennett JS, 1997, J BIOL CHEM, V272, P8137, DOI 10.1074/jbc.272.13.8137; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; Clemetson KJ, 1997, THROMB HAEMOSTASIS, V78, P266; COLLER BS, 1980, BLOOD, V55, P169; COLLER BS, 1991, BLOOD, V77, P75; CONNOLLY DT, 1986, ANAL BIOCHEM, V152, P136, DOI 10.1016/0003-2697(86)90131-4; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; Du X, 1997, THROMB HAEMOSTASIS, V78, P96; DU XP, 1999, ADV MOL CEL, V28, P269; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GAN ZR, 1988, J BIOL CHEM, V263, P19827; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; IUPAC-IUB commission on biochemical nomenclature, 1968, J BIOL CHEM, V243, P3557; KINLOUGHRATHBONE RL, 1977, THROMB HAEMOSTASIS, V37, P291; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; LAM SCT, 1987, J BIOL CHEM, V262, P947; LAM SCT, 1989, J BIOL CHEM, V264, P3742; LATINKIC BV, 1994, THESIS U ILLINOIS CH; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1153; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Oemar BS, 1997, CIRCULATION, V95, P831; PACKHAM MA, 1989, THROMB HAEMOSTASIS, V62, P968; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	45	189	203	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24321	24327		10.1074/jbc.274.34.24321	http://dx.doi.org/10.1074/jbc.274.34.24321			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446209	hybrid			2022-12-25	WOS:000082110900088
J	Tacchini, L; Bianchi, L; Bernelli-Zazzera, A; Cairo, G				Tacchini, L; Bianchi, L; Bernelli-Zazzera, A; Cairo, G			Transferrin receptor induction by hypoxia - HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; FERRITIN SYNTHESIS; MESSENGER-RNA; IRON-METABOLISM; POSTTRANSCRIPTIONAL REGULATION; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; NITRIC-OXIDE; RAT-LIVER; GENE	The tight relationship between oxygen and iron prompted us to investigate whether the expression of transferrin receptor (TfR), which mediates cellular iron uptake, is regulated by hypoxia. In Hep3B human hepatoma cells incubated in 1% O-2 or treated with CoCl2, which mimics hypoxia, we detected a 3-fold increase of TfR mRNA despite a decrease of iron regulatory proteins activity. Increased expression resulted from a 4-fold stimulation of the nuclear transcription rate of the TfR gene by both hypoxia and CoCl2. A role for hypoxia-inducible factor (HIF-1), which activates transcription by binding to hypoxia-responsive elements in the activation of TfR, stems from the following observations. (a) Hypoxia and CoCl2-dependent expression of luciferase reporter gene in transiently transfected Hep3B cells was mediated by a fragment of the human TfR promoter containing a putative hypoxia-responsive element sequence, (b) mutation of this sequence prevented hypoxic stimulation of luciferase activity, (c) binding to this sequence of HIF-1 alpha, identified by competition experiments and supershift assays, was induced in Hep3B cells by hypoxia and CoCl2. In erythroid K562 cells, the same treatments did not affect iron regulatory proteins activity, thus resulting in a stimulation of TfR gene expression higher than in hepatoma cells.	Univ Milan, Ist Patol Gen, I-20133 Milan, Italy; CNR, Ctr Studio Patol Cellulare, I-20133 Milan, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR)	Cairo, G (corresponding author), Univ Milan, Ist Patol Gen, Via Mangiagalli 31, I-20133 Milan, Italy.		Tacchini, Lorenza/L-1418-2016; Cairo, Gaetano/M-5104-2016	Tacchini, Lorenza/0000-0002-4863-178X; Cairo, Gaetano/0000-0002-8147-4720				AISEN P, 1984, SEMIN LIVER DIS, V4, P193, DOI 10.1055/s-2008-1041770; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Cairo G, 1996, FASEB J, V10, P1326, DOI 10.1096/fasebj.10.11.8836047; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; Debnam ES, 1997, NEWS PHYSIOL SCI, V12, P184; Hanson ES, 1999, J BIOL CHEM, V274, P5047, DOI 10.1074/jbc.274.8.5047; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; Henderson BR, 1996, BIOESSAYS, V18, P739, DOI 10.1002/bies.950180909; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIRSCH S, 1995, CELL GROWTH DIFFER, V6, P719; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUHN LC, 1984, CELL, V37, P95, DOI 10.1016/0092-8674(84)90304-0; Kuriyama-Matsumura K, 1998, BIOCHEM BIOPH RES CO, V249, P241, DOI 10.1006/bbrc.1998.9046; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NECKERS LM, 1991, PATHOBIOLOGY, V59, P11, DOI 10.1159/000163610; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; PIETRANGELO A, 1991, HEPATOLOGY, V14, P1083, DOI 10.1002/hep.1840140623; Ponka P, 1997, BLOOD, V89, P1; QI Y, 1994, J NEUROCHEM, V63, P1485; Recalcati S, 1998, BLOOD, V91, P1059, DOI 10.1182/blood.V91.3.1059.1059_1059_1066; Recalcati S, 1999, EUR J BIOCHEM, V259, P304, DOI 10.1046/j.1432-1327.1999.00038.x; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; ROUAULT TA, 1996, STRESS INDUCIBLE CEL, P183; SANTORO C, 1986, NUCLEIC ACIDS RES, V14, P2863, DOI 10.1093/nar/14.7.2863; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 1998, J LAB CLIN MED, V131, P207, DOI 10.1016/S0022-2143(98)90091-9; Simpson RJ, 1996, J NUTR, V126, P1858; Tacchini L, 1997, GASTROENTEROLOGY, V113, P946, DOI 10.1016/S0016-5085(97)70191-4; TESTA U, 1993, CRIT REV ONCOGENESIS, V4, P241; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 1997, BIOL CHEM, V378, P609; Wood SM, 1997, INT J BIOCHEM CELL B, V29, P1419, DOI 10.1016/S1357-2725(97)00129-5; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	39	280	290	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24142	24146		10.1074/jbc.274.34.24142	http://dx.doi.org/10.1074/jbc.274.34.24142			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446187	hybrid			2022-12-25	WOS:000082110900066
J	Philipp, J; Vo, K; Gurley, KE; Seidel, K; Kemp, CJ				Philipp, J; Vo, K; Gurley, KE; Seidel, K; Kemp, CJ			Tumor suppression by p27(Kip1) and p21(Cip1) during chemically induced skin carcinogenesis	ONCOGENE			English	Article						p27(Kip1); p21(Cip1); p53; H-ras; tumor promotion; intestinal neoplasia	DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; MOUSE SKIN; POTENTIAL MEDIATOR; BREAST-CANCER; RAS; EXPRESSION; DIFFERENTIATION; P21; P53	p27(Kip1)and p21(Cip1) are cyclin dependent kinase inhibitors which can arrest cell proliferation and p27 is a tumor suppressor gene. To address the mechanism of tumor suppression by p27 and to determine if p21 has a tumor suppressor phenotype, we utilized the two stage skin carcinogenesis model on p27 and p21 knockout mice. In this model, initiation, which involves mutation of H-ras induced by DMBA, can be distinguished from promotion induced by TPA, and progression to carcinoma. The mean number of papillomas did not differ between p27 - / - and control littermates, but papilloma growth rate was increased and carcinomas developed earlier. Thus, p27 deficiency did not enhance initiation, but resulted in more rapid clonal expansion of initiated cells during promotion. TPA treatment reduced p27 expression in keratinocytes also supporting a role for p27 during promotion. Tumors from p27 - / - mice contained mutant H-ras indicating that p27 deficiency did not substitute for mutant ras and further, that during ras driven tumor growth, p27 is partially antagonistic since its removal led to faster growth. The treated p27 - / - mice also developed intestinal adenomas, p21 - / - mice did not display a significant increase in tumor numbers, growth rate or progression to carcinomas and these tumors also had mutated H-rns. Carcinomas from p21 - / - mice were more poorly differentiated with a high frequency of anaplastic spindle cell carcinomas. Thus p21 deficiency mainly resulted in higher grade undifferentiated tumors.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview N, Seattle, WA 98109 USA.							Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURNS PA, 1991, ONCOGENE, V6, P2363; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Harvat BL, 1998, J CELL SCI, V111, P1185; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; Kalbfleish J., 1980, STAT ANAL FAILURE TI; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KLEINSZANTO AJP, 1989, SKIN TUMORS EXPT CLI, P19; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RUGGERI B, 1991, CANCER RES, V51, P6615; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P419; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Singh SP, 1998, CANCER RES, V58, P1730; StCroix B, 1996, NAT MED, V2, P1204; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tikoo R, 1997, J BIOL CHEM, V272, P442; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1998, CANCER RES, V58, P542; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; WINBERG LD, 1995, SKIN CANC MECH HUMAN, P113; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	62	84	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4689	4698		10.1038/sj.onc.1202840	http://dx.doi.org/10.1038/sj.onc.1202840			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467416				2022-12-25	WOS:000082154400006
J	Pham, CD; Vuyyuru, VB; Yang, YD; Bai, WL; Singh, B				Pham, CD; Vuyyuru, VB; Yang, YD; Bai, WL; Singh, B			Evidence for an important role of serine 16 and its phosphorylation in the stabilization of c-Mos	ONCOGENE			English	Article						mos oncogene; protein phosphorylation; enzyme regulation	PROTEIN-KINASE ACTIVITY; MURINE SARCOMA-VIRUS; V-MOS; NUCLEOTIDE-SEQUENCE; OOCYTE MATURATION; MAP KINASE; XENOPUS-OOCYTES; CELL-CYCLE; GENE; TRANSFORMATION	The c-Mos serine/threonine protein kinase is an essential component of cytostatic factor (CSF), which is required for metaphase Il arrest of eggs in vertebrates. Previously, we showed that c-Mos residue Ser-16 is phosphorylated in the ts110 Mo-MuSV-encoded Gag-Mos fusion protein, Here we provide evidence that Mos is phosphorylated at Ser-16 in transfected COS-1 cells. To investigate the role of this phosphorylation, Ser-16 was substituted with alanine or glutamic acid in full-length v-Mos (an Env-Mos fusion protein that contains 31 additional amino acids at the amino terminus of c-Mos), its mouse c-Mos equivalent version (v-Mos residues 32-374, hereafter referred to as Mos), and mouse c-Mos, Constructs expressing mutant versions of Mos,were transfected into COS-l and NIH3T3 cells in a transient and stable manner, respectively, Synthesis and proteolysis of Mos were evaluated by pulse-chase analysis of S-35-methionine-labeled proteins. Our findings indicate that the S16A mutant of Mos was highly unstable. It accumulated to approximately 10% of the level of wild-type Mos or its S16E mutant. In addition, the S16A mutation but not the S16E mutation inhibited Mos interaction with a cellular protein, p35, suggesting that phosphorylation at Ser-16 may promote Riles interaction with p35, As expected from its destabilizing effect, the S16A mutation caused a dramatic decrease in the cellular transforming activity of Mos (determined by soft-agar colony-formation assay with the stably transfected NIH3T3 cells), which is known to correlate with its CSF function. Efficient ubiquitin-mediated proteolysis of c-Mos requires proline as the second residue from the amino-terminus. In contrast to Mos, neither the stability nor protein kinase activity of v-Mos (in which c-Mos residue Pro-2 becomes Pro-33) was affected by the S16A mutation. To provide further proof that, similar to c-Mos, the S16A mutant is recognized by the proteolysis system through Pro-2, we show that the effect of the S16A mutation is reversed by the Pro-2-Ala mutation. Thus, our results indicate that Ser-16 has an important role in the regulation of c-Mos and that phosphorylation at Ser-16 mag inhibit proteolysis of c-Mos.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Singh, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 172,1515 Holcombe Blvd, Houston, TX 77030 USA.		Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NCI NIH HHS [CA16672, R01 CA45125] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAI WL, 1991, ONCOGENE, V6, P1715; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN MZ, 1995, MOL CELL BIOL, V15, P4727; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; Huang CYF, 1996, EMBO J, V15, P2169, DOI 10.1002/j.1460-2075.1996.tb00570.x; LIU H, 1999, IN PRESS ONCOGENE, V18; LIU JX, 1990, ONCOGENE, V5, P171; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; PHAM CD, 1995, ONCOGENE, V10, P1683; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Roy LM, 1996, ONCOGENE, V12, P2203; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sambrook J, 1989, MOL CLONING; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1988, ONCOGENE, V3, P79; Singh B, 1997, Prog Cell Cycle Res, V3, P251; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yang YD, 1996, MOL CELL BIOL, V16, P800; Yang YD, 1998, J BIOL CHEM, V273, P15946, DOI 10.1074/jbc.273.26.15946; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604	29	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4287	4294		10.1038/sj.onc.1202804	http://dx.doi.org/10.1038/sj.onc.1202804			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439036				2022-12-25	WOS:000081732700001
J	Zauberman, A; Zipori, D; Krupsky, M; Ben-Levy, R				Zauberman, A; Zipori, D; Krupsky, M; Ben-Levy, R			Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3	ONCOGENE			English	Article						p38; STAT; IL-6 signaling	SIGNAL-TRANSDUCTION PATHWAY; ACUTE-PHASE RESPONSE; MAP KINASE; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS; MOLECULAR-CLONING; CELLULAR STRESSES; HAPTOGLOBIN GENE; REGULATED KINASE	The acute phase protein expression In HepG2 human hepatoma cells and promotes the growth of mouse B9 hybridoma. The signaling cascades leading to these biological functions are only partially known. We analysed the involvement of MAPK homologues in IL-6 transduction pathways and found that interleukin-6 triggered activation of p38 stress-activated protein kinase (p38) but not of jun kinase. p38 activity was required for biological functions including acute phase protein secretion from HepG2 hepatoma and proliferation of B9 hybridoma cells. Using a reporter gene construct containing a 190 bp promoter fragment of the acute phase protein haptoglobin we found that p38 is involved in transcriptional activation of the haptoglobin promoter by STAT3 but not by NF-IL6. Thus, we present evidence for a role of p38 in IL-6 induced functions and a possible cross-talk between this MAPK homologue and the STAT pathway.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Zipori, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BRETON J, 1995, EUR J BIOCHEM, V227, P573, DOI 10.1111/j.1432-1033.1995.tb20427.x; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAULDIE J, 1992, RES IMMUNOL, V143, P755, DOI 10.1016/0923-2494(92)80018-G; HELLE M, 1988, EUR J IMMUNOL, V18, P1535, DOI 10.1002/eji.1830181010; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KISHIMOTO T, 1992, PROG IMMUNOL, V8, P887; KUSHNER I, 1987, DIS MARKERS, V5, P1; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nagata Y, 1997, BLOOD, V90, P929, DOI 10.1182/blood.V90.3.929.929_929_934; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Ogata A, 1997, J IMMUNOL, V159, P2212; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PAJOVIC S, 1994, J BIOL CHEM, V269, P2215; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	58	71	71	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3886	3893		10.1038/sj.onc.1202738	http://dx.doi.org/10.1038/sj.onc.1202738			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445852				2022-12-25	WOS:000081171700010
J	Li, YQ; Hua, F; Carraway, KL; Carraway, CAC				Li, YQ; Hua, F; Carraway, KL; Carraway, CAC			The p185(neu)-containing glycoprotein complex of a microfilament-associated signal transduction particle - Purification, reconstitution, and molecular associations with p58(gag) and actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL MICROVILLI; DYSTROPHIN-ASSOCIATED GLYCOPROTEIN; RAT MAMMARY ADENOCARCINOMA; ASCITES ADENOCARCINOMA; MUSCULAR-DYSTROPHIES; AGRIN RECEPTOR; FOCAL ADHESION; ANIMAL-CELLS; HUMAN-BREAST; MEMBRANE	Microfilaments associate with the microvillar membrane of 13762 ascites mammary adenocarcinoma cells via a large transmembrane complex (TMC) comprising the major glycoproteins TMC-gp120, -110, -80, -65, and -55, the receptor kinase p185(neu), and the cytoplasmic proteins actin and p58(gag), linking the receptor with microfilaments in a signal transduction particle. Immunoblot screening with polyclonal antisera to TMC glycoproteins showed selective epithelial expression in normal rat tissues and epithelially derived tumor cells. The TMC glycoproteins were isolated by solubilization of microfilament core preparations in SDS, dilution, and separation on a concanavalin A-agarose affinity column. The large p185(neu)-containing complex was reconstituted from the column eluate after displacement of SDS with nonionic detergent, demonstrated by gel filtration and co-immunoprecipitation of the glycoproteins with anti-gp55 or anti-p185(neu). Exhaustive biotinylation of the glycoproteins gave a stoichiometry of gp120:gp110:gp80: gp65:gp55 of approximately 1:1:1:0.5:1, Overlay blots with biotinylated actin and in vitro translated, [S-35]methionine-labeled p58(gag), respectively, showed specific interactions of actin with gp55 and gp120 and of p58(gag) with gp65 and gp55, These results provide evidence for a specific complex of microfilament-associated glycoproteins containing p185(neu) and p58(gag) and suggest a role for the complex in signal transduction scaffolding.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, CAC (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, R-629, Miami, FL 33101 USA.	ccarrawa@mednet.med.miami.edu			NATIONAL CANCER INSTITUTE [R01CA072577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033795] Funding Source: NIH RePORTER; NCI NIH HHS [CA72577] Funding Source: Medline; NIGMS NIH HHS [GM 33795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Apel Elizabeth D., 1995, Current Opinion in Neurobiology, V5, P62, DOI 10.1016/0959-4388(95)80088-3; BLOCH RJ, 1994, CURR BIOL, V4, P936, DOI 10.1016/S0960-9822(00)00211-6; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CAPLAN S, 1995, IMMUNOL RES, V14, P98, DOI 10.1007/BF02918171; CARRAWAY C A C, 1992, P123; Carraway C. A. C., 1996, TREATISE CYTOSKELETO, V2; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; Carraway CAC, 1999, J BIOL CHEM, V274, P25659, DOI 10.1074/jbc.274.36.25659; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1991, J BIOL CHEM, V266, P16238; CARRAWAY CAC, 1985, EXP CELL RES, V157, P71, DOI 10.1016/0014-4827(85)90153-3; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; CARRAWAY KL, 1998, SIGNALING CYTOSKELET; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FOX JE, 1993, ADV EXP MED BIOL, V344, P75; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; Huang JQ, 1999, ONCOGENE, V18, P4099, DOI 10.1038/sj.onc.1202779; HUGGINS JW, 1980, EXP CELL RES, V126, P279, DOI 10.1016/0014-4827(80)90266-9; JUANG SH, 1994, J BIOL CHEM, V269, P15067; Juang SH, 1996, ONCOGENE, V12, P1033; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; LIN YZJ, 1991, ONCOGENE, V6, P639; LIU YC, 1989, J BIOL CHEM, V264, P1208; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; OKABE S, 1989, J CELL BIOL, V109, P1581, DOI 10.1083/jcb.109.4.1581; Pumplin David W., 1993, Trends in Cell Biology, V3, P113, DOI 10.1016/0962-8924(93)90173-X; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; SEALOCK R, 1994, CELL, V77, P617, DOI 10.1016/0092-8674(94)90045-0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SNABES MC, 1983, EXP CELL RES, V146, P63, DOI 10.1016/0014-4827(83)90324-5; SOBUE K, 1993, NEUROSCI RES, V18, P91, DOI 10.1016/0168-0102(93)90012-F; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SUNADA Y, 1995, CURR OPIN NEUROL, V8, P379, DOI 10.1097/00019052-199510000-00010; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VANDERPUYE OA, 1988, EXP CELL RES, V178, P211, DOI 10.1016/0014-4827(88)90392-8; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3	53	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25651	25658		10.1074/jbc.274.36.25651	http://dx.doi.org/10.1074/jbc.274.36.25651			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464301	hybrid			2022-12-25	WOS:000082554200065
J	Misra, UK; Gawdi, G; Gonzalez-Gronow, M; Pizzo, SV				Misra, UK; Gawdi, G; Gonzalez-Gronow, M; Pizzo, SV			Coordinate regulation of the alpha(2)-macroglobulin signaling receptor and the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; INTRACELLULAR CALCIUM; RECOGNIZED FORMS; RAT ADIPOCYTES; DNA-SYNTHESIS; BINDING; ALPHA-2-MACROGLOBULIN; TRANSDUCTION	We have studied insulin-dependent regulation of macrophage alpha(2)-macroglobulin signaling receptors (alpha(2)MSR) and low density lipoprotein receptor-related protein/ alpha(2)M receptors (LRP/alpha(2)MR) employing cell binding of I-125-alpha(2)M*, inhibition of binding by receptor-associated protein (RAP) or Ni2+, LRP/alpha(2)MR mRNA levels, and generation of second messengers. Insulin treatment increased the number of alpha(2)M* high (alpha(2)MSR) and low (LRP/ alpha(2)MR) affinity binding sites from 1,600 and 67,000 to 2,900 and 115,200 sites per cell, respectively. Neither RAP nor Ni2+ blocked the binding of I-125-alpha(2)M* to alpha(2)MSR on insulin- or buffer-treated cells, but they both blocked binding to LRP/alpha(2)MR, Insulin significantly increased LRP/alpha(2)MR mRNA levels in a dose- and time-dependent manner. Insulin-augmented I-125-alpha(2),MX binding to macrophages was severely reduced by wortmannin, LY294002, PD98059, SB203580, or rapamycin, The increase in alpha(2)MSR receptor synthesis was reflected by augmented generation of IP3 and increased [Ca2+](i) levels upon receptor ligation. Incubation of macrophages with wortmannin, LY294002, PD98059, SB203580, rapamycin, or antibodies against insulin receptors before insulin treatment and alpha(2)M* stimulation significantly reduced the insulin-augmented increase in IP3 and [Ca2+](i) levels. Pretreatment of cells with actinomycin D or cycloheximide blocked the synthesis of new alpha(2)MSR, In conclusion, we show here that insulin coordinately regulates macrophage alpha(2)MSR and LRP/alpha(2)MR, utilizing both the PI 3-kinase and Pas signaling pathways to induce new synthesis of these receptors.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.				NHLBI NIH HHS [HL-24066] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALESSI MC, 1988, THROMB HAEMOSTASIS, V60, P509; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bu GJ, 1998, J BIOL CHEM, V273, P13359, DOI 10.1074/jbc.273.21.13359; Ceresa BP, 1998, MOL CELL BIOCHEM, V182, P23, DOI 10.1023/A:1006819008507; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHU CT, 1994, LAB INVEST, V71, P792; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CORVERA S, 1989, J BIOL CHEM, V264, P10133; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DARDEVET D, 1996, J ENDOCRINOL, V137, P4987; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1400; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLIEMANN J, 1985, BIOCHIM BIOPHYS ACTA, V845, P124, DOI 10.1016/0167-4889(85)90063-1; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; JUHN JB, 1995, BIOCHEMISTRY-US, V34, P7996; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; Kim SJ, 1997, BIOCHEM J, V323, P621, DOI 10.1042/bj3230621; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LEEKWON W, 1998, BIOCHEM J, V331, P5691; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; Misra UK, 1998, CELL SIGNAL, V10, P441, DOI 10.1016/S0898-6568(97)00171-X; MISRA UK, 1995, BIOCHEM J, V309, P151, DOI 10.1042/bj3090151; Misra UK, 1998, BBA-MOL CELL RES, V1401, P121, DOI 10.1016/S0167-4889(97)00123-7; Misra UK, 1997, J BIOL CHEM, V272, P497; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; Misra UK, 1998, J BIOL CHEM, V273, P13399, DOI 10.1074/jbc.273.22.13399; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MISRA UK, 1994, J BIOL CHEM, V269, P18303; NEY KA, 1984, BIOCHEMISTRY-US, V23, P3395, DOI 10.1021/bi00310a003; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Odom AR, 1997, BIOCHEMISTRY-US, V36, P12395, DOI 10.1021/bi970806k; OKADA T, 1994, J BIOL CHEM, V269, P3568; PODLECKI DA, 1987, J BIOL CHEM, V262, P3362; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1997, BIOCHEM J, V328, P329; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SALVESEN G, 1993, HEMOSTASIS THROMBOSE, P241; Sano H, 1998, J BIOL CHEM, V273, P8630, DOI 10.1074/jbc.273.15.8630; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VIGNERI R, 1978, J BIOL CHEM, V253, P2098; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Webb DJ, 1995, EUR J BIOCHEM, V234, P714, DOI 10.1111/j.1432-1033.1995.714_a.x; WHITE MF, 1994, J BIOL CHEM, V269, P1; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063	61	40	40	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25785	25791		10.1074/jbc.274.36.25785	http://dx.doi.org/10.1074/jbc.274.36.25785			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464317	hybrid			2022-12-25	WOS:000082554200081
J	Zardo, G; Marenzi, S; Perilli, M; Caiafa, P				Zardo, G; Marenzi, S; Perilli, M; Caiafa, P			Inhibition of poly(ADP-ribosyl)ation introduces an anomalous methylation pattern in transfected foreign DNA	FASEB JOURNAL			English	Article						poly(ADP . ribose) polymerase; 5; methylcytosine; 3; aminobenzamide; transfection	CPG BINDING-PROTEIN; TRANSCRIPTIONAL REPRESSION; HISTONE ACETYLATION; CHROMATIN STRUCTURE; GENE; PROMOTER; SEQUENCES; ISLANDS; SITE; CIS	The aim of this paper is to verify whether the control played by poly(ADP-ribosyl)-ation on genomic DNA methylation, and in particular on CpG islands, can also be seen on foreign DNA transfected in cells where inhibition of the poly(ADP-ribosyl)ation process was obtained by treating them with 2 mM 3-aminobenzamide for 24 h. The CPG island-like pVHCk plasmid containing the bacterial chloramphenicol acyltransferase (CAT) gene under the control of SV40 early promoter was transfected in L929 mouse fibroblast cells. The bisulfite reaction, which is capable of immortalizing the methylation state of cytosine on DNA, was performed before amplification of the plasmid DNA fragment, then used for sequence analysis. Our results have shown that I) when transfected in control cells, the plasmid maintains its characteristic unmethylated pattern, whereas this pattern is lost when the plasmid is transfected in cells treated with S-aminobenzamide; and 2) the presence of new methyl groups on plasmid DNA is paralleled by a decrease of CAT reporter gene expression. These data confirm that Poly(ADP-ribosyl)ation is a process tightly involved in protecting genomic DNA from full methylation and suggest the use of 3-aminobenzamide as a possible experimental strategy to mime other conditions of DNA hypermethylation in cells.	Univ Aquila, Dipartimento Sci & Tecnol Biomed, I-67100 Laquila, Italy; Univ Rome La Sapienza, Dept Biol Sci A Rossi Fanelli, Rome, Italy; CNR, Ctr Biol Mol, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of L'Aquila; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR)	Caiafa, P (corresponding author), Univ Aquila, Dipartimento Sci & Tecnol Biomed, Loc Coppito,Via Vetoio, I-67100 Laquila, Italy.							ADAMS RLP, 1985, SPRINGER SERIES MOL; ALTHAUS FR, 1997, BASE EXCISION REPAIR, P1669; Bestor TH, 1998, NATURE, V393, P311, DOI 10.1038/30613; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; BRUHAT A, 1995, P NATL ACAD SCI USA, V92, P3678, DOI 10.1073/pnas.92.9.3678; BRYANS M, 1992, FEBS LETT, V309, P97, DOI 10.1016/0014-5793(92)80748-6; CAIAFA P, 1991, BIOCHIM BIOPHYS ACTA, V1090, P38, DOI 10.1016/0167-4781(91)90034-J; CHRISTMAN JK, 1995, P NATL ACAD SCI USA, V92, P7347, DOI 10.1073/pnas.92.16.7347; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; De Capoa A, 1999, FASEB J, V13, P89; DErme M, 1996, BIOCHEM J, V316, P475, DOI 10.1042/bj3160475; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hsieh CL, 1997, MOL CELL BIOL, V17, P5897, DOI 10.1128/MCB.17.10.5897; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0; HULETSKY A, 1989, J BIOL CHEM, V264, P8878; Jones PB, 1998, PETROL GEOSCI, V4, P187, DOI 10.1144/petgeo.4.2.187; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KHAN R, 1988, J BIOL CHEM, V263, P14374; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Lindsay H, 1996, BIOCHEM J, V320, P473, DOI 10.1042/bj3200473; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; PAWLAK A, 1991, NUCLEIC ACIDS RES, V19, P1029; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; SANTORO R, 1995, BIOCHEM J, V305, P739, DOI 10.1042/bj3050739; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; SZYF M, 1991, BIOCH CELL BIOL, V10, P4396; Tollefsbol TO, 1997, J MOL BIOL, V269, P494, DOI 10.1006/jmbi.1997.1064; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Zardo G, 1998, BIOL CHEM, V379, P647; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s; Zardo G, 1996, BIOCHEM BIOPH RES CO, V220, P102, DOI 10.1006/bbrc.1996.0364; ZHANG XY, 1995, NUCLEIC ACIDS RES, V23, P3026, DOI 10.1093/nar/23.15.3026; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387	54	20	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1518	1522		10.1096/fasebj.13.12.1518	http://dx.doi.org/10.1096/fasebj.13.12.1518			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463942	Bronze			2022-12-25	WOS:000082347600006
J	Blanchard, F; Duplomb, L; Raher, S; Vusio, P; Hoflack, B; Jacques, Y; Godard, A				Blanchard, F; Duplomb, L; Raher, S; Vusio, P; Hoflack, B; Jacques, Y; Godard, A			Mannose 6-phosphate/insulin-like growth factor II receptor mediates internalization and degradation of leukemia inhibitory factor but not signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULAR BASOLATERAL MEMBRANES; MYELOMA CELL-LINES; 6-PHOSPHATE RECEPTOR; HUMAN INTERLEUKIN; BINDING-PROTEIN; ONCOSTATIN-M; PERINATAL LETHALITY; AFFINITY RECEPTOR; ARGININE RESIDUES; LYSOSOMAL-ENZYMES	Leukemia inhibitory factor (LIF) is a multifunctional cytokine belonging to the interleukin-6 subfamily of helical cytokines, all of which use the glycoprotein (gp) 130 subunit for signal transduction. The specific receptor for LIF, gp190, binds this cytokine with low affinity and is also required for signal transduction. We have recently reported that glycosylated LIF produced by transfected Chinese hamster ovary cells also binds to a lectin-like receptor, mannose 6-phosphate/insulin-like growth factor II receptor (Man-6-P/IGFII-R) (Blanchard, F., Raher, S., Duplomb, L., Vusio, P., Pitard, V., Taupin, J. L., Moreau, J. F., Hoflack, B., Minvielle, S., Jacques, Y., and Godard, A. (1998) J. Biol. Chem. 273, 20886-20893). The present study shows that (i) mannose 6-phosphate-containing LIF is naturally produced by a number of normal and tumor cell lines; (ii) other cytokines in the interleukin-6 family do not bind to Man-6-P/IGFII-R; and (iii) another unrelated cytokine, macrophage-colony-stimulating factor, is also able to bind to Man-6-P/IG-FII-R in a mannose 6-phosphate-sensitive manner. No functional effects or signal transductions mediated by this lectin-like receptor were observed in various biological assays after LIF binding, and mannose B-phosphate-containing LIF was as active as non-glycosylated LIF. However, mannose 6-phosphate-sensitive LIF binding resulted in rapid internalization and degradation of the cytokine on numerous cell lines, which suggests that Man-6-P/IGFII-R plays an important role in regulating the amounts of LIF available in vivo.	Inst Biol, INSERM, U463, Grp Rech Cytokines Recepteurs Transduct, F-44035 Nantes 01, France; Inst Pasteur, Inst Biol, CNRS, EP 525, F-59021 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Blanchard, F (corresponding author), Inst Biol, INSERM, U463, Grp Rech Cytokines Recepteurs Transduct, 9 Quai Moncousu, F-44035 Nantes 01, France.	fblan@inserm.nantes.fr	Blanchard, Frederic/K-8018-2015; Blanchard, Frederic/AAS-1930-2021; HOFLACK, Bernard/AAZ-6668-2020	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Duplomb, Laurence/0000-0002-5715-3759				Aikawa J, 1998, BIOSCI BIOTECH BIOCH, V62, P1318, DOI 10.1271/bbb.62.1318; BAIER TG, 1992, LEUKEMIA RES, V16, P807, DOI 10.1016/0145-2126(92)90160-9; Blanchard F, 1997, INT IMMUNOL, V9, P1775, DOI 10.1093/intimm/9.12.1775; Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; Cullinan EB, 1996, P NATL ACAD SCI USA, V93, P3115, DOI 10.1073/pnas.93.7.3115; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DEGROOTE D, 1994, J IMMUNOL METHODS, V167, P253, DOI 10.1016/0022-1759(94)90094-9; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; ESTROV Z, 1995, J INTERF CYTOK RES, V15, P905, DOI 10.1089/jir.1995.15.905; FELDMAN EL, 1991, BRAIN RES, V562, P111, DOI 10.1016/0006-8993(91)91194-6; FILSON AJ, 1993, DEVELOPMENT, V118, P731; GARMROUDI F, 1994, J BIOL CHEM, V269, P26944; GASCAN H, 1989, J BIOL CHEM, V264, P21509; GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GODARD A, 1992, J BIOL CHEM, V267, P3214; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; Hankins GR, 1996, ONCOGENE, V12, P2003; Heymann D, 1996, CYTOKINE, V8, P197, DOI 10.1006/cyto.1996.0028; HEYMANN D, 1995, IMMUNOL LETT, V46, P245, DOI 10.1016/0165-2478(95)00049-B; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; JACQUES Y, 1996, CYTOKINES, P349; JUGEMORINEAU N, 1995, BRIT J HAEMATOL, V90, P707, DOI 10.1111/j.1365-2141.1995.tb05605.x; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; Kang JX, 1998, P NATL ACAD SCI USA, V95, P13687, DOI 10.1073/pnas.95.23.13687; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KIESS W, 1988, J BIOL CHEM, V263, P9339; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LEHTINEN PK, 1996, INT J CANCER, V66, P515; Levy Y, 1996, CLIN EXP IMMUNOL, V104, P167, DOI 10.1046/j.1365-2249.1996.d01-637.x; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; MOREAU JF, 1986, ANN INST PASTEUR IMM, VC137, P25, DOI 10.1016/S0771-050X(86)80003-1; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; Nishiura T, 1996, BLOOD, V88, P3546, DOI 10.1182/blood.V88.9.3546.bloodjournal8893546; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; Pitard V, 1997, J IMMUNOL METHODS, V205, P177, DOI 10.1016/S0022-1759(97)00074-4; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; ROGERS SA, 1990, J BIOL CHEM, V265, P9722; ROGERS SA, 1989, J BIOL CHEM, V264, P4273; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; SCHMELZER CH, 1993, ARCH BIOCHEM BIOPHYS, V302, P484, DOI 10.1006/abbi.1993.1243; SOSA MA, 1993, J BIOL CHEM, V268, P12537; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TALLY M, 1987, BIOCHEM BIOPH RES CO, V148, P811, DOI 10.1016/0006-291X(87)90948-X; TODDERUD G, 1988, J BIOL CHEM, V263, P17893; Wang MQ, 1997, TRANSPORT RES D-TR E, V2, P43, DOI 10.1016/S1361-9209(96)00017-X; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Zhang QM, 1996, MOL CELL BIOCHEM, V154, P47; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	67	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24685	24693		10.1074/jbc.274.35.24685	http://dx.doi.org/10.1074/jbc.274.35.24685			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455136	hybrid			2022-12-25	WOS:000082193400035
J	Gurvitz, A; Mursula, AM; Yagi, AI; Hartig, A; Ruis, H; Rottensteiner, H; Hiltunen, JK				Gurvitz, A; Mursula, AM; Yagi, AI; Hartig, A; Ruis, H; Rottensteiner, H; Hiltunen, JK			Alternatives to the isomerase-dependent pathway for the beta-oxidation of oleic acid are dispensable in Saccharomyces cerevisiae - Identification of YOR180c/DCI1 encoding peroxisomal Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; TRANSCRIPTION FACTORS PIP2P; RAT-LIVER; 2,4-DIENOYL-COA REDUCTASE; DOUBLE-BONDS; DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE; MOLECULAR CHARACTERIZATION; ARACHIDONIC-ACID; YEAST; GENE	Fatty acids with double bonds at odd-numbered positions such as oleic acid can enter beta-oxidation via a pathway relying solely on the auxiliary enzyme Delta(3)-Delta(2)-enoyl-CoA isomerase, termed the isomerase-dependent pathway. Two novel alternative pathways have recently been postulated to exist in mammals, and these additionally depend on Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase (di-isomerase-dependent) or on Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase and a,4-dienoyl-CoA reductase (reductase-dependent). We report the identification of the Saccharomyces cerevisiae oleic acid-inducible DCI1 (YOR180c) gene encoding peroxisomal di-isomerase. Enzyme assays conducted on soluble extracts derived from yeast cells overproducing Dci1p using 3,5,8,11,14-eicosapentenoyl-CoA as substrate demonstrated a specific di-isomerase activity of 6 nmol x min(-1) per mg of protein. Similarly enriched extracts from eci1 Delta cells lacking peroxisomal 3,2-isomerase additionally contained an intrinsic 3,2-isomerase activity that could generate 3,5,8,11,14-eicosapentenoyl-CoA from 2,5,8,11,14-eicosapentenoyl-CoA but not metabolize trans-3-hexenoyl-CoA. Amplification of this intrinsic activity replaced Eci1p since it restored growth of the eci1 Delta strain on petroselinic acid for which di-isomerase is not required whereas Eci1p is. Heterologous expression in yeast of rat di-isomerase resulted in a peroxisomal protein that was enzymatically active but did not re-establish growth of the eci1 Delta mutant on oleic acid. A strain devoid of Dci1p grew on oleic acid to wild-type levels, whereas one lacking both Eci1p and Dci1p grew as poorly as the eci1 Delta mutant. Hence, we reasoned that yeast di-isomerase does not additionally represent a physiological 3,2-isomerase and that Dci1p and the postulated alternative pathways in which it is entrained are dispensable for degrading oleic acid.	Univ Vienna, Inst Biochem & Mol Zellbiol, A-1030 Vienna, Austria; Vienna Bioctr, Ludwig Boltzmann Forschungsstelle Biochem, A-1030 Vienna, Austria; Univ Oulu, Dept Biochem, Bioctr Oulu, FIN-90570 Oulu, Finland	University of Vienna; Ludwig Boltzmann Institute; Vienna Biocenter (VBC); Finland National Institute for Health & Welfare; University of Oulu	Rottensteiner, H (corresponding author), Inst Biochem, Limonenstr 7, D-12203 Berlin, Germany.			Hartig, Andreas/0000-0003-3334-2763; Mursula, Anu/0000-0001-7975-7505				BOYLE JS, 1995, TRENDS GENET, V11, P8, DOI 10.1016/S0168-9525(00)88977-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHEN LS, 1994, BIOCHEMISTRY-US, V33, P10527, DOI 10.1021/bi00200a039; Chen Q, 1998, ARCH BIOCHEM BIOPHYS, V349, P371, DOI 10.1006/abbi.1997.0461; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; FILPPULA SA, 1995, J BIOL CHEM, V270, P27453, DOI 10.1074/jbc.270.46.27453; Filppula SA, 1998, J BIOL CHEM, V273, P349, DOI 10.1074/jbc.273.1.349; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; Geisbrecht BV, 1998, J BIOL CHEM, V273, P33184, DOI 10.1074/jbc.273.50.33184; Geraghty MT, 1999, P NATL ACAD SCI USA, V96, P2937, DOI 10.1073/pnas.96.6.2937; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gurvitz A, 1997, MOL MICROBIOL, V26, P675, DOI 10.1046/j.1365-2958.1997.5931969.x; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; Gurvitz A, 1998, J BIOL CHEM, V273, P31366, DOI 10.1074/jbc.273.47.31366; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; HILTUNEN JK, 1983, BIOCHIM BIOPHYS ACTA, V752, P223, DOI 10.1016/0005-2760(83)90116-9; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; IGUAL JC, 1991, YEAST, V7, P379, DOI 10.1002/yea.320070408; JONES EW, 1977, GENETICS, V85, P23; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; Kiema TR, 1999, BIOCHEMISTRY-US, V38, P2991, DOI 10.1021/bi981646v; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; LUTHRIA DL, 1995, J BIOL CHEM, V270, P13771, DOI 10.1074/jbc.270.23.13771; MULLERNEWEN G, 1993, BIOCHEMISTRY-US, V32, P11405; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; RICHTER K, 1980, J BIOL CHEM, V255, P8019; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; Sambrook J., 2002, MOL CLONING LAB MANU; Shoukry K, 1998, J BIOL CHEM, V273, P6892, DOI 10.1074/jbc.273.12.6892; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; Tserng KY, 1996, BIOCHEM J, V313, P581, DOI 10.1042/bj3130581; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; VOORNBROUWER T, 1993, BIOCHIM BIOPHYS ACTA, V1216, P325, DOI 10.1016/0167-4781(93)90166-B; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; YANG SY, 1983, J BIOL CHEM, V258, P9780	46	33	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24514	24521		10.1074/jbc.274.35.24514	http://dx.doi.org/10.1074/jbc.274.35.24514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455114	hybrid			2022-12-25	WOS:000082193400013
J	Schramm, NL; Limbird, LE				Schramm, NL; Limbird, LE			Stimulation of mitogen-activated protein kinase by G protein-coupled alpha(2)-adrenergic receptors does not require agonist-elicited endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT PATHWAYS; DESENSITIZATION; CLATHRIN; DYNAMIN; SUBTYPE; FIBROBLASTS; MECHANISMS; CELLS	Agonist-elicited receptor sequestration is strikingly different for the alpha(2A)-versus alpha(2B)-adrenergic receptor (alpha(2)-AR) subtypes; the alpha(2B)-AR undergoes rapid and extensive disappearance from the HEK 293 cell surface, whereas the alpha(2A)-AR does not (Daunt, D. A, Hurt, C., Hein, L., Kallio, J., Feng, F., and Kobilka, B. K. (1997) Mel. Pharmacol. 51, 711-720; Eason, M. G., and Liggett, S. B. (1992) J. Biol. Chem. 267, 25478-25479). Since recent reports suggest that endocytosis is required for some Gr protein-coupled receptors to stimulate the mitogen-activated protein (MAP) kinase cascade (Daaka, Y., Luttrell, L. M., Ahn, S., Della Rocca, G. J., Ferguson, S. S., Caron, M. G., and Lefkowitz, R. J. (1998) J. Biol. Chem. 273, 685-688; Luttrell, L. M., Daaka, Y., Della Rocca, G. J,, and Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 31648-31656; Ignatova, E. G,, Belcheva, M. M., Bohn, L. M., Neuman, M. C., and Coscia, C. J. (1999) J. Neurosci. 19, 56-63), we evaluated the differential ability of these two subtypes to activate MAPkinase. We observed no correlation between subtype-dependent agonist-elicited receptor redistribution and receptor activation of the MAP kinase cascade. Furthermore, incubation of cells with K+-depleted medium eliminated alpha(2B)-AR internalization but did not eliminate MAP kinase activation, suggesting that receptor internalization is not a general prerequisite for activation of the MAP kinase cascade via G(i)-coupled receptors. We also noted that neither dominant negative dynamin (K44A) nor concanavalin A treatment dramatically altered MAP kinase activation or receptor redistribution, indicating that these experimental tools do not universally block G protein-coupled receptor internalization.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Limbird, LE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.				NHLBI NIH HHS [HL 25182] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025182] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BOULOUMIE A, 1994, J BIOL CHEM, V269, P30254; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; EASON MG, 1992, J BIOL CHEM, V267, P25473; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; TOEWS ML, 1984, J BIOL CHEM, V259, P1844; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Williams NG, 1998, J BIOL CHEM, V273, P24624, DOI 10.1074/jbc.273.38.24624; WILSON AL, 1991, MOL PHARMACOL, V39, P481; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	22	93	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24935	24940		10.1074/jbc.274.35.24935	http://dx.doi.org/10.1074/jbc.274.35.24935			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455169	hybrid			2022-12-25	WOS:000082193400068
J	Wheeler, MB; Gelling, RW; Hinke, SA; Tu, B; Pederson, RA; Lynn, F; Ehses, J; McIntosh, CHS				Wheeler, MB; Gelling, RW; Hinke, SA; Tu, B; Pederson, RA; Lynn, F; Ehses, J; McIntosh, CHS			Characterization of the carboxyl-terminal domain of the rat glucose-dependent insulinotropic polypeptide (GIP) receptor - A role for serines 426 and 427 in regulating the rate of internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; HUMAN BETA-2-ADRENERGIC RECEPTOR; INTESTINAL-PEPTIDE RECEPTOR; PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; BETA-ADRENERGIC-RECEPTOR; GLUCAGON-LIKE PEPTIDE-1; PARATHYROID-HORMONE; CYTOPLASMIC TAIL; CALCITONIN RECEPTOR	Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone involved in the regulation of insulin secretion. In non-insulin-dependent diabetes mellitus insulin responses to GIP are blunted, possibly due to altered signal transduction or reduced receptor number. Site-directed mutagenesis was used to construct truncated GIP receptors to study the importance of the carboxyl-terminal tail (CT) in binding, signaling, and receptor internalization. Receptors truncated at amino acids 425, 418, and 405, expressed in COS-7 or CHO-K1 cells, exhibited similar binding to wild type receptors, GIP-dependent cAMP production with the 405 mutant was decreased in COS-7 cells. Maximal cAMP production in CHO-K1 cells was reduced with all truncated forms. Binding was undetectable with a receptor truncated at amino acid 400; increasing tail length by adding 5 alanines restored binding and signaling. Mutants produced by alanine scanning of residues 394-401, adjacent to transmembrane domain 7, were all functional. CT truncation by 30 or more amino acids, mutation of serines 426/427, singly or combined, or complete CT serine knockout all reduced receptor internalization rate, The majority of the GIP receptor CT is therefore not required for signaling, a minimum chain length of similar to 405 amino acids is needed for receptor expression, and serines 426 and 427 are important for regulating rate of receptor internalization.	Univ British Columbia, Fac Med, Dept Physiol, Vancouver, BC V6T 1Z3, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of British Columbia; University of Toronto; University of Toronto	McIntosh, CHS (corresponding author), Univ British Columbia, Fac Med, Dept Physiol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.		Ehses, Jan/AAK-1635-2020; Hinke, Simon/R-7120-2019	Lynn, Francis/0000-0001-9318-1063; Wheeler, Michael B./0000-0002-7480-7267; Ehses, Jan/0000-0001-9066-7607				AMIRANOFF B, 1984, BIOCHEM BIOPH RES CO, V123, P671, DOI 10.1016/0006-291X(84)90281-X; Bohm SK, 1997, BIOCHEM J, V322, P1; Buggy JJ, 1997, DIABETES, V46, P1400, DOI 10.2337/diabetes.46.9.1400; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691; Gelling RW, 1997, ENDOCRINOLOGY, V138, P2640, DOI 10.1210/en.138.6.2640; GREMLICH S, 1995, DIABETES, V44, P1202, DOI 10.2337/diabetes.44.10.1202; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; Holst JJ, 1997, DIABETOLOGIA, V40, P984, DOI 10.1007/s001250050779; HUANG ZM, 1995, MOL ENDOCRINOL, V9, P1240, DOI 10.1210/me.9.9.1240; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; ISHAHARA T, 1991, EMBO J, V10, P1635; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LU M, 1993, ENDOCRINOLOGY, V132, P94, DOI 10.1210/en.132.1.94; MALETTI M, 1987, DIABETES, V36, P1336, DOI 10.2337/diabetes.36.11.1336; Mathi SK, 1997, MOL ENDOCRINOL, V11, P424, DOI 10.1210/me.11.4.424; Moens K, 1996, DIABETES, V45, P257, DOI 10.2337/diabetes.45.2.257; NAUCK M, 1986, DIABETOLOGIA, V29, P46, DOI 10.1007/BF02427280; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186; Nygaard SC, 1997, J BONE MINER RES, V12, P1681, DOI 10.1359/jbmr.1997.12.10.1681; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PARKER EM, 1991, J BIOL CHEM, V266, P9987; Petrou C, 1997, J BIOL CHEM, V272, P2326; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SCHNEIDER H, 1994, FEBS LETT, V351, P281, DOI 10.1016/0014-5793(94)00878-7; SREEDHARAN SP, 1991, P NATL ACAD SCI USA, V88, P4986, DOI 10.1073/pnas.88.11.4986; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Takhar S, 1996, ENDOCRINOLOGY, V137, P2175, DOI 10.1210/en.137.5.2175; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; Tseng CC, 1998, MOL CELL ENDOCRINOL, V139, P179, DOI 10.1016/S0303-7207(98)00061-6; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; Widmann C, 1997, MOL ENDOCRINOL, V11, P1094, DOI 10.1210/me.11.8.1094	42	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24593	24601		10.1074/jbc.274.35.24593	http://dx.doi.org/10.1074/jbc.274.35.24593			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455124	hybrid, Green Published			2022-12-25	WOS:000082193400023
J	Grunden, AM; Self, WT; Villain, M; Blalock, JE; Shanmugam, KT				Grunden, AM; Self, WT; Villain, M; Blalock, JE; Shanmugam, KT			An analysis of the binding of repressor protein ModE to modABCD (Molybdate transport) operator/promoter DNA of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM-COFACTOR; OPERATOR; OPERON; NITROGENASE; EXPRESSION; SEQUENCE; ENZYMES; GENE	Expression of the modABCD operon in Escherichia coli, which codes for a molybdate-specific transporter, is repressed by ModE in vivo in a molybdate-dependent fashion. In vitro DNase I-footprinting experiments identified three distinct regions of protection by ModE-molybdate on the modA operator/promoter DNA, GTTATATT (-15 to -8; region 1), GCCTACAT (-4 to +4; region 2), and GTTACAT (+8 to +14; region 3), Within the three regions of the protected DNA, a pentamer sequence, TAYAT (Y = C or T), can be identified. DNA-electrophoretic mobility experiments showed that the protected regions 1 and 2 are essential for binding of ModE-molybdate to DNA, whereas the protected region 3 increases the affinity of the DNA to the repressor. The stoichiometry of this interaction was found to be two ModE-molybdate per modA operator DNA. ModE-molybdate at 5 nM completely protected the modABCD operator/promoter DNA from DNase I-catalyzed hydrolysis, whereas ModE alone failed to protect the DNA even at 100 nM. The apparent K-d for the interaction between the modA operator DNA and ModE-molybdate was 0.3 nM, and the K-d increased to 8 nM in the absence of molybdate, Among the various oxyanions tested, only tungstate replaced molybdate in the repression of modA by ModE, but the affinity of ModE-tungstate for modABCD operator DNA was 6 times lower than with ModE-molybdate. A mutant ModE(T125I) protein, which repressed modA-lac even in the absence of molybdate, protected the same region of modA operator DNA in the absence of molybdate. The apparent K-d for the interaction between modA operator DNA and ModE(T125I) was 3 a rr in the presence of molybdate and 4 nM without molybdate. The binding of molybdate to ModE: resulted in a decrease in fluorescence emission, indicating a conformational change of the protein upon molybdate binding. The fluorescence emission spectra of mutant ModE proteins, ModE(T125I) and ModE(Q216*), were unaffected by molybdate, The molybdate-independent mutant ModE proteins apparently mimic in its conformation the native ModE-molybdate complex, which binds to a DNA sequence motif of TATAT-7bp-TAYAT.	Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA	State University System of Florida; University of Florida; University of Alabama System; University of Alabama Birmingham	Shanmugam, KT (corresponding author), Univ Florida, Dept Microbiol & Cell Sci, Box 110700, Gainesville, FL 32611 USA.	Shan@micro.ifas.ufl.edu	Self, William/Q-4113-2019; Self, William/A-6704-2008	Blalock, J. Edwin/0000-0001-5303-8123; Self, William/0000-0001-9874-0194	NIAID NIH HHS [AI37670] Funding Source: Medline; NIGMS NIH HHS [GM48667] Funding Source: Medline; NIMH NIH HHS [MH52527] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI037670, R01AI037670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052527] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN RM, 1994, CRIT REV BIOTECHNOL, V14, P225, DOI 10.3109/07388554409079834; Anderson LA, 1997, EUR J BIOCHEM, V246, P119, DOI 10.1111/j.1432-1033.1997.00119.x; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORCUERA GL, 1993, J GEN MICROBIOL, V139, P1869, DOI 10.1099/00221287-139-8-1869; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Edwards PR, 1997, ANAL BIOCHEM, V246, P1, DOI 10.1006/abio.1996.9922; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Grunden AM, 1996, J BACTERIOL, V178, P735, DOI 10.1128/jb.178.3.735-744.1996; Grunden AM, 1997, ARCH MICROBIOL, V168, P345, DOI 10.1007/s002030050508; GRUNDEN AM, 1996, THESIS U FLORIDA GAI; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HURLBURT BK, 1992, J BIOL CHEM, V267, P16783; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Kletzin A, 1996, FEMS MICROBIOL REV, V18, P5, DOI 10.1016/0168-6445(95)00025-9; KLIG LS, 1988, J BIOL CHEM, V263, P243; Kutsche M, 1996, J BACTERIOL, V178, P2010, DOI 10.1128/jb.178.7.2010-2017.1996; LEE JH, 1990, J BACTERIOL, V172, P2079, DOI 10.1128/jb.172.4.2079-2087.1990; LIU YC, 1993, J BIOL CHEM, V268, P23239; McNicholas PM, 1997, MOL MICROBIOL, V23, P515, DOI 10.1046/j.1365-2958.1997.d01-1864.x; McNicholas PM, 1996, FEMS MICROBIOL LETT, V145, P117, DOI 10.1111/j.1574-6968.1996.tb08565.x; MILLER JB, 1987, J BACTERIOL, V169, P1853, DOI 10.1128/jb.169.5.1853-1860.1987; NEGRE D, 1992, J MOL BIOL, V228, P23, DOI 10.1016/0022-2836(92)90488-6; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; RECH S, 1995, J BACTERIOL, V177, P1023, DOI 10.1128/jb.177.4.1023-1029.1995; Rech S, 1996, J BIOL CHEM, V271, P2557, DOI 10.1074/jbc.271.5.2557; ROSENTEL JK, 1995, J BACTERIOL, V177, P4857, DOI 10.1128/jb.177.17.4857-4864.1995; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANKAR P, 1987, THESIS U FLORIDA GAI; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Self WT, 1999, MICROBIOL-UK, V145, P41, DOI 10.1099/13500872-145-1-41; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Walkenhorst HM, 1995, MICROBIOL RES, V150, P347; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8	37	35	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24308	24315		10.1074/jbc.274.34.24308	http://dx.doi.org/10.1074/jbc.274.34.24308			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446207	hybrid			2022-12-25	WOS:000082110900086
J	Kozak, SL; Kuhmann, SE; Platt, EJ; Kabat, D				Kozak, SL; Kuhmann, SE; Platt, EJ; Kabat, D			Roles of CD4 and coreceptors in binding, endocytosis, and proteolysis of gp120 envelope glycoproteins derived from human immunodeficiency virus type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTORS CXCR4; CENTRAL-NERVOUS-SYSTEM; RAPID INTERNALIZATION; ADAPTER COMPLEXES; PRIMARY PATIENT; HIV-1 ENTRY; CCR5; CELLS; INFECTION; SIGNAL	Infections by human immunodeficiency virus type 1 (HIV-1) involve interactions of the viral envelope glycoprotein gp120 with CD4 and then with a coreceptor, R5 isolates of HIV-1 use CCR5 as a coreceptor, whereas X4 isolates use CXCR4, It is not known whether coreceptors merely trigger fusion of the viral and cellular membranes or whether they also influence the energetics of virus adsorption, the placement of the membrane fusion reaction, and the metabolism of adsorbed gp120, Surprisingly, the pathway for metabolism of adsorbed gp120 has not been investigated thoroughly in any cells. To address these issues, we used purified I-125-gp120s derived from the R5 isolate Bat and from the X4 isolate IIIB as ligands for binding onto human cells that expressed CD4 alone or CD4 with a coreceptor, The gp120 preparations were active in forming ternary complexes with CD4 and the appropriate coreceptor, Moreover, the cellular quantities of CD4 and coreceptors were sufficient for efficient infections by the corresponding HIV-1 isolates, In these conditions, the kinetics and affinities of I-125-gp120 adsorptions and their subsequent metabolisms were strongly dependent on CD4 but were not significantly influenced by CCR5 or CXCR4, After binding to CD4, the I-125-gp120s slowly became resistant to extraction from the cell monolayers by pH 3.0 buffer, suggesting that they were endocytosed with half-times of 1-2 h, Within 20-30 min of endocytosis, the I-125-gp120s were proteolytically degraded to small products that were shed into the media. The weak base chloroquine strongly inhibited I-125-gp120 proteolysis and caused its intracellular accumulation, suggesting involvement of a low pH organelle, Results supporting these methods and conclusions were obtained by confocal immunofluorescence microscopy, We conclude that the energetics, kinetics, and pathways of I-125-gp120 binding, endocytosis, and proteolysis are determined principally by CD4 rather than by coreceptors in cells that contain sufficient coreceptors for efficient infections. Therefore, the role of coreceptors in HIV-1 infections probably does not include steerage or subcellular localization of adsorbed virus.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Kabat, D (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	kabat@ohsu.edu			NCI NIH HHS [CA67358] Funding Source: Medline; NIAID NIH HHS [1F32AID9735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067358, R56CA067358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Broder CC, 1996, PATHOBIOLOGY, V64, P171, DOI 10.1159/000164032; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; GELEZIUNAS R, 1992, AIDS, V6, P1411, DOI 10.1097/00002030-199212000-00001; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P343, DOI 10.1089/aid.1994.10.343; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Hill CM, 1997, J VIROL, V71, P6296, DOI 10.1128/JVI.71.9.6296-6304.1997; HORUK R, 1987, J BIOL CHEM, V262, P16275; IVEYHOYLE M, 1991, P NATL ACAD SCI USA, V88, P512, DOI 10.1073/pnas.88.2.512; Iyengar S, 1998, J VIROL, V72, P5251, DOI 10.1128/JVI.72.6.5251-5255.1998; KABAT D, 1994, J VIROL, V68, P2570, DOI 10.1128/JVI.68.4.2570-2577.1994; Kozak SL, 1997, J VIROL, V71, P873, DOI 10.1128/JVI.71.2.873-882.1997; Kuhmann SE, 1997, J VIROL, V71, P8642, DOI 10.1128/JVI.71.11.8642-8656.1997; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; LYERLY HK, 1987, P NATL ACAD SCI USA, V84, P4601, DOI 10.1073/pnas.84.13.4601; Madani N, 1998, P NATL ACAD SCI USA, V95, P8005, DOI 10.1073/pnas.95.14.8005; MALDARELLI F, 1995, J VIROL, V69, P6457, DOI 10.1128/JVI.69.10.6457-6465.1995; MARSH M, 1990, BIOCHEM SOC T, V18, P139, DOI 10.1042/bst0180139; Martin KA, 1997, SCIENCE, V278, P1470, DOI 10.1126/science.278.5342.1470; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Popik W, 1996, MOL CELL BIOL, V16, P6532; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; RHEE SS, 1994, J VIROL, V68, P5156, DOI 10.1128/JVI.68.8.5156-5163.1994; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; SLECKMAN BP, 1992, P NATL ACAD SCI USA, V89, P7566, DOI 10.1073/pnas.89.16.7566; Tarasova NI, 1998, J BIOL CHEM, V273, P15883, DOI 10.1074/jbc.273.26.15883; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; Warren RA, 1997, J BIOL CHEM, V272, P2116; WEINHOLD KJ, 1989, J IMMUNOL, V142, P3091; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884	55	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23499	23507		10.1074/jbc.274.33.23499	http://dx.doi.org/10.1074/jbc.274.33.23499			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438529	hybrid			2022-12-25	WOS:000082012800079
J	Nakai, T; Yamasaki, A; Sakaguchi, M; Kosaka, K; Mihara, K; Amaya, Y; Miura, S				Nakai, T; Yamasaki, A; Sakaguchi, M; Kosaka, K; Mihara, K; Amaya, Y; Miura, S			Membrane topology of Alzheimer's disease-related presenilin 1 - Evidence for the existence of a molecular species with a seven membrane-spanning and one membrane-embedded structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; IN-VIVO; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; INTRACELLULAR MEMBRANES; CAENORHABDITIS-ELEGANS; MISSENSE MUTATIONS; LEADER PEPTIDASE; SIGNAL SEQUENCE; PRION PROTEIN	A significant member of early-onset familial type of Alzheimer's disease cases has been shown to be caused by dominant mutations in either of the two genes encoding presenilin 1 (PS1) and presenilin 2 (PS2). These two proteins are highly homologous to each other and have been reported to be mainly localized to the membranes of intracellular compartments such as the endoplasmic reticulum. Information about the membrane topological structures of these proteins is indispensable for understanding their physiological and pathological roles. Although several models have been proposed previously, their precise membrane topologies remain unknown. In this study, we examined this issue in detail by expressing a series of C-terminally deleted PS1 mutants fused to the hydrophilic portion of Escherichia coli leader peptidase in vitro using a reticulocyte lysate in the presence of microsomal membranes. Our results predict that PS1 exists mainly in a seven membrane-spanning structure with its C-terminal end exposed to the luminal space. This was also confirmed by expressing these fusion proteins in cultured cells, We further showed that a ninth hydrophobic segment is tightly bound to the membrane without spanning it. Based on the above observations, we propose a novel "seven membrane-spanning and one membrane-embedded" topological model for presenilins.	Yokohama City Univ, Sch Med, Radioisotope Res Ctr, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Psychiat, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Biochem, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan	Yokohama City University; Yokohama City University; Yokohama City University; Kyushu University	Miura, S (corresponding author), Yokohama City Univ, Sch Med, Radioisotope Res Ctr, Kanazawa Ku, 3-9 Fukuuraocho, Yokohama, Kanagawa 2360004, Japan.							BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Culvenor JG, 1997, J NEUROSCI RES, V49, P719, DOI 10.1002/(SICI)1097-4547(19970915)49:6<719::AID-JNR6>3.0.CO;2-A; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Dewji NN, 1997, P NATL ACAD SCI USA, V94, P14025, DOI 10.1073/pnas.94.25.14025; Dewji NN, 1997, P NATL ACAD SCI USA, V94, P9926, DOI 10.1073/pnas.94.18.9926; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; FINBOW ME, 1994, J CELL SCI, V107, P1817; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; HALLMANN M, 1994, NEURON, V13, P1331; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1995, P NATL ACAD SCI USA, V92, P12180, DOI 10.1073/pnas.92.26.12180; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; MOORE KE, 1987, J BIOL CHEM, V262, P8806; MORI M, 1980, J BIOCHEM, V88, P1829, DOI 10.1093/oxfordjournals.jbchem.a133158; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Takashima A, 1996, BIOCHEM BIOPH RES CO, V227, P423, DOI 10.1006/bbrc.1996.1523; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; VENKATACHALAM CM, 1968, BIOPOLYMERS, V6, P1425, DOI 10.1002/bip.1968.360061006; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; YAMAMOTO K, 1997, ADV COMP ENDOCRINOL, V2, P921; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	51	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23647	23658		10.1074/jbc.274.33.23647	http://dx.doi.org/10.1074/jbc.274.33.23647			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438548	hybrid			2022-12-25	WOS:000082012800098
J	Goto, H; Tomono, Y; Ajiro, K; Kosako, H; Fujita, M; Sakurai, M; Okawa, K; Iwamatsu, A; Okigaki, T; Takahashi, T; Inagaki, M				Goto, H; Tomono, Y; Ajiro, K; Kosako, H; Fujita, M; Sakurai, M; Okawa, K; Iwamatsu, A; Okigaki, T; Takahashi, T; Inagaki, M			Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-ASSOCIATED KINASE; FIBRILLARY ACIDIC PROTEIN; CELL-CYCLE; CHROMATIN CONDENSATION; LINKER HISTONES; INTERMEDIATE FILAMENTS; MITOSIS; DNA; H1; INVITRO	Histone H3 (H3) phosphorylation at Ser(10) occurs during mitosis in eukaryotes and was recently shown to play an important role in chromosome condensation in Tetrahymena. When producing monoclonal antibodies that recognize glial fibrillary acidic protein phosphorylation at Thr(7), we obtained some monoclonal antibodies that cross-reacted with early mitotic chromosomes. They reacted with 15-kDa phosphoprotein specifically in mitotic cell lysate, With microsequencing, this phosphoprotein was proved to be H3, Mutational analysis revealed that they recognized H3 Ser(28) phosphorylation. Then we produced a monoclonal antibody, HTA28, using a phosphopeptide corresponding to phosphorylated H3 Ser(28), This antibody specifically recognized the phosphorylation of H3 Ser(28) but not that of glial fibrillary acidic protein Thr(7). Immunocytochemical studies with HTA28 revealed that Ser(28) phosphorylation occurred in chromosomes predominantly during early mitosis and coincided with the initiation of mitotic chromosome condensation, Biochemical analyses using P-32-labeled mitotic cells also confirmed that H3 is phosphorylated at Ser(28) during early mitosis. In addition, we found that H3 is phosphorylated at Ser(28) as well as Ser(10) when premature chromosome condensation was induced in tsBN2 cells. These observations suggest that H3 phosphorylation at Ser(28), together with Ser(10), is a conserved event and is likely to be involved in mitotic chromosome condensation.	Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Cell Biol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Lab Viral Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Shigei Med Res Inst, Div Cell & Mol Biol, Okayama 7010202, Japan; Mie Univ, Sch Med, Dept Pediat, Tsu, Mie 5148507, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Mie University; Kirin Brewery Company Limited	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	minagaki@aichi-cc.pref.aichi.jp	Inagaki, Masaki/B-9920-2016	Goto, Hidemasa/0000-0002-6796-4467; Fujita, Masatoshi/0000-0001-6617-2452				Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; AJIRO K, 1983, J BIOL CHEM, V258, P4534; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1445, DOI 10.1021/bi00509a007; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1454, DOI 10.1021/bi00509a008; ALLIS CD, 1981, BIOCHEMISTRY-US, V20, P3828, DOI 10.1021/bi00516a025; Beavo J A, 1974, Methods Enzymol, V38, P299; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BRADBURY EM, 1973, EUR J BIOCHEM, V33, P131, DOI 10.1111/j.1432-1033.1973.tb02664.x; BRADBURY EM, 1992, BIOESSAYS, V14, P9; DANNA JA, 1974, BIOCHEMISTRY-US, V13, P4992, DOI 10.1021/bi00721a019; Davie JR, 1998, J CELL BIOCHEM, P203; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Doenecke D, 1997, HISTOCHEM CELL BIOL, V107, P1, DOI 10.1007/s004180050083; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1983, ANAL BIOCHEM, V129, P132, DOI 10.1016/0003-2697(83)90061-1; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HANKS SK, 1983, EXP CELL RES, V148, P293, DOI 10.1016/0014-4827(83)90153-2; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Inagaki M, 1997, J BIOCHEM, V121, P407; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KISHIRO Y, 1995, CELL STRUCT FUNCT, V20, P151, DOI 10.1247/csf.20.151; Kosako H, 1997, J BIOL CHEM, V272, P10333; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; MOSS T, 1976, BIOCHEMISTRY-US, V15, P2261, DOI 10.1021/bi00656a003; Murray AW, 1998, SCIENCE, V282, P425, DOI 10.1126/science.282.5388.425; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; Patterton HG, 1998, J BIOL CHEM, V273, P7268, DOI 10.1074/jbc.273.13.7268; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; TAYLOR SS, 1982, J BIOL CHEM, V257, P6056; Van Hooser A, 1998, J CELL SCI, V111, P3497; Vignali M, 1998, NAT STRUCT BIOL, V5, P1025, DOI 10.1038/4133; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; ZLATANOVA J, 1991, DNA CELL BIOL, V10, P239, DOI 10.1089/dna.1991.10.239	56	354	375	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25543	25549		10.1074/jbc.274.36.25543	http://dx.doi.org/10.1074/jbc.274.36.25543			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464286	hybrid			2022-12-25	WOS:000082554200050
J	Kaur, P				Kaur, P			The anion-stimulated ATPase ArsA shows unisite and multisite catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING SITE; TRANSLOCATING ATPASE; MUTAGENESIS; MECHANISM; PROTEINS; PUMP	ArsA, an anion-stimulated ATPase, consists of two nucleotide binding domains, A1 in the N terminus and A2 in the C terminus of the protein, connected by a linker. The A1 domain contains a high affinity ATP binding site, whereas the A2 domain has low affinity and it requires the allosteric ligand antimonite for binding ATP, ArsA is known to form a UV-activated adduct with [alpha-P-32]ATP in the linker region. This study shows that on addition of antimonite, much more adduct is formed. Characterization of the nature of the adduct suggests that it is between ArsA and ADP, instead of ATP, indicating that the adduct formation reflects hydrolysis of ATP, The present study also demonstrates that the A1 domain is capable of carrying out unisite catalysis in the absence of antimonite, On addition of antimonite, multisite catalysis involving both A1 and A2 sites occurs, resulting in a 40-fold increase in ATPase activity. Studies with mutant proteins suggest that the A2 site may be second in the sequence of events, so that its role in catalysis is dependent on a functional A1 site, It is also proposed that ArsA goes through an ATP-bound and an ADP-bound conformation, and the linker region, where ADP binds under both unisite and multisite catalytic conditions, may play an important role in the energy transduction process.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Kaur, P (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Ctr Ave, Atlanta, GA 30303 USA.	bioppk@panther.gsu.edu			NIGMS NIH HHS [R29 GM51981-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051981] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; CROSS RL, 1982, J BIOL CHEM, V257, P2101; Hiromura M, 1998, J BIOL CHEM, V273, P5435, DOI 10.1074/jbc.273.10.5435; HSU CM, 1989, J BIOL CHEM, V264, P17349; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1993, J BACTERIOL, V175, P351, DOI 10.1128/JB.175.2.351-357.1993; KAUR P, 1994, J BIOL CHEM, V269, P9698; KAUR P, 1992, J BIOL CHEM, V267, P19272; KAUR P, 1994, BIOCHEMISTRY-US, V33, P6456, DOI 10.1021/bi00187a010; KAUR P, 1998, ADV MOL CEL A&B, V23, P455; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Ramaswamy S, 1998, J BIOL CHEM, V273, P9243, DOI 10.1074/jbc.273.15.9243; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; YUE VT, 1997, BIOCHEMISTRY-US, V16, P4678	17	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25849	25854		10.1074/jbc.274.36.25849	http://dx.doi.org/10.1074/jbc.274.36.25849			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464326	hybrid			2022-12-25	WOS:000082554200090
J	Ruppert, C; Kavermann, H; Wimmers, S; Schmid, R; Kellermann, J; Lottspeich, F; Huber, H; Stetter, KO; Muller, V				Ruppert, C; Kavermann, H; Wimmers, S; Schmid, R; Kellermann, J; Lottspeich, F; Huber, H; Stetter, KO; Muller, V			The proteolipid of the A(1)A(0) ATP synthase from Methanococcus jannaschii has six predicted transmembrane helices but only two proton-translocating carboxyl groups	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOSARCINA-MAZEI GO1; COENZYME-M METHYLTRANSFERASE; ESCHERICHIA-COLI; STRAIN GO1; F-0 SECTOR; ARCHAEON; STOICHIOMETRY; ORGANIZATION; EXPRESSION; EVOLUTION	The proteolipid, a hydrophobic ATPase subunit essential for ion translocation, was purified from membranes of Methanococcus jannaschii by chloroform/methanol extraction and gel chromatography and was studied using molecular and biochemical techniques. Its apparent molecular mass as determined in SDS-polyacrylamide gel electrophoresis varied considerably with the conditions applied. The N-terminal sequence analysis made it possible to define the open reading frame and revealed that the gene is a triplication of the gene present in bacteria. In some of the proteolipids, the N-terminal methionine is excised. Consequently, two forms with molecular masses of 21,316 and 21,183 Da were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The molecular and biochemical data gave clear evidence that the mature proteolipid from M. jannaschii is a triplication of the 8-kDa proteolipid present in bacterial F1F0 ATPases and most archaeal A(1)A(0) ATPases, Moreover, the triplicated form lacks a proton-translocating carboxyl group in the first of three pairs of transmembrane helices, This finding puts in question the current view of the evolution of H+ ATPases and has important mechanistic consequences for the structure and function of H+ ATPases in general.	Univ Munich, Lehrstuhl Mikrobiol, D-80638 Munich, Germany; Univ Osnabruck, AG Mikrobiol, D-49069 Osnabruck, Germany; Max Planck Inst Biochem, Prot Chem Abt, D-82152 Martinsried, Germany; Univ Regensburg, Lehrstuhl Mikrobiol, D-93053 Regensburg, Germany	University of Munich; University Osnabruck; Max Planck Society; University of Regensburg	Muller, V (corresponding author), Univ Munich, Lehrstuhl Mikrobiol, Maria Ward Str 1A, D-80638 Munich, Germany.		Mueller, Volker/ABE-4305-2021; Cordeiro, Soenke/A-1782-2012; Cordeiro, Soenke/H-9002-2012	Mueller, Volker/0000-0001-7955-5508; Cordeiro, Soenke/0000-0002-1049-8303				ARAI H, 1988, J BIOL CHEM, V263, P8796; BALCH WE, 1976, APPL ENVIRON MICROB, V32, P781, DOI 10.1128/AEM.32.6.781-791.1976; BECHER B, 1992, FEMS MICROBIOL LETT, V91, P239; BECHER B, 1994, J BACTERIOL, V176, P2543, DOI 10.1128/JB.176.9.2543-2550.1994; BECHER B, 1992, J BACTERIOL, V174, P7656, DOI 10.1128/JB.174.23.7656-7660.1992; Beechey R B, 1979, Methods Enzymol, V55, P426; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; Deppenmeier U, 1996, ARCH MICROBIOL, V165, P149, DOI 10.1007/BF01692856; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; GALLAGHER SR, 1993, CURRENT PROTOCOLS MO; GOGARTEN JP, 1992, PHOTOSYNTH RES, V33, P137, DOI 10.1007/BF00039176; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HJERTEN S, 1962, ARCH BIOCHEM BIOPHYS, V99, P466, DOI 10.1016/0003-9861(62)90295-3; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Lienard T, 1998, FEBS LETT, V425, P204, DOI 10.1016/S0014-5793(98)00229-4; Muller V, 1999, J BIOENERG BIOMEMBR, V31, P15, DOI 10.1023/A:1005451311009; MULLER V, 1988, EUR J BIOCHEM, V178, P519, DOI 10.1111/j.1432-1033.1988.tb14478.x; Muller V, 1993, METHANOGENESIS, P360; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; Ruppert C, 1998, J BACTERIOL, V180, P3448, DOI 10.1128/JB.180.13.3448-3452.1998; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P369; Wilms R, 1996, J BIOL CHEM, V271, P18843, DOI 10.1074/jbc.271.31.18843	25	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25281	25284		10.1074/jbc.274.36.25281	http://dx.doi.org/10.1074/jbc.274.36.25281			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464251	hybrid			2022-12-25	WOS:000082554200016
J	Rutjes, SK; van der Heijden, A; Utz, PJ; van Venrooij, WJ; Pruijn, GJM				Rutjes, SK; van der Heijden, A; Utz, PJ; van Venrooij, WJ; Pruijn, GJM			Rapid nucleolytic degradation of the small cytoplasmic Y RNAs during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; RO RIBONUCLEOPROTEINS; HETERODIMERIC PROTEIN; 52-KD PROTEIN; BINDING-SITE; IDENTIFICATION; CLEAVAGE; RECOGNITION; INHIBITOR; CASPASES	We have investigated the fate of the RNA components of small ribonucleoprotein particles in apoptotic cells. We show that the cytoplasmic Ro ribonucleoprotein-associated Y RNAs are specifically and rapidly degraded during apoptosis via a caspase-dependent mechanism. This is the first study describing the selective degradation of a specific class of small structural RNA molecules in apoptotic cells. Cleavage and subsequent truncation of Y RNAs was observed upon exposure of cells to a variety of apoptotic stimuli and were found to be inhibited by Bcl-2, zinc, and several caspase inhibitors, These results indicate that apoptotic degradation of Y RNAs is dependent on caspase activation, which suggests that the nucleolytic activity responsible for Y RNA degradation is activated downstream of the caspase cascade. The Y RNA degradation products remain bound by the Ro60 protein and in part also by the La protein, the only two proteins known to be stably associated with intact Ro ribonucleoprotein particles. The size of the Y RNA degradation products is consistent with the protection from degradation of the most highly conserved region of the Y RNAs by the bound Ro60 and La proteins. Our results indicate that the rapid abrogation of the yet unknown function of Y RNAs might be an early step in the systemic deactivation of the dying cell.	Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Radboud University Nijmegen; Harvard University; Brigham & Women's Hospital	Pruijn, GJM (corresponding author), Univ Nijmegen, Dept Biochem, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Pruijn, Ger/D-6664-2012	Rutjes, Saskia/0000-0001-7851-3402	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR042689] Funding Source: NIH RePORTER; NIAID NIH HHS [K08AI01521] Funding Source: Medline; NIAMS NIH HHS [AR42689] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BENCHETRIT E, 1988, J EXP MED, V167, P1560, DOI 10.1084/jem.167.5.1560; BOIRE G, 1995, CLIN EXP IMMUNOL, V100, P489; Brouwer R, 1998, ARTHRITIS RHEUM, V41, P1428, DOI 10.1002/1529-0131(199808)41:8<1428::AID-ART12>3.0.CO;2-J; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Crawford DR, 1997, FREE RADICAL BIO MED, V22, P1295, DOI 10.1016/S0891-5849(96)00544-8; Cuppen E, 1997, J BIOL CHEM, V272, P30215, DOI 10.1074/jbc.272.48.30215; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Green CD, 1998, RNA, V4, P750, DOI 10.1017/S1355838298971667; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; HENDRICK JP, 1981, MOL CELL BIOL, V1, P1138, DOI 10.1128/MCB.1.12.1138; KATO N, 1982, BIOCHEM BIOPH RES CO, V108, P363, DOI 10.1016/0006-291X(82)91875-7; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MONDINO A, 1995, J BIOL CHEM, V270, P26593, DOI 10.1074/jbc.270.44.26593; OBRIEN CA, 1990, EMBO J, V9, P3683, DOI 10.1002/j.1460-2075.1990.tb07580.x; OWENS GP, 1992, CANCER METAST REV, V11, P149, DOI 10.1007/BF00048061; PEEK R, 1994, J IMMUNOL, V153, P4321; Pellizzoni L, 1998, J MOL BIOL, V281, P593, DOI 10.1006/jmbi.1998.1961; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Pruijn GJM, 1997, EUR J CELL BIOL, V74, P123; PRUIJN GJM, 1991, NUCLEIC ACIDS RES, V19, P5173, DOI 10.1093/nar/19.19.5173; PRUIJN GJM, 1993, BIOCHIM BIOPHYS ACTA, V1216, P395, DOI 10.1016/0167-4781(93)90006-Y; Rosen A, 1999, CELL DEATH DIFFER, V6, P6, DOI 10.1038/sj.cdd.4400460; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SLOBBE RL, 1992, J MOL BIOL, V227, P361, DOI 10.1016/0022-2836(92)90890-V; STRUB K, 1991, MOL CELL BIOL, V11, P3949, DOI 10.1128/MCB.11.8.3949; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TORIGOE T, 1994, CANCER RES, V54, P4851; Utz PJ, 1998, J BIOL CHEM, V273, P35362, DOI 10.1074/jbc.273.52.35362; VANGELDER CWG, 1994, NUCLEIC ACIDS RES, V22, P2498, DOI 10.1093/nar/22.13.2498; WOLIN SL, 1984, P NATL ACAD SCI-BIOL, V81, P1996, DOI 10.1073/pnas.81.7.1996; WOLIN SL, 1983, CELL, V32, P735, DOI 10.1016/0092-8674(83)90059-4; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	43	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24799	24807		10.1074/jbc.274.35.24799	http://dx.doi.org/10.1074/jbc.274.35.24799			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455152	hybrid			2022-12-25	WOS:000082193400051
J	Wassnehove-McCarthy, DJ; McCarthy, KJ				Wassnehove-McCarthy, DJ; McCarthy, KJ			Molecular characterization of a novel basement membrane-associated proteoglycan, leprecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; DENSITY-LIPOPROTEIN-RECEPTOR; CELL-ADHESION MOLECULES; EPIDERMAL GROWTH-FACTOR; CORE PROTEIN; CDNA CLONING; SEQUENCE; PERLECAN; LAMININ; MATRIX	A monoclonal antibody was used in early studies to identify a novel chondroitin sulfate proteoglycan, secreted by L-2 cells, the core protein of which was approximately 100 kDa. To characterize this proteoglycan core protein at the molecular level, an L-2 cell cDNA library was probed by expression screening and solution hybridization. Northern blot analysis assigned transcript size to approximately 3.1 kilobases and, after contig assembly, the coding region of the mRNA corresponded to 2.18 kilobases. Immunoassays were performed to confirm the identity of this sequence, using a polyclonal antibody raised against an expressed fusion protein encoded by sequence representing the carboxyl half of the molecule. The antibody recognized the core protein in Western blots after prior digestion of the intact proteoglycan with chondroitinase ABC, Immunostaining tissue sections with the same antibody localized the proteoglycan to basement membranes, and expression of the entire sequence in Chinese hamster ovary K-1 cells showed that the protein encoded by the sequence secreted as a chondroitin sulfate proteoglycan. The core protein not only has motifs permitting glycosylation as a proteoglycan, but also possesses the endoplasmic reticulum retrieval signal, KDEL, which suggests that, in addition to its role as a basement membrane component, it may also participate in the secretory pathway of cells.	Louisiana State Univ, Med Ctr, Sch Med, Dept Pathol, Shreveport, LA 71130 USA; Louisiana State Univ, Med Ctr, Sch Med, Dept Cell Biol & Anat, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	McCarthy, KJ (corresponding author), Louisiana State Univ, Med Ctr, Sch Med, Dept Pathol, 1501 Kings Highway, Shreveport, LA 71130 USA.			McCarthy, Kevin/0000-0001-9317-5624	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048055] Funding Source: NIH RePORTER; NIDDK NIH HHS [1-RO1-DK48055] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altmeyer A, 1996, INT J CANCER, V69, P340, DOI 10.1002/(SICI)1097-0215(19960822)69:4<340::AID-IJC18>3.0.CO;2-9; AnsariLari MA, 1996, GENOME RES, V6, P314, DOI 10.1101/gr.6.4.314; Castagnola P, 1997, J CELL SCI, V110, P1351; CHEN QF, 1992, BIOCHEM CELL BIOL, V70, P1030, DOI 10.1139/o92-147; COUCHMAN JR, 1984, NATURE, V307, P650, DOI 10.1038/307650a0; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; GOODE NP, 1995, DIABETOLOGIA, V38, P1455, DOI 10.1007/BF00400607; HAGEN SG, 1993, J BIOL CHEM, V268, P7261; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; HASSELL JR, 1992, INVEST OPHTH VIS SCI, V33, P547; HASSELL JR, 1985, J BIOL CHEM, V260, P8098; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; IOZZO RV, 1987, HISTOCHEMISTRY, V88, P23, DOI 10.1007/BF00490162; IOZZO RV, 1986, J BIOL CHEM, V261, P6658; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; Martire G, 1996, J BIOL CHEM, V271, P3541; McCarthy K. J., 1993, Molecular Biology of the Cell, V4, p61A; MCCARTHY KJ, 1989, J CELL BIOL, V109, P3187, DOI 10.1083/jcb.109.6.3187; MCCARTHY KJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1479, DOI 10.1177/38.10.2401786; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; Ochs RL, 1996, MOL BIOL CELL, V7, P1015, DOI 10.1091/mbc.7.7.1015; OKAMOTO T, 1994, FEBS LETT, V351, P31, DOI 10.1016/0014-5793(94)00809-4; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHITTNY JC, 1995, HISTOCHEM CELL BIOL, V103, P271, DOI 10.1007/BF01457411; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; VELAN B, 1994, J BIOL CHEM, V269, P22719; Wu RR, 1997, J CELL BIOL, V136, P433, DOI 10.1083/jcb.136.2.433; Zhu Q, 1997, BIOCHEM BIOPH RES CO, V232, P354, DOI 10.1006/bbrc.1997.6195; [No title captured]	37	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25004	25017		10.1074/jbc.274.35.25004	http://dx.doi.org/10.1074/jbc.274.35.25004			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455179	hybrid			2022-12-25	WOS:000082193400078
J	Krutzsch, HC; Choe, BJ; Sipes, JM; Guo, NH; Roberts, DD				Krutzsch, HC; Choe, BJ; Sipes, JM; Guo, NH; Roberts, DD			Identification of an alpha(3)beta(1) integrin recognition sequence in thrombospondin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING PEPTIDES; MELANOMA CELL-ADHESION; I REPEATS; MULTIPLE ALIGNMENT; TERMINAL DOMAIN; LAMININ-5; RECEPTOR; PROTEIN; VLA-3; CHAIN	A synthetic peptide containing amino acid residues 190-201 of thrombospondin-l (TSP1) promoted adhesion of MDA-MB-435 breast carcinoma cells when immobilized and inhibited adhesion of the same cells to TSP1 when added in solution. Adhesion to this peptide was enhanced by a beta(1) integrin-activating antibody, Mn2+, and insulin-like growth factor I and was inhibited by an alpha(3)beta(1) integrin function-blocking antibody. The soluble peptide inhibited adhesion of cells to the immobilized TSP1 peptide or spreading on intact TSP1 but at the same concentrations did not inhibit attachment or spreading on type Iv collagen or fibronectin, Substitution of several residues in the TSP1 peptide with Ala residues abolished or diminished the inhibitory activity of the peptide in solution, but only substitution of Arg-198 completely inactivated the adhesive activity of the immobilized peptide. The essential residues for activity of the peptide as a soluble inhibitor are Asn-196, Val-197, and Arg-198, but flanking residues enhance the inhibitory activity of this core sequence, either by altering the conformation of the active sequence or by interacting with the integrin, This functional sequence is conserved in all known mammalian TSP1 sequences and in TSP1 from Xenopus laevis, The TSP1 peptide also inhibited adhesion of MDA-MB-435 cells to the laminin-l peptide GD6, which contains a potential integrin-recognition sequence Asn-Leu-Arg and is derived from a similar position in a pentraxin module. Adhesion studies using recombinant TSP1 fragments also localized beta 1 integrin-dependent adhesion to residues 175-242 of this region, which contain the active sequence.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2A33,10 Ctr Dr,MSC 1500, Bethesda, MD 20892 USA.		Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981				Adachi M, 1998, J CLIN ONCOL, V16, P1060, DOI 10.1200/JCO.1998.16.3.1060; ADAMS JC, 1995, J CELL SCI, V108, P1977; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; Aota S, 1995, Adv Enzymol Relat Areas Mol Biol, V70, P1; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Clezardin P, 1997, BIOCHEM J, V321, P819, DOI 10.1042/bj3210819; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DEFREITAS MF, 1995, NEURON, V15, P333, DOI 10.1016/0896-6273(95)90038-1; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; FERNANDEZ C, 1998, FRONT BIOSCI, V3, P684; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; Gresham HD, 1996, J BIOL CHEM, V271, P30587, DOI 10.1074/jbc.271.48.30587; GUO NH, 1992, J BIOL CHEM, V267, P19349; Guo NH, 1997, J PEPT RES, V50, P210; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HEMLER ME, 1990, CELL DIFFER DEV, V32, P229, DOI 10.1016/0922-3371(90)90035-U; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Krukonis ES, 1998, J BIOL CHEM, V273, P31837, DOI 10.1074/jbc.273.48.31837; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LEGRAND C, 1992, BLOOD, V79, P1995; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; Sipes JM, 1999, J BIOL CHEM, V274, P22755, DOI 10.1074/jbc.274.32.22755; Stahl S, 1997, J CELL SCI, V110, P55; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; Weitzman JB, 1996, CELL ADHES COMMUN, V4, P41, DOI 10.3109/15419069609010762; WU CY, 1995, J CELL SCI, V108, P2511; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	41	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24080	24086		10.1074/jbc.274.34.24080	http://dx.doi.org/10.1074/jbc.274.34.24080			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446179	hybrid			2022-12-25	WOS:000082110900058
J	Olsen, DB; Stahlhut, MW; Rutkowski, CA; Schock, HB; vanOlden, AL; Kuo, LC				Olsen, DB; Stahlhut, MW; Rutkowski, CA; Schock, HB; vanOlden, AL; Kuo, LC			Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 PROTEASE; CLINICAL-TRIALS; MUTATIONS; RITONAVIR	Three high level, cross-resistant variants of the HIV-1 protease have beers analyzed for their ability to bind four protease inhibitors approved by the Food and Drug Administration (saquinavir, ritonavir, indinavir, and nelfinavir) as AIDS therapeutics. The loss in binding energy (Delta Delta G(b)) going from the wild-type enzyme to mutant enzymes ranges from 2.5 to 4.4 kcal/mol, 40-65% of which is attributed to amino acid substitutions away from the active site of the protease and not in direct contact with the inhibitor. The data suggest that non-active site changes are collectively a major contributor toward engendering resistance against the protease inhibitor and cannot be ignored when considering cross-resistance issues of drugs against the HIV-1 protease.	Merck Res Labs, Dept Antiviral Res, W Point, PA 19486 USA	Merck & Company	Olsen, DB (corresponding author), Merck Res Labs, Dept Antiviral Res, Sumneytown Pke WP26-344, W Point, PA 19486 USA.			olsen, david/0000-0001-5521-0206				Ala PJ, 1997, BIOCHEMISTRY-US, V36, P6556, DOI 10.1021/bi9750044; Boden D, 1998, ANTIMICROB AGENTS CH, V42, P2775, DOI 10.1128/AAC.42.11.2775; Carroll S. S., 1998, International Antiviral News, V6, P103; CHEN ZG, 1995, J BIOL CHEM, V270, P21433, DOI 10.1074/jbc.270.37.21942; Condra JH, 1998, DRUG RESIST UPDATE, V1, P292, DOI 10.1016/S1368-7646(98)80045-9; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; Craig C, 1998, AIDS, V12, P1611, DOI 10.1097/00002030-199813000-00007; Dulioust A, 1999, J VIROL, V73, P850, DOI 10.1128/JVI.73.1.850-854.1999; IDO E, 1991, J BIOL CHEM, V266, P24359; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Pazhanisamy S, 1996, J BIOL CHEM, V271, P17979, DOI 10.1074/jbc.271.30.17979; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Schmit JC, 1996, AIDS, V10, P995, DOI 10.1097/00002030-199610090-00010; Schock HB, 1996, J BIOL CHEM, V271, P31957, DOI 10.1074/jbc.271.50.31957; Winters MA, 1998, J VIROL, V72, P5303, DOI 10.1128/JVI.72.6.5303-5306.1998	15	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23699	23701		10.1074/jbc.274.34.23699	http://dx.doi.org/10.1074/jbc.274.34.23699			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446127	hybrid			2022-12-25	WOS:000082110900006
J	Takami, Y; Kikuchi, H; Nakayama, T				Takami, Y; Kikuchi, H; Nakayama, T			Chicken histone deacetylase-2 controls the amount of the IgM H-chain at the steps of both transcription of its gene and alternative processing of its pre-mRNA in the DT40 cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT CAUSES CHANGES; 2 MESSENGER-RNAS; TARGETED DISRUPTION; POLYADENYLATION FACTOR; GEL-ELECTROPHORESIS; PROTEIN-PATTERNS; 3' ENDS; N-COR; REPRESSION; EXPRESSION	Histone deacetylases (HDACs) are involved in the deacetylation of core histones, which is an important event in transcription regulation in eukaryotes through alterations in the chromatin structure. We cloned cDNAs and genomic DNAs encoding two chicken HDACs (chHDAC-1 and -2), which are preferentially localized in nuclei. Treatment with trichostatin A reduced the HDAC activities in immunoprecipitates obtained with anti-chHDAC-1 and -2 antisera. Using gene targeting techniques, we generated homozygous DT40 mutants, Delta chHDAC-1 and -2, devoid of two alleles of the chHDAC-1 and -2 genes, respectively. The protein patterns on two-dimensional PAGE definitely changed for Delta chH-DAC-2, and the amounts of the IgM H- and L-chains increased in it. Of the two IgM H-chain forms, the secreted form (mu s) increased in Delta chHDAC-2, but the membrane-bound form (mu m) decreased. The IgM H-chain gene was transcribed more in Delta chHDAC-2 than in DT40 cells. In the mutant, the alternative processing of IgM H-chain pre-mRNA preferentially occurred, resulting in an increase in the amount of mu s mRNA, whereas the stability of the two types of mRNA, mu s and mu m, was unchanged. In DT40 cells, treatment with trichostatin A increased both the amounts of IgM H-chain mRNAs and the switch from mu m to mu s mRNAs. Based on these results, we propose a model for a role of chHDAC-2 in both the transcription and alternative processing steps, resulting in control of the amount of the mu s IgM H-chain in the DT40 cell line.	Miyazaki Med Coll, Dept Biochem, Kiyotake, Miyazaki 8891692, Japan	University of Miyazaki	Nakayama, T (corresponding author), Miyazaki Med Coll, Dept Biochem, Kiyotake, Miyazaki 8891692, Japan.							Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALT FW, 1980, CELL, V20, P293, DOI 10.1016/0092-8674(80)90615-7; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; BEZZUBOVA O, 1997, CELL, V89, P189; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; EDWALDSGILBERT G, 1995, MOL CELL BIOL, V15, P6420; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; Guise J. W., 1989, Immunoglobulin genes., P275; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Ladomery M, 1997, GENE, V198, P275, DOI 10.1016/S0378-1119(97)00325-9; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; Martincic K, 1998, P NATL ACAD SCI USA, V95, P11095, DOI 10.1073/pnas.95.19.11095; MIYAZAKI J, 1989, GENE, V79, P269; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NAKAYAMA T, 1998, TREND COMPAR BIOCHEM, V4, P211; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PANABIERES F, 1984, BIOCHEM BIOPH RES CO, V118, P767, DOI 10.1016/0006-291X(84)91461-X; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Pennisi E, 1997, SCIENCE, V275, P155, DOI 10.1126/science.275.5297.155; PETERSON ML, 1994, HDB B T LYMPHOCYTES, P321; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; Sambrook J., 2002, MOL CLONING LAB MANU; SEGUCHI K, 1995, J MOL BIOL, V254, P869, DOI 10.1006/jmbi.1995.0662; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Takami Y, 1997, J MOL BIOL, V265, P394, DOI 10.1006/jmbi.1996.0733; Takami Y, 1997, GENES CELLS, V2, P711, DOI 10.1046/j.1365-2443.1997.1550353.x; Takami Y, 1995, J BIOL CHEM, V270, P30664, DOI 10.1074/jbc.270.51.30664; TAKAMI Y, 1995, J MOL BIOL, V250, P420, DOI 10.1006/jmbi.1995.0387; Takami Y, 1997, BBA-GENE STRUCT EXPR, V1354, P105, DOI 10.1016/S0167-4781(97)00077-8; Takami Y, 1996, DNA Res, V3, P95, DOI 10.1093/dnares/3.2.95; TAKEDA S, 1992, P NATL ACAD SCI USA, V89, P4023, DOI 10.1073/pnas.89.9.4023; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wolffe AP, 1997, GENES CELLS, V2, P291, DOI 10.1046/j.1365-2443.1997.1260323.x; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	60	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23977	23990		10.1074/jbc.274.34.23977	http://dx.doi.org/10.1074/jbc.274.34.23977			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446166	hybrid			2022-12-25	WOS:000082110900045
J	Ismail, RS; Cada, M; Vanderhyden, BC				Ismail, RS; Cada, M; Vanderhyden, BC			Transforming growth factor-beta regulates Kit ligand expression in rat ovarian surface epithelial cells	ONCOGENE			English	Article						ovary; receptor tyrosine kinase; ovulation; cytokine; cell-cell communication	FACTOR RECEPTOR EXPRESSION; LEUKEMIA INHIBITORY FACTOR; COLONY-STIMULATING FACTORS; PRIMORDIAL GERM-CELLS; MOUSE SERTOLI CELLS; C-KIT; MESSENGER-RNA; STEEL FACTOR; OOCYTE GROWTH; CANCER	In preparation for ovulation, paracrine communication between the preovulatory follicle and overlying theca/ stromal cells and ovarian surface epithelium (OSE) must take place to facilitate the degradative and apoptotic events associated with ovulation. Kit tyrosine kinase receptors and their ligand, kit ligand (KL) are expressed within ovarian follicles. and ligand-induced receptor activation appears to account for some of the cell-cell interactions important for oocyte development. We investigated the expression of Kit receptors and KL in OSE cells and the possibility that modulation of their expression could affect OSE cell activity.. KL mRNA and protein,were detected in the OSE cell layer of rat ovaries, and primary cultures of rat OSE as well as the immortalized rat OSE cell line, ROSE 199, expressed KL, but not Kit receptors, Both primary and immortalized OSE cells preferentially expressed KL-1, rather than KL-2. transcripts, suggesting that these cells produce predominantly the soluble form of KL. Activation of the cAMP signalling pathway using dibutyryl cAMP decreased proliferation of ROSE 199 cells and elicited a threefold increase in KL expression. TGF-P similarly inhibited ROSE 199 cell proliferation but strongly inhibited dibutyryl cAMP-induced KL expression, indicating that changes in KL expression were not directly associated with OSE cell proliferation. The expression of mostly soluble KL in the surface epithelium suggests that this cytokine may be acting in a paracrine fashion, perhaps interacting with nearby Kit receptor-bearing theca cells.	Univ Ottawa, Ottawa Reg Canc Ctr, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ottawa Reg Canc Ctr, Dept Med, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ottawa Reg Canc Ctr, Dept Obstet & Gynaecol, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Vanderhyden, BC (corresponding author), Univ Ottawa, Ottawa Reg Canc Ctr, Dept Cellular & Mol Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		xu, huanfang/I-4315-2012					ADAMS AT, 1981, CANCER RES, V41, P2063; ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Allard EK, 1996, BIOL REPROD, V55, P185, DOI 10.1095/biolreprod55.1.185; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P669, DOI 10.1016/S0002-9378(11)80044-X; BERCHUCK A, 1992, AM J OBSTET GYNECOL, V166, P676, DOI 10.1016/0002-9378(92)91697-9; BJERSING L, 1975, EXPERIENTIA, V31, P605, DOI 10.1007/BF01932485; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; CHEGINI N, 1992, ENDOCRINOLOGY, V130, P1707, DOI 10.1210/en.130.3.1707; Chen TC, 1998, LAB INVEST, V78, P165; DAngelo G, 1997, J CELL BIOCHEM, V67, P353, DOI 10.1002/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.3.CO;2-2; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODWIN AK, 1992, HEMATOL ONCOL CLIN N, V6, P829; HEINRICH MC, 1995, BLOOD, V85, P1769, DOI 10.1182/blood.V85.7.1769.bloodjournal8571769; HORIE K, 1991, BIOL REPROD, V45, P547, DOI 10.1095/biolreprod45.4.547; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Ismail RS, 1997, DEV BIOL, V184, P333, DOI 10.1006/dbio.1997.8531; Ismail RS, 1996, MOL REPROD DEV, V43, P458, DOI 10.1002/(SICI)1098-2795(199604)43:4&lt;458::AID-MRD8&gt;3.0.CO;2-O; JINDAL SK, 1994, GYNECOL ONCOL, V53, P17, DOI 10.1006/gyno.1994.1080; JULIAN C G, 1974, Clinical Obstetrics and Gynecology, V17, P241, DOI 10.1097/00003081-197403000-00019; KARLAN BY, 1995, GYNECOL ONCOL, V59, P67, DOI 10.1006/gyno.1995.1269; KRUK PA, 1994, IN VITRO CELL DEV-AN, V30A, P217; LAMMIE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1417, DOI 10.1177/42.11.7523489; LIDOR YJ, 1993, EXP CELL RES, V207, P332, DOI 10.1006/excr.1993.1200; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MEKORI YA, 1994, J IMMUNOL, V153, P2194; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MOTRO B, 1993, DEV DYNAM, V197, P69, DOI 10.1002/aja.1001970107; Murdoch WJ, 1996, BIOL REV, V71, P529, DOI 10.1111/j.1469-185X.1996.tb01283.x; MURPHY ED, 1972, J NATL CANCER I, V48, P1283; NICOSIA SV, 1985, INT J GYNECOL PATHOL, V4, P58, DOI 10.1097/00004347-198501000-00005; NISHINA Y, 1992, EXP CELL RES, V198, P352, DOI 10.1016/0014-4827(92)90390-T; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OGAWA K, 1995, BLOOD, V85, P1496, DOI 10.1182/blood.V85.6.1496.bloodjournal8561496; OSTERHOLZER HO, 1985, BIOL REPROD, V33, P247, DOI 10.1095/biolreprod33.1.247; PACKER AI, 1994, DEV BIOL, V161, P194, DOI 10.1006/dbio.1994.1020; Parrott JA, 1997, ENDOCRINOLOGY, V138, P3819, DOI 10.1210/en.138.9.3819; PESCE M, 1993, DEVELOPMENT, V118, P1089; Ramsfjell V, 1997, J IMMUNOL, V158, P5169; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; RODRIGUEZ GC, 1991, AM J OBSTET GYNECOL, V164, P745, DOI 10.1016/0002-9378(91)90508-O; ROSSI P, 1991, BIOCHEM BIOPH RES CO, V176, P910, DOI 10.1016/S0006-291X(05)80272-4; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; Sambrook J., 2002, MOL CLONING LAB MANU; SKINNER MK, 1987, ENDOCRINOLOGY, V121, P786, DOI 10.1210/endo-121-2-786; Tisdall DJ, 1997, J MOL ENDOCRINOL, V18, P127, DOI 10.1677/jme.0.0180127; Tortora G, 1997, CANCER RES, V57, P5107; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; Vadiveloo PK, 1996, ONCOGENE, V13, P599; VIGNE JL, 1994, BIOL REPROD, V51, P1213, DOI 10.1095/biolreprod51.6.1213; Zheng WX, 1996, AM J PATHOL, V148, P47; ZILTENER HJ, 1993, BIOL REPROD, V49, P635, DOI 10.1095/biolreprod49.3.635	53	15	16	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4734	4741		10.1038/sj.onc.1202865	http://dx.doi.org/10.1038/sj.onc.1202865			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467421				2022-12-25	WOS:000082154400011
J	Phalipou, S; Seyer, R; Cotte, N; Breton, C; Barberis, C; Hibert, M; Mouillac, B				Phalipou, S; Seyer, R; Cotte, N; Breton, C; Barberis, C; Hibert, M; Mouillac, B			Docking of linear peptide antagonists into the human V-1a vasopressin receptor - Identification of binding domains by photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MOLECULAR-CLONING; N-ETHYLMALEIMIDE; V1A RECEPTOR; AGONIST; LIGAND; SITE; EXPRESSION; RESIDUE; SELECTIVITY	A novel photoactivatable linear peptide antagonist selective for the V-1a vasopressin receptor, [I-125][Lys(3N(3) Phpa)(8)]HO-LVA, was synthesized, characterized, and used to photolabel the human receptor expressed in Chinese hamster ovary cells. Two specific glycosylated protein species at 85-90 and 46 kDa were covalently labeled, a result identical to that obtained with a previous photosensitive ligand, [I-125]3N(3)Phpa-LVA (Phalipou, S., Cotte, N,, Carnazzi, E., Seyer, R., Mahe, E., Jard, S., Barberis, C., and Mouillac, B, (1997) J. Biol. Chem. 272, 26536-26544). To identify contact sites between the new photoreactive analogue and the V-1a receptor, the labeled receptors were digested with Lys-C or Asp-N endoproteinases and chemically cleaved with CNBr. Fragmentation with CNBr, Lyc-C, and Asp N used alone or in combination, led to the identification of a restricted receptor region spanning the first extracellular loop. The results established that sequence Asp(112)-Pro(120) could be considered as the smallest covalently labeled fragment with [I-125][LyS(3N(3)Phpa)(8)]HO-LVA. Based on the present experimental result and on previous photoaffinity labeling data obtained with [I-125]3N(3)Phpa-LVA (covalent attachment to transmembrane domain W), three-dimensional models of the antagonist-bound receptors were constructed and then verified by site-directed mutagenesis studies. Strikingly, these two linear peptide antagonists, when bound to the V-1a receptor, could adopt a pseudocyclic conformation similar to that of the cyclic agonists. Despite divergent functional properties, these peptide antagonists could interact with a transmembrane binding site significantly overlapping that of the natural hormone vasopressin.	U469 INSERM, F-34094 Montpellier 5, France; CCIPE, UPR 9023 CNRS, F-34094 Montpellier, France; Fac Pharm, ERS 655 CNRS, F-67401 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Mouillac, B (corresponding author), U469 INSERM, 141 Rue de la Cardonille, F-34094 Montpellier 5, France.		MOUILLAC, Bernard/M-3896-2014	MOUILLAC, Bernard/0000-0002-3906-8673				BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; Carnazzi E, 1997, EUR J BIOCHEM, V247, P906, DOI 10.1111/j.1432-1033.1997.00906.x; CARNAZZI E, 1994, J MED CHEM, V37, P1841, DOI 10.1021/jm00038a013; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; Cotte N, 1998, J BIOL CHEM, V273, P29462, DOI 10.1074/jbc.273.45.29462; Dong MQ, 1999, J BIOL CHEM, V274, P4778, DOI 10.1074/jbc.274.8.4778; Durroux T, 1999, J MED CHEM, V42, P1312, DOI 10.1021/jm9804782; Girault S, 1996, EUR J BIOCHEM, V240, P215, DOI 10.1111/j.1432-1033.1996.0215h.x; GOPALAKRISHNAN V, 1988, ENDOCRINOLOGY, V123, P922, DOI 10.1210/endo-123-2-922; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; JI H, 1994, J BIOL CHEM, V269, P16533; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; KASSIS S, 1984, J BIOL CHEM, V259, P4910; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; KOTZYBAHIBERT F, 1995, ANGEW CHEM INT EDIT, V34, P1296, DOI 10.1002/anie.199512961; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JA, 1994, P NATL ACAD SCI USA, V91, P7164, DOI 10.1073/pnas.91.15.7164; MANNING M, 1992, INT J PEPT PROT RES, V40, P261; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Park C, 1996, BIOCHEMISTRY-US, V35, P9807, DOI 10.1021/bi9602223; PAVO I, 1990, FEBS LETT, V272, P205, DOI 10.1016/0014-5793(90)80485-2; Phalipou S, 1997, J BIOL CHEM, V272, P26536, DOI 10.1074/jbc.272.42.26536; Postina R, 1996, J BIOL CHEM, V271, P31593, DOI 10.1074/jbc.271.49.31593; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SEYER R, 1990, J CHEM SOC PERK T 1, P3289, DOI 10.1039/p19900003289; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; TURCATTI G, 1995, BIOCHEMISTRY-US, V34, P3972, DOI 10.1021/bi00012a015; UFER E, 1995, FEBS LETT, V362, P19, DOI 10.1016/0014-5793(95)00150-8; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S	42	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23316	23327		10.1074/jbc.274.33.23316	http://dx.doi.org/10.1074/jbc.274.33.23316			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438508	hybrid			2022-12-25	WOS:000082012800058
J	Zuckerman, JB; Chen, XY; Jacobs, JD; Hu, BF; Kleyman, TR; Smith, PR				Zuckerman, JB; Chen, XY; Jacobs, JD; Hu, BF; Kleyman, TR; Smith, PR			Association of the epithelial sodium channel with Apx and alpha-spectrin in A6 renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; LIDDLES-SYNDROME; APICAL MEMBRANE; XENOPUS-LAEVIS; BETA-SUBUNIT; K+ CHANNEL; STOICHIOMETRY; CYTOSKELETON; PROTEIN; NA+,K+-ATPASE	Recent molecular cloning of the epithelial sodium channel (ENaC) provides the opportunity to identify ENaC-associated proteins that function in regulating its cell surface expression and activity. We have examined whether ENaC is associated with Apr (apical protein Xenopus) and the spectrin-based membrane cytoskeleton in Xenopus A6 renal epithelial cells. We have also addressed whether Apr is required for the expression of amiloride-sensitive Na+ currents by cloned ENaC, Sucrose density gradient centrifugation of A6 cell detergent extracts showed co-sedimentation of xENaC, alpha-spectrin, and Apr. Immunoblot analysis of proteins co-immunoprecipitating under high stringency conditions from peak Xenopus ENaC/Apx-containing gradient fractions indicate that ENaC, Apr, and alpha-spectrin are associated in a macromolecular complex. To examine whether Apr is required for the functional expression of ENaC, alpha beta gamma mENaC cRNAs were coinjected into Xenopus oocytes with Apr sense or antisense oligodeoxynucleotides. The two-electrode voltage clamp technique showed there was a marked reduction in amiloride-sensitive current in oocytes coinjected with antisense oligonucleotides when to compared with oocytes coinjected with sense oligonucleotides. These studies indicate that ENaC is associated in a macromolecular complex with Apr and alpha-spectrin in A6 cells and suggest that Apr is required for the functional expression of ENaC in Xenopus epithelia.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Med Coll Penn & Hahnemann Univ, Dept Physiol, Philadelphia, PA 19129 USA	University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Drexel University	Smith, PR (corresponding author), Univ Alabama, Dept Physiol & Biophys, 1918 Univ Blvd, Birmingham, AL 35294 USA.		Zuckerman, Jonathan/AAU-1857-2020	Zuckerman, Jonathan/0000-0002-8190-9210	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK051391, R01DK051391, R01DK046705] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 59596, DK 51391, DK 46705] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BENOS DJ, 1986, P NATL ACAD SCI USA, V83, P8525, DOI 10.1073/pnas.83.22.8525; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Caplan MJ, 1997, AM J PHYSIOL-GASTR L, V272, pG1304, DOI 10.1152/ajpgi.1997.272.6.G1304; Cheng C, 1998, J BIOL CHEM, V273, P22693, DOI 10.1074/jbc.273.35.22693; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; EATON DC, 1995, KIDNEY INT, V48, P941, DOI 10.1038/ki.1995.375; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Gee SH, 1998, J NEUROSCI, V18, P128; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HAYS RM, 1994, AM J PHYSIOL-CELL PH, V267, pC1507, DOI 10.1152/ajpcell.1994.267.6.C1507; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Kieber-Emmons T, 1999, J BIOL CHEM, V274, P9648, DOI 10.1074/jbc.274.14.9648; KLEYMAN TR, 1991, J BIOL CHEM, V266, P3907; KLEYMAN TR, 1994, AM J PHYSIOL, V266, pF506, DOI 10.1152/ajprenal.1994.266.3.F506; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; May A, 1997, J AM SOC NEPHROL, V8, P1813; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1992, CELL CELL INTERACTIO, P227; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Prat AG, 1996, J BIOL CHEM, V271, P18045, DOI 10.1074/jbc.271.30.18045; Prince LS, 1998, BIOCHEM J, V336, P705, DOI 10.1042/bj3360705; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SARIBANSOHRABY S, 1986, BIOCHEMISTRY-US, V25, P4639, DOI 10.1021/bi00364a028; SCHIAFFINO MV, 1995, HUM MOL GENET, V4, P373, DOI 10.1093/hmg/4.3.373; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Smith PR, 1997, AM J PHYSIOL-CELL PH, V272, pC1295, DOI 10.1152/ajpcell.1997.272.4.C1295; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SMITH PR, 1995, J MEMBRANE BIOL, V147, P195; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; STONER LC, 1995, J MEMBRANE BIOL, V144, P147; TOKUNAGA M, 1979, EUR J BIOCHEM, V95, P441, DOI 10.1111/j.1432-1033.1979.tb12983.x; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	45	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23286	23295		10.1074/jbc.274.33.23286	http://dx.doi.org/10.1074/jbc.274.33.23286			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438504	hybrid			2022-12-25	WOS:000082012800054
J	Wu, Y; Ma, GZ; Lu, D; Lin, F; Xu, HJ; Liu, JX; Arlinghaus, RB				Wu, Y; Ma, GZ; Lu, D; Lin, F; Xu, HJ; Liu, JX; Arlinghaus, RB			Bcr: a negative regulator of the Bcr-Abl oncoprotein	ONCOGENE			English	Article						Bcr; Bcr-Abl; Bcr-Abl inhibitor; tyrosine kinase	TYROSINE PHOSPHORYLATION; CELL-LINES; C-ABL; KINASE; SEQUENCES; PROTEIN; ACTIVATION; ONCOGENE; DOMAIN; EXPRESSION	Chronic myelogenous leukemia is typically characterized by the presence of the Philadelphia chromosome (Ph) in which 5' portions of the BCR gene are fused to a large portion of the ABL gene. Our studies and those of others indicate that Bcr sequences within the Bcr-Abl oncoprotein are critically involved in activating the Abl tyrosine kinase and actively participate in the oncogenic response, which is generated by the Bcr-Abl oncoprotein, We investigated the role of the Bcr protein in the oncogenic effects of Bcr-Abl. Reduction of the level of the Bcr protein by incubating cells with a 3' BCR anti-sense oligodeoxynucleotide increased the growth rate and survival of hematopoietic cell lines expressing Bcr-Abl. Also, enforced expression of Bcr in Bcr-Abl cell lines strongly reduced transformation efficiency. Induction of Bcr expression drastically reduced the phosphotyrosine content of Bcr-Abl in Rat-1 fibroblasts transformed by P185 BCR-ABL and in hematopoietic cells expressing P210 Bcr-Abl within days following induction of Bcr. Rat-1/P185 cells maintained for three weeks after Bcr induction had dramatically reduced amounts of phosphotyrosine proteins compared to cells in which Bcr expression was repressed by the addition of Tet. In contrast Bcr expression did not decrease the phosphotyrosine content of either v-Src or activated Neu tyrosine kinase. Importantly, the phosphotyrosine content of total P160 BCR (induced plus endogenous) was strongly reduced by inducing expression of Bcr, indicating that the induced Bcr protein was not a target of the tyrosine kinase activity of Bcr-Abl but instead functioned as an inhibitor of Bcr-Abl, These results show that the Bcr protein can function as a negative regulator of Bcr-Abl, but that the inhibitory effects of Bcr are dependent on achieving an elevated level of Bcr expression relative to Bcr-Abl.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA49639, CA65611, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065611, P01CA049639, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; GARCIA R, 1991, ONCOGENE, V6, P1983; Hu SX, 1997, CANCER RES, V57, P3339; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; Li JZ, 1996, J BIOL CHEM, V271, P32930, DOI 10.1074/jbc.271.51.32930; Liu JX, 1996, CANCER RES, V56, P5120; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MARU Y, 1995, MOL CELL BIOL, V15, P835; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAUMOVSKI L, 1988, CANCER RES, V48, P2876; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RON D, 1991, NEW BIOL, V3, P372; SIRARD C, 1994, BLOOD, V83, P1575; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; Voncken JW, 1998, ONCOGENE, V16, P2029, DOI 10.1038/sj.onc.1201730; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524	26	31	32	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4416	4424		10.1038/sj.onc.1202828	http://dx.doi.org/10.1038/sj.onc.1202828			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442632				2022-12-25	WOS:000081813500003
J	Klugbauer, S; Rabes, HM				Klugbauer, S; Rabes, HM			The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas	ONCOGENE			English	Article						Chernobyl; dimerization domain; new RET rearrangements; RT-PCR; transcriptional regulatory proteins	CHERNOBYL REACTOR ACCIDENT; NUCLEAR RECEPTORS; RET/PTC1 ONCOGENE; REARRANGEMENT; CHILDREN; PROTOONCOGENE; EXPRESSION; ACTIVATION; GENE; CANCER	Children exposed to radioactive iodine as a consequence of the Chernobyl reactor accident ha ce an increased risk of papillary thyroid carcinomas (PTC), The predominant molecular lesions in these tumors are rearrangements of the RET receptor tyrosine kinase (tk), Here me report on two novel types of RET rearrangement, PTC6 and 7, and describe the fusion products and the ret fused gene (rfg) proteins, Like the other rfg proteins identified so far they are ubiquitously expressed, not membrane-bound and contain coiled coil domains required for constitutive activation of the ret tk domain. In the PTC6 rearrangement the ret tk domain is fused to the aminoterminal part of the human transcription intermediary factor htif 1, In the PTC7 rearrangement the ret tk domain is fused to a novel protein that is strongly related to htif1, Like htif1 it contains a RBCC motif (ring finger, B boxes, coiled coil domain) located in the aminoterminal part and a phd finger and a bromodomain in the carboxyterminal part. Htif1 and related proteins are transcription coactivators for nuclear receptors, thus participating in controlling cellular development, differentiation and homeostasis, This is the first report on their involvement in human thyroid carcinogenesis.	Univ Munich, Inst Pathol, D-80337 Munich, Germany	University of Munich	Rabes, HM (corresponding author), Univ Munich, Inst Pathol, Thalkirchner Str 36, D-80337 Munich, Germany.							Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; Fugazzola L, 1996, ONCOGENE, V13, P1093; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1996, ONCOGENE, V13, P1099; Klugbauer S, 1995, ONCOGENE, V11, P2459; Klugbauer S, 1998, ONCOGENE, V16, P671, DOI 10.1038/sj.onc.1201526; Klugbauer S, 1998, CANCER RES, V58, P198; KUNIEDA T, 1991, GENE, V107, P323, DOI 10.1016/0378-1119(91)90334-8; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEHRACH H., 1990, GENOME ANAL, P39; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Nikiforov YE, 1997, CANCER RES, V57, P1690; Rabes H M, 1997, Verh Dtsch Ges Pathol, V81, P139; Rabes HM, 1998, RECENT RES CANCER, V154, P248; Sagartz JE, 1997, LAB INVEST, V76, P307; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; Tong Q, 1997, J BIOL CHEM, V272, P9043; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	35	139	158	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4388	4393		10.1038/sj.onc.1202824	http://dx.doi.org/10.1038/sj.onc.1202824			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439047				2022-12-25	WOS:000081732700012
J	Umikawa, M; Obaishi, H; Nakanishi, H; Satoh-Horikawa, K; Takahashi, K; Hotta, I; Matsuura, Y; Takai, Y				Umikawa, M; Obaishi, H; Nakanishi, H; Satoh-Horikawa, K; Takahashi, K; Hotta, I; Matsuura, Y; Takai, Y			Association of frabin with the actin cytoskeleton is essential for microspike formation through activation of Cdc42 small G protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; BINDING PROTEIN; RHO-FAMILY; KINASE; INVOLVEMENT; CLEAVAGE; GTPASES; PRODUCT; FGD1; GENE	We have recently isolated a novel actin filament-binding protein, named frabin. Frabin has one actin filament-binding domain (ABD), one Dbl homology domain (DHD), first pleckstrin homology domains (PHD) adjacent to DHD, one cysteine rich-domain (CRD), and second PHD from the N terminus to the C terminus in this order. Full-length frabin induces microspike formation and c-Jun N-terminal kinase (JNK) activation. We found here that the fragment of frabin containing DHD and first PHD stimulated guanine nucleotide exchange of Cdc42Hs small G protein, but not that of RhoA or Rad small G protein. However, this fragment of frabin did not induce microspike formation, and ABD was additionally necessary for microspike formation. Frabin having ABD was associated with the actin cytoskeleton, whereas frabin lacking ABD was diffusely distributed in the cytoplasm, in contrast, ABD was not necessary for JNK activation but CRD and second PHD were additionally necessary for this activation. These results indicate that the association of frabin with the actin cytoskeleton is essential for microspike formation but not for JNK activation and that different domains of frabin are involved in microspike formation and JNK activation through Cdc42 activation.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, ERATO, Takai Biotimer Project, JCR Pharmaceut Co Ltd,Nishi Ku, Kobe, Hyogo 6512241, Japan; Natl Inst Infect Dis, Dept Virol 2, Tokyo 1628640, Japan	Osaka University; Japan Science & Technology Agency (JST); National Institute of Infectious Diseases (NIID)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan.			Nakanishi, Hiroyuki/0000-0002-9765-0266				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nagata K, 1998, J BIOL CHEM, V273, P15453, DOI 10.1074/jbc.273.25.15453; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; PASTERIS NG, 1994, CELL, V79, P669; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Sambrook J., 2002, MOL CLONING LAB MANU; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169	22	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25197	25200		10.1074/jbc.274.36.25197	http://dx.doi.org/10.1074/jbc.274.36.25197			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464238	hybrid			2022-12-25	WOS:000082554200003
J	Bolhuis, A; Matzen, A; Hyyrylainen, HL; Kontinen, VP; Meima, R; Chapuis, J; Venema, G; Bron, S; Freudl, R; van Dijl, JM				Bolhuis, A; Matzen, A; Hyyrylainen, HL; Kontinen, VP; Meima, R; Chapuis, J; Venema, G; Bron, S; Freudl, R; van Dijl, JM			Signal peptide peptidase- and ClpP-like proteins of Bacillus subtilis required for efficient translocation and processing of secretory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPORALLY CONTROLLED EXPRESSION; DEGRADATIVE ENZYME-SYNTHESIS; ESCHERICHIA-COLI; PROTEASE-IV; MEMBRANE-PROTEIN; CYTOPLASMIC MEMBRANE; ANTIGEN PRESENTATION; MOLECULAR-CLONING; SPPA GENE; SEQUENCE	Signal peptides direct the export of secretory proteins from the cytoplasm, After processing by signal peptidase, they are degraded in the membrane and cytoplasm. The resulting fragments can have signaling functions. These observations suggest important roles for signal peptide peptidases. The present studies show that the Gram-positive eubacterium Bacillus subtilis contains two genes for proteins, denoted SppA and TepA, with similarity to the signal peptide peptidase A of Escherichia coli, Notably, TepA also shows similarity to ClpP proteases, SppA of B. subtilis was only required for efficient processing of pre-proteins under conditions of hyper-secretion. In contrast, TepA depletion had a strong effect on pre-protein translocation across the membrane and subsequent processing, not only under conditions of hyper-secretion. Unlike SppA, which is a typical membrane protein, TepA appears to have a cytosolic localization, which is consistent with the observation that TepA is involved in early stages of the secretion process. Our observations demonstrate that SppA and TepA have a role in protein secretion in B, subtilis. Based on their similarity to known proteases, it seems likely that SppA and TepA are specifically required for the degradation of proteins or (signal) peptides that are inhibitory to protein translocation.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany; Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9751 NN Haren, Netherlands; Natl Publ Hlth Inst, Lab Vaccine Dev, FIN-00300 Helsinki, Finland; INRA, Lab Genet Microbienne, F-78352 Jouy En Josas, France	Helmholtz Association; Research Center Julich; University of Groningen; Finland National Institute for Health & Welfare; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Freudl, R (corresponding author), Forschungszentrum Julich, Inst Biotechnol 1, Postfach 1913, D-52425 Julich, Germany.	r.freudl@fz-juelich.de	Bolhuis, Albert/E-9932-2010; van Dijl, Jan Maarten/G-1205-2013; Freudl, Roland/N-4179-2017; Kontinen, Vesa P/A-2260-2012	Bolhuis, Albert/0000-0001-9307-0515; Freudl, Roland/0000-0003-0743-1279; 				Bolhuis A, 1996, MOL MICROBIOL, V22, P605, DOI 10.1046/j.1365-2958.1996.d01-4676.x; Bolhuis A, 1998, J BIOL CHEM, V273, P21217, DOI 10.1074/jbc.273.33.21217; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; CONLIN CA, 1993, J BACTERIOL, V175, P5731, DOI 10.1128/JB.175.17.5731-5732.1993; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; DALBEY RE, 1994, SIGNAL PEPTIDASES, P5; DRIESSEN AJM, 1994, J MEMBRANE BIOL, V142, P145; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferrari Eugenio, 1993, P917; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; Herbort M, 1999, J BACTERIOL, V181, P493, DOI 10.1128/JB.181.2.493-500.1999; HOMBACH J, 1995, J EXP MED, V182, P1615, DOI 10.1084/jem.182.5.1615; Huang XJ, 1999, MOL MICROBIOL, V31, P361, DOI 10.1046/j.1365-2958.1999.01180.x; HUSSAIN M, 1982, EUR J BIOCHEM, V129, P233, DOI 10.1111/j.1432-1033.1982.tb07044.x; ICHIHARA S, 1986, J BIOL CHEM, V261, P9405; ICHIHARA S, 1984, J BIOL CHEM, V259, P9853; JACOBS M, 1993, MOL MICROBIOL, V8, P957, DOI 10.1111/j.1365-2958.1993.tb01640.x; Jander G, 1996, J BACTERIOL, V178, P3049, DOI 10.1128/jb.178.11.3049-3058.1996; Kim L, 1996, GENE, V181, P71, DOI 10.1016/S0378-1119(96)00466-0; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; KONTINEN VP, 1988, J GEN MICROBIOL, V134, P2333; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KUNST F, 1995, J BACTERIOL, V177, P2403, DOI 10.1128/jb.177.9.2403-2407.1995; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Lory S, 1994, SIGNAL PEPTIDASES, P31; Martoglio B, 1997, EMBO J, V16, P6636, DOI 10.1093/emboj/16.22.6636; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; Meens J, 1997, APPL ENVIRON MICROB, V63, P2814, DOI 10.1128/AEM.63.7.2814-2820.1997; Miller J. H., 1982, EXPT MOL GENETICS; Msadek T, 1998, MOL MICROBIOL, V27, P899, DOI 10.1046/j.1365-2958.1998.00735.x; NOVAK P, 1986, J BIOL CHEM, V261, P420; NOVAK P, 1988, J BACTERIOL, V170, P5067, DOI 10.1128/jb.170.11.5067-5075.1988; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sambrook F., 1989, MOL CLONING LAB MANU; SANKARAN K, 1994, SIGNAL PEPTIDASES, P17; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; SUZUKI T, 1987, J BACTERIOL, V169, P2523, DOI 10.1128/jb.169.6.2523-2528.1987; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WICKNER W, 1987, J BACTERIOL, V169, P3821, DOI 10.1128/jb.169.8.3821-3822.1987	52	65	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24585	24592		10.1074/jbc.274.35.24585	http://dx.doi.org/10.1074/jbc.274.35.24585			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455123	hybrid			2022-12-25	WOS:000082193400022
J	Koga, H; Terasawa, H; Nunoi, H; Takeshige, K; Inagaki, F; Sumimoto, H				Koga, H; Terasawa, H; Nunoi, H; Takeshige, K; Inagaki, F; Sumimoto, H			Tetratricopeptide repeat (TPR) motifs of p67(phox) participate in interaction with the small GTPase Rac and activation of the phagocyte NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; SRC HOMOLOGY-3 DOMAINS; CELL-FREE SYSTEM; PROTEIN PHOSPHATASE-5; SUPEROXIDE PRODUCTION; BINDING PROTEIN; SH3 DOMAIN; TARGET PROTEINS; RHO-GTPASES	The small GTPase Rac functions as a molecular switch in several important cellular events including cytoskeletal reorganization and activation of the phagocyte NADPH oxidase, the latter of which leads to production of superoxide, a precursor of microbicidal oxidants. During formation of the active oxidase complex at the membrane, the GTP-bound Rac appears to interact with the N-terminal region of p67(phox), another indispensable activator that translocates from the cytosol upon phagocyte stimulation. Here we show that the p67(phox) N terminus lacks the CRIB motif, a well known Rac target, but contains four tetratricopeptide repeat (TPR) motifs with highly alpha-helical structure. Disruption of any of the N-terminal three TPRs, but the last one, results in defective interaction with Rac, while all the four are required for the NADPH oxidase activation. We also find that Arg-102 in the third repeat is likely involved in binding to Rac via an ionic interaction, and that replacement of this residue with Glu completely abrogates the capability of activating the oxidase both in vivo and in vitro, Thus the TPR motifs of p67(phox) are packed to function as a Rac target, thereby playing a crucial role in the active oxidase complex formation.	Kyushu Univ, Grad Sch Med Sci, Dept Biol Mol & Struct, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Sch Med, Dept Biochem, Fukuoka 8128582, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Physiol, Tokyo 1138613, Japan; Japan Sci & Technol Corp, CREST, Kumamoto 8608556, Japan; Kumamoto Univ, Sch Med, Dept Pediat, Kumamoto 8608556, Japan	Kyushu University; Kyushu University; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST); Kumamoto University	Sumimoto, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Biol Mol & Struct, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Ahmed S, 1998, J BIOL CHEM, V273, P15693, DOI 10.1074/jbc.273.25.15693; Bomer U, 1996, FEBS LETT, V382, P153, DOI 10.1016/0014-5793(96)00156-1; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DEBOER M, 1994, BLOOD, V83, P531, DOI 10.1182/blood.V83.2.531.bloodjournal832531; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; FINAN P, 1994, J BIOL CHEM, V269, P13752; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; Gale M, 1996, MOL CELL BIOL, V16, P4172; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Hata K, 1997, BIOCHEM BIOPH RES CO, V241, P226, DOI 10.1006/bbrc.1997.7807; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; Iwata M, 1998, HUM GENET, V103, P419, DOI 10.1007/s004390050844; JONES OTG, 1994, BIOESSAYS, V16, P919, DOI 10.1002/bies.950161211; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Kyrpides NC, 1998, TRENDS BIOCHEM SCI, V23, P245, DOI 10.1016/S0968-0004(98)01228-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Leusen JHW, 1996, J EXP MED, V184, P1243, DOI 10.1084/jem.184.4.1243; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mizuki K, 1998, EUR J BIOCHEM, V251, P573, DOI 10.1046/j.1432-1327.1998.2510573.x; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; NAKAMURA M, 1987, BLOOD, V69, P1404; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; Patino P. J., 1996, Blood, V88, p622A; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Roos D, 1996, BLOOD, V87, P1663; SIKORSKI RS, 1993, MOL CELL BIOL, V13, P1212, DOI 10.1128/MCB.13.2.1212; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; SMITH RL, 1995, GENE DEV, V9, P2903, DOI 10.1101/gad.9.23.2903; SUGIMOTO Y, 1994, BIO-TECHNOL, V12, P694, DOI 10.1038/nbt0794-694; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Sumimoto H, 1997, MEMBRANE PROTEINS - STRUCTURE, FUNCTION AND EXPRESSION CONTROL: INTERNATIONAL SYMPOSIUM, P235; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; XU XM, 1994, J BIOL CHEM, V269, P23569; YANG JT, 1986, METHOD ENZYMOL, V130, P208	59	182	189	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25051	25060		10.1074/jbc.274.35.25051	http://dx.doi.org/10.1074/jbc.274.35.25051			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455184	hybrid			2022-12-25	WOS:000082193400083
J	Leppanen, A; Mehta, P; Ouyang, YB; Ju, TZ; Helin, J; Moore, KL; van Die, I; Canfield, WM; McEver, RP; Cummings, RD				Leppanen, A; Mehta, P; Ouyang, YB; Ju, TZ; Helin, J; Moore, KL; van Die, I; Canfield, WM; McEver, RP; Cummings, RD			A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte adhesion to P-selectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN LIGAND-1 PSGL-1; TYROSYLPROTEIN SULFOTRANSFERASE; FUNCTIONAL-CHARACTERIZATION; FUCOSYL-TRANSFERASE; EXPRESSION CLONING; TYROSINE SULFATION; MOLECULAR-CLONING; PRECURSOR PROTEIN; HUMAN NEUTROPHILS; KINETIC-ANALYSIS	P-selectin glycoprotein ligand-1 (PSGL-1) is a dimeric membrane mucin on leukocytes that binds selectins, The molecular features of PSGL-1 that determine this high affinity binding are unclear. Here we demonstrate the in vitro synthesis of a novel glycosulfopeptide (GSP-6) modeled after the extreme N terminus of PSGL-1, which has been predicted to be important for P-selectin binding, GSP-6 contains three tyrosine sulfate (TyrSO(3)) residues and a monosialylated, core 2-based O-glycan with a sialyl Lewis x (C2-O-sLe(x) motif at a specific Thr residue. GSP-6 binds tightly to immobilized P-selectin, whereas glycopeptides lacking either TyrSO(3) or C2-O-sLe(x) do not detectably bind. Remarkably, an isomeric glycosulfopeptide to GSP-6, termed GSP-6', which contains sLe(x) on an extended core 1-based O-glycan, does not bind immobilized P-selectin, Equilibrium gel filtration analysis revealed that GSP-6 binds to soluble P-selectin with a K-d of similar to 350 nM. GSP-6 (<5 mu M) substantially inhibits neutrophil adhesion to P-selectin in vitro, whereas free sLe(x) (5 mM) only slightly inhibits adhesion. In contrast to the inherent heterogeneity of post-translational modifications of recombinant proteins, glycosulfopeptides permit the placement of sulfate groups and glycans of precise structure at defined positions on a polypeptide, This approach should expedite the probing of structure-function relationships in sulfated and glycosylated proteins, and may facilitate development of novel drugs to treat inflammatory diseases involving P-selectin-mediated leukocyte adhesion.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Vrije Univ Amsterdam, Dept Med Chem, NL-1081 Amsterdam, Netherlands; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; Vrije Universiteit Amsterdam; University of Helsinki	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th St,BRC417, Oklahoma City, OK 73104 USA.	richard-cummings@ouhsc.edu			NHLBI NIH HHS [P01 HL54804] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackers G K, 1973, Methods Enzymol, V27, P441; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BLIXT O, 1999, IN PRESS GLYCOBIOLOG; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; Britten CJ, 1998, GLYCOBIOLOGY, V8, P321, DOI 10.1093/glycob/8.4.321; CECCONI O, 1994, J BIOL CHEM, V269, P15060; CUMMINGS RD, 1992, BIOESSAYS, V14, P849, DOI 10.1002/bies.950141210; DAMLE NK, 1992, EUR J IMMUNOL, V22, P1789, DOI 10.1002/eji.1830220718; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Fujimoto TT, 1996, INT J HEMATOL, V64, P231; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hanisch FG, 1999, J BIOL CHEM, V274, P9946, DOI 10.1074/jbc.274.15.9946; Hindsgaul O, 1999, ESSENTIALS GLYCOBIOL; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Kumar A, 1999, CIRCULATION, V99, P1363, DOI 10.1161/01.CIR.99.10.1363; Kumar R, 1996, BLOOD, V88, P3872, DOI 10.1182/blood.V88.10.3872.bloodjournal88103872; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; Lowe JB, 1997, KIDNEY INT, V51, P1418, DOI 10.1038/ki.1997.194; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; Mehta P, 1997, BLOOD, V90, P2381, DOI 10.1182/blood.V90.6.2381.2381_2381_2389; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; MELDAL M, 1994, INT J PEPT PROT RES, V43, P529; Moini M, 1998, J AM SOC MASS SPECTR, V9, P977, DOI 10.1016/S1044-0305(98)00079-8; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NELSON RM, 1993, BLOOD, V82, P3253; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; Ouyang YB, 1998, J BIOL CHEM, V273, P24770, DOI 10.1074/jbc.273.38.24770; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; Patel KD, 1995, J CELL BIOL, V131, P1893, DOI 10.1083/jcb.131.6.1893; POLLEXKRUGER A, 1993, GLYCOCONJUGATE J, V10, P365, DOI 10.1007/BF00731042; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA M, 1993, BIOCHEM BIOPH RES CO, V193, P337, DOI 10.1006/bbrc.1993.1629; Scalia R, 1999, CIRC RES, V84, P93; Scalia R, 1999, J EXP MED, V189, P931, DOI 10.1084/jem.189.6.931; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; Snapp KR, 1998, J CELL BIOL, V142, P263, DOI 10.1083/jcb.142.1.263; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; Wagers AJ, 1998, J IMMUNOL, V160, P5122; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yang J, 1999, THROMB HAEMOSTASIS, V81, P1; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	67	177	192	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24838	24848		10.1074/jbc.274.35.24838	http://dx.doi.org/10.1074/jbc.274.35.24838			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455156	hybrid			2022-12-25	WOS:000082193400055
J	Sytkowski, AJ; Lunn, ED; Risinger, MA; Davis, KL				Sytkowski, AJ; Lunn, ED; Risinger, MA; Davis, KL			An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; RECEPTOR MESSENGER-RNA; ENDOTHELIAL-CELLS; STRUCTURAL ROLE; AMINO-ACIDS; SITE; MUTAGENESIS; EXPRESSION; PEGYLATION; PEPTIDE	The hematopoietic growth factor erythropoietin (Epo) initiates its intracellular signaling cascade by binding to and inducing the homodimerization of two identical receptor molecules, We have now constructed and expressed in COS cells a cDNA encoding a fusion protein consisting of two complete human Epo domains linked in tandem by a 17-amino acid flexible peptide. On SDS-polyacrylamide gel electrophoresis, the Epo-Epo fusion protein migrated as a broad band with an average apparent molecular mass of 76 kDa, slightly more than twice the average apparent molecular mass of Epo, 37 kDa, Enzymatic N-deglycosylation resulted in an Epo-Epo species that migrated on SDS-polyacrylamide gel electrophoresis as a narrow band with an average apparent molecular mass of 39 kDa, The specific activity of the Epo-Epo fusion protein in vitro (1,007 IU/mu g; 76 IU/pmol) was significantly greater than that of Epo (352 IU/mu g; 13 IU/pmol). Moreover, secretion of Epo-Epo by COS cells was 8-fold greater than that of Epo, Subcutaneous administration of a single dose of Epo-Epo to mice resulted in a significant increase in red blood cell production within 7 days. In contrast, administration of an equivalent dose of conventional recombinant Epo was without effect. The pharmacokinetic behavior of Epo-Epo differed significantly from that of Epo, The results suggest that Epo-Epo may have important biological and therapeutic advantages.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Hematol & Oncol,Lab Cell & Mol Biol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Sytkowski, AJ (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Hematol & Oncol,Lab Cell & Mol Biol, 1 Deaconess Rd,21-27 Burlington, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038841] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38841] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; CHERN Y, 1991, EUR J BIOCHEM, V202, P225, DOI 10.1111/j.1432-1033.1991.tb16366.x; CHERN YJ, 1990, BLOOD, V76, P2204; CURTIS BM, 1991, P NATL ACAD SCI USA, V88, P5809, DOI 10.1073/pnas.88.13.5809; DELGADO C, 1992, CRIT REV THER DRUG, V9, P249; FIBI MR, 1991, BLOOD, V77, P1203; GRODBERG J, 1993, EUR J BIOCHEM, V218, P597, DOI 10.1111/j.1432-1033.1993.tb18413.x; Grodberg J, 1996, ARCH BIOCHEM BIOPHYS, V333, P427, DOI 10.1006/abbi.1996.0411; Haller H, 1996, KIDNEY INT, V50, P481, DOI 10.1038/ki.1996.339; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; KNUSLI C, 1992, BRIT J HAEMATOL, V82, P654, DOI 10.1111/j.1365-2141.1992.tb06940.x; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; MABROUK PA, 1994, BIOCONJUGATE CHEM, V5, P236, DOI 10.1021/bc00027a008; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; Mockridge JW, 1998, EUR J ENDOCRINOL, V138, P449, DOI 10.1530/eje.0.1380449; Pettit DK, 1997, J BIOL CHEM, V272, P2312; Qiu HW, 1998, J BIOL CHEM, V273, P11173, DOI 10.1074/jbc.273.18.11173; RYALL RG, 1982, ANAL BIOCHEM, V127, P308, DOI 10.1016/0003-2697(82)90178-6; SUE JM, 1983, P NATL ACAD SCI-BIOL, V80, P3651, DOI 10.1073/pnas.80.12.3651; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Sytkowski AJ, 1998, P NATL ACAD SCI USA, V95, P1184, DOI 10.1073/pnas.95.3.1184; SYTKOWSKI AJ, 1991, BIOCHEM BIOPH RES CO, V176, P698, DOI 10.1016/S0006-291X(05)80240-2; SYTKOWSKI AJ, 1985, J BIOL CHEM, V260, P4727; TAKEUCHI M, 1990, J BIOL CHEM, V265, P12127; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TSUDA E, 1990, EUR J BIOCHEM, V188, P405, DOI 10.1111/j.1432-1033.1990.tb15417.x; Tsutsumi Y, 1997, THROMB HAEMOSTASIS, V77, P168; Vogel V, 1997, AM J HYPERTENS, V10, P289, DOI 10.1016/S0895-7061(96)00410-4; WEN DY, 1994, J BIOL CHEM, V269, P22839; Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; YONEKURA S, 1991, P NATL ACAD SCI USA, V88, P2535, DOI 10.1073/pnas.88.6.2535	33	51	81	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24773	24778		10.1074/jbc.274.35.24773	http://dx.doi.org/10.1074/jbc.274.35.24773			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455149	hybrid			2022-12-25	WOS:000082193400048
J	Gonzalez-Garay, ML; Chang, L; Blade, K; Menick, DR; Cabral, F				Gonzalez-Garay, ML; Chang, L; Blade, K; Menick, DR; Cabral, F			A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MAMMALIAN-CELLS; ALPHA-TUBULIN; NUCLEOTIDE-SEQUENCES; ALTERED EXPRESSION; TAXOL; ISOTYPES; MUTANTS; MECHANISM; DRUGS	Analysis of beta-tubulin alleles from nine paclitaxel-resistant Chinese hamster ovary cell lines revealed an unexpected cluster of mutations affecting Leu-215, Leu-217, and Leu-228, Six of the mutant alleles encode a His, Arg, or Phe substitution at Leu-215; another mutant allele has an Arg substitution at Leu-217; and the final two mutant alleles have substitutions of His or Phe at Leu-228, Using plasmids that allow tetracycline regulated expression, the L215H, L217R, and L228F mutations were introduced into a hemagglutinin antigen-tagged beta-tubulin cDNA and transfected into wild-type Chinese hamster ovary cells. In all three cases, low to moderate expression of the transfected mutant gene conferred paclitaxel resistance. Higher levels of expression caused disruption of microtubule assembly, cell cycle arrest at mitosis, and failure to proliferate, Consistent with reduced microtubule stability, cells expressing mutant hemagglutinin beta-tubulin had fewer acetylated microtubules than nonexpressing cells in the same population. These data, together with previous studies showing the paclitaxel-resistant mutant cell lines have less stable microtubules, indicate that the leucine cluster represents an important structural motif for microtubule assembly.	Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77225 USA; Med Univ S Carolina, Gazes Cardiac Res Inst, Charleston, SC 29425 USA	University of Texas System; Medical University of South Carolina	Cabral, F (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, POB 20708, Houston, TX 77225 USA.			Gonzalez-Garay, Manuel/0000-0003-3412-0353	NATIONAL CANCER INSTITUTE [R01CA052962] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044202] Funding Source: NIH RePORTER; NCI NIH HHS [CA52962] Funding Source: Medline; NHLBI NIH HHS [HL44202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P252, DOI 10.1016/0167-4781(91)90112-Y; BARLOW S, 1994, J CELL BIOL, V126, P1017, DOI 10.1083/jcb.126.4.1017; BOGGS B, 1987, MOL CELL BIOL, V7, P2700, DOI 10.1128/MCB.7.8.2700; Boggs BA, 1996, DNA SEQUENCE, V6, P171, DOI 10.3109/10425179609010205; CABRAL F, 1991, PHARMACOL THERAPEUT, V52, P159, DOI 10.1016/0163-7258(91)90006-8; CABRAL F, 1989, FASEB J, V3, P1593, DOI 10.1096/fasebj.3.5.2646163; CABRAL F, 1981, P NATL ACAD SCI-BIOL, V78, P4388, DOI 10.1073/pnas.78.7.4388; CABRAL F, 1983, J CELL BIOL, V97, P30, DOI 10.1083/jcb.97.1.30; CABRAL F, 1980, CELL, V20, P29, DOI 10.1016/0092-8674(80)90231-7; Cabral F, 1979, Methods Enzymol, V56, P602; CABRAL FR, 1986, ANN NY ACAD SCI, V466, P745, DOI 10.1111/j.1749-6632.1986.tb38456.x; CABRAL FR, 1983, J CELL BIOL, V97, P22, DOI 10.1083/jcb.97.1.22; Casazza A M, 1996, Cancer Treat Res, V87, P149; Erickson HP, 1998, TRENDS CELL BIOL, V8, P133, DOI 10.1016/S0962-8924(98)01237-9; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; GonzalezGaray ML, 1996, J CELL BIOL, V135, P1525, DOI 10.1083/jcb.135.6.1525; GONZALEZGARAY ML, 1995, CELL MOTIL CYTOSKEL, V31, P259, DOI 10.1002/cm.970310403; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haber M, 1995, J BIOL CHEM, V270, P31269, DOI 10.1074/jbc.270.52.31269; Jaffrezou JP, 1995, ONCOL RES, V7, P517; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; KOBAYASHI K, 1990, J BIOL CHEM, V265, P11361; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; OHTA S, 1994, JPN J CANCER RES, V85, P290, DOI 10.1111/j.1349-7006.1994.tb02096.x; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Ranganathan S, 1998, BBA-GENE STRUCT EXPR, V1395, P237, DOI 10.1016/S0167-4781(97)00168-1; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SAWADA T, 1989, J BIOL CHEM, V264, P3013; SCHIBLER MJ, 1989, FASEB J, V3, P163, DOI 10.1096/fasebj.3.2.2563346; SCHIBLER MJ, 1986, J CELL BIOL, V102, P1522, DOI 10.1083/jcb.102.4.1522; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SCHULZE E, 1987, J CELL BIOL, V104, P277, DOI 10.1083/jcb.104.2.277; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; TOMBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; WHITFIELD C, 1986, MOL CELL BIOL, V6, P1422, DOI 10.1128/MCB.6.5.1422	41	126	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23875	23882		10.1074/jbc.274.34.23875	http://dx.doi.org/10.1074/jbc.274.34.23875			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446152	hybrid			2022-12-25	WOS:000082110900031
J	Hedges, JC; Dechert, MA; Yamboliev, IA; Martin, JL; Hickey, E; Weber, LA; Gerthoffer, WT				Hedges, JC; Dechert, MA; Yamboliev, IA; Martin, JL; Hickey, E; Weber, LA; Gerthoffer, WT			A role for p38(MAPK)/HSP27 pathway in smooth muscle cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; HEAT-SHOCK PROTEIN-27; OBSTRUCTIVE PULMONARY-DISEASE; SIGNALING CASCADE; AIRWAY WALL; PHOSPHORYLATION; STRESS; MODULATION; DYNAMICS	Smooth muscle cells are exposed to growth factors and cytokines that contribute to pathological states including airway hyperresponsiveness, atherosclerosis, angiogenesis, smooth muscle hypertrophy, and hyperplasia. A common feature of several of these conditions is migration of smooth muscle beyond the initial boundary of the organ. Signal transduction pathways activated by extracellular signals that instigate migration are mostly undefined in smooth muscles. We measured migration of cultured tracheal myocytes in response to platelet-derived growth factor, interleukin-1 beta, and transforming growth factor-beta. Cellular migration was blocked by SB203580, an inhibitor of p38(MAPK). Time course experiments demonstrated increased phosphorylation of p38(MAPK). Activation of p38(MAPK) resulted in the phosphorylation of HSP27 (heat shock protein 27), which may modulate F-actin polymerization. Inhibition of p38(MAPK) activity inhibited phosphorylation of HSP27. Adenovirus-mediated expression of activated mutant MAPK kinase 6b(E), an upstream activator for p38(MAPK), increased cell migration, whereas overexpression p38 alpha MAPK dominant negative mutant and an HSP27 phosphorylation mutant blocked cell migration completely, The results indicate that activation of the p38(MAPK) pathway by growth factors and proinflammatory cytokines regulates smooth muscle cell migration and may contribute to pathological states involving smooth muscle dysfunction.	Univ Nevada, Sch Med, Dept Pharmacol 318, Reno, NV 89557 USA; Univ Nevada, Sch Med, Cell & Mol Biol Program, Reno, NV 89557 USA; Univ Nevada, Sch Med, Dept Biol, Reno, NV 89557 USA; Loyola Univ, Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; Loyola University Chicago	Gerthoffer, WT (corresponding author), Univ Nevada, Sch Med, Dept Pharmacol 318, Reno, NV 89557 USA.			Gerthoffer, William/0000-0001-5154-4962	NATIONAL CANCER INSTITUTE [R01CA058724] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048183] Funding Source: NIH RePORTER; NCI NIH HHS [CA58724] Funding Source: Medline; NHLBI NIH HHS [HL48183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CRAWLEY JB, 1997, J BIOL CHEM, V272, P10523; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; Guay J, 1997, J CELL SCI, V110, P357; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hedges JC, 1998, AM J PHYSIOL-CELL PH, V275, pC527, DOI 10.1152/ajpcell.1998.275.2.C527; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; JEFFERY PK, 1991, AM REV RESPIR DIS, V143, P1152, DOI 10.1164/ajrccm/143.5_Pt_1.1152; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LANDRY J, 1992, J BIOL CHEM, V267, P794; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Larsen JK, 1997, AM J PHYSIOL-LUNG C, V273, pL930, DOI 10.1152/ajplung.1997.273.5.L930; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Martin JL, 1997, CIRCULATION, V96, P4343; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Piotrowicz RS, 1997, J BIOL CHEM, V272, P25920, DOI 10.1074/jbc.272.41.25920; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Schwartz SM, 1997, J CLIN INVEST, V100, pS87; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STEWART AG, 1993, TRENDS PHARMACOL SCI, V14, P275, DOI 10.1016/0165-6147(93)90130-C; Stewart EA, 1998, OBSTET GYNECOL, V92, P624, DOI 10.1016/S0029-7844(98)00243-9; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	51	348	359	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24211	24219		10.1074/jbc.274.34.24211	http://dx.doi.org/10.1074/jbc.274.34.24211			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446196	hybrid			2022-12-25	WOS:000082110900075
J	Johansson, M; Van Rompay, AR; Degreve, B; Balzarini, J; Karlsson, A				Johansson, M; Van Rompay, AR; Degreve, B; Balzarini, J; Karlsson, A			Cloning and characterization of the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL DEOXYGUANOSINE KINASE; HUMAN THYMIDINE KINASE-1; DEOXYCYTIDINE KINASE; NUCLEOSIDE ANALOGS; SUBSTRATE-SPECIFICITY; CELL-LINES; CDNA; EXPRESSION; GENE; PHOSPHORYLATION	A Drosophila melanogaster deoxyribonucleoside kinase (Dm-dNK) was reported to phosphorylate all four natural deoxyribonucleosides as well as several nucleoside analogs (Munch-Petersen, B., Piskur, J., and Sondergaard, L. (1998) J. Biol. Chem. 273, 3926-3931). The broad substrate specificity of this enzyme together with a high catalytic rate makes it unique among the nucleoside kinases, We have in the present study cloned the Dm-dNK cDNA, expressed the 29-kDa protein in Escherichia colt, and characterized the recombinant enzyme for the phosphorylation of nucleosides and clinically important nucleoside analogs. The recombinant enzyme preferentially phosphorylated the pyrimidine nucleosides dThd, dCyd, and dUrd, but phosphorylation of the purine nucleosides dAdo and dGuo was also efficiently catalyzed. Dm-dNK is closely related to human and herpes simplex virus deoxyribonucleoside kinases. The highest level of sequence similarity was noted with human mitochondrial thymidine kinase 2, and these enzymes also share many substrates. The cDNA cloning and characterization of Dm-dNK will be the basis for studies on the use of this multisubstrate nucleoside kinase as a suicide gene in combined gene/chemotherapy of cancer.	Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Huddinge, Sweden	KU Leuven; Karolinska Institutet	Karlsson, A (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.	anna.karlsson@mbb.ki.se	Karlsson, Anna/E-7945-2018	Karlsson, Anna/0000-0001-6843-6685; Van Rompay, An/0000-0001-7636-858X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; Champness JN, 1998, PROTEINS, V32, P350, DOI 10.1002/(SICI)1097-0134(19980815)32:3<350::AID-PROT10>3.0.CO;2-8; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; Christians FC, 1999, NAT BIOTECHNOL, V17, P259, DOI 10.1038/7003; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; Evans JS, 1998, J GEN VIROL, V79, P2083, DOI 10.1099/0022-1317-79-9-2083; Hapke DM, 1996, CANCER RES, V56, P2343; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; JOHANSSON M, 1995, BIOCHEM PHARMACOL, V50, P163, DOI 10.1016/0006-2952(95)00129-N; Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258; MA GT, 1995, J BIOL CHEM, V270, P6595, DOI 10.1074/jbc.270.12.6602; Manome Y, 1996, NAT MED, V2, P567, DOI 10.1038/nm0596-567; Munch-Petersen B, 1998, J BIOL CHEM, V273, P3926, DOI 10.1074/jbc.273.7.3926; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; MUNIR KM, 1992, J BIOL CHEM, V267, P6584; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569; WANG LY, 1993, J BIOL CHEM, V268, P22847; Zhu CY, 1998, J BIOL CHEM, V273, P14707, DOI 10.1074/jbc.273.24.14707; Zhu CY, 1998, BIOCHEM PHARMACOL, V56, P1035, DOI 10.1016/S0006-2952(98)00150-6	24	86	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23814	23819		10.1074/jbc.274.34.23814	http://dx.doi.org/10.1074/jbc.274.34.23814			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446143	hybrid			2022-12-25	WOS:000082110900022
J	Guardiola-Diaz, HM; Rehnmark, S; Usuda, N; Albrektsen, T; Feltkamp, D; Gustafsson, JA; Alexson, SEH				Guardiola-Diaz, HM; Rehnmark, S; Usuda, N; Albrektsen, T; Feltkamp, D; Gustafsson, JA; Alexson, SEH			Rat peroxisome proliferator-activated receptors and brown adipose tissue function during cold acclimatization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL UNCOUPLING PROTEIN; KINASE-MEDIATED PHOSPHORYLATION; LIPOPROTEIN-LIPASE GENE; AMINO-ACID-SEQUENCE; ACYL-COA OXIDASE; PPAR-GAMMA; FATTY-ACIDS; RESPONSE ELEMENT; 3-HYDROXYACYL-COA DEHYDROGENASE; ADIPOCYTE DIFFERENTIATION	Brown adipose tissue (BAT) hyperplasia is a fundamental physiological response to cold; it involves an acute phase of mitotic cell growth followed by a prolonged differentiation phase. Peroxisome proliferator-activated receptors (PPARs) are key regulators of fatty acid metabolism and adipocyte differentiation and may therefore mediate important metabolic changes during non-shivering thermogenesis. In the present study we have investigated PPAR mRNA expression in relation to peroxisome proliferation in rat BAT during cold acclimatization. By immunoelectron microscopy we show that the number of peroxisomes per cytoplasmic volume and acyl-CoA oxidase immunolabeling density remained constant (thus increasing in parallel with tissue mass and cell number) during the initial proliferative phase and the acute thermogenic response but increased after 14 days of cold exposure, correlating with terminal differentiation of BAT. A pronounced decrease in BAT PPAR alpha and PPAR gamma mRNA levels was found within hours of exposure to cold, which was reversed after 14 days, suggesting a role for either or both of these subtypes in the proliferation and induction of peroxisomes and peroxisomal beta-oxidation enzymes. In contrast, PPAR delta mRNA levels increased progressively during cold exposure. Transactivation assays in HIB 1B and HEK-293 cells demonstrated an adrenergic stimulation of peroxisome proliferator response element reporter activity via PPAR, establishing a role for these nuclear receptors in hormonal regulation of gene transcription in BAT.	Huddinge Univ Hosp, Karolinska Inst, Dept Clin Chem, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Ctr Biotechnol, S-14186 Huddinge, Sweden; Univ Stockholm, Wenner Gren Inst, Dept Metab Res, S-10691 Stockholm, Sweden; Shinshu Univ, Sch Med, Dept Anat & Cell Biol, Matsumoto, Nagano 390, Japan	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Stockholm University; Shinshu University	Alexson, SEH (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Clin Chem, S-14186 Huddinge, Sweden.							Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; AHLABO I, 1971, J HISTOCHEM CYTOCHEM, V19, P670, DOI 10.1177/19.11.670; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; ARNOLD J, 1985, BIOSCIENCE REP, V5, P57, DOI 10.1007/BF01117441; ASSIMACOPOULOSJEANNET F, 1991, AM J PHYSIOL, V260, pR278, DOI 10.1152/ajpregu.1991.260.2.R278; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BARNARD T, 1969, J ULTRA MOL STRUCT R, V29, P311, DOI 10.1016/S0022-5320(69)90109-9; Bengtsson T, 1996, J BIOL CHEM, V271, P33366, DOI 10.1074/jbc.271.52.33366; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CAMERON IL, 1964, J CELL BIOL, V23, P89, DOI 10.1083/jcb.23.1.89; Cannon B, 1996, INT J OBESITY, V20, pS36; CARNEHEIM C, 1984, AM J PHYSIOL, V246, pE327, DOI 10.1152/ajpendo.1984.246.4.E327; CARNEHEIM CMH, 1989, AM J PHYSIOL, V256, pE645, DOI 10.1152/ajpendo.1989.256.5.E645; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; FoellmiAdams LA, 1996, BIOCHEM PHARMACOL, V52, P693, DOI 10.1016/0006-2952(96)00345-0; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GIACOBINO JP, 1989, MOL CELL ENDOCRINOL, V61, P217, DOI 10.1016/0303-7207(89)90133-0; GOTTLICHER M, 1993, BIOCHEM PHARMACOL, V46, P2177, DOI 10.1016/0006-2952(93)90607-X; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HAKKOLA EH, 1994, J LIPID RES, V35, P1820; HORWITZ BA, 1976, COMP BIOCHEM PHYS A, V54, P45, DOI 10.1016/S0300-9629(76)80070-9; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HUNT TE, 1967, ANAT REC, V157, P537, DOI 10.1002/ar.1091570313; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEAN MEJ, 1983, BIOSCIENCE REP, V3, P61, DOI 10.1007/BF01121572; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; Lindquist JM, 1998, J BIOL CHEM, V273, P30147, DOI 10.1074/jbc.273.46.30147; MITCHELL JRD, 1992, AM J PHYSIOL, V263, pE500, DOI 10.1152/ajpendo.1992.263.3.E500; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEDERGAARD J, 1980, AM J PHYSIOL, V239, pC208, DOI 10.1152/ajpcell.1980.239.5.C208; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; PAGE E, 1950, REV CAN BIOL, V9, P202; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; REHNMARK S, 1993, FEBS LETT, V318, P235, DOI 10.1016/0014-5793(93)80519-Z; REHNMARK S, 1989, EXP CELL RES, V180, P574, DOI 10.1016/0014-4827(89)90086-4; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SEYDOUX J, 1986, PFLUG ARCH EUR J PHY, V407, P377, DOI 10.1007/BF00652621; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; Shimizu Y, 1997, ENDOCRINOLOGY, V138, P248, DOI 10.1210/en.138.1.248; Tai TAC, 1996, J BIOL CHEM, V271, P29909, DOI 10.1074/jbc.271.47.29909; THOMSON JF, 1969, J CELL BIOL, V41, P312, DOI 10.1083/jcb.41.1.312; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; USUDA N, 1988, LAB INVEST, V58, P100; VUDAC N, 1994, J BIOL CHEM, V269, P31012; WONG CW, 1995, MOL ENDOCRINOL, V9, P551, DOI 10.1210/me.9.5.551; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; XANTHOPOULOS KG, 1989, CYTOGENET CELL GENET, V50, P174, DOI 10.1159/000132754; Xing GQ, 1995, BIOCHEM BIOPH RES CO, V217, P1015, DOI 10.1006/bbrc.1995.2871; YEH WC, 1995, GENE DEV, V9, P169; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	69	55	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23368	23377		10.1074/jbc.274.33.23368	http://dx.doi.org/10.1074/jbc.274.33.23368			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438514	hybrid			2022-12-25	WOS:000082012800064
J	Kristal, BS; Brown, AM				Kristal, BS; Brown, AM			Apoptogenic ganglioside GD3 directly induces the mitochondrial permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CERAMIDE-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; ACIDIC SPHINGOMYELINASE; CYTOCHROME-C; LIVER-MITOCHONDRIA; NUCLEAR APOPTOSIS; PLASMA-MEMBRANE; L929 CELLS; KAPPA-B	Early events in apoptotic cascades initiated by ceramides or by activation of the surface receptor CD95 (Fas/APO-1) include the formation of ganglioside GD3, GD3 appears to be both necessary and sufficient to propagate this lipid-mediated apoptotic pathway. Later events common to many apoptotic pathways include induction of the mitochondrial permeability transition (PT) and cytochrome c release, which in turn triggers downstream caspases and cell death. The links between GD3 formation and downstream stages of apoptosis are unknown. We report that ganglioside GD3 directly induces the PT in isolated rat liver mitochondria at 30-100 mu M in the presence of exogenous substrate (succinate) and at similar to 3 mu M in the absence of exogenous substrate. In contrast, other gangliosides tested (e.g. GM1) have only weak stimulatory effects in the presence of succinate and protect against PT induction in the absence of respiratory substrates, GD3-mediated induction of PT was antagonized by known PT inhibitors, namely cyclosporin A, ADP, trifluoperazine, and Mg2+. GD3 induced PT even in the presence of submicromolar Ca2+; GD3 is therefore the first biological PT inducer identified that does not require elevated Ca2+. Exposure to GD8 also led to mitochondrial cytochrome c release. In contrast, C-2-ceramide, which can initiate the lipid-mediated apoptotic cascade in susceptible cells, failed to either induce PT or release cytochrome c, These observations suggest that GD3 propagates apoptosis by inducing the PT and cytochrome c release. This model provides a mechanistic link between the earlier and later stages of CD95-induced/ceramide-mediated apoptosis.	Burke Med Res Inst, Dementia Res Serv, White Plains, NY 10605 USA; Cornell Univ, Coll Med, Dept Biochem, New York, NY 10021 USA	Cornell University	Kristal, BS (corresponding author), Burke Med Res Inst, Dementia Res Serv, 785 Mamaroneck Ave, White Plains, NY 10605 USA.		brown, abraham/R-8823-2019		NATIONAL INSTITUTE ON AGING [R35AG009014, R01AG015354] Funding Source: NIH RePORTER; NIA NIH HHS [AG09014, AG15354] Funding Source: Medline; NINDS NIH HHS [R01 NS038741] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adam-Klages S, 1998, J LEUKOCYTE BIOL, V63, P678, DOI 10.1002/jlb.63.6.678; ALLAN D, 1993, PROG LIPID RES, V32, P195, DOI 10.1016/0163-7827(93)90015-O; Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; Castedo M, 1996, J IMMUNOL, V157, P512; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Dong J, 1998, J CELL PHYSIOL, V174, P179, DOI 10.1002/(SICI)1097-4652(199802)174:2<179::AID-JCP5>3.0.CO;2-L; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; FADY C, 1995, J INTERF CYTOK RES, V15, P71, DOI 10.1089/jir.1995.15.71; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Hadjiconstantinou M, 1998, J NEUROCHEM, V70, P1335; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; Krammer PH, 1996, CELL DEATH DIFFER, V3, P159; Kristal BS, 1996, J BIOL CHEM, V271, P6033, DOI 10.1074/jbc.271.11.6033; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; MATYAS GR, 1987, BIOCHIM BIOPHYS ACTA, V921, P599, DOI 10.1016/0005-2760(87)90089-0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Oshimi S, 1996, J PHYSIOL-LONDON, V495, P319, DOI 10.1113/jphysiol.1996.sp021596; OSHIMI Y, 1995, J IMMUNOL, V154, P599; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PEREIRA RS, 1992, BIOCHEM PHARMACOL, V44, P1795, DOI 10.1016/0006-2952(92)90074-S; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; RIGOBELLO MP, 1993, BIOCHEM BIOPH RES CO, V194, P1276, DOI 10.1006/bbrc.1993.1961; SanchezAlcazar JA, 1997, J BIOL CHEM, V272, P30167, DOI 10.1074/jbc.272.48.30167; SARTI P, 1990, BIOCHEM J, V267, P413, DOI 10.1042/bj2670413; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCHLEGEL J, 1992, BIOCHEM J, V285, P65, DOI 10.1042/bj2850065; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; TETTAMANTI G, 1994, PROG BRAIN RES, V101, P77; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; Weber M, 1996, INVEST OPHTH VIS SCI, V37, P267; White RJ, 1996, J NEUROSCI, V16, P5688; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; [No title captured]	60	115	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23169	23175		10.1074/jbc.274.33.23169	http://dx.doi.org/10.1074/jbc.274.33.23169			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438487	hybrid			2022-12-25	WOS:000082012800037
J	Laouar, A; Glesne, D; Huberman, E				Laouar, A; Glesne, D; Huberman, E			Involvement of protein kinase C-beta and ceramide in tumor necrosis factor-alpha-induced but not Fas-induced apoptosis of human myeloid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERLEUKIN-1-BETA CONVERTING-ENZYME; MEDIATED APOPTOSIS; HL-60 CELLS; SIGNAL-TRANSDUCTION; TNF RECEPTOR-1; CD95(FAS/APO-1)-MEDIATED APOPTOSIS; MACROPHAGE DIFFERENTIATION; INDUCED ACTIVATION; DEPENDENT PATHWAY	The role of protein kinase C-beta (PKC-beta) in apoptosis induced by tumor necrosis factor (TNF)-alpha and anti-Fas monoclonal antibody (mAb) in the human myeloid HL-60 leukemia cell line was studied by using its variant HL-525, which is deficient in PKC-beta. In contrast to the parental HL-60 cells, HL-525 is resistant to TNF-alpha-induced apoptosis but sensitive to anti-Fas mAb-induced apoptosis. Both cell types expressed similar levels of the TNF-receptor I, whereas the Fas receptor was detected only in HL-525 cells. Transfecting the HL-525 cells with an expression vector containing PKC-beta reestablished their susceptibility to TNF-alpha-induced apoptosis. The apoptotic effect of TNF-alpha in HL-60 and the transfectants was abrogated by fumonisin, an inhibitor of ceramide generation, and by the peptide Ac-YVAD-BoMX, an inhibitor of caspase-1 and -4. Supplementing HL-525 cells with exogenous ceramides bypassed the PKC-beta deficiency and induced apoptosis, which was also restrained by the caspase-1 and -4 inhibitor. The apoptotic effect of anti-Fas mAb in HL-525 cells was abrogated by the antioxidants N-acetylcysteine and glutathione and by the peptide z-DEVD-FMK, an inhibitor of caspase-3 and -7. We suggest that TNF-alpha-induced apoptosis involves PKC-beta and then ceramide and, in turn, caspase-1 and/or -4, whereas anti-Fas mAb-induced apoptosis utilizes reactive oxygen intermediates and, in turn, caspase-3 and/or -7.	Argonne Natl Lab, Biochip Technol Ctr, Gene Express & Funct Grp, Argonne, IL 60439 USA	United States Department of Energy (DOE); Argonne National Laboratory	Huberman, E (corresponding author), Argonne Natl Lab, Biochip Technol Ctr, Gene Express & Funct Grp, 9700 S Cass Ave, Argonne, IL 60439 USA.							BAIERBITTERLICH G, 1995, FEBS LETT, V364, P234, DOI 10.1016/0014-5793(95)00403-V; Basu A, 1998, MOL PHARMACOL, V53, P105, DOI 10.1124/mol.53.1.105; BERTRAND R, 1993, EXP CELL RES, V207, P388, DOI 10.1006/excr.1993.1206; BHALLA K, 1993, BLOOD, V82, P3133; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; CIFONE MG, 1993, J EXP MED, V177, P1547; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; De Valck D, 1998, J CELL BIOCHEM, V71, P392, DOI 10.1002/(SICI)1097-4644(19981201)71:3<392::AID-JCB8>3.0.CO;2-N; Declercq W, 1998, J IMMUNOL, V161, P390; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Delneste Y, 1997, BLOOD, V90, P1124, DOI 10.1182/blood.V90.3.1124.1124_1124_1132; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Frey T, 1997, CYTOMETRY, V28, P253, DOI 10.1002/(SICI)1097-0320(19970701)28:3<253::AID-CYTO10>3.0.CO;2-O; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Haridas V, 1998, J IMMUNOL, V160, P3152; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOMMA Y, 1986, P NATL ACAD SCI USA, V83, P7316, DOI 10.1073/pnas.83.19.7316; HSU H, 1995, CELL, V85, P495; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; Kasahara Y, 1997, BLOOD, V89, P1748, DOI 10.1182/blood.V89.5.1748.1748_1748_1753; KING LB, 1993, CURR OPIN IMMUNOL, V5, P368, DOI 10.1016/0952-7915(93)90055-W; Kohno T, 1996, J IMMUNOL, V156, P4722; Kojima H, 1996, ONCOL RES, V8, P497; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Kumakura S, 1996, LEUKEMIA LYMPHOMA, V23, P383, DOI 10.3109/10428199609054843; LEEUWENBERG JFM, 1995, CYTOKINE, V7, P457, DOI 10.1006/cyto.1995.0062; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mansat V, 1997, CANCER RES, V57, P5300; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PIHLGREN M, 1996, BIOCHEMICA, V3, P12; PornAres MI, 1997, EXP CELL RES, V235, P48, DOI 10.1006/excr.1997.3641; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Shirafuji N, 1997, BLOOD, V90, P4567, DOI 10.1182/blood.V90.11.4567.4567_4567_4577; Sillence DJ, 1997, BIOCHEM J, V324, P29, DOI 10.1042/bj3240029; Tatsuta T, 1996, J IMMUNOL, V157, P3949; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; Um HD, 1996, J IMMUNOL, V156, P3469; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WARZOCHA K, 1995, EUR CYTOKINE NETW, V6, P83; Weiss T, 1998, J IMMUNOL, V161, P3136; Weller M, 1997, NEUROL RES, V19, P459; WINSTON BW, 1995, J BIOL CHEM, V270, P27391, DOI 10.1074/jbc.270.46.27391; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Wright SC, 1997, FASEB J, V11, P843, DOI 10.1096/fasebj.11.11.9285482; Wright SC, 1996, J EXP MED, V183, P463, DOI 10.1084/jem.183.2.463; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; Yoshida K, 1996, INT J HEMATOL, V65, P41	73	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23526	23534		10.1074/jbc.274.33.23526	http://dx.doi.org/10.1074/jbc.274.33.23526			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438532	hybrid			2022-12-25	WOS:000082012800082
J	Desaintes, C; Goyat, S; Garbay, S; Yaniv, M; Thierry, F				Desaintes, C; Goyat, S; Garbay, S; Yaniv, M; Thierry, F			Papillomavirus E2 induces p53-independent apoptosis in HeLa cells	ONCOGENE			English	Article						HPV18 E2 mutants; apoptosis; p53 HeLa cells	CERVICAL-CARCINOMA CELLS; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; DNA-REPLICATION; FUNCTIONAL INTERACTION; CYCLE ARREST; E6 PROMOTER; TYPE-1 E2; PROTEIN; P53	We have previously shown that expression of the papillomavirus E2 protein in HeLa cells induces p53 accumulation and causes both cell cycle arrest and apoptosis, In contrast to growth arrest, onset of apoptosis was not correlated with an increase of p53 transcriptional activity, In the present study, we conducted biochemical and genetic experiments in order to determine whether Et-induced apoptosis was independent of p53 induction. We showed that E2 did not alter the transcription of Bar, a known p53-activated cell death inducer. The time course of apoptotic cell death preceded p53 induction by several hours. Overexpression of the HPV18 E6 oncogene prevented E2-mediated p53 accumulation, but did not alter the rate of cell death. Finally, point mutants of the HPV18 E2 transactivation domain induced apoptosis, although they were unable to induce high p53 accumulation or cell cycle arrest. In addition, the results obtained with these mutants indicated that both transcriptional activation and replication functions of E2 were dispensable for the induction of cell death. These observations show that E2-induced apoptosis is an early event, independent of p53 accumulation and unrelated to downstream p53-dependent transcriptional events.	Inst Pasteur, Dept Biotechnol, CNRS,URA 1644, Unite Virus Oncogenes, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Thierry, F (corresponding author), Inst Pasteur, Dept Biotechnol, CNRS,URA 1644, Unite Virus Oncogenes, 25 Rue Dr Roux, F-75724 Paris 15, France.							ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; Benson JD, 1997, J VIROL, V71, P8041, DOI 10.1128/JVI.71.10.8041-8047.1997; BENSON JD, 1995, J VIROL, V69, P4364, DOI 10.1128/JVI.69.7.4364-4372.1995; BERUMEN J, 1994, INT J CANCER, V56, P640, DOI 10.1002/ijc.2910560506; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; Demeret C, 1995, NUCLEIC ACIDS RES, V23, P4777, DOI 10.1093/nar/23.23.4777; Demeret C, 1997, J VIROL, V71, P9343, DOI 10.1128/JVI.71.12.9343-9349.1997; DEMERET C, 1994, J VIROL, V68, P7075, DOI 10.1128/JVI.68.11.7075-7082.1994; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DONALDSON KL, 1994, INT J CANCER, V57, P847, DOI 10.1002/ijc.2910570614; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; Hwang ES, 1996, ONCOGENE, V12, P795; LEMOAL MA, 1994, J VIROL, V68, P1085, DOI 10.1128/JVI.68.2.1085-1093.1994; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCBRIDE A, 1996, THEORETICAL BIOL BIO, V3, P15; MIYASHITA T, 1995, CELL, V80, P293; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; TAN SH, 1992, NUCLEIC ACIDS RES, V20, P251, DOI 10.1093/nar/20.2.251; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yao JM, 1998, J VIROL, V72, P1013, DOI 10.1128/JVI.72.2.1013-1019.1998	48	71	74	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4538	4545		10.1038/sj.onc.1202818	http://dx.doi.org/10.1038/sj.onc.1202818			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467398				2022-12-25	WOS:000082018600003
J	Loffler, M; Ausserlechner, MJ; Tonko, M; Hartmann, BL; Bernhard, D; Geley, S; Helmberg, A; Kofler, R				Loffler, M; Ausserlechner, MJ; Tonko, M; Hartmann, BL; Bernhard, D; Geley, S; Helmberg, A; Kofler, R			c-Myc does not prevent glucocorticoid-induced apoptosis of human leukemic lymphoblasts	ONCOGENE			English	Article						glucocorticoid; apoptosis; leukemia; c-myc; tetracycline-regulated gene expression	T-CELL HYBRIDOMAS; LINE CCRF-CEM; GENE-EXPRESSION; RECEPTOR; DEATH; RESISTANCE; ALPHA; SUSCEPTIBILITY; PROTOONCOGENES; DEXAMETHASONE	Due to their growth arrest- and apoptosis-inducing ability, glucocorticoids (GC) are widely used in the therapy of various lymphoid malignancies, The signal transduction pathways leading to this clinically-relevant form of apoptosis have, however, not been sufficiently elucidated. GC bind to their specific receptor, a ligand-activated transcription factor of the Zn-finger type, that activates or represses transcription of GC-responsive genes. Previous studies in leukemia cells suggested that transcriptional repression of c-myc expression might be the crucial event in CC-induced apoptosis, although in other systems, c-Myc apparently increased the sensitivity to cell-death inducers. To address this controversy, we stably transfected the GC-sensitive human T-ALL cell Line CEM-C7H2 with constructs allowing tetracycline-regulated expression of c-Myc. Subsequent analyses of these cell lines showed that overexpression of c-Myc per se had little, if any, effect on cell viability, although it rendered the cells more sensitive to apoptosis induced by low serum, confirming the functionality of the expressed transgene, More importantly, however, when the cells were treated with GC in the presence of exogenous c-Myc, they underwent apoptosis exceeding that in cells treated in the absence of transgenic c-Myc. The data indicate that c-myc downregulation is not critical for induction of cell-death by GC in this system, and support the notion that c-Myc sensitizes cells to apoptosis-inducing agents.	Univ Innsbruck, Sch Med, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria	University of Innsbruck	Kofler, R (corresponding author), Univ Innsbruck, Sch Med, Inst Gen & Expt Pathol, Div Mol Pathophysiol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.			Ausserlechner, Michael/0000-0002-1015-2302; Bernhard, David/0000-0002-2383-6607				ASHRAF J, 1993, MOL ENDOCRINOL, V7, P631, DOI 10.1210/me.7.5.631; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geley S, 1996, CANCER RES, V56, P5033; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hala M, 1996, INT J CANCER, V68, P663, DOI 10.1002/(SICI)1097-0215(19961127)68:5<663::AID-IJC17>3.0.CO;2-2; Han JW, 1997, CANCER RES, V57, P176; HARTMANN BL, 1998, IN PRESS ONCOGENE, V17; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Kaptein JS, 1996, J BIOL CHEM, V271, P18875, DOI 10.1074/jbc.271.31.18875; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; MA TL, 1992, MOL ENDOCRINOL, V6, P960, DOI 10.1210/me.6.6.960; MIYAZAKI J, 1989, GENE, V79, P269; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; POWERS JH, 1993, CANCER RES, V53, P4059; RHEE K, 1995, CANCER RES, V55, P4188; SCHWEIGERT FJ, 1993, COMP BIOCHEM PHYS A, V105, P347, DOI 10.1016/0300-9629(93)90219-T; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; THULASI R, 1993, J BIOL CHEM, V268, P18306; WOOD AC, 1994, BRIT J CANCER, V69, P663, DOI 10.1038/bjc.1994.128; YUH YS, 1989, J BIOL CHEM, V264, P10904; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4626	4631		10.1038/sj.onc.1202820	http://dx.doi.org/10.1038/sj.onc.1202820			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467407				2022-12-25	WOS:000082018600012
J	Akhand, AK; Pu, MY; Senga, T; Kato, M; Suzuki, H; Miyata, T; Hamaguchi, M; Nakashima, I				Akhand, AK; Pu, MY; Senga, T; Kato, M; Suzuki, H; Miyata, T; Hamaguchi, M; Nakashima, I			Nitric oxide controls Src kinase activity through a sulfhydryl group modification-mediated Tyr-527-independent and Tyr-416-linked mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; C-SRC; PHOSPHORYLATION; ACTIVATION; PP60C-SRC; CELLS; SITE; DNA; PROLIFERATION; MUTATIONS	c-Src kinase was activated when either murine NIH3T3 fibroblast cells or immunoprecipitated c-Src proteins were treated with nitric oxide generator, S-nitroso-N-acetyl penicillamine (SNAP) or sodium nitroprusside, Nitric oxide (NO) scavenger hemoglobin and N2O3 scavenger homocysteine abolished the SNAP-mediated c-Src kinase activation, Phosphoamino acid analysis and peptide mapping of in vitro labeled phospho-c-Src proteins revealed that SNAP promoted the autophosphorylation at tyrosine, which preferentially took place at Tyr-416, Peptide mapping of in vivo labeled c-Src kinase excluded the involvement of phospho-Tyr-527 dephosphorylation in the SNAP-mediated activation mechanism. Correspondingly, protein-tyrosine phosphatase inhibitor Na3VO4 did not abolish the SNAP-mediated activation of Src kinase, and the constitutively activated v-Src kinase was also further up-regulated in activity by SNAP, SNAP, however, failed to up-regulate the kinase activity of Phe 416 mutant v-Src, 2-Mercaptoethanol or dithiothreitol, which should disrupt N2O3-mediated S-nitrosylation and subsequent formation of the S-S bond, abolished the up-regulated catalytic activity, and the activity was regained after re-exposing the enzyme to SNAP. Exposure of Src kinase to SNAP promoted both autophosphorylation and S-S bond-mediated aggregation of the kinase molecules, demonstrating a linkage between the two events. These results suggest that the NO/N2O3-provoked S-nitrosylation/S-S bond formation destabilizes the Src structure for Tyr-416 autophosphorylation-associated activation bypassing the Tyr-527-linked regulation.	Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Lab Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Tokai Univ, Sch Med, Inst Med Sci, Isehara, Kanagawa 25911, Japan; Tokai Univ, Sch Med, Dept Internal Med, Isehara, Kanagawa 25911, Japan	Nagoya University; Nagoya University; Tokai University; Tokai University	Nakashima, I (corresponding author), Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		KATO, Masashi/I-7250-2014; Miyata, Toshio/A-4872-2010					Bauer J A, 1995, Adv Pharmacol, V34, P361; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GROOT MAD, 1996, SCIENCE, V272, P414; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V89, P1031; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LANDER HM, 1993, J IMMUNOL, V150, P1509; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Maccarrone M, 1997, FEBS LETT, V410, P470, DOI 10.1016/S0014-5793(97)00643-1; Maccarrone M, 1996, BIOCHEM BIOPH RES CO, V219, P128, DOI 10.1006/bbrc.1996.0193; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MURRELL GAC, 1995, BIOCHEM BIOPH RES CO, V206, P15, DOI 10.1006/bbrc.1995.1003; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAKASHIMA I, 1991, J IMMUNOL, V147, P1153; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RICHARDSON DR, 1995, BLOOD, V86, P3211; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; Trachtman H, 1996, BIOCHEM BIOPH RES CO, V218, P704, DOI 10.1006/bbrc.1996.0125; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	40	139	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25821	25826		10.1074/jbc.274.36.25821	http://dx.doi.org/10.1074/jbc.274.36.25821			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464322	hybrid			2022-12-25	WOS:000082554200086
J	Bennett, EP; Hassan, H; Mandel, U; Hollingsworth, MA; Akisawa, N; Ikematsu, Y; Merkx, G; van Kessel, AG; Olofsson, S; Clausen, H				Bennett, EP; Hassan, H; Mandel, U; Hollingsworth, MA; Akisawa, N; Ikematsu, Y; Merkx, G; van Kessel, AG; Olofsson, S; Clausen, H			Cloning and characterization of a close homologue of human UDP-N-acetyl-alpha-D-galactosamine : polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6 - Evidence for genetic but not functional redundancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED GLYCOSYLATION; CDNA CLONING; ACETYLGALACTOSAMINYLTRANSFERASE FAMILY; CHROMOSOMAL LOCALIZATION; ONCOFETAL FIBRONECTIN; MOLECULAR-CLONING; 3 MEMBERS; EXPRESSION; TRANSFERASES; PROTEIN	The UDP-GalAc:polypeptide N-acetylgalactosaminyltransferase, designated GalNAc-T3, exhibits unique functions, Specific acceptor substrates are used by GalNAc-T3 and not by other GalNAc-transferases. The expression pattern of GalNAc-T3 is restricted, and loss of expression is a characteristic feature of poorly differentiated pancreatic tumors. In the present study, a sixth human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, designated GalNAc-T6, with high similarity to GalNAc-T3, was characterized. GalNAc-T6 exhibited high sequence similarity to GalNAc-T3 throughout the coding region, in contrast to the limited similarity that exists between homologous glycosyltransferase genes, which is usually restricted to the putative catalytic domain. The genomic organizations of GALNT3 and GALNT6 are identical with the coding regions placed in 10 exons, but the genes are localized differently at 2q31 and 12q13, respectively. Acceptor substrate specificities of GalNAc-T3 and -T6 were similar and different from other GalNAc-transferases. Northern analysis revealed distinct expression patterns, which were confirmed by immunocytology using monoclonal antibodies. In contrast to GalNAc-T3, GalNAc-T6 was expressed in WI38 fibroblast cells, indicating that GalNAc-T6 represents a candidate for synthesis of oncofetal fibronectin, The results demonstrate the existence of genetic redundancy of a polypeptide GalNAc-transferase that does not provide full functional redundancy.	Sch Dent, Fac Hlth Sci, DK-2200 Copenhagen N, Denmark; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Gothenburg Univ, Dept Virol, S-41346 Gothenburg, Sweden; Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands	University of Nebraska System; University of Nebraska Medical Center; University of Gothenburg; Radboud University Nijmegen	Clausen, H (corresponding author), Sch Dent, Fac Hlth Sci, Norre Alle 20, DK-2200 Copenhagen N, Denmark.		clausen, henrik/AAD-8016-2021; van Kessel, Ad Geurts/A-2810-2010; Bennett, Eric/AAG-6120-2020	Bennett, Eric/0000-0002-4976-0647	NATIONAL CANCER INSTITUTE [R01CA066234] Funding Source: NIH RePORTER; NCI NIH HHS [1 RO1 CA66234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1998, GLYCOBIOLOGY, V8, P547, DOI 10.1093/glycob/8.6.547; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HOMA FL, 1993, J BIOL CHEM, V268, P12609; Imberty A, 1997, PROTEIN ENG, V10, P1353, DOI 10.1093/protein/10.12.1353; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LORIDONROSA B, 1990, CANCER RES, V50, P1608; Mandel U, 1999, GLYCOBIOLOGY, V9, P43, DOI 10.1093/glycob/9.1.43; MANDEL U, 1994, APMIS, V102, P695, DOI 10.1111/j.1699-0463.1994.tb05222.x; MANDEL U, 1992, APMIS, V100, P817, DOI 10.1111/j.1699-0463.1992.tb04005.x; Marth JD, 1996, GLYCOBIOLOGY, V6, P701, DOI 10.1093/glycob/6.7.701; MATSUURA H, 1989, J BIOL CHEM, V264, P10472; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; MEURER JA, 1995, J BIOCHEM-TOKYO, V118, P568, DOI 10.1093/oxfordjournals.jbchem.a124947; Meurer JA, 1996, GLYCOBIOLOGY, V6, P231, DOI 10.1093/glycob/6.2.231; MOLLICONE R, 1994, TRANSFUS CLIN BIOL, V1, P91, DOI 10.1016/S1246-7820(94)80002-2; Nehrke K, 1997, GLYCOBIOLOGY, V7, P1053, DOI 10.1093/glycob/7.8.1053-c; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; REGUIGNEARNOULD I, 1995, CYTOGENET CELL GENET, V71, P158, DOI 10.1159/000134098; Rottger S, 1998, J CELL SCI, V111, P45; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; SUIJKERBUIJK RF, 1991, AM J HUM GENET, V48, P269; Sutherlin ME, 1997, CANCER RES, V57, P4744; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	38	164	175	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25362	25370		10.1074/jbc.274.36.25362	http://dx.doi.org/10.1074/jbc.274.36.25362			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464263	hybrid			2022-12-25	WOS:000082554200028
J	Demoulin, JB; Van Roost, E; Stevens, M; Groner, B; Renauld, JC				Demoulin, JB; Van Roost, E; Stevens, M; Groner, B; Renauld, JC			Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE RESPONSE FACTOR/STAT3; SIGNAL TRANSDUCER GP130; CELL-PROLIFERATION; THYMIC LYMPHOMAS; TYROSINE PHOSPHORYLATION; GLUCOCORTICOID RECEPTOR; CYTOPLASMIC DOMAIN; INTERFERON-GAMMA; TRANSGENIC MICE; ACTIVATION	Interleukin-9 (IL-9) activates three distinct STAT proteins: STAT1, STAT3, and STAT5. This process depends on one tyrosine of the n-9 receptor, which is necessary for proliferation, gene induction, and inhibition of apoptosis induced by glucocorticoids. By introduction of point mutations in amino acids surrounding this tyrosine, we obtained receptors that activated either STAT5 alone or both STAT1 and STAT3, thus providing us with the possibility to study the respective roles of these factors in the biological activities of IL-9. Both mutant receptors were able to prevent apoptosis, but only the mutant that activated STAT1 and STAT3 was able to support induction of granzyme A and L-selectin. In line with these results, constitutively activated STATE blocked glucocorticoid-induced apoptosis. In Ba/F3 cells, significant proliferation and pim-1 induction were observed with both STAT-restricted mutants, though proliferation was lower than with the wild-type receptor. These results suggest that survival and cell growth are redundantly controlled by multiple STAT factors, whereas differentiation gene induction is more specifically correlated with individual STAT activation by IL-9.	Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Catholique Louvain, Expt Med Unit, B-1200 Brussels, Belgium; Inst Expt Canc Res, Tumor Biol Ctr, D-79106 Freiburg, Germany	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain	Renauld, JC (corresponding author), Univ Catholique Louvain, Ludwig Inst Canc Res, Ave Hippocrate 74, B-1200 Brussels, Belgium.		Demoulin, Jean-Baptiste/E-5847-2010; Renauld, Jean-Christophe/B-7268-2012	Demoulin, Jean-Baptiste/0000-0002-8016-6689; Renauld, Jean-Christophe/0000-0003-1736-2131				Bauer JH, 1998, J BIOL CHEM, V273, P9255, DOI 10.1074/jbc.273.15.9255; Berchtold S, 1997, J BIOL CHEM, V272, P30237, DOI 10.1074/jbc.272.48.30237; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Demoulin J B, 1998, Int Rev Immunol, V16, P345, DOI 10.3109/08830189809043001; Demoulin JB, 1998, CYTOKINES CELL MOL T, V4, P243; Demoulin JB, 1999, EUR CYTOKINE NETW, V10, P49; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Grasso L, 1998, J BIOL CHEM, V273, P24016, DOI 10.1074/jbc.273.37.24016; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Higuchi M, 1996, J IMMUNOL, V157, P297; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LILLY M, 1992, ONCOGENE, V7, P727; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Louahed J, 1996, J IMMUNOL, V156, P3704; LOUAHED J, 1995, J IMMUNOL, V154, P5061; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RENAULD JC, 1992, P NATL ACAD SCI USA, V89, P5690, DOI 10.1073/pnas.89.12.5690; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Takeda K, 1998, J IMMUNOL, V161, P4652; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; VINK A, 1993, EUR J IMMUNOL, V23, P1134, DOI 10.1002/eji.1830230523; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; YIPSCHNEIDER MT, 1995, BLOOD, V85, P3494, DOI 10.1182/blood.V85.12.3494.bloodjournal85123494; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	40	71	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25855	25861		10.1074/jbc.274.36.25855	http://dx.doi.org/10.1074/jbc.274.36.25855			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464327	hybrid			2022-12-25	WOS:000082554200091
J	Fogaca, AC; da Silva, PI; Miranda, MTM; Bianchi, AG; Miranda, A; Ribolla, PEM; Daffre, S				Fogaca, AC; da Silva, PI; Miranda, MTM; Bianchi, AG; Miranda, A; Ribolla, PEM; Daffre, S			Antimicrobial activity of a bovine hemoglobin fragment in the tick Boophilus microplus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBACTERIAL PEPTIDE; INSECT IMMUNITY; HEMOLYMPH; ACARI; PURIFICATION; NEUTROPHILS; PROTEINS; DISEASE; BLOOD	Antifungal and antibacterial activities were detected in the hemolymph and gut contents of the cattle tick, Boophilus microplus. A peptide with antibacterial activity from the tick gut contents was purified to homogeneity by reversed-phase chromatography. The molecular mass of the purified peptide was 3,205.7 Da, measured by matrix-assisted laser desorption/ionization mass spectrometry. The amino acid sequence was obtained by Edman degradation and showed that the peptide was identical to a fragment of the bovine cu-hemoglobin. A synthetic peptide based on the sequence obtained showed characterization data identical to those of the isolated material, confirming its structure. The synthetic peptide was active in micromolar concentrations against Gram-positive bacteria and fungi. These data led us to conclude that the antibacterial activity detected in tick gut contents is the result of enzymatic processing of a host protein, hemoglobin. This activity may be used by ticks as a defense against microorganisms.	Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508900 Sao Paulo, Brazil; Inst Butantan, Lab Artropodes, BR-05503900 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Dept Biofis, BR-04044020 Sao Paulo, Brazil	Universidade de Sao Paulo; Instituto Butantan; Universidade de Sao Paulo; Universidade de Sao Paulo	Daffre, S (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Av Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.	sidaffre@icb.usp.br	Fogaca, Andrea C/M-4267-2013; Miranda, Antonio/C-8855-2012; Machini, M. Teresa/D-2009-2012; Daffre, Sirlei/M-4233-2013; Fogaca, Andrea/C-1322-2012; Silva Junior, Pedro Ismael/E-1437-2011; Ribolla, Paulo EM/B-9122-2012; Ribolla, Paulo/AAH-3354-2020	Machini, M. Teresa/0000-0001-5772-004X; Daffre, Sirlei/0000-0002-9966-0433; Silva Junior, Pedro Ismael/0000-0001-6619-6489; Ribolla, Paulo EM/0000-0001-8735-6090; Fogaca, Andrea/0000-0002-0890-6136				AZAMBUJA P, 1993, J INSECT PHYSL, V29, P833; BENYAKIR D, 1989, J MED ENTOMOL, V26, P243, DOI 10.1093/jmedent/26.4.243; BULET P, 1993, J BIOL CHEM, V268, P14893; CARLSON GP, 1973, P SOC EXP BIOL MED, V142, P853, DOI 10.3181/00379727-142-37131; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778; EhretSabatier L, 1996, J BIOL CHEM, V271, P29537, DOI 10.1074/jbc.271.47.29537; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; FRAIDENRAICH D, 1993, P NATL ACAD SCI USA, V90, P10140, DOI 10.1073/pnas.90.21.10140; Garcia ES, 1995, EXP PARASITOL, V81, P255, DOI 10.1006/expr.1995.1116; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENNARO R, 1983, INFECT IMMUN, V40, P684, DOI 10.1128/IAI.40.2.684-690.1983; GENNARO R, 1989, INFECT IMMUN, V57, P3142, DOI 10.1128/IAI.57.10.3142-3146.1989; Hetru C., 1997, MOL MECH IMMUNE RESP, P40; HOBSON D, 1958, J EXP MED, V107, P167, DOI 10.1084/jem.107.2.167; HOFFMANN D, 1981, INSECT BIOCHEM, V11, P537, DOI 10.1016/0020-1790(81)90022-6; Ivanov VT, 1997, BIOPOLYMERS, V43, P171; Iwanaga S, 1998, J BIOCHEM, V123, P1; Johns R, 1998, J MED ENTOMOL, V35, P458, DOI 10.1093/jmedent/35.4.458; KUHN KH, 1994, CELL TISSUE RES, V277, P493, DOI 10.1007/BF00300222; MIRANDA A, 1994, J MED CHEM, V37, P1450, DOI 10.1021/jm00036a010; SAUER MCV, 1972, COMP BIOCHEM PHYSIOL, V42, P205, DOI 10.1016/0305-0491(72)90267-2; SCHALLY AV, 1978, BIOCHEM BIOPH RES CO, V82, P582, DOI 10.1016/0006-291X(78)90914-2; SLEMMON JR, 1994, J NEUROSCI, V14, P2225; Slemmon JR, 1997, BIOPOLYMERS, V43, P157; Sonenshine D.E., 1991, BIOL TICKS, P3; Varanda LM, 1997, J PEPT RES, V50, P102; Yans LZ, 1998, J BIOL CHEM, V273, P2059, DOI 10.1074/jbc.273.4.2059	28	154	176	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25330	25334		10.1074/jbc.274.36.25330	http://dx.doi.org/10.1074/jbc.274.36.25330			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464258	hybrid			2022-12-25	WOS:000082554200023
J	Fukuoka, T; Kitami, Y; Okura, T; Hiwada, K				Fukuoka, T; Kitami, Y; Okura, T; Hiwada, K			Transcriptional regulation of the platelet-derived growth factor alpha receptor gene via CCAAT/enhancer-binding protein-delta in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RATS; 3 C/EBP ISOFORMS; MOLECULAR-STRUCTURE; FIBROBLAST PROLIFERATION; MITOGENIC ACTIVITY; BETA-RECEPTOR; EXPRESSION; INTERLEUKIN-1; PDGF; ATHEROSCLEROSIS	Inflammatory cytokines stimulate the proliferation of vascular smooth muscle cells (VSMC) and play a pivotal role in the pathogenesis of vascular diseases including atherosclerosis and restenosis. Mitogenic response of interleukin-1 beta (IL-1 beta) on VSMC is thought to be mediated by induction of endogenous platelet-derived growth factor (PDGF), especially PDGF-AA. Although the action of PDGF-AA is mediated by its specific receptor, PDGF alpha-receptor (PDGF alpha R), very little is known about the regulatory mechanism of PDGF alpha R gene expression in VSMC. To understand the mechanism, we studied the transcriptional control of the PDGF alpha R gene in VSMC after treatment with IL-1 beta, IL-1 beta (10 ng/ml) drastically increased both PDGF alpha R and CCAAT/enhancer-binding protein delta (C/EBP delta) mRNA levels in a time dependent manner. A rapid induction of C/EBP delta mRNA within 30 min was followed by slower emergence of PDGF alpha R mRNA, which reached the maximum level in 12 h, whereas C/EBP delta mRNA was detectable at 30 min and reached the maximum level at 3 h, Electromobility shift and supershift assays revealed that IL-1 beta markedly increased DNA-protein complex, which was mainly composed of C/EBP beta and/or -delta. Both Western blotting and immunohistochemistry demonstrated that either C/EBP beta or -delta expression was induced by IL-1 beta exclusively in nuclei of VSMC, On the other hand, overexpression of C/EBP delta specifically transactivated the promoter activity of the PDGF alpha R gene and significantly enhanced VSMC proliferation in PDGF-treated cells. We conclude that induction of PDGF alpha R expression is mainly mediated by C/EBP delta expression in VSMC, and a high level of C/EBP delta expression may be involved in the pathogenesis of atherosclerosis and restenosis.	Ehime Univ, Sch Med, Dept Internal Med 2, Matsuyama, Ehime 7910295, Japan	Ehime University	Kitami, Y (corresponding author), Ehime Univ, Sch Med, Dept Internal Med 2, Matsuyama, Ehime 7910295, Japan.							ALAM T, 1992, J BIOL CHEM, V267, P5021; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BITTERMAN PB, 1986, J CLIN INVEST, V77, P700, DOI 10.1172/JCI112364; BONIN PD, 1989, EXP CELL RES, V181, P475, DOI 10.1016/0014-4827(89)90104-3; Bonner JC, 1998, AM J PHYSIOL-LUNG C, V274, pL72, DOI 10.1152/ajplung.1998.274.1.L72; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOWLER S, 1980, CIRC RES, V46, P520, DOI 10.1161/01.RES.46.4.520; Fukuoka T, 1997, BIOCHEM BIOPH RES CO, V231, P30, DOI 10.1006/bbrc.1996.6031; GOWN AM, 1986, AM J PATHOL, V125, P191; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; IKEDA U, 1990, ATHEROSCLEROSIS, V84, P183, DOI 10.1016/0021-9150(90)90089-2; INUI H, 1993, J BIOL CHEM, V268, P17045; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KITAMI Y, 1989, J HYPERTENS, V7, P727; Kitami Y, 1998, J HYPERTENS, V16, P437, DOI 10.1097/00004872-199816040-00005; Kitami Y, 1999, CIRC RES, V84, P64; KITAMI Y, 1995, J CLIN INVEST, V96, P558, DOI 10.1172/JCI118068; Kolyada AY, 1995, AM J PHYSIOL-CELL PH, V269, pC1408, DOI 10.1152/ajpcell.1995.269.6.C1408; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; LIBBY P, 1985, ARTERIOSCLEROSIS, V5, P186, DOI 10.1161/01.ATV.5.2.186; Lindroos PM, 1997, AM J RESP CELL MOL, V16, P283, DOI 10.1165/ajrcmb.16.3.9070613; MULVANY MJ, 1978, CIRC RES, V43, P854, DOI 10.1161/01.RES.43.6.854; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SPAET TH, 1975, CIRC RES, V36, P58, DOI 10.1161/01.RES.36.1.58; Takata Y, 1999, HYPERTENSION, V33, P298, DOI 10.1161/01.HYP.33.1.298; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731	36	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25576	25582		10.1074/jbc.274.36.25576	http://dx.doi.org/10.1074/jbc.274.36.25576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464291	hybrid			2022-12-25	WOS:000082554200055
J	Gasdaska, JR; Harney, JW; Gasdaska, PY; Powis, G; Berry, MJ				Gasdaska, JR; Harney, JW; Gasdaska, PY; Powis, G; Berry, MJ			Regulation of human thioredoxin reductase expression and activity by 3 '-untranslated region selenocysteine insertion sequence and mRNA instability elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IODOTHYRONINE DEIODINASE; EUKARYOTIC SECIS ELEMENTS; GLUTATHIONE-PEROXIDASE; TARGETED DISRUPTION; CELL-PROLIFERATION; CANCER-CELLS; SELENIUM; GENE; PURIFICATION; MUTANT	Thioredoxin reductases function in regulating cellular redox and function through their substrate, thioredoxin, in the proper folding of enzymes and redox regulation of transcription factor activity. These enzymes are overexpressed in certain tumors and cancer cells and down-regulated in apoptosis and may play a role in regulating cell growth. Mammalian thioredoxin reductases contain a selenocysteine residue, encoded by a UGA codon, as the penultimate carboxyl-terminal amino acid. This amino acid has been proposed to carry reducing equivalents from the active site to substrates. We report; expression of a wild-type thioredoxin reductase selenoenzyme, a cysteine mutant enzyme, and the UGA-terminated protein in mammalian cells and overexpression of the cysteine mutant and UGA-terminated proteins in the baculovirus insect cell system. We show that substitution of cysteine for selenocysteine decreases enzyme activity for thioredoxin by 2 orders magnitude, and that termination at the UGA codon abolishes activity. We further demonstrate the presence of a functional selenacysteine insertion sequence element that is highly active but only moderately responsive to selenium supplementation. Finally, we show that thioredoxin reductase mRNA levels are down-regulated by other sequences in the 3'-untranslated region, which contains multiple AU-rich instability elements. These sequences are found in a number of cytokine and proto-oncogene mRNAs and have been shown to confer rapid mRNA turnover.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Thyroid Div, Boston, MA 02115 USA; Arizona Canc Ctr, Tucson, AZ 85724 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Arizona Center Cancer Care	Berry, MJ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Thyroid Div, 77 Ave Louis Pasteur, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA077204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047320, R01DK052963, R56DK047320] Funding Source: NIH RePORTER; NCI NIH HHS [CA77204] Funding Source: Medline; NIDDK NIH HHS [DK47320, DK52963] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGHIB DF, 1990, ONCOGENE, V5, P707; AXLEY MJ, 1991, P NATL ACAD SCI USA, V88, P8450, DOI 10.1073/pnas.88.19.8450; Baker A, 1997, CANCER RES, V57, P5162; Bermano G, 1996, BIOCHEM J, V320, P891, DOI 10.1042/bj3200891; BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Buettner C, 1998, J BIOL CHEM, V273, P33374, DOI 10.1074/jbc.273.50.33374; Chen CY, 1995, TRENDS BIOCHEM SCI, V11, P465, DOI DOI 10.1016/S0968-0004(00)89102-1.PUBMED:8578590; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; Gallegos A, 1996, CANCER RES, V56, P5765; Gasdaska PY, 1999, FEBS LETT, V442, P105, DOI 10.1016/S0014-5793(98)01638-X; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gorlatov SN, 1998, P NATL ACAD SCI USA, V95, P8520, DOI 10.1073/pnas.95.15.8520; Gromer S, 1998, BIOCHEM J, V332, P591, DOI 10.1042/bj3320591; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hennemann, 1996, THYROID ITS DIS; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Kim IY, 1997, P NATL ACAD SCI USA, V94, P418, DOI 10.1073/pnas.94.2.418; Kim SW, 1998, ENDOCRINOLOGY, V139, P4895, DOI 10.1210/en.139.12.4895; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Martin GW, 1998, RNA, V4, P65; Martin GW, 1996, RNA, V2, P171; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; MAU BL, 1992, BIOCHEM PHARMACOL, V43, P1621; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; Powis G, 1997, ONCOL RES, V9, P303; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581	39	88	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25379	25385		10.1074/jbc.274.36.25379	http://dx.doi.org/10.1074/jbc.274.36.25379			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464265	hybrid			2022-12-25	WOS:000082554200030
J	Kandror, KV				Kandror, KV			Insulin regulation of protein traffic in rat adipose cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 GLUCOSE-TRANSPORTER; FACTOR-II RECEPTORS; 3T3-L1 ADIPOCYTES; GROWTH-FACTOR; TRANSFERRIN RECEPTORS; PLASMA-MEMBRANE; MANNOSE 6-PHOSPHATE; SUBCELLULAR TRAFFICKING; POTENTIAL MECHANISM; VESICLES	Rat adipocytes were biotinylated with cell-impermeable reagents, sulfo-N-hydroxysuccinimide-biotin and sulfo-N-hydroxysuccinimide-S-S-biotin in the absence and presence of insulin. Biotinylated and nonbiotinylated populations of the insulin-like growth factor-II/mannose B-phosphate receptor, the transferrin receptor, and insulin-responsive aminopeptidase were separated by adsorption to streptavidin-agarose to determine the percentage of the biotinylated protein molecules versus their total amount in different subcellular compartments. Results indicate that adipose cells possess at least two distinct cell surface recycling pathways for insulin-like growth factor-II/mannose 6-phosphate receptor (MPR) and transferrin receptor (TfR): one which is mediated by glucose transporter isoform 4(Glu4)-vesicles and another that bypasses this compartment, Under basal conditions, the first pathway is not active, and cell surface recycling of TfR and, to a lesser extent, MPR proceeds via the second pathway. Insulin dramatically stimulates recycling through the first pathway and has little effect on the second. Within the Glut4-containing compartment, insulin has profoundly different effects on intracellular trafficking of insulin-responsive aminopeptidase on one hand and MPR and TfR on the other. After insulin administration, insulin-responsive aminopeptidase is redistributed from Glut4-containing vesicles to the plasma membrane and stays there for at least 30 min with minimal detectable internalization and recycling, whereas MPR and TfR rapidly shuttle between Glut4 vesicles and the plasma membrane in such a way that after 30 min of insulin treatment, virtually every receptor molecule in this compartment completes at least one trafficking cycle to the cell surface. Thus, different recycling proteins, which compose Glut4-containing vesicles, are internalized into this compartment at their own distinctive rates.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Kandror, KV (corresponding author), Boston Univ, Sch Med, Dept Biochem, K121,715 Albany St, Boston, MA 02118 USA.			Kandror, Konstantin/0000-0002-8601-9313	NIDDK NIH HHS [DK52057] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052057, R56DK052057] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DAMKE H, 1992, BIOCHEM J, V281, P225, DOI 10.1042/bj2810225; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; HARE JF, 1992, ARCH BIOCHEM BIOPHYS, V293, P416, DOI 10.1016/0003-9861(92)90414-R; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Johnson AO, 1998, J BIOL CHEM, V273, P17968, DOI 10.1074/jbc.273.28.17968; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kandror KV, 1998, BIOCHEM J, V331, P829, DOI 10.1042/bj3310829; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; Kandror KV, 1996, SEMIN CELL DEV BIOL, V7, P269, DOI 10.1006/scdb.1996.0035; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; Martin S, 1997, J CELL SCI, V110, P2281; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; OKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P4028, DOI 10.1073/pnas.81.13.4028; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; RODBELL M, 1964, J BIOL CHEM, V239, P375; Ross SA, 1998, BIOCHEM J, V330, P1003; Ross SA, 1997, BIOCHEM BIOPH RES CO, V239, P247, DOI 10.1006/bbrc.1997.7459; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SATOH S, 1993, J BIOL CHEM, V268, P17820; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TANNER LI, 1987, J BIOL CHEM, V262, P8975; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378	41	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25210	25217		10.1074/jbc.274.36.25210	http://dx.doi.org/10.1074/jbc.274.36.25210			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464241	hybrid			2022-12-25	WOS:000082554200006
J	Lyford, LK; Rosenberg, RL				Lyford, LK; Rosenberg, RL			Cell-free expression and functional reconstitution of homo-oligomeric alpha 7 nicotinic acetylcholine receptors into planar lipid bilayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; PHARMACOLOGICAL PROPERTIES; ENDOPLASMIC-RETICULUM; SYNAPTIC TRANSMISSION; TORPEDO-CALIFORNICA; CHANNEL DOMAIN; ION CHANNELS; BINDING SITE; SUBUNIT; SUBTYPES	The alpha 7 nicotinic acetylcholine receptor (nAChR) is a ligand-gated ion channel that modulates neurotransmitter release in the central nervous system. We show here that functional, homo-oligomeric alpha 7 nAChRs can be synthesized in vitro with a rabbit reticulocyte lysate translation system supplemented with endoplasmic reticulum microsomes, reconstituted into planar lipid bilayers, and evaluated using single-channel recording techniques. Because wild-type alpha 7 nAChRs desensitize rapidly, we used a nondesensitizing form of the alpha 7 receptor with mutations in the second transmembrane domain (S2'T and L9'T) to record channel activity in the continuous presence of agonist. Endoglycosidase H treatment of microsomes containing nascent alpha 7 S2'T/L9'T nAChRs indicated that the receptors were glycosylated. A proteinase K protection assay revealed a 36-kDa fragment in the ER lumen, consistent with a large extracellular domain predicted by most topological models, indicating that the protein was folded integrally through the ER membrane. alpha 7 S2'T/L9'T receptors reconstituted into planar lipid bilayers had a unitary conductance of similar to 50 pS, were highly selective for monovalent cations over Cl-, were nonselective between K+ and Na+, and were blocked by alpha-bungarotoxin, This is the first demonstration that a functional ligand-gated ion channel can be synthesized using an in vitro expression system.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Rosenberg, RL (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.				NINDS NIH HHS [NS37317] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037317] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albuquerque EX, 1997, J PHARMACOL EXP THER, V280, P1117; ANAND R, 1991, J BIOL CHEM, V266, P11192; ANAND R, 1993, FEBS LETT, V327, P241, DOI 10.1016/0014-5793(93)80177-V; ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; Arias HR, 1997, BRAIN RES REV, V25, P133, DOI 10.1016/S0165-0173(97)00020-9; AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; BIELEFELDT K, 1994, J PHYSIOL-LONDON, V475, P241, DOI 10.1113/jphysiol.1994.sp020065; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BULLER AL, 1990, MOL PHARMACOL, V37, P423; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; Chen DN, 1997, J BIOL CHEM, V272, P24024, DOI 10.1074/jbc.272.38.24024; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; Cooper ST, 1997, J NEUROCHEM, V68, P2140; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DAS RC, 1980, J BIOL CHEM, V255, P7933; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; Gelman MS, 1996, J BIOL CHEM, V271, P10709, DOI 10.1074/jbc.271.18.10709; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GOPALAKRISHNAN M, 1995, EUR J PHARM-MOLEC PH, V290, P237, DOI 10.1016/0922-4106(95)00083-6; GOTTI C, 1993, J RECEPTOR RES, V13, P453, DOI 10.3109/10799899309073672; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; Hille B., 1992, IONIC CHANNELS EXCIT; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kassner PD, 1997, J NEUROBIOL, V33, P968, DOI 10.1002/(SICI)1097-4695(199712)33:7<968::AID-NEU8>3.0.CO;2-6; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; KEYSER KT, 1993, J NEUROSCI, V13, P442; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; KRUSE M, 1995, J BIOL CHEM, V270, P2588, DOI 10.1074/jbc.270.6.2588; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MILEDI R, 1971, NATURE, V233, P599, DOI 10.1038/233599a0; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; PAPKE RL, 1993, PROG NEUROBIOL, V41, P509, DOI 10.1016/0301-0082(93)90028-Q; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; Rangwala F, 1997, J NEUROSCI, V17, P8201; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; ROBINSON RA, 1961, J PHYS CHEM-US, V65, P662, DOI 10.1021/j100822a016; ROBINSON RA, 1968, ELECTROLYTE SOLUTION, P445; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; ROSENBERG RL, 1992, NATURE, V360, P166, DOI 10.1038/360166a0; SANDS SB, 1993, BIOPHYS J, V65, P2614, DOI 10.1016/S0006-3495(93)81296-7; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SEGUELA P, 1993, J NEUROSCI, V13, P596; Shtrom SS, 1996, J BIOL CHEM, V271, P25506, DOI 10.1074/jbc.271.41.25506; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Yu CR, 1998, J PHYSIOL-LONDON, V509, P651, DOI 10.1111/j.1469-7793.1998.651bm.x	59	22	27	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25675	25681		10.1074/jbc.274.36.25675	http://dx.doi.org/10.1074/jbc.274.36.25675			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464304	hybrid, Green Published			2022-12-25	WOS:000082554200068
J	Mourey, L; Kotra, LP; Bellettini, J; Bulychev, A; O'Brien, M; Miller, MJ; Mobashery, S; Samama, JP				Mourey, L; Kotra, LP; Bellettini, J; Bulychev, A; O'Brien, M; Miller, MJ; Mobashery, S; Samama, JP			Inhibition of the broad spectrum nonmetallocarbapenamase of class A (NMC-A) beta-lactamase from Enterobacter cloacae by monocyclic beta-lactams	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENZYME; REACTIVATION; MECHANISM; CLONING; PACKAGE; GENE	beta-Lactamases hydrolyze beta-lactam antibiotics, a reaction that destroys their antibacterial activity. These enzymes, of which four classes are known, are the primary cause of resistance to beta-lactam antibiotics. The class A beta-lactamases form the largest group. A novel class A beta-lactamase, named the nonmetallocarbapenamase of class A (NMC-A) beta-lactamase, has been discovered recently that has a broad substrate profile that included carbapenem antibiotics. This is a serious development, since carbapenems have been relatively immune to the action of these resistance enzymes. Inhibitors for this enzyme are sought. We describe herein that a type of monobactam molecule of our design inactivates the NMC-A beta-lactamase rapidly, efficiently, and irreversibly, The mechanism of inactivation was investigated by solving the x-ray structure of the inhibited NMC-A enzyme to 1.95 Angstrom resolution. The structure shed light on the nature of the fragmentation of the inhibitor on enzyme acylation and indicated that there are two acyl-enzyme species that account for enzyme inhibition. Each of these inhibited enzyme species is trapped in a distinct local energy minimum that does not predispose the inhibitor species for deacylation, accounting for the irreversible mode of enzyme inhibition. Molecular dynamics simulations provided evidence in favor of a dynamic motion for the acyl-enzyme species, which samples a considerable conformational space prior to the entrapment of the two stable acyl-enzyme species in the local energy minima, A discussion of the likelihood of such dynamic motion for turnover of substrates during the normal catalytic processes of the enzyme is presented.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; CNRS, Inst Pharmacol & Biol Struct, Grp Cristallog Biol, F-31077 Toulouse, France; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	Wayne State University; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Notre Dame	Mobashery, S (corresponding author), Wayne State Univ, Dept Chem, Detroit, MI 48202 USA.	som@mobashery.chem.wayne.edu; samama@ipbs.fr	Mourey, Lionel/B-5662-2009	Mourey, Lionel/0000-0002-8259-1259				[Anonymous], SYBYL MOL MOD SOFTW; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; BULYCHEV A, 1995, J AM CHEM SOC, V117, P5938, DOI 10.1021/ja00127a005; Bush K, 1998, ADV EXP MED BIOL, V456, P71; CASE DA, 1997, AMBER 5; GLICK BR, 1978, CAN J BIOCHEM CELL B, V56, P1055, DOI 10.1139/o78-166; HARDY LW, 1989, ARCH BIOCHEM BIOPHYS, V268, P338, DOI 10.1016/0003-9861(89)90595-X; KOERBER SC, 1987, ANAL BIOCHEM, V165, P75, DOI 10.1016/0003-2697(87)90203-X; Matagne A, 1998, BIOCHEM J, V330, P581, DOI 10.1042/bj3300581; Maveyraud L, 1998, J AM CHEM SOC, V120, P9748, DOI 10.1021/ja9818001; Maveyraud L, 1996, J AM CHEM SOC, V118, P7435, DOI 10.1021/ja9609718; Mourey L, 1998, J AM CHEM SOC, V120, P9382, DOI 10.1021/ja9817996; NAAS T, 1994, ANTIMICROB AGENTS CH, V38, P1262, DOI 10.1128/AAC.38.6.1262; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NORDMANN P, 1993, ANTIMICROB AGENTS CH, V37, P939, DOI 10.1128/AAC.37.5.939; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Rasmussen BA, 1996, ANTIMICROB AGENTS CH, V40, P2080, DOI 10.1128/AAC.40.9.2080; Rasmussen BA, 1997, ANTIMICROB AGENTS CH, V41, P223, DOI 10.1128/AAC.41.2.223; ROUSSEL A, TURBO FRODO PROGRAM; Swaren P, 1998, J BIOL CHEM, V273, P26714, DOI 10.1074/jbc.273.41.26714; Swaren P, 1999, J AM CHEM SOC, V121, P5353, DOI 10.1021/ja990400q; Wilkinson AS, 1999, BIOCHEMISTRY-US, V38, P3851, DOI 10.1021/bi990030i	24	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25260	25265		10.1074/jbc.274.36.25260	http://dx.doi.org/10.1074/jbc.274.36.25260			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464248	hybrid			2022-12-25	WOS:000082554200013
J	Moz, Y; Silver, J; Naveh-Many, T				Moz, Y; Silver, J; Naveh-Many, T			Protein-RNA interactions determine the stability of the renal NaPi-2 cotransporter mRNA and its translation in hypophosphatemic rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE GENE-EXPRESSION; OPOSSUM KIDNEY-CELLS; NA/P-I-COTRANSPORT; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; PARATHYROID-GLANDS; PTH SECRETION; PHOSPHATE; PHOSPHORUS; ADAPTATION	Hypophosphatemia leads to an increase in type II Na+ dependent inorganic phosphate cotransporter (NaPi-2) mRNA and protein levels in the kidney and increases renal phosphate reabsorption. Nuclear transcript run-on experiments showed that the effect of a low phosphate diet was post-transcriptional. In an in vitro degradation assay, renal proteins from hypophosphatemic rats stabilized the NaPi-2 transcript g-fold compared with control rats and this was dependent upon an intact NaPi-2 3'-untranslated region (UTR), To determine an effect of hypophosphatemia upon NaPi-a protein synthesis, the incorporation of injected [S-35]methionine into renal proteins was studied in vivo, Hypophosphatemia leads to increased [S-35]methionine incorporation only into NaPi-2 protein. The effect of hypophosphatemia on translation was studied in an in vitro translation assay, where hypophosphatemic renal proteins led to increased translation of NaPi-2 and other transcripts. NaPi-2 RNA interaction with cytosolic proteins was studied by UV cross-linking and Northwestern gels. Hypophosphatemic proteins led to increased binding of renal cytosolic proteins to the 5'-UTR of NaPi-2 mRNA. Therefore, hypophosphatemia increases NaPi-2 gene expression post-transcriptionally, which correlates with a more stable transcript mediated by the 3'-UTR, and an increase in NaPi-2 translation involving protein binding to the 5'-UTR. These findings show that phosphate regulates gene expression by affecting protein-RNA interactions in vivo.	Hadassah Univ Hosp, Serv Nephrol, Minerva Ctr Calcium & Bone Metab, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Moz, Y (corresponding author), Hadassah Univ Hosp, Serv Nephrol, Minerva Ctr Calcium & Bone Metab, IL-91120 Jerusalem, Israel.							Almaden Y, 1996, J BONE MINER RES, V11, P970; Beck L, 1997, J CLIN INVEST, V99, P1200, DOI 10.1172/JCI119276; Biber J, 1996, KIDNEY INT, V49, P981, DOI 10.1038/ki.1996.139; BIBER J, 1993, RENAL PHYSIOL BIOCH, V16, P37; BIBER J, 1988, AM J PHYSIOL, V255, pC155, DOI 10.1152/ajpcell.1988.255.2.C155; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Friedlander G, 1996, Curr Opin Nephrol Hypertens, V5, P316, DOI 10.1097/00041552-199607000-00005; Jackson RJ, 1997, CURR OPIN GENET DEV, V7, P233, DOI 10.1016/S0959-437X(97)80133-5; KEMPSON SA, 1995, AM J PHYSIOL-RENAL, V268, pF784, DOI 10.1152/ajprenal.1995.268.4.F784; KILAV R, 1995, AM J PHYSIOL-RENAL, V268, pF1017, DOI 10.1152/ajprenal.1995.268.6.F1017; KILAV R, 1995, J CLIN INVEST, V96, P327, DOI 10.1172/JCI118038; LEVI M, 1995, J CLIN INVEST, V96, P207, DOI 10.1172/JCI118022; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; LEVI M, 1994, PFLUG ARCH EUR J PHY, V426, P5, DOI 10.1007/BF00374664; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LoghmanAdham M, 1997, J LAB CLIN MED, V129, P176, DOI 10.1016/S0022-2143(97)90137-2; Lotscher M, 1997, J CLIN INVEST, V99, P1302, DOI 10.1172/JCI119289; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MANDLA S, 1992, J CLIN ENDOCR METAB, V74, P814, DOI 10.1210/jc.74.4.814; MARKOVICH D, 1995, PFLUG ARCH EUR J PHY, V430, P459, DOI 10.1007/BF00373881; Moallem E, 1998, J BIOL CHEM, V273, P5253, DOI 10.1074/jbc.273.9.5253; MURER H, 1994, J EXP BIOL, V196, P167; MURER H, 1992, J AM SOC NEPHROL, V2, P1649; Nielsen PK, 1996, NEPHROL DIAL TRANSPL, V11, P1762; Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909; SAXENA S, 1995, BIOCHEM BIOPH RES CO, V216, P141, DOI 10.1006/bbrc.1995.2602; Slatopolsky E, 1996, J CLIN INVEST, V97, P2534, DOI 10.1172/JCI118701; Tatsumi S, 1998, ENDOCRINOLOGY, V139, P1692, DOI 10.1210/en.139.4.1692; TENENHOUSE HS, 1993, PEDIATR NEPHROL, V7, P312, DOI 10.1007/BF00853232; THEIL EC, 1994, BIOCHEM J, V304, P1; VRTOVSNIK F, 1994, J BIOL CHEM, V269, P8872; WERNER A, 1994, J BIOL CHEM, V269, P6637; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Xiao YS, 1997, BIOCHEM J, V323, P401, DOI 10.1042/bj3230401; YANAGAWA N, 1991, DISORDERS BONE MINER, P3	35	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25266	25272		10.1074/jbc.274.36.25266	http://dx.doi.org/10.1074/jbc.274.36.25266			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464249	hybrid			2022-12-25	WOS:000082554200014
J	Perret, P; Sarda, X; Wolff, M; Wu, TT; Bushey, D; Goeldner, M				Perret, P; Sarda, X; Wolff, M; Wu, TT; Bushey, D; Goeldner, M			Interaction of non-competitive blockers within the gamma-aminobutyric acid type A chloride channel using chemically reactive probes as chemical sensors for cysteine mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; A-RECEPTOR; DROSOPHILA-MELANOGASTER; GABA(A) RECEPTORS; XENOPUS OOCYTES; LINING RESIDUES; ALPHA-SUBUNIT; BINDING-SITE; BETA-SUBUNIT; C-RECEPTOR	Selected channel-lining cysteine mutants from the M2 segment of rat al gamma-aminobutyric acid (GABA) type A receptor subunit, at positions 257, 261, 264, and 272 were co-expressed with beta 1 and gamma 2 subunits in Xenopus oocytes, They generated functional receptors displaying conductance and response to both GABA and picrotoxinin similar to the wild type (alpha 1 beta 1 gamma 2 receptor. Three chemically reactive affinity probes derived from noncompetitive blockers were synthesized to react with the engineered cysteines: 1) dithiane bis-sulfone derivative modified by an isothiocyanate function (probe A); 2) fiprole derivatives modified by an alpha-chloroketone (probe B) and alpha-bromoketone (probe C) moiety, These probes blocked the GABA-induced currents on all receptors, This blockade could be fully reversed by a washing procedure on the wild type, the (alpha 1T261C beta 1 gamma 2 and (alpha 1L264C beta 1 gamma 2 mutant receptors. In contrast, an irreversible effect was observed for all three probes on both (alpha 1V257C beta 1 gamma 2 and alpha 1S272 beta 1 gamma 2 mutant receptors. This effect was probe concentration-dependent and could be abolished by picrotoxinin and/or t-butyl bicyclophosphorothionate. These data indicate a major interaction of non-competitive blockers at position 257 of the presumed M2 segment of rat alpha 1 subunit but also suggest an interaction at the more extracellular position 272.	Univ Louis Pasteur Strasbourg 1, Fac Pharm, UMR 7514 CNRS, Chim Bioorgan Lab, F-67401 Illkirch Graffenstaden, France; Rhone Poulenc AG Co, Res Triangle Pk, NC 27709 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Goeldner, M (corresponding author), Univ Louis Pasteur Strasbourg 1, Fac Pharm, UMR 7514 CNRS, Chim Bioorgan Lab, BP 24, F-67401 Illkirch Graffenstaden, France.							BARNARD EA, 1995, GABAA RECEPTORS ANXI, P1; BOWERY NG, 1995, PHARMACOLOGICAL SCIENCES: PERSPECTIVES FOR RESEARCH AND THERAPY IN THE LATE 1990S, P219; CASIDA JE, 1993, ARCH INSECT BIOCHEM, V22, P13, DOI 10.1002/arch.940220104; COLE LM, 1993, PESTIC BIOCHEM PHYS, V46, P47, DOI 10.1006/pest.1993.1035; DENG YL, 1991, PESTIC BIOCHEM PHYS, V41, P60, DOI 10.1016/0048-3575(91)90060-Y; DIPAOLA M, 1990, J BIOL CHEM, V265, P11017; ELLIOTT M, 1992, J AGR FOOD CHEM, V40, P147, DOI 10.1021/jf00013a029; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; FFRENCHCONSTANT RH, 1991, P NATL ACAD SCI USA, V88, P7209, DOI 10.1073/pnas.88.16.7209; GANT D B, 1990, Pesticide Science, V30, P355; Gant DB, 1998, PESTICIDES AND THE FUTURE, P147; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GURLEY D, 1995, RECEPTOR CHANNEL, V3, P13; HARVEY RJ, 1994, J NEUROCHEM, V62, P2480; HENDERSON JE, 1993, BIOCHEM BIOPH RES CO, V193, P474, DOI 10.1006/bbrc.1993.1648; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSIE AM, 1995, BRIT J PHARMACOL, V115, P909, DOI 10.1111/j.1476-5381.1995.tb15896.x; Johnston GAR, 1996, PHARMACOL THERAPEUT, V69, P173, DOI 10.1016/0163-7258(95)02043-8; KAPFER I, 1995, BIOCONJUGATE CHEM, V6, P109, DOI 10.1021/bc00031a013; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MAHLER H, 1996, ION CHANNELS, V4, P89; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; Tierney ML, 1996, J MEMBRANE BIOL, V154, P11, DOI 10.1007/s002329900128; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WANG TL, 1995, P NATL ACAD SCI USA, V92, P11751, DOI 10.1073/pnas.92.25.11751; WOODWARD RM, 1992, MOL PHARMACOL, V42, P165; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756	38	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25350	25354		10.1074/jbc.274.36.25350	http://dx.doi.org/10.1074/jbc.274.36.25350			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464261	hybrid			2022-12-25	WOS:000082554200026
J	Crespo, E; Macias, M; Pozo, D; Escames, G; Martin, M; Vives, F; Guerrero, JM; Acuna-Castroviejo, D				Crespo, E; Macias, M; Pozo, D; Escames, G; Martin, M; Vives, F; Guerrero, JM; Acuna-Castroviejo, D			Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats	FASEB JOURNAL			English	Article						iNOS; endotoxic shock; genomic effects	NITRIC-OXIDE SYNTHASE; L-ARGININE; NUCLEAR RECEPTOR; GENE-EXPRESSION; SEPTIC SHOCK; MICE; ANTIOXIDANT; PATHOPHYSIOLOGY; THERAPY; DAMAGE	We evaluated the role of melatonin in endotoxemia caused by lipopolysaccharide (LPS) in unanesthetized rats. The expression of inducible isoform of nitric oxide synthase (iNOS) and the increase in the oxidative stress seem to be responsible for the failure of lungs, liver, and kidneys in endotoxemia, Bacterial LPS (10 mg/kg b.w) was i.v. injected 6 h before rats were killed and melatonin (10-60 mg/kg b.w.) was i.p. injected before and/or after LPS, Endotoxemia was associated with a significant rise in the serum levels of aspartate and alanine aminotransferases, gamma-glutamyl-transferase, alkaline phosphatase, creatinine, urea, and uric acid, and hence liver and renal dysfunction. LPS also increased serum levels of cholesterol and triglycerides and reduced glucose levels. Melatonin administration counteracted these organ and metabolic alterations at doses ranging between 20 and 60 mg/kg b.w. Melatonin significantly decreased lung lipid peroxidation and counteracted the LPS induced NO levels in lungs and liver. Our results also show an inhibition of iNOS activity in rat lungs by melatonin in a dose-dependent manner. Expression of iNOS mRNA in lungs and liver was significantly decreased by melatonin (60 mg/kg b.w., 58-65%), We conclude that melatonin inhibits NO production mainly by inhibition of iNOS expression. The inhibition of NO levels may account for the protection of the indoleamine against LPS-induced endotoxemia in rats.	Fac Med, Dept Fisiol, Inst Biotecnol, E-18012 Granada, Spain; Univ Sevilla, Dept Bioquim Med & Biol Mol, Fac Med, Seville, Spain	University of Sevilla	Acuna-Castroviejo, D (corresponding author), Fac Med, Dept Fisiol, Inst Biotecnol, Avda Madrid 11, E-18012 Granada, Spain.		Pozo, David/C-2149-2017; Guerrero, Josep M./D-5519-2014; Crespo-Lopez, Maria Elena/X-7912-2018; Guerrero, Josep M./Y-2929-2019; IBIS, NEUROINMUNO/O-9306-2015; Acuña-Castroviejo, Dario/N-7456-2016; Escames, Germaine/N-7501-2016	Pozo, David/0000-0002-3732-4960; Guerrero, Josep M./0000-0001-5236-4592; Crespo-Lopez, Maria Elena/0000-0002-1335-6853; Acuña-Castroviejo, Dario/0000-0002-9680-1560; Escames, Germaine/0000-0003-1256-7656; Guerrero, Juan Miguel/0000-0001-7553-0119				ACUNACASTROVIEJO D, 1995, J PINEAL RES, V19, P57; ACUNACASTROVIEJO D, 1994, J PINEAL RES, V16, P100, DOI 10.1111/j.1600-079X.1994.tb00089.x; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; BARRON RL, 1993, CLIN PHARMACY, V12, P829; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bettahi I, 1996, J PINEAL RES, V20, P205, DOI 10.1111/j.1600-079X.1996.tb00260.x; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; DEITCH EA, 1992, ANN SURG, V216, P117, DOI 10.1097/00000658-199208000-00002; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; HARBRECHT RG, 1994, AM J PHYSIOL, V266, pG1004; Iuvone T, 1996, LIFE SCI, V59, pPL207; LAEMMLI UK, 1970, NATURE, V263, P789; Leon J, 1998, J NEUROENDOCRINOL, V10, P297, DOI 10.1046/j.1365-2826.1998.00203.x; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maestroni GJM, 1996, J PINEAL RES, V20, P84, DOI 10.1111/j.1600-079X.1996.tb00244.x; MARTIN M, 1997, J PHYSL BIOCH, V53, P179; MCCALLUM RE, 1973, INFECT IMMUN, V7, P642, DOI 10.1128/IAI.7.4.642-654.1973; Melchiorri Daniela, 1995, Life Sciences, V56, P83, DOI 10.1016/0024-3205(94)00417-Q; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P9; MOHAUPT MG, 1994, KIDNEY INT, V46, P653, DOI 10.1038/ki.1994.318; MolinaCarballo A, 1997, J PINEAL RES, V23, P97, DOI 10.1111/j.1600-079X.1997.tb00341.x; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; Pablos MI, 1995, J PINEAL RES, V19, P111, DOI 10.1111/j.1600-079X.1995.tb00178.x; PARKS DA, 1983, SURGERY, V94, P428; Pierre C., 1994, LIFE SCI, V55, P271; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; REITER RJ, 1995, J PINEAL RES, V18, P1, DOI 10.1111/j.1600-079X.1995.tb00133.x; Reiter RJ, 1997, ANN NY ACAD SCI, V825, P70, DOI 10.1111/j.1749-6632.1997.tb48415.x; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; SAKAGUCHI O, 1979, MICROBIOL IMMUNOL, V23, P71, DOI 10.1111/j.1348-0421.1979.tb00443.x; SAKAGUCHI S, 1981, MICROBIOL IMMUNOL, V25, P229, DOI 10.1111/j.1348-0421.1981.tb00026.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SEWERYNEK E, 1995, EUR J PHARM-ENVIRON, V293, P327, DOI 10.1016/0926-6917(95)90052-7; SEWERYNEK E, 1995, FREE RADICAL BIO MED, V19, P903, DOI 10.1016/0891-5849(95)00101-3; STADLER J, 1993, J LEUKOCYTE BIOL, V53, P165, DOI 10.1002/jlb.53.2.165; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; SUGINO K, 1989, SURGERY, V105, P200; Szabo C, 1995, New Horiz, V3, P2; Thiemermann C, 1994, Adv Pharmacol, V28, P45, DOI 10.1016/S1054-3589(08)60493-7; THIEMERMANN C, 1995, BRIT J PHARMACOL, V116, P2845, DOI 10.1111/j.1476-5381.1995.tb15935.x; Tracey K.J., 1992, TUMOR NECROSIS FACTO, P255; TRACEY WR, 1995, J PHARMACOL EXP THER, V272, P1011; VESLEY DL, 1997, AM J PHYSIOL, V314, P311; Vijayalaxmi Russel J. Reiter, 1995, Mutation Research, V346, P23; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48; EXPERIENTIA, V45, P739; [No title captured]	59	249	264	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1537	1546		10.1096/fasebj.13.12.1537	http://dx.doi.org/10.1096/fasebj.13.12.1537			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463945				2022-12-25	WOS:000082347600009
J	Alley, SC; Jones, AD; Soumillion, P; Benkovic, SJ				Alley, SC; Jones, AD; Soumillion, P; Benkovic, SJ			The carboxyl terminus of the bacteriophage T4 DNA polymerase contacts its sliding clamp at the subunit interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-ANALYSES; HOLOENZYME COMPLEX; ACCESSORY PROTEINS; REPLICATION; GENE; PROMOTER	The location of the interaction of the COOH terminus of the bacteriophage T4 DNA polymerase with its trimeric, circular sliding clamp has been established. A peptide corresponding to the COOH terminus of the DNA polymerase was labeled with a fluorophore and fluorescence spectroscopy used to show that it forms a specific complex with the sliding clamp by virtue of its low K-D value (7.1 +/- 1.0 mu M). The same peptide was labeled with a photoaffinity probe and cross-linked to the sliding clamp. Mass spectrometry of tryptic digests determined the sole linkage point to be Ala-159 on the sliding clamp, an amino acid that lies on the subunit interface. These results demonstrate that the COOH terminus of the DNA polymerase is inserted into the subunit interface of its sliding clamp, thereby conferring processivity to the DNA polymerase.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.		Jones, Arthur D/C-2670-2013	Jones, A. Daniel/0000-0002-7408-6690	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019492] Funding Source: NIH RePORTER; NCRR NIH HHS [RR11318] Funding Source: Medline; NIGMS NIH HHS [GM19492, GM13306] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alley SC, 1999, BIOCHEMISTRY-US, V38, P7696, DOI 10.1021/bi9827971; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; Berdis AJ, 1996, P NATL ACAD SCI USA, V93, P12822, DOI 10.1073/pnas.93.23.12822; Goodrich LD, 1997, BIOCHEMISTRY-US, V36, P10474, DOI 10.1021/bi9708949; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; KASSAVETIS GA, 1984, P NATL ACAD SCI-BIOL, V81, P5101, DOI 10.1073/pnas.81.16.5101; Latham Gary J., 1998, Research Communications in Biochemistry and Cell and Molecular Biology, V2, P139; Latham GJ, 1997, J BIOL CHEM, V272, P31677, DOI 10.1074/jbc.272.50.31677; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; NOSSAL NG, 1979, J BIOL CHEM, V254, P6026; Pietroni P, 1997, J BIOL CHEM, V272, P31666, DOI 10.1074/jbc.272.50.31666; Sanders GM, 1997, EMBO J, V16, P3124, DOI 10.1093/emboj/16.11.3124; Sexton DJ, 1997, CURR OPIN CHEM BIOL, V1, P316, DOI 10.1016/S1367-5931(97)80068-3; Sexton DJ, 1998, BIOCHEMISTRY-US, V37, P7749, DOI 10.1021/bi980088h; SPICER EK, 1982, J BIOL CHEM, V257, P8972; WANG CC, 1995, J BIOL CHEM, V270, P26558, DOI 10.1074/jbc.270.44.26558; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Yeh LS, 1998, J BACTERIOL, V180, P2005, DOI 10.1128/JB.180.8.2005-2013.1998; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	21	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24485	24489		10.1074/jbc.274.35.24485	http://dx.doi.org/10.1074/jbc.274.35.24485			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455110	hybrid			2022-12-25	WOS:000082193400009
J	Schafer, U; Beck, K; Muller, M				Schafer, U; Beck, K; Muller, M			Skp, a molecular chaperone of gram-negative bacteria, is required for the formation of soluble periplasmic intermediates of outer membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MALTOSE-BINDING PROTEIN; ESCHERICHIA-COLI K-12; RHODOBACTER-CAPSULATUS; FIRA-GENE; SALMONELLA-TYPHIMURIUM; PLASMA-MEMBRANE; EXPORT; TRANSLOCATION; SEQUENCE	Using a cross-linking approach, we have analyzed the function of Skp, a presumed molecular chaperone of the periplasmic space of Escherichia coli, during the biogenesis of an outer membrane protein (OmpA), Following its transmembrane translocation, OmpA interacts with Skp in close vicinity to the plasma membrane. In vitro, Skp was also found to bind strongly and specifically to pOmpA nascent chains after their release from the ribosome suggesting the ability of Skp to recognize early folding intermediates of outer membrane proteins. Pulse labeling of OmpA in spheroplasts prepared from an skp null mutant revealed a specific requirement of Skp for the release of newly translocated outer membrane proteins from the plasma membrane. Delta skp mutant cells are viable and show only slight changes in the physiology of their outer membranes. In contrast, double mutants deficient both in Skp and the periplasmic protease DegP (HtrA) do not grow at 37 degrees C in rich medium. We show that in the absence of an active DegP, a lack of Skp leads to the accumulation of protein aggregates in the periplasm, Collectively, our data demonstrate that Skp is a molecular chaperone involved in generating and maintaining the solubility of early folding intermediates of outer membrane proteins in the periplasmic space of Gram-negative bacteria.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Muller, M (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	mumatthi@ruf.uni-freiburg.de						AASLAND R, 1988, J BACTERIOL, V170, P5916, DOI 10.1128/jb.170.12.5916-5918.1988; AHREM B, 1989, J CELL BIOL, V108, P1637, DOI 10.1083/jcb.108.5.1637; Behrmann M, 1998, J BIOL CHEM, V273, P13898, DOI 10.1074/jbc.273.22.13898; Bothmann H, 1998, NAT BIOTECHNOL, V16, P376, DOI 10.1038/nbt0498-376; Chen R, 1996, MOL MICROBIOL, V19, P1287, DOI 10.1111/j.1365-2958.1996.tb02473.x; DANESE PN, 1995, GENE DEV, V9, P387, DOI 10.1101/gad.9.4.387; Danese PN, 1997, GENE DEV, V11, P1183, DOI 10.1101/gad.11.9.1183; Dartigalongue C, 1998, EMBO J, V17, P3968, DOI 10.1093/emboj/17.14.3968; de Cock H, 1999, EUR J BIOCHEM, V259, P96, DOI 10.1046/j.1432-1327.1999.00010.x; DICKER IB, 1991, J BACTERIOL, V173, P334, DOI 10.1128/jb.173.1.334-344.1991; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FREUDL R, 1986, J BIOL CHEM, V261, P1355; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; GEYER R, 1979, EUR J BIOCHEM, V98, P27, DOI 10.1111/j.1432-1033.1979.tb13156.x; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; Helde R, 1997, J BACTERIOL, V179, P4003, DOI 10.1128/jb.179.12.4003-4012.1997; HOLCK A, 1988, GENE, V67, P117; HOLCK A, 1987, BIOCHIM BIOPHYS ACTA, V914, P49, DOI 10.1016/0167-4838(87)90160-9; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KOSKI P, 1990, GENE, V88, P117; KOSKI P, 1989, J BIOL CHEM, V264, P18973; LATHE R, 1980, P NATL ACAD SCI-BIOL, V77, P3548, DOI 10.1073/pnas.77.6.3548; Lazar SW, 1996, J BACTERIOL, V178, P1770, DOI 10.1128/jb.178.6.1770-1773.1996; MANEEWANNAKUL S, 1994, PLASMID, V31, P300, DOI 10.1006/plas.1994.1032; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; Missiakas D, 1998, MOL MICROBIOL, V28, P1059, DOI 10.1046/j.1365-2958.1998.00865.x; NIKAIDO H, 1996, ESCHERICHIA COLI SAL, P29; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; POTGETER M, 1994, THESIS U FREIBURG GE; RICE CE, 1992, J HYDRAUL ENG-ASCE, V118, P1077, DOI 10.1061/(ASCE)0733-9429(1992)118:7(1077.2); Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; ROY AM, 1994, J BACTERIOL, V176, P1639, DOI 10.1128/jb.176.6.1639-1646.1994; SINGER M, 1989, MICROBIOL REV, V53, P1; SkorkoGlonek J, 1997, J BIOL CHEM, V272, P8974; SNYDER WB, 1995, J BACTERIOL, V177, P4216, DOI 10.1128/jb.177.15.4216-4223.1995; THOME BM, 1990, FEBS LETT, V269, P113, DOI 10.1016/0014-5793(90)81132-8; THOME BM, 1991, MOL MICROBIOL, V5, P2815, DOI 10.1111/j.1365-2958.1991.tb01990.x; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; VANGELDER P, 1997, MOL B INT U, P63; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WIESELER B, 1993, MOL MICROBIOL, V7, P167, DOI 10.1111/j.1365-2958.1993.tb01108.x	47	179	189	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24567	24574		10.1074/jbc.274.35.24567	http://dx.doi.org/10.1074/jbc.274.35.24567			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455120	hybrid			2022-12-25	WOS:000082193400019
J	Fournel, M; Sapieha, P; Beaulieu, N; Besterman, JM; MacLeod, AR				Fournel, M; Sapieha, P; Beaulieu, N; Besterman, JM; MacLeod, AR			Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21(WAF/Cip1) by distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-METHYLTRANSFERASE; GENE-EXPRESSION; 5-AZACYTIDINE TREATMENT; SIGNALING PATHWAY; HUMAN CANCERS; METHYLATION; INHIBITION; 5-AZA-2'-DEOXYCYTIDINE; 5-AZADEOXYCYTIDINE; DEMETHYLATION	A common event in the development of human neoplasia is the loss of growth regulatory tumor suppressor functions. Methylation of 5' CpG islands of tumor suppressor genes and elevated levels of the DNA-(cytosine-5)-methyltransferase enzyme (DNA MeTase) are also prevalent features of human neoplasia, However, direct evidence that elevated DNA MeTase levels alter gene expression and influence oncogenesis has been difficult to obtain, in part due to the lack of specific DNA MeTase inhibitors. Here we show that specific reduction of cellular DNA MeTase levels in human cancer cells with potent antisense inhibitors: 1) causes demethylation of the p16(ink4A) gene promoter; 2) causes re-expression of the p16(ink4A) protein; 3) leads to accumulation of the hypophosphorylated form of the retinoblastoma protein (pRb); and 4) inhibits cell proliferation. Stepwise reduction of cellular DNA MeTase protein levels also induced a corresponding rapid increase in the cell cycle regulator p21(WAF/Cip1) protein demonstrating a regulatory link between DNA MeTase and the growth regulator p21(WAF/Cip1) that is independent of methylation of DNA. These results suggest that the elevated levels of DNA MeTase seen in cancer cells can inhibit tumor suppressors by distinct mechanisms involving either transcriptional inactivation through DNA methylation or by a methylation independent regulation.	MethylGene Inc, Montreal, PQ H4S 2A1, Canada	MethylGene Inc	MacLeod, AR (corresponding author), MethylGene Inc, 7220 Freder Banting, Montreal, PQ H4S 2A1, Canada.	macleodr@methylgene.com						ADAMS RLP, 1979, BIOCHIM BIOPHYS ACTA, V561, P345, DOI 10.1016/0005-2787(79)90143-6; Baghdassarian N, 1996, HEMATOL CELL THER, V38, P313, DOI 10.1007/s00282-996-0313-4; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; Bender CM, 1998, CANCER RES, V58, P95; Bestor TH, 1998, NATURE, V393, P311, DOI 10.1038/30613; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Costello JF, 1996, CANCER RES, V56, P2405; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gaudet F, 1998, J BIOL CHEM, V273, P32725, DOI 10.1074/jbc.273.49.32725; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Gotz C, 1996, ONCOGENE, V13, P391; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; HAAF T, 1989, CHROMOSOMA, V98, P93, DOI 10.1007/BF00291043; HERMAN JG, 1995, CANCER RES, V55, P4525; HORI T, 1983, MUTAT RES, V121, P47, DOI 10.1016/0165-7992(83)90085-4; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; LAL D, 1988, MUTAT RES, V193, P229, DOI 10.1016/0167-8817(88)90033-8; Lei H, 1996, DEVELOPMENT, V122, P3195; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lo KW, 1996, CANCER RES, V56, P2721; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MONIA BP, 1993, J BIOL CHEM, V268, P14514; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SZYF M, 1991, J BIOL CHEM, V266, P10027; TAM SW, 1994, CANCER RES, V54, P5816; TAMAME M, 1983, MOL CELL BIOL, V3, P2287, DOI 10.1128/MCB.3.12.2287; Taylor EM, 1996, MOL GEN GENET, V253, P128, DOI 10.1007/s004380050305; Warnecke PM, 1998, DEV GENET, V22, P111, DOI 10.1002/(SICI)1520-6408(1998)22:2&lt;111::AID-DVG1&gt;3.0.CO;2-9; WOODCOCK DM, 1998, GENE AMST, V5, P63; Yeivin A, 1993, EXS, V64, P523; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125	49	101	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24250	24256		10.1074/jbc.274.34.24250	http://dx.doi.org/10.1074/jbc.274.34.24250			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446200	hybrid			2022-12-25	WOS:000082110900079
J	Jain, N; Zhang, T; Kee, WH; Li, WQ; Cao, XM				Jain, N; Zhang, T; Kee, WH; Li, WQ; Cao, XM			Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TRANSCRIPTION FACTOR APRF; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; GENE-REGULATION; V-SRC; ACTIVATION; PATHWAY	Stat3 is activated by phosphorylation on Tyr-705, which leads to dimer formation, nuclear translocation, and regulation of gene expression. Serine phosphorylation of Stat3 by mitogen-activated protein kinase has also been observed in cells responding to epidermal growth factor and shown to affect its tyrosine phosphorylation and transcriptional activity. Serine phosphorylation of Stat3 is also induced by interleukin-6 (IL-6) stimulation, which is shown to be independent of mitogen activated protein kinase and sensitive to the Ser/ Thr kinase inhibitor H7. In this study, we investigated whether protein kinase C (PKC) is the kinase that is induced and responsible for Stat3 serine phosphorylation by IL-6 stimulation and which isoform of PKCs is likely to be involved. Here, we report that Stat3 was specifically associated with PKC delta in vivo in an IL-6-dependent manner in several cell types. Furthermore, Stat3 was phosphorylated by PKC delta in vivo on Ser-727, which could be inhibited either by a specific PKC delta inhibitor or by a dominant-negative mutant of PKC delta. Finally, we showed that the phosphorylation of Stat3 by PKC delta led to a negative regulation of Stat3 DNA binding and transcriptional activity. These results indicate that PKC delta is likely to be the kinase that phosphorylates Stat3 in response to IL-6 stimulation and suggest a possible regulatory role of PKC delta on Stats function.	Natl Univ Singapore, Signal Transduct Lab, Inst Mol & Cell Biol, Singapore 117609, Singapore; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cao, XM (corresponding author), Natl Univ Singapore, Signal Transduct Lab, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbcaoxm@imcb.nus.edu.sg						AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENNING MF, 1993, J BIOL CHEM, V268, P26079; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HELM MH, 1995, SCIENCE, V267, P1347; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, J BIOL CHEM, V269, P2349; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MALATHY S, 1998, ONCOGENE, V16, P1649; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Saharinen P, 1997, BLOOD, V90, P4341; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu YY, 1996, J BIOL CHEM, V271, P13033, DOI 10.1074/jbc.271.22.13033; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	47	172	174	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24392	24400		10.1074/jbc.274.34.24392	http://dx.doi.org/10.1074/jbc.274.34.24392			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446219	hybrid			2022-12-25	WOS:000082110900098
J	Kumar, LVS; Ramakrishna, T; Rao, CM				Kumar, LVS; Ramakrishna, T; Rao, CM			Structural and functional consequences of the mutation of a conserved arginine residue in alpha A and alpha B crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; HEAT-SHOCK PROTEIN; QUATERNARY STRUCTURE; MOLECULAR CHAPERONE; MISSENSE MUTATION; LENS; DESMIN; GENE; TEMPERATURE; FILAMENTS	A point mutation of a highly conserved arginine residue in alpha A and alpha B crystallins was shown to cause autosomal dominant congenital cataract and desmin-related myopathy, respectively, in humans. To study the structural and functional consequences of this mutation, human alpha A and alpha B crystallin genes were cloned and the conserved arginine residue (Arg-116 in alpha A crystallin and Arg-120 in alpha B crystallin) mutated to Cys and Gly, respectively, by site-directed mutagenesis, The recombinant wild-type and mutant proteins were expressed in Escherichia coli and purified. The mutant and wild-type proteins were characterized by SDS-polyacrylamide gel electrophoresis, Western immunoblotting, gel permeation chromatography, fluorescence, and circular dichroism spectroscopy. Biophysical studies reveal significant differences between the wild-type and mutant proteins. The chaperone-like activity was studied by analyzing the ability of the recombinant proteins to prevent dithiothreitol-induced aggregation of insulin. The mutations R116C in alpha A crystallin and R120G in alpha B crystallin reduce the chaperone-like activity of these proteins significantly. Near UV circular dichroism and intrinsic fluorescence spectra indicate a change in tertiary structure of the mutants, Bar UV circular dichroism spectra suggest altered packing of the secondary structural elements. Gel permeation chromatography reveals polydispersity for both of the mutant proteins. An appreciable increase in the molecular mass of the mutant alpha A crystallin is also observed. However, the change in oligomer size of the alpha B mutant is less significant. These results suggest that the conserved arginine of the alpha-crystallin domain of the small heat shock proteins is essential for their structural integrity and subsequent in vivo function.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Rao, CM (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.	mohan@ccmb.ap.nic.in		Tangirala, Ramakrishna/0000-0002-0738-329X				BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; DEJONG WW, 1984, EUR J BIOCHEM, V141, P131; Djabali K, 1997, J CELL SCI, V110, P2759; DUBIN RA, 1990, GENOMICS, V7, P594, DOI 10.1016/0888-7543(90)90204-8; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IJSSELL PVD, 1999, CURR BIOL, V9, pR103; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P113, DOI 10.1007/BF00221052; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; Quinlan RA, 1999, INVEST OPHTH VIS SCI, V40, pS3; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAMAN B, 1995, J BIOL CHEM, V270, P19888, DOI 10.1074/jbc.270.34.19888; RAPPAPORT L, 1988, FEBS LETT, V231, P421, DOI 10.1016/0014-5793(88)80863-9; Shroff NP, 1999, INVEST OPHTH VIS SCI, V40, pS786; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SMULDERS RHPH, 1995, J BIOL CHEM, V270, P13916, DOI 10.1074/jbc.270.23.13916; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; VANDENOETELAAR PJM, 1985, J BIOL CHEM, V260, P4030; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; WYNN R, 1993, PROTEIN SCI, V2, P395	34	133	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24137	24141		10.1074/jbc.274.34.24137	http://dx.doi.org/10.1074/jbc.274.34.24137			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446186	hybrid			2022-12-25	WOS:000082110900065
J	Volk, R; Schwartz, JJ; Li, J; Rosenberg, RD; Simons, M				Volk, R; Schwartz, JJ; Li, J; Rosenberg, RD; Simons, M			The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; PROTEIN-KINASE-C; CELL-SURFACE; ENDOTHELIAL-CELLS; RECEPTOR ACTIVATION; MOLECULAR-CLONING; ARTERIAL INJURY; NERVOUS-SYSTEM; EXPRESSION; BINDING	To determine the role played by syndecan-4 cytoplasmic mic domain in the mediation of basic fibroblast growth factor (bFGF) signaling, immortalized human cells (ECV) were used to generate cell lines expressing constructs encoding full-length sequences for syndecan-4 (S4), syndecan-1 (S1), glypican-1 (G1), or chimeric proteins consisting of the ectoplasmic domain of glypican-1 linked to the transmembrane/cytoplasmic domain of syndecan-4 (G1-S4c) and the ectoplasmic domain of syndecan-4 linked to the glypican-1 glycosylphosphatidylinositol (GPI) anchor sequence (S4-GPI). Vector-transduced cells (VC) were used as controls. Expression of all these proteoglycans (except for the vector control) significantly increased cell-associated heparan sulfate mass and the number of low affinity bFGF-binding sites. However, in low serum medium, the addition of bFGF stimulated growth and migration of cells expressing S4 and G1-S4c constructs but not G1, S1, S4-GPI, or VC cells. Similar results were obtained using Matrigel growth assays. Mutations of heparan sulfate attachment sites on S4 construct abolished syndecan-4-dependent augmentation of bFGF responses. We conclude that cytoplasmic tail of syndecan-4 plays an important role in bFGF-mediated signal transduction.	Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med, Angiogenesis Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Simons, M (corresponding author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med, Angiogenesis Res Ctr, 330 Brookline Ave, Boston, MA 02215 USA.	msimons@caregroup.harvard.edu	Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056993, R01HL053793] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL56993, R01 HL53793] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIEZER D, 1994, J BIOL CHEM, V269, P114; Bein K, 1997, J CELL PHYSIOL, V173, P319, DOI 10.1002/(SICI)1097-4652(199712)173:3<319::AID-JCP3>3.0.CO;2-Q; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; Carey DJ, 1997, BIOCHEM J, V327, P1; CizmeciSmith G, 1997, ARTERIOSCL THROM VAS, V17, P172, DOI 10.1161/01.ATV.17.1.172; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; DAVID G, 1992, ADV EXP MED BIOL, V313, P69; Dhanabal M, 1999, CANCER RES, V59, P189; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HAWLEY RG, 1994, GENE THER, V1, P136; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Ihrcke NS, 1996, J CELL PHYSIOL, V168, P625, DOI 10.1002/(SICI)1097-4652(199609)168:3<625::AID-JCP15>3.3.CO;2-A; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; Li JA, 1997, CIRC RES, V81, P785; LIEBERSBACH BF, 1994, J BIOL CHEM, V269, P20013; LITWACK ED, 1994, J NEUROSCI, V14, P3713; MALI M, 1993, J BIOL CHEM, V268, P24215; MERTENS G, 1992, J BIOL CHEM, V267, P20435; NAKATO H, 1995, DEVELOPMENT, V121, P3687; NIKKARI ST, 1994, AM J PATHOL, V144, P1348; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; NUMA F, 1995, CANCER RES, V55, P4676; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; VAINIO S, 1991, DEV BIOL, V147, P322, DOI 10.1016/0012-1606(91)90290-J; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	46	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24417	24424		10.1074/jbc.274.34.24417	http://dx.doi.org/10.1074/jbc.274.34.24417			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446222	hybrid			2022-12-25	WOS:000082110900101
J	Gillert, E; Leis, T; Repp, R; Reichel, M; Hosch, A; Breitenlohner, I; Angermuller, S; Borkhardt, A; Harbott, J; Lampert, F; Griesinger, F; Greil, J; Fey, GH; Marschalek, R				Gillert, E; Leis, T; Repp, R; Reichel, M; Hosch, A; Breitenlohner, I; Angermuller, S; Borkhardt, A; Harbott, J; Lampert, F; Griesinger, F; Greil, J; Fey, GH; Marschalek, R			A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells	ONCOGENE			English	Article						MLL gene; AF-4/FEL gene; leukemia; chromosomal translocation t(4;11); recombination	BREAKPOINT CLUSTER REGION; TOPOISOMERASE-II INHIBITORS; NONHOMOLOGOUS RECOMBINATION; EXON/INTRON STRUCTURE; DROSOPHILA-TRITHORAX; SEQUENCE-ANALYSIS; MAMMALIAN-CELLS; ALL-1 GENE; AF-4 GENE; 11Q23	Some chromosomal translocations involved in the origin of leukemias and lymphomas are due to malfunctions of the recombinatorial machinery of immunoglobulin and T-cell receptor-genes, This mechanism has also been proposed for translocations t(4;11)(q21;q23), which are regularly associated with acute pro-B cell leukemias in early childhood. Here, reciprocal chromosomal breakpoints in primary biopsy material of fourteen t(4;11)leukemia patients were analysed. In all cases, duplications, deletions and inversions of less than a few hundred nucleotides indicative of malfunctioning DNA repair mechanisms were observed. We concluded that these translocation events were initiated by several DNA strand breaks on both participating chromosomes and subsequent DNA repair by 'error-prone-repair' mechanisms, but not by the action of recombinases of the immune system.	Univ Erlangen Nurnberg, Chair Genet, D-91058 Erlangen, Germany; Univ Giessen, Childrens Hosp, Dept Pediat Hematol & Oncol, D-35392 Giessen, Germany; Univ Gottingen Hosp, D-37075 Gottingen, Germany; Univ Erlangen Nurnberg, Dept Pediat, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; Justus Liebig University Giessen; University of Gottingen; University of Erlangen Nuremberg	Marschalek, R (corresponding author), Univ Erlangen Nurnberg, Chair Genet, Staudtstr 5, D-91058 Erlangen, Germany.		Marschalek, Rolf/D-3404-2011	Marschalek, Rolf/0000-0003-4870-3445; Reichel, Martin/0000-0001-7886-2784				Aplan PD, 1996, BLOOD, V87, P2649, DOI 10.1182/blood.V87.7.2649.bloodjournal8772649; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BREIT TM, 1993, J EXP MED, V177, P965, DOI 10.1084/jem.177.4.965; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; CHEN SJ, 1989, ONCOGENE, V4, P195; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HALUSKA FG, 1990, MOL GENETICS CANC DI, P143; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; Leis T, 1998, LEUKEMIA, V12, P758, DOI 10.1038/sj.leu.2401006; Marschalek R, 1997, LEUKEMIA LYMPHOMA, V27, P417, DOI 10.3109/10428199709058308; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; NEGRINI M, 1993, CANCER RES, V53, P4489; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; ONNO M, 1992, ONCOGENE, V7, P2519; PLESNER P, 1987, P NATL ACAD SCI USA, V84, P1936, DOI 10.1073/pnas.84.7.1936; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAIMONDI SC, 1995, BLOOD, V86, P1881, DOI 10.1182/blood.V86.5.1881.bloodjournal8651881; Reichel M, 1998, ONCOGENE, V17, P3035, DOI 10.1038/sj.onc.1202229; REPP R, 1995, LEUKEMIA, V9, P210; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Stanulla M, 1997, LEUKEMIA, V11, P490, DOI 10.1038/sj.leu.2400632; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDERPOEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735	32	82	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4663	4671		10.1038/sj.onc.1202842	http://dx.doi.org/10.1038/sj.onc.1202842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467413				2022-12-25	WOS:000082154400003
J	Conrad, PW; Rust, RT; Han, JH; Millhorn, DE; Beitner-Johnson, D				Conrad, PW; Rust, RT; Han, JH; Millhorn, DE; Beitner-Johnson, D			Selective activation of p38 alpha and p38 gamma by hypoxia - Role in regulation of cyclin D1 by hypoxia in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAP KINASE; NERVE GROWTH-FACTOR; TYROSINE-HYDROXYLASE GENE; PROTEIN-KINASE; TRANSCRIPTION FACTOR; CELLULAR STRESSES; RESPONSE ELEMENT; PHOSPHORYLATION; EXPRESSION; PATHWAY	Hypoxic/ischemic trauma is a primary factor in the pathology of a multitude of disease states, The effects of hypoxia on the stress- and mitogen-activated protein kinase signaling pathways were studied in PC12 cells. Exposure to moderate hypoxia (5% O-2) progressively stimulated phosphorylation and activation of p38 gamma in particular, and also p38 alpha, two stress-activated protein kinases, In contrast, hypoxia had no effect on enzyme activity of p38 beta, p38 beta(2), p38 delta, or on c-Jun N-terminal kinase, another stress-activated protein kinase. Prolonged hypoxia also induced phosphorylation and activation of p42/p44 mitogen-activated protein kinase, although this activation was modest compared with nerve growth factor- and ultraviolet light-induced activation. Hypoxia also dramatically down-regulated immunoreactivity of cyclin D1, a gene that is known to be regulated negatively by p38 at the level of gene expression (Lavoie, J, N., L'Allemain, G,, Brunet, A., Muller, R., and Pouyssegur, J. (1996) J. Biol. Chem. 271, 20608-20616). This effect was partially blocked by SB203580, an inhibitor of p38 alpha but not p38 gamma, Overexpression of a kinase-inactive form of p38 gamma was also able to reverse in part the effect of hypoxia on cyclin D1 levels, suggesting that p38 alpha and p38 gamma converge to regulate cyclin D1 during hypoxia, These studies demonstrate that an extremely typical physiological stress (hypoxia) causes selective activation of specific p38 signaling elements; and they also identify a downstream target of these pathways.	Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University System of Ohio; University of Cincinnati; Scripps Research Institute	Beitner-Johnson, D (corresponding author), Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA.		Han, J/G-4671-2010		NHLBI NIH HHS [R37HL33831, R01HL59945, HL07571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL033831, R01HL059945] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHSEGAWA M, 1999, J BIOL CHEM, V274, P12626; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; Beitner-Johnson D, 1998, BIOCHEM BIOPH RES CO, V242, P61, DOI 10.1006/bbrc.1997.7907; Conforti L, 1997, J PHYSIOL-LONDON, V502, P293, DOI 10.1111/j.1469-7793.1997.293bk.x; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; DEMPSEY E, 1991, AM J PHYSIOL, V260, P136; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Green S. H., 1995, Methods (Orlando), V7, P222, DOI 10.1006/meth.1995.1028; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kumar GK, 1998, AM J PHYSIOL-CELL PH, V274, pC1592, DOI 10.1152/ajpcell.1998.274.6.C1592; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Laderoute KR, 1999, J BIOL CHEM, V274, P12890, DOI 10.1074/jbc.274.18.12890; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PRABHAKAR NR, 1995, BRAIN RES, V697, P266, DOI 10.1016/0006-8993(95)00994-2; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Raymond R, 1997, KIDNEY INT, V51, P536, DOI 10.1038/ki.1997.74; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Sahai A, 1997, AM J PHYSIOL-RENAL, V273, pF954, DOI 10.1152/ajprenal.1997.273.6.F954; Sahai A, 1997, AM J PHYSIOL-RENAL, V272, pF809, DOI 10.1152/ajprenal.1997.272.6.F809; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Taylor SC, 1998, BIOCHEM BIOPH RES CO, V248, P13, DOI 10.1006/bbrc.1998.8905; VINDELOV LL, 1994, METHOD CELL BIOL, V41, P219; Wang XM, 1997, BIOCHEM BIOPH RES CO, V238, P207, DOI 10.1006/bbrc.1997.7273; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Woodgett JR, 1996, CANCER SURV, V27, P127; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yan GZ, 1997, J NEUROSCI, V17, P6122; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658	64	163	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23570	23576		10.1074/jbc.274.33.23570	http://dx.doi.org/10.1074/jbc.274.33.23570			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438538	hybrid			2022-12-25	WOS:000082012800088
J	Ariumi, Y; Masutani, M; Copeland, TD; Mimori, T; Sugimura, T; Shimotohno, K; Ueda, K; Hatanaka, M; Noda, M				Ariumi, Y; Masutani, M; Copeland, TD; Mimori, T; Sugimura, T; Shimotohno, K; Ueda, K; Hatanaka, M; Noda, M			Suppression of the poly(ADP-ribose) polymerase activity by DNA-dependent protein kinase in vitro	ONCOGENE			English	Article						DNA-PK; PARP; Ku; poly(ADP-ribosyl)ation; dsDNA break	HUMAN-IMMUNODEFICIENCY-VIRUS; ABL TYROSINE KINASE; C-ABL; V(D)J RECOMBINATION; DAMAGE; REPAIR; CELLS; P53; ACTIVATION; ANTIGEN	It has been suggested that DNA-dependent protein kinase (DNA-PK) is a central component of DNA double-strand-break repair. The mechanism of DNA-PK action, however, has not been fully understood. Poly(ADP-ribose) polymerase (PARP) is another nuclear enzyme which has high affinity to DNA ends. In this study, we analysed the interaction between these tao enzymes. First, DNA-PK was found to suppress the PARP activity and alters the pattern of poly(ADP-ribosyl)ation. Although DNA-PK phosphorylates PARP in a DNA-dependent manner, this modification is unlikely to be responsible for the suppression of PARP activity, since this suppression occurs even in the absence of ATP. Conversely, PARP was found to ADP-ribosylate DNA-PK in vitro. However, the autophosphorylation activity of DNA-PK was not influenced by this modification. In a competitive electrophoretic mobility shift assay, Ku 70/80 complex, the DNA binding component of DNA-PK, was found to have higher affinity to a short fragment of DNA than does PARP. Furthermore, co-immunoprecipitation analysis suggested direct or close association between Ku and PARP. Thus, DNA-PK suppresses PARP activity, probably through direct binding and/or sequestration of DNA-ends which serve as an important stimulator for both enzymes.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Natl Canc Ctr, Res Inst, Div Biochem, Tokyo 1040045, Japan; NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Keio Univ, Sch Med, Tokyo 1600016, Japan; Kyoto Univ, Chem Res Inst, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Kyoto 6068501, Japan	Kyoto University; National Cancer Center - Japan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Keio University; Kyoto University; Kyoto University	Ariumi, Y (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.		Ariumi, Yasuo/F-5804-2013					Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; Ariumi Y, 1998, FEBS LETT, V423, P25, DOI 10.1016/S0014-5793(98)00051-9; Ariumi Yasuo, 1997, Leukemia (Basingstoke), V11, P29; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; DARBY MK, 1985, EMBO J, V4, P2129, DOI 10.1002/j.1460-2075.1985.tb03903.x; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; IKEJIMA M, 1989, BIOCHEM BIOPH RES CO, V163, P739, DOI 10.1016/0006-291X(89)92285-7; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Kamata T, 1998, MOL BRAIN RES, V54, P219, DOI 10.1016/S0169-328X(97)00332-X; KAWAGUCHI H, 1989, NUCLEIC ACIDS RES, V17, P6229, DOI 10.1093/nar/17.15.6229; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; NOSAKA T, 1993, NUCLEIC ACIDS RES, V21, P5124, DOI 10.1093/nar/21.22.5124; OHTSUKI M, 1984, FEBS LETT, V168, P275, DOI 10.1016/0014-5793(84)80261-6; REEVES WH, 1989, J BIOL CHEM, V264, P5047; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; TANIGUCHI T, 1988, BIOCHEM BIOPH RES CO, V154, P1034, DOI 10.1016/0006-291X(88)90244-6; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; UEDA K, 1975, P NATL ACAD SCI USA, V72, P205, DOI 10.1073/pnas.72.1.205; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; YAMAGOE S, 1991, MOL CELL BIOL, V11, P3522, DOI 10.1128/MCB.11.7.3522; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	49	112	115	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4616	4625		10.1038/sj.onc.1202823	http://dx.doi.org/10.1038/sj.onc.1202823			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467406				2022-12-25	WOS:000082018600011
J	Imazu, T; Shimizu, S; Tagami, S; Matsushima, M; Nakamura, Y; Miki, T; Okuyama, A; Tsujimoto, Y				Imazu, T; Shimizu, S; Tagami, S; Matsushima, M; Nakamura, Y; Miki, T; Okuyama, A; Tsujimoto, Y			Bcl-2/E1B 19kDa-interacting protein 3-like protein (Bnip3L) interacts with Bcl-2/Bcl-x(L) and induces apoptosis by altering mitochondrial membrane permeability	ONCOGENE			English	Article						Bnip3L; BH3; apoptosis; Bcl-2; mitochondrial; cytochrome c	CYTOCHROME-C RELEASE; CELL-DEATH; LOCALIZATION; DYSFUNCTION; SURVIVAL; BINDING; DOMAIN; NIP3	We have previously reported on cloning of the human gene encoding Bcl-2/adenovirus E1B 19 kDa-interacting protein 3-like protein (Bnip3L) and its growth inhibitory effect on cancer cells. Here we show that Bnip3L contains a motif similar to the BH3 domain which is conserved in Bcl-2 family proteins as well as containing a membrane-anchoring domain, and that Bnip3L interacts with Bcl-2 and Bcl-x(L). Immunofluorescence microscopy revealed that Bnip3L was localized in the mitochondria, when in the presence of the membrane-anchoring domain. Transient expression of Bnip3L induced apoptosis of Rat-1 and HeLa cells and mutational analysis revealed that the BH3 domain and the membrane-anchoring domain were required for Bnip3L to induce cell death. Addition of recombinant Bnip3L to isolated mitochondria induced membrane potential loss and cytochrome c release both of which hale been suggested to be prerequisite for apoptotic cell death, These results suggest that Bnip3L is one of the BH3-containing proapoptotic proteins and that it targets the mitochondria when inducing apoptosis.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Urol, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo 1080071, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); University of Tokyo	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, 2-2 Yamadaoka, Osaka 5650871, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	22	120	126	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4523	4529		10.1038/sj.onc.1202722	http://dx.doi.org/10.1038/sj.onc.1202722			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467396				2022-12-25	WOS:000082018600001
J	Ogihara, H; Kanno, T; Morii, E; Kim, DK; Lee, YM; Sato, M; Kim, WY; Nomura, S; Ito, Y; Kitamura, Y				Ogihara, H; Kanno, T; Morii, E; Kim, DK; Lee, YM; Sato, M; Kim, WY; Nomura, S; Ito, Y; Kitamura, Y			Synergy of PEBP2/CBF with mi transcription factor (MITF) for transactivation of mouse mast cell protease 6 gene	ONCOGENE			English	Article						mast cells; mi transcription factor (MITF); PEBP2/CBF; AML1; mouse mast cell protease 6	CORE-BINDING-FACTOR; STIMULATING FACTOR-RECEPTOR; NERVE GROWTH-FACTOR; MI/MI GENOTYPE; MUTANT MICE; C-KIT; IMPAIRED EXPRESSION; DELTA-ENHANCER; LOCUS; MICROPHTHALMIA	The mi locus encodes a member of the basic-helix-loop-helix-leucine zipper (bHLH-Zip) protein family of transcription factors (hereafter called MITF), Although the bHLH-Zip family transcription factors generally recognize and bind CANNTG motifs, the expression of mouse mast cell protease 6 (MMCP-6) gene is regulated by MITF through the (G) under bar ACCTG motif in the promoter region. The GACC<(TG)under bar> motif was partly overlapped the <(TG)under bar>TGGTC sequence, which was bound by polyomavirus enhancer binding protein 2 (PEBP2), In the present study, the effect of PEBP2 on the expression of MMCP-6 gene was examined, PEBP2 that is composed of alpha and beta subunits was expressed by mast cell Lines and cultured mast cells derived from spleen, The overexpression of dominant negative PEBP2 cDNA reduced the expression of MMCP-6. Moreover, the simultaneous transfection of the plasmid containing MITF cDNA and the plasmid containing PEBP2 cDNA increased the MMCP-6 promoter activity, For the synergistic action of PEBP2 and MITF, the intact GACC<(TG)under bar> and <(TG)under bar>TGGTC motifs were prerequisite. The PEBP2 alpha B1 mutant which lacked the region downstream from the Runt domain did not bind MITF and lost the synergistic function. These results indicated that PEBP2 and MITF synergistically transactivated the MMCP-6 gene and that the region downstream from the Runt domain of PEBP2 alpha B1 was essential for the physical and functional interactions with MITF.	Osaka Univ, Sch Med, Dept Pathol, Osaka 5650871, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068397, Japan	Osaka University; Kyoto University	Morii, E (corresponding author), Osaka Univ, Sch Med, Dept Pathol, 2-2 Yamadaoka, Osaka 5650871, Japan.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAE SC, 1993, ONCOGENE, V8, P809; Cross MA, 1997, CURR OPIN GENET DEV, V7, P609, DOI 10.1016/S0959-437X(97)80007-X; EBI Y, 1992, BLOOD, V80, P1454; EBI Y, 1990, BLOOD, V75, P1247; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GREEN MC, 1981, GENETIC VARIANTS STR, P158; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; ISOZAKI K, 1994, AM J PATHOL, V145, P827; Ito A, 1998, BLOOD, V91, P3210, DOI 10.1182/blood.V91.9.3210.3210_3210_3221; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; JIPPO T, 1994, BLOOD, V84, P2977; Jippo T, 1997, BLOOD, V90, P2601, DOI 10.1182/blood.V90.7.2601.2601_2601_2608; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; KASUGAI T, 1993, AM J PATHOL, V143, P1337; Kim DK, 1998, BLOOD, V92, P1973, DOI 10.1182/blood.V92.6.1973.418k23_1973_1980; KIM WY, 1999, IN PRESS EMBO J; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; MORII E, 1994, BIOCHEM BIOPH RES CO, V205, P1299, DOI 10.1006/bbrc.1994.2806; Morii E, 1997, BLOOD, V90, P3057, DOI 10.1182/blood.V90.8.3057; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; STECHSCHULTE DJ, 1987, J CELL PHYSIOL, V132, P565, DOI 10.1002/jcp.1041320321; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; STEVENS J, 1982, PROC R SOC SER B-BIO, V215, P405, DOI 10.1098/rspb.1982.0050; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	45	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4632	4639		10.1038/sj.onc.1202844	http://dx.doi.org/10.1038/sj.onc.1202844			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467408				2022-12-25	WOS:000082018600013
J	Sleeman, JP; Kim, U; LePendu, J; Howells, N; Coquerelle, T; Ponta, H; Herrlich, P				Sleeman, JP; Kim, U; LePendu, J; Howells, N; Coquerelle, T; Ponta, H; Herrlich, P			Inhibition of MT-450 rat mammary tumour growth by antibodies recognising subtypes of blood group antigen B	ONCOGENE			English	Article						blood group antigens; tumour progression; metastasis; subtractive immunization	COLON-CARCINOMA CELLS; MONOCLONAL-ANTIBODIES; PROSTATIC-CANCER; ABERRANT GLYCOSYLATION; FUCOSYL-TRANSFERASE; BREAST-CANCER; EXPRESSION; METASTASIS; BINDING; ABH	Using subtractive immunization to identify cell surface epitopes expressed in a metastasis-specific fashion on cells of the rat MT-W9 mammary carcinoma model, we generated a monoclonal antibody called M-N#1. This antibody binds specifically to metastasizing cells of the MT-W9 series and also to certain other metastasizing rat mammary carcinoma cell lines. We demonstrate that the M-N#1 antibody recognizes a fucosylated N-glycosyl sugar modification, and furthermore show that the epitope specificity of the M-N#1 antibody is for blood group antigen B subtypes 2, 3 and 4 with slight cross-reactivity with blood group antigen A subtype 2. The expression of these carbohydrate epitopes on MT-450 cells is functionally important, because the M-N#1 antibody efficiently inhibits MT-450 tumour growth in spontaneous metastasis assays. These results suggest that expression of the subtypes of blood group antigen B recognized by the M-N#1 antibody does not directly participate in the metastatic cascade but rather confers a growth or survival advantage on the tumour cells.	Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; INSERM, U419, Inst Biol, F-44035 Nantes, France	Helmholtz Association; Karlsruhe Institute of Technology; Institut National de la Sante et de la Recherche Medicale (Inserm)	Sleeman, JP (corresponding author), Forschungszentrum Karlsruhe, Inst Genet, POB 3640, D-76021 Karlsruhe, Germany.		Sleeman, Jonathan P/H-2515-2013; Le Pendu, Jacques/F-4760-2013	Sleeman, Jonathan P/0000-0003-1718-7687; Le Pendu, Jacques/0000-0002-4856-0387				Akahani S, 1997, CANCER RES, V57, P5272; AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; BROOKS PC, 1993, J CELL BIOL, V122, P1351, DOI 10.1083/jcb.122.6.1351; BYRNE G, 1986, DEV BIOL, V117, P442, DOI 10.1016/0012-1606(86)90313-1; CHAMMAS R, 1991, J BIOL CHEM, V266, P3349; CHATTERJEE SK, 1978, J NATL CANCER I, V61, P151, DOI 10.1093/jnci/61.1.151; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; DABELSTEEN E, 1988, CANCER RES, V48, P181; DALL P, 1995, INT J CANCER, V60, P471, DOI 10.1002/ijc.2910600408; DENK H, 1974, EUR J CANCER, V10, P487, DOI 10.1016/0014-2964(74)90071-1; GHOSH SK, 1983, IN VITRO CELL DEV B, V19, P919; Goupille C, 1997, GLYCOBIOLOGY, V7, P221, DOI 10.1093/glycob/7.2.221; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hakomori S, 1996, CANCER RES, V56, P5309; HALLOUIN F, 1998, IN PRESS GLYCOCONJ J; HARLOW E, 1988, COLD SPRING HARBOR L; HOLMES EH, 1990, CARCINOGENESIS, V11, P89, DOI 10.1093/carcin/11.1.89; ICHIKAWA T, 1991, CANCER RES, V51, P3788; ICHIKAWA T, 1992, CANCER RES, V52, P3486; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; ISAACS JT, 1978, CANCER RES, V38, P4353; KIM U, 1986, J SURG ONCOL, V33, P151, DOI 10.1002/jso.2930330303; KING MJ, 1994, BBA-REV BIOMEMBRANES, V1197, P15, DOI 10.1016/0304-4157(94)90017-5; LABARRIERE N, 1994, CANCER RES, V54, P6275; LEE AK, 1985, AM J CLIN PATHOL, V83, P308, DOI 10.1093/ajcp/83.3.308; LeMarer N, 1996, J CELL PHYSIOL, V168, P51, DOI 10.1002/(SICI)1097-4652(199607)168:1<51::AID-JCP7>3.0.CO;2-7; LICHTNER RB, 1987, INVAS METAST, V7, P73; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; NERI A, 1981, CANCER RES, V41, P5082; Ogawa J, 1996, CANCER RES, V56, P325; ORIOL R, 1984, LAB INVEST, V50, P514; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RUDY W, 1993, CANCER RES, V53, P1262; SATO S, 1992, J BIOL CHEM, V267, P6983; SCHOENTAG R, 1987, CANCER RES, V47, P1695; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; STRAUCHEN JA, 1980, CANCER, V45, P2149, DOI 10.1002/1097-0142(19800415)45:8<2149::AID-CNCR2820450823>3.0.CO;2-7; SUN J, 1995, P NATL ACAD SCI USA, V92, P5724, DOI 10.1073/pnas.92.12.5724; URA Y, 1992, INT J CANCER, V50, P57, DOI 10.1002/ijc.2910500113; VERMA M, 1994, CANCER BIOCHEM BIOPH, V14, P151; VOWDEN P, 1986, BRIT J CANCER, V53, P313, DOI 10.1038/bjc.1986.54; WANG JW, 1995, CANCER RES, V55, P3654; WILLIAMS CV, 1992, BIOTECHNIQUES, V12, P842; Xing RH, 1996, INT J CANCER, V67, P423, DOI 10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; YUAN M, 1985, CANCER RES, V45, P4499; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	49	18	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4485	4494		10.1038/sj.onc.1202808	http://dx.doi.org/10.1038/sj.onc.1202808			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442639				2022-12-25	WOS:000081813500010
J	Brakebusch, C; Wennerberg, K; Krell, HW; Weidle, UH; Sallmyr, A; Johansson, S; Fassler, R				Brakebusch, C; Wennerberg, K; Krell, HW; Weidle, UH; Sallmyr, A; Johansson, S; Fassler, R			beta 1 integrin promotes but is not essential for metastasis of ras-myc transformed fibroblasts	ONCOGENE			English	Article						beta 1 integrin; tumor; metastasis; extracellular matrix; knockout cell line	BREAST-CARCINOMA CELLS; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY; SYNTHETIC PEPTIDES; CANCER; FIBRONECTIN; MELANOMA; ADHESION; INVASION	To investigate the role of beta 1 integrin during tumor metastasis, we established a ras-myc transformed fibroblastoid cell line with a disrupted beta 1 integrin gene on both alleles (GERM 11), Stable transfection of this cell line with an expression vector encoding beta 1A integrin resulted in beta 1A integrin-expressing sublines. Tumors were induced by subcutaneous injection of GERM 11 cells and 3 independent beta 1 integrin expressing sublines (GERM 116, 1A10, 2F2) into syngeneic mice. After 10 days tumors were surgically removed. While average weights of GERM 11 and GERM 116 tumors were similar, tumors induced by the high expressing clones 1A10 and 2F2 were markedly smaller, suggesting an inverse correlation of tumor growth and beta 1 integrin expression. The metastasis potential of all three beta 1 integrin-expressing GERM 11 sublines tested was significantly higher than that of the beta 1-deficient GERM 11 cells. GERM 116 tumors led in all animals to severe metastasis in lung and liver, while GERM 11 tumors induced only a few metastatic foci in the lung. Stroma of both tumors contained nidogen and high amounts of tenascin C, but only a few very low levels of fibronectin, laminin-1, and collagen type I. beta 1 integrin, therefore, increases but is not essential for metastasis of ras-myc transformed fibroblasts.	Univ Lund Hosp, Dept Expt Pathol, S-22185 Lund, Sweden; Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Boehringer Mannheim GmbH, D-82372 Penzberg, Germany	Lund University; Skane University Hospital	Fassler, R (corresponding author), Univ Lund Hosp, Dept Expt Pathol, S-22185 Lund, Sweden.		Wennerberg, Krister/AAH-2919-2022; Wennerberg, Krister/AFM-0539-2022	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220; Brakebusch, Cord/0000-0002-9342-1634				ALBELDA SM, 1990, CANCER RES, V50, P6757; Bloch W, 1997, J CELL BIOL, V139, P265, DOI 10.1083/jcb.139.1.265; BOTTGER BA, 1989, DIFFERENTIATION, V41, P158, DOI 10.1111/j.1432-0436.1989.tb00743.x; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; Coopman PJ, 1996, MOL BIOL CELL, V7, P1789, DOI 10.1091/mbc.7.11.1789; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; ELLIOTT BE, 1994, CELL ADHES COMMUN, V1, P319, DOI 10.3109/15419069409097263; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FUJITA S, 1995, CANCER LETT, V91, P145, DOI 10.1016/0304-3835(95)03735-F; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gui GPH, 1997, BRIT J CANCER, V75, P623, DOI 10.1038/bjc.1997.113; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HUMPHRIES MJ, 1988, J CLIN INVEST, V81, P782, DOI 10.1172/JCI113384; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KADLER K, 1994, PROTEIN PROFILE, V1, P519; KOUKOULIS GK, 1991, HUM PATHOL, V22, P636, DOI 10.1016/0046-8177(91)90285-W; LARJAVA H, 1993, J CELL PHYSIOL, V157, P190, DOI 10.1002/jcp.1041570125; LESSEY BA, 1995, AM J PATHOL, V146, P717; Matsuura N, 1996, AM J PATHOL, V148, P55; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; NEWTON SA, 1995, INT J ONCOL, V6, P1063; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Peters D. M. P., 1994, EXTRACELLULAR MATRIX, P315; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; RUIZ P, 1993, CELL ADHES COMMUN, V1, P67, DOI 10.3109/15419069309095682; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SMILENOV L, 1992, FEBS LETT, V302, P227, DOI 10.1016/0014-5793(92)80447-O; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Stroeken PJM, 1998, CANCER RES, V58, P1569; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; YAMADA KM, 1990, CANCER RES, V50, P4485; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	37	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3852	3861		10.1038/sj.onc.1202770	http://dx.doi.org/10.1038/sj.onc.1202770			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445848				2022-12-25	WOS:000081171700006
J	Harrison, MA; Murray, J; Powell, B; Kim, YI; Finbow, ME; Findlay, JBC				Harrison, MA; Murray, J; Powell, B; Kim, YI; Finbow, ME; Findlay, JBC			Helical interactions and membrane disposition of the 16-kDa proteolipid subunit of the vacuolar H+ ATPase analyzed by cysteine replacement mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE CROSS-LINKING; VESICLE PROTON PUMP; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SENSORY RECEPTOR; ALPHA-SUBUNIT; SYNTHASE; MUTANTS; POLYPEPTIDE; PROTEIN	Theoretical mechanisms of proton translocation by the vacuolar H+-ATPase require that a transmembrane acidic residue of the multicopy 16-kDa proteolipid subunit be exposed at the exterior surface of the membrane sector of the enzyme, contacting the lipid phase. However, structural support for this theoretical mechanism is lacking. To address this, we have used cysteine mutagenesis to produce a molecular model of the 16-kDa proteolipid complex. Transmembrane helical contacts were determined using oxidative cysteine cross-linking, and accessibility of cysteines to the lipid phase was determined by their reactivity to the lipid-soluble probe N-(1-pyrenyl)maleimide. A single model for organization of the four helices of each monomeric proteolipid was the best fit to the experimental data, with helix 1 lining a central pore and helix 2 and helix 3 immediately external to it and forming the principal intermolecular contacts. Helix 4, containing the crucial acidic residue, is peripheral to the complex. The model is consistent not only with theoretical proton transport mechanisms, but has structural similarity to the dodecameric ring complex formed by the related 8-kDa proteolipid of the F1F0-ATPase, This suggests some commonality between the proton translocating mechanisms of the vacuolar and F1F0-ATPases.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	University of Leeds; Beatson Institute	Harrison, MA (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.	m.a.harrison@leeds.ac.uk	Harrison, Michael/A-4886-2010; Harrison, Michael/GYD-8608-2022	Harrison, Michael/0000-0002-7826-7472				ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1988, J BIOL CHEM, V263, P8796; Baldwin E, 1996, J MOL BIOL, V259, P542, DOI 10.1006/jmbi.1996.0338; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; DONNELLY D, 1993, PROTEIN SCI, V2, P55; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FENG Y, 1994, J BIOL CHEM, V269, P13224; Fillingame RH, 1997, J EXP BIOL, V200, P217; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; FINBOW ME, 1992, PROTEIN ENG, V5, P7, DOI 10.1093/protein/5.1.7; FINBOW ME, 1995, BIOESSAYS, V17, P247, DOI 10.1002/bies.950170311; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; GREENHALGH DA, 1991, P NATL ACAD SCI USA, V88, P8626, DOI 10.1073/pnas.88.19.8626; HARRISON MA, 1994, EUR J BIOCHEM, V221, P111, DOI 10.1111/j.1432-1033.1994.tb18719.x; Harrison MA, 1997, MOL MEMBR BIOL, V14, P1, DOI 10.3109/09687689709048162; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; John SA, 1997, J STRUCT BIOL, V120, P22, DOI 10.1006/jsbi.1997.3893; Jones PC, 1995, BIOCHEM J, V312, P739, DOI 10.1042/bj3120739; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; KANE PM, 1992, J BIOL CHEM, V267, P447; Kim J, 1998, BIOCHEMISTRY-US, V37, P4680, DOI 10.1021/bi972666k; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE GF, 1994, J BIOL CHEM, V269, P29920; LEE GF, 1995, P NATL ACAD SCI USA, V92, P5416, DOI 10.1073/pnas.92.12.5416; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PALI T, 1995, BIOCHEMISTRY-US, V34, P9211, DOI 10.1021/bi00028a034; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sedgwick EG, 1997, BIOCHEMISTRY-US, V36, P15285, DOI 10.1021/bi9708996; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUPEK F, 1994, J BIOL CHEM, V269, P26479; VIK SB, 1994, J BIOL CHEM, V269, P30364; WU JH, 1995, BIOCHEMISTRY-US, V34, P8257, DOI 10.1021/bi00026a007	46	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25461	25470		10.1074/jbc.274.36.25461	http://dx.doi.org/10.1074/jbc.274.36.25461			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464277	hybrid			2022-12-25	WOS:000082554200041
J	Mora, R; Bonilha, VL; Marmorstein, A; Scherer, PE; Brown, D; Lisanti, MP; Rodriguez-Boulan, E				Mora, R; Bonilha, VL; Marmorstein, A; Scherer, PE; Brown, D; Lisanti, MP; Rodriguez-Boulan, E			Caveolin-2 localizes to the Golgi complex but redistributes to plasma membrane, caveolae, and rafts when co-expressed with caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; ANCHORED PROTEINS; MDCK CELLS; IN-VIVO; TRANSPORT; VESICLES; VIP21-CAVEOLIN; VIP21/CAVEOLIN; CHOLESTEROL; COMPONENT	We have characterized comparatively the subcellular distributions of caveolins-1 and -2, their interactions and their roles in caveolar formation in polarized epithelial cells. In Fischer rat thyroid (FRT) cells, which express low levels of caveolin-2 and no caveolin-1, caveolin-2 localizes exclusively to the Golgi complex but is partially redistributed to the plasma membrane upon co-expression of caveolin-1 by transfection or by adenovirus-mediated transduction. In Madin-Darby canine kidney (MDCK) cells, which constitutively express both caveolin-1 and -2, caveolin-2 localized to both the Gels complex and to the plasma membrane, where it co-distributed with caveolin-1 in flat patches and in caveolae. In FRT cells, endogenous or overexpressed caveolin-2 did not associate with low density Triton insoluble membranes that floated in sucrose density gradients but was recruited to these membranes when co-expressed together with caveolin-1. In MDCK cells, both caveolin-1 and caveolin-2 associated with low density Triton-insoluble membranes. In FRT cells, transfection of caveolin-1 promoted the assembly of plasma membrane caveolae that localized preferentially (over 99%) to the basolateral surface, like constitutive caveolae of MDCK cells. In contrast, as expected from its intracellular distribution, endogenous or overexpressed caveolin-2 did not promote the assembly of caveolae; rather, it appeared to promote the assembly of intracellular vesicles in the peri-Golgi area. The data reported here demonstrate that caveolin-1 and -2 have different and complementary subcellular localizations and functional properties in polarized epithelial cells and suggest that the two proteins co-operate to carry out specific as yet unknown tasks between the Golgi complex and the cell surface.	Cornell Univ, Weill Med Coll, Dyson Vis Res Inst, Dept Ophthalmol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell Biol, New York, NY 10021 USA; Massachusetts Gen Hosp, Renal Unit, Boston, MA 02129 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Cornell University; Dyson; Cornell University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rodriguez-Boulan, E (corresponding author), Cornell Univ, Weill Med Coll, Dyson Vis Res Inst, Dept Ophthalmol, LC300,1300 York Ave, New York, NY 10021 USA.		Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107, R01GM041771] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34107, R01 GM41771, R01 GM034107] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Breton S, 1998, J HISTOCHEM CYTOCHEM, V46, P205, DOI 10.1177/002215549804600209; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; KURZCHALIA TV, 1996, FEBS LETT, V389, P552; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; Li SW, 1996, J BIOL CHEM, V271, P3863; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; MOLDOVAN NI, 1995, EXP CELL RES, V219, P309, DOI 10.1006/excr.1995.1233; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; VANT HOF W, 1994, CURR TOP MEMBR, V40, P539, DOI 10.1016/S0070-2161(08)60995-8; Vogel U, 1998, J CELL SCI, V111, P825; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	31	174	176	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25708	25717		10.1074/jbc.274.36.25708	http://dx.doi.org/10.1074/jbc.274.36.25708			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464308	hybrid			2022-12-25	WOS:000082554200072
J	Sartipy, P; Camejo, G; Svensson, L; Hurt-Camejo, E				Sartipy, P; Camejo, G; Svensson, L; Hurt-Camejo, E			Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERIAL-WALL PROTEOGLYCANS; CHOLESTEROL-FED RABBITS; ATHEROSCLEROTIC LESIONS; OXIDATIVE SUSCEPTIBILITY; HYPERLIPIDEMIC RABBITS; SELECTIVE RETENTION; LDL PARTICLES; BINDING; APOLIPOPROTEIN; SUBFRACTIONS	The presence of a lipoprotein profile with abundance of small, dense low density lipoproteins (LDL), low levels of high density lipoproteins (HDL), and elevated levels of triglyceride-rich very low density lipoproteins is associated with an increased risk for coronary heart disease. The atherogenicity of small, dense LDL is believed to be one of the main reasons for this association. This particle contains less phospholipids (PL) and unesterified cholesterol than large LDL, and the apoB-100 appears to occupy a more extensive area at its surface. Although there are experiments that suggest a metabolic pathway leading to the overproduction of small, dense LDL, no clear molecular model exists to explain its association with atherogenesis. A current hypothesis is that small, dense LDL, because of its higher affinity for proteoglycans, is entrapped in the intima extracellular matrix and is more susceptible to oxidative modifications than large LDL. Here we describe how a specific reduction of approximately 50% of the PL of a normal buoyant LDL by immobilized phospholipase A(2) (PLA(2)) (EC 3.1.1.4) produces smaller and denser particles without inducing significant lipoprotein aggregation (<5%), These smaller LDL particles display a higher tendency to form nonsoluble complexes with proteoglycans and glycosaminoglycans than the parent LDL, Binding parameters of LDL and glycosaminoglycans and proteoglycans produced by human arterial smooth muscle cells were measured at near to physiological conditions. The PLA(2)-modified LDL has about 2 times higher affinity for the sulfated polysaccharides than control LDL, In addition, incubation of human plasma in the presence of PLA(2) generated smaller LDL and HDL particles compared with the control plasma incubated without PLA(2). These in vitro results indicate that the reduction of surface PL characteristic of small, dense LDL subfractions, besides contributing to its small size and density, may enhance its tendency to be retained by proteoglycans.	Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, Dept Heart & Lung Dis, S-41345 Gothenburg, Sweden; AstraZeneca, Preclin Res, S-4313 Molndal, Sweden	Sahlgrenska University Hospital; AstraZeneca	Sartipy, P (corresponding author), Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, Dept Heart & Lung Dis, S-41345 Gothenburg, Sweden.	Peter.Sartipy@wlab.wall.gu.se						ABATE N, 1995, ATHEROSCLEROSIS, V118, P111, DOI 10.1016/0021-9150(95)05597-P; AGGERBECK LP, 1976, J BIOL CHEM, V251, P3823; Anber V, 1997, ARTERIOSCL THROM VAS, V17, P2507, DOI 10.1161/01.ATV.17.11.2507; Anber V, 1996, ATHEROSCLEROSIS, V124, P261, DOI 10.1016/0021-9150(96)05842-X; AUSTIN MA, 1995, CIRCULATION, V92, P1770, DOI 10.1161/01.CIR.92.7.1770; AVIRAM M, 1982, BIOCHEM BIOPH RES CO, V185, P465; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Betteridge DJ, 1997, DIABETOLOGIA, V40, pS149, DOI 10.1007/s001250051434; Bjornheden T, 1996, ATHEROSCLEROSIS, V123, P43, DOI 10.1016/0021-9150(95)05770-6; CAMEJO G, 1993, J BIOL CHEM, V268, P14131; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; CAMEJO G, 1985, BIOMED BIOCHIM ACTA, V44, P389; CAMEJO G, 1989, ATHEROSCLEROSIS, V79, P121, DOI 10.1016/0021-9150(89)90116-0; Capell WH, 1996, ARTERIOSCL THROM VAS, V16, P1040, DOI 10.1161/01.ATV.16.8.1040; CHAO FF, 1990, AM J PATHOL, V136, P169; Chapman MJ, 1998, EUR HEART J, V19, pA24; COLLINS E, 1997, CIRC RES, V80, P208; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Elinder LS, 1997, ARTERIOSCL THROM VAS, V17, P2257, DOI 10.1161/01.ATV.17.10.2257; Galeano NF, 1998, J LIPID RES, V39, P1263; GAYTON J, 1996, ATHEROSCLER THROMB V, V16, P4; Gutierrez P, 1997, CARDIOVASC PATHOL, V6, P271, DOI 10.1016/S1054-8807(97)00001-X; HALLBERG C, 1994, J LIPID RES, V35, P1; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOKANSON JE, 1995, ARTERIOSCL THROM VAS, V15, P452, DOI 10.1161/01.ATV.15.4.452; Homan R, 1998, J CHROMATOGR B, V708, P21, DOI 10.1016/S0378-4347(97)00651-8; Hoover-Plow J, 1998, THROMB HAEMOSTASIS, V79, P640; Hurt-Camejo E, 1998, Methods Mol Biol, V110, P267; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P1011, DOI 10.1161/01.ATV.17.6.1011; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; IBDAH JA, 1989, BIOCHEMISTRY-US, V28, P1126, DOI 10.1021/bi00429a029; Ivandic B, 1999, ARTERIOSCL THROM VAS, V19, P1284, DOI 10.1161/01.ATV.19.5.1284; KRAUSS RM, 1982, J LIPID RES, V23, P97; Krauss RM, 1997, WORLD REV NUTR DIET, V80, P22; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; McNamara JR, 1996, J LIPID RES, V37, P1924; Menschikowski M, 1995, ATHEROSCLEROSIS, V118, P173, DOI 10.1016/0021-9150(95)05604-1; Neuzil J, 1998, BIOCHEMISTRY-US, V37, P9203, DOI 10.1021/bi9730745; NORDESTGAARD BG, 1995, ARTERIOSCL THROM VAS, V15, P534, DOI 10.1161/01.ATV.15.4.534; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; Olsson U, 1997, ARTERIOSCL THROM VAS, V17, P149, DOI 10.1161/01.ATV.17.1.149; Oorni K, 1998, J BIOL CHEM, V273, P29127, DOI 10.1074/jbc.273.44.29127; OTVOS JD, 1991, CLIN CHEM, V37, P377; OTVOS JD, 1992, CLIN CHEM, V38, P1632; Pentikainen MO, 1997, J BIOL CHEM, V272, P7633, DOI 10.1074/jbc.272.12.7633; Romano M, 1998, ARTERIOSCL THROM VAS, V18, P519, DOI 10.1161/01.ATV.18.4.519; Sartipy P, 1996, J BIOL CHEM, V271, P26307, DOI 10.1074/jbc.271.42.26307; Sattar N, 1998, ATHEROSCLEROSIS, V138, P229, DOI 10.1016/S0021-9150(98)00037-9; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P908, DOI 10.1161/01.ATV.9.6.908; SIEDEL J, 1983, CLIN CHEM, V29, P1075; SPARROW CP, 1988, J LIPID RES, V29, P745; TAILLEUX A, 1993, J LIPID RES, V34, P719; TRIBBLE DL, 1995, J LIPID RES, V36, P662; TRIBBLE DL, 1994, P NATL ACAD SCI USA, V91, P1183, DOI 10.1073/pnas.91.3.1183; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012	59	107	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25913	25920		10.1074/jbc.274.36.25913	http://dx.doi.org/10.1074/jbc.274.36.25913			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464335	hybrid			2022-12-25	WOS:000082554200099
J	Takematsu, H; Diaz, S; Stoddart, A; Zhang, Y; Varki, A				Takematsu, H; Diaz, S; Stoddart, A; Zhang, Y; Varki, A			Lysosomal and cytosolic sialic acid 9-O-acetylesterase activities can be encoded by one gene via differential usage of a signal peptide-encoding exon at the N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; DE-ORTHO-ACETYLATION; I-TYPE LECTINS; O-ACETYLESTERASE; RAT-LIVER; HELICOBACTER-PYLORI; MOLECULAR-CLONING; BINDING; CELLS; LIGANDS	9-O-Acetylation is one of the most common modifications of sialic acids, and it can affect several sialic acid-mediated recognition phenomena. We previously reported a cDNA encoding a lysosomal sialic acid-specific 9-O-acetylesterase, which traverses the endoplasmic reticulum-Golgi pathway and localizes primarily to lysosomes and endosomes, In this study, we report a variant cDNA derived from the same gene that contains a different 5' region, This cDNA has a putative open reading frame lacking a signal peptide-encoding sequence and is thus a candidate for the previously described cytosolic sialic acid 9-O-acetylesterase activity. Epitope-tagged constructs confirm that the new sequence causes the protein product to be targeted to the cytosol and has esterase activity. Using reverse transcription-polymerase chain reaction to distinguish the two forms of message, we show that although the lysosomal sialic acid-specific 9-O-acetylesterase message has a widespread pattern of expression in adult mouse tissues, this cytosolic sialic acid 9-O-acetylesterase form has a rather restricted distribution, with the strongest expression in the liver, ovary, and brain. Using a polyclonal antibody directed against the 69-amino acid region common to both proteins, we confirmed that the expression of glycosylated and nonglycosylated polypeptides occurred in appropriate subcellular fractions of normal mouse tissues. Rodent liver polypeptides reacting to the antibody also co-purify with previously described lysosomal sialic acid esterase activity and at least a portion of the cytosolic activity. Thus, two sialic acid 9-O-acetylesterases found in very different subcellular compartments can be encoded by a single gene by differential usage of a signal peptide-encoding exon at the N terminus. The 5'-rapid amplification of cDNA ends results and the differences in tissue-specific expression suggest that expression of these two products may be differentially regulated by independent promoters.	Univ Calif San Diego, Glycobiol Res & Training Ctr, Div Hematol Oncol, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Varki, A (corresponding author), Univ Calif San Diego, Sch Med, Ctr Canc, 0687, La Jolla, CA 92093 USA.				NHLBI NIH HHS [HL57345] Funding Source: Medline; NIGMS NIH HHS [GM32373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032373, R01GM032373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BUTOR C, 1993, J BIOL CHEM, V268, P10207; BUTOR C, 1995, J CELL SCI, V108, P2213; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CARLSON M, 1983, MOL CELL BIOL, V3, P439, DOI 10.1128/MCB.3.3.439; Chammas R, 1996, MOL BIOL CELL, V7, P1691, DOI 10.1091/mbc.7.11.1691; Coligan JE, 1996, CURRENT PROTOCOLS PR; Collins BE, 1997, J BIOL CHEM, V272, P16889, DOI 10.1074/jbc.272.27.16889; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker PR, 1998, GLYCOBIOLOGY, V8; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; DIAZ S, 1989, J BIOL CHEM, V264, P19416; Guimaraes MJ, 1996, J BIOL CHEM, V271, P13697, DOI 10.1074/jbc.271.23.13697; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HIGA HH, 1989, J BIOL CHEM, V264, P19435; HIGA HH, 1985, J BIOL CHEM, V260, P8838; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HIGA HH, 1989, METHOD ENZYMOL, V179, P409; Johansson L, 1998, GLYCOCONJUGATE J, V15, P713, DOI 10.1023/A:1006992616254; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kelm S, 1998, EUR J BIOCHEM, V255, P663, DOI 10.1046/j.1432-1327.1998.2550663.x; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; Meuillet EJ, 1999, CANCER RES, V59, P234; MillerPodraza H, 1997, GLYCOCONJUGATE J, V14, P467, DOI 10.1023/A:1018599401772; MillerPodraza H, 1997, INFECT IMMUN, V65, P2480, DOI 10.1128/IAI.65.6.2480-2482.1997; MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAUER R, 1987, METHOD ENZYMOL, V138, P611; SCHAUER R, 1971, H-S Z PHYSIOL CHEM, V352, P1282, DOI 10.1515/bchm2.1971.352.2.1282; SCHAUER R, 1989, J BIOCHEM-TOKYO, V106, P143, DOI 10.1093/oxfordjournals.jbchem.a122804; SCHAUER R, 1970, H-S Z PHYSIOL CHEM, V351, P749, DOI 10.1515/bchm2.1970.351.1.749; Schauer R, 1982, SIALIC ACIDS CHEM ME, V10; SCHLOSSHAUER B, 1988, J NEUROSCI, V8, P580; Shi WX, 1996, J BIOL CHEM, V271, P15130, DOI 10.1074/jbc.271.25.15130; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SPARROW JR, 1988, J NEUROSCI RES, V21, P398, DOI 10.1002/jnr.490210231; Stoddart A, 1996, NUCLEIC ACIDS RES, V24, P4003, DOI 10.1093/nar/24.20.4003; Strenge K, 1998, EUR J BIOCHEM, V258, P677, DOI 10.1046/j.1432-1327.1998.2580677.x; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Tokuyama S, 1997, INT J CANCER, V73, P410, DOI 10.1002/(SICI)1097-0215(19971104)73:3<410::AID-IJC16>3.0.CO;2-G; VARKI A, 1986, P NATL ACAD SCI USA, V83, P882, DOI 10.1073/pnas.83.4.882; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; 1993, CURRENT PROTOCOLS MO	52	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25623	25631		10.1074/jbc.274.36.25623	http://dx.doi.org/10.1074/jbc.274.36.25623			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464298	hybrid			2022-12-25	WOS:000082554200062
J	Vogl, T; Propper, C; Hartmann, M; Strey, A; Strupat, K; van den Bos, C; Sorg, C; Roth, J				Vogl, T; Propper, C; Hartmann, M; Strey, A; Strupat, K; van den Bos, C; Sorg, C; Roth, J			S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; DESORPTION/IONIZATION MASS-SPECTROMETRY; INTRACELLULAR CALCIUM; MOLECULAR-CLONING; HUMAN-NEUTROPHILS; MYELOID DIFFERENTIATION; RESPIRATORY BURST; PIG GRANULOCYTES; PLASMA-MEMBRANE; CALGRANULIN-C	Changes in cytosolic calcium concentrations regulate a wide variety of cellular processes, and calcium-binding proteins are the key molecules in signal transduction, differentiation, and cell cycle control. S100A12, a recently described member of the S100 protein family, has been shown to be coexpressed in granulocytes and monocytes together with two other S100 proteins, MRP8 (S100A8) and MRP14 (S100A9), and a functional relationship between these three S100 proteins has been suggested. Using Western blotting, calcium overlays, intracellular flow cytometry, and cytospin preparations, we demonstrate that S100A12 expression in leukocytes is specifically restricted to granulocytes and that S100A12 represents one of the major calcium-binding proteins in these cells. S100A12, MRPS, and MRP14 translocate simultaneously from the cytosol to cytoskeletal and membrane structures in a calcium-dependent manner. However, no evidence for direct protein-protein interactions of S100A12 with either MRPS or MRP14 or the heterodimer was found by chemical cross-linking, density gradient centrifugation, mass spectrometric measurements, or yeast two hybrid detection. Thus, S100A12 acts individually during calcium-dependent signaling, independent of MRP8, MRP14, and the heterodimer MRP8/ MRP14. This granulocyte-specific signal transduction pathway may offer attractive targets for therapeutic intervention with exaggerated granulocyte activity in pathological states.	Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany; Osiris Therapeut Inc, Baltimore, MD 21231 USA; Dept Pediat, D-48129 Munster, Germany	University of Munster; University of Munster; Osiris Therapeutics	Vogl, T (corresponding author), Univ Munster, Inst Expt Dermatol, Von Esmarchstr 56, D-48149 Munster, Germany.							BHARDWAJ RS, 1992, EUR J IMMUNOL, V22, P1891, DOI 10.1002/eji.1830220732; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Burmester GR, 1997, ARTHRITIS RHEUM, V40, P5, DOI 10.1002/art.1780400104; Cohen LRH, 1997, J AM SOC MASS SPECTR, V8, P1046, DOI 10.1016/S1044-0305(97)00148-7; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; Coulin F, 1997, EUR J BIOCHEM, V248, P507, DOI 10.1111/j.1432-1033.1997.00507.x; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; FEIGE U, 1982, J IMMUNOL METHODS, V54, P309, DOI 10.1016/0022-1759(82)90315-5; FERBER E, 1972, BIOCHIM BIOPHYS ACTA, V266, P494, DOI 10.1016/0005-2736(72)90105-8; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORDON S, 1995, CURR OPIN IMMUNOL, V7, P24, DOI 10.1016/0952-7915(95)80025-5; GORDON S, 1995, BIOESSAYS, V17, P977, DOI 10.1002/bies.950171111; GROSS AK, 1997, CYTOKINE, V9, P521; Gross J, 1998, TRAC-TREND ANAL CHEM, V17, P470, DOI 10.1016/S0165-9936(98)00060-0; GUIGNARD F, 1995, BIOCHEM J, V309, P395, DOI 10.1042/bj3090395; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Hitomi J, 1996, J CELL SCI, V109, P805; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; Ilg EC, 1996, BIOCHEM BIOPH RES CO, V225, P146, DOI 10.1006/bbrc.1996.1144; KURUTO R, 1990, J BIOCHEM, V108, P650, DOI 10.1093/oxfordjournals.jbchem.a123257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; LEMARCHAND P, 1992, J BIOL CHEM, V267, P19379; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; Marti T, 1996, BIOCHEM BIOPH RES CO, V221, P454, DOI 10.1006/bbrc.1996.0616; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MURAO S, 1989, J BIOL CHEM, V264, P8356; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Propper C, 1999, J BIOL CHEM, V274, P183, DOI 10.1074/jbc.274.1.183; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROSINKE B, 1995, J MASS SPECTROM, V30, P1462, DOI 10.1002/jms.1190301012; ROTH J, 1993, BLOOD, V82, P1875; RUGTVEIT J, 1995, GUT, V37, P367, DOI 10.1136/gut.37.3.367; Rugtveit J, 1997, GASTROENTEROLOGY, V112, P1493, DOI 10.1016/S0016-5085(97)70030-1; SARTOR BF, 1997, AM J GASTROENTEROL, V92, pS5; Sastry M, 1998, STRUCTURE, V6, P223, DOI 10.1016/S0969-2126(98)00023-9; SAWYER DW, 1985, SCIENCE, V230, P663, DOI 10.1126/science.4048951; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHLEICHER CH, 1993, INT J BIOCHEM, V25, P1251, DOI 10.1016/0020-711X(93)90075-P; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V677, P512, DOI 10.1016/0304-4165(81)90267-1; SNYDERMAN R, 1981, SCIENCE, V213, P830, DOI 10.1126/science.6266014; STAROS JV, 1983, J MEMBRANE BIOL, V74, P247, DOI 10.1007/BF02332127; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; van den Bos C, 1998, PROTEIN EXPRES PURIF, V13, P313, DOI 10.1006/prep.1998.0917; vandenBos C, 1996, J IMMUNOL, V156, P1247; VASAULT A, 1974, METHOD ENZYMAT AN, P607; VOGL T, 1999, IN PRESS J AM SOC MA; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; Yamamura T, 1996, BIOCHEM BIOPH RES CO, V221, P356, DOI 10.1006/bbrc.1996.0600; Yang Q, 1999, EXP CELL RES, V246, P501, DOI 10.1006/excr.1998.4314; Youn BS, 1997, J IMMUNOL, V159, P5201; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	59	163	168	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25291	25296		10.1074/jbc.274.36.25291	http://dx.doi.org/10.1074/jbc.274.36.25291			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464253	hybrid			2022-12-25	WOS:000082554200018
J	Yang, CZ; Mueckler, M				Yang, CZ; Mueckler, M			ADP-ribosylation factor 6 (ARF6) defines two insulin-regulated secretory pathways in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; GUANINE-NUCLEOTIDE EXCHANGE; PERMEABILIZED MAST-CELLS; ELONGATION FACTOR-TU; GTP-GAMMA-S; MAMMALIAN-CELLS; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; RAT ADIPOCYTES; SACCHAROMYCES-CEREVISIAE	ADP-ribosylation factor 6 (ARF6) appears to play an essential role in the endocytic/recycling pathway in several cell types. To determine whether ARF6 is involved in insulin-regulated exocytosis, 3T3-L1 adipocytes were infected with recombinant adenovirus expressing wildtype ARF6 or an ARF6 dominant negative mutant (D125N) that encodes a protein with nucleotide specificity modified from guanine to xanthine, Overexpression of these ARF6 proteins affected neither basal nor insulin-regulated glucose uptake in 3T3-L1 adipocytes, nor did it affect the subcellular distribution of Glut1 or Glu4. In contrast, the secretion of adipsin, a serine protease specifically expressed in adipocytes, was increased by the expression of wild-type ARF6 and was inhibited by the expression of D125N, These results indicate a requirement for ARF6 in basal and insulinregulated adipsin secretion but not in glucose transport. Our results suggest the existence of at least two distinct pathways that undergo insulin-stimulated exocytosis in 3T3-L1 adipocytes, one for adipsin release and one for glucose transporter translocation.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038495] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38495] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAO SC, 1995, J BIOL CHEM, V270, P30199; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; FIJIWARA T, 1988, J BIOL CHEM, V263, P18545; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HOFFENBERG S, 1995, BIOCHEM BIOPH RES CO, V215, P241, DOI 10.1006/bbrc.1995.2459; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; HWANG YW, 1993, J BIOL CHEM, V268, P24692; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JONES S, 1995, J CELL BIOL, V130, P1051, DOI 10.1083/jcb.130.5.1051; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; ORCI L, 1991, CELL, V64, P1183; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; RAMPAL AL, 1995, J BIOL CHEM, V270, P3938, DOI 10.1074/jbc.270.8.3938; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RYBIN V, 1996, NATURE, V383, P220; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Song J, 1998, J CELL SCI, V111, P2257; Spurlock ME, 1996, PHYSIOL BEHAV, V60, P1217, DOI 10.1016/S0031-9384(96)00219-3; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	53	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25297	25300		10.1074/jbc.274.36.25297	http://dx.doi.org/10.1074/jbc.274.36.25297			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464254	hybrid			2022-12-25	WOS:000082554200019
J	Hausdorff, SF; Fingar, DC; Morioka, K; Garza, LA; Whiteman, EL; Summers, SA; Birnbaum, MJ				Hausdorff, SF; Fingar, DC; Morioka, K; Garza, LA; Whiteman, EL; Summers, SA; Birnbaum, MJ			Identification of wortmannin-sensitive targets in 3T3-L1 adipocytes - Dissociation of insulin-stimulated glucose uptake and GLUT4 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAY; SKELETAL-MUSCLE; INHIBITOR WORTMANNIN; RECEPTOR SUBSTRATE-1; TRANSPORT ACTIVITY; KINASE ACTIVATION; PROTEIN-SYNTHESIS	The current studies investigated the contribution of phosphatidylinositol 3-kinase (PI3-kinase) isoforms to insulin-stimulated glucose uptake and glucose transporter 4 (GLUT4) translocation, Experiments involving the microinjection of antibodies specific for the p110 catalytic subunit of class I PI3-kinases demonstrated an absolute requirement for this form of the enzyme in GLUT4 translocation. This finding was confirmed by the demonstration that the PI3-kinase antagonist wortmannin inhibits GLUT4 and insulin-responsive aminopeptidase translocation with a dose response identical to that required to inhibit another class I PI3-kinase-dependent event, activation of pp70 SG-kinase, Interestingly, wortmannin inhibited insulin-stimulated glucose uptake at much lower doses, suggesting the existence of a second, higher affinity target of the drug. Subsequent removal of wortmannin from the media shifted this dose-response curve to one resembling that for GLUT4 translocation and pp70 SG-kinase, This is consistent with the lower affinity target being p110, which is irreversibly inhibited by wortmannin, Wortmannin did not reduce glucose uptake in cells stably expressing Myr-Akt, which constitutively induced GLUT4 translocation to the plasma membrane; this demonstrates that wortmannin does not inhibit the transporters directly. In addition to elucidating a second wortmannin-sensitive pathway in 3T3-L1 adipocytes, these studies suggest that the presence of GLUT4 on the plasma membrane is not sufficient for activation of glucose uptake.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cox Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Birnbaum, MJ (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	birnbaum@hhmi.upenn.edu	/AAE-5384-2020	Birnbaum, Morris/0000-0001-9972-8680; garza, luis/0000-0002-6547-9695	NIDDK NIH HHS [DK39615, DK09375] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039615, F32DK009375] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; BERGER J, 1994, BIOCHEM BIOPH RES CO, V205, P570, DOI 10.1006/bbrc.1994.2703; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CALDERHEAD DM, 1990, BIOCHEM J, V269, P597, DOI 10.1042/bj2690597; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; Hansen PA, 1998, J BIOL CHEM, V273, P18173, DOI 10.1074/jbc.273.29.18173; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; HERRERA R, 1986, J BIOL CHEM, V261, P1980; JOOST HG, 1986, J BIOL CHEM, V261, P33; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KURODA M, 1987, J BIOL CHEM, V262, P245; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; OKADA T, 1994, J BIOL CHEM, V269, P3568; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; SATOH S, 1993, J BIOL CHEM, V268, P17820; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHIMIZU Y, 1994, BIOCHEM BIOPH RES CO, V202, P660, DOI 10.1006/bbrc.1994.1981; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; YANO H, 1993, J BIOL CHEM, V268, P25846; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	51	85	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24677	24684		10.1074/jbc.274.35.24677	http://dx.doi.org/10.1074/jbc.274.35.24677			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455135	hybrid			2022-12-25	WOS:000082193400034
J	Watson, AD; Subbanagounder, G; Welsbie, DS; Faull, KF; Navab, M; Jung, ME; Fogelman, AM; Berliner, JA				Watson, AD; Subbanagounder, G; Welsbie, DS; Faull, KF; Navab, M; Jung, ME; Fogelman, AM; Berliner, JA			Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-1; HUMAN ATHEROSCLEROTIC LESIONS; SMOOTH-MUSCLE CELLS; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; MASS-SPECTROMETRY; IN-VIVO; FATTY-ACIDS; F-2-ISOPROSTANES; OXIDATION	One of the earliest steps in the development of the atherosclerotic lesion is the accumulation of monocyte/macrophages within:the vessel wall. Oxidized lipids present in minimally modified-low density lipoproteins (RIM-LDL) contribute to this process by activating endothelial cells to express; monocyte-specific adhesion molecules and chemoattractant factors. A major focus of our group has been the isolation and characterization of the biologically active oxidized lipids in MRI-LDL. We have previously characterized three oxidized phospholipids present in MM-LDL, atherosclerotic lesions of fat fed rabbits, and autoxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (Ox-PAPC) that induced human aortic endothelial cells to adhere human monocytes in vitro. We have used sequential normal and reverse phase-high performance liquid chromatography to isolate various isomers of an oxidized phospholipid from autoxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine. The fatty acid in the sn-2 position of this biologically active isomer and its dehydration product was released by phospholipase A(2) and characterized. Hydrogenation with platinum(IV) oxide/hydrogen suggested a cyclic moiety, and reduction with sodium borohydride suggested two reducible oxygen-containing groups in the molecule. The fragmentation pattern produced by:electrospray ionization-collision induced dissociation-tandem mass spectrometry was consistent with a molecule resembling an E-ring prostaglandin with an epoxide at the 5,6 position. The structure of this lipid was confirmed by proton nuclear magnetic resonance spectroscopy analysis of the free fatty acid isolated from the dehydration product of m/z 828.5, Based on these studies, we arrived at the structure of the biologically active oxidized phospholipids as 1-palmitoyl-2-(5,6-epoxyisoprostane E-2)-sn-glycero-3-phosphocholine. The identification of this molecule adds epoxyisoprostanes to the growing list of biologically active isoprostanes.	Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Watson, AD (corresponding author), Univ Calif Los Angeles, Med Ctr, Ctr Hlth Sci, Dept Med Cardiol, Rm 47-123, Los Angeles, CA 90095 USA.				NHLBI NIH HHS [HL 30568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Batsanov AS, 1996, SYNLETT, P401; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BOAZ NW, 1995, TETRAHEDRON-ASYMMETR, V6, P15, DOI 10.1016/0957-4166(94)00339-D; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; CHINI M, 1993, J ORG CHEM, V58, P1221, DOI 10.1021/jo00057a040; CHO MJ, 1977, J MED CHEM, V20, P1525, DOI 10.1021/jm00221a036; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; Davi G, 1997, ARTERIOSCL THROM VAS, V17, P3230, DOI 10.1161/01.ATV.17.11.3230; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FOGELMAN AM, 1988, J LIPID RES, V29, P1243; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; Gniwotta C, 1997, ARTERIOSCL THROM VAS, V17, P3236, DOI 10.1161/01.ATV.17.11.3236; GOPAUL NK, 1994, FEBS LETT, V348, P297, DOI 10.1016/0014-5793(94)00628-8; Han XL, 1996, BIOCHEMISTRY-US, V35, P5822, DOI 10.1021/bi952927v; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; JOHNSON MR, 1970, J ORG CHEM, V35, P1041, DOI 10.1021/jo00829a039; MOORE KP, 1995, CIRC RES, V77, P335, DOI 10.1161/01.RES.77.2.335; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; Morrow JD, 1998, ARCH BIOCHEM BIOPHYS, V353, P160, DOI 10.1006/abbi.1998.0645; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; Parthasarathys S., 1994, MODIFIED LIPOPROTEIN, P91; Porter NA, 1998, J ORG CHEM, V63, P5547, DOI 10.1021/jo980654e; Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735; PROUDFOOT JM, 1995, BIOCHEM BIOPH RES CO, V206, P455, DOI 10.1006/bbrc.1995.1064; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P823, DOI 10.1016/S0090-6980(97)00183-4; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Silverstein R. M., 1991, SPECTROMETRIC IDENTI, P289; Stein B, 1990, CIRCULATION, V2, P1147; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Strong JP, 1997, ANN NY ACAD SCI, V811, P226, DOI 10.1111/j.1749-6632.1997.tb52004.x; Subbanagounder G, 1997, J ORG CHEM, V62, P7658, DOI 10.1021/jo970858f; THOMAS DW, 1991, ANAL BIOCHEM, V198, P104, DOI 10.1016/0003-2697(91)90513-S; WAGNER AC, 1996, CIRCULATION S, V94, P2; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WEBER C, 1995, BIOCHEM BIOPH RES CO, V206, P621, DOI 10.1006/bbrc.1995.1088; WESTCOTT JY, 1985, BIOMED ENVIRON MASS, V12, P714, DOI 10.1002/bms.1200121208; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	46	177	180	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24787	24798		10.1074/jbc.274.35.24787	http://dx.doi.org/10.1074/jbc.274.35.24787			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455151	hybrid			2022-12-25	WOS:000082193400050
J	Zhang, ZY; Hernandez-Lagunas, L; Horne, WC; Baron, R				Zhang, ZY; Hernandez-Lagunas, L; Horne, WC; Baron, R			Cytoskeleton-dependent tyrosine phosphorylation of the p130(Cas) family member HEF1 downstream of the G protein-coupled calcitonin receptor - Calcitonin induces the association of HEF1, paxillin, and focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRK-ASSOCIATED SUBSTRATE; CYTOSOLIC-FREE CALCIUM; SWISS 3T3 CELLS; SIGNALING PATHWAYS; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; ACTIN CYTOSKELETON; PHOSPHOLIPASE-C; DOCKING PROTEIN; LIGAND-BINDING	HEF1 is a recently described p130(Cas)-like docking protein that contains one SH3 domain and multiple SH2 binding motifs, In B cells, HEF1 is phosphorylated by a cytoskeleton-dependent mechanism that is triggered by integrin ligation. However, the induction of HEF1 phosphorylation by G protein-coupled receptors has not been reported. We found that HEF1, but not p130(Cas), is tyrosine-phosphorylated following stimulation of the rabbit C1a calcitonin receptor stably expressed in HEK-293 cells. The calcitonin-induced tyrosine phosphorylation of HEF1 increased in a time- and dose-dependent manner. Dibutyryl cAMP and forskolin had little or no effect on HEF1 phosphorylation, and the protein kinase A inhibitor H89 failed to detectably inhibit the response to calcitonin, indicating that the G(s)/cAMP/protein kinase A pathway does not mediate the calcitonin effect. Pertussis toxin, which selectively blocks G(i/o) signaling, also had no effect. Increasing cytosolic Ca2+ with ionomycin stimulated HEF1 phosphorylation and preventing any calcitonin-induced change in cytosolic calcium by a combination of BAPTA and extracellular EGTA completely blocked the calcitonin induced tyrosine phosphorylation of HEF1. Phorbol 12-myristate 13-acetate also induced HEF1 tyrosine phosphorylation, and the protein kinase C inhibitor calphostin C completely inhibited both calcitonin- and phorbol 12-myristate 13-acetate-stimulated HEF1 phosphorylation. Calcitonin also induced the tyrosine phosphorylation of paxillin and focal adhesion kinase, and the association of these two proteins with HEF1. Pretreatment with cytochalasin D, which disrupts actin microfilaments, prevented the calcitonin-induced HEF1 and paxillin phosphorylation. In conclusion, the calcitonin-stimulated tyrosine phosphorylation of HEF1 is mediated by calcium- and protein kinase C-dependent mechanisms and requires the integrity of the actin cytoskeleton.	Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Horne, WC (corresponding author), Yale Univ, Sch Med, Dept Orthopaed, POB 208044, New Haven, CT 06520 USA.	william.horne@yale.edu			NIAMS NIH HHS [AR-46032, AR-42927] Funding Source: Medline; NIDCR NIH HHS [DE-04724] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046032, R01AR042927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE004724, R37DE004724] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; HORNE WC, 1994, TRENDS ENDOCRIN MET, V5, P395, DOI 10.1016/1043-2760(95)92521-J; HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183; Hunter AJ, 1997, J IMMUNOL, V159, P4806; Ishino M, 1995, ONCOGENE, V11, P2331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kobayashi S, 1998, J BIOCHEM-TOKYO, V123, P624; Law SF, 1998, MOL CELL BIOL, V18, P3540, DOI 10.1128/MCB.18.6.3540; Law SF, 1996, MOL CELL BIOL, V16, P3327; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; MOONGA BS, 1992, J ENDOCRINOL, V132, P241, DOI 10.1677/joe.0.1320241; Naro F, 1998, ENDOCRINOLOGY, V139, P3241, DOI 10.1210/en.139.7.3241; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ohashi Y, 1998, J BIOL CHEM, V273, P6446, DOI 10.1074/jbc.273.11.6446; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; Shyu JF, 1999, EUR J BIOCHEM, V262, P95, DOI 10.1046/j.1432-1327.1999.00346.x; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; TETI A, 1995, J BIOL CHEM, V270, P16666, DOI 10.1074/jbc.270.28.16666; Vuori K, 1996, MOL CELL BIOL, V16, P2606; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	51	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25093	25098		10.1074/jbc.274.35.25093	http://dx.doi.org/10.1074/jbc.274.35.25093			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455189	hybrid			2022-12-25	WOS:000082193400088
J	Jilani, A; Ramotar, D; Slack, C; Ong, C; Yang, XM; Scherer, SW; Lasko, DD				Jilani, A; Ramotar, D; Slack, C; Ong, C; Yang, XM; Scherer, SW; Lasko, DD			Molecular cloning of the human gene, PNKP, encoding a polynucleotide kinase 3 '-phosphatase and evidence for its role in repair of DNA strand breaks caused by oxidative damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSITU HYBRIDIZATION; ESCHERICHIA-COLI; HUMAN CHROMOSOME-19; SACCHAROMYCES-CEREVISIAE; IRRADIATED THYMOCYTES; DATABASE SEARCH; EXONUCLEASE-III; END-GROUPS; ENZYMES; COMPLEMENTATION	Mammalian polynucleotide kinases catalyze the 5'-phosphorylation of nucleic acids and can have associated 3'-phosphatase activity, predictive of an important function in DNA repair following ionizing radiation or oxidative damage, The sequences of three tryptic peptides from a bovine 60-kDa polypeptide that correlated with 5'-DNA kinase and 3'-phosphatase activities identified human and murine dbEST clones. The 57.1-kDa conceptual translation product of this gene, polynucleotide kinase 3'-phosphatase (PNKP), contained a putative ATP binding site and a potential 3'-phosphatase domain with similarity to L-2-haloacid dehalogenases. BLAST searches identified possible homologs in Caenorhabditis elegans, Schizosaccharomyces Sces pombe, and Drosophila melanogaster. The gene was localized to chromosome 19q13.3-13.4. Northern analysis indicated a a-kilobase mRNA in eight human tissues. A glutathione S-transferase-PNKP fusion protein displayed 5'-DNA kinase and 3'-phosphatase activities. PNKP is the first gene for a DNA-specific kinase from any organism. PNKP expression partially rescued the sensitivity to oxidative damaging agents of the Escherichia coli DNA repair-deficient xth nfo double mutant. PNKP gene function restored termini suitable for DNA polymerase, consistent with in vivo removal of S'-phosphate groups, facilitating DNA repair.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med & Human Genet, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3T 1E2, Canada; Hop Maison Neuve Rosemont, Res Ctr, Montreal, PQ H1T 2M4, Canada; Univ Toronto, Dept Genet, Hosp Sick Children, Toronto, ON M5G 1X8, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; Universite de Montreal; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Lasko, DD (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Mol Oncol Grp, Rm 502,3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	dlasko@ldi.jgh.mcgill.ca	Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; AYRES MD, 1994, VIROLOGY, V202, P586, DOI 10.1006/viro.1994.1380; BARNES DE, 1992, GENOMICS, V12, P164, DOI 10.1016/0888-7543(92)90422-O; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BELLO MJ, 1995, INT J CANCER, V64, P207; Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS R, 1991, METHOD ENZYMOL, V208, P2; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; CHAMPOUX JJ, 1978, J MOL BIOL, V118, P441, DOI 10.1016/0022-2836(78)90238-3; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; COQUERELLE T, 1973, INT J RADIAT BIOL, V24, P397, DOI 10.1080/09553007314551251; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Durantel D, 1998, J GEN VIROL, V79, P629, DOI 10.1099/0022-1317-79-3-629; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HABRAKEN Y, 1986, NUCLEIC ACIDS RES, V14, P8103, DOI 10.1093/nar/14.20.8103; HABRAKEN Y, 1983, FEBS LETT, V160, P46, DOI 10.1016/0014-5793(83)80933-8; HABRAKEN Y, 1988, EUR J BIOCHEM, V171, P59, DOI 10.1111/j.1432-1033.1988.tb13758.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; HUYNH HT, 1993, CANCER RES, V53, P1727; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jilani A, 1999, J CELL BIOCHEM, V73, P188, DOI 10.1002/(SICI)1097-4644(19990501)73:2<188::AID-JCB5>3.3.CO;2-8; Karimi-Busheri F, 1998, NUCLEIC ACIDS RES, V26, P4395, DOI 10.1093/nar/26.19.4395; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; KarimiBusheri F, 1997, J CELL BIOCHEM, V64, P258, DOI 10.1002/(SICI)1097-4644(199702)64:2<258::AID-JCB9>3.0.CO;2-W; KEMPER RR, 1992, GENOMICS, V14, P205, DOI 10.1016/S0888-7543(05)80311-8; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JY, 1998, CANCER RES, V58, P1140; LENNARTZ M, 1975, INT J RADIAT BIOL, V27, P577, DOI 10.1080/09553007514550611; LEVIN CJ, 1976, J BIOL CHEM, V251, P1767; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P376, DOI 10.1097/00004647-199704000-00003; Masson JY, 1997, MOL MICROBIOL, V24, P711, DOI 10.1046/j.1365-2958.1997.3841748.x; McDonald JM, 1998, CANCER RES, V58, P1387; MCKUSICK V, 1998, J HOPKINS U BALTIMOR; MIDGLEY CA, 1985, EMBO J, V4, P2695, DOI 10.1002/j.1460-2075.1985.tb03989.x; MOHRENWEISER HW, 1989, CYTOGENET CELL GENET, V52, P11, DOI 10.1159/000132829; NOVOGRODSKY A, 1966, J BIOL CHEM, V241, P2933; PHEIFFER BH, 1982, BIOCHEM BIOPH RES CO, V109, P1297, DOI 10.1016/0006-291X(82)91918-0; Pohjanpelto P, 1996, EMBO J, V15, P1193, DOI 10.1002/j.1460-2075.1996.tb00458.x; PRINOS P, 1995, J CELL BIOCHEM, V58, P115, DOI 10.1002/jcb.240580114; Ramotar D, 1997, BIOCHEM CELL BIOL, V75, P327, DOI 10.1139/bcb-75-4-327; Ramotar D, 1996, CAN J MICROBIOL, V42, P835, DOI 10.1139/m96-105; RAMOTAR D, 1991, MOL MICROBIOL, V5, P149, DOI 10.1111/j.1365-2958.1991.tb01835.x; Richardson C.C., 1981, ENZYMES A, V14, P299, DOI DOI 10.1016/S1874-6047(08)60342-X; Sambrook J., 2002, MOL CLONING LAB MANU; SHUMAN S, 1979, J BIOL CHEM, V254, P396; SOLTIS DA, 1982, J BIOL CHEM, V257, P1340; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; TAMURA S, 1981, EUR J BIOCHEM, V115, P449; THOMPSON LH, 1989, GENOMICS, V5, P670, DOI 10.1016/0888-7543(89)90107-9; TRASK B, 1993, GENOMICS, V15, P133, DOI 10.1006/geno.1993.1021; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WINOCOV I, 1982, MOL CELL BIOL, V2, P241; WINTERS TA, 1992, NUCLEIC ACIDS RES, V20, P2573, DOI 10.1093/nar/20.10.2573; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410; ZIMMERMAN SB, 1981, ENZYMES, V14, P315	67	222	229	3	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24176	24186		10.1074/jbc.274.34.24176	http://dx.doi.org/10.1074/jbc.274.34.24176			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446192	hybrid			2022-12-25	WOS:000082110900071
J	Morrione, A; Plant, P; Valentinis, B; Staub, O; Kumar, S; Rotin, D; Baserga, R				Morrione, A; Plant, P; Valentinis, B; Staub, O; Kumar, S; Rotin, D; Baserga, R			mGrb10 interacts with Nedd4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-DEPENDENT MANNER; RECEPTOR-BINDING-PROTEIN; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTORS; INSULIN-RECEPTOR; ADAPTER PROTEIN; SH2 DOMAINS; SRC HOMOLOGY-2; C2 DOMAIN; BCR-ABL	We have utilized the yeast two-hybrid system to identify proteins interacting with mouse Grb10, an adapter protein known to interact with both the insulin and the insulin-like growth factor-I receptors. We have isolated a mouse cDNA clone containing the C2 domain of mouse Nedd4, a ubiquitin protein ligase (E3) that also contains a beet (homologous to the EG-AP carboxyl-terminus) domain and three WW domains. The interaction with Grb10 in the two-hybrid system was confirmed using the full-length Nedd4, and it was abolished by deleting the last 148 amino acids of Grb10, a region that includes the SH2 domain and the newly identified BPS domain. The interaction between Grb10 and Nedd4 was also reproduced in vivo in mouse embryo fibroblasts, where endogenous Nedd4 co-immunoprecipitated constitutively with both the endogenous and an overexpressed Grb10. This interaction was Ca2+-independent. Grb10 interacting with Nedd4 was not ubiquitinated in vivo, raising the possibility that this interaction may be used to target other proteins, like tyrosine kinase receptors, for ubiquitination.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Hanson Ctr Canc Res, Inst Med & Vet Sci, Adelaide, SA 5000, Australia	Jefferson University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Institute Medical & Veterinary Science Australia	Morrione, A (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.		Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814	NATIONAL CANCER INSTITUTE [R01CA053484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NCI NIH HHS [CA53484] Funding Source: Medline; NIGMS NIH HHS [GM33694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; Davis AJ, 1996, J BIOL CHEM, V271, P24333, DOI 10.1074/jbc.271.40.24333; DELLES C, 1995, J PHYSIOL-LONDON, V486, P557, DOI 10.1113/jphysiol.1995.sp020834; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; HARPER JW, 1993, CELL, V75, P805; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; HIUBREGSTE JM, 1995, P NATL ACAD SCI USA, V92, P2563; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; LANG F, 1990, RENAL PHYSIOL BIOCH, V13, P82; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Miyoshi N, 1998, P NATL ACAD SCI USA, V95, P1102, DOI 10.1073/pnas.95.3.1102; MORI S, 1992, J BIOL CHEM, V267, P6429; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; MORRIONE A, 1996, CANCER RES, V56, P3167; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	49	91	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24094	24099		10.1074/jbc.274.34.24094	http://dx.doi.org/10.1074/jbc.274.34.24094			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446181	Green Published, hybrid			2022-12-25	WOS:000082110900060
J	Schaub, M; Krol, A; Carbon, P				Schaub, M; Krol, A; Carbon, P			Flexible zinc finger requirement for binding of the transcriptional activator Staf to U6 small nuclear RNA and tRNA(Sec) promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA RECOGNITION; CRYSTAL-STRUCTURE; POLYMERASE-III; COMPLEX; PROTEIN; SPECIFICITY; REVEALS; DOMAINS; TFIIIA; GENE	The transactivator Staf, which contains seven zinc finger motifs, exerts its effect on gene expression by binding to specific targets in small nuclear RNA (snRNA) and snRNA-type gene promoters. In this work, binding site selection allowed us to identify the al-base pair ATTACCCATAATGCATYGCGG sequence as the high affinity consensus binding site for Staf. It shows a high sequence divergence with Staf-responsive elements in the Xenopus selenocysteine tRNA (tRNA(Sec)) and human U6 snRNA promoters, By using a combination of approaches, we analyzed the interaction of wildtype and truncated Staf zinc finger domains with the consensus, Xenopus tRNA(Sec), and human U6 sites. Two main conclusions emerged from our data. First, the data clearly indicate that zinc finger 7 does not establish base specific contacts in Staf-DNA complexes. The second conclusion concerns zinc finger 1, which is required for the binding to the Xenopus tRNA(Sec) site but is dispensable in the case of the human U6 site. Taking into account the sequence differences in the two sites, these findings demonstrate that Staf utilizes zinc finger 1 in a rather flexible manner, illustrating how a protein can interact with DNAs containing targets of different sequences.	Inst Biol Mol & Cellulaire, CNRS, UPR 9002, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Carbon, P (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9002, 15 Rue Rene Descartes, F-67084 Strasbourg, France.							CHOO Y, 1993, NUCLEIC ACIDS RES, V21, P3341, DOI 10.1093/nar/21.15.3341; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; MYSLINSKI E, 1992, NUCLEIC ACIDS RES, V20, P203, DOI 10.1093/nar/20.2.203; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; Omichinski JG, 1997, NAT STRUCT BIOL, V4, P122, DOI 10.1038/nsb0297-122; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Schuster C, 1998, MOL CELL BIOL, V18, P2650, DOI 10.1128/MCB.18.5.2650; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291	20	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24241	24249		10.1074/jbc.274.34.24241	http://dx.doi.org/10.1074/jbc.274.34.24241			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446199	hybrid			2022-12-25	WOS:000082110900078
J	Bangur, CS; Faitar, SL; Folster, JP; Ponticelli, AS				Bangur, CS; Faitar, SL; Folster, JP; Ponticelli, AS			An interaction between the N-terminal region and the core domain of yeast TFIIB promotes the formation of TATA-binding protein-TFIIB-DNA complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR-TFIIB; VP16 ACTIVATION DOMAIN; START SITE SELECTION; IN-VIVO; FUNCTIONAL DOMAINS; INITIATION; ELEMENT; TBP; HOLOENZYME	The general transcription factor IIB (TFIIB) plays an essential role in transcription of protein-coding genes by eukaryotic RNA polymerase II. We previously identified a yeast TFIIB mutant (R64E) that exhibited increased activity in the formation of stable TATA-binding protein-TFIIB-DNA (DB) complexes in vitro. We report here that the homologous human TFIIB mutant (R53E) also displayed increased activity in DB complex formation in vitro. Biochemical analyses revealed that the increased activity of the R64E mutant in DB complex formation was associated with an altered protease sensitivity of the protein and an enhanced interaction between the N-terminal region and the C-terminal core domain. These results suggest that the intramolecular interaction in yeast TFIIB stabilizes a productive conformation of the protein for the association with promoter-bound TATA-binding protein.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA; SUNY Buffalo, Ctr Adv Mol Biol & Immunol, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ponticelli, AS (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, 3435 Main St,140 Faber Hall, Buffalo, NY 14214 USA.				NIGMS NIH HHS [GM51124] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051124, R29GM051124] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; Bangur CS, 1997, MOL CELL BIOL, V17, P6784, DOI 10.1128/MCB.17.12.6784; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Hayashi F, 1998, BIOCHEMISTRY-US, V37, P7941, DOI 10.1021/bi9801098; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PINTO I, 1994, J BIOL CHEM, V269, P30569; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; Shaw SP, 1996, MOL CELL BIOL, V16, P3651; Shaw SP, 1997, P NATL ACAD SCI USA, V94, P2427, DOI 10.1073/pnas.94.6.2427; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	35	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23203	23209		10.1074/jbc.274.33.23203	http://dx.doi.org/10.1074/jbc.274.33.23203			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438492	hybrid			2022-12-25	WOS:000082012800042
J	Holmes, M; Turner, J; Fox, A; Chisholm, O; Crossley, M; Chong, B				Holmes, M; Turner, J; Fox, A; Chisholm, O; Crossley, M; Chong, B			hFOG-2, a novel zinc finger protein, binds the co-repressor mCtBP2 and modulates GATA-mediated activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; DNA-BINDING; MEGAKARYOCYTIC DIFFERENTIATION; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; HEMATOPOIETIC-CELLS; MICE LACKING; TRANSFORMATION; COFACTOR; DOMAIN	We have identified a novel human zinc finger protein, hFOG-2, which is related to but distinct from the murine transcription factor Friend-of-GATA-1 (mFOG-1). The hFOG-2 gene was initially detected in K562 cells using a polymerase chain reaction approach with degenerate primers corresponding to zinc finger regions of mFOG-1, A murine homologue of hFOG-2 was also identified in the mouse expressed sequence tag data banks, indicating that a family of FOG genes exists in mammals. hFOG-2 appears to be widely expressed, while mFOG-1 is expressed primarily in erythroid and megakaryocytic cells and plays a fundamental role in the development of these lineages. Sequencing of the full-length hFOG-2 cDNA indicates that the interaction domains for transcription factors GATA-1 and mCtBP2 are both conserved and we have shown that this new FOG protein also physically interacts with these factors. We have demonstrated that hFOG-2, like mFOG-1, can act in concert with GATA-1 to activate gene expression from the p45 NF-E2 promoter region, but that it can also act to repress GATA-mediated activation of additional reporter constructs. Finally, we have identified a repression domain in hFOG-2 and show that repression is dependent upon the integrity of the mCtBP2 interaction motif Pro-Ile-Asp-Leu-Ser.	Prince Wales Hosp, Dept Haematol, Randwick, NSW 2031, Australia; Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	University of New South Wales Sydney; University of Sydney	Chong, B (corresponding author), Prince Wales Hosp, Dept Haematol, Randwick, NSW 2031, Australia.		Fox, Archa H/H-9219-2014; Chong, Beng/AAM-9010-2021; Crossley, Merlin/D-7888-2011; Chisholm, Orin/L-4206-2016; Chong, Beng/AAE-2617-2019	Fox, Archa H/0000-0003-1962-270X; Crossley, Merlin/0000-0003-2057-3642; Chisholm, Orin/0000-0002-9749-4160; Holmes, Melissa/0000-0001-5894-6649				Bellefroid EJ, 1996, CELL, V87, P1191, DOI 10.1016/S0092-8674(00)81815-2; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; Cubadda Y, 1997, GENE DEV, V11, P3083, DOI 10.1101/gad.11.22.3083; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642	29	94	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23491	23498		10.1074/jbc.274.33.23491	http://dx.doi.org/10.1074/jbc.274.33.23491			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438528	hybrid			2022-12-25	WOS:000082012800078
J	Rousseau, D; Cannella, D; Boulaire, J; Fitzgerald, P; Fotedar, A; Fotedar, R				Rousseau, D; Cannella, D; Boulaire, J; Fitzgerald, P; Fotedar, A; Fotedar, R			Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway	ONCOGENE			English	Article						p21(WAF1,Cip1); CDK; cell cycle; ubiquitination; proteasome; PCNA	DEPENDENT KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; DNA-REPLICATION; RETINOBLASTOMA PROTEIN; POTENTIAL MEDIATOR; MAMMALIAN-CELLS; P21(CIP1); SUBUNIT; CLONING	The CDK inhibitor, p21(WAF1/Cip1) blocks cell cycle progression. In vitro, the N-terminus of p21 binds and inhibits CDK-cyclin kinase activity, whereas the C-terminus binds and inhibits PCNA (proliferating cell nuclear antigen) function. PCNA is essential for processivity of both DNA polymerase delta and epsilon. We have performed a detailed analysis of growth inhibition by the N- and C-terminal regions of p21, and determined whether the N- and C-terminal regions mediate this effect by different mechanisms. Expression of either the N- or the C-terminal region of p21 inhibits DNA synthesis and cell growth, but not as efficiently as full length p21, The effectiveness of the two p21 domains is dependent on their stability which is determined by the ubiquitin-proteasome pathway. The stabilization of the N- and C-terminal region of p21 increases their effectiveness as inhibitors of DNA synthesis to levels comparable to full length p21, Inhibition of DNA synthesis by the N-terminal region of p21 involves suppression of E2F activity. In contrast, inhibition by the C-terminal region of p21 is not accompanied by suppression of E2F activity, but is mediated via PCNA binding. The C-terminal region of p21 therefore inhibits cell growth by a mechanism distinct from that of the N-terminal region containing the CDK-cyclin inhibitory domain.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Inst Biol Struct JP Ebel, F-38027 Grenoble 1, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Fotedar, A (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Rd, San Diego, CA 92121 USA.		Boulaire, Jerome/A-5954-2009; Cannella, Dominique/F-4879-2019	Cannella, Dominique/0000-0002-1665-9833	NATIONAL CANCER INSTITUTE [R01CA074435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER; NCI NIH HHS [CA74435] Funding Source: Medline; NIAID NIH HHS [AI31453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; FOTEDAR R, 1991, COLD SH Q B, V56, P325; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Fotedar R, 1996, ONCOGENE, V12, P2155; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	84	85	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4313	4325		10.1038/sj.onc.1202686	http://dx.doi.org/10.1038/sj.onc.1202686			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439039				2022-12-25	WOS:000081732700004
J	McPherson, RA; Harding, A; Roy, S; Lane, A; Hancock, JF				McPherson, RA; Harding, A; Roy, S; Lane, A; Hancock, JF			Interactions of c-Raf-1 with phosphatidylserine and 14-3-3	ONCOGENE			English	Article						Ras; Raf-1; 14-3-3; phosphatidylserine	ACTIVATED PROTEIN-KINASE; DISTINCT BINDING DOMAINS; CYSTEINE-RICH DOMAIN; PLASMA-MEMBRANE; RAF-1 KINASE; IN-VITRO; TYROSINE PHOSPHORYLATION; AMINO-TERMINUS; RAS; 14-3-3-PROTEINS	Activation of Raf-1 occurs at the plasma membrane. We recently showed that 14-3-3 must be complexed with Raf-1 for efficient recruitment to the plasma membrane and activation by Ras, but that 14-3-3 is completely displaced from Raf-1 following plasma membrane binding. We show here that the Raf-1 zinc finger is not absolutely required for 14-3-3 binding but is required to stabilize the interaction between Raf-1 and 14-3-3, Incubation of Raf-1 with phosphatidylserine, an inner plasma membrane phospholipid, results in removal of 14-3-3 and an increase in Raf-1 kinase activity, whereas removal of 14-3-3 from Raf-1 using specific phosphopeptides substantially reduces Raf-1 basal kinase activity. Displacement of 14-3-3 from activated Raf-1 by phosphopeptides has no effect on kinase activity if Raf-1 is first removed from solution, but completely eradicates kinase activity of soluble activated Raf-1. These results suggest a mechanism for the removal of 14-3-3 from Raf-1 at the plasma membrane and show that removal of 14-3-3 from Raf-1 has markedly different effects depending on experimental conditions.	Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund Lab Expt Oncol, Herston, Qld 4006, Australia	University of Queensland	Hancock, JF (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund Lab Expt Oncol, Herston, Qld 4006, Australia.		Harding, Angus/B-4120-2012	Hancock, John/0000-0003-0542-4710				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BUNDAY L, 1993, CELL, V73, P611; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; Kockel L, 1997, GENE DEV, V11, P1140, DOI 10.1101/gad.11.9.1140; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUEN KL, 1995, ONCOGENE, V11, P825; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	46	56	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3862	3869		10.1038/sj.onc.1202730	http://dx.doi.org/10.1038/sj.onc.1202730			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445849				2022-12-25	WOS:000081171700007
J	Kanayasu-Toyoda, T; Yamaguchi, T; Uchida, E; Hayakawa, T				Kanayasu-Toyoda, T; Yamaguchi, T; Uchida, E; Hayakawa, T			Commitment of neutrophilic differentiation and proliferation of HL-60 cells coincides with expression of transferrin receptor - Effect of granulocyte colony stimulating factor on differentiation and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; TERMINAL DIFFERENTIATION; TYROSINE PHOSPHORYLATION; RETINOIC ACID; G-CSF; ACTIVATION; GROWTH; INDUCTION; RAPAMYCIN; STAT3	To examine the regulatory mechanisms of proliferation and maturation in neutrophilic lineage cells, we have tried to sort dimethyl sulfoxide (Me2SO)-treated HL-60 cells into transferrin receptor (Trf-R) positive (Trf-R+) and negative (Trf-R-) cells. Differentiated Trf-R- cells expressed more formyl-Met-Leu-Phe receptor (fMLP-receptor) and ability of O(2)radical anion genaration, as markers of differentiation, than Trf-R+ cells, and Trf-R cell differentiation was markedly accelerated by the incubation with granulocyte colony stimulating factor (G-CSF), On the other hand, Trf-R+ cells had a tendency to proliferate rather than differentiate, and proliferation was enhanced by G-CSF, These results indicate that Trf-R expression coincides with the commitment to proliferate or differentiate of HL-60 cells, and G-CSF accelerates these commitments. G-CSF-induced tyrosine phosphorylation of STAT 3 in Trf-R- cells much more than in Trf-R+ cells. Protein 70 S6 kinase expression was higher in Trf-R+ cells than in Trf-R- cells. Furthermore, p70 S6 kinase was hyperphosphorylated by G-CSF in Trf-R+ cells, but not in Trf-R- cells. Rapamycin, an inhibitor of p70 S6 kinase activity, inhibited G-CSF-dependent proliferation of Trf-R+ cells and increased fMLP-R expression on these cells. These results suggest that commitment to proliferation and differentiation in Me2SO-treated HL-60 cells is preprogrammed and correlated with Trf-R expression, and G-CSF potentiates the cellular commitment. STAT 3 may promote differentiation of Me2SO-treated HL-60 cells into neutrophils, while p70 S6 kinase may promote proliferation and negatively regulate neutrophilic differentiation.	Natl Inst Hlth Sci, Div Biol Chem & Biol, Setagaya Ku, Tokyo 1588501, Japan	National Institute of Health Sciences - Japan	Yamaguchi, T (corresponding author), Natl Inst Hlth Sci, Div Biol Chem & Biol, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.							Barge RMY, 1996, BLOOD, V87, P2148, DOI 10.1182/blood.V87.6.2148.bloodjournal8762148; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOLLAG W, 1991, BRIT J HAEMATOL, V79, P87, DOI 10.1111/j.1365-2141.1991.tb08129.x; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Busca R, 1996, J BIOL CHEM, V271, P31824, DOI 10.1074/jbc.271.50.31824; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CAZZOLA M, 1990, BLOOD, V75, P1903; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; Crawley JB, 1996, J BIOL CHEM, V271, P16357, DOI 10.1074/jbc.271.27.16357; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DEMETRI GD, 1991, BLOOD, V78, P2791; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Kanwar VS, 1993, NEUTROPHIL, P1; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LESLEY JF, 1985, MOL CELL BIOL, V5, P1814, DOI 10.1128/MCB.5.8.1814; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074-7613(00)80504-X; Liu FL, 1997, BLOOD, V90, P2583, DOI 10.1182/blood.V90.7.2583.2583_2583_2590; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; NECKERS LM, 1991, PATHOBIOLOGY, V59, P11, DOI 10.1159/000163610; NECKERS LM, 1983, P NATL ACAD SCI-BIOL, V80, P3494, DOI 10.1073/pnas.80.11.3494; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NICOLA NA, 1987, INT J CELL CLONING, V5, P1, DOI 10.1002/stem.5530050102; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; RAUPRICH P, 1995, BLOOD, V86, P4500, DOI 10.1182/blood.V86.12.4500.bloodjournal86124500; Rodel JE, 1996, BLOOD, V87, P858, DOI 10.1182/blood.V87.3.858.bloodjournal873858; SAKASHITA A, 1991, LEUKEMIA, V5, P26; SHIMODA K, 1994, BIOCHEM BIOPH RES CO, V203, P922, DOI 10.1006/bbrc.1994.2270; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; TIAN SS, 1994, BLOOD, V84, P1760; TROWBRIDGE IS, 1982, P NATL ACAD SCI-BIOL, V79, P1175, DOI 10.1073/pnas.79.4.1175; Yamaguchi T, 1998, ARCH BIOCHEM BIOPHYS, V353, P93, DOI 10.1006/abbi.1998.0622	45	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25471	25480		10.1074/jbc.274.36.25471	http://dx.doi.org/10.1074/jbc.274.36.25471			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464278	hybrid			2022-12-25	WOS:000082554200042
J	Mizumura, H; Shibata, T; Morishima, N				Mizumura, H; Shibata, T; Morishima, N			Stable association of 70-kDa heat shock protein induces latent multisite specificity of a unisite-specific endonuclease in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC ENDONUCLEASE; SITE-SPECIFIC ENDONUCLEASE; MOLECULAR CHAPERONE DNAK; SACCHAROMYCES-CEREVISIAE; ENDO SCEI; GENETIC-RECOMBINATION; SUBSTRATE-BINDING; ESCHERICHIA-COLI; ATP HYDROLYSIS; HSP70	The multisite-specific endonuclease Endo.SceI of yeast mitochondria is unique among endonucleases because its 50-kDa subunit forms a stable dimer with the mitochondrial 70-kDa heat shock protein (mtHSP70), which otherwise fulfills a chaperone function by binding transiently to unfolded proteins. Here we show that the mtHSP70 subunit confers broader sequence specificity, greater stability, and higher activity on the 50-kDa subunit. The 50-kDa subunit alone displayed weaker activity and highly sequence-specific endonuclease activity. The 50-kDa protein exists as a heterodimer with mtHSP70 in vivo allowing Endo,SceI to cleave specifically at multiple sites on mitochondrial DNA. Endo.SceI may have evolved from a highly specific endonuclease that gained broader sequence specificity after becoming a stable partner of mtHSP70.	RIKEN, Inst Phys & Chem Res, Cellular & Mol Biol Lab, Wako, Saitama 3510198, Japan; Saitama Univ, Fac Biosci & Biotechnol, Dept Regulat Biol, Urawa, Saitama 3388570, Japan	RIKEN; Saitama University	Morishima, N (corresponding author), RIKEN, Inst Phys & Chem Res, Cellular & Mol Biol Lab, Wako, Saitama 3510198, Japan.		Morishima, Nobuhiro/D-3946-2017					BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; COLLEAUX L, 1986, CELL, V44, P521, DOI 10.1016/0092-8674(86)90262-X; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Juris O, 1990, METHOD ENZYMOL, V182, P587; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KAWASAKI K, 1991, J BIOL CHEM, V266, P5342; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; Kubo Y, 1999, J MOL BIOL, V286, P447, DOI 10.1006/jmbi.1998.2465; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; MORISHIMA N, 1990, J BIOL CHEM, V265, P15189; MORISHIMA N, 1993, CURR GENET, V23, P537, DOI 10.1007/BF00312648; MUKAI H, 1993, GENE, V132, P57; NAKAGAWA K, 1988, EUR J BIOCHEM, V171, P23, DOI 10.1111/j.1432-1033.1988.tb13753.x; NAKAGAWA K, 1991, J BIOL CHEM, V266, P1977; NAKAGAWA K, 1992, EMBO J, V11, P2707, DOI 10.1002/j.1460-2075.1992.tb05336.x; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; SHIBATA T, 1984, J BIOL CHEM, V259, P499; SHIBATA T, 1995, ADV BIOPHYS, V31, P77, DOI 10.1016/0065-227X(95)99384-2; SHIRAYAMA M, 1993, MOL GEN GENET, V240, P323, DOI 10.1007/BF00280382; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; WATABE HO, 1981, J BIOCHEM-TOKYO, V90, P1623, DOI 10.1093/oxfordjournals.jbchem.a133637; Westermann B, 1996, MOL CELL BIOL, V16, P7063; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	44	10	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25682	25690		10.1074/jbc.274.36.25682	http://dx.doi.org/10.1074/jbc.274.36.25682			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464305	hybrid			2022-12-25	WOS:000082554200069
J	Beum, PV; Singh, J; Burdick, M; Hollingsworth, MA; Cheng, PW				Beum, PV; Singh, J; Burdick, M; Hollingsworth, MA; Cheng, PW			Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN GLYCOPROTEIN LIGAND-1; MONOCLONAL-ANTIBODIES; O-GLYCANS; VASCULAR ENDOTHELIUM; EPITHELIAL-CELLS; BREAST-CANCER; P-SELECTIN; GALNAC ALPHA-2,6-SIALYLTRANSFERASE; MOLECULAR-CLONING; TANDEM REPEAT	Many tumor-associated epitopes possess carbohydrate as a key component, and thus changes in the activity of glycosyltransferases could play a role in generating these epitopes, In this report we describe the stable transfection of a human pancreatic adenocarcinoma cell line, Panc1-MUC1, with the cDNA for mucin core 2 GlcNAc-transferase (C2GnT), which creates the core 2 beta-1,6 branch in mucin-type glycans, These cells lack endogenous C2GnT activity but express a recombinant human MUC1 cDNA, C2GnT-transfected clones expressing different levels of C2GnT were characterized using monoclonal antibodies CC49, CSLEX-1, and SM-3, which recognize tumor-associated epitopes, Increased C2GnT expression led to greatly diminished expression of the CC49 epitope, which we identified as NeuAc alpha 2,6-(Ga1 beta 1,3)GalNAc alpha-Ser/Thr in the Panc1-MUC1 cells. This was accompanied by the emergence of the CSLEX-1 epitope, sialyl Lewis x (NeuAc alpha 2,3Gal beta 1,4(Fuc alpha 1,3)GlcNAc-R), an important selectin ligand, Despite this, however, the C2GnT transfectants could not bind to selectins, Increased C2GnT expression also led to masking of the SM-3 peptide epitope, which persisted after the removal of sialic acid, further suggesting greater complexity of the core a-associated O-glycans on MUC1. The results of this study suggest that C2GnT could play a regulatory role in the expression of certain tumor-associated epitopes.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Cheng, PW (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 984525 Nebraska Med Ctr, Omaha, NE 68198 USA.				NATIONAL CANCER INSTITUTE [P30CA036727, R01CA069234] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048242] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA69234, P30 CA36727] Funding Source: Medline; NHLBI NIH HHS [HL48242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARKLIE J, 1981, INT J CANCER, V28, P23, DOI 10.1002/ijc.2910280105; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BROCKHAUSEN I, 1995, N COMP BIOC A, V29, P201; BURCHELL J, 1983, J IMMUNOL, V131, P508; BURCHELL J, 1987, CANCER RES, V47, P5476; Burdick MD, 1997, J BIOL CHEM, V272, P24198, DOI 10.1074/jbc.272.39.24198; CHENG PW, 1982, J BIOL CHEM, V257, P6251; Cheng PW, 1996, HUM GENE THER, V7, P275, DOI 10.1089/hum.1996.7.3-275; CHENG PW, 1980, FED PROC, V39, P2002; DENNIS JW, 1993, GLYCOBIOLOGY, V3, P91, DOI 10.1093/glycob/3.2.91; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; Farah RA, 1998, CRIT REV EUKAR GENE, V8, P321, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.50; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; HANISCH FG, 1989, BIOL CHEM H-S, V370, P21, DOI 10.1515/bchm3.1989.370.1.21; HEFFERNAN M, 1993, J BIOL CHEM, V268, P1242; HO JJL, 1995, BIOCHEM BIOPH RES CO, V210, P866, DOI 10.1006/bbrc.1995.1738; Ho S B, 1991, Semin Cancer Biol, V2, P389; Karsten U, 1998, CANCER RES, V58, P2541; Kumar R, 1996, BLOOD, V88, P3872, DOI 10.1182/blood.V88.10.3872.bloodjournal88103872; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; Li CM, 1998, AM J RESP CELL MOL, V18, P343, DOI 10.1165/ajrcmb.18.3.2593; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; LIN Y, 1974, BIOCHEM BIOPH RES CO, V59, P1192, DOI 10.1016/0006-291X(74)90440-9; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MAJURI ML, 1992, BIOCHEM BIOPH RES CO, V182, P1376, DOI 10.1016/0006-291X(92)91885-T; Makiguchi Y, 1996, JPN J CANCER RES, V87, P505, DOI 10.1111/j.1349-7006.1996.tb00252.x; MCDERMOTT KM, 1999, MIDW STUD BIOM RES F; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOLINOLO A, 1990, CANCER RES, V50, P1291; MURARO R, 1988, CANCER RES, V48, P4588; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; OBoyle KP, 1996, HYBRIDOMA, V15, P401, DOI 10.1089/hyb.1996.15.401; OHMORI K, 1993, BLOOD, V81, P101; PILLER F, 1988, J BIOL CHEM, V263, P15146; REARICK JI, 1979, J BIOL CHEM, V254, P4444; ROPP PA, 1991, J BIOL CHEM, V266, P23863; Rowlinson-Busza Gail, 1992, Current Opinion in Oncology, V4, P1142, DOI 10.1097/00001622-199212000-00020; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; TAKADA A, 1993, CANCER RES, V53, P354; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WALTZ G, 1990, SCIENCE, V250, P1132; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732	50	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24641	24648		10.1074/jbc.274.35.24641	http://dx.doi.org/10.1074/jbc.274.35.24641			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455130	hybrid			2022-12-25	WOS:000082193400029
J	Dzierszinski, F; Popescu, O; Toursel, C; Slomianny, C; Yahiaoui, B; Tomavo, S				Dzierszinski, F; Popescu, O; Toursel, C; Slomianny, C; Yahiaoui, B; Tomavo, S			The protozoan parasite Toxoplasma gondii expresses two functional plant-like glycolytic enzymes - Implications for evolutionary origin of apicomplexans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRADYZOITE-SPECIFIC ANTIGENS; PLASMODIUM-FALCIPARUM; ESCHERICHIA-COLI; EUKARYOTIC CHROMOSOMES; SWISS-MODEL; GENES; ISOMERASE; PATHWAY; ENOLASE; DNA	The recent discovery of a vestigial, nonphotosynthetic plastid ("apicoplast") in the Apicomplexa has considerably modified our perception of the evolutionary origin of these parasites. Phylogenetic analysis and the presence of four surrounding membranes of the apicoplast provide important support for the hypothesis that apicomplexans have acquired their apicoplast by secondary endosymbiosis, probably from a green alga. This suggests that genes encoding predicted homologs of proteins of green algae or related photosynthetic lineages could have entered the nucleus of apicomplexan parasites by transfer from the ancestor harboring the apicoplast, We describe here complementary DNAs encoding two Toxoplasma gondii glycolytic enzymes, glucose-6-phosphate isomerase (G6-PI) and enolase, which have considerable identities with land plant counterparts. Both cDNAs of T, gondii complement Escherichia coli mutants lacking G6-PI and enolase genes and lead to the expression of active enzymes. In the drug untreatable encysted bradyzoites of T, gondii, G6-PI and enolase genes are overexpressed or exclusively expressed at both transcriptional and protein levels. Moreover, three-dimensional models and protein phylogeny confirmed that G6-PIs and enolases of T, gondii, Plasmodium falciparum, and land plants are closely related. Because these glycolytic enzymes are plant homologs, which differ from those of animals, they will be useful to trace the evolutionary origin of Apicomplexa and might offer novel chemotherapeutic targets in diseases caused by apicomplexan parasites.	Univ Sci & Tech Lille Flandres Artois, Chim Biol Lab, CNRS, UMR 111, F-59655 Villeneuve Dascq, France; INSERM, U42, F-59650 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	Tomavo, S (corresponding author), Univ Sci & Tech Lille Flandres Artois, Chim Biol Lab, CNRS, UMR 111, Batiment C9, F-59655 Villeneuve Dascq, France.		Popescu, Octavian/O-2134-2019; Popescu, Octavian/C-4027-2011; Popescu, Octavian/E-4942-2010; Slomianny, Christian/L-8285-2018	Popescu, Octavian/0000-0002-2597-7155; Popescu, Octavian/0000-0002-2597-7155; Yahiaoui, Bilal/0000-0003-0823-9860				ADACHI J, 1995, MOLPHY VERSION 2 2; Bakker BM, 1997, J BIOL CHEM, V272, P3207, DOI 10.1074/jbc.272.6.3207; BEUTLER E, 1984, RED CELL METABOLISM, P40; BOHNE W, 1994, INFECT IMMUN, V62, P1761, DOI 10.1128/IAI.62.5.1761-1767.1994; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; Denton H, 1996, FEMS MICROBIOL LETT, V137, P103, DOI 10.1111/j.1574-6968.1996.tb08090.x; EGEA N, 1995, J EUKARYOT MICROBIOL, V42, P679, DOI 10.1111/j.1550-7408.1995.tb01615.x; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FOTHERGILLGILMORE LA, 1986, TRENDS BIOCHEM SCI, V11, P47, DOI 10.1016/0968-0004(86)90233-1; GomezPuyou A, 1995, CHEM BIOL, V2, P847, DOI 10.1016/1074-5521(95)90091-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; HILLMAN JD, 1975, J BACTERIOL, V122, P1175, DOI 10.1128/JB.122.3.1175-1179.1975; KASLOW DC, 1990, J BIOL CHEM, V265, P12337; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; LAL SK, 1991, PLANT MOL BIOL, V16, P787, DOI 10.1007/BF00015071; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; Manger ID, 1998, INFECT IMMUN, V66, P1632, DOI 10.1128/IAI.66.4.1632-1637.1998; Martin W, 1997, CURR GENET, V32, P1, DOI 10.1007/s002940050241; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; MCFADDEN GI, 1994, P NATL ACAD SCI USA, V91, P3690, DOI 10.1073/pnas.91.9.3690; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NAGEL SD, 1988, MOL BIOCHEM PARASIT, V29, P261, DOI 10.1016/0166-6851(88)90081-3; Nowitzki U, 1998, GENE, V214, P205, DOI 10.1016/S0378-1119(98)00229-7; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; READ M, 1994, EUR J BIOCHEM, V220, P513, DOI 10.1111/j.1432-1033.1994.tb18650.x; Roberts F, 1998, NATURE, V393, P801, DOI 10.1038/31723; ROTH E, 1990, BLOOD CELLS, V16, P453; Sambrook J., 2002, MOL CLONING LAB MANU; TOMAVO S, 1995, INT J PARASITOL, V25, P1293, DOI 10.1016/0020-7519(95)00066-B; TOMAVO S, 1992, J BIOL CHEM, V267, P11721; TOMAVO S, 1991, INFECT IMMUN, V59, P3750, DOI 10.1128/IAI.59.10.3750-3753.1991; TRINQUIER M, 1995, BIOORGAN MED CHEM, V11, P1423; VanDePeer Y, 1996, P NATL ACAD SCI USA, V93, P7732, DOI 10.1073/pnas.93.15.7732; VINOPAL RT, 1975, J BACTERIOL, V122, P1172, DOI 10.1128/JB.122.3.1172-1174.1975; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WILLIAMSON DH, 1994, MOL GEN GENET, V243, P249, DOI 10.1007/BF00280323; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; Yang SM, 1997, GENE, V184, P1, DOI 10.1016/S0378-1119(96)00566-5; Zhang E, 1997, BIOCHEMISTRY-US, V36, P12526, DOI 10.1021/bi9712450	44	91	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24888	24895		10.1074/jbc.274.35.24888	http://dx.doi.org/10.1074/jbc.274.35.24888			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455162	hybrid			2022-12-25	WOS:000082193400061
J	He, H; Venema, VJ; Guo, XL; Venema, RC; Marrero, MB; Caldwell, RB				He, H; Venema, VJ; Guo, XL; Venema, RC; Marrero, MB; Caldwell, RB			Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II AT(1) RECEPTOR; PROTEIN-KINASE-C; TYROSINE KINASES; IN-VITRO; INHIBITOR; FAMILY; PERMEABILITY; TRANSDUCTION; ASSOCIATION; ANGIOGENESIS	Vascular endothelial growth factor (VEGF) is a potent endothelial cell-specific mitogen that promotes angiogenesis, vascular hyperpermeability, and vasodilation by autocrine mechanisms involving nitric oxide (NO) and prostacyclin (PGI(2)) production, These experiments used immunoprecipitation and immunoassay procedures to characterize the signaling pathways by which VEGF induces NO and PGI(2) formation in cultured endothelial cells. The data showed that VEGF stimulates complex formation of the flk-1/kinase-insert domain-containing receptor (KDR) VEGF receptor with c-Src and that Src activation is required for VEGF induction of phospholipase C gamma 1 activation and inositol 1,4,5-trisphosphate formation. Reporter cell assays showed that VEGF promotes a similar to 50-fold increase in NO formation, which peaks at 5-20 min. This effect is mediated by a signaling cascade initiated by flk-1/KDR activation of c-Src, leading to phospholipase C gamma 1 activation, inositol 1,4,5-trisphosphate formation, release of [Ca2+](i) and nitric oxide synthase activation. Immunoassays of VEGF-induced 6-keto prostaglandin F-1 alpha formation as an indicator of PGI(2) production revealed a 3-4-fold increase that peaked at 45-60 min. The PGI(2) signaling pathway follows the NO pathway through release of [Ca2+](i), but diverges prior to NOS activation and also requires activation of mitogen-activated protein kinase, These results suggest that NO and PGI(2) function in parallel in mediating the effects of VEGF.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Anat & Cellular Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Caldwell, RB (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.			Caldwell, Ruth/0000-0003-0168-0354	NATIONAL EYE INSTITUTE [R01EY004618, R01EY011766] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057201, R29HL057201] Funding Source: NIH RePORTER; NEI NIH HHS [EY04618, EY11766] Funding Source: Medline; NHLBI NIH HHS [HL57201] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; ATLAS D, 1981, P NATL ACAD SCI-BIOL, V78, P1237, DOI 10.1073/pnas.78.2.1237; Behzadian MA, 1995, GLIA, V15, P480, DOI 10.1002/glia.440150411; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BROCK TA, 1991, AM J PATHOL, V138, P213; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DAVIDGE ST, 1995, CIRC RES, V77, P274, DOI 10.1161/01.RES.77.2.274; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Feng YY, 1999, INVEST OPHTH VIS SCI, V40, P157; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fleming I, 1996, J BIOL CHEM, V271, P11009, DOI 10.1074/jbc.271.18.11009; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fujii E, 1996, EUR J PHARMACOL, V297, P257, DOI 10.1016/0014-2999(95)00758-X; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; ISHII K, 1991, AM J PHYSIOL, V261, pH598, DOI 10.1152/ajpheart.1991.261.2.H598; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; KU DD, 1993, AM J PHYSIOL, V265, P586; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MONCADA S, 1991, PHARMACOL REV, V43, P104; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PARK JE, 1994, J BIOL CHEM, V269, P25646; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; WILSON LK, 1989, MOL CELL BIOL, V91, P536; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; YAMADA Y, 1988, NEUROSCI LETT, V90, P338, DOI 10.1016/0304-3940(88)90212-1; Yamamoto T, 1996, EUR J PHARMACOL, V302, P53, DOI 10.1016/0014-2999(96)00019-2; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	55	384	404	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25130	25135		10.1074/jbc.274.35.25130	http://dx.doi.org/10.1074/jbc.274.35.25130			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455194	hybrid			2022-12-25	WOS:000082193400093
J	Hukovic, N; Rocheville, M; Kumar, U; Sasi, R; Khare, S; Patel, YC				Hukovic, N; Rocheville, M; Kumar, U; Sasi, R; Khare, S; Patel, YC			Agonist-dependent up-regulation of human somatostatin receptor type 1 requires molecular signals in the cytoplasmic C-tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; BETA-3-ADRENERGIC RECEPTOR; INDUCED DESENSITIZATION; DOPAMINE-RECEPTORS; BINDING-SITES; CELLS; INTERNALIZATION; EXPRESSION; PHOSPHORYLATION; ANTAGONISTS	We have previously reported that the human somatostatin receptor type 1 (hSSTR1) stably expressed in Chinese hamster ovary-Iii cells does not internalize but instead up-regulates at the membrane during continued agonist treatment (1 mu M somatostatin (SST)-14 x 22 h), Here we have investigated the molecular basis of hSSTR1 up-regulation. hSSTR1 was up-regulated by SST in a time-, temperature-, and dose-dependent manner to saturable levels, in intact cells but not in membrane preparations. Although hSSTR1 was acutely desensitized to adenylyl cyclase coupling after 1 h SST-14 treatment, continued agonist exposure (22 h) restored functional effector coupling. Up-regulation was unaffected by cycloheximide but blocked by okadaic acid. Confocal fluorescence immunocytochemistry of intact and permeabilized cells showed progressive, time-dependent increase in surface hSSTR1 labeling, associated with depletion of intracellular SSTR1 immunofluorescent vesicles. To investigate the structural domains of hSSTR1 responsible for up-regulation, we constructed C-tail deletion (Delta) mutants and chimeric hSSTR1-hSSTR5 receptors, Human SSTR5 was chosen because it internalizes readily, displays potent C-tail internalization signals, and does not up-regulate. Like wild type hSSTR1, Delta C-tail hSSTR1 did not internalize and additionally lost the ability to up-regulate. Swapping the C-tail of hSSTR1 with that of hSSTR5 induced internalization (27%) but not up-regulation. Substitution of hSSTR5 C-tail with that of hSSTR1 converted the chimeric receptor to one resembling wild type hSSTR1 (poor internalization, 71% up-regulation). These results show that ligand-induced up-regulation of hSSTR1 occurs by a temperature-dependent active process of receptor recruitment from a pre-existing cytoplasmic pool to the plasma membrane. It does not require new protein synthesis or signal transduction, is sensitive to dephosphorylation events, and critically dependent on molecular signals in the receptor C-tail.	McGill Univ, Royal Victoria Hosp, Dept Med, Fraser Labs, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Neurol & Neurosurg, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Pharmacol & Therapeut, Montreal, PQ H3A 1A1, Canada; Montreal Neurol Inst, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University	Patel, YC (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, Fraser Labs, Rm M3-15,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032160] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS32160-04A1] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYOSHI J, 1993, MOL PHARMACOL, V43, P349; BARTON AC, 1991, MOL PHARMACOL, V39, P650; CHEN H, 1995, J PHARMACOL EXP THER, V275, P674; COV BA, 1995, SYNAPSE, V21, P1; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUDLEY DT, 1993, REGUL PEPTIDES, V44, P199, DOI 10.1016/0167-0115(93)90243-2; FERRY RC, 1993, MOL PHARMACOL, V43, P726; FILTZ TM, 1994, J PHARMACOL EXP THER, V271, P1574; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOU CF, 1994, J BIOL CHEM, V269, P10357; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; Khare S, 1999, FASEB J, V13, P387, DOI 10.1096/fasebj.13.2.387; Kumar U, 1999, DIABETES, V48, P77, DOI 10.2337/diabetes.48.1.77; Kumar U, 1997, ENDOCRINOLOGY, V138, P4473, DOI 10.1210/en.138.10.4473; Lamberts SWJ, 1996, NEW ENGL J MED, V334, P246, DOI 10.1056/NEJM199601253340408; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LOUMAYE E, 1983, J BIOL CHEM, V258, P2002; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; NANTEL F, 1993, MOL PHARMACOL, V43, P548; Ng GYK, 1997, ENDOCRINOLOGY, V138, P4199, DOI 10.1210/en.138.10.4199; Patel YC, 1997, TRENDS ENDOCRIN MET, V8, P398, DOI 10.1016/S1043-2760(97)00168-9; PRESKY DH, 1988, J BIOL CHEM, V263, P714; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; ROCHEVILLE M, 1999, 81 ANN M END SOC SAN; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Sharma K, 1999, MOL ENDOCRINOL, V13, P82, DOI 10.1210/me.13.1.82; STARR S, 1995, J NEUROCHEM, V65, P569; THOMAS RF, 1992, P NATL ACAD SCI USA, V89, P4490, DOI 10.1073/pnas.89.10.4490; Whiteaker P, 1998, MOL PHARMACOL, V53, P950; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; ZHANG LJ, 1994, MOL PHARMACOL, V45, P878	36	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24550	24558		10.1074/jbc.274.35.24550	http://dx.doi.org/10.1074/jbc.274.35.24550			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455118	hybrid			2022-12-25	WOS:000082193400017
J	Itano, N; Sawai, T; Yoshida, M; Lenas, P; Yamada, Y; Imagawa, M; Shinomura, T; Hamaguchi, M; Yoshida, Y; Ohnuki, Y; Miyauchi, S; Spicer, AP; McDonald, JA; Kimata, K				Itano, N; Sawai, T; Yoshida, M; Lenas, P; Yamada, Y; Imagawa, M; Shinomura, T; Hamaguchi, M; Yoshida, Y; Ohnuki, Y; Miyauchi, S; Spicer, AP; McDonald, JA; Kimata, K			Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; OLIGODENDROGLIOMA CELLS; BINDING-PROTEINS; EXPRESSION; CHROMATOGRAPHY; LOCALIZATION; ANGIOGENESIS; SYNTHETASE; INHIBITOR; FAMILY	Three mammalian hyaluronan synthase genes, HAS1, HAS2, and HAS3, have recently been cloned. In this study, we characterized and compared the enzymatic properties of these three HAS proteins. Expression of any of these genes in COS-1 cells or rat 3Y1 fibroblasts yielded de novo formation of a hyaluronan coat. The pericellular coats formed by HAS1 transfectants were significantly smaller than those formed by HAS2 or HAS3 transfectants. Kinetic studies of these enzymes in the membrane fractions isolated from HAS transfectants demonstrated that HAS proteins are distinct from each other in enzyme stability, elongation rate of HA, and apparent K-m values for the two substrates UDP-GlcNAc and UDP-GlcUA. Analysis of the size distributions of hyaluronan generated in vitro by the recombinant proteins demonstrated that HAS3 synthesized hyaluronan with a molecular mass of 1 x 10(5) to 1 x 10(6) Da, shorter than those synthesized by HAS1 and HAS2 which have molecular masses of 2 x 10(5) to similar to 2 x 10(6) Da. Furthermore, comparisons of hyaluronan secreted into the culture media by stable HAS transfectants showed that HAS1 and HAS2 generated hyaluronan with broad size distributions (molecular masses of 2 x 10(5) to similar to 2 x 106 Ha), whereas HAS2 generated hyaluronan with a broad but extremely large size (average molecular mass of >2 x 10(6) Da). The occurrence of three HAS isoforms with such distinct enzymatic characteristics may provide the cells with flexibility in the control of hyaluronan biosynthesis and functions.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 466, Japan; Seikagaku Corp, Tokyo Inst, Tokyo 207, Japan; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; Mayo Clin Scottsdale, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA	Aichi Medical University; Nagoya University; Seikagaku Corporation; University of California System; University of California Davis; Mayo Clinic; Mayo Clinic Phoenix	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 48011, Japan.				NIAMS NIH HHS [1RO1AR44698] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; BROWN JJG, 1993, DEVELOPMENT, V117, P483; CHEN L, 1994, J BIOL CHEM, V269, P28282; FENDERSON BA, 1993, DIFFERENTIATION, V54, P85; GAINEY PA, 1972, BIOCHEM J, V128, P215, DOI 10.1042/bj1280215; GOLDBERG RL, 1987, ARTHRITIS RHEUM, V30, P769, DOI 10.1002/art.1780300707; HANDLEY CJ, 1972, BIOCHEM J, V127, P911, DOI 10.1042/bj1270911; Itano N, 1999, CANCER RES, V59, P2499; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1998, TRENDS GLYCOSCI GLYC, V10, P23, DOI 10.4052/tigg.10.23; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; KLEWES L, 1993, BIOCHEM J, V290, P791, DOI 10.1042/bj2900791; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KNUDSON W, 1989, CIBA F SYMP, V143, P150; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; KNUDSON W, 1991, J CELL SCI, V99, P227; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; MIAN N, 1986, BIOCHEM J, V237, P343, DOI 10.1042/bj2370343; NG KF, 1989, J BIOL CHEM, V264, P11776; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; Pummill PE, 1998, J BIOL CHEM, V273, P4976, DOI 10.1074/jbc.273.9.4976; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; SPEIGHT G, 1978, BIOCHIM BIOPHYS ACTA, V540, P238, DOI 10.1016/0304-4165(78)90136-8; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Spicer AP, 1997, J BIOL CHEM, V272, P8957; Sugiyama Y, 1998, J INVEST DERMATOL, V110, P116, DOI 10.1046/j.1523-1747.1998.00093.x; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; TENGBLAD A, 1980, BIOCHEM J, V185, P101, DOI 10.1042/bj1850101; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Toole BP, 1989, CIBA FDN S, V143, P138; TOYODA H, 1988, ANAL SCI, V4, P381, DOI 10.2116/analsci.4.381; TURLEY EA, 1989, CIBA F SYMP, V143, P121; VERTEL BM, 1993, J CELL SCI, V104, P939; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEST DC, 1989, CIBA F SYMP, V143, P187; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; ZHAO M, 1997, 3 INT WORLD C BIOM S	43	655	686	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25085	25092		10.1074/jbc.274.35.25085	http://dx.doi.org/10.1074/jbc.274.35.25085			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455188	hybrid			2022-12-25	WOS:000082193400087
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; HIV-1 PROTEASE INHIBITORS; SUBSTRATE-SPECIFICITY; FUNCTIONAL CONSEQUENCES; MUTATIONAL ANALYSIS; LABELING SITES; MOUSE MDR1; NUCLEOTIDE; MUTANTS; PURIFICATION	The human multidrug resistance P-glycoprotein (P-gp) is organized in two tandem repeats with each repeat consisting of an N-terminal hydrophobic domain containing six potential transmembrane segments followed by a hydrophilic domain containing a nucleotide-binding fold. A series of deletion mutants together with an in vivo drug-binding assay were used to test whether the deletion mutants interacted with substrates or were transported to the cell surface. We found that a deletion mutant consisting of only the transmembrane domains (residues 1-379 plus 681-1025) retained the ability to interact with drug substrates. In the absence of drug substrates, the deletion mutant was sensitive to trypsin and endoglycosidase H. Expression in the presence of verapamil, vinblastine, capsaicin, or cyclosporin A, however, resulted in a mutant protein that was resistant to trypsin and endoglycosidase H. The mutant was then detected at the cell surface and was sensitive to digestion by endoglycosidase F, By contrast, the N-terminal transmembrane domain (residues 1-379) alone did not interact with drug substrates, since it was sensitive to only endoglycosidase H and was not detected at the cell surface. These results show that the nucleotide-binding domains are not required for interaction of P-gp with substrate or for trafficking of P-gp to the cell surface.	Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Bakos E, 1997, BIOCHEM J, V323, P777, DOI 10.1042/bj3230777; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; Beaudet L, 1998, BIOCHEMISTRY-US, V37, P9073, DOI 10.1021/bi972656j; BIBI E, 1993, P NATL ACAD SCI USA, V90, P9209, DOI 10.1073/pnas.90.19.9209; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CHAN HS, 1996, EUR J CANCER, V6, P1051; Charuk JHM, 1998, AM J PHYSIOL-RENAL, V274, pF1127, DOI 10.1152/ajprenal.1998.274.6.F1127; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Conseil G, 1998, P NATL ACAD SCI USA, V95, P9831, DOI 10.1073/pnas.95.17.9831; Dayan G, 1996, J BIOL CHEM, V271, P11652, DOI 10.1074/jbc.271.20.11652; Fisher GA, 1996, EUR J CANCER, V32A, P1082, DOI 10.1016/0959-8049(96)00111-6; Germann UA, 1998, CYTOTECHNOLOGY, V27, P31, DOI 10.1023/A:1008023629269; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hrycyna CA, 1998, BIOCHEMISTRY-US, V37, P13660, DOI 10.1021/bi9808823; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOO TW, 1994, J BIOL CHEM, V269, P28683; Loo TW, 1998, METHOD ENZYMOL, V292, P480; MIERENDORF R, 1994, INNOVATIONS, V1, P1; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; Sparreboom A, 1997, P NATL ACAD SCI USA, V94, P2031, DOI 10.1073/pnas.94.5.2031; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	48	126	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24759	24765		10.1074/jbc.274.35.24759	http://dx.doi.org/10.1074/jbc.274.35.24759			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455147	hybrid			2022-12-25	WOS:000082193400046
J	Miyake, A; Mochizuki, S; Yokoi, H; Kohda, M; Furuichi, K				Miyake, A; Mochizuki, S; Yokoi, H; Kohda, M; Furuichi, K			New ether-a-go-go K(+) channel family members localized in human telencephalon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; GENE; DROSOPHILA; CLONING; MUTATIONS; CELLS; LOCUS; EAG; IDENTIFICATION	A cDNA encoding a novel voltage-gated K(+) channel protein was isolated from human brain. This protein, termed BEC1, is 46% identical to rat elk in the ether-a-go-go K(+) channel family. The BEC1 gene maps to the 12q13 region of the human genome. Northern blot analysis indicates that BEC1 is exclusively expressed in human brain, where the expression is concentrated in the telencephalic areas such as the cerebral cortex, amygdala, hippocampus, and striatum, By in situ hybridization, BEC1 is detected in the CA1-CA3 pyramidal cell layers and the dentate gyrus granule cell layers of the hippocampus. Specific signals are also found in neocortical neurons. Transfection of mammalian L929 and Chinese hamster ovary cells with BEC1 cDNA induces a voltage-gated outward current with a fast inactivation component. This current is insensitive to tetraethylammonium and quinidine, Additionally, a second related gene BEC2 was isolated from human brain. BEC2 is also brain specific, located in the neocortex and the striatum, and functional as a channel gene. Phylogenetic analysis indicates that BEC1 and BEC2 constitute a subfamily, together with elh, in the ether-a-go-go family. The two genes may be involved in cellular excitability of restricted neurons in the human central nervous system.	Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan	Astellas Pharmaceuticals	Miyake, A (corresponding author), Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan.	miyake@yamanouchi.co.jp						Arnell H, 1997, J MED GENET, V34, P360, DOI 10.1136/jmg.34.5.360; ATTALI B, 1992, J BIOL CHEM, V267, P8650; Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; DIXON JE, 1994, CIRC RES, V75, P252, DOI 10.1161/01.RES.75.2.252; Engel JE, 1998, J NEUROSCI, V18, P2254; Ganetzky B, 1983, J NEUROGENET, V1, P17, DOI 10.3109/01677068309107069; GHANSHANI S, 1992, GENOMICS, V12, P190, DOI 10.1016/0888-7543(92)90365-Y; GRISSMER S, 1992, J BIOL CHEM, V267, P20971; Hille B., 1992, IONIC CHANNELS EXCIT; Levitan IB, 1991, NEURON CELL MOL BIOL; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; Maruyama K, 1990, MED IMMUNOL, V20, P27; Matsumoto M, 1996, J BIOL CHEM, V271, P27217, DOI 10.1074/jbc.271.44.27217; MIYAKE A, 1995, MOL PHARMACOL, V48, P407; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOCHIZUKI S, 1999, IN PRESS AMINO ACIDS; Okumura K, 1997, ONCOGENE, V14, P713, DOI 10.1038/sj.onc.1200878; PericakVance MA, 1997, JAMA-J AM MED ASSOC, V278, P1237, DOI 10.1001/jama.278.15.1237; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; Shi WM, 1998, J PHYSIOL-LONDON, V511, P675, DOI 10.1111/j.1469-7793.1998.675bg.x; Shi WM, 1997, J NEUROSCI, V17, P9423; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; STRONG M, 1993, MOL BIOL EVOL, V10, P221; Sugimoto T, 1995, INT CONGR SER, V1098, P409; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Titus SA, 1997, J NEUROSCI, V17, P875; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wang XJ, 1997, J NEUROSCI, V17, P882; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Yang T, 1997, CIRC RES, V80, P782	39	33	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25018	25025		10.1074/jbc.274.35.25018	http://dx.doi.org/10.1074/jbc.274.35.25018			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455180	hybrid			2022-12-25	WOS:000082193400079
J	Tory, MC; Merrill, AR				Tory, MC; Merrill, AR			Adventures in membrane protein topology - A study of the membrane-bound state of colicin E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROCHLORIDE-INDUCED DENATURATION; INSERTION-COMPETENT STATE; CHANNEL-FORMING COLICINS; ION-CHANNEL; CRYSTAL-STRUCTURE; TRYPTOPHAN RESIDUES; ESCHERICHIA-COLI; ENERGY-TRANSFER; LIPID BILAYERS; FLUORESCENCE	The molecular aggregate size of the closed state of the colicin E1 channel was determined by fluorescence resonance energy transfer experiments involving a fluorescence donor (three tryptophans, wild-type protein) and a fluorescence acceptor (5-(((acetyl)amino)ethyl)aminonaphthalene-1-sulfonic acid (AEDANS), Trp-deficient protein). There was no evidence of energy transfer between the donor and acceptor species when bound to membrane large unilamellar vesicles. These experiments led to the conclusion that the colicin E1 channel is monomeric in the membrane-bound closed channel state. Experiments were also conducted to study the membrane topology of the closed colicin channel in membrane large unilamellar vesicles using acrylamide as the membrane-impermeant, nonionic quencher of tryptophan fluorescence in a battery of single tryptophan mutant proteins. Furthermore, additional fluorescence parameters, including fluorescence emission maximum, fluorescence quantum yield, and fluorescence decay times, were used to assist in mapping the topology of the closed channel. Results suggest that the closed channel comprises most of the polypeptide of the channel domain and that the hydrophobic anchor domain does not transverse the membrane bilayer but nonetheless is deeply embedded within the hydrocarbon core of the membrane. Finally, a model is proposed which features at least two states that are in rapid equilibrium with each other and in which one state is more heavily populated than the other.	Univ Guelph, Dept Chem & Biochem, Guelph Waterloo Ctr Grad Work Chem & Biochem, Guelph, ON N1G 2W1, Canada	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry	Merrill, AR (corresponding author), Univ Guelph, Dept Chem & Biochem, Guelph Waterloo Ctr Grad Work Chem & Biochem, Guelph, ON N1G 2W1, Canada.	merrill@chembio.uoguelph.ca	Merrill, Rod/M-8313-2014					AMES BN, 1960, J BIOL CHEM, V235, P769; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BRUGGEMANN EP, 1986, P NATL ACAD SCI USA, V83, P4273, DOI 10.1073/pnas.83.12.4273; BRUNDEN KR, 1984, J BIOL CHEM, V259, P7682; BULLOCK JO, 1983, J BIOL CHEM, V258, P9908; Callis PR, 1997, METHOD ENZYMOL, V278, P113; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; CLEVELAND MV, 1983, P NATL ACAD SCI-BIOL, V80, P3706, DOI 10.1073/pnas.80.12.3706; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; CRAMER WA, 1983, BIOCHIM BIOPHYS ACTA, V737, P173, DOI 10.1016/0304-4157(83)90016-3; CREED D, 1984, PHOTOCHEM PHOTOBIOL, V39, P537; DANKERT JR, 1982, J BIOL CHEM, V257, P3857; DIMASI DR, 1973, J BACTERIOL, V115, P506, DOI 10.1128/JB.115.2.506-513.1973; Duche D, 1996, J BIOL CHEM, V271, P15401, DOI 10.1074/jbc.271.26.15401; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Elkins P, 1997, STRUCTURE, V5, P443, DOI 10.1016/S0969-2126(97)00200-1; GOULD JM, 1977, J BIOL CHEM, V252, P5491; JACOB F, 1952, ANN I PASTEUR PARIS, V83, P295; Jakes KS, 1998, P NATL ACAD SCI USA, V95, P4321, DOI 10.1073/pnas.95.8.4321; Kienker PK, 1997, J MEMBRANE BIOL, V157, P27, DOI 10.1007/s002329900213; Krasilnikov OV, 1998, J MEMBRANE BIOL, V161, P83; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; LANGNER M, 1991, CHEM PHYS LIPIDS, V60, P127, DOI 10.1016/0009-3084(91)90035-A; LEVINTHAL F, 1991, PROTEINS, V11, P254, DOI 10.1002/prot.340110404; LIU Q R, 1986, Proteins Structure Function and Genetics, V1, P218, DOI 10.1002/prot.340010304; Malenbaum SE, 1998, J NAT TOXINS, V7, P269; MASSOTTE D, 1993, BIOCHEMISTRY-US, V32, P13787, DOI 10.1021/bi00213a006; MERRILL AR, 1993, BIOCHEMISTRY-US, V32, P6974, DOI 10.1021/bi00078a023; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P5829, DOI 10.1021/bi00476a026; Merrill AR, 1997, BIOCHEMISTRY-US, V36, P6874, DOI 10.1021/bi970222i; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; OHNOIWASHITA Y, 1982, J BIOL CHEM, V257, P6446; PALMER LR, 1994, J BIOL CHEM, V269, P4187; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; PETERSON AA, 1987, J MEMBRANE BIOL, V99, P197, DOI 10.1007/BF01995700; QUI XQ, 1996, J GEN PHYSIOL, V107, P313; RAYMOND L, 1986, J MEMBRANE BIOL, V92, P255, DOI 10.1007/BF01869394; SCHENDEL SL, 1994, PROTEIN SCI, V3, P2272, DOI 10.1002/pro.5560031212; SCHWARTZ SA, 1971, J BIOL CHEM, V246, P6318; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Sillen A, 1998, PHOTOCHEM PHOTOBIOL, V67, P475, DOI 10.1562/0031-8655(1998)067<0475:TCUOFP>2.3.CO;2; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; Steer BA, 1997, BIOCHEMISTRY-US, V36, P3037, DOI 10.1021/bi961926f; STEER BA, 1995, BIOCHEMISTRY-US, V34, P7225, DOI 10.1021/bi00021a038; STEER BA, 1994, BIOCHEMISTRY-US, V33, P1108, DOI 10.1021/bi00171a009; Stroud RM, 1998, CURR OPIN STRUC BIOL, V8, P525, DOI 10.1016/S0959-440X(98)80132-2; VEATCH W, 1977, J MOL BIOL, V113, P89, DOI 10.1016/0022-2836(77)90042-0; Vetter IR, 1998, STRUCTURE, V6, P863, DOI 10.1016/S0969-2126(98)00088-4; WENDT L, 1970, J BACTERIOL, V104, P1236, DOI 10.1128/JB.104.3.1236-1241.1970; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; YAMADA M, 1982, P NATL ACAD SCI-BIOL, V79, P2827, DOI 10.1073/pnas.79.9.2827; Zakharov SD, 1998, P NATL ACAD SCI USA, V95, P4282, DOI 10.1073/pnas.95.8.4282; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215	57	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24539	24549		10.1074/jbc.274.35.24539	http://dx.doi.org/10.1074/jbc.274.35.24539			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455117	hybrid			2022-12-25	WOS:000082193400016
J	Amara, A; Lorthioir, O; Valenzuela, A; Magerus, A; Thelen, M; Montes, M; Virelizier, JL; Delepierre, M; Baleux, F; Lortat-Jacob, H; Arenzana-Seisdedos, F				Amara, A; Lorthioir, O; Valenzuela, A; Magerus, A; Thelen, M; Montes, M; Virelizier, JL; Delepierre, M; Baleux, F; Lortat-Jacob, H; Arenzana-Seisdedos, F			Stromal cell-derived factor-1 alpha associates with heparan sulfates through the first beta-strand of the chemokine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET FACTOR-IV; RECEPTOR CXCR4; LYMPHOCYTE CHEMOATTRACTANT; GLYCOSAMINOGLYCAN-BINDING; ENDOTHELIAL-CELLS; HIV-1; PROTEOGLYCANS; SDF-1; INHIBITION; LIGAND	Biological properties of chemokines are believed to be influenced by their association with glycosaminoglycans. Surface plasmon resonance kinetic analysis shows that the CXC chemokine stromal cell-derived factor-1 alpha (SDF-1 alpha), which binds the CXCR4 receptor, associates with heparin with an affinity constant of 38.4 nM (k(on) = 2.16 x 10(6) m(-1) s(-1) and k(off) = 0.083 x s(-1)). A modified SDF-1 alpha (SDF-1 3/6) was generated by combined substitution of the basic cluster of residues Lys(24), His(25), and Lys(27) by Ser. SDF-1 3/6 conserves the global native structure and functional properties of SDF-1 alpha, but it is unable to interact with sensor chip-immobilized heparin. The biological relevance of these in vitro findings was investigated. SDF-1 alpha was unable to bind in a CXCR4-independent manner on epithelial cells that were treated with heparan sulfate (HS)-degrading enzymes or constitutively lack HS expression. The inability of SDF-1 3/6 to bind to cells underlines the importance of the identified basic cluster for the physiological interactions of SDF-1 alpha with HS. importantly, the amino-terminal domain of SDF-1 alpha which is required for binding to, and activation of, CXCR4 remains exposed after binding to HS and is recognized by a neutralizing monoclonal antibody directed against the first residues of the chemokine. Overall, these findings indicate that the Lys(24), His(,)(25) and Lys(27) cluster of residues forms, or is an essential part of, the MS-binding site which is distinct from that required for binding to, and signaling through, CXCR4.	Inst Pasteur, CNRS, Unite Immunol Virale, URA 1129, F-75724 Paris 15, France; Inst Pasteur, CNRS, Unite Chim Organ, URA 1129, F-75724 Paris, France; Inst Pasteur, CNRS, Lab Resonance Magnet Nucl, URA 1129, F-75724 Paris 15, France; Univ Bern, Theodor Kocher Inst, CH-3000 Bern 9, Switzerland; Cervi, CNRS, URA 625, Immunol Cellulaire Lab, Paris, France; Inst Biol Struct, F-38027 Grenoble 01, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Bern; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Arenzana-Seisdedos, F (corresponding author), Inst Pasteur, CNRS, Unite Immunol Virale, URA 1129, 28 Rue Dr Roux, F-75724 Paris 15, France.		Valenzuela-Fernández, Agustín/P-1638-2019; Magerus-Chatinet, Aude/I-6245-2017; Arenzana-Seisdedos, Fernando/E-5835-2016; Amara, Ali/E-8803-2017; Valenzuela-Fernández, Agustín/B-6219-2014; AMARA, Ali/ABX-9903-2022	Valenzuela-Fernández, Agustín/0000-0002-2585-8703; Magerus-Chatinet, Aude/0000-0001-7365-699X; Valenzuela-Fernández, Agustín/0000-0002-2585-8703; AMARA, Ali/0000-0002-0283-1815				Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Burns JM, 1998, J EXP MED, V188, P1917, DOI 10.1084/jem.188.10.1917; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chakravarty L, 1998, J BIOL CHEM, V273, P29641, DOI 10.1074/jbc.273.45.29641; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Koopmann W, 1997, J BIOL CHEM, V272, P10103; Kudryavtseva EV, 1997, J PEPT RES, V49, P52; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LOSCALZO J, 1985, ARCH BIOCHEM BIOPHYS, V240, P446, DOI 10.1016/0003-9861(85)90049-9; MAIONE TE, 1991, CANCER RES, V51, P2077; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Mondor I, 1998, VIROLOGY, V248, P394, DOI 10.1006/viro.1998.9282; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Sadir R, 1998, J BIOL CHEM, V273, P10919, DOI 10.1074/jbc.273.18.10919; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TANCHOU V, 1995, J GEN VIROL, V76, P2457, DOI 10.1099/0022-1317-76-10-2457; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	41	283	298	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23916	23925		10.1074/jbc.274.34.23916	http://dx.doi.org/10.1074/jbc.274.34.23916			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446158	hybrid			2022-12-25	WOS:000082110900037
J	Daiho, T; Yamasaki, K; Suzuki, H; Saino, T; Kanazawa, T				Daiho, T; Yamasaki, K; Suzuki, H; Saino, T; Kanazawa, T			Deletions or specific substitutions of a few residues in the NH2-terminal region (Ala(3) to Thr(9)) of sarcoplasmic reticulum Ca2+-ATPase cause inactivation and rapid degradation of the enzyme expressed in COS-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PHOSPHOENZYME INTERMEDIATE; ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL CONSEQUENCES; INORGANIC-PHOSPHATE; SKELETAL-MUSCLE; ALPHA-SUBUNIT; CA-2+ ATPASE; CA-2+-ATPASE; MUTATIONS	Amino acid residues in the NH2-terminal region (Glu(2) - Ala(14)) of adult fast twitch skeletal muscle sarcoplasmic reticulum Ca2+-ATPase (SERCA1a) were deleted or substituted, and the mutants were expressed in COS-1 cells. Deletion of any single residue in the Ala(3)-Ser(6) region or deletion of two or more consecutive residues in the Ala(3)-Thr(9) region caused strongly reduced expression. Substitution mutants A4K, A4D, and H5K also showed very low expression levels. Deletion of any single residue in the Ala(3)-Ser(6) region caused only a small decrease in the specific Ca2+ transport rate/mg of SERCA1a protein. In contrast, other mutants showing low expression levels had greatly reduced specific Ca2+ transport rates. In vitro expression experiments indicated that translation, transcription, and integration into the microsomal membranes were not impaired in the mutants that showed very low expression levels in COS-1 cells. Pulse-chase experiments using [S-35]methionine/cysteine labeling of transfected COS-1 cells demonstrated that degradation of the mutants showing low expression levels was substantially faster than that of the wild type. Lactacystin, a specific inhibitor of proteasome, inhibited the degradation accelerated by single-residue deletion of Ala(3). These results suggest that the NH2-terminal region (Ala(3)-Thr(9)) of SERCA1a is sensitive to the endoplasmic reticulum-mediated quality control and is thus critical for either correct folding of the SERCA1a protein or stabilization of the correctly folded SERCA1a protein or both.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College	Daiho, T (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.			Saino, Tomoyuki/0000-0001-6360-9516				ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; DEGANI C, 1973, J BIOL CHEM, V248, P8222; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Grimaldi ME, 1996, J BIOL CHEM, V271, P26995, DOI 10.1074/jbc.271.43.26995; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMAMURA Y, 1989, J BIOCHEM-TOKYO, V105, P775, DOI 10.1093/oxfordjournals.jbchem.a122743; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1986, EUR J BIOCHEM, V156, P489, DOI 10.1111/j.1432-1033.1986.tb09607.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; Meissner G, 1974, Methods Enzymol, V32, P475; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Saino T, 1997, J BIOL CHEM, V272, P21142, DOI 10.1074/jbc.272.34.21142; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SKERJANC IS, 1993, FEBS LETT, V336, P168, DOI 10.1016/0014-5793(93)81633-B; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; Yamasaki K, 1997, J BIOL CHEM, V272, P30627, DOI 10.1074/jbc.272.49.30627; Yu MH, 1999, ARCH BIOCHEM BIOPHYS, V362, P225, DOI 10.1006/abbi.1998.1049; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	42	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23910	23915		10.1074/jbc.274.34.23910	http://dx.doi.org/10.1074/jbc.274.34.23910			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446157	hybrid			2022-12-25	WOS:000082110900036
J	Fushimi, N; Ee, CE; Nakajima, T; Ichishima, E				Fushimi, N; Ee, CE; Nakajima, T; Ichishima, E			Aspzincin, a family of metalloendopeptidases with a new zinc-binding motif - Identification of new zinc-binding sites (His(128), His(132), and Asp(164)) and three catalytically crucial residues (Glu(129), Asp(143), and Tyr(106)) of deuterolysin from Aspergillus oryzae by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIUM-CITRINUM; SPECIFICITY; PROTEINASE; METALLOPROTEINASE; PENICILLOLYSIN; EXPRESSION; CLONING; SOJAE; GENE	Deuterolysin (EC 3.4.24.39; formerly designated as neutral proteinase Il) from Aspergillus oryzae, which contains 1 g atom of zinc/mol of enzyme, is a single chain of 177 amino acid residues, includes three disulfide bonds, and has a molecular mass of 19,018 Da, Active-site determination of the recombinant enzyme expressed in Escherichia coli was performed by site-directed mutagenesis, Substitutions of His(128) and His(132) With Arg, of Glu(129) with Gin or Asp, of Asp(143) With Asn or Glu, of Asp(164) With Asn, and of Tyr(106) with ph, resulted in almost complete loss of the activity of the mutant enzymes. It can be concluded that His(128), His(132) and Asp(164) provide the Zn2+ ligands of the enzyme according to a Zn-65 binding assay. Based on site-directed mutagenesis experiments, it was demonstrated that the three essential amino acid residues Glu(129), Asp(143) and Tyr(106) are catalytically crucial residues in the enzyme. Glu(129),ay be implicated in a central role in the catalytic function, We conclude that deuterolysin is a member of a family of Zn2+ metalloendopeptidases with a new zinc-binding motif, aspzincin, defined by the "HEXXH + D" motif and an aspartic acid as the third zinc ligand.	Tohoku Univ, Grad Sch Agr Sci, Div Life Sci, Cellular & Mol Biol Lab,Aoba Ku, Sendai, Miyagi 9818555, Japan; Soka Univ, Grad Sch Engn, Dept Bioengn, Hachioji, Tokyo 1928577, Japan	Tohoku University; Soka University	Ichishima, E (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Div Life Sci, Cellular & Mol Biol Lab,Aoba Ku, 1-1 Tsutsumidori Amaniyamachi, Sendai, Miyagi 9818555, Japan.							CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Creighton TE, 1993, PROTEINS STRUCTURES, P417; FUKUSHIMA D, 1985, Food Reviews International, V1, P149, DOI 10.1080/87559128509540768; GRIPON JC, 1980, INT J BIOCHEM, V12, P451, DOI 10.1016/0020-711X(80)90127-5; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; ICHISHIMA E, 1986, CURR MICROBIOL, V13, P231, DOI 10.1007/BF01568952; ICHISHIMA E, 1983, FOOD CHEM, V11, P187, DOI 10.1016/0308-8146(83)90102-4; ICHISHIMA E, 1991, AGR BIOL CHEM TOKYO, V55, P2191, DOI 10.1080/00021369.1991.10870913; Ichishima E., 1986, NIPPON JOZO GAKKAISH, V81, P756; Ichishima E., 1986, NIPPON JOZO GAKKAISH, V81, P844; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; MATHEWS BW, 1972, NATURE-NEW BIOL, V238, P37; MATSUMOTO K, 1994, BBA-GENE STRUCT EXPR, V1218, P469, DOI 10.1016/0167-4781(94)90209-7; MONOD M, 1993, INFECT IMMUN, V61, P4099, DOI 10.1128/IAI.61.10.4099-4104.1993; MORIHARA K, 1974, ADV ENZYMOL RAMB, V41, P179; MORIHARA K, 1968, ARCH BIOCHEM BIOPHYS, V123, P572, DOI 10.1016/0003-9861(68)90179-3; Nonaka T, 1997, J BIOL CHEM, V272, P30032, DOI 10.1074/jbc.272.48.30032; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; RHODES JC, 1990, INFECT IMMUN, V58, P2529, DOI 10.1128/IAI.58.8.2529-2534.1990; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; SEKINE H, 1972, AGR BIOL CHEM TOKYO, V36, P198, DOI 10.1080/00021369.1972.10860230; SEKINE H, 1972, AGR BIOL CHEM TOKYO, V36, P2143, DOI 10.1080/00021369.1972.10860530; SEKINE H, 1973, AGR BIOL CHEM TOKYO, V37, P1765, DOI 10.1080/00021369.1973.10860907; SEKINE H, 1970, AGR BIOL CHEM TOKYO, V34, P1690, DOI 10.1080/00021369.1970.10859834; SEKINE H, 1972, AGR BIOL CHEM TOKYO, V36, P207; SEKINE H, 1976, AGR BIOL CHEM TOKYO, V40, P29; TATSUMI H, 1991, MOL GEN GENET, V228, P97, DOI 10.1007/BF00282453; TATSUMI H, 1994, BBA-PROTEIN STRUCT M, V1208, P179, DOI 10.1016/0167-4838(94)90176-7; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Webb E. C., 1992, ENZYME NOMENCLATURE; YAMAGUCHI M, 1993, PHYTOCHEMISTRY, V33, P1317, DOI 10.1016/0031-9422(93)85082-3; YANG JT, 1986, METHOD ENZYMOL, V130, P208; [No title captured]	35	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24195	24201		10.1074/jbc.274.34.24195	http://dx.doi.org/10.1074/jbc.274.34.24195			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446194	hybrid			2022-12-25	WOS:000082110900073
J	Sagan, S; Karoyan, P; Chassaing, G; Lavielle, S				Sagan, S; Karoyan, P; Chassaing, G; Lavielle, S			Further delineation of the two binding sites (R-n(*)) associated with tachykinin neurokinin-1 receptors using [3-prolinomethionine(11)]SP analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P RECEPTOR; HAMSTER OVARY CELLS; AMINO-ACID FLUORIDES; NK-1 RECEPTOR; SEPTIDE; EFFICACY; PEPTIDES; MODEL; DESENSITIZATION; G(ALPHA-Q/11)	Two binding sites are associated with neurokinin-l substance P receptors in both transfected cells and mammalian tissues. To further delineate the interactions between the crucial C-terminal methionine of substance P and these two binding sites, we have incorporated newly designed constrained methionines, i.e. (2S, 3S)- and (2S,3R)-prolinomethionines. The potencies of these C terminus-modified SP analogues to bind both sites and to activate phosphatidylinositol hydrolysis and cAMP formation have been measured, together with those of their corresponding sulfoxides and sulfones. The molecular nature of these two binding sites and their selective coupling to effector signaling pathways are discussed in the light of current models of receptor activation. The less abundant binding site is coupled to G(q/11) proteins, whereas the most abundant one interacts with G(s) proteins in Chinese hamster ovary cells transfected with human neurokinin-1 receptors. The specific orientation of the C-terminal methionine side chain imposed by these constraints shows that macroscopically chi(1) and chi(2) angles of this crucial C-terminal residue are similar in both binding sites, However, slight but significant variations in the rotation around the C gamma-S bond yield different either stabilizing or destabilizing interactions in the two binding sites. These results highlight the need of such constrained amino acids to probe subtle interactions in ligand-receptor complexes.	Univ Paris 06, CNRS, UMR 7613, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Sagan, S (corresponding author), Univ Paris 06, CNRS, UMR 7613, Aile 44-45,4 Pl Jussieu, F-75252 Paris 05, France.		s, s/GVS-3323-2022; QI, DANDAN/GVR-9324-2022; S, SAGAN/I-8132-2013; s, s/HHD-0404-2022; s, s/GYR-2278-2022; SAGAN, Sandrine/AAA-8537-2022; s, s/HIK-1178-2022	S, SAGAN/0000-0003-0083-4411; 				ABRAHAM MH, 1989, J CHEM SOC PERK T 2, P1355, DOI 10.1039/p29890001355; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; BERTHO JN, 1991, TETRAHEDRON LETT, V32, P1303, DOI 10.1016/S0040-4039(00)79651-1; BLOUNT P, 1993, J BIOL CHEM, V268, P16388; CARPINO LA, 1990, J AM CHEM SOC, V112, P9651, DOI 10.1021/ja00182a041; CHASSAING G, 1985, TETRAHEDRON LETT, V26, P623, DOI 10.1016/S0040-4039(00)89163-7; COSTA T, 1990, MOL PHARMACOL, V37, P383; Djellas Y, 1998, P NATL ACAD SCI USA, V95, P10944, DOI 10.1073/pnas.95.18.10944; DRAGO RS, 1963, J AM CHEM SOC, V85, P3125, DOI 10.1021/ja00903a016; FOURNIER A, 1980, CAN J BIOCHEM CELL B, V58, P272, DOI 10.1139/o80-036; GARCIA M, 1994, BIOCHEM PHARMACOL, V48, P1735, DOI 10.1016/0006-2952(94)90459-6; GLOWINSKI J, 1995, TRENDS PHARMACOL SCI, V16, P365, DOI 10.1016/S0165-6147(00)89076-8; Hastrup H, 1996, FEBS LETT, V399, P264, DOI 10.1016/S0014-5793(96)01337-3; JOSIEN H, 1994, J MED CHEM, V37, P1586, DOI 10.1021/jm00037a009; KAGE R, 1993, J NEUROCHEM, V60, P347, DOI 10.1111/j.1471-4159.1993.tb05857.x; Karoyan P, 1997, TETRAHEDRON LETT, V38, P85, DOI 10.1016/S0040-4039(96)02221-6; Karoyan P, 1997, TETRAHEDRON-ASYMMETR, V8, P2025, DOI 10.1016/S0957-4166(97)00203-6; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kenakin T, 1996, PHARMACOL REV, V48, P413; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; LAVIELLE S, 1986, NEUROPEPTIDES, V7, P191, DOI 10.1016/0143-4179(86)90094-6; Leff P, 1998, TRENDS PHARMACOL SCI, V19, P13, DOI 10.1016/S0165-6147(97)01150-4; Leff P, 1997, TRENDS PHARMACOL SCI, V18, P355, DOI 10.1016/S0165-6147(97)90664-7; Li HZ, 1997, P NATL ACAD SCI USA, V94, P9475, DOI 10.1073/pnas.94.17.9475; LIANG T, 1981, J NEUROSCI, V1, P1133; MAGGI CA, 1993, EUR J PHARMACOL, V235, P309, DOI 10.1016/0014-2999(93)90152-8; Maggi CA, 1997, TRENDS PHARMACOL SCI, V18, P351, DOI 10.1016/S0165-6147(97)90663-5; Mantyh PW, 1996, BRAIN RES, V719, P8, DOI 10.1016/0006-8993(96)00050-9; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; Roush ED, 1998, FEBS LETT, V428, P291, DOI 10.1016/S0014-5793(98)00553-5; RUBINI E, 1988, PEPTIDE CHEM 1987, P553; Sagan S, 1996, J PHARMACOL EXP THER, V276, P1039; Sagan S, 1997, MOL PHARMACOL, V52, P120, DOI 10.1124/mol.52.1.120; Sagan S, 1996, BIOORGAN MED CHEM, V4, P2167, DOI 10.1016/S0968-0896(96)00230-1; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Torrens Y, 1998, J NEUROCHEM, V70, P2091; Weiss JM, 1996, J THEOR BIOL, V181, P381, DOI 10.1006/jtbi.1996.0139	39	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23770	23776		10.1074/jbc.274.34.23770	http://dx.doi.org/10.1074/jbc.274.34.23770			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446137	hybrid			2022-12-25	WOS:000082110900016
J	Wassell, J; Davies, S; Bardsley, W; Boulton, M				Wassell, J; Davies, S; Bardsley, W; Boulton, M			The photoreactivity of the retinal age pigment lipofuscin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SERUM-ALBUMIN; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; LYSOSOMAL-ENZYMES; EPITHELIAL-CELLS; SINGLET OXYGEN; FREE-RADICALS; ANTIOXIDANTS; ACCUMULATION; GENERATION	The presence of the age pigment lipofuscin is associated with numerous age-related diseases. In the retina Lipofuscin is located within the pigment epithelium where it is exposed to high oxygen and visible light, a prime environment for the generation of reactive oxygen species. Although we, and others, have demonstrated that retinal lipofuscin is a photoinducible generator of reactive oxygen species it is unclear how this may translate into cell damage. The position of lipofuscin within the lysosome infers that irradiated lipofuscin is liable to cause oxidative damage to either the lysosomal membrane or the lysosomal enzymes. We have found that illumination of lipofuscin with visible light is capable of extragranular lipid peroxidation, enzyme inactivation, and protein oxidation. These effects, which were pH-dependent, were significantly reduced by the addition of the antioxidants, superoxide dismutase and 1,4-diazabicyclo (2,2,2)-octane, confirming a role for both the superoxide anion and singlet oxygen. We postulate that lipofuscin may compromise retinal cell function by causing loss of lysosomal integrity and that this may be a major contributory factor to the pathology associated with retinal light damage and diseases such as age-related macular degeneration.	Cardiff Univ, Dept Optometry & Vis Sci, Cell & Mol Biol Unit, Cardiff CF1 3XF, S Glam, Wales; Univ Manchester, Manchester Royal Eye Hosp, Dept Ophthalmol, Manchester M13 9WH, Lancs, England	Cardiff University; Manchester Royal Eye Hospital; University of Manchester	Boulton, M (corresponding author), Cardiff Univ, Dept Optometry & Vis Sci, Cell & Mol Biol Unit, Redwood Bldg,POB 905, Cardiff CF1 3XF, S Glam, Wales.							BARDSLEY WG, 1993, MODERN TRENDS IN BIOTHERMOKINETICS, P455; BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125; BOULTON M, 1991, PROG RETIN RES, V11, P125, DOI 10.1016/0278-4327(91)90027-Y; BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4; BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2; BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82; BOULTON ME, 1983, EXP EYE RES, V37, P307, DOI 10.1016/0014-4835(83)90166-5; Brizee K, 1981, AGE PIGMENTS, P317; Buege J A, 1978, Methods Enzymol, V52, P302; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; CABRAL L, 1990, INVEST OPHTH VIS SCI, V31, P670; CHOE M, 1995, FREE RADICAL BIO MED, V18, P977, DOI 10.1016/0891-5849(94)00217-8; COHEN G, 1970, ANAL BIOCHEM, V34, P30, DOI 10.1016/0003-2697(70)90083-7; DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497; DELMELLE M, 1978, PHOTOCHEM PHOTOBIOL, V27, P731, DOI 10.1111/j.1751-1097.1978.tb07671.x; ELSTNER EF, 1991, KLIN WOCHENSCHR, V69, P949, DOI 10.1007/BF01645138; FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416; GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x; GANTCHEV TG, 1995, PHOTOCHEM PHOTOBIOL, V62, P123, DOI 10.1111/j.1751-1097.1995.tb05248.x; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HARMAN D, 1990, LIPOFUSCIN CEROID PI, P3; JAHNGENHODGE J, 1994, METHOD ENZYMOL, V233, P512; JAIN SK, 1989, BIOCHEM MED METAB B, V42, P60, DOI 10.1016/0885-4505(89)90041-8; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; MIURA T, 1992, CHEM-BIOL INTERACT, V85, P243, DOI 10.1016/0009-2797(92)90065-S; MO JQ, 1995, MECH AGEING DEV, V81, P73, DOI 10.1016/0047-6374(95)01586-O; Ogino T, 1995, BBA-GEN SUBJECTS, V1245, P359, DOI 10.1016/0304-4165(95)00101-8; OHIA SE, 1994, RES COMMUN MOL PATH, V85, P21; PAILLOUS N, 1994, BIOCHIMIE, V76, P355, DOI 10.1016/0300-9084(94)90109-0; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X; ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; SOHAL RS, 1981, AGE PIGMENTS; SOHAL RS, 1990, LIPOFUSCIN CEROID PI, P17; Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2; YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9; YU BP, 1992, MECH AGEING DEV, V65, P17, DOI 10.1016/0047-6374(92)90123-U	38	115	128	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23828	23832		10.1074/jbc.274.34.23828	http://dx.doi.org/10.1074/jbc.274.34.23828			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446145	hybrid			2022-12-25	WOS:000082110900024
J	Aguirre-Ghiso, JA; Frankel, P; Farias, EF; Lu, ZM; Jiang, H; Olsen, A; Feig, LA; Joffe, EB; Foster, DA				Aguirre-Ghiso, JA; Frankel, P; Farias, EF; Lu, ZM; Jiang, H; Olsen, A; Feig, LA; Joffe, EB; Foster, DA			RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases	ONCOGENE			English	Article						GTPase; metalloproteases; Ral; Ras; Src; tumorigenicity; uPA	PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE-D; SIGNALING PATHWAY; GENE-EXPRESSION; CELL-LINE; COLLAGENASE; RECEPTOR; METASTASIS; TRANSFORMATION; MECHANISM	Overproduction of urokinase-type plasminogen activator (uPA) and metalloproteases (MMPs) is strongly correlated with tumorigenicity and with invasive and metastatic phenotypes of human and experimental tumors. We demonstrated previously that overproduction of uPA in turner cells is mediated by a phospholipase D (PLD)and protein kinase C-dependent mechanism. The oncogenic stimulus of v-Src and v-Ras results in the activation of PLD, which is dependent upon the monomeric GTPase RalA, We have therefore investigated whether RaLA plays a role in uPA and MNP overproduction that is observed in response to oncogenic signals, We report here that NIH3T3 cells transformed by both v-Src and v-Ras, constitutively overproduce uPA and that expression of a dominant negative RalA mutant (S28N) blocks overproduction of uPA in both the v-Src-and v-Ras-transformed cells. v-Src and v-Ras also induced an upregulation of the activity of MMP-2 and MMP-9 as detected by zymograms, however only the v-Src induction correlated with MMP protein levels detected by Western blot analysis, The dominant negative RalA mutant blocked increased MMP-2 and 9 overproduction induced by v-Src, but not the increased activity of MMP-2 and 9 induced by v-Ras. And, consistent with a role for the RalA/PLD pathway in mitogenesis and tumor development, the dominant negative RaLA mutant completely blocked tumor formation by v-Src- and v-Ras-transformed NIH3T3 cells injected subcutaneously in syngeneic mice, The data presented here implicate RalA and PLD as signaling mediators for tumor formation and protease production by transformed cells.	Univ Buenos Aires, Inst Oncol Angel H Roffo, Dept Cell Biol, Res Area, RA-1417 Buenos Aires, DF, Argentina; CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	University of Buenos Aires; City University of New York (CUNY) System; Hunter College (CUNY); Tufts University	Aguirre-Ghiso, JA (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Neoplast Dis, New York, NY 10029 USA.			Aguirre-Ghiso, Julio/0000-0002-6694-6507; BAL de KIER JOFFE, ELISA DORA/0000-0001-6952-0029	NCRR NIH HHS [RR-03037] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALONSO DF, 1993, CANCER LETT, V70, P181, DOI 10.1016/0304-3835(93)90229-3; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Boyd D, 1996, CANCER METAST REV, V15, P77, DOI 10.1007/BF00049488; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; FOSTER DA, 1993, CELL SIGNAL, V5, P389, DOI 10.1016/0898-6568(93)90078-Z; Ghiso JAA, 1997, BBA-MOL CELL RES, V1356, P171, DOI 10.1016/S0167-4889(96)00173-5; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MOLLER LB, 1993, BLOOD COAGUL FIBRIN, V4, P293; OSSOWSKI L, 1992, CANCER RES, V52, P6754; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PITTMAN RN, 1985, DEV BIOL, V110, P91, DOI 10.1016/0012-1606(85)90067-3; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; SAKSELA O, 1981, ANAL BIOCHEM, V111, P276, DOI 10.1016/0003-2697(81)90564-9; SATO H, 1993, J BIOL CHEM, V268, P23460; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Werb Z, 1996, BRAZ J MED BIOL RES, V29, P1087; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735; YU H, 1990, CANCER RES, V50, P7623; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	41	69	72	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4718	4725		10.1038/sj.onc.1202850	http://dx.doi.org/10.1038/sj.onc.1202850			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467419				2022-12-25	WOS:000082154400009
J	Deshpande, A; Sonar, S				Deshpande, A; Sonar, S			Bacterioopsin-triggered retinal biosynthesis is inhibited by bacteriorhodopsin formation in Halobacterium salinarium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURPLE MEMBRANE; OPSIN GENE; ESCHERICHIA-COLI; MECHANISM; TRANSPORT; HALOBIUM; FUSION; TRANSFECTION; EXPRESSION; LIPOSOMES	Factors regulating retinal biosynthesis in halobacteria are not clearly understood. In halobacteria, events leading to the biosynthesis of bacteriorhodopsin have been proposed to participate in stringent regulation of retinal biosynthesis, The present study describes a novel approach of in vivo introductions of mRNA and membrane proteins via liposome fusion to test their role in cellular metabolism. Both the bacterioopsin-encoding mRNA and the liposome-encapsulated bacterioopsin (apoprotein) are independently introduced in spheroplasts of the purple membrane-negative strain Halobacterium salinarium that initially contain neither bacterioopsin nor retinal, Isoprenoid analyses of these cells indicate that the expression/presence of bacterioopsin triggers retinal biosynthesis from lycopene, and its subsequent binding to opsin generates bacteriorhodopsin, When bacteriorhodopsin and excess retinal were independently introduced into spheroplasts of purple membrane-negative cells, the introduction of bacteriorhodopsin resulted in an accumulation of lycopene, indicating an inhibition of retinal biosynthesis, These results provide direct evidence that the formation of bacterioopsin acts as a trigger for lycopene conversion to beta-carotene in retinal biosynthesis. The trigger for this event does not lie with either transcription or translation of the bop gene, It is clearly associated with the folded and the membrane-integrated state of bacterioopsin. On the other hand, the trigger signaling inhibition of retinal biosynthesis does not lie with the presence of excess retinal but with the correctly folded, retinal-bound form, bacteriorhodopsin.	Indian Inst Technol, Ctr Biotechnol, Prot Engn Lab, Bombay 400076, Maharashtra, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Sonar, S (corresponding author), Indian Inst Technol, Ctr Biotechnol, Prot Engn Lab, Bombay 400076, Maharashtra, India.	sonar@btc.iitb.ernet.in						ARVINTE T, 1986, P NATL ACAD SCI USA, V83, P962, DOI 10.1073/pnas.83.4.962; BETLACH M, 1984, NUCLEIC ACIDS RES, V12, P7949, DOI 10.1093/nar/12.20.7949; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; CLINE SW, 1987, J BACTERIOL, V169, P1341, DOI 10.1128/jb.169.3.1341-1344.1987; COLEMAN M, 1994, TECHNOLOGIES APPL C, V1, P326; DANON A, 1977, BIOPHYS STRUCT MECH, V3, P1, DOI 10.1007/BF00536449; DASSARMA S, 1983, P NATL ACAD SCI-BIOL, V80, P2201, DOI 10.1073/pnas.80.8.2201; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; DUNN RJ, 1987, J BIOL CHEM, V262, P9246; HARTMANN R, 1980, P NATL ACAD SCI-BIOL, V77, P3821, DOI 10.1073/pnas.77.7.3821; JARRELL KF, 1984, CURR MICROBIOL, V10, P147, DOI 10.1007/BF01576776; KUSHWAHA SC, 1980, CAN J MICROBIOL, V26, P1011, DOI 10.1139/m80-171; LANYI JK, 1990, FEBS LETT, V265, P1, DOI 10.1016/0014-5793(90)80869-K; Lanyi JK, 1997, J BIOL CHEM, V272, P31209, DOI 10.1074/jbc.272.50.31209; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MESCHER MF, 1976, P NATL ACAD SCI USA, V73, P2687, DOI 10.1073/pnas.73.8.2687; Oesterhelt D, 1998, CURR OPIN STRUC BIOL, V8, P489, DOI 10.1016/S0959-440X(98)80128-0; OESTERHELT D, 1973, P NATL ACAD SCI USA, V70, P2853, DOI 10.1073/pnas.70.10.2853; Oesterhelt D, 1974, Methods Enzymol, V31, P667; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; ROTHSCHILD KJ, 1982, J BIOL CHEM, V257, P8592; SEEHRA JS, 1984, J BIOL CHEM, V259, P4187; SIMSEK M, 1982, P NATL ACAD SCI-BIOL, V79, P7268, DOI 10.1073/pnas.79.23.7268; SONAR S, 1993, BIOCHEMISTRY-US, V32, P2263, DOI 10.1021/bi00060a019; SONAR S, 1993, BIOCHEMISTRY-US, V32, P13777, DOI 10.1021/bi00213a004; SONAR S, 1994, J BIOL CHEM, V269, P28851; Song, 1995, CRC HDB ORGANIC PHOT, P1521; Spudich JL, 1998, MOL MICROBIOL, V28, P1051, DOI 10.1046/j.1365-2958.1998.00859.x; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; SUMPER M, 1976, FEBS LETT, V71, P333, DOI 10.1016/0014-5793(76)80964-7; SUMPER M, 1976, FEBS LETT, V69, P149, DOI 10.1016/0014-5793(76)80673-4; SUMPER M, 1976, ANGEW CHEM INT EDIT, V15, P187, DOI 10.1002/anie.197601871; VANDERGEER G, 1982, NAGOYA MATH J, V88, P17, DOI 10.1017/S0027763000020080; XUI ZJ, 1995, J BIOL CHEM, V270, P24858, DOI 10.1074/jbc.270.42.24858	35	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23535	23540		10.1074/jbc.274.33.23535	http://dx.doi.org/10.1074/jbc.274.33.23535			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438533	hybrid			2022-12-25	WOS:000082012800083
J	Osmani, AH; May, GS; Osmani, SA				Osmani, AH; May, GS; Osmani, SA			The extremely conserved pyroA gene of Aspergillus nidulans is required for pyridoxine synthesis and is required indirectly for resistance to photosensitizers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; SACCHAROMYCES-CEREVISIAE; BIOSYNTHESIS; ORGANISMS; SEQUENCE; MEMBER; FAMILY; OPERON; SYSTEM; LINK	Numerous disparate studies in plants, filamentous fungi, yeast, Archaea, and bacteria have identified one of the most highly conserved proteins (SNZ family) for which no function was previously defined. Members have been implicated in the stress response of plants and yeast and resistance to singlet oxygen toxicity in the plant pathogen Cercospora, However, it is found in some anaerobic bacteria and is absent in some aerobic bacteria. We have cloned the Aspergillus nidulans homologue (pyroA) of this highly conserved gene and define this gene family as encoding an enzyme specifically required for pyridoxine biosynthesis. This realization has enabled us to define a second pathway for pyridoxine biosynthesis. Some bacteria utilize the pdx pyridoxine biosynthetic pathway defined in Escherichia coli and others utilize the pyroA pathway. However, Eukarya and Archaea exclusively use the pyroA pathway. We also found that pyridoxine is destroyed in the presence of singlet oxygen, helping to explain the connection to singlet oxygen sensitivity defined in Cercospora, These data bring clarity to the previously confusing data on this gene family. However, a new conundrum now exists; why have highly related bacteria evolved with different pathways for pyridoxine biosynthesis?.	Penn State Univ, Coll Med, Weis Ctr Res, Henry Hood Res Program, Danville, PA 17822 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Baylor College of Medicine	Osmani, SA (corresponding author), Penn State Univ, Coll Med, Weis Ctr Res, Henry Hood Res Program, Danville, PA 17822 USA.		Osmani, Stephen A./AAS-3904-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042564, R01GM053027] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42564, GM53027] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Braun EL, 1996, J BACTERIOL, V178, P6865, DOI 10.1128/jb.178.23.6865-6872.1996; Bussink HJ, 1998, EMBO J, V17, P3990, DOI 10.1093/emboj/17.14.3990; DEMPSEY WB, 1969, J BACTERIOL, V100, P295, DOI 10.1128/JB.100.1.295-300.1969; DEMPSEY WB, 1969, J BACTERIOL, V97, P1403, DOI 10.1128/JB.97.3.1403-1410.1969; DEMPSEY WB, 1971, J BACTERIOL, V108, P415, DOI 10.1128/JB.108.1.415-421.1971; DEMPSEY WB, 1970, J BACTERIOL, V104, P658, DOI 10.1128/JB.104.2.658-667.1970; Ehrenshaft M, 1998, MOL CELL, V1, P603, DOI 10.1016/S1097-2765(00)80060-X; Galperin MY, 1997, MOL MICROBIOL, V24, P443, DOI 10.1046/j.1365-2958.1997.3671706.x; HILL RE, 1970, SCIENCE, V169, P773, DOI 10.1126/science.169.3947.773; Hill RE, 1996, J BIOL CHEM, V271, P30426, DOI 10.1074/jbc.271.48.30426; HILL RE, 1971, J AM CHEM SOC, V93, P518; HILL RE, 1972, J BIOL CHEM, V247, P1869; HILL RE, 1977, J AM CHEM SOC, V99, P4179, DOI 10.1021/ja00454a058; HILL RE, 1973, CAN J BIOCHEM CELL B, V51, P1412, DOI 10.1139/o73-185; LAM HM, 1992, J BACTERIOL, V174, P1554, DOI 10.1128/jb.174.5.1554-1567.1992; MAY GS, 1989, F BIOTECH IND FERMEN, V6, P11; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; SHIMIZU S, 1978, J BACTERIOL, V134, P944, DOI 10.1128/JB.134.3.944-949.1978; SHIMIZU S, 1976, J BACTERIOL, V127, P1593, DOI 10.1128/JB.127.3.1593-1594.1976; SPENSER ID, 1995, NAT PROD REP, V12, P555, DOI 10.1039/np9951200555; TAZUYA K, 1995, BBA-GEN SUBJECTS, V1244, P113, DOI 10.1016/0304-4165(94)00205-C; Tazuya K, 1997, METHOD ENZYMOL, V279, P97; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	27	145	148	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23565	23569		10.1074/jbc.274.33.23565	http://dx.doi.org/10.1074/jbc.274.33.23565			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438537	hybrid			2022-12-25	WOS:000082012800087
J	Nagao, M; Kaziro, Y; Itoh, H				Nagao, M; Kaziro, Y; Itoh, H			The Src family tyrosine kinase is involved in Rho-dependent activation of c-Jun N-terminal kinase by G alpha(12)	ONCOGENE			English	Article						G alpha(12); Src; Rho; JNK	SERUM RESPONSE FACTOR; GTP-BINDING PROTEIN; CELL-SHAPE CHANGES; ALPHA-SUBUNIT; DROSOPHILA GASTRULATION; TRANSFORMING ACTIVITY; SIGNALING PATHWAY; G13 PROTEINS; GENE-PRODUCT; P115 RHOGEF	G alpha(12), a member of alpha subunit of heterotrimeric G protein G(12) subfamily, has been shown to stimulate c-Jun N-terminal kinase (JNK) activity through the low molecular weight GTP-binding proteins Ras, Rac, and Cdc42. In this study using the transient expression of a constitutively activated mutant of G alpha(12) (G alpha(12)Q229L) in human embryonic kidney (HEK) 293 cells, we found that Rho and Src family kinase are also involved in the Gu,,induced activation of JNK. The activation of JNK by G alpha(12)Q229L was inhibited by dominant-negative RhoA(T19N), and botulinum C3 exoenzyme which specifically inactivates Rho. In addition, the expression of activated RhoA(G14V) elevated JNK activity in HEK 293 cells. The G alpha(12)Q229L-stimulated activation of JNK was blocked by a specific inhibitor of protein tyrosine kinases (PP2), and C-terminal Src kinase (Csk). Moreover, we observed that G alpha(12)Q229L stimulated Src family kinase activity and v-Src induced JNK activation. Interestingly, the v-Src-induced activation of JNK was inhibited by dominant-negative RhoA(T19N). In contrast, Csk did not inhibit the JNK activation by activated RhoA(G14V). These results suggest that Rho and Src family kinase are required for the G alpha(12)-induced JNK activation, and that Src family kinase acts upstream of Rho activation in the JNK pathway.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Itoh, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.							Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744	52	65	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4425	4434		10.1038/sj.onc.1202832	http://dx.doi.org/10.1038/sj.onc.1202832			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442633				2022-12-25	WOS:000081813500004
J	Taylor, JK; Zhang, QQ; Monia, BP; Marcusson, EG; Dean, NM				Taylor, JK; Zhang, QQ; Monia, BP; Marcusson, EG; Dean, NM			Inhibition of Bcl-x(L) expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli	ONCOGENE			English	Article						Bcl-x(L); keratinocytes; epithelial cells; apoptosis	BCL-X EXPRESSION; 2ND-GENERATION ANTISENSE OLIGONUCLEOTIDES; C-ALPHA EXPRESSION; MESSENGER-RNA; IMMUNOHISTOCHEMICAL ANALYSIS; EPIDERMAL-KERATINOCYTES; PROTOONCOGENE BCL-2; GENE-EXPRESSION; IN-VIVO; UV-B	The epidermis is continually exposed to harmful mutagens that have the potential to cause DNA damage. To protect the skin from accumulating mutated cells, keratinocytes have developed a highly regulated mechanism of eliminating damaged cells through apoptosis. Bcl-x(L) is a well-described cell survival protein that when overexpressed in skin can protect keratinocytes from UV radiation-induced apoptosis. To begin to unravel the complex mechanisms that keratinocytes use to survive, we wanted to characterize the role of endogenous Bcl-x(L) in protecting cells from death. In this study, we describe the development and characterization of an antisense inhibitor to Bcl-x(L). We show that this inhibitor reduces Bcl-x(L) RNA and protein in a concentration-dependent, sequence-specific manner, Furthermore, treatment of keratinocytes and epithelial cells with this inhibitor sensitizes these cells to UV-B radiation and cisplatinum treatment-induced apoptosis. Thus, these results offer direct evidence that Bcl-x(L) is critical in the protection of skin and epithelial cells from apoptosis and provide a basis for the role of Bcl-x(L) in keratinocyte and epithelial cell survival.	ISIS Pharmaceut, Dept Pharmacol, Carlsbad, CA 92008 USA; ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc; Isis Pharmaceuticals Inc	Dean, NM (corresponding author), ISIS Pharmaceut, Dept Pharmacol, 2280 Faraday Ave, Carlsbad, CA 92008 USA.			Marcusson, Eric/0000-0002-0504-8674				Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Altmann KH, 1996, BIOCHEM SOC T, V24, P630, DOI 10.1042/bst0240630; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CARSON DA, 1995, LANCET, V346, P1009, DOI 10.1016/S0140-6736(95)91693-8; Condon TP, 1996, J BIOL CHEM, V271, P30398, DOI 10.1074/jbc.271.48.30398; Cotton J, 1997, RADIAT RES, V147, P148, DOI 10.2307/3579415; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Dassonneville L, 1998, B CANCER, V85, P254; Dean N, 1996, CANCER RES, V56, P3499; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DHANWADA KR, 1995, ONCOGENE, V11, P1947; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; Henseleit U, 1996, ARCH DERMATOL RES, V288, P676, DOI 10.1007/s004030050123; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KAMB A, 1994, NATURE, V372, P730, DOI 10.1038/372730a0; Kirsh EJ, 1998, J UROLOGY, V159, P1348, DOI 10.1016/S0022-5347(01)63614-0; Kondo S, 1996, INT J CANCER, V68, P727, DOI 10.1002/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewski S, 1997, AM J PATHOL, V150, P805; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; MARVEL J, 1994, ONCOGENE, V9, P1117; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIYASHITA T, 1992, CANCER RES, V52, P5407; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; Olopade OI, 1997, CANCER J SCI AM, V3, P230; OLTAVI ZN, 1994, CELL, V79, P189; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Pena JC, 1998, CANCER RES, V58, P2111; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Ramaswamy NT, 1998, ONCOGENE, V16, P1501, DOI 10.1038/sj.onc.1201628; Reed JC, 1997, J NATL CANCER I, V89, P988, DOI 10.1093/jnci/89.14.988; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Saini KS, 1998, MOL CELL BIOCHEM, V178, P9, DOI 10.1023/A:1006891430596; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sermadiras S, 1997, BRIT J DERMATOL, V137, P883, DOI 10.1046/j.1365-2133.1997.19812085.x; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WALTON MI, 1993, CANCER RES, V53, P1853; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; WRONESMITH T, 1995, AM J PATHOL, V146, P1079; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	62	79	80	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4495	4504		10.1038/sj.onc.1202836	http://dx.doi.org/10.1038/sj.onc.1202836			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442640				2022-12-25	WOS:000081813500011
J	Sun, SY; Yue, P; Shroot, B; Hong, WK; Lotan, R				Sun, SY; Yue, P; Shroot, B; Hong, WK; Lotan, R			Implication of c-Myc in apoptosis induced by the retinoid CD437 in human lung carcinoma cells	ONCOGENE			English	Article						lung cancer; retinoids; CD437; apoptosis; c-Myc; ODC; cdc25A	MEDIATED APOPTOSIS; CANCER; P53; LINES; PROLIFERATION; ACTIVATION; INDUCTION; RECEPTORS; GROWTH; ARREST	The novel synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) has been recently identified to be a potent inducer of apoptosis in human non-small cell lung carcinoma (NSCLC) cells through a nuclear retinoic acid receptor independent mechanism. To approach the mechanism by which CD437 induces apoptosis in NSCLC cells, we investigated the involvement of c-Myc in CD437-induced apoptosis, CD437 (1 mu M) up-regulated the expression of c-Myc and of its downstream target genes ornithine decarboxylase (ODC) and cdc25A in all three NSCLC cell lines (i.e., H460, SK-MES-1 and H1792) used. These effects were correlated with cellular susceptibilities to induction of apoptosis by CD437. Furthermore, CD437-induced apoptosis could be blocked by the ODC inhibitor difluoromethylornithine, the caspase inhibitors Z-VAD FMK and Z-DEVD FMK, and c-Myc antisense oligodeoxynucleotide, respectively. These data indicate that c-Myc gene plays an important role in mediating CD437-induced apoptosis in human NSCLC cells.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Galderma Res & Dev, Sophia Antipolis, France	University of Texas System; UTMD Anderson Cancer Center; Galderma R&D SNC	Sun, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [U19 CA68437] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA068437] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi H, 1998, AM J RESP CELL MOL, V18, P323, DOI 10.1165/ajrcmb.18.3.2974; Benner S E, 1995, Oncology (Williston Park), V9, P205; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Desbarats L, 1996, EXPERIENTIA, V52, P1123, DOI 10.1007/BF01952111; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Gudas Lorraine J., 1994, P443; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hong Waun Ki, 1994, P597; HSU B, 1995, ONCOGENE, V11, P175; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Jehn BM, 1997, CRIT REV EUKAR GENE, V7, P179, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.100; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KIM YH, 1995, CANCER RES, V55, P5603; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Li XS, 1996, CANCER RES, V56, P5055; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LOTAN R, 1995, RETINOIDS ONCOLOGY, P27; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; RAMET M, 1995, CARCINOGENESIS, V16, P2117, DOI 10.1093/carcin/16.9.2117; Sakamuro D, 1995, ONCOGENE, V11, P2411; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SHAO ZM, 1995, ONCOGENE, V11, P493; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8; Sun SY, 1997, CANCER RES, V57, P4931; SUN SY, 1999, IN PRESS ONCOGENE; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817	43	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3894	3901		10.1038/sj.onc.1202771	http://dx.doi.org/10.1038/sj.onc.1202771			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445853				2022-12-25	WOS:000081171700011
J	Baudin-Creuza, V; Vasseur-Godbillon, C; Griffon, N; Kister, J; Kiger, L; Poyart, C; Marden, MC; Pagnier, J				Baudin-Creuza, V; Vasseur-Godbillon, C; Griffon, N; Kister, J; Kiger, L; Poyart, C; Marden, MC; Pagnier, J			Additive effects of beta chain mutations in low oxygen affinity hemoglobin beta F41Y,K66T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RECOMBINANT HEMOGLOBINS; VARIANT; COOPERATIVITY; AUTOXIDATION; EQUILIBRIUM; BINDING; STATE	In order to decrease significantly the oxygen affinity of human hemoglobin, we have associated the mutation beta F41Y with another point mutation also known to decrease the oxygen affinity of Hb. We have synthesized a recombinant Hb (rHb) with two mutations in the beta chains: rHb beta F41Y,K66T. In the absence of 2,3-diphosphoglycerate, additive effects of the mutations are evident, since the doubly mutated Hb exhibits a larger decrease in oxygen affinity than for the individual single mutations. In the presence of 2,3-diphosphoglycerate, the second mutation did not significantly increase the P-50 value relative to the single mutations. However, the kinetics of CO binding still indicate combined effects on the allosteric equilibrium, as evidenced by more of the slow bimolecular phase characteristic of binding to the deoxy conformation. Dimer-tetramer equilibrium studies indicate an increase in stability of the mutants relative to rHb A; the double mutant rHb beta F41Y,K66T at pH 7.5 showed a K-4,K-2 value of 0.26 mu M. Despite the lower oxygen affinity, the single mutant beta F41Y and double mutant beta F41Y,K66T show only a moderate increase of 20% in the autoxidation rate. These mutations are thus of interest in developing a Hb-based blood substitute.	INSERM, U473, F-94276 Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Baudin-Creuza, V (corresponding author), INSERM, U473, 84 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.		Marden, Michael/AAA-5923-2020; Kiger, Laurent/Q-1686-2018; BAUDIN-CREUZA, Véronique/K-7309-2017; POYART, Claire/P-4225-2017; Marden, Michael C/G-3139-2012	BAUDIN-CREUZA, Véronique/0000-0003-1032-3236; POYART, Claire/0000-0003-2158-6293; Marden, Michael C/0000-0002-5254-6385; VASSEUR, Corinne/0000-0002-4422-7069				BAUDIN V, 1992, BIOCHIM BIOPHYS ACTA, V1159, P223, DOI 10.1016/0167-4838(92)90029-D; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; BONAVENTURA C, 1991, J BIOL CHEM, V266, P23033; BURKERT LB, 1976, BLOOD, V48, P645; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FRONTICELLI C, 1994, BIOPHYS CHEM, V51, P53, DOI 10.1016/0301-4622(94)00028-X; GACON G, 1977, FEBS LETT, V82, P243, DOI 10.1016/0014-5793(77)80593-0; Griffon N, 1996, J BIOL CHEM, V271, P25916, DOI 10.1074/jbc.271.42.25916; Griffon N, 1998, PROTEIN SCI, V7, P673, DOI 10.1002/pro.5560070316; Hardison RC, 1998, HEMOGLOBIN, V22, P113, DOI 10.3109/03630269809092136; KIM HW, 1995, J MOL BIOL, V248, P867, DOI 10.1006/jmbi.1995.0267; KISTER J, 1987, J BIOL CHEM, V262, P12085; Kono M, 1998, PROTEIN ENG, V11, P199, DOI 10.1093/protein/11.3.199; LABIE D, 1971, BIOCHIM BIOPHYS ACTA, V236, P201, DOI 10.1016/0005-2795(71)90166-8; Manning LR, 1996, PROTEIN SCI, V5, P775; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; Marden MC, 1995, TRANSFUS CLIN BIOL, V2, P473, DOI 10.1016/S1246-7820(05)80074-6; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; ROSA J, 1969, NATURE, V223, P190, DOI 10.1038/223190a0; SHIH DT, 1987, FED PROC, V46, P1972; SHIH DTB, 1987, HEMOGLOBIN, V11, P453, DOI 10.3109/03630268708998005; STABLER SP, 1994, MAYO CLIN PROC, V69, P237, DOI 10.1016/S0025-6196(12)61062-3; THOMAS JO, 1973, J BIOL CHEM, V248, P2901; TURNER GJ, 1992, PROTEINS, V14, P330; WAJCMAN H, 1973, NOUV REV FR HEMATOL, V13, P89	28	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25550	25554		10.1074/jbc.274.36.25550	http://dx.doi.org/10.1074/jbc.274.36.25550			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464287	hybrid			2022-12-25	WOS:000082554200051
J	Ben-Shlomo, H; Levitan, A; Shay, NE; Goncharov, I; Michaeli, S				Ben-Shlomo, H; Levitan, A; Shay, NE; Goncharov, I; Michaeli, S			RNA editing associated with the generation of two distinct conformations of the trypanosomatid Leptomonas collosoma 7SL RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; 16S RIBOSOMAL-RNA; ENDOPLASMIC-RETICULUM; MICROSOMAL-MEMBRANES; PROTEINS; BRUCEI; TRANSCRIPTION; TRANSLOCATION; EXPRESSION; EVOLUTION	Analysis of the trypanosomatid Leptomonas collosoma 7SL RNA revealed the existence of two distinct stable 7SL RNA conformers (7SL I and II). Sequence analysis of the RNAs indicated a single base difference between the conformers at position 133 (C in 7SL II and U in 7SL I) located in domain III, This change appears to be the result of a post-transcriptional editing event, since the single-copy 7SL RNA gene codes exclusively for a C at this position. The edited form (7SL I) was found preferentially in the cytoplasm, and the pre-edited form in the nucleus. 7SL I is mainly bound to ribosomes, whereas 7SL II is more abundant in ribosome-free particles. Mutations introduced in regions outside the editing site were found to occur in a single conformation, suggesting that the editing event is not the only factor that determines the conformation of the molecule. This study is the first description of an editing event on a small RNA other than tRNA and is the first report of C --> U editing in trypanosomes. We propose a novel role for RNA editing in controlling the conformation of the 7SL RNA in vivo.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Michaeli, Shulamit/AAC-8255-2022					ALTHOFF S, 1994, NUCLEIC ACIDS RES, V22, P1933, DOI 10.1093/nar/22.11.1933; ANDREAZZOLI M, 1991, EMBO J, V10, P767, DOI 10.1002/j.1460-2075.1991.tb08008.x; BEJA O, 1993, MOL BIOCHEM PARASIT, V57, P223, DOI 10.1016/0166-6851(93)90198-7; Ben-Shlomo H, 1997, NUCLEIC ACIDS RES, V25, P4977, DOI 10.1093/nar/25.24.4977; DIGWEED M, 1982, EUR J BIOCHEM, V127, P531; DONISKELLER H, 1997, NUCLEIC ACIDS RES, V4, P2527; Goldring A, 1996, EXP PARASITOL, V84, P28, DOI 10.1006/expr.1996.0087; GOLDRING A, 1995, EXPT PARASITOLOGY, V80, P333; Gowda K, 1997, NUCLEIC ACIDS RES, V25, P2835, DOI 10.1093/nar/25.14.2835; GUNDELFINGER ED, 1984, EMBO J, V3, P2325, DOI 10.1002/j.1460-2075.1984.tb02134.x; KROL A, 1989, METHOD ENZYMOL, V180, P212; Levitan A, 1998, NUCLEIC ACIDS RES, V26, P1775, DOI 10.1093/nar/26.7.1775; LOCKARD RE, 1978, NUCLEIC ACIDS RES, V5, P37, DOI 10.1093/nar/5.1.37; Maniatis T., 1982, MOL CLONING LAB MANU; MARCHFELDER A, 1998, MODIFICATION EDITING, P307; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MICHAELI S, 1992, MOL BIOCHEM PARASIT, V51, P55, DOI 10.1016/0166-6851(92)90200-4; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; PATZELT E, 1989, MOL CELL BIOL, V9, P4291, DOI 10.1128/MCB.9.10.4291; Price DH, 1998, MODIFICATION EDITING, P289; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SIEGEL V, 1988, TRENDS BIOCHEM SCI, V13, P314, DOI 10.1016/0968-0004(88)90127-2; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; Smith HC, 1997, RNA, V3, P1105; STEBBINSBOAZ B, 1991, J MOL BIOL, V217, P93, DOI 10.1016/0022-2836(91)90614-C; Stuart K, 1997, CURR OPIN CHEM BIOL, V1, P340, DOI 10.1016/S1367-5931(97)80071-3; WALTER P, 1983, J CELL BIOL, V97, P1693, DOI 10.1083/jcb.97.6.1693; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WOLIN SL, 1993, J CELL BIOL, V121, P1211, DOI 10.1083/jcb.121.6.1211; YOUVAN DC, 1979, P NATL ACAD SCI USA, V76, P3751, DOI 10.1073/pnas.76.8.3751; ZWIEB C, 1986, NUCLEIC ACIDS RES, V14, P4639, DOI 10.1093/nar/14.11.4639	34	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25642	25650		10.1074/jbc.274.36.25642	http://dx.doi.org/10.1074/jbc.274.36.25642			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464300	hybrid			2022-12-25	WOS:000082554200064
J	Dugan, LL; Kim, JS; Zhang, YJ; Bart, RD; Sun, YL; Holtzman, DM; Gutmann, DH				Dugan, LL; Kim, JS; Zhang, YJ; Bart, RD; Sun, YL; Holtzman, DM; Gutmann, DH			Differential effects of cAMP in neurons and astrocytes - Role of B-raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; CEREBELLAR GRANULE NEURONS; MAP-KINASE; CYCLIC-AMP; BINDING PROTEINS; FACTOR-I; SURVIVAL; RAP1; PATHWAY	Mitogen-activated protein kinase (MAPK) activation provides cell type-specific signals important for cellular differentiation, proliferation, and survival. Cyclic AMP (cAMP) has divergent effects on MAPK activity depending on whether signaling is through Ras/Raf-1 or Rap1/B-raf. We found that central nervous system-derived neurons, but not astrocytes, express B-raf. In neurons, cAMP activated MAPK in a Rap1/B-raf-dependent manner, while in astrocytes, cAMP decreased MAPK activity. Inhibition of MAPK in neurons decreased neuronal growth factor-mediated survival, and activation of MAPK by cAMP analogues rescued neurons from death. Furthermore, constitutive expression of B-raf in astrocytoma cells increased MAPK activation, as seen in neurons, and enhanced proliferation. These data provide the first experimental evidence that B-raf is the molecular switch which dominantly permits differential cAMP-dependent regulation of MAPK in neurons versus astrocytes, with important implications for both survival and proliferation.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.			Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS032553] Funding Source: NIH RePORTER; NIA NIH HHS [AG00599] Funding Source: Medline; NINDS NIH HHS [NS32553] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson CNG, 1999, J NEUROSCI, V19, P664; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Bazan HEP, 1997, CURR EYE RES, V16, P372, DOI 10.1076/ceyr.16.4.372.10699; Benzeroual K, 1997, AM J PHYSIOL-GASTR L, V272, pG1425, DOI 10.1152/ajpgi.1997.272.6.G1425; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; BRENNEMAN DE, 1985, J PHARMACOL EXP THER, V233, P402; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Chin TY, 1998, AM J PHYSIOL-CELL PH, V275, pC1255, DOI 10.1152/ajpcell.1998.275.5.C1255; CROWDER RJ, 1999, IN PRESS J NEUROCHEM; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUGAN LL, 1995, J NEUROSCI, V15, P4545; Dulin NO, 1998, P NATL ACAD SCI USA, V95, P8098, DOI 10.1073/pnas.95.14.8098; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Gutmann D H, 1998, Semin Pediatr Neurol, V5, P276, DOI 10.1016/S1071-9091(98)80006-5; Gutmann DH, 1996, ONCOGENE, V12, P2121; Gutmann DH, 1997, ONCOGENE, V15, P1611, DOI 10.1038/sj.onc.1201314; Hanson MG, 1998, J NEUROSCI, V18, P7361; HARTIKKA J, 1992, J NEUROSCI RES, V32, P190, DOI 10.1002/jnr.490320208; KAISER PK, 1990, NEURON, V5, P373, DOI 10.1016/0896-6273(90)90173-D; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Miller TM, 1997, J BIOL CHEM, V272, P9847; MITRA G, 1993, CELL MOL BIOL RES, V39, P517; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Muthalif MM, 1998, P NATL ACAD SCI USA, V95, P12701, DOI 10.1073/pnas.95.21.12701; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; Potchinsky MB, 1998, J CELL PHYSIOL, V176, P266; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; Schiemann WP, 1998, ONCOGENE, V16, P2671, DOI 10.1038/sj.onc.1201800; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wienecke R, 1997, ANN NEUROL, V42, P230, DOI 10.1002/ana.410420215; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHOU J, 1994, P NATL ACAD SCI USA, V91, P3824, DOI 10.1073/pnas.91.9.3824	43	188	192	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25842	25848		10.1074/jbc.274.36.25842	http://dx.doi.org/10.1074/jbc.274.36.25842			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464325	hybrid			2022-12-25	WOS:000082554200089
J	Hastings, RA; Eyheralde, I; Dawson, SP; Walker, G; Reynolds, SE; Billett, MA; Mayer, RJ				Hastings, RA; Eyheralde, I; Dawson, SP; Walker, G; Reynolds, SE; Billett, MA; Mayer, RJ			A 220-kDa activator complex of the 26 S proteasome in insects and humans - A role in type II programmed insect muscle cell death and cross-activation of proteasomes from different species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAT-BINDING-PROTEIN; MANDUCA-SEXTA; INTERSEGMENTAL MUSCLES; DEVELOPMENTAL-CHANGES; THYMOCYTE APOPTOSIS; REGULATORY COMPLEX; SUBUNIT; PROTEOLYSIS; INVOLVEMENT; INHIBITION	The S10b (SUG2) ATPase cDNA has been cloned by reverse transcription-polymerase chain reaction/rapid amplification of cDNA ends from mRNA of intersegmental muscles of the tobacco horn moth (Manduca sexta), The S10b ATPase is a component of the 26 S proteasome, and its concentration and that of its mRNA increase dramatically during development in a manner similar to other ATPases of the 19 S regulator of the 26 S proteasome. The S10b and S6' (TBP1) ATPases are also present in a complex of similar to 220 kDa in intersegmental muscles. The 220-kDa complex markedly activates (2-10-fold) the 26 S proteasome, even when bound to anti-S10b antibodies immobilized on Sepharose, and increases in concentration similar to 5-fold like the 26 S proteasome in the intersegmental muscles in preparation for the programmed death of the muscle cells. A similar activator complex is present in human brain and placenta. Free activator complexes cross-activate: the Manduca complex activates rat skeletal muscle 26 S proteasomes, and the placental complex activates Manduca 26 S proteasomes. The placental activator complex contains S10b and S6', but not p27, This 220-kDa activator complex has been evolutionarily conserved between species from insect to man and may have a fundamental role in proteasome regulation.	Univ Nottingham, Sch Med, Queens Med Ctr,Lab Intracellular Proteolysis Mol, Fac Med & Hlth Sci,Sch Biomed Sci, Nottingham NG7 2UH, England; Univ Nottingham, Sch Med, Queens Med Ctr,Mol & Cellular Biol Sect, Fac Med & Hlth Sci,Sch Biomed Sci, Nottingham NG7 2UH, England; Univ Bath, Dept Biochem & Biol Sci, Bath BA2 7AY, Avon, England	University of Nottingham; University of Nottingham; University of Bath	Mayer, RJ (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr,Lab Intracellular Proteolysis Mol, Fac Med & Hlth Sci,Sch Biomed Sci, Clifton Blvd, Nottingham NG7 2UH, England.	John.Mayer@nottingham.ac.uk	Reynolds, Stuart/AAI-6616-2021	Reynolds, Stuart/0000-0001-5043-0242				Adams GM, 1998, BIOCHEMISTRY-US, V37, P12927, DOI 10.1017/S1431927600024880; Adams GM, 1997, J MOL BIOL, V273, P646, DOI 10.1006/jmbi.1997.1334; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Choi HS, 1996, J STEROID BIOCHEM, V56, P23, DOI 10.1016/0960-0760(95)00220-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Cui HL, 1997, P NATL ACAD SCI USA, V94, P7515, DOI 10.1073/pnas.94.14.7515; DAWSON SP, 1995, J BIOL CHEM, V270, P1850, DOI 10.1074/jbc.270.4.1850; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; Hirsch T, 1998, J IMMUNOL, V161, P35; JONES MEE, 1995, DEV BIOL, V169, P436, DOI 10.1006/dbio.1995.1159; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; Lin KI, 1998, CELL DEATH DIFFER, V5, P577, DOI 10.1038/sj.cdd.4400384; Low P, 1997, FEBS LETT, V400, P345, DOI 10.1016/S0014-5793(96)01413-5; MA CP, 1994, J BIOL CHEM, V269, P3539; Makino Y, 1996, BIOCHEM BIOPH RES CO, V220, P1049, DOI 10.1006/bbrc.1996.0530; McDonald HB, 1997, J CELL BIOL, V137, P539, DOI 10.1083/jcb.137.3.539; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; Richmond C, 1997, J BIOL CHEM, V272, P13403, DOI 10.1074/jbc.272.20.13403; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; Sawada H, 1997, FEBS LETT, V412, P521, DOI 10.1016/S0014-5793(97)00851-X; SCHWARTZ LM, 1990, NEURON, V5, P411, DOI 10.1016/0896-6273(90)90080-Y; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; Takayanagi K, 1996, BIOCHEM BIOPH RES CO, V228, P517, DOI 10.1006/bbrc.1996.1692; Tanaka K, 1998, BIOCHEM BIOPH RES CO, V247, P537, DOI 10.1006/bbrc.1998.8617; TRUMAN JW, 1983, J COMP NEUROL, V216, P445, DOI 10.1002/cne.902160410; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Watanabe TK, 1998, GENOMICS, V50, P241, DOI 10.1006/geno.1998.5301	39	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25691	25700		10.1074/jbc.274.36.25691	http://dx.doi.org/10.1074/jbc.274.36.25691			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464306	hybrid			2022-12-25	WOS:000082554200070
J	Lafont, V; Ottones, F; Liautard, J; Favero, J				Lafont, V; Ottones, F; Liautard, J; Favero, J			Evidence for a p21(ras)/Raf-1/MEK-1/ERK-2-independent pathway in stimulation of IL-2 gene transcription in human primary T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PLECKSTRIN HOMOLOGY DOMAIN; SIGNAL-REGULATED KINASE-2; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; ACTIVATION; PHOSPHORYLATION; P21RAS; EXPRESSION	T cell stimulation leads to triggering of signals transmitted from the cell membrane to the nucleus through TCR/CD3 proteins. Characterization of these signals largely results from the use of cell lines stimulated with anti-CDB monoclonal antibodies. These studies have established that activation caused a rapid increase in the formation of GTP-bound has, which stimulates the mitogen-activated protein kinase pathway involving the extracellular-regulated kinase-2 (ERK-2) and activates the nuclear factor of activated T cells (NF-AT) that regulates interleukin-2 (IL-2) gene transcription. In the present study, we used human primary T cells, and we investigated the intracellular signals triggered by two different anti-CD3 monoclonal antibodies (UCHT1 and X-35), which both strongly induce cell proliferation. We found that, in contrast to the commonly used UCHT1, X-35 activated IL-2 gene transcription without stimulation of the Raf-1/mitogen-activated ERK kinase-1 (MEK-1)/ERK-2 phosphorylation cascade; we also showed that X-35 stimulation, which triggers an ERK-2-independent pathway, does not involve activation of p21(ras). In addition to demonstrating that activation of p21(ras) and of its Raf-1/MEK-1/ERK-2 effector pathway is not an event obligatorily triggered upon TCR/CD3 ligation, these results provide the first evidence of the existence of a p21(ras)/ERK-2-independent pathway for IL-2 gene transcription in human primary T lymphocytes.	Univ Montpellier 2, INSERM, U431, F-34095 Montpellier 05, France; Imperial Canc Res Fund, Lymphocyte Activat Lab, London WC2A 3PX, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Cancer Research UK	Favero, J (corresponding author), Univ Montpellier 2, INSERM, U431, Pl Eugene Bataillon,CC 100, F-34095 Montpellier 05, France.	favero@univ-montp2.fr	Lafont, Virginie/R-9356-2017	Lafont, Virginie/0000-0001-9612-3934				ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; BALDARI CT, 1992, J BIOL CHEM, V267, P4289; Boudewijn MT, 1995, NATURE, V376, P599; BOUREL D, 1987, PATHOL BIOL, V35, P1285; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; deAos I, 1997, J BIOL CHEM, V272, P25310, DOI 10.1074/jbc.272.40.25310; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DENNING MD, 1987, LEUKOCYTE TYPING 3, P144; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dumont FJ, 1998, J IMMUNOL, V160, P2579; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Genot E, 1998, ONCOGENE, V17, P1731, DOI 10.1038/sj.onc.1202101; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Gibson S, 1996, J IMMUNOL, V156, P2716; GOLD MR, 1994, J IMMUNOL, V153, P2369; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; Lafont V, 1997, EUR J IMMUNOL, V27, P2261, DOI 10.1002/eji.1830270921; Lafont V, 1998, BIOCHEM PHARMACOL, V55, P319, DOI 10.1016/S0006-2952(97)00471-1; LOBACH DF, 1987, LEUKOCYTE TYPING 3, P174; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; Ruckdeschel K, 1997, J BIOL CHEM, V272, P15920, DOI 10.1074/jbc.272.25.15920; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Trotta R, 1996, J EXP MED, V184, P1027, DOI 10.1084/jem.184.3.1027; Tunnacliffe A, 1989, Int Immunol, V1, P546, DOI 10.1093/intimm/1.5.546; WATTS JD, 1993, J BIOL CHEM, V268, P23275; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; YANG SY, 1987, LEUKOCYTE TYPING 3, P116; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607	37	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25743	25748		10.1074/jbc.274.36.25743	http://dx.doi.org/10.1074/jbc.274.36.25743			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464312	hybrid			2022-12-25	WOS:000082554200076
J	Kumar, R; Baskakov, IV; Srinivasan, G; Bolen, DW; Lee, JC; Thompson, EB				Kumar, R; Baskakov, IV; Srinivasan, G; Bolen, DW; Lee, JC; Thompson, EB			Interdomain signaling in a two-domain fragment of the human glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; TRANSACTIVATION DOMAIN; GENE ACTIVATION; IN-VITRO; PROTEIN; COMPLEX; TERMINUS	Studies of individual domains or subdomains of the proteins making up the nuclear receptor family have stressed their modular nature. Nevertheless, these receptors function as complete proteins. Studies of specific mutations suggest that in the holoreceptors, intramolecular domain-domain interactions are important for complete function, but there is little knowledge concerning these interactions, The important transcriptional transactivation function in the N-terminal part of the glucocorticoid receptor (GR) appears to have little inherent structure. To study its interactions with the DNA binding domain (DBD) of the GR, we have expressed the complete sequence from the N-terminal through the DBD of the human GR. Circular dichroism analyses of this highly purified, multidomain protein show that it has a considerable helical content, We hypothesized that binding of its DBD to the cognate glucocorticoid response element would confer additional structure upon the N-terminal domain, Circular dichroism and fluorescence emission studies suggest that additional helicity as well as tertiary structure occur in the two-domain protein upon DNA binding. In sum, our data suggest that interdomain interactions consequent to DNA binding imparts structure to the portion of the GR that contains a major transactivation domain.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Thompson, EB (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 301 Univ Blvd,605 Basic Sci Bldg, Galveston, TX 77555 USA.		Lee, James C/A-7849-2009		NATIONAL CANCER INSTITUTE [R01CA041407] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1 CA 41407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskakov IV, 1999, J BIOL CHEM, V274, P10693, DOI 10.1074/jbc.274.16.10693; BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P13463, DOI 10.1021/bi00212a011; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P418; Chen H, 1997, J BIOL CHEM, V272, P25873, DOI 10.1074/jbc.272.41.25873; DahlmanWright K, 1996, BIOCHEMISTRY-US, V35, P1323, DOI 10.1021/bi952409k; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Ford J, 1997, MOL ENDOCRINOL, V11, P1467, DOI 10.1210/me.11.10.1467; Gandini O, 1997, STEROIDS, V62, P508, DOI 10.1016/S0039-128X(97)00001-9; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; Henriksson A, 1997, MOL CELL BIOL, V17, P3065, DOI 10.1128/MCB.17.6.3065; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; SIMONS SS, 1994, VITAM HORM, V49, P49; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5	27	88	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24737	24741		10.1074/jbc.274.35.24737	http://dx.doi.org/10.1074/jbc.274.35.24737			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455143	hybrid			2022-12-25	WOS:000082193400042
J	Reif, A; Frohlich, LG; Kotsonis, P; Frey, A; Bommel, HM; Wink, DA; Pfleiderer, W; Schmidt, HHHW				Reif, A; Frohlich, LG; Kotsonis, P; Frey, A; Bommel, HM; Wink, DA; Pfleiderer, W; Schmidt, HHHW			Tetrahydrobiopterin inhibits monomerization and is consumed during catalysis in neuronal NO synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; L-ARGININE; PROTEIN INHIBITOR; OXYGENASE DOMAIN; ESCHERICHIA-COLI; PROSTHETIC GROUP; BINDING-SITES; CENTER-DOT; ENZYME; HEME	The biosynthesis of nitric oxide (NO) is catalyzed by homodimeric NO synthases (NOS), For unknown reasons, all NOS co-purify with substoichiometric amounts of (6R)-5,6,7,8-tetrahydrobiopterin (H(4)Bip) and require additional H(4)Bip for maximal activity. We examined the effects of H(4)Bip and pterin-derived inhibitors (antipterins) on purified neuronal NOS-I quaternary structure and H(4)Bip content. During L-arginine turnover, NOS-I dimers time dependently dissociated into inactive monomers, paralleled by a loss of enzyme-associated pterin. Dimer dissociation was inhibited when saturating levels of H(4)Bip were added during catalysis, Similar results were obtained with pterin-free NOS-I expressed in Escherichia coli. This stabilizing effect of H(4)Bip was mimicked by the anti-pterin 2-amino-4,6-dioxo-3,4,5,6,8,8a,9, 10-octahydro-oxazolo [1,2f]-pteridine (PHS-32), which also displaced NOS-associated H(4)Bip in a competitive manner. Surprisingly, H(4)Bip not only dissociated from NOS during catalysis, but was only partially recovered in the solute (50.0 +/- 16.5% of control at 20 min). NOS-associated H(4)Bip appeared to react with a NOS catalysis product to a derivative distinct from dihydrobiopterin or biopterin. Under identical conditions, reagent H(4)Bip was chemically stable and fully recovered (95.5 +/- 3.4% of control). A similar loss of both reagent and enzyme-bound H(4)Bip and dimer content was observed by NO generated from spermine NONO-ate. In conclusion, we propose a role for H(4)Bip as a dimer-stabilizing factor of neuronal NOS during catalysis, possibly by interfering with enzyme destabilizing products.	Univ Wurzburg, Dept Pharmacol & Toxicol, D-97078 Wurzburg, Germany; NCI, Bethesda, MD 20892 USA; Univ Konstanz, Fac Chem, D-78434 Constance, Germany	University of Wurzburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Konstanz	Reif, A (corresponding author), Univ Wurzburg, Dept Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.	a.reif@gmx.net	Schmidt, Harald HHW/B-1549-2008	Schmidt, Harald HHW/0000-0003-0419-5549; Azad, Mahan/0000-0002-8633-3513; Wink, David/0000-0002-5652-7480				ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Adamson DC, 1996, SCIENCE, V274, P1917, DOI 10.1126/science.274.5294.1917; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bommel HM, 1998, J BIOL CHEM, V273, P33142, DOI 10.1074/jbc.273.50.33142; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; Hellermann GR, 1997, J BIOL CHEM, V272, P12030, DOI 10.1074/jbc.272.18.12030; Hemmens B, 1998, FEBS LETT, V430, P397, DOI 10.1016/S0014-5793(98)00704-2; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; HYUN J, 1995, BIOCHEM BIOPH RES CO, V206, P380, DOI 10.1006/bbrc.1995.1052; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; KAUFMAN S, 1963, P NATL ACAD SCI USA, V50, P1085, DOI 10.1073/pnas.50.6.1085; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KWON NS, 1989, J BIOL CHEM, V264, P20496; List BM, 1996, BIOCHEM J, V315, P57, DOI 10.1042/bj3150057; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; Mayer B, 1995, Adv Pharmacol, V34, P251; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Narayanasami R, 1997, NITRIC OXIDE-BIOL CH, V1, P39, DOI 10.1006/niox.1996.0103; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; OGILVIE P, 1995, FASEB J, V9, P799, DOI 10.1096/fasebj.9.9.7541381; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SahinToth M, 1997, MOL HUM REPROD, V3, P293, DOI 10.1093/molehr/3.4.293; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1991, FASEB J, V5, pA1591; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; SCHMIDT HHHW, 1992, LANCET, V339, P986, DOI 10.1016/0140-6736(92)91556-N; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SHMIDT HHHW, 1992, CELL CALCIUM, V13, P427, DOI 10.1016/0143-4160(92)90055-W; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Toth M, 1997, PLACENTA, V18, P189, DOI 10.1016/S0143-4004(97)90092-8; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Werner ER, 1996, BIOCHEM J, V320, P193, DOI 10.1042/bj3200193; Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954	59	98	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24921	24929		10.1074/jbc.274.35.24921	http://dx.doi.org/10.1074/jbc.274.35.24921			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455167	hybrid			2022-12-25	WOS:000082193400066
J	Hayes, JS; Lawler, OA; Walsh, MT; Kinsella, BT				Hayes, JS; Lawler, OA; Walsh, MT; Kinsella, BT			The prostacyclin receptor is isoprenylated - Isoprenylation is required for efficient receptor-effector coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; PROSTANOID RECEPTORS; ADENYLATE-CYCLASE; POSTTRANSLATIONAL MODIFICATION; BETA-2-ADRENERGIC RECEPTOR; MOLECULAR MECHANISMS; SIGNAL-TRANSDUCTION; HUMAN PLATELETS; SMOOTH-MUSCLE; RAS PROTEINS	The prostacyclin receptor (IP), a G protein-coupled receptor, mediates the actions of the prostanoid prostacyclin and its mimetics, IPs from a number of species each contain identically conserved putative isoprenylation CAAX motifs, each with the sequence CSLC, Metabolic labeling of human embryonic kidney (HEK) 293 cells stably overexpressing the hemagluttinin epitopetagged IP in the presence of [H-3]mevalonolactone established that the mouse IP is isoprenylated. Studies involving in vitro assays confirmed that recombinant forms of the human and mouse IP are modified by carbon 15 farnesyl isoprenoids. Disruption of isoprenylation, by site-directed mutagenesis of Cys(414) to Ser(414) within the CAAX motif, abolished isoprenylation of IPSSLC both in vitro and in transfected cells. Scatchard analysis of the wild type (IP) and mutant (IPSSLC) receptor confirmed that each receptor exhibited high and low affinity binding sites for [H-3]iloprost, which were not influenced by receptor isoprenylation. Whereas stable cell lines overexpressing IP generated significant agonist (iloprost and cicaprost)-mediated increases in cAMP relative to nontransfected cells, cAMP generation by IPSSLC cells was not significantly different from the control, nontransfected HEK 293 cells. Moreover, co-expression of the alpha (alpha) subunit of Gs generated significant augmentations in cAMP by IP but not by IPSSLC cells, Whereas IP also demonstrated significant, dose-dependent increases in [Ca2+](i) in response to iloprost or cicaprost compared with the nontransfected HEK 293 cells, mobilization of [Ca2+](i) by IPSSLC was significantly impaired. Co-transfection of cells with either G alpha(q) or G alpha(11) resulted in significant augmentation of agonist-mediated [Ca2+](i) mobilization by IP cells but not by IPSSLC cells or by the control, HEK 293 cells. In addition, inhibition of isoprenylation by lovastatin treatment significantly reduced agonist-mediated cAMP generation by IP in comparison to the nonisoprenylated beta(2) adrenergic receptor or nontreated cells. Hence, isoprenylation of TP does not influence ligand binding but is required for efficient coupling to the effecters adenylyl cyclase and phospholipase C.	Natl Univ Ireland Univ Coll Dublin, Dept Biochem, Dublin 4, Ireland	University College Dublin	Kinsella, BT (corresponding author), Natl Univ Ireland Univ Coll Dublin, Dept Biochem, Merville House, Dublin 4, Ireland.	Therese.Kinsella@ucd.ie		Kinsella, B. Therese/0000-0003-3072-941X				ABRAMOVITZ M, 1995, ADV PROSTAG THROMB L, V23, P499; Ausubel FM, 1994, CURRENT PROTOCOLS MO; AVIRAM M, 1992, CURRENT OPINION LIPI, V3, P344; Bellosta S, 1998, ATHEROSCLEROSIS, V137, pS101, DOI 10.1016/S0021-9150(97)00319-5; BOIE Y, 1994, J BIOL CHEM, V269, P12173; Campbell W. B., 1990, PHARMACOL BASIS THER, P600; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHATZIPANTELI K, 1992, DIABETES, V41, P927, DOI 10.2337/diabetes.41.8.927; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; COX AD, 1994, J BIOL CHEM, V269, P19203; DeSmedt F, 1997, J BIOL CHEM, V272, P17367, DOI 10.1074/jbc.272.28.17367; DORN GW, 1993, J PHARMACOL EXP THER, V265, P447; ELLIS EF, 1976, SCIENCE, V193, P1135, DOI 10.1126/science.959827; EXTON JH, 1993, ADV SEC MESS PHOSPH, V28, P65; Exton JH, 1997, ADV EXP MED BIOL, V400, P3; Farnier M, 1998, AM J CARDIOL, V82, p3J, DOI 10.1016/S0002-9149(98)00423-8; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Giovanazzi S, 1997, BIOCHEM J, V325, P71, DOI 10.1042/bj3250071; Goldman F, 1996, BLOOD, V88, P4611, DOI 10.1182/blood.V88.12.4611.bloodjournal88124611; GORMAN RR, 1977, PROSTAGLANDINS, V13, P377, DOI 10.1016/0090-6980(77)90018-1; GRYGLEWSKI RJ, 1978, ATHEROSCLEROSIS, V31, P385, DOI 10.1016/0021-9150(78)90133-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HASHIMOTO H, 1990, PROSTAGLANDINS, V40, P491, DOI 10.1016/0090-6980(90)90111-8; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HOLGATE ST, 1980, J IMMUNOL, V125, P1367; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KENNEDY ME, 1994, J BIOL CHEM, V269, P31915; KIM CM, 1992, J BIOL CHEM, V267, P23113; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; Kinsella BT, 1997, J PHARMACOL EXP THER, V281, P957; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; KRANE A, 1994, BIOCHEM PHARMACOL, V47, P953, DOI 10.1016/0006-2952(94)90405-7; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LEFER A, 1990, P NATL ACAD SCI USA, V77, P1706; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEIGH PJ, 1985, BRIT J PHARMACOL, V85, P237, DOI 10.1111/j.1476-5381.1985.tb08852.x; MA YT, 1992, P NATL ACAD SCI USA, V89, P6275, DOI 10.1073/pnas.89.14.6275; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Miggin SM, 1998, BBA-GEN SUBJECTS, V1425, P543, DOI 10.1016/S0304-4165(98)00109-3; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NAKAGAWA O, 1994, CIRCULATION, V90, P1643, DOI 10.1161/01.CIR.90.4.1643; NAMBA T, 1994, J BIOL CHEM, V269, P9986; Nash DT, 1996, AM J CARDIOL, V78, P26, DOI 10.1016/S0002-9149(96)00659-5; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Osamah H, 1997, BRIT J CLIN PHARMACO, V44, P77, DOI 10.1046/j.1365-2125.1997.00625.x; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; RASMANIS G, 1995, PROSTAG OTH LIPID M, V49, P247, DOI 10.1016/0090-6980(95)00019-7; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; SAKAI A, 1990, LIFE SCI, V47, P711, DOI 10.1016/0024-3205(90)90626-3; SASAKI Y, 1994, BBA-MOL CELL RES, V1224, P601, DOI 10.1016/0167-4889(94)90300-X; SCHWANER I, 1995, BBA-MOL CELL RES, V1265, P8, DOI 10.1016/0167-4889(94)00198-N; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Siegel G, 1989, Eicosanoids, V2, P213; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; Smyth EM, 1998, J BIOL CHEM, V273, P23258, DOI 10.1074/jbc.273.36.23258; TAKAHARA K, 1990, J BIOL CHEM, V265, P6836; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; VANE JR, 1995, J CARDIOL, V75, pA3; Walsh MT, 1998, J PHARMACOL EXP THER, V286, P1026; Watson S., 1994, G PROTEIN LINKED REC; Wise H, 1996, TRENDS PHARMACOL SCI, V17, P17, DOI 10.1016/0165-6147(96)81565-3; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	80	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23707	23718		10.1074/jbc.274.34.23707	http://dx.doi.org/10.1074/jbc.274.34.23707			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446129	hybrid			2022-12-25	WOS:000082110900008
J	Taira, T; Sawai, M; Ikeda, M; Tamai, K; Iguchi-Ariga, SMM; Ariga, H				Taira, T; Sawai, M; Ikeda, M; Tamai, K; Iguchi-Ariga, SMM; Ariga, H			Cell cycle-dependent switch of up- and down-regulation of human hsp70 gene expression by interaction between c-Myc and CBF/NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING TRANSCRIPTION FACTOR; FACTOR NF-Y; DNA-BINDING; STIMULATES TRANSCRIPTION; FUNCTIONAL INTERACTION; SEQUENCE IDENTITY; CDNA CLONING; YEAST HAP2; PROTEIN; PROMOTER	A CCAAT box-binding protein subunit, CBF-C/NF-YC, was cloned as a protein involved in the c-Myc complex formed on the G(1)-specific enhancer in the human hsp70 gene. CBF-C/NF-YC directly bound to c-Myc in vitro and in vivo in cultured cells. The CBF/NF-Y.c-Myc complex required the HSP-MYC-B element as well as CCAAT in the hsp70 G(1)-enhancer, while the purified CBF subunits recognized only CCAAT even in the presence of c-Myc. Both the HSP-MYC-B and CCAAT elements were also required for the enhancer activity. In transient transfection experiments, the CBF/NF-Y.c-Myc complex, as well as transcription due to the G(1)-enhancer, was increased by the introduction of c-Myc at low doses but decreased at high doses. The repression of both complex formation and transcription by c-Myc at high doses was abrogated by the introduction of CBF/NF-Y in a dose-dependent manner. Furthermore, the CBF/NF-Y.c-Myc complex bound to the G(1)-enhancer appeared in the early G(1) phase of the cell cycle when c-Myc was not higly expressed and gradually disappeared after the c-Myc expression reached its maximum. The results indicate that the cell cycle-dependent expression of the hsp70 gene is regulated by the intracellular amount of c-Myc through the complex formation states between CBF/NF-Y and c-Myc.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Univ, Coll Med Technol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; MBL Co Ltd, Ina Labs, Ina, Saitama 396, Japan	Hokkaido University; Hokkaido University	Ariga, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.		Ariga, Sanae/H-9647-2013; Ariga, Hiroyoshi/B-5895-2013; Tamai, Katsuyuki/F-4743-2013	Ariga, Hiroyoshi/0000-0001-7384-2143; Tamai, Katsuyuki/0000-0003-4094-3911				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; CRAIG EA, 1989, BIOESSAYS, V11, P48, DOI 10.1002/bies.950110203; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Dmitrenko V, 1997, GENE, V197, P161, DOI 10.1016/S0378-1119(97)00255-2; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Iida M, 1997, BIOL PHARM BULL, V20, P10; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KAO HT, 1985, MOL CELL BIOL, V5, P628, DOI 10.1128/MCB.5.4.628; Kim IS, 1996, MOL CELL BIOL, V16, P4003; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; Liang SG, 1998, J BIOL CHEM, V273, P31590, DOI 10.1074/jbc.273.47.31590; Lin H, 1998, J CELL BIOCHEM, V69, P181, DOI 10.1002/(SICI)1097-4644(19980501)69:2<181::AID-JCB8>3.0.CO;2-O; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; Mayer MP, 1998, BIOL CHEM, V379, P261; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; NEGISHI Y, 1994, ONCOGENE, V9, P1133; PiseMasison CA, 1997, MOL CELL BIOL, V17, P1236, DOI 10.1128/MCB.17.3.1236; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; TAIRA T, 1994, MOL CELL BIOL, V14, P6386, DOI 10.1128/MCB.14.9.6386; TAIRA T, 1992, BIOCHIM BIOPHYS ACTA, V1130, P166, DOI 10.1016/0167-4781(92)90524-4; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Taira T, 1997, NUCLEIC ACIDS RES, V25, P1975, DOI 10.1093/nar/25.10.1975; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822	50	58	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24270	24279		10.1074/jbc.274.34.24270	http://dx.doi.org/10.1074/jbc.274.34.24270			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446203	hybrid			2022-12-25	WOS:000082110900082
J	Chaturvedi, V; Qin, JZ; Denning, MF; Choubey, D; Diaz, MO; Nickoloff, BJ				Chaturvedi, V; Qin, JZ; Denning, MF; Choubey, D; Diaz, MO; Nickoloff, BJ			Apoptosis in proliferating, senescent, and immortalized keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RADIATION-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CELL-DEATH; REPLICATIVE SENESCENCE; HUMAN FIBROBLASTS; EPIDERMAL DIFFERENTIATION; SQUAMOUS DIFFERENTIATION; TERMINAL DIFFERENTIATION; MOUSE KERATINOCYTES	Skin provides an attractive organ system for exploring coordinated regulation of keratinocyte (KC) proliferation, differentiation, senescence, and apoptosis, Our main objective was to determine whether various types of cell cycle arrest confer resistance to apoptosis, We postulated that KC cell cycle and cell death programs are tightly regulated to ensure epidermal homeostasis, In this report, simultaneous expression of cyclin-dependent kinase inhibitors (p15, pig, p21, and p27), a marker of early differentiation (keratin I), mediators of apoptosis (caspases 3 and 8), and NF-kappa B were analyzed in three types of KCs, By comparing the response of proliferating, senescent, and immortalized KCs (HaCaT cells) to antiproliferative agents followed by UV exposure, we observed: 1) Normal KCs follow different pathways to abrupt cell cycle arrest; 2) KCs undergoing spontaneous replicative senescence or confluency predominantly express pie; 3) Abruptly induced growth arrest, confluency, and senescence pathways are associated with resistance to apoptosis; 4) The death-defying phenotype of KCs does not require early differentiation; 5) NF-kappa B is one regulator of resistance to apoptosis; and 6) BaCaT cells have undetectable p16 protein (hypermethylation of the promoter), dysfunctional NF-kappa B, and diminished capacity to respond to antiproliferative treatments, and they remain highly sensitive to apoptosis with cleavage of caspases 3 and 8. These data indicate that KCs (but not HaCaT cells) undergoing abruptly induced cell cycle arrest or senescence become resistant to apoptosis requiring properly regulated activation of NF-kappa B but not early differentiation.	Loyola Univ, Med Ctr, Skin Canc Res Labs, Dept Pathol,Cardinal Bernadin Canc Ctr, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Radiat Oncol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Med, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago	Nickoloff, BJ (corresponding author), Loyola Univ, Med Ctr, Skin Canc Res Labs, Dept Pathol,Cardinal Bernadin Canc Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA.	bnickol@luc.edu	Choubey, Divaker/A-4771-2008		NCI NIH HHS [R0-1CA49133] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049133] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campbell T, 1998, EXOT PET PRACT, V3, P1; Dang CV, 1999, MOL CELL BIOL, V19, P1; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOTTO P, 1998, FRONT BIOSCI, V3, P502; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; Flatt PM, 1998, CELL GROWTH DIFFER, V9, P535; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; Fusenig NE, 1998, MOL CARCINOGEN, V23, P144, DOI 10.1002/(SICI)1098-2744(199811)23:3<144::AID-MC3>3.0.CO;2-U; Garrido C, 1997, CANCER RES, V57, P2661; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; HAAKE AR, 1993, J INVEST DERMATOL, V101, P107, DOI 10.1111/1523-1747.ep12363594; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harvat BL, 1998, J CELL SCI, V111, P1185; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LILES WC, 1995, J IMMUNOL, V155, P2175; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LINSKENS MHK, 1995, SCIENCE, V267, P17, DOI 10.1126/science.7848496; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Loughran O, 1996, ONCOGENE, V13, P561; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Mitra RS, 1997, LAB INVEST, V76, P99; NICKOLOFF BJ, 1988, DERMATOLOGICA, V177, P265, DOI 10.1159/000248577; NICKOLOFF BJ, 1988, AM J PATHOL, V132, P543; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Reed AL, 1996, CANCER RES, V56, P3630; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Saunders N, 1996, J DERMATOL SCI, V13, P98, DOI 10.1016/S0923-1811(96)00535-X; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; Todd C, 1998, AM J PATHOL, V153, P39, DOI 10.1016/S0002-9440(10)65543-5; Tomic-Canic M, 1998, J DERMATOL SCI, V17, P167, DOI 10.1016/S0923-1811(98)00016-4; Vairo G, 1996, ONCOGENE, V13, P1511; VANRUISSEN F, 1994, J CELL SCI, V107, P2219; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WANG E, 1994, J CELL BIOCHEM, V54, P432, DOI 10.1002/jcb.240540410; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WRONESMITH T, 1995, AM J PATHOL, V146, P1079; WroneSmith T, 1997, AM J PATHOL, V151, P1321; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	61	181	189	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23358	23367		10.1074/jbc.274.33.23358	http://dx.doi.org/10.1074/jbc.274.33.23358			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438513	hybrid			2022-12-25	WOS:000082012800063
J	Louis, JM; Wondrak, EM; Kimmel, AR; Wingfield, PT; Nashed, NT				Louis, JM; Wondrak, EM; Kimmel, AR; Wingfield, PT; Nashed, NT			Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GAG-POL POLYPROTEIN; PARTICLE MATURATION; TRANSFRAME REGION; VIRAL INFECTIVITY; PROTEINASE; CLEAVAGE; ACTIVATION; INHIBITION; SEQUENCES	Previously it was demonstrated using a model precursor that processing at the N terminus of the HIV-1 protease (PR) precedes processing at its C terminus. We now show the expression, purification, and kinetics of the autoprocessing reaction of a PR precursor linked to 53 amino acids of the native flanking transframe region (Delta TFP-p6(pol)) of Gag-Pol and containing its two native cleavage sites. The PR contains the two cysteine residues exchanged to alanines, mutations that do not alter the kinetics or the structural stability of the mature PR. Delta TFP-p6(pol)-PR, which encompasses the known PR inhibitor sequence Glu-Asp-Leu within Delta TFP, undergoes cleavage at the Delta TFP/p6(pol) and p6(pol)/PR sites in two consecutive steps to produce the mature PR. Both Delta TFP-p6(pol)-PR and p6(pol)-PR exhibit low intrinsic enzymatic activity. The appearance of the mature PR is accompanied by a large increase in catalytic activity, It follows first-order kinetics in protein concentration with a rate constant of 0.13 +/- 0.01 min(-1) in 0.1 ar acetate at pH 4.8, The pH-rate profile for the observed first-order rate constant is bell-shaped with two ionizable groups of pK(a) 4.9 and 5.1. The rate constant also exhibits approximately 7-fold higher sensitivity to urea denaturation as compared with that of the mature PR, suggesting that the cleavage at the N terminus of the PR domain from the precursor leads to the stabilization of the dimeric structure.	NIH, Phys Chem Lab, NIDDK, Bethesda, MD 20892 USA; NIH, Cellular & Dev Biol Lab, NIDDK, Bethesda, MD 20892 USA; NIH, Lab Protein Express, NIAMS, Bethesda, MD 20892 USA; NIH, NIDDK, Lab Bioorg Chem, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Louis, JM (corresponding author), NIH, Phys Chem Lab, NIDDK, Bldg 5,Room 411, Bethesda, MD 20892 USA.	jmlouis@helix.nih.gov		Wingfield, Paul/0000-0002-9515-4752; Louis, John M/0000-0002-0052-1899	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041115, Z01AR041115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015503] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALJANABI J, 1972, J BIOL CHEM, V247, P4628; Beissinger M, 1996, EUR J BIOCHEM, V237, P383, DOI 10.1111/j.1432-1033.1996.0383k.x; BOUTELJE J, 1990, ARCH BIOCHEM BIOPHYS, V283, P141, DOI 10.1016/0003-9861(90)90624-8; CANDOTTI D, 1994, CR ACAD SCI III-VIE, V317, P183; CHENG YSE, 1990, GENE, V87, P243, DOI 10.1016/0378-1119(90)90308-E; CO E, 1994, BIOCHEMISTRY-US, V33, P1248, DOI 10.1021/bi00171a027; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IDO E, 1991, J BIOL CHEM, V266, P24359; KAPLAN AH, 1994, J VIROL, V68, P6782, DOI 10.1128/JVI.68.10.6782-6786.1994; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KARACOSTAS V, 1993, VIROLOGY, V193, P661, DOI 10.1006/viro.1993.1174; Khan AR, 1998, PROTEIN SCI, V7, P815; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LOEB DD, 1989, J VIROL, V63, P111, DOI 10.1128/JVI.63.1.111-121.1989; LOUIS JM, 1991, ADV EXP MED BIOL, V306, P499; Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x; LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; PARTIN K, 1991, P NATL ACAD SCI USA, V88, P4776, DOI 10.1073/pnas.88.11.4776; PEPINSKY RB, 1991, ANAL BIOCHEM, V195, P177, DOI 10.1016/0003-2697(91)90315-K; PHYLIP LH, 1992, FEBS LETT, V314, P449, DOI 10.1016/0014-5793(92)81524-P; POLGAR L, 1994, BIOCHEMISTRY-US, V33, P9351, DOI 10.1021/bi00197a040; ROSE JR, 1995, J VIROL, V69, P2751; Segel I.H., 1975, ENZYME KINETICS, P892; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tessmer U, 1998, J VIROL, V72, P3459, DOI 10.1128/JVI.72.4.3459-3463.1998; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; Vogt VM, 1996, CURR TOP MICROBIOL, V214, P95; WONDRAK EM, 1993, FEBS LETT, V333, P21, DOI 10.1016/0014-5793(93)80367-4; Wondrak EM, 1996, BIOCHEMISTRY-US, V35, P12957, DOI 10.1021/bi960984y; Wondrak EM, 1996, J BIOL CHEM, V271, P4477, DOI 10.1074/jbc.271.8.4477; Wu J, 1998, BIOCHEMISTRY-US, V37, P4518, DOI 10.1021/bi972183g; ZYBARTH G, 1994, J VIROL, V68, P240, DOI 10.1128/JVI.68.1.240-250.1994; ZYBARTH G, 1995, J VIROL, V69, P3878, DOI 10.1128/JVI.69.6.3878-3884.1995	37	54	54	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23437	23442		10.1074/jbc.274.33.23437	http://dx.doi.org/10.1074/jbc.274.33.23437			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438521	hybrid			2022-12-25	WOS:000082012800071
J	Handschuh, G; Candidus, S; Luber, B; Reich, U; Schott, C; Oswald, S; Becke, H; Hutzler, P; Birchmeier, W; Hofler, H; Becker, KF				Handschuh, G; Candidus, S; Luber, B; Reich, U; Schott, C; Oswald, S; Becke, H; Hutzler, P; Birchmeier, W; Hofler, H; Becker, KF			Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility	ONCOGENE			English	Article						E-cadherin; gastric carcinoma; cell adhesion; motility; morphology	TRANSCRIPTION FACTOR LEF-1; ALPHA-CATENIN EXPRESSION; HUMAN GASTRIC CARCINOMAS; BETA-CATENIN; GENE-MUTATIONS; FUNCTIONAL INTERACTION; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS	A major function of the cell-to-cell adhesion molecule E-cadherin is the maintenance of cell adhesion and tissue integrity. E-cadherin deficiency in rumours leads to changes in cell morphology and motility, so that E-cadherin is considered to be a suppressor of invasion. In this study we investigated the functional consequences of three tumour-associated gene mutations that affect the extracellular portion of E-cadherin: in-frame deletions of exons 8 or 9 and a point mutation in exon 8, as they were found in human gastric carcinomas. Human MDA-MB-435S breast carcinoma cells and mouse L fibroblasts were stably transfected with the wild-type and mutant cDNAs, and the resulting changes in localization of E-cadherin, cell morphology, strength of calcium-dependent aggregation as well as cell motility and actin cytoskeleton organization were studied. We found that cells transfected with wild-ty pe E-cadherin showed an epitheloid morphology, while all cell lines expressing mutant E-cadherin exhibited more irregular cell shapes. Cells expressing E-cadherin mutated in exon 8 showed the most scattered appearance, whereas cells with deletion of exon 9 had an intermediate state, Mutant E-cadherins were localized to the lateral regions of cell-to-cell contact sites. Additionally, both exon 8-mutated E-cadherins showed apical and perinuclear localization, and actin filaments were drastically reduced. MDA-MB-435S cells with initial calcium-dependent cell aggregation exhibited decreased aggregation and, remarkably, increased cell motility, when mutant E-cadherin was expressed. Therefore, we conclude that these E-cadherin mutations may not simply affect cell adhesion but may act in a trans-dominant-active manner, i.e. lead to increased cell motility. Our study suggests that E-cadherin mutations affecting exons 8 or 9 are the cause of multiple morphological and functional disorders and could induce the scattered morphology and the invasive behaviour of diffuse type-gastric carcinomas.	GSF Forschungszentrum Umwelt & Gesundheit, Inst Pathol, D-85764 Neuherberg, Germany; Tech Univ Munich, Klinikum Rechts Isar, D-81675 Munich, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Becker, KF (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Ismaningerstr 22, D-81675 Munich, Germany.		Becker, Karl-Friedrich/D-3636-2015	Becker, Karl-Friedrich/0000-0002-6801-4498				Alattia JR, 1997, FEBS LETT, V417, P405, DOI 10.1016/S0014-5793(97)01333-1; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Bailey T, 1998, AM J PATHOL, V152, P135; BECKER KF, 1993, HUM MOL GENET, V2, P803, DOI 10.1093/hmg/2.6.803; BECKER KF, 1994, CANCER RES, V54, P3845; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BEHRENS J, 1991, EXP SUPPL, V59, P109; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; Berx G, 1996, ONCOGENE, V13, P1919; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; Candidus S, 1996, CANCER RES, V56, P49; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; Chen HY, 1997, J CELL SCI, V110, P345; Coman DR, 1944, CANCER RES, V4, P625; CUNNINGHAM BA, 1984, P NATL ACAD SCI-BIOL, V81, P5787, DOI 10.1073/pnas.81.18.5787; Dahl U, 1996, DEVELOPMENT, V122, P2895; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; Gabbert HE, 1996, INT J CANCER, V69, P184, DOI 10.1002/(SICI)1097-0215(19960621)69:3<184::AID-IJC6>3.0.CO;2-W; Gayther SA, 1998, CANCER RES, V58, P4086; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hay ED, 1995, ACTA ANAT, V154, P8; Hedrick Lora, 1993, Trends in Cell Biology, V3, P36, DOI 10.1016/0962-8924(93)90148-T; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Hertig CM, 1996, J CELL SCI, V109, P1; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken Joerg, 1994, Journal of Cell Biology, V127, P2061; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KANAI Y, 1994, JPN J CANCER RES, V85, P1035, DOI 10.1111/j.1349-7006.1994.tb02902.x; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Masuda A, 1996, ONCOGENE, V12, P2081; MATSUI S, 1994, VIRCHOWS ARCH, V424, P375; MAYER B, 1993, CANCER RES, V53, P1690; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MURRAY AB, 1991, BIOTECH HISTOCHEM, V66, P269, DOI 10.3109/10520299109109985; Muta H, 1996, JPN J CANCER RES, V87, P843, DOI 10.1111/j.1349-7006.1996.tb02109.x; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OKA H, 1993, CANCER RES, V53, P1696; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; PIGNATELLI M, 1994, J PATHOL, V174, P243, DOI 10.1002/path.1711740403; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; ROSAI J, 1989, ACKERMANNS SURG PATH, V1; ROSAI J, 1989, ACKERMANNS SURG PATH, V3; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Shibata T, 1996, CANCER LETT, V99, P147, DOI 10.1016/0304-3835(95)04047-1; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHINO Y, 1995, CANCER, V76, P2193, DOI 10.1002/1097-0142(19951201)76:11<2193::AID-CNCR2820761104>3.0.CO;2-2; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Streit M, 1996, J MOL MED-JMM, V74, P253, DOI 10.1007/s001090050027; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAHARA E, 1993, J CANCER RES CLIN, V119, P265, DOI 10.1007/BF01212724; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; Zhu AJ, 1996, J CELL SCI, V109, P3013; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	84	174	176	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4301	4312		10.1038/sj.onc.1202790	http://dx.doi.org/10.1038/sj.onc.1202790			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439038				2022-12-25	WOS:000081732700003
J	Huang, WB; Shostak, Y; Tarr, P; Sawyers, C; Carey, M				Huang, WB; Shostak, Y; Tarr, P; Sawyers, C; Carey, M			Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; RESPONSIVE ELEMENT; ESTROGEN-RECEPTOR; BINDING DOMAINS; GENE-EXPRESSION; PROTEIN COMPLEX; DNA-BINDING; CELL-FREE; IN-VITRO	Prostate cancer is characterized by elevated serum levels of prostate-specific antigen (PSA), PSA gene expression is controlled by an androgen-responsive transcriptional enhancer, Our study suggests that formation of a nucleoprotein complex, encompassing 170 base pairs of enhancer DNA, mediates androgen-responsive PSA enhancer activity. The complex is assembled by cooperative binding of androgen receptor to at least four tandem, nonconsensus androgen response elements (AREs). Systematic mutagenesis of the AREs demonstrated that they act synergistically to stimulate androgen receptor-responsive gene expression. We discuss a mechanism whereby a combination of high androgen receptor levels in the prostate and low affinity AREs contribute to the cell type specificity and activity of the enhancer.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Carey, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Box 1737, Los Angeles, CA 90095 USA.		Sawyers, Charles/G-5327-2016	Carey, Michael/0000-0003-3899-6280	NCI NIH HHS [CA76682] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA076682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Cheng L, 1996, J NATL CANCER I, V88, P607, DOI 10.1093/jnci/88.9.607; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; DEVOS P, 1994, NUCLEIC ACIDS RES, V22, P1161, DOI 10.1093/nar/22.7.1161; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gotoh A, 1998, J UROLOGY, V160, P220, DOI 10.1016/S0022-5347(01)63094-5; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KALLIO PJ, 1994, J BIOL CHEM, V269, P11514; KANG T, 1993, J BIOL CHEM, V268, P9629; KASPER S, 1994, J BIOL CHEM, V269, P31763; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LIMONTA P, 1995, J STEROID BIOCHEM, V53, P401, DOI 10.1016/0960-0760(95)00086-F; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUKE MC, 1994, J ANDROL, V15, P41; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; ONATE SA, 1995, SCIENCE, V270, P1354; PANG S, 1995, HUM GENE THER, V6, P1417, DOI 10.1089/hum.1995.6.11-1417; Pang S, 1997, CANCER RES, V57, P495; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Rodriguez R, 1997, CANCER RES, V57, P2559; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Sun ZJ, 1997, NUCLEIC ACIDS RES, V25, P3318, DOI 10.1093/nar/25.16.3318; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; WARRIAR N, 1993, J STEROID BIOCHEM, V46, P699, DOI 10.1016/0960-0760(93)90311-J; WONG CI, 1993, J BIOL CHEM, V268, P19004; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhang SB, 1997, BIOCHEM BIOPH RES CO, V231, P784, DOI 10.1006/bbrc.1997.6197	59	126	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25756	25768		10.1074/jbc.274.36.25756	http://dx.doi.org/10.1074/jbc.274.36.25756			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464314	hybrid			2022-12-25	WOS:000082554200078
J	McIntosh, DB; Woolley, DG; MacLennan, DH; Vilsen, B; Andersen, JP				McIntosh, DB; Woolley, DG; MacLennan, DH; Vilsen, B; Andersen, JP			Interaction of nucleotides with Asp(351) and the conserved phosphorylation loop of sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ADENOSINE-TRIPHOSPHATASE; CATALYTIC SITE; CA2+ BINDING; ATP-BINDING; FUNCTIONAL CONSEQUENCES; ACTIVE-SITE; CA-2+-ATPASE; CA-2+; MODULATION	The nucleotide binding properties of mutants with alterations to Asp(351) and four of the other residues in the conserved phosphorylation loop, (351)DKTGTLT(357), Of sarcoplasmic reticulum Ca2+-ATPase were investigated using an assay based on the 2',3'-O-(2,4,6-trinitrophenyl)-8-azidoadenosine triphosphate (TNP-8N(3)-ATP) photolabeling of Lys(492) and competition with ATP, In selected cases where the competition assay showed extremely high affinity, ATP binding was also measured by a direct filtration assay, At pH 8.5 in the absence of Ca2+,mutations removing the negative charge of Asp351 (D351N, D351A, and D351T) produced pumps that bound MgTNP-8N(3)-ATP and MgATP with affinities 20-156-fold higher than wild type (K-D as low as 0.006 mu M), whereas the affinity of mutant D351E was comparable with wild type. Mutations K352R, K352Q, T355A, and T357A lowered the affinity for MgATP and MgTNP-8N(3)-ATP 2-1000- and 1-6-fold, respectively, and mutation L356T completely prevented photolabeling of Lys492. In the absence of Ca2+, mutants D351N and D351A exhibited the highest nucleotide affinities in the presence of Mg2+ and at alkaline pH (El state). The affinity of mutant D351A for MgATP was extraordinarily high in the presence of Ca2+ (K-D = 0.001 mu M), suggesting a transition state like configuration at the active site under these conditions. The mutants with reduced ATP affinity, as well as mutants D351N and D351A, exhibited reduced or zero CrATP-induced Ca2+ occlusion due to defective CrATP binding.	Univ Cape Town, Sch Med, Dept Chem Pathol, ZA-7925 Cape Town, South Africa; Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Aarhus Univ, Dept Physiol, DK-8000 Aarhus, Denmark	University of Cape Town; University of Toronto; Aarhus University	McIntosh, DB (corresponding author), Univ Cape Town, Sch Med, Dept Chem Pathol, ZA-7925 Cape Town, South Africa.			Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382				ANDERSEN JP, 1985, BIOCHIM BIOPHYS ACTA, V815, P9, DOI 10.1016/0005-2736(85)90467-5; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; DEGANI C, 1973, J BIOL CHEM, V248, P8222; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; FORGE V, 1993, J BIOL CHEM, V268, P10953; GREEN NM, 1989, BIOCHEM SOC T, V17, P970; GUTOWSKIECKEL Z, 1993, FEBS LETT, V324, P314, DOI 10.1016/0014-5793(93)80142-H; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; INESI G, 1980, J BIOL CHEM, V255, P3025; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LEVY D, 1990, J BIOL CHEM, V265, P19524; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MCINTOSH DB, 1994, J BIOL CHEM, V269, P21587; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MINTZ E, 1995, J BIOL CHEM, V270, P27160, DOI 10.1074/jbc.270.45.27160; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; Pedersen PA, 1996, BIOCHEMISTRY-US, V35, P16085, DOI 10.1021/bi961614c; PICKART CM, 1984, J BIOL CHEM, V259, P1629; REINSTEIN J, 1993, BIOCHEMISTRY-US, V32, P6632, DOI 10.1021/bi00077a016; SAGARA V, 1991, J BIOL CHEM, V267, P1286; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; Suzuki H, 1996, J BIOL CHEM, V271, P5481, DOI 10.1074/jbc.271.10.5481; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; VILSEN B, 1995, ACTA PHYSIOL SCAND, V154, P1; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	40	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25227	25236		10.1074/jbc.274.36.25227	http://dx.doi.org/10.1074/jbc.274.36.25227			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464243	hybrid			2022-12-25	WOS:000082554200008
J	Bellio, M; Oliveira, ACSC; Mermelstein, CS; Capella, MAM; Viola, JPB; Levraud, JP; Dosreis, GA; Previato, JO; Mendonca-Previato, L				Bellio, M; Oliveira, ACSC; Mermelstein, CS; Capella, MAM; Viola, JPB; Levraud, JP; Dosreis, GA; Previato, JO; Mendonca-Previato, L			Costimulatory action of glycoinositolphospholipids from Trypanosoma cruzi: increased interleukin 2 secretion and induction of nuclear translocation of the nuclear factor of activated T cells 1	FASEB JOURNAL			English	Article						T cell activation; ceramide; costimulation; Chagas' disease; cytosolic calcium	TRANSCRIPTION FACTOR NFAT1; GENE-EXPRESSION; KAPPA-B; LEISHMANIA-DONOVANI; SIGNAL TRANSDUCTION; IFN-GAMMA; IN-VITRO; CERAMIDE; MACROPHAGES; SPHINGOSINE	The effects of the glycoinositolphospholipids (GIPLs) from Trypanosoma cruzi on T lymphocyte activation were investigated in a mouse T cell hybridoma (DO-11.10), Purified GIPLs from T. cruzi strains Y and G markedly increased IL-2 mRNA transcripts and IL-2 secretion induced by mitogenic anti-CD3 and anti-Thy1 mAbs, This costimulatory function was also revealed by the induction of IL-2 secretion after the simultaneous addition of the T, cruzi GIPLs and either the calcium ionophore A23187 or phorbol ester, The capacity of the GIPL molecule to induce an increase in cytoplasmic calcium levels was also demonstrated, After exposure of T cell hybridoma to GIPL, the nuclear transcription factor NFAT1 became partially dephosphorylated, and its nuclear localization was demonstrated both in the T cell hybridoma and in Balb/c CD3(+) cells. These results demonstrate that T. cruzi GIPL molecules are capable of signaling to T cells and therefore could be valuable tools for the study of T cell activation, besides playing a potential role in subverting the T lymphocyte immune response during T, cruzi infection.	UFRJ, Dept Imunol, Inst Microbiol Prof Paulo de Goes, BR-21941590 Rio De Janeiro, Brazil; UFRJ, ICB, Dept Histol & Embriol, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941590 Rio De Janeiro, Brazil; Inst Nacl Canc, Programa Med Expt, Rio De Janeiro, Brazil; Inst Pasteur, ISERM U277, F-75724 Paris 15, France	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; National Cancer Institute (Inca); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bellio, M (corresponding author), UFRJ, Dept Imunol, Inst Microbiol Prof Paulo de Goes, CCS Bl 1-2 Andar Sala 12-053, BR-21941590 Rio De Janeiro, Brazil.		Capella, Marcia/F-1097-2013; Oliveira, Ana Carolina/GRF-1435-2022; Oliveira, Ana Carolina/O-6791-2014; Viola, Joao P.B./AAP-4125-2020; mermelstein, Claudia S/C-1464-2010; Bellio, Maria/N-8525-2018	Capella, Marcia/0000-0001-8407-9235; Oliveira, Ana Carolina/0000-0002-0036-3720; Viola, Joao P.B./0000-0002-0698-3146; mermelstein, Claudia S/0000-0002-8897-8526; Bellio, Maria/0000-0002-3360-2740; DosReis, George/0000-0002-8924-4727; Previato, Jose Osvaldo/0000-0002-9233-9954; Mendonca Previato, Lucia/0000-0003-3927-3244				Azuara V, 1997, EUR J IMMUNOL, V27, P544, DOI 10.1002/eji.1830270228; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bento CAM, 1996, J IMMUNOL, V157, P4996; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Burleigh BA, 1998, CURR OPIN MICROBIOL, V1, P461, DOI 10.1016/S1369-5274(98)80066-0; Camargo MM, 1997, J IMMUNOL, V159, P6131; Carreira JC, 1996, GLYCOCONJUGATE J, V13, P955, DOI 10.1007/BF01053191; CHAN G, 1995, EUR J IMMUNOL, V25, P1999, DOI 10.1002/eji.1830250730; CHELLY J, 1990, EUR J BIOCHEM, V187, P691, DOI 10.1111/j.1432-1033.1990.tb15355.x; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DELASSUS S, 1994, J IMMUNOL, V152, P2411; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; DESCOTEAUX A, 1991, J IMMUNOL, V146, P2747; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Freire-de-Lima CG, 1998, J IMMUNOL, V161, P4909; Gazzinelli RT, 1997, CHEM IMMUNOL, V68, P136; Ghosh P, 1996, J BIOL CHEM, V271, P7700, DOI 10.1074/jbc.271.13.7700; GOLGHER DB, 1993, MOL BIOCHEM PARASIT, V60, P249, DOI 10.1016/0166-6851(93)90136-L; Gomes NA, 1996, J IMMUNOL, V156, P628; GOTTLIEB M, 1978, EXP PARASITOL, V45, P200, DOI 10.1016/0014-4894(78)90060-7; GOTTLIEB M, 1977, J IMMUNOL, V119, P465; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hashizume T, 1998, BIOCHEM MOL BIOL INT, V44, P489; HO AM, 1994, J BIOL CHEM, V269, P28181; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; KAPPLER J, 1986, HDB EXPT IMMUNOLOGY, V2; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; LOPES MF, 1995, J IMMUNOL, V154, P744; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MATTHIAS S, 1993, SCIENCE, V259, P519; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; Michel C, 1997, FEBS LETT, V416, P153, DOI 10.1016/S0014-5793(97)01187-3; MINOPRIO P, 1989, IMMUNOL REV, V112, P187; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; Proudfoot L, 1996, P NATL ACAD SCI USA, V93, P10984, DOI 10.1073/pnas.93.20.10984; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; Routier Francoise, 1993, Ciencia e Cultura (Sao Paulo), V45, P66; Sakano S, 1996, J BIOL CHEM, V271, P11148, DOI 10.1074/jbc.271.19.11148; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SMITH SW, 1974, J BIOL CHEM, V249, P3395; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tokura Y, 1996, J INVEST DERMATOL, V107, P34, DOI 10.1111/1523-1747.ep12297849; UMLAUF SW, 1995, MOL CELL BIOL, V15, P3197; XAVIER MT, 1991, CULT J BRAZ ASS ADV, V43, P49; YAGUE J, 1985, CELL, V42, P81, DOI 10.1016/S0092-8674(85)80103-3; YANG ZH, 1993, J BIOL CHEM, V268, P20520	57	13	13	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1627	1636		10.1096/fasebj.13.12.1627	http://dx.doi.org/10.1096/fasebj.13.12.1627			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463955				2022-12-25	WOS:000082347600019
J	Klatt, P; Molina, EP; De Lacoba, MG; Padilla, CA; Martinez-Galisteo, E; Barcena, JA; Lamas, S				Klatt, P; Molina, EP; De Lacoba, MG; Padilla, CA; Martinez-Galisteo, E; Barcena, JA; Lamas, S			Redox regulation of c-Jun DNA binding by reversible S-glutathiolation	FASEB JOURNAL			English	Article						glutathione; redox regulation; S; thiolation; transcription factor	THIOLTRANSFERASE GLUTAREDOXIN; INSULIN DISULFIDES; OXIDATIVE STRESS; NITRIC-OXIDE; RAT-LIVER; PROTEIN; FOS; THIOREDOXIN; THIOLATION; REDUCTION	Redox control of the transcription factor c-Jun maps to a single cysteine in its DNA binding domain. However, the nature of the oxidized state of this cysteine and, thus, the potential molecular mechanisms accounting for the redox regulation of c-Jun DNA binding remain unclear. To address this issue, we have analyzed the purified recombinant c-Jun DNA binding domain for redox-dependent thiol modifications and concomitant changes in DNA binding activity. We show that changes in the ratio of reduced to oxidized glutathione provide the potential to oxidize c-Jun sulfhydryls by mechanisms that include both protein disulfide formation and S-glutathiolation, We provide evidence that S-glutathiolation, which is specifically targeted to the cysteine residue located in the DNA binding site of the protein, may account for the reversible redox regulation of c-Jun DNA binding. Furthermore, based on a molecular model of the S-glutathiolated protein, we discuss the structural elements facilitating S-glutathiolation and how this modification interferes with DNA binding, Given the structural similarities between the positively charged cysteine-containing DNA binding motif of c-Jun and the DNA binding site of related oxidant-sensitive transcriptional activators, the unprecedented phenomenon of redox-triggered S-thiolation of a transcription factor described in this report suggests a novel role for protein thiolation in the redox control of transcription.	CSIC, Ctr Invest Biol, Dept Estructura & Func Prot, Inst Reina Invest Nefrol, E-28006 Madrid, Spain; Univ Cordoba, Fac Vet, Dept Bioquim & Biol Mol, E-14071 Cordoba, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universidad de Cordoba	Klatt, P (corresponding author), CSIC, Ctr Invest Biol, Dept Estructura & Func Prot, Inst Reina Invest Nefrol, Velazquez 144, E-28006 Madrid, Spain.		Padilla, C. Alicia/H-4736-2015; Bárcena, José Antonio/I-2622-2015; Lamas, Santiago/G-7308-2015; Pineda-Molina, Estela/K-9969-2014	Padilla, C. Alicia/0000-0002-9503-8284; Bárcena, José Antonio/0000-0002-5626-5943; Lamas, Santiago/0000-0001-5166-4155; Pineda-Molina, Estela/0000-0002-4266-0192				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BUSHWELLER JH, 1997, EUR J BIOCHEM, V235, P1585; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Gergel D, 1996, BIOCHEMISTRY-US, V35, P16186, DOI 10.1021/bi962043r; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nikitovic D, 1998, BIOCHEM BIOPH RES CO, V242, P109, DOI 10.1006/bbrc.1997.7930; OEHLER T, 1993, ONCOGENE, V8, P1141; Padilla CA, 1996, FEBS LETT, V378, P69; PAJARES MA, 1992, J BIOL CHEM, V267, P17598; PEREIRA MEF, 1998, J BIOL CHEM, V273, P12703; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SIES H, 1975, EUR J BIOCHEM, V57, P503, DOI 10.1111/j.1432-1033.1975.tb02325.x; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, METHOD ENZYMOL, V234, P163; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	37	232	236	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1481	1490		10.1096/fasebj.13.12.1481	http://dx.doi.org/10.1096/fasebj.13.12.1481			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463938				2022-12-25	WOS:000082347600002
J	Schliess, F; Wiese, S; Haussinger, D				Schliess, F; Wiese, S; Haussinger, D			Osmotic regulation of the heat shock response in H4IIE rat hepatoma cells	FASEB JOURNAL			English	Article						MAP kinase; JNK; heat; c-Jun; Hsp70; MKP-1; cell volume; arsenite	PROTEIN-KINASE; TAUROCHOLATE EXCRETION; HSP70 EXPRESSION; STRESS PROTEINS; GENE-EXPRESSION; PATHWAY; LIVER; ACTIVATION; VOLUME; THERMOTOLERANCE	The influence of cell hydration on the heat shock response was investigated in H4IIE hepatoma cells at the levels of HSP70 expression, MAP kinase activation, induction of c-jun and the RAP kinase phosphatase MKP-1, heat resistance, and development of tolerance/sensitization to arsenite after a priming heat treatment. Induction of HSP70, MKP-1, and c-jun by heat was delayed, but more pronounced or sustained, under hyperosmotic conditions compared with normo- and hypo-osmotically exposed cells. Anisosmolarity per sc was ineffective to induce HSP70; some expression of the mRNAs for MKP-1 and c-jun in response to hyperosmolarity nas found, but was small compared with the response to heat. Heat-induced activation of JNK-1 was increased under hyperosmotic conditions and more sustained than the JNK-activity induced by hyperosmolarity at 37 degrees C, A prominent Erk-2 activation was found immediately after heat shock under hypo- and normo-osmotic conditions, but Erk-2 activation was weak in hyperosmolarity-exposed cells. Despite anisosmotic alterations of the heat shock response at the molecular level, the heat resistance of H4IIE cells toward heat shock was not affected by ambient osmolarity, However, an osmolarity-dependent sensitization to arsenite was: induced by a priming heat shock. The osmodependence of the H4IIE cell response to heat differs from that recently found in primary rat hepatocytes, The data are discussed in terms of cellular adaption mechanisms and their physiological relevance.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-4000 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Haussinger, D (corresponding author), Univ Dusseldorf, Med Einrichtungen, Klin Gastroenterol, Moorenstr 5, D-40225 Dusseldorf, Germany.							Bisht K. S., 1996, Indian Journal of Experimental Biology, V34, P1183; Cantoni O, 1996, FEBS LETT, V389, P285, DOI 10.1016/0014-5793(96)00605-9; Caruccio L, 1997, BIOCHEM J, V327, P341, DOI 10.1042/bj3270341; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COWLEY DB, 1995, AM J PHYSIOL, V269, pF854; FINKENZELLER G, 1994, FEBS LETT, V340, P163, DOI 10.1016/0014-5793(94)80129-0; HALLBRUCKER C, 1992, BIOCHEM J, V281, P593, DOI 10.1042/bj2810593; HAUSSINGER D, 1992, TRENDS PHARMACOL SCI, V13, P371, DOI 10.1016/0165-6147(92)90114-L; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; Hightower LE, 1997, HEPATOLOGY, V25, P1279, DOI 10.1002/hep.510250539; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KLEMPERER NS, 1989, J BIOL CHEM, V264, P19245; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; Kurz AK, 1998, HEPATOLOGY, V28, P774, DOI 10.1002/hep.510280326; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LI DX, 1995, EUR J BIOCHEM, V231, P454, DOI 10.1111/j.1432-1033.1995.tb20719.x; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; PARSELL DA, 1993, PHILOS T R SOC B, V339, P279, DOI 10.1098/rstb.1993.0026; PETRONINI PG, 1993, BIOCHEM J, V293, P553, DOI 10.1042/bj2930553; Rauchman MI, 1997, AM J PHYSIOL-RENAL, V273, pF9, DOI 10.1152/ajprenal.1997.273.1.F9; SAHA N, 1992, EUR J BIOCHEM, V209, P437, DOI 10.1111/j.1432-1033.1992.tb17307.x; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SATO N, 1991, ENDOCRINOLOGY, V129, P2541, DOI 10.1210/endo-129-5-2541; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; Schliess F, 1998, ARCH BIOCHEM BIOPHYS, V351, P35, DOI 10.1006/abbi.1997.0517; SHEIKHHAMAD D, 1994, AM J PHYSIOL, V267, pF28, DOI 10.1152/ajprenal.1994.267.1.F28; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wettstein M, 1997, HEPATOLOGY, V26, P1560; Wiese S, 1998, BIOL CHEM, V379, P667, DOI 10.1515/bchm.1998.379.6.667; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	35	19	19	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1557	1564		10.1096/fasebj.13.12.1557	http://dx.doi.org/10.1096/fasebj.13.12.1557			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463947				2022-12-25	WOS:000082347600011
J	Schmid, E; Hotz-Wagenblatt, A; Hack, V; Droge, W				Schmid, E; Hotz-Wagenblatt, A; Hack, V; Droge, W			Phosphorylation of the insulin receptor kinase by phosphocreatine in combination with hydrogen peroxide: the structural basis of redox priming	FASEB JOURNAL			English	Article						insulin responsiveness; redox regulation; signal transduction; tyrosine kinase	DEPENDENT DIABETES-MELLITUS; PROTEIN-TYROSINE KINASE; CRYSTAL-STRUCTURE; SKELETAL-MUSCLE; GLUCOSE-TOLERANCE; RAT ADIPOCYTES; FREE-RADICALS; BETA-SUBUNIT; INTACT-CELLS; AUTOPHOSPHORYLATION	Signaling by insulin requires autophosphorylation of the insulin receptor kinase (IRK) at Tyr1158, Tyr1162, and Tyr1163, Earlier experiments with P-32-gamma-ATP indicated that the nonphosphorylated IRK (IRK-0P) is relatively inactive, and crystallogaphic data indicated that the ATP binding site of IRK-OP is blocked by its activation loop. We now show that phosphocreatine (PCr) in combination with hydrogen peroxide serves as an alternative phosphate donor and that ATP and PCr use distinct binding sites. Whereas phosphorylation of the Wt by ATP is inhibited by the nonhydrolyzable competitor adenylyl-imidodiphosphate, phosphorylation by PCr is enhanced, The IRK mutant Try1158Phe showed no phosphorylation with PCr but almost normal phosphorylation with ATP, whereas: Tyr1162Phe was phosphorylated well with PCr but less then normal with ATP, 3-Dimensional models of IRK-OP revealed that the conversion of any of the four cysteine residues 1056, 1138, 1234, and 1245 into sulfenic acid produces structural changes that bring Tyr1158 into close contact with Asp1083 and render the well-known catalytic site at Asp1132 and Tyr1162 accessible from a direction that differs from the known ATP binding site. The mutant Cys1158Ala, in contrast, showed relatively inaccessible catalytic sites and weak catalytic activity in functional experiments, Taken together, these findings indicate that 'redox priming' of the IRK facilitates its autophosphorylation by PCr in the activation loop.	Deutsch Krebsforschungszentrum, Div Immunochem, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Mol Biophys, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Droge, W (corresponding author), Deutsch Krebsforschungszentrum, Div Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							BERNIER M, 1995, BIOCHEMISTRY-US, V34, P8357, DOI 10.1021/bi00026a017; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; CAHILL GF, 1971, DIABETES, V20, P785, DOI 10.2337/diab.20.12.785; Carvalho CRO, 1996, ENDOCRINOLOGY, V137, P151, DOI 10.1210/en.137.1.151; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; Cunningham ME, 1998, EMBO J, V17, P7282, DOI 10.1093/emboj/17.24.7282; DAMSBO P, 1991, DIABETOLOGIA, V34, P239, DOI 10.1007/BF00405082; DAVIES KJA, 1982, BIOCHEM BIOPH RES CO, V107, P1198, DOI 10.1016/S0006-291X(82)80124-1; DeFronzo RA, 1997, DIABETES REV, V5, P177; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; FUKAGAWA NK, 1989, AM J PHYSIOL, V256, pE288, DOI 10.1152/ajpendo.1989.256.2.E288; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Hack V, 1996, FASEB J, V10, P1219, DOI 10.1096/fasebj.10.10.8751725; HAGLER AT, 1974, J AM CHEM SOC, V96, P5327, DOI 10.1021/ja00824a005; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JI LL, 1990, AM J PHYSIOL, V258, pR918, DOI 10.1152/ajpregu.1990.258.4.R918; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KANEMITSU F, 1982, CLIN CHIM ACTA, V119, P307; KING DS, 1995, J APPL PHYSIOL, V78, P17, DOI 10.1152/jappl.1995.78.1.17; KOSHIO O, 1988, BIOCHEM J, V250, P95, DOI 10.1042/bj2500095; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LEW H, 1985, FEBS LETT, V185, P262, DOI 10.1016/0014-5793(85)80919-4; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MACAULAY SL, 1985, BIOCHEM J, V306, P811; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; POOLE LB, 1989, J BIOL CHEM, V264, P12330; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; Schmid E, 1998, FASEB J, V12, P863, DOI 10.1096/fasebj.12.10.863; SCHNEIDER SH, 1992, DIABETES CARE, V15, P1800, DOI 10.2337/diacare.15.11.1800; Segal RA, 1996, J BIOL CHEM, V271, P20175, DOI 10.1074/jbc.271.33.20175; SEN CK, 1994, J APPL PHYSIOL, V77, P2177, DOI 10.1152/jappl.1994.77.5.2177; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STEPHENS RM, 1994, NEURON, V12, P1; Supinski G, 1998, MOL CELL BIOCHEM, V179, P99, DOI 10.1023/A:1006859920875; TAKAYAMA S, 1988, J CLIN ENDOCR METAB, V66, P992, DOI 10.1210/jcem-66-5-992; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; VERTECHY M, 1989, EXP GERONTOL, V24, P211, DOI 10.1016/0531-5565(89)90012-0; Wallberg-Henriksson H, 1992, Exerc Sport Sci Rev, V20, P339; WALLIMANN T, 1994, MOL CELL BIOCHEM, V133, P193, DOI 10.1007/BF01267955; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1987, BIOCHEM J, V245, P325, DOI 10.1042/bj2450325; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	62	69	69	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1491	1500		10.1096/fasebj.13.12.1491	http://dx.doi.org/10.1096/fasebj.13.12.1491			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463939				2022-12-25	WOS:000082347600003
J	Bing, ZY; Reddy, SAG; Ren, YS; Qin, J; Liao, WSL				Bing, ZY; Reddy, SAG; Ren, YS; Qin, J; Liao, WSL			Purification and characterization of the serum amyloid A3 enhancer factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACUTE-PHASE RESPONSE; RAT ALPHA-2-MACROGLOBULIN GENE; POLYMERASE-II TRANSCRIPTION; DNA-BINDING; NUCLEAR FACTOR; HEPATOMA-CELLS; FACTOR LSF; C/EBP-LIKE; PROTEIN	Serum amyloid A (SAA) is a major acute-phase protein synthesized and secreted mainly by the liver. In response to acute inflammation, its expression may be induced up to 1000-fold, primarily as a result of a 200-fold increase in the rate of SAA gene transcription. We showed previously that cytokine-induced transcription of the SAA3 gene promoter requires a transcriptional enhancer that contains three functional elements: two CCAAT/enhancer-binding protein (C/EBP)-binding sites and a third site that interacts with a constitutively expressed transcription factor, SAA3 enhancer factor (SEF), Each of these binding sites as well as cooperation among their binding factors is necessary for maximum transcription activation by inflammatory cytokines. Deletion or site-specific mutations in the SEF-binding site drastically reduced SAA3 promoter activity, strongly suggesting that SEF is important in SAA3 promoter function. To further elucidate its role in the regulation of the SAA3 gene, we purified SEF from HeLa nuclear extracts to near homogeneity by using conventional liquid chromatography and DNA affinity chromatography, Ultraviolet cross-linking and Southwestern experiments indicated that SEF consisted of a single polypeptide with an apparent molecular mass of 65 kDa, Protein sequencing and antibody supershift experiments identified SEF as transcription factor LBP-1c/CP2/LSF. Cotransfection of SEF expression vector with SAA3-luciferase reporter resulted in approximately a 5-fold increase in luciferase activity. Interestingly, interleukin-1 treatment of SEF-transfected cells caused dramatic synergistic activation (31-fold) of the SAA3 promoter. In addition to its role in regulating SAA3 gene expression, we provide evidence that SEF could also bind in a sequence-specific manner to the promoters of the alpha(2)-macroglobulin and A alpha-fibrinogen genes and to an intronic enhancer of the human Wilm's tumor 1 gene, suggesting a functional role in the regulation of these genes.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Liao, WSL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117, Houston, TX 77030 USA.				NIAMS NIH HHS [AR 38858] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038858, R01AR038858] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DEBEER MC, 1991, BIOCHEM J, V280, P45, DOI 10.1042/bj2800045; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GABRIELSEN OS, 1993, METHOD ENZYMOL, V218, P508; GEISTERFER M, 1993, CYTOKINE, V5, P1, DOI 10.1016/1043-4666(93)90017-Y; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HOFFMAN JS, 1982, J BIOL CHEM, V257, P510; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; ITO T, 1989, NUCLEIC ACIDS RES, V17, P9425, DOI 10.1093/nar/17.22.9425; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KOJ A, 1974, STRUCTURE FUNCTION P, P73; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1990, MOL CELL BIOL, V10, P6624, DOI 10.1128/MCB.10.12.6624; LI XX, 1991, J BIOL CHEM, V266, P15192; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; MALIM MH, 1989, J VIROL, V63, P3213, DOI 10.1128/JVI.63.8.3213-3219.1989; MORROW JF, 1981, P NATL ACAD SCI-BIOL, V78, P4718, DOI 10.1073/pnas.78.8.4718; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; OREN M, 1980, P NATL ACAD SCI-BIOL, V77, P220, DOI 10.1073/pnas.77.1.220; Philippe J, 1994, Methods Mol Biol, V31, P349; Romerio F, 1997, J VIROL, V71, P9375, DOI 10.1128/JVI.71.12.9375-9382.1997; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; SHIRRA MK, 1994, MOL CELL BIOL, V14, P5076, DOI 10.1128/MCB.14.8.5076; STEARMAN RS, 1986, NUCLEIC ACIDS RES, V14, P797, DOI 10.1093/nar/14.2.797; STEINMETZ A, 1989, BIOCHIM BIOPHYS ACTA, V1006, P173, DOI 10.1016/0005-2760(89)90192-6; SUNDSETH R, 1992, J BIOL CHEM, V267, P7845; TAGA T, 1990, P219; TONIATTI C, 1990, EMBO J, V9, P4467, DOI 10.1002/j.1460-2075.1990.tb07897.x; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; YAKAR S, 1995, SEMIN ARTHRITIS RHEU, V24, P255, DOI 10.1016/S0049-0172(95)80035-2; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; Zhang XH, 1997, J BIOL CHEM, V272, P29272, DOI 10.1074/jbc.272.46.29272	45	37	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24649	24656		10.1074/jbc.274.35.24649	http://dx.doi.org/10.1074/jbc.274.35.24649			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455131	hybrid			2022-12-25	WOS:000082193400030
J	Bolhuis, A; Venema, G; Quax, WJ; Bron, S; van Dijl, JM				Bolhuis, A; Venema, G; Quax, WJ; Bron, S; van Dijl, JM			Functional analysis of paralogous thiol-disulfide oxidoreductases in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE-I; ESCHERICHIA-COLI GENE; TEMPORALLY CONTROLLED EXPRESSION; BOND FORMATION INVIVO; ALKALINE-PHOSPHATASE; SECRETORY PROTEINS; DNA-BINDING; IDENTIFICATION; ISOMERASE; DSBB	The in vivo formation of disulfide bonds, which is critical for the stability and/or activity of many proteins, is catalyzed by thiol-disulfide oxidoreductases. In the present studies, we show that the Gram-positive eubacterium Bacillus subtilis contains three genes, denoted bdbA, bdbB, and bdbC, for thiol-disulfide oxidoreductases, Escherichia coli alkaline phosphatase, containing two disulfide bonds, was unstable when secreted by B. subtilis cells lacking BdbB or BdbC, and notably, the expression levels of bdbB and bdbC appeared to set a limit for the secretion of active alkaline phosphatase, Cells lacking BdbC also showed decreased stability of cell-associated forms of E. coli TEM-beta-lactamase, containing one disulfide bond. In contrast, BdbA was not required for the stability of alkaline phosphatase or beta-lactamase. Because BdbB and BdbC are typical membrane proteins, our findings suggest that they promote protein folding at the membrane-cell wall interface. Interestingly, pre-beta-lactamase processing to its mature form was stimulated in cells lacking BdbC, suggesting that the unfolded form of this precursor is a preferred substrate for signal peptidase. Surprisingly, cells lacking BdbC did not develop competence for DNA uptake, indicating the involvement of disulfide bond-containing proteins in this process. Unlike E. coli and yeast, none of the thiol-disulfide oxidoreductases of B, subtilis was required for growth in the presence of reducing agents. In conclusion, our observations indicate that BdbB and BdbC have a general role in disulfide bond formation, whereas BdbA may be dedicated to a specific process.	Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands; Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	van Dijl, JM (corresponding author), Univ Groningen, Dept Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	j.m.van.dijl@farm.rug.nl	van Dijl, Jan Maarten/G-1205-2013; Bolhuis, Albert/E-9932-2010; Quax, Wim/K-2802-2012; Quax, Wim/O-2875-2019	Bolhuis, Albert/0000-0001-9307-0515; Quax, Wim/0000-0002-5162-9947; Quax, Wim/0000-0002-5162-9947				Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bolhuis A, 1996, MOL MICROBIOL, V22, P605, DOI 10.1046/j.1365-2958.1996.d01-4676.x; Bolhuis A, 1998, J BIOL CHEM, V273, P21217, DOI 10.1074/jbc.273.33.21217; BRON S, 1972, MUTAT RES, V15, P1, DOI 10.1016/0027-5107(72)90086-3; Chung YS, 1998, MOL MICROBIOL, V29, P905, DOI 10.1046/j.1365-2958.1998.00989.x; Chung YS, 1998, J BACTERIOL, V180, P41, DOI 10.1128/JB.180.1.41-45.1998; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; Herbort M, 1999, J BACTERIOL, V181, P493, DOI 10.1128/JB.181.2.493-500.1999; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; ISHIHARA T, 1995, J BACTERIOL, V177, P745, DOI 10.1128/jb.177.3.745-749.1995; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; KLEIN M, 1994, FEMS MICROBIOL LETT, V124, P393; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KUNST F, 1995, J BACTERIOL, V177, P2403, DOI 10.1128/jb.177.9.2403-2407.1995; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; MEIJER WJJ, 1995, MOL MICROBIOL, V17, P621, DOI 10.1111/j.1365-2958.1995.mmi_17040621.x; Miller J. H., 1982, EXPT MOL GENETICS; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Nicholson WL., 1990, MOL BIOL METHODS BAC, P391, DOI DOI 10.1111/J.1751-1097.1991.TB02087.X; Paik SH, 1998, J BIOL CHEM, V273, P23134, DOI 10.1074/jbc.273.36.23134; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; PAYNE MS, 1991, J BACTERIOL, V173, P2278, DOI 10.1128/JB.173.7.2278-2282.1991; PETERS T, 1982, J BIOL CHEM, V257, P8847; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; SCHULTZ SC, 1987, PROTEINS, V2, P290, DOI 10.1002/prot.340020405; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SMITH H, 1987, J BACTERIOL, V169, P3321, DOI 10.1128/jb.169.7.3321-3328.1987; Sone M, 1997, J BIOL CHEM, V272, P6174, DOI 10.1074/jbc.272.10.6174; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VANDENBURG B, 1993, PROTEIN ENG, V6, P521, DOI 10.1093/protein/6.5.521; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263	49	78	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24531	24538		10.1074/jbc.274.35.24531	http://dx.doi.org/10.1074/jbc.274.35.24531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455116	hybrid			2022-12-25	WOS:000082193400015
J	Hara, R; Selby, CP; Liu, MY; Price, DH; Sancar, A				Hara, R; Selby, CP; Liu, MY; Price, DH; Sancar, A			Human transcription release factor 2 dissociates RNA polymerases I and II stalled at a cyclobutane thymine dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR COUPLING FACTOR; NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM GROUP-C; RIBOSOMAL-RNA; XERODERMA-PIGMENTOSUM; COCKAYNE-SYNDROME; DNA DAMAGE; DEPENDENT TRANSCRIPTION; TERMINATION FACTOR; BINDING-PROPERTIES	RNA polymerase II stalled at a lesion in the transcribed strand is thought to constitute a signal for transcription-coupled repair. Transcription factors that act on RNA polymerase in elongation mode potentially influence this mode of repair. Previously, it was shown that transcription elongation factors TFIIS and Cockayne's syndrome complementation group B protein did not disrupt the ternary complex of RNA polymerase II stalled at a thymine cyclobutane dimer, nor did they enable RNA polymerase II to bypass the dimer, Here we investigated the effect of the transcription factor 2 on RNA polymerase II and RNA polymerase I stalled at thymine dimers. Transcription factor 2 is known to release transcripts from RNA polymerase II early elongation complex generated by pulse-transcription. We found that factor 2 (which is also called release factor) disrupts the ternary complex of RNA polymerase II at a thymine dimer and surprisingly exerts the same effect on RNA polymerase I. These findings show that in mammalian cells a RNA polymerase I or RNA polymerase II transcript truncated by a lesion in the template strand may be discarded unless repair is accomplished rapidly by a mechanism that does not displace stalled RNA polymerases.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Iowa	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Mary Ellen Jones Bldg,CB 7260, Chapel Hill, NC 27599 USA.		Price, David H/F-6173-2010	Liu, Mingyi/0000-0002-8101-8522; Price, David/0000-0002-5597-385X	NIGMS NIH HHS [GM35500, GM32833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500, R01GM032833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayaki H, 1996, J RADIAT RES, V37, P107, DOI 10.1269/jrr.37.107; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CHRISTIANS FC, 1994, MUTAT RES, V323, P179, DOI 10.1016/0165-7992(94)90031-0; CHRISTIANS FC, 1993, BIOCHEMISTRY-US, V32, P10512, DOI 10.1021/bi00090a030; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; FRITZ LK, 1995, BIOCHEMISTRY-US, V34, P13117, DOI 10.1021/bi00040a024; HAAF T, 1991, EXP CELL RES, V193, P78, DOI 10.1016/0014-4827(91)90540-B; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Jansa P, 1998, EMBO J, V17, P2855, DOI 10.1093/emboj/17.10.2855; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEARNED R M, 1982, Journal of Molecular and Applied Genetics, V1, P575; Liu MY, 1998, J BIOL CHEM, V273, P25541, DOI 10.1074/jbc.273.40.25541; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MIESFELD R, 1982, NUCLEIC ACIDS RES, V10, P3933, DOI 10.1093/nar/10.13.3933; Peng J, 1998, COLD SPRING HARB SYM, V63, P365, DOI 10.1101/sqb.1998.63.365; PIERCE JR, 1993, BIOCHEMISTRY-US, V32, P7069, DOI 10.1021/bi00079a002; PRICE DH, 1987, J BIOL CHEM, V262, P3244; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; Schnapp G, 1996, MOL GEN GENET, V252, P412, DOI 10.1007/s004380050245; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; Tijsterman M, 1999, J BIOL CHEM, V274, P1199, DOI 10.1074/jbc.274.3.1199; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; van Oosterwijk MF, 1998, J BIOL CHEM, V273, P13599, DOI 10.1074/jbc.273.22.13599; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Verhage RA, 1996, NUCLEIC ACIDS RES, V24, P1020, DOI 10.1093/nar/24.6.1020; VOS JMH, 1991, MOL CELL BIOL, V11, P2245, DOI 10.1128/MCB.11.4.2245; Xie Z, 1997, J BIOL CHEM, V272, P31902, DOI 10.1074/jbc.272.50.31902; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; Xie Z, 1998, J BIOL CHEM, V273, P3771, DOI 10.1074/jbc.273.6.3771; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	47	46	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24779	24786		10.1074/jbc.274.35.24779	http://dx.doi.org/10.1074/jbc.274.35.24779			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455150	hybrid, Green Published			2022-12-25	WOS:000082193400049
J	Sellers, LA				Sellers, LA			Prolonged activation of extracellular signal-regulated kinase by a protein kinase C-dependent and N17Ras-insensitive mechanism mediates the proliferative response of G(i/o)-coupled somatostatin sst(4) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANALOG SMS 201-995; CELL-PROLIFERATION; GROWTH-FACTOR; TYROSINE PHOSPHATASE; INHIBITION; CANCER; SUBTYPES; INVITRO; SSTR2; PHOSPHORYLATION	The human sst, receptor, recombinantly expressed in Chinese hamster ovary cells, mediates proliferative activity of the peptide hormone somatostatin. This effect was shown to involve activation of pertussis toxin-sensitive G proteins and was inhibited by overexpression of the beta gamma-sequestrant, transducin. Somatostatin-induced proliferation was abolished by the MEK1 inhibitor, PD 98059, whereas the Src inhibitor, PP1, had no effect. A marked increase was observed in the phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1 and ERK2) 10 min after sst, receptor activation, which was blocked by pertussis toxin, decreased by PP1 and the beta gamma-sequestrant, but unaffected by PD 98059. In contrast, the somatostatin-induced phosphorylation of ERK obtained at 4 h, although sensitive to both pertussis toxin and transducin, was unaffected by PP1 but ablated by PD 98059. Protein kinase C inhibition also abolished this somatostatin-induced sustained phosphorylation of ERK together with the associated increase in cell proliferation. Expression of dominant negative Ras (N17) failed to significantly reduce the proliferative effect mediated by the sst, receptor but markedly attenuated the acute phase of the somatostatin-induced phosphorylation of ERK obtained at 10 min. In contrast, the phosphorylation induced at 4 h was unaffected. We conclude that ERK activation by G(i/o)-coupled sst, receptors involves a Src and Ras dependent acute phase, but the proliferative response is dependent upon the prolonged ERK-induced activity, mediated by protein kinase C.	Univ Cambridge, Dept Pharmacol, Glaxo Inst Appl Pharmacol, Cambridge CB2 1QJ, England	University of Cambridge	Sellers, LA (corresponding author), Univ Cambridge, Dept Pharmacol, Glaxo Inst Appl Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.							AKBAR M, 1994, FEBS LETT, V348, P192, DOI 10.1016/0014-5793(94)00603-2; Alderton F, 1998, BRIT J PHARMACOL, V125, P1630, DOI 10.1038/sj.bjp.0702282; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BITO H, 1994, J BIOL CHEM, V269, P12722; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; Charlesworth A, 1997, ONCOGENE, V14, P2323, DOI 10.1038/sj.onc.1201075; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Douziech N, 1999, ENDOCRINOLOGY, V140, P765, DOI 10.1210/en.140.2.765; DY DY, 1992, CANCER RES, V52, P917; ERIKSEN UH, 1995, AM HEART J, V130, P1, DOI 10.1016/0002-8703(95)90227-9; EVERS BM, 1991, ANN SURG, V213, P190, DOI 10.1097/00000658-199103000-00002; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; GERICH JE, 1981, AM J MED, V70, P619, DOI 10.1016/0002-9343(81)90584-2; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hofland LJ, 1996, BAILLIERE CLIN ENDOC, V10, P163, DOI 10.1016/S0950-351X(96)80362-4; HOYER D, 1995, TRENDS PHARMACOL SCI, V16, P86, DOI 10.1016/S0165-6147(00)88988-9; ISHIZUKA J, 1992, BIOCHEM BIOPH RES CO, V185, P577, DOI 10.1016/0006-291X(92)91663-B; KAMIYA Y, 1993, BIOCHEM BIOPH RES CO, V191, P302, DOI 10.1006/bbrc.1993.1217; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAMBERTS SWJ, 1985, J CLIN ENDOCR METAB, V60, P1161, DOI 10.1210/jcem-60-6-1161; Lauder H, 1998, Angiogenesis, V2, P67, DOI 10.1023/A:1009006527462; Lauder H, 1997, BRIT J PHARMACOL, V122, P663, DOI 10.1038/sj.bjp.0701443; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MACAULAY VM, 1991, BRIT J CANCER, V64, P451, DOI 10.1038/bjc.1991.330; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; PAGLIACCI MC, 1991, ENDOCRINOLOGY, V129, P2555, DOI 10.1210/endo-129-5-2555; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; REUBI JC, 1994, CANCER RES, V54, P3455; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RUIZTORRES P, 1993, BIOCHEM BIOPH RES CO, V195, P1057, DOI 10.1006/bbrc.1993.2151; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; Sellers LA, 1999, J BIOL CHEM, V274, P16423, DOI 10.1074/jbc.274.23.16423; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	45	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24280	24288		10.1074/jbc.274.34.24280	http://dx.doi.org/10.1074/jbc.274.34.24280			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446204	hybrid			2022-12-25	WOS:000082110900083
J	Tan, KO; Tan, KML; Yu, VC				Tan, KO; Tan, KML; Yu, VC			A novel BH3-like domain in BID is required for intramolecular interaction and autoinhibition of pro-apoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVAL-PROMOTING PROTEINS; PROGRAMMED CELL-DEATH; BH3 DOMAIN; BCL-2 FAMILY; BAX; DISTINCT; BCL-X(L); BINDING; AGONIST; PHOSPHORYLATION	Upon activation of the Fas apoptotic signaling pathway, Bid, a "BH3 domain-only" pro-apoptotic molecule, is cleaved by caspase-8 into a 6.5-kDa N-terminal and a 15-kDa BH3 domain-containing C-terminal fragment, referred to as t(n)-Bid and t(c)-Bid, respectively. t(c)-Bid is a more potent inducer of apoptosis than full-length Bid, suggesting that the N-terminal region of Bid has an inhibitory effect on its pro-apoptotic activity. Here, we report the identification of a novel BH3-like motif (amino acid residues 35-43) in t(n)-Bid. Although Bid does not homodimerize, t(n)-Bid is able to associate avidly with t(n)-Bid. Site directed mutagenesis revealed that both the novel BH3-like and BH3 domains are necessary for direct binding between t(n)-Bid and t(c)-Bid. While full-length Bid does not associate with t(n)-Bid, substitution of Leu(35) a critical residue in mediating t(n)-Bid/t(c)-Bid interaction, with Ala in full-length Bid is sufficient to establish Bid/t(n)-Bid interaction. Interestingly, the L35A Bid mutant is as effective as t(c)-Bid in inducing apoptosis and binding Bcl-X-L. We propose that the intramolecular interaction involving the BH3-like and BH3 domains serves to regulate the pro-apoptotic potential of Bid.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Yu, VC (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Yu, Victor/A-7899-2015	Yu, Victor/0000-0003-3270-4734; Tan, Kuan/0000-0002-0947-7337; Tan, Karen/0000-0002-7768-037X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bai C, 1997, METHOD ENZYMOL, V283, P141; BOYD JM, 1995, ONCOGENE, V11, P1921; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; PESO LD, 1997, SCIENCE, V278, P687; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	29	47	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23687	23690		10.1074/jbc.274.34.23687	http://dx.doi.org/10.1074/jbc.274.34.23687			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446124	hybrid			2022-12-25	WOS:000082110900003
J	Cherny, RA; Legg, JT; McLean, CA; Fairlie, DP; Huang, XD; Atwood, CS; Beyreuther, K; Tanzi, RE; Masters, CL; Bush, AI				Cherny, RA; Legg, JT; McLean, CA; Fairlie, DP; Huang, XD; Atwood, CS; Beyreuther, K; Tanzi, RE; Masters, CL; Bush, AI			Aqueous dissolution of Alzheimer's disease A beta amyloid deposits by biometal depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENILE PLAQUES; PROTEIN; PEPTIDES; ZINC; AGGREGATION	Zn(II) and Cu(II) precipitate AP in vitro into insoluble aggregates that are dissolved by metal chelators. We now report evidence that these biometals also mediate the deposition of AP amyloid in Alzheimer's disease, since the solubilization of AP from post-mortem brain tissue was significantly increased by the presence of chelators, EGTA, N,N,N',N'-tetrakis(2-pyridyl-methyl) ethylene diamine, and bathocuproine. Efficient extraction of A beta also required Mg(II) and Ca(II), The chelators were more effective in extracting AP from Alzheimer's disease brain tissue than age-matched controls, suggesting that metal ions differentiate the chemical architecture of amyloid in Alzheimer's disease. Agents that specifically chelate copper and zinc ions but preserve Mg(II) and Ca(II) may be of therapeutic value in Alzheimer's disease.	Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Mental Hlth Res Inst, Parkville, Vic 3052, Australia; Univ Queensland, Ctr Drug Design & Drug Dev, Brisbane, Qld 4072, Australia; Harvard Univ, Lab Oxidat Biol, Genet & Aging Unit, Massachusetts Gen Hosp,Sch Med, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02129 USA; Heidelberg Univ, Ctr Mol Biol, D-69120 Heidelberg, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Unit, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02129 USA	University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Queensland; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Ruprecht Karls University Heidelberg; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Bush, AI (corresponding author), Massachusetts Gen Hosp E, Lab Oxidat Biol, Genet & Aging Unit, Bldg 149,13th St, Charlestown, MA 02129 USA.	bush@helix.mgh.harvard.edu	Tanzi, Rudolph/AAE-9622-2019; Fairlie, David P/F-8865-2014; , Craig/AAB-3963-2022; Bush, Ashley/Y-2457-2019; Bush, Ashley I/A-1186-2007	Tanzi, Rudolph/0000-0002-7032-1454; Fairlie, David P/0000-0002-7856-8566; Bush, Ashley/0000-0001-8259-9069; Bush, Ashley I/0000-0001-8259-9069; McLean, Catriona/0000-0002-0302-5727	NIA NIH HHS [5R29AG12686] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG012686] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Du YS, 1997, J NEUROCHEM, V69, P299; HARIGAYA Y, 1995, BIOCHEM BIOPH RES CO, V211, P1015, DOI 10.1006/bbrc.1995.1912; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Kuo YM, 1996, J BIOL CHEM, V271, P4077; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MORISHIMAKAWASH.M, 1998, BICOHEMISTRY, V37, P15248; *NAT I STAND TECHN, 1995, DAT CRIT SEL STAB CO; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; TAMAOKA A, 1994, BIOCHEM BIOPH RES CO, V205, P834, DOI 10.1006/bbrc.1994.2740	23	426	445	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23223	23228		10.1074/jbc.274.33.23223	http://dx.doi.org/10.1074/jbc.274.33.23223			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438495	hybrid			2022-12-25	WOS:000082012800045
J	Rowlinson, SW; Crews, BC; Lanzo, CA; Marnett, LJ				Rowlinson, SW; Crews, BC; Lanzo, CA; Marnett, LJ			The binding of arachidonic acid in the cyclooxygenase active site of mouse prostaglandin endoperoxide synthase-2 (COX-2) - A putative L-shaped binding conformation utilizing the top channel region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HIGHER OXIDATION-STATE; H SYNTHASE-1; INHIBITORS; ARGININE-120; SPECTROSCOPY; TYROSINE-385; CATALYSIS; MEMBRANE; ASPIRIN	The chemical mandates for arachidonic acid conversion to prostaglandin G(2) within the cyclooxygenase (COX) active site predict that the substrate will orient in a kinked or L-shaped conformation. Molecular modeling of arachidonic acid in sheep COX-1 confirms that this L-shaped conformation is possible, with the carboxylate moiety binding to Arg-120 and the omega-end positioned above Ser-530 in a region termed the top channel. Mutations of Gly-533 to valine or leucine in the top channel of mCOX-2 abolished the conversion of arachidonic acid to prostaglandin G(2), presumably because of a steric clash between the omega-end of the substrate and the introduced side chains. A smaller G533A mutant retained partial COX activity. The loss of COX activity with these mutants was not the result of reduced peroxidase activity, because the activity of all mutants was equivalent to the wild-type enzyme and the addition of exogenous peroxide did not restore full COX activity to any of the mutants. However, the Gly-533 mutants were able to oxidize the carbon 18 fatty acid substrates linolenic acid and stearidonic acid, which contain an allylic carbon at the omega-5 position. In contrast, linoleic acid, which is like arachidonic acid in that its most omega-proximal allylic carbon is at the omega-8 position, was not oxidized by the Gly-533 mutants, Finally, the ability of Gly-533 mutants to efficiently process omega-5 allylic substrates suggests that the top channel does not serve as a product exit route indicating that oxygenated substrate diffuses from the cyclooxygenase active site in a membrane proximal direction.	Vanderbilt Univ, Sch Med, Dept Biochem,Vanderbilt Canc Ctr,Ctr Mol Toxicol, AB Hancock Jr Mem Lab Canc Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem,Vanderbilt Canc Ctr,Ctr Mol Toxicol, AB Hancock Jr Mem Lab Canc Res, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P30CA068485, R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479, CA68485] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Kalgutkar AS, 1996, BIOCHEMISTRY-US, V35, P9076, DOI 10.1021/bi9605752; Kalgutkar AS, 1998, SCIENCE, V280, P1268, DOI 10.1126/science.280.5367.1268; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; Lanzo CA, 1998, BIOCHEMISTRY-US, V37, P217, DOI 10.1021/bi971691n; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; ODENWALLER R, 1992, J BIOL CHEM, V267, P13863; OHKI S, 1979, J BIOL CHEM, V254, P829; PICOT D, 1994, FEBS LETT, V346, P21, DOI 10.1016/0014-5793(94)00314-9; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; STRIEDER S, 1992, J BIOL CHEM, V267, P13870; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	27	107	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23305	23310		10.1074/jbc.274.33.23305	http://dx.doi.org/10.1074/jbc.274.33.23305			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438506	hybrid			2022-12-25	WOS:000082012800056
J	Ashcroft, M; Stephens, RM; Hallberg, B; Downward, J; Kaplan, DR				Ashcroft, M; Stephens, RM; Hallberg, B; Downward, J; Kaplan, DR			The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth	ONCOGENE			English	Article						Trk; PC12; NGF; phosphatidylinositol 3-kinase; differentiation; survival	NERVE-GROWTH-FACTOR; TRK TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; NEURONAL DIFFERENTIATION; PHOSPHOINOSITIDE 3-KINASE; AKT PROTOONCOGENE; FACTOR RECEPTORS	The Trk/Nerve Growth Factor receptor mediates the rapid activation of a number of intracellular signaling proteins, including phosphatidylinositol 3-kinase (PI 3-kinase). Here, we describe a novel, NGF-inducible system that we used to specifically address the signaling potential of endogenous PI 3-kinase in NGF-mediated neuronal survival and differentiation processes. This system utilizes a Trk receptor mutant (Trk(def)) lacking sequences Y490, Y785 and KFG important for the activation of the major Trk targets; SHC, PLC-gamma I, Ras, PI 3-kinase and SNT. TrKdef was kinase active but defective for NGF-induced responses when stably expressed in PC12nnr5 cells (which lack detectable levels of TrkA and are non-responsive to NGF). The PI 3-kinase consensus binding site, YxxM (YYPM), was introduced into the insert region within the kinase domain of Trk(def). NGF-stimulated tyrosine phosphorylation of the Trk(def)+PI 3-kinase addback receptor, resulted in the direct association and selective activation ;of PI 3-kinase in vitro and the production of PI(3,4)P-2 and PI(3,4,5)P-3 in rivo (comparable to wild-type). PC12nnr5 cells stably expressing Trk(def)+PI 3-kinase, initiated neurite outgrowth but failed to stably extend and maintain these neurites in response to NGF as compared to PC12 parental cells, or PC12nnr5 cells overexpressing wild-type Trk. However, Trk(def)+PI 3-kinase was fully competent in mediating NGF-induced survival processes. We propose that while endogenous PI 3-kinase can contribute in part to neurite initiation professes, its selective activation and subsequent signaling to downstream effecters such as Akt, functions mainly to promote cell survival in the PC12 system.	NCI, ABL Basic Res Program, FCRDC, Frederick, MD 21702 USA; Imperial Canc Res Fund, London WC2A 3PX, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Research UK	Ashcroft, M (corresponding author), NCI, ABL Basic Res Program, FCRDC, W 7th St, Frederick, MD 21702 USA.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; CARTER AN, 1992, J BIOL CHEM, V267, P14563; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; Fanger GR, 1997, MOL CELL BIOL, V17, P89, DOI 10.1128/MCB.17.1.89; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUKUDA M, 1995, ONCOGENE, V11, P239; Greene L. A., 1991, METHODOLOGIES CULTUR; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; INAGAKI N, 1995, EUR J NEUROSCI, V7, P1125, DOI 10.1111/j.1460-9568.1995.tb01102.x; Jackson TR, 1996, J CELL SCI, V109, P289; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LOEB DM, 1993, J NEUROSCI, V13, P2919; MEAKIN SO, 1999, IN PRESS J BIOL CHEM; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miller TM, 1997, J BIOL CHEM, V272, P9847; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Park EK, 1996, MOL CELLS, V6, P494; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Summers MD, 1987, MANUAL METHODS BACUL; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Teng KK, 1996, MOL CELL NEUROSCI, V8, P157, DOI 10.1006/mcne.1996.0054; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	63	76	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4586	4597		10.1038/sj.onc.1202814	http://dx.doi.org/10.1038/sj.onc.1202814			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467403				2022-12-25	WOS:000082018600008
J	Shridhar, V; Staub, J; Huntley, B; Cliby, W; Jenkins, R; Pass, HI; Hartmann, L; Smith, DI				Shridhar, V; Staub, J; Huntley, B; Cliby, W; Jenkins, R; Pass, HI; Hartmann, L; Smith, DI			A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer	ONCOGENE			English	Article						6q23.3 loss; invasive epithelial ovarian cancer; tumor suppressor	TUMOR-SUPPRESSOR GENE; BREAST CARCINOMAS; MULTIPLE REGIONS; FREQUENT LOSS; FRAGILE SITE; ARM 6Q; HETEROZYGOSITY; LOCI; IDENTIFICATION; MELANOMA	Detailed deletion mapping of chromosome 6q sequences in invasive ovarian tumors have implicated several broad regions involving 6q14- 16, 6q21 -23, 6q25 -26, and the telomeric portion in band 6q27 as regions of frequent loss in this malignancy. In order to define regions of loss involved in the development of ovarian cancer, we used 23 polymorphic markers on 6q to examine allelic loss in 25 high-grade, late stage ovarian tumors. Four nonoverlapping deletion regions were observed: (1) at 6q21-22.3 (D6S301-D6S292); (2) within a 1 cM region at 23.2-23.3 between markers D6S978-D6S1637 (at D6S311); (3) at 6q26 (between markers D6S411-D6S1277) and (4) at 6q27 with the markers D6S297 and D6S193. The highest region of loss was observed with marker D6S311 (lost in 17 of 19 informative cases, 89%) in 6q23.3, followed by D6S977 and D6S1637 (71 and 55%, respectively). The average fractional allele loss in the high-grade tumors was around 35%. Previous reports have shown 6q27 as the region of most frequent loss in invasive ovarian cancer. However, our results indicate a novel region in 6q23.3 (spanning less than 500 Kb distance between the markers) with the highest loss, implicating this region of chromosome 6q to harbor a putative tumor suppressor gene involved in the development of invasive epithelial ovarian cancer.	Mayo Clin & Mayo Fdn, Dept Expt Pathol & Lab Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Gynecol Surg, Rochester, MN 55905 USA; Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA; Karmanos Canc Inst, Detroit, MI USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Wayne State University; Barbara Ann Karmanos Cancer Institute	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol & Lab Med, 200 1st St SW, Rochester, MN 55905 USA.			Pass, Harvey/0000-0003-3222-3471	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Bell DW, 1997, CANCER RES, V57, P4057; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CLIBY W, 1993, CANCER RES, V53, P2393; Colitti CV, 1998, ONCOGENE, V16, P555, DOI 10.1038/sj.onc.1201523; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooney KA, 1996, CANCER RES, V56, P4150; DODSON MK, 1993, CANCER RES, V53, P4456; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; Guan XY, 1996, BLOOD, V88, P1418, DOI 10.1182/blood.V88.4.1418.bloodjournal8841418; Hauptschein RS, 1998, GENOMICS, V50, P170, DOI 10.1006/geno.1998.5321; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; Jiang XX, 1996, CANCER RES, V56, P3534; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LEARY JA, 1993, INT J GYNECOL CANCER, V3, P293, DOI 10.1046/j.1525-1438.1993.03050293.x; LEE JH, 1990, CANCER RES, V50, P2724; MORELLI C, 1997, CANCER RES, V57, P4152; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; QUIMADO L, 1995, GENES CHROMOSOM CANC, V14, P28; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Shridhar R, 1996, CANCER RES, V56, P4347; Shridhar V, 1997, ONCOGENE, V14, P1269, DOI 10.1038/sj.onc.1201100; SHRIDHAR V, 1994, CANCER RES, V54, P2084; Theile M, 1996, ONCOGENE, V13, P677; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; WANG ND, 1993, GENOMICS, V17, P341, DOI 10.1006/geno.1993.1330	35	32	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3913	3918		10.1038/sj.onc.1202756	http://dx.doi.org/10.1038/sj.onc.1202756			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445856				2022-12-25	WOS:000081171700014
J	Hsu, SC; Gavrilin, MA; Tsai, MH; Han, JH; Lai, MZ				Hsu, SC; Gavrilin, MA; Tsai, MH; Han, JH; Lai, MZ			p38 mitogen-activated protein kinase is involved in Fas ligand expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ICE/CED-3 FAMILY PROTEASES; STRESS-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; T-CELL HYBRIDOMAS; SIGNALING PATHWAY; RESPONSE ELEMENT; TERMINAL KINASE; CAMP INHIBITION; HEPATOMA-CELLS	p38 mitogen-activated protein kinase (MAPK) is activated by T cell receptor engagement. Here we showed that T cell receptor activated p38 alpha but not p38 delta, Inhibition of p38 alpha by the specific inhibitor SE 203580 prevented activation-induced cell death in T cells. SE 203580 had no effect on Fas-initiated apoptosis. Instead, SE 203580 preferentially inhibited activation-induced Fas ligand (FasL) expression. The inhibition on Fast expression by SE 203580 was correlated with the suppression on the Fast promoter activation. Overexpression of active MAPK kinase 3b, the activator of p38 MAPK, led to activation of Fast promoter and induction of Fast transcripts in T cells. Stress stimulation of T cells by anisomycin also induced Fast expression in a p38 MAPK-dependent manner, The induction of Fast expression in nonlymphoid cells such as 293T also required activation of p38 MAPK. Our results suggest that p38 MAPK is essential for FasL expression.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Natl Taiwan Univ, Sch Med, Grad Inst Microbiol, Taipei 10018, Taiwan; Natl Yang Ming Univ, Grad Inst Microbiol & Immunol, Taipei 11221, Taiwan; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Natl Taiwan Univ, Sch Med, Grad Inst Immunol, Taipei 10018, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Yang Ming Chiao Tung University; Scripps Research Institute; National Taiwan University	Lai, MZ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.		Hsu, Shu-Ching/E-3869-2010; Lai, Ming-Zong/AAA-4408-2021; Han, J/G-4671-2010	Gavrilin, Mikhail/0000-0003-2003-768X; Lai, Ming-Zong/0000-0002-3237-4803				BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHENG JH, 1995, J IMMUNOL, V154, P1239; Collette Y, 1997, EUR J IMMUNOL, V27, P3283, DOI 10.1002/eji.1830271227; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DERIJARD B, 1995, SCIENCE, V267, P683; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Hale KK, 1999, J IMMUNOL, V162, P4246; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Ho HY, 1997, EUR J IMMUNOL, V27, P222, DOI 10.1002/eji.1830270133; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; Hsueh YP, 1997, J IMMUNOL, V158, P85; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE MR, 1993, J IMMUNOL, V151, P5208; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Matsui K, 1998, J IMMUNOL, V161, P3469; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Norian LA, 1998, J IMMUNOL, V161, P1078; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salmon RA, 1997, J IMMUNOL, V159, P5309; Schafer PH, 1999, J IMMUNOL, V162, P659; Sen J, 1996, J IMMUNOL, V156, P4535; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; Wang CH, 1998, NEUROGENETICS, V1, P273; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhang J, 1999, J IMMUNOL, V162, P3819	72	72	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25769	25776		10.1074/jbc.274.36.25769	http://dx.doi.org/10.1074/jbc.274.36.25769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464315	hybrid			2022-12-25	WOS:000082554200079
J	Larsson, H; Klint, P; Landgren, E; Claesson-Welsh, L				Larsson, H; Klint, P; Landgren, E; Claesson-Welsh, L			Fibroblast growth factor receptor-1-mediated endothelial cell proliferation is dependent on the Src homology (SH) 2/SH3 domain-containing adaptor protein Crk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; FACTOR FAMILY; CDNA CLONING; AUTOPHOSPHORYLATION SITES; STRUCTURAL SIMILARITY; INDUCED ACTIVATION; TYROSINE KINASES; PHOSPHOLIPASE-C; POINT MUTATION	Stimulation of fibroblast growth factor receptor-2 (FGFR-1) expressed on endothelial cells leads to cellular migration and proliferation. We have examined the role of the Src homology (SH) 2/SH3 domain-containing adaptor protein Crk in these processes. Transient tyrosine phosphorylation of Crk in fibroblast growth factor-2-stimulated endothelial cells was dependent on the juxtamembrane tyrosine residue 463 in FGFR-1, and a Crk SH2 domain precipitated FGFR-1 via phosphorylated Tyr-463, indicating direct complex formation between Crk and FGFR-1. Furthermore, Crk SH2 and SH3 domains formed ligand-independent complexes with Shc, C3G, and the Crk-associated substrate (Cas). Tyrosine phosphorylation of C3G and Cas increased as a consequence of growth factor treatment, We examined the role of Crk in FGFR-1-mediated cellular responses by use of cells expressing chimeric platelet-derived growth factor receptor-alpha/FGFR-1 (alpha R/FR) wild type and mutant Y463F receptors. The kinase activity of alpha R/FR Y463F was intact, but both Crk and the adaptor FRS-2 were no longer tyrosine-phosphorylated in the mutant cells. Both wild type and mutant receptor cells migrated efficiently, whereas cells expressing the mutant alpha R/FR Y463F failed to proliferate and Erk2 and Jun kinase activities were suppressed in these cells. In wild type alpha R/FR cells transiently expressing an SH2 domain mutant of Crk, Erk and Jun kinase activities as well as DNA synthesis were attenuated. Our data indicate that Crk participates in signaling complexes downstream of FGFR-1, which propagate mitogenic signals.	Uppsala Univ, Dept Med Biochem & Microbiol, Ctr Biomed, S-75123 Uppsala, Sweden	Uppsala University	Claesson-Welsh, L (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Ctr Biomed, Box 575, S-75123 Uppsala, Sweden.	lena.welsh@medkem.uu.se		Claesson-Welsh, Lena/0000-0003-4275-2000				AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063; HUANG W, 1996, SIGNAL TRANSDUCTION, P159; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Landgren E, 1998, ONCOGENE, V17, P283, DOI 10.1038/sj.onc.1201936; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Marshall CJ, 1998, NATURE, V392, P553, DOI 10.1038/33293; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATTHEWS JA, 1985, ANAL BIOCHEM, V151, P205, DOI 10.1016/0003-2697(85)90073-9; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; Ryan PJ, 1998, BIOCHEM BIOPH RES CO, V244, P763, DOI 10.1006/bbrc.1998.8326; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Teng DHF, 1997, CANCER RES, V57, P4177; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Torres M, 1996, ONCOGENE, V12, P77; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Yokote K, 1998, ONCOGENE, V16, P1229, DOI 10.1038/sj.onc.1201641; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	58	91	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25726	25734		10.1074/jbc.274.36.25726	http://dx.doi.org/10.1074/jbc.274.36.25726			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464310	hybrid			2022-12-25	WOS:000082554200074
J	Mikhailov, D; Young, HC; Linhardt, RJ; Mayo, KH				Mikhailov, D; Young, HC; Linhardt, RJ; Mayo, KH			Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha - Induction of a partially folded state and implications for heparin-induced thrombocytopenia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-IV; H-1-NMR SPECTROSCOPY; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; NMR-SPECTROSCOPY; AMINO-ACIDS; SENSITIVITY; ASSOCIATION; RESONANCE; SULFATE	alpha-Chemokines are known heparin-binding proteins. Here, a heparin dodecasaccharide (H12) was purified and used in NMR studies to investigate binding to growth-related protein-alpha (Gro-alpha) and to platelet factor4-M2 (PF4-M2), an N-terminal chimera of PF4. Pulsed field gradient NMR was used to derive diffusion coefficients as the protein (monomer):H12 ratio was varied. In the absence of H12, both PF4-M2 and Gro-alpha give diffusion coefficients consistent with the presence of mostly dimers. As the PF4-M2:H12 ratio is increased from 1:6 to 2:1, the diffusion coefficient increases, indicating dissociation to the monomer state. On addition of H12 to either protein, N-15/H-1 heteronuclear single quantum coherence NMR data demonstrate loss of H-1 resonance dispersion and intensity, particularly at protein:Hla ratios of 2:1 to 4:1, indicating significant perturbation to native structures. For Gro-alpha in particular, 1H resonance dispersion appears random coil-like, At these same ratios, circular dichroism (CD) data show general retention of secondary structure elements with a slight shift to additional helix formation. Random coil NMR resonance dispersion suggests a shift to a less compact, partially folded, and/or more flexible state. Further addition of H12 causes resonance intensity and dispersion to return making NMR spectra appear native-like. At low PF4-M2:H12 ratios, loss of resonance intensity for residues proximal to Arg-20 and Arg-22 in three-dimensional NMR HCCH-TOCSY spectra suggests that the Arg-20-Arg-22 loop either interacts most strongly with H12 and/or that binding at this site is heterogeneous. This domain was previously shown to be crucial to heparin binding. Of particular interest to the biology of PF4-heparin complex formation, heparin-induced thrombocytopenia antibody binding occurs at about the same PF4-M2:H12 ratio as does this transition to a partially folded PF4-M2 state, strongly suggesting that heparin-induced thrombocytopenia antibody recognizes a less folded, lower aggregate state of the protein.	Univ Minnesota, Hlth Sci Ctr, Ctr Biomed Engn, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Iowa, Dept Chem & Biochem Engn, Iowa City, IA 52242 USA; Univ Iowa, Div Med & Nat Prod, Iowa City, IA 52242 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Iowa; University of Iowa	Mayo, KH (corresponding author), Univ Minnesota, Hlth Sci Ctr, Dept Biochem, Ctr Biomed Engn, 4-225 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.				NHLBI NIH HHS [HL52622] Funding Source: Medline; NIGMS NIH HHS [GM38060] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; BARKER S, 1995, FEBS LETT, V357, P301, DOI 10.1016/0014-5793(94)01384-D; BARNES DW, 1985, J BIOL CHEM, V260, P9117; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Benton RE, 1998, SOUTHERN MED J, V91, P133, DOI 10.1097/00007611-199802000-00002; BURKE CJ, 1993, BIOCHEMISTRY-US, V32, P6419, DOI 10.1021/bi00076a015; Caldwell EEO, 1996, INT J BIOCHEM CELL B, V28, P203, DOI 10.1016/1357-2725(95)00123-9; Cantor C.R., 1980, BIOPHYS CHEM; Chen BL, 1996, J PHARM SCI, V85, P419, DOI 10.1021/js9504393; CLORE GM, 1989, J BIOL CHEM, V264, P18907; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; COWAN SW, 1986, BIOCHEM J, V234, P485, DOI 10.1042/bj2340485; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FAIRBROTHER WJ, 1994, J MOL BIOL, V242, P252, DOI 10.1006/jmbi.1994.1577; FINOTTI P, 1994, BBA-PROTEIN STRUCT M, V1207, P80, DOI 10.1016/0167-4838(94)90054-X; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; GELMAN RA, 1974, BIOPOLYMERS, V13, P139, DOI 10.1002/bip.1974.360130109; GIBBS SJ, 1991, J MAGN RESON, V93, P395, DOI 10.1016/0022-2364(91)90014-K; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Horne MK, 1998, AM J HEMATOL, V58, P24, DOI 10.1002/(SICI)1096-8652(199805)58:1<24::AID-AJH5>3.0.CO;2-2; Ilyina E, 1997, BIOCHEMISTRY-US, V36, P3383, DOI 10.1021/bi9622229; Ishihara M, 1997, J BIOCHEM-TOKYO, V121, P345; Jeanloz R W, 1975, Adv Exp Med Biol, V52, P3; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; LINHARDT RJ, 1988, BIOCHEM J, V254, P781, DOI 10.1042/bj2540781; LOSCALZO J, 1985, ARCH BIOCHEM BIOPHYS, V240, P446, DOI 10.1016/0003-9861(85)90049-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYON M, 1994, J BIOL CHEM, V269, P11216; MACHOVICH R, 1978, EUR J BIOCHEM, V83, P473, DOI 10.1111/j.1432-1033.1978.tb12113.x; MASCOTTI DP, 1995, BIOCHEMISTRY-US, V34, P2908, DOI 10.1021/bi00009a022; MAYO KH, 1995, BIOCHEMISTRY-US, V34, P11399, DOI 10.1021/bi00036a012; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; Mikhailov D, 1996, BIOCHEM J, V315, P447, DOI 10.1042/bj3150447; MIRESLIUS A, 1998, CYTOKINES; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; Suh JS, 1998, BLOOD, V91, P916, DOI 10.1182/blood.V91.3.916.916_916_922; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; VEMURI S, 1994, J PHARM PHARMACOL, V46, P481, DOI 10.1111/j.2042-7158.1994.tb03831.x; VISENTIN GP, 1994, J CLIN INVEST, V93, P81, DOI 10.1172/JCI116987; Visentin GP, 1996, J LAB CLIN MED, V128, P376, DOI 10.1016/S0022-2143(96)80009-6; VONBOECKEL CAA, 1994, STRUCT BIOL, V1, P423; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; Wijmenga SS, 1996, J BIOMOL NMR, V8, P319, DOI 10.1007/BF00410330; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; YANG YQ, 1994, J BIOL CHEM, V269, P20110; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025	58	61	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25317	25329		10.1074/jbc.274.36.25317	http://dx.doi.org/10.1074/jbc.274.36.25317			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464257	hybrid			2022-12-25	WOS:000082554200022
J	Stringer, SE; Mayer-Proschel, M; Kalyani, A; Rao, M; Gallagher, JT				Stringer, SE; Mayer-Proschel, M; Kalyani, A; Rao, M; Gallagher, JT			Heparin is a unique marker of progenitors in the glial cell lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; NEUROEPITHELIAL STEM-CELLS; RAT OPTIC-NERVE; TYPE-2 ASTROCYTE DEVELOPMENT; FACTOR-A-CHAIN; SULFATE; BINDING; DIFFERENTIATION; EXPRESSION; INVITRO	The oligodendrocyte-type-2 astrocyte progenitor cells (precursors of oligodendrocytes and type-2 astrocytes) are an excellent system in which to study differentiation as they can be manipulated in vitro. Maintenance of oligodendrocyte-type-2 astrocyte progenitor cells requires basic fibroblast growth factor, a growth factor whose action normally depends on a heparan sulfate coreceptor. Biochemical analysis revealed a most surprising result: that the oligodendrocyte type-2 astrocyte progenitors did not synthesize heparan sulfate, the near ubiquitous N-sulfated cell surface polysaccharide, but the chemically related heparin in a form that was almost completely N- and O-sulfated. The heparin was detected in the pericellular fraction of the cells and the culture medium. In contrast the differentiated glial subpopulations (oligodendrocytes and type-2 astrocytes) synthesized typical heparan sulfate but with distinctive fine structural features for each cell type. Thus heparin is a unique differentiation marker in the glial lineage. Previously heparin has been found only in a subset of mature mast cells called the connective tissue mast cells. Its presence within the developing nervous system on a precise population of progenitors may confer specific and essential recognition properties on those cells in relation to binding soluble growth and/or differentiation factors and the extracellular matrix.	Paterson Inst Canc Res, Canc Res Campaign, Drug Dev & Imaging Sect, Manchester M20 4BX, Lancs, England; Univ Manchester, Christie Hosp, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Anat & Neurobiol, Salt Lake City, UT 84132 USA	Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Stringer, SE (corresponding author), Paterson Inst Canc Res, Canc Res Campaign, Drug Dev & Imaging Sect, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	sstringer@picr.man.ac.uk						Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; ANDERSSON M, 1994, J BIOL CHEM, V269, P926; Aschner M, 1998, NEUROTOXICOLOGY, V19, P269; Bansal R, 1997, J NEUROSCI RES, V50, P215; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; FFRENCHCONSTANT C, 1986, NATURE, V323, P335, DOI 10.1038/323335a0; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HAMEL W, 1992, INT J ONCOL, V1, P673; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; Joseph SJ, 1996, DEVELOPMENT, V122, P3443; Kalyani A, 1997, DEV BIOL, V186, P202, DOI 10.1006/dbio.1997.8592; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Lindahl U., 1989, HEPARIN, P159; LINHARDT RJ, 1992, BIOCHEMISTRY-US, V31, P12441, DOI 10.1021/bi00164a020; LYON M, 1994, J BIOL CHEM, V269, P11216; Mabie PC, 1997, J NEUROSCI, V17, P4112; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MAXWELL M, 1991, CANCER RES, V51, P1345; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; NOBLE M, 1984, EMBO J, V3, P2243, DOI 10.1002/j.1460-2075.1984.tb02122.x; Noble M, 1997, J NEURO-ONCOL, V35, P193, DOI 10.1023/A:1005898228116; Norenberg M.D, 1996, ROLE GLIA NEUROTOXIC, P93; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RAFF MC, 1985, CELL, V42, P61, DOI 10.1016/S0092-8674(85)80101-X; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUSNATI M, 1994, BIOCHEM BIOPH RES CO, V203, P450, DOI 10.1006/bbrc.1994.2203; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SKOFF RP, 1976, J COMP NEUROL, V169, P313, DOI 10.1002/cne.901690304; SKOFF RP, 1976, J COMP NEUROL, V169, P291, DOI 10.1002/cne.901690303; STEVENS RL, 1988, J BIOL CHEM, V263, P7287; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; Walz A, 1997, DEVELOPMENT, V124, P2421; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	56	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25455	25460		10.1074/jbc.274.36.25455	http://dx.doi.org/10.1074/jbc.274.36.25455			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464276	hybrid			2022-12-25	WOS:000082554200040
J	Walsh, DM; Hartley, DM; Kusumoto, Y; Fezoui, Y; Condron, MM; Lomakin, A; Benedek, GB; Selkoe, DJ; Teplow, DB				Walsh, DM; Hartley, DM; Kusumoto, Y; Fezoui, Y; Condron, MM; Lomakin, A; Benedek, GB; Selkoe, DJ; Teplow, DB			Amyloid beta-protein fibrillogenesis - Structure and biological activity of protofibrillar intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MTT FORMAZAN EXOCYTOSIS; HELICAL HAIRPIN PEPTIDE; DE-NOVO DESIGN; CIRCULAR-DICHROISM; PRECURSOR PROTEIN; PATHOGENIC MUTATION; FIBRIL FORMATION; APP GENE; IN-VITRO	Alzheimer's disease is characterized by extensive cerebral amyloid deposition. Amyloid deposits associated with damaged neuropil and blood vessels contain abundant fibrils formed by the amyloid beta-protein (A beta). Fibrils, both in vitro and in vivo, are neurotoxic. For this reason, substantial effort has been expended to develop therapeutic approaches to control A beta production and amyloidogenesis. Achievement of the latter goal is facilitated by a rigorous mechanistic understanding of the fibrillogenesis process. Recently, we discovered a novel intermediate in the pathway of A beta fibril formation, the amyloid protofibril (Walsh, D, RI,, Lomakin, A., Benedek, G. B., Condron, RI. Ri,, and Teplow, D. B. (1997) J. Biol. Chem. 272-, 22364-22372). We report here results of studies of the assembly, structure, and biological activity of these polymers. We find that protofibrils: 1) are in equilibrium with low molecular weight A beta (monomeric or dimeric); 2) have a secondary structure characteristic of amyloid fibrils; 3) appear as beaded chains in rotary shadowed preparations examined electron microscopically; 4) give rise to mature amyloid-like fibrils; and 5) affect the normal metabolism of cultured neurons. The implications of these results for the development of therapies for Alzheimer's disease and for our understanding of fibril assembly are discussed.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA; MIT, Dept Phys, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Teplow, DB (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, 77 Ave Louis Pasteur HIM756, Boston, MA 02115 USA.	teplow@cnd.bwh.harvard.edu			NIA NIH HHS [1PO1 AG14366, 1RO1 AG12749] Funding Source: Medline; NINDS NIH HHS [1RO1 NS38328] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012749, P01AG014366] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe K, 1998, NEUROSCI RES, V31, P295, DOI 10.1016/S0168-0102(98)00055-8; Alzheimer A, 1906, NEUROLOGISCHES CENTR, V23, P1129; BALDWIN MA, 1994, PHILOS T ROY SOC B, V343, P435, DOI 10.1098/rstb.1994.0041; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; Clements A, 1996, J NEUROCHEM, V66, P740; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DELELLIS RA, 1968, J HISTOCHEM CYTOCHEM, V16, P663, DOI 10.1177/16.10.663-a; Eckman CB, 1997, HUM MOL GENET, V6, P2087, DOI 10.1093/hmg/6.12.2087; FEZOUI Y, 1994, P NATL ACAD SCI USA, V91, P3675, DOI 10.1073/pnas.91.9.3675; Fezoui Y, 1997, PROTEIN SCI, V6, P1869, DOI 10.1002/pro.5560060907; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hartley D. M., 1998, Society for Neuroscience Abstracts, V24, P508; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; IVERSEN LL, 1995, BIOCHEM J, V311, P1; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Klunk WE, 1999, ANAL BIOCHEM, V266, P66, DOI 10.1006/abio.1998.2933; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Liu YB, 1998, P NATL ACAD SCI USA, V95, P13266, DOI 10.1073/pnas.95.22.13266; Liu YB, 1997, J NEUROCHEM, V69, P2285; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; LOMAKIN A, 1999, IN PRESS METHODS ENZ, V309; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MAY PC, 1992, NEUROBIOL AGING, V13, P605, DOI 10.1016/0197-4580(92)90064-5; McKee AC, 1998, AMYLOID, V5, P1, DOI 10.3109/13506129809007283; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Naiki H, 1996, LAB INVEST, V74, P374; Nybo M, 1999, SCAND J IMMUNOL, V49, P219; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; SCHENK DB, 1995, J MED CHEM, V38, P4141, DOI 10.1021/jm00021a001; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; SHEARMAN MS, 1995, J NEUROCHEM, V65, P218, DOI 10.1046/j.1471-4159.1995.65010218.x; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Soto C, 1996, BIOCHEM J, V314, P701, DOI 10.1042/bj3140701; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	68	963	996	0	101	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25945	25952		10.1074/jbc.274.36.25945	http://dx.doi.org/10.1074/jbc.274.36.25945			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464339	hybrid			2022-12-25	WOS:000082554200103
J	Wenk, J; Brenneisen, P; Wlaschek, M; Poswig, A; Briviba, K; Oberley, TD; Scharffetter-Kochanek, K				Wenk, J; Brenneisen, P; Wlaschek, M; Poswig, A; Briviba, K; Oberley, TD; Scharffetter-Kochanek, K			Stable overexpression of manganese superoxide dismutase in mitochondria identifies hydrogen peroxide as a major oxidant in the AP-1-mediated induction of matrix-degrading metalloprotease-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DERMAL FIBROBLASTS; MESSENGER-RNA LEVELS; INDUCED AUTOCRINE STIMULATION; QUIESCENT BALB/3T3 CELLS; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; GENE-EXPRESSION; C-FOS; INTERSTITIAL COLLAGENASE; GLUTATHIONE-PEROXIDASE	Reactive oxygen species (ROS) are important second messengers for the induction of several genes in a variety of physiological and pathological conditions. Here we addressed the question of whether isolated, unbalanced overexpression of the antioxidant enzyme manganese superoxide dismutase (Mn-SOD) may modulate signal transduction cascades, finally leading to connective tissue degradation, a hallmark in carcinogenesis and aging, Therefore, we generated stably Mn-SOD-overexpressing fibroblasts with an up to 4.6-fold increase in Mn-SOD activity. The Mn-SOD-overexpressing cells revealed specific resistance to the superoxide anion (O-2 radical anion)-generating agent paraquat, whereas no resistance to UVA-generated oxidative stress was found. Treatment of the Mn-SOD overexpressing cells with various ROS-generating systems resulted (due to the enhanced dismutation of superoxide anion to hydrogen peroxide) in an up to 9.5-fold increase in matrix-degrading metalloprotease-1 (MMP-1) mRNA levels, A similar increase in MMP-1 mRNA was also seen when the intracellular H2O2 concentration was increased by the inhibition of different H2O2-detoxifying pathways, Furthermore, prooxidant conditions led to a strong induction of c-jun and c-fos mRNA levels resulting in a 4-fold higher transactivation of the transcription factor AP-1 in the Mn-SOD-overexpressing cells. Collectively, we have found that enhanced Mn-SOD activity, via an unbalanced H2O2 overproduction and detoxification, induces MMP-1 mRNA levels, and this effect is at least partly mediated by the DNA recognition sequence AP-1.	Univ Cologne, Dept Dermatol, D-50931 Cologne, Germany; Univ Dusseldorf, Dept Physiol Chem, D-40225 Dusseldorf, Germany; Univ Wisconsin, Dept Pathol, Madison, WI 53705 USA	University of Cologne; Heinrich Heine University Dusseldorf; University of Wisconsin System; University of Wisconsin Madison	Scharffetter-Kochanek, K (corresponding author), Univ Cologne, Dept Dermatol, Josef Stelzmann Str 9, D-50931 Cologne, Germany.	Karin.Scharffetter@uni-koeln.de		Briviba, Karlis/0000-0003-3338-7515				AEBI H, 1984, METHOD ENZYMOL, V105, P121; Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; AMSTAD PA, 1992, CANCER RES, V52, P3952; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1985, J CELL BIOCHEM, V29, P351, DOI 10.1002/jcb.240290408; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenneisen P, 1996, PHOTOCHEM PHOTOBIOL, V64, P649, DOI 10.1111/j.1751-1097.1996.tb03119.x; Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2; Brenneisen P, 1998, J BIOL CHEM, V273, P5279, DOI 10.1074/jbc.273.9.5279; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CEBALLOS I, 1991, FREE RADICAL RES COM, V12-3, P581; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; CHEATLE T, 1991, BRIT J DERMATOL, V124, P508, DOI 10.1111/j.1365-2133.1991.tb00641.x; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; CRAWFORD HC, 1994, INVAS METAST, V14, P234; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; deHaan JB, 1996, HUM MOL GENET, V5, P283, DOI 10.1093/hmg/5.2.283; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; GALLAGHER RP, 1989, INT J CANCER, V44, P813, DOI 10.1002/ijc.2910440511; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HARRIS CA, 1991, J IMMUNOL, V147, P149; HENRIKSEN T, 1990, PHOTOCHEM PHOTOBIOL, V51, P579, DOI 10.1111/j.1751-1097.1990.tb01968.x; Herrmann G, 1993, Exp Dermatol, V2, P92, DOI 10.1111/j.1600-0625.1993.tb00015.x; INOUE S, 1992, CARCINOGENESIS, V13, P1497, DOI 10.1093/carcin/13.9.1497; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; KADIISKA MB, 1993, TOXICOL APPL PHARM, V123, P187, DOI 10.1006/taap.1993.1236; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KRAEMER KM, 1979, P NATL ACAD SCI USA, V91, P11; Lee SF, 1996, FREE RADICAL BIO MED, V21, P437, DOI 10.1016/0891-5849(96)00040-8; LEHMANN P, 1986, ZENTRALBL HAUT GESCH, V152, P667, DOI DOI 10.1007/978-3-642-72828-0_8; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; MAIORINO M, 1991, J BIOL CHEM, V266, P7728; MAJMUDAR G, 1994, MOL CARCINOGEN, V9, P17, DOI 10.1002/mc.2940090105; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Moulton PJ, 1996, BRIT J BIOMED SCI, V53, P317; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; MUTZHAS MF, 1981, J INVEST DERMATOL, V76, P42, DOI 10.1111/1523-1747.ep12524813; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OBERLEY LW, 1979, CANCER RES, V39, P1141; PETERSEN MJ, 1992, J INVEST DERMATOL, V99, P440, DOI 10.1111/1523-1747.ep12616142; Poswig A, 1999, J INVEST DERMATOL, V112, P13, DOI 10.1046/j.1523-1747.1999.00465.x; SATO H, 1993, ONCOGENE, V8, P395; SATO M, 1995, ARCH BIOCHEM BIOPHYS, V316, P738, DOI 10.1006/abbi.1995.1098; Sawamura D, 1996, ARCH DERMATOL RES, V288, P628, DOI 10.1007/s004030050115; SCHARFFETTER K, 1991, ARCH DERMATOL RES, V283, P506, DOI 10.1007/BF00371923; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SCHARFFETTERKOC.K, 1992, ENV THREAT SKIN, P77; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; Sies H., 1991, OXIDATIVE STRESS OXI; SINGH S, 1994, FREE RADICAL DAMAGE, P189; SOHAL RS, 1995, J BIOL CHEM, V270, P15671, DOI 10.1074/jbc.270.26.15671; STCLAIR DK, 1994, FREE RADICAL BIO MED, V16, P275, DOI 10.1016/0891-5849(94)90153-8; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tyrrel R.M., 1991, OXIDATIVE STRESS OXI, P57; TYRRELL RM, 1987, CANCER RES, V47, P1825; URBACH F, 1989, PHOTOCHEM PHOTOBIOL, V50, P507, DOI 10.1111/j.1751-1097.1989.tb05556.x; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WLASCHEK M, 1993, J INVEST DERMATOL, V101, P164, DOI 10.1111/1523-1747.ep12363644; WLASCHEK M, 1994, PHOTOCHEM PHOTOBIOL, V59, P550, DOI 10.1111/j.1751-1097.1994.tb02982.x; Wlaschek M, 1997, FEBS LETT, V413, P239, DOI 10.1016/S0014-5793(97)00919-8; WOESSNER JF, 1991, J RHEUMATOL, V18, P99	85	189	194	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25869	25876		10.1074/jbc.274.36.25869	http://dx.doi.org/10.1074/jbc.274.36.25869			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464329	hybrid			2022-12-25	WOS:000082554200093
J	Kiningham, KK; Oberley, TD; Lin, SM; Mattingly, CA; St Clair, DK				Kiningham, KK; Oberley, TD; Lin, SM; Mattingly, CA; St Clair, DK			Overexpression of manganese superoxide dismutase protects against mitochondrial-initiated poly(ADP-ribose) polymerase-mediated cell death	FASEB JOURNAL			English	Article						apoptosis; reactive oxygen species; caspase 3; antimycin	CYTOCHROME-C; OXIDATIVE STRESS; INDUCED APOPTOSIS; NEURONAL APOPTOSIS; HYDROGEN-PEROXIDE; DNA-DAMAGE; IN-VIVO; OXYGEN; BCL-2; NUCLEAR	Mitochondria have recently been shown to serve a central role in programmed cell death. In addition, reactive oxygen species (ROS) have been implicated in cell death pathways upon treatment with a variety of agents; however, the specific cellular source of the ROS generation is unknown. We hypothesize that mitochondria-derived free radicals play a critical role iu apoptotic cell death. To directly test this hypothesis, we treated murine fibrosarcoma cell lines, which expressed a range of mitochondrial manganese superoxide dismutase (MnSOD) activities, with respiratory chain inhibitors, Apoptosis was confirmed by DNA fragmentation analysis and electron microscopy, MnSOD overexpression specifically protected against cell death upon treatment with rotenone or antimycin. We examined bcl-x(L), p53 and poly(ADP-ribose) polymerase (PARP) to identify specific cellular pathways that might contribute to the mitochondrial-initiated ROS-mediated tell death. Cells overexpressing MnSOD contained less bcl-x(L) within the mitochondria compared to control (NEO) cells, therefore excluding the role of bcl-x(L), p53 was undetectable by Western analysis and examination of the proapoptotic protein bax, a p53 target gene, did not increase with treatment, Activation of caspase-3 (CPP-32) occurred in the NEO cells independent of cytochrome c release from the mitochondria, PARP, a target protein of CPP-32 activity, was cleaved to a 64 kDa fragment in the NEO cells prior to generation of nucleosomal fragments. Taken together, these findings suggest that mitochondrial-mediated ROS generation is a key event by which inhibition of respiration causes cell death, and identifies CPP-32 and the PARP-linked pathway as targets of mitochondrial-derived ROS-induced cell death.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Wisconsin, Vet Adm Hosp, Dept Pathol, Sch Med, Madison, WI USA	University of Kentucky; University of Wisconsin System; University of Wisconsin Madison	St Clair, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 360 Hlth Sci Res Bldg, Lexington, KY 40536 USA.				NATIONAL CANCER INSTITUTE [R29CA049797, R01CA049797, R01CA059835] Funding Source: NIH RePORTER; NCI NIH HHS [CA49797, CA59835] Funding Source: Medline; NHLBI NIH HHS [HL03544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; Atabay C, 1996, J NEUROSCI RES, V43, P465; BASS DA, 1983, J IMMUNOL, V130, P1910; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1982, SUPEROXIDE DISMUTASE, V2, P15; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; GUIDOT DM, 1995, J CLIN INVEST, V96, P1131, DOI 10.1172/JCI118100; Hagar H, 1996, KIDNEY INT, V49, P355, DOI 10.1038/ki.1996.52; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Higuchi M, 1998, ONCOGENE, V17, P2753, DOI 10.1038/sj.onc.1202211; Keller JN, 1998, J NEUROSCI, V18, P687; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kiningham KK, 1997, CANCER RES, V57, P5265; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kruman I, 1997, J NEUROSCI, V17, P5089; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MAJIMA H, 1992, INT J RADIAT ONCOL, V22, P1019, DOI 10.1016/0360-3016(92)90802-O; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Marin MC, 1996, ONCOGENE, V12, P2259; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PASTORINO JG, 1995, AM J PHYSIOL-CELL PH, V268, pC676, DOI 10.1152/ajpcell.1995.268.3.C676; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SAFFORD SE, 1994, CANCER RES, V54, P4261; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; URANO M, 1995, CANCER RES, V55, P2490; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; [No title captured]	54	91	91	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1601	1610		10.1096/fasebj.13.12.1601	http://dx.doi.org/10.1096/fasebj.13.12.1601			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463952				2022-12-25	WOS:000082347600016
J	Kasir, J; Ren, XY; Furman, I; Rahamimoff, H				Kasir, J; Ren, XY; Furman, I; Rahamimoff, H			Truncation of the C terminus of the rat brain Na+-Ca2+ exchanger RBE-1 (NCX1.4) impairs surface expression of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; SODIUM-CALCIUM EXCHANGER; ENDOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; SIGNAL SEQUENCE; TRANSMEMBRANE SEGMENTS; SECRETORY PATHWAY; QUALITY-CONTROL; HELA-CELLS; MEMBRANE	The C terminus of the rat brain Na+-Ca2+ exchanger (RBE-1; NCX1.4) (amino acids 875-903) is modeled to contain the last transmembrane alpha helix (amino acids 875-894) and an intracellular extramembraneous tail of 9 amino acids (895-903). Truncation of the last 9 C-terminal amino acids, Glu-895 to stop, did not significantly impair functional expression in HeLa or HEK 293 cells. Truncation, however, of 10 amino acids (Leu-894 to stop; mutant C10) reduced Na+ gradient-dependent Ca2+ uptake to 35-39% relative to the wild type parent exchanger, and further truncation of 13 or more amino acids resulted in expression of trace amounts of transport activity. Western analysis indicated that Na+-Ca2+ exchanger protein was produced whether transfection was carried out with functional or non-functional mutants. Immunofluorescence studies of HEK 293 cells expressing N-Flag epitope-tagged wild type and mutant Na+-Ca2+ exchangers revealed that transport activity in whole cells correlated with surface expression. All cells expressing the wild type exchanger or C9 exhibited surface expression of the protein. Only 39% of the cells expressing C10 exhibited surface expression, and none was detected in cells transfected with non-functional mutants C13 and C29, Since functional and non-functional mutants were glycosylated, the C terminus is not mandatory to translocation into the endoplasmic reticulum (ER), Endoglycosidase H digestion of [S-35]methionine-labeled protein derived from wild type Na+-Ca2+ exchanger and from C10 indicated that resistance to the digestion was acquired after 1 and 5 h of chase, respectively. C29 did not acquire detectable resistance to endoglycosidase H digestion even after 10 h of chase. Taken together, these results suggest that the "cellular quality control machinery" can tolerate the structural change introduced by truncation of the C terminus up to Ser-893 albeit with reduced rate of ER-->Golgi transfer and reduced surface expression of the truncated protein. Further truncation of C-terminal amino acids leads to retention of the truncated protein in the ER, no transfer to the Golgi, and no surface expression.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Rahamimoff, H (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.							Cook O, 1998, BBA-BIOMEMBRANES, V1371, P40, DOI 10.1016/S0005-2736(97)00272-1; Cottet S, 1997, EUR J BIOCHEM, V246, P23, DOI 10.1111/j.1432-1033.1997.00023.x; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; FURMAN I, 1995, J BIOL CHEM, V270, P19120, DOI 10.1074/jbc.270.32.19120; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; Gabellini N, 1996, EUR J BIOCHEM, V239, P897, DOI 10.1111/j.1432-1033.1996.0897u.x; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li XF, 1999, J BIOL CHEM, V274, P8153, DOI 10.1074/jbc.274.12.8153; LI ZP, 1994, J BIOL CHEM, V269, P17434; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOO TW, 1995, J BIOL CHEM, V270, P19345, DOI 10.1074/jbc.270.33.19345; LOW W, 1993, FEBS LETT, V316, P63, DOI 10.1016/0014-5793(93)81737-K; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; ROST B, 1995, PROTEIN SCI, V4, P521; SAHINTOTH M, 1995, BIOCHEM BIOPH RES CO, V212, P968, DOI 10.1006/bbrc.1995.2064; Sambrock J, 1989, MOL CLONING LAB MANU; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l	37	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24873	24880		10.1074/jbc.274.35.24873	http://dx.doi.org/10.1074/jbc.274.35.24873			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455160	hybrid			2022-12-25	WOS:000082193400059
J	Sato, R; Miyamoto, W; Inoue, J; Terada, T; Imanaka, T; Maeda, M				Sato, R; Miyamoto, W; Inoue, J; Terada, T; Imanaka, T; Maeda, M			Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SYNTHASE PROMOTER; APOLIPOPROTEIN-B; MEMBRANE; ABETALIPOPROTEINEMIA; CHOLESTEROL; DEGRADATION; EXPRESSION; PROTEOLYSIS; METABOLISM; ACTIVATION	We herein report that mRNA expression of microsomal triglyceride transfer protein (MTP) and its protein synthesis decline in response to sterol depletion in HepG2 cells, and we functionally characterized the MTP gene promoter in an effort to investigate the molecular mechanisms by which MTP gene transcription is regulated. Luciferase assays using truncated versions of the reporter gene revealed that the region at -124 to +33 base pairs of the human promoter contains the elements required for the suppression of transcription by sterol depletion. Enforced expression of an active form of sterol regulatory element-binding protein (SREBP)-1 (amino acids 1-487) or -2 (amino acids 1-481), both of which are activated under sterol-depleted conditions, is able to mimic sterol-mediated down-regulation. Either further truncation of the promoter region or mutation of the putative SREBP-binding sequence (5'-GCAGCCCAC-3', -124 to -116 base pairs) abolishes the sterol- and SREBP-dependent transcriptional regulation. Gel mobility shift assay showed that recombinant SREBP-2-(1-481) is able to bind the sequence. Enforced expression of a truncated form of SREBP-2 (amino acids 31-481), which acts as an inhibitor of transcription of the low density lipoprotein receptor gene because it lacks the transcriptional activation domain, also diminishes the luciferase activity, suggesting that direct binding to the promoter region might be sufficient and that the mechanism by which SREBPs inhibit MTP gene expression is distinct from that for the transcriptional stimulation of sterol-regulated genes. Although the SREBP-binding site overlaps a negative insulin-responsive element, insulin negatively regulates MTP gene expression even when the amount of the active form of SREBPs is quite low under the sterol-loaded conditions, indicating that SREBPs only slightly mediate, if at all, the insulin effects. Overall, we conclude that SREBPs are responsible for regulation of lipoprotein secretion via their control of MTP gene expression. Moreover, our results describe for the first time a novel mechanism by which SREBPs negatively regulate expression of the gene encoding the protein involved in lipid metabolism.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Biochem & Mol Biol Lab, Osaka 5650871, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Toyama 9300194, Japan	University of Tokyo; Osaka University; University of Toyama	Sato, R (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, 1-1-1 Yayou, Tokyo 1138657, Japan.		INOUE, Jun/O-7352-2016	INOUE, Jun/0000-0003-4145-3754; Imanaka, Tsuneo/0000-0003-4677-1356				Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; BENNETT AJ, 1995, BIOCHEM BIOPH RES CO, V212, P473, DOI 10.1006/bbrc.1995.1994; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Horton JD, 1999, J CLIN INVEST, V103, P1067, DOI 10.1172/JCI6246; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Korn BS, 1998, J CLIN INVEST, V102, P2050, DOI 10.1172/JCI5341; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; LIN MCM, 1994, J BIOL CHEM, V269, P29138; LIN MCM, 1995, J LIPID RES, V36, P1073; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; NITCHELL DM, 1998, P NATL ACAD SCI USA, V95, P14733; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SATO R, 1990, J BIOL CHEM, V265, P11880; SATO R, 1994, J BIOL CHEM, V269, P17267; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHARP D, 1994, BIOCHEMISTRY-US, V33, P9057, DOI 10.1021/bi00197a005; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WETTERAU JR, 1992, SCIENCE, V258, P999; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	34	155	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24714	24720		10.1074/jbc.274.35.24714	http://dx.doi.org/10.1074/jbc.274.35.24714			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455139	hybrid			2022-12-25	WOS:000082193400038
J	Schaub, M; Myslinski, E; Krol, A; Carbon, P				Schaub, M; Myslinski, E; Krol, A; Carbon, P			Maximization of selenocysteine tRNA and U6 small nuclear RNA transcriptional activation achieved by flexible utilization of a Staf zinc finger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA(SER)SEC GENE; POLYMERASE-III PROMOTER; CRYSTAL-STRUCTURE; SNRNA GENES; DNA COMPLEX; POU DOMAIN; PROTEIN; ELEMENTS; BOX; RECOGNITION	Transcriptional activators Staf and Oct-1 play critical roles in the activation of small nuclear RNA (snRNA) and snRNA-type gene transcription. Recently, we established that Staf binding to the human U6 snRNA (hU6) and Xenopus selenocysteine tRNA (xtRNA(Sec)) genes requires different sets of the seven C2-H2 zinc fingers. In this work, using a combination of oocyte microinjection, electrophoretic mobility shift assays, and missing nucleoside experiments with wild-type and mutant promoters, me demonstrate that the hU6 gene requires zinc fingers 2-7 for Staf binding and Oct-1 for maximal transcriptional activity. In contrast, the xtRNA(Sec) gene needs the binding of the seven Staf zinc fingers, but not Oct-1, for optimal transcriptional capacity. Mutation in the binding site for Staf zinc finger 1 in the tRNA(Sec) promoter reduced both Staf binding and transcriptional activity. Conversely, introduction of a zinc finger 1 binding site in the hU6 promoter increased Staf binding but interfered with the simultaneous Staf and Oct-1 binding, thus reducing transcriptional activity. Collectively, these results show that the differential utilization of Staf zinc finger 1 represents a new, critical determinant of the transcriptional activation mechanism for the Xenopus tRNA(Sec) and human U6 snRNA genes.	Inst Biol Mol & Cellulaire, CNRS, Struct Macromol Biol & Mecanismes Reconnaissance, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Carbon, P (corresponding author), Inst Biol Mol & Cellulaire, CNRS, Struct Macromol Biol & Mecanismes Reconnaissance, 15 Rue Rene Descartes, F-67084 Strasbourg, France.							CARBON P, 1991, EMBO J, V10, P599, DOI 10.1002/j.1460-2075.1991.tb07987.x; DANZEISER DA, 1993, MOL CELL BIOL, V13, P4670, DOI 10.1128/MCB.13.8.4670; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HERR W, 1992, TRANSCRIPTIONAL REGU, V1, P1103; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; MYSLINSKI E, 1993, J MOL BIOL, V234, P311, DOI 10.1006/jmbi.1993.1588; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; MYSLINSKI E, 1992, NUCLEIC ACIDS RES, V20, P203, DOI 10.1093/nar/20.2.203; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; ROEBUCK KA, 1990, MOL CELL BIOL, V10, P341, DOI 10.1128/MCB.10.1.341; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Schaub M, 1999, J BIOL CHEM, V274, P24241, DOI 10.1074/jbc.274.34.24241; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Schuster C, 1998, MOL CELL BIOL, V18, P2650, DOI 10.1128/MCB.18.5.2650; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582	25	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25042	25050		10.1074/jbc.274.35.25042	http://dx.doi.org/10.1074/jbc.274.35.25042			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455183	hybrid			2022-12-25	WOS:000082193400082
J	Ali, SA; Joao, HC; Hammerschmid, F; Eder, J; Steinkasserer, A				Ali, SA; Joao, HC; Hammerschmid, F; Eder, J; Steinkasserer, A			Transferrin Trojan horses as a rational approach for the biological delivery of therapeutic peptide domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECEPTOR-MEDIATED ENDOCYTOSIS; HUMAN-SERUM TRANSFERRIN; PROTEASE CLEAVAGE SITE; HUMAN-TUMOR CELLS; DIFERRIC TRANSFERRIN; FUSION MECHANISM; INHIBITION; TOXIN; REPLICATION	One novel approach for the biological delivery of peptide drugs is to incorporate the sequence of the peptide into the structure of a natural transport protein, such as human serum transferrin. To examine whether this is feasible, a peptide sequence cleavable by the human immunodeficiency virus type 1 protease (VSQNYPIVL) was inserted into various regions of human serum transferrin, and the resultant proteins were tested for function. Experimentally, molecular modeling was used to identify five candidate insertion sites in surface exposed loops of human serum transferrin that were distant from biologically active domains. These insertions were cloned using polymerase chain reaction mutagenesis, and the proteins were expressed using a baculovirus expression vector system. Analysis of the mutant proteins provided a number of important findings: (a) they retained native human serum transferrin function, (b) the inserted peptide sequence was surface exposed, and most importantly, (c) two of these mutants could be cleaved by human immunodeficiency virus-1 protease. In conclusion, this investigation has validated the use of human serum transferrin as a carrier protein for functional peptide domains introduced into its structure using protein engineering. These findings will be useful for developing a novel class of therapeutic agents for a broad spectrum of diseases.	Novartis Res Inst, A-1230 Vienna, Austria	Novartis	Steinkasserer, A (corresponding author), Univ Erlangen Nurnberg, Dept Dermatol, Hartmannstr 14, D-91052 Erlangen, Germany.		Ali, Stuart/P-5514-2019; Ali, Stuart/D-4445-2013	Ali, Stuart/0000-0002-4124-2896; Ali, Stuart/0000-0002-4124-2896				Ali SA, 1996, BIOCHEM J, V319, P191, DOI 10.1042/bj3190191; ALI SA, 1995, BIOTECHNIQUES, V18, P746; Ali SA, 1996, ANAL BIOCHEM, V238, P93, DOI 10.1006/abio.1996.0256; Ali SA, 1997, BIOTECHNIQUES, V22, P1060, DOI 10.2144/97226bm10; ALI SA, 1997, GENE CLONING ANAL CU, P133; BARABAS K, 1992, J BIOL CHEM, V267, P9437; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P10023, DOI 10.1073/pnas.87.24.10023; BERGAMASCHI G, 1993, BRIT J HAEMATOL, V68, P379; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Choudhury I, 1998, J ACQ IMMUN DEF SYND, V17, P104, DOI 10.1097/00042560-199802010-00002; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; Dibbern DA, 1997, J CLIN INVEST, V99, P2837, DOI 10.1172/JCI119476; FAULK W P, 1990, Molecular Biotherapy, V2, P57; FAULK WP, 1980, LANCET, V2, P390; Finkelstein AV, 1997, CURR OPIN STRUC BIOL, V7, P60, DOI 10.1016/S0959-440X(97)80008-5; GATTER KC, 1983, J CLIN PATHOL, V36, P539, DOI 10.1136/jcp.36.5.539; HALL WA, 1994, NEUROSURGERY, V34, P649, DOI 10.1227/00006123-199404000-00012; HATANO T, 1993, TUMOR BIOL, V14, P288, DOI 10.1159/000217841; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HUEBERS H, 1985, P SOC EXP BIOL MED, V179, P222; HUEBERS H, 1981, P NATL ACAD SCI-BIOL, V78, P621, DOI 10.1073/pnas.78.1.621; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; IACOPETTA BJ, 1982, BIOCHIM BIOPHYS ACTA, V687, P204, DOI 10.1016/0005-2736(82)90547-8; ISHIGURO K, 1992, SOMAT CELL MOLEC GEN, V18, P45, DOI 10.1007/BF01233448; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; Kashanchi F, 1997, VIROLOGY, V227, P431, DOI 10.1006/viro.1996.8346; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; LASKE DW, 1994, J NEUROSURG, V80, P520, DOI 10.3171/jns.1994.80.3.0520; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x; MACGILLIVRAY RTA, 1982, P NATL ACAD SCI-BIOL, V79, P2504, DOI 10.1073/pnas.79.8.2504; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OKEEFE DO, 1985, J BIOL CHEM, V260, P932; PACUSZKA T, 1992, BIOCHEMISTRY-US, V31, P4773, DOI 10.1021/bi00135a005; PANACCIO M, 1987, IMMUNOL CELL BIOL, V65, P461, DOI 10.1038/icb.1987.55; RASO V, 1984, J BIOL CHEM, V259, P1143; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; Serio D, 1997, P NATL ACAD SCI USA, V94, P3346, DOI 10.1073/pnas.94.7.3346; SEYMOUR GJ, 1987, UROL RES, V15, P341; SIZENSKY JA, 1992, AM J REPROD IMMUNOL, V27, P163, DOI 10.1111/j.1600-0897.1992.tb00744.x; TRITCH RJ, 1991, J VIROL, V65, P922, DOI 10.1128/JVI.65.2.922-930.1991; TROWBRIDGE IS, 1981, NATURE, V294, P171, DOI 10.1038/294171a0; YEH CJG, 1984, CLIN IMMUNOL IMMUNOP, V32, P1, DOI 10.1016/0090-1229(84)90037-0; YEH CJG, 1984, VOX SANG, V46, P217, DOI 10.1111/j.1423-0410.1984.tb00078.x; ZOLOTUKHIN AS, 1994, NUCLEIC ACIDS RES, V22, P4725, DOI 10.1093/nar/22.22.4725	51	20	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24066	24073		10.1074/jbc.274.34.24066	http://dx.doi.org/10.1074/jbc.274.34.24066			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446177	hybrid			2022-12-25	WOS:000082110900056
J	Blanc, V; Alfonzo, JD; Aphasizhev, R; Simpson, L				Blanc, V; Alfonzo, JD; Aphasizhev, R; Simpson, L			The mitochondrial RNA ligase from Leishmania tarentolae can join RNA molecules bridged by a complementary RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR MESSENGER-RNA; TRYPANOSOMA-BRUCEI; GUIDE RNA; IN-VITRO; RIBONUCLEOPROTEIN COMPLEXES; KINETOPLASTID MITOCHONDRIA; DIRECTED ENDONUCLEASE; EDITING COMPLEX; MAXICIRCLE DNA; PROTEIN	A biochemical characterization was performed with a partially purified RNA ligase from isolated mitochondria of Leishmania tarentolae. This ligase has a K-m of 25 +/- 0.75 nM and a V-max of 1.0 x 10(-4) + 2.4 x 10(-4) nmol/min when ligating a nicked double-stranded RNA substrate. Ligation was negatively affected by a gap between the donor and acceptor nucleotides. The catalytic efficiency of the circularization of a single-stranded substrate was B-fold less than that of the ligation of a nicked substrate. These properties of the mitochondrial RNA ligase are consistent with an expected in vivo role in the process of uridine insertion/deletion RNA editing, in which the mRNA cleavage fragments are bridged by a cognate guide RNA.	Univ Calif Los Angeles, Sch Med, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Simpson, L (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.			Afasizhev, Ruslan/0000-0002-4595-6618				Adler BK, 1997, MOL CELL BIOL, V17, P5377, DOI 10.1128/MCB.17.9.5377; Alfonzo JD, 1997, NUCLEIC ACIDS RES, V25, P3751, DOI 10.1093/nar/25.19.3751; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; Arn EA, 1996, J BIOL CHEM, V271, P31145, DOI 10.1074/jbc.271.49.31145; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; Bringaud F, 1997, MOL CELL BIOL, V17, P3915, DOI 10.1128/MCB.17.7.3915; BRINGAUD F, 1995, MOL BIOCHEM PARASIT, V71, P65, DOI 10.1016/0166-6851(95)00023-T; Byrne EM, 1996, EMBO J, V15, P6758, DOI 10.1002/j.1460-2075.1996.tb01065.x; Campbell TB, 1996, BIOCHEMISTRY-US, V35, P11493, DOI 10.1021/bi960510z; Cohen SB, 1998, RNA, V4, P1179, DOI 10.1017/S1355838298001010; Corell RA, 1996, MOL CELL BIOL, V16, P1410; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; Cruz-Reyes J, 1998, NUCLEIC ACIDS RES, V26, P3634, DOI 10.1093/nar/26.16.3634; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; CUNNINGHAM PR, 1990, BIOTECHNIQUES, V9, P713; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; FRECH GC, 1995, EMBO J, V14, P178, DOI 10.1002/j.1460-2075.1995.tb06988.x; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; KAPUSHOC S, 1999, RNA, V5, P1; KAUFMANN G, 1974, FEBS LETT, V46, P271, DOI 10.1016/0014-5793(74)80385-6; Koller J, 1997, J BIOL CHEM, V272, P3749, DOI 10.1074/jbc.272.6.3749; LEEGWATER P, 1995, EUR J BIOCHEM, V227, P780, DOI 10.1111/j.1432-1033.1995.tb20201.x; Madison-Antenucci S, 1998, EMBO J, V17, P6368, DOI 10.1093/emboj/17.21.6368; MASLOV DA, 1992, MOL CELL BIOL, V12, P56, DOI 10.1128/MCB.12.1.56; PAN T, 1993, GENE, V125, P111, DOI 10.1016/0378-1119(93)90317-V; Peris M, 1997, MOL BIOCHEM PARASIT, V85, P9, DOI 10.1016/S0166-6851(96)02795-8; PERIS M, 1994, EMBO J, V13, P1664, DOI 10.1002/j.1460-2075.1994.tb06430.x; Piller KJ, 1997, RNA, V3, P279; SABATINI R, 1995, J BIOL CHEM, V270, P7233, DOI 10.1074/jbc.270.13.7233; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; SUGINO A, 1977, J BIOL CHEM, V252, P1732; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; Vanhamme L, 1998, J BIOL CHEM, V273, P21825, DOI 10.1074/jbc.273.34.21825	37	36	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24289	24296		10.1074/jbc.274.34.24289	http://dx.doi.org/10.1074/jbc.274.34.24289			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446205	hybrid			2022-12-25	WOS:000082110900084
J	Krucken, J; Stamm, O; Schmitt-Wrede, HP; Mincheva, A; Lichter, P; Wunderlich, F				Krucken, J; Stamm, O; Schmitt-Wrede, HP; Mincheva, A; Lichter, P; Wunderlich, F			Spleen-specific expression of the malaria-inducible intronless mouse gene imap38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-CHABAUDI MALARIA; ACID RESPONSE ELEMENT; MESSENGER-RNAS; MEDIATED AMPLIFICATION; REPETITIVE ELEMENTS; NEGATIVE REGULATION; SPLENIC CONTROL; MURINE MALARIA; GENOMIC DNA; SEQUENCE	We characterize the mouse gene imap38 and its inducibility by Plasmodium chabaudi malaria among different lymphoid tissues and mouse strains of different H-2 complex and non-H-2 background. Imap38 is a single copy gene assigned to chromosome 6B, It consists of only one exon of 1900 base pairs encoding a highly basic 25.8-kDa protein. Confocal laser scanning microscopy localizes differently tagged IMAP38 proteins in nuclei of transfected cells. Reporter gene assays reveal that the 1730-base pair 5'-flanking region, containing an RSINE1 repeat immediately adjacent to initiation site +1, exhibits promoter activity in nonmurine cells, while it is largely repressed in diverse mouse cell lines, which corresponds to the situation in mouse tissues. P. chabaudi malaria induces imap38 expression almost exclusively in the spleen but not in other lymphoid organs. parasite lysates are able to induce imap38 in the spleen, but not in spleen cells er vivo, Activation of spleen cells by LPS and other stimuli is not sufficient to induce imap38. Inducibility of imap38 requires signals from both parasites and the intact spleen, and it is controlled by genes of that non-H-2 background, which also controls development of protective immunity against P. chabaudi malaria.	Univ Dusseldorf, Abt Mol Parasitol, Div Mol Parasitol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Ctr Biol Med Res, D-40225 Dusseldorf, Germany; German Canc Res Ctr, Div Org Complex Genomes, D-69120 Heidelberg, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Helmholtz Association; German Cancer Research Center (DKFZ)	Wunderlich, F (corresponding author), Univ Dusseldorf, Abt Mol Parasitol, Div Mol Parasitol, D-40225 Dusseldorf, Germany.		Schmitt-Wrede, Hans-Peter/ABD-6206-2021; Krücken, Jürgen/AAE-3133-2021; Krücken, Jürgen/B-6794-2009; Krücken, Jürgen/CAF-6903-2022	Krücken, Jürgen/0000-0002-2842-8100; Krücken, Jürgen/0000-0002-2842-8100; Krücken, Jürgen/0000-0002-2842-8100				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Alves HJ, 1996, AM J TROP MED HYG, V55, P370, DOI 10.4269/ajtmh.1996.55.370; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; ARRANZ V, 1994, GENE, V149, P293, DOI 10.1016/0378-1119(94)90164-3; ATANASOSKI S, 1995, GENOMICS, V26, P272, DOI 10.1016/0888-7543(95)80211-4; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Baltzinger M, 1996, MECH DEVELOP, V58, P103, DOI 10.1016/S0925-4773(96)00563-1; Benten WPM, 1999, FASEB J, V13, P123, DOI 10.1096/fasebj.13.1.123; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRANE G G, 1986, Parasitology Today, V2, P4, DOI 10.1016/0169-4758(86)90067-0; FROMONTRACINE M, 1993, NUCLEIC ACIDS RES, V21, P1683, DOI 10.1093/nar/21.7.1683; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Gentles AJ, 1999, TRENDS GENET, V15, P47, DOI 10.1016/S0168-9525(98)01648-5; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; Jurka J, 1996, COMPUT CHEM, V20, P119, DOI 10.1016/S0097-8485(96)80013-1; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Krucken J, 1997, BIOCHEM BIOPH RES CO, V230, P167, DOI 10.1006/bbrc.1996.5876; KWIATKOWSKI D, 1992, CURR OPIN IMMUNOL, V4, P425, DOI 10.1016/S0952-7915(06)80034-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG TKC, 1990, BIOCHEM J, V267, P125, DOI 10.1042/bj2670125; LEWIN B, 1997, GENES, V6, P668; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIU XW, 1993, NUCLEIC ACIDS RES, V21, P4954, DOI 10.1093/nar/21.21.4954; MAXSON R, 1983, ANNU REV GENET, V17, P239, DOI 10.1146/annurev.ge.17.120183.001323; MILNER CM, 1990, IMMUNOGENETICS, V32, P242; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; OLIVA R, 1989, J BIOL CHEM, V264, P12472; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRY MD, 1994, GENE, V146, P273, DOI 10.1016/0378-1119(94)90305-0; Phillips RS, 1997, PARASITE IMMUNOL, V19, P427, DOI 10.1046/j.1365-3024.1997.d01-239.x; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; PLAYFAIR JHL, 1990, IMMUNOL TODAY, V11, P25; Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; SAWYER JR, 1987, CHROMOSOMA, V95, P350, DOI 10.1007/BF00293182; SCHLUTER G, 1995, CYTOGENET CELL GENET, V71, P352, DOI 10.1159/000134138; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; SILVER J, 1991, PCR PRACTICAL APPROA, V1, P137; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; TOUZE JE, 1989, T ROY SOC TROP MED H, V83, P161, DOI 10.1016/0035-9203(89)90626-3; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VANSANT G, 1995, P NATL ACAD SCI USA, V92, P8229, DOI 10.1073/pnas.92.18.8229; VOLLOCH V, 1994, NUCLEIC ACIDS RES, V22, P2507, DOI 10.1093/nar/22.13.2507; WEISS L, 1989, AM J TROP MED HYG, V41, P144, DOI 10.4269/ajtmh.1989.41.144; WEISS L, 1986, AM J ANAT, V176, P251, DOI 10.1002/aja.1001760303; WUNDERLICH F, 1987, EUR J CELL BIOL, V43, P499; WUNDERLICH F, 1991, PARASITE IMMUNOL, V13, P357, DOI 10.1111/j.1365-3024.1991.tb00289.x; WUNDERLICH F, 1988, INFECT IMMUN, V56, P2400, DOI 10.1128/IAI.56.9.2400-2406.1988; WUNDERLICH F, 1992, PARASITE IMMUNOL, V14, P307, DOI 10.1111/j.1365-3024.1992.tb00470.x; WYLER DJ, 1983, LYMPHOLOGY, V16, P121; YAP GS, 1994, INFECT IMMUN, V62, P4219, DOI 10.1128/IAI.62.10.4219-4225.1994	62	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24383	24391		10.1074/jbc.274.34.24383	http://dx.doi.org/10.1074/jbc.274.34.24383			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446218	hybrid			2022-12-25	WOS:000082110900097
J	Lok, CN; Ponka, P				Lok, CN; Ponka, P			Identification of a hypoxia response element in the transferrin receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; HUMAN ERYTHROPOIETIN GENE; TRANSCRIPTIONAL REGULATION; IRON-METABOLISM; MESSENGER-RNA; NITRIC-OXIDE; OXIDATIVE STRESS; PROMOTER REGION; ACTIVATION; PROTEIN	Expression of the transferrin receptor, which mediates iron uptake from transferrin, is negatively regulated post-transcriptionally by intracellular iron through iron-responsive elements in the 3'-untranslated region of the transferrin receptor mRNA. Transcriptional mechanisms are also involved in receptor expression, but these are poorly understood. In this study we have characterized the transferrin receptor promoter region and identified a functional hypoxia response element that contains a binding site for hypoxia-inducible factor-1 (HIF-1). Exposure of K562 and HeLa cells to hypoxia for 16 h resulted in a 2- to 3-fold increase in transferrin receptor mRNA expression. A motif with multipartite organization similar to the hypoxia response element of a number of hypoxia-inducible genes such as erythropoietin was identified within a 100-base pair sequence upstream of the transcriptional start site. Mutation of a site similar to the consensus HIF-binding site (HBS) in this motif attenuated the hypoxic response by 80%. Transient co-expression of the two HIF-1 subunits (HIP-1 alpha and HIF-1 beta) enhanced the wild type transferrin receptor promoter activity, but that which contained a mutated HBS yielded no such response. Electrophoretic mobility shift assays revealed that HIF-1 was stimulated and bound to the transferrin receptor HBS upon hypoxic challenge. Our results indicate that the transferrin receptor is a target gene for HIF-1.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Ponka, P (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.		Ponka, Prem/A-4123-2011	Ponka, Prem/0000-0001-5835-1477				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; BECK I, 1991, J BIOL CHEM, V266, P15563; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Dore-Duffy P, 1999, MICROVASC RES, V57, P75, DOI 10.1006/mvre.1998.2112; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Fleming MD, 1998, J LAB CLIN MED, V132, P464, DOI 10.1016/S0022-2143(98)90123-8; Guiang SF, 1998, CAN J PHYSIOL PHARM, V76, P930, DOI 10.1139/cjpp-76-9-930; GUIANG SF, 1993, J DEV PHYSIOL, V19, P99; Hanson ES, 1999, J BIOL CHEM, V274, P5047, DOI 10.1074/jbc.274.8.5047; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Morgan E. H., 1994, IRON METABOLISM HLTH, P63; OUYANG Q, 1993, MOL CELL BIOL, V13, P1796, DOI 10.1128/MCB.13.3.1796; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Ponka P, 1997, BLOOD, V89, P1; RAO K, 1986, MOL CELL BIOL, V6, P236, DOI 10.1128/MCB.6.1.236; RICHARDSON DR, 1995, BLOOD, V86, P3211; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 1998, J LAB CLIN MED, V131, P207, DOI 10.1016/S0022-2143(98)90091-9; TERRADOS N, 1990, J APPL PHYSIOL, V68, P2369, DOI 10.1152/jappl.1990.68.6.2369; TESTA U, 1993, CRIT REV ONCOGENESIS, V4, P241; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x	36	287	301	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24147	24152		10.1074/jbc.274.34.24147	http://dx.doi.org/10.1074/jbc.274.34.24147			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446188	hybrid			2022-12-25	WOS:000082110900067
J	Sabbatini, P; McCormick, F				Sabbatini, P; McCormick, F			Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; CELL-CYCLE ARREST; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; P53-DEPENDENT APOPTOSIS; C-AKT; E1A-INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; GROWTH ARREST; V-AKT	The phosphoinositide 3-OH kinase (PI3K)-PKB/Akt signaling pathway has been shown to mediate both Ras- and cytokine-induced protection from apoptosis. In addition, apoptosis induced by the p53 tumor suppressor protein can be inhibited by Ras- and cytokine-mediated signaling pathways. It was therefore of interest to determine if the PI3K-PKB/Akt signaling pathway was capable of conferring protection from apoptosis induced by p53. We demonstrate in this report that constitutively active PI3K and PKB/Akt are capable of significantly delaying the onset of p53-mediated apoptosis. This was manifested as a delay in the kinetics of DNA degradation and cell death as well as a profound attenuation in the accumulation of cells with a sub-G, DNA content. Moreover, we found that this effect is mediated in the absence of changes in expression of Bcl-2, Bcl-XI, and the proapoptotic protein Pax. Our results provide the first direct and unambiguous link between p53-mediated apoptosis and the PI3K-PKB/Akt signaling pathway.	Univ Calif San Francisco, Sch Med, Inst Canc Res, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Sabbatini, P (corresponding author), Univ Calif San Francisco, Sch Med, Inst Canc Res, San Francisco, CA 94143 USA.	sabbatini@cc.ucsf.edu						Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; BEDI A, 1995, CANCER RES, V55, P1811; BELLACOSA A, 1993, ONCOGENE, V8, P745; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Canman C E, 1997, Adv Pharmacol, V41, P429, DOI 10.1016/S1054-3589(08)61068-6; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; IWABUCHI H, 1995, CANCER RES, V55, P6172; KASTAN MB, 1991, CANCER RES, V51, P6304; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kitada S, 1998, AM J PATHOL, V152, P51; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OCONNOR PM, 1993, CANCER RES, V53, P4776; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SCHOTT AF, 1995, ONCOGENE, V11, P1389; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	81	121	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24263	24269		10.1074/jbc.274.34.24263	http://dx.doi.org/10.1074/jbc.274.34.24263			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446202	hybrid			2022-12-25	WOS:000082110900081
J	Loizos, N; Darst, SA				Loizos, N; Darst, SA			Mapping interactions of Escherichia coli GreB with RNA polymerase and ternary elongation complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPT CLEAVAGE FACTORS; NASCENT RNA; DNA; DETERMINANTS; MECHANISM; FIDELITY; EPITOPE; SUBUNIT; 3'-END	Escherichia coli GreA and GreB modulate transcription elongation by interacting with the ternary elongation complex (containing RNA polymerase, DNA template, and RNA transcript) to induce hydrolytic cleavage of the transcript and release of the 3'-terminal fragment. Hydroxyl radical protein footprinting and alanine-scanning mutagenesis were used to investigate the interactions of GreB with RNA polymerase alone and in a ternary elongation complex. A major determinant for binding GreB to both RNA polymerase and the ternary elongation complex was identified. In addition, the hydroxyl radical footprinting indicated major conformational changes of GreB, in terms of reorientations of the N- and C-terminal domains with respect to each other, particularly upon interactions with the ternary elongation complex.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Darst, SA (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	darst@rockvax.rockefeller.edu			NIGMS NIH HHS [GM53759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borukhov S, 1996, METHOD ENZYMOL, V274, P315; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FENG GH, 1994, J BIOL CHEM, V269, P22282; HAGLER J, 1993, J BIOL CHEM, V268, P2166; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1998, P NATL ACAD SCI USA, V95, P14699, DOI 10.1073/pnas.95.25.14699; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Koulich D, 1998, J MOL BIOL, V276, P379, DOI 10.1006/jmbi.1997.1545; Koulich D, 1997, J BIOL CHEM, V272, P7201, DOI 10.1074/jbc.272.11.7201; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; Loizos N, 1998, STRUCT FOLD DES, V6, P691, DOI 10.1016/S0969-2126(98)00071-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; ORLOVA M, 1995, THESIS I MOL GENETIC; Polyakov A, 1998, J MOL BIOL, V281, P465, DOI 10.1006/jmbi.1998.1958; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1992, J BIOL CHEM, V267, P3795; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; Tschochner H, 1996, P NATL ACAD SCI USA, V93, P12914, DOI 10.1073/pnas.93.23.12914; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299	36	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23378	23386		10.1074/jbc.274.33.23378	http://dx.doi.org/10.1074/jbc.274.33.23378			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438515	hybrid			2022-12-25	WOS:000082012800065
J	Adriaenssens, E; Lottin, S; Dugimont, T; Fauquette, W; Coll, J; Dupouy, JP; Boilly, B; Curgy, JJ				Adriaenssens, E; Lottin, S; Dugimont, T; Fauquette, W; Coll, J; Dupouy, JP; Boilly, B; Curgy, JJ			Steroid hormones modulate H19 gene expression in both mammary gland and uterus	ONCOGENE			English	Article						H19 gene regulation; mammary gland; uterus; steroid hormones; mammary cells; nuclear receptors	GROWTH FACTOR-II; LIGAND-INDEPENDENT ACTIVATION; HUMAN ESTROGEN-RECEPTOR; TUMOR-SUPPRESSOR GENE; IMPRINTED GENES; BREAST-CANCER; WILMS-TUMOR; PROGESTERONE-RECEPTOR; IGF2 EXPRESSION; CELL-LINES	H19 is an imprinted and developmentally regulated gene whose product remains apparently untranslated. In a previous study on breast adenocarcinomas, we reported that overexpression of the H19 gene was significantly correlated with the presence of steroid receptors, suggesting the putative role of hormones in H19 transcription. To determine the mode of steroid action, we have detected levels of H19 RNA. synthesis during mammary gland development by in situ hybridization (ISH): two peaks of H19 transcription occur during puberty and pregnancy. Furthermore, we demonstrated by ISH that in the uterus H19 RNA synthesis is high during estrus and metestrus phases. To test steroid control of H19 transcription, ovariectomized and adrenalectomized mice were supplemented, 1 week after surgery, with 17-beta-estradiol (E2, 20 mu g/kg/day), progesterone (P, 1 mg/kg/day) or corticosterone (B, 0.3 mg/kg/day) for 2 weeks. According to ISH data, E2 and to a lesser extent B stimulated H19 transcription in the uterus, whereas P inhibited it. To confirm the in vivo results, in vitro experiments were performed using cultures of MCF-7 cells (a hormone-sensitive mammary cell line). E2 stimulated the endogenous H19 gene of this cell line and tamoxifen inhibited this effect. Furthermore, we performed transient cotransfections in MCF-7, in HBL-100 (another hormone-sensitive mammary cell line) and in BT-20 (a hormone-insensitive mammary cell line) with various constructs of ER alpha (WT or mutated) and PR-A, in presence or absence of steroid hormones. We demonstrated that ER alpha up-regulated the H19 promoter in MCF-7 and in HBL-100, whereas PR-A did not have any effect pel se. Moreover, in MCF-7, PR-A antagonized clearly the ER alpha-mediated promoter enhancement, but in HBL-100 this counteracting effect on the ER alpha up-regulation was not found. Interestingly, the same experiments performed in BT-20 cell line provided very similar results as those obtained in MCF-7 cells, with a clear down-regulation mediated by PR-A on the H19 promoter. All these in vitro data are in agreement with irt vivo results. In addition, data obtained with ERI mutants indicate that H19 promoter activation is both ligand-dependent and ligand-independent. We have thus demonstrated that H19 gene expression is controlled by steroid hormones; furthermore, this gene is highly expressed in hormone-sensitive organs when the hormonal stimulation is accompanied, with a morphological repair.	UST Lille, UPRES EA 1033, Dev Biol Lab, F-59655 Villeneuve Dascq, France; Univ Artois, Fac Sci Jean Perrin, F-62307 Lens, France; URA 1854, F-59021 Lille, France; UST Lille, Biol Cellulaire Lab, Lab Neuroendocrinol Dev, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille; Universite d'Artois; Universite de Lille - ISITE; Universite de Lille	Curgy, JJ (corresponding author), UMR 8527, BP 447, F-59021 Lille, France.							Adriaenssens E, 1998, AM J PATHOL, V153, P1597, DOI 10.1016/S0002-9440(10)65748-3; Ariel I, 1997, J CLIN PATHOL-MOL PA, V50, P34, DOI 10.1136/mp.50.1.34; ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; Ariel I, 1997, DIAGN MOL PATHOL, V6, P17, DOI 10.1097/00019606-199702000-00004; Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BERNET F, 1994, REGUL PEPTIDES, V52, P187, DOI 10.1016/0167-0115(94)90053-1; BIRAN H, 1994, TUMOR BIOL, V15, P123, DOI 10.1159/000217882; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CHATELAIN A, 1989, J ENDOCRINOL, V123, P421, DOI 10.1677/joe.0.1230421; Cooper MJ, 1996, J UROLOGY, V155, P2120, DOI 10.1016/S0022-5347(01)66120-2; Cui HM, 1997, CANCER RES, V57, P4469; Cunha G R, 1992, Epithelial Cell Biol, V1, P105; DALLE M, 1978, J ENDOCRINOL, V76, P303, DOI 10.1677/joe.0.0760303; DANIEL CW, 1992, MOL REPROD DEV, V32, P145, DOI 10.1002/mrd.1080320210; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DOUCRASY S, 1993, INT J ONCOL, V2, P753; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; Dugimont T, 1995, BIOL CELL, V85, P117, DOI 10.1016/0248-4900(96)85272-5; DUPOUY JP, 1975, J ENDOCRINOL, V65, P347, DOI 10.1677/joe.0.0650347; DUPOUY JP, 1975, CR ACAD SCI D NAT, V280, P463; El Yazidi I, 1998, BBA-MOL CELL RES, V1403, P127, DOI 10.1016/S0167-4889(98)00033-0; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; GRONEMEYER H, 1991, J STEROID BIOCHEM, V40, P271, DOI 10.1016/0960-0760(91)90192-8; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; Han DKM, 1996, J CLIN INVEST, V97, P1276, DOI 10.1172/JCI118543; Hanstein B, 1999, MOL ENDOCRINOL, V13, P129, DOI 10.1210/me.13.1.129; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Haslam S. Z., 1987, The mammary gland. Development, regulation, and function., P499; HASLAM SZ, 1980, J CELL BIOL, V86, P730, DOI 10.1083/jcb.86.3.730; Hemberger M, 1998, DEV GENES EVOL, V208, P393, DOI 10.1007/s004270050195; ILENCHUK TT, 1987, ENDOCRINOLOGY, V120, P1449, DOI 10.1210/endo-120-4-1449; INCE BA, 1995, ENDOCRINOLOGY, V136, P3194, DOI 10.1210/en.136.8.3194; JONES CM, 1991, DEVELOPMENT, V111, P531; Joubel A, 1996, CELL MOL BIOL, V42, P1159; KATO S, 1995, MOL CELL BIOL, V15, P5858; Kondo M, 1996, Nihon Rinsho, V54, P492; Kopf E, 1998, FEBS LETT, V432, P123, DOI 10.1016/S0014-5793(98)00841-2; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Lesage J, 1996, NEUROCHEM RES, V21, P87, DOI 10.1007/BF02527676; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; LustigYariv O, 1997, ONCOGENE, V15, P169, DOI 10.1038/sj.onc.1201175; MARIE J, 1980, PATHOL BIOL, V28, P377; MARIE J, 1981, PATHOL BIOL, V29, P367; MCCORMACK JT, 1974, J ENDOCRINOL, V62, P101, DOI 10.1677/joe.0.0620101; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NANDI S, 1958, J NATL CANCER I, V21, P1039; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PEYRAT JP, 1991, CANCER COMMUN, V3, P323, DOI 10.3727/095535491820873803; QUEVA C, 1992, DEVELOPMENT, V114, P125; REESE JC, 1991, J BIOL CHEM, V266, P10880; RHODA J, 1984, ENDOCRINOLOGY, V114, P1754, DOI 10.1210/endo-114-5-1754; RHODA J, 1983, CR ACAD SCI III-VIE, V296, P405; SAKAKURA T, 1991, INT REV CYTOL, V125, P165, DOI 10.1016/S0074-7696(08)61219-X; Sambrook J., 1989, MOL CLONING LABORATO, V2, P916; SANYAL MK, 1978, J ENDOCRINOL, V79, P179, DOI 10.1677/joe.0.0790179; Schodin DJ, 1995, J BIOL CHEM, V270, P31163, DOI 10.1074/jbc.270.52.31163; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; van Roozendaal CEP, 1998, FEBS LETT, V437, P107, DOI 10.1016/S0014-5793(98)01211-3; VOUTILAINEN R, 1994, ENDOCRINOLOGY, V134, P2051, DOI 10.1210/en.134.5.2051; Wang WH, 1996, J BIOL CHEM, V271, P27863, DOI 10.1074/jbc.271.44.27863; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; WEISZ J, 1980, ENDOCRINOLOGY, V106, P306, DOI 10.1210/endo-106-1-306; Yballe CM, 1996, J CLIN ENDOCR METAB, V81, P1607, DOI 10.1210/jc.81.4.1607; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	82	69	70	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	1999	18	31					4460	4473		10.1038/sj.onc.1202819	http://dx.doi.org/10.1038/sj.onc.1202819			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442637				2022-12-25	WOS:000081813500008
J	Christmas, P; Fox, JW; Ursino, SR; Soberman, RJ				Christmas, P; Fox, JW; Ursino, SR; Soberman, RJ			Differential localization of 5-and 15-lipoxygenases to the nuclear envelope in RAW macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID 15-LIPOXYGENASE; BASOPHILIC LEUKEMIA-CELLS; ACTIVATED PROTEIN-KINASE; MOLECULAR-CLONING; 5-LIPOXYGENASE-ACTIVATING PROTEIN; ALVEOLAR MACROPHAGES; HUMAN-LEUKOCYTES; TRANSLOCATION; EXPRESSION; SYNTHASE	Leukotriene formation is initiated in myeloid cells by an increase in intracellular calcium and translocation of B-lipoxygenase from the cytoplasm to the nuclear envelope where it can utilize arachidonic acid. Monocyte-macrophages and eosinophils also express 15-lipoxygenase, which converts arachidonic acid to 15(S)-hydroxyeicosatetraenoic acid. Enhanced green fluorescent B-lipoxygenase (5-LO) and 15-lipoxygenase (15-LO) fusion proteins were expressed in the cytoplasm of RAW 264.7 macrophages, Only B-lipoxygenase translocated 60 the nuclear envelope after cell stimulation, suggesting that differential subcellular compartmentalization can regulate the generation of leukotrienes versus 15(S)-hydroxyeicosatetraenoic acid in cells that possess both lipoxygenases, A series of truncation mutants of 5-LO were created to identify putative targeting domains; none of these mutants localized to the nuclear envelope. The lack of targeting of 15-LO was then exploited to search for specific targeting motifs in 5-LO, by creating 5-LO/15-LO chimeric molecules. The only chimera that could sustain nuclear envelope translocation was one which involved replacement of the N-terminal 237 amino acids with the corresponding segment of 15-LO, Significantly, no discrete targeting domain could be identified in 5-LO, suggesting that sequences throughout the molecule are required for nuclear envelope localization.	Massachusetts Gen Hosp, Arthrit Unit, Dept Med, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Soberman, RJ (corresponding author), Massachusetts Gen Hosp, Arthrit Unit, Dept Med, E 149 Navy Yard,13th St, Charlestown, MA 02129 USA.				NIDDK NIH HHS [P30DK43351, P01DK-38452] Funding Source: Medline; NIEHS NIH HHS [R01ES-50859] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, P01DK038452] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Belkner J, 1998, J BIOL CHEM, V273, P23225, DOI 10.1074/jbc.273.36.23225; BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; BROCK TG, 1994, J BIOL CHEM, V269, P22059; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; KARGMAN S, 1992, J CELL BIOL, V119, P1701, DOI 10.1083/jcb.119.6.1701; Kuhn H, 1997, J CLIN INVEST, V99, P888, DOI 10.1172/JCI119253; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Lepley RA, 1998, ARCH BIOCHEM BIOPHYS, V356, P71, DOI 10.1006/abbi.1998.0744; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Lepley RA, 1996, ARCH BIOCHEM BIOPHYS, V331, P141, DOI 10.1006/abbi.1996.0292; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; NADEL JA, 1991, J CLIN INVEST, V87, P1139, DOI 10.1172/JCI115110; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Pouliot M, 1997, J IMMUNOL, V158, P4930; Prigge ST, 1996, PROTEINS, V24, P275; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHEWE T, 1986, ADV ENZYMOL RAMB, V58, P191; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGAL E, 1991, AM J PHYSIOL, V260, P13; SOBERMAN RJ, 1985, J BIOL CHEM, V260, P4508; TAKAHASHI Y, 1993, EUR J BIOCHEM, V218, P165, DOI 10.1111/j.1432-1033.1993.tb18362.x; TURK J, 1982, J BIOL CHEM, V257, P7068; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; WATSON A, 1994, BIOCHEM J, V298, P377, DOI 10.1042/bj2980377; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	46	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25594	25598		10.1074/jbc.274.36.25594	http://dx.doi.org/10.1074/jbc.274.36.25594			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464294	hybrid			2022-12-25	WOS:000082554200058
J	Fujita, M; Yamada, C; Goto, H; Yokoyama, N; Kuzushima, K; Inagaki, M; Tsurumi, T				Fujita, M; Yamada, C; Goto, H; Yokoyama, N; Kuzushima, K; Inagaki, M; Tsurumi, T			Cell cycle regulation of human CDC6 protein - Intracellular localization, interaction with the human MCM complex, and CDC2 kinase-mediated hyperphosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION LICENSING SYSTEM; ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; S-PHASE; BUDDING YEAST; FISSION YEAST; HETEROHEXAMERIC COMPLEXES; SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; CHROMATIN BINDING	The binding of mammalian MCM complexes to chromatin is cell cycle-regulated and under CDC2 kinase negative control. Here, we investigated the properties of mammalian CDC6 protein, a candidate regulator of MCM. The levels of CDC6 were relatively constant during the HeLa cell cycle. In asynchronous cells, CDC6 was mainly detected in the nuclei with immunostaining, but some CDC6 was not extractable with nonionic detergent. In contrast to the chromatin-bound MCM, this fraction of CDC6 was resistant to DNase I treatment, suggesting that it binds to the detergent- and nuclease-resistant nuclear structure. In S phase cells, CDC6 became detectable in the cytoplasm with immunostaining; however, the level of the bound CDC6 was unchanged. In G(2)/M phase cells, the level of the bound CDC6 was still maintained, which was hyperphosphorylated by CDC2 kinase, These data suggest that some CDC6 protein is associated with the specific nuclear structure throughout the cell cycle and that major binding sites on chromatin differ between MCM and CDC6, However, co-immunoprecipitation assays with chemical cross-linking indicated that a small part of the chromatin-bound MCM is present close to the bound CDC6.	Aichi Canc Ctr, Res Inst, Lab Viral Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center	Fujita, M (corresponding author), Aichi Canc Ctr, Res Inst, Lab Viral Oncol, Chikusa Ku, Kanokoden 1-1, Nagoya, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016	Fujita, Masatoshi/0000-0001-6617-2452; Goto, Hidemasa/0000-0002-6796-4467				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P45; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Fujita M, 1996, BIOCHEM BIOPH RES CO, V219, P604, DOI 10.1006/bbrc.1996.0280; Fujita M, 1996, J BIOL CHEM, V271, P4349; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Fujita M, 1997, J BIOL CHEM, V272, P10928; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; Lei M, 1996, MOL CELL BIOL, V16, P5081; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MINEO C, 1986, EXP CELL RES, V167, P53, DOI 10.1016/0014-4827(86)90203-X; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603	49	96	96	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25927	25932		10.1074/jbc.274.36.25927	http://dx.doi.org/10.1074/jbc.274.36.25927			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464337	hybrid			2022-12-25	WOS:000082554200101
J	Peabody, DS; Chakerian, A				Peabody, DS; Chakerian, A			Asymmetric contributions to RNA binding by the Thr(45) residues of the MS2 coat protein dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SHEET; AMINO-ACIDS; OPERATOR FRAGMENTS; CRYSTAL-STRUCTURE; SITE; BACTERIOPHAGE-MS2; SEQUENCE; DETERMINANTS; PROPENSITIES; RECOGNITION	A prominent feature of the interaction of MS2 coat protein with RNA is the quasi-symmetric insertion of a bulged adenine (A-10) and a loop adenine (A-4) into conserved pockets on each subunit of the coat protein dimer, Because of its presence in both of these adenine-binding pockets, Thr(45) is thought to play an important role in interaction with RNA on both subunits of the dimer. To test the significance of Thr(45), We introduced all 19 amino acid substitutions, However, we were initially unable to determine the effects of the mutations on RNA binding because every substitution compromised the ability of coat protein to fold correctly, Genetic fusion of coat protein subunits reverted these protein structural defects, allowing us to show that the RNA binding activity of coat protein tolerates substitution of Thr(45), but only on one or the other subunit of the dimer. Single-chain heterodimer complementation experiments suggest that the primary site of Thr(45) interaction with RNA is with A-4 in the translational operator. Either contact of Thr(45) With A-10 makes little contribution to stability of the RNA-protein complex, or the effects of Thr(45) substitution are offset by conformational adjustments that introduce new, favorable contacts at nearby sites.	Univ New Mexico, Sch Med, Dept Microbiol & Mol Genet, Albuquerque, NM 87131 USA	University of New Mexico	Peabody, DS (corresponding author), Univ New Mexico, Sch Med, Dept Microbiol & Mol Genet, Albuquerque, NM 87131 USA.	dpeabody@salud.unm.edu						BORER PN, 1995, BIOCHEMISTRY-US, V34, P6488, DOI 10.1021/bi00019a030; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DRAPER DE, 1988, METHOD ENZYMOL, V164, P221; GOLMOHAMMADI R, 1993, J MOL BIOL, V234, P620, DOI 10.1006/jmbi.1993.1616; Hutchinson EG, 1998, PROTEIN SCI, V7, P2287, DOI 10.1002/pro.5560071106; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIFSON S, 1980, J MOL BIOL, V139, P627, DOI 10.1016/0022-2836(80)90052-2; LIM F, 1994, J BIOL CHEM, V269, P9006; Miller JH., 1972, EXPT MOL GENETICS; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; NI CZ, 1995, STRUCTURE, V3, P255, DOI 10.1016/S0969-2126(01)00156-3; PEABODY DS, 1990, J BIOL CHEM, V265, P5684; Peabody DS, 1996, NUCLEIC ACIDS RES, V24, P2352, DOI 10.1093/nar/24.12.2352; PEABODY DS, 1993, EMBO J, V12, P595, DOI 10.1002/j.1460-2075.1993.tb05691.x; Peabody DS, 1997, ARCH BIOCHEM BIOPHYS, V347, P85, DOI 10.1006/abbi.1997.0312; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; Valegard K, 1997, J MOL BIOL, V270, P724, DOI 10.1006/jmbi.1997.1144; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; van den Worm SHE, 1998, NUCLEIC ACIDS RES, V26, P1345, DOI 10.1093/nar/26.5.1345; van Duin J., 1988, BACTERIOPHAGES, P117, DOI [10.1007/978-1-4684-5424-6_4, DOI 10.1007/978-1-4684-5424-6_4]; WU HN, 1987, BIOCHEMISTRY-US, V26, P8221, DOI 10.1021/bi00399a030	30	13	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25403	25410		10.1074/jbc.274.36.25403	http://dx.doi.org/10.1074/jbc.274.36.25403			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464269	hybrid			2022-12-25	WOS:000082554200033
J	Standaert, ML; Bandyopadhyay, G; Perez, L; Price, D; Galloway, L; Poklepovic, A; Sajan, MP; Cenni, V; Sirri, A; Moscat, J; Toker, A; Farese, RV				Standaert, ML; Bandyopadhyay, G; Perez, L; Price, D; Galloway, L; Poklepovic, A; Sajan, MP; Cenni, V; Sirri, A; Moscat, J; Toker, A; Farese, RV			Insulin activates protein kinases C-zeta and C-lambda by an autophosphorylation-dependent mechanism and stimulates their translocation to GLUT4 vesicles and other membrane fractions in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; REQUIREMENT; TISSUES; CELLS; ALPHA; PDK1	In rat adipocytes, insulin provoked rapid increases in (a) endogenous immunoprecipitable combined protein kinase C (PKC)-zeta/lambda activity in plasma membranes and microsomes and (b) immunoreactive PKC-zeta and PKC-zeta in GLUT4 vesicles. Activity and autophosphorylation of immunoprecipitable epitope-tagged PKC-zeta and PKC-A were also increased by insulin in situ and phosphatidylinositol 3,4,5-(PO4)(3) (PIP3) in vitro, Because phosphoinositide-dependent kinase-1 (PDK-1) is required for phosphorylation of activation loops of PKC-zeta and protein kinase B, we compared their activation. Both RO 31-8220 and myristoylated PKC-zeta pseudosubstrate blocked insulin-induced activation and autophosphorylation of PKC-IIA but did not inhibit PDK-1-dependent (a) protein kinase B phosphorylation/activation or (b) threonine 410 phosphorylation in the activation loop of PKC-zeta. Also, insulin in situ and PIP3 in vitro activated and stimulated autophosphorylation of a PKC-zeta mutant, in which threonine 410 is replaced by glutamate (but not by an inactivating alanine) and cannot be activated by PDK-1. Surprisingly, insulin activated a truncated PKC-zeta that lacks the regulatory (presumably PIP(3)binding) domain; this may reflect PIP3 effects on PDK-1 or transphosphorylation by endogenous full-length PKC-lambda, Our findings suggest that insulin activates both PKC-zeta and PKC-zeta in plasma membranes, microsomes, and GLUT4 vesicles by a mechanism requiring increases in PIP3, PDK-1-dependent phosphorylation of activation loop sites in PKC-zeta and lambda, and subsequent autophosphorylation and/or transphosphorylation.	James A Haley Vet Hosp, Res Serv VAR 151, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Boston Biomed Res Inst, Signal Transduct Grp, Boston, MA 02114 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Boston Biomedical Research Institute	Farese, RV (corresponding author), James A Haley Vet Hosp, Res Serv VAR 151, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rfarese@com1.med.usf.ed	Moscat, Jorge/A-7011-2009; Cenni, Vittoria/C-7361-2019; Farese, Robert/B-3605-2015	Cenni, Vittoria/0000-0001-8062-1840; 	NATIONAL CANCER INSTITUTE [R01CA075134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038079, R01DK065969] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA75134] Funding Source: Medline; NIDDK NIH HHS [2RO1DK38079-09A1, R01 DK065969] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KELLY KL, 1993, J BIOL CHEM, V268, P4391; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; WEBER TM, 1998, BIOCH METHOD B, V12, P171; YANK J, 1996, BIOCHEM J, V313, P125	22	182	189	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25308	25316		10.1074/jbc.274.36.25308	http://dx.doi.org/10.1074/jbc.274.36.25308			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464256	hybrid			2022-12-25	WOS:000082554200021
J	Andrieu-Abadie, N; Jaffrezou, JP; Hatem, S; Laurent, G; Levade, T; Mercadier, JJ				Andrieu-Abadie, N; Jaffrezou, JP; Hatem, S; Laurent, G; Levade, T; Mercadier, JJ			L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation	FASEB JOURNAL			English	Article						staurosporine; cardiotoxicity; oxidative stress; tumor necrosis factor	DAUNORUBICIN-INDUCED APOPTOSIS; GROWTH-FACTOR-I; CELL-DEATH; CARDIOMYOCYTE APOPTOSIS; KAPPA-B; ADRIAMYCIN; CARDIOTOXICITY; ISCHEMIA; NECROSIS; STRESS	Besides the well-documented effect of the chemotherapeutic drug doxorubicin on free radical generation, the exact signaling mechanisms by which it causes cardiac damage remain largely unknown and are of fundamental importance in understanding anthracycline cardiotoxicity In this study, we describe that a 1 h treatment of isolated adult rat cardiac myocytes with doxorubicin (0.5 mu M) induced DNA fragmentation associated with the classical morphological features of apoptosis observed after 7 days of culture, The doxorubicin toxicity was preceded by an increase in intracellular ceramide levels with a concurrent decrease in sphingomyelin, Anthracycline-induced ceramide accumulation resulted from the activation of a sphingomyelinase assayed under acidic conditions, an effect related to an increase in V-max. Pretreatment of cardiac myocytes with L-carnitine (200 mu g/ml), a compound known for its protective effect on cardiac metabolic injuries, was found to dose-dependently inhibit the doxorubicin-induced sphingomyelin hydrolysis and ceramide generation as well as subsequent cell death. However, L-carnitine did not protect cardiac myocytes from apoptosis induced by exogenous cell-permeant ceramide, L-carnitine pretreatment did not affect the sphingomyelinase basal activity but abolished the doxorubicin-induced increase in V-max. Moreover, in vitro studies conducted on cell extracts or with purified acid sphingomyelinase demonstrated that L-carnitine exerted a dose-dependent, sphingomyelinase inhibitory effect (through V-max reduction). Taken together, these findings show that by inhibiting a (perhaps novel) drug-activated acid sphingomyelinase and ceramide generation, L-carnitine can prevent doxorubicin-induced apoptosis of cardiac myocytes.	INSERM U460, UFR Med X Bichat, F-75870 Paris 18, France; CHU Rangueil, Lab Biochim Med, INSERM U466, F-31054 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Andrieu-Abadie, N (corresponding author), INSERM U460, UFR Med X Bichat, 16 Rue Henri Huchard, F-75870 Paris 18, France.	andrieu@bichat.inserm.fr	Levade, Thierry/O-8948-2014; Andrieu-Abadie, Nathalie/N-6793-2013	Andrieu-Abadie, Nathalie/0000-0003-2698-1970; hatem, stephane/0000-0002-9790-0755				AbdelAleem S, 1997, J MOL CELL CARDIOL, V29, P789, DOI 10.1006/jmcc.1996.0323; ALESSE E, 1997, CARNITINE TODAY, P105; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; Bielawska AE, 1997, AM J PATHOL, V151, P1257; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; Bromme HJ, 1996, MOL CELL BIOCHEM, V164, P261; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cossarizza A, 1997, AIDS, V11, P19, DOI 10.1097/00002030-199701000-00004; Delpy E, 1998, CIRCULATION, V98, P742; DiMarzio L, 1997, P ASSOC AM PHYSICIAN, V109, P154; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; ETTINGHAUSEN SE, 1986, ARCH SURG-CHICAGO, V121, P1445; FOLCH J, 1957, J BIOL CHEM, V226, P497; GALLI G, 1993, EXP CELL RES, V204, P54, DOI 10.1006/excr.1993.1008; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GOLDSMITH MA, 1979, CANCER TREAT REP, V63, P558; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HITCHCOCKBRYAN S, 1986, MED PEDIATR ONCOL, V14, P211, DOI 10.1002/mpo.2950140405; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAFFREZOU JP, 1991, J BIOL CHEM, V266, P19858; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Kawasaki N, 1996, J Card Fail, V2, P293, DOI 10.1016/S1071-9164(96)80016-9; KISIC A, 1974, J LIPID RES, V15, P179; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; KUMARI SS, 1987, INDIAN J EXP BIOL, V25, P419; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; MACCARI F, 1981, BIOMED EXPRESS, V35, P65; MCFALLS EO, 1986, LIFE SCI, V38, P497, DOI 10.1016/0024-3205(86)90028-7; MEDIN JA, 1999, IN PRESS HUM GENE TH; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; NERI B, 1986, ANTICANCER RES, V6, P659; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLSON HM, 1974, AM J PATHOL, V77, P439; OLSON RD, 1981, LIFE SCI, V29, P1393, DOI 10.1016/0024-3205(81)90001-1; OLSON RD, 1990, FASEB J, V4, P3076, DOI 10.1096/fasebj.4.13.2210154; PATERNA S, 1984, INT J TISSUE REACT, V6, P91; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; PRIGENT P, 1993, J IMMUNOL METHODS, V160, P139, DOI 10.1016/0022-1759(93)90018-3; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RAJAGOPALAN S, 1988, CANCER RES, V48, P4766; REVOLTELLA RP, 1994, BBA-MOL CELL RES, V1224, P333, DOI 10.1016/0167-4889(94)90265-8; ROSENOFF SH, 1975, BIOCHEM PHARMACOL, V24, P1898, DOI 10.1016/0006-2952(75)90413-X; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Shan K, 1996, ANN INTERN MED, V125, P47, DOI 10.7326/0003-4819-125-1-199607010-00008; SHUG AL, 1978, ARCH BIOCHEM BIOPHYS, V187, P25, DOI 10.1016/0003-9861(78)90003-6; Singal PK, 1997, FASEB J, V11, P931, DOI 10.1096/fasebj.11.12.9337145; SPETH PAJ, 1987, CANCER CHEMOTH PHARM, V20, P311; Tatlican O, 1998, CARDIOVASC SURG, V6, P145, DOI 10.1016/S0967-2109(97)00138-5; Umansky SR, 1997, CELL DEATH DIFFER, V4, P608, DOI 10.1038/sj.cdd.4400282; VANVELDHOVEN PP, 1995, BIOCHEM MOL BIOL INT, V36, P21; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yue TL, 1998, CIRC RES, V82, P166; Yue TL, 1998, J MOL CELL CARDIOL, V30, P495, DOI 10.1006/jmcc.1997.0614	65	156	169	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1999	13	12					1501	1510		10.1096/fasebj.13.12.1501	http://dx.doi.org/10.1096/fasebj.13.12.1501			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463940				2022-12-25	WOS:000082347600004
J	Dreier, J; Shah, AN; Khosla, C				Dreier, J; Shah, AN; Khosla, C			Kinetic analysis of the actinorhodin aromatic polyketide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; STREPTOMYCES-COELICOLOR A3(2); MALONYL-COENZYME-A; ESCHERICHIA-COLI; FATTY-ACID; IN-VITRO; ANTIBIOTIC ACTINORHODIN; ENGINEERED BIOSYNTHESIS; 3-DIMENSIONAL STRUCTURE; HYBRID ANTIBIOTICS	Type II polyketide synthases (PKSs) are bacterial multienzyme systems that catalyze the biosynthesis of a broad range of natural products. A core set of subunits, consisting of a ketosynthase, a chain length factor, an acyl carrier protein (ACP) and possibly a malonyl CoA:ACP transacylase (MAT) forms a "minimal" PKS, They generate a poly-beta-ketone backbone of a specified length from malonyl-CoA derived building blocks. Here we (a) report on the kinetic properties of the actinorhodin minimal PKS, and (b) present further data in support of the requirement of the MAT. Kinetic analysis showed that the apoACP is a competitive inhibitor of minimal PKS activity, demonstrating the importance of protein-protein interactions between the polypeptide moiety of the ACP and the remainder of the minimal PKS, In further support of the requirement of MAT for PKS activity, two new findings are presented. First, we observe hyperbolic dependence of PKS activity on MAT concentration, saturating at very low amounts (half-maximal rate at 19.7 +/- 5.1 nM), Since MAT can support PKS activity at less than 1/100 the typical concentration of the ACP and ketosynthase/chain length factor components, it is difficult to rule out the presence of trace quantities of MAT in a PKS reaction mixture. Second, an S97A mutant was constructed at the nucleophilic active site of the MAT, Not only can this mutant protein support PKS activity, it is also covalently labeled by [C-14]malonyl-CoA, demonstrating that the serine nucleophile (which has been the target of PMSF inhibition in earlier studies) is dispensible for MAT activity in a Type II PKS system.	Stanford Univ, Dept Chem Engn MC5025, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Khosla, C (corresponding author), Stanford Univ, Dept Chem Engn MC5025, Stanford, CA 94305 USA.			Khosla, Chaitan/0000-0001-6529-495X	NATIONAL CANCER INSTITUTE [R01CA077248] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREC M, 1995, PROTEIN SCI, V4, P983; Bao WL, 1998, BIOCHEMISTRY-US, V37, P8132, DOI 10.1021/bi980466i; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; Carreras CW, 1996, J AM CHEM SOC, V118, P5158, DOI 10.1021/ja960479o; Carreras CW, 1997, TOP CURR CHEM, V188, P85; Carreras CW, 1997, BIOCHEMISTRY-US, V36, P11757, DOI 10.1021/bi971350+; Carreras CW, 1998, BIOCHEMISTRY-US, V37, P2084, DOI 10.1021/bi972919+; Crump MP, 1997, BIOCHEMISTRY-US, V36, P6000, DOI 10.1021/bi970006+; Crump MP, 1996, FEBS LETT, V391, P302, DOI 10.1016/0014-5793(96)00756-9; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; Ghose R, 1996, FEBS LETT, V388, P66, DOI 10.1016/0014-5793(96)00512-1; GRAMAJO HC, 1991, J BACTERIOL, V173, P6475, DOI 10.1128/jb.173.20.6475-6483.1991; Hitchman TS, 1998, CHEM BIOL, V5, P35, DOI 10.1016/S1074-5521(98)90085-0; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P6135, DOI 10.1021/bi00416a046; HOLAK TA, 1988, EUR J BIOCHEM, V175, P9, DOI 10.1111/j.1432-1033.1988.tb14159.x; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; JACKOWSKI S, 1983, J BIOL CHEM, V258, P5186; Jacobsen JR, 1997, SCIENCE, V277, P367, DOI 10.1126/science.277.5324.367; JOSHI VC, 1971, ARCH BIOCHEM BIOPHYS, V143, P493, DOI 10.1016/0003-9861(71)90234-7; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Keating DH, 1996, J BACTERIOL, V178, P2662, DOI 10.1128/jb.178.9.2662-2667.1996; KHOSLA C, 1993, J BACTERIOL, V175, P2197, DOI 10.1128/JB.175.8.2197-2204.1993; Khosla C, 1996, TRENDS BIOTECHNOL, V14, P335, DOI 10.1016/0167-7799(96)10046-9; KIM YM, 1990, PROTEINS, V8, P377, DOI 10.1002/prot.340080411; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; Matharu AL, 1998, CHEM BIOL, V5, P699, DOI 10.1016/S1074-5521(98)90663-9; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; NAKANO MM, 1992, MOL GEN GENET, V232, P313, DOI 10.1007/BF00280011; Oswood MC, 1997, PROTEINS, V27, P131; REVILL WP, 1995, J BACTERIOL, V177, P3946, DOI 10.1128/jb.177.14.3946-3952.1995; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SUMMERS RG, 1995, BIOCHEMISTRY-US, V34, P9389, DOI 10.1021/bi00029a015	38	51	53	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25108	25112		10.1074/jbc.274.35.25108	http://dx.doi.org/10.1074/jbc.274.35.25108			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455191	hybrid			2022-12-25	WOS:000082193400090
J	Libermann, TA; Pan, Z; Akbarali, Y; Hetherington, CJ; Boltax, J; Yergeau, DA; Zhang, DE				Libermann, TA; Pan, Z; Akbarali, Y; Hetherington, CJ; Boltax, J; Yergeau, DA; Zhang, DE			AML1 (CBF alpha 2) cooperates with B cell-specific activating protein (BSAP/PAX5) in activation of the B cell-specific BLK gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR BSAP; CORE-BINDING-FACTOR; STIMULATING FACTOR-RECEPTOR; IMMATURE MYELOID CELLS; TYROSINE KINASE GENE; LYMPHOCYTES-B; NF-HB; SYNERGISTICALLY ACTIVATE; MURINE MYELOPEROXIDASE; ANTIGEN RECEPTOR	AML1 plays a critical role during hematopoiesis and chromosomal translocations involving ARML1 are commonly associated with different forms of leukemia, including pre-B acute lymphoblastic leukemia. To understand the function of AML1 during B cell differentiation, we analyzed regulatory regions of B cell-specific genes for potential AML1-binding sites and have identified a putative AML1-binding site in the promoter of the B cell-specific tyrosine kinase gene, blk, Gel mobility shift assays and transient transfection assays demonstrate that AML1 binds specifically to this site in the blk promoter and this binding site is important for blk promoter activity. Furthermore, in vitro binding analysis revealed that the AML1 runt DNA-binding domain physically interacts with the paired DNA-binding domain of BSAP, a B cell-specific transcription factor. BSAP has been shown previously to be important for B cell-specific regulation of the blk gene. Physical interaction of AML1 with BSAP correlates with functional cooperativity in transfection studies where AML1 and BSAP synergistically activate blk promoter transcription by more than 50-fold. These results demonstrate physical and functional interactions between AML1 and BSAP and suggest that AML1 is an important factor for regulating a critical B cell-specific gene, blk.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02115 USA; New England Baptist Bone & Joint Inst, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; New England Baptist Hospital	Zhang, DE (corresponding author), Harvard Inst Med, Rm 953,77 Ave Louis Pasteur, Boston, MA 02115 USA.		Libermann, Towia/F-9866-2010	Libermann, Towia/0000-0002-4006-8179	NCI NIH HHS [CA/AI59589, CA72009] Funding Source: Medline; NIAID NIH HHS [AI39613] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072009, R29CA059589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039613] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; ERICKSON P, 1992, BLOOD, V80, P1825; Erman B, 1998, MOL CELL BIOL, V18, P1322, DOI 10.1128/MCB.18.3.1322; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIAO F, 1994, J IMMUNOL, V152, P2904; LIN JJ, 1992, J IMMUNOL, V149, P1548; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Malek SN, 1998, P NATL ACAD SCI USA, V95, P7351, DOI 10.1073/pnas.95.13.7351; MASON DY, 1992, EUR J IMMUNOL, V22, P2753, DOI 10.1002/eji.1830221044; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NEURATH MF, 1995, IMMUNOL TODAY, V16, P564, DOI 10.1016/0167-5699(95)80078-6; NEURATH MF, 1994, J IMMUNOL, V153, P730; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1995, BLOOD, V86, P1; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; Rinkenberger JL, 1996, IMMUNITY, V5, P377, DOI 10.1016/S1074-7613(00)80263-0; ROWLEY JD, 1990, SEMIN HEMATOL, V27, P122; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; YAO XR, 1993, IMMUNOL REV, V132, P163, DOI 10.1111/j.1600-065X.1993.tb00842.x; YAO XR, 1993, P NATL ACAD SCI USA, V90, P7946, DOI 10.1073/pnas.90.17.7946; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310; Zwollo P, 1998, J BIOL CHEM, V273, P18647, DOI 10.1074/jbc.273.29.18647	63	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24671	24676		10.1074/jbc.274.35.24671	http://dx.doi.org/10.1074/jbc.274.35.24671			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455134	hybrid			2022-12-25	WOS:000082193400033
J	Petrakis, TG; Ktistaki, E; Wang, LY; Eriksson, S; Talianidis, I				Petrakis, TG; Ktistaki, E; Wang, LY; Eriksson, S; Talianidis, I			Cloning and characterization of mouse deoxyguanosine kinase - Evidence for a cytoplasmic isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; SUBSTRATE-SPECIFICITY; DEOXYCYTIDINE KINASE; THYMIDINE KINASE; MAMMALIAN-CELLS; EXPRESSION; CDNA; PHOSPHORYLATION; DEOXYTHYMIDINE; OVEREXPRESSION	Deoxyguanosine kinase (dGK) is a nuclear gene product that catalyzes the phosphorylation of purine deoxyribonucleosides and their analogues. The human enzyme is located predominantly in the mitochondria, as shown by biochemical fractionation studies and in situ localization of the overexpressed recombinant protein. Here we describe the cloning of mouse dGK cDNA and the identification of a novel amino-terminally truncated isoform that corresponds to about 14% of the total dGK mRNA population in mouse spleen. In situ fluorescence assays suggest that the new isoform cannot translocate into the mitochondria and thus may represent a cytoplasmic enzyme. Expression of mouse dGK mRNA was highly tissue-specific and differed from the tissue distribution observed in humans. Recombinant mouse dGK showed similar specific activity and substrate specificity as compared with the human enzyme. The broad specificity, restricted tissue distribution, and location of mouse dGK in multiple cellular compartments raise new considerations with respect to the role of the individual deoxynucleoside kinases in nucleotide metabolism.	Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Heraklion 71110, Crete, Greece; Biomed Ctr, Dept Vet Med Chem, S-75123 Uppsala, Sweden	Foundation for Research & Technology - Hellas (FORTH)	Talianidis, I (corresponding author), Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, POB 1527, Heraklion 71110, Crete, Greece.		Talianidis, Iannis/F-7556-2016	Talianidis, Iannis/0000-0002-1209-3609				ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; Bianchi V, 1997, J BIOL CHEM, V272, P16118, DOI 10.1074/jbc.272.26.16118; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; CHANG CN, 1992, J BIOL CHEM, V267, P22414; Eriksson S, 1997, NUCLEOS NUCLEOT, V16, P653, DOI 10.1080/07328319708002930; HABTEYESUS A, 1991, BIOCHEM PHARMACOL, V42, P1829, DOI 10.1016/0006-2952(91)90522-7; Hatzis P, 1998, J BIOL CHEM, V273, P30239, DOI 10.1074/jbc.273.46.30239; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; Johansson M, 1997, P NATL ACAD SCI USA, V94, P11941, DOI 10.1073/pnas.94.22.11941; Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258; KARLSSON A, 1994, J BIOL CHEM, V269, P24374; Kritis AA, 1996, GENE, V173, P275, DOI 10.1016/0378-1119(96)00183-7; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; NEUPERT W, 1994, CLIN INVESTIGATOR, V72, P251; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Sambrook J., 2002, MOL CLONING LAB MANU; Sjoberg AH, 1998, MOL PHARMACOL, V53, P270, DOI 10.1124/mol.53.2.270; Wang JH, 1996, ANTIMICROB AGENTS CH, V40, P1555, DOI 10.1128/AAC.40.6.1555; Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6; WANG LY, 1993, J BIOL CHEM, V268, P22847; Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0; XU YZ, 1995, J BIOL CHEM, V270, P631, DOI 10.1074/jbc.270.2.631; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459; ZHU C, 1998, BIOCHEM PHARMACOL, V15, P1035; Zhu CY, 1998, J BIOL CHEM, V273, P14707, DOI 10.1074/jbc.273.24.14707	30	13	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24726	24730		10.1074/jbc.274.35.24726	http://dx.doi.org/10.1074/jbc.274.35.24726			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455141	hybrid			2022-12-25	WOS:000082193400040
J	Coombs, GS; Rao, MS; Olson, AJ; Dawson, PE; Madison, EL				Coombs, GS; Rao, MS; Olson, AJ; Dawson, PE; Madison, EL			Revisiting catalysis by chymotrypsin family serine proteases using peptide substrates and inhibitors with unnatural main chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-VENTRAL PATTERN; PLASMINOGEN-ACTIVATOR; DROSOPHILA EMBRYO; CONVERTING TRYPSIN; BLOOD-COAGULATION; AUTOMATED DOCKING; FLEXIBLE LIGANDS; SPECIFICITY; TISSUE; UROKINASE	Chymotrypsin family serine proteases play essential roles in key biological and pathological processes and are frequently targets of drug discovery efforts. This large enzyme family is also among the most advanced model systems for detailed studies of enzyme mechanism and structure/function relationships. Productive interactions between these enzymes and their substrates are widely believed to mimic the "canonical" interactions between serine proteases and "standard" inhibitors observed in numerous protease-inhibitor complexes. To test this central hypothesis we have synthesized and characterized a series of peptide analogs, based on model substrates and inhibitors of trypsin, that contain unnatural main chains. These results call into question a long accepted theory regarding the interaction of chymotrypsin family serine proteases with substrates and suggest that the canonical interactions observed between these enzymes and standard inhibitors may represent nonproductive rather than productive, substrate-like interactions.	Corvas Int, Dept Mol Biol, San Diego, CA 92121 USA; Skaggs Inst Chem Biol, Dept Cell Biol, Scripps Res Inst, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, Dept Vasc Biol, Scripps Res Inst, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, Dept Mol Biol, Scripps Res Inst, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, Dept Chem, Scripps Res Inst, La Jolla, CA 92037 USA; Corvas Int, Dept Mol Biol, San Diego, CA 92121 USA; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Torrey Pines Institute for Molecular Studies, California	Madison, EL (corresponding author), Corvas Int, Dept Mol Biol, 3030 Sci Pk Rd, San Diego, CA 92121 USA.			Coombs, Gary/0000-0002-0711-185X	NHLBI NIH HHS [R01 HL52475] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052475] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; ARAD O, 1990, BIOPOLYMERS, V29, P1633, DOI 10.1002/bip.360291212; ARNETT EM, 1974, J AM CHEM SOC, V96, P3875, DOI 10.1021/ja00819a028; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; BODE W, 1990, EUR J BIOCHEM, V193, P175, DOI 10.1111/j.1432-1033.1990.tb19320.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BRAMSON HN, 1985, J BIOL CHEM, V260, P5452; Chapman E, 1997, J AM CHEM SOC, V119, P7151, DOI 10.1021/ja970826+; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; COOMBS GS, 1995, BIOORG MED CHEM LETT, V5, P611, DOI 10.1016/0960-894X(95)00082-5; Coombs GS, 1996, J BIOL CHEM, V271, P4461; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; EICHLER J, 1993, BIOCHEMISTRY-US, V32, P11035, DOI 10.1021/bi00092a013; ESMON CT, 1989, J BIOL CHEM, V264, P4743; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8757, DOI 10.1021/bi00195a017; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8764, DOI 10.1021/bi00195a018; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; INGWALL RT, 1974, MACROMOLECULES, V7, P598, DOI 10.1021/ma60041a011; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; Ke SH, 1997, J BIOL CHEM, V272, P20456, DOI 10.1074/jbc.272.33.20456; Koh JT, 1997, BIOCHEMISTRY-US, V36, P11314, DOI 10.1021/bi9707685; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; Lu WY, 1997, BIOCHEMISTRY-US, V36, P673, DOI 10.1021/bi9625612; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; READ RJ, 1986, PROTEINASE INHIBITOR, P301; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; THOMAS NE, 1987, BIOCHEMISTRY-US, V26, P4461, DOI 10.1021/bi00388a041; TURK D, 1991, FEBS LETT, V287, P133, DOI 10.1016/0014-5793(91)80033-Y; WALZ DA, 1986, BIOREGULATORY FUNCTI, V485; WIBERG KB, 1987, J AM CHEM SOC, V109, P5935, DOI 10.1021/ja00254a006	47	39	48	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24074	24079		10.1074/jbc.274.34.24074	http://dx.doi.org/10.1074/jbc.274.34.24074			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446178	hybrid			2022-12-25	WOS:000082110900057
J	Hale, TK; Braithwaite, AW				Hale, TK; Braithwaite, AW			The adenovirus oncoprotein E1a stimulates binding of transcription factor ETF to transcriptionally activate the p53 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; DNA-DAMAGE; TUMOR-SUPPRESSOR; MOUSE CELLS; TRANSACTIVATION DOMAIN; MESSENGER-RNAS; NUCLEAR FACTOR; TATA BOX; PROTEIN; APOPTOSIS	Expression of the tumor suppressor protein p53 plays an important role in regulating the cellular response to DNA damage. During adenovirus infection, levels of p53 protein also increase. It has been shown that this increase is due not only to increased stability of the p53 protein but to the transcriptional activation of the p53 gene during infection. We demonstrate here that the E1a proteins of adenovirus are responsible for activating the mouse p53 gene and that both major E1a proteins, 243R and 289R, are required for complete activation. E1a brings about the binding of two cellular transcription factors to the mouse p53 promoter. One of these, ETF, binds to three upstream sites in the p53 promoter and one downstream site, whereas E2F binds to one upstream site in the presence of E1a. Our studies indicate that E2F binding is not essential for activation of the p53 promoter but that ETF is. Our data indicate the ETF site located downstream of the start site of transcription is the key site in conferring E1a responsiveness on the p53 promoter.	Univ Otago, Dunedin Sch Mecd, Dept Pathol, Dunedin 9000, New Zealand	University of Otago	Hale, TK (corresponding author), Univ Otago, Dunedin Sch Mecd, Dept Pathol, POB 913, Dunedin 9000, New Zealand.	tracy.hale@stonebow.otago.ac.nz						Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BELLETT AJD, 1979, J CELL PHYSIOL, V101, P33, DOI 10.1002/jcp.1041010106; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BIENZTADMOR B, 1985, THESIS WEIZMANN I SC, P53; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GINSBERG D, 1990, ONCOGENE, V5, P1285; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; HALE TK, 1995, NUCLEIC ACIDS RES, V23, P663, DOI 10.1093/nar/23.4.663; HALL PA, 1993, ONCOGENE, V8, P203; Hansen RS, 1996, ONCOGENE, V13, P995; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; JACKSON P, 1993, ONCOGENE, V8, P589; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; Lane D, 1998, NATURE, V394, P616, DOI 10.1038/29166; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU HT, 1985, MOL CELL BIOL, V5, P2936, DOI 10.1128/MCB.5.11.2936; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAGUIRE K, 1991, ONCOGENE, V6, P1417; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mazzarelli JM, 1997, J VIROL, V71, P7978, DOI 10.1128/JVI.71.10.7978-7983.1997; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; Nakajima T, 1998, J BIOL CHEM, V273, P20036, DOI 10.1074/jbc.273.32.20036; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHENK T, 1991, ADV CANCER RES, V57, P47; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SUN XG, 1995, MOL CELL BIOL, V15, P4489; TEODORO JG, 1995, ONCOGENE, V11, P467; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU HY, 1994, J BIOL CHEM, V269, P20067	82	21	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23777	23786		10.1074/jbc.274.34.23777	http://dx.doi.org/10.1074/jbc.274.34.23777			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446138	hybrid			2022-12-25	WOS:000082110900017
J	Hellmich, MR; Ives, KL; Udupi, V; Soloff, MS; Greeley, GH; Christensen, BN; Townsend, CM				Hellmich, MR; Ives, KL; Udupi, V; Soloff, MS; Greeley, GH; Christensen, BN; Townsend, CM			Multiple protein kinase pathways are involved in gastrin-releasing peptide receptor-regulated secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOID CELL-LINE; INTRACELLULAR CALCIUM; NA+/CA2+ EXCHANGE; CA2+ OSCILLATIONS; BOMBESIN ANALOGS; ACID-SECRETION; RAT; PHOSPHORYLATION; CANCER; GROWTH	Gastrin-releasing peptide (GRP) and its amphibian homolog, bombesin, are potent secretogogues in mammals. We determined the roles of intracellular free Ca2+ ([Ca2+](i)), protein kinase C (PKC), and mitogen-activated protein kinases (MASK) in GRP receptor (GRP-R)-regulated secretion. Bombesin induced either [Ca2+](i) oscillations or a biphasic elevation in [Ca2+](i). The biphasic response was associated with peptide secretion. Receptor-activated secretion was blocked by removal of extracellular Ca2+, by chelation of [Ca2+](i), and by treatment with inhibitors of phospholipase C, conventional PKC isozymes, and MAPK kinase (MEK). Agonist-induced increases in [Ca2+](i) were also inhibited by dominant negative MEK-1 and the MEK inhibitor, PD89059, but not by an inhibitor of PKC. Direct activation of PKC by a phorbol ester activated MAPK and stimulated peptide secretion without a concomitant increase in [Ca2+](i). Inhibition of MEK blocked both bombesin- and phorbol la-myristate 13-acetate induced secretion. GRP-R-regulated secretion is initiated by an increase in [Ca2+](i); however, elevated [Ca2+](i) is insufficient to stimulate secretion in the absence of activation of PKC and the downstream MEK/MAPK pathways. We demonstrated that the activity of MEK is important for maintaining elevated [Ca2+](i) levels induced by GRP-R activation, suggesting that MEK may affect receptor-regulated secretion by modulating the activity of Ca2+-sensitive PKC.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Hellmich, MR (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035608] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK35608] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdullah LH, 1997, AM J PHYSIOL-LUNG C, V273, pL201, DOI 10.1152/ajplung.1997.273.1.L201; Aprikian AG, 1996, J MOL ENDOCRINOL, V16, P297, DOI 10.1677/jme.0.0160297; BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BEAUGE L, 1991, ANN NY ACAD SCI, V639, P147, DOI 10.1111/j.1749-6632.1991.tb17298.x; BOLD RJ, 1994, J CELL PHYSIOL, V161, P519, DOI 10.1002/jcp.1041610315; CHILDS GV, 1987, AM J PHYSIOL, V252, pE347, DOI 10.1152/ajpendo.1987.252.3.E347; Cox ME, 1997, J NEUROCHEM, V69, P1119; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DOYLE H, 1985, SURGERY, V97, P337; Ethridge RT, 1998, GASTROENTEROLOGY, V115, P1454, DOI 10.1016/S0016-5085(98)70024-1; EVERS BM, 1991, GASTROENTEROLOGY, V101, P303, DOI 10.1016/0016-5085(91)90004-5; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; HOLL RW, 1988, J BIOL CHEM, V263, P9682; JENG YJ, 1991, ENDOCRINOLOGY, V128, P220, DOI 10.1210/endo-128-1-220; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kim HJ, 1996, SURGERY, V120, P130, DOI 10.1016/S0039-6060(96)80279-0; Kim JS, 1997, AM J RESP CELL MOL, V16, P259, DOI 10.1165/ajrcmb.16.3.9070610; Kohjitani A, 1996, PEPTIDES, V17, P927; KOVACS TOG, 1995, AM J PHYSIOL-GASTR L, V268, pG54, DOI 10.1152/ajpgi.1995.268.1.G54; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; Ladenheim EE, 1997, EUR J PHARMACOL, V319, P245, DOI 10.1016/S0014-2999(96)00854-0; LI G, 1996, CELL CALCIUM, V19, P523; LIU JP, 1994, MOL CELL ENDOCRINOL, V101, P247, DOI 10.1016/0303-7207(94)90241-0; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MALGORZATA A, 1998, J NEUROSCI, V18, P112; MARKI W, 1981, PEPTIDES, V2, P169, DOI 10.1016/0196-9781(81)90027-9; MICCI MA, 1998, AM J PHYSIOL-CELL PH, V43, pC1625; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nemoz-Gaillard E, 1998, BIOCHEM J, V331, P129, DOI 10.1042/bj3310129; OSTROWSKI J, 1989, AM J PHYSIOL, V256, pC873, DOI 10.1152/ajpcell.1989.256.4.C873; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH D, 1994, PANCREAS, V9, P83, DOI 10.1097/00006676-199401000-00013; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; Poitras P, 1997, AM J PHYSIOL-GASTR L, V272, pG4, DOI 10.1152/ajpgi.1997.272.1.G4; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Rottingen JA, 1997, CELL CALCIUM, V21, P195, DOI 10.1016/S0143-4160(97)90044-0; Seensalu R, 1997, J CLIN INVEST, V100, P1037, DOI 10.1172/JCI119614; Shimizu H, 1997, CELL CALCIUM, V21, P31, DOI 10.1016/S0143-4160(97)90094-4; Shuttleworth TJ, 1997, J EXP BIOL, V200, P303; SNOW ND, 1994, AM J PHYSIOL-GASTR L, V267, pG859, DOI 10.1152/ajpgi.1994.267.5.G859; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; Weigert N, 1996, NEUROPEPTIDES, V30, P521, DOI 10.1016/S0143-4179(96)90033-5; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; ZHANG T, 1995, ENDOCRINOLOGY, V136, P2252, DOI 10.1210/en.136.5.2252	47	53	56	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23901	23909		10.1074/jbc.274.34.23901	http://dx.doi.org/10.1074/jbc.274.34.23901			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446156	hybrid			2022-12-25	WOS:000082110900035
J	Karimi-Busheri, F; Daly, G; Robins, P; Canas, B; Pappin, DJC; Sgouros, J; Miller, GG; Fakhrai, H; Davis, EM; Le Beau, MM; Weinfeld, M				Karimi-Busheri, F; Daly, G; Robins, P; Canas, B; Pappin, DJC; Sgouros, J; Miller, GG; Fakhrai, H; Davis, EM; Le Beau, MM; Weinfeld, M			Molecular characterization of a human DNA kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYNUCLEOTIDE KINASE; STRAND BREAKS; IRRADIATED THYMOCYTES; DEOXYRIBONUCLEASE-II; MAMMALIAN-CELLS; END-GROUPS; IDENTIFICATION; APOPTOSIS; PROTEINS; CLONING	Human polydeoxyribonucleotide kinase is an enzyme that has the capacity to phosphorylate DNA at 5'-hydroxyl termini and dephosphorylate 3'-phosphate termini and, therefore, can be considered a putative DNA repair enzyme. The enzyme was purified from HeLa cells. Amino acid sequence was obtained for several tryptic fragments by mass spectrometry, The sequences were matched through the dbEST data base with an incomplete human cDNA clone, which was used as a probe to retrieve the 5' end of the cDNA sequence from a separate cDNA library. The complete cDNA, which codes for a 521-amino acid protein (57.1 kDa), was expressed in Escherichia coli, and the recombinant protein was shown to possess the kinase and phosphatase activities. Comparison with other sequenced proteins identified a P-loop motif, indicative of an ATP-binding domain, and a second motif associated with several different phosphatases, There is reasonable sequence similarity to putative open reading frames in the genomes of Caenorhabditis elegans and Schizosaccharomyces pombe, but similarity to bacteriophage T4 polynucleotide kinase is limited to the kinase and phosphatase domains noted above. Northern hybridization revealed a major transcript of approximately 2.3 kilobases and a minor transcript of approximately 7 kilobases, Pancreas, heart, and kidney appear to have higher levels of mRNA than brain, lung, or liver. Confocal microscopy of human A549 cells indicated that the kinase resides predominantly in the nucleus. The gene encoding the enzyme was mapped to chromosome band 19q13.4.	Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Imperial Canc Res Fund, London WC2A 3PX, England; Univ Alberta, Noujaim Inst Pharmaceut Oncol Res, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada; Adv Biotherapies, San Diego, CA 92121 USA; Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA	University of Alberta; Cancer Research UK; University of Alberta; University of Chicago	Weinfeld, M (corresponding author), Univ Alberta, Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	mweinfel@gpu.srv.ualberta.ca	Karimi-Busheri, Feridoun/AAX-7541-2020; CANAS, BENITO/O-9256-2019	Sgouros, John G./0000-0002-9141-5257; Pappin, Darryl/0000-0002-8981-8401; Karimi-Busheri, Feridoun/0000-0002-1936-0503	NCI NIH HHS [CA40046] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; AUSTIN GE, 1978, BIOCHIM BIOPHYS ACTA, V522, P412, DOI 10.1016/0005-2744(78)90074-8; BARRY MA, 1993, CANCER RES, V53, P2349; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BERNARDI G, 1968, ADV ENZYMOL RAMB, V31, P1; BOSDAL T, 1985, BIOCHIM BIOPHYS ACTA, V840, P280, DOI 10.1016/0304-4165(85)90129-1; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; COQUERELLE T, 1973, INT J RADIAT BIOL, V24, P397, DOI 10.1080/09553007314551251; COULL J M, 1990, Journal of Protein Chemistry, V9, P259; HABRAKEN Y, 1983, FEBS LETT, V160, P46, DOI 10.1016/0014-5793(83)80933-8; HABRAKEN Y, 1988, EUR J BIOCHEM, V171, P59, DOI 10.1111/j.1432-1033.1988.tb13758.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HENNER WD, 1983, J BIOL CHEM, V258, P711; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; ICHIMURA M, 1971, J BIOCHEM-TOKYO, V69, P823, DOI 10.1093/oxfordjournals.jbchem.a129533; Jilani A, 1999, J CELL BIOCHEM, V73, P188, DOI 10.1002/(SICI)1097-4644(19990501)73:2<188::AID-JCB5>3.3.CO;2-8; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; Karimi-Busheri F, 1998, NUCLEIC ACIDS RES, V26, P4395, DOI 10.1093/nar/26.19.4395; KarimiBusheri F, 1997, J CELL BIOCHEM, V64, P258, DOI 10.1002/(SICI)1097-4644(199702)64:2<258::AID-JCB9>3.0.CO;2-W; Kleppe K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P245; LENNARTZ M, 1975, INT J RADIAT BIOL, V27, P577, DOI 10.1080/09553007514550611; LEVIN CJ, 1976, J BIOL CHEM, V251, P1767; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MIDGLEY CA, 1985, EMBO J, V4, P2695, DOI 10.1002/j.1460-2075.1985.tb03989.x; MILLER GG, 1995, PHOTOCHEM PHOTOBIOL, V61, P632, DOI 10.1111/j.1751-1097.1995.tb09880.x; MOCK KK, 1992, RAPID COMMUN MASS SP, V6, P233, DOI 10.1002/rcm.1290060402; OHMURA Y, 1987, EUR J BIOCHEM, V162, P15, DOI 10.1111/j.1432-1033.1987.tb10534.x; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Pappin DJC, 1996, MASS SPECTROMETRY BI, P135; PHEIFFER BH, 1982, BIOCHEM BIOPH RES CO, V109, P1297, DOI 10.1016/0006-291X(82)91918-0; Pohjanpelto P, 1996, EMBO J, V15, P1193, DOI 10.1002/j.1460-2075.1996.tb00458.x; PRINOS P, 1995, J CELL BIOCHEM, V58, P115, DOI 10.1002/jcb.240580114; RICHARDSON CC, 1965, P NATL ACAD SCI USA, V54, P158, DOI 10.1073/pnas.54.1.158; RICHARDSON CC, 1971, PROCEDURES NUCLEIC A, V2, P815; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; Sambrook J., 2002, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHERMAN NE, 1995, P 43 ASMS C MASS SPE; SUTTON CW, 1995, ELECTROPHORESIS, V16, P308, DOI 10.1002/elps.1150160151; TAMURA S, 1981, EUR J BIOCHEM, V115, P449; TERAOKA H, 1975, EUR J BIOCHEM, V58, P297, DOI 10.1111/j.1432-1033.1975.tb02376.x; TORRIGLIA A, 1995, J BIOL CHEM, V270, P28579, DOI 10.1074/jbc.270.48.28579; Torriglia A, 1998, MOL CELL BIOL, V18, P3612, DOI 10.1128/MCB.18.6.3612; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; Yasuda T, 1998, J BIOL CHEM, V273, P2610, DOI 10.1074/jbc.273.5.2610; YOKOI T, 1990, FORENSIC SCI INT, V45, P39, DOI 10.1016/0379-0738(90)90219-O	48	189	194	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24187	24194		10.1074/jbc.274.34.24187	http://dx.doi.org/10.1074/jbc.274.34.24187			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446193	hybrid			2022-12-25	WOS:000082110900072
J	Olivares, M; Thomas, MC; Alonso, C; Lopez, MC				Olivares, M; Thomas, MC; Alonso, C; Lopez, MC			The L1Tc, long interspersed nucleotide element from Trypanosoma cruzi, encodes a protein with 3 '-phosphatase and 3 '-phosphodiesterase enzymatic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENDONUCLEASE-IV; NUCLEASE ACTIVITY; EXONUCLEASE-III; DNA-DAMAGE; RETROTRANSPOSON; REPAIR; MUTANT; BREAKS	The presence of a long interspersed nucleotide element, named L1Tc, which is actively transcribed in the parasite Trypanosoma cruzi, has been recently described. The open reading frame 1 of this element encodes the NL1Tc protein, which has apurinic/apyrimidinic endonuclease activity and is probably implicated in the first stage of the transposition of the element. In the present paper we show that NL1Tc effectively removes 3'-blocking groups (3'-phosphate and 3'-phosphoglycolate) from damaged DNA substrates. Thus, both 3'-phosphatase and 3'-phosphodiesterase activities are present in NL1Tc. We propose that these enzymatic activities would allow the 3'-blocking ends to function as targets for the insertion of L1Tc element, in addition to the apurinic/apyrimidinic sites previously described. The potential biological function of the NL1Tc protein has also been evidenced by its ability to repair the DNA damage induced by the methyl methanesulfonate alkylating or oxidative agents such as hydrogen peroxide and t-butyl hydroperoxide in Escherichia coli (xth and xth, nfo) mutants.	Consejo Super Invest Cient, Dept Biol Mol, Inst Parasitol & Biomed Lopez Neyra, Granada 18001, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cient, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Lopez, MC (corresponding author), Consejo Super Invest Cient, Dept Biol Mol, Inst Parasitol & Biomed Lopez Neyra, Ventanilla 11, Granada 18001, Spain.		Lopez, Manuel/Z-5641-2019; Thomas, María Carmen PhD/D-9065-2016	Thomas, M Carmen/0000-0003-3586-9657; Lopez, Manuel Carlos/0000-0003-0002-3678				BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Cost GJ, 1998, BIOCHEMISTRY-US, V37, P18081, DOI 10.1021/bi981858s; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; EICKBUSH TH, 1992, NEW BIOL, V4, P430; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P32; GABRIEL A, 1993, REVERSE TRANSCRIPTAS, P275; GU LY, 1994, J BIOL CHEM, V269, P32685; IZUMI T, 1992, J BACTERIOL, V174, P7711, DOI 10.1128/JB.174.23.7711-7716.1992; MARTIN F, 1995, J MOL BIOL, V247, P49, DOI 10.1006/jmbi.1994.0121; Martin F, 1996, TRENDS BIOCHEM SCI, V21, P283, DOI 10.1016/S0968-0004(96)80130-7; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; Olivares M, 1997, J BIOL CHEM, V272, P25224, DOI 10.1074/jbc.272.40.25224; REQUENA JM, 1994, GENE, V146, P245, DOI 10.1016/0378-1119(94)90300-X; Sambrook J., 2002, MOL CLONING LAB MANU; SANDER M, 1995, BIOCHEMISTRY-US, V34, P1267, DOI 10.1021/bi00004a021; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; Teng SC, 1996, NATURE, V383, P641, DOI 10.1038/383641a0; [No title captured]	21	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23883	23886		10.1074/jbc.274.34.23883	http://dx.doi.org/10.1074/jbc.274.34.23883			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446153	hybrid			2022-12-25	WOS:000082110900032
J	Yoo, HY; Chang, MS; Rho, HM				Yoo, HY; Chang, MS; Rho, HM			The activation of the rat copper/zinc superoxide dismutase gene by hydrogen peroxide through the hydrogen peroxide-responsive element and by paraquat and heat shock through the same heat shock element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS RESPONSES; TRANSCRIPTIONAL ACTIVATION; ESCHERICHIA-COLI; CELLS; INDUCTION; DNA; TRANSITION; PROMOTERS; PROTEINS; TOXICITY	Copper/zinc superoxide dismutase (SOD1) protects cells against oxidative hazards by the dismutation of superoxide radicals. The promoter activity of the SOD1 gene was increased 3-5-fold by hydrogen peroxide, paraquat (PQ) and heat shock, Functional analyses of the regulatory region of the SOD1 gene by deletions, mutations, and heterologous promoter systems confirmed the induction of the SOD1 gene by H2O2 through the hydrogen peroxide-responsive element (HRE) (between nucleotides -533 and -520), Gel mobility shift assays showed that the existence of an H2O2-inducible protein bound to the oligonucleotide of the HRE. Similar analyses showed that the heat shock activated the SOD1 promoter through the heat shock element (HSE) (between nucleotides -185 and -171), A strong specific far-shifted complex with the oligonucleotide of the HSE was observed by the treatment of heat shock. When cells were treated with PQ, a strong far-shifted complex with the HSE was observed and was competed out by the cold HSE probe, indicating that PQ also activated the SOD1 promoter through the same HSE site. It is very interesting to note that chemical and physical stresses, such as PQ and heat shock, respectively, activated the SOD1 promoter through the same cis-element HSE, These results indicate that the SOD1 was inducible by H2O2 through the HRE and by PQ and heat shock through the same HSE to protect cells from oxidative hazards.	Seoul Natl Univ, Dept Biol Mol, Seoul 151742, South Korea; Seoul Natl Univ, Res Ctr Cell Differentiat, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Rho, HM (corresponding author), Seoul Natl Univ, Dept Biol Mol, Seoul 151742, South Korea.	hyunerho@plaza.snu.ac.kr						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; BROWN RH, 1995, CELL, V80, P687, DOI 10.1016/0092-8674(95)90346-1; Chang MS, 1999, BIOCHEM J, V339, P335, DOI 10.1042/0264-6021:3390335; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DAVIES KJA, 1990, UCLA SYM BI, V123, P123; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HUBER W, 1980, CLIN RHEUM DIS, V6, P465; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; Kim YH, 1997, FEBS LETT, V401, P267, DOI 10.1016/S0014-5793(96)01487-1; KIM YH, 1993, GENE, V133, P267; Kim YH, 1996, J BIOL CHEM, V271, P24539, DOI 10.1074/jbc.271.40.24539; LALORAYA M, 1988, BIOCHEM BIOPH RES CO, V157, P146, DOI 10.1016/S0006-291X(88)80025-1; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCCORD JM, 1971, P NATL ACAD SCI USA, V68, P1024, DOI 10.1073/pnas.68.5.1024; NICOTERA TM, 1989, CANCER RES, V49, P5239; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OMAR R, 1993, EUR ARCH PSY CLIN N, V242, P262, DOI 10.1007/BF02190384; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PERCIVAL SS, 1991, BIOCHEM J, V274, P153, DOI 10.1042/bj2740153; REDDY MV, 1992, INFECT IMMUN, V60, P2386, DOI 10.1128/IAI.60.6.2386-2390.1992; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608	35	93	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23887	23892		10.1074/jbc.274.34.23887	http://dx.doi.org/10.1074/jbc.274.34.23887			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446154	hybrid			2022-12-25	WOS:000082110900033
J	Scharnhorst, V; Dekker, P; van der Eb, AJ; Jochemsen, AG				Scharnhorst, V; Dekker, P; van der Eb, AJ; Jochemsen, AG			Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR GENE; GROWTH-FACTOR RECEPTOR; DENYS-DRASH SYNDROME; ZINC FINGER PROTEIN; FACTOR-II GENE; SUPPRESSOR WT1; EMBRYONAL CARCINOMA; KIDNEY DEVELOPMENT; DNA-BINDING; CELLS	The Wilms' tumor 1 gene, WT1, is homozygously mutated in a subset of Wilms' tumors. Heterozygous mutations in WT1 give rise to congenital anomalies. During embryogenesis, WT1 is expressed mainly in the kidneys, uterus, and testes, Alternative splicing of the WT1 mRNA results in synthesis of four main WT1 protein isoforms with molecular masses of 52-54 kDa, In addition, translation initiation at a CUG upstream of the initiator AUG generates four larger WT1 proteins of 60-62 kDa. We describe here the existence of novel WT1 isoforms and demonstrate that they are derived from translation initiation at the second in-frame AUG of the WT1 mRNA. These N-terminally truncated WT1 proteins of 36-38 kDa can be detected in several cell lines, mouse testes, and Wilms' tumor specimens. They can bind to DNA and direct transcription from reporter constructs. The shorter WT1 protein lacking the two splice inserts has a greater transcription activation potential than the corresponding main WT1 protein isoform but shows no transcription repression potential. Overexpression of full-length or N-terminally truncated WT1 efficiently induces apoptosis. These data show that additional WT1 isoforms with distinct transcription-regulatory properties exist, which further increases the complexity of WT1 expression and activity.	Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jochemsen, AG (corresponding author), Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, POB 9503, NL-2300 RA Leiden, Netherlands.			Scharnhorst, Volkher/0000-0002-1243-9251				ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HASTIE ND, 1994, ANNU REV GENET, V28, P523; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE M, 1995, HUM MOL GENET, V4, P351, DOI 10.1093/hmg/4.3.351; LUO XN, 1995, ONCOGENE, V11, P743; MADDEN SL, 1993, ONCOGENE, V8, P1713; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; Menke AL, 1997, CANCER RES, V57, P1353; Menke AL, 1996, ONCOGENE, V12, P537; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; MORRIS JF, 1991, ONCOGENE, V6, P2339; MUMMERY CL, 1985, DEV BIOL, V109, P402, DOI 10.1016/0012-1606(85)90466-X; Murata Y, 1997, FEBS LETT, V409, P41, DOI 10.1016/S0014-5793(97)00477-8; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Scharnhorst V, 1997, CELL GROWTH DIFFER, V8, P133; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; SEKIYA M, 1994, BLOOD, V83, P1876; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; WANG ZY, 1995, ONCOGENE, V10, P1243	41	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23456	23462		10.1074/jbc.274.33.23456	http://dx.doi.org/10.1074/jbc.274.33.23456			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438524	hybrid			2022-12-25	WOS:000082012800074
J	Stephenson, SA; Verity, K; Ashworth, LK; Clements, JA				Stephenson, SA; Verity, K; Ashworth, LK; Clements, JA			Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; CDNA; EXPRESSION; LOCUS; IDENTIFICATION; EVOLUTION; PROMOTER; BREAST; CANCER	The human tissue kallikrein (KLK) family of serine proteases, which is important in post-translational processing events, currently consists of just three genes-tissue kallikrein (KLK1), KLK2, and prostate-specific antigen (PSA) (KLK3)-clustered at chromosome 19q13.3-13.4. We identified an expressed sequence tag from an endometrial carcinoma cDNA library with 50% identity to the three known KLK genes. Primers designed to putative exon 2 and exon 3 regions from this novel kallikrein-related sequence were used to polymerase chain reaction-screen five cosmids spanning 130 kb around the KIK locus on chromosome 19. This new gene, which we have named KLK4, is 25 kb downstream of the KLK2 gene and follows a region that includes two other putative KLK-like gene fragments KLK4 spans 5.2 kb, has an identical genomic structure-five exons and four introns-to the other KLK genes and is transcribed on the reverse strand, in the same direction as KLK1 but opposite to that of KLK2 and KLK3. It encodes a 254-amino acid prepro-serine protease that is most similar (78% identical) to pig enamel matrix serine protease but is also 37% identical to PSA. These data suggest that the human kallikrein gene family locus on chromosome 19 is larger than previously thought and also indicate a greater sequence divergence within this family compared with the highly conserved rodent kallikrein genes.	Queensland Univ Technol, Sch Life Sci, Ctr Mol Biotechnol, Brisbane, Qld 4001, Australia; Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia; Univ Calif Lawrence Livermore Natl Lab, Ctr Human Genome, Livermore, CA 94551 USA	Queensland University of Technology (QUT); Prince Henry's Institute of Medical Research; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Clements, JA (corresponding author), Queensland Univ Technol, Sch Life Sci, Ctr Mol Biotechnol, GPO Box 2434, Brisbane, Qld 4001, Australia.		Stephenson, Sally-Anne/I-9801-2012	Clements, Judith/0000-0001-6026-1964; Stephenson, Sally-Anne/0000-0003-3227-2476				Adams MJ, 1998, BIOCHEM J, V329, P165; Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; BAKER AR, 1985, DNA-J MOLEC CELL BIO, V4, P445, DOI 10.1089/dna.1985.4.445; BERG T, 1992, RECENT PROGR KININS, V1, P19; CLEMENTS JA, 1997, KININ SYSTEM, P72; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; DIGBY MR, 1990, P GEN C LORN AUSTR; EVANS BA, 1988, BIOCHEMISTRY-US, V27, P3124, DOI 10.1021/bi00409a003; EVANS BA, 1987, J BIOL CHEM, V262, P8027; FUKUSHIMA D, 1985, BIOCHEMISTRY-US, V24, P8037, DOI 10.1021/bi00348a030; GERALD WL, 1986, BIOCHIM BIOPHYS ACTA, V866, P1, DOI 10.1016/0167-4781(86)90093-X; HENTTU P, 1989, BIOCHEM BIOPH RES CO, V160, P903, DOI 10.1016/0006-291X(89)92520-5; HOWLES PN, 1984, NUCLEIC ACIDS RES, V12, P2791, DOI 10.1093/nar/12.6.2791; IRWIN DM, 1988, NATURE, V336, P429, DOI 10.1038/336429b0; KURTZ TW, 1992, J AM SOC NEPHROL, V3, P28; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; Liu XL, 1996, CANCER RES, V56, P3371; Luo LY, 1998, BIOCHEM BIOPH RES CO, V247, P580, DOI 10.1006/bbrc.1998.8793; Murray S R, 1992, Agents Actions Suppl, V38 ( Pt 1), P26; MURRAY SR, 1990, J CARDIOVASC PHARM, V15, pS7, DOI 10.1097/00005344-199000156-00003; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; REIGMAN PHJ, 1988, BIOCHEM BIOPH RES CO, V159, P95; RIEGMAN PHJ, 1989, FEBS LETT, V247, P123, DOI 10.1016/0014-5793(89)81253-0; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RIEGMAN PHJ, 1992, GENOMICS, V14, P6, DOI 10.1016/S0888-7543(05)80275-7; Rittenhouse HG, 1998, CRIT REV CL LAB SCI, V35, P275, DOI 10.1080/10408369891234219; SCHEDLICH LJ, 1988, CLIN EXP PHARMACOL P, V15, P339, DOI 10.1111/j.1440-1681.1988.tb01084.x; SCHEDLICH LJ, 1987, DNA-J MOLEC CELL BIO, V6, P429, DOI 10.1089/dna.1987.6.429; SOUTHARDSMITH M, 1994, GENOMICS, V22, P404, DOI 10.1006/geno.1994.1402; WINES DR, 1989, J BIOL CHEM, V264, P7653; WINES DR, 1991, J MOL EVOL, V32, P476, DOI 10.1007/BF02102650; YAMISHUIRO K, 1997, BIOCHIM BIOPHYS ACTA, V1350, P11	34	88	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23210	23214		10.1074/jbc.274.33.23210	http://dx.doi.org/10.1074/jbc.274.33.23210			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438493	hybrid			2022-12-25	WOS:000082012800043
J	Gutmann, DH; Loehr, A; Zhang, YJ; Kim, J; Henkemeyer, M; Cashen, A				Gutmann, DH; Loehr, A; Zhang, YJ; Kim, J; Henkemeyer, M; Cashen, A			Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation	ONCOGENE			English	Article						tumor suppressor gene; glioma; p21-ras; GTPase activating protein; neurofibromin	TYPE-1 GENE-PRODUCT; PROTEIN PRODUCT; RAS PROTEINS; EXPRESSION; CELLS; IDENTIFICATION; BRAIN; TISSUES; NEURONS; GAP	Individuals affected with neurofibromatosis 1 (NF1) harbor increased numbers of GFAP-immunoreactive cerebral astrocytes and develop astrocytomas that can lead to blindness and death. Mice heterozygous for a targeted Nf1 mutation (Nf1+/-) mere employed as a model for the human disease to evaluate the hypothesis that reduced NF1 protein (neurofibromin) expression may confer a growth advantage for astrocytes, such that inactivation of only one NF1 allele is sufficient for abnormal astrocyte proliferation. Here, me report that Nf1+/- mice have increased numbers of cerebral astrocytes and increased astrocyte proliferation compared to wild-type littermates. Intriguingly, primary Nf1+/- astrocyte cultures failed to demonstrate a cell-autonomous growth advantage unless they mere cocultured with C17 neuronal cells. This C17 neuronal cell-induced Nf1+/- increase in proliferation was blocked by MEK inhibition (PD98059), suggesting a p21-ras-dependent effect. Furthermore, mice heterozygous for a targeted mutation in another GAP molecule, p120-GAP, demonstrated no increases in cerebral astrocyte number. These findings suggest that reduced NF1 expression results in a cell context-dependent increase in astrocyte proliferation that may be sufficient for the development of astrocytic growth abnormalities in patients with NF1.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Texas SW, Dallas, TX 75235 USA	Washington University (WUSTL); University of Texas System; University of Texas Southwestern Medical Center Dallas	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.			Gutmann, David/0000-0002-3127-5045; Henkemeyer, Mark/0000-0002-7525-1061	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033494] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33494] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADER JL, 1986, ANN NY ACAD SCI, V486, P57; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; CAWTHON RM, 1990, GENOMICS, V7, P555, DOI 10.1016/0888-7543(90)90199-5; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DASTON MM, 1992, DEV DYNAM, V195, P216, DOI 10.1002/aja.1001950307; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; ECCLESTON PA, 1989, DEVELOPMENT, V107, P107; Geist RT, 1996, NEUROBIOL DIS, V3, P111, DOI 10.1006/nbdi.1996.0011; Giordano MJ, 1996, J NEUROSCI RES, V43, P246; GOLUBIC M, 1992, ONCOGENE, V7, P2151; Greenwood RS, 1997, ANN NEUROL, V42, pP4; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Gutmann DH, 1996, ONCOGENE, V12, P2121; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1995, CELL GROWTH DIFFER, V6, P315; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; HABIBY R, 1995, J PEDIATR-US, V126, P364, DOI 10.1016/S0022-3476(95)70449-3; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HEWETT SJ, 1993, BRAIN RES, V625, P337, DOI 10.1016/0006-8993(93)91078-7; HEWETT SJ, 1995, NEUROREPORT, V6, P1565, DOI 10.1097/00001756-199507310-00025; HUYNH DP, 1992, NEUROSCI LETT, V143, P233, DOI 10.1016/0304-3940(92)90272-9; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JANECZKO K, 1988, BRAIN RES, V456, P280, DOI 10.1016/0006-8993(88)90229-6; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; Listernick R, 1997, ANN NEUROL, V41, P143, DOI 10.1002/ana.410410204; LISTERNICK R, 1989, J PEDIATR-US, V114, P778, DOI 10.1016/s0022-3476(89)80137-4; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MOLLOY PT, 1995, NEUROLOGY, V45, P1897, DOI 10.1212/WNL.45.10.1897; NORDLUND M, 1993, J NEUROSCI, V13, P1588; NORDLUND ML, 1995, J NEUROPATH EXP NEUR, V54, P588, DOI 10.1097/00005072-199507000-00013; Norton KK, 1996, NEUROREPORT, V7, P601, DOI 10.1097/00001756-199601310-00054; NORTON KK, 1995, NEUROBIOL DIS, V2, P13, DOI 10.1006/nbdi.1995.0002; PAXINOS G, 1986, MOUSE BRAIN STEREOTA; Pollack IF, 1996, NEUROLOGY, V46, P1652, DOI 10.1212/WNL.46.6.1652; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; Rizvi TA, 1999, BRAIN RES, V816, P111, DOI 10.1016/S0006-8993(98)01133-0; Rose K, 1993, IN VITRO BIOL METHOD, P46; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Said SMA, 1996, NEUROREPORT, V7, P1941, DOI 10.1097/00001756-199608120-00015; SOBUE G, 1984, BRAIN RES, V324, P175, DOI 10.1016/0006-8993(84)90639-5; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINSTEIN DE, 1990, GLIA, V3, P130, DOI 10.1002/glia.440030207; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; [No title captured]	52	88	93	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	1999	18	31					4450	4459		10.1038/sj.onc.1202829	http://dx.doi.org/10.1038/sj.onc.1202829			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442636				2022-12-25	WOS:000081813500007
J	Bennett, JS; Zigmond, S; Vilaire, G; Cunningham, ME; Bednar, B				Bennett, JS; Zigmond, S; Vilaire, G; Cunningham, ME; Bednar, B			The platelet cytoskeleton regulates the affinity of the integrin alpha(IIb)beta(3) for fibrinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; ACTIN POLYMERIZATION; ACTIVATED PLATELETS; MONOCLONAL-ANTIBODY; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; MEMBRANE SKELETON; BINDING PROTEIN; CELL-ADHESION; GPIIB-IIIA	Agonist-generated inside-out signals enable the platelet integrin alpha(IIb)beta(3), to bind soluble ligands such as fibrinogen, We found that inhibiting actin polymerization in unstimulated platelets with cytochalasin D or latrunculin A mimics the effects of platelet agonists by inducing fibrinogen binding to alpha(IIb)beta(3) By contrast, stabilizing actin filaments with jasplakinolide prevented cytochalasin D-, latrunculin A-, and ADP-induced fibrinogen binding, Cytochalasin D- and latrunculin A-induced fibrinogen was inhibited by ADP scavengers, suggesting that subthreshold concentrations of ADP provided the stimulus for the actin filament turnover required to see cytochalasin D and latrunculin A effects. Gelsolin, which severs actin filaments, is activated by calcium, whereas the actin disassembly factor cofilin is inhibited by serine phosphorylation. Consistent with a role for these factors in regulating alpha(IIb)beta(3), function, cytochalasin D- and latrunculin A-induced fibrinogen binding was inhibited by the intracellular calcium chelators 1,2-bis(2-aminophenoxy)ethane-N,N,N' ,N' -tetra-acetic acid acetoxymethyl ester and EGTA acetoxymethyl ester and the Ser/Thr phosphatase inhibitors okadaic acid and calyculin A. Our results suggest that the actin cytoskeleton in unstimulated platelets constrains alpha(IIb)beta(3) in a low affinity state. We propose that agonist-stimulated increases in platelet cytosolic calcium initiate actin filament turnover. Increased actin filament turnover then relieves cytoskeletal constraints on alpha(IIb)beta(3) allowing it to assume the high affinity conformation required for soluble ligand binding.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Merck Res Labs, Dept Pharmacol, W Point, PA 19486 USA	University of Pennsylvania; University of Pennsylvania; Merck & Company	Bennett, JS (corresponding author), Div Hematol Oncol, Rm 914,BRB-2,421 Curie Blvd, Philadelphia, PA 19014 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051258, P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40387, HL51258] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADDO JB, 1995, ARTERIOSCL THROM VAS, V15, P1466, DOI 10.1161/01.ATV.15.9.1466; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bednar B, 1997, CYTOMETRY, V28, P58, DOI 10.1002/(SICI)1097-0320(19970501)28:1<58::AID-CYTO7>3.0.CO;2-D; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; ELEMER GS, 1994, J BIOL CHEM, V269, P3159; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; FOX JEB, 1984, J CELL BIOL, V98, P1985, DOI 10.1083/jcb.98.6.1985; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; HOYT CH, 1995, BIOCHEMISTRY-US, V34, P9565, DOI 10.1021/bi00029a033; HUANG EM, 1980, J LAB CLIN MED, V95, P59; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; NACHMIAS VT, 1993, EUR J CELL BIOL, V61, P314; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PEERSCHKE EIB, 1984, P SOC EXP BIOL MED, V175, P109; Qi WW, 1998, J BIOL CHEM, V273, P15271, DOI 10.1074/jbc.273.24.15271; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	43	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25301	25307		10.1074/jbc.274.36.25301	http://dx.doi.org/10.1074/jbc.274.36.25301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464255	hybrid			2022-12-25	WOS:000082554200020
J	Suzuki, K; Kodama, S; Watanabe, M				Suzuki, K; Kodama, S; Watanabe, M			Recruitment of ATM protein to double strand DNA irradiated with ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA GENE; CYCLE CHECKPOINT PATHWAY; C-ABL; CELLULAR-RESPONSE; P53 PROTEIN; DAMAGE; KINASE; PRODUCT; PHOSPHORYLATION; CELLS	The product of the ATM gene, which is mutated in ataxia telangiectasia, is a nuclear phosphoprotein, and it involves the activation of the p53 pathway after ionizing radiation. Here we show that the ATM protein is constitutively associated with double strand DNA and that the interaction increases when the DNA is exposed to ionizing radiation. The ATM protein also had affinity to restriction endonuclease PvuII-digested DNA, but not to UV-irradiated DNA nor X-irradiated single-stranded DNA, The immunoprecipitation experiment detected very weak association between ATM and DNA-PK proteins, and immunodepletion of DNA-PK showed little or no effect on the interaction of the ATM protein with damaged DNA, indicating that an interaction with DNA-PK might not be required for the recruitment of the ATM protein to damaged DNA. Furthermore, the association was also confirmed in xrs-5 and xrs-6e cells, which are Chinese hamster ovary mutant cell lines defective in Ku80 function. These results indicate that the ATM protein is recruited to the site of DNA damage and it recognizes double strand breaks by itself or through an association with other DNA-binding protein other than DNA-PK and Ku80 proteins.	Nagasaki Univ, Sch Pharmaceut Sci, Lab Radiat & Life Sci, Nagasaki 8528521, Japan	Nagasaki University	Suzuki, K (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Lab Radiat & Life Sci, 1-14 Bunkyo Machi, Nagasaki 852, Japan.							Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Ghosh JC, 1999, J RADIAT RES, V40, P23, DOI 10.1269/jrr.40.23; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; JACHSON SP, 1995, CURR BIOL, V5, P1210; Jongmans W, 1996, ONCOGENE, V13, P1133; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1996, ONCOGENE, V13, P2707; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; Suzuki K, 1998, RADIAT RES, V149, P195, DOI 10.2307/3579930; WATANABE M, 1992, INT J RADIAT BIOL, V62, P711, DOI 10.1080/09553009214552661; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	40	99	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25571	25575		10.1074/jbc.274.36.25571	http://dx.doi.org/10.1074/jbc.274.36.25571			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464290	hybrid			2022-12-25	WOS:000082554200054
J	Hogaboam, CM; Bone-Larson, CL; Steinhauser, ML; Lukacs, NW; Colletti, LM; Simpson, KJ; Strieter, RM; Kunkel, SL				Hogaboam, CM; Bone-Larson, CL; Steinhauser, ML; Lukacs, NW; Colletti, LM; Simpson, KJ; Strieter, RM; Kunkel, SL			Novel CXCR2-dependent liver regenerative qualities of ELR-containing CXC chemokines	FASEB JOURNAL			English	Article						acetaminophen; acute liver injury; hepatic regeneration	IL-8 RECEPTOR; ACETAMINOPHEN; NEUTROPHIL; MICE; FAILURE; TRANSPLANTATION; CHEMOATTRACTANT; HEPATOTOXICITY; INTERLEUKIN-8; ANGIOGENESIS	Severe acute liver injury due to accidental or intentional acetaminophen overdose presents a major clinical dilemma often requiring liver transplantation. In the present study, liver regeneration after profound liver injury in mice challenged with acetaminophen was facilitated by the exogenous addition of ELR-containing CXC chemokines such as macrophage inflammatory protein-a (MIP-2), epithelial neutrophil-actavating protein-78 (ENA-78), or interleukin 8, Intravenous administration of ELR-CXC chemokines or N-acetyl-cysteine (NAC) immediately after acetaminophen challenge in mice significantly reduced histological and biochemical markers of hepatic injury. However, when the intervention was delayed until 10 h after acetaminophen challenge, only ELR-CXC chemokines significantly reduced liver injury and mouse mortality. The delayed addition of ELR-CXC chemokines to cultured hepatocytes maintained the proliferation of these cells in a CXCR2-dependent fashion after acetaminophen challenge whereas delayed NAC treatment did not. These observations demonstrate that ELR-CXC chemokines represent novel hepatic regenerative factors that exhibit prolonged therapeutic effects after acetaminophen-induced hepatotoxicity.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA; Univ Edinburgh, Dept Med, Edinburgh, Midlothian, Scotland	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Edinburgh	Hogaboam, CM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 E Catherine, Ann Arbor, MI 48109 USA.		Hogaboam, Cory M./AAI-1433-2021; Steinhauser, Matthew L./GVT-6393-2022; Lukacs, Nicholas W/ABH-5583-2020	Hogaboam, Cory M./0000-0003-3366-4850; Steinhauser, Matthew L./0000-0001-5287-9246; 	NCI NIH HHS [CA66180] Funding Source: Medline; NHLBI NIH HHS [1P50HL60289, 1P50HL56402] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066180] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056402, P50HL060289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATILLASOY E, 1995, ANNU REV MED, V46, P181; Bernal W, 1998, HEPATOLOGY, V27, P1050, DOI 10.1002/hep.510270421; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Casey PB, 1997, IRISH MED J, V90, P38; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; Colletti LM, 1996, SHOCK, V6, P397, DOI 10.1097/00024382-199612000-00002; Colletti LM, 1998, SHOCK, V10, P248, DOI 10.1097/00024382-199810000-00004; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DEGROOTE J, 1995, ACTA GASTRO-ENT BELG, V58, P326; Delanty N, 1996, IRISH MED J, V89, P156; DRISCOLL KE, 1995, J LEUKOCYTE BIOL, V58, P359, DOI 10.1002/jlb.58.3.359; EVANOFF HL, 1992, IMMUNOL INVEST, V21, P39, DOI 10.3109/08820139209069361; Farrell GC, 1997, J GASTROEN HEPATOL, V12, pS242, DOI 10.1111/j.1440-1746.1997.tb00507.x; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Heubi JE, 1998, J PEDIATR-US, V132, P22, DOI 10.1016/S0022-3476(98)70479-2; Kay MA, 1997, MOL MED TODAY, V3, P108, DOI 10.1016/S1357-4310(96)10062-9; LEE J, 1995, J IMMUNOL, V155, P2158; Lentsch AB, 1998, HEPATOLOGY, V27, P1172; Lentsch AB, 1998, HEPATOLOGY, V27, P507, DOI 10.1002/hep.510270226; Makin AJ, 1997, ADV INTERNAL MED, V42, P453; Manautou JE, 1996, TOXICOL APPL PHARM, V140, P30, DOI 10.1006/taap.1996.0194; MICHALEK SM, 1992, VACCINE RES, V1, P241; Riordan SM, 1999, LIVER TRANSPLANT SUR, V5, P86, DOI 10.1002/lt.500050107; Rosen HR, 1996, MED CLIN N AM, V80, P1069, DOI 10.1016/S0025-7125(05)70480-6; SHERON N, 1993, HEPATOLOGY, V18, P41, DOI 10.1002/hep.1840180108; Sprenger H, 1997, GASTROENTEROLOGY, V113, P277, DOI 10.1016/S0016-5085(97)70105-7; Strieter RM, 1996, J IMMUNOL, V156, P3583; STRIETER RM, 1995, SHOCK, V4, P155, DOI 10.1097/00024382-199509000-00001; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; TAKADA H, 1995, DIGEST DIS SCI, V40, P1831, DOI 10.1007/BF02212709; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	32	94	103	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1565	1574		10.1096/fasebj.13.12.1565	http://dx.doi.org/10.1096/fasebj.13.12.1565			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463948	Green Submitted			2022-12-25	WOS:000082347600012
J	Chu, GC; Tomita, T; Sonnichsen, FD; Yoshida, T; Ikeda-Saito, M				Chu, GC; Tomita, T; Sonnichsen, FD; Yoshida, T; Ikeda-Saito, M			The heme complex of Hmu O, a bacterial heme degradation enzyme from Corynebacterium diphtheriae - Structure of the catalytic site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; SPIN FERRIC HEMOPROTEINS; OXYGENASE COMPLEX; HORSERADISH-PEROXIDASE; TRANSPORT-SYSTEM; CARBON-MONOXIDE; LIGAND; RAMAN; BINDING; IRON	Hmu O, a heme degradation enzyme in Corynebacterium diphtheriae, forms a stoichiometric complex with iron protoporphyrin IX and catalyzes the oxygen-dependent conversion of hemin to biliverdin, carbon monoxide, and free iron. Using a multitude of spectroscopic techniques, we have determined the axial ligand coordination of the heme-Hmu O complex. The ferric complex shows a pH-dependent reversible transition between a water-bound hexacoordinate high spin neutral pH form and an alkaline form, having high spin and low spin states, with a pK(a) of 9, H-1 NMR, EPR, and resonance Raman of the heme-Hmu O complex establish that a neutral imidazole of a histidine residue is the proximal ligand of the complex, similar to mammalian heme oxygenase, EPR of the deoxy cobalt porphyrin IX-Hmu O complex confirms this proximal histidine coordination. Oxy cobalt-Hmu O EPR reveals a hydrogen-bonding interaction between the O-2 and an exchangeable proton in the Hmu O distal pocket and two distinct orientations for the bound O-2. Mammalian heme oxygenase has only one O-2 orientation. This difference and the mixed spin states at alkaline pH indicate structural differences in the distal environment between Hmu O and its mammalian counterpart.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Tohoku Univ, Inst Chem React Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan; Yamagata Univ, Sch Med, Dept Biochem, Yamagata 9909585, Japan	Case Western Reserve University; Tohoku University; Yamagata University	Ikeda-Saito, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	mis2@po.cwru.edu	Ikeda-Saito, Masao/K-2703-2015; Sönnichsen, Frank D/D-8408-2011; Ikeda-Saito, Masao/A-5992-2008	Sönnichsen, Frank D/0000-0002-4539-3755; Tomita, Takeshi/0000-0001-6815-2244	NIGMS NIH HHS [GM57272, GM55362] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057272, R01GM055362, R29GM055362] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, V21, P436, DOI 10.1126/science.178.4058.296; ARGADE PV, 1984, SCIENCE, V225, P329, DOI 10.1126/science.6330890; BUDD DL, 1979, J AM CHEM SOC, V101, P6091, DOI 10.1021/ja00514a036; Chu GC, 1999, J STRUCT BIOL, V126, P171, DOI 10.1006/jsbi.1999.4122; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; Fujii H, 1998, J AM CHEM SOC, V120, P8251, DOI 10.1021/ja973925w; GUPTA RK, 1979, BIOCHEM BIOPH RES CO, V89, P1334, DOI 10.1016/0006-291X(79)92155-7; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; HOFFMAN BM, 1970, J AM CHEM SOC, V92, P61, DOI 10.1021/ja00704a010; HORI H, 1982, J BIOL CHEM, V257, P3636; Ikeda-Saito M, 1998, KEIO UNIV SYMP LIFE, V1, P304; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; ISHIKAWA K, 1995, J BIOL CHEM, V270, P6345, DOI 10.1074/jbc.270.11.6345; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; LAMAR GN, 1979, BIOCHEM BIOPH RES CO, V90, P36, DOI 10.1016/0006-291X(79)91586-9; LEE BC, 1995, MOL MICROBIOL, V18, P383, DOI 10.1111/j.1365-2958.1995.mmi_18030383.x; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Matera KM, 1997, BIOCHEMISTRY-US, V36, P4909, DOI 10.1021/bi962321m; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; RAJARATHNAM K, 1991, J AM CHEM SOC, V113, P7886, DOI 10.1021/ja00021a010; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; SCHULLER DJ, 1999, IN PRESS NAT STRUCT; Shokhirev NV, 1998, J BIOL INORG CHEM, V3, P581, DOI 10.1007/s007750050271; SMULEVICH G, 1988, BIOCHEMISTRY-US, V27, P5486, DOI 10.1021/bi00415a015; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; UNO T, 1987, J BIOL CHEM, V262, P4549; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VUKPAVLOVIC S, 1977, BIOCHEM BIOPH RES CO, V79, P885, DOI 10.1016/0006-291X(77)91193-7; WALKER FA, HDB PORPHYRIN CHEM; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; WILKS A, 1993, J BIOL CHEM, V268, P22357; YONETANI T, 1972, J BIOL CHEM, V247, P2447; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	43	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24490	24496		10.1074/jbc.274.35.24490	http://dx.doi.org/10.1074/jbc.274.35.24490			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455111	hybrid			2022-12-25	WOS:000082193400010
J	Hansen, LL; Ikeda, Y; Olsen, GS; Busch, AK; Mosthaf, L				Hansen, LL; Ikeda, Y; Olsen, GS; Busch, AK; Mosthaf, L			Insulin signaling is inhibited by micromolar concentrations of H2O2 - Evidence for a role of H2O2 in tumor necrosis factor alpha-mediated insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INSULINOMIMETIC AGENTS H2O2; RECEPTOR TYROSINE KINASE; HYDROGEN-PEROXIDE PRODUCTION; DEPENDENT DIABETES-MELLITUS; OXIDATIVE STRESS; RAT-1 FIBROBLASTS; HEPATOMA-CELLS; INTACT-CELLS; FAT-CELLS	Both hyperglycemia and tumor necrosis factor alpha (TNF alpha) were found to induce insulin resistance at the level of the insulin receptor (IR), How this effect is mediated is, however, not understood. We investigated whether oxidative stress and production of hydrogen peroxide could be a common mediator of the inhibitory effect, We report here that micromolar concentrations of H2O2 dramatically inhibit insulin-induced IR tyrosine phosphorylation (pretreatment with 500 mu M H2O2 for 5 min inhibits insulin-induced IR tyrosine phosphorylation to 8%), insulin receptor substrate 1 phosphorylation, as well as insulin downstream signaling such as activation of phosphatidylinositol 3-kinase (inhibited to 57%), glucose transport (inhibited to 36%), and mitogen-activated protein kinase activation (inhibited to 7.2%). Both sodium orthovanadate, a selective inhibitor of tyrosine-specific phosphatases, as well as the protein kinase C inhibitor Go6976 reduced the inhibitory effect of hydrogen peroxide on IR tyrosine phosphorylation, To investigate whether H2O2 is involved in hyperglycemia- and/or TNF alpha-induced insulin resistance, we preincubated the cells with the H2O2 scavenger catalase prior to incubation with 25 mM glucose, 25 mM 2-deoxyglucose, 5.7 nM TNF alpha, or 500 mu m H2O2, respectively, and subsequent insulin stimulation. Whereas catalase treatment completely abolished the inhibitory effect of H2O2 and TNF alpha on insulin receptor autophosphorylation, it did not reverse the inhibitory effect of hyperglycemia. In conclusion, these results demonstrate that hydrogen peroxide at low concentrations is a potent inhibitor of insulin signaling and may be involved in the development of insulin resistance in response to TNF alpha.	Hagedorn Res Inst, Dept Mol Signaling, DK-2820 Gentofte, Denmark	Novo Nordisk; Hagedorn Research Institute	Mosthaf, L (corresponding author), Hagedorn Res Inst, Dept Mol Signaling, Niels Steensens Vej 6, DK-2820 Gentofte, Denmark.							Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BERTI L, 1994, J BIOL CHEM, V269, P3381; CERIELLO A, 1993, DIABETOLOGIA, V36, P1119, DOI 10.1007/BF00401055; CHEN C, 1987, MOL CELL BIOL, V7, P27; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ERMEL B, 1989, DIABETOLOGIA S1, V32, P485; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HARING HU, 1993, DIABETOLOGIA, V36, P176, DOI 10.1007/BF00399946; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; IDE R, 1994, BIOCHEM BIOPH RES CO, V201, P71, DOI 10.1006/bbrc.1994.1670; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Keller U, 1995, Biotechnology, V28, P173; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kozlovsky N, 1997, FREE RADICAL BIO MED, V23, P859, DOI 10.1016/S0891-5849(97)00069-5; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; MULLER HK, 1991, DIABETES, V40, P1440, DOI 10.2337/diabetes.40.11.1440; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOUROOZZADEH J, 1995, DIABETES, V44, P1054, DOI 10.2337/diabetes.44.9.1054; OLEFSKY JM, 1995, AM J CLIN NUTR, V61, P980; Paolisso G, 1996, DIABETOLOGIA, V39, P357, DOI 10.1007/BF00418354; ROTH RA, 1994, HORM RES, V41, P51, DOI 10.1159/000183961; Rudich A, 1997, AM J PHYSIOL-ENDOC M, V272, pE935, DOI 10.1152/ajpendo.1997.272.5.E935; Rudich A, 1997, DIABETOLOGIA, V40, P559; Rudich A, 1998, DIABETES, V47, P1562, DOI 10.2337/diabetes.47.10.1562; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; SEEDORF K, 1995, METABOLISM, V44, P24, DOI 10.1016/0026-0495(95)90217-1; SPAGNOLI A, 1995, HORM RES, V43, P286, DOI 10.1159/000184313; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; Wang Y, 1996, J BIOL CHEM, V271, P18107, DOI 10.1074/jbc.271.30.18107; WEISS RH, 1993, J BIOL CHEM, V268, P23049; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; WIERUSZWYSOCKA B, 1995, DIABETES RES CLIN PR, V27, P193, DOI 10.1016/0168-8227(95)01043-D; WILDEN PA, 1995, J CELL BIOCHEM, V58, P279, DOI 10.1002/jcb.240580303; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; Yan SR, 1996, J BIOL CHEM, V271, P23464, DOI 10.1074/jbc.271.38.23464; Zozulinska DA, 1996, DIABETES RES CLIN PR, V33, P139, DOI 10.1016/0168-8227(96)01289-2	60	147	155	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25078	25084		10.1074/jbc.274.35.25078	http://dx.doi.org/10.1074/jbc.274.35.25078			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455187	hybrid			2022-12-25	WOS:000082193400086
J	Liu, XB; Singh, BB; Ambudkar, IS				Liu, XB; Singh, BB; Ambudkar, IS			ATP-dependent activation of K-Ca and ROMK-type K-ATP channels in human submandibular gland ductal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; TRANSMEMBRANE CONDUCTANCE REGULATOR; EXTRACELLULAR ATP; SMOOTH-MUSCLE; HSG-PA; RAT; RECEPTORS; LINE; PURINOCEPTORS; LOCALIZATION	[Ca2+](i) and membrane current were measured in human submandibular gland ductal (HSG) cells to determine the regulation of salivary cell function by ATP, 1-10 mu M ATP activated internal Ca2+ release, outward Ca2+-dependent K+ channel (K-Ca), and inward store-operated Ca2+ current (I-SOC). The subsequent addition of 100 mu M ATP activated an inwardly rectifying K+ current, without increasing [Ca2+](i). The K+ current was also stimulated by ATP in cells treated with thapsigargin in a Ca2+-free medium and was blocked by glibenclamide and tolbutamide, but not by charybdotoxin, This suggests the involvement of a Ca2+-independent, sulfonylurea-sensitive K+ channel (K-ATP). UTP mimicked the low [ATP] effects, while benzoyl-ATP activated internal Ca2+ release, a Ca2+ influx pathway, and K-Ca. Thus, ATP acts via P-2U (P2Y(2)) and P-2Z (P2X(7)) receptors to increase [Ca2+](i) and activate K-Ca, but not K-ATP. Importantly, (i) ROMK1 and the cystic fibrosis transmembrane regulator protein (but not SUR1, SUR2A, or SUR2B) and (ii) cAMP-stimulated Cl- and K+ currents were detected in HSG cells. These data demonstrate for the first time that a ROMK-type K-ATP channel is present in salivary gland duct cells that is regulated by extracellular ATP and possibly by the cystic fibrosis transmembrane regulator. This reveals a potentially novel mechanism for K+ secretion in these cells.	NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ambudkar, IS (corresponding author), NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10,Rm 1N-113, Bethesda, MD 20892 USA.			Singh, Brij/0000-0003-0535-5997	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Amsallem H, 1996, AM J PHYSIOL-CELL PH, V271, pC1546, DOI 10.1152/ajpcell.1996.271.5.C1546; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; Burnstock G, 1996, DRUG DEVELOP RES, V38, P67, DOI 10.1002/(SICI)1098-2299(199605)38:1<67::AID-DDR9>3.0.CO;2-J; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Chan CM, 1998, EXP NEPHROL, V6, P200; Christoffersen BC, 1998, PFLUG ARCH EUR J PHY, V436, P33, DOI 10.1007/s004240050601; Cook DI, 1998, EUR J MORPHOL, V36, P67; Fukushi Y, 1997, EUR J PHARMACOL, V336, P89, DOI 10.1016/S0014-2999(97)01228-4; HE XJ, 1990, J MEMBRANE BIOL, V115, P159, DOI 10.1007/BF01869454; He XJ, 1997, PFLUG ARCH EUR J PHY, V433, P260; Ho K, 1998, CURR OPIN NEPHROL HY, V7, P49, DOI 10.1097/00041552-199801000-00009; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; IZUTSU KT, 1994, AM J PHYSIOL, V266, pC58, DOI 10.1152/ajpcell.1994.266.1.C58; Kohda Y, 1998, KIDNEY INT, V54, P1214, DOI 10.1046/j.1523-1755.1998.00120.x; Kurihara K, 1997, ARCH ORAL BIOL, V42, P547, DOI 10.1016/S0003-9969(97)89060-7; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 1998, AM J PHYSIOL-CELL PH, V275, pC571, DOI 10.1152/ajpcell.1998.275.2.C571; MCMILLIAN MK, 1993, BRIT J PHARMACOL, V108, P453, DOI 10.1111/j.1476-5381.1993.tb12825.x; MOTTE S, 1995, INT J BIOCHEM CELL B, V27, P1, DOI 10.1016/1357-2725(94)00059-X; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sheppard David N., 1999, Physiological Reviews, V79, pS23; SOLTOFF SP, 1990, J GEN PHYSIOL, V95, P319, DOI 10.1085/jgp.95.2.319; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; Tojyo Y, 1997, ARCH ORAL BIOL, V42, P393, DOI 10.1016/S0003-9969(97)00016-2; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; TURNER JT, 1999, IN PRESS CRIT REV OR; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Xu JZ, 1997, AM J PHYSIOL-RENAL, V273, pF739, DOI 10.1152/ajprenal.1997.273.5.F739; XU X, 1996, J PHYSIOL-LONDON, V491, P620; YU HX, 1991, J PHARMACOL EXP THER, V259, P1344; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442; [No title captured]	36	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25121	25129		10.1074/jbc.274.35.25121	http://dx.doi.org/10.1074/jbc.274.35.25121			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455193	hybrid			2022-12-25	WOS:000082193400092
J	Makeyev, AV; Chkheidze, AN; Liebhaber, SA				Makeyev, AV; Chkheidze, AN; Liebhaber, SA			A set of highly conserved RNA-binding proteins, alpha CP-1 and alpha CP-2, implicated in mRNA stabilization, are coexpressed from an intronless gene and its intron-containing paralog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-SPECIFIC EXPRESSION; MESSENGER-RNA; FUNCTIONAL RETROPOSON; KH DOMAIN; HNRNP-K; REGION; MOUSE; STABILITY; PROMOTER; DNA	Gene families normally expand by segmental genomic duplication and subsequent sequence divergence. Although copies of partially or fully processed mRNA transcripts are occasionally retrotransposed into the genome, they are usually nonfunctional ("processed pseudogenes"), The two major cytoplasmic poly(C)-binding proteins in mammalian cells, alpha CP-1 and alpha CP-2, are implicated in a spectrum of post-transcriptional controls. These proteins are highly similar in structure and are encoded by closely related mRNAs. Based on this close relationship, we were surprised to find that one of these proteins, alpha CP-2, was encoded by a multiexon gene, whereas the second gene, alpha CP-1, was identical to and colinear with its mRNA. The alpha CP-1 and alpha CP-2 genes were shown to be single copy and were mapped to separate chromosomes. The linkage groups encompassing each of the two loci were concordant between mice and humans. These data suggested that the alpha CP-1 gene was generated by retrotransposition of a fully processed alpha CP-2 mRNA and that this event occurred well before the mammalian radiation. The stringent structural conservation of alpha CP-1 and its ubiquitous tissue distribution suggested that the retrotransposed alpha CP-1 gene was rapidly recruited to a function critical to the cell and distinct from that of its alpha CP-2 progenitor.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Liebhaber, SA (corresponding author), Univ Penn, Sch Med, Dept Genet, Rm 428 CRB, Philadelphia, PA 19104 USA.				NATIONAL CANCER INSTITUTE [P01CA072765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632] Funding Source: NIH RePORTER; NCI NIH HHS [CA72765-01] Funding Source: Medline; NHLBI NIH HHS [HL38632-6] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AASHEIM HC, 1994, NUCLEIC ACIDS RES, V22, P959, DOI 10.1093/nar/22.6.959; ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; BHANDARI B, 1991, J BIOL CHEM, V266, P7784; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; CHAKRABARTI R, 1995, GENE, V153, P163, DOI 10.1016/0378-1119(94)00751-D; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; FITZGERALD J, 1992, BIOCHIM BIOPHYS ACTA, V1131, P83, DOI 10.1016/0167-4781(92)90102-6; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; Funke B, 1996, NUCLEIC ACIDS RES, V24, P3821, DOI 10.1093/nar/24.19.3821; Gao MX, 1998, J BIOL CHEM, V273, P4622, DOI 10.1074/jbc.273.8.4622; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; Graff J, 1998, J VIROL, V72, P9668, DOI 10.1128/JVI.72.12.9668-9675.1998; HAHM K, 1993, NUCLEIC ACIDS RES, V21, P3894, DOI 10.1093/nar/21.16.3894; Hendriksen PJM, 1997, GENOMICS, V41, P350, DOI 10.1006/geno.1997.4673; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; INA Y, 1995, J MOL EVOL, V40, P190, DOI 10.1007/BF00167113; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; LI WH, 1997, MOL EVOLUTION, P1; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; PERSSON K, 1995, J BIOL CHEM, V270, P5642, DOI 10.1074/jbc.270.10.5642; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SHASHIDHARAN P, 1994, J BIOL CHEM, V269, P16971; Smith Christopher W. J., 1996, P411; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; Tommerup N, 1996, GENOMICS, V32, P297, DOI 10.1006/geno.1996.0121; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WILDE CD, 1986, CRIT REV BIOCHEM MOL, V19, P323	39	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24849	24857		10.1074/jbc.274.35.24849	http://dx.doi.org/10.1074/jbc.274.35.24849			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455157	hybrid			2022-12-25	WOS:000082193400056
J	Scorrano, L; Petronilli, V; Colonna, R; Di Lisa, F; Bernardi, P				Scorrano, L; Petronilli, V; Colonna, R; Di Lisa, F; Bernardi, P			Chloromethyltetramethylrosamine (Mitotracker Orange (TM)) induces the mitochondrial permeability transition and inhibits respiratory complex I - Implications for the mechanism of cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; BINDING-SITE; MEMBRANE; PORE; BCL-2; DEPOLARIZATION; MODULATION; INDUCTION; CELLS	We have investigated the interactions with isolated mitochondria and intact cells of chloromethyltetramethylrosamine (CMTMRos), a probe (Mitotracker Orange(TM)) that is increasingly used to monitor the mitochondrial membrane potential (Delta psi(m)) in situ. CMTRIRos binds to isolated mitochondria and undergoes a large fluorescence quenching. Most of the binding is energy-independent and can be substantially reduced by sulfhydryl reagents. A smaller fraction of the probe is able to redistribute across the inner membrane in response to a membrane potential, with further fluorescence quenching. Within minutes, however, this energy-dependent fluorescence quenching spontaneously reverts to the same level obtained by treating mitochondria with the uncoupler carbonylcyanide-p-trifluoromethoxyphenyl hydrazone, We show that this event depends on inhibition of the mitochondrial respiratory chain at complex I and on induction of the permeability transition pore by CMTMRos, with concomitant depolarization, swelling, and release of cytochrome c, After staining cells with CMTMRos, depolarization of mitochondria in situ with protonophores is accompanied by changes of CMTMRos fluorescence that range between small and undetectable, depending on the probe concentration. A lasting decrease of cellular CMTMRos fluorescence associated with mitochondria only results from treatment with thiol reagents, suggesting that CMTMRos binding to mitochondria in living cells largely occurs at SH groups via the probe chloromethyl moiety irrespective of the magnitude of Delta psi(m). Induction of the permeability transition precludes the use of CMTMRos as a reliable probe of Delta psi(m) in situ and demands a reassessment of the conclusion that cytochrome c release can occur without membrane depolarization and/or onset of the permeability transition.	Univ Padua, CNR, Unit Study Biomembranes, I-35121 Padua, Italy; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Dept Biol Chem, I-35121 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; University of Padua	Bernardi, P (corresponding author), Dipartimento Sci Biomed Sperimentale, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.		Scorrano, Luca/A-6652-2008; Bernardi, Paolo/C-3656-2008; Scorrano, Luca/K-3967-2019; Petronilli, Valeria/C-3558-2015	Scorrano, Luca/0000-0002-8515-8928; Bernardi, Paolo/0000-0001-9187-3736; Scorrano, Luca/0000-0002-8515-8928; Petronilli, Valeria/0000-0003-4026-6404				Adachi S, 1998, J BIOL CHEM, V273, P19892, DOI 10.1074/jbc.273.31.19892; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1999, IN PRESS PHYSL REV, V79; BERNARDI P, 1999, IN PRESS EUR J BIOCH; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOEW LM, 1993, BIOPHYS J, V65, P2396, DOI 10.1016/S0006-3495(93)81318-3; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Wadia JS, 1998, J NEUROSCI, V18, P932; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; [No title captured]	29	77	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24657	24663		10.1074/jbc.274.35.24657	http://dx.doi.org/10.1074/jbc.274.35.24657			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455132	hybrid			2022-12-25	WOS:000082193400031
J	Zhang, SS; Xing, HM; Muslin, AJ				Zhang, SS; Xing, HM; Muslin, AJ			Nuclear localization of protein kinase U-alpha is regulated by 14-3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POLYMERASE-ALPHA; SERINE PHOSPHORYLATION; IN-VIVO; TRYPTOPHAN-HYDROXYLASE; 14-3-3-PROTEINS; RAF-1; CELL; ASSOCIATION; DROSOPHILA; ACTIVATION	14-3-3 proteins are intracellular, dimeric molecules that bind to and modify the activity of several signaling proteins. We used human 14-3-3 zeta as a bait in the yeast two-hybrid system to screen a murine embryonic cDNA library. One interacting clone was found to encode the carboxyl terminus of a putative protein kinase, The coding sequence of the human form (protein kinase U alpha, PKU alpha) of this protein kinase was found in GenBank(TM) on the basis of sequence homology, The two-hybrid clone was also highly homologous to TOUSLED, an Arabidopsis thaliana protein kinase that is required for normal flower and leaf development. PKU alpha has been found by coimmunoprecipitation to bind to 14-3-3 zeta in vivo. Our confocal laser immunofluorescence microscopic experiments revealed that PKU alpha colocalizes with the cytoplasmic intermediate filament system of cultured fibroblasts in the G(1) phase of the cell cycle. PKU alpha is found in the perinuclear area of S phase cells and in the nucleus of late G(2) cells, Transfection of cells with a dominant negative form of 14-3-3 eta promotes the nuclear localization of PKU alpha. These results suggest that the subcellular localization of PKU alpha is regulated, at least in part, by its association with 14-3-3.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Muslin, AJ (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.				NIGMS NIH HHS [GM54670] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054670] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; delPeso L, 1997, SCIENCE, V278, P687; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kockel L, 1997, GENE DEV, V11, P1140, DOI 10.1101/gad.11.9.1140; LAZARIDES E, 1982, ANNU REV BIOCHEM, V101, P518; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; ROE JL, 1993, CELL, V75, P939, DOI 10.1016/0092-8674(93)90537-Z; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yamakawa A, 1997, GENE, V202, P193, DOI 10.1016/S0378-1119(97)00495-2; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	40	22	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24865	24872		10.1074/jbc.274.35.24865	http://dx.doi.org/10.1074/jbc.274.35.24865			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455159	hybrid			2022-12-25	WOS:000082193400058
J	Wang, JP; Enjoji, M; Tiebel, M; Ochsner, S; Chan, L; Teng, BB				Wang, JP; Enjoji, M; Tiebel, M; Ochsner, S; Chan, L; Teng, BB			Hammerhead ribozyme cleavage of apolipoprotein B mRNA generates a truncated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CULTURED LIVER-CELLS; MESSENGER-RNA LEVELS; FAMILIAL HYPOBETALIPOPROTEINEMIA; CHOLESTEROL LEVELS; TRANSGENIC MICE; METABOLIC BASIS; MOUSE MODEL; GENE; EXPRESSION	Target substrate-specific hammerhead ribozyme cleaves the specific mRNA and results in the inhibition of gene expression. In humans, overproduction of apolipoprotein B (apoB) is positively associated with premature coronary artery diseases. To modulate apoB gene expression, we designed hammerhead ribozymes targeted at AUA(6665) down arrow and GUA(6679) down arrow Of apoB mRNA, designated RB16 and RB15, respectively, and investigated their effects on apoB mRNA in HepG2 cells. The results demonstrated that RB15 and RB16 ribozyme RNAs cleaved apoB RNA efficiently in vitro. Both ribozymes, RB15 and RB16, were used to construct recombinant adenoviral vectors, designated AvRB15 and AvRB16, respectively, for in vivo gene transfer. HepG2 cells were infected with 2 x 10(5) plaque-forming units of AvRB15 for 5, 10, 15, and 24 h, An RNase protection assay showed that the expression of the RB15 transcript was time-dependent; it increased similar to 300-fold from 5 to 24 h, Using reverse ligation-mediated polymerase chain reaction, the 3' cleavage product of apoB mRNA was detected, and the exact cleavage site of apoB mRNA was confirmed by sequencing. Importantly, the levels of apoB mRNA in HepG2 cells decreased similar to 80% after AvRB15 infection. Pulse/chase experiments on HepG2 cells treated with AvRB15 and AvRB16 demonstrated that ribozyme cleavage produced a truncated protein that was secreted at a density of 1.063-1.210 g/ml, The cleavage activity of RB15 on apoB mRNA was more efficient than that of RB16, Moreover, pulse/chase experiments in HepG2 cells treated with AvRB15 revealed that most of the truncated apoB protein was degraded intracellularly, We conclude that hammerhead ribozyme targeted at GUA(6679) down arrow Of apoB mRNA cleaves apoB mRNA, results in decreased apoB mRNA levels, and generates a truncated apoB of the expected size in vivo. Thus, the therapeutic application of ribozyme in regulating apoB production holds promise.	Univ Texas, Inst Mol Med, Res Ctr Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; Baylor College of Medicine; Baylor College of Medicine	Teng, BB (corresponding author), Univ Texas, Inst Mol Med, Res Ctr Human Genet, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Enjoji, Munechika/F-1881-2010		NHLBI NIH HHS [HL-53441, HL-53914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053441] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1219, P1, DOI 10.1016/0167-4781(94)90240-2; Bertrand E, 1997, Methods Mol Biol, V74, P311; Bertrand E, 1997, RNA, V3, P75; BERTRAND E, 1996, NUCL ACIDS MOL BIOL, V10, P301; Birikh KR, 1997, EUR J BIOCHEM, V245, P1, DOI 10.1111/j.1432-1033.1997.t01-3-00001.x; BRESLOW JL, 1988, PHYSIOL REV, V68, P85, DOI 10.1152/physrev.1988.68.1.85; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DIXON JL, 1993, J LIPID RES, V34, P167; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; FARESE RV, 1992, J INTERN MED, V231, P643, DOI 10.1111/j.1365-2796.1992.tb01253.x; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; FROSTER AC, 1987, CELL, V49, P211; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GU JL, 1995, CIRC RES, V77, P14, DOI 10.1161/01.RES.77.1.14; HARDMAN DA, 1991, J CLIN INVEST, V88, P1722, DOI 10.1172/JCI115490; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; Ingram MF, 1996, J LIPID RES, V37, P2202; KAHN JA, 1978, JAMA-J AM MED ASSOC, V240, P47, DOI 10.1001/jama.240.1.47; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; Kim E, 1998, J CLIN INVEST, V101, P1468; KNOTT TJ, 1986, NUCLEIC ACIDS RES, V14, P7501, DOI 10.1093/nar/14.18.7501; KRUL ES, 1992, J LIPID RES, V33, P1037; LARSSON S, 1994, NUCLEIC ACIDS RES, V22, P2242, DOI 10.1093/nar/22.12.2242; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LHuillier PJ, 1996, P NATL ACAD SCI USA, V93, P6698, DOI 10.1073/pnas.93.13.6698; LHUILLIER PJ, 1992, EMBO J, V11, P4411, DOI 10.1002/j.1460-2075.1992.tb05541.x; PARHOFER KG, 1990, J LIPID RES, V31, P2001; PEASE RJ, 1990, J BIOL CHEM, V265, P553; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Powell-Braxton L, 1998, NAT MED, V4, P934, DOI 10.1038/nm0898-934; PULLINGER CR, 1989, J LIPID RES, V30, P1065; Smith H C, 1993, Semin Cell Biol, V4, P267, DOI 10.1006/scel.1993.1032; Smith HC, 1997, RNA, V3, P1105; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; SPERGEL JM, 1991, P NATL ACAD SCI USA, V88, P6472, DOI 10.1073/pnas.88.15.6472; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; Sun CK, 1996, PORTL PR P, V10, P329; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1994, J BIOL CHEM, V269, P29395; TENG BB, 1990, BIOCHEM BIOPH RES CO, V173, P74, DOI 10.1016/S0006-291X(05)81023-X; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Yao ZM, 1997, J LIPID RES, V38, P1937; ZHAO JJG, 1993, NATURE, V365, P448, DOI 10.1038/365448a0	51	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24161	24170		10.1074/jbc.274.34.24161	http://dx.doi.org/10.1074/jbc.274.34.24161			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446190	hybrid			2022-12-25	WOS:000082110900069
J	Zhang, GL; Hiraiwa, H; Yasue, H; Wu, H; Ross, CR; Troyer, D; Blecha, F				Zhang, GL; Hiraiwa, H; Yasue, H; Wu, H; Ross, CR; Troyer, D; Blecha, F			Cloning and characterization of the gene for a new epithelial beta-defensin - Genomic structure, chromosomal localization, and evidence for its constitutive expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ANTIMICROBIAL PEPTIDE; HUMAN BETA-DEFENSIN-1; MOLECULAR-CLONING; AIRWAY EPITHELIA; INNATE IMMUNITY; CYSTIC-FIBROSIS; HOST-DEFENSE; HUMAN LUNG; HUMAN SKIN	Mammalian beta-defensins are endogenous cysteine-rich peptide antibiotics that are produced either by epithelial cells lining the respiratory, digestive, and urogenital tracts or by granulocytes and macrophages. A growing body of evidence has implicated these peptides in host defense, particularly mucosal innate immunity. We previously reported the cloning of the full-length cDNA for a porcine beta-defensin (pBD-1), which was found to be expressed throughout the airway and oral mucosa. Here, we provide the structural organization of the pBD-1 gene, showing that the entire gene spans similar to 1.9 kilobases with two short exons separated by a 1.5-kilobase intron. Fluorescence in situ hybridization mapped the pBD-1 gene to porcine chromosome 15q14-q15.1 within a region of conserved synteny to the chromosomal locations of human and mouse alpha- and beta-defensins. We also provide several independent lines of evidence showing that the pBD-1 gene is expressed constitutively during inflammation and infection, despite its resemblance to many inducible epithelial beta-defensins in amino acid sequence, genomic structure, and sites of expression. First, stimulation of primary porcine tongue epithelial cells with lipopolysaccharide, tumor necrosis factor-alpha, and interleukin (IL)-1 beta failed to up-regulate the expression of pBD-1 mRNA, Second, pBD-1 gene expression was not enhanced in either digestive or respiratory mucosa of pigs following a a-day infection with Salmonella typhimurium or Actinobacillus pleuropneumoniae. Last, direct transfection of the pBD-1 gene promoter into NIH/3T3 cells showed no difference in reporter gene activity in response to stimulation by lipopolysaccharide and IL-1 beta, The constitutive expression of pBD-1 in airway and oral mucosa, which is consistent with a lack of consensus binding sites for nuclear factor-kappa B or NF-IL-6 in its promoter region, suggests that it may play a surveillance role in maintaining the steady state of microflora on mucosal surfaces.	Kansas State Univ, Dept Anat & Physiol, Manhattan, KS 66506 USA; Forestry & Fisheries Inst, Soc Technoinnovat Agr, Anim Genome Program Team, Tsukuba, Ibaraki 3050854, Japan; Natl Inst Anim Ind, Dept Anim Genet & Breeding, Tsukuba, Ibaraki 3050901, Japan	Kansas State University; National Agriculture & Food Research Organization - Japan	Blecha, F (corresponding author), Kansas State Univ, Dept Anat & Physiol, 1600 Denison Ave,VMS 228, Manhattan, KS 66506 USA.		Zhang, Guolong/HCI-5587-2022; Zhang, Guolong/AAU-8197-2020	Zhang, Guolong/0000-0003-4781-5816				Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Asakawa S, 1997, GENE, V191, P69, DOI 10.1016/S0378-1119(97)00044-9; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bals R, 1998, INFECT IMMUN, V66, P1225, DOI 10.1128/IAI.66.3.1225-1232.1998; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Bevins CL, 1996, GENOMICS, V31, P95, DOI 10.1006/geno.1996.0014; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; Diamond G, 1998, CLIN IMMUNOL IMMUNOP, V88, P221, DOI 10.1006/clin.1998.4587; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; FRENGEN E, 1991, GENOMICS, V10, P949, DOI 10.1016/0888-7543(91)90184-G; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Fronicke L, 1996, MAMM GENOME, V7, P285, DOI 10.1007/s003359900084; Fulton C, 1997, LANCET, V350, P1750, DOI 10.1016/S0140-6736(05)63574-X; GALLAGHER DS, 1995, MAMM GENOME, V6, P554, DOI 10.1007/BF00356177; Gallo RL, 1998, J INVEST DERMATOL, V111, P739, DOI 10.1046/j.1523-1747.1998.00361.x; GANZ T, 1994, CIBA F SYMP, V186, P62; George Catherine P., 1996, P133; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Goureau A, 1996, GENOMICS, V36, P252, DOI 10.1006/geno.1996.0460; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Huttner KM, 1997, FEBS LETT, V413, P45, DOI 10.1016/S0014-5793(97)00875-2; Huttner KM, 1998, GENE, V206, P85, DOI 10.1016/S0378-1119(97)00569-6; Iannuzzi L, 1996, CYTOGENET CELL GENET, V75, P10; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; Krisanaprakornkit S, 1998, INFECT IMMUN, V66, P4222; Lehrer RI, 1996, ANN NY ACAD SCI, V797, P228, DOI 10.1111/j.1749-6632.1996.tb52963.x; LICHTENSTEIN A, 1991, J CLIN INVEST, V88, P93, DOI 10.1172/JCI115310; Liu L, 1998, GENE, V222, P237, DOI 10.1016/S0378-1119(98)00480-6; Liu LD, 1997, GENOMICS, V43, P316, DOI 10.1006/geno.1997.4801; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; McCray PB, 1997, AM J RESP CELL MOL, V16, P343, DOI 10.1165/ajrcmb.16.3.9070620; OUELLETTE AJ, 1989, GENOMICS, V5, P233, DOI 10.1016/0888-7543(89)90051-7; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; Russell JP, 1996, INFECT IMMUN, V64, P1565, DOI 10.1128/IAI.64.5.1565-1568.1996; Sambrook J., 2002, MOL CLONING LAB MANU; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Shi JS, 1999, INFECT IMMUN, V67, P3121, DOI 10.1128/IAI.67.6.3121-3127.1999; SINGER DS, 1987, NUCLEIC ACIDS RES, V15, P2780, DOI 10.1093/nar/15.6.2780; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; SPARKES RS, 1989, GENOMICS, V5, P240, DOI 10.1016/0888-7543(89)90052-9; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Tarver AP, 1998, INFECT IMMUN, V66, P1045, DOI 10.1128/IAI.66.3.1045-1056.1998; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Weinberg A, 1998, CRIT REV ORAL BIOL M, V9, P399, DOI 10.1177/10454411980090040201; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; YASUE H, 1995, CYTOGENET CELL GENET, V71, P249, DOI 10.1159/000134120; YASUE H, 1999, IN PRESS ANIM GENET; Zanetti M, 1997, ANN NY ACAD SCI, V832, P147, DOI 10.1111/j.1749-6632.1997.tb46244.x; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; Zhang GL, 1998, FEBS LETT, V424, P37, DOI 10.1016/S0014-5793(98)00134-3; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	61	46	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24031	24037		10.1074/jbc.274.34.24031	http://dx.doi.org/10.1074/jbc.274.34.24031			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446172	hybrid			2022-12-25	WOS:000082110900051
J	Robles, AI; Wang, XW; Harris, CC				Robles, AI; Wang, XW; Harris, CC			Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death	ONCOGENE			English	Article						DNA helicase; doxorubicin; DNA repair; programmed cell death	NUCLEOTIDE EXCISION-REPAIR; DNA-DAMAGE; XERODERMA-PIGMENTOSUM; IONIZING-RADIATION; POLY(ADP-RIBOSE) POLYMERASE; GAMMA-RADIATION; P53; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION	The tumor suppressor gene product p53 can bind to and inhibit the helicase activity of the multisubunit transcription-repair factor TFIIH, We previously reported that p53-mediated apoptosis is attenuated in primary human fibroblasts from individuals with Xeroderma Pigmentosum (XP) that harbor mutations in the TFIIH DNA helicases XPD or XPB, In this study we show that apoptosis is reduced and delayed in three XPD Iymphoblastoid cell lines (LCLs), but not in an XPD heterozygote LCL, after exposure to doxorubicin, a DNA-damaging agent and topoisomerase II inhibitor frequently used in cancer therapy. Apoptosis was assessed by quantitation of Annexin V binding to exposed phosphatidylserine residues and by caspase-mediated cleavage of Poly(ADP)Ribose Polymerase (PARP). Apoptosis induced by doxorubicin was suppressed in LCLs retrovirally transduced with the Human Papillomavirus 16 E6 oncoprotein, consistent with the hypothesis that this is a p53-dependent process. PARP cleavage was not delayed in XPD LCLs in response to anti-Fas (CD95) antibody-mediated apoptosis, thus, the defect in the apoptotic pathway in these cells lies upstream of caspase activation. Similar changes in the expression of apoptosis-effector genes, p53, and p53-responsive genes p21(cip/WAF-1/Sid1) p21), gadd45, bcl-2 and bar were observed in normal and XPD LCLs after treatment with doxorubicin, indicating that delayed apoptosis was not a consequence of defective transcription of these genes. Thus, our studies provide further support to the hypothesis that XPD and p53 can functionally interact in a p53-mediated apoptotic pathway.	NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bldg 37 Rm 2C05, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Robles, Ana/0000-0001-5019-4374	DIVISION OF BASIC SCIENCES - NCI [Z01BC005794] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; de Boer J, 1998, MOL CELL, V1, P981, DOI 10.1016/S1097-2765(00)80098-2; de Boer J, 1998, CANCER RES, V58, P89; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1998, TRENDS MICROBIOL, V6, P173, DOI 10.1016/S0966-842X(98)01267-0; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MIYASHITA T, 1995, CELL, V80, P293; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; Sheikh MS, 1998, CANCER RES, V58, P1593; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SPETH PAJ, 1988, CLIN PHARMACOKINET, V15, P15, DOI 10.2165/00003088-198815010-00002; Stary A, 1996, CANCER SURV, V26, P155; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Whitacre CM, 1997, CANCER RES, V57, P2157; Wolf CM, 1997, EXP CELL RES, V230, P22, DOI 10.1006/excr.1996.3401; Yu YJ, 1998, CANCER RES, V58, P4277	41	48	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4681	4688		10.1038/sj.onc.1202862	http://dx.doi.org/10.1038/sj.onc.1202862			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467415				2022-12-25	WOS:000082154400005
J	Falcon-Perez, JM; Mazon, MJ; Molano, J; Eraso, P				Falcon-Perez, JM; Mazon, MJ; Molano, J; Eraso, P			Functional domain analysis of the yeast ABC transporter Ycf1p by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RESISTANCE-ASSOCIATED PROTEIN; ATP-DEPENDENT TRANSPORT; MEMBRANE H+-ATPASE; CYSTIC-FIBROSIS; MULTIDRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; MUTATIONAL ANALYSIS; INTRACELLULAR LOOP	The yeast cadmium factor (Ycf1p) is a vacuolar protein involved in resistance to Cd2+ and to exogenous glutathione S-conjugate precursors in yeast. It belongs to the superfamily of ATP binding cassette transporters, which includes the human cystic fibrosis transmembrane conductance regulator and the multidrug resistance-associated protein. To examine the functional significance of conserved amino acid residues in Ycf1p, we performed an extensive mutational analysis. Twenty-two single amino acid substitutions or deletions were generated by site-directed mutagenesis in the nucleotide binding domains, the proposed regulatory domain, and the fourth cytoplasmic loop. Mutants were analyzed phenotypically by measuring their ability to grow in the presence of Cd2+. Expression and subcellular localization of the mutant proteins were examined by immunodetection in vacuolar membranes. For functional characterization of the Ycf1p variants, the kinetic parameters of glutathione S-conjugated leukotriene C-4 transport were measured. Our analysis shows that residues Ile(711), Leu(712), Phe(713), Glu(927), and Gly(1413) are essential for Ycf1p expression. Five other amino acids, Gly(663), Gly(756), Asp(777), Gly(1306), and Gly(1311), are critical for Ycf1p function, and two residues, Glu(709) and Asp(821) are unnecessary for Ycf1p biogenesis and function. We also identify several regulatory domain mutants in which Cd2+ tolerance of the mutant strain and transport activity of the protein are dissociated.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Hosp La Paz, Unidad Genet Mol, Serv Bioquim, Madrid 28046, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Universitario La Paz	Eraso, P (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	peraso@biomed.iib.uam.es	Calpena, María Jesús Mazón/E-9168-2016; Mazmela, Pilar Eraso/E-9248-2016; Falcon-Perez, Juan M/F-5920-2011	Calpena, María Jesús Mazón/0000-0003-4151-4051; Mazmela, Pilar Eraso/0000-0002-6928-3219; Molano Mateos, Jesus/0000-0002-9289-1239; Falcon-Perez, Juan M/0000-0003-3133-0670				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; Bakos E, 1997, BIOCHEM J, V323, P777, DOI 10.1042/bj3230777; BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Bianchet MA, 1997, J BIOENERG BIOMEMBR, V29, P503, DOI 10.1023/A:1022443209010; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSIUS J, 1989, DNA-J MOLEC CELL BIO, V8, P759, DOI 10.1089/dna.1989.8.759; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cotten JF, 1996, J BIOL CHEM, V271, P21279, DOI 10.1074/jbc.271.35.21279; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; dExaerde AD, 1996, YEAST, V12, P907; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DULHANTY AM, 1994, FEBS LETT, V343, P109, DOI 10.1016/0014-5793(94)80300-5; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOOF T, 1994, J BIOL CHEM, V269, P20575; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Ishikawa T, 1997, BIOSCIENCE REP, V17, P189, DOI 10.1023/A:1027385513483; ISHIKAWA T, 1989, FEBS LETT, V259, P95, DOI 10.1016/0014-5793(89)81503-0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIER I, 1994, J BIOL CHEM, V269, P27807; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Michaelis S, 1995, COLD SPRING HARB SYM, V60, P291, DOI 10.1101/SQB.1995.060.01.034; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Rebbeor JF, 1998, J BIOL CHEM, V273, P33449, DOI 10.1074/jbc.273.50.33449; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Romero I, 1997, BIOCHEM J, V322, P823, DOI 10.1042/bj3220823; RONNE H, 1988, P NATL ACAD SCI USA, V85, P2696, DOI 10.1073/pnas.85.8.2696; Sambrook J., 1989, MOL CLONING LAB MANU, P931; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1991, BIOCHIM BIOPHYS ACTA, V1062, P157, DOI 10.1016/0005-2736(91)90387-N; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SIKORSKI RS, 1989, GENETICS, V122, P19; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Vankeerberghen A, 1998, HUM MOL GENET, V7, P1761, DOI 10.1093/hmg/7.11.1761; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wemmie JA, 1997, MOL MICROBIOL, V25, P683, DOI 10.1046/j.1365-2958.1997.5061868.x; XIE JX, 1995, J BIOL CHEM, V270, P28084; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7	57	23	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23584	23590		10.1074/jbc.274.33.23584	http://dx.doi.org/10.1074/jbc.274.33.23584			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438540	hybrid			2022-12-25	WOS:000082012800090
J	Fischer, N; Setif, P; Rochaix, JD				Fischer, N; Setif, P; Rochaix, JD			Site-directed mutagenesis of the PsaC subunit of photosystem I - F-B is the cluster interacting with soluble ferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; IRON-SULFUR PROTEINS; PEPTOCOCCUS-AEROGENES FERREDOXIN; FLASH ABSORPTION-SPECTROSCOPY; IMMEDIATE ELECTRON-DONOR; CHLAMYDOMONAS-REINHARDTII; CHLOROPLAST DNA; INSERTIONAL INACTIVATION; SYNECHOCOCCUS-ELONGATUS; SPINACH-CHLOROPLASTS	The two [4Fe-4S] clusters F-A and F-B are the terminal electron accepters of photosystem I (PSI) that are bound by the stromal subunit PsaC. Soluble ferredoxin (Fd) binds to PSI via electrostatic interactions and is reduced by the outermost iron-sulfur cluster of PsaC. We have generated six site-directed mutants of the green alga Chlamydomonas reinhardtii in which residues located close to the iron-sulfur clusters of PsaC are changed. The acidic residues Asp(9) and GlU(46), which are located one residue upstream of the first cysteine liganding cluster F-B and F-A, respectively, were changed to a neutral or a basic amino acid. Although Fd reduction is not affected by the E46Q and E46K mutations, a slight increase of Fd affinity (from 1.3- to S-fold) was observed by flash absorption spectroscopy for the D9N and D9K mutant PSI complexes. In the FA(2) triple mutant (V49I/K52T/R53Q), modification of residues located next to the F-A cluster leads to partial destabilization of the PSI complex. The electron paramagnetic resonance properties of cluster F-A are affected, and a 3-fold decrease of Fd affinity is observed. The introduction of positively charged residues close to the F-B cluster in the FB, triple mutant (I12V/T15K/Q16R) results in a 60-fold increase of Fd affinity as measured by flash absorption spectroscopy and a larger amount of PsaC-Fd cross-linking product. The first-order kinetics are similar to wild type kinetics (two phases with t1/2 of < 1 and approximate to 4.5 ys) for all mutants except FB1, where Fd reduction is almost monophasic with tM < 1 mu s. These data indicate that F-B is the cluster interacting with Fd and therefore the outermost iron-sulfur cluster of PSI.	Univ Geneva, Dept Biol Mol, CH-1211 Geneva, Switzerland; Univ Geneva, Dept Plant Biol, CH-1211 Geneva, Switzerland; Ctr Etud Saclay, CNRS, URA 2096, Dept Biol Cellulaire & Mol,CEA, F-91191 Gif Sur Yvette, France	University of Geneva; University of Geneva; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Rochaix, JD (corresponding author), Univ Geneva, Dept Biol Mol, 30 Quai ERnest Ansermet, CH-1211 Geneva, Switzerland.		Rochaix, Jean-David/ABC-5243-2020					ADMAN ET, 1976, J BIOL CHEM, V251, P3801; ANDERSEN B, 1992, FEBS LETT, V311, P169, DOI 10.1016/0014-5793(92)81391-X; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; Barth P, 1998, BIOCHEMISTRY-US, V37, P16233, DOI 10.1021/bi981379t; Bennoun P, 1982, METHODS CHLOROPLAST, P25; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; Chiou HC, 1998, J PHYS CHEM B, V102, P8216, DOI 10.1021/jp981211h; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; Diaz-Quintana A, 1998, BIOCHEMISTRY-US, V37, P3429, DOI 10.1021/bi972469l; DUNN PPJ, 1988, PLANT MOL BIOL, V11, P311, DOI 10.1007/BF00027388; EVANS MCW, 1974, FEBS LETT, V49, P111, DOI 10.1016/0014-5793(74)80644-7; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; Fischer N, 1997, BIOCHEMISTRY-US, V36, P93, DOI 10.1021/bi962244v; Fischer N, 1998, EMBO J, V17, P849, DOI 10.1093/emboj/17.4.849; Fischer N, 1996, MOL GEN GENET, V251, P373, DOI 10.1007/s004380050179; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; Golbeck JH, 1994, MOL BIOL CYANOBACTER, P319; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; Hanley J, 1996, BIOCHEMISTRY-US, V35, P8563, DOI 10.1021/bi960399x; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HAYASHIDA N, 1987, CURR GENET, V12, P247, DOI 10.1007/BF00435285; HE WZ, 1994, PHOTOSYNTH RES, V41, P381, DOI 10.1007/BF02183040; HEATHCOTE P, 1978, BIOCHIM BIOPHYS ACTA, V503, P333, DOI 10.1016/0005-2728(78)90192-5; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; HOJ PB, 1987, J BIOL CHEM, V262, P12676; JENSEN GM, 1994, BIOCHEMISTRY-US, V33, P10911, DOI 10.1021/bi00202a010; Kamlowski A, 1997, BBA-BIOENERGETICS, V1319, P199, DOI 10.1016/S0005-2728(96)00162-4; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; Kruip J, 1997, J BIOL CHEM, V272, P17061, DOI 10.1074/jbc.272.27.17061; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEN R, 1992, J BIOL CHEM, V267, P25625; LELONG C, 1994, J BIOL CHEM, V269, P10034; Lelong C, 1996, EMBO J, V15, P2160, DOI 10.1002/j.1460-2075.1996.tb00569.x; MALKIN R, 1984, BIOCHIM BIOPHYS ACTA, V764, P63, DOI 10.1016/0005-2728(84)90141-5; Mannan RM, 1996, EMBO J, V15, P1826, DOI 10.1002/j.1460-2075.1996.tb00532.x; Naver H, 1996, J BIOL CHEM, V271, P8996, DOI 10.1074/jbc.271.15.8996; Naver H, 1998, J BIOL CHEM, V273, P18778, DOI 10.1074/jbc.273.30.18778; NITSCHKE W, 1990, BIOCHEMISTRY-US, V29, P11079, DOI 10.1021/bi00502a010; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; ROCHAIX JD, 1978, J MOL BIOL, V126, P597, DOI 10.1016/0022-2836(78)90011-6; Rodday SM, 1996, BIOCHEMISTRY-US, V35, P11832, DOI 10.1021/bi9612834; ROGERS WJ, 1992, FEBS LETT, V310, P240, DOI 10.1016/0014-5793(92)81340-R; SAKURAI H, 1991, PHOTOSYNTH RES, V27, P65, DOI 10.1007/BF00029977; Sambrook J., 2002, MOL CLONING LAB MANU; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; Scott MP, 1997, EUR J BIOCHEM, V244, P454, DOI 10.1111/j.1432-1033.1997.00454.x; SETIF PQY, 1994, BIOCHEMISTRY-US, V33, P8495, DOI 10.1021/bi00194a014; SETIF PQY, 1995, BIOCHEMISTRY-US, V34, P9059, DOI 10.1021/bi00028a015; SONOIKE K, 1993, BIOCHIM BIOPHYS ACTA, V1141, P52, DOI 10.1016/0005-2728(93)90188-L; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; Takahashi YM, 1992, RES PHOTOSYNTHESIS, VIII, P393; Vassiliev IR, 1998, BIOPHYS J, V74, P2029, DOI 10.1016/S0006-3495(98)77909-3; XU Q, 1994, J BIOL CHEM, V269, P21512; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	57	47	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23333	23340		10.1074/jbc.274.33.23333	http://dx.doi.org/10.1074/jbc.274.33.23333			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438510	hybrid, Green Published			2022-12-25	WOS:000082012800060
J	Jarmuszkiewicz, W; Sluse-Goffart, CM; Hryniewiecka, L; Sluse, FE				Jarmuszkiewicz, W; Sluse-Goffart, CM; Hryniewiecka, L; Sluse, FE			Identification and characterization of a protozoan uncoupling protein in Acanthamoeba castellanii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL CARRIER FAMILY; ACID CYCLING MECHANISM; ALTERNATIVE OXIDASE; STEADY-STATE; GENE; RESPIRATION; TISSUE	An uncoupling protein (UCP) has been identified in mitochondria from Acanthamoeba castellanii, a nonphotosynthetic soil amoeboid protozoon that, in molecular phylogenesis, appears on a branch basal to the divergence points of plants, animals, and fungi. The existence of UCP in A. castellanii (AcUCP) has been revealed using antibodies raised against plant UCP, Its molecular mass (32,000 Da) was similar to those of plant and mammalian UCPs, The activity of AcUCP has been investigated in mitochondria depleted of free fatty acids. Additions of linoleic acid stimulated state 4 respiration and decreased transmembrane electrical potential (hly) in a manner expected from fatty acid cycling-linked H+ reuptake, The half-maximal stimulation by linoleic acid was reached at 8.1 +/- 0.4 mu M. Bovine serum albumin (fatty acid-free), which adsorbs linoleic acid, reversed the respiratory stimulation and correspondingly restored Delta Psi. AcUCP was only weakly inhibited by purine nucleotides like UCP in plants. A single force-flow relationship has been observed for state 4 respiration with increasing concentration of linoleic acid or of an uncoupler and for state 3 respiration with increasing concentration of oligomycin, indicating that linoleic acid has a pure protonophoric effect. The activity of AcUCP in state 3 has been evidenced by ADP/oxygen atom determination. The discovery of AcUCP indicates that UCPs emerged, as specialized proteins for H+ cycling, early during phylogenesis before the major radiation of phenotypic diversity in eukaryotes and could occur in the whole eukaryotic world.	Adam Mickiewicz Univ, Dept Bioenerget, PL-61701 Poznan, Poland; Univ Liege, Ctr Oxygen Biochem, Lab Bioenerget, B-4000 Liege, Belgium	Adam Mickiewicz University; University of Liege	Jarmuszkiewicz, W (corresponding author), Adam Mickiewicz Univ, Dept Bioenerget, Fredry 10, PL-61701 Poznan, Poland.	wiesiaj@main.amu.edu.pl		Jarmuszkiewicz, Wieslawa/0000-0001-8550-8337				Almeida AM, 1999, PLANT PHYSIOL, V119, P1323, DOI 10.1104/pp.119.4.1323; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; DOUSSIERE J, 1984, BIOCHEM J, V220, P787, DOI 10.1042/bj2200787; ElMoualij B, 1997, YEAST, V13, P573, DOI 10.1002/(SICI)1097-0061(199705)13:6<573::AID-YEA107>3.0.CO;2-I; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Hryniewiecka L., 1978, Plant mitochondria. Developments in plant biology. Vol. 1., P307; Jarmuszkiewicz W, 1997, FEBS LETT, V411, P110, DOI 10.1016/S0014-5793(97)00676-5; Jarmuszkiewicz W, 1998, J BIOL CHEM, V273, P10174, DOI 10.1074/jbc.273.17.10174; Jarmuszkiewicz W, 1998, J BIOL CHEM, V273, P34882, DOI 10.1074/jbc.273.52.34882; Jezek P, 1997, J BIOL CHEM, V272, P24272, DOI 10.1074/jbc.272.39.24272; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; Maia IG, 1998, FEBS LETT, V429, P403, DOI 10.1016/S0014-5793(98)00634-6; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; Sakajo S, 1997, BIOSCI BIOTECH BIOCH, V61, P396, DOI 10.1271/bbb.61.396; SHARPLESS TK, 1970, J BIOL CHEM, V245, P58; SKULACHEV VP, 1998, BIOCHIM BIOPHYS ACTA, V1383, P100; Sluse FE, 1998, FEBS LETT, V433, P237, DOI 10.1016/S0014-5793(98)00922-3; TOMASZEWSKA B, 1991, PLANT PHYSIOL BIOCH, V29, P489; VANDERLEYDEN J, 1980, BIOCHEM J, V186, P309, DOI 10.1042/bj1860309; VANDERLEYDEN J, 1980, BIOCHEM J, V188, P141, DOI 10.1042/bj1880141; VANDERLEYDEN J, 1997, BIOCHEM J, V48, P703; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; WESTERHOFF HV, 1984, BIOCHIM BIOPHYS ACTA, V768, P257, DOI 10.1016/0304-4173(84)90019-3	33	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23198	23202		10.1074/jbc.274.33.23198	http://dx.doi.org/10.1074/jbc.274.33.23198			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438491	hybrid, Green Published			2022-12-25	WOS:000082012800041
J	Zanusso, G; Petersen, RB; Jin, TC; Jing, Y; Kanoush, R; Ferrari, S; Gambetti, P; Singh, N				Zanusso, G; Petersen, RB; Jin, TC; Jing, Y; Kanoush, R; Ferrari, S; Gambetti, P; Singh, N			Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; ENDOPLASMIC-RETICULUM; INEFFICIENT CLEAVAGE; TRANSFECTED CELLS; SECRETORY PROTEIN; SIGNAL PEPTIDASE; SCRAPIE ISOFORM; CULTURED-CELLS; MUTATION; CONVERSION	An amber mutation at codon 145 (Y145stop) of the prion protein gene results in a variant of an inherited human prion disease named Gerstmann-Straussler-Scheinker syndrome. The characteristic features of this disorder include amyloid deposits of prion protein in cerebral parenchyma and vessels. We have studied the biosynthesis and processing of the prion protein containing the Y145stop mutation (PrP145) in, transfected human neuroblastoma cells in an attempt to clarify the effect of the mutation on the metabolism of PrP145 and to gain insight into the underlying pathogenetic mechanism. Our results demonstrate that 1) a significant proportion of PrP145 is not processed post-translationally and retains the N-terminal signal peptide, 2) most PrP145 is degraded very rapidly by the proteasome-mediated pathway, 3) blockage of proteasomal degradation results in intracellular accumulation of PrP145, 4) most of the accumulated PrP145 is detergent-insoluble, and both the detergent-soluble and -insoluble fractions are resistant to mild proteinase K (PK) treatment, suggesting that PK resistance is not simply because of aggregation. The present study demonstrates for the first time that a mutant prion protein is degraded through the proteasomal pathway and acquires PK-resistance if degradation is impaired.	Case Western Reserve Univ, Inst Pathol, Div Neuropathol, Cleveland, OH 44106 USA	Case Western Reserve University	Singh, N (corresponding author), Case Western Reserve Univ, Inst Pathol, Div Neuropathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.		Zanusso, Gianluigi/K-2823-2018; Petersen, Robert/B-5075-2011	Zanusso, Gianluigi/0000-0001-5199-6264; Petersen, Robert/0000-0002-3154-0072; ferrari, sergio/0000-0003-3855-5135				ARNOLD A, 1990, J CLIN INVEST, V86, P1084, DOI 10.1172/JCI114811; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BRADNER S, 1996, NATURE, V379, P339; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; GHETTI B, 1999, IN PRESS GENETIC ABE; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; ITO M, 1993, J CLIN INVEST, V91, P2565, DOI 10.1172/JCI116494; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Kim TW, 1997, J BIOL CHEM, V272, P11006; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V192, P525, DOI 10.1006/bbrc.1993.1447; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Li Y, 1996, P NATL ACAD SCI USA, V93, P9606, DOI 10.1073/pnas.93.18.9606; Muramoto T, 1997, NAT MED, V3, P750, DOI 10.1038/nm0797-750; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1998, P NATL ACAD SCI USA, V95, P8322, DOI 10.1073/pnas.95.14.8322; Parchi P., 1998, PROGR PATHOLOGY, P39; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Prusiner SB, 1996, COLD SPRING HARB SYM, V61, P473; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RACCHI M, 1993, J BIOL CHEM, V268, P5735; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	47	140	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23396	23404		10.1074/jbc.274.33.23396	http://dx.doi.org/10.1074/jbc.274.33.23396			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438517	hybrid			2022-12-25	WOS:000082012800067
J	Wieland, I; Arden, KC; Michels, D; Klein-Hitpass, L; Bohm, M; Viars, CS; Weidle, UH				Wieland, I; Arden, KC; Michels, D; Klein-Hitpass, L; Bohm, M; Viars, CS; Weidle, UH			Isolation of DICE1: A gene frequently affected by LOH and downregulated in lung carcinomas	ONCOGENE			English	Article						chromosome 13; cDNA cloning; DBI-1 homologue; lung cancer; MOMeNT	RETINOBLASTOMA SUSCEPTIBILITY GENE; SQUAMOUS-CELL CARCINOMAS; TUMOR-SUPPRESSOR GENE; FACTOR-I RECEPTOR; DISTINCT REGIONS; CHROMOSOME 13Q; EXON AMPLIFICATION; ALLELIC DELETION; PROSTATE-CANCER; BREAST-CANCER	In the development and progression of sporadic tumors multiple tumor suppressor genes are inactivated that may be distinct from predisposing cancer genes. Previously, a tumor suppressor locus on human chromosome 13q14 that is distinct from the retinoblastoma predisposing gene 1 (RBI) has been identified in lung, head and neck, breast, ovarian and prostate tumors, By an approach that combines genomic difference cloning and positional cloning we isolated the cDNA of a novel gene (DICE1) located at 13q14.12-14.2. The DICE1 gene is highly conserved in evolution and its mRNA is expressed in a nide variety of fetal and adult tissues, The DICE1 cDNA encodes a predicted protein of 887 amino acids corresponding to an 100 kD protein that shows 92.9% identity to the carboxy-terminal half of the mouse EGF repeat transmembrane protein DBI-1. The DBI-1 protein interferes with the mitogenic response to insulin-like growth factor 1 (IGF-I) and is presumably involved in anchorage-dependent growth. When compared to normal lung tissue expression of the DICE1 mRNA aas reduced or undetectable in the majority of non-small cell lung carcinomas analysed, The location of the DICE1 gene in the region of allelic loss, its high evolutionary conservation and the downregulation of expression in carcinoma cells suggests that DICE1 is a candidate tumor suppressor gene in non-small cell lung carcinomas and possibly in other sporadic carcinomas.	Univ Essen Gesamthsch, Sch Med, Inst Cell Biol Canc Res, D-45122 Essen, Germany; Univ Calif San Diego, Dept Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Essen Gesamthsch, Sch Med, Dept Urol, D-45122 Essen, Germany; Roche Diagnost GmbH, D-82377 Penzberg, Germany	University of Duisburg Essen; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of Duisburg Essen; Roche Holding	Wieland, I (corresponding author), Univ Klinikum Magdeburg, Inst Human Genet, Leipziger Str 44, D-39120 Magdeburg, Germany.			Wieland, Ilse/0000-0002-8017-3029				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; BASERGA R, 1995, CANCER RES, V55, P249; Bohm M, 1997, INT J ONCOL, V10, P131; Bohm M, 1997, AM J PATHOL, V151, P63; BOHM M, 1993, CANCER GENET CYTOGEN, V65, P83, DOI 10.1016/0165-4608(93)90211-4; Bohm M, 1997, INT J CANCER, V74, P291; BORG A, 1992, CANCER RES, V52, P2991; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Cooney KA, 1996, CANCER RES, V56, P1142; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; Hoff HB, 1998, EXP CELL RES, V238, P359, DOI 10.1006/excr.1997.3865; KIM TM, 1994, CANCER RES, V54, P605; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Li CD, 1998, ONCOGENE, V16, P481, DOI 10.1038/sj.onc.1201554; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Maestro R, 1996, CANCER RES, V56, P1146; Peralta RC, 1998, INT J CANCER, V78, P600, DOI 10.1002/(SICI)1097-0215(19981123)78:5<600::AID-IJC12>3.0.CO;2-1; SACHSE R, 1994, ONCOGENE, V9, P39; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOTT DR, 1994, CANCER RES, V54, P1393; SELTMANN M, 1994, CYTOGENET CELL GENET, V67, P46, DOI 10.1159/000133795; SHAPIRO GI, 1995, CANCER RES, V54, P5643; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; Tamura K, 1997, INT J CANCER, V74, P45, DOI 10.1002/(SICI)1097-0215(19970220)74:1<45::AID-IJC8>3.0.CO;2-0; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Wieland I, 1996, ONCOGENE, V12, P97; WIELAND I, 1994, CANCER RES, V54, P1772; WIELAND I, 1992, P NATL ACAD SCI USA, V89, P9705, DOI 10.1073/pnas.89.20.9705; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YOO GH, 1994, CANCER RES, V54, P4603	44	48	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4530	4537		10.1038/sj.onc.1202806	http://dx.doi.org/10.1038/sj.onc.1202806			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467397				2022-12-25	WOS:000082018600002
J	Rutherford, JC; Cavet, JS; Robinson, NJ				Rutherford, JC; Cavet, JS; Robinson, NJ			Cobalt-dependent transcriptional switching by a dual-effector MerR-like protein regulates a cobalt-exporting variant CPx-type ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; METALLOTHIONEIN REPRESSOR SMTB; ESCHERICHIA-COLI; METALLOREGULATORY PROTEINS; GENE-EXPRESSION; DNA; IDENTIFICATION; SITE; CONSTRUCTION; RESISTANCE	CoaR associates with and confers cobalt-dependent activation of the coaT operator-promoter. A CoaR mutant (Ser-Asn-Ser) in a carboxyl-terminal Cys-His-Cys motif bound the coaT operator-promoter but did not activate expression in response to cobalt, implicating thiolate and/or imidazole ligands at these residues in an allosteric cobalt binding site. Deletion of 1 or 2 nucleotides from between near consensus, but with aberrant (20 base pairs) spacing, -10 and -35 elements enhanced expression from the coaT operator-promoter but abolished activation by cobalt-CoaR, It is inferred that cobalt effects a transition in CoaR that underwinds the coaT operator-promoter to realign promoter elements, In the absence of cobalt, CoaR represses expression (similar to 50%). CoaR is a fusion of ancestral MerR (mercury-responsive transcriptional activator)- and precorrin isomerase (enzyme of vitamin B-12 biosynthesis)-related sequences. Expression from the coaT operator-promoter was enhanced in a partial mutant of cbiE (encoding an enzyme preceding precorrin isomerase in B-12 biosynthesis), revealing that this pathway "inhibits" coaT expression. Disruption of coaT reduced cobalt tolerance and increased cytoplasmic Co-57 accumulation. coaT-mediated restoration of cobalt tolerance has been used as a selectable marker.	Univ Newcastle, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robinson, NJ (corresponding author), Univ Newcastle, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.j.robinson@newcastle.ac.uk	Robinson, Nigel J/J-6363-2012	Robinson, Nigel J/0000-0001-5586-1092; Cavet, Jennifer/0000-0001-5913-7157				AHMED M, 1995, J BACTERIOL, V177, P3904, DOI 10.1128/jb.177.14.3904-3910.1995; AMES GFL, 1994, METHOD ENZYMOL, V235, P234; ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; Beard SJ, 1997, MOL MICROBIOL, V25, P883, DOI 10.1111/j.1365-2958.1997.mmi518.x; Bird AJ, 1998, J BIOL CHEM, V273, P21246, DOI 10.1074/jbc.273.33.21246; Brocklehurst KR, 1999, MOL MICROBIOL, V31, P893, DOI 10.1046/j.1365-2958.1999.01229.x; Chiu ML, 1996, BIOCHEMISTRY-US, V35, P2332, DOI 10.1021/bi952073e; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; ENDO G, 1995, J BACTERIOL, V177, P4437, DOI 10.1128/jb.177.15.4437-4441.1995; Frausto da Silva J. J. R., 1993, BIOL CHEM ELEMENTS I, DOI 10.1021/ed069pA326.1; HAGEMANN M, 1992, ARCH MICROBIOL, V158, P429; HAWKINS AR, 1993, GENE, V136, P49, DOI 10.1016/0378-1119(93)90446-A; Hidalgo E, 1998, EMBO J, V17, P2629, DOI 10.1093/emboj/17.9.2629; HILDAGO E, 1997, EMBO J, V16, P1056; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; KRATZ WA, 1955, AM J BOT, V42, P282, DOI 10.2307/2438564; LUND PA, 1986, J GEN MICROBIOL, V132, P465; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Maniatis T., 1989, MOL CLONING LAB MAN; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; Milkowski C, 1998, CURR MICROBIOL, V37, P108; MORBY AP, 1993, NUCLEIC ACIDS RES, V21, P921, DOI 10.1093/nar/21.4.921; Nies DH, 1997, CH MICROBIOL SER, P77; Noll M, 1998, J BIOL CHEM, V273, P21393, DOI 10.1074/jbc.273.33.21393; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; PARKHILL J, 1993, EMBO J, V12, P413, DOI 10.1002/j.1460-2075.1993.tb05673.x; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Raux E, 1996, J BACTERIOL, V178, P753, DOI 10.1128/jb.178.3.753-767.1996; Rensing C, 1998, J BIOL CHEM, V273, P32614, DOI 10.1074/jbc.273.49.32614; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Roth JR, 1996, ANNU REV MICROBIOL, V50, P137, DOI 10.1146/annurev.micro.50.1.137; SADOWSKY MJ, 1991, P NATL ACAD SCI USA, V88, P637, DOI 10.1073/pnas.88.2.637; SCANLAN DJ, 1990, GENE, V90, P43, DOI 10.1016/0378-1119(90)90437-V; SHI WP, 1994, J BIOL CHEM, V269, P19826; Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Thelwell C, 1998, P NATL ACAD SCI USA, V95, P10728, DOI 10.1073/pnas.95.18.10728; THIBAUT D, 1992, J BACTERIOL, V174, P1043, DOI 10.1128/jb.174.3.1043-1049.1992; Turner JS, 1996, NUCLEIC ACIDS RES, V24, P3714, DOI 10.1093/nar/24.19.3714; TURNER JS, 1993, J BIOL CHEM, V268, P4494	42	103	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25827	25832		10.1074/jbc.274.36.25827	http://dx.doi.org/10.1074/jbc.274.36.25827			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464323	hybrid			2022-12-25	WOS:000082554200087
J	Seidel, MG; Klinger, M; Freissmuth, M; Holler, C				Seidel, MG; Klinger, M; Freissmuth, M; Holler, C			Activation of mitogen-activated protein kinase by the A(2A)-adenosine receptor via a rap1-dependent and via a p21(ras)-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; RAS-DEPENDENT ACTIVATION; HUMAN ENDOTHELIAL-CELLS; BETA-GAMMA-SUBUNITS; ADENOSINE RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; SIGNALING PATHWAY; BINDING PROTEINS; GROWTH-FACTOR; CYCLIC-AMP	The A(2A)-adenosine receptor, a prototypical G(s)-coupled receptor, activates mitogen-activated protein (MAP) kinase in a manner independent of cAMP in primary human endothelial cells. In order to delineate signaling pathways that link the receptor to the regulation of MAP kinase, the human A(2A) receptor was heterologously expressed in Chinese hamster ovary (CHO) and HEK293 cells. In both cell lines, A(2A) agonist-mediated cAMP accumulation was accompanied by activation of the small G protein rap1, However, rap1 mediates A(2A) receptor-dependent activation of MAP kinase only in CHO cells, the signaling cascade being composed of G(s), adenylyl cyclase, rap1, and the p68 isoform of B-raf, This isoform was absent in HEK293 cells. Contrary to CHO cells, in HEK293 cells activation of MAP kinase by A(2A) agonists was not mimicked by 8-bromo-cAMP, was independent of G alpha(s), and was associated with activation of p21(ras), Accordingly, overexpression of the inactive S17N mutant of p21(ras) and of a dominant negative version of mSos (the exchange factor of p21(ras)) blocked MAP kinase stimulation by the A(2A) receptor in HEK 293 but not in CHO cells. In spite of the close homology between p21(ras) and rap1, the S17N\ mutant of rap1 was not dominant negative because (i) overexpression of rap1(S17N) failed to inhibit A(2A) receptor-dependent MAP kinase activation, (ii) rap1(S17N) was recovered in the active form with a GST fusion protein comprising the rap1-binding domain of ralGDS after A(2A) receptor activation, and (iii) A(2A) agonists promoted the association of rap1(S17N) with the 68-kDa isoform of B-raf in CHO cells. We conclude that the A(2A) receptor has the capacity two activate MAP kinase via at least two signaling pathways, which depend on two distinct small G proteins, namely p21(ras) and rap1, Our observations also show that the S17N version of rap1 cannot be assumed a priori to act as a dominant negative interfering mutant.	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria	University of Vienna	Freissmuth, M (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	michael.freissmuth@univie.ac.at	Seidel, Markus G/N-9951-2017	Seidel, Markus G/0000-0003-0981-8661; Freissmuth, Michael/0000-0001-9398-1765; Klinger, Markus/0000-0001-8381-1543				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 1997, FEBS LETT, V410, P59, DOI 10.1016/S0014-5793(97)00324-4; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHEN SY, 1994, ONCOGENE, V9, P2691; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COLLIS MG, 1993, TRENDS PHARMACOL SCI, V14, P360; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; ETHIER MF, 1993, AM J PHYSIOL, V265, pH131, DOI 10.1152/ajpheart.1993.265.1.H131; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Holler C, 1998, DRUG DEVELOP RES, V45, P140, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<140::AID-DDR9>3.0.CO;2-M; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klotz KN, 1998, N-S ARCH PHARMACOL, V357, P1; LEITMAN DC, 1986, J CELL PHYSIOL, V127, P237, DOI 10.1002/jcp.1041270208; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MALY FE, 1994, J BIOL CHEM, V269, P18743; MEININGER CJ, 1990, AM J PHYSIOL, V258, pH198, DOI 10.1152/ajpheart.1990.258.1.H198; MILLIGAN G, 1989, BIOCHEM J, V262, P643, DOI 10.1042/bj2620643; NANOFF C, 1993, J RECEPTOR RES, V13, P961, DOI 10.3109/10799899309073703; NANOFF C, 1991, MOL PHARMACOL, V39, P130; NANOFF C, 1994, J BIOL CHEM, V269, P31999; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PALMER TM, 1994, MOL PHARMACOL, V45, P1082; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; SEXL V, 1995, BRIT J PHARMACOL, V114, P1577, DOI 10.1111/j.1476-5381.1995.tb14942.x; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Waldhoer M, 1998, MOL PHARMACOL, V53, P808; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	57	110	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25833	25841		10.1074/jbc.274.36.25833	http://dx.doi.org/10.1074/jbc.274.36.25833			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464324	hybrid			2022-12-25	WOS:000082554200088
J	Toth, C; Coffino, P				Toth, C; Coffino, P			Regulated degradation of yeast ornithine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYAMINE-MEDIATED REGULATION; SACCHAROMYCES-CEREVISIAE; PROTEASOME; CELLS; ANTIZYME; PROTEIN; MOUSE; GENE; SEQUENCE; REQUIRES	Ornithine decarboxylase (ODC) declines in cells that accumulate an excess of polyamines, the downstream products of the enzyme, Superfluous production of polyamines is thus prevented. In animal cells, polyamines reduce ODC activity by accelerating its degradation. Similar down-regulation of ODC activity has been observed in the budding yeast Saccharomyces cerevisiae, but induced degradation has not been documented. Here we show using pulse-chase analysis that the loss of enzyme activity is the result of increased degradation of ODC. Polyamines reduce the half-life of the newly synthesized protein from 3 h to approximately 10 min. Degradation of bulk ODC pools is also accelerated by polyamines, but the absolute rate of turnover is slower, with a half-life of 5 h in untreated and 1 h in treated cells. Newly synthesized ODC polypeptide thus undergoes a process of maturation that renders it relatively resistant to both basal and polyamine-induced degradation. Proteasome mutants have a blunted or absent regulatory response, implicating both the core protease and the regulatory cap of the proteasome in induced degradation of yeast ODC.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Coffino, P (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.			Coffino, Philip/0000-0003-0344-5083	NIGMS NIH HHS [GM45335] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUNDARAM D, 1991, P NATL ACAD SCI USA, V88, P5872, DOI 10.1073/pnas.88.13.5872; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Coffino P, 1998, UBIQUITIN BIOL CELL, P411; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; ELIAS S, 1995, EUR J BIOCHEM, V229, P276, DOI 10.1111/j.1432-1033.1995.0276l.x; FONZI WA, 1987, J BIOL CHEM, V262, P10127; FONZI WA, 1989, J BIOL CHEM, V264, P18110; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MAMROUDKIDRON E, 1994, FEBS LETT, V337, P239, DOI 10.1016/0014-5793(94)80199-1; MAMROUDKIDRON E, 1994, FEBS LETT, V356, P162, DOI 10.1016/0014-5793(94)01260-1; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; PEGG AE, 1992, PHARMACOL THERAPEUT, V56, P359, DOI 10.1016/0163-7258(92)90025-U; Sambrook J., 2002, MOL CLONING LAB MANU; SIKORSKI RS, 1989, GENETICS, V122, P19; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TYAGI AK, 1981, J BIOL CHEM, V256, P2156; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; WHEATLEY DN, 1980, CELL BIOL INT REP, V4, P1081, DOI 10.1016/0309-1651(80)90045-4; WILLIAMS LJ, 1992, MOL CELL BIOL, V12, P347, DOI 10.1128/MCB.12.1.347	30	29	29	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25921	25926		10.1074/jbc.274.36.25921	http://dx.doi.org/10.1074/jbc.274.36.25921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464336	hybrid			2022-12-25	WOS:000082554200100
J	Hearn, AS; Tu, CK; Nick, HS; Silverman, DN				Hearn, AS; Tu, CK; Nick, HS; Silverman, DN			Characterization of the product inhibited complex in catalysis by human manganese superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-STEAROTHERMOPHILUS; THERMUS-THERMOPHILUS; PULSE-RADIOLYSIS; TYROSINE-34; ENZYME	The reduction with excess H2O2 of human Mn(III) superoxide dismutase (SOD) and the active-site mutant Y34F Mn(III)SOD was measured by scanning stopped-flow spectrophotometry and revealed the presence of an intermediate in the reduction of the manganese. The visible absorption spectrum of this intermediate closely resembled that of the enzyme in the inhibited, zero-order phase of the catalyzed disproportionation of superoxide, The decay of the visible spectrum of this intermediate was a-fold faster for the wild-type compared with the mutant Y34F Mn-SOD, This correlates with the enhanced product inhibition of Y34F during the catalysis of O-2(radical anion) dismutation. The visible spectrum of the product-inhibited complex resembles that of the azide-Mn-SOD complex, suggesting that the inhibited complex has expanded geometry about the metal to octahedral, This study shows that the inhibited complex responsible for the zero-order phase in the catalysis by Mn-SOD of superoxide dismutation can be reached through both the forward (O-2(radical anion)) and reverse (H2O2) reactions, supporting a mechanism in which the zero-order phase results from product inhibition.	Univ Florida, Coll Med, Dept Pharmacol, Ctr Hlth, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Silverman, DN (corresponding author), Univ Florida, Coll Med, Dept Pharmacol, Ctr Hlth, Box 100267, Gainesville, FL 32610 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054903] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54903] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK Y, 1988, BIO-TECHNOL, V6, P930, DOI 10.1038/nbt0888-930; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BULL C, 1991, J AM CHEM SOC, V113, P4069, DOI 10.1021/ja00011a003; CABELLI DE, 1999, IN PRESS BIOMIMETIC; FEE JA, 1976, J BIOL CHEM, V251, P6157; FRIDOVICH I, 1974, ADV ENZYMOL RAMB, V41, P35; Guan Y, 1998, BIOCHEMISTRY-US, V37, P4722, DOI 10.1021/bi972394l; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; Hsu JL, 1996, J BIOL CHEM, V271, P17687, DOI 10.1074/jbc.271.30.17687; Hunter T, 1997, BIOCHEMISTRY-US, V36, P4925, DOI 10.1021/bi9629541; LAH MS, 1995, BIOCHEMISTRY-US, V34, P1646, DOI 10.1021/bi00005a021; MCADAM ME, 1977, BIOCHEM J, V165, P71, DOI 10.1042/bj1650071; MCADAM ME, 1977, BIOCHEM J, V165, P81, DOI 10.1042/bj1650081; MCCLUNE GJ, 1976, FEBS LETT, V67, P294, DOI 10.1016/0014-5793(76)80550-9; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; Sorkin DL, 1997, BIOCHEMISTRY-US, V36, P8202, DOI 10.1021/bi970533t; Whittaker MM, 1996, BIOCHEMISTRY-US, V35, P6762, DOI 10.1021/bi960088m; Whittaker MM, 1997, BIOCHEMISTRY-US, V36, P8923, DOI 10.1021/bi9704212; Yamakura F, 1998, EUR J BIOCHEM, V253, P49, DOI 10.1046/j.1432-1327.1998.2530049.x	19	57	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24457	24460		10.1074/jbc.274.35.24457	http://dx.doi.org/10.1074/jbc.274.35.24457			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455106	hybrid			2022-12-25	WOS:000082193400005
J	Liu, J; Marians, KJ				Liu, J; Marians, KJ			PriA-directed assembly of a primosome on D loop DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; REPLICATION PROTEIN; HOMOLOGOUS RECOMBINATION; PHI-X174-TYPE PRIMOSOME; HELICASE; FORM; PURIFICATION; CONVERSION; IDENTIFICATION	Escherichia coli strains carrying null mutations in priA are chronically induced for the SOS response and are defective in homologous recombination, repair of UV damaged DNA, double-strand break repair, and both induced and constitutive stable DNA replication. This led to the proposal that PriA directed replication fork assembly at D loops formed by the homologous recombination machinery. The demonstration that PriA specifically recognized and bound D loop DNA supported this hypothesis. Using DNA footprinting as an assay, we show here that PriA also directs the assembly of a phi X174-type primosome on D loop DNA. The ability to load a complete primosome on D loop DNA is a step necessary for replication fork assembly.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Grad Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Liu, J (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; GREENBAUM JH, 1984, J BIOL CHEM, V259, P2594; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE MS, 1989, J BIOL CHEM, V264, P14531; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Liu J, 1996, J BIOL CHEM, V271, P15656, DOI 10.1074/jbc.271.26.15656; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; LOW RL, 1982, J BIOL CHEM, V257, P6242; MARIANS KJ, 1984, CRC CR REV BIOCH MOL, V17, P153, DOI 10.3109/10409238409113604; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; Maxam A M, 1980, Methods Enzymol, V65, P499; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P16644; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; Ng JY, 1996, J BIOL CHEM, V271, P15649, DOI 10.1074/jbc.271.26.15649; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; Sandler SJ, 1996, GENETICS, V143, P5; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SMITH GR, 1988, MICROBIOL REV, V52, P1; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WICKNER S, 1977, P NATL ACAD SCI USA, V74, P2815, DOI 10.1073/pnas.74.7.2815	35	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25033	25041		10.1074/jbc.274.35.25033	http://dx.doi.org/10.1074/jbc.274.35.25033			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455182	hybrid			2022-12-25	WOS:000082193400081
J	Oleszewski, M; Beer, S; Katich, S; Geiger, C; Zeller, Y; Rauch, U; Altevogt, P				Oleszewski, M; Beer, S; Katich, S; Geiger, C; Zeller, Y; Rauch, U; Altevogt, P			Integrin and neurocan binding to L1 involves distinct Ig domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CHONDROITIN SULFATE PROTEOGLYCANS; IMMUNOGLOBULIN-LIKE DOMAIN; N-CAM; NEURITE OUTGROWTH; MONOCLONAL-ANTIBODY; HEPARIN-BINDING; NERVOUS-SYSTEM; FIBRONECTIN; EXPRESSION	The cell adhesion molecule L1, a 200-220-kDa type I membrane glycoprotein of the Ig superfamily, mediates many neuronal processes. Originally studied in the nervous system, L1 is expressed by hematopoietic and many epithelial cells, suggesting a more expanded role, L1 supports homophilic L1-L1 and integrin-mediated cell binding and can also bind with high affinity to the neural proteoglycan neurocan; however, the binding site is unknown. We have dissected the L1 molecule and investigated the cell binding ability of Ig domains 1 and 6. We report that RGD sites in domain 6 support alpha 5 beta 1- or alpha v beta 3-mediated integrin binding and that both RGD sites are essential. Cooperation of RGD sites with neighboring domains are necessary for alpha(5)beta(1). A T cell hybridoma and activated T cells could bind to L1 in the absence of RGDs. This binding was supported by Ig domain 1 and mediated by cell surface-exposed neurocan. Lymphoid and brain-derived neurocan were structurally similar. We also present evidence that a fusion protein of the Ig 1-like domain of L1 can bind to recombinant neurocan. Our results support the notion that L1 provides distinct cell binding sites that may serve in cell-cell or cell-matrix interactions.	German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany; Univ Lund Hosp, Dept Expt Pathol, S-22185 Lund, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Lund University; Skane University Hospital	Altevogt, P (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, G0100,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Beer-Hammer, Sandra/AAK-4516-2020; Beer-Hammer, Sandra/C-7442-2014	Beer-Hammer, Sandra/0000-0001-6049-0257; 				Akiyama S K, 1996, Hum Cell, V9, P181; ALTEVOGT P, 1994, EUR J IMMUNOL, V24, P731, DOI 10.1002/eji.1830240336; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; Blaess S, 1998, J NEUROCHEM, V71, P2615, DOI 10.1046/j.1471-4159.1998.71062615.x; Blase L, 1996, LEUKEMIA, V10, P1000; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; Burns JM, 1998, J EXP MED, V188, P1917, DOI 10.1084/jem.188.10.1917; CHANG S, 1987, J CELL BIOL, V104, P355, DOI 10.1083/jcb.104.2.355; Chen J, 1996, CELL ADHES COMMUN, V4, P237, DOI 10.3109/15419069609010769; Cohen NR, 1998, CURR BIOL, V8, P26, DOI 10.1016/S0960-9822(98)70017-X; COLE GJ, 1987, NEUROSCI LETT, V78, P227, DOI 10.1016/0304-3940(87)90638-0; Copie V, 1998, J MOL BIOL, V277, P663; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Di Sciullo G, 1998, J EXP MED, V187, P1953, DOI 10.1084/jem.187.12.1953; Duczmal A, 1997, BIOCHEM BIOPH RES CO, V232, P236, DOI 10.1006/bbrc.1997.6265; Ebeling O, 1996, EUR J IMMUNOL, V26, P2508, DOI 10.1002/eji.1830261035; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; Fransen E, 1998, HUM MOL GENET, V7, P999, DOI 10.1093/hmg/7.6.999; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Grumet M, 1996, PERSPECT DEV NEUROBI, V3, P319; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; Herndon ME, 1999, GLYCOBIOLOGY, V9, P143, DOI 10.1093/glycob/9.2.143; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; Kadmon G, 1997, DIFFERENTIATION, V61, P143, DOI 10.1046/j.1432-0436.1997.6130143.x; KADMON G, 1995, EUR J NEUROSCI, V7, P993, DOI 10.1111/j.1460-9568.1995.tb01087.x; Kamiguchi H, 1998, ANNU REV NEUROSCI, V21, P97, DOI 10.1146/annurev.neuro.21.1.97; Kiselyov VV, 1997, J BIOL CHEM, V272, P10125; KOBAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P238, DOI 10.1016/0167-4781(91)90108-X; KOWITZ A, 1993, CLIN EXP METASTAS, V11, P419, DOI 10.1007/BF00132985; KOWITZ A, 1992, EUR J IMMUNOL, V22, P1199, DOI 10.1002/eji.1830220514; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; Margolis RK, 1996, PERSPECT DEV NEUROBI, V3, P273; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; MCGUIRE JC, 1978, CELL, V15, P357, DOI 10.1016/0092-8674(78)90004-1; MIAO HQ, 1995, J CELL PHYSIOL, V164, P482, DOI 10.1002/jcp.1041640306; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; MORAN N, 1988, FEBS LETT, V242, P121, DOI 10.1016/0014-5793(88)80998-0; Pancook JD, 1997, J IMMUNOL, V158, P4413; RATHJEN FG, 1984, EMBO J, V3, P1; Retzler C, 1996, J BIOL CHEM, V271, P27304, DOI 10.1074/jbc.271.44.27304; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; Sammar M, 1997, BBA-PROTEIN STRUCT M, V1337, P287, DOI 10.1016/S0167-4838(96)00177-X; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Schwartz NB, 1999, PROG NUCLEIC ACID RE, V62, P177; Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124; Sun QH, 1998, J BIOL CHEM, V273, P11483, DOI 10.1074/jbc.273.19.11483; THOR G, 1987, EMBO J, V6, P2581, DOI 10.1002/j.1460-2075.1987.tb02548.x; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; WOLFF JM, 1988, J BIOL CHEM, V263, P11943; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6; Zhao XN, 1998, J NEUROCHEM, V71, P960; ZHAO XO, 1995, J BIOL CHEM, V270, P29413, DOI 10.1074/jbc.270.49.29413	63	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24602	24610		10.1074/jbc.274.35.24602	http://dx.doi.org/10.1074/jbc.274.35.24602			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455125	hybrid			2022-12-25	WOS:000082193400024
J	Parrott, LA; Templeton, DJ				Parrott, LA; Templeton, DJ			Osmotic stress inhibits p70/85 s6 kinase through activation of a protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOSUPPRESSANT RAPAMYCIN; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; OKADAIC ACID; C-JUN; PHOSPHORYLATION; P70(S6K); EXPRESSION; TRANSLATION; SITES	While studying the stress regulation of p70/85 S6 kinase (S6K), we observed that anisomycin and UV light stimulated S6K activity, but that sorbitol inactivated S6K, Pretreatment with hyperosmotic stress also prevented the activation of S6K by both 12-O-tetradecanoylphorbol-13-acetate and anisomycin, Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412) a residue essential to S6K regulation, as determined by phospho-specific antibodies. Rapamycin-resistant S6K truncation mutants were similarly resistant to deactivation by sorbitol, Additionally, the PHAS-1 mobility shift, which is sensitive to rapamycin, was also found to be sensitive to osmotic stress. Experiments using the p38 inhibitor SB203580 and dominant negative mutants involving both stress-activated protein kinase/c-Jun NH2-terminal kinase and p38 stress pathways indicated that these pathways are probably not involved in osmotic stress inhibition of S6K. Examining the potential involvement of a phosphatase, we found that sodium pyrophosphate, sodium vanadate, cyclosporin A, tautomycin, and okadaic acid had no effect on osmotic stress inhibition of S6K, However, calyculin A prevented both rapamycin- and sorbitol-mediated deactivation of S6K, Our results suggest that osmotic stress and rapamycin act through a calyculin A-sensitive phosphatase to cause dephosphorylation and deactivation of S6K.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Templeton, DJ (corresponding author), Case Western Reserve Univ, Inst Pathol, 10900 Euclid Ave, Cleveland, OH 44106 USA.		Templeton, Dennis J/F-7695-2011					Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Grammer TC, 1996, J BIOL CHEM, V271, P23650, DOI 10.1074/jbc.271.39.23650; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hosoi H, 1999, CANCER RES, V59, P886; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kultz D, 1998, J EXP BIOL, V201, P3015; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Kuroda S, 1998, BIOCHEM BIOPH RES CO, V249, P781, DOI 10.1006/bbrc.1998.9140; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lin TA, 1997, DIABETOLOGIA, V40, pS18, DOI 10.1007/s001250051391; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; SABORIO JL, 1974, J MOL BIOL, V85, P195, DOI 10.1016/0022-2836(74)90360-X; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Somwar R, 1998, AM J PHYSIOL-ENDOC M, V275, pE618, DOI 10.1152/ajpendo.1998.275.4.E618; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; YAN MH, 1994, J BIOL CHEM, V269, P19067; YU GY, 1995, J BIOL CHEM, V270, P8739, DOI 10.1074/jbc.270.15.8739	51	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24731	24736		10.1074/jbc.274.35.24731	http://dx.doi.org/10.1074/jbc.274.35.24731			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455142	hybrid			2022-12-25	WOS:000082193400041
J	Sato, M; Mueckler, M				Sato, M; Mueckler, M			A conserved amino acid motif (R-X-G-R-R) in the GLUT1 glucose transporter is an important determinant of membrane topology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGED RESIDUES; XENOPUS OOCYTES; PROTEIN; ORIENTATION; SEQUENCE; ANTIBODIES; HEPG2	The Glut1 glucose transporter is one of over 300 members of the major facilitator superfamily of membrane transporters. These proteins are extremely diverse in substrate specificity and differ in their transport mechanisms. The two most common features shared by many members of this superfamily are the presence of 12 predicted transmembrane segments and an amino acid motif, R-X-G-R-R, present at equivalent positions within the cytoplasmic loops joining transmembrane segments 2-3 and 8-9. The structural and functional roles of the arginine residues within these motifs in Glut1 were investigated by expression of site-directed mutant transporters in Xenopus oocytes followed by analyses of intrinsic transport activity and the membrane topology of mutant glycosylation-scanning reporter Glut1 molecules. Substitution of lysine residues for the cluster of 3 arginine residues in each of the 2 cytoplasmic pentameric motifs of Glut1 revealed no absolute requirement for arginine side chains at any of the 6 positions for transport of 2-deoxyglucose. However, removal of the 3 positive charges at either site by substitution of glycines for the arginines completely abolished transport activity as the result of a local perturbation in the membrane topology in which the cytoplasmic loop was aberrantly translocated into the exoplasm along with the two flanking transmembrane segments. Substitution of lysines for the arginines had no affect on membrane topology. We conclude that the positive charges in the R-X-G-R-R motif form critical local cytoplasmic anchor points involved in determining the membrane topology of Glut1. These data provide a simple explanation for the presence of this conserved amino acid motif in hundreds of functionally diverse membrane transporters that share a common predicted membrane topology.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43695] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLARD WJ, 1985, J BIOL CHEM, V260, P8668; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; DAVIES A, 1987, J BIOL CHEM, V262, P9347; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; JESSENMARSHALL AE, 1995, J BIOL CHEM, V270, P16251, DOI 10.1074/jbc.270.27.16251; KELLER K, 1989, J BIOL CHEM, V264, P18884; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Sato M, 1998, J BIOL CHEM, V273, P25203, DOI 10.1074/jbc.273.39.25203; VonHeijne G, 1996, PROG BIOPHYS MOL BIO, V66, P113, DOI 10.1016/S0079-6107(97)85627-1; WELLNER M, 1994, BIOCHEM J, V299, P813, DOI 10.1042/bj2990813; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155	20	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24721	24725		10.1074/jbc.274.35.24721	http://dx.doi.org/10.1074/jbc.274.35.24721			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455140	hybrid			2022-12-25	WOS:000082193400039
J	Sun, QA; Wu, YL; Zappacosta, F; Jeang, KT; Lee, BJ; Hatfield, DL; Gladyshev, VN				Sun, QA; Wu, YL; Zappacosta, F; Jeang, KT; Lee, BJ; Hatfield, DL; Gladyshev, VN			Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HYDROGEN-PEROXIDE; HUMAN PLACENTA; PROTEIN; PURIFICATION; ACTIVATION; REDUCTION; GENE; SELENOPROTEIN; INVOLVEMENT	The intracellular generation of reactive oxygen species, together with the thioredoxin and glutathione systems, is thought to participate in redox signaling in mammalian cells. The activity of thioredoxin is dependent on the redox status of thioredoxin reductase (TR), the activity of which in turn is dependent on a selenocysteine residue. Two mammalian TR isozymes (TR2 and TR3), in addition to that previously characterized (TR1), have now been identified in humans and mice. All three TR isozymes contain a selenocysteine residue that is located in the penultimate position at the carboxyl terminus and which is encoded by a UGA codon. The generation of reactive oxygen species in a human carcinoma cell line was shown to result in both the oxidation of the selenocysteine in TR1 and a subsequent increase in the expression of this enzyme. These observations identify the carboxyl-terminal selenocysteine of TR1 as a cellular redox sensor and support an essential role for mammalian TR isozymes in redox-regulated cell signaling.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; NIAID, Mol Struct Lab, NIH, Bethesda, MD 20892 USA; Seoul Natl Univ, Inst Mol Biol & Genet, Mol Genet Lab, Seoul 151742, South Korea; NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Lincoln; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.			Gladyshev, Vadim/0000-0002-0372-7016	NATIONAL CANCER INSTITUTE [ZIABC005317, Z01BC005317] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Baker A, 1997, CANCER RES, V57, P5162; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Gallegos A, 1996, CANCER RES, V56, P5765; Gasdaska PY, 1999, FEBS LETT, V442, P105, DOI 10.1016/S0014-5793(98)01638-X; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1999, P NATL ACAD SCI USA, V96, P835, DOI 10.1073/pnas.96.3.835; Gladyshev VN, 1999, BIOCHEM BIOPH RES CO, V259, P244, DOI 10.1006/bbrc.1999.0765; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Gorlatov SN, 1998, P NATL ACAD SCI USA, V95, P8520, DOI 10.1073/pnas.95.15.8520; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Hatfield D, 1999, COMPREHENSIVE NATURA, P353; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Howie AF, 1998, J CLIN ENDOCR METAB, V83, P2052, DOI 10.1210/jc.83.6.2052; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Koishi R, 1997, J BIOL CHEM, V272, P2570; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; May JM, 1998, J BIOL CHEM, V273, P23039, DOI 10.1074/jbc.273.36.23039; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; Rigobello MP, 1998, FREE RADICAL BIO MED, V24, P370, DOI 10.1016/S0891-5849(97)00216-5; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; RUBARTELLI A, 1995, CANCER RES, V55, P675; Saito Y, 1998, BIOL PHARM BULL, V21, P805; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Wu YL, 1998, FEBS LETT, V440, P111, DOI 10.1016/S0014-5793(98)01415-X; WU YL, 1998, FASEB J, V12; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581	48	248	267	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24522	24530		10.1074/jbc.274.35.24522	http://dx.doi.org/10.1074/jbc.274.35.24522			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455115	Green Submitted, hybrid			2022-12-25	WOS:000082193400014
J	Terato, H; Masaoka, A; Kobayashi, M; Fukushima, S; Ohyama, Y; Yoshida, M; Ide, H				Terato, H; Masaoka, A; Kobayashi, M; Fukushima, S; Ohyama, Y; Yoshida, M; Ide, H			Enzymatic repair of 5-formyluracil II. Mismatch formation between 5-formyluracil and guanine during DNA replication and its recognition by two proteins involved in base excision repair (AlkA) and mismatch repair (MutS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SPECIFICALLY BINDS; ALKYLATING-AGENTS; HETERODUPLEX DNA; ENCODED PROTEIN; DAMAGED DNA; LESION; GLYCOSYLASE; THYMINE; ADDUCT	5-Formyluracil (fU), a major methyl oxidation product of thymine, forms correct (fU:A) and incorrect (fU:G) base pairs during DNA replication. In the accompanying paper (Masaoka, A., Terato, H., Kobayashi, M., Honsho, A., Ohyama, Y., and Ide, H. (1999) J. Biol. Chem. 274, 25136-25143), it has been shown that fU correctly paired with A is recognized by AlkA protein (Escherichia coli 3-methyladenine DNA glycosylase II). In the present work, mispairing frequency of fU with G and cellular repair protein that specifically recognized fU:G mispairs were studied using defined oligonucleotide substrates, Mispairing frequency of fU was determined by incorporation of 2'-deoxyribonucleoside 5'-triphosphate of fU opposite template G using DNA polymerase I Klenow fragment deficient in 3'-5' exonuclease. Mispairing frequency of fU was dependent on the nearest neighbor base pair in the primer terminus and 2-12 times higher than that of thymine at pH 7.8 and 2.6-6.7 times higher at pH 9.0 with an exception of the nearest neighbor T(template):A(primer), AlkA catalyzed the excision of fU placed opposite G, as well as A, and the excision efficiencies of fU for fU:G and fU:A pairs were comparable. In addition, MutS protein involved in methyl-directed mismatch repair also recognized fU:G mispairs and bound them with an efficiency comparable to T:G; mispairs, but it did not recognize fU:A pairs. Prior complex formation between MutS and a heteroduplex containing an fU:G mispair inhibited the activity of AlkA to fU, These results suggest that fU present in DNA can be restored by two independent repair pathways, i.e. the base excision repair pathway initiated by AlkA and the methyl-directed mismatch repair pathway initiated by MutS, Biological relevance of the present results is discussed in light of DNA replication and repair in cells.	Hiroshima Univ, Fac Sci, Grad Dept Gene Sci, Higashihiroshima 7398526, Japan; Kyoto Inst Technol, Dept Polymer Sci & Engn, Sakyo Ku, Kyoto 6068585, Japan	Hiroshima University; Kyoto Institute of Technology	Ide, H (corresponding author), Hiroshima Univ, Fac Sci, Grad Dept Gene Sci, Higashihiroshima 7398526, Japan.			Terato, Hiroaki/0000-0002-7070-5263				Babic I, 1996, MUTAT RES-FUND MOL M, V372, P87, DOI 10.1016/S0027-5107(96)00170-4; Biswas I, 1997, J BIOL CHEM, V272, P13355, DOI 10.1074/jbc.272.20.13355; BJELLAND S, 1987, NUCLEIC ACIDS RES, V15, P2787, DOI 10.1093/nar/15.7.2787; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; EVANS J, 1993, MUTAT RES, V299, P147, DOI 10.1016/0165-1218(93)90092-R; Feng G, 1996, J BACTERIOL, V178, P2388, DOI 10.1128/jb.178.8.2388-2396.1996; Fujikawa K, 1998, NUCLEIC ACIDS RES, V26, P4582, DOI 10.1093/nar/26.20.4582; HARTWICK RA, 1977, J CHROMATOGR, V143, P383, DOI 10.1016/S0378-4347(00)80984-6; IDE H, 1991, J BIOL CHEM, V266, P1469; IDE H, 1993, BIOCHEM MOL BIOL INT, V31, P485; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; KARRAN P, 1982, NATURE, V296, P770, DOI 10.1038/296770a0; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; Li GM, 1996, J BIOL CHEM, V271, P24084, DOI 10.1074/jbc.271.39.24084; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; MACARTHY TV, 1984, EMBO J, V3, P545; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Masaoka A, 1999, J BIOL CHEM, V274, P25136, DOI 10.1074/jbc.274.35.25136; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NEUHARD J, 1987, ESCHERICHIA COLI SAL, V1, P445; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Privat EJ, 1996, MUTAT RES-FUND MOL M, V354, P151, DOI 10.1016/0027-5107(96)00005-X; Rasmussen LJ, 1996, CARCINOGENESIS, V17, P2085, DOI 10.1093/carcin/17.9.2085; RYDBERG B, 1978, MUTAT RES, V52, P11, DOI 10.1016/0027-5107(78)90091-X; RYDBERG B, 1977, MOL GEN GENET, V152, P19, DOI 10.1007/BF00264935; SAITO Y, 1997, J BACTERIOL, V179, P3773; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Singer B, 1997, CHEM RES TOXICOL, V10, P713, DOI 10.1021/tx970011e; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; Terato H, 1998, NUCLEOS NUCLEOT, V17, P131, DOI 10.1080/07328319808005164; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6; YAMAMOTO Y, 1978, J BACTERIOL, V135, P144, DOI 10.1128/JB.135.1.144-152.1978; Yoshida M, 1997, NUCLEIC ACIDS RES, V25, P1570, DOI 10.1093/nar/25.8.1570; YU M, 1993, J BIOL CHEM, V268, P15935; Zhang QM, 1997, NUCLEIC ACIDS RES, V25, P3969, DOI 10.1093/nar/25.20.3969	46	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25144	25150		10.1074/jbc.274.35.25144	http://dx.doi.org/10.1074/jbc.274.35.25144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455196	hybrid			2022-12-25	WOS:000082193400095
J	Day, FL; Rafty, LA; Chesterman, CN; Khachigian, LM				Day, FL; Rafty, LA; Chesterman, CN; Khachigian, LM			Angiotensin II (ATII)-inducible platelet-derived growth factor A-chain gene expression is p42/44 extracellular signal-regulated kinase-1/2 and Egr-1-dependent and mediated via the ATII type 1 but not type 2 receptor - Induction by ATII antagonized by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NF-KAPPA-B; VASCULAR ENDOTHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; AT(1) RECEPTOR; MESSENGER-RNA; C-ZETA; INDUCED PHOSPHORYLATION; TRANSCRIPTION FACTORS; NEOINTIMA FORMATION	Angiotensin II (ATII) and platelet-derived growth factor (PDGF) are two vasoconstrictors implicated in the maintenance of normal vascular homeostasis. PDGF A-chain levels increase in cultured vascular smooth muscle cells (SMCs) exposed to ATII. The molecular mechanisms underlying this induction are not known. We used transient transfection analysis to show that ATII can increase reporter gene activity driven by fragments of the PDGF-A promoter bearing recognition elements for the transcription factor, Egr-1. Nuclear run-off experiments indicate that ATII induces Egr-1 expression at the level of transcription. Gel shift and supershift studies show that Egr-1 protein accumulates in the nuclei of SMCs exposed to ATII and binds to the proximal region of the PDGF-A promoter in a specific, time-dependent manner. ATII induced extracellular-signal regulated kinase (p42/44 ERK) activity as did phorbol 12-myristate 13-acetate. The specific MEK1/2 inhibitor, PD98059, suppressed both PDGF-A and Egr-1 endogenous and promoter-dependent expression inducible by ATII. The ATII type 1 receptor (AT1) antagonist, Losartan, inhibited ATII-induction of p42/44 ERK as well as Egr-1 and PDGF-A, whereas neither PD123319, an AT2 receptor antagonist, nor wortmannin, an inhibitor of phosphatidylinositol S-kinase and c-Jun N-terminal kinase, had any effect. ATII-induction of Egr-1 and PDGF-A was blocked by SIN-1, a NO donor. In addition, this pathway was blocked by overexpression of NO synthase. Collectively, these findings demonstrate that ATII activation of the PDGF-A promoter is mediated via the MEK/ERK/Egr-1 pathway and AT1 receptor and that this process is antagonized by NO.	Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.		Khachigian, Levon/AAZ-7458-2020	Day, Fiona/0000-0002-5905-9408; Khachigian, Levon/0000-0003-3446-0323				ADAM LP, 1995, CIRC RES, V76, P183, DOI 10.1161/01.RES.76.2.183; Baylis C, 1996, KIDNEY INT, V49, P1727, DOI 10.1038/ki.1996.256; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; Berman RS, 1997, BRIT J PHARMACOL, V120, P639, DOI 10.1038/sj.bjp.0700962; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bhat GJ, 1997, MOL CELL BIOCHEM, V170, P171, DOI 10.1023/A:1006865721939; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; Buhimschi IA, 1998, HUM REPROD UPDATE, V4, P25, DOI 10.1093/humupd/4.1.25; CAMPBELLBOSWELL M, 1981, EXP MOL PATHOL, V35, P265, DOI 10.1016/0014-4800(81)90066-6; Chen LH, 1998, CIRC RES, V82, P862; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; DE CR, 1995, J CLIN INVEST, V96, P60; Delbridge GJ, 1997, CIRC RES, V81, P282, DOI 10.1161/01.RES.81.2.282; DUBEY RK, 1995, J CLIN INVEST, V96, P141, DOI 10.1172/JCI118014; DZAU VJ, 1994, J HYPERTENS, V12, pS1; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; Goto M, 1997, HYPERTENSION, V30, P358, DOI 10.1161/01.HYP.30.3.358; Guo K, 1998, CIRCULATION, V97, P2066, DOI 10.1161/01.CIR.97.20.2066; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; HultgardhNilsson A, 1996, CIRC RES, V78, P589, DOI 10.1161/01.RES.78.4.589; Ishida M, 1998, CIRC RES, V82, P7; Ishizuka T, 1996, J BIOL CHEM, V271, P12762, DOI 10.1074/jbc.271.22.12762; ITOH H, 1991, BIOCHEM BIOPH RES CO, V176, P1601, DOI 10.1016/0006-291X(91)90471-I; Janssens S, 1998, CIRCULATION, V97, P1274, DOI 10.1161/01.CIR.97.13.1274; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; Khachigian LM, 1999, CIRC RES, V84, P1258, DOI 10.1161/01.RES.84.11.1258; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KHACHIGIAN LM, 1993, PLATELETS, V4, P304, DOI 10.3109/09537109309013233; Kim S, 1998, CIRCULATION, V97, P1731, DOI 10.1161/01.CIR.97.17.1731; KIM SK, 1995, CIRCULATION, V92, P88, DOI 10.1161/01.CIR.92.1.88; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Ma J, 1998, KIDNEY INT, V53, P937, DOI 10.1111/j.1523-1755.1998.00893.x; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MORISHITA R, 1994, J CLIN INVEST, V94, P978, DOI 10.1172/JCI117464; Myers PR, 1996, INT J CARDIOL, V55, P183, DOI 10.1016/0167-5273(96)02684-8; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAKAHARA K, 1992, BIOCHEM BIOPH RES CO, V184, P811, DOI 10.1016/0006-291X(92)90662-5; NAKAYAMA I, 1994, J BIOL CHEM, V269, P11628; Papadaki M, 1998, AM J PHYSIOL-HEART C, V274, pH616; Paul A, 1997, BRIT J PHARMACOL, V120, P940, DOI 10.1038/sj.bjp.0700976; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Rafty LA, 1998, J BIOL CHEM, V273, P5758, DOI 10.1074/jbc.273.10.5758; Raines E.W., 1990, PEPTIDE GROWTH FACTO, DOI [10.1007/978-3-642-49295-2_5, DOI 10.1007/978-3-642-49295-2_5]; Ralevic V, 1996, BRIT J PHARMACOL, V117, P1463, DOI 10.1111/j.1476-5381.1996.tb15307.x; Reagan LP, 1996, ADV EXP MED BIOL, V396, P199; Ruschitzka FT, 1997, CARDIOLOGY, V88, P3, DOI 10.1159/000177500; Sabri A, 1997, ARTERIOSCL THROM VAS, V17, P257, DOI 10.1161/01.ATV.17.2.257; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; SANTIAGO FS, 1999, IN PRESS AM J PATHOL; Schaefer KL, 1996, ANN PHARMACOTHER, V30, P625, DOI 10.1177/106002809603000611; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Schmitz U, 1998, CIRC RES, V82, P1272, DOI 10.1161/01.RES.82.12.1272; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SCOTTBURDEN T, 1990, J CARDIOVASC PHARM, V16, pS36, DOI 10.1097/00005344-199016004-00009; SCOTTBURDEN T, 1990, J CARDIOVASC PHARM, V16, pS17, DOI 10.1097/00005344-199006167-00007; SEKI J, 1995, ATHEROSCLEROSIS, V117, P97, DOI 10.1016/0021-9150(95)05563-C; Shin WS, 1996, J BIOL CHEM, V271, P11317, DOI 10.1074/jbc.271.19.11317; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; STOUFFER GA, 1993, AM J PHYSIOL, V264, pC390, DOI 10.1152/ajpcell.1993.264.2.C390; Taddei S, 1998, CURR OPIN NEPHROL HY, V7, P203, DOI 10.1097/00041552-199803000-00010; Takizawa T, 1997, HYPERTENSION, V30, P1035, DOI 10.1161/01.HYP.30.5.1035; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; Timmermans P B, 1996, Blood Press Suppl, V2, P53; Van Zwieten P A, 1997, Blood Press Suppl, V2, P67; vanKleef EM, 1996, ARTERIOSCL THROM VAS, V16, P857, DOI 10.1161/01.ATV.16.7.857; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WHITING MV, 1995, BRIT J PHARMACOL, V114, P969, DOI 10.1111/j.1476-5381.1995.tb13299.x; Wong J, 1997, CIRCULATION, V96, P1631, DOI 10.1161/01.CIR.96.5.1631; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156; Yang H, 1997, HYPERTENSION, V30, P351, DOI 10.1161/01.HYP.30.3.351; Yang H, 1997, J NEUROSCI, V17, P1660; Yu SM, 1997, CIRCULATION, V95, P1269; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	85	47	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23726	23733		10.1074/jbc.274.34.23726	http://dx.doi.org/10.1074/jbc.274.34.23726			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446131	hybrid			2022-12-25	WOS:000082110900010
J	Kimura, A; Yoshida, I; Takagi, N; Takahashi, T				Kimura, A; Yoshida, I; Takagi, N; Takahashi, T			Structure and localization of the mouse prolyl oligopeptidase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; PROLINE CLEAVING ENZYME; BOVINE BRAIN; FLAVOBACTERIUM-MENINGOSEPTICUM; CDNA CLONING; MOLECULAR-CLONING; ESCHERICHIA-COLI; SERINE PROTEASES; PORCINE OVARY; DNA-SYNTHESIS	We have cloned and characterized the genomic structure of the mouse gene for prolyl oligopeptidase that is mapped to chromosome 10B2-B3. The gene is about 92 kilobases in size and contains 15 exons. All exon-intron junction sequences conform to the GT/AG rule. Comparison with the presumed domain structures of the mouse prolyl oligopeptidase indicates that the propeller domain of the enzyme is encoded by exons 3-10, whereas the catalytic domain is encoded by exons 1-3 and 10-15. The catalytic triad residues are encoded by two exons (Ser(554) on exon 13 and His(680) and Asp(642) on exon 15). The 5'-flanking region of the mouse prolyl oligopeptidase gene has structural features found in housekeeping gene promoters, including a GC-rich segment and an absence of TATA and CAAT boxes. A primer extension assay showed the presence of multiple sites for the initiation of transcription. Transient transfection analysis demonstrated that the 5'-flanking region of the gene can direct efficient expression in COS1 cells. Deletion studies revealed that the downstream 125-base pair sequence of the region is required for promoter activity in the cells.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Res Ctr Mol Genet, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Div Biosci, Sapporo, Hokkaido 0600810, Japan	Hokkaido University; Hokkaido University; Hokkaido University	Takahashi, T (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan.	ttakaha@sci.hokudai.ac.jp						ABBOTT CA, 1994, IMMUNOGENETICS, V40, P331, DOI 10.1007/BF01246674; ATACK JR, 1991, EUR J PHARMACOL, V205, P157, DOI 10.1016/0014-2999(91)90814-7; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARRETT AJ, 1992, BIOL CHEM H-S, V373, P353, DOI 10.1515/bchm3.1992.373.2.353; BERNARD AM, 1994, BIOCHEMISTRY-US, V33, P15204, DOI 10.1021/bi00254a032; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOHM SK, 1995, BIOCHEM J, V311, P835; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CHEVALLIER S, 1992, J BIOL CHEM, V267, P8192; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cunningham DF, 1997, EUR J BIOCHEM, V244, P900, DOI 10.1111/j.1432-1033.1997.00900.x; DIEFENTHAL T, 1993, APPL MICROBIOL BIOT, V40, P90, DOI 10.1007/BF00170434; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKUNARI A, 1994, NEUROSCI LETT, V176, P201, DOI 10.1016/0304-3940(94)90082-5; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; GOOSSENS F, 1995, EUR J BIOCHEM, V233, P432, DOI 10.1111/j.1432-1033.1995.432_2.x; Goossens FJ, 1996, CYTOGENET CELL GENET, V74, P99, DOI 10.1159/000134391; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Ishino T, 1998, J BIOCHEM-TOKYO, V123, P540; ISHIURA S, 1990, FEBS LETT, V260, P131, DOI 10.1016/0014-5793(90)80084-V; KALWANT S, 1991, BIOCHEM J, V276, P237, DOI 10.1042/bj2760237; Kimura A, 1998, MOL REPROD DEV, V50, P121, DOI 10.1002/(SICI)1098-2795(199806)50:2&lt;121::AID-MRD1&gt;3.0.CO;2-M; KOIDA M, 1976, J BIOL CHEM, V251, P7593; MAES M, 1994, BIOL PSYCHIAT, V35, P545, DOI 10.1016/0006-3223(94)90101-5; MARGUET D, 1992, J BIOL CHEM, V267, P2200; Matsubara Y, 1998, EUR J BIOCHEM, V252, P178, DOI 10.1046/j.1432-1327.1998.2520178.x; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MIURA N, 1995, NEUROSCI LETT, V196, P128, DOI 10.1016/0304-3940(95)11821-D; MIZUTANI S, 1984, BIOCHIM BIOPHYS ACTA, V786, P113, DOI 10.1016/0167-4838(84)90161-4; MORIYAMA A, 1988, J BIOCHEM, V104, P112, DOI 10.1093/oxfordjournals.jbchem.a122404; MORIYAMA A, 1983, J BIOCHEM, V94, P1387, DOI 10.1093/oxfordjournals.jbchem.a134485; Ohtsuki S, 1997, INSECT BIOCHEM MOLEC, V27, P337, DOI 10.1016/S0965-1748(97)00004-0; OHTSUKI S, 1994, J BIOCHEM-TOKYO, V115, P449, DOI 10.1093/oxfordjournals.jbchem.a124358; Ohtsuki S, 1997, J BIOCHEM-TOKYO, V121, P1176, DOI 10.1093/oxfordjournals.jbchem.a021712; OLeary RM, 1996, INT J BIOCHEM CELL B, V28, P441, DOI 10.1016/1357-2725(95)00154-9; OLEARY RM, 1995, EUR J BIOCHEM, V227, P277, DOI 10.1111/j.1432-1033.1995.tb20385.x; ORLOWSKI M, 1979, J NEUROCHEM, V33, P461, DOI 10.1111/j.1471-4159.1979.tb05176.x; POLGAR L, 1992, BIOL CHEM H-S, V373, P361, DOI 10.1515/bchm3.1992.373.2.361; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SATTAR AKMA, 1990, J BIOCHEM, V107, P256, DOI 10.1093/oxfordjournals.jbchem.a123035; Shinoda M, 1997, BIOCHEM BIOPH RES CO, V235, P641, DOI 10.1006/bbrc.1997.6730; SHIRASAWA Y, 1994, J BIOCHEM-TOKYO, V115, P724, DOI 10.1093/oxfordjournals.jbchem.a124402; Takahashi T, 1996, BIOMED RES-TOKYO, V17, P435, DOI 10.2220/biomedres.17.435; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANHOOF G, 1994, GENE, V149, P363, DOI 10.1016/0378-1119(94)90177-5; WALTER R, 1971, SCIENCE, V173, P828, DOI 10.1126/science.173.3999.827; WELCHES WR, 1993, LIFE SCI, V52, P1461, DOI 10.1016/0024-3205(93)90108-F; WILK S, 1983, LIFE SCI, V33, P2149, DOI 10.1016/0024-3205(83)90285-0; Williams RSB, 1999, EMBO J, V18, P2734, DOI 10.1093/emboj/18.10.2734; YOSHIMOTO T, 1981, J BIOCHEM, V90, P325, DOI 10.1093/oxfordjournals.jbchem.a133477; YOSHIMOTO T, 1991, J BIOCHEM-TOKYO, V110, P873, DOI 10.1093/oxfordjournals.jbchem.a123682; Yoshimoto T, 1997, BIOL PHARM BULL, V20, P1047; YOSHIMOTO T, 1987, J PHARMACOBIO-DYNAM, V10, P730, DOI 10.1248/bpb1978.10.730; YOSHIMOTO T, 1983, J BIOCHEM, V94, P1179, DOI 10.1093/oxfordjournals.jbchem.a134463; YOSHIMOTO T, 1980, J BIOL CHEM, V255, P4786; YOSHIMOTO T, 1987, BIOCHIM BIOPHYS ACTA, V916, P29, DOI 10.1016/0167-4838(87)90207-X; YOSHIMOTO T, 1988, J BIOCHEM, V104, P622, DOI 10.1093/oxfordjournals.jbchem.a122522	60	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24047	24053		10.1074/jbc.274.34.24047	http://dx.doi.org/10.1074/jbc.274.34.24047			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446174	hybrid			2022-12-25	WOS:000082110900053
J	Oyedotun, KS; Lemire, BD				Oyedotun, KS; Lemire, BD			The Saccharomyces cerevisiae succinate-ubiquinone oxidoreductase - Identification of Sdh3p amino acid residues involved in ubiquinone binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE FLAVOPROTEIN SUBUNIT; COLI FUMARATE REDUCTASE; RESPIRATORY COMPLEX-II; ESCHERICHIA-COLI; QUINONE OXIDOREDUCTASE; GENE; DOMAIN; POLYPEPTIDE; TOPOLOGY; LIGATION	Succinate dehydrogenase (SDH) participates in the mitochondrial electron transport chain by oxidizing succinate to fumarate and transferring the electrons to ubiquinone. In yeast, it is composed of a catalytic dimer, comprising the Sdh1p and Sdh2p subunits,, and a membrane domain, comprising two smaller hydrophobic subunits, Sdh3p and Sdh4p, which anchor the enzyme to the mitochondrial inner membrane. To investigate the role of the Sdh3p anchor polypeptide in enzyme assembly and catalysis, we isolated and characterized seven mutations in the SDH3 gene. Two mutations are premature truncations of Sdh3p with losses of one or three transmembrane segments. The remaining five are missense mutations that are clustered between amino acids 103 and 117, which are proposed to be located in transmembrane segment II or the matrix-localized loop connecting segments II and III. Three mutations, F103V, H113Q, and W116R, strongly but specifically impair quinone reductase activities but have only minor effects on enzyme assembly. The clustering of the mutations strongly suggests that a ubiquinone-binding site is associated with this region of Sdh3p. In addition, the biphasic inhibition of quinone reductase activity by a dinitrophenol inhibitor supports the hypothesis that two distinct quinone-binding sites are present in the yeast SDH.	Univ Alberta, Dept Biochem, Med Res Council Canada, Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada	University of Alberta	Lemire, BD (corresponding author), Univ Alberta, Dept Biochem, Med Res Council Canada, Grp Mol Biol Membranes, 474 Mes Sci Bldg, Edmonton, AB T6G 2H7, Canada.							ABRAHAM PR, 1994, MOL GEN GENET, V242, P708, DOI 10.1007/BF00283426; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; Brasseur G, 1997, EUR J BIOCHEM, V246, P103, DOI 10.1111/j.1432-1033.1997.t01-1-00103.x; BRUEL C, 1995, J BIOL CHEM, V270, P22321, DOI 10.1074/jbc.270.38.22321; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; CHAPMAN KB, 1992, GENE, V118, P131, DOI 10.1016/0378-1119(92)90260-V; Cleland W W, 1979, Methods Enzymol, V63, P500; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; DAIGNANFORNIER B, 1994, J BIOL CHEM, V269, P15469; FRIDEN H, 1990, MOL MICROBIOL, V4, P1045, DOI 10.1111/j.1365-2958.1990.tb00677.x; HAGERHALL C, 1995, BIOCHEMISTRY-US, V34, P11080; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hederstedt L, 1998, BIOCHEM SOC T, V26, P408, DOI 10.1042/bst0260408; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; Lee GY, 1998, BBA-BIOENERGETICS, V1363, P35, DOI 10.1016/S0005-2728(97)00089-3; LOMBARDO A, 1990, J BIOL CHEM, V265, P10419; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; OYDEDOTUN KS, 1999, BIOCHB BIOPHYS ACTA, V1411, P170; OYDEDOTUN KS, 1999, FEBS LETT, V442, P203; Oyedotun KS, 1997, J BIOL CHEM, V272, P31382, DOI 10.1074/jbc.272.50.31382; Robinson KM, 1996, J BIOL CHEM, V271, P4055; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1992, J BIOL CHEM, V267, P10101; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; SCHULKE N, 1992, P NATL ACAD SCI USA, V89, P8011, DOI 10.1073/pnas.89.17.8011; Shenoy SK, 1999, J BIOL CHEM, V274, P8717, DOI 10.1074/jbc.274.13.8717; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; Vibat CRT, 1998, BIOCHEMISTRY-US, V37, P4148, DOI 10.1021/bi9716635; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020	34	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23956	23962		10.1074/jbc.274.34.23956	http://dx.doi.org/10.1074/jbc.274.34.23956			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446163	hybrid			2022-12-25	WOS:000082110900042
J	Rova, U; Adrait, A; Potsch, S; Graslund, A; Thelander, L				Rova, U; Adrait, A; Potsch, S; Graslund, A; Thelander, L			Evidence by mutagenesis that Tyr(370) of the mouse ribonucleotide reductase R2 protein is the connecting link in the intersubunit radical transfer pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; T7 RNA-POLYMERASE; ESCHERICHIA-COLI; SUBUNIT INTERACTION; CARBOXYL TERMINUS; ELECTRON-TRANSFER; CATALYTIC ACTIVITY; RECOMBINANT MOUSE; R1 SUBUNIT; INHIBITION	Ribonucleotide reductase catalyzes all de novo synthesis of deoxyribonucleotides. The mammalian enzyme consists of two non-identical subunits, the R1 and R2 proteins, each inactive alone. The R1 subunit contains the active site, whereas the R2 protein harbors a binuclear iron center and a tyrosyl free radical essential for catalysis. It has been proposed that the radical properties of the R2 subunit are transferred similar to 35 Angstrom to the active site of the R1 protein, through a coupled electron/proton transfer along a conserved hydrogen-bonded chain, i.e. a radical transfer pathway (RTP). To gain a better insight into the properties and requirements of the proposed RTP, we have used site directed mutagenesis to replace the conserved tyrosine 370 in the mouse R2 protein with tryptophan or phenylalanine. This residue is located close to the flexible C terminus, known to be essential for binding to the R1 protein. Our results strongly indicate that Tyr(370) links the RTP between the R1 and R2 proteins. Interruption of the hydrogen-bonded chain in Y370F inactivates the enzyme complex. Alteration of the same chain in Y370W slows down the RTP, resulting in a 58 times lower specific activity compared with the native R2 protein and a loss of the free radical during catalysis.	Umea Univ, Dept Med Biosci Med Biochem, SE-90187 Umea, Sweden; Stockholm Univ, Dept Biophys, SE-10691 Stockholm, Sweden	Umea University; Stockholm University	Thelander, L (corresponding author), Umea Univ, Dept Med Biosci Med Biochem, SE-90187 Umea, Sweden.	lars.thelander@medchem.umu.se		Adrait, Annie/0000-0002-1565-2859				ATKIN CL, 1973, J BIOL CHEM, V248, P7464; Behravan G, 1995, BBA-GENE STRUCT EXPR, V1264, P323, DOI 10.1016/0167-4781(95)00168-9; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; COSENTINO G, 1991, BIOCHEM CELL BIOL, V69, P79, DOI 10.1139/o91-011; DAVIS R, 1994, J BIOL CHEM, V269, P23171; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; Ekberg M, 1998, J BIOL CHEM, V273, P21003, DOI 10.1074/jbc.273.33.21003; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; FILATOV D, 1992, J BIOL CHEM, V267, P15816; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; LYCKSELL PO, 1994, BIOCHEMISTRY-US, V33, P2838, DOI 10.1021/bi00176a013; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; Schmidt PP, 1998, J BIOL CHEM, V273, P21463, DOI 10.1074/jbc.273.34.21463; Siegbahn PEM, 1997, THEOR CHEM ACC, V97, P289, DOI 10.1007/s002140050264; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1987, J BIOL CHEM, V262, P9736; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tong W, 1998, BIOCHEMISTRY-US, V37, P5840, DOI 10.1021/bi9728811; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; YANG FD, 1990, FEBS LETT, V272, P61, DOI 10.1016/0014-5793(90)80449-S	37	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23746	23751		10.1074/jbc.274.34.23746	http://dx.doi.org/10.1074/jbc.274.34.23746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446134	hybrid			2022-12-25	WOS:000082110900013
J	Sloan, JL; Mager, S				Sloan, JL; Mager, S			Cloning and functional expression of a human Na+ and Cl--dependent neutral and cationic amino acid transporter B0+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED MENTAL-RETARDATION; HUMAN DOPAMINE TRANSPORTER; GROWTH-HORMONE DEFICIENCY; XENOPUS-LAEVIS OOCYTES; PROTEIN-KINASE-C; GLYCINE TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; MOLECULAR-BIOLOGY; HEAVY-CHAIN; RAT-BRAIN	A Na+-dependent neutral and cationic amino acid transport system (B0+) plays an important role in many cells and tissues; however, the molecular basis for this transport system is still unknown. To identify new transporters, the expressed sequence tag database was queried, and cDNA fragments with sequence similarity to the Na+/Cl--dependent neurotransmitter transporter family were identified. Based on these sequences, rapid amplification of cDNA ends of human mammary gland cDNA was used to obtain a cDNA of 4.5 kilobases (kb). The open reading frame encodes a 642-amino acid protein named amino acid transporter B0+. Human ATB(0+) (hATB(0+)) is a novel member of the Na+/Cl--dependent neurotransmitter transporter family with the highest sequence similarity to the glycine and proline transporters. Northern blot analysis identified transcripts of similar to 4.5 kb and similar to 2 kb in the lung. Another tissue survey suggests expression in the trachea, salivary gland, mammary gland, stomach, and pituitary gland. Electrophysiology and radiolabeled amino acid uptake measurements were used to functionally characterize the transporter expressed in Xenopus oocytes. hATB(0+) was found to transport both neutral and cationic amino acids, with the highest affinity for hydrophobic amino acids and the lowest affinity for proline. Amino acid transport was Na+ and Cl--dependent and was attenuated in the presence of 2-aminobicyclo-[2.2.1]-heptane-2-carboxylic acid, a system B0+ inhibitor. These characteristics are consistent with system B0+ amino acid transport. Thus, hATB(0+) is the first cloned B0+ amino acid transporter.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Neurobiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Mager, S (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, CB 7545, Chapel Hill, NC 27599 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMARA SG, 1998, ADV PHARMACOL, V42, P166; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BOROWSKY B, 1993, NEURON, V10, P851, DOI 10.1016/0896-6273(93)90201-2; Borowsky B, 1995, INT REV NEUROBIOL, V38, P139, DOI 10.1016/S0074-7742(08)60526-7; CAMPA MJ, 1989, J CELL PHYSIOL, V141, P645, DOI 10.1002/jcp.1041410324; Castagna M, 1998, P NATL ACAD SCI USA, V95, P5395, DOI 10.1073/pnas.95.9.5395; CHEN JY, 1994, J NUTR, V124, P1907, DOI 10.1093/jn/124.10.1907; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; COREY JL, 1994, J BIOL CHEM, V269, P14759; desPortes V, 1997, AM J MED GENET, V72, P324, DOI 10.1002/(SICI)1096-8628(19971031)72:3<324::AID-AJMG14>3.0.CO;2-V; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; Galietta LJV, 1998, AM J PHYSIOL-LUNG C, V275, pL917, DOI 10.1152/ajplung.1998.275.5.L917; Gedeon AK, 1996, AM J MED GENET, V64, P121, DOI 10.1002/(SICI)1096-8628(19960712)64:1<121::AID-AJMG20>3.0.CO;2-O; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GOMEZA J, 1995, BBA-BIOMEMBRANES, V1233, P41, DOI 10.1016/0005-2736(94)00249-O; Gregg RG, 1996, HUM MOL GENET, V5, P411, DOI 10.1093/hmg/5.3.411; Gu XX, 1996, J MED GENET, V33, P52, DOI 10.1136/jmg.33.1.52; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; Hamel BCJ, 1996, AM J MED GENET, V64, P35, DOI 10.1002/(SICI)1096-8628(19960712)64:1<35::AID-AJMG5>3.0.CO;2-Q; HOSOYA KI, 1997, J PHARMACOL EXP THER, V285, P223; Illarioshkin SN, 1996, ANN NEUROL, V40, P75, DOI 10.1002/ana.410400113; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; Kawarai T, 1997, GENE, V195, P11, DOI 10.1016/S0378-1119(97)00131-5; KIM KJ, 1988, J APPL PHYSIOL, V65, P1655, DOI 10.1152/jappl.1988.65.4.1655; KNOPF RF, 1965, J CLIN ENDOCR METAB, V25, P1140, DOI 10.1210/jcem-25-8-1140; KOMPELLA UB, 1995, LIFE SCI, V57, P1427, DOI 10.1016/0024-3205(95)02105-R; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; LESTER HA, 1994, ANNU REV PHARMACOL, V34, P219; LIU QR, 1993, J BIOL CHEM, V268, P22802; MACKENZIE B, 1994, PFLUG ARCH EUR J PHY, V426, P121, DOI 10.1007/BF00374679; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; MUNCK LK, 1995, BBA-BIOMEMBRANES, V1235, P93, DOI 10.1016/0005-2736(94)00309-D; Nelson N, 1998, J NEUROCHEM, V71, P1785; OSAWA I, 1994, NEUROSCI RES, V19, P287, DOI 10.1016/0168-0102(94)90041-8; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Quick MW, 1997, J NEUROSCI, V17, P2967; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Raynaud M, 1998, AM J MED GENET, V76, P255, DOI 10.1002/(SICI)1096-8628(19980319)76:3<255::AID-AJMG10>3.0.CO;2-G; Ryan SG, 1997, NAT GENET, V17, P92, DOI 10.1038/ng0997-92; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; SATO K, 1995, J NEUROCHEM, V65, P1967; SHAFQAT S, 1993, MOL ENDOCRINOL, V7, P1517, DOI 10.1210/me.7.12.1517; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TAYLOR PM, 1989, J MEMBRANE BIOL, V112, P149, DOI 10.1007/BF01871276; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118; VANWINKLE LJ, 1990, BIOCHIM BIOPHYS ACTA, V1025, P225, DOI 10.1016/0005-2736(90)90101-S; VANWINKLE LJ, 1987, BIOCHIM BIOPHYS ACTA, V925, P164, DOI 10.1016/0304-4165(87)90106-1; VANWINKLE LJ, 1993, BIOCHIM BIOPHYS ACTA, V1154, P157, DOI 10.1016/0304-4157(93)90009-D; Villalobos C, 1997, J PHYSIOL-LONDON, V502, P421, DOI 10.1111/j.1469-7793.1997.421bk.x; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; [No title captured]	66	259	275	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23740	23745		10.1074/jbc.274.34.23740	http://dx.doi.org/10.1074/jbc.274.34.23740			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446133	hybrid, Green Published			2022-12-25	WOS:000082110900012
J	Wang, J; Brown, EJ				Wang, J; Brown, EJ			Immune complex-induced integrin activation and L-plastin phosphorylation require protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED NEUTROPHIL FUNCTION; CYCLASE-ASSOCIATED PROTEIN; CYCLIC-AMP; PHOSPHATIDYLINOSITOL 3-KINASE; PHAGOCYTIC FUNCTION; ACTIN CYTOSKELETON; RESPIRATORY BURST; MEDIATED ADHESION; CELL-ADHESION; RECEPTOR	Integrins in resting leukocytes are poorly adhesive, and cell activation is required to induce integrin-mediated adhesion. We recently demonstrated a close correlation between phosphorylation of Ser(5) in L-plastin (LPL), a leukocyte-specific 67-kDa actin bundling protein, and activation of alpha(M)beta(2)-mediated adhesion in polymorphonuclear neutrophils (PMN) (Jones, S. L., Wang, J., Turck, C. W., and Brown, E. J. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 9331-9336), However, the kinase that phosphorylates LPL Ser(5) has not been identified. We found that cAMP dependent protein kinase (PKA), but not a variety of other serine kinases, can specifically phosphorylate LPL and LPL-derived peptides on Ser5 in vitro, The cell-permeable cAMP analog 8-bromo-cAMP and the adenylate cyclase activator forskolin both induce LPL phosphorylation in cells. Two PKA inhibitors, H89 and KT5720, inhibited immune complex (IC)-stimulated LPL phosphorylation as well as IC-induced activation of alpha(M)beta(2)-mediated adhesion in PMN, The dose response of H89 inhibition of PMN adhesion correlated with its inhibition of LPL phosphorylation in response to IC, IC stimulation also transiently increased intracellular cAMP concentration in PMN, Thus, PKA functions in an integrin activation pathway initiated by IC binding to Fc gamma receptors in addition to its better known role as a negative regulator of cell activation by G protein-coupled receptors, In contrast, LPL Ser(5) phosphorylation and PMN adhesion induced by formylmethionyl-leucylphenylalanine or phorbol myristate acetate were not affected by PKA inhibitors, suggesting that a different kinase(s) is responsible for LPL phosphorylation in response to these agonists, Phosphoinositidyl S-kinase also is required for Fc gamma R but not formylmethionyl-leucylphenylalanine- or phorbol myristate acetate-induced LPL phosphorylation and activation of alpha(M)beta(2). Two phosphoinositidyl 3-kinase inhibitors blocked Fc gamma R induced cAMP accumulation, demonstrating that this kinase acts upstream of PKA These data demonstrate a necessary role for PKA in IC-induced integrin activation and LPL phosphorylation.	Univ Calif San Francisco, Program Microbial Pathogenesis & Host Def, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA; Washington Univ, Sch Med, Program Mol Cell Biol, St Louis, MO 63110 USA	University of California System; University of California San Francisco; Washington University (WUSTL); Washington University (WUSTL)	Brown, EJ (corresponding author), Univ Calif San Francisco, Program Microbial Pathogenesis & Host Def, HSE 201,Campus Box 0513,513 Parnassus Ave, San Francisco, CA 94143 USA.				NIAID NIH HHS [AI35811] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035811] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGWU DE, 1991, J IMMUNOL, V146, P3895; AHMED MU, 1995, J BIOL CHEM, V270, P23816, DOI 10.1074/jbc.270.40.23816; BengisGarber C, 1996, CELL SIGNAL, V8, P291, DOI 10.1016/0898-6568(96)00052-6; Bloemen PGM, 1997, AM J PHYSIOL-LUNG C, V272, pL580, DOI 10.1152/ajplung.1997.272.4.L580; Brown EJ, 1997, TRENDS CELL BIOL, V7, P289, DOI 10.1016/S0962-8924(97)01076-3; BROWN EJ, 1994, METHOD CELL BIOL, V45, P147; BROWN EJ, 1993, BLOOD CELL BIOCH, V5, P279; BURNS GF, 1988, J CELL BIOL, V107, P1225, DOI 10.1083/jcb.107.3.1225; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; CRONSTEIN BN, 1992, BIOCHEM J, V281, P631, DOI 10.1042/bj2810631; DERIAN CK, 1995, J IMMUNOL, V154, P308; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; FELSCH A, 1995, J IMMUNOL, V155, P333; Freeman NL, 1996, MOL CELL BIOL, V16, P548; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GRAHAM IL, 1993, J CELL BIOL, V120, P1509, DOI 10.1083/jcb.120.6.1509; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; Hidaka H, 1996, Adv Pharmacol, V36, P193, DOI 10.1016/S1054-3589(08)60583-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jones SL, 1998, J BIOL CHEM, V273, P10556, DOI 10.1074/jbc.273.17.10556; Jones SL, 1998, P NATL ACAD SCI USA, V95, P9331, DOI 10.1073/pnas.95.16.9331; Jones SL, 1996, J BIOL CHEM, V271, P14623, DOI 10.1074/jbc.271.24.14623; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; NATHAN C, 1990, J CELL BIOL, V111, P2171, DOI 10.1083/jcb.111.5.2171; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; OTTONELLO L, 1995, CLIN EXP IMMUNOL, V101, P502; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Pryzwansky Katherine B., 1998, Cell Biochemistry and Biophysics, V28, P251, DOI 10.1007/BF02737813; PRYZWANSKY KB, 1981, SCIENCE, V211, P407, DOI 10.1126/science.6261328; Revan S, 1996, J BIOL CHEM, V271, P17114, DOI 10.1074/jbc.271.29.17114; ROSALES C, 1994, P NATL ACAD SCI USA, V91, P3534, DOI 10.1073/pnas.91.9.3534; Rovere P, 1996, J IMMUNOL, V156, P2273; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; SHINOMIYA H, 1995, J IMMUNOL, V154, P3471; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Tang T, 1997, J EXP MED, V186, P1853, DOI 10.1084/jem.186.11.1853; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Vossebeld PJM, 1997, BIOCHEM J, V323, P87, DOI 10.1042/bj3230087; WATSON PA, 1990, J BIOL CHEM, V265, P6569; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WRIGHT SD, 1986, J IMMUNOL, V136, P1758	52	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24349	24356		10.1074/jbc.274.34.24349	http://dx.doi.org/10.1074/jbc.274.34.24349			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446213	hybrid			2022-12-25	WOS:000082110900092
J	Gay, B; Suarez, S; Weber, C; Rahuel, J; Fabbro, D; Furet, P; Caravatti, G; Schoepfer, J				Gay, B; Suarez, S; Weber, C; Rahuel, J; Fabbro, D; Furet, P; Caravatti, G; Schoepfer, J			Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; SCATTER; RAS; PROTEIN; TRANSFORMATION; REORGANIZATION; CARCINOMA; COMPLEXES; RESPONSES	Cell motility has been correlated both with oncogenic invasiveness and metastatic potential. The development of selective inhibitors of motility has thus great potential importance. Grb2 is a SH2/SH3 domain-containing adaptor protein that links growth factor receptor tyrosine kinases to the Ras signaling pathway, We have developed specific small molecule inhibitors of the Grb2 SH2 domain as potential leads for drug discovery, Synthesis of the inhibitors and their effects on growth factor-induced growth in cells have been reported previously. In the current study, we establish that these inhibitors inhibit hepatocyte growth factor/scatter factor-induced A431 and Madin-Darby canine kidney cell motility and various cell motility-related events, including epidermal growth factor-induced ruffling of A431 cells and epidermal growth factor-induced translocation of the small GTPase Rac in these cells. We demonstrate for the first time a direct role for Grb2 in cell motility and indicate a new avenue for cancer therapeutics.	Novartis Pharma AG, Dept Oncol, CH-4002 Basel, Switzerland	Novartis	Gay, B (corresponding author), Novartis Pharma AG, Dept Oncol, K-136-4-26, CH-4002 Basel, Switzerland.	brigitgay@aol.com						ANJARUWEE SN, 1998, SCIENCE, V279, P560; Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CANTLEY LC, 1994, J CELL SCI, P121; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Furet P, 1998, J MED CHEM, V41, P3442, DOI 10.1021/jm980159a; GAY B, 1999, IN PRESS INT J CANC; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUNGJOHANSEN M, 1990, CANCER RES, V50, P6039; MATSUMOTO K, 1989, J ORAL PATHOL MED, V18, P498, DOI 10.1111/j.1600-0714.1989.tb01350.x; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahuel J, 1996, NAT STRUCT BIOL, V3, P586, DOI 10.1038/nsb0796-586; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIJKEN PJ, 1991, J CELL SCI, V100, P491; Sastry L, 1997, INT J CANCER, V70, P208, DOI 10.1002/(SICI)1097-0215(19970117)70:2<208::AID-IJC12>3.0.CO;2-E; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Small J V, 1988, Electron Microsc Rev, V1, P155; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STRAULI P, 1977, EUR J CANCER, V13, P1, DOI 10.1016/0014-2964(77)90222-5; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THIERY JP, 1984, CELL DIFFER DEV, V15, P1, DOI 10.1016/0045-6039(84)90024-1	30	50	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23311	23315		10.1074/jbc.274.33.23311	http://dx.doi.org/10.1074/jbc.274.33.23311			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438507	hybrid			2022-12-25	WOS:000082012800057
J	Krysan, DJ; Rockwell, NC; Fuller, RS				Krysan, DJ; Rockwell, NC; Fuller, RS			Quantitative characterization of furin specificity - Energetics of substrate discrimination using an internally consistent set of hexapeptidyl methylcoumarinamides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUENCHED FLUOROGENIC SUBSTRATE; SUBTILISIN-LIKE ENDOPROTEASE; TOXIN PROTECTIVE ANTIGEN; PROPROTEIN CONVERTASES; PROCESSING ENDOPROTEASE; SEQUENCE SPECIFICITY; INFLUENZA-VIRUS; KEX2 PROTEASE; CELL-SURFACE; CLEAVAGE	Furin, an essential mammalian proprotein processing enzyme of the kexin/furin family of subtilisin-related eukaryotic processing proteases, is implicated in maturation of substrates involved in development, signaling, coagulation, and pathogenesis, We examined the energetics of furin specificity using a series of peptidyl methylcoumarinamide substrates, In contrast to previous reports, we found that furin can cleave such substrates with kinetics comparable to those observed with extended peptides and physiological substrates, With the best of these hexapeptidyl methylcoumarinamides, furin displayed k(cat)/K-m values greater than 10(6) M-1 s(-1) Furin exhibited striking substrate inhibition with hexapeptide but not tetrapeptide substrates, an observation of significance to the evaluation of peptide-based furin inhibitors. Quantitative comparison of furin and Kex2 recognition at P-1, P-2, and P-4 demonstrates that whereas interactions at P-1 make comparable contributions to catalysis by the two enzymes, furin exhibited a similar to 10-fold lesser dependence on P-2 recognition but a 10-100-fold greater dependence on P-4 recognition. Furin has recently been shown to exhibit P-6 recognition and we found that this interaction contributes similar to 1.4 kcal/mol toward catalysis independent of the nature of the P-4 residue. We have also shown that favorable residues at P-2 and P-6 will compensate for less than optimal residues at either P-1 or P-4, The quantitative analysis of furin and Kex2 specificity sharply distinguish the nature of substrate recognition by the processing and degradative members of subtilisin-related proteases.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Stanford Univ, Dept Biochem, Beckman Ctr B400, Stanford, CA 94305 USA	University of Michigan System; University of Michigan; Stanford University	Fuller, RS (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.			Krysan, Damian/0000-0001-6330-3365				Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; ANGLIKER H, 1995, ANAL BIOCHEM, V224, P409, DOI 10.1006/abio.1995.1058; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P80; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; GOTOH B, 1992, J VIROL, V66, P6391, DOI 10.1128/JVI.66.11.6391-6397.1992; GRON H, 1992, BIOCHEMISTRY-US, V31, P6011, DOI 10.1021/bi00141a008; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Ngola SM, 1999, J AM CHEM SOC, V121, P1192, DOI 10.1021/ja982499r; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PHILIPP M, 1983, MOL CELL BIOCHEM, V51, P5, DOI 10.1007/BF00215583; Rehemtulla Alnawaz, 1992, Current Opinion in Biotechnology, V3, P560, DOI 10.1016/0958-1669(92)90086-X; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; Rockwell NC, 1997, BIOCHEMISTRY-US, V36, P1912, DOI 10.1021/bi961779l; Rockwell NC, 1998, BIOCHEMISTRY-US, V37, P3386, DOI 10.1021/bi972534r; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; TAKEUCHI Y, 1991, J MOL BIOL, V221, P309, DOI 10.1016/0022-2836(91)80221-F; Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762; WALKER JA, 1994, J VIROL, V68, P1213, DOI 10.1128/JVI.68.2.1213-1218.1994; ZIMMERMAN M, 1977, ANAL BIOCHEM, V78, P47, DOI 10.1016/0003-2697(77)90006-9	34	86	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23229	23234		10.1074/jbc.274.33.23229	http://dx.doi.org/10.1074/jbc.274.33.23229			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438496	hybrid			2022-12-25	WOS:000082012800046
J	Wakasugi, K; Schimmel, P				Wakasugi, K; Schimmel, P			Highly differentiated motifs responsible for two cytokine activities of a split human tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ACTIVATING POLYPEPTIDE-II; MONOMERIC INTERLEUKIN-8; NEUTROPHIL ACTIVATION; RECEPTOR-BINDING; GENETIC-CODE; PROTEIN; IL-8; AMINOACYLATION; DOMAIN	While native human tyrosyl-tRNA synthetase (TyrRS) is inactive as a cell-signaling molecule, it can be split into two distinct cytokines. The enzyme is secreted under apoptotic conditions in culture where it is cleaved into an N-terminal fragment that harbors the catalytic site and into a C-domain fragment found only in the mammalian enzymes, The N-terminal fragment is an interleukin-8 (IL-8)-like cytokine, whereas the released C-domain is an endothelial-monocyte-activating polypeptide II (EMAP II)-like cytokine. Although the IL-8-like activity of the N-fragment depends on an ELR motif found in alpha-chemokines and conserved among mammalian TyrRSs, here we show that a similar (NYR) motif in the context of a lower eukaryote TyrRS does not confer the ILS-like activity. We also show that a heptapeptide from the C-domain has EMAP II-like chemotaxis activity for mononuclear phagocytes and polymorphonuclear leukocytes. Eukaryote proteins other than human TyrRS that have EMAP II-like domains have variants of the heptapeptide motif. Peptides based on these sequences are inactive as cytokines. Thus, the cytokine activities of split human TyrRS depend on highly differentiated motifs that are idiosyncratic to the mammalian system.	Scripps Res Inst, Skaggs Inst Chem Biol, Beckman Ctr, La Jolla, CA 92037 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, Beckman Ctr, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schimmel@scripps.edu	Wakasugi, Keisuke/AAQ-1642-2020	Wakasugi, Keisuke/0000-0002-8408-5616	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; Bocchetta M, 1996, J BACTERIOL, V178, P1762, DOI 10.1128/jb.178.6.1762-1765.1996; BRANDT E, 1991, CYTOKINE, V3, P311, DOI 10.1016/1043-4666(91)90499-4; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; Brown JR, 1997, J MOL EVOL, V45, P9, DOI 10.1007/PL00006206; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CHERNIACK AD, 1990, CELL, V62, P745, DOI 10.1016/0092-8674(90)90119-Y; CHOW CM, 1993, J BIOL CHEM, V268, P12855; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; DEPOUPLANA LR, 1916, P NATL ACAD SCI USA, P93; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FAULHAMMER HG, 1977, UR J BIOCH, V75, P561; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Holzer W, 1996, CYTOKINE, V8, P214, DOI 10.1006/cyto.1996.0030; Horcher M, 1998, CYTOKINE, V10, P1, DOI 10.1006/cyto.1997.0251; KAMPER U, 1992, MOL CELL BIOL, V12, P499; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P25106; KAO J, 1994, J BIOL CHEM, V269, P9774; KITTLE JD, 1991, GENE DEV, V5, P1009, DOI 10.1101/gad.5.6.1009; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; KUMAGAI K, 1979, J IMMUNOL METHODS, V29, P17, DOI 10.1016/0022-1759(79)90121-2; Leong SR, 1997, PROTEIN SCI, V6, P609; Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0; Lowman HB, 1997, PROTEIN SCI, V6, P598; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; Morales AJ, 1999, EMBO J, V18, P3475, DOI 10.1093/emboj/18.12.3475; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; PITULLE C, 1994, INT J SYST BACTERIOL, V44, P620, DOI 10.1099/00207713-44-4-620; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; QUINN CL, 1995, BIOCHEMISTRY-US, V34, P12489, DOI 10.1021/bi00039a001; RAJARATHNAM K, 1995, BIOCHEMISTRY-US, V34, P12983, DOI 10.1021/bi00040a008; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; SCHIMMEL P, 1991, TRENDS BIOCHEM SCI, V16, P1, DOI 10.1016/0968-0004(91)90002-D; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; Tas MPR, 1997, CYTOKINE, V9, P535, DOI 10.1006/cyto.1997.0198; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; WALTZ A, 1990, J EXP MED, V171, P449	49	114	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23155	23159		10.1074/jbc.274.33.23155	http://dx.doi.org/10.1074/jbc.274.33.23155			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438485	hybrid			2022-12-25	WOS:000082012800035
J	McIntyre, M; Desdouets, C; Senamaud-Beaufort, C; Laurent-Winter, C; Lamas, E; Brechot, C				McIntyre, M; Desdouets, C; Senamaud-Beaufort, C; Laurent-Winter, C; Lamas, E; Brechot, C			Differential expression of the cyclin-dependent kinase inhibitor P27 in primary hepatocytes in early-mid G1 and G1/S transitions	ONCOGENE			English	Article						cell cycle; p27; hepatocyte proliferation; cyclin dependent kinase; phosphorylation	CELL-CYCLE; LIVER-REGENERATION; CDK INHIBITOR; GROWTH-FACTOR; MICE LACKING; 3T3 CELLS; S-PHASE; P27(KIP1); ACTIVATION; PROGRESSION	P27, an inhibitor of cyclin-dependent kinases, plays an important role in the control of cell adhesion and contact inhibition-dependent cell cycle regulation, Hepatocytes, maintained in primary culture, offer a model of synchronized primary epithelial cells which retain a differentiated profile while stimulated to proliferate, We therefore investigated the pattern of endogenous p27 expression in cyclin rat hepatocytes isolated by collagenase perfusion followed by mitogenic stimulation, P27 mas expressed in whole normal liver and freshly isolated hepatocytes. We then observed a sharp decrease in p27 levels, concomitant with the progression in early-mid G1, followed by reaccumulation in late G1 and the G1/S transition, Immunochemistry and BrdU labelling demonstrated nuclear localization of p27 and its expression in cells engaged in both G1 and S phase, P27 was detected in late G1 in complexes containing cyclins D1, E and A, Cyclin E- and A-associated kinase activities, however, mere detected at the G1/S transition and depletion experiments confirmed that most active complexes were free of p27, Phosphorylated forms of p27 mere detected in unstimulated and stimulated hepatocytes in both early-mid G1 and G1/S, Finally, two-dimensional gel electrophoresis showed evidence for several forms of p27 with a distinct profile of distribution in quiescent and stimulated hepatocytes, Collectively, our data offer a model in which p27 shows a biphasic profile of accumulation, with the early decrease possibly involved in the progression through early and mid G1, In contrast with most cell types tested so far, the late G1 accumulation did not impair formation of active cyclin E- and a associated kinases, and thus G1/S transition.	Necker Inst, INSERM, U370, F-75015 Paris, France; Inst Pasteur, Lab Chim Struct Macromol Electrophorese Bidimensi, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Brechot, C (corresponding author), Necker Inst, INSERM, U370, 156 Rue Vaugirard, F-75015 Paris, France.		Desdouets, Chantal/M-3430-2017; Lamas, Eugenia/L-9654-2018	Lamas, Eugenia/0000-0001-7677-9442				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; ALBRECHT JH, 1993, AM J PHYSIOL, V265, P857; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CHENG M, 1998, P NATL ACAD SCI USA, V95, P1; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; deMora JF, 1997, ONCOGENE, V15, P2541, DOI 10.1038/sj.onc.1201420; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; Glaise D, 1998, CELL GROWTH DIFFER, V9, P165; GRANA X, 1995, ONCOGENE, V11, P211; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Katayose Y, 1997, CANCER RES, V57, P5441; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LaurentWinter C, 1997, EUR J BIOCHEM, V244, P767, DOI 10.1111/j.1432-1033.1997.00767.x; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loyer P, 1996, Prog Cell Cycle Res, V2, P37; LOYER P, 1994, J BIOL CHEM, V269, P2491; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; LU XP, 1992, J BIOL CHEM, V267, P2844; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; McGowan J.A, 1986, RES ISOLATED CULTURE, P13; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; MURPHY D, 1994, J INFECT DIS, V169, P473, DOI 10.1093/infdis/169.2.473; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Reed SI, 1997, CANCER SURV, V29, P7; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Sanchez JC, 1997, ELECTROPHORESIS, V18, P638, DOI 10.1002/elps.1150180349; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Tikoo R, 1997, J BIOL CHEM, V272, P442; TOYASHIMA H, 1994, CELL, V78, P67; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	56	23	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4577	4585		10.1038/sj.onc.1202815	http://dx.doi.org/10.1038/sj.onc.1202815			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467402				2022-12-25	WOS:000082018600007
J	Iwashita, T; Kato, M; Murakami, H; Asai, N; Ishiguro, Y; Ito, S; Iwata, Y; Kawai, K; Asai, M; Kurokawa, K; Kajita, H; Takahashi, M				Iwashita, T; Kato, M; Murakami, H; Asai, N; Ishiguro, Y; Ito, S; Iwata, Y; Kawai, K; Asai, M; Kurokawa, K; Kajita, H; Takahashi, M			Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma	ONCOGENE			English	Article						Ret; tyrosine kinase; MEN 2A; MEN 2B; FMTC	DISEASE PHENOTYPE; TYROSINE KINASE; MEN 2A; TRANSFORMING ACTIVITY; POINT MUTATION; PROTOONCOGENE; ACTIVATION; FMTC; SHC; CODON-883	Several mutations were identified in the kinase domain of the RET proto-oncogene in patients with multiple endocrine neoplasia (MEN) 2B, familial medullary thyroid carcinoma (FMTC) or sporadic medullary thyroid carcinoma. We introduced seven mutations (glutamic acid 768-->aspartic acid (E768D), valine 804-->leucine (V804L), alanine 883-->phenylalanine (A1883F), serine 891-->alanine (S891A), methionine 918 -->threonine (M918T), alanine 919-->proline (A919P) and E768D/A919P) into the short and long isoforms of RET cDNA and transfected the mutant cDNAs into NIH3T3 cells, The transforming activity of the long isoform of Ret with each mutation was much higher that that of its short isoform, Based on the levels of the transforming activity, these mutant RET genes were classified into two groups; a group with high transforming activity (A883F, M918T and E768D/A919P) and a group with low transforming activity (E768D, V804L, S891A and A919P) (designated high group and low group). Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Bet with the A883F or M918T mutation and low group Ret with the E768D, V804L or S891A mutation were associated with the development of MEN 2B and FMTC, respectively. in addition, we found that substitution of phenylalanine for tyrosine 905 present in the kinase domain abolished both transforming and autophosphorylation activities of low group Ret whereas it did not affect the activities of high group Ret.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Immunol, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai-cho, Nagoya, Aichi 4668550, Japan.		Takahashi, Masahide/AAN-4770-2020; KATO, Masashi/I-7250-2014; ASAI, Naoya/I-7377-2014; Kumi, Kawai/I-6275-2014; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Kumi, Kawai/0000-0002-7772-2605; 				Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; Carlomagno F, 1997, CANCER RES, V57, P391; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hofstra RMW, 1997, J CLIN ENDOCR METAB, V82, P4176, DOI 10.1210/jc.82.12.4176; Ito S, 1997, CANCER RES, V57, P2870; Iwashita T, 1996, ONCOGENE, V12, P481; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Miyauchi A, 1997, JPN J CANCER RES, V88, P527, DOI 10.1111/j.1349-7006.1997.tb00414.x; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Smith DP, 1997, ONCOGENE, V15, P1213, DOI 10.1038/sj.onc.1201481; TAHIRA T, 1990, ONCOGENE, V5, P97	28	96	102	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3919	3922		10.1038/sj.onc.1202742	http://dx.doi.org/10.1038/sj.onc.1202742			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445857				2022-12-25	WOS:000081171700015
J	Joyce, D; Bouzahzah, B; Fu, MF; Albanese, C; D'Amico, M; Steer, J; Klein, JU; Lee, RJ; Segall, JE; Westwick, JK; Der, CJ; Pestell, RG				Joyce, D; Bouzahzah, B; Fu, MF; Albanese, C; D'Amico, M; Steer, J; Klein, JU; Lee, RJ; Segall, JE; Westwick, JK; Der, CJ; Pestell, RG			Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappa B-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVITY; C-JUN; ACTIVATION; TRANSFORMATION; PROMOTER; PROTEINS; MULTIPLE; GTPASES; RHO; PROGRESSION	The small GTP-binding protein Rad, a member of the Ras superfamily, plays a fundamental role in cytoskeleton reorganization, cellular transformation, the induction of DNA synthesis, and superoxide production. Cyclin D1 abundance is rate-limiting in normal G(1), phase progression, and the abundance of cyclin D1 is induced by activating mutations of both Res and Rad, Nuclear factor-KB (NF-kappa B) proteins consist of cytoplasmic hetero- or homodimeric Rel-related proteins complexed to a member of the I kappa B family of inhibitor proteins. In the current studies, activating mutants of Rac1 (Rac(Leu-61), Rac(Val-12)) induced cyclin D1 expression and the cyclin D1 promoter in NIH 3T3 cells. Induction of cyclin D1 by Rad required both an NF-kappa B and an ATF-2 binding site. Inhibiting NF-kappa B by overexpression of an NF-kappa B transdominant inhibitor (nonphosphorylatable IKBa) reduced cyclin D1 promoter activation by the Rad mutants, placing NF-kappa B in a pathway of Rad activation of cyclin D1, Specific amino acid mutations in the aminoterminal effector domain of Rac(Leu-61) had comparable effects on NF-kappa B transcriptional activity and activation of the cyclin D1 promoter. The NF-kappa B factors Rel A (p65) and NF-kappa B-1 (p50) induced the cyclin D1 promoter, requiring both the NF-kappa B binding site and the ATF-8 site. Stable overexpression of Rae(Leu-61) increased binding of Rel A and NF-kappa B, to the cyclin D1 promoter NF-kappa B site. Activation of Rad in NIH 3T3 cells induces both NF-kappa B binding and activity and enhances expression of cyclin D1 through an NF-kappa B and ATF-2 site in the proximal promoter, suggesting a critical role for NP-kappa B in cell cycle regulation through cyclin D1 and Rad.	Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med, Bronx, NY 10461 USA; Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Univ Western Australia, Dept Pharmacol, Nedlands, WA 6907, Australia; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Yeshiva University; Albert Einstein College of Medicine; University of Western Australia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Pestell, RG (corresponding author), Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med, Chanin 302,1300 Morris Pk Ave, Bronx, NY 10461 USA.		Joyce, David/H-5156-2014	Der, Channing/0000-0002-7751-2747	NCI NIH HHS [R01CA75503, 5-P30-CA13330-26, R29CA70897] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330, R01CA070897, R01CA075503] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pestell RG, 1996, MOL ENDOCRINOL, V10, P1084, DOI 10.1210/me.10.9.1084; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SNAPPER CM, 1996, J IMMUNOL, V183; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	34	256	280	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25245	25249		10.1074/jbc.274.36.25245	http://dx.doi.org/10.1074/jbc.274.36.25245			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464245	hybrid			2022-12-25	WOS:000082554200010
J	Scheel, J; Pierre, P; Rickard, JE; Diamantopoulos, GS; Valetti, C; van der Goot, FG; Haner, M; Aebi, U; Kreis, TE				Scheel, J; Pierre, P; Rickard, JE; Diamantopoulos, GS; Valetti, C; van der Goot, FG; Haner, M; Aebi, U; Kreis, TE			Purification and analysis of authentic CLIP-170 and recombinant fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; ACTIN-RELATED PROTEIN; BOVINE BRAIN KINESIN; ELECTRON-MICROSCOPY; DYNACTIN COMPLEX; BINDING PROTEIN; SMOOTH-MUSCLE; COILED-COIL; IDENTIFICATION; MYOSIN	We have purified authentic CLIP-170 (cytoplasmic linker protein of 170 kDa) and fragments comprising functional domains of the protein to characterize the structural basis of the function of CLIP-170, Analysis of authentic CLIP-170 and the recombinant fragments by electron microscopy after glycerol spraying/low angle rotary metal shadowing reveals CLIP-170 as a thin, 135-nm-long molecule with two kinks in its central rod domain, which are approximately equally spaced from the two ends of the protein. The central domain consisting of heptad repeats, which is cu-helical in nature and forms a 2-stranded coiled-coil, mediates dimerization of CLIP-170, The rod domain harbors two kinks, each spaced similar to 37 nm from the corresponding end of the molecule, thus providing mechanical flexibility to the highly elongated molecule. The N-terminal domain of CLIP-170 binds to microtubules in vitro with a stoichiometry of one dimeric head domain per four tubulin heterodimers. Authentic CLIP-170 binds to microtubules with lower stoichiometry, indicating that the rod and tail domains affect microtubule binding of CLIP-170, These results document that CLIP-170 is a highly elongated polar molecule with the microtubule-binding domain and the organelle-interacting domains at opposite ends of the homodimer, thus providing a structural basis for the function of CLIP-170 as a microtubule-organelle linker protein.	Univ Geneva, Dept Biochem Sci 2, CH-1211 Geneva 4, Switzerland; Univ Basel, Biozentrum, ME Muller Inst Struct Biol, CH-4056 Basel, Switzerland	University of Geneva; University of Basel	Rickard, JE (corresponding author), Univ Aberdeen, Sch Med, Dept Mental Hlth, Aberdeen AB25 2ZD, Scotland.		van der Goot, Gisou G/B-2279-2012	van der Goot, Gisou G/0000-0002-8522-274X; pierre, philippe/0000-0003-0863-8255				AMOS LA, 1987, J CELL SCI, V87, P105; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BOURNE HR, 1991, NATURE, V351, P188, DOI 10.1038/351188a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCH MD, 1991, PROTEINS, V10, P130, DOI 10.1002/prot.340100206; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; Diamantopoulos GS, 1999, J CELL BIOL, V144, P99, DOI 10.1083/jcb.144.1.99; Diamantopoulos GS, 1998, METHOD ENZYMOL, V298, P197, DOI 10.1016/S0076-6879(98)98019-3; FOWLER WE, 1983, J ULTRA MOL STRUCT R, V83, P319, DOI 10.1016/S0022-5320(83)90139-9; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; Griparic L, 1998, GENE, V206, P195, DOI 10.1016/S0378-1119(97)00585-4; Griparic L, 1998, BBA-MOL CELL RES, V1405, P35, DOI 10.1016/S0167-4889(98)00096-2; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HANER M, 1997, CELL BIOL LAB HDB, P292; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lantz VA, 1998, J CELL BIOL, V140, P897, DOI 10.1083/jcb.140.4.897; Mandelkow Eva-Maria, 1993, P127; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; PEDROTTI B, 1994, BIOCHEMISTRY-US, V33, P12463, DOI 10.1021/bi00207a013; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; PIERRE P, 1994, J CELL SCI, V107, P1909; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; RICKARD JE, 1999, GUIDEBOOK CYTOSKELET; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; SCHLIWA M, 1989, CELL, V56, P719, DOI 10.1016/0092-8674(89)90672-7; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; Schroer TA, 1996, TRENDS CELL BIOL, V6, P212, DOI 10.1016/0962-8924(96)20014-5; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; SUZUKI H, 1982, J BIOCHEM-TOKYO, V91, P1699, DOI 10.1093/oxfordjournals.jbchem.a133861; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573	50	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25883	25891		10.1074/jbc.274.36.25883	http://dx.doi.org/10.1074/jbc.274.36.25883			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464331	hybrid			2022-12-25	WOS:000082554200095
J	Mueller, SC; Ghersi, G; Akiyama, SK; Sang, QXA; Howard, L; Pineiro-Sanchez, M; Nakahara, H; Yeh, Y; Chen, WT				Mueller, SC; Ghersi, G; Akiyama, SK; Sang, QXA; Howard, L; Pineiro-Sanchez, M; Nakahara, H; Yeh, Y; Chen, WT			A novel protease-docking function of integrin at invadopodia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIGNANT MELANOMA-CELLS; FIBRONECTIN RECEPTOR; MOLECULAR-CLONING; TYROSINE PHOSPHORYLATION; ONCOGENIC TRANSFORMATION; MONOCLONAL-ANTIBODIES; MEMBRANE GLYCOPROTEIN; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; ADHESION RECEPTORS	Invadopodia are membrane extensions of aggressive tumor cells that function in the activation of membrane-bound proteases occurring during tumor cell invasion. We explore a novel and provocative activity of integrins in docking proteases to sites of invasion, termed invadopodia. In the absence of collagen, alpha(3)beta(1) integrin and the gelatinolytic enzyme, seprase, exist as nonassociating membrane proteins. Type I collagen substratum induces the association of alpha(3)beta(1) integrin with seprase as a complex on invadopodia. The results show that alpha(3)beta(1) integrin is a docking protein for seprase to form functional invadopodia, In addition, alpha(5)beta(1) integrin may participate in the adhesion process necessary for invadopodial formation. Thus, alpha(3)beta(1) and alpha(5)beta(1) integrins play major organizational roles in the adhesion and formation of invadopodia, promoting invasive cell behavior.	SUNY Stony Brook, Dept Med, Div Med Oncol, Stony Brook, NY 11794 USA; Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA; NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Florida State Univ, Dept Chem, Tallahassee, FL 32306 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); State University System of Florida; Florida State University	Chen, WT (corresponding author), SUNY Stony Brook, Dept Med, Div Med Oncol, HSC T-17,Rm 080, Stony Brook, NY 11794 USA.		Howard, Linda/B-2463-2009	HOWARD, LINDA/0000-0003-4760-7996; Ghersi, Giulio/0000-0001-7250-9808	NATIONAL CANCER INSTITUTE [R01CA039077, R21CA062232, R01CA061273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023025] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA61273, R21CA62232, R01CA39077] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AOYAMA A, 1990, P NATL ACAD SCI USA, V87, P8296, DOI 10.1073/pnas.87.21.8296; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; CHEN WT, 1986, J CELL BIOL, V103, P1073, DOI 10.1083/jcb.103.3.1073; Coopman PJ, 1996, MOL BIOL CELL, V7, P1789, DOI 10.1091/mbc.7.11.1789; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; Goldstein LA, 1997, BBA-MOL BASIS DIS, V1361, P11, DOI 10.1016/S0925-4439(97)00032-X; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; Lafrenie RM, 1996, J CELL BIOCHEM, V61, P543, DOI 10.1002/(SICI)1097-4644(19960616)61:4<543::AID-JCB7>3.0.CO;2-O; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONSKY WL, 1994, CANCER RES, V54, P5702; MUELLER SC, 1988, J HISTOCHEM CYTOCHEM, V36, P297, DOI 10.1177/36.3.2449491; MUELLER SC, 1991, J CELL SCI, V99, P213; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PineiroSanchez ML, 1997, J BIOL CHEM, V272, P7595, DOI 10.1074/jbc.272.12.7595; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TSUJI T, 1990, J BIOL CHEM, V265, P7016; TSUJI T, 1991, J BIOCHEM-TOKYO, V109, P659, DOI 10.1093/oxfordjournals.jbchem.a123436; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551	28	180	191	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24947	24952		10.1074/jbc.274.35.24947	http://dx.doi.org/10.1074/jbc.274.35.24947			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455171	hybrid			2022-12-25	WOS:000082193400070
J	Evans, DRH; Myles, T; Hofsteenge, J; Hemmings, BA				Evans, DRH; Myles, T; Hofsteenge, J; Hemmings, BA			Functional expression of human PP2Ac in yeast permits the identification of novel C-terminal and dominant-negative mutant forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; REGULATORY SUBUNIT; METHYL ESTERIFICATION; BOVINE BRAIN; B-SUBUNIT; GENES; MORPHOGENESIS; DROSOPHILA	The protein phosphatase 2A (PP2A) holoenzyme is structurally conserved among eukaryotes. This reflects a conservation of function in vivo because the human catalytic subunit (PP2Ac) functionally replaced the endogenous PP2Ac of Saccharomyces cerevisiae and bound the yeast regulatory PR65/A subunit (Tpd3p) forming a dimer. Yeast was employed as a novel system for mutagenesis and functional analysis of human PP2Ac, revealing that the invariant C-terminal leucine residue, a site of regulatory methylation, is apparently dispensable for protein function. However, truncated forms of human PP2Ac lacking larger portions of the C terminus exerted a dominant interfering effect, as did several mutant forms containing a substitution mutation. Computer modeling of PP2Ac structure revealed that interfering amino acid substitutions clustered to the active site, and consistently, the PP2Ac-L199P mutant protein was catalytically impaired despite binding Tpd3p. Thus, interfering forms of PP2Ac titrate regulatory subunits and/or substrates into non-productive complexes and will serve as useful tools for studying PP2A function in mammalian cells. The transgenic approach employed here, involving a simple screen for interfering mutants, may be applicable generally to the analysis of structure-function relationships within protein phosphatases and other conserved proteins and demonstrates further the utility of yeast for analyzing gene function.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.							Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRUNELLI JP, 1993, YEAST, V9, P1299, DOI 10.1002/yea.320091203; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Evangelista CC, 1996, GENETICS, V142, P1083; Evans DRH, 1998, NATURE, V394, P23, DOI 10.1038/27782; Evans DRH, 1997, GENETICS, V145, P227; FAVRE B, 1994, J BIOL CHEM, V269, P16311; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Kaiser C., 1994, METHODS YEAST GENETI; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; SALI A, 1993, MOL BIOL, V2324, P779; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; XIE HY, 1994, BIOCHEM BIOPH RES CO, V203, P1710, DOI 10.1006/bbrc.1994.2383; XIE HY, 1994, J BIOL CHEM, V269, P1981; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256	42	62	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24038	24046		10.1074/jbc.274.34.24038	http://dx.doi.org/10.1074/jbc.274.34.24038			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446173	hybrid			2022-12-25	WOS:000082110900052
J	Guzder, SN; Sung, P; Prakash, L; Prakash, S				Guzder, SN; Sung, P; Prakash, L; Prakash, S			Synergistic interaction between yeast nucleotide excision repair factors NEF2 and NEF4 in the binding of ultraviolet-damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIH; REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; COCKAYNE-SYNDROME; RAD16 GENES; COMPLEX; RECOGNITION; AFFINITY; NUCLEASE; PURIFICATION	Saccharomyces cerevisiae RAD4, RAD7, RAD16, and RAD23 genes function in the nucleotide excision repair (NER) of ultraviolet light (UV)-damaged DNA. Previous biochemical studies have shown that the Rad4 and Rad23 proteins are associated in a stoichiometric complex named NEF2, and the Rad7 and Rad16 proteins form another stoichiometric complex named NEF4. While NEF2 is indispensable for the incision of W-damaged DNA in the in vitro reconstituted system, NEF4 stimulates the incision reaction. Both NEF2 and NEF4 bind W-damaged DNA, which raises the intriguing possibility that these two complexes cooperate to achieve the high degree of specificity for DNA damage demarcation required for nucleotide excision repair in vivo. Consistent with this hypothesis, we find that NEF2 and NEF4 bind in a synergistic fashion to UV-damaged DNA in a reaction that is dependent on ATP. We also purify the Rad7 protein and show that it binds DNA but has no preference for W-damaged DNA. Rad7 physically interacts with NEF2, suggesting a role for Rad7 in linking NEF2 with NEF4.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Health San Antonio	Prakash, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech Sts, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NATIONAL CANCER INSTITUTE [R37CA041261, R01CA041261] Funding Source: NIH RePORTER; NCI NIH HHS [CA41261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CLUGSTON CK, 1992, CANCER RES, V52, P6375; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; Guzder SN, 1998, J BIOL CHEM, V273, P6292, DOI 10.1074/jbc.273.11.6292; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Guzder SN, 1997, J BIOL CHEM, V272, P21665, DOI 10.1074/jbc.272.35.21665; Guzder SN, 1998, J BIOL CHEM, V273, P31541, DOI 10.1074/jbc.273.47.31541; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; Habraken Y, 1996, P NATL ACAD SCI USA, V93, P10718, DOI 10.1073/pnas.93.20.10718; Jansen LET, 1998, J BIOL CHEM, V273, P33111, DOI 10.1074/jbc.273.50.33111; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P4215; MUELLER JP, 1995, NUCLEIC ACIDS RES, V23, P3457, DOI 10.1093/nar/23.17.3457; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; Reed SH, 1998, J BIOL CHEM, V273, P29481, DOI 10.1074/jbc.273.45.29481; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757	23	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24257	24262		10.1074/jbc.274.34.24257	http://dx.doi.org/10.1074/jbc.274.34.24257			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446201	hybrid			2022-12-25	WOS:000082110900080
J	Iitsuka, Y; Shimizu, H; Kang, MM; Sasagawa, K; Sekiya, S; Tokuhisa, T; Hatano, M				Iitsuka, Y; Shimizu, H; Kang, MM; Sasagawa, K; Sekiya, S; Tokuhisa, T; Hatano, M			An enhancer element for expression of the Ncx (Enx, Hox11L1) gene in neural crest-derived cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACHAETE-SCUTE HOMOLOG-1; ACID RESPONSE ELEMENT; HOMEOBOX GENE; TRANSCRIPTION FACTOR; BLASTOMA CELLS; ALL-TRANS; HOX GENES; DIFFERENTIATION; RECEPTORS; PROMOTER	The murine Ncx (Enx, Hox11L1) gene is specifically expressed in a neuronal subset of neural crest-derived tissues. In attempts to elucidate the regulatory DNA element of the tissue-specific expression, we sequenced the 5'-flanking region of the Ncx gene. The transcriptional initiation site was determined at 297 nucleotides (-297) upstream from the ATG start codon (+1). A retinoic acid response element was located on the region between -1163 and -1150. Transient transfection assays with the 5'-flanking sequences fused to the luciferase gene showed that the region between -1387 and -1368 was crucial for the tissue-specific enhancer activity. Furthermore, nuclear proteins extracted from neural crest-derived cells such as murine and human neuroblastoma cells bind to the DNA region between -1387 and -1368. This DNA element was also conserved in the 5'-flanking region of the human NCX gene. Our observations strongly suggest that the DNA element (between -1387 and -1368) contributes to tissue-specific expression of the Ncx gene in murine and human species.	Chiba Univ, Grad Sch Med, Dept Dev Genet, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Sch Med, Dept Gynecol & Obstet, Chiba 2608670, Japan	Chiba University; Chiba University	Hatano, M (corresponding author), Chiba Univ, Grad Sch Med, Dept Dev Genet, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.							Arai Y, 1997, GENE, V193, P73, DOI 10.1016/S0378-1119(97)00088-7; AWGULEWITSCH A, 1990, P NATL ACAD SCI USA, V87, P6428, DOI 10.1073/pnas.87.16.6428; COHEN PS, 1995, CANCER RES, V55, P2380; COLETTA PL, 1991, MECH DEVELOP, V35, P129, DOI 10.1016/0925-4773(91)90063-C; DE LUCA LM, 1991, FASEB J, V5, P2924; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DUBE ID, 1991, BLOOD, V78, P2996; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GEADA AMC, 1992, DEVELOPMENT, V116, P497; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; GUTMAN A, 1994, MOL CELL BIOL, V14, P8143, DOI 10.1128/MCB.14.12.8143; HAMMERLING U, 1987, ONCOGENE, V2, P73; Hatano M, 1997, ANAT EMBRYOL, V195, P419, DOI 10.1007/s004290050061; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Hatano M, 1997, J CLIN INVEST, V100, P795, DOI 10.1172/JCI119593; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MALTESE WA, 1981, J CELL PHYSIOL, V108, P475, DOI 10.1002/jcp.1041080322; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OCHI Y, 1994, J IMMUNOL, V153, P3485; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SELLECK MAJ, 1993, DEV BIOL, V159, P1, DOI 10.1006/dbio.1993.1217; Shirasawa S, 1997, NAT MED, V3, P646, DOI 10.1038/nm0697-646; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; WEN XY, 1994, GENOMICS, V24, P388, DOI 10.1006/geno.1994.1634; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642	40	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24401	24407		10.1074/jbc.274.34.24401	http://dx.doi.org/10.1074/jbc.274.34.24401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446220	hybrid			2022-12-25	WOS:000082110900099
J	Kleerekoper, Q; Putkey, JA				Kleerekoper, Q; Putkey, JA			Drug binding to cardiac troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CALCIUM-BINDING; REGULATORY DOMAIN; CA2+ SENSITIZER; STOPPED-FLOW; LEVOSIMENDAN; BEPRIDIL; PROTEIN; CALMODULIN; MECHANISMS	Compounds that sensitize cardiac muscle to Ca2+ by intervening at the level of regulatory thin filament proteins would have potential therapeutic benefit in the treatment of myocardial infarctions. Two putative Ca2+ sensitizers, EMD 57033 and levosimendan, are reported to bind to cardiac troponin C (cTnC). In this study, we use heteronuclear NMR techniques to study drug binding to [methyl-C-13]methionine-labeled cTnC when free or when complexed with cardiac troponin I (cTnI). In the absence of Ca2+, neither drug interacted with cTnC. In the presence of Ca2+, one molecule of EMD 57033 bound specifically to the C-terminal domain of free cTnC. NMR and equilibrium dialysis failed to demonstrate binding of levosimendan to free cTnC, and the presence of levosimendan had no apparent effect on the Ca2+ binding affinity of cTnC. Changes in the N-terminal methionine methyl chemical shifts in cTnC upon association with cTnI suggest that cTnI associates with the A-B helical interface and the N terminus of the central helix in cTnC. NMR experiments failed to show evidence of binding of levosimendan to the cTnC cTnI complex. However, levosimendan covalently bound to a small percentage of free cTnC after prolonged incubation with the protein. These findings suggest that levosimendan exerts its positive inotropic effect by mechanisms that do not involve binding to cTnC.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System	Putkey, JA (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St,POB 77030, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045724] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL45724] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; Boknik P, 1997, J PHARMACOL EXP THER, V280, P277; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6745, DOI 10.1021/bi962226d; EDES I, 1995, CIRC RES, V77, P107, DOI 10.1161/01.RES.77.1.107; Endoh M, 1998, JPN HEART J, V39, P1; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GILL A, 1992, AM J CARDIOL, V69, pD11; GUO XD, 1994, J BIOL CHEM, V269, P15210; HAIKALA H, 1995, J CARDIOVASC PHARM, V25, P794, DOI 10.1097/00005344-199505000-00016; HAIKALA H, 1995, J MOL CELL CARDIOL, V27, P1859, DOI 10.1016/0022-2828(95)90009-8; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; Holubarsch C, 1997, CARDIOLOGY, V88, P12, DOI 10.1159/000177480; Kleerekoper Q, 1998, J BIOL CHEM, V273, P8153, DOI 10.1074/jbc.273.14.8153; KLEERKOPER Q, 1995, BIOCHEMISTRY-US, V34, P13343, DOI 10.1021/bi00041a010; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; LIN X, 1994, BIOCHEMISTRY-US, V33, P14434, DOI 10.1021/bi00252a009; LINSE S, 1991, J BIOL CHEM, V266, P8050; LUES I, 1993, J CARDIOVASC PHARM, V21, P883, DOI 10.1097/00005344-199306000-00006; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; MARTIN SR, 1992, EUR J BIOCHEM, V205, P1107, DOI 10.1111/j.1432-1033.1992.tb16879.x; OVASKA M, 1992, J MOL CELL CARDIOL S, V24, P260; Pan BS, 1996, J BIOL CHEM, V271, P817, DOI 10.1074/jbc.271.2.817; POLLESELLO P, 1994, J BIOL CHEM, V269, P28584; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PUTKEY JA, 1993, J BIOL CHEM, V268, P6827; Sato S, 1998, J MOL CELL CARDIOL, V30, P1115, DOI 10.1006/jmcc.1998.0677; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLARO RJ, 1986, J PHARMACOL EXP THER, V238, P502; SOLARO RJ, 1993, CIRC RES, V73, P981, DOI 10.1161/01.RES.73.6.981; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; Yokoshiki H, 1997, EUR J PHARMACOL, V333, P249, DOI 10.1016/S0014-2999(97)01108-4; Zimmermann N, 1998, EUR J CARDIO-THORAC, V14, P70, DOI 10.1016/S1010-7940(98)00129-8	35	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23932	23939		10.1074/jbc.274.34.23932	http://dx.doi.org/10.1074/jbc.274.34.23932			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446160	hybrid			2022-12-25	WOS:000082110900039
J	Soler-Lopez, M; Malinina, L; Liu, J; Huynh-Dinh, T; Subirana, JA				Soler-Lopez, M; Malinina, L; Liu, J; Huynh-Dinh, T; Subirana, JA			Water and ions in a high resolution structure of B-DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-C-G; CRYSTAL-STRUCTURE; ATOMIC RESOLUTION; MINOR-GROOVE; HYDRATION; DECAMER; TRACTS; SPINE	A detailed picture of hydration and counterion location in the B-DNA duplex d(GCGAATTCG) is presented. Detailed data have been obtained by single crystal x-ray diffraction at atomic resolution (0.89 Angstrom) in the presence of Mg2+. The latter is the highest resolution ever obtained for a B-DNA oligonucleotide. Minor groove hydration is compared with that found in the Na+ and Ca2+ crystal forms of the related dodecamer d(CGCGAAT-TCGCG). High resolution data (1.45 Angstrom) of the Ca2+ form obtained in our laboratory are used for that purpose. The central GAATTC has a very stable hydration spine identical in all cases, independent of duplex length and crystallization conditions (counterions, space group). However, the organization of the water molecules (tertiary and quaternary layers) associated with the central spine vary in each case.	Univ Barcelona, Dept Engn Quim, E-08028 Barcelona, Spain; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 117984, Russia; Inst Pasteur, Unite Chim Organ, F-75724 Paris, France	University of Barcelona; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Subirana, JA (corresponding author), Univ Barcelona, Dept Engn Quim, Avinguda Diagonal 647, E-08028 Barcelona, Spain.		Malinina, Lucy/B-8161-2013; Subirana, juan/L-7192-2014	Subirana, juan/0000-0002-1706-9341; Malinina, Lucy/0000-0001-7973-1831				Billeter M, 1996, CELL, V85, P1057, DOI 10.1016/S0092-8674(00)81306-9; BRUNGER AT, 1996, X PLOR MANUAL VERSIO; DREW HR, 1981, J MOL BIOL, V151, P536; ElHassan MA, 1997, PHILOS T R SOC A, V355, P43, DOI 10.1098/rsta.1997.0002; GOODSELL DS, 1995, BIOCHEMISTRY-US, V34, P1022, DOI 10.1021/bi00003a037; Hud NV, 1997, J AM CHEM SOC, V119, P5756, DOI 10.1021/ja9704085; Liu J, 1998, FEBS LETT, V438, P211, DOI 10.1016/S0014-5793(98)01295-2; LIU J, 1999, IN PRESS J BIOL CHEM; MCFAILISOM L, IN PRESS CURR OPIN S; Neidle S, 1998, NAT STRUCT BIOL, V5, P754, DOI 10.1038/1780; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QUINTANA JR, 1992, J MOL BIOL, V225, P379, DOI 10.1016/0022-2836(92)90928-D; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shui XQ, 1998, BIOCHEMISTRY-US, V37, P8341, DOI 10.1021/bi973073c; Shui XQ, 1998, BIOCHEMISTRY-US, V37, P16877, DOI 10.1021/bi982063o; Subirana JA, 1997, BIOPHYS J, V73, P333, DOI 10.1016/S0006-3495(97)78073-1; TEETER MM, 1993, J MOL BIOL, V230, P292, DOI 10.1006/jmbi.1993.1143; Tereshko V, 1999, J AM CHEM SOC, V121, P470, DOI 10.1021/ja9832919; Tereshko V, 1999, J AM CHEM SOC, V121, P3590, DOI 10.1021/ja984346+; Vlieghe D, 1996, ACTA CRYSTALLOGR D, V52, P766, DOI 10.1107/S0907444996003216; Young MA, 1997, J AM CHEM SOC, V119, P59, DOI 10.1021/ja960459m; YUAN H, 1992, BIOCHEMISTRY-US, V31, P8009, DOI 10.1021/bi00149a035	23	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23683	23686		10.1074/jbc.274.34.23683	http://dx.doi.org/10.1074/jbc.274.34.23683			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446123	hybrid			2022-12-25	WOS:000082110900002
J	Wang, PY; Munford, RS				Wang, PY; Munford, RS			CD14-dependent internalization and metabolism of extracellular phosphatidylinositol by monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL LIPOPOLYSACCHARIDE; PHOSPHOLIPID-COMPOSITION; DENSITY-LIPOPROTEIN; BINDING PROTEIN; HUMAN-PLASMA; FATTY-ACID; CELLS; 5-LIPOXYGENASE; MACROPHAGES; CD14	We report that membrane CD14 (mCD14), a cell surface receptor found principally on leukocytes, can mediate the uptake and metabolism of extracellular phosphatidylinositol (PtdIns), mCD14 facilitates PtdIns internalization, targeting it to intracellular sites where, following stimulation with a calcium ionophore, it can be acted upon by cytosolic phospholipase A(2). The [C-14]arachidonate released from mCD14-acquired [C-14]arachidonyl-PtdIns is either esterified to triacylglycerol and retained in the cell or secreted as free arachidonate or leukotrienes. Although less than 10% of the arachidonate-derived lipids secreted from endogenous cellular stores are Ei-lipoxygenase metabolites, over one-half of the secreted C-14-lipids derived from mCD14-acquired PtdIns are hydroxyeicosatetraenoic acids or leukotriene B-4, mCD14 may allow these highly active blood cells to acquire and use extracellular Pt-dIns as a source of arachidonate for leukotriene synthesis.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Cell Regulat Grad Program, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Munford, RS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NIAID NIH HHS [AI18188] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018188, R01AI018188, R56AI018188] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGDADE JD, 1995, ATHEROSCLEROSIS, V117, P209, DOI 10.1016/0021-9150(95)05573-F; BAILEY JM, 1984, PROSTAGLANDINS LEUKO, P148; Bailie MB, 1996, J IMMUNOL, V157, P5221; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BENNETT CF, 1993, BIOCHEM J, V289, P33, DOI 10.1042/bj2890033; Bozza PT, 1996, P NATL ACAD SCI USA, V93, P11091, DOI 10.1073/pnas.93.20.11091; BRADAMANTE S, 1990, ANAL BIOCHEM, V185, P299, DOI 10.1016/0003-2697(90)90297-M; BRECKENRIDGE WC, 1982, BIOCHIM BIOPHYS ACTA, V712, P707, DOI 10.1016/0005-2760(82)90302-2; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; Catz SD, 1998, PROSTAG OTH LIPID M, V55, P245, DOI 10.1016/S0090-6980(98)00021-5; CHILTON FH, 1989, BIOCHEM J, V258, P327, DOI 10.1042/bj2580327; CUNNANE SC, 1989, AM J CLIN NUTR, V50, P801, DOI 10.1093/ajcn/50.4.801; Dobner P, 1998, AM J PHYSIOL-ENDOC M, V275, pE777, DOI 10.1152/ajpendo.1998.275.5.E777; Engelmann B, 1998, J BIOL CHEM, V273, P27800, DOI 10.1074/jbc.273.43.27800; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; Glaser K B, 1990, Adv Exp Med Biol, V275, P1; HOHENGASSER CJM, 1986, J BIOL CHEM, V261, P6255; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; Kitchens RL, 1998, J IMMUNOL, V161, P5534; KUWAE T, 1990, J BIOL CHEM, V265, P5002; Mancuso P, 1998, INFECT IMMUN, V66, P5140, DOI 10.1128/IAI.66.11.5140-5146.1998; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SALBACH PB, 1992, P NATL ACAD SCI USA, V89, P2439, DOI 10.1073/pnas.89.6.2439; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; Thieblemont N, 1997, J EXP MED, V185, P2095, DOI 10.1084/jem.185.12.2095; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; Wang PY, 1996, J INFLAMM, V47, P126; WASSEF NM, 1984, P NATL ACAD SCI-BIOL, V81, P2655, DOI 10.1073/pnas.81.9.2655; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; WONGKAJORNSILP A, 1995, J BIOL CHEM, V270, P9147, DOI 10.1074/jbc.270.16.9147; WURFEL MM, 1995, J EXP MED, V181, P1743, DOI 10.1084/jem.181.5.1743; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160; Yu WG, 1998, AM J PATHOL, V152, P759	36	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23235	23241		10.1074/jbc.274.33.23235	http://dx.doi.org/10.1074/jbc.274.33.23235			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438497	hybrid			2022-12-25	WOS:000082012800047
J	Condorelli, G; Vigliotta, G; Cafieri, A; Trencia, A; Andalo, P; Oriente, F; Miele, C; Caruso, M; Formisano, P; Beguinot, F				Condorelli, G; Vigliotta, G; Cafieri, A; Trencia, A; Andalo, P; Oriente, F; Miele, C; Caruso, M; Formisano, P; Beguinot, F			PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis	ONCOGENE			English	Article						apoptosis; TNF alpha; FAS; death signalling; death receptors	DOMAIN-CONTAINING PROTEIN; SIGNALING COMPLEX DISC; CELL-DEATH; FAS; FLICE; RECEPTOR; FADD; INTERACTS; PROTEASES	FED/PEA-15 is a recently cloned 15kDa protein possessing a death effector domain (DED). In MCF-7 and HeLa cells, a fivefold overexpression of PED/PEA-15 blocked Fast and TNF alpha. apoptotic effects. This effect of FED overexpression was blocked by inhibition of PKC activity. In MCF-7 and HeLa cell lysates, PED/ PEA-15 co-precipitated with both FADD and FLICE. PED/PEA-15-FLICE association was inhibited by overexpression of the wild-type but not of a DED-deletion mutant of FADD. Simultaneous overexpression of PED/ PEA-15 with FADD and FLICE inhibited FADD-FLICE co-precipitation by threefold. Based on cleavage of the FLICE substrate PARP, this inhibitory effect was paralleled by a threefold decline in FLICE activation in response to TNF-alpha. TNF alpha, in turn, reduces FED association with the endogenous FADD and FLICE of the cells. Thus, FED/PEA-15 is an endogenous protein inhibiting FAS and TNFR1-mediated apoptosis. At least in part, this function may involve displacement of FADD-FLICE binding through the death effector domain of PED/PEA-15.	Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, Sch Med, I-80131 Naples, Italy; Univ Naples, Ctr Endocrinol Oncol Sperimentale, Sch Med, CNR G Salvatore, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Beguinot, F (corresponding author), Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, Sch Med, Via S Pansini 5, I-80131 Naples, Italy.		vigliotta, giovanni/AAW-6401-2020; Vigliotta, Giovanni/GPF-7237-2022; Formisano, Pietro/J-4237-2018; Condorelli, Gerolama/AAC-3472-2022; ORIENTE, Francesco/J-6652-2018	vigliotta, giovanni/0000-0001-5132-0037; Condorelli, Gerolama/0000-0003-0177-8829; Formisano, Pietro/0000-0001-7020-6870; ORIENTE, Francesco/0000-0003-4375-4526				Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; DARZYNKIEWICZ Z, 1994, METHODS CELL BIOL; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Sambrook J., 2002, MOL CLONING LAB MANU; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464	24	136	144	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4409	4415		10.1038/sj.onc.1202831	http://dx.doi.org/10.1038/sj.onc.1202831			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442631				2022-12-25	WOS:000081813500002
J	Yin, J; Harpaz, N; Souza, RF; Zou, TT; Kong, DH; Wang, SN; Leytin, AL; Medalie, NS; Smolinski, KN; Abraham, JM; Fleisher, AS; Meltzer, SJ				Yin, J; Harpaz, N; Souza, RF; Zou, TT; Kong, DH; Wang, SN; Leytin, AL; Medalie, NS; Smolinski, KN; Abraham, JM; Fleisher, AS; Meltzer, SJ			Low prevalence of the APC I1307K sequence in Jewish and non-Jewish patients with inflammatory bowel disease	ONCOGENE			English	Article						APC gene; I1307K sequence; inflammatory bowel disease; colorectal carcinoma; cancer genetics; Jewish	COLORECTAL-CANCER; ASHKENAZI JEWS; RISK; BREAST	A germline sequence alteration at codon 1307 of the APC gene (I1307K) has been reported in 6-7% of the Ashkenazi Jewish population in the United States. This alteration is believed to predispose the APC gene to a secondary mutation at the same locus, resulting in an increased risk of colorectal carcinoma. There is an increased risk of colorectal carcinoma in patients with inflammatory bowel disease (IBD), a relatively large proportion of whom are Ashkenazi Jews. We therefore sought to determine whether the I1307K sequence variant occurred in the germline DNA of IBD patients. To our surprise, we found this sequence in only two of 267 patients with IBD (0.7%), occurring in only 1.5% of Jewish IBD patients. The I1307K sequence variant was not found in 67 patients with esophageal cancer, 53 patients with gastric carcinoma (13 MSI-H and 44 MSI-negative), or ten patients with sporadic MSI-H colon cancer. These findings suggest that the I1307K sequence is relatively rare in the germline of Jewish as well as non-Jewish IBD patients. It does not appear to contribute to the increased colorectal cancer risk present in these patients.	Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Mol Biol Grad Program, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; NYU, Mt Sinai Sch Med, Dept Pathol, New York, NY USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Icahn School of Medicine at Mount Sinai; New York University	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, N3W62,22 S Greene St, Baltimore, MD 21201 USA.		Harpaz, Noam/L-3411-2017	Harpaz, Noam/0000-0003-4923-2200	NATIONAL CANCER INSTITUTE [R01CA077057, R01CA078843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA78843, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrahamson J, 1998, CANCER RES, V58, P2919; Asaka M, 1997, GASTROENTEROLOGY, V113, pS56, DOI 10.1016/S0016-5085(97)80013-3; CHO KR, 1992, J CELL BIOCHEM, P137; EKBOM A, 1992, GASTROENTEROLOGY, V103, P954, DOI 10.1016/0016-5085(92)90029-X; Harpaz N, 1996, SEMIN DIAGN PATHOL, V13, P339; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Lothe RA, 1998, CANCER RES, V58, P2923; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; NUGENT FW, 1991, GASTROENTEROLOGY, V100, P1241, DOI 10.1016/0016-5085(91)70010-U; Petrukhin L, 1997, CANCER RES, V57, P5480; ROTH MP, 1989, GASTROENTEROLOGY, V96, P1016, DOI 10.1016/0016-5085(89)91618-1; Rozen P, 1999, GASTROENTEROLOGY, V116, P54, DOI 10.1016/S0016-5085(99)70228-3; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; ZLOTOGORA J, 1991, DIGEST DIS SCI, V36, P471, DOI 10.1007/BF01298876	14	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	1999	18	26					3902	3904		10.1038/sj.onc.1202638	http://dx.doi.org/10.1038/sj.onc.1202638			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445854				2022-12-25	WOS:000081171700012
J	Fojta, M; Kubicarova, T; Vojtesek, B; Palecek, E				Fojta, M; Kubicarova, T; Vojtesek, B; Palecek, E			Effect of p53 protein redox states on binding to supercoiled and linear DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC DNA; TUMOR-SUPPRESSOR PROTEIN-P53; WILD-TYPE P53; METAL-IONS; CONFORMATION; PHOSPHORYLATION; OLIGOMERIZATION; ACTIVATION; MODULATION; DOMAIN	The binding of p53 to its DNA consensus sequence is modulated by the redox state of the protein in vitro, We have shown previously that reduced wild-type p53 binds strongly to supercoiled DNA (scDNA) regardless of the presence or absence of p53CON, Here we compare the effects of oxidation of p53 by azodicarboxylic acid bis-[dimethylamide] (diamide) and other agents on p53 binding to p53CON and to scDNA, Oxidation decreases the binding of p53 to scDNA; however, under conditions where binding to p53CON in a DNA fragment is completely abolished, some residual binding to scDNA is still observed. Increasing the concentration of oxidized p53 confers minimal changes in p53 binding to both scDNA and p53CON, Reduction of the oxidized protein by dithiothreitol neither restores its binding to DNA nor to p53CON in DNA fragments. In the presence of excess zinc ions, oxidation of p53 is, however, reversible. We conclude that the irreversibility of p53 oxidation is due, at least in part, to the removal of intrinsic zinc from its position in the DNA binding domain accompanied by a conformational change of the p53 molecule after oxidation of the three cysteines to which the zinc ion is coordinated in the reduced protein.	Acad Sci Czech Republ, Inst Biophys, CZ-61265 Brno, Czech Republic; Masaryk Mem Canc Inst, Brno 65653, Czech Republic	Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences; Masaryk Memorial Cancer Institute	Palecek, E (corresponding author), Acad Sci Czech Republ, Inst Biophys, Kralovopolska 135, CZ-61265 Brno, Czech Republic.	palecek@ibp.cz	Palecek, Emil/C-1075-2013; Fojta, Miroslav/D-6971-2012	Palecek, Emil/0000-0003-2561-8336; Fojta, Miroslav/0000-0003-1854-6506				ANDERSON ME, 1995, BIOESSAYS, V17, P3, DOI 10.1002/bies.950170103; Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Brdicka R., 1933, COLLECT CZECH CHEM C, V5, P112, DOI DOI 10.1135/CCCC19330112; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, METHOD ENZYMOL, V283, P245; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; OLAFSON RW, 1991, METHOD ENZYMOL, V205, P205; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; Palecek E, 1999, ONCOGENE, V18, P3617, DOI 10.1038/sj.onc.1202710; PALECEK E, 1971, ANAL BIOCHEM, V42, P59, DOI 10.1016/0003-2697(71)90010-8; Palecek E., 1983, TOPICS BIOELECTROCHE, V5, P65; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sambrook J, 1989, MOL CLONING; Shaw P, 1996, ONCOGENE, V12, P921; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Tomschik M, 1998, ELECTROANAL, V10, P403, DOI 10.1002/(SICI)1521-4109(199805)10:6<403::AID-ELAN403>3.3.CO;2-U; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1995, ONCOGENE, V10, P779; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167	48	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25749	25755		10.1074/jbc.274.36.25749	http://dx.doi.org/10.1074/jbc.274.36.25749			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464313	hybrid			2022-12-25	WOS:000082554200077
J	Hall, SW; Nagashima, M; Zhao, L; Morser, J; Leung, LLK				Hall, SW; Nagashima, M; Zhao, L; Morser, J; Leung, LLK			Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRINOGEN CLOTTING ACTIVITY; ANION-BINDING EXOSITE; ANTITHROMBIN-III; ALPHA-THROMBIN; PROTHROMBIN DEFICIENCY; KUNITZ INHIBITORS; IDENTIFICATION; ANTICOAGULANT; SUBSTITUTION; COAGULATION	A collection of 56 purified thrombin mutants, in which 76 charged or polar surface residues on thrombin were mutated to alanine, was used to identify key residues mediating the interactions of thrombin with thrombomodulin (TM), protein C, and thrombin-activatable fibrinolysis inhibitor (TAFI). Comparison of protein C activation in the presence and absence of TM identified 11 residues mediating the thrombin-TM interaction (Lys(21), Gln(24), Arg(62), Lys(65), His(66), Arg(68), Thr(69), Tyr(71), Arg(73), Lys(77), Lys(106)). Three mutants (E25A, D51A, R89A/R93A/E94A) were found to have decreased ability to activate TAFI yet retained normal protein C activation, whereas three other mutants (R178A/R180A/D183A, E229A, R233A) had decreased ability to activate protein C but maintained normal TAFI activation. One mutant (W50A) displayed decreased activation of both substrates. Mapping of these functional residues on thrombin revealed that the 11 residues mediating the thrombin-TM interaction are all located in exosite I. Residues important in TAFI activation are located above the active-site cleft, whereas residues involved in protein C are located below the active-site cleft. In contrast to the extensive overlap of residues mediating TM binding and fibrinogen clotting, these data show that distinct domains in thrombin mediate its interactions with TM, protein C, and TAFI. These studies demonstrate that selective enzymatic properties of thrombin can be dissociated by site-directed mutagenesis.	Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA; Berlex Biosci, Richmond, CA 94804 USA	Stanford University	Hall, SW (corresponding author), Stanford Univ, Sch Med, Div Hematol, Rm S-161, Stanford, CA 94305 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057530] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL57530-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1998, J BIOL CHEM, V273, P2792, DOI 10.1074/jbc.273.5.2792; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BEZEAUD A, 1988, J BIOL CHEM, V263, P3576; BOARD PG, 1993, BLOOD REV, V7, P229, DOI 10.1016/0268-960X(93)90010-2; Colwell NS, 1999, BIOCHEMISTRY-US, V38, P2610, DOI 10.1021/bi995066p; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DECRISTOFARO R, 1992, BIOCHEMISTRY-US, V31, P257, DOI 10.1021/bi00116a035; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; ESMON CT, 1989, J BIOL CHEM, V264, P4743; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GRALNICK HR, 1994, P NATL ACAD SCI USA, V91, P6334, DOI 10.1073/pnas.91.14.6334; HANSON S, 1997, THROMB HAEMOSTASIS S, V1, P419; HENRIKSEN RA, 1988, BIOCHEMISTRY-US, V27, P9160, DOI 10.1021/bi00426a013; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; Kokame K, 1998, J BIOL CHEM, V273, P12135, DOI 10.1074/jbc.273.20.12135; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; Liaw PCY, 1998, J BIOL CHEM, V273, P8932, DOI 10.1074/jbc.273.15.8932; LIU LW, 1991, J BIOL CHEM, V266, P16977; MIYATA T, 1987, BIOCHEMISTRY-US, V26, P1117, DOI 10.1021/bi00378a020; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; MORISHITA E, 1991, THROMB RES, V62, P697, DOI 10.1016/0049-3848(91)90373-5; MOSESSON MW, 1993, SEMIN THROMB HEMOST, V19, P361, DOI 10.1055/s-2007-993287; NASKI MC, 1990, J BIOL CHEM, V265, P13484; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; NOE G, 1988, J BIOL CHEM, V263, P11729; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; Sun WY, 1998, P NATL ACAD SCI USA, V95, P7597, DOI 10.1073/pnas.95.13.7597; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Tsiang M, 1997, J BIOL CHEM, V272, P12024, DOI 10.1074/jbc.272.18.12024; Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; VONDEMBORNE PAK, 1995, BLOOD, V86, P3035; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; WU QY, 1994, J BIOL CHEM, V269, P3725; Xue JC, 1998, P NATL ACAD SCI USA, V95, P7603, DOI 10.1073/pnas.95.13.7603; Zhao L, 1998, THROMB HAEMOSTASIS, V80, P949	51	89	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25510	25516		10.1074/jbc.274.36.25510	http://dx.doi.org/10.1074/jbc.274.36.25510			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464282	hybrid			2022-12-25	WOS:000082554200046
J	Mammoto, A; Ohtsuka, T; Hotta, I; Sasaki, T; Takai, Y				Mammoto, A; Ohtsuka, T; Hotta, I; Sasaki, T; Takai, Y			Rab11BP/Rabphilin-11, a downstream target of Rab11 small G protein implicated in vesicle recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; MDCK CELLS; MOLECULAR-CLONING; SYNAPTIC VESICLES; PLASMA-MEMBRANE; PC12 CELLS; RAT-LIVER; TRANSPORT; ENDOSOME; RABPHILIN-3A	Rab11 small G protein has been implicated in vesicle recycling, but its upstream regulators or downstream targets have not yet been identified. We isolated here a downstream target of Rab11, named rabphilin-11, from bovine brain. Moreover, we isolated from a rat brain cDNA library its cDNA, which encoded a protein with a M-r of 100,946 and 908 amino acids (aa), Rabphilin-11 bound GTP-Rab11 more preferentially than GDP-Rab11 at the N-terminal region and was specific for Rab11 and inactive for other Rab and Rho small G proteins. Both GTP-Rab11 and rabphilin-11 were colocalized at perinuclear regions, presumably the Gels complex and recycling endosomes, in Madin-Darby canine kidney cells. In HeLa cells cultured on fibronectin, both the proteins were localized not only at perinuclear regions but also along microtubules, which were oriented toward membrane lamellipodia, Treatment of HeLa cells with nocodazole caused disruption of microtubules and dispersion of GTP-Rab11 and rabphilin-11, Overexpression of the C-terminal fragment of rabphilin-11 (aa 607-730), lacking the GTP-Rab11 binding domain, in HeLa cells reduced accumulation of transferrin at perinuclear regions and cell migration. Rabphilin-11 turned out to be a rat counterpart of recently reported bovine Rab11BP. These results indicate that rabphilin-11 is a downstream target of Rab11 which is involved in vesicle recycling.	Osaka Univ, Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan.							ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BRETSCHER MS, 1992, EMBO J, V11, P383, DOI 10.1002/j.1460-2075.1992.tb05066.x; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Hori Y, 1996, DIGEST DIS SCI, V41, P133, DOI 10.1007/BF02208595; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; MANSER E, 1992, J BIOL CHEM, V267, P16025; Maples CJ, 1997, J BIOL CHEM, V272, P6741, DOI 10.1074/jbc.272.10.6741; McKiernan CJ, 1996, MOL CELL BIOL, V16, P4985; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OHMORI T, 1990, BIOCHEM BIOPH RES CO, V169, P816, DOI 10.1016/0006-291X(90)90404-B; Ohya T, 1998, J BIOL CHEM, V273, P613, DOI 10.1074/jbc.273.1.613; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; SAKURADA K, 1991, BIOCHEM BIOPH RES CO, V177, P1224, DOI 10.1016/0006-291X(91)90672-T; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840	42	75	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25517	25524		10.1074/jbc.274.36.25517	http://dx.doi.org/10.1074/jbc.274.36.25517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464283	hybrid			2022-12-25	WOS:000082554200047
J	Olshevskaya, EV; Ermilov, AN; Dizhoor, AM				Olshevskaya, EV; Ermilov, AN; Dizhoor, AM			Dimerization of guanylyl cyclase-activating protein and a mechanism of photoreceptor guanylyl cyclase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; CALCIUM; EXPRESSION; CLONING; BINDING; VISION; PHOTOTRANSDUCTION; GCAP-2; MUTANT; DOMAIN	Ca2+-binding guanylyl cyclase-activating proteins (GCAPs) stimulate photoreceptor membrane guanylyl cyclase (retGC) in the light when the free Ca2+ concentrations in photoreceptors decrease from 600 to 50 lull. RetGC activated by GCAPs exhibits tight dimerization revealed by chemical cross-linking (Yu, H., Olshevskaya, E,, Duda, T., Seno, K,, Hayashi, F,, Sharma, R, K,, Dizhoor, A. M., and Yamazaki, A. (1999) J, Biol, Chem, 274, 15547-15555), We have found that the Ca2+-loaded GCAP-2 monomer undergoes reversible dimerization upon dissociation of Ca2+, The ability of GCAP-2 and its several mutants to activate retGC in vitro correlates with their ability to dimerize at low free Ca2+ concentrations. A constitutively active GCAP-2 mutant E80Q/E116Q/D158N that stimulates retGC regardless of the free Ca2+ concentrations forms dimers both in the absence and in the presence of Ca2+. Several GCAP-2/neurocalcin chimera proteins that cannot efficiently activate retGC in low Ca2+ concentrations are also unable to dimerize in the absence of Ca2+. Additional mutation that restores normal activity of the GCAP-2 chimera mutant also restores its ability to dimerize in the absence of Ca2+, These results suggest that dimerization of GCAP-2 can be a part of the mechanism by which GCAP-2 regulates the photoreceptor guanylyl cyclase, The Ca2+-free GCAP-1 is also capable of dimerization in the absence of Ca2+, but unlike GCAP-2, dimerization of GCAP-1 is resistant to the presence of Ca2+.	Wayne State Univ, Sch Med, Dept Ophthalmol, Kresge Eye Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Dizhoor, AM (corresponding author), Wayne State Univ, Sch Med, Dept Ophthalmol, Kresge Eye Inst, 4717 St Antoine, Detroit, MI 48201 USA.			Dizhoor, Alexander/0000-0001-6770-9186	NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER; NEI NIH HHS [EY11522] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; Howes K, 1998, INVEST OPHTH VIS SCI, V39, P867; Kachi S, 1999, EXP EYE RES, V68, P465, DOI 10.1006/exer.1998.0629; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; Krishnan A, 1998, MOL CELL BIOCHEM, V178, P251, DOI 10.1023/A:1006860018300; Krylov DM, 1999, J BIOL CHEM, V274, P10833, DOI 10.1074/jbc.274.16.10833; LADANT D, 1995, J BIOL CHEM, V270, P3179; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; Laura RP, 1998, BIOCHEMISTRY-US, V37, P11264, DOI 10.1021/bi9809674; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; Olshevskaya EV, 1999, J BIOL CHEM, V274, P10823, DOI 10.1074/jbc.274.16.10823; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Sampath AP, 1998, J GEN PHYSIOL, V111, P53, DOI 10.1085/jgp.111.1.53; SITARAMAYYA A, 1995, MOL CELL BIOCHEM, V148, P139, DOI 10.1007/BF00928151; Sokal I, 1999, BIOCHEMISTRY-US, V38, P1387, DOI 10.1021/bi982512k; Stryer L, 1996, P NATL ACAD SCI USA, V93, P557, DOI 10.1073/pnas.93.2.557; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Surgucheva I., 1997, Investigative Ophthalmology and Visual Science, V38, pS477; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Yang RB, 1997, J BIOL CHEM, V272, P13738, DOI 10.1074/jbc.272.21.13738; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; Yu H, 1999, J BIOL CHEM, V274, P15547, DOI 10.1074/jbc.274.22.15547; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	44	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25583	25587		10.1074/jbc.274.36.25583	http://dx.doi.org/10.1074/jbc.274.36.25583			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464292	hybrid			2022-12-25	WOS:000082554200056
J	Boczkowski, J; Lisdero, CL; Lanone, S; Samb, A; Carreras, MC; Boveris, A; Aubier, M; Poderoso, JJ				Boczkowski, J; Lisdero, CL; Lanone, S; Samb, A; Carreras, MC; Boveris, A; Aubier, M; Poderoso, JJ			Endogenous peroxynitrite mediates mitochondrial dysfunction in rat diaphragm during endotoxemia	FASEB JOURNAL			English	Article						sepsis; respiratory insufficiency; respiratory muscles; mitochondria; nitric oxide; oxidative stress; nitrotyrosine	NITRIC-OXIDE SYNTHASE; HYDROGEN-PEROXIDE; SKELETAL-MUSCLE; SUPEROXIDE-DISMUTASE; RADICAL PRODUCTION; ESCHERICHIA-COLI; OXIDATIVE STRESS; METABOLISM; INHIBITION; GENERATION	It has been shown that nitric oxide (NO), synthesized by the inducible NO synthase (iNOS) expressed in the diaphragm during endotoxemia, participates in the development of muscular contractile failure. The aim of the present study was to investigate whether this deleterious action of NO was related to its effects on cellular oxidative pathways. Rats were inoculated with E. coli lipopolysaccharide (LPS) or sterile saline solution (controls) and studied at 3 and 6 h after inoculation. iNOS protein and activity could be detected in the rat diaphragm as early as 3 h after LPS, with a sustained steady-state concentration of 0.5 mu M NO in the muscle associated with increased detection of hydrogen peroxide (H2O2). In vitro, the same NO concentration produced a marked increase in H2O2 production by isolated control diaphragm mitochondria, thus reflecting a higher intramitochondrial concentration of nondiffusible superoxide anion (O-2(-.)). In a similar way, whole diaphragmatic muscle and diaphragm mitochondria from endotoxemic rats showed a progressive increase in H2O2 production associated with uncoupling and decreased phosphorylating capacity. Simultaneous with the maximal impairment in respiration (6 h after LPS), nitration of mitochondrial proteins (a peroxynitrite footprint) was detected and diaphragmatic force was reduced. Functional mitochondrial abnormalities, nitration of mitochondrial proteins, and the decrease in force were significantly attenuated by administration of the NOS inhibitor L-NMMA. These results show that increased and sustained NO levels lead to a consecutive formation of O-2(-.) that reacts with NO to form peroxynitrite, which in turn impairs mitochondrial function, which probably contributes to the impairment of muscle contractility.	Fac Xavier Bichat, INSERM U408, F-75870 Paris 18, France; Fac Xavier Bichat, IFR 02, F-75870 Paris 18, France; Univ Hosp Buenos Aires, Lab Oxygen Metab, Buenos Aires, DF, Argentina; Univ Buenos Aires, Sch Pharm & Biochem, Lab Free Radical Biol, RA-1053 Buenos Aires, DF, Argentina	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Buenos Aires; University of Buenos Aires	Boczkowski, J (corresponding author), Fac Xavier Bichat, INSERM U408, BP416, F-75870 Paris 18, France.	jbb2@bichat.inserm.fr	Lanone, Sophie/I-4042-2016; Boczkowski, Jorge/S-7474-2018	Lanone, Sophie/0000-0003-2509-8799; Boczkowski, Jorge/0000-0001-6619-5785				Bates TE, 1996, BIOCHEM BIOPH RES CO, V218, P40, DOI 10.1006/bbrc.1996.0008; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Boczkowski J, 1996, J CLIN INVEST, V98, P1550, DOI 10.1172/JCI118948; BOCZKOWSKI J, 1988, AM REV RESPIR DIS, V138, P260, DOI 10.1164/ajrccm/138.2.260; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; BYRNE E, 1989, J NEUROL SCI, V92, P215, DOI 10.1016/0022-510X(89)90138-X; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; CLOSE RI, 1972, PHYSIOL REV, V52, P129, DOI 10.1152/physrev.1972.52.1.129; COHEN CA, 1982, AM J MED, V73, P308, DOI 10.1016/0002-9343(82)90711-2; Costa LE, 1997, AM J PHYSIOL-CELL PH, V273, pC852, DOI 10.1152/ajpcell.1997.273.3.C852; Cuzzocrea S, 1998, IMMUNOLOGY, V93, P96; El-Dwairi Q, 1998, AM J PHYSIOL-CELL PH, V274, pC770, DOI 10.1152/ajpcell.1998.274.3.C770; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; HANTLER PD, 1975, EUR J BIOCHEM, V60, P67; HAYES DJ, 1985, BIOCHEM J, V229, P109, DOI 10.1042/bj2290109; HUSSAIN SNA, 1985, J APPL PHYSIOL, V58, P2033, DOI 10.1152/jappl.1985.58.6.2033; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LLESUY S, 1994, FREE RADICAL BIO MED, V16, P445, DOI 10.1016/0891-5849(94)90121-X; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Poderoso JJ, 1998, AM J PHYSIOL-CELL PH, V274, pC112, DOI 10.1152/ajpcell.1998.274.1.C112; Poderoso JJ, 1999, FREE RADICAL BIO MED, V26, P925, DOI 10.1016/S0891-5849(98)00277-9; PUNTARULO S, 1991, BIOCHIM BIOPHYS ACTA, V1074, P277, DOI 10.1016/0304-4165(91)90164-C; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; ROCHESTER DF, 1991, AM REV RESPIR DIS, V143, P901, DOI 10.1164/ajrccm/143.5_Pt_1.901; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SHINDOH C, 1992, AM REV RESPIR DIS, V145, P1350, DOI 10.1164/ajrccm/145.6.1350; Supinski G, 1996, J APPL PHYSIOL, V81, P1370, DOI 10.1152/jappl.1996.81.3.1370; Szabo C, 1997, FEBS LETT, V409, P147, DOI 10.1016/S0014-5793(97)00466-3; VANSURELL C, 1992, AM REV RESPIR DIS, V146, P730, DOI 10.1164/ajrccm/146.3.730; VIIRES N, 1988, J APPL PHYSIOL, V64, P26, DOI 10.1152/jappl.1988.64.1.26; Viner RI, 1996, FREE RADICAL RES, V24, P243, DOI 10.3109/10715769609088022; Voisin L, 1996, J CLIN INVEST, V97, P1610, DOI 10.1172/JCI118586; Xie YW, 1998, CIRC RES, V82, P891; Zhang HY, 1997, J IMMUNOL, V158, P1392	52	137	145	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1999	13	12					1637	1646		10.1096/fasebj.13.12.1637	http://dx.doi.org/10.1096/fasebj.13.12.1637			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463956				2022-12-25	WOS:000082347600020
J	Rosenquist, TH; Schneider, AM; Monaghan, DT				Rosenquist, TH; Schneider, AM; Monaghan, DT			N-methyl-D-aspartate receptor agonists modulate homocysteine-induced developmental abnormalities	FASEB JOURNAL			English	Article						neural tube defects; neural crest defects; orofacial defects; prevention	NEURAL-TUBE DEFECTS; CONOTRUNCAL HEART-DEFECTS; CEREBELLAR GRANULE CELLS; CENTRAL-NERVOUS-SYSTEM; RISK FACTOR; FOLIC-ACID; NMDA RECEPTORS; HYPERHOMOCYSTEINEMIA; EMBRYOS; NEURONS	We showed previously that the induction of neural crest (NC) and neural tube (NT) defects is a general property of N-methyl-D-aspartate receptor (NMDAR) antagonists. Since homocysteine induces NC and NT defects and can also act as an NMDAR antagonist, we hypothesized that the mechanism of homocysteine-induced developmental defects is mediated by competitive inhibition of the NMDAR by homocysteine. If this hypothesis is correct, homocysteine-induced defects will be reduced by NMDAR agonists, To test the hypothesis, we treated chicken embryos during the process of neural tube closure with sufficient homocysteine thiolactone to induce NC and NT defects in similar to 40% of survivors or with homocysteine thiolactone in combination with each of a selected set of NMDAR agonists in 0.05-5000 nmol doses. Glutamate site agonists selected were L-glutamate and N-methyl-D-aspartate. Glycine site agonists were glycine, D-cycloserine, and aminocyclopropane-carboxylic acid. Glycine was the most effective overall, reducing defects significantly at two different doses (each P>0.001), These results support the hypothesis that homocysteine may affect NC and NT development by its ability to inhibit the NMDAR, One potentially important consequence of this putative mechanism is that homocysteine may interact synergistically with other NMDAR antagonists to enhance its effect on development.	Univ Nebraska, Med Ctr, Dept Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Rosenquist, TH (corresponding author), Univ Nebraska, Med Ctr, Dept Cell Biol & Anat, 600 S 42nd St, Omaha, NE 68198 USA.	throsenq@unmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055940] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-55940] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andaloro VJ, 1998, PEDIATR RES, V43, P1, DOI 10.1203/00006450-199801000-00001; BALAZS R, 1989, NEUROSCI LETT, V101, P241, DOI 10.1016/0304-3940(89)90539-9; BOSTOM AG, 1995, POST METHIONINE LOAD; Botto LD, 1996, PEDIATRICS, V98, P911; BULLER AL, 1994, J NEUROSCI, V14, P5471; CHRISTENSEN B, 1995, BAILLIERE CLIN HAEM, V8, P617, DOI 10.1016/S0950-3536(05)80223-9; CORNELLBELL AH, 1990, GLIA, V3, P322, DOI 10.1002/glia.440030503; Crews FT, 1996, INT REV NEUROBIOL, V39, P283, DOI 10.1016/S0074-7742(08)60670-4; Czeizel AE, 1996, TERATOLOGY, V53, P345, DOI 10.1002/(SICI)1096-9926(199606)53:6&lt;345::AID-TERA5&gt;3.0.CO;2-Z; ELMAZAR MMA, 1995, REPROD TOXICOL, V9, P427, DOI 10.1016/0890-6238(95)00023-4; ESKES TKAB, 1994, EUR J OBSTET GYN R B, V53, P147, DOI 10.1016/0028-2243(94)90225-9; FINEMAN RM, 1986, AM J MED GENET, V25, P489, DOI 10.1002/ajmg.1320250311; FOHR KJ, 1995, NEUROSCI LETT, V183, P87, DOI 10.1016/0304-3940(94)11121-X; GoddijnWessel TAW, 1996, EUR J OBSTET GYN R B, V66, P23, DOI 10.1016/0301-2115(96)02383-4; Gofflot F, 1996, DEV BRAIN RES, V93, P62, DOI 10.1016/0165-3806(96)00031-4; Graham A, 1996, MOL CELL NEUROSCI, V8, P76, DOI 10.1006/mcne.1996.0046; Graham A, 1996, BIOCHEM SOC SYMP, P77; Hladovec J, 1997, THROMB RES, V88, P361, DOI 10.1016/S0049-3848(97)00266-1; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; ISHII T, 1993, J BIOL CHEM, V268, P2836; Johnson VP, 1996, AM J MED GENET, V61, P329, DOI 10.1002/(SICI)1096-8628(19960202)61:4<329::AID-AJMG6>3.0.CO;2-P; Kim W.-K., 1995, Society for Neuroscience Abstracts, V21, P521; Kim WK, 1996, NEUROSCI LETT, V216, P117; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; LAEGREID L, 1993, NEUROPEDIATRICS, V24, P88, DOI 10.1055/s-2008-1071520; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Maden M, 1998, J NUTR, V128, p471S, DOI 10.1093/jn/128.2.471S; MANSOOR MA, 1992, CLIN CHEM, V38, P1316; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Munger RG, 1996, TERATOLOGY, V54, P27, DOI 10.1002/(SICI)1096-9926(199607)54:1<27::AID-TERA4>3.0.CO;2-0; NODEN DM, 1990, ANN NY ACAD SCI, V588, P236, DOI 10.1111/j.1749-6632.1990.tb13214.x; RASHID NA, 1992, DEV BRAIN RES, V67, P301, DOI 10.1016/0165-3806(92)90231-K; REFSUM H, 1989, CLIN CHEM, V35, P1921; ROBINSON LK, 1987, J PEDIATR-US, V111, P236, DOI 10.1016/S0022-3476(87)80074-4; Romanoff A.L., 1960, AVIAN EMBRYO STRUCTU; Rosenquist TH, 1996, P NATL ACAD SCI USA, V93, P15227, DOI 10.1073/pnas.93.26.15227; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SHAW GM, 1995, AM J MED GENET, V59, P536, DOI 10.1002/ajmg.1320590428; SNEDECOR GW, 1962, STAT METHODS, P90; STEEGERSTHEUNISSEN RP, 1995, AM J OBSTET GYNECOL, V172, P1436, DOI 10.1016/0002-9378(95)90474-3; STEEGERSTHEUNISSEN RPM, 1994, METABOLISM, V43, P1475, DOI 10.1016/0026-0495(94)90004-3; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; Tyagi SC, 1998, AM J PHYSIOL-CELL PH, V274, pC396, DOI 10.1152/ajpcell.1998.274.2.C396; Uberti D, 1998, EUR J NEUROSCI, V10, P246, DOI 10.1046/j.1460-9568.1998.00042.x; VanStraaten HWM, 1996, DEV DYNAM, V207, P309, DOI 10.1002/(SICI)1097-0177(199611)207:3<309::AID-AJA8>3.0.CO;2-L; Wang C, 1996, J CELL BIOL, V135, P1565, DOI 10.1083/jcb.135.6.1565; Wang H, 1997, J BIOL CHEM, V272, P25380, DOI 10.1074/jbc.272.40.25380; Weil M, 1997, CURR BIOL, V7, P281, DOI 10.1016/S0960-9822(06)00125-4; WITT G, 1999, THESIS U NEBRASKA ME; Wood AM, 1998, J NEUROCHEM, V70, P677; WOUTERS MGAJ, 1993, FERTIL STERIL, V60, P820	53	48	49	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1999	13	12					1523	1531		10.1096/fasebj.13.12.1523	http://dx.doi.org/10.1096/fasebj.13.12.1523			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463943				2022-12-25	WOS:000082347600007
J	Sainz, RM; Mayo, JC; Reiter, RJ; Antolin, I; Esteban, MM; Rodriguez, C				Sainz, RM; Mayo, JC; Reiter, RJ; Antolin, I; Esteban, MM; Rodriguez, C			Melatonin regulates glucocorticoid receptor: an answer to its antiapoptotic action in thymus	FASEB JOURNAL			English	Article						antioxidant enzymes; glucocorticoids; apoptosis; DNA fragmentation	PROGRAMMED CELL-DEATH; MESSENGER-RNA; NUCLEAR RECEPTOR; GENE-EXPRESSION; NEUROHORMONE MELATONIN; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; ANTIOXIDANT ENZYMES; HORMONE MELATONIN; RAT THYMUS	We have previously reported that low doses of melatonin inhibit apoptosis in both dexamethasone-treated cultured thymocytes (standard model for the study of apoptosis) and the intact thymus. Here we elucidate the mechanism by which this agent protects thymocytes from cell death induced by glucocorticoids. Our results demonstrate an effect of melatonin on the mRNA for antioxidant enzymes in thymocytes, also showing an unexpected regulation by dexamethasone of these mRNA Both an effect of melatonin on the general machinery of apoptosis and a possible regulation of the expression of the cell death related genes bcl-2 and p53 are shown not to be involved, We found melatonin to down-regulate the mRNA for the glucocorticoid receptor in thymocytes (glucocorticoids up-regulate their own receptor). The decrease by melatonin of mRNA levels for this receptor in IM-9 cells (where glucocorticoids down-regulate it) demonstrates that melatonin actually down-regulates glucocorticoid receptor. These findings allow us to propose the effects of melatonin on this receptor as the likely mediator of its thymocyte protection against dexamethasone-induced cell death. This effect of melatonin, given the oxidant properties of glucocorticoids, adds another mechanism to explain its antioxidant effects.	Fac Med, Dept Morfol & Biol Celular, Oviedo 33006, Spain; Fac Med, Dept Biol Func, Oviedo 33006, Spain; Univ Texas, Ctr Hlth Sci, Dept Cell & Struct Biol, San Antonio, TX 78285 USA	University of Texas System; University of Texas Health San Antonio	Rodriguez, C (corresponding author), Fac Med, Dept Morfol & Biol Celular, Julian Claveria, Oviedo 33006, Spain.		Rodríguez, Carmen/R-9541-2019; Sainz, Rosa M./N-5885-2014; Mayo, Juan Carlos/H-3435-2011; Antolin, Isaac/L-6210-2014	Rodríguez, Carmen/0000-0002-3203-4753; Sainz, Rosa M./0000-0003-3048-5582; Mayo, Juan Carlos/0000-0002-0882-2047; Antolin, Isaac/0000-0002-4232-9248; Martinez-Esteban, Manuel/0000-0001-8904-6010				Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; BARCENA A, 1990, J EXP MED, V172, P439, DOI 10.1084/jem.172.2.439; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BEAVER JP, 1995, EUR J CELL BIOL, V68, P47; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; Behl C, 1997, ENDOCRINOLOGY, V138, P101, DOI 10.1210/en.138.1.101; BENITEZKING G, 1991, BRAIN RES, V557, P289, DOI 10.1016/0006-8993(91)90146-M; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CAGNOLI CM, 1995, J PINEAL RES, V20, P187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEARY ML, 1996, CELL, V47, P19; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DENTON RR, 1993, ENDOCRINOLOGY, V133, P248, DOI 10.1210/en.133.1.248; ENOCH T, 1995, TRENDS BIOL SCI, V20, P427; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; HILL SM, 1988, CANCER RES, V48, P6121; HO YS, 1987, NUCLEIC ACIDS RES, V15, P6746, DOI 10.1093/nar/15.16.6746; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kotler M, 1998, J PINEAL RES, V24, P83, DOI 10.1111/j.1600-079X.1998.tb00371.x; MAESTRONI GJM, 1994, CANCER RES, V54, P4740; MAHMOUD I, 1994, J ANAT, V185, P143; Mayo JC, 1998, J PINEAL RES, V25, P12, DOI 10.1111/j.1600-079X.1998.tb00380.x; Mayo JC, 1998, J PINEAL RES, V24, P179, DOI 10.1111/j.1600-079X.1998.tb00531.x; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MOCCHEGIANI E, 1994, J NEUROIMMUNOL, V53, P189, DOI 10.1016/0165-5728(94)90029-9; MolinaCarballo A, 1997, J PINEAL RES, V23, P97, DOI 10.1111/j.1600-079X.1997.tb00341.x; Mor F, 1996, J IMMUNOL, V156, P515; Pappolla MA, 1997, J NEUROSCI, V17, P1683; PELEDKAMAR M, 1995, EMBO J, V14, P4985, DOI 10.1002/j.1460-2075.1995.tb00181.x; Pozo D, 1997, FASEB J, V11, P466, DOI 10.1096/fasebj.11.6.9194527; POZO D, 1994, LIFE SCI, V55, P455; Provinciali M, 1996, MECH AGEING DEV, V90, P1, DOI 10.1016/0047-6374(96)01746-0; Rafii-El-Idrissi M, 1998, J NEUROIMMUNOL, V86, P190, DOI 10.1016/S0165-5728(98)00048-4; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; Reiter R J, 1997, Adv Pharmacol, V38, P103; Reiter RJ, 1997, ANN NY ACAD SCI, V825, P70, DOI 10.1111/j.1749-6632.1997.tb48415.x; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; RODRIGUEZ C, 1994, ENDOCRINE, V2, P863; Sainz RM, 1998, LIFE SCI, V63, P1109; Sainz RM, 1995, J PINEAL RES, V19, P178, DOI 10.1111/j.1600-079X.1995.tb00187.x; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHORTMAN K, 1974, CELL IMMUNOL, V12, P230, DOI 10.1016/0008-8749(74)90075-6; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Tan DX, 1993, ENDOCR J, V1, P57; TILLY JL, 1992, ENDOCRINOLOGY, V131, P1670, DOI 10.1210/en.131.4.1670; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WALKER PR, 1991, CANCER RES, V51, P1078; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2	58	78	88	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1547	1556		10.1096/fasebj.13.12.1547	http://dx.doi.org/10.1096/fasebj.13.12.1547			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463946				2022-12-25	WOS:000082347600010
J	Bruzzaniti, A; Marx, R; Mains, RE				Bruzzaniti, A; Marx, R; Mains, RE			Activation and routing of membrane-tethered prohormone convertases 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ALPHA-AMIDATING MONOOXYGENASE; TRANS-GOLGI NETWORK; KEX2-LIKE PROCESSING ENDOPROTEASE; GRANULE-ASSOCIATED PROTEINS; PRO-ACTH ENDORPHIN; ATT-20 CELLS; ENZYMATIC CHARACTERIZATION; NEUROENDOCRINE CELLS; CYTOPLASMIC DOMAIN; CHROMOSOMAL LOCALIZATION	Many peptide hormones and neuropeptides are processed by members of the subtilisin-like family of prohormone convertases (PCs), which are either soluble or integral membrane proteins. PC1 and PC2 are soluble PCs that are primarily localized to large dense core vesicles in neurons and endocrine cells. We examined whether PC1 and PC2 were active when expressed as membrane-tethered proteins, and how tethering to membranes alters the biosynthesis, enzymatic activity, and intracellular routing of these PCs. PC1 and PC2 chimeras were constructed using the transmembrane domain and cytoplasmic domain of the amidating enzyme, peptidylglycine cu-amidating monooxygenase (PAM). The membrane-tethered PCs were rerouted from large dense core vesicles to the Golgi region. In addition, the chimeras were transiently expressed at the cell surface and rapidly internalized to the Golgi region in a fashion similar to PAM. Membrane-tethered PC1 and PC2 exhibited changes in pro domain maturation rates, N-glycosylation, and in the pH and calcium optima required for maximal enzymatic activity against a fluorogenic substrate. In addition, the PC chimeras efficiently cleaved endogenous pro-opiomelanocortin to the correct bioactive peptides. The PAM transmembrane domain/cytoplasmic domain also prevented stimulated secretion of pro-opiomelanocortin products in AtT-20 cells.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Mains, RE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	dmains@jhmi.edu	Bruzzaniti, Angela/AAP-2225-2020		NIDA NIH HHS [DA-00266] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BAILYES EM, 1995, BIOCHEM J, V309, P587, DOI 10.1042/bj3090587; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; Ciccotosto GD, 1999, J CELL BIOL, V144, P459, DOI 10.1083/jcb.144.3.459; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; Creemers JWM, 1998, SEMIN CELL DEV BIOL, V9, P3, DOI 10.1006/scdb.1997.0195; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; EIPPER BA, 1993, PROTEIN SCI, V2, P489; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HORNBY PJ, 1993, NEUROENDOCRINOLOGY, V58, P555, DOI 10.1159/000126590; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUSTEN EJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P487, DOI 10.1006/abbi.1994.1336; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; Johanning K, 1996, J NEUROCHEM, V66, P898; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KIRCHMAIR R, 1992, FEBS LETT, V297, P302, DOI 10.1016/0014-5793(92)80560-4; Klumperman J, 1996, J NEUROSCI, V16, P7930; Kolhekar AS, 1998, J BIOL CHEM, V273, P23012, DOI 10.1074/jbc.273.36.23012; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; LEWIN B, 1985, GENES, V2, P99; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587; Mains RE, 1999, J BIOL CHEM, V274, P2929, DOI 10.1074/jbc.274.5.2929; MAINS RE, 1990, TRENDS ENDOCRIN MET, V1, P388, DOI 10.1016/1043-2760(90)90097-M; MAINS RE, 1995, MOL ENDOCRINOL, V9, P3, DOI 10.1210/me.9.1.3; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; Meerabux J, 1996, CANCER RES, V56, P448; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; Milgram SL, 1996, MOL ENDOCRINOL, V10, P837, DOI 10.1210/me.10.7.837; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Milgram SL, 1997, J CELL SCI, V110, P695; MILGRAM SL, 1994, J CELL SCI, V107, P737; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; Nishihara S, 1999, GLYCOBIOLOGY, V9, P607, DOI 10.1093/glycob/9.6.607; OYARCE AM, 1993, J NEUROCHEM, V60, P1105, DOI 10.1111/j.1471-4159.1993.tb03261.x; OYARCE AM, 1995, J CELL SCI, V108, P287; PATEL YC, 1995, CIBA F SYMP, V190, P26; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; REAVES B, 1994, FEBS LETT, V351, P448, DOI 10.1016/0014-5793(94)00813-2; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; Schaner P, 1997, J BIOL CHEM, V272, P19958, DOI 10.1074/jbc.272.32.19958; SCHMIDT WK, 1995, MOL BIOL CELL, V6, P1271, DOI 10.1091/mbc.6.10.1271; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1992, DNA CELL BIOL, V11, P283, DOI 10.1089/dna.1992.11.283; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; SEIDAH NG, 1992, FEBS LETT, V310, P235, DOI 10.1016/0014-5793(92)81339-N; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; Siezen RJ, 1996, ADV EXP MED BIOL, V379, P75; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; VOLLENWEIDER F, 1995, DIABETES, V44, P1075, DOI 10.2337/diabetes.44.9.1075; Vollenweider F, 1996, BIOCHEM J, V314, P521, DOI 10.1042/bj3140521; VOLZ B, 1995, J CELL BIOL, V130, P537, DOI 10.1083/jcb.130.3.537; Wolins N, 1997, J CELL BIOL, V139, P1735, DOI 10.1083/jcb.139.7.1735; YI Z, 1993, J BIOL CHEM, V268, P5615; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117; ZHOU A, 1994, J BIOL CHEM, V269, P17440; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; ZHOU Y, 1995, J BIOL CHEM, V270, P24702, DOI 10.1074/jbc.270.42.24702; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641; Zhu XR, 1998, J BIOL CHEM, V273, P1158, DOI 10.1074/jbc.273.2.1158	100	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24703	24713		10.1074/jbc.274.35.24703	http://dx.doi.org/10.1074/jbc.274.35.24703			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455138	hybrid			2022-12-25	WOS:000082193400037
J	Liu, Y; Tergaonkar, V; Krishna, S; Androphy, EJ				Liu, Y; Tergaonkar, V; Krishna, S; Androphy, EJ			Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor alpha correlates with increased accumulation of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; MANGANOUS SUPEROXIDE-DISMUTASE; MAMMARY EPITHELIAL-CELLS; CALCIUM-BINDING PROTEIN; INDUCED APOPTOSIS; E6 ONCOPROTEIN; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; CERVICAL KERATINOCYTES; GENE-EXPRESSION	Human papillomavirus type 16 (HPV-16) E6 has been shown to prevent or enhance apoptosis depending on the stimulus and cell type, Here we present evidence that HPV-16 E6 sensitized murine fibrosarcoma L929 cells to tumor necrosis factor alpha (TNF)-induced cytolysis, The EG enhanced cytolysis correlated with a precedent increase in reactive oxygen species (ROS) level and antioxidant treatment could completely block the EG-dependent sensitization. These findings represent the first demonstration of a link between a viral oncogene-sensitized cytolysis and ROS. Previous studies have shown conflicting results regarding whether TNF-induced cytolysis of L929 cells is through necrosis or apoptosis, Here we report that, although L929 cells underwent DNA fragmentation after exposure to TNF, they retained the morphology of intact nuclei while gaining permeability to propidium iodide, features characteristic of necrosis rather than apoptosis, We confirmed that the broad spectrum caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone markedly increased the susceptibility of L929 cells to TNF, and further demonstrated that E6 enhanced this susceptibility, which again correlated with increased ROS accumulation. We showed that the expression of E6 in L929 cells did not alter the stability of p53, and the cells retained a p53 response to actinomycin D, Furthermore, two E6 mutants defective for p53 degradation in other systems exhibited differential effects on TNF sensitization. These results suggest that the enhancement of TNF-induced L929 cytolysis by E6 is independent of p53 degradation. We also found that TNF-induced activation of NF-kappa B did not account for the enhanced TNF susceptibility by E6.	New England Med Ctr, Dept Dermatol, Boston, MA 02111 USA; Univ Agr Sci, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Tufts Medical Center; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); University of Agricultural Sciences Bangalore; Tufts University	Liu, Y (corresponding author), New England Med Ctr, Dept Dermatol, Box 166,750 Washington St, Boston, MA 02111 USA.			Androphy, Elliot/0000-0002-8104-0703	NATIONAL CANCER INSTITUTE [R01CA073558, F32CA069738] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA69738-03, R01 CA73558] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; Baichwal V. R., 1997, CURR BIOL, V7, P94; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Bergqvist A, 1997, J VIROL, V71, P276, DOI 10.1128/JVI.71.1.276-283.1997; Brown J, 1997, J CELL BIOCHEM, V66, P245, DOI 10.1002/(SICI)1097-4644(19970801)66:2<245::AID-JCB11>3.0.CO;2-G; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Chen JJ, 1998, J BIOL CHEM, V273, P13537, DOI 10.1074/jbc.273.22.13537; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Dellas A, 1997, INT J GYNECOL PATHOL, V16, P212, DOI 10.1097/00004347-199707000-00004; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; FEHSEL K, 1991, AM J PATHOL, V139, P251; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Fiers W, 1996, J INFLAMM, V47, P67; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; FRANSEN L, 1986, CELL IMMUNOL, V100, P260, DOI 10.1016/0008-8749(86)90025-0; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; Gansauge S, 1997, FEBS LETT, V404, P6, DOI 10.1016/S0014-5793(97)00059-8; Gao QS, 1999, MOL CELL BIOL, V19, P733; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GROOTEN J, 1993, CYTOKINE, V5, P546, DOI 10.1016/S1043-4666(05)80003-1; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Higuchi M, 1998, ONCOGENE, V17, P2753, DOI 10.1038/sj.onc.1202211; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Iglesias M, 1998, ONCOGENE, V17, P1195, DOI 10.1038/sj.onc.1202054; Inoue T, 1998, MOL CARCINOGEN, V21, P215; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kinnula VL, 1998, CANCER LETT, V125, P191, DOI 10.1016/S0304-3835(97)00511-9; Kinoshita T, 1997, VIROLOGY, V232, P53, DOI 10.1006/viro.1997.8536; KOFF WC, 1986, LYMPHOKINE RES, V5, P215; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; KYO S, 1994, VIROLOGY, V200, P130, DOI 10.1006/viro.1994.1171; LASTER SM, 1988, J IMMUNOL, V141, P2629; Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102; Li JJ, 1997, CANCER RES, V57, P1991; LIU Y, 1999, IN PRESS J VIROL, V73; MALLERY SR, 1994, J CELL BIOCHEM, V56, P568, DOI 10.1002/jcb.240560418; MALLERY SR, 1995, J CELL BIOCHEM, V59, P317, DOI 10.1002/jcb.240590304; MATSUYAMA T, 1989, J VIROL, V63, P2504, DOI 10.1128/JVI.63.6.2504-2509.1989; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MESTAN J, 1986, NATURE, V323, P816, DOI 10.1038/323816a0; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; POWELL CB, 1995, GYNECOL ONCOL, V58, P327, DOI 10.1006/gyno.1995.1238; Rapp L, 1999, ONCOGENE, V18, P607, DOI 10.1038/sj.onc.1202373; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; ROTHE G, 1991, J IMMUNOL METHODS, V138, P133, DOI 10.1016/0022-1759(91)90074-P; SAMBHI SK, 1991, P NATL ACAD SCI USA, V88, P4025, DOI 10.1073/pnas.88.9.4025; SanchezAlcazar JA, 1997, J BIOL CHEM, V272, P30167, DOI 10.1074/jbc.272.48.30167; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Schwarz KB, 1996, FREE RADICAL BIO MED, V21, P641, DOI 10.1016/0891-5849(96)00131-1; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; Steller MA, 1996, CANCER RES, V56, P5087; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Vercesi AE, 1997, BIOSCIENCE REP, V17, P43, DOI 10.1023/A:1027335217774; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WEIS K, 1994, J BIOL CHEM, V269, P19142; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WONG GHW, 1988, J IMMUNOL, V140, P120; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1991, P NATL ACAD SCI USA, V88, P4372, DOI 10.1073/pnas.88.10.4372; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; WOODWORTH CD, 1993, AM J PATHOL, V142, P1544; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; Yang XL, 1997, J CELL BIOCHEM, V66, P309, DOI 10.1002/(SICI)1097-4644(19970901)66:3<309::AID-JCB4>3.3.CO;2-Y; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	86	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24819	24827		10.1074/jbc.274.35.24819	http://dx.doi.org/10.1074/jbc.274.35.24819			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455154	hybrid			2022-12-25	WOS:000082193400053
J	Markuns, JF; Wojtaszewski, JFP; Goodyear, LJ				Markuns, JF; Wojtaszewski, JFP; Goodyear, LJ			Insulin and exercise decrease glycogen synthase kinase-3 activity by different mechanisms in rat skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GLUCOSE-TRANSPORT; EPIDIDYMAL FAT-CELLS; B C-AKT; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAYS; ALPHA-ISOFORM; PHOSPHORYLATION; ACTIVATION; INHIBITION	Glycogen synthase activity is increased in response to insulin and exercise in skeletal muscle. Part of the mechanism by which insulin stimulates glycogen synthesis may involve phosphorylation and activation of Akt, serine phosphorylation and deactivation of glycogen synthase kinase-3 (GSK-3), leading to dephosphorylation and activation of glycogen synthase, To study Akt and GSK-3 regulation in muscle, time course experiments on the effects of insulin injection and treadmill running exercise were performed in hindlimb skeletal muscle from male rats, Both insulin and exercise increased glycogen synthase activity (%I-form) by 2-3-fold over basal. Insulin stimulation significantly increased Akt phosphorylation and activity, whereas exercise had no effect. The time course of the insulin-stimulated increase in Akt was closely matched by GSK-3 alpha Ser(21) phosphorylation and a 40-60% decrease in GSK-3 alpha and GSK-3 beta activity. Exercise also deactivated GSK-3 alpha and beta activity by 40-60%. However, in contrast to the effects of insulin, there was no change in Ser21 phosphorylation in response to exercise. Tyrosine dephosphorylation of GSK-3, another putative mechanism for GSK-3 deactivation, did not occur with insulin or exercise, These data suggest the following: 1) GSK-3 is constitutively active and tyrosine phosphorylated under basal conditions in skeletal muscle, 2) both exercise and insulin are effective regulators of GSK-3 activity in vivo, 3) the insulin-induced deactivation of GSK-3 occurs in response to increased Akt activity and GSK-3 serine phosphorylation, and 4) there is an Akt-independent mechanism for deactivation of GSK-3 in skeletal muscle.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Goodyear, LJ (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.		Wojtaszewski, Jørgen FP/P-6583-2014	Wojtaszewski, Jørgen FP/0000-0001-9785-6830; wojtaszewski, jorgen/0000-0001-8185-3408; Markuns, Jeffrey/0000-0002-8044-2575	NIAMS NIH HHS [AR42238, AR45670] Funding Source: Medline; PHS HHS [T32-DR07260-21] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR042238, R01AR045670, R01AR042238] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aronson D, 1997, J BIOL CHEM, V272, P25636, DOI 10.1074/jbc.272.41.25636; Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; BONDAR RJL, 1974, CLIN CHEM, V20, P586; BOOTH FW, 1985, FED PROC, V44, P2293; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Brozinick JT, 1998, J BIOL CHEM, V273, P14679, DOI 10.1074/jbc.273.24.14679; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Furnsinn C, 1997, AM J PHYSIOL-ENDOC M, V273, pE514, DOI 10.1152/ajpendo.1997.273.3.E514; GARETTO LP, 1984, AM J PHYSIOL, V246, pE471, DOI 10.1152/ajpendo.1984.246.6.E471; GOODE N, 1992, J BIOL CHEM, V267, P16878; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; GOODYEAR LJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE987, DOI 10.1152/ajpendo.1995.268.5.E987; Halse R, 1999, J BIOL CHEM, V274, P776, DOI 10.1074/jbc.274.2.776; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Lund S, 1998, FEBS LETT, V425, P472, DOI 10.1016/S0014-5793(98)00293-2; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Murai H, 1996, FEBS LETT, V392, P153, DOI 10.1016/0014-5793(96)00806-X; SAKSELA K, 1992, ONCOGENE, V7, P347; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHERWOOD DJ, 1999, IN PRESS AM J PHYSL; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SKOGLUND G, 1985, EUR J BIOCHEM, V148, P407, DOI 10.1111/j.1432-1033.1985.tb08854.x; SOELDNER JS, 1965, DIABETES, V14, P771, DOI 10.2337/diab.14.12.771; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; WANG QM, 1994, J BIOL CHEM, V269, P14566; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WILLIAMS RS, 1999, HDB PHYSL 12, P1124; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x	52	107	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24896	24900		10.1074/jbc.274.35.24896	http://dx.doi.org/10.1074/jbc.274.35.24896			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455163	hybrid			2022-12-25	WOS:000082193400062
J	Ulianich, L; Suzuki, K; Mori, A; Nakazato, M; Pietrarelli, M; Goldsmith, P; Pacifico, F; Consiglio, E; Formisano, S; Kohn, LD				Ulianich, L; Suzuki, K; Mori, A; Nakazato, M; Pietrarelli, M; Goldsmith, P; Pacifico, F; Consiglio, E; Formisano, S; Kohn, LD			Follicular thyroglobulin (TG) suppression of thyroid-restricted genes involves the apical membrane asialoglycoprotein receptor and TG phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-I; HEPATIC LECTIN-1 SUBUNIT; PROMOTER OKADAIC ACID; GROWTH-FACTOR-I; THYROTROPIN RECEPTOR; TUMOR PROMOTER; RAT; EXPRESSION; PROTEIN; CELLS	Follicular thyroglobulin (TG) decreases expression of the thyroid-restricted transcription factors, thyroid transcription factor (TTF)-1, TTF-2, and Pax-8, thereby suppressing expression of the sodium iodide symporter, thyroid peroxidase, TG, and thyrotropin receptor genes (Suzuki, K., Lavaroni, S., Mori, A., Ohta, M., Saito, J., Pietrarelli, M., Singer, D. S., Kimura, S., Katoh, R., Kawaoi, A., and Kohn, L, D. (1997) Proc. Natl. Acad. Sci. U. S. A. 95, 8251-8256). The ability of highly purified 27, 19, or 12 S follicular TG to suppress thyroid-restricted gene expression correlates with their ability to bind to FRTL-5 thyrocytes and is inhibited by a specific antibody to the thyroid apical membrane asialoglycoprotein receptor (ASGPR), which is related to the ASGPR of liver cells. Phosphorylating serine/threonine residues of TG, by autophosphorylation or protein kinase A, eliminates TG suppression and enhances transcript levels of the thyroid-restricted genes 2-fold in the absence of a change in TG binding to the ASGPR. Follicular TG suppression of thyroid-restricted genes is thus mediated by the ASPGR on the thyrocyte apical membrane and regulated by a signal system wherein phosphorylation of serine/threonine residues on the bound ligand is an important component. These data provide a hitherto unsuspected role for the ASGPR in transcriptional signaling, aside from its role in endocytosis. They establish a functional role for phosphorylated serine/threonine residues on the TG molecule.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; Federico II Med Sch, CNR, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Federico II Med Sch, Dipartimento Biol & Patol Cellulare & Mol L Calif, I-80131 Naples, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II	Kohn, LD (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 9C101B, Bethesda, MD 20892 USA.		Ulianich, Luca/ABD-2530-2020; Pacifico, Francesco/AAX-3958-2020; Suzuki, Koichi/C-4177-2013	Pacifico, Francesco/0000-0001-9563-3596; Suzuki, Koichi/0000-0001-8659-4660				ALVINO CG, 1995, ENDOCRINOLOGY, V136, P3179, DOI 10.1210/en.136.8.3179; Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; Baptist M, 1991, Thyroidology, V3, P109; CONSIGLIO E, 1981, J BIOL CHEM, V256, P592; CONSIGLIO E, 1987, J BIOL CHEM, V262, P10304; CONSIGLIO E, 1979, J BIOL CHEM, V254, P5065; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DUNN JT, 1996, THYROID, P85; EGGO MC, 1983, CAN J BIOCHEM CELL B, V61, P662, DOI 10.1139/o83-084; Endo T, 1997, MOL ENDOCRINOL, V11, P1747, DOI 10.1210/me.11.11.1747; FALLON RJ, 1988, J BIOL CHEM, V263, P13159; FIELD JB, 1986, WERNERS THYROID FUND, P288; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GEFFEN I, 1992, INT REV CYTOL, V137B, P181; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HAYNES PA, 1994, J BIOL CHEM, V269, P33146; HAYNES PA, 1994, J BIOL CHEM, V269, P33152; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HERZOG V, 1987, EMBO J, V6, P5555; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; KARAKI H, 1989, BRIT J PHARMACOL, V98, P590, DOI 10.1111/j.1476-5381.1989.tb12633.x; Kohn L D, 1995, Vitam Horm, V50, P287, DOI 10.1016/S0083-6729(08)60658-5; KOHN LD, 1989, ADV EXP MED BIOL, V261, P151; KOHN LD, 1985, PROGR ENDOCRINE RES, V2, P171; KOHN LD, 1986, Patent No. 4609622; MIZUNO K, 1991, MOL CELL BIOL, V11, P4927, DOI 10.1128/MCB.11.10.4927; Ohno M, 1999, MOL CELL BIOL, V19, P2051; Ortiz L, 1997, J BIOL CHEM, V272, P23334, DOI 10.1074/jbc.272.37.23334; PACIFICO F, 1995, BIOCHEM BIOPH RES CO, V210, P138, DOI 10.1006/bbrc.1995.1638; PAULSON JC, 1977, J BIOL CHEM, V252, P8624; Poleev A, 1997, EUR J BIOCHEM, V247, P860, DOI 10.1111/j.1432-1033.1997.00860.x; REDPATH NT, 1989, BIOCHEM J, V262, P69, DOI 10.1042/bj2620069; Salvatore G, 1973, HORMONAL PROTEINS PE, P201; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; Schwartz A L, 1991, Targeted Diagn Ther, V4, P3; SCHWARTZ AL, 1984, BIOCHEM J, V223, P481, DOI 10.1042/bj2230481; SHIFRIN S, 1981, J BIOL CHEM, V256, P600; SHIMURA H, 1995, MOL ENDOCRINOL, V9, P527, DOI 10.1210/me.9.5.527; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; SPIRO MJ, 1986, ENDOCRINOLOGY, V119, P1146, DOI 10.1210/endo-119-3-1146; STEER CJ, 1986, PROG LIVER DIS, V8, P99; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; STUDER H, 1989, ENDOCR REV, V10, P125, DOI 10.1210/edrv-10-2-125; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Suzuki K, 1999, ACTA HISTOCHEM CYTOC, V32, P111, DOI 10.1267/ahc.32.111; Suzuki K, 1999, THYROID, V9, P319, DOI 10.1089/thy.1999.9.319; Suzuki K, 1998, P NATL ACAD SCI USA, V95, P8251, DOI 10.1073/pnas.95.14.8251; SUZUKI K, 1992, ACTA HISTOCHEM CYTOC, V25, P13, DOI 10.1267/ahc.25.13; SUZUKI K, 1999, IN PRESS ENDOCRINOLO; TAKAHASHI T, 1985, BIOCHEM BIOPH RES CO, V126, P1054, DOI 10.1016/0006-291X(85)90292-X; VANDENHOVE MF, 1982, EUR J BIOCHEM, V122, P415; VanRenterghem P, 1996, BBA-GENE STRUCT EXPR, V1307, P97, DOI 10.1016/0167-4781(96)00018-8; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEIGEL PH, 1993, ENDOCYTIC COMPONENTS, P125; YAMAMOTO K, 1988, ACTA HISTOCHEM CYTOC, V21, P455, DOI 10.1267/ahc.21.455; YAMAMOTO K, 1985, BIOCHIM BIOPHYS ACTA, V838, P84, DOI 10.1016/0304-4165(85)90253-3; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	59	51	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					25099	25107		10.1074/jbc.274.35.25099	http://dx.doi.org/10.1074/jbc.274.35.25099			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455190	hybrid			2022-12-25	WOS:000082193400089
J	Okada, K; Wangpoengtrakul, C; Osawa, T; Toyokuni, S; Tanaka, K; Uchida, K				Okada, K; Wangpoengtrakul, C; Osawa, T; Toyokuni, S; Tanaka, K; Uchida, K			4-hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress - Identification of proteasomes as target molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-CELL CARCINOMA; MEMBRANE LIPID-PEROXIDATION; HEMOGLOBIN-ALPHA-CHAINS; AMYLOID BETA-PEPTIDE; FERRIC NITRILOTRIACETATE; MULTICATALYTIC PROTEINASE; ALDEHYDIC PRODUCT; 4-HYDROXYNONENAL PROTEIN; UBIQUITIN; INVOLVEMENT	Oxidative stress is associated with important pathophysiological events in a variety of diseases. It has been postulated that free radicals and lipid peroxidation products generated during the process may be responsible for these effects because of their ability to damage cellular components such as membranes, proteins, and DNA, In the present study, we provide evidence that oxidative stress causes a transient impairment of intracellular proteolysis via covalent binding of 4-hydroxy-2-nonenal (HNE), a major end product of lipid peroxidation, to proteasomes. A single intraperitoneal treatment with the renal carcinogen, ferric nitrilotriacetate, caused oxidative stress, as monitored by accumulation of lipid peroxidation products and 8-hydroxy-2'-deoxyguanosine, in the kidney of mice. In addition, transient accumulation of HNE-modified proteins in the kidney was also found by competitive enzyme-linked immunosorbent assay and immunohistochemical analyses. This and the observation that the HNE-modified proteins were significantly ubiquitinated suggested a crucial role of proteasomes in the metabolism of HNE-modified proteins. In vitro incubation of the kidney homogenates with HNE indeed resulted in a transient accumulation of HNE-modified proteins, whereas the proteasome inhibitor significantly suppressed the time-dependent elimination of HNE-modified proteins. We found that, among three proteolytic activities (trypsin, chymotrypsin, and peptidylglutamyl peptide hydrolase activities) of proteasomes, both trypsin and peptidylglutamyl peptide hydrolase activities in the kidney were transiently diminished in accordance with the accumulation of HNE-modified proteins during oxidative stress. The loss of proteasome activities was partially ascribed to the direct attachment of HNE to the protein, based on the detection of HNE-proteasome conjugates by an immunoprecipitation technique. These results suggest that HNE may contribute to the enhanced accumulation of oxidatively modified proteins via an impairment of ubiquitin/proteasome-dependent intracellular proteolysis.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 606, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 113, Japan	Nagoya University; Kyoto University; Tokyo Metropolitan Institute of Medical Science	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.		Toyokuni, Shinya/C-1358-2010; Toyokuni, Shinya/ABE-7714-2021	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109; Uchida, Koji/0000-0003-3894-5299				AGARWAL S, 1994, ARCH BIOCHEM BIOPHYS, V309, P24, DOI 10.1006/abbi.1994.1078; Ando Y, 1998, J NEUROL SCI, V156, P172, DOI 10.1016/S0022-510X(98)00042-2; Ando Y, 1997, BIOCHEM BIOPH RES CO, V232, P497, DOI 10.1006/bbrc.1996.5997; Blanc EM, 1997, J NEUROCHEM, V69, P570; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; Conconi M, 1997, MOL BIOL REP, V24, P45, DOI 10.1023/A:1006852506884; DAVIES KJA, 1993, BIOCHEM SOC T, V21, P346, DOI 10.1042/bst0210346; EBINA Y, 1986, J NATL CANCER I, V76, P107; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1976, TETRAHEDRON, V32, P285, DOI 10.1016/0040-4020(76)87015-9; ESTERBAUER H, 1975, Z NATURFORSCH C, V30, P466; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAMAZAKI S, 1986, AM J PATHOL, V123, P343; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Itakura K, 1998, J ORG CHEM, V63, P185, DOI 10.1021/jo971239+; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JL, 1987, CANCER RES, V47, P1867; Mark RJ, 1997, J NEUROSCI, V17, P1046; Mark RJ, 1997, J NEUROCHEM, V68, P255; MASAKI N, 1989, ARCH BIOCHEM BIOPHYS, V269, P390, DOI 10.1016/0003-9861(89)90122-7; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; Mattson MP, 1997, NEUROREPORT, V8, P2275, DOI 10.1097/00001756-199707070-00036; Morikawa S, 1997, BIOCHEM MOL BIOL INT, V41, P767; Okada S., 1982, JPN ARCH INTERN MED, V29, P485; OKAMOTO K, 1994, INT J CANCER, V58, P825, DOI 10.1002/ijc.2910580613; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; SAYRE LM, 1993, CHEM RES TOXICOL, V6, P19, DOI 10.1021/tx00031a002; Sayre LM, 1997, J NEUROCHEM, V68, P2092; SCHAUENSTEIN E, 1971, MONATSH CHEM, V102, P517, DOI 10.1007/BF00909348; SHAEFFER JR, 1988, J BIOL CHEM, V263, P13663; SHAEFFER JR, 1983, J BIOL CHEM, V258, P3172; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TAYLOR A, 1993, J AM COLL NUTR, V12, P138; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; TOYOKUNI S, 1995, FEBS LETT, V359, P189, DOI 10.1016/0014-5793(95)00033-6; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6; Toyokuni S, 1997, LAB INVEST, V76, P365; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; UCHIDA K, 1995, ARCH BIOCHEM BIOPHYS, V317, P405, DOI 10.1006/abbi.1995.1181; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P5611, DOI 10.1073/pnas.89.12.5611; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696	57	278	282	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23787	23793		10.1074/jbc.274.34.23787	http://dx.doi.org/10.1074/jbc.274.34.23787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446139	hybrid			2022-12-25	WOS:000082110900018
J	Shen, ZW; Batzer, A; Koehler, JA; Polakis, P; Schlessinger, J; Lydon, NB; Moran, MF				Shen, ZW; Batzer, A; Koehler, JA; Polakis, P; Schlessinger, J; Lydon, NB; Moran, MF			Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src	ONCOGENE			English	Article						p68; SH3; Src; kinase	FAMILY TYROSINE KINASES; C-SRC; PROTEIN; MITOSIS; RNA; P62; PURIFICATION; ASSOCIATION; SH2-DOMAIN; PEPTIDES	Sam68 is a 68 kDa protein that associates with and is phosphorylated by the c-Src kinase at mitosis. It contains a KH domain implicated in RNA binding and several proline-rich motifs that resemble known SH3 binding sites. The SH3 domains of c-Src, phosphatidylinositol 3-OH kinase, phospholipase C-gamma and Grb2 protein (containing two SH3 domains), but not other SH3 domains tested, were capable of binding Sam68 in vitro. Synthetic peptides corresponding to the proline motifs of Sam68 inhibited with different efficiencies the binding of SH3 domains to Sam68 suggesting that the proline motifs of Sam68 function as specific SH3 domain binding sites. Mutation of Sam68 SH3 binding sites further indicated that the SRC SH3 domain mediates binding of Src to unphosphorylated Sam68. Phosphorylation of Sam68 by Src kinase was inhibited when the Src SH3 binding site of Sam68 was mutated or when corresponding peptides were added to in vitro kinase reactions indicating that binding of the Src SH3 domain to a specific site near the amino-terminus of Sam68 (including residues 38-45: PPLPHRSR) facilitates phosphorylation of Sam68 by the Src kinase domain. Sam68-based proline peptides had no effect on the phosphorylation of another in vitro substrate of Src, enolase. These results suggest that Src effectively mounts Sam68 through its SH3 domain, possibly as a mechanism to position the kinase domain close to substrate tyrosine residues in the carboxyl-half of the protein.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON, Canada; Univ Toronto, Dept Med & Mol Genet, Toronto, ON, Canada; NYU, Dept Pharmacol, New York, NY 10016 USA; ONYX Pharmaceut, Richmond, CA USA; Kinetix Pharmaceut Inc, Medford, MA USA	University of Toronto; University of Toronto; New York University	Moran, MF (corresponding author), Hoechst Marion Roussel Deutschland GMBH, DG Rheumatol, H528,Postfach 35 40, D-65174 Wiesbaden, Germany.		Moran, Michael/GYD-3631-2022					BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LYDON NB, 1992, BIOCHEM J, V287, P985, DOI 10.1042/bj2870985; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STONE JC, 1991, METHOD ENZYMOL, V200, P673; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	30	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4647	4653		10.1038/sj.onc.1203079	http://dx.doi.org/10.1038/sj.onc.1203079			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467411				2022-12-25	WOS:000082154400001
J	Abbaszade, I; Liu, RQ; Yang, F; Rosenfeld, SA; Ross, OH; Link, JR; Ellis, DM; Tortorella, MD; Pratta, MA; Hollis, JM; Wynn, R; Duke, JL; George, HJ; Hillman, MC; Murphy, K; Wiswall, BH; Copeland, RA; Decicco, CP; Bruckner, R; Nagase, H; Itoh, Y; Newton, RC; Magolda, RL; Trzaskos, JM; Hollis, GF; Arner, EC; Burn, TC				Abbaszade, I; Liu, RQ; Yang, F; Rosenfeld, SA; Ross, OH; Link, JR; Ellis, DM; Tortorella, MD; Pratta, MA; Hollis, JM; Wynn, R; Duke, JL; George, HJ; Hillman, MC; Murphy, K; Wiswall, BH; Copeland, RA; Decicco, CP; Bruckner, R; Nagase, H; Itoh, Y; Newton, RC; Magolda, RL; Trzaskos, JM; Hollis, GF; Arner, EC; Burn, TC			Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER CELLS; NEUTROPHIL COLLAGENASE MMP-8; HUMAN ARTICULAR-CARTILAGE; NECROSIS-FACTOR-ALPHA; HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; METALLOPROTEINASE-DISINTEGRIN; BINDING PEPTIDES; HEPARIN-BINDING; CYSTEINE SWITCH	Aggrecan is responsible for the mechanical properties of cartilage. One of the earliest changes observed in arthritis is the depletion of cartilage aggrecan due to increased proteolytic cleavage within the interglobular domain. Two major sites of cleavage have been identified in this region at Asn(341)-Phe(342) and Glu(373)-Ala(374) While several matrix metalloproteinases have been shown to cleave at Asn(341)-Phe(342), an as yet unidentified protein termed "aggrecanase" is responsible for cleavage at Glu(373)-Ala(374) and is hypothesized to play a pivotal role in cartilage damage. We have identified and cloned a novel disintegrin metalloproteinase with thrombospondin motifs that possesses aggrecanase activity, ADAMTS11 (aggrecanase-2), which has extensive homology to ADAMTS4 (aggrecanase-1) and the inflammation-associated gene ADAMTS1, ADAMTS11 possesses a number of conserved domains that have been shown to play a role in integrin binding, cell-cell interactions, and extracellular matrix binding. We have expressed recombinant human ADAMTS11 in insect cells and shown that it cleaves aggrecan at the Glu(373)-Ala(374) site, with the cleavage pattern and inhibitor profile being indistinguishable from that observed with native aggrecanase, A comparison of the structure and expression patterns of ADAMTS11, ADAMTS4, and ADAMTS1 is also described. Our findings will facilitate the study of the mechanisms of cartilage degradation and provide targets to search for effective inhibitors of cartilage depletion in arthritic disease.	Dupont Merck Pharmaceut Co, Expt Stn, Dept Appl Biotechnol, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Expt Stn, Dept Inflammatory Dis Branch, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Expt Stn, Dept Chem Enzymol, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Expt Stn, Dept Chem & Phys Sci, Wilmington, DE 19880 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	DuPont; DuPont; DuPont; DuPont; University of Kansas; University of Kansas Medical Center	Burn, TC (corresponding author), Dupont Merck Pharmaceut Co, Expt Stn, Dept Appl Biotechnol, E336-237B,POB 336, Wilmington, DE 19880 USA.	Timothy.C.Burn@dupontpharma.com		Burn, Timothy/0000-0001-6648-4333; Itoh, Yoshifumi/0000-0002-2128-2823				ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Arner EC, 1997, J BIOL CHEM, V272, P9294; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; Bryson H, 1998, ARCH BIOCHEM BIOPHYS, V355, P15, DOI 10.1006/abbi.1998.0696; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CAMPION C, 1989, Patent No. 01399; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; ILIC MZ, 1995, ARCH BIOCHEM BIOPHYS, V322, P22, DOI 10.1006/abbi.1995.1431; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; Jia LG, 1996, TOXICON, V34, P1269, DOI 10.1016/S0041-0101(96)00108-0; Jia LG, 1997, J BIOL CHEM, V272, P13094, DOI 10.1074/jbc.272.20.13094; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; PRATTA MA, 1997, T ORTHOP RES SOC, V22, P453; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; SALTER DM, 1992, BRIT J RHEUMATOL, V31, P231; Sandy JD, 1995, ACTA ORTHOP SCAND, V66, P26, DOI 10.3109/17453679509157643; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1991, J BIOL CHEM, V266, P8198; Shimokawa KI, 1996, ARCH BIOCHEM BIOPHYS, V335, P283, DOI 10.1006/abbi.1996.0509; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; XUE CB, 1997, Patent No. 9718207; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	58	405	440	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23443	23450		10.1074/jbc.274.33.23443	http://dx.doi.org/10.1074/jbc.274.33.23443			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438522	hybrid			2022-12-25	WOS:000082012800072
J	Miyatake, H; Mukai, M; Adachi, S; Nakamura, H; Tamura, K; Iizuka, T; Shiro, Y; Strange, RW; Hasnain, SS				Miyatake, H; Mukai, M; Adachi, S; Nakamura, H; Tamura, K; Iizuka, T; Shiro, Y; Strange, RW; Hasnain, SS			Iron coordination structures of oxygen sensor FixL characterized by FeK-edge extended x-ray absorption fine structure and resonance Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CURVED-WAVE THEORY; RHIZOBIUM-MELILOTI; KINASE-ACTIVITY; 2-COMPONENT REGULATORS; SIGNAL-TRANSDUCTION; EXAFS CALCULATIONS; LIGAND-BINDING; CO-MYOGLOBINS; HEME PROTEIN; NITRIC-OXIDE	FixL is a heme-based O-2 sensor protein involved in a two-component system of a symbiotic bacterium, In the present study, the iron coordination structure in the heme domain of Rhizobium meliloti FixLT (RmFixLT, a soluble truncated FixL) was examined using Fe K-edge extended x-ray absorption fine structure (EXAFS) and resonance Raman spectroscopic techniques. In the EXAFS analyses, the interatomic distances and angles of the Fe-ligand bond and the iron displacement from the heme plane were obtained for RmFixLT in the Fe2+, Fe2+O2, Fe2+CO, Fe3+, Fe3+F-, and Fe3+CN- states. An apparent correlation was found between the heme-nitrogen (proximal His-194) distance in the heme domain and the phosphorylation activity of the histidine kinase domain. Comparison of the Fe-CO coordination geometry between RmFixLT and RmFixLH (heme domain of RmFixL), based on the EXAFS and Raman results, has suggested that the kinase domain directly or indirectly influences steric interaction between the iron-bound ligand and the heme pocket. Referring to the crystal structure of the heme domain of Bradyrhizobium japonicum FixL (Gong, W., Hao, B., Mansy, S. S., Gonzalez, G., Gilles-Gonzalez, M. A., and Chan, M. K. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 15177-15182), we discussed details of the iron coordination structure of RmFixLT and RmFixLH in relation to an intramolecular signal transduction mechanism in its O-2 sensing.	RIKEN Harima Inst, Inst Phys & Chem Res, Sayo, Hyogo 6795143, Japan; SERC, Daresbury Lab, Warrington WA4 4AD, Cheshire, England	RIKEN; STFC Daresbury Laboratory	Shiro, Y (corresponding author), RIKEN Harima Inst, Inst Phys & Chem Res, Mikazuki Cho, Sayo, Hyogo 6795143, Japan.		Shiro, Yoshitsugu Y/J-3757-2014	Shiro, Yoshitsugu Y/0000-0003-0695-8327; Adachi, Shin-ichi/0000-0002-3676-1165				Aime S, 1996, BIOPHYS J, V70, P482, DOI 10.1016/S0006-3495(96)79593-0; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; BINSTED N, 1991, EXCURV92 SERV; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; DEATHERAGE JF, 1976, J MOL BIOL, V104, P723, DOI 10.1016/0022-2836(76)90131-5; FISCHER HM, 1994, MICROBIOL REV, V58, P352, DOI 10.1128/MMBR.58.3.352-386.1994; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; GALINIER A, 1994, J BIOL CHEM, V269, P23784; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027; GILLESGONZALEZ MA, 1993, J BIOL CHEM, V268, P16293; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; GURMAN SJ, 1984, J PHYS C SOLID STATE, V17, P143, DOI 10.1088/0022-3719/17/1/019; GURMAN SJ, 1986, J PHYS C SOLID STATE, V19, P1845, DOI 10.1088/0022-3719/19/11/021; HASNAIN SS, 1990, RECENT ADV XAFS DATA, P104; Hedin L., 1969, SOLID STATE PHYS, V23, P1, DOI [10.1016/S0081-1947(08)60615-3, DOI 10.1016/S0081-1947(08)60615-3]; HILL S, 1988, FEMS MICROBIOL LETT, V54, P111; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LOIS AF, 1993, J BACTERIOL, V175, P1103, DOI 10.1128/JB.175.4.1103-1109.1993; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Mansy SS, 1998, BIOCHEMISTRY-US, V37, P12452, DOI 10.1021/bi980516j; MICHEL D, 1988, CELL, V54, P671; Miyatake H, 1999, ACTA CRYSTALLOGR D, V55, P1215, DOI 10.1107/S0907444999004047; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; MORRELL C, 1989, EXBACK EXAFS USERS M; Nakamura H, 1998, BIOCHEM BIOPH RES CO, V247, P427, DOI 10.1006/bbrc.1998.8694; Nakashima S, 1998, CHEM PHYS, V228, P323, DOI 10.1016/S0301-0104(97)00353-4; NOMURA M, 1998, 984 KEK; NOMURA M, 1996, 9515 KEK; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PERTZU MF, 1970, NATURE, V228, P726; POWERS L, 1994, SYNCHROTRON RADIATION IN THE BIOSCIENCES, P302; Rodgers KR, 1996, BIOCHEMISTRY-US, V35, P9539, DOI 10.1021/bi9530853; SCHEIDT WR, 1982, IRON PORPHYRIN, V2, P89; SHIRO Y, 1990, J AM CHEM SOC, V112, P2921, DOI 10.1021/ja00164a012; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STRYER L, 1964, J MOL BIOL, V8, P96, DOI 10.1016/S0022-2836(64)80152-2; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; Winkler WC, 1996, CHEM BIOL, V3, P841, DOI 10.1016/S1074-5521(96)90070-8; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123; YU NT, 1983, BIOCHEMISTRY-US, V22, P4534, DOI 10.1021/bi00288a028; YU NT, 1988, BIOL APPL RAMAN SPEC, V3, P40; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	53	55	56	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23176	23184		10.1074/jbc.274.33.23176	http://dx.doi.org/10.1074/jbc.274.33.23176			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438488	hybrid			2022-12-25	WOS:000082012800038
J	Wu, SY; Thomas, MC; Hou, SY; Likhite, V; Chiang, CM				Wu, SY; Thomas, MC; Hou, SY; Likhite, V; Chiang, CM			Isolation of mouse TFIID and functional characterization of TBP and TFIID in mediating estrogen receptor and chromatin transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; CELL-FREE SYSTEM; HISTONE-LIKE TAFS; ACTIVATED TRANSCRIPTION; IN-VITRO; EUKARYOTIC TRANSCRIPTION; PROMOTER SELECTIVITY; GENE-TRANSCRIPTION; ACETYLASE COMPLEX	TFIID is a general transcription factor required for the assembly of the transcription machinery on most eukaryotic promoters transcribed by RNA polymerase II. Although the TATA-binding subunit (TBP) of TFIID is able to support core promoter and activator-dependent transcription under some circumstances, the roles of TBP-associated factors (TAF(II)s) in TFIID-mediated activation remain unclear. To define the evolutionarily conserved function of TFIID and to elucidate the roles of TAF(II)s in gene activation, we have cloned the mouse TAF(II)55 subunit of TFIID and further isolated mouse TFIID from a murine FM3A-derived cell line that constitutively expresses FLAG-tagged mouse TAF(II)55. Both mouse and human TFIIDs are capable of mediating transcriptional activation by Ga14 fusions containing different activation domains in a highly purified human cell-free transcription system devoid of TFIIA and Mediator. Although TAF(II)-independent activation by Ga14-VP16 can also be observed in this highly purified human transcription system with either mouse or yeast TBP, TAF(II)s are strictly required for estrogen receptor-mediated activation independently of the core promoter sequence. In addition, TAF(II)s are necessary for transcription from a preassembled chromatin template. These findings clearly demonstrate an essential role of TAF(II)s as a transcriptional coactivator for estrogen receptor and in chromatin transcription.	Univ Illinois, Dept Biochem, Roger Adams Lab 430, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Chiang, CM (corresponding author), Univ Illinois, Dept Biochem, Roger Adams Lab 430, 600 S Mathews Ave, Urbana, IL 61801 USA.							Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHIANG CM, 1993, PEPTIDE RES, V6, P62; CORMACK BP, 1994, GENE DEV, V8, P1335, DOI 10.1101/gad.8.11.1335; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; Kershnar E, 1998, J BIOL CHEM, V273, P34444, DOI 10.1074/jbc.273.51.34444; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; Lavigne AC, 1996, J BIOL CHEM, V271, P19774, DOI 10.1074/jbc.271.33.19774; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Olave I, 1998, GENE DEV, V12, P1621, DOI 10.1101/gad.12.11.1621; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Sabbah M, 1998, BIOCHEM J, V336, P639, DOI 10.1042/bj3360639; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Sambrook J., 2002, MOL CLONING LAB MANU; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Song WJ, 1998, EMBO J, V17, P5757, DOI 10.1093/emboj/17.19.5757; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Wu SY, 1996, BIOTECHNIQUES, V21, P718; Wu SY, 1998, J BIOL CHEM, V273, P12492, DOI 10.1074/jbc.273.20.12492; Wu SY, 1998, EMBO J, V17, P4478, DOI 10.1093/emboj/17.15.4478; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	99	37	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23480	23490		10.1074/jbc.274.33.23480	http://dx.doi.org/10.1074/jbc.274.33.23480			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438527	hybrid			2022-12-25	WOS:000082012800077
J	Carter, PS; Jarquin-Pardo, M; De Benedetti, A				Carter, PS; Jarquin-Pardo, M; De Benedetti, A			Differential expression of Myc1 and Myc2 isoforms in cells transformed by eIF4E: evidence for internal ribosome repositioning in the human c-myc 5 ' UTR	ONCOGENE			English	Article						translation initiation factor 4E; c-myc expression; internal ribosome repositioning; oncogenic transformation; alternate start-codon selection	INITIATION-FACTOR 4G; 5' NONCODING REGION; PROTEIN-SYNTHESIS; MESSENGER-RNA; BURKITT-LYMPHOMA; TRANSLATIONAL INITIATION; EUKARYOTIC RIBOSOMES; SECONDARY STRUCTURE; AUG CODONS; ONCOGENE	eIF4E is essential for translation initiation, but its overexpression causes malignant transformation. Recent work demonstrated that eIF4E/F participates in exposing and locating alternate translation start codons during scanning. Translation initiation of several important protooncogenes and growth-regulators, such as Myc and FGF-2, can start at CUG start codon(s) upstream of the normal open reading frame (ORF), The resulting amino-terminal extension alters the properties of these proteins and their intracellular distribution, In cells overexpressing eIF4E, c-myc is overexpressed and particularly the larger, CUG-initiated form (Myc1), Recent reports suggest that synthesis of Myc2, the normally expressed AUG-initiated form, is mediated by an IRES. To determine,what role eIF4E might play in c-myc expression, the c-myc 5' untranslated region (UTR) was fused in-frame to CAT reporters, and several more derivative constructs were made. In vitro translation experiments (with and without eIF4E/F); expression in CHO cells transformed with eIF4E; and deletion/mutation analysis demonstrated that Myc1 is translated by a scanning mechanism, while Myc2 is translated by Internal Ribosome Repositioning. Moreover, the existence of a true IRES in the 5'UTR was contradicted by its failure to direct translation of a circular transcript, in contrast to hsp70, The c-myc 5'UTR also failed to engage in translation in the absence of functional eIF4F, after cleavage of the eIF4G component with CVB4 protease-2A, The Internal Repositioning Element (IRPE) in c-myc 5'UTR was delimited to nucleotides (nt) 394-440 from the P1 transcription start site.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	De Benedetti, A (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.			de benedetti, arrigo/0000-0002-4198-8647	NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER; NCI NIH HHS [CA69148-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Borman AM, 1997, VIROLOGY, V237, P129, DOI 10.1006/viro.1997.8761; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; CLEMENS MJ, 1987, TRANSCRIPTION TRANSL, P263; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Fraser SD, 1996, ONCOGENE, V12, P1223; FUTTERER J, 1993, TIBS, V22, P177; GANDORI C, 1997, TIBS, V22, P177; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P7; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; Kevil C, 1995, ONCOGENE, V11, P2339; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; Lamphear BJ, 1996, BIOCHEMISTRY-US, V35, P15726, DOI 10.1021/bi961864t; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; LAZARUS P, 1992, ONCOGENE, V7, P1037; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nathan CA, 1997, ONCOGENE, V15, P1087, DOI 10.1038/sj.onc.1201272; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; Paulin FEM, 1996, ONCOGENE, V13, P505; Paus R, 1993, Exp Dermatol, V2, P3, DOI 10.1111/j.1600-0625.1993.tb00192.x; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Reddy KS, 1997, CANCER GENET CYTOGEN, V95, P206, DOI 10.1016/S0165-4608(96)00424-4; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; West MJ, 1995, ONCOGENE, V11, P2515; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; ZUKER M, 1989, METHOD ENZYMOL, P262	42	39	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4326	4335		10.1038/sj.onc.1202890	http://dx.doi.org/10.1038/sj.onc.1202890			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439040				2022-12-25	WOS:000081732700005
J	Iwamoto, R; Handa, K; Mekada, E				Iwamoto, R; Handa, K; Mekada, E			Contact-dependent growth inhibition and apoptosis of epidermal growth factor (EGF) receptor-expressing cells by the membrane-anchored form of heparin-binding EGF-like growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; KIT-LIGAND; SIGNAL TRANSDUCTION; VERO CELLS; ALPHA; PROLIFERATION; TRANSMEMBRANE; JUXTACRINE; PRECURSOR; MUTATION	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) transduces mitogenic signals through the EGF receptor (EGFR). There are two forms of HB-EGF, the membrane-anchored form (pro-HB-EGF) and the soluble form (sHB-EGF), We studied the biological activity of pro-HB-EGF by using a model in which pro-HB-EGF-expressing effector cells was co-cultured with EGFR-expressing target cells. The DER cell, an EGFR-expressing derivative of the interleukin-3-dependent hematopoietic 32D cell line, grows well in the presence of EGF or sHB-EGF without IL-3, When DER cells were co-cultured on a monolayer of Vero-H cells overexpressing pro-HB-EGF, growth inhibition and subsequent apoptosis were induced in the DER cells even in the presence of excess amounts of EGF or sHB-EGF, Such growth inhibition of DER cells was abrogated when specific antagonists for pro-HB-EGF were added in the culture medium or when direct contact of DER cells with Vero-H cells was prevented, indicating that pro-HB-EGF is involved in this inhibitory effect. Pro-HB-EGF-induced apoptosis of DER cells was also observed even in the presence of IL-3. This rules out the possibility of simple competition between soluble EGFR ligands and pro-HB-EGF. Moreover, 32D cells expressing EGFR mutant composed of the extracellular and the transmembrane domain of EGFR and the cytoplasmic domain of erythropoietin receptor did not undergo apoptosis by co-culture with Vero-H cells, indicating that the inhibitory signal induced by pro-HB-EGF-expressing Vero-H cells is mediated to DER cells via EGFR and that the cytoplasmic domain of EGFR is essential for pro-HB-EGF-induced apoptosis, From these results, we concluded that pro-HB-EGF has unique biological activity through cell-cell contact that is distinct from the activity of sHB-EGF.	Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Ctr Innovat Canc Res, Kurume, Fukuoka 8390861, Japan; Japan Sci & Technol Corp, PRESTO, Kyoto 6190237, Japan	Kurume University; Kurume University; Japan Science & Technology Agency (JST)	Mekada, E (corresponding author), Kurume Univ, Inst Life Sci, 2432-8 Aikawa, Kurume, Fukuoka 8390861, Japan.			Mekada, Eisuke/0000-0001-8858-4781				ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CHEN CY, 1995, ONCOGENE, V11, P1487; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FUKASAWA K, 1995, ONCOGENE, V10, P1; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KOUPMAN G, 1994, BLOOD, V84, P1415; MEKADA E, 1985, J BIOL CHEM, V260, P2148; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; Miyoshi E, 1997, J BIOL CHEM, V272, P14349, DOI 10.1074/jbc.272.22.14349; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; SHISHIDO Y, 1995, J BIOL CHEM, V270, P29578, DOI 10.1074/jbc.270.49.29578; Sung Kyung Jeh, 1997, Journal of Dermatology (Tokyo), V24, P427; Tajima Y, 1998, J EXP MED, V187, P1451, DOI 10.1084/jem.187.9.1451; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Tower B B, 1980, Methods Enzymol, V70, P322; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; UMATA T, 1990, J BIOL CHEM, V265, P21940; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	37	82	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25906	25912		10.1074/jbc.274.36.25906	http://dx.doi.org/10.1074/jbc.274.36.25906			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464334	hybrid			2022-12-25	WOS:000082554200098
J	Roullet, JB; Spaetgens, RL; Burlingame, T; Feng, ZP; Zamponi, GW				Roullet, JB; Spaetgens, RL; Burlingame, T; Feng, ZP; Zamponi, GW			Modulation of neuronal voltage-gated calcium channels by farnesol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CA2+ CHANNELS; N-TYPE; SUBCELLULAR-DISTRIBUTION; ALPHA(1A) SUBUNITS; G-PROTEINS; CELLS; BRAIN; IDENTIFICATION; RECEPTOR	The modulation of presynaptic voltage-dependent calcium channels by classical second messenger molecules such as protein kinase C and G protein beta gamma subunits is well established and considered a key factor for the regulation of neurotransmitter release. However, little is known of other endogenous mechanisms that control the activity of these channels. Here, we demonstrate a unique modulation of N-type calcium channels by farnesol, a dephosphorylated intermediate of the mammalian mevalonate pathway, At micromolar concentrations, farnesol acts as a relatively non-discriminatory rapid open channel blocker of all types of high voltage-activated calcium channels, with a mild specificity for L-type channels. However, at 250 nM, farnesol induces an N-type channel-specific hyperpolarizing shift in channel availability that results in similar to 50% inhibition at a typical neuronal resting potential. Additional experiments demonstrated the presence of farnesol in the brain (rodents and humans) at physiologically relevant concentrations (100-800 pmol/g (wet weight)). Altogether, our results indicate that farnesol is a selective, high affinity inhibitor of N-type Ca2+ channels and raise the possibility that endogenous farnesol and the mevalonate pathway are implicated in neurotransmitter release through regulation of presynaptic voltage-gated Ca2+ channels.	Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada; Oregon Hlth Sci Univ, Dept Med Genet, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Div Nephrol Hypertens & Clin Pharmacol, Portland, OR 97201 USA; NeuroMed Technol Inc, Vancouver, BC V5Z 4C2, Canada	University of Calgary; Oregon Health & Science University; Oregon Health & Science University	Zamponi, GW (corresponding author), Univ Calgary, Dept Pharmacol & Therapeut, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Tuluc, Petronel/C-2527-2011	Zamponi, Gerald W./0000-0002-0644-9066				ADANY I, 1994, CANCER LETT, V79, P175, DOI 10.1016/0304-3835(94)90257-7; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bech-Hansen NT, 1998, NAT GENET, V19, P264, DOI 10.1038/947; Bentinger M, 1998, ARCH BIOCHEM BIOPHYS, V353, P191, DOI 10.1006/abbi.1998.0611; Bostedor RG, 1997, J BIOL CHEM, V272, P9197; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ERICSSON J, 1993, J BIOL CHEM, V268, P832; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FORSCHER P, 1986, J PHYSIOL-LONDON, V379, P131, DOI 10.1113/jphysiol.1986.sp016244; GOLDSTEIN JL, 1990, NATURE, V343, P426; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; HAUG JS, 1994, BBA-MOL CELL RES, V1223, P133, DOI 10.1016/0167-4889(94)90082-5; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Jackson S M, 1997, Subcell Biochem, V28, P1; KACZOROWSKI GJ, 1994, ION CHANNELS CARDIOV, P468; Lee JH, 1999, J NEUROSCI, V19, P1912; LEVIN MS, 1989, BIOCHIM BIOPHYS ACTA, V1003, P293, DOI 10.1016/0005-2760(89)90235-X; McCleskey Edwin W., 1994, Current Opinion in Neurobiology, V4, P304, DOI 10.1016/0959-4388(94)90090-6; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NESS GC, 1994, AM J MED GENET, V50, P355, DOI 10.1002/ajmg.1320500411; OBrien ML, 1996, CARCINOGENESIS, V17, P185, DOI 10.1093/carcin/17.2.185; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; REUTER H, 1995, NEURON, V14, P773, DOI 10.1016/0896-6273(95)90221-X; Roullet JB, 1997, J BIOL CHEM, V272, P32240, DOI 10.1074/jbc.272.51.32240; ROULLET JB, 1995, J CLIN INVEST, V96, P239, DOI 10.1172/JCI118027; Roullet JB, 1996, J CLIN INVEST, V97, P2384, DOI 10.1172/JCI118682; RUNQUIST M, 1995, J NEUROCHEM, V65, P2299; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; STEA A, 1994, P NATL ACAD SCI USA, V91, P10567; STEA A, 1995, HDB RECEPTORS CHANNE, P113; STRIESSNIG J, 1994, ION CHANNELS CARDIOV, P441; SWARTZ KJ, 1993, NEURON, V11, P302; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; Westfall D, 1997, BIOCHEM BIOPH RES CO, V230, P562, DOI 10.1006/bbrc.1996.6014; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Yokoyama CT, 1997, J NEUROSCI, V17, P6929; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1997, DRUG DEVELOP RES, V42, P131, DOI 10.1002/(SICI)1098-2299(199711/12)42:3/4<131::AID-DDR4>3.0.CO;2-R	54	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25439	25446		10.1074/jbc.274.36.25439	http://dx.doi.org/10.1074/jbc.274.36.25439			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464274	hybrid			2022-12-25	WOS:000082554200038
J	Pezet, A; Favre, H; Kelly, PA; Edery, M				Pezet, A; Favre, H; Kelly, PA; Edery, M			Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; ACTIVATION; PROTEIN; STAT5; ASSOCIATION; EXPRESSION; SOCS-3; KINASE; JAK2; MICE	Prolactin (PRL) has been shown to activate the cytoplasmic tyrosine kinase Janus kinase 2 (Jak2) and the subsequent recruitment of various signaling molecules including members of the signal transducer and activator of transcription family of transcription factors. Recently, an expanding family of cytokine-inducible inhibitors of signaling has been identified that initially included four members: suppressor of cytokine signaling (SOCS)-1, SOCS-2, SOCS-3, and cytokine-inducible src homology domain 2 (SH-2) proteins. The present study analyzes the role of these members in PRL signaling. Constitutive expression of SOCS-1 and SOCS-3 suppressed PRL-induced signal transducer and activator of transcription B-dependent gene transcription, and Jak2 tyrosine kinase activity was greatly reduced in the presence of SOCS-1 or SOCS-3. SOCS-1 was shown to associate with Jak2, whereas SOCS-2 was associated with the prolactin receptor. Co-transfection studies were conducted to further analyze the interactions of SOCS proteins. SOCS-2 was shown to suppress the inhibitory effect of SOCS-1 by restoring Jak2 kinase activity but did not affect the inhibitory effect of SOCS-3 on PRL signaling. Northern blot analysis revealed that SOCS-3 and SOCS-1 genes were transiently expressed in response to PRL, both in vivo and in vitro, whereas the expression of SOCS-2 and CIS genes was still elevated 24 h after hormonal stimulation. We thus propose that the early expressed SOCS genes (SOCS-1 and SOCS-3) switch off PRL signaling and that the later expressed SOCS-2 gene can restore the sensitivity of cells to PRL, partly by suppressing the SOCS-1 inhibitory effect.	Fac Med Necker Enfants Malad, INSERM, U344, F-75730 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Edery, M (corresponding author), Fac Med Necker Enfants Malad, INSERM, U344, 156 Rue Vaugirard, F-75730 Paris 15, France.							Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Berchtold S, 1998, MOL ENDOCRINOL, V12, P556, DOI 10.1210/me.12.4.556; Berlanga JJ, 1997, J BIOL CHEM, V272, P2050; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Helman D, 1998, FEBS LETT, V441, P287, DOI 10.1016/S0014-5793(98)01555-5; Martini JF, 1997, J BIOL CHEM, V272, P18951, DOI 10.1074/jbc.272.30.18951; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Pezet A, 1997, J BIOL CHEM, V272, P25043, DOI 10.1074/jbc.272.40.25043; Pezet A, 1997, MOL CELL ENDOCRINOL, V129, P199, DOI 10.1016/S0303-7207(97)00063-4; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Starr R, 1998, INT J BIOCHEM CELL B, V30, P1081, DOI 10.1016/S1357-2725(98)00067-3; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; Yoshimura A, 1998, CYTOKINE GROWTH F R, V9, P197, DOI 10.1016/S1359-6101(98)00019-7; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	26	154	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24497	24502		10.1074/jbc.274.35.24497	http://dx.doi.org/10.1074/jbc.274.35.24497			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455112	hybrid			2022-12-25	WOS:000082193400011
J	Wickrema, A; Uddin, S; Sharma, A; Chen, F; Alsayed, Y; Ahmad, S; Sawyer, ST; Krystal, G; Yi, TL; Nishada, K; Hibi, M; Hirano, T; Platanias, LC				Wickrema, A; Uddin, S; Sharma, A; Chen, F; Alsayed, Y; Ahmad, S; Sawyer, ST; Krystal, G; Yi, TL; Nishada, K; Hibi, M; Hirano, T; Platanias, LC			Engagement of Gab1 and Gab2 in erythropoietin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID PROGENITOR CELLS; INSULIN-RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; PROTEIN-KINASE; GROWTH-FACTOR; ASSOCIATION; PATHWAY; ALPHA	Several signaling cascades are activated during engagement of the erythropoietin receptor to mediate the biological effects of erythropoietin, The members of the insulin receptor substrate (IRS) family of proteins play a central role in signaling for various growth factor receptors and cytokines by acting as docking proteins for the SH2 domains of signaling elements, linking cytokine receptors to diverse downstream pathways. In the present study we provide evidence that the recently cloned IRS-related proteins, Gab1 and Gab2, of the Gab family of proteins, are rapidly phosphorylated on tyrosine during erythropoietin treatment of erythropoietin-responsive cells and provide docking sites for the engagement of the SHP2 phosphatase and the p85 subunit of the phosphatidylinositol 3'-kinase. Furthermore, our data show that Gab1 is the primary IRS-related protein activated by erythropoietin in primary erythroid progenitor cells, In studies to identify the erythropoietin receptor domains required for activation of Gab proteins, we found that tyrosines 425 and 367 in the cytoplasmic domain of the erythropoietin receptor are required for the phosphorylation of Gab2. Taken together, our data demonstrate that Gab proteins are engaged in erythropoietin signaling to mediate downstream activation of the SHP2 and phosphatidylinositol 3'-kinase pathways and possibly participate in the generation of the erythropoietin-induced mitogenic responses.	Univ Illinois, Hematol Oncol Sect, Chicago, IL 60607 USA; W Side Vet Affairs Med Ctr, Chicago, IL 60607 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; British Columbia Canc Res Ctr, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Osaka Univ, Grad Sch Med, Biomed Res Ctr, Div Mol Oncol, Osaka 5650871, Japan	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Virginia Commonwealth University; British Columbia Cancer Agency; Cleveland Clinic Foundation; Osaka University	Wickrema, A (corresponding author), Univ Illinois, Hematol Oncol Sect, 900 S Ashland Ave, Chicago, IL 60607 USA.	Awickrem@uic.edu	Hirano, Toshio/C-8194-2009; Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444; Krystal, Gerald/0000-0002-1961-6281; Uddin, Shahab/0000-0003-1886-6710	NATIONAL CANCER INSTITUTE [R01CA079891, R29CA073381, R01CA077816] Funding Source: NIH RePORTER; NCI NIH HHS [CA79891, CA77816, CA73381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; Devemy E, 1997, CELL SIGNAL, V9, P41, DOI 10.1016/S0898-6568(96)00095-2; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HE TC, 1993, BLOOD, V82, P3530; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; JacobsHelber SM, 1997, J BIOL CHEM, V272, P6850, DOI 10.1074/jbc.272.11.6850; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; Joneja B, 1997, J BIOL CHEM, V272, P11176, DOI 10.1074/jbc.272.17.11176; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRANTZ SB, 1991, BLOOD, V77, P419; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; TODOKORO K, 1994, BIOCHEM BIOPH RES CO, V203, P1912, DOI 10.1006/bbrc.1994.2411; Uddin S, 1997, J IMMUNOL, V158, P2390; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497	40	89	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24469	24474		10.1074/jbc.274.35.24469	http://dx.doi.org/10.1074/jbc.274.35.24469			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455108	hybrid			2022-12-25	WOS:000082193400007
J	Eliasson, C; Sahlgren, C; Berthold, CH; Stakeberg, J; Celis, JE; Betsholtz, C; Eriksson, JE; Pekny, M				Eliasson, C; Sahlgren, C; Berthold, CH; Stakeberg, J; Celis, JE; Betsholtz, C; Eriksson, JE; Pekny, M			Intermediate filament protein partnership in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MICE; MOUSE MODEL; GFAP; CELLS; DESMIN; EXPRESSION; MUSCLE; GENE; ARCHITECTURE	Intermediate filaments are general constituents of the cytoskeleton. The function of these structures and the requirement for different types of intermediate filament proteins by individual cells are only partly understood. Here we have addressed the role of specific intermediate filament protein partnerships in the formation of intermediate filaments in astrocytes. Astrocytes may express three types of intermediate filament proteins: glial fibrillary acidic protein (GFAP), vimentin, and nestin. me used mice with targeted mutations in the GFAP or vimentin genes, or both, to study the impact of loss of either or both of these proteins on intermediate filament formation in cultured astrocytes and in normal or reactive astrocytes in vivo. We report that nestin cannot form intermediate filaments on its own, that vimentin may form intermediate filaments with either nestin or GFAP as obligatory partners, and that GFAP is the only intermediate filament protein of the three that may form filaments on its own. However, such filaments show abnormal organization. Aberrant intermediate filament formation is linked to diseases affecting epithelial, neuronal, and muscle cells. Here we present models by which the normal and pathogenic functions of intermediate filaments may be elucidated in astrocytes.	Univ Gothenburg, Dept Biochem Med, SE-40530 Gothenburg, Sweden; Abo Akad Univ, Dept Biol, Turku 20520, Finland; Univ Gothenburg, Dept Anat & Cell Biol, SE-40530 Gothenburg, Sweden; Danish Ctr Human Genome Res, Aarhus 8000, Denmark; Turku Univ, Turku Ctr Biotechnol, Turku 20520, Finland	University of Gothenburg; Abo Akademi University; University of Gothenburg; Aarhus University; University of Turku	Pekny, M (corresponding author), Univ Gothenburg, Dept Biochem Med, Box440, SE-40530 Gothenburg, Sweden.	Milos.Pekny@medkem.gu.se		Sahlgren, Cecilia/0000-0003-3350-4937; , cecilia/0000-0001-6365-6275				Capetanaki Y, 1997, CELL STRUCT FUNCT, V22, P103, DOI 10.1247/csf.22.103; CELIS JE, 1997, CELL BIOL LAB HDB, V4, P375; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Galou M, 1996, J CELL BIOL, V133, P853, DOI 10.1083/jcb.133.4.853; Hemken PM, 1997, J BIOL CHEM, V272, P32489, DOI 10.1074/jbc.272.51.32489; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Li ZL, 1997, J CELL BIOL, V139, P129, DOI 10.1083/jcb.139.1.129; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; Marszalek JR, 1996, J CELL BIOL, V135, P711, DOI 10.1083/jcb.135.3.711; Marvin NJ, 1998, J CELL SCI, V111, P1951; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; Messing A, 1998, AM J PATHOL, V152, P391; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Pekny M, 1998, GLIA, V22, P390, DOI 10.1002/(SICI)1098-1136(199804)22:4<390::AID-GLIA8>3.0.CO;2-7; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 1998, EXP CELL RES, V239, P332, DOI 10.1006/excr.1997.3922; PRICE MG, 1983, J CELL BIOL, V97, P1860, DOI 10.1083/jcb.97.6.1860; Quinlan R, 1995, PROTEIN PROFILE, V2, P801; QUINLAN R, 1994, PROTEIN PROFILE, V1, P779; RASMUSSEN HH, 1993, J INVEST DERMATOL, V101, P560, DOI 10.1111/1523-1747.ep12365986; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; Thornell LE, 1997, J MOL CELL CARDIOL, V29, P2107, DOI 10.1006/jmcc.1997.0446; TOHYAMA T, 1992, LAB INVEST, V66, P303; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; XU ZS, 1993, J CELL SCI, P101	39	286	297	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23996	24006		10.1074/jbc.274.34.23996	http://dx.doi.org/10.1074/jbc.274.34.23996			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446168	hybrid			2022-12-25	WOS:000082110900047
J	Hall, RA; Spurney, RF; Premont, RT; Rahman, N; Blitzer, JT; Pitcher, JA; Lefkowitz, RJ				Hall, RA; Spurney, RF; Premont, RT; Rahman, N; Blitzer, JT; Pitcher, JA; Lefkowitz, RJ			G protein-coupled receptor kinase 6A phosphorylates the Na+/H+ exchanger regulatory factor via a PDZ domain-mediated interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; H+ EXCHANGER; BETA(2)-ADRENERGIC RECEPTOR; MEMBRANE-PROTEIN; NHE-RF; BINDING; FAMILY; IDENTIFICATION; COFACTOR; TUBULIN	The Na+/H+ exchanger regulatory factor (NHERF) is constitutively phosphorylated in cells, but the site(s) of this phosphorylation and the kinase(s) responsible for it have not been identified. We show here that the primary site of constitutive NHERF phosphorylation in human embryonic kidney 293 (HEK-293) cells is Ser(289), and that the stoichiometry of phosphorylation is near 1 mol/mol, NHERF contains two PDZ domains that recognize the sequence S/T-X-L at the carboxyl terminus of target proteins, and thus we examined the possibility that kinases containing this motif might associate with and phosphorylate NHERF, Overlay experiments and co-immunoprecipitation studies revealed that NRERF binds with high affinity to a splice variant of the G protein-coupled receptor kinase 6, GRK6A, which terminates in the motif T-R-L, NHERF does not associate with GRK6B or GRK6C, alternatively spliced variants that differ from GRK6A at their extreme carboxyl termini, GRK6A phosphorylates NHERF efficiently on Ser(289) in vitro, whereas GRK6B, GRK6C, and GRK2 do not, Furthermore, the endogenous "NHERF kinase" activity in HEK-293 cell lysates is sensitive to treatments that alter the activity of GRK6A. These data suggest that GRK6A phosphorylates NHERF via a PDZ domain-mediated interaction and that GRK6A is the kinase in HER-293 cells responsible for the constitutive phosphorylation of NHERF.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.		Pitcher, Julie/ABH-2078-2020; Lefkowitz, Robert/AAW-2649-2021	Premont, Richard/0000-0002-8053-5026; Hall, Randy/0000-0002-8318-8728	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Firsov D, 1997, AM J PHYSIOL-CELL PH, V273, pC953, DOI 10.1152/ajpcell.1997.273.3.C953; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Haga K, 1998, EUR J BIOCHEM, V255, P363, DOI 10.1046/j.1432-1327.1998.2550363.x; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEINMAN E, 1992, MINER ELECTROL METAB, V18, P35; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	31	123	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24328	24334		10.1074/jbc.274.34.24328	http://dx.doi.org/10.1074/jbc.274.34.24328			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446210	hybrid			2022-12-25	WOS:000082110900089
J	Komano, H; Rockwell, N; Wang, GT; Krafft, GA; Fuller, RS				Komano, H; Rockwell, N; Wang, GT; Krafft, GA; Fuller, RS			Purification and characterization of the yeast glycosylphosphatidylinositol-anchored, monobasic-specific aspartyl protease yapsin 2 (Mkc7p)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; NECROSIS-FACTOR-ALPHA; SACCHAROMYCES-CEREVISIAE; KEX2 PROTEASE; CLEAVAGE; BETA; YAP3; GENE; MECHANISMS; METALLOPROTEINASE	The Saccharomyces cerevisiae YPS2 (formerly MKC7) gene product is a glycosylphosphatidylinositol-linked aspartyl protease that functions as a yeast secretase, Here, the glycosylphosphatidylinositol-linked form of yapsin 2 (Mkc7p) was purified to homogeneity from the membrane fraction of an overexpressing yeast strain. Purified yapsin 2 migrated diffusely in SDS-polyacrylamide gel electrophoresis (molecular mass similar to 200 kDa), suggesting extensive, heterogeneous glycosylation, Studies using internally quenched fluorogenic peptide substrates revealed cleavage by the enzyme carboxyl to Lys or Arg. No cleavage was seen when both Lys and Arg were absent. No significant enhancement was seen with multiple basic residues. However, cleavage always occurred carboxyl to the most COOH-terminal basic residue. V-max/K-m was insensitive to P-2 and P-3 residues except that Pro at P-2 blocked cleavage entirely. These results suggest that yapsin 2 is a monobasic amino acid-specific protease that requires a basic residue at P-1 and excludes basic residues from P-1'. The pH dependence of V-max/K-m for a substrate containing a pro-alpha factor cleavage site was bell-shaped, with a maximum near pH 4.0. However, V-max/K-m for a substrate mimicking the alpha-secretase site in human beta amyloid precursor protein was optimal near pH 6.0, consistent with cleavage of beta amyloid precursor protein by yapsin 2 when expressed in yeast.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Abbott Labs, Dept Combinatorial Chem, Abbott Pk, IL 60064 USA; NW Healthcare Res Inst, Evanston, IL 60201 USA; Northwestern Univ, Sch Med, Evanston, IL 60201 USA	University of Michigan System; University of Michigan; Stanford University; Abbott Laboratories; Northwestern University	Fuller, RS (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039697] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM39697] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASH J, 1995, J BIOL CHEM, V270, P20847, DOI 10.1074/jbc.270.35.20847; AZARYAN AV, 1993, J BIOL CHEM, V268, P11968; AZUMA T, 1989, J BIOL CHEM, V264, P16748; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BOURBONNAIS Y, 1993, EMBO J, V12, P285, DOI 10.1002/j.1460-2075.1993.tb05655.x; Brickner JH, 1997, J CELL BIOL, V139, P23, DOI 10.1083/jcb.139.1.23; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; Cawley NX, 1996, J BIOL CHEM, V271, P4168; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10068; FERSHT A, 1985, ENZYME STRUCTURE MEC, P422; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GLUSCHANKOF P, 1994, EMBO J, V2, P1791; HINES V, 1994, CELL MOL BIOL RES, V40, P273; HIRANI S, 1987, ANAL BIOCHEM, V162, P485, DOI 10.1016/0003-2697(87)90424-6; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; Komano H, 1998, J BIOL CHEM, V273, P31648, DOI 10.1074/jbc.273.48.31648; LADROR US, 1994, J BIOL CHEM, V269, P18422; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ledgerwood EC, 1996, FEBS LETT, V383, P67, DOI 10.1016/0014-5793(96)00219-0; Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Olsen V, 1998, BIOCHEMISTRY-US, V37, P2768, DOI 10.1021/bi9724826; POLGAR L, 1994, BIOCHEMISTRY-US, V33, P9351, DOI 10.1021/bi00197a040; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Rockwell NC, 1997, BIOCHEMISTRY-US, V36, P1912, DOI 10.1021/bi961779l; Rose MD., 1990, METHODS YEAST GENETI; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Sambrook J., 2002, MOL CLONING LAB MANU; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; ZHANG HY, 1994, J BIOL CHEM, V269, P27799; Zhang W, 1997, BBA-MOL CELL RES, V1359, P110, DOI 10.1016/S0167-4889(97)00082-7	39	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24431	24437		10.1074/jbc.274.34.24431	http://dx.doi.org/10.1074/jbc.274.34.24431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446224	hybrid			2022-12-25	WOS:000082110900103
J	Muda, M; Manning, ER; Orth, K; Dixon, JE				Muda, M; Manning, ER; Orth, K; Dixon, JE			Identification of the human YVH1 protein-tyrosine phosphatase orthologue reveals a novel zinc binding domain essential for in vivo function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; KINASE PHOSPHATASE; YEAST	A human orthologue of the Saccharomyces cerevisiae YVH1 protein-tyrosine phosphatase is able to rescue the slow growth defect caused by the disruption of the S. cerevisiae YVH1 gene. The human YVH1 gene is located on chromosome 1q21-q22, which falls in a region amplified in human liposarcomas. The evolutionary conserved COOH-terminal noncatalytic domain of human YVH1 is essential for in vivo function. The cysteine-rich COOH-terminal domain is capable of coordinating 2 mol of zinc/mol of protein, defining it as a novel zinc finger domain. Human YVH1 is the first protein-tyrosine phosphatase that contains and is regulated by a zinc finger domain.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Dixon, JE (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 5416 Med Sci Bldg 1, Ann Arbor, MI 48109 USA.		Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620	NIDDK NIH HHS [DK18024] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018024, R01DK018024] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Forus A, 1998, BRIT J CANCER, V78, P495, DOI 10.1038/bjc.1998.521; FORUS A, 1995, GENE CHROMOSOME CANC, V4, P8; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1994, P NATL ACAD SCI USA, V89, P12175; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Harlow E., 1988, ANTIBODIES LAB MANUA; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; MULLERSMAN JE, 1995, TRENDS BIOCHEM SCI, V20, P56; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Park HD, 1996, YEAST, V12, P1135, DOI 10.1002/(SICI)1097-0061(19960915)12:11<1135::AID-YEA11>3.0.CO;2-L; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4	21	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23991	23995		10.1074/jbc.274.34.23991	http://dx.doi.org/10.1074/jbc.274.34.23991			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446167	hybrid			2022-12-25	WOS:000082110900046
J	Pastorcic, M; Das, HK				Pastorcic, M; Das, HK			An upstream element containing an ETS binding site is crucial for transcription of the human presenilin-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONSET ALZHEIMER-DISEASE; AMYLOID BETA-PEPTIDE; CAENORHABDITIS-ELEGANS; MESSENGER-RNA; PC12 CELLS; APOPTOSIS; EXPRESSION; BRAIN; MUTATION; FAMILY	Deletion mapping of the human presenilin-1 (PS1) promoter delineated the most active fragment from -118 to +178 in relation to the transcription start site mapped in this study, in both human neuroblastoma SK-N-SH and hepatoma HepG2 cells. 5' deletions revealed that a crucial element controlling over 90% of the promoter activity in these cell lines is located between -22 and -6, A mutation altering only two nucleotides of the ETS consensus sequence present at -12 (GGAA to TTAA) has a similar effect. Electrophoretic mobility shift assays showed that a set of specific complexes between nuclear factors and the PS1 promoter are eliminated by this point mutation, as well as by competition with an ETS consensus oligonucleotide. Competition experiments in DNase I footprinting correlated with electrophoretic mobility shift assays and showed that only one of several footprints over the PS1 promoter is eliminated by competition with an ETS consensus oligonucleotide. It extends from -14 to -6 and surrounds the ETS motif present at -12, Thus, a crucial ETS element is present at -12 and binds a protein(s) recognizing specifically the ETS consensus motif. At least one such complex is eliminated by preincubating the nuclear extract with an antibody with broad cross-reactivity with Ets-l and Ets-a proteins, thus confirming that an ETS transcription factor(s) recognizes the -12 motif. Several Spl binding motifs at positions -70, -55, and +20 surround this ETS element. Competition DNase I footprinting showed that Spl-like nuclear factors recognize specifically these sites in both cell lines. Furthermore, a combination of 5' and 3' deletions indicated the presence of positive promoter elements between -96 and -35 as well as between +6 and +42. Thus, transfection and footprinting assays correlate to suggest that Spl transcription factor(s) bind at several sites upstream and downstream from the initiation site and activate the transcription of the PS1 promoter. Sequences downstream from the transcription initiation site also contain major control elements. 3' deletions from +178 to +107 decreased promoter activity by 80%. However, further deletion to +42 increased promoter activity by 3-4-fold. Collectively, these data indicate that sequences upstream and downstream from the transcription start site each control over 80% of the promoter activity. Hence, this suggests that protein-protein interactions between factors recognizing downstream and upstream sequences are involved.	Univ N Texas, Hlth Sci Ctr, Dept Pharmacol, Ft Worth, TX 76107 USA; Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center	Das, HK (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Pharmacol, Ft Worth, TX 76107 USA.							ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Baumeister R, 1997, Genes Funct, V1, P149; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUANG SS, 1995, BIOCHEM BIOPH RES CO, V215, P394, DOI 10.1006/bbrc.1995.2478; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Cribbs DH, 1996, NEUROREPORT, V7, P1773, DOI 10.1097/00001756-199607290-00016; Cruts M, 1996, HUM MOL GENET, V5, P1449, DOI 10.1093/hmg/5.Supplement_1.1449; DAS HK, 1988, J BIOL CHEM, V263, P11452; DAS HK, 1997, FRONT BIOSCI, V2, P253; DE A, 1994, J BIOL CHEM, V269, P26697; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hartmann H, 1997, J BIOL CHEM, V272, P14505, DOI 10.1074/jbc.272.23.14505; Iotsova V, 1996, ONCOGENE, V13, P2331; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Johnston JA, 1996, FEBS LETT, V394, P279, DOI 10.1016/0014-5793(96)00969-6; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kruman I, 1997, J NEUROSCI, V17, P5089; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lamb BT, 1997, NAT MED, V3, P28, DOI 10.1038/nm0197-28; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Mitsuda N, 1997, J BIOL CHEM, V272, P23489, DOI 10.1074/jbc.272.38.23489; Page K, 1996, P NATL ACAD SCI USA, V93, P14020, DOI 10.1073/pnas.93.24.14020; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; Rogaev EI, 1997, GENOMICS, V40, P415, DOI 10.1006/geno.1996.4523; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Sgambato V, 1998, J NEUROSCI, V18, P8814; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; Takami K, 1997, BRAIN RES, V748, P122, DOI 10.1016/S0006-8993(96)01274-7; Tysoe C, 1998, AM J HUM GENET, V62, P70, DOI 10.1086/301672; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0	53	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24297	24307		10.1074/jbc.274.34.24297	http://dx.doi.org/10.1074/jbc.274.34.24297			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446206	hybrid			2022-12-25	WOS:000082110900085
J	Serre, V; Guy, H; Penverne, B; Lux, M; Rotgeri, A; Evans, D; Herve, G				Serre, V; Guy, H; Penverne, B; Lux, M; Rotgeri, A; Evans, D; Herve, G			Half of Saccharomyces cerevisiae carbamoyl phosphate synthetase produces and channels carbamoyl phosphate to the fused aspartate transcarbamoylase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITES; MULTIFUNCTIONAL PROTEIN CAD; PYRIMIDINE PATHWAY ENZYMES; ESCHERICHIA-COLI; CARBOXY-PHOSPHATE; URA2 GENE; 5-PHOSPHORIBOSYL 1-PYROPHOSPHATE; REVERSIBLE DISSOCIATION; ALLOSTERIC REGULATION; ARGININE PATHWAYS	The first two steps of the de novo pyrimidine biosynthetic pathway in Saccharomyces cerevisiae are catalyzed by a 240-kDa bifunctional protein encoded by the ura2 locus. Although the constituent enzymes, carbamoyl phosphate synthetase (CPSase) and aspartate transcarbamoylase (ATCase) function independently, there are interdomain interactions uniquely associated with the multifunctional protein. Both CPSase and ATCase are feedback inhibited by UTP. Moreover, the intermediate carbamoyl phosphate is channeled from the CPSase domain where it is synthesized to the ATCase domain where it is used in the synthesis of carbamoyl aspartate. To better understand these processes, a recombinant plasmid was constructed that encoded a protein lacking the amidotransferase domain and the amino half of the CPSase domain, a 100-kDa chain segment. The truncated complex consisted of the carboxyl half of the CPSase domain fused to the ATCase domain via the pDHO domain, an inactive dihydroorotase homologue that bridges the two functional domains in the native molecule. Not only was the "half CPSase" catalytically active, but it was regulated by UTP to the same extent as the parent molecule. In contrast, the ATCase domain was no longer sensitive to the nucleotide, suggesting that the two catalytic activities are controlled by distinct mechanisms. Most remarkably, isotope dilution and transient time measurements showed that the truncated complex channels carbamoyl phosphate. The overall CPSase-ATCase reaction is much less sensitive than the parent molecule to the ATCase bisubstrate analogue, N-phosphonacetyl-L-aspartate (PALA), providing evidence that the endogenously produced carbamoyl phosphate is sequestered and channeled to the ATCase active site.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Paris 06, CNRS, UMR 7631, Lab Biochim Signaux Regulateurs Cellulaires & Mol, F-75006 Paris, France	Wayne State University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Evans, D (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	devans@cmb.biosci.wayne.edu			NIGMS NIH HHS [GM43799] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043799] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELAL A, 1969, J BIOL CHEM, V244, P4033; ABDELAL A, 1985, EUR J BIOCHEM, V129, P697; ABDELAL AT, 1982, J BACTERIOL, V151, P1411, DOI 10.1128/JB.151.3.1411-1419.1982; AITKEN DM, 1973, BIOCHIM BIOPHYS ACTA, V309, P50, DOI 10.1016/0005-2744(73)90316-1; ALONSO E, 1995, EUR J BIOCHEM, V229, P377, DOI 10.1111/j.1432-1033.1995.tb20478.x; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3164, DOI 10.1021/bi00874a013; BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; BELKAID M, 1988, ARCH BIOCHEM BIOPHYS, V262, P171, DOI 10.1016/0003-9861(88)90179-8; BISHOP SH, 1966, BIOCHIM BIOPHYS ACTA, V118, P211, DOI 10.1016/S0926-6593(66)80163-7; BOETTCHER BR, 1980, J BIOL CHEM, V255, P7129; Braxton BL, 1996, BIOCHEMISTRY-US, V35, P11918, DOI 10.1021/bi961305m; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P1381; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; DAVIDSON JN, 1993, BIOESSAYS, V15, P157, DOI 10.1002/bies.950150303; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; DENISDUPHIL M, 1981, J BACTERIOL, V148, P659, DOI 10.1128/JB.148.2.659-669.1981; Durbecq V, 1997, P NATL ACAD SCI USA, V94, P12803, DOI 10.1073/pnas.94.24.12803; EASTERBY JS, 1981, BIOCHEM J, V199, P155, DOI 10.1042/bj1990155; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; Guy HI, 1998, J BIOL CHEM, V273, P14172, DOI 10.1074/jbc.273.23.14172; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; Hanahan D., 1985, DNA CLONING PRACTICA, VI, P109; HERVE G, 1993, BIOCHEM SOC T, V21, P195, DOI 10.1042/bst0210195; Irvine HS, 1997, EUR J BIOCHEM, V247, P1063, DOI 10.1111/j.1432-1033.1997.01063.x; JAQUET L, 1995, J MOL BIOL, V248, P639, DOI 10.1006/jmbi.1995.0248; JavidMajd F, 1996, BIOCHEMISTRY-US, V35, P14362, DOI 10.1021/bi961184q; KAPLAN JG, 1967, ARCH BIOCHEM BIOPHYS, V119, P541, DOI 10.1016/0003-9861(67)90489-4; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KIM HS, 1992, J BIOL CHEM, V267, P7177; Kothe M, 1997, P NATL ACAD SCI USA, V94, P12348, DOI 10.1073/pnas.94.23.12348; LACROUTE F, 1965, J GEN MICROBIOL, V40, P127, DOI 10.1099/00221287-40-1-127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; Lovry O.H., 1951, J BIOL CHEM, V193, P265; LUE PF, 1969, BIOCHEM BIOPH RES CO, V34, P426, DOI 10.1016/0006-291X(69)90399-4; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING LAB MANU; Marina A, 1998, EUR J BIOCHEM, V253, P280, DOI 10.1046/j.1432-1327.1998.2530280.x; MARSHALL M, 1966, J BIOL CHEM, V241, P4197; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NAGY M, 1989, J BIOL CHEM, V264, P8366; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; PENVERNE B, 1994, ARCH BIOCHEM BIOPHYS, V309, P85, DOI 10.1006/abbi.1994.1089; PIERARD A, 1964, BIOCHEM BIOPH RES CO, V15, P76, DOI 10.1016/0006-291X(64)90106-8; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POWERS SG, 1977, J BIOL CHEM, V252, P3558; POWERS SG, 1978, J BIOL CHEM, V253, P1258; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; Purcarea C, 1996, EUR J BIOCHEM, V236, P189, DOI 10.1111/j.1432-1033.1996.00189.x; ROBIN JP, 1989, EUR J BIOCHEM, V183, P519, DOI 10.1111/j.1432-1033.1989.tb21080.x; RUBIO V, 1993, BIOCHEM SOC T, V21, P198, DOI 10.1042/bst0210198; SCHIMKE RT, 1966, J BIOL CHEM, V241, P2228; Serre V, 1998, J MOL BIOL, V281, P363, DOI 10.1006/jmbi.1998.1856; SHAW SM, 1992, EUR J BIOCHEM, V207, P957, DOI 10.1111/j.1432-1033.1992.tb17130.x; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SOUCIET JL, 1987, MOL GEN GENET, V207, P314, DOI 10.1007/BF00331595; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; STARK GR, 1977, TRENDS BIOCHEM SCI, V2, P64, DOI 10.1016/0968-0004(77)90133-5; TATIBANA M, 1972, J BIOCHEM, V72, P549, DOI 10.1093/oxfordjournals.jbchem.a129934; TATIBANA M, 1972, BIOCHEM BIOPH RES CO, V46, P491, DOI 10.1016/S0006-291X(72)80165-7; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; THORNE KJI, 1963, J BIOL CHEM, V238, P2992; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P492; VILLOUTREIX BO, 1994, PROTEINS, V19, P230, DOI 10.1002/prot.340190307; WILLIAMS NK, 1994, ADV EXP MED BIOL, V370, P597	78	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23794	23801		10.1074/jbc.274.34.23794	http://dx.doi.org/10.1074/jbc.274.34.23794			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446140	hybrid			2022-12-25	WOS:000082110900019
J	Okamoto, K; Prives, C				Okamoto, K; Prives, C			A role of cyclin G in the process of apoptosis	ONCOGENE			English	Article						cyclin G; apoptosis; p53; TNF-alpha; retinoic acid; Bone Morphogenic Protein-4	EMBRYONAL CARCINOMA-CELLS; P53 TUMOR-SUPPRESSOR; CELLULAR-SUSCEPTIBILITY; DNA-DAMAGE; EXPRESSION; PROTEIN; DEATH; INDUCTION; GENE; FAMILY	Cyclin G was previously identified as a target gene of the p53 tumor suppresser protein, and levels of cyclin G are increased after induction of p53 by DNA damage. However, the function of cyclin G has not been established. To determine the effect of increased expression of cyclin G, retroviruses encoding cyclin G mere constructed and used to infect three different murine tell Lines. Cyclin G protein levels induced by the retroviruses were within the range seen after DNA damage induction of p53. In each case we observed that such over-expression of cyclin G augments the apoptotic process. TNF-alpha induction of apoptosis is increased by expression of cyclin G in NIH3T3 fibroblasts which express p53, as well as in 10.1 fibroblasts which contain no p53 allele. Additionally, we observed that while cyclin G expression is markedly reduced upon aggregate formation in embryonic carcinoma P19 cells, retrovirus-mediated over-expression of cyclin G enhances apoptotic cell death in aggregated P19 cells, and increases the extent of apoptosis caused by retinoic acid or serum starvation of these cells. These data demonstrate that cyclin G plays a facilitating role in modulating apoptosis induced by different stimuli. Moreover, we have discovered that cyclin G expression is rapidly induced in P19 cells after exposure to Bone Morphogenic Protein-4 (BMP-4), suggesting that cyclin G may mediate apoptotic signals generated by BMP-4.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.				NCI NIH HHS [CA 58316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058316, R37CA058316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bates S, 1996, ONCOGENE, V13, P1103; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Glozak MA, 1996, DEV BIOL, V179, P458, DOI 10.1006/dbio.1996.0275; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Jensen MR, 1998, HEPATOLOGY, V28, P537, DOI 10.1002/hep.510280235; Kanaoka Y, 1997, FEBS LETT, V402, P73, DOI 10.1016/S0014-5793(96)01484-6; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; Ninomiya Y, 1997, J CELL PHYSIOL, V172, P25, DOI 10.1002/(SICI)1097-4652(199707)172:1<25::AID-JCP3>3.3.CO;2-P; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Robbins PB, 1997, J VIROL, V71, P9466, DOI 10.1128/JVI.71.12.9466-9474.1997; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; SoferLevi Y, 1996, ONCOGENE, V13, P2431; SORENSON B, 1994, NUCLEIC ACIDS RES, V22, P3551; TAMURA K, 1993, ONCOGENE, V8, P2113; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WHITE DW, 1995, ONCOGENE, V10, P857; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	47	92	96	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4606	4615		10.1038/sj.onc.1202821	http://dx.doi.org/10.1038/sj.onc.1202821			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467405				2022-12-25	WOS:000082018600010
J	Chan, BS; Satriano, JA; Schuster, VL				Chan, BS; Satriano, JA; Schuster, VL			Mapping the substrate binding site of the prostaglandin transporter PGT by cysteine scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR CHANNEL; ORGANIC ANION TRANSPORTER; TRANSMEMBRANE CONDUCTANCE REGULATOR; FLANKING HYDROPHILIC DOMAINS; MEMBRANE-SPANNING SEGMENT; HUMAN P-GLYCOPROTEIN; AMINO-ACID-RESIDUES; ESCHERICHIA-COLI; LACTOSE PERMEASE; LINING RESIDUES	We have identified a cDNA, PGT, that encodes a widely expressed transporter for prostaglandin (PG) E-2, PGF(2 alpha), PGD(2), 8-iso-PGF(2 alpha), and thromboxane B-2. To begin to understand the molecular mechanisms of transporter function, we have initiated a structure-function analysis of PGT to identify its substrate-binding region. We have found that by introducing the small, water-soluble, thiol-reactive anion Na(2-sulfonatoethyl)methanethiosulfonate (MTSES) into the substrate pathway, we were able to cause inhibition of transport that could be reversed with dithiothreitol. Importantly, co-incubation with PGE, protected PGT from this inhibition, suggesting that MTSES gains access to the aqueous pore pathway of PGT to form a mixed disulfide near the substrate-binding site. To identify the susceptible cysteine, we mutated, one at a time, all six of the putative transmembrane cysteines to serine, Only the mutation of Cys-530 to serine within putative transmembrane 10 became resistant to inhibition by MTSES, Thus, Cys-530 is the substrate-protectable, MTSES-inhibitable residue. To identify other residues that may be lining the substrate-binding site, we initiated cysteine-scanning mutagenesis of transmembrane 10 using Cys-530 as an entry point. On a C530S, MTSES-resistant background, residues in the N- and C-terminal directions were individually mutated to cysteine (Ala-513 to His-536), one at a time, and then analyzed for MTSES inhibition. Of the 24 cysteine-substituted mutants generated, 6 were MTSES-sensitive and, among these, 4 were substrate-protectable. The pattern of sensitivity to MTSES places these residues on the same face of an Lu-helix. The results of cysteine-scanning mutagenesis and molecular modeling of putative transmembrane 10 indicate that the substrate binding of PGT is formed among its membrane-spanning segments, with 4 residues along the cytoplasmic end of helix 10 contributing to one surface of the binding site.	Yeshiva Univ Albert Einstein Coll Med, Div Renal, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Med Biophys, Bronx, NY 10461 USA; Univ Calif San Diego, Vet Affairs Med Ctr, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92161 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Chan, BS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Div Renal, Ullman 615,1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIDDK NIH HHS [R01 DK049688, K08-DK02492, R01-DK49688] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002492, R01DK049688] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe T, 1998, J BIOL CHEM, V273, P22395, DOI 10.1074/jbc.273.35.22395; Akabas MH, 1998, BIOCHEMISTRY-US, V37, P12233, DOI 10.1021/bi980969o; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; Chan BS, 1998, J BIOL CHEM, V273, P6689, DOI 10.1074/jbc.273.12.6689; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Frillingos S, 1997, PROTEIN SCI, V6, P431; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P5333, DOI 10.1021/bi953068d; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P14284, DOI 10.1021/bi972314d; FRILLINGOS S, 1994, BIOCHEMISTRY-US, V33, P8074, DOI 10.1021/bi00192a012; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; ITOH S, 1996, MOL PHARMACOL, V50, P738; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; Pascual JM, 1998, J GEN PHYSIOL, V112, P611, DOI 10.1085/jgp.112.5.611; SAHINTOTH M, 1994, PROTEIN SCI, V3, P240; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Satlin LM, 1997, J BIOL CHEM, V272, P26340, DOI 10.1074/jbc.272.42.26340; WEINER PK, 1981, J COMPUT CHEM, V2, P287, DOI 10.1002/jcc.540020311; Weissborn AC, 1997, BBA-BIOMEMBRANES, V1329, P237, DOI 10.1016/S0005-2736(97)00116-8; WEITZMAN C, 1995, BIOCHEMISTRY-US, V34, P9374, DOI 10.1021/bi00029a013; WELLNER M, 1995, FEBS LETT, V370, P19, DOI 10.1016/0014-5793(95)00783-6; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020; XU M, 1993, J BIOL CHEM, V268, P21505; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; Zhang H, 1997, BIOCHEMISTRY-US, V36, P15856, DOI 10.1021/bi972357u; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	38	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25564	25570		10.1074/jbc.274.36.25564	http://dx.doi.org/10.1074/jbc.274.36.25564			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464289	hybrid			2022-12-25	WOS:000082554200053
J	Kim, HJ; Takahashi, M; Ezaki, O				Kim, HJ; Takahashi, M; Ezaki, O			Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver - A possible mechanism for down-regulation of lipogenic enzyme mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; PROLIFERATOR-ACTIVATED RECEPTORS; LIPID-METABOLISM; LIPOPROTEIN RECEPTOR; RAT-LIVER; TRANSGENIC MICE; POSTTRANSCRIPTIONAL REGULATION; EICOSAPENTAENOIC ACID; CHOLESTEROL-SYNTHESIS; NUCLEAR-PROTEIN	Dietary fish oil induces hepatic peroxisomal and microsomal fatty acid oxidation by peroxisome proliferator-activator receptor alpha activation, whereas it downregulates lipogenic gene expression by unknown mechanism(s), Because sterol regulatory element-binding proteins (SREBPs) up-regulated lipogenic genes, investigation was made on the effects of fish oil feeding on SREBPs and sterol regulatory element (SRE)-dependent gene expression in C57BL/6J mice. Three forms of SREBPs, SREBP-1a, -1c, and -2, are expressed in liver, and their truncated mature forms activate transcription of sterol-regulated genes. C57BL/6J mice were divided into three groups; the first group was given a high carbohydrate diet, and the other two groups were given a high fat diet (60% of total energy), with the fat in the form of safflower oil or fish oil, for 5 months. Compared with safflower oil feeding, fish oil feeding decreased triglyceride and cholesterol concentrations in liver. There were no differences in amount of SREBP-1 and -2 in both precursor and mature forms between carbohydrate- and safflower oil-fed mice. However, compared with safflower oil feeding, fish oil feeding reduced the amounts of precursor SREBP-1 in membrane fraction by 90% and of mature SREBP-1 in liver nuclei by 57%. Fish oil feeding also reduced precursor SREBP-2 by 65% but did not alter the amount of mature SREBP-2, Compared with safflower oil feeding, fish oil feeding decreased liver SREBP-1c mRNA level by 86% but did not alter SERBP-1a mRNA Consistent with decrease of mature SREBP-1, compared with safflower oil feeding, fish oil feeding down-regulated the expression of liver SRE-dependent genes, such as low density lipoprotein receptor, 3-hydroxy-3-methylglutaryl-CoA reductase, 3-hydroxy-3-methylglutaryl-CoA synthase, fatty acid synthase, acetyl-CoA carboxylase, and stearoyl-CoA desaturase-l. These data suggested that in liver, fish oil feeding downregulates the mature form of SREBP-1 by decreasing SREBP-1c mRNA expression, with corresponding decreases of mRNAs of cholesterologenic and lipogenic enzymes.	Natl Inst Hlth & Nutr, Div Clin Nutr, Shinjuku Ku, Tokyo 1628636, Japan	National Institute of Health & Nutrition - Japan	Ezaki, O (corresponding author), Natl Inst Hlth & Nutr, Div Clin Nutr, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628636, Japan.							BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; FIELD FJ, 1987, J LIPID RES, V28, P50; Froyland L, 1996, LIPIDS, V31, P169, DOI 10.1007/BF02522617; HALMINSKI MA, 1991, J NUTR, V121, P1554, DOI 10.1093/jn/121.10.1554; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; IKEDA I, 1994, J NUTR, V124, P1898, DOI 10.1093/jn/124.10.1898; Ikemoto S, 1997, AM J PHYSIOL-ENDOC M, V273, pE37, DOI 10.1152/ajpendo.1997.273.1.E37; Ikemoto S, 1996, METABOLISM, V45, P1539, DOI 10.1016/S0026-0495(96)90185-7; KATSURADA A, 1990, EUR J BIOCHEM, V190, P427, DOI 10.1111/j.1432-1033.1990.tb15592.x; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LANDSCHULZ KT, 1994, BIOCHEM BIOPH RES CO, V200, P763, DOI 10.1006/bbrc.1994.1516; Latruffe N, 1997, BIOCHIMIE, V79, P81, DOI 10.1016/S0300-9084(97)81496-4; Miserez AR, 1997, GENOMICS, V40, P31, DOI 10.1006/geno.1996.4525; NESTEL PJ, 1990, ANNU REV NUTR, V10, P149, DOI 10.1146/annurev.nu.10.070190.001053; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Pegorier J P, 1998, Curr Opin Clin Nutr Metab Care, V1, P329, DOI 10.1097/00075197-199807000-00003; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; ROACH PD, 1987, FEBS LETT, V222, P159, DOI 10.1016/0014-5793(87)80211-9; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; RUSTAN AC, 1988, J LIPID RES, V29, P1417; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SAMBROOK J, 1989, MOL CLONING LAB MANU, P187; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; Tsunoda N, 1998, METABOLISM, V47, P724, DOI 10.1016/S0026-0495(98)90037-3; WANG XD, 1993, J BIOL CHEM, V268, P14497; Wilkinson J, 1998, ARTERIOSCL THROM VAS, V18, P1490, DOI 10.1161/01.ATV.18.9.1490; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Yamada N, 1998, J NUTR SCI VITAMINOL, V44, P279, DOI 10.3177/jnsv.44.279	46	304	308	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25892	25898		10.1074/jbc.274.36.25892	http://dx.doi.org/10.1074/jbc.274.36.25892			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464332	hybrid			2022-12-25	WOS:000082554200096
J	Kwak, YG; Navarro-Polanco, RA; Grobaski, T; Gallagher, DJ; Tamkun, MM				Kwak, YG; Navarro-Polanco, RA; Grobaski, T; Gallagher, DJ; Tamkun, MM			Phosphorylation is required for alteration of Kv1.5 K+ channel function by the Kv beta 1.3 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-SUBUNIT; POTASSIUM CHANNEL; TYROSINE KINASE; IN-VITRO; RECEPTOR; CELLS; INACTIVATION; EXPRESSION; SUPPRESSION	The Kv1.5 K+ channel is functionally altered by coassembly with the Kv beta 1.3 subunit, which induces fast inactivation and a hyperpolarizing shift in the activation curve. Here we examine kinase regulation of Kv1.5/ Kv beta 1.3 interaction after coexpression in human embryonic kidney 293 cells. The protein kinase C inhibitor calphostin C (3 mu M) removed the fast inactivation (66 +/- 1.9 versus 11 +/- 0.25%, steady state/peak current) and the P-induced hyperpolarizing voltage shift in the activation midpoint (V-1/2) (-21.9 +/- 1.4 versus -4.3 +/- 2.0 mV), Calphostin C had no effect on Kv1.5 alone with respect to inactivation kinetics and V-1/2. Okadaic acid, but not the inactive derivative, blunted both calphostin C effects (V-1/2 = -17.6 +/- 2.2 mV, 38 +/- 1.8% inactivation), consistent with dephosphorylation being required for calphostin C action. Calphostin C also removed the fast inactivation (57 +/- 2.6 versus 16 +/- 0.6%) and the shift in V-1/2 (-22.1 +/- 1.4 versus -2.1 +/- 2.0 mV) conferred onto Kv1.5 by the Kv beta 1.2 subunit, which shares only C terminus sequence identity with Kv beta 1.3, In contrast, modulation of Kv1.5 by the Kv beta 2.1 subunit was unaffected by calphostin C, These data suggest that Kv beta 1.2 and Kv beta 1.3 subunit modification of Kv1.5 inactivation and voltage sensitivity require phosphorylation by protein kinase C or a related kinase.	Colorado State Univ, Dept Physiol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Tamkun, MM (corresponding author), Colorado State Univ, Dept Physiol, Ft Collins, CO 80523 USA.		Navarro-Polanco, Ricardo/AAQ-6152-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049330] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49330] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Accili EA, 1997, J BIOL CHEM, V272, P25824, DOI 10.1074/jbc.272.41.25824; CAI YC, 1993, J BIOL CHEM, V268, P23720; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Eilers H, 1997, MOL PHARMACOL, V52, P1105, DOI 10.1124/mol.52.6.1105; ENGLAND SK, 1995, J BIOL CHEM, V270, P28531, DOI 10.1074/jbc.270.48.28531; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; Hartzell HC, 1996, AM J PHYSIOL-CELL PH, V270, pC1293; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUANG XY, 1994, P NATL ACAD SCI USA, V91, P624, DOI 10.1073/pnas.91.2.624; Innamorati G, 1998, J BIOL CHEM, V273, P7155, DOI 10.1074/jbc.273.12.7155; Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y; Kwak YG, 1999, J BIOL CHEM, V274, P13928, DOI 10.1074/jbc.274.20.13928; Levin G, 1996, J BIOL CHEM, V271, P29321, DOI 10.1074/jbc.271.46.29321; Levy M, 1998, J BIOL CHEM, V273, P6495, DOI 10.1074/jbc.273.11.6495; Martel J, 1998, J MEMBRANE BIOL, V161, P183, DOI 10.1007/s002329900325; PAYET MD, 1992, J BIOL CHEM, V267, P18270; Peretz T, 1996, FEBS LETT, V381, P71, DOI 10.1016/0014-5793(96)00085-3; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; SHI GY, 1994, J BIOL CHEM, V269, P23204; SNYDERS DJ, 1992, MOL PHARMACOL, V41, P332; SWAIN JE, 1991, J NEUROBIOL, V22, P855, DOI 10.1002/neu.480220806; TAKIMOTO K, 1993, NEURON, V11, P359, DOI 10.1016/0896-6273(93)90191-S; UEBELE VN, 1994, FEBS LETT, V340, P104, DOI 10.1016/0014-5793(94)80181-9; Uebele VN, 1996, J BIOL CHEM, V271, P2406, DOI 10.1074/jbc.271.5.2406; Uebele VN, 1998, AM J PHYSIOL-CELL PH, V274, pC1485, DOI 10.1152/ajpcell.1998.274.6.C1485; Vogalis F, 1995, MOL PHARMACOL, V48, P1015; WATTS SW, 1994, J PHARMACOL EXP THER, V271, P832	34	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25355	25361		10.1074/jbc.274.36.25355	http://dx.doi.org/10.1074/jbc.274.36.25355			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464262	hybrid			2022-12-25	WOS:000082554200027
J	McGinty, A; Scholfield, CN; Liu, WH; Anderson, P; Hoey, DEE; Trimble, ER				McGinty, A; Scholfield, CN; Liu, WH; Anderson, P; Hoey, DEE; Trimble, ER			Effect of glucose on endothelin-1-induced calcium transients in cultured bovine retinal pericytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-FLOW; RETINOPATHY; GENERATION; CELLS	Published work has shown that endothelin-l-induced contractility of bovine retinal pericytes is reduced after culture in high concentrations of glucose. The purpose of the present study was to establish the profile of endothelin-l-induced calcium transients in pericytes and to identify changes occurring after culture in high concentrations of glucose. Glucose had no effect on basal levels of cytosolic calcium or on endothelin-l-induced calcium release from intracellular stores. However, influx of calcium from the extracellular medium after endothelin-l stimulation was reduced in pericytes that had been cultured in 25 mM D-glucose. L-type Ca2+ currents were identified by patch clamping. The L-type Ca2+ channel agonist, (-)-Bay K8644, caused less influx of calcium from the extracellular medium in pericytes that had been cultured in 25 mM D-glucose than in those cultured with 5 mM D-glucose. However, 3-O-methylglucose, a nonmetabolizable analogue of glucose which can cause glycation, had similar effects to those of high concentrations of glucose. The results suggest that reduced function of the L-type Ca2+ channel that occurs in bovine retinal pericytes after culture in high concentrations of D-glucose is probably due to glycation of a channel protein.	Royal Grp Hosp, Dept Clin Biochem, Inst Clin Sci, Belfast BT12 6BA, Antrim, North Ireland; Queens Univ Belfast, Dept Clin Biochem, Belfast BT12 6BA, Antrim, North Ireland; Queens Univ Belfast, Sch Biomed Sci, Belfast BT12 6BA, Antrim, North Ireland	Queens University Belfast; Queens University Belfast	Trimble, ER (corresponding author), Royal Grp Hosp, Dept Clin Biochem, Inst Clin Sci, Belfast BT12 6BA, Antrim, North Ireland.			Scholfield, Charles Norman/0000-0001-7288-590X				BERWECK S, 1993, DIABETES, V42, P1347, DOI 10.2337/diabetes.42.9.1347; CHAKRAVARTHY U, 1994, DIABETOLOGIA, V37, P36; GITLIN JD, 1983, MICROVASC RES, V26, P74, DOI 10.1016/0026-2862(83)90056-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTTERIDGE JMC, 1994, THORAX, V49, P707, DOI 10.1136/thx.49.7.707; KOHNER EM, 1995, DIABETES, V44, P603, DOI 10.2337/diabetes.44.6.603; RIVA CE, 1983, INVEST OPHTH VIS SCI, V24, P47; SCHWARTZ A, 1987, J MOL CELL CARDIOL, V19, P49, DOI 10.1016/S0022-2828(87)80004-4; Sharpe PC, 1998, DIABETES, V47, P801, DOI 10.2337/diabetes.47.5.801; Takagi C, 1996, INVEST OPHTH VIS SCI, V37, P2504; TOOKE JE, 1995, DIABETES, V44, P721, DOI 10.2337/diabetes.44.7.721; WEST KM, 1980, DIABETES, V29, P501, DOI 10.2337/diab.29.7.501; YE XO, 1990, INVEST OPHTH VIS SCI, V31, P1731	13	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25250	25253		10.1074/jbc.274.36.25250	http://dx.doi.org/10.1074/jbc.274.36.25250			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464246	hybrid			2022-12-25	WOS:000082554200011
J	Westberg, JA; Zhang, KZ; Andersson, LC				Westberg, JA; Zhang, KZ; Andersson, LC			Regulation of neural differentiation by normal and mutant (G654A, amyloidogenic) gelsolin	FASEB JOURNAL			English	Article						PMA; neural sprouting; familial amyloidosis of the Finnish type (FAF); brain	FINNISH HEREDITARY AMYLOIDOSIS; FAMILIAL AMYLOIDOSIS; PLASMA GELSOLIN; ACTIN-FILAMENTS; GENE; IDENTIFICATION; LOCALIZATION; ACTIVATION; MODULATION; MOTILITY	Gelsolin belongs to a family of proteins that modulate the structural dynamics of cytoskeletal actin, Gelsolin activity is required for the redistribution of actin occurring during membrane ruffling, cell crawling, and platelet activation. A point mutation (G654A) in the gelsolin gene causes a dominantly inherited systemic amyloidosis called familial amyloidosis of the Finnish type (FAF), This disease is characterized by a cranial neuropathy that cannot be explained solely by amyloid deposits. To address the question of whether gelsolin has a specific role in neural cell development, we transfected cDNA for wild type and G654A point-mutated gelsolin into a neural cell line, Paju, which can be induced to differentiate by treatment with phorbol 12-myristate Ig-acetate. Overexpressed wild type gelsolin inhibited neural differentiation whereas mutated gelsolin did not, indicating that appropriate gelsolin activity is essential for neural sprouting. The G654A mutant gelsolin induced stabilization of F-actin and reduced the plasticity of neural development. This provides a novel etiopathogenetic mechanism for the neuronal dysfunction in FAF.	Univ Helsinki, Dept Pathol, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki Hosp, Dept Pathol, Helsinki, Finland; Karolinska Hosp & Inst, Stockholm, Sweden	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Karolinska Institutet; Karolinska University Hospital	Andersson, LC (corresponding author), Univ Helsinki, Dept Pathol, Haartman Inst, Haartmaninkatu 3,POB 21, FIN-00014 Helsinki, Finland.							Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KIURU S, 1994, MUSCLE NERVE, V17, P299, DOI 10.1002/mus.880170307; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1988, AM J HUM GENET, V42, P565; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAMB JA, 1993, J BIOL CHEM, V268, P8999; Lu M, 1997, J CELL BIOL, V138, P1279, DOI 10.1083/jcb.138.6.1279; MAURY CPJ, 1992, GENOMICS, V13, P902, DOI 10.1016/0888-7543(92)90183-S; MAURY CPJ, 1990, FEBS LETT, V276, P75, DOI 10.1016/0014-5793(90)80510-P; Maury CPJ, 1997, LAB INVEST, V77, P299; MAURY CPJ, 1990, FEBS LETT, V260, P85, DOI 10.1016/0014-5793(90)80072-Q; Paunio T, 1997, FEBS LETT, V406, P49, DOI 10.1016/S0014-5793(97)00237-8; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; TANAKA J, 1994, J NEUROSCI, V14, P1038, DOI 10.1523/JNEUROSCI.14-03-01038.1994; WANG E, 1984, J CELL BIOL, V98, P761, DOI 10.1083/jcb.98.2.761; WEEDS AG, 1993, FEBS LETT, V335, P119, DOI 10.1016/0014-5793(93)80452-Z; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0	23	21	21	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1621	1626		10.1096/fasebj.13.12.1621	http://dx.doi.org/10.1096/fasebj.13.12.1621			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463954				2022-12-25	WOS:000082347600018
J	Arava, Y; Seger, R; Walker, MD				Arava, Y; Seger, R; Walker, MD			GRF beta, a novel regulator of calcium signaling, is expressed in pancreatic beta cells and brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAS EXCHANGE FACTOR; INSULIN GENE; TRANSCRIPTION FACTOR; GLUCOSE; CDC25(MM); LINE; IDENTIFICATION; MODULATION; PLECKSTRIN	By screening for genes expressed differentially in pancreatic beta cells, we have isolated a cDNA encoding GRF beta, a novel 178-amino acid protein whose N terminus is identical to that of GRF1, a calcium-dependent guanine nucleotide exchange factor, and whose C terminus is unrelated to known proteins. We show that both GRF1 and GRF beta are expressed selectively in beta cell lines, pancreatic islet cells and brain. Treatment of beta cell lines (beta TC1 and HIT) with calcium ionophore led to a significant elevation in activity of the Ras signal transduction pathway, as determined by phosphorylation of extracellular signal-related kinase (ERK). Transfection of beta cells with a plasmid encoding a dominant negative variant of GRF1 led to 70% reduction in ERK phosphorylation, consistent with a role for GRF1 in calcium-dependent Ras signaling in these cells. To examine the possible function of GRF beta, cultured cells were transfected with a GRF beta expression vector. This led to a significant reduction in both GRF1-dependent ERK phosphorylation and AP1-dependent reporter gene activity. The results suggest that GRF1 plays a role in mediating calcium-dependent signal transduction in beta cells and that GRF beta represents a novel dominant negative modulator of Ras signaling.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Walker, MD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							Arava Y, 1999, DIABETES, V48, P552, DOI 10.2337/diabetes.48.3.552; Arava Y, 1998, FEBS LETT, V425, P24, DOI 10.1016/S0014-5793(98)00186-0; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; Benes C, 1998, J BIOL CHEM, V273, P15507, DOI 10.1074/jbc.273.25.15507; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Burns CJ, 1999, MOL CELL ENDOCRINOL, V148, P29, DOI 10.1016/S0303-7207(98)00239-1; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; Guerrero C, 1996, ONCOGENE, V12, P1097; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Itier JM, 1998, NATURE, V393, P125, DOI 10.1038/30120; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Zippel R, 1996, ONCOGENE, V12, P2697	31	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24449	24452		10.1074/jbc.274.35.24449	http://dx.doi.org/10.1074/jbc.274.35.24449			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455104	hybrid			2022-12-25	WOS:000082193400003
J	Goya, L; de la Puente, A; Ramos, S; Martin, MA; Escriva, F; Pascual-Leone, AM				Goya, L; de la Puente, A; Ramos, S; Martin, MA; Escriva, F; Pascual-Leone, AM			Regulation of insulin-like growth factor-I and -II by glucose in primary cultures of fetal rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; AMINO-ACID AVAILABILITY; IGF-I; BINDING-PROTEINS; MOLECULAR REGULATION; MESSENGER-RNA; DIFFERENTIAL REGULATION; DEPENDENT REGULATION; METABOLIC-REGULATION; EXPRESSION	A selective primary culture of fetal rat hepatocytes was established in our laboratory in order to elucidate the molecular mechanisms of action of different factors and conditions on insulin-like growth factor (IGF)-I and -II gene expression during the perinatal period of the rat, In this model we report that, in a serum-free condition and the presence of non-stimulatory doses of insulin, 5-20 mM glucose evoked an increase of IGF-I and -II mRNA abundance, Glucose regulated in a parallel manner IGF peptide secretion, and an excellent correlation was observed between IGF-I and -II mRNA and IGF-I and -II peptide levels in the conditioned media in response to the carbohydrate. The experiment with 2-deoxyglucose suggests that glucose 6-phosphate, but not its further metabolism, is necessary for the induction of IGF transcript abundance in cultured fetal hepatocytes. Finally, the glucose-induced rise in IGF-II mRNA, the main IGF in fetal stages, was mediated by stimulation of gene transcription and increased transcript stability. The results support the idea that IGFs belong to a family of genes that are positively regulated by glucose.	UCM, Fac Farm, CSIC, Inst Bioquim,Ctr Mixto, Madrid 28040, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Pascual-Leone, AM (corresponding author), UCM, Fac Farm, CSIC, Inst Bioquim,Ctr Mixto, Ciudad Univ, Madrid 28040, Spain.		Ramos, Sonia/K-4594-2012; Martín, María/HDL-9512-2022; Goya, Luis/H-5735-2012; Escrivá, Fernando/B-3890-2015; Martín, Maria Angeles/C-5768-2014	Ramos, Sonia/0000-0003-2649-2616; Goya, Luis/0000-0001-9449-6200; Escrivá, Fernando/0000-0002-9936-0721; Martín, Maria Angeles/0000-0001-8173-4521				ARANY E, 1993, J CELL PHYSIOL, V155, P426, DOI 10.1002/jcp.1041550225; BONISCHNETZLER M, 1991, AM J PHYSIOL, V260, pE846, DOI 10.1152/ajpendo.1991.260.6.E846; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAWKINS MJR, 1963, ANN NY ACAD SCI, V111, P203, DOI 10.1111/j.1749-6632.1963.tb36960.x; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; DONOVAN SM, 1991, ENDOCRINOLOGY, V129, P149, DOI 10.1210/endo-129-1-149; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GLUCKMAN PD, 1995, J CLIN ENDOCR METAB, V80, P1047, DOI 10.1210/jc.80.4.1047; GOLDSTEIN S, 1991, J MOL ENDOCRINOL, V6, P33, DOI 10.1677/jme.0.0060033; Goya L, 1996, AM J PHYSIOL-ENDOC M, V271, pE223, DOI 10.1152/ajpendo.1996.271.2.E223; HARP JB, 1991, DIABETES, V40, P95, DOI 10.2337/diabetes.40.1.95; HAYDEN JM, 1994, ENDOCRINOLOGY, V134, P760, DOI 10.1210/en.134.2.760; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LORENZO M, 1986, BIOCHEM J, V239, P135, DOI 10.1042/bj2390135; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MARIE S, 1993, J BIOL CHEM, V268, P23881; MENUELLE P, 1991, BIOCHEM J, V277, P111, DOI 10.1042/bj2770111; MENUELLE P, 1995, ENDOCRINOLOGY, V136, P5305, DOI 10.1210/en.136.12.5305; PAO CI, 1993, MOL ENDOCRINOL, V7, P1561, DOI 10.1210/me.7.12.1561; PHILLIPS LS, 1991, DIABETES, V40, P1525, DOI 10.2337/diabetes.40.11.1525; RECHLER MM, 1979, J BIOL CHEM, V254, P7942; RICHMAN RA, 1985, ENDOCRINOLOGY, V116, P180, DOI 10.1210/endo-116-1-180; RIVERO F, 1995, J ENDOCRINOL, V145, P427, DOI 10.1677/joe.0.1450427; RONCERO C, 1989, BIOCHIM BIOPHYS ACTA, V1012, P320, DOI 10.1016/0167-4889(89)90115-8; SCOTT CD, 1985, ENDOCRINOLOGY, V116, P1102, DOI 10.1210/endo-116-3-1102; SCOTT CD, 1985, ENDOCRINOLOGY, V116, P1094, DOI 10.1210/endo-116-3-1094; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; STRAUS DS, 1995, ENDOCRINOLOGY, V136, P365, DOI 10.1210/en.136.1.365; THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80; THISSEN JP, 1994, ENDOCRINOLOGY, V134, P1570, DOI 10.1210/en.134.3.1570; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Townsend Susan F., 1993, In Vitro Cellular and Developmental Biology, V29A, P592, DOI 10.1007/BF02634153; UCHIJIMA Y, 1995, BIOSCI BIOTECH BIOCH, V59, P1503, DOI 10.1271/bbb.59.1503; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888	39	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24633	24640		10.1074/jbc.274.35.24633	http://dx.doi.org/10.1074/jbc.274.35.24633			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455129	Green Published, hybrid			2022-12-25	WOS:000082193400028
J	Kirsch, M; de Groot, H				Kirsch, M; de Groot, H			Reaction of peroxynitrite with reduced nicotinamide nucleotides, the formation of hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA STRAND-BREAKS; NITRIC-OXIDE; ADENINE-DINUCLEOTIDE; TRANSCRIPTION FACTOR; PULSE-RADIOLYSIS; CARBON-DIOXIDE; ONE-ELECTRON; OXIDATIVE DAMAGE; NITROGEN-DIOXIDE	NAD(P)H acts as a two-electron reductant in physiological, enzyme-controlled processes. Under nonenzymatic conditions, a couple of one-electron oxidants easily oxidize NADH to the NAD(.) radical. This radical reduces molecular oxygen to the superoxide radical (O-2(radical anion)) at a near to the diffusion-controlled rate, thereby subsequently forming hydrogen peroxide (H2O2), Because peroxynitrite can act as a one-electron oxidant, the reaction of NAD(P)H with both authentic peroxynitrite and the nitric oxide ((NO)-N-.) and O-2(radical anion) releasing compound 3-morpholinosydnonimine N-ethylcarbamide (SIN-1) was studied. Authentic peroxynitrite oxidized NADH with an efficiency of similar to 25 and 8% in the absence and presence of bicarbonate/carbon dioxide (HCO3-/CO2), respectively. NADH reacted 5-100 times faster with peroxynitrite than do the known peroxynitrite scavengers glutathione, cysteine, and tryptophan, Furthermore, NADH was found to be highly effective in suppressing peroxynitrite-mediated nitration reactions even in the presence of HCO3-/CO2. Reaction of NADH with authentic peroxynitrite resulted in the formation of NAD(+) and O-2(radical anion) and, thus, of H2O2 with yields of about 3 and 10% relative to the added amounts of peroxynitrite and NADH, respectively. Peroxynitrite generated in situ from SIN-1 gave virtually the same results; however, two remarkable exceptions were recognized. First, the efficiency of NADH oxidation increased to 60-90% regardless of the presence of HCO3-/CO2, along with an increase of H2O2 formation to about 23 and 35%, relative to the amounts of added SIN-1 and NADH, Second, and more interesting, the peroxynitrite scavenger glutathione (GSH) was needed in a 75-fold surplus to inhibit the SIN-1-dependent oxidation of NADH half-maximal in the presence of HCO3-/CO2. Similar results were obtained with NADPH, Hence, peroxynitrite or radicals derived from it (such as, e.g. the bicarbonate radical or nitrogen dioxide) indeed oxidize NADH, leading to the formation of NAD(+) and, via O-2(radical) (anion), of H2O2. When peroxynitrite is generated in situ in the presence of HCO3-/CO2, i.e. under conditions mimicking the in vivo situation, NAD(P)H effectively competes with other known scavengers of peroxynitrite.	Univ Essen Gesamthsch Klinikum, Inst Physiol Chem, D-45122 Essen, Germany	University of Duisburg Essen	de Groot, H (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Physiol Chem, Hufelandstr 55, D-45122 Essen, Germany.							Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; BALDWIN SR, 1986, LANCET, V1, P11; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; CARLSON BW, 1984, J AM CHEM SOC, V106, P7233, DOI 10.1021/ja00335a062; CHEN SN, 1973, RADIAT RES, V56, P40, DOI 10.2307/3573789; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Ewing JF, 1997, ARCH BIOCHEM BIOPHYS, V343, P131, DOI 10.1006/abbi.1997.0169; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; Handel ML, 1995, ARTHRITIS RHEUM, V38, P1762, DOI 10.1002/art.1780381209; HOFFMANN ME, 1984, BIOCHIM BIOPHYS ACTA, V781, P234, DOI 10.1016/0167-4781(84)90088-5; HOWARD JA, 1984, LANDOLTBORNSTEIN RAD, V2, P193; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; Kirsch M, 1998, J BIOL CHEM, V273, P12716, DOI 10.1074/jbc.273.21.12716; KLINGENBERG M, 1985, METHOD ENZYMAT AN, V7, P251; KOBAYASHI K, 1995, J CHEM SOC DALTON, P2885, DOI 10.1039/dt9950002885; Kobayashi K, 1995, ENDOTHELIUM S, V3, P65; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; Koppenol WH, 1998, CHEM RES TOXICOL, V11, P87, DOI 10.1021/tx970200x; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LAND EJ, 1971, BIOCHIM BIOPHYS ACTA, V234, P34, DOI 10.1016/0005-2728(71)90126-5; LEHNIG M, 1999, IN PRESS ARCH BIOCH; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; Lin KT, 1997, BIOCHEM BIOPH RES CO, V230, P115, DOI 10.1006/bbrc.1996.5897; LOGAGER T, 1993, J PHYS CHEM-US, V97, P10047; Lomonosova EE, 1998, FREE RADICAL BIO MED, V24, P522, DOI 10.1016/S0891-5849(97)00295-5; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MASUDA Y, 1993, FEBS LETT, V334, P109, DOI 10.1016/0014-5793(93)81692-S; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NADEZHDIN A, 1979, J PHYS CHEM-US, V83, P1957, DOI 10.1021/j100478a007; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Richeson CE, 1998, J AM CHEM SOC, V120, P7211, DOI 10.1021/ja980871x; SALGO MG, 1995, BIOCHEM BIOPH RES CO, V210, P1025, DOI 10.1006/bbrc.1995.1759; SCHELLENBERG KA, 1958, J BIOL CHEM, V231, P547; Schmidt KN, 1996, ADV EXP MED BIOL, V387, P63; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sies H., 1982, METABOLIC COMPARTMEN, P205; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Stanbury D. M., 1989, ADV INORG CHEM RA, V33, P69, DOI 10.1016/S0898-8838(08)60194-4; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; THOMSON L, 1995, ARCH BIOCHEM BIOPHYS, V319, P491, DOI 10.1006/abbi.1995.1321; UETA K, 1985, ANNU REV BIOCHEM, V54, P73; Uppu RM, 1996, ANAL BIOCHEM, V236, P242, DOI 10.1006/abio.1996.0162; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044	57	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24664	24670		10.1074/jbc.274.35.24664	http://dx.doi.org/10.1074/jbc.274.35.24664			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455133	hybrid			2022-12-25	WOS:000082193400032
J	Rich, RL; Deivanayagam, CCS; Owens, RT; Carson, M; Hook, A; Moore, D; Yang, VWC; Narayana, SVL; Hook, M				Rich, RL; Deivanayagam, CCS; Owens, RT; Carson, M; Hook, A; Moore, D; Yang, VWC; Narayana, SVL; Hook, M			Trench-shaped binding sites promote multiple classes of interactions between collagen and the adherence receptors, alpha(1)beta(1) integrin and Staphylococcus aureus Cna MSCRAMM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; CRYSTAL-STRUCTURE; LIGAND-BINDING; I-DOMAIN; ESCHERICHIA-COLI; SEPTIC ARTHRITIS; ALPHA-SUBUNITS; A3 DOMAIN; PROTEIN; ADHESIN	Most mammalian cells and some pathogenic bacteria are capable of adhering to collagenous substrates in processes mediated by specific cell surface adherence molecules. Crystal structures of collagen-binding regions of the human integrin alpha(2)beta(1) and a Staphylococcus aureus adhesin reveal a "trench" on the surface of both of these proteins. This trench can accommodate a collagen triple-helical structure and presumably represents the ligand-binding site (Emsley, J., Ring, S. L., Bergelson, J. M., and Liddington, R. C. (1997) J. Biol. Chem. 272, 28512-28517; Symersky, J., Patti, J. M., Carson, M., House-Pompeo, K., Teale, M,, Moore, D., Jin, L., Schneider, A, DeLucas, L. J., Hook, M., and Narayana, S. V. L. (1997) Nat. Struct. Biol. 4, 833-838). We report here the crystal structure of the alpha subunit I domain from the alpha(1)beta(1) integrin. This collagen-binding protein also contains a trench on one face in which the collagen triple helix may be docked. Furthermore, we compare the collagen-binding mechanisms of the human alpha(1) integrin I domain and the A domain from the S. aureus collagen adhesin, Cna. Although the S. aureus and human proteins have unrelated amino acid sequences, secondary structure composition, and cation requirements for effective ligand binding, both proteins bind at multiple sites within one collagen molecule, with the sites in collagen varying in their affinity for the adherence molecule. We propose that (i) these evolutionarily dissimilar adherence proteins recognize collagen via similar mechanisms, (ii) the multisite, multiclass protein/ligand interactions observed in these two systems result from a binding-site trench, and (iii) this unusual binding mechanism may be thematic for proteins binding extended, rigid ligands that contain repeating structural motifs.	Univ Alabama, Ctr Macromol Crystallog, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Rich, RL (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA.			Deivanayagam, Champion/0000-0003-2972-1824	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044415] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44415] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; BRUNGER AT, 1992, XPLOR MANUAL VERSION; Calderwood DA, 1995, BIOCHEM SOC T, V23, pS504, DOI 10.1042/bst023504s; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Cantor C.R., 1980, BIOPHYS CHEM; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; EMODY L, 1989, J BACTERIOL, V171, P6674; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; FORSBERG E, 1994, EXP CELL RES, V213, P183, DOI 10.1006/excr.1994.1189; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; House-Pompeo Karen, 1994, Methods (Orlando), V6, P134, DOI 10.1006/meth.1994.1016; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; JIANG F, 1991, J MOL BIOL, V219, P79, DOI 10.1016/0022-2836(91)90859-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LEE JO, 1995, STRUCTURE, V3, P1222; LESKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; PATTI JM, 1992, J BIOL CHEM, V267, P4766; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; Perona JJ, 1997, BIOCHEMISTRY-US, V36, P5381, DOI 10.1021/bi9617522; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RICH R, 1995, THESIS IOWA STATE U; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO SA, 1982, COLLAGEN REL RES, V2, P31; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SWITALSKI LM, 1993, MOL MICROBIOL, V7, P99, DOI 10.1111/j.1365-2958.1993.tb01101.x; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; Tuckwell DS, 1997, BIOCHEMISTRY-US, V36, P6605, DOI 10.1021/bi963155l; Vaughn DE, 1997, BIOCHEMISTRY-US, V36, P9374, DOI 10.1021/bi970841r; VERCELLOTTI GM, 1985, AM J PATHOL, V120, P13; WALZOG B, 1995, EXP CELL RES, V218, P28, DOI 10.1006/excr.1995.1127; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WESTERLUND B, 1989, MOL MICROBIOL, V3, P329, DOI 10.1111/j.1365-2958.1989.tb00178.x; Yang VWC, 1999, J BIOL CHEM, V274, P12454, DOI 10.1074/jbc.274.18.12454	56	84	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24906	24913		10.1074/jbc.274.35.24906	http://dx.doi.org/10.1074/jbc.274.35.24906			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229KH	10455165	hybrid			2022-12-25	WOS:000082193400064
J	Passer, BJ; Pellegrini, L; Vito, P; Ganjei, JK; D'Adamio, L				Passer, BJ; Pellegrini, L; Vito, P; Ganjei, JK; D'Adamio, L			Interaction of Alzheimer's presenilin-1 and presenilin-2 with Bcl-X-L - A potential role in modulating the threshold of cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED PRESENILINS; AMYLOID BETA-PEPTIDE; CYTOCHROME-C; IN-VIVO; ISOLATED-MITOCHONDRIA; MISSENSE MUTATIONS; APOPTOSIS; GENE; PROTEINS; EXPRESSION	The familial Alzheimer's disease gene products, presenilin-1 and presenilin-2, have been reported to be functionally involved in amyloid precursor protein processing, notch receptor signaling, and programmed cell death or apoptosis. However, the molecular mechanisms by which presenilins regulate these processes remain unknown. With regard to the latter, we describe a molecular link between presenilins and the apoptotic pathway. Bcl-X-L, an anti-apoptotic member of the Bcl-2 family was shown to interact with the carboxyl-terminal fragments of PS1 and PS2 by the yeast two-hybrid system. In vivo interaction analysis revealed that both PS2 and its naturally occurring carboxyl-terminal products, PS2short and PS2Ccas, associated with Bcl-X-L, whereas the caspase-3-generated amino-terminal PS2Ncas fragment did not. This interaction was corroborated by demonstrating that Bcl-X-L and PS2 partially co-localized to sites of the vesicular transport system. Functional analysis revealed that presenilins can influence mitochondrial-dependent apoptotic activities, such as cytochrome c release and Bar-mediated apoptosis. Together, these data support a possible role of the Alzheimer's presenilins in modulating the anti-apoptotic effects of Bcl-X-L.	NIAID, Cellular & Mol Immunol Lab, T Cell Apoptosis Unit, NIH, Bethesda, MD 20892 USA; Basel Inst Immunol, CH-4005 Basel, Switzerland	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	D'Adamio, L (corresponding author), NIAID, Cellular & Mol Immunol Lab, T Cell Apoptosis Unit, NIH, Bldg 4,Rm 431, Bethesda, MD 20892 USA.		vito, pasquale/ABF-5505-2020	Pellegrini, Luca/0000-0002-4235-7708; vito, pasquale/0000-0002-5721-7716; D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Dewji NN, 1997, P NATL ACAD SCI USA, V94, P14025, DOI 10.1073/pnas.94.25.14025; Dewji NN, 1997, P NATL ACAD SCI USA, V94, P9926, DOI 10.1073/pnas.94.18.9926; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; FINLEY RL, 1995, DNA CLONING EXPRESSI, P169; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XJ, 1997, P NATL ACAD SCI USA, V94, P12204, DOI 10.1073/pnas.94.22.12204; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281	45	91	93	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24007	24013		10.1074/jbc.274.34.24007	http://dx.doi.org/10.1074/jbc.274.34.24007			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446169	hybrid			2022-12-25	WOS:000082110900048
J	Schmitz-Peiffer, C; Craig, DL; Biden, TJ				Schmitz-Peiffer, C; Craig, DL; Biden, TJ			Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; RECEPTOR SUBSTRATE-1 PHOSPHORYLATION; GLYCOGEN-SYNTHASE ACTIVATION; N-TERMINAL KINASE; GLUCOSE-TRANSPORT; IN-VIVO; CARDIAC MYOCYTES; AKT KINASE; RAT; RESISTANCE	We have employed C2C12 myotubes to investigate lipid inhibition of insulin-stimulated signal transduction and glucose metabolism. Cells were preincubated for 18 h in the absence or presence of free fatty acids (FFAs) and stimulated with insulin, and the effects on glycogen synthesis and signaling intermediates were determined. While the unsaturated FFAs oleate and linoleate inhibited both basal and insulin-stimulated glycogen synthesis, the saturated FFA palmitate reduced only insulin-stimulated glycogen synthesis, and was found to inhibit insulin-stimulated phosphorylation of glycogen synthase kinase-3 and protein kinase B (PKB). However, no effect of palmitate was observed on tyrosine phosphorylation, p85 association, or phosphatidylinositol 3-kinase activity in IRS-1 immunoprecipitates. In contrast, palmitate promoted phosphorylation of mitogen-activated protein MAP) kinases. Ceramide, a derivative of palmitate, has recently been associated with similar inhibition of PKB, and here, ceramide levels were found to be elevated 2-fold in palmitate-treated C2C12 cells. Incubation of C2C12 cells with ceramide closely reproduced the effects of palmitate, leading to inhibition of glycogen synthesis and PKB and to stimulation of MAP kinase. We conclude that palmitate-induced insulin resistance occurs by a mechanism distinct from that of unsaturated FFAs, and involves elevation of ceramide by de novo synthesis, leading to PKB inhibition without affecting IRS-1 function.	St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Schmitz-Peiffer, C (corresponding author), St Vincents Hosp, Garvan Inst Med Res, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	c.schmitz-peiffer@garvan.unsw.edu.au	Biden, Trevor/AAW-2829-2021; Schmitz-Peiffer, Carsten/J-6918-2012	Schmitz-Peiffer, Carsten/0000-0001-7330-7255; Biden, Trevor/0000-0001-5211-0234				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Berti L, 1997, DIABETOLOGIA, V40, P606, DOI 10.1007/s001250050722; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938; ECKEL J, 1991, ENDOCRINOLOGY, V129, P345, DOI 10.1210/endo-129-1-345; ECKEL J, 1990, BIOCHEM SOC T, V18, P1125, DOI 10.1042/bst0181125; FERRE P, 1985, BIOCHEM J, V228, P103, DOI 10.1042/bj2280103; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Gorski J, 1998, MOL CELL BIOCHEM, V178, P113, DOI 10.1023/A:1006820907955; Guo JH, 1998, J BIOL CHEM, V273, P16487, DOI 10.1074/jbc.273.26.16487; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Holness MJ, 1997, BIOCHEM SOC T, V25, P1; HUNNICUTT JW, 1994, DIABETES, V43, P540, DOI 10.2337/diabetes.43.4.540; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; Ragolia L, 1998, MOL CELL BIOCHEM, V182, P49, DOI 10.1023/A:1006827227162; RANDLE PJ, 1988, DIABETES METAB REV, V4, P623, DOI 10.1002/dmr.5610040702; SchmitzPeiffer C, 1997, DIABETES, V46, P169, DOI 10.2337/diabetes.46.2.169; SchmitzPeiffer C, 1997, AM J PHYSIOL-ENDOC M, V273, pE915, DOI 10.1152/ajpendo.1997.273.5.E915; SHILLABEER G, 1995, BIOCHEM BIOPH RES CO, V207, P768, DOI 10.1006/bbrc.1995.1253; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SKURAT AV, 1995, J BIOL CHEM, V270, P12491, DOI 10.1074/jbc.270.21.12491; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; SVEDBERG J, 1990, DIABETES, V39, P570, DOI 10.2337/diabetes.39.5.570; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; Usui I, 1997, DIABETOLOGIA, V40, P894, DOI 10.1007/s001250050765; VanEppsFung M, 1997, ENDOCRINOLOGY, V138, P4338, DOI 10.1210/en.138.10.4338; VILLARPALASI C, 1994, DIABETOLOGIA, V37, P885; Wang CN, 1998, DIABETES, V47, P24, DOI 10.2337/diabetes.47.1.24; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	48	488	502	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24202	24210		10.1074/jbc.274.34.24202	http://dx.doi.org/10.1074/jbc.274.34.24202			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446195	hybrid			2022-12-25	WOS:000082110900074
J	Waller, KL; Cooke, BM; Nunomura, W; Mohandas, N; Coppel, RL				Waller, KL; Cooke, BM; Nunomura, W; Mohandas, N; Coppel, RL			Mapping the binding domains involved in the interaction between the Plasmodium falciparum knob-associated histidine-rich protein (KAHRP) and the cytoadherence ligand P-falciparum erythrocyte membrane protein 1 (PfEMP1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; INFECTED ERYTHROCYTES; SURFACE-ANTIGEN; OPTICAL BIOSENSOR; MALARIAL ANTIGEN; RESONANT MIRROR; GENE; SPECTRIN; SEQUENCE; THROMBOSPONDIN	Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) clusters at electron-dense knob-like structures on the surface of malaria-infected red blood cells and mediates their adhesion to the vascular endothelium. In parasites lacking knobs, vascular adhesion is less efficient, and infected red cells are not able 60 immobilize successfully under hemodynamic flow conditions even though PfEMP1 is still present on the exterior of the infected red cell. me examined the interaction between the knob-associated histidine-rich protein (KAHRP), the parasite protein upon which knob formation is dependent, and PfEMP1, and we show evidence of a direct interaction between KAHRP and the cytoplasmic region of PfEMP1 (VARC). We have identified three fragments of KAHRP which bind VARC. Two of these KAHRP fragments (K1A and K2A) interact with VARC with binding affinities (K-D(kin)) of 1 x 10(-7) M and 3.3 x 10(-6) M respectively, values comparable to those reported previously for protein-protein interactions in normal and infected red cells. Further experiments localized the high affinity binding regions of KAHRP to the 63-residue histidine-rich and 70-residue 5' repeats. Deletion of these two regions from the KAHRP fragments abolished their ability to bind to VARC. Identification of the critical domains involved in interaction between KAHRP and PfEMP1 may aid development of new therapies to prevent serious complications of P. falciparum malaria.	Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Monash University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Coppel, RL (corresponding author), Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia.		Coppel, Ross L/A-6626-2008	Coppel, Ross L/0000-0002-4476-9124; Waller, Karena/0000-0001-8786-4407	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32094] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEY SB, 1986, J EXP MED, V164, P1915, DOI 10.1084/jem.164.6.1915; ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; ANDERS RF, 1988, PROG ALLERGY, V41, P148; ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x; ANDERS RF, 1987, UCLA S MOL CELL BIOL, V42, P333; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Bennett BJ, 1997, J BIOL CHEM, V272, P15299, DOI 10.1074/jbc.272.24.15299; BERENDT AR, 1994, PARASITOLOGY, V108, P19; Bonnefoy S, 1997, MOL BIOCHEM PARASIT, V87, P1, DOI 10.1016/S0166-6851(97)00033-9; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; Coppel R L, 1998, Curr Opin Hematol, V5, P132; COPPEL RL, 1983, NATURE, V306, P751, DOI 10.1038/306751a0; COPPEL RL, 1986, MOL BIOCHEM PARASIT, V20, P265, DOI 10.1016/0166-6851(86)90107-6; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; FOLEY M, 1991, MOL BIOCHEM PARASIT, V46, P137, DOI 10.1016/0166-6851(91)90207-M; FOLEY M, 1994, EXP PARASITOL, V79, P340, DOI 10.1006/expr.1994.1096; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; HERRERA S, 1993, EMBO J, V12, P1607, DOI 10.1002/j.1460-2075.1993.tb05805.x; Hirawake H, 1997, BBA-MOL BASIS DIS, V1360, P105, DOI 10.1016/S0925-4439(97)00007-0; HOWARD RJ, 1988, MOL BIOCHEM PARASIT, V27, P207, DOI 10.1016/0166-6851(88)90040-0; Kant R, 1996, FEBS LETT, V380, P147, DOI 10.1016/0014-5793(96)00024-5; KILEJIAN A, 1991, MOL BIOCHEM PARASIT, V44, P175, DOI 10.1016/0166-6851(91)90003-O; KILEJIAN A, 1979, P NATL ACAD SCI USA, V76, P4650, DOI 10.1073/pnas.76.9.4650; LEECH JH, 1984, J CELL BIOL, V98, P1256, DOI 10.1083/jcb.98.4.1256; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; LUSTIGMAN S, 1990, MOL BIOCHEM PARASIT, V38, P261, DOI 10.1016/0166-6851(90)90029-L; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; POLOGE LG, 1986, NATURE, V322, P474, DOI 10.1038/322474a0; RUANGJIRACHUPORN W, 1991, PARASITOLOGY, V102, P325, DOI 10.1017/S003118200006426X; Rubio JP, 1996, EMBO J, V15, P4069, DOI 10.1002/j.1460-2075.1996.tb00780.x; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; TRIGLIA T, 1987, EMBO J, V6, P1413, DOI 10.1002/j.1460-2075.1987.tb02382.x; TYLER JM, 1980, J BIOL CHEM, V255, P7034; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WATTS HJ, 1994, ANAL CHEM, V66, P2465, DOI 10.1021/ac00087a010; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x	41	111	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					23808	23813		10.1074/jbc.274.34.23808	http://dx.doi.org/10.1074/jbc.274.34.23808			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446142	hybrid			2022-12-25	WOS:000082110900021
J	Cosper, NJ; Stalhandske, CMV; Iwasaki, H; Oshima, T; Scott, RA; Iwasaki, T				Cosper, NJ; Stalhandske, CMV; Iwasaki, H; Oshima, T; Scott, RA; Iwasaki, T			Structural conservation of the isolated zinc site in archaeal zinc-containing ferredoxins as revealed by x-ray absorption spectroscopic analysis and its evolutionary implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOLOBUS SP STRAIN-7; POLYPEPTIDE-ASSOCIATED COMPLEX; COMPLETE GENOME SEQUENCE; AMINO-ACID-SEQUENCE; TRANSFER-RNA NUCLEOTIDYLTRANSFERASE; SIGNAL RECOGNITION PARTICLE; IRON-SULFUR CLUSTERS; THERMOACIDOPHILIC ARCHAEON; THERMOPLASMA-ACIDOPHILUM; ARCHAEBACTERIUM SULFOLOBUS	The zfx gene encoding a zinc-containing ferredoxin from Thermoplasma acidophilum strain HO-62 was cloned and sequenced. It is located upstream of two genes encoding an archaeal homolog of nascent polypeptide-associated complex alpha subunit and a tRNA nucleotidyltransferase. This gene organization is not conserved in several euryarchaeoteal genomes, The multiple sequence alignments of the zfx gene product suggest significant sequence similarity of the ferredoxin core fold to that of a low potential 8Fe-containing dicluster ferredoxin without a zinc center. The tightly bound zinc site of zinc-containing ferredoxins from two phylogenetically distantly related Archaea, T. acidophilum HO-62 and Sulfolobus sp. strain 7, was further investigated by x-ray absorption spectroscopy. The zinc K-edge x-ray absorption spectra of both archaeal ferredoxins are strikingly similar, demonstrating that the same zinc site is found in T. acidophilum ferredoxin as in Sulfolobus sp, ferredoxin, which suggests the structural conservation of isolated zinc binding sites among archaeal zinc-containing ferredoxins, The sequence and spectroscopic data provide the common structural features of the archaeal zinc-containing ferredoxin family.	Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan; Tokyo Univ Pharm & Life Sci, Dept Mol Biol, Tokyo 1920392, Japan; Nippon Med Sch, Dept Biochem & Mol Biol, Tokyo 1138602, Japan	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Nagoya University; Tokyo University of Pharmacy & Life Sciences; Nippon Medical School	Scott, RA (corresponding author), Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA.			Scott, Robert/0000-0003-2236-1336; Iwasaki, Hideo/0000-0002-3754-4955; Iwasaki, Toshio/0000-0001-9562-4649	NIGMS NIH HHS [GM 42025] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042025] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MWW, 1994, FEMS MICROBIOL REV, V15, P261, DOI 10.1111/j.1574-6976.1994.tb00139.x; ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; BEAR CA, 1975, ACTA CRYSTALLOGR B, V31, P2713, DOI 10.1107/S056774087500859X; BELLY RT, 1973, ANN NY ACAD SCI, V225, P94, DOI 10.1111/j.1749-6632.1973.tb45639.x; Bentrop D, 1997, BIOCHEMISTRY-US, V36, P13629, DOI 10.1021/bi9714058; Bentrop D, 1996, EUR J BIOCHEM, V236, P92, DOI 10.1111/j.1432-1033.1996.00092.x; Bertini I, 1997, BIOCHEMISTRY-US, V36, P3570, DOI 10.1021/bi962799q; Brereton PS, 1998, BIOCHEMISTRY-US, V37, P7351, DOI 10.1021/bi972864b; BRETON JL, 1995, EUR J BIOCHEM, V233, P937, DOI 10.1111/j.1432-1033.1995.937_3.x; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; Clark-Baldwin K, 1998, J AM CHEM SOC, V120, P8401, DOI 10.1021/ja980580o; Cosper NJ, 1999, J BIOL INORG CHEM, V4, P122, DOI 10.1007/s007750050295; DARLAND G, 1970, SCIENCE, V170, P1416, DOI 10.1126/science.170.3965.1416; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Fujii T, 1996, NAT STRUCT BIOL, V3, P834, DOI 10.1038/nsb1096-834; GARTNER P, 1991, EUR J BIOCHEM, V200, P215, DOI 10.1111/j.1432-1033.1991.tb21070.x; GOLBECK JH, 1994, ADV PHOTOSYNTHESIS M, P319; HAIN J, 1992, NUCLEIC ACIDS RES, V20, P5423, DOI 10.1093/nar/20.20.5423; HARROCKS WD, 1980, J INORG BIOCHEM, V12, P131; Iwasaki T, 1997, FEBS LETT, V417, P223, DOI 10.1016/S0014-5793(97)01286-6; Iwasaki T, 1997, J BIOL CHEM, V272, P3453, DOI 10.1074/jbc.272.6.3453; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; IWASAKI T, 1995, J BIOL CHEM, V270, P17878, DOI 10.1074/jbc.270.30.17878; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; Kawarabayasi Y, 1998, DNA Res, V5, P147, DOI 10.1093/dnares/5.2.147; KERSCHER L, 1982, EUR J BIOCHEM, V128, P223; KERSCHER L, 1982, TRENDS BIOCHEM SCI, V7, P371, DOI 10.1016/0968-0004(82)90118-9; KERSCHER L, 1976, EUR J BIOCHEM, V71, P101, DOI 10.1111/j.1432-1033.1976.tb11094.x; KERSCHER L, 1977, FEBS LETT, V83, P197, DOI 10.1016/0014-5793(77)81004-1; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; LUBBEN M, 1995, BBA-BIOENERGETICS, V1229, P1, DOI 10.1016/0005-2728(94)00174-4; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MINAMI Y, 1985, J BIOCHEM-TOKYO, V97, P745, DOI 10.1093/oxfordjournals.jbchem.a135114; MOLL R, 1988, FEBS LETT, V232, P359, DOI 10.1016/0014-5793(88)80769-5; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; PFEIFER F, 1993, MOL GEN GENET, V239, P66, DOI 10.1007/BF00281602; Powers T, 1996, CURR BIOL, V6, P331, DOI 10.1016/S0960-9822(02)00484-0; RANDALL CR, 1995, INORG CHEM, V34, P1036, DOI 10.1021/ic00109a007; REE HK, 1989, CAN J MICROBIOL, V35, P124, DOI 10.1139/m89-019; REITER WD, 1988, NUCLEIC ACIDS RES, V16, P2445, DOI 10.1093/nar/16.6.2445; ROE AL, 1984, J AM CHEM SOC, V106, P1676, DOI 10.1021/ja00318a021; Sambrook J., 2002, MOL CLONING LAB MANU; SATO S, 1981, BIOCHIM BIOPHYS ACTA, V668, P277, DOI 10.1016/0005-2795(81)90035-0; Schafer G, 1996, BBA-BIOENERGETICS, V1277, P163, DOI 10.1016/S0005-2728(96)00104-1; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; SHI XM, 1995, GENE, V165, P199, DOI 10.1016/0378-1119(95)00577-S; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STETTER KO, 1995, ASM NEWS, V61, P285; TEIXEIRA M, 1995, EUR J BIOCHEM, V227, P322, DOI 10.1111/j.1432-1033.1995.tb20392.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thurlow DL, 1997, J MOL EVOL, V44, P686, DOI 10.1007/PL00013143; WAKABAYASHI S, 1983, FEBS LETT, V162, P21, DOI 10.1016/0014-5793(83)81041-2; Wakagi T, 1996, BIOCHEM BIOPH RES CO, V225, P489, DOI 10.1006/bbrc.1996.1200; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; Westre TE, 1997, J AM CHEM SOC, V119, P6297, DOI 10.1021/ja964352a; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; YASUDA M, 1995, APPL ENVIRON MICROB, V61, P3482, DOI 10.1128/AEM.61.9.3482-3485.1995; Yotov WV, 1998, MOL CELL BIOL, V18, P1303, DOI 10.1128/MCB.18.3.1303; Yue DX, 1996, RNA, V2, P895; ZABINSKY SI, 1995, PHYS REV B, V52, P2995, DOI 10.1103/PhysRevB.52.2995; Zhang Q, 1996, J BIOCHEM-TOKYO, V120, P587	70	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23160	23168		10.1074/jbc.274.33.23160	http://dx.doi.org/10.1074/jbc.274.33.23160			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438486	hybrid			2022-12-25	WOS:000082012800036
J	Islam, MR; Tomatsu, S; Shah, GN; Grubb, JH; Jain, S; Sly, WS				Islam, MR; Tomatsu, S; Shah, GN; Grubb, JH; Jain, S; Sly, WS			Active site residues of human beta-glucuronidase - Evidence for Glu(540) as the nucleophile and Glu(451) as the acid-base residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDASE ESCHERICHIA-COLI; MUCOPOLYSACCHARIDOSIS TYPE-VII; GLYCOSYL HYDROLASES; DEFICIENCY MUCOPOLYSACCHARIDOSIS; SEQUENCE SIMILARITIES; CATALYTIC ACTIVITY; EXPRESSION; MUTATIONS; PHOSPHORYLATION; CLASSIFICATION	Human beta-glucuronidase (hGUSB) is a member of family 2 glycosylhydrolases that cleaves beta-D-glucuronic acid residues from the nonreducing termini of glycosaminoglycans. Amino acid sequence and structural homology of hGUSB and Escherichia coli beta-galactosidase active sites led us to propose that residues Glu(451), Glu(540), and Tyr(504), hGUSB are involved in catalysis, Glu(451) being the acid-base residue and Glu(540) the nucleophile. To test this hypothesis, we introduced mutations in these residues and determined their effects on enzymes expressed in COS cells and GUSB-deficient fibroblasts, The extremely low activity in cells expressing Glu(451), Glu(540), and Tyr(504) hGUSBs supported their roles in catalysis. For kinetic analysis, wild type and mutant enzymes were produced in baculovirus and purified to homogeneity by affinity chromatography. The k(cat)/K-m values (mM(-1).s(-1)) of the E540A, E451A, and Y504A enzymes were 34,000-, 9100-, and 830-fold lower than that of wild type hGUSB, respectively. High concentrations of azide stimulated the activity of the E451A mutant enzyme, supporting the role of Glu451 as the acid-base catalyst. We conclude that, like their homologues in E. coli beta-galactosidase, Glu(540) is the nucleophilic residue, Glu(451) the acid-base catalyst, and Tyr(504) is, also important for catalysis, although its role is unclear. All three residues are located in the active site cavity previously determined by structural analysis of hGUSB.	St Louis Univ, Hlth Sci Ctr, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Sly, WS (corresponding author), St Louis Univ, Hlth Sci Ctr, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034182, R01GM034182] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40163] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROT FE, 1974, BIOCHEM BIOPH RES CO, V57, P1, DOI 10.1016/S0006-291X(74)80349-9; BROT FE, 1978, BIOCHEMISTRY-US, V17, P385, DOI 10.1021/bi00596a001; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GEHRMANN MC, 1994, BIOCHEM J, V301, P821, DOI 10.1042/bj3010821; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HALL CW, 1973, ARCH BIOCHEM BIOPHYS, V155, P32, DOI 10.1016/S0003-9861(73)80006-2; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Ho K J, 1991, Protein Expr Purif, V2, P63, DOI 10.1016/1046-5928(91)90011-7; Islam MR, 1996, HUM GENET, V98, P281, DOI 10.1007/s004390050207; ISLAM MR, 1993, J BIOL CHEM, V268, P22627; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luckow V. A, 1991, Recombinant DNA technology and applications., P97; MACLEOD AM, 1994, BIOCHEMISTRY-US, V33, P6371, DOI 10.1021/bi00186a042; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MIYAZAKI J, 1989, GENE, V79, P269; RING M, 1990, ARCH BIOCHEM BIOPHYS, V283, P342, DOI 10.1016/0003-9861(90)90652-F; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIPLEY JM, 1993, J BIOL CHEM, V268, P12193; SHIPLEY JM, 1993, AM J HUM GENET, V52, P517; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; SPRAGUE J, 1983, J VIROL, V45, P773, DOI 10.1128/JVI.45.2.773-781.1983; TOMATSU S, 1991, AM J HUM GENET, V48, P89; Vervoort R, 1996, AM J HUM GENET, V58, P457; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WANG CC, 1972, J BIOL CHEM, V247, P2644; Wong AW, 1998, J BIOL CHEM, V273, P34057, DOI 10.1074/jbc.273.51.34057; WU BM, 1994, J BIOL CHEM, V269, P23681; YUAN JM, 1994, BIOCHEM J, V299, P527, DOI 10.1042/bj2990527	35	67	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23451	23455		10.1074/jbc.274.33.23451	http://dx.doi.org/10.1074/jbc.274.33.23451			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438523	hybrid			2022-12-25	WOS:000082012800073
